FN Thomson Reuters Web of Science™
VR 1.0
PT J
AU Hoffmann, E
Kline-Rogers, E
Braverman, AG
Voehringer, M
Steg, PG
Gourineni, V
Montgomery, DG
Isselbacher, EM
Eagle, KA
Nienaber, CA
AF Hoffmann, E.
Kline-Rogers, E.
Braverman, A. G.
Voehringer, M.
Steg, P. G.
Gourineni, V.
Montgomery, D. G.
Isselbacher, E. M.
Eagle, K. A.
Nienaber, C. A.
CA Int Registry Acute Aortic Dissecti
TI The use of chest x-ray as a diagnostic tool in acute aortic dissection:
insights from the International Registry of Acute Aortic Dissection
(IRAD)
SO EUROPEAN HEART JOURNAL
LA English
DT Meeting Abstract
CT Congress of the European-Society-of-Cardiology (ESC)
CY AUG 25-29, 2012
CL Munchen, GERMANY
SP European Soc Cardiol (ESC)
C1 [Hoffmann, E.; Nienaber, C. A.] Univ Hosp Rostock, Rostock, Germany.
[Kline-Rogers, E.; Gourineni, V.; Montgomery, D. G.; Eagle, K. A.] Univ Michigan, Ann Arbor, MI 48109 USA.
[Braverman, A. G.] Washington Univ, St Louis, MO USA.
[Voehringer, M.] Robert Bosch Krankenhaus, Stuttgart, Germany.
[Steg, P. G.] Hosp Bichat Claude Bernard, AP HP, Paris, France.
[Isselbacher, E. M.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0195-668X
J9 EUR HEART J
JI Eur. Heart J.
PD AUG
PY 2012
VL 33
SU 1
BP 250
EP 250
PG 1
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 995MO
UT WOS:000308012402253
ER
PT J
AU Duerschmied, D
Suidan, GL
Herr, N
Carbo, C
Demers, M
Brill, A
Cifuni, SM
Cicko, S
Idzko, M
Bode, C
AF Duerschmied, D.
Suidan, G. L.
Herr, N.
Carbo, C.
Demers, M.
Brill, A.
Cifuni, S. M.
Cicko, S.
Idzko, M.
Bode, C.
TI Platelet serotonin promotes the efficient recruitment of neutrophils to
sites of acute inflammation
SO EUROPEAN HEART JOURNAL
LA English
DT Meeting Abstract
CT Congress of the European-Society-of-Cardiology (ESC)
CY AUG 25-29, 2012
CL Munchen, GERMANY
SP European Soc Cardiol (ESC)
C1 [Duerschmied, D.; Herr, N.; Bode, C.] Univ Med Ctr Freiburg, Dept Cardiol Angiol, Freiburg, Germany.
[Suidan, G. L.; Carbo, C.; Demers, M.; Brill, A.; Cifuni, S. M.] Harvard Univ, Sch Med, Childrens Hosp, Immune Dis Inst, Boston, MA USA.
[Cicko, S.; Idzko, M.] Univ Med Ctr, Dept Pneumol, Freiburg, Germany.
NR 0
TC 0
Z9 0
U1 1
U2 5
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0195-668X
J9 EUR HEART J
JI Eur. Heart J.
PD AUG
PY 2012
VL 33
SU 1
BP 277
EP 277
PG 1
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 995MO
UT WOS:000308012402354
ER
PT J
AU Amabile, N
Cheng, S
Larson, MG
Ghorbani, A
Mc Cabe, E
Griffin, G
Cohen, KS
Tedgui, A
Boulanger, CM
Wang, TJ
AF Amabile, N.
Cheng, S.
Larson, M. G.
Ghorbani, A.
Mc Cabe, E.
Griffin, G.
Cohen, K. S.
Tedgui, A.
Boulanger, C. M.
Wang, T. J.
TI Association of circulating endothelial microparticles with
cardiovascular risk factors in the Framingham Heart Study
SO EUROPEAN HEART JOURNAL
LA English
DT Meeting Abstract
CT Congress of the European-Society-of-Cardiology (ESC)
CY AUG 25-29, 2012
CL Munchen, GERMANY
SP European Soc Cardiol (ESC)
C1 [Amabile, N.; Tedgui, A.; Boulanger, C. M.] Paris Cardiovasc Res Ctr PARCC, INSERM, U970, Paris, France.
[Cheng, S.; Larson, M. G.; Wang, T. J.] Framingham Heart Dis Epidemiol Study, Framingham, MA USA.
[Ghorbani, A.] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA.
[Mc Cabe, E.] Boston Univ, Dept Math & Stat, Boston, MA 02215 USA.
[Griffin, G.] Duke Univ, Sch Med, Durham, NC USA.
[Cohen, K. S.] Univ Chicago, Med Ctr, Sect Hematol Oncol, Chicago, IL 60637 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0195-668X
J9 EUR HEART J
JI Eur. Heart J.
PD AUG
PY 2012
VL 33
SU 1
BP 344
EP 344
PG 1
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 995MO
UT WOS:000308012403014
ER
PT J
AU Udell, J
Scirica, BM
Steg, PG
Eagle, KA
Goto, S
Cho, JI
Raz, I
Bhatt, DL
AF Udell, J.
Scirica, B. M.
Steg, P. G.
Eagle, K. A.
Goto, S.
Cho, J. I.
Raz, I.
Bhatt, D. L.
TI Hypoglycemia and cardiovascular risk in diabetic and non-diabetic
outpatients at risk of or with atherothrombosis in the REACH registry
SO EUROPEAN HEART JOURNAL
LA English
DT Meeting Abstract
CT Congress of the European-Society-of-Cardiology (ESC)
CY AUG 25-29, 2012
CL Munchen, GERMANY
SP European Soc Cardiol (ESC)
C1 [Udell, J.; Scirica, B. M.; Cho, J. I.] Harvard Univ, Brigham & Womens Hosp, TIMI Study Grp, Sch Med, Boston, MA 02115 USA.
[Steg, P. G.] AP HP, INSERM, U698, Paris, France.
[Steg, P. G.] Univ Paris 07, Paris, France.
[Eagle, K. A.] Univ Michigan, Div Cardiol, Ann Arbor, MI 48109 USA.
[Goto, S.] Tokai Univ, Sch Med, Isehara, Kanagawa 25911, Japan.
[Raz, I.] Hadassah Hebrew Univ, Med Ctr, Jerusalem, Israel.
[Bhatt, D. L.] Harvard Univ, Brigham & Womens Hosp, Sch Med, VA Boston Healthcare Syst, Boston, MA 02115 USA.
NR 0
TC 4
Z9 4
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0195-668X
J9 EUR HEART J
JI Eur. Heart J.
PD AUG
PY 2012
VL 33
SU 1
BP 359
EP 359
PG 1
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 995MO
UT WOS:000308012403070
ER
PT J
AU Kohli, P
Chakrabarti, A
Bansilal, S
Dangas, G
Nienaber, C
Prats, J
Gibson, CM
AF Kohli, P.
Chakrabarti, A.
Bansilal, S.
Dangas, G.
Nienaber, C.
Prats, J.
Gibson, C. M.
CA TIMI Study Grp
TI Reduction in mortality from thrombin inhibition in CHF patients: results
from the premier hospital database
SO EUROPEAN HEART JOURNAL
LA English
DT Meeting Abstract
CT Congress of the European-Society-of-Cardiology (ESC)
CY AUG 25-29, 2012
CL Munchen, GERMANY
SP European Soc Cardiol (ESC)
C1 [Kohli, P.; Bansilal, S.] Brigham & Womens Hosp, Dept Med, Div Cardiovasc, TIMI Study Grp, Boston, MA 02115 USA.
[Chakrabarti, A.; Gibson, C. M.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
[Dangas, G.] Mt Sinai Hosp, New York, NY 10029 USA.
[Nienaber, C.] Univ Hosp Rostock, Rostock, Germany.
[Prats, J.] Med Co, Parsippany, NJ USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0195-668X
J9 EUR HEART J
JI Eur. Heart J.
PD AUG
PY 2012
VL 33
SU 1
BP 393
EP 393
PG 1
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 995MO
UT WOS:000308012403199
ER
PT J
AU Ducrocq, G
Labreuche, J
Gao, R
Panchenko, E
Liau, CS
Ikeda, Y
Goto, S
Amarenco, P
Bhatt, DL
Steg, PG
AF Ducrocq, G.
Labreuche, J.
Gao, R.
Panchenko, E.
Liau, C. S.
Ikeda, Y.
Goto, S.
Amarenco, P.
Bhatt, D. L.
Steg, P. G.
CA REACH Registry Investigators
TI International differences in outcomes in stable outpatients with
atherothrombosis: Results from the REACH Registry
SO EUROPEAN HEART JOURNAL
LA English
DT Meeting Abstract
CT Congress of the European-Society-of-Cardiology (ESC)
CY AUG 25-29, 2012
CL Munchen, GERMANY
SP European Soc Cardiol (ESC)
C1 [Ducrocq, G.; Labreuche, J.; Amarenco, P.; Steg, P. G.] Hosp Bichat Claude Bernard, AP HP, Paris, France.
[Gao, R.] Cardiovasc Inst, Beijing, Peoples R China.
[Gao, R.] Fuwai Hosp, Beijing, Peoples R China.
[Panchenko, E.] Cardiol Res Ctr, Moscow, Russia.
[Liau, C. S.] Natl Taiwan Univ Hosp, Taipei, Taiwan.
[Ikeda, Y.] Kokura Mem Hosp, Fukuoka, Japan.
[Goto, S.] Tokai Univ, Hiratsuka, Kanagawa 25912, Japan.
[Bhatt, D. L.] Harvard Univ, Brigham & Womens Hosp, Sch Med, TIMI Study Grp, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0195-668X
J9 EUR HEART J
JI Eur. Heart J.
PD AUG
PY 2012
VL 33
SU 1
BP 443
EP 443
PG 1
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 995MO
UT WOS:000308012403388
ER
PT J
AU Focks, JJ
Brouwer, MA
Van Oijen, MGH
Lanas, A
Bhatt, DL
Verheugt, FWA
AF Focks, J. Jaspers
Brouwer, M. A.
Van Oijen, M. G. H.
Lanas, A.
Bhatt, D. L.
Verheugt, F. W. A.
TI Recommendations on the combined use of clopidogrel and proton pump
inhibitors: "Gut feeling" or "State of the heart"?
SO EUROPEAN HEART JOURNAL
LA English
DT Meeting Abstract
CT Congress of the European-Society-of-Cardiology (ESC)
CY AUG 25-29, 2012
CL Munchen, GERMANY
SP European Soc Cardiol (ESC)
C1 [Focks, J. Jaspers; Brouwer, M. A.; Verheugt, F. W. A.] Radboud Univ Nijmegen, Med Ctr, Dept Cardiol, NL-6525 ED Nijmegen, Netherlands.
[Van Oijen, M. G. H.] Univ Calif Los Angeles, Los Angeles, CA USA.
[Lanas, A.] Univ Hosp, CIBERehd, Zaragoza, Spain.
[Bhatt, D. L.] Harvard Univ, Brigham & Womens Hosp, Sch Med, VA Boston Healthcare Syst, Boston, MA 02115 USA.
RI Brouwer, Marc/B-1158-2014; Verheugt, F.W.A./H-8105-2014
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0195-668X
J9 EUR HEART J
JI Eur. Heart J.
PD AUG
PY 2012
VL 33
SU 1
BP 495
EP 495
PG 1
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 995MO
UT WOS:000308012404040
ER
PT J
AU Singh, JP
Shen, J
Chung, ES
Martin, DO
Abraham, WT
Coles, JA
AF Singh, J. P.
Shen, J.
Chung, E. S.
Martin, D. O.
Abraham, W. T.
Coles, J. A., Jr.
TI Clinical response with adaptive CRT algorithm compared with echo guided
AV optimization: a propensity score analysis of multi-center trials
SO EUROPEAN HEART JOURNAL
LA English
DT Meeting Abstract
CT Congress of the European-Society-of-Cardiology (ESC)
CY AUG 25-29, 2012
CL Munchen, GERMANY
SP European Soc Cardiol (ESC)
C1 [Singh, J. P.] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA.
[Shen, J.; Coles, J. A., Jr.] Medtronic Inc, Mounds View, NY USA.
[Chung, E. S.] Christ Hosp, Heart & Vasc Ctr, Cincinnati, OH 45219 USA.
[Martin, D. O.] Cleveland Clin, Cleveland, OH 44106 USA.
[Abraham, W. T.] Ohio State Univ, Columbus, OH 43210 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0195-668X
J9 EUR HEART J
JI Eur. Heart J.
PD AUG
PY 2012
VL 33
SU 1
BP 538
EP 538
PG 1
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 995MO
UT WOS:000308012404197
ER
PT J
AU Ducrocq, G
Amarenco, P
Labreuche, J
Alberts, M
Mas, JL
Ohman, M
Goto, S
Lavallee, P
Bhatt, DL
Steg, PG
AF Ducrocq, G.
Amarenco, P.
Labreuche, J.
Alberts, M.
Mas, J. L.
Ohman, M.
Goto, S.
Lavallee, P.
Bhatt, D. L.
Steg, P. G.
CA REACH Registry Investigators
TI History of stroke in patients with coronary artery disease in the REACH
Registry: impact on cardiovascular and bleeding event rates
SO EUROPEAN HEART JOURNAL
LA English
DT Meeting Abstract
CT Congress of the European-Society-of-Cardiology (ESC)
CY AUG 25-29, 2012
CL Munchen, GERMANY
SP European Soc Cardiol (ESC)
C1 [Ducrocq, G.; Steg, P. G.] Hosp Bichat Claude Bernard, AP HP, Dept Cardiol, Paris, France.
[Amarenco, P.; Labreuche, J.; Lavallee, P.] Hosp Bichat Claude Bernard, AP HP, Dept Neurol, Paris, France.
[Amarenco, P.; Labreuche, J.; Lavallee, P.] Hosp Bichat Claude Bernard, AP HP, Stroke Ctr, Paris, France.
[Alberts, M.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.
[Ohman, M.] Duke Univ, Med Ctr, Durham, NC 27706 USA.
[Mas, J. L.] Hosp St Anne, AP HP, Paris, France.
[Goto, S.] Tokai Univ, Hiratsuka, Kanagawa 25912, Japan.
[Bhatt, D. L.] Harvard Univ, Brigham & Womens Hosp, Sch Med, TIMI Study Grp, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0195-668X
J9 EUR HEART J
JI Eur. Heart J.
PD AUG
PY 2012
VL 33
SU 1
BP 673
EP 674
PG 2
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 995MO
UT WOS:000308012405062
ER
PT J
AU Kohli, P
Steg, PG
Crowley, K
Murphy, SA
Goto, S
Bhatt, DL
AF Kohli, P.
Steg, P. G.
Crowley, K.
Murphy, S. A.
Goto, S.
Bhatt, D. L.
CA TIMI Study Grp
TI NSAID use is associated with an increase in adverse cardiac events:
4-year results from the REACH registry
SO EUROPEAN HEART JOURNAL
LA English
DT Meeting Abstract
CT Congress of the European-Society-of-Cardiology (ESC)
CY AUG 25-29, 2012
CL Munchen, GERMANY
SP European Soc Cardiol (ESC)
C1 [Kohli, P.; Crowley, K.; Murphy, S. A.] Brigham & Womens Hosp, Dept Med, Div Cardiol, TIMI Study Grp, Boston, MA USA.
[Steg, P. G.] Hosp Bichat Claude Bernard, AP HP, Dept Cardiol, Paris, France.
[Goto, S.] Tokai Univ, Sch Med, Isehara, Kanagawa 25911, Japan.
[Bhatt, D. L.] Vet Affairs Med Ctr, TIMI Study Grp, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0195-668X
J9 EUR HEART J
JI Eur. Heart J.
PD AUG
PY 2012
VL 33
SU 1
BP 673
EP 673
PG 1
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 995MO
UT WOS:000308012405061
ER
PT J
AU Berghausen, EM
Vantler, M
Janssen, W
Ten Freyhaus, H
Zhao, JJ
Schermuly, RT
Rosenkranz, S
AF Berghausen, E. M.
Vantler, M.
Janssen, W.
Ten Freyhaus, H.
Zhao, J. J.
Schermuly, R. T.
Rosenkranz, S.
TI The PI 3-kinase isoform p110alpha promotes vascular remodelling in
pulmonary arterial hypertension
SO EUROPEAN HEART JOURNAL
LA English
DT Meeting Abstract
CT Congress of the European-Society-of-Cardiology (ESC)
CY AUG 25-29, 2012
CL Munchen, GERMANY
SP European Soc Cardiol (ESC)
C1 [Berghausen, E. M.; Vantler, M.; Ten Freyhaus, H.; Rosenkranz, S.] Univ Cologne, Dept Internal Med 3, D-50931 Cologne, Germany.
[Janssen, W.] Max Planck Inst Heart & Lung Res, Bad Nauheim, Germany.
[Zhao, J. J.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA.
[Schermuly, R. T.] Univ Giessen, Lung Ctr, Univ Hosp, Giessen, Germany.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0195-668X
J9 EUR HEART J
JI Eur. Heart J.
PD AUG
PY 2012
VL 33
SU 1
BP 753
EP 754
PG 2
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 995MO
UT WOS:000308012405372
ER
PT J
AU Turagam, M
Velagapudi, P
Hanumanthu, VS
Kocheril, A
Holley, J
AF Turagam, M.
Velagapudi, P.
Hanumanthu, V. S.
Kocheril, A.
Holley, J.
TI Continuous furosemide infusion versus furosemide mannitol infusion in
acute congestive heart failure
SO EUROPEAN HEART JOURNAL
LA English
DT Meeting Abstract
CT Congress of the European-Society-of-Cardiology (ESC)
CY AUG 25-29, 2012
CL Munchen, GERMANY
SP European Soc Cardiol (ESC)
C1 [Turagam, M.] Med Coll Wisconsin, Milwaukee, WI 53226 USA.
[Velagapudi, P.] Univ Wisconsin, Dept Med, Madison, WI 53706 USA.
[Hanumanthu, V. S.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Kocheril, A.; Holley, J.] Univ Illinois, Carle Fdn Hosp, Urbana, IL 61801 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0195-668X
J9 EUR HEART J
JI Eur. Heart J.
PD AUG
PY 2012
VL 33
SU 1
BP 807
EP 807
PG 1
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 995MO
UT WOS:000308012406046
ER
PT J
AU Kohli, P
Murphy, SA
Cannon, CP
AF Kohli, P.
Murphy, S. A.
Cannon, C. P.
CA TIMI Study Grp
TI Who funds the evidence in the ESC guidelines: government or industry?
Analysis of class I acute coronary syndrome recommendations from 2011
SO EUROPEAN HEART JOURNAL
LA English
DT Meeting Abstract
CT Congress of the European-Society-of-Cardiology (ESC)
CY AUG 25-29, 2012
CL Munchen, GERMANY
SP European Soc Cardiol (ESC)
C1 [Kohli, P.; Murphy, S. A.; Cannon, C. P.; TIMI Study Grp] Brigham & Womens Hosp, Dept Med, Div Cardiovasc, TIMI Study Grp, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0195-668X
J9 EUR HEART J
JI Eur. Heart J.
PD AUG
PY 2012
VL 33
SU 1
BP 908
EP 909
PG 2
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 995MO
UT WOS:000308012406432
ER
PT J
AU Salomaa, V
Havulinna, AS
Kettunen, J
Eriksson, J
Jula, A
Kontula, K
Newton-Cheh, C
AF Salomaa, V.
Havulinna, A. S.
Kettunen, J.
Eriksson, J.
Jula, A.
Kontula, K.
Newton-Cheh, C.
TI A blood pressure genetic risk score predicts incident cardiovascular
events in 36,950 Finnish individuals
SO EUROPEAN HEART JOURNAL
LA English
DT Meeting Abstract
CT Congress of the European-Society-of-Cardiology (ESC)
CY AUG 25-29, 2012
CL Munchen, GERMANY
SP European Soc Cardiol (ESC)
C1 [Salomaa, V.; Havulinna, A. S.; Kettunen, J.; Eriksson, J.] Natl Inst Hlth & Welf, Helsinki, Finland.
[Jula, A.] Natl Inst Hlth & Welf, Turku, Finland.
[Kontula, K.] Univ Helsinki, Dept Med, Helsinki, Finland.
[Newton-Cheh, C.] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
[Newton-Cheh, C.] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0195-668X
J9 EUR HEART J
JI Eur. Heart J.
PD AUG
PY 2012
VL 33
SU 1
BP 943
EP 943
PG 1
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 995MO
UT WOS:000308012407001
ER
PT J
AU Duivenvoorden, R
Mani, V
Woodward, M
Kallend, D
Suchankova, G
Fuster, V
Rudd, JHF
Tawakol, A
Farkouh, ME
Fayad, ZA
AF Duivenvoorden, R.
Mani, V.
Woodward, M.
Kallend, D.
Suchankova, G.
Fuster, V.
Rudd, J. H. F.
Tawakol, A.
Farkouh, M. E.
Fayad, Z. A.
TI Serum inflammatory biomarkers and plaque inflammation assessed by
[18F]-fluorodeoxyglucose positron emission tomography in the dal-PLAQUE
study: a post-hoc analysis by baseline features
SO EUROPEAN HEART JOURNAL
LA English
DT Meeting Abstract
CT Congress of the European-Society-of-Cardiology (ESC)
CY AUG 25-29, 2012
CL Munchen, GERMANY
SP European Soc Cardiol (ESC)
C1 [Duivenvoorden, R.] Mt Sinai Sch Med, Translat & Mol Imaging Inst, New York, NY USA.
[Woodward, M.] Univ Sydney, George Inst, Sydney, NSW 2006, Australia.
[Kallend, D.; Suchankova, G.] F Hoffmann La Roche & Co Ltd, CH-4002 Basel, Switzerland.
[Fuster, V.] Mt Sinai Sch Med, Cardiovasc Inst, New York, NY USA.
[Rudd, J. H. F.] Univ Cambridge, Div Cardiovasc Med, Cambridge, England.
[Tawakol, A.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Tawakol, A.] Harvard Univ, Sch Med, Boston, MA USA.
[Farkouh, M. E.] Peter Munk Cardiac Ctr, Toronto, ON, Canada.
[Farkouh, M. E.] Li Ka Shing Knowledge Inst, Toronto, ON, Canada.
RI Mani, Venkatesh/B-8939-2011; Woodward, Mark/D-8492-2015
NR 0
TC 0
Z9 0
U1 0
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0195-668X
J9 EUR HEART J
JI Eur. Heart J.
PD AUG
PY 2012
VL 33
SU 1
BP 945
EP 945
PG 1
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 995MO
UT WOS:000308012407011
ER
PT J
AU Piccini, JP
Harrell, F
Lokhnygina, Y
Wang, J
Oppenheimer, L
Patel, MR
Singer, DE
Mahaffey, KW
Fox, KAA
Califf, RM
AF Piccini, J. P.
Harrell, F.
Lokhnygina, Y.
Wang, J.
Oppenheimer, L.
Patel, M. R.
Singer, D. E.
Mahaffey, K. W.
Fox, K. A. A.
Califf, R. M.
CA ROCKET AF Investigators
TI Relationship between center time in therapeutic range and comparative
treatment effect of rivaroxaban and warfarin: results from the ROCKET AF
trial
SO EUROPEAN HEART JOURNAL
LA English
DT Meeting Abstract
CT Congress of the European-Society-of-Cardiology (ESC)
CY AUG 25-29, 2012
CL Munchen, GERMANY
SP European Soc Cardiol (ESC)
C1 [Piccini, J. P.; Lokhnygina, Y.; Patel, M. R.; Mahaffey, K. W.] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC 27706 USA.
[Harrell, F.] Vanderbilt Univ, Nashville, TN USA.
[Wang, J.; Oppenheimer, L.] Johnson & Johnson Pharmaceut Res & Dev, Raritan, NJ USA.
[Singer, D. E.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
[Fox, K. A. A.] Univ Edinburgh, Edinburgh, Midlothian, Scotland.
[Fox, K. A. A.] Royal Infirm Edinburgh NHS Trust, Edinburgh, Midlothian, Scotland.
[Califf, R. M.] Duke Univ, Med Ctr, Duke Translat Med Inst, Durham, NC 27706 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0195-668X
J9 EUR HEART J
JI Eur. Heart J.
PD AUG
PY 2012
VL 33
SU 1
BP 968
EP 969
PG 2
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 995MO
UT WOS:000308012407093
ER
PT J
AU Gaggin, H
Szymonifka, J
Bhardwaj, A
Mohammed, A
Rehman, S
Truong, Q
Januzzi, J
AF Gaggin, H.
Szymonifka, J.
Bhardwaj, A.
Mohammed, A.
Rehman, S.
Truong, Q.
Januzzi, J.
TI Serial measurement of soluble ST2, GDF-15, and highly sensitive troponin
T in patients with chronic heart failure: results from the protect study
SO EUROPEAN HEART JOURNAL
LA English
DT Meeting Abstract
CT Congress of the European-Society-of-Cardiology (ESC)
CY AUG 25-29, 2012
CL Munchen, GERMANY
SP European Soc Cardiol (ESC)
C1 [Gaggin, H.; Szymonifka, J.; Bhardwaj, A.; Mohammed, A.; Rehman, S.; Truong, Q.; Januzzi, J.] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0195-668X
J9 EUR HEART J
JI Eur. Heart J.
PD AUG
PY 2012
VL 33
SU 1
BP 1093
EP 1094
PG 2
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 995MO
UT WOS:000308012407570
ER
PT J
AU Houbballah, R
Raux, M
LaMuraglia, G
AF Houbballah, R.
Raux, M.
LaMuraglia, G.
TI Part Two: Against the Motion. Endovascular Therapy is the Preferred
Treatment for Patients < 65 Years Old with Symptomatic Infrainguinal
Arterial Disease
SO EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY
LA English
DT Editorial Material
ID CRITICAL LIMB ISCHEMIA; LEG BASIL TRIAL; SUPERFICIAL FEMORAL-ARTERY;
LOWER-EXTREMITY BYPASS; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY;
FEMOROPOPLITEAL OCCLUSIVE DISEASE; ISOLATED TIBIAL INTERVENTION;
INTER-SOCIETY CONSENSUS; GRAFT FAILURE; REVASCULARIZATION STRATEGY
C1 [LaMuraglia, G.] Massachusetts Gen Hosp, Gen Surg Serv, Div Vasc & Endovasc Surg, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA 02114 USA.
RP LaMuraglia, G (reprint author), Massachusetts Gen Hosp, Gen Surg Serv, Div Vasc & Endovasc Surg, ACC440,15 Pkman St, Boston, MA 02114 USA.
EM glamuraglia@partners.org
NR 49
TC 1
Z9 1
U1 0
U2 3
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 1078-5884
J9 EUR J VASC ENDOVASC
JI Eur. J. Vasc. Endovasc. Surg.
PD AUG
PY 2012
VL 44
IS 2
BP 116
EP 119
DI 10.1016/j.ejvs.2012.06.012
PG 4
WC Surgery; Peripheral Vascular Disease
SC Surgery; Cardiovascular System & Cardiology
GA 005TC
UT WOS:000308772000003
PM 22878046
ER
PT J
AU Rolfson, O
Strom, O
Karrholm, J
Malchau, H
Garellick, G
AF Rolfson, Ola
Strom, Oskar
Karrholm, Johan
Malchau, Henrik
Garellick, Goran
TI Costs Related to Hip Disease in Patients Eligible for Total Hip
Arthroplasty
SO JOURNAL OF ARTHROPLASTY
LA English
DT Article
DE cost of illness; hip disease; hip osteoarthritis; waiting time; total
hip arthroplasty
ID RHEUMATOID-ARTHRITIS; ECONOMIC BURDEN; OSTEOARTHRITIS; PROJECTIONS;
SURGERY; HEALTH; CARE
AB This study was designed to estimate direct and indirect costs incurred by hip disease in patients eligible for total hip arthroplasty (THA). Before THA, 2635 patients completed a questionnaire regarding the use of resources because of their hip disease. Costs were assigned using official statistical sources or market prices. Annual costs amounted to US$ 7666 per patient. In a regression analysis, higher annual costs were associated with working age, female gender, comorbidity, and operation waiting time more than 90 days (P < .005). The burden of disease for THA candidates is extensive, where loss of productivity is the principal cost. Long wait for surgery is associated with increased costs. This study provides baseline cost data, which will be useful for further health economic analyses and could provide guidance for health care decision makers.
C1 [Rolfson, Ola; Karrholm, Johan; Garellick, Goran] Univ Gothenburg, Dept Orthoped, Inst Clin Sci, Sahlgrenska Acad, Gothenburg, Sweden.
[Strom, Oskar] Karolinska Inst, Med Management Ctr, Stockholm, Sweden.
[Malchau, Henrik] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Orthoped, Boston, MA USA.
RP Rolfson, O (reprint author), Sahlgrenska Univ Hosp Molndal, SE-43182 Molndal, Sweden.
OI Malchau, Henrik/0000-0002-4291-2441; Rolfson, Ola/0000-0001-6534-1242
NR 25
TC 8
Z9 8
U1 0
U2 1
PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS
PI PHILADELPHIA
PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA
SN 0883-5403
J9 J ARTHROPLASTY
JI J. Arthroplast.
PD AUG
PY 2012
VL 27
IS 7
BP 1261
EP 1266
DI 10.1016/j.arth.2011.09.030
PG 6
WC Orthopedics
SC Orthopedics
GA 986CF
UT WOS:000307317100001
PM 22209159
ER
PT J
AU Jones, DL
Bhanegaonkar, AJ
Billings, AA
Kriska, AM
Irrgang, JJ
Crossett, LS
Kwoh, CK
AF Jones, Dina L.
Bhanegaonkar, Abhijeet J.
Billings, Anthony A.
Kriska, Andrea M.
Irrgang, James J.
Crossett, Lawrence S.
Kwoh, C. Kent
TI Differences Between Actual and Expected Leisure Activities After Total
Knee Arthroplasty for Osteoarthritis
SO JOURNAL OF ARTHROPLASTY
LA English
DT Article
DE leisure activities; total knee arthroplasty; osteoarthritis; physical
activity; expectations
ID TOTAL JOINT REPLACEMENT; HEALTH SURVEY SF-36; TOTAL HIP-ARTHROPLASTY;
QUALITY-OF-LIFE; PHYSICAL-ACTIVITY; SELF-EFFICACY; PATIENTS
EXPECTATIONS; PATIENT EXPECTATIONS; OUTCOMES; QUESTIONNAIRE
AB This prospective cohort study determined the type, frequency, intensity, and duration of actual vs expected leisure activity among a cohort undergoing total knee arthroplasty. Data on actual and expected participation in 36 leisure activities were collected preoperatively and at 12 months in 90 patients with knee osteoarthritis. Despite high expectations, there were statistically and clinically significant differences between actual and expected activity at 12 months suggesting that expectations may not have been fulfilled. The differences were equivalent to walking 14 less miles per week than expected, which is more than the amount of activity recommended in national physical activity guidelines. Perhaps an educational intervention could be implemented to help patients establish appropriate and realistic leisure activity expectations before surgery.
C1 [Jones, Dina L.] W Virginia Univ, Sch Med, Dept Orthopaed, Hlth Sci Ctr S, Morgantown, WV 26506 USA.
[Jones, Dina L.] W Virginia Univ, Div Phys Therapy, Sch Med, Hlth Sci Ctr S, Morgantown, WV 26506 USA.
[Bhanegaonkar, Abhijeet J.] W Virginia Univ, Dept Pharmaceut Syst & Policy, Sch Pharm, Morgantown, WV 26506 USA.
[Billings, Anthony A.] W Virginia Univ, Dept Stat, Eberly Coll Arts & Sci, Morgantown, WV 26506 USA.
[Kriska, Andrea M.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA.
[Irrgang, James J.; Crossett, Lawrence S.] Univ Pittsburgh, Dept Orthopaed Surg, Pittsburgh, PA USA.
[Kwoh, C. Kent] Univ Pittsburgh, Div Rheumatol & Clin Immunol, VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
RP Jones, DL (reprint author), W Virginia Univ, Sch Med, Dept Orthopaed, Hlth Sci Ctr S, POB 9196,1 Med Ctr Dr,Room 3603A, Morgantown, WV 26506 USA.
OI Kriska, Andrea/0000-0002-3522-0869
FU American College of Rheumatology Research and Education Foundation
FX This study was funded by a grant from the American College of
Rheumatology Research and Education Foundation.
NR 49
TC 9
Z9 9
U1 2
U2 6
PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS
PI PHILADELPHIA
PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA
SN 0883-5403
J9 J ARTHROPLASTY
JI J. Arthroplast.
PD AUG
PY 2012
VL 27
IS 7
BP 1289
EP 1296
DI 10.1016/j.arth.2011.10.030
PG 8
WC Orthopedics
SC Orthopedics
GA 986CF
UT WOS:000307317100006
PM 22480521
ER
PT J
AU Elias, PZ
Spector, M
AF Elias, Paul Z.
Spector, Myron
TI Viscoelastic characterization of rat cerebral cortex and type I collagen
scaffolds for central nervous system tissue engineering
SO JOURNAL OF THE MECHANICAL BEHAVIOR OF BIOMEDICAL MATERIALS
LA English
DT Article
DE Rat brain; Collagen; Scaffold; Viscoelastic; Mechanical properties
ID BRAIN-INJURY; CROSS-LINKING; GAG SCAFFOLDS; CELL THERAPY; VIVO;
MATRICES; MODEL; LEVEL; VITRO; BIOMECHANICS
AB In the field of tissue engineering and regenerative medicine for the central nervous system, therapeutic strategies may involve implantation of biomaterial scaffolds into the brain. An understanding of the relationship between the brain and the scaffold mechanical properties can help in the selection of a safe and effective biomaterial. This research demonstrates the use of indentation testing along with viscoelastic modeling to characterize and compare mechanical properties of in situ rat cerebral cortex and collagen scaffolds of varying collagen concentration. The stress-relaxation solution for indentation of a viscoelastic material was derived based on a five-element Maxwell model and use of the correspondence principle. Applying the model to experimental stress-relaxation data, the brain was characterized by three shear moduli G(1) = 1.6 +/- 0.10 kPa, G(2) = 2.0 +/- 0.15 kPa, G(3) = 1.8 +/- 0.20 kPa, and two viscosities eta(2) = 11.0 +/- 0.44 kPa.s, eta(3) = 148.7 +/- 6.70 kPa.s, with corresponding relaxation time constants tau(1) = 5.7 +/- 0.3 s and tau(2) = 88.4 +/- 7.6 s. The brain showed average relaxation of 74% from its peak force during loading to an approximately asymptotic force over a 5 minute hold at constant displacement. Collagen scaffolds generally showed increasing trends in the shear moduli, viscosities, and percentage relaxation with increasing collagen concentration. While the brain had similar stiffness to the 1.0% collagen scaffold during the loading phase, the brain's relaxation behavior was distinct from all of the scaffolds. Similarities and differences between the mechanical behavior of the brain and collagen scaffolds of varying collagen concentration are discussed in relation to application of biomaterials for regenerative medicine. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Elias, Paul Z.; Spector, Myron] VA Boston Healthcare Syst, Tissue Engn Labs, Boston, MA 02130 USA.
[Elias, Paul Z.] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
[Spector, Myron] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Orthoped Surg, Boston, MA 02115 USA.
RP Elias, PZ (reprint author), VA Boston Healthcare Syst, Tissue Engn Labs, Mail Stop 151 Res,Room D1-151,150 S Huntington Av, Boston, MA 02130 USA.
EM pzelias@alum.mit.edu
FU U.S. Department of Veterans Affairs, Veterans Health Administration,
Rehabilitation Research and Development Service
FX The research reported here was supported by the U.S. Department of
Veterans Affairs, Veterans Health Administration, Rehabilitation
Research and Development Service. We thank Dr. Simona Socrate and Dr.
Thibault Prevost (MIT Department of Mechanical Engineering) for
assistance with the mechanical testing.
NR 48
TC 14
Z9 14
U1 1
U2 17
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1751-6161
J9 J MECH BEHAV BIOMED
JI J. Mech. Behav. Biomed. Mater.
PD AUG
PY 2012
VL 12
BP 63
EP 73
DI 10.1016/j.jmbbm.2012.03.014
PG 11
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 003QL
UT WOS:000308626300007
PM 22659367
ER
PT J
AU Loewenstein, G
Volpp, KG
Asch, DA
AF Loewenstein, George
Volpp, Kevin G.
Asch, David A.
TI Incentives in Health: Different Prescriptions for Physicians and
Patients EDITORIAL COMMENT
SO OBSTETRICAL & GYNECOLOGICAL SURVEY
LA English
DT Editorial Material
AB Financial incentives in health care are different for physicians and patients. For physicians, financial incentives involve methods of payment for their services. For patients, incentives involve the structuring of health insurance coverage, co-payments, and deductibles. It is often assumed that individuals act according to conventional economic principles and respond directly to changes in incentives in a rational manner. However, in many instances, neither physicians nor patients act rationally. This lack of rationality among patients can be related to the lack of information or to actions that are contrary to their own best interests such as overeating, failure to take medication, or not wearing seatbelts. Rationality is dependent on individual psychological or personality differences, as well as differences in education or income. Whether a medical decision is economically rational or irrational is influenced by differences among individuals in knowledge about alternatives, prior experience in similar decision making, availability of rapid feedback on the consequences of decisions, and the ability to make thoughtful dispassionate decisions or rapid decisions when emotionally stressed.
Rationality is highly relevant to the discussion of the role of incentives in medicine for reducing widespread overuse of low-value services. Compared to physicians paid on a capitated basis, there is a tendency among physicians paid for specific procedures to recommend these procedures more frequently. Improvement in the value of health care spending in the US health care system will require moving away from payment systems that contribute to overuse of high-cost, low-value services, in large part, by exploiting the rationality of physicians.
The primary focus of efforts to address overuse of low-value services should be physicians rather than patients. Insurance payments to physicians for services of low value should be reduced. Coupling lower payment to physicians for low-value services with higher payment for high-value services that are underused could offset the adverse financial effects of this approach. Broad-based physician incentive schemes, such as capitated payment or fee for service, can lead to unintended consequences-too much care with fee-for-service medicine and too little with capitation-that have little regard to value.
Financial incentives for patients using health care services involve substantially different issues than for physicians. Patients receive relatively little useful feedback about the quality of their medical decisions. The behavior of ill and emotionally vulnerable patients can be less than perfectly rational, and it is difficult for them to balance the costs and benefits of alternative tests or treatments in a rational, dispassionate fashion. Patients play a significant role in cost sharing programs. The role of patient cost sharing is different for acute and chronic illnesses. Acutely ill patients are poor targets of cost-sharing incentive programs. Unlike the acutely ill, patients with chronic conditions, who have prior experience in making similar decisions, can make a dispassionate evaluation of costs and benefits and are more appropriate targets of higher cost sharing for low-value services.
It is hoped that financial incentives can change patient behavior (ie, lifestyle changes), thereby improving health care outcomes. There are only limited data on how much measured indicators of health outcomes resulting from changes in patient behaviors can be modified through use of premium-based health incentives. With financial incentives, the intended goals of improved health care at lower cost, while minimizing unintended consequences, can only be achieved through the design and implementation of programs that consider the individual response of patients and physicians to incentives and how they respond in different circumstances.
C1 [Loewenstein, George] Carnegie Mellon Univ, Pittsburgh, PA 15213 USA.
Univ Penn, Wharton Sch, Penn CMU Roybal P30 Ctr Behav Econ & Hlth, Philadelphia, PA 19104 USA.
Univ Penn, Wharton Sch, Leonard Davis Inst Ctr Hlth Incent & Behav Econom, Philadelphia, PA 19104 USA.
Univ Penn, Wharton Sch, Dept Med, Philadelphia, PA 19104 USA.
Univ Penn, Wharton Sch, Dept Hlth Care Management, Philadelphia, PA 19104 USA.
Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equity Res & Promot, Philadelphia, PA USA.
RP Loewenstein, G (reprint author), Carnegie Mellon Univ, Pittsburgh, PA 15213 USA.
NR 0
TC 0
Z9 0
U1 1
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0029-7828
J9 OBSTET GYNECOL SURV
JI Obstet. Gynecol. Surv.
PD AUG
PY 2012
VL 67
IS 8
BP 464
EP 465
DI 10.1097/01.ogx.0000419560.63610.67
PG 2
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 005LG
UT WOS:000308751300006
ER
PT J
AU van Ravesteyn, NT
Miglioretti, DL
Stout, NK
Lee, SJ
Schechter, CB
Buist, DSM
Huang, H
Heijnsdijk, EAM
Trentham-Dietz, A
Alagoz, O
Near, AM
Kerlikowske, K
Nelson, HD
Mandelblatt, JS
de Koning, HJ
AF van Ravesteyn, Nicolien T.
Miglioretti, Diana L.
Stout, Natasha K.
Lee, Sandra J.
Schechter, Clyde B.
Buist, Diana S. M.
Huang, Hui
Heijnsdijk, Eveline A. M.
Trentham-Dietz, Amy
Alagoz, Oguzhan
Near, Aimee M.
Kerlikowske, Karla
Nelson, Heidi D.
Mandelblatt, Jeanne S.
de Koning, Harry J.
TI Tipping the Balance of Benefits and Harms to Favor Screening Mammography
Starting at Age 40 Years: A Comparative Modeling Study of Risk
SO OBSTETRICAL & GYNECOLOGICAL SURVEY
LA English
DT Editorial Material
AB The US Preventive Services Task Force recommends biennial breast cancer mammography screening for women aged 50 to 74 years. A large body of evidence has shown a favorable balance of benefits and harms for screening in this age group. All current guidelines support this recommendation. However, the US Preventive Services Task Force did not recommend routine screening before age 50 based on the high false-positive rate in younger women. A strategy focused on screening only the younger women at greatest risk of breast cancer would address concerns over the high ratio of harm to benefit.
The aim of this comparative modeling study was to determine the threshold relative risk (RR) at which the harm-benefit ratio of starting screening women aged 40 to 49 years equals that of biennial screening for average-risk women aged 50 to 74 years. The effect of screening method (film, digital) and screening interval (annual, biennial) on the threshold RR was also evaluated. Data from the Surveillance, Epidemiology, and End Results program, the Breast Cancer Surveillance Consortium, and the medical literature were used to generate simulation models estimating risk/benefits of screening before and after the age of 50 years. A cohort of women eligible for routine screening who were born in 1960 was simulated and observed throughout their lifetime. Outcome measures evaluated included the following: benefits (life-years gained, breast cancer deaths averted, harms (false-positive mammography findings), and harm-benefit ratios (false-positive findings/life-years gained, false-positive findings/deaths averted).
Screening of women at increased risk for breast cancer results in a more favorable harm-benefit ratio in all models. Starting biennial screening with digital mammography at the age of 40 years in high-risk women (those with a 2-fold increased risk above average) yields the same false-positive findings/life-years gained as biennial screening of average-risk women aged 50 to 74 years [ threshold RR, 1.9 (range across models, 1.5-4.4)]. The model predicts that threshold RRs for annual screening with digital mammography for women aged 40 to 49 years would be 4-fold higher to achieve the same false-positive findings/life-years gained as biennial screening of average-risk women aged 50 to 74 years [ median threshold RR, 4.3 (range, 3.3-10)]. A more favorable harm-benefit ratio was found with the use of film mammography than digital mammography because of the lower false-positive rate for film. There were only small differences between film and digital mammography with respect to benefits of screening. Use of a more comprehensive measure of harm led to a slight change in predicted median threshold RRs. One limitation of the study was the assumption that that the higher risk influenced only the onset of disease and not the screening performance (sensitivity, specificity).
These findings show that harm-benefit ratios for biennial screening mammography in women aged 40 to 49 years with a 2-fold increased risk for breast cancer are comparable to those of average-risk women aged 50 to 74 years. Variations in screening method, interval, and outcome measures influence the threshold RRs required for a favorable harm-benefit ratio.
C1 [van Ravesteyn, Nicolien T.] Erasmus MC, Rotterdam, Netherlands.
Univ Washington, Seattle, WA 98195 USA.
Harvard Univ, Sch Med, Harvard Pilgrim Hlth Care Inst, Boston, MA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Albert Einstein Coll Med, Bronx, NY 10467 USA.
Univ Wisconsin, Madison, WI USA.
Georgetown Univ, Med Ctr, Washington, DC 20007 USA.
Lombardi Comprehens Canc Ctr, Canc Prevent & Control Program, Washington, DC USA.
San Francisco VA Med Ctr, San Francisco, CA USA.
Univ Calif San Francisco, San Francisco, CA 94143 USA.
Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
Providence Hlth & Serv, Providence Canc Ctr, Portland, OR USA.
RP van Ravesteyn, NT (reprint author), Erasmus MC, Rotterdam, Netherlands.
NR 0
TC 0
Z9 0
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0029-7828
J9 OBSTET GYNECOL SURV
JI Obstet. Gynecol. Surv.
PD AUG
PY 2012
VL 67
IS 8
BP 481
EP 482
DI 10.1097/01.ogx.0000418532.21029.ea
PG 2
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 005LG
UT WOS:000308751300015
ER
PT J
AU McMahon, PM
Hazelton, WD
Kimmel, M
Clarke, LD
AF McMahon, Pamela M.
Hazelton, William D.
Kimmel, Marek
Clarke, Lauren D.
TI CISNET Lung Models: Comparison of Model Assumptions and Model Structures
SO RISK ANALYSIS
LA English
DT Article
DE Lung cancer; modeling; population trends; tobacco control
ID CLONAL EXPANSION MODEL; CPS-I DATA; CANCER MORTALITY; MULTISTAGE
CARCINOGENESIS; 2-STAGE MODEL; TEMPORAL VARIATION; SMOKING-CESSATION;
CIGARETTE-SMOKING; 2-MUTATION MODEL; TOBACCO CONTROL
AB Sophisticated modeling techniques can be powerful tools to help us understand the effects of cancer control interventions on population trends in cancer incidence and mortality. Readers of journal articles are, however, rarely supplied with modeling details. Six modeling groups collaborated as part of the National Cancer Institute's Cancer Intervention and Surveillance Modeling Network (CISNET) to investigate the contribution of U.S. tobacco-control efforts toward reducing lung cancer deaths over the period 1975-2000. The six models included in this monograph were developed independently and use distinct, complementary approaches toward modeling the natural history of lung cancer. The models used the same data for inputs, and agreed on the design of the analysis and the outcome measures. This article highlights aspects of the models that are most relevant to similarities of or differences between the results. Structured comparisons can increase the transparency of these complex models.
C1 [McMahon, Pamela M.] Massachusetts Gen Hosp, Inst Technol Assessment, Boston, MA 02114 USA.
[McMahon, Pamela M.] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA.
[Hazelton, William D.] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98104 USA.
[Kimmel, Marek] Rice Univ, Dept Stat, Houston, TX 77251 USA.
[Clarke, Lauren D.] Cornerstone Syst NW, Lynden, WA USA.
RP McMahon, PM (reprint author), Massachusetts Gen Hosp, Inst Technol Assessment, 101 Merrimac St,10th Floor, Boston, MA 02114 USA.
EM pamela@mgh-ita.org
FU CISNET Lung investigators, the National Cancer Institute [R01 CA97337,
R00 CA126147, U01 CA152956]
FX CISNET Lung investigators, the National Cancer Institute (R01 CA97337,
R00 CA126147, U01 CA152956).
NR 63
TC 10
Z9 10
U1 2
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0272-4332
EI 1539-6924
J9 RISK ANAL
JI Risk Anal.
PD AUG
PY 2012
VL 32
SU 1
SI SI
BP S166
EP S178
DI 10.1111/j.1539-6924.2011.01714.x
PG 13
WC Public, Environmental & Occupational Health; Mathematics,
Interdisciplinary Applications; Social Sciences, Mathematical Methods
SC Public, Environmental & Occupational Health; Mathematics; Mathematical
Methods In Social Sciences
GA 986KA
UT WOS:000307339300014
PM 22882887
ER
PT J
AU McMahon, PM
Kong, CY
Johnson, BE
Weinstein, MC
Weeks, JC
Tramontano, AC
Cipriano, LE
Bouzan, C
Gazelle, GS
AF McMahon, Pamela M.
Kong, Chung Yin
Johnson, Bruce E.
Weinstein, Milton C.
Weeks, Jane C.
Tramontano, Angela C.
Cipriano, Lauren E.
Bouzan, Colleen
Gazelle, G. Scott
TI The MGH-HMS Lung Cancer Policy Model: Tobacco Control Versus Screening
SO RISK ANALYSIS
LA English
DT Article
DE Lung cancer; mass screening; microsimulation modeling; tobacco control
ID MULTISTAGE CARCINOGENESIS; MORTALITY; SMOKING; PERIOD; HEALTH; DEATH
AB The natural history model underlying the MGH Lung Cancer Policy Model (LCPM) does not include the two-stage clonal expansion model employed in other CISNET lung models. We used the LCPM to predict numbers of U. S. lung cancer deaths for ages 30-84 between 1975 and 2000 under four scenarios as part of the comparative modeling analysis described in this issue. The LCPM is a comprehensive microsimulation model of lung cancer development, progression, detection, treatment, and survival. Individual-level patient histories are aggregated to estimate cohort or population-level outcomes. Lung cancer states are defined according to underlying disease variables, test results, and clinical events. By simulating detailed clinical procedures, the LCPM can predict benefits and harms attributable to a variety of patient management practices, including annual screening programs. Under the scenario of observed smoking patterns, predicted numbers of deaths from the calibrated LCPM were within 2% of observed over all years (1975-2000). The LCPM estimated that historical tobacco control policies achieved 28.6% (25.2% in men, 30.5% in women) of the potential reduction in U. S. lung cancer deaths had smoking had been eliminated entirely. The hypothetical adoption in 1975 of annual helical CT screening of all persons aged 55-74 with at least 30 pack-years of cigarette exposure to historical tobacco control would have yielded a proportion realized of 39.0% (42.0% in men, 33.3% in women). The adoption of annual screening would have prevented less than half as many lung cancer deaths as the elimination of cigarette smoking.
C1 [McMahon, Pamela M.; Kong, Chung Yin; Tramontano, Angela C.; Cipriano, Lauren E.; Bouzan, Colleen; Gazelle, G. Scott] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[McMahon, Pamela M.; Kong, Chung Yin; Johnson, Bruce E.; Weinstein, Milton C.; Weeks, Jane C.; Gazelle, G. Scott] Harvard Univ, Sch Med, Boston, MA USA.
[Weinstein, Milton C.; Gazelle, G. Scott] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
[Johnson, Bruce E.; Weeks, Jane C.] Dana Farber Canc Inst, Boston, MA 02115 USA.
RP McMahon, PM (reprint author), Inst Technol Assessment, 101 Merrimac St,10th Floor, Boston, MA 02114 USA.
EM pamela@mgh-ita.org
RI Cipriano, Lauren/C-3521-2017
OI Cipriano, Lauren/0000-0001-5568-4516
FU CISNET Lung Investigators; National Cancer Institute [R01 CA97337, R00
CA126147, U01CA152956]; American Cancer Society [RSG 2008A060554]
FX Karen M. Kuntz, Sc.D., David C. Christiani, M.D., M.P.H., CISNET Lung
Investigators, the National Cancer Institute (R01 CA97337, R00 CA126147,
U01CA152956), and the American Cancer Society (RSG 2008A060554).
NR 18
TC 17
Z9 17
U1 1
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0272-4332
EI 1539-6924
J9 RISK ANAL
JI Risk Anal.
PD AUG
PY 2012
VL 32
SU 1
SI SI
BP S117
EP S124
DI 10.1111/j.1539-6924.2011.01652.x
PG 8
WC Public, Environmental & Occupational Health; Mathematics,
Interdisciplinary Applications; Social Sciences, Mathematical Methods
SC Public, Environmental & Occupational Health; Mathematics; Mathematical
Methods In Social Sciences
GA 986KA
UT WOS:000307339300010
PM 22882882
ER
PT J
AU Rosenberg, MA
Feuer, EJ
Yu, BB
Sun, JF
Henley, SJ
Shanks, TG
Anderson, CM
McMahon, PM
Thun, MJ
Burns, DM
AF Rosenberg, Marjorie A.
Feuer, Eric J.
Yu, Binbing
Sun, Jiafeng
Henley, S. Jane
Shanks, Thomas G.
Anderson, Christy M.
McMahon, Pamela M.
Thun, Michael J.
Burns, David M.
TI Cohort Life Tables by Smoking Status, Removing Lung Cancer as a Cause of
Death
SO RISK ANALYSIS
LA English
DT Article
DE Competing risks; life tables; lung cancer and smoking
ID MORTALITY; DISEASE
AB The purpose of this study was to develop life tables by smoking status removing lung cancer as a cause of death. These life tables are inputs to studies that compare the effectiveness of lung cancer treatments or interventions, and provide a way to quantify time until death from causes other than lung cancer. The study combined actuarial and statistical smoothing methods, as well as data from multiple sources, to develop separate life tables by smoking status, birth cohort, by single year of age, and by sex. For current smokers, separate life tables by smoking quintiles were developed based on the average number of cigarettes smoked per day by birth cohort. The end product is the creation of six non-lung-cancer life tables for males and six tables for females: five current smoker quintiles and one for never smokers. Tables for former smokers are linear combinations of the appropriate table based on the current smoker quintile before quitting smoking and the never smoker probabilities, plus added covariates for the smoking quit age and time since quitting.
C1 [Rosenberg, Marjorie A.; Sun, Jiafeng] Univ Wisconsin, Madison, WI 53706 USA.
[Feuer, Eric J.] NCI, Bethesda, MD 20892 USA.
[Yu, Binbing] NIA, Baltimore, MD 21224 USA.
[Henley, S. Jane; Thun, Michael J.] Amer Canc Soc, Atlanta, GA 30329 USA.
[Shanks, Thomas G.; Anderson, Christy M.; Burns, David M.] Univ Calif San Diego, San Diego, CA 92103 USA.
[McMahon, Pamela M.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[McMahon, Pamela M.] Harvard Univ, Sch Med, Boston, MA USA.
RP Rosenberg, MA (reprint author), Univ Wisconsin, 975 Univ Ave, Madison, WI 53706 USA.
EM mrosenberg@bus.wisc.edu
FU NCI [263-MQ-319824, 263-MQ-416726-1]; Clinical and Translational Science
Award (CTSA) program of the National Center for Research Resources,
National Institutes of Health [1UL1RR025011]; Intramural Research
Program of the National Institute on Aging
FX Partially supported by NCI contract numbers 263-MQ-319824 and
263-MQ-416726-1, by Grant 1UL1RR025011 from the Clinical and
Translational Science Award (CTSA) program of the National Center for
Research Resources, National Institutes of Health, and by the Intramural
Research Program of the National Institute on Aging. We acknowledge
Jerry Vaughn of the University of California San Diego for his
contribution on this article.
NR 15
TC 20
Z9 20
U1 0
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0272-4332
J9 RISK ANAL
JI Risk Anal.
PD AUG
PY 2012
VL 32
SU 1
SI SI
BP S25
EP S38
DI 10.1111/j.1539-6924.2011.01662.x
PG 14
WC Public, Environmental & Occupational Health; Mathematics,
Interdisciplinary Applications; Social Sciences, Mathematical Methods
SC Public, Environmental & Occupational Health; Mathematics; Mathematical
Methods In Social Sciences
GA 986KA
UT WOS:000307339300004
PM 22882890
ER
PT J
AU Helenius, J
Arsava, EM
Goldstein, JN
Cestari, DM
Buonanno, FS
Rosen, BR
Ay, H
AF Helenius, Johanna
Arsava, E. Murat
Goldstein, Joshua N.
Cestari, Dean M.
Buonanno, Ferdinando S.
Rosen, Bruce R.
Ay, Hakan
TI Concurrent acute brain infarcts in patients with monocular visual loss
SO ANNALS OF NEUROLOGY
LA English
DT Article
ID CENTRAL RETINAL ARTERY; ISCHEMIC-STROKE; TRANSIENT; HEMORRHAGE;
MANAGEMENT; EMBOLISM; DISEASE
AB Objective: Embolism from a proximal source to the retinal circulation could be a sign of embolism from the same source to the hemispheric circulation. We sought to determine the frequency of acute brain infarcts on diffusion-weighted imaging (DWI) in patients with monocular visual loss of presumed ischemic origin (MVL). Methods: We retrospectively studied 129 consecutive patients with MVL secondary to retinal ischemia. All patients underwent DWI, comprehensive ophthalmologic and neurologic examination, and diagnostic evaluations for the underlying etiology. Statistical analyses explored univariate and multivariate predictors of DWI evidence of acute brain infarcts. Results: DWI revealed concurrent acute brain infarct(s) in 31 of the 129 patients (24%). The probability of positive DWI was higher in embolic versus nonembolic MVL (28 vs 8%, p = 0.04), in MVL characterized by permanent visual loss versus transient symptoms (33 vs 18%, p = 0.04), and in MVL associated with concurrent hemispheric symptoms versus isolated MVL (53 vs 20%, p < 0.01). Patients with positive DWI were more likely to harbor a major underlying etiology as compared to those with normal DWI (odds ratio, 3.7; 95% confidence interval, 1.59.4). Interpretation: This study demonstrates that MVL does not always represent an isolated disease of the retina; approximately 1 of every 4 patients with MVL demonstrates acute brain infarcts on DWI. Because patients with concurrent brain infarcts are more likely to exhibit a cardiac or vascular source of embolism, imaging evidence of brain injury in patients with MVL may be a useful marker to guide the timing and extent of diagnostic examinations. ANN NEUROL 2012;72:286293.
C1 [Helenius, Johanna; Arsava, E. Murat; Rosen, Bruce R.; Ay, Hakan] Harvard Univ, Sch Med, Dept Radiol, AA Martinos Ctr Biomed Imaging,Massachusetts Gen, Boston, MA 02115 USA.
[Goldstein, Joshua N.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Emergency Med, Boston, MA USA.
[Cestari, Dean M.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol, Boston, MA USA.
[Buonanno, Ferdinando S.; Ay, Hakan] Harvard Univ, Sch Med, Dept Neurol, Stroke Serv,Massachusetts Gen Hosp, Boston, MA 02115 USA.
RP Ay, H (reprint author), Massachusetts Gen Hosp, AA Martinos Ctr Biomed Imaging, 13th St,Bldg 149-2301, Charlestown, MA 02129 USA.
EM hay@partners.org
RI Arsava, Ethem Murat/I-9197-2013; Goldstein, Joshua/H-8953-2016
OI Arsava, Ethem Murat/0000-0002-6527-4139;
FU NIH National Institute of Neurological Disorders and Stroke
[R01-NS059710]; Finnish Cultural Foundation; Paulo Foundation;
Orion-Farmos Foundation; Paavo Nurmi Foundation; Emil Aaltonen
Foundation; Finnish Foundation for Cardiovascular Research; National
Institute of Neurological Disorders and Stroke [K23-NS059774]; Finnish
Medical Foundation; Finnish Brain Research Foundation; Maire Taponen
Foundation; Swedish Cultural Foundation in Finland
FX H.A. was funded by NIH National Institute of Neurological Disorders and
Stroke grant R01-NS059710. J.H. was partly supported by the Finnish
Cultural Foundation, Paulo Foundation, Orion-Farmos Foundation, Paavo
Nurmi Foundation, Emil Aaltonen Foundation, and Finnish Foundation for
Cardiovascular Research. J.N.G. was supported by National Institute of
Neurological Disorders and Stroke grant K23-NS059774.; J.H.:
grants/grants pending, Finnish Medical Foundation, Finnish Brain
Research Foundation, Maire Taponen Foundation, and Swedish Cultural
Foundation in Finland.
NR 24
TC 19
Z9 19
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0364-5134
J9 ANN NEUROL
JI Ann. Neurol.
PD AUG
PY 2012
VL 72
IS 2
BP 286
EP 293
DI 10.1002/ana.23597
PG 8
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 994QK
UT WOS:000307946000018
PM 22926859
ER
PT J
AU Wheeler, JM
Guthrie, CR
Kraemer, BC
AF Wheeler, Jeanna M.
Guthrie, Chris R.
Kraemer, Brian C.
TI Potential neuroprotective strategies against tauopathy
SO BIOCHEMICAL SOCIETY TRANSACTIONS
LA English
DT Article
DE autophagy; mammalian suppressor of tau pathology 2 (MSUT2);
neurodegeneration; neuroprotection; tau; tauopathy
ID TAU-INDUCED NEUROTOXICITY; CAENORHABDITIS-ELEGANS; NEUROFIBRILLARY
TANGLES; FRONTOTEMPORAL DEMENTIA; ALZHEIMERS-DISEASE; FTDP-17 MUTATIONS;
IN-VITRO; EXON 10; PROTEIN; AGGREGATION
AB Tauopathies are neurodegenerative diseases, including AD (Alzheimer's disease) and FTLD-T (tau-positive frontotemporal lobar degeneration), with shared pathology presenting as accumulation of detergent-insoluble hyperphosphorylated tau deposits in the central nervous system. The currently available treatments for AD address only some of the symptoms, and do not significantly alter the progression of the disease, namely the development of protein aggregates and loss of functional neurons. The development of effective treatments for various tauopathies will require the identification of common mechanisms of tau neurotoxicity, and pathways that can be modulated to protect against neurodegeneration. Model organisms, such as Caenorhabditis elegans, provide methods for identifying novel genes and pathways that are involved in tau pathology and may be exploited for treatment of various tauopathies. In the present paper, we summarize data regarding characterization of MSUT2 (mammalian suppressor of tau pathology 2), a protein identified in a C. elegans tauopathy model and subsequently shown to modify tau toxicity in mammalian cell culture via the effects on autophagy pathways. MSUT2 represents a potential drug target for prevention of tau-related neurodegeneration.
C1 [Wheeler, Jeanna M.; Guthrie, Chris R.; Kraemer, Brian C.] Vet Affairs Puget Sound Hlth Care Syst, Seattle Div, Ctr Geriatr Res Educ & Clin, Seattle, WA 98108 USA.
[Wheeler, Jeanna M.; Guthrie, Chris R.; Kraemer, Brian C.] Univ Washington, Dept Med, Div Gerontol, Seattle, WA 98195 USA.
[Wheeler, Jeanna M.; Guthrie, Chris R.; Kraemer, Brian C.] Univ Washington, Dept Med, Div Geriatr Med, Seattle, WA 98195 USA.
RP Kraemer, BC (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Seattle Div, Ctr Geriatr Res Educ & Clin, 1660 S Columbian Way, Seattle, WA 98108 USA.
EM kraemerb@u.washington.edu
FU Department of Veterans Affairs Merit Review Grant; National Institute of
Neurological Disorders and Stroke [R01NS064131]
FX This work was supported by a Department of Veterans Affairs Merit Review
Grant and by the National Institute of Neurological Disorders and Stroke
[grant number R01NS064131] (to B.C.K.).
NR 47
TC 1
Z9 1
U1 0
U2 9
PU PORTLAND PRESS LTD
PI LONDON
PA THIRD FLOOR, EAGLE HOUSE, 16 PROCTER STREET, LONDON WC1V 6 NX, ENGLAND
SN 0300-5127
J9 BIOCHEM SOC T
JI Biochem. Soc. Trans.
PD AUG
PY 2012
VL 40
BP 656
EP 660
DI 10.1042/BST20120017
PN 4
PG 5
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 987QH
UT WOS:000307431700011
PM 22817711
ER
PT J
AU Schroy, PC
Coe, AM
Mylvaganam, SR
Ahn, LB
Lydotes, MA
Robinson, PA
Davis, JT
Chen, CA
Ashba, J
Atkinson, ML
Colditz, GA
Heeren, TC
AF Schroy, Paul C., III
Coe, Alison M.
Mylvaganam, Shamini R.
Ahn, Lynne B.
Lydotes, Maria A.
Robinson, Patricia A.
Davis, Julie T.
Chen, Clara A.
Ashba, Jacqueline
Atkinson, Michael L.
Colditz, Graham A.
Heeren, Timothy C.
TI The Your Disease Risk Index for Colorectal Cancer Is an Inaccurate Risk
Stratification Tool for Advanced Colorectal Neoplasia at Screening
Colonoscopy
SO CANCER PREVENTION RESEARCH
LA English
DT Article
ID SERVICES-TASK-FORCE; UNITED-STATES; AVERAGE-RISK; ADENOMATOUS POLYPS;
PRIMARY PREVENTION; PREDICTION TOOL; WHITE PATIENTS; METAANALYSIS;
VALIDATION; CAPACITY
AB Tailoring the use of screening colonoscopy based on the risk of advanced colorectal neoplasia (ACN) could optimize the cost-effectiveness of colorectal cancer (CRC) screening. Our goal was to assess the accuracy of the Your Disease Risk (YDR) CRC risk index for stratifying average risk patients into low-versus intermediate/high-risk categories for ACN. The YDR risk assessment tool was administered to 3,317 asymptomatic average risk patients 50 to 79 years of age just before their screening colonoscopy. Associations between YDR-derived relative risk (RR) scores and ACN prevalence were examined using logistic regression and chi(2) analyses. ACN was defined as a tubular adenoma >= 1 cm, tubulovillous or villous adenoma of any size, and the presence of high-grade dysplasia or cancer. The overall prevalence of ACN was 5.6%. Although YDR-derived RR scores were linearly associated with ACN after adjusting for age and gender (P = 0.033), the index was unable to discriminate "below average" from "above/average" risk patients [OR, 1.01; 95% confidence interval (CI), 0.75-1.37]. Considerable overlap in rates of ACN was also observed between the different YDR risk categories in our age-and gender-stratified analyses. The YDR index lacks accuracy for stratifying average risk patients into low-versus intermediate/high-risk categories for ACN. Cancer Prev Res; 5(8); 1044-52. (C) 2012 AACR.
C1 [Schroy, Paul C., III; Coe, Alison M.; Mylvaganam, Shamini R.; Ahn, Lynne B.; Lydotes, Maria A.; Robinson, Patricia A.; Davis, Julie T.] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA.
[Heeren, Timothy C.] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA.
[Chen, Clara A.; Ashba, Jacqueline] Boston Univ, Sch Publ Hlth, Data Coordinating Ctr, Boston, MA USA.
[Atkinson, Michael L.] Dana Farber Canc Inst, Channing Lab, Boston, MA 02115 USA.
[Colditz, Graham A.] Washington Univ, Sch Med, Prevent & Control Siteman Canc Ctr, St Louis, MO USA.
RP Schroy, PC (reprint author), Boston Med Ctr, 85 E Concord St,Suite 7715, Boston, MA 02118 USA.
EM paul.schroy@bmc.org
RI Colditz, Graham/A-3963-2009;
OI Colditz, Graham/0000-0002-7307-0291; Heeren, Timothy/0000-0001-5643-3559
FU National Cancer Institute [R01 CA131197]
FX The study was supported by the National Cancer Institute Award R01
CA131197 (to P. C. Schroy III)
NR 42
TC 13
Z9 13
U1 0
U2 9
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1940-6207
J9 CANCER PREV RES
JI Cancer Prev. Res.
PD AUG
PY 2012
VL 5
IS 8
BP 1044
EP 1052
DI 10.1158/1940-6207.CAPR-12-0014
PG 9
WC Oncology
SC Oncology
GA 998FS
UT WOS:000308223500007
PM 22689913
ER
PT J
AU Casement, MD
Swanson, LM
AF Casement, Melynda D.
Swanson, Leslie M.
TI A meta-analysis of imagery rehearsal for post-trauma nightmares: Effects
on nightmare frequency, sleep quality, and posttraumatic stress
SO CLINICAL PSYCHOLOGY REVIEW
LA English
DT Article
DE Imagery rehearsal therapy; Rescripting therapy; Nightmares; Sleep;
Post-traumatic stress
ID SEXUAL ASSAULT SURVIVORS; COGNITIVE-BEHAVIORAL THERAPY; RANDOMIZED
CONTROLLED-TRIAL; DISORDER; PTSD; VETERANS; DISTURBANCE; INSOMNIA;
IMPAIRMENT; INSTRUMENT
AB This meta-analysis evaluates the efficacy of imagery rehearsal as a treatment for nightmares, general sleep disturbance, and symptoms of post-traumatic stress. Bibliographic databases and cited references were searched to identify clinical trials of imagery rehearsal in individuals with post-trauma nightmares. Thirteen studies met inclusion criteria and reported sleep and post-traumatic stress outcomes in sufficient detail to calculate effect sizes. Results indicate that imagery rehearsal had large effects on nightmare frequency, sleep quality, and PTSD symptoms from the initial to post-treatment assessments. These effects were sustained through 6 to 12 months follow-up. Furthermore, interventions that included both imagery rehearsal and cognitive behavioral therapy for insomnia resulted in greater treatment-related improvement in sleep quality than imagery rehearsal alone. Combined treatment did not improve outcomes for PTSD or nightmares. Notably, effect sizes were small in the single study that included an active-treatment control condition. Future research should identify necessary and sufficient components of interventions for trauma-related sleep disturbance and post-traumatic stress (e.g., exposure, cognitive reappraisal, sleep and circadian regulation). Published by Elsevier Ltd.
C1 [Casement, Melynda D.] VA Boston Healthcare Syst, Natl Ctr Posttraumat Stress Disorder, Boston, MA USA.
[Casement, Melynda D.] Boston Univ, Med Ctr, Boston, MA USA.
[Swanson, Leslie M.] Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA.
RP Casement, MD (reprint author), Univ Pittsburgh, Western Psychiat Inst & Clin, Med Ctr, 3811 OHara St,Keystone 310, Pittsburgh, PA 15213 USA.
EM casementmd@upmc.edu
OI Casement, Melynda/0000-0002-5906-0994
FU NIMH NIH HHS [T32 MH019836, T32MH019836]
NR 53
TC 33
Z9 33
U1 4
U2 29
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0272-7358
J9 CLIN PSYCHOL REV
JI Clin. Psychol. Rev.
PD AUG
PY 2012
VL 32
IS 6
BP 566
EP 574
DI 10.1016/j.cpr.2012.06.002
PG 9
WC Psychology, Clinical
SC Psychology
GA 995XW
UT WOS:000308049600012
PM 22819998
ER
PT J
AU Koshkareva, YA
Cohen, M
Gaughan, JP
Callanan, V
Szeremeta, W
AF Koshkareva, Yekaterina A.
Cohen, Michael
Gaughan, John P.
Callanan, Vincent
Szeremeta, Wasyl
TI Utility of preoperative hematologic screening for pediatric
adenotonsillectomy
SO ENT-EAR NOSE & THROAT JOURNAL
LA English
DT Article
ID LUPUS ANTICOAGULANT SYNDROME; POST-TONSILLECTOMY; HEMOSTATIC ASSESSMENT;
COAGULATION; HEMORRHAGE; CHILDREN; ADENOIDECTOMY; PREDICTOR; HISTORY
AB We conducted a 3-year retrospective study to examine the results of preoperative hematologic screening, the incidence of postoperative bleeding, and the possible relationship between the two factors in patients who had undergone tonsillectomy with or without adenoidectomy. Our study population was made up of 875 patients-441 boys and 434 girls, aged 2 to 18 years (mean: 7.52 +/- 4.25)-who had been treated at our institution from January 2004 through December 2006. In addition to demographic data, we compiled information on each patient's medical and surgical history, personal and family history of abnormal bleeding, indication for tonsillectomy, and preoperative hematologic screening results. The latter included determinations of the prothrombin time, activated partial thromboplastin time, international normalized ratio (INR), and platelet count. A total of 748 patients (85.5%) had normal findings on preoperative hematologic screening, and 127(14.5%) had at least one abnormality. Postoperatively, hemorrhagic complications occurred in 31 children (3.5%)-in 22 of the 748 patients with normal screening results (2.9%) and in 9 of the 127 with a screening abnormality (7.1%); the difference between the two groups was statistically significant (p = 0.041). The abnormalities in the latter group consisted of an elevated INR but no otherwise identifiable coagulopathy. Another 14 patients with an abnormal screening result (11.0%) were found to have at least one coagulopathy that was newly diagnosed during our preoperative evaluation; they were treated perioperatively, and none bled postoperatively. Of 21 patients who had a personal or family history of abnormal bleeding, 5 (23.8%) were found to have a coagulopathy, but none bled following surgery. In conclusion, we found that preoperative hematologic screening identified patients with undiagnosed coagulopathies, and with appropriate treatment our surgeons were able to prevent some bleeding events in these patients. Our finding that patients with a mildly elevated INR had a higher incidence of postoperative hemorrhage warrants further study.
C1 [Koshkareva, Yekaterina A.] Univ Pittsburgh, Med Ctr, Dept Otolaryngol, Pittsburgh, PA 15213 USA.
[Cohen, Michael] Massachusetts Eye & Ear Infirm, ENT Serv, Boston, MA 02114 USA.
[Gaughan, John P.] Temple Univ, Sch Med, Biostat Consulting Ctr, Philadelphia, PA 19122 USA.
[Callanan, Vincent] Women & Childrens Hosp Buffalo, Dept Pediat Otolaryngol Head & Neck Surg, Buffalo, NY USA.
[Szeremeta, Wasyl] SUNY Stony Brook, Dept Surg, Div Otolaryngol Head & Neck Surg, Med Ctr, Stony Brook, NY 11794 USA.
Temple Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Philadelphia, PA 19122 USA.
RP Koshkareva, YA (reprint author), Univ Pittsburgh, Med Ctr, Dept Otolaryngol, 200 Lothrop St,EI 500, Pittsburgh, PA 15213 USA.
EM koshkarevaye@ph.upmc.edu
NR 23
TC 1
Z9 1
U1 0
U2 1
PU VENDOME GROUP LLC
PI NEW YORK
PA 149 FIFTH AVE, 10TH FLOOR, NEW YORK, NY 10010 USA
SN 0145-5613
J9 ENT-EAR NOSE THROAT
JI ENT-Ear Nose Throat J.
PD AUG
PY 2012
VL 91
IS 8
BP 346
EP +
PG 6
WC Otorhinolaryngology
SC Otorhinolaryngology
GA 994HG
UT WOS:000307920900010
PM 22930084
ER
PT J
AU Tanaka, M
Bailey, JN
Bai, DS
Ishikawa-Brush, Y
Delgado-Escueta, AV
Olsen, RW
AF Tanaka, Miyabi
Bailey, Julia N.
Bai, Dongsheng
Ishikawa-Brush, Yumiko
Delgado-Escueta, Antonio V.
Olsen, Richard W.
TI Effects on promoter activity of common SNPs in 5 ' region of GABRB3 exon
1A
SO EPILEPSIA
LA English
DT Article
DE Luciferase activity; rs20317; rs4906902; Epigenetic modulator REST;
Childhood absence epilepsy
ID CHILDHOOD ABSENCE EPILEPSY; GABA(A) RECEPTOR; TARGET GENES; REST;
SUBUNIT; GENOME; IDENTIFICATION; DISORDERS; REPRESSOR; ELEMENT
AB Purpose: The beta 3 subunit of the c-aminobutyric acid type A receptors (GABA(A)-Rs) is an essential component of GABA(A)-Rs in fetal, perinatal, and adult mammalian brain. Various transcripts of the beta 3 subunit gene (GABRB3) produce various proteins with different N-termini. Rare variants in this N-terminus (exon 1A and exon 2) of GABRB3 protein segregate in affected family members of two multigeneration-multiplex families with remitting childhood absence epilepsy (rCAE), suggesting GABRB3 is a major Mendelian epilepsy gene for rare families with CAE. Therefore, the N-terminus of GABRB3 could be important for GABRB3 regulation in development, and its alteration could produce rCAE. Herein we determine if single nucleotide polymorphisms (SNPs) within the 1,148-bp region upstream from exon 1A influence the expression of GABRB3.
Methods: We studied luciferase reporter expression for promoter activity, 1,148-bp upstream from exon 1A, using human embryonic kidney 293 cells. We generated constructs of the promoter region and compared different SNP haplotypes in 48 patients with rCAE. Next, we compared frequencies of rs20317, located in the core promoter region, and rs4906902, located in the enhancer region between 48 patients with rCAE and >500 healthy controls matched for ethnicity and ancestral origin.
Key Findings: Highest luciferase expression occurred 230-bp upstream of exon 1A. The construct that excluded this region lost luciferase activity. Therefore, this region contains the core promoter of exon 1A. Allele C but not allele G (rs20317) significantly increased luciferase expression activity. Allele C creates binding motifs for cMYB and EGR-3. Longer constructs overlapping this region have a binding motif for REST (RE1-silencing transcription factor), a critical epigenetic modulator for neuronal genes. REST represses expression of neuronal genes in nonneuronal tissues, resulting in reduced luciferase expression activity. Even in the suppressed condition, the longer construct enhanced luciferase expression activity of the shorter construct, which excluded the distal end containing rs4906902. However, allele frequencies of rs20317 and rs4906902 were not significantly associated with 48 rCAE patients in comparison to >500 controls matched for ethnicity and ancestral origin.
Significance: Common SNPs in the promoter region increase luciferase expression activity. An epigenetic modulator, REST, specifically alters expression of GABRB3 exon 1A transcripts, suggesting epigenetic regulation by REST dominantly controls the expression of GABRB3 variant 2 transcript in early life GABA(A) signaling. Abnormal epigenetic regulation could be involved in absence seizures.
C1 [Tanaka, Miyabi; Olsen, Richard W.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA.
[Tanaka, Miyabi; Bailey, Julia N.; Bai, Dongsheng; Delgado-Escueta, Antonio V.] Vet Affairs Greater Los Angeles Healthcare Syst, Genom Lab, Neurol & Res Serv, Los Angeles, CA USA.
[Bailey, Julia N.] Univ Calif Los Angeles, Dept Epidemiol, Sch Publ Hlth, Los Angeles, CA 90095 USA.
[Bai, Dongsheng; Delgado-Escueta, Antonio V.] Univ Calif Los Angeles, Dept Neurol, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Ishikawa-Brush, Yumiko] Univ Calif San Francisco, Ernest Gallo Clin & Res Ctr, San Francisco, CA 94143 USA.
RP Olsen, RW (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA.
EM escueta@ucla.edu; rolsen@mednet.ucla.edu
OI Delgado-Escueta, Antonio V./0000-0002-1581-6999
FU National Institutes of Health [NS35985]; National Institutes of Health
NINDS [NS055057]; Veterans Administration Merit Review Grant
FX We thank all CAE patients and their families for their cooperation,
GENESS site neurologists and staff for their help, Ziwei Chen for
helpful advice, the J Huang laboratory, and Computational Sciences
Group, UCLA Pharmacology Dept, for their cooperation. This work was
supported by National Institutes of Health Grant NS35985 to RWO; by
National Institutes of Health NINDS Grant NS055057 to AVDE, and a
Veterans Administration Merit Review Grant to AVDE.
NR 21
TC 7
Z9 8
U1 0
U2 11
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0013-9580
J9 EPILEPSIA
JI Epilepsia
PD AUG
PY 2012
VL 53
IS 8
BP 1450
EP 1456
DI 10.1111/j.1528-1167.2012.03572.x
PG 7
WC Clinical Neurology
SC Neurosciences & Neurology
GA 001EI
UT WOS:000308442800026
PM 22765836
ER
PT J
AU Jiwani, AZ
Rhee, DJ
Brauner, SC
Gardiner, MF
Chen, TC
Shen, LQ
Chen, SH
Grosskreutz, CL
Chang, KK
Kloek, CE
Greenstein, SH
Borboli-Gerogiannis, S
Pasquale, DL
Chaudhry, S
Loomis, S
Wiggs, JL
Pasquale, LR
Turalba, AV
AF Jiwani, A. Z.
Rhee, D. J.
Brauner, S. C.
Gardiner, M. F.
Chen, T. C.
Shen, L. Q.
Chen, S. H.
Grosskreutz, C. L.
Chang, K. K.
Kloek, C. E.
Greenstein, S. H.
Borboli-Gerogiannis, S.
Pasquale, D. L.
Chaudhry, S.
Loomis, S.
Wiggs, J. L.
Pasquale, L. R.
Turalba, A. V.
TI Effects of caffeinated coffee consumption on intraocular pressure,
ocular perfusion pressure, and ocular pulse amplitude: a randomized
controlled trial
SO EYE
LA English
DT Article
DE caffeine; coffee; intraocular pressure; ocular perfusion pressure;
ocular pulse amplitude; primary open-angle glaucoma
ID OPEN-ANGLE GLAUCOMA; BLOOD-PRESSURE; RISK-FACTORS; NORMAL-TENSION;
BARBADOS EYE; LONG-TERM; HYPERTENSION; POPULATION; ADENOSINE; DISEASE
AB Purpose To examine the effects of caffeinated coffee consumption on intraocular pressure (IOP), ocular perfusion pressure (OPP), and ocular pulse amplitude (OPA) in those with or at risk for primary open-angle glaucoma (POAG).
Methods We conducted a prospective, double-masked, crossover, randomized controlled trial with 106 subjects: 22 with high tension POAG, 18 with normal tension POAG, 20 with ocular hypertension, 21 POAG suspects, and 25 healthy participants. Subjects ingested either 237 ml of caffeinated (182mg caffeine) or decaffeinated (4mg caffeine) coffee for the first visit and the alternate beverage for the second visit. Blood pressure (BP) and pascal dynamic contour tonometer measurements of IOP, OPA, and heart rate were measured before and at 60 and 90 min after coffee ingestion per visit. OPP was calculated from BP and IOP measurements.
Results were analysed using paired t-tests. Multivariable models assessed determinants of IOP, OPP, and OPA changes. Results There were no significant differences in baseline IOP, OPP, and OPA between the caffeinated and decaffeinated visits. After caffeinated as compared with decaffeinated coffee ingestion, mean mmHg changes (+/- SD) in IOP, OPP, and OPA were as follows: 0.99 (+/- 1.52, P<0.0001), 1.57 (+/- 6.40, P = 0.0129), and 0.23 (+/- 0.52, P<0.0001) at 60 min, respectively; and 1.06 (+/- 1.67, P<0.0001), 1.26 (+/- 6.23, P = 0.0398), and 0.18 (+/- 0.52, P = 0.0006) at 90 min, respectively. Regression analyses revealed sporadic and inconsistent associations with IOP, OPP, and OPA changes.
Conclusion Consuming one cup of caffeinated coffee (182mg caffeine) statistically increases, but likely does not clinically impact, IOP and OPP in those with or at risk for POAG. Eye (2012) 26, 1122-1130; doi:10.1038/eye.2012.113; published online 8 June 2012
C1 [Jiwani, A. Z.; Rhee, D. J.; Brauner, S. C.; Gardiner, M. F.; Chen, T. C.; Shen, L. Q.; Chen, S. H.; Grosskreutz, C. L.; Chang, K. K.; Kloek, C. E.; Greenstein, S. H.; Borboli-Gerogiannis, S.; Pasquale, D. L.; Loomis, S.; Wiggs, J. L.; Pasquale, L. R.; Turalba, A. V.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Boston, MA 02114 USA.
[Jiwani, A. Z.] Yale Univ, Sch Med, New Haven, CT USA.
[Chaudhry, S.] Univ Maryland, Sch Med, Baltimore, MD 21201 USA.
RP Pasquale, LR (reprint author), Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, 243 Charles St, Boston, MA 02114 USA.
EM louis_pasquale@meei.harvard.edu
OI Gardiner, Matthew/0000-0002-8864-2379
FU Fight for Sight Postdoctoral Grant; Doris Duke Charitable Foundation;
Yale School of Medicine Summer Fellowship; Research to Prevent Blindness
Physician Scientist Award; Harvard Medical School Ophthalmology Scholar
Award; Allergan Horizon Award
FX This work was supported by a Fight for Sight Postdoctoral Grant (Angela
V Turalba). Aliya Z Jiwani is funded by a Doris Duke Charitable
Foundation One-Year Clinical Research Fellowship and a Yale School of
Medicine Summer Fellowship. Louis R Pasquale is supported by a Research
to Prevent Blindness Physician Scientist Award, Harvard Medical School
Ophthalmology Scholar Award, and an Allergan Horizon Award.
NR 55
TC 7
Z9 8
U1 0
U2 26
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
J9 EYE
JI Eye
PD AUG
PY 2012
VL 26
IS 8
BP 1122
EP 1130
DI 10.1038/eye.2012.113
PG 9
WC Ophthalmology
SC Ophthalmology
GA 991TW
UT WOS:000307726000017
PM 22678051
ER
PT J
AU Ogino, S
Giovannucci, E
AF Ogino, Shuji
Giovannucci, Edward
TI Commentary: Lifestyle factors and colorectal cancer microsatellite
instability-molecular pathological epidemiology science, based on unique
tumour principle
SO INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
LA English
DT Editorial Material
ID ISLAND METHYLATOR PHENOTYPE; ACID SYNTHASE EXPRESSION; BODY-MASS INDEX;
COLON-CANCER; RISK; ASSOCIATIONS; SURVIVAL; FIELD; DIET
C1 [Ogino, Shuji] Brigham & Womens Hosp, Dana Farber Canc Inst, Ctr Mol Oncol Pathol, Dept Pathol, Boston, MA 02215 USA.
[Ogino, Shuji; Giovannucci, Edward] Dana Farber Harvard Canc Ctr, Canc Epidemiol Program, Boston, MA USA.
[Ogino, Shuji] Harvard Univ, Sch Med, Boston, MA USA.
[Ogino, Shuji] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Ogino, Shuji; Giovannucci, Edward] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Giovannucci, Edward] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
[Giovannucci, Edward] Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA 02215 USA.
RP Ogino, S (reprint author), Brigham & Womens Hosp, Dana Farber Canc Inst, Ctr Mol Oncol Pathol, Dept Pathol, 450 Brookline Ave,Room JF-215C, Boston, MA 02215 USA.
EM shuji_ogino@dfci.harvard.edu
FU NCI NIH HHS [R01 CA151993, P01 CA55075, P01 CA87969]
NR 22
TC 20
Z9 22
U1 0
U2 4
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0300-5771
J9 INT J EPIDEMIOL
JI Int. J. Epidemiol.
PD AUG
PY 2012
VL 41
IS 4
BP 1072
EP 1074
DI 10.1093/ije/dys076
PG 3
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 998IV
UT WOS:000308232200025
PM 22596930
ER
PT J
AU Kitahara, CM
Wang, SS
Melin, BS
Wang, ZM
Braganza, M
Inskip, PD
Albanes, D
Andersson, U
Freeman, LEB
Buring, JE
Carreon, T
Feychting, M
Gapstur, SM
Gaziano, JM
Giles, GG
Hallmans, G
Hankinson, SE
Henriksson, R
Hsing, AW
Johansen, C
Linet, MS
McKean-Cowdin, R
Michaud, DS
Peters, U
Purdue, MP
Rothman, N
Ruder, AM
Sesso, HD
Severi, G
Shu, XO
Stevens, VL
Visvanathan, K
Waters, MA
White, E
Wolk, A
Zeleniuch-Jacquotte, A
Zheng, W
Hoover, R
Fraumeni, JF
Chatterjee, N
Yeager, M
Chanock, SJ
Hartge, P
Rajaraman, P
AF Kitahara, Cari M.
Wang, Sophia S.
Melin, Beatrice S.
Wang, Zhaoming
Braganza, Melissa
Inskip, Peter D.
Albanes, Demetrius
Andersson, Ulrika
Freeman, Laura E. Beane
Buring, Julie E.
Carreon, Tania
Feychting, Maria
Gapstur, Susan M.
Gaziano, J. Michael
Giles, Graham G.
Hallmans, Goran
Hankinson, Susan E.
Henriksson, Roger
Hsing, Ann W.
Johansen, Christoffer
Linet, Martha S.
McKean-Cowdin, Roberta
Michaud, Dominique S.
Peters, Ulrike
Purdue, Mark P.
Rothman, Nathaniel
Ruder, Avima M.
Sesso, Howard D.
Severi, Gianluca
Shu, Xiao-Ou
Stevens, Victoria L.
Visvanathan, Kala
Waters, Martha A.
White, Emily
Wolk, Alicja
Zeleniuch-Jacquotte, Anne
Zheng, Wei
Hoover, Robert
Fraumeni, Joseph F., Jr.
Chatterjee, Nilanjan
Yeager, Meredith
Chanock, Stephen J.
Hartge, Patricia
Rajaraman, Preetha
TI Association between adult height, genetic susceptibility and risk of
glioma
SO INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
LA English
DT Article
DE Height; brain cancer; glioma; cancer; epidemiology
ID BASE-LINE CHARACTERISTICS; BODY-MASS INDEX; GENOME-WIDE ASSOCIATION;
CANCER-RISK; PROSPECTIVE COHORT; WOMENS HEALTH; LEG LENGTH; GROWTH;
MORTALITY; DESIGN
AB Background Some, but not all, observational studies have suggested that taller stature is associated with a significant increased risk of glioma. In a pooled analysis of observational studies, we investigated the strength and consistency of this association, overall and for major sub- types, and investigated effect modification by genetic susceptibility to the disease.
Methods We standardized and combined individual-level data on 1354 cases and 4734 control subjects from 13 prospective and 2 case-control studies. Pooled odds ratios (ORs) and 95% confidence intervals (CIs) for glioma and glioma sub-types were estimated using logistic regression models stratified by sex and adjusted for birth cohort and study. Pooled ORs were additionally estimated after stratifying the models according to seven recently identified glioma-related genetic variants.
Results Among men, we found a positive association between height and glioma risk (epsilon 190 vs 170-174 cm, pooled OR = 1.70, 95% CI: 1.11-2.61; P-trend = 0.01), which was slightly stronger after restricting to cases with glioblastoma (pooled OR = 1.99, 95% CI: 1.17-3.38; P-trend = 0.02). Among women, these associations were less clear (epsilon 175 vs 160-164 cm, pooled OR for glioma = 1.06, 95% CI: 0.70-1.62; P-trend = 0.22; pooled OR for glioblastoma = 1.36, 95% CI: 0.77-2.39; P-trend = 0.04). In general, we did not observe evidence of effect modification by glioma-related genotypes on the association between height and glioma risk.
Conclusion An association of taller adult stature with glioma, particularly for men and stronger for glioblastoma, should be investigated further to clarify the role of environmental and genetic determinants of height in the etiology of this disease.
C1 [Kitahara, Cari M.; Wang, Zhaoming; Braganza, Melissa; Inskip, Peter D.; Albanes, Demetrius; Freeman, Laura E. Beane; Hsing, Ann W.; Linet, Martha S.; Purdue, Mark P.; Rothman, Nathaniel; Hoover, Robert; Fraumeni, Joseph F., Jr.; Chatterjee, Nilanjan; Yeager, Meredith; Chanock, Stephen J.; Hartge, Patricia; Rajaraman, Preetha] NCI, Div Canc Epidemiol & Genet, Rockville, MD 20852 USA.
[Wang, Sophia S.] City Hope Natl Med Ctr, Dept Populat Sci, Div Canc Etiol, Duarte, CA USA.
[Wang, Sophia S.] City Hope Natl Med Ctr, Beckman Res Inst, Duarte, CA 91010 USA.
[Melin, Beatrice S.; Andersson, Ulrika; Henriksson, Roger] Umea Univ, Dept Radiat Sci, Umea, Sweden.
[Wang, Zhaoming; Yeager, Meredith; Chanock, Stephen J.] NCI, Core Genotyping Facil, SAIC Frederick Inc, Gaithersburg, MD USA.
[Buring, Julie E.; Gaziano, J. Michael; Sesso, Howard D.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Prevent Med, Boston, MA 02115 USA.
[Carreon, Tania; Ruder, Avima M.; Waters, Martha A.] NIOSH, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA.
[Feychting, Maria; Wolk, Alicja] Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden.
[Gapstur, Susan M.; Stevens, Victoria L.] Amer Canc Soc, Epidemiol Res Program, Atlanta, GA 30329 USA.
[Gaziano, J. Michael; Sesso, Howard D.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Aging, Boston, MA 02115 USA.
[Gaziano, J. Michael] VA Boston Healthcare Syst, Massachusetts Vet Epidemiol Res & Informat Ctr, Geriatr Res Educ & Clin Ctr, Boston, MA USA.
[Giles, Graham G.; Severi, Gianluca] Canc Council Victoria, Canc Epidemiol Ctr, Melbourne, Vic, Australia.
[Giles, Graham G.; Severi, Gianluca] Univ Melbourne, Ctr Mol Environm Genet & Analyt Epidemiol, Melbourne, Vic, Australia.
[Hallmans, Goran] Umea Univ, Dept Publ Hlth & Clin Med Nutr Res, Umea, Sweden.
[Hankinson, Susan E.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Channing Lab, Boston, MA 02115 USA.
[Henriksson, Roger] Karolinska Univ Hosp, Dept Oncol, Stockholm, Sweden.
[Johansen, Christoffer] Danish Canc Soc, Unit Survivorship, Copenhagen, Denmark.
[McKean-Cowdin, Roberta] Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA.
[Michaud, Dominique S.] Brown Univ, Dept Epidemiol, Providence, RI 02912 USA.
[Peters, Ulrike; White, Emily] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
[Peters, Ulrike; White, Emily] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
[Shu, Xiao-Ou; Zheng, Wei] Vanderbilt Univ, Med Ctr, Dept Med, Div Epidemiol, Nashville, TN USA.
[Visvanathan, Kala] Johns Hopkins Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
[Visvanathan, Kala] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA.
[Zeleniuch-Jacquotte, Anne] NYU, Dept Environm Med, Sch Med, Div Epidemiol, New York, NY 10016 USA.
RP Kitahara, CM (reprint author), NCI, Div Canc Epidemiol & Genet, EPS 7053,6120 Execut Blvd, Rockville, MD 20852 USA.
EM kitaharac@mail.nih.gov
RI Ruder, Avima/I-4155-2012; Michaud, Dominique/I-5231-2014; Albanes,
Demetrius/B-9749-2015; Purdue, Mark/C-9228-2016; Beane Freeman,
Laura/C-4468-2015; Kitahara, Cari/R-8267-2016;
OI Ruder, Avima/0000-0003-0419-6664; Purdue, Mark/0000-0003-1177-3108;
Beane Freeman, Laura/0000-0003-1294-4124; Giles,
Graham/0000-0003-4946-9099; Zeleniuch-Jacquotte,
Anne/0000-0001-9350-1303
FU NCI, National Institutes of Health; American Cancer Society; Centers for
Disease Control and Prevention's National Program of Cancer Registries
and cancer registries; National Cancer Institute's Surveillance
Epidemiology and End Results Program; National Cancer Institute [R01
CA098661, P30 CA016087]; National Institute of Environmental Health
Sciences [ES000260]; National Institutes of Health [CA 97193, CA 34944,
CA 40360, HL 26490, HL 34595]; State of Maryland; Maryland Cigarette
Restitution Fund; National Program of Cancer Registries of the Centers
for Disease Control and Prevention; Division of Cancer Epidemiology and
Genetics; Division of Cancer Prevention, NCI, National Institutes of
Health (NIH); Department of Health and Human Services (DHHS); VicHealth;
Australian National Health and Medical Research Council [209057, 251533,
396414]; NCI [K05CA154337]; NIH Office of Dietary Supplements (ODS)
FX This work was supported in part by the Intramural Research Program of
the NCI, National Institutes of Health.; For CPS-II Nutrition Cohort:
The Cancer Prevention Studies are supported by the American Cancer
Society. Efforts of the ACS the study management group to maintain and
follow the cohort are acknowledged. ACS investigators also acknowledge
the contributions from central cancer registries supported through the
Centers for Disease Control and Prevention's National Program of Cancer
Registries and cancer registries supported by the National Cancer
Institute's Surveillance Epidemiology and End Results Program.; For
NYUWHS: The NYUWHS is supported by National Cancer Institute grants R01
CA098661 and P30 CA016087 and by Center grant ES000260 from the National
Institute of Environmental Health Sciences.; For PHS: The PHS is
supported by grants CA 97193, CA 34944, CA 40360, HL 26490, and HL 34595
from the National Institutes of Health.; For CLUE: Cancer incidence data
were provided by the Maryland Cancer Registry, Center for Cancer
Surveillance and Control, Department of Health and Mental Hygiene, 201
W. Preston Street, Room 400, Baltimore, MD 21201, USA;
www.fha.state.md.us/cancer/registry/, 410-767-4055. The authors
acknowledge the State of Maryland, the Maryland Cigarette Restitution
Fund and the National Program of Cancer Registries of the Centers for
Disease Control and Prevention for the funds that support the collection
and availability of the cancer registry data. The findings and
conclusions of this report are those of the authors and do not
necessarily represent the views of the Maryland Cancer Registry.; For
PLCO: This research was supported by the Intramural Research Program of
the Division of Cancer Epidemiology and Genetics and by contracts from
the Division of Cancer Prevention, NCI, National Institutes of Health
(NIH) and Department of Health and Human Services (DHHS). The authors
thank Drs Christine Berg and Philip Prorok, Division of Cancer
Prevention, NCI, the Screening Center investigators and staff of the
PLCO cancer screening trial, Mr Tom Riley and staff, Information
Management Services, Inc., Ms Barbara O'Brien and staff, Westat, Inc.,
Mr Tim Sheehy and staff, DNA Extraction and Staging Laboratory,
SAIC-Frederick, Inc. and Ms Jackie King and staff, BioReliance, Inc.;
For MCCS: Infrastructure support for the MCCS recruitment and follow-up
is provided by the Cancer Council Victoria, and cohort recruitment was
partly funded by VicHealth. This work using the MCCS was supported by
the Australian National Health and Medical Research Council (grant
numbers 209057, 251533 and 396414).; For VITAL: Grant K05CA154337 is
funded by the NCI and the NIH Office of Dietary Supplements (ODS).
NR 47
TC 7
Z9 7
U1 0
U2 6
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0300-5771
EI 1464-3685
J9 INT J EPIDEMIOL
JI Int. J. Epidemiol.
PD AUG
PY 2012
VL 41
IS 4
BP 1075
EP 1085
DI 10.1093/ije/dys114
PG 11
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 998IV
UT WOS:000308232200026
PM 22933650
ER
PT J
AU Elmariah, S
Delaney, JAC
Bluemke, DA
Budoff, MJ
O'Brien, KD
Fuster, V
Kronmal, RA
Halperin, JL
AF Elmariah, Sammy
Delaney, Joseph A. C.
Bluemke, David A.
Budoff, Matthew J.
O'Brien, Kevin D.
Fuster, Valentin
Kronmal, Richard A.
Halperin, Jonathan L.
TI Associations of LV Hypertrophy With Prevalent and Incident Valve
Calcification Multi-Ethnic Study of Atherosclerosis
SO JACC-CARDIOVASCULAR IMAGING
LA English
DT Article
DE aortic valve; calcification; left ventricular mass; mitral valve annulus
ID MITRAL ANNULAR CALCIFICATION; LEFT-VENTRICULAR HYPERTROPHY;
COMPUTED-TOMOGRAPHY; DISEASE; SCLEROSIS; CALCIUM; RISK; MESA;
HYPERTENSION; MORBIDITY
AB OBJECTIVES The aim of this study was to evaluate the relationship between percentage of predicted left ventricular mass (%PredLVM) and valve calcification in the MESA (Multi-Ethnic Study of Atherosclerosis) study.
BACKGROUND Cardiac valve calcification has been associated with left ventricular hypertrophy (LVH), which portends cardiovascular events. However, this relationship and its mediators are poorly understood.
METHODS The MESA study is a longitudinal cohort study of men and women 45 to 84 years of age without clinical cardiovascular disease in whom serial cardiac magnetic resonance and computed tomography imaging were performed. The relationships between baseline %PredLVM and the prevalence, severity, and incidence of aortic valve (AVC) and mitral annulus calcification (MAC) were determined by regression modeling.
RESULTS Prevalent AVC was observed in 630, and MAC was observed in 442 of 5,042 subjects (median 55.9 and 71.1 Agatston units, respectively). After adjustment for age, sex, body mass index (BMI), ethnicity, socioeconomic status, physical activity, diabetes, cholesterol levels, blood pressure, smoking, kidney function, serum lipids, and antihypertensive and statin medications, %PredLVM was associated with prevalent AVC (odds ratio [OR]: 1.18/SD increase in %PredLVM [95% confidence interval (CI): 1.08 to 1.30]; p = 0.0004) and MAC (OR: 1.18 [95% CI: 1.06 to 1.32]; p = 0.002). Similarly, %PredLVM was associated with increased severity of prevalent AVC (risk difference = 0.26 [95% CI: 0.15 to 0.38]; p < 0.0001) and MAC (risk difference = 0.20 [95% CI: 0.03 to 0.37]; p = 0.02). During follow-up (mean 2.4 +/- 0.9 years), 153 subjects (4%) developed AVC, and 198 (5%) developed MAC. The %PredLVM was associated with incident AVC (OR: 1.24 [95% CI: 1.04 to 1.47]; p = 0.02) and MAC (OR: 1.18 [95% CI: 1.01 to 1.40]; p = 0.04). Further adjustment for inflammatory markers and coronary artery calcification did not attenuate these associations. Specifically, concentric LVH most strongly predicted incident valve calcification.
CONCLUSIONS Within the MESA cohort, LVH was associated with prevalence, severity, and incidence of valve calcification independent of hypertension and other identified confounders. (J Am Coll Cardiol Img 2012; 5: 781-8) (C) 2012 by the American College of Cardiology Foundation
C1 [Elmariah, Sammy] Harvard Univ, Div Cardiol, Massachusetts Gen Hosp, Sch Med,Dept Med, Boston, MA 02114 USA.
[Elmariah, Sammy; Fuster, Valentin; Halperin, Jonathan L.] Mt Sinai Sch Med, Zena & Michael A Wiener Cardiovasc Inst, New York, NY USA.
[Delaney, Joseph A. C.] Univ Florida, Dept Pharmaceut Outcomes & Policy, Gainesville, FL USA.
[Bluemke, David A.] Natl Inst Biomed Imaging & Bioengn, NIH, Ctr Clin, Bethesda, MD USA.
[Budoff, Matthew J.] Harbor UCLA, Div Cardiol, Los Angeles Biomed Res Inst, Torrance, CA USA.
[O'Brien, Kevin D.] Univ Washington, Div Cardiol, Seattle, WA 98195 USA.
[Fuster, Valentin] CNIC, Madrid, Spain.
[Kronmal, Richard A.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
RP Elmariah, S (reprint author), Harvard Univ, Div Cardiol, Massachusetts Gen Hosp, Sch Med,Dept Med, 55 Fruit St,GRB 800, Boston, MA 02114 USA.
EM selmariah@partners.org
RI Fuster, Valentin/H-4319-2015;
OI Fuster, Valentin/0000-0002-9043-9986; Bluemke, David/0000-0002-8323-8086
FU National Heart, Lung, and Blood Institute at the National Institutes of
Health [R01 HL071739, T32 HL007824, N01-HC-95159, N01-HC-95165,
N01-HC-95169]; GlaxoSmithKline Research and Education Foundation for
Cardiovascular Disease International Competitive Grants Award Program
for Young Investigators; BG Medicine; Astellas Pharma; Bayer AG
Healthcare; Bristol-Myers Squibb/Sanofi Partnership;
Boehringer-Ingelheim; Daiichi Sankyo; Johnson Johnson; Sanofi-Aventis;
Biotronik
FX This work was supported by the National Heart, Lung, and Blood Institute
at the National Institutes of Health (Grants R01 HL071739 [to Dr.
Budoff] and T32 HL007824 [to Dr. Elmariah] and by contracts N01-HC-95159
through N01-HC-95165 and N01-HC-95169) and the GlaxoSmithKline Research
and Education Foundation for Cardiovascular Disease International
Competitive Grants Award Program for Young Investigators (to Dr.
Elmariah). Dr. Budoff has a modest consulting agreement with the General
Electric Company. Dr. O'Brien receives speaker honoraria from
AstraZeneca and Merck. Dr. Fuster chairs the HRP study, which is funded
by BG Medicine. Dr. Halperin receives consulting fees from Astellas
Pharma, Bayer AG Healthcare, the Bristol-Myers Squibb/Sanofi
Partnership, Boehringer-Ingelheim, Daiichi Sankyo, Johnson & Johnson,
and Sanofi-Aventis; honoraria from Genzyme and Portola Pharmaceuticals;
and is co-chairman of the IMPACT trial, which is sponsored by Biotronik.
All other authors have reported that they have no relationships relevant
to the contents of this paper to disclose. H. William Strauss, MD,
served as Guest Editor for this paper.
NR 27
TC 7
Z9 9
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1936-878X
J9 JACC-CARDIOVASC IMAG
JI JACC-Cardiovasc. Imag.
PD AUG
PY 2012
VL 5
IS 8
BP 781
EP 788
DI 10.1016/j.jcmg.2011.12.025
PG 8
WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical
Imaging
SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine &
Medical Imaging
GA 003DN
UT WOS:000308588500003
PM 22897991
ER
PT J
AU Bruijnzeel, H
Neuhaus, V
Fostvedt, S
Jupiter, JB
Mudgal, CS
Ring, DC
AF Bruijnzeel, Hanneke
Neuhaus, Valentin
Fostvedt, Sigrid
Jupiter, Jesse B.
Mudgal, Chaitanya S.
Ring, David C.
TI Adverse Events of Open A1 Pulley Release for Idiopathic Trigger Finger
SO JOURNAL OF HAND SURGERY-AMERICAN VOLUME
LA English
DT Article
DE A1 pulley; classification; complications; open release; trigger finger
ID MANAGEMENT; SURGERY
AB Purpose To classify and report adverse events of trigger finger release in a large cohort of patients.
Methods We retrospectively reviewed 1,598 trigger finger releases performed by 12 surgeons in 984 patients between 2001 and 2011. Adverse events were classified based on a system derived from the Centers for Disease Control and Prevention criteria and clinical experience. Risk factors for various adverse events were sought in bivariate and multivariable statistical analysis.
Results At the latest follow-up, 66 patients (7%), or 84 operated trigger digits (5%), experienced a documented adverse event. The most common adverse events were recovery issues in 46 patients (3%) (such as postoperative symptoms treated with steroid injection or slow recovery of motion treated with hand therapy), wound problems in 30 patients (2%) (consisting of suture abscess, superficial infection, or wound separation), persistent postoperative triggering in 10 patients (0.6%), and recurrent triggering in 4 patients (0.3%). Diabetes mellitus was associated with wound problems, slow recovery of motion, and recurrence. Concomitant carpal tunnel release on the same side was associated with slow recovery.
Conclusions Fourteen patients, less than 1%, in this cohort experienced an adverse event, such as persistent or recurrent triggering, requiring secondary surgery. No nerve injury or deep infection occurred in our cohort. One in 15 patients experienced a minor transient or treatable adverse event, and patients with diabetes were at greater risk. (J Hand Surg 2012;37A: 1650-1656. Copyright (C) 2012 by the American Society for Surgery of the Hand. All rights reserved.)
Type of study/level of evidence Therapeutic IV.
C1 [Ring, David C.] Massachusetts Gen Hosp, Orthopaed Hand Serv, Yawkey Ctr, Boston, MA 02114 USA.
RP Ring, DC (reprint author), Massachusetts Gen Hosp, Orthopaed Hand Serv, Yawkey Ctr, Suite 2100,55 Fruit St, Boston, MA 02114 USA.
EM dring@partners.org
OI Neuhaus, Valentin/0000-0003-4012-5628
NR 15
TC 15
Z9 15
U1 0
U2 0
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0363-5023
J9 J HAND SURG-AM
JI J. Hand Surg.-Am. Vol.
PD AUG
PY 2012
VL 37A
IS 8
BP 1650
EP 1656
DI 10.1016/j.jhsa.2012.05.014
PG 7
WC Orthopedics; Surgery
SC Orthopedics; Surgery
GA 985JK
UT WOS:000307260200020
PM 22763058
ER
PT J
AU Pace-Schott, EF
Verga, PW
Bennett, TS
Spencer, RMC
AF Pace-Schott, Edward F.
Verga, Patrick W.
Bennett, Tobias S.
Spencer, Rebecca M. C.
TI Sleep promotes consolidation and generalization of extinction learning
in simulated exposure therapy for spider fear
SO JOURNAL OF PSYCHIATRIC RESEARCH
LA English
DT Article
DE Sleep; Extinction; Spider phobia; Fear conditioning; Exposure therapy
ID POSTTRAUMATIC-STRESS-DISORDER; ANXIETY DISORDERS; CONDITIONED FEAR;
POTENTIATED STARTLE; HUMANS; PHOBIA; ACQUISITION; ETIOLOGY; AMYGDALA;
QUESTIONNAIRES
AB Simulated exposure therapy for spider phobia served as a clinically naturalistic model to study effects of sleep on extinction. Spider-fearing, young adult women (N = 66), instrumented for skin conductance response (SCR), heart rate acceleration (HRA) and corrugator electromyography (EMG), viewed 14 identical 1-min videos of a behaving spider before a 12-hr delay containing a normal night's Sleep (N = 20) or continuous daytime Wake (N = 23), or a 2-hr delay of continuous wake in the Morning (N = 11) or Evening (N = 12). Following the delay, all groups viewed this same video 6 times followed by six 1-min videos of a novel spider. After each video, participants rated disgust, fearfulness and unpleasantness. In all 4 groups, all measures except corrugator EMG diminished across Session 1 (extinction learning) and, excepting SCR to a sudden noise, increased from the old to novel spider in Session 2. In Wake only, summed subjective ratings and SCR to the old spider significantly increased across the delay (extinction loss) and were greater for the novel vs. the old spider when it was equally novel at the beginning of Session 1 (sensitization). In Sleep only, SCR to a sudden noise decreased across the inter-session delay (extinction augmentation) and, along with HRA, was lower to the novel spider than initially to the old spider in Session 1 (extinction generalization). None of the above differentiated Morning and Evening groups suggesting that intervening sleep, rather than time-of-testing, produced differences between Sleep and Wake. Thus, sleep following exposure therapy may promote retention and generalization of extinction learning. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Pace-Schott, Edward F.; Verga, Patrick W.; Bennett, Tobias S.; Spencer, Rebecca M. C.] Univ Massachusetts, Dept Psychol, Amherst, MA 01003 USA.
[Pace-Schott, Edward F.; Spencer, Rebecca M. C.] Univ Massachusetts, Neurosci & Behav Program, Amherst, MA 01003 USA.
[Pace-Schott, Edward F.] Harvard Univ, Sch Med, Dept Psychiat, Massachusetts Gen Hosp, Boston, MA 02115 USA.
RP Pace-Schott, EF (reprint author), Univ Massachusetts, Dept Psychol, Tobin Hall,Rm 522,135 Hicks Way, Amherst, MA 01003 USA.
EM epacesch@psych.umass.edu
OI Spencer, Rebecca/0000-0002-8674-2384
FU NIA [R00AG029710]; NIMH [R21MH090357]
FX NIA R00AG029710 provided salary support for Edward F. Pace-Schott and
Rebecca M.C. Spencer, Ph.D. as well as equipment and materials support
for the study. NIMH R21MH090357 provided salary support for Edward F.
Pace-Schott.
NR 52
TC 34
Z9 34
U1 4
U2 26
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0022-3956
J9 J PSYCHIATR RES
JI J. Psychiatr. Res.
PD AUG
PY 2012
VL 46
IS 8
BP 1036
EP 1044
DI 10.1016/j.jpsychires.2012.04.015
PG 9
WC Psychiatry
SC Psychiatry
GA 980AF
UT WOS:000306865300010
PM 22578824
ER
PT J
AU Xiu, MH
Chen, DC
Wang, D
Zhang, K
Dong, AL
Tang, W
Zhang, FX
Liu, LJ
Liu, JH
Liu, HB
Yang, FD
Kosten, TR
Zhang, XY
AF Xiu, Mei Hong
Chen, Da Chun
Wang, Dong
Zhang, Kui
Dong, AiLing
Tang, Wei
Zhang, Feixue
Liu, Lian Jing
Liu, Jia Hong
Liu, Hai Bo
Yang, Fu De
Kosten, Thomas R.
Zhang, Xiang Yang
TI Elevated interleukin-18 serum levels in chronic schizophrenia:
Association with psychopathology
SO JOURNAL OF PSYCHIATRIC RESEARCH
LA English
DT Article
DE Schizophrenia; Interleukin; Cytokines; Immune
ID CYTOTOXIC T-LYMPHOCYTES; CYTOKINE ALTERATIONS; IL-18; AUTOIMMUNITY;
PATHOGENESIS; RISPERIDONE; INDUCTION; INFECTION; DISEASES; PLASMA
AB Background: Schizophrenia is associated with various abnormalities in the immune system including elevated levels of Interleukin-18 (IL-18), a potent inflammatory cytokine in T-helper 1 (Th1) responses. The aim of this study was to assess the clinical significance of serum IL-18 levels in various stages of schizophrenia.
Methods: We measured serum IL-18 levels using a sandwich enzyme-linked immunosorbent assay (ELISA) from 78 never-medicated first-episode schizophrenia, 79 medicated chronic schizophrenia and 78 healthy control subjects. The symptoms of schizophrenia were assessed by the Positive and Negative Syndrome Scale (PANSS).
Results: The chronic patients had significantly greater serum IL-18 levels than both first-episode patients and controls. Serum IL-18 was also positively correlated with the PANSS general psychopathology subscore in chronic schizophrenic patients.
Conclusions: Our results showed elevated IL-18 pathway activity may be involved in the psychopathology of schizophrenia. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Xiu, Mei Hong; Chen, Da Chun; Liu, Hai Bo; Yang, Fu De; Kosten, Thomas R.; Zhang, Xiang Yang] Peking Univ, Beijing HuiLongGuan Hosp, Psychiat Res Ctr, Beijing 100871, Peoples R China.
[Wang, Dong; Zhang, Kui; Dong, AiLing] JingQu Hosp, Dept Psychiat, Weihai, Shandong, Peoples R China.
[Tang, Wei; Zhang, Feixue; Liu, Lian Jing; Liu, Jia Hong] Kangning Hosp, Dept Psychiat, Wenzhou, Zhejiang, Peoples R China.
[Kosten, Thomas R.; Zhang, Xiang Yang] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA.
RP Kosten, TR (reprint author), VA Med Ctr, Res Bldg 110,Room 229,2002 Holcombe Blvd, Houston, TX 77030 USA.
EM kosten@bcm.edu; xyzhang@bcm.edu
FU National Natural Science Foundation of China [81000509]; Beijing
Municipal Excellent Talents Foundation [2010D003034000032]; Stanley
Medical Research Institute [03T-459, 05T-726]; United States National
Institute of Health [K05-DA0454, P50-DA18827, U01-MH79639]
FX This study was funded by National Natural Science Foundation of China
(81000509), and Beijing Municipal Excellent Talents Foundation
(2010D003034000032), and the Stanley Medical Research Institute (03T-459
and 05T-726), and the United States National Institute of Health
K05-DA0454, P50-DA18827 and U01-MH79639. These sources had no further
role in study design; in the collection, analysis and interpretation of
data; in the writing of the report; and in the decision to submit the
paper for publication.
NR 44
TC 20
Z9 20
U1 1
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0022-3956
EI 1879-1379
J9 J PSYCHIATR RES
JI J. Psychiatr. Res.
PD AUG
PY 2012
VL 46
IS 8
BP 1093
EP 1098
DI 10.1016/j.jpsychires.2012.04.026
PG 6
WC Psychiatry
SC Psychiatry
GA 980AF
UT WOS:000306865300018
PM 22647522
ER
PT J
AU Adelmant, G
Calkins, AS
Garg, BK
Card, JD
Askenazi, M
Miron, A
Sobhian, B
Zhang, Y
Nakatani, Y
Silver, PA
Iglehart, JD
Marto, JA
Lazaro, JB
AF Adelmant, Guillaume
Calkins, Anne S.
Garg, Brijesh K.
Card, Joseph D.
Askenazi, Manor
Miron, Alex
Sobhian, Bijan
Zhang, Yi
Nakatani, Yoshihiro
Silver, Pamela A.
Iglehart, J. Dirk
Marto, Jarrod A.
Lazaro, Jean-Bernard
TI DNA Ends Alter the Molecular Composition and Localization of Ku
Multicomponent Complexes
SO MOLECULAR & CELLULAR PROTEOMICS
LA English
DT Article
ID DEPENDENT PROTEIN-KINASE; RNA-POLYMERASE-II; INDUCED REPLICATION STRESS;
TRANSCRIPTION INITIATION; CATALYTIC SUBUNIT; HUMAN TELOMERASE;
GENE-EXPRESSION; WERNER PROTEIN; IN-VITRO; PHOSPHORYLATION
AB The Ku heterodimer plays an essential role in non-homologous end-joining and other cellular processes including transcription, telomere maintenance and apoptosis. While the function of Ku is regulated through its association with other proteins and nucleic acids, the specific composition of these macromolecular complexes and their dynamic response to endogenous and exogenous cellular stimuli are not well understood. Here we use quantitative proteomics to define the composition of Ku multicomponent complexes and demonstrate that they are dramatically altered in response to UV radiation. Subsequent biochemical assays revealed that the presence of DNA ends leads to the substitution of RNA-binding proteins with DNA and chromatin associated factors to create a macromolecular complex poised for DNA repair. We observed that dynamic remodeling of the Ku complex coincided with exit of Ku and other DNA repair proteins from the nucleolus. Microinjection of sheared DNA into live cells as a mimetic for double strand breaks confirmed these findings in vivo. Molecular & Cellular Proteomics 11: 10.1074/mcp.M111.013581, 411-421, 2012.
C1 [Adelmant, Guillaume; Garg, Brijesh K.; Card, Joseph D.; Askenazi, Manor; Miron, Alex; Sobhian, Bijan; Zhang, Yi; Nakatani, Yoshihiro; Iglehart, J. Dirk; Marto, Jarrod A.] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02215 USA.
[Adelmant, Guillaume; Garg, Brijesh K.; Card, Joseph D.; Askenazi, Manor; Zhang, Yi; Marto, Jarrod A.] Dana Farber Canc Inst, Blais Prote Ctr, Boston, MA 02215 USA.
[Adelmant, Guillaume; Askenazi, Manor; Nakatani, Yoshihiro; Marto, Jarrod A.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.
[Silver, Pamela A.] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA.
[Calkins, Anne S.; Miron, Alex; Iglehart, J. Dirk; Lazaro, Jean-Bernard] Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA.
RP Marto, JA (reprint author), Dana Farber Canc Inst, Dept Canc Biol, 450 Brookline Ave, Boston, MA 02215 USA.
EM Jarrod_Marto@dfci.harvard.edu
FU National Institutes of Health (NIH) [P50HG004233, P01NS047572]; Susan
Smith Center for Women's Cancers; Strategic Research Initiative at the
Dana-Farber Cancer Institute; NIH [R37GM36373-24]; Marsha Rivkin
Foundation; Catt Family Foundation; James and Kimberly Pallotta Fund for
Ovarian Cancer Research
FX This work was supported by the National Institutes of Health (NIH)
(P50HG004233 and P01NS047572), the Susan Smith Center for Women's
Cancers, and the Strategic Research Initiative at the Dana-Farber Cancer
Institute (to J. A. M.), in addition to NIH (R37GM36373-24) to P. A. S.,
along with support from the Marsha Rivkin Foundation, The Catt Family
Foundation, and The James and Kimberly Pallotta Fund for Ovarian Cancer
Research (to J. D. I.).
NR 50
TC 15
Z9 15
U1 0
U2 6
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 1535-9476
EI 1535-9484
J9 MOL CELL PROTEOMICS
JI Mol. Cell. Proteomics
PD AUG
PY 2012
VL 11
IS 8
BP 411
EP 421
DI 10.1074/mcp.M111.013581
PG 11
WC Biochemical Research Methods
SC Biochemistry & Molecular Biology
GA 995PW
UT WOS:000308024200015
PM 22535209
ER
PT J
AU Xu, CJ
Miranda-Nieves, D
Ankrum, JA
Matthiesen, ME
Phillips, JA
Roes, I
Wojtkiewicz, GR
Juneja, V
Kultima, JR
Zhao, WA
Vemula, PK
Lin, CP
Nahrendorf, M
Karp, JM
AF Xu, Chenjie
Miranda-Nieves, David
Ankrum, James A.
Matthiesen, Mads Emil
Phillips, Joseph A.
Roes, Isaac
Wojtkiewicz, Gregory R.
Juneja, Vikram
Kultima, Jens Roat
Zhao, Weian
Vemula, Praveen Kumar
Lin, Charles P.
Nahrendorf, Matthias
Karp, Jeffrey M.
TI Tracking Mesenchymal Stem Cells with Iron Oxide Nanoparticle Loaded
Poly(lactide-co-glycolide) Microparticles
SO NANO LETTERS
LA English
DT Article
DE Stem cell tracking; MRI contrast agents; iron oxide nanoparticles; cell
therapy; mesenchymal stem cell; cell homing
ID VERSUS-HOST-DISEASE; BONE-MARROW; CONTRAST AGENTS; MRI; PARTICLES;
THERAPIES
AB Monitoring the location, distribution and long-term engraftment of administered cells is critical for demonstrating the success of a cell therapy. Among available imaging-based cell tracking tools, magnetic resonance imaging (MRI) is advantageous due to its noninvasiveness, deep penetration, and high spatial resolution. While tracking cells in preclinical models via internalized MRI contrast agents (iron oxide nanoparticles, IO-NPs) is a widely used method, IO-NPs suffer from low iron content per particle, low uptake in nonphagocytotic cell types (e.g., mesenchymal stem cells, MSCs), weak negative contrast, and decreased MRI signal due to cell proliferation and cellular exocytosis. Herein, we demonstrate that internalization of IO-NP (10 nm) loaded biodegradable poly(lactide-co-glycolide) microparticles (IO/PLGA-MPs, 0.4-3 mu m) in MSCs enhances MR parameters such as the r(2) relaxivity (5-fold), residence time inside the cells (3-fold) and R-2 signal (2-fold) compared to IO-NPs alone. Intriguingly, in vitro and in vivo experiments demonstrate that internalization of IO/PLGA-MPs in MSCs does not compromise inherent cell properties such as viability, proliferation, migration and their ability to home to sites of inflammation.
C1 [Xu, Chenjie; Miranda-Nieves, David; Ankrum, James A.; Matthiesen, Mads Emil; Phillips, Joseph A.; Roes, Isaac; Juneja, Vikram; Kultima, Jens Roat; Zhao, Weian; Vemula, Praveen Kumar; Karp, Jeffrey M.] Harvard Univ, Brigham & Womens Hosp,Div Hlth Sci & Technol, Sch Med,Harvard Stem Cell Inst,Harvard MIT, Div Biomed Engn,Dept Med,Ctr Regenerat Therapeut, Cambridge, MA 02139 USA.
[Lin, Charles P.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Adv Microscopy Program,Ctr Syst Biol, Boston, MA 02114 USA.
[Lin, Charles P.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA 02114 USA.
[Kultima, Jens Roat] EMBL, D-69117 Heidelberg, Germany.
[Xu, Chenjie] Xiamen Univ, Sch Publ Hlth, Ctr Mol Imaging & Translat Med, Xiamen 361005, Peoples R China.
RP Karp, JM (reprint author), Harvard Univ, Brigham & Womens Hosp,Div Hlth Sci & Technol, Sch Med,Harvard Stem Cell Inst,Harvard MIT, Div Biomed Engn,Dept Med,Ctr Regenerat Therapeut, 65 Landsdowne St, Cambridge, MA 02139 USA.
EM jkarp@rics.bwh.harvard.edu
RI Ankrum, James/N-4175-2014; xu, chenjie/E-4075-2012;
OI Ankrum, James/0000-0003-3959-6158; Xu, Chenjie/0000-0002-8278-3912
FU Harvard Stem Cell Institute; National Institute of Health [HL095722,
HL097172]; MIT-UROP program; John Reed Fund; Hugh Hampton Young Memorial
Fund; National Science Foundation; National Heart, Lung, and Blood
Institute, National Institutes of Health, Department of Health and Human
Services [HHSN268201000044C]
FX This work was supported by the Harvard Stem Cell Institute, and the
National Institute of Health Grants HL095722 and HL097172 to J.M.K.
D.M.N is supported by MIT-UROP program and the John Reed Fund. J.A.A. is
supported by the Hugh Hampton Young Memorial Fund and the National
Science Foundation. M.N. was supported by funds from the National Heart,
Lung, and Blood Institute, National Institutes of Health, Department of
Health and Human Services, under Contract No. HHSN268201000044C. We
thank Dr. Nikolay Sergeyev (MGH) in "Center for Systems Biology Mouse
Imaging Program" for helping us perform the relaxivity measurement with
the benchtop relaxometer.
NR 30
TC 62
Z9 64
U1 7
U2 71
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1530-6984
J9 NANO LETT
JI Nano Lett.
PD AUG
PY 2012
VL 12
IS 8
BP 4131
EP 4139
DI 10.1021/nl301658q
PG 9
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
Physics, Condensed Matter
SC Chemistry; Science & Technology - Other Topics; Materials Science;
Physics
GA 984SD
UT WOS:000307211000042
PM 22769232
ER
PT J
AU Howitt, MR
Garrett, WS
AF Howitt, Michael R.
Garrett, Wendy S.
TI A complex microworld in the gut Gut microbiota and cardiovascular
disease connectivity
SO NATURE MEDICINE
LA English
DT Editorial Material
ID OBESITY; MICE
AB Millions of healthy bacteria colonize our guts from the moment we are born. Changes in the composition and abundance of these commensals affect the entire immune system and can predispose us to a variety of diseases, including intestinal infections, inflammatory and metabolic diseases, and cancer. The gut microbiome interacts not only with the host mucosa but also with potential pathogens; understanding what interactions and pathways are crucial for maintaining homeostasis and protecting the host from harmful bacteria and diseases can open new avenues to developing gut microbiota-based therapeutic approaches. In 'Bench to Bedside', Michael R. Howitt and Wendy S. Garrett examine the importance of metabolic crosstalk between the microbiota and the host in human metabolism and the development of cardiovascular disease. This adds one more layer of complexity to understanding what contributes to this pathology and how to harness the microbiota and their metabolic pathways to prevent it. In 'Bedside to Bench', Nobuhiko Kamada, Grace Chen and Gabriel Nunez discuss how targeting interactions between commensals and bacteria causing intestinal disease can lead to effective therapies to control these infections, which currently seem to lack an adequate treatment. Unraveling how commensals help the host prevent or block colonization of these pathogens can suggest new ways to increase our armamentarium to deal with these sometimes deadly intestinal infections.
C1 [Howitt, Michael R.; Garrett, Wendy S.] Harvard Univ, Sch Publ Hlth, Sch Med, Boston, MA 02115 USA.
[Howitt, Michael R.; Garrett, Wendy S.] Dana Farber Canc Inst, Boston, MA 02115 USA.
RP Howitt, MR (reprint author), Harvard Univ, Sch Publ Hlth, Sch Med, 665 Huntington Ave, Boston, MA 02115 USA.
EM wgarrett@hsph.harvard.edu
FU NCI NIH HHS [R01 CA154426]; NIAID NIH HHS [K08 AI078942]
NR 16
TC 24
Z9 28
U1 4
U2 38
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1078-8956
J9 NAT MED
JI Nat. Med.
PD AUG
PY 2012
VL 18
IS 8
BP 1188
EP 1189
DI 10.1038/nm.2895
PG 2
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
Experimental
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
Medicine
GA 988DU
UT WOS:000307469300022
PM 22869188
ER
PT J
AU Deng, XY
Li, QL
Hoff, J
Novak, M
Yang, HL
Jin, HY
Erfani, SF
Sharma, C
Zhou, PC
Rabinovitz, I
Sonnenberg, A
Yi, YJ
Zhou, P
Stipp, CS
Kaetzel, DM
Hemler, ME
Yang, XWH
AF Deng, Xinyu
Li, Qinglin
Hoff, John
Novak, Marian
Yang, Helen
Jin, Hongyan
Erfani, Sonia F.
Sharma, Chandan
Zhou, Pengcheng
Rabinovitz, Isaac
Sonnenberg, Arnoud
Yi, Yajun
Zhou, Peter
Stipp, Christopher S.
Kaetzel, David M.
Hemler, Martin E.
Yang, Xiuwei H.
TI Integrin-Associated CD151 Drives ErbB2-Evoked Mammary Tumor Onset and
Metastasis
SO NEOPLASIA
LA English
DT Article
ID GENE-EXPRESSION SIGNATURE; LAMININ-BINDING INTEGRINS; BREAST-CANCER;
TETRASPANIN CD151; IN-VIVO; EPITHELIAL-CELLS; BETA-4 INTEGRIN; MICE
LACKING; MOUSE MODEL; STEM-CELLS
AB ErbB2(+) human breast cancer is a major clinical problem. Prior results have suggested that tetraspanin CD151 might contribute to ErbB2-driven breast cancer growth, survival, and metastasis. In other cancer types, CD151 sometimes supports tumor growth and metastasis. However, a definitive test of CD151 effects on de novo breast cancer initiation, growth, and metastasis has not previously been done. We used CD151 gene-deleted mice expressing the MMTV-ErbB2 transgene to show that CD151 strongly supports ErbB2(+) mammary tumor initiation and metastasis. Delayed tumor onset (by 70-100 days) in the absence of CD151 was accompanied by reduced survival of mammary epithelial cells and impaired activation of FAK- and MAPK-dependent pathways. Both primary tumors and metastatic nodules showed smooth, regular borders, consistent with a less invasive phenotype. Furthermore, consistent with impaired oncogenesis and decreased metastasis, CD151-targeted MCF-10A/ErbB2 cells showed substantial decreases in three-dimensional colony formation, EGF-stimulated tumor cell motility, invasion, and transendothelial migration. These CD151-dependent functions were largely mediated through alpha(6)beta(4) integrin. Moreover, CD151 ablation substantially prevented PKC- and EGFR/ERK-dependent alpha(6)beta(4) integrin phosphorylation, consistent with retention of epithelial cell polarity and intermediate filament cytoskeletal connections, which helps to explain diminished metastasis. Finally, clinical data analyses revealed a strong correlation between CD151 and ErbB2 expression and metastasis-free survival of breast cancer patients. In conclusion, we provide strong evidence that CD151 collaborates with LB integrins (particularly alpha(6)beta(4)) and ErbB2 (and EGFR) receptors to regulate multiple signaling pathways, thereby driving mammary tumor onset, survival, and metastasis. Consequently, CD151 is a useful therapeutic target in malignant ErbB2(+) breast cancer.
C1 [Deng, Xinyu; Hoff, John; Novak, Marian; Jin, Hongyan; Erfani, Sonia F.; Zhou, Peter; Kaetzel, David M.; Yang, Xiuwei H.] Univ Kentucky, Dept Mol & Biomed Pharmacol, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA.
[Deng, Xinyu; Hoff, John; Novak, Marian; Jin, Hongyan; Erfani, Sonia F.; Zhou, Peter; Kaetzel, David M.; Yang, Xiuwei H.] Univ Kentucky, Markey Canc Ctr, Lexington, KY 40536 USA.
[Li, Qinglin; Sharma, Chandan; Zhou, Pengcheng; Hemler, Martin E.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Li, Qinglin; Sharma, Chandan; Zhou, Pengcheng; Rabinovitz, Isaac; Hemler, Martin E.] Harvard Univ, Sch Med, Boston, MA USA.
[Yang, Helen] MIT, Dept Mat Sci & Engn, Cambridge, MA 02139 USA.
[Rabinovitz, Isaac] Beth Israel Deaconess Med Ctr, Dept Pathol, Div Canc Biol & Angiogenesis, Boston, MA 02215 USA.
[Sonnenberg, Arnoud] Netherlands Canc Inst, Div Cell Biol, Amsterdam, Netherlands.
[Yi, Yajun] Vanderbilt Univ, Div Med Genet, Nashville, TN USA.
[Stipp, Christopher S.] Univ Iowa, Dept Biol, Iowa City, IA 52242 USA.
RP Yang, XWH (reprint author), Univ Kentucky, Dept Mol & Biomed Pharmacol, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA.
EM xiuwei-yang@uky.edu
RI Deng, Xinyu/J-5732-2015; Li, Qinglin/K-2570-2015
OI Li, Qinglin/0000-0002-4125-1944
FU Susan G. Komen Career Catalyst Award; Department of Defense Concept
award [W81XWH-06-BCRP-CA]; National Institutes of Health [2P20
RR020171/Pilot, RO1 CA42368]; Dana-Farber Cancer Institute/Claudia Adams
Barr Grant
FX This work was supported by the Susan G. Komen Career Catalyst Award, a
Department of Defense Concept award (W81XWH-06-BCRP-CA), National
Institutes of Health grant 2P20 RR020171/Pilot Project, and Dana-Farber
Cancer Institute/Claudia Adams Barr Grant (to X.H.Y.), and National
Institutes of Health grant RO1 CA42368 (to M.E.H.). The authors declare
that they have no competing interests.
NR 61
TC 35
Z9 39
U1 2
U2 9
PU NEOPLASIA PRESS
PI ANN ARBOR
PA 1150 W MEDICAL CENTER DR, MSRB III, RM 9303, ANN ARBOR, MI 48109-0648
USA
SN 1522-8002
J9 NEOPLASIA
JI Neoplasia
PD AUG
PY 2012
VL 14
IS 8
BP 678
EP +
DI 10.1593/neo.12922
PG 14
WC Oncology
SC Oncology
GA 001WJ
UT WOS:000308490500002
PM 22952421
ER
PT J
AU Raj, A
Ko, N
Battaglia, TA
Chabner, BA
Moy, B
AF Raj, Aparna
Ko, Naomi
Battaglia, Tracy A.
Chabner, Bruce A.
Moy, Beverly
TI Patient Navigation for Underserved Patients Diagnosed with Breast Cancer
SO ONCOLOGIST
LA English
DT Article
DE Patient navigation; Cancer disparities; Breast cancer; Outcomes
ID AFFORDABLE CARE ACT; LOW-INCOME WOMEN; MAMMOGRAPHY; DISPARITIES;
PROTECTION; PROGRAMS; IMPACT
AB The elimination of cancer disparities is critically important for lessening the burden of breast cancer (BC). Patient navigator programs (PNPs) have been shown to improve rates of BC screening in underserved communities, but there is a dearth of evidence regarding their benefits after the actual diagnosis of BC. We retrospectively examined sociodemographic characteristics, disease characteristics, and concordance to quality measures (QMs) of BC care among women participating in a PNP that services disadvantaged minority communities in the greater Boston area. Of the 186 PNP patients diagnosed with BC in 2001-2011 in three neighborhood community health centers, treatment data was available for 158 (85%) and race and disease stage information was available for 149 (80%). Regarding stage, 25% were diagnosed with in situ cancer, 32% had stage 1, 25% had stage 2, 13% had stage 3, and 5% had stage 4 BC. Guideline-indicated care was received by 70 of 74 patients (95%) for the hormonal therapy QM, 15 of 17 (88%) patients for the chemotherapy QM, and 65 of 71 (92%) patients for the radiation QM, all similar to published concordance rates at elite National Comprehensive Cancer Network institutions. These findings suggest that PNPs may facilitate evidence-based quality care for vulnerable populations. Future research should prospectively analyze quality metrics to assess measures to improve the process and outcomes of patient navigation in diverse underserved settings, compared with control non-navigated populations. The Oncologist 2012;17:1027-1031
C1 [Raj, Aparna; Chabner, Bruce A.; Moy, Beverly] Harvard Univ, Sch Med, Gillette Ctr Womens Cancers, Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Ko, Naomi; Battaglia, Tracy A.] Boston Med Ctr, Boston, MA USA.
RP Moy, B (reprint author), Harvard Univ, Sch Med, Gillette Ctr Womens Cancers, Massachusetts Gen Hosp, 55 Fruit St,Yawkey 9A, Boston, MA 02114 USA.
EM bmoy@partners.org
OI Battaglia, Tracy/0000-0001-8475-1212
FU Avon Foundation; Novartis; Roche; AstraZeneca; Pfizer; Abraxis;
Boehringer-Ingelheim; GlaxoSmithKline
FX Disclosures: Bruce A. Chabner: BOD - PharmaMar (Spain) BOD - CTNET SAB-
Epizyme (E); Merrimack, Sanofi, Peregrine, Allergan, Redwood (C/A);
Beverly Moy: Avon Foundation (RF). The other authors indicated no
financial relationships.; Section Editors: Gabriel Hortobagyi: Amgen,
Antigen Express, Galena Biopharma, Genentech, Novartis, Rockpointe
(C/A); Novartis (RF); Taivex (O); Citizen's Oncology Foundation (founder
and member of the board of directors); Kathleen Pritchard: Novartis,
Roche, AstraZeneca, Pfizer, Abraxis, Boehringer-Ingelheim,
GlaxoSmithKline (C/A, RF)
NR 24
TC 6
Z9 6
U1 1
U2 10
PU ALPHAMED PRESS
PI DURHAM
PA 318 BLACKWELL ST, STE 260, DURHAM, NC 27701-2884 USA
SN 1083-7159
EI 1549-490X
J9 ONCOLOGIST
JI Oncologist
PD AUG
PY 2012
VL 17
IS 8
BP 1027
EP 1031
DI 10.1634/theoncologist.2012-0191
PG 5
WC Oncology
SC Oncology
GA 996WS
UT WOS:000308126100005
PM 22752069
ER
PT J
AU Cannon, JW
Chung, KK
King, DR
AF Cannon, Jeremy W.
Chung, Kevin K.
King, David R.
TI Advanced Technologies in Trauma Critical Care Management
SO SURGICAL CLINICS OF NORTH AMERICA
LA English
DT Article
DE Innovation; Trauma critical care; Ultrasound; Hemodynamic monitoring;
Extracorporeal therapy; Wound management
ID PULMONARY-ARTERY CATHETERS; HEART-RATE-VARIABILITY; EXTRACORPOREAL
MEMBRANE-OXYGENATION; HYPOTHERMIC CARDIOPULMONARY BYPASS;
RESPIRATORY-DISTRESS-SYNDROME; SURGEON-PERFORMED ULTRASOUND; PENETRATING
CARDIAC WOUNDS; VACUUM-ASSISTED CLOSURE; CENTRAL VENOUS CATHETER; ACUTE
LUNG INJURY
AB Care of critically injured patients has evolved over the 50 years since Shoemaker established one of the first trauma units at Cook County Hospital in 1962. Modern trauma intensive care units offer a high nurse-to-patient ratio, physicians and midlevel providers who manage the patients, and technologically advanced monitors and therapeutic devices designed to optimize the care of patients. This article describes advances that have transformed trauma critical care, including bedside ultrasonography, novel patient monitoring techniques, extracorporeal support, and negative pressure dressings. It also discusses how to evaluate the safety and efficacy of future advances in trauma critical care.
C1 [Cannon, Jeremy W.] San Antonio Mil Med Ctr, Div Trauma & Acute Care Surg, Ft Sam Houston, TX 78234 USA.
[Cannon, Jeremy W.] Uniformed Serv Univ Hlth Sci, Dept Surg, Bethesda, MD 20814 USA.
[Chung, Kevin K.] USA, Clin Div, Inst Surg Res, Ft Sam Houston, TX 78234 USA.
[King, David R.] Massachusetts Gen Hosp, Div Trauma Emergency Surg & Surg Crit Care, Boston, MA 02114 USA.
[King, David R.] Harvard Univ, Sch Med, Boston, MA 02114 USA.
RP Cannon, JW (reprint author), San Antonio Mil Med Ctr, Div Trauma & Acute Care Surg, 3551 Roger Brooke Dr, Ft Sam Houston, TX 78234 USA.
EM jcannon@massmed.org
OI King, David/0000-0003-1028-1478
NR 113
TC 2
Z9 2
U1 2
U2 11
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0039-6109
J9 SURG CLIN N AM
JI Surg. Clin.-North Am.
PD AUG
PY 2012
VL 92
IS 4
BP 903
EP +
DI 10.1016/j.suc.2012.04.001
PG 22
WC Surgery
SC Surgery
GA 000IE
UT WOS:000308379100009
PM 22850154
ER
PT J
AU Matar, AJ
Pathiraja, V
Wang, ZR
Duran-Struuck, R
Gusha, A
Crepeau, R
Tasaki, M
Sachs, DH
Huang, CA
AF Matar, Abraham J.
Pathiraja, Vimukthi
Wang, Zhirui
Duran-Struuck, Raimon
Gusha, Ashley
Crepeau, Rebecca
Tasaki, Masayuki
Sachs, David H.
Huang, Christene A.
TI Effect of pre-existing anti-diphtheria toxin antibodies on T cell
depletion levels following diphtheria toxin-based recombinant
anti-monkey CD3 immunotoxin treatment
SO TRANSPLANT IMMUNOLOGY
LA English
DT Article
DE Immunotoxin; T cell depletion; Antibody; Diphtheria toxin
ID SINGLE-CHAIN IMMUNOTOXIN; LYMPHOMA
AB Diphtheria toxin (DT)-based anti-CD3 immunotoxins have clinical relevance in numerous applications including autoimmune disease therapies and organ transplantation tolerance protocols. Pre-existing anti-DT antibodies acquired either by vaccination against diphtheria toxin or infections with C diphtheriae may interfere or inhibit the function of these anti-CD3 immunotoxins. Previously, a full-length anti-rhesus monkey CD3 immunotoxin, FN18-CRM9, was shown to be less effective at depleting circulating T cells in animals with pre-existing anti-DT antibody titers than in animals without antibodies, and subsequent doses were ineffective. In this study, the T cell depletion function of a truncated DT based recombinant anti-monkey CD3 immunotoxin, A-dmDT390-scfbDb (C207), as part of a reduced intensity conditioning regimen prior to hematopoietic cell transplantation, was compared between two groups of monkeys: those with and without pre-existing anti-diphtheria titers. T cell depletion was comparable in both groups of monkeys, and therefore appeared to be unaffected by the presence of moderate levels of pre-existing anti-diphtheria antibodies. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Matar, Abraham J.; Pathiraja, Vimukthi; Wang, Zhirui; Duran-Struuck, Raimon; Gusha, Ashley; Crepeau, Rebecca; Tasaki, Masayuki; Sachs, David H.; Huang, Christene A.] Massachusetts Gen Hosp, Transplantat Biol Res Ctr, Boston, MA 02114 USA.
RP Huang, CA (reprint author), Massachusetts Gen Hosp, Transplantat Biol Res Ctr, Boston, MA 02114 USA.
EM huangc@helix.mgh.harvard.edu
FU NIH [U01DK080653, U19AI051731]
FX This work was supported by NIH grants U01DK080653 and U19AI051731. The
authors would like to acknowledge Ms. Jaclyn Peraino and Dr. Isabel
Hanekamp for the critical review of this manuscript.
NR 12
TC 6
Z9 6
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0966-3274
J9 TRANSPL IMMUNOL
JI Transpl. Immunol.
PD AUG
PY 2012
VL 27
IS 1
BP 52
EP 54
DI 10.1016/j.trim.2012.05.003
PG 3
WC Immunology; Transplantation
SC Immunology; Transplantation
GA 002HB
UT WOS:000308521600009
PM 22676970
ER
PT J
AU Guzman-Suarez, BB
Buckley, MW
Gilmore, ET
Vocca, E
Moss, R
Marty, FM
Sanders, R
Baden, LR
Wurtman, D
Issa, NC
Fang, F
Koo, S
AF Guzman-Suarez, B. B.
Buckley, M. W.
Gilmore, E. T.
Vocca, E.
Moss, R.
Marty, F. M.
Sanders, R.
Baden, L. R.
Wurtman, D.
Issa, N. C.
Fang, F.
Koo, S.
TI Clinical potential of DAS181 for treatment of parainfluenza-3 infections
in transplant recipients
SO TRANSPLANT INFECTIOUS DISEASE
LA English
DT Article
DE parainfluenza-3 infection; respiratory viruses; sialic acid; DAS181
ID RESPIRATORY VIRUS-INFECTIONS; SIALIDASE FUSION PROTEIN; STEM-CELL
TRANSPLANTATION; SYNCYTIAL VIRUS; IN-VITRO; INFLUENZA; OUTBREAK; SAFETY;
UNIT
AB Parainfluenza virus (PIV) infections can cause serious respiratory infections and death in immunocompromised patients. No antiviral agents have proven efficacy against PIV, and therapy generally consists of supportive care. DAS181, a novel sialidase fusion protein that temporarily disables airway epithelial PIV receptors by enzymatic removal of sialic acid moieties, has been shown to inhibit infection with PIV strains in vitro and in an animal model. We describe here the clinical course of 2 immunocompromised patients with PIV-3 infection, one with a history of lung transplantation and the other neutropenic after autologous hematopoietic stem cell transplantation for multiple myeloma. Both patients had substantial clinical improvement in respiratory and systemic symptoms after a 5-day DAS181 treatment course, although the clinical improvement in the autologous stem cell transplantation patient also paralleled neutrophil engraftment.
C1 [Guzman-Suarez, B. B.; Buckley, M. W.; Gilmore, E. T.; Vocca, E.; Marty, F. M.; Baden, L. R.; Issa, N. C.; Koo, S.] Brigham & Womens Hosp, Div Infect Dis, Boston, MA 02115 USA.
[Guzman-Suarez, B. B.; Buckley, M. W.; Gilmore, E. T.; Vocca, E.; Marty, F. M.; Baden, L. R.; Issa, N. C.; Koo, S.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Guzman-Suarez, B. B.; Marty, F. M.; Baden, L. R.; Issa, N. C.; Koo, S.] Harvard Univ, Sch Med, Boston, MA USA.
[Moss, R.; Sanders, R.; Wurtman, D.; Fang, F.] NexBio Inc, San Diego, CA USA.
RP Koo, S (reprint author), Brigham & Womens Hosp, Div Infect Dis, 75 Francis St,PBB-A4 Boston, Boston, MA 02115 USA.
EM skoo@partners.org
OI Koo, Sophia/0000-0002-4973-7439
NR 20
TC 23
Z9 23
U1 0
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1398-2273
J9 TRANSPL INFECT DIS
JI Transpl. Infect. Dis.
PD AUG
PY 2012
VL 14
IS 4
BP 427
EP 433
DI 10.1111/j.1399-3062.2012.00718.x
PG 7
WC Immunology; Infectious Diseases; Transplantation
SC Immunology; Infectious Diseases; Transplantation
GA 991VT
UT WOS:000307731800024
PM 22340538
ER
PT J
AU Brizendine, KD
Baddley, JW
Pappas, PG
Leon, KJ
Rodriguez, JM
AF Brizendine, K. D.
Baddley, J. W.
Pappas, P. G.
Leon, K. J.
Rodriguez, J. M.
TI Fatal Burkholderia gladioli infection misidentified as Empedobacter
brevis in a lung transplant recipient with cystic fibrosis
SO TRANSPLANT INFECTIOUS DISEASE
LA English
DT Article
DE Burkholderia gladioli; Burkholderia; Empedobacter brevis; cystic
fibrosis; lung transplantation
ID PSEUDOMONAS-CEPACIA; SURVIVAL; PATIENT; COMPLEX
AB Data describing the risk of lung transplantation (LT), clinical features, and outcomes of patients with cystic fibrosis (CF) infected with Burkholderia gladioli are limited. Herein, we report a case of disseminated B. gladioli infection characterized by bacteremia, necrotizing pneumonia, lung abscess, and empyema in a lung transplant recipient with CF, highlight the importance of accurate microbiological identification, and review published outcomes of LT in CF patients infected with B. gladioli, which include cases of pneumonia, tracheobronchitis, bacteremia, and abscesses, and demonstrate an all-cause 1-year mortality of approximately 23%, often after combined medical and surgical treatment.
C1 [Brizendine, K. D.; Baddley, J. W.; Pappas, P. G.; Rodriguez, J. M.] Univ Alabama Birmingham, Div Infect Dis, Dept Med, Birmingham, AL 35294 USA.
[Baddley, J. W.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
[Leon, K. J.] Univ Alabama Birmingham, Div Pulm Allergy & Crit Care Med, Dept Med, Birmingham, AL 35294 USA.
RP Rodriguez, JM (reprint author), Univ Alabama Birmingham, Div Infect Dis, Dept Med, Tinsley Harrison Tower 229,1530 3rd Ave S, Birmingham, AL 35294 USA.
EM mrodri2@uab.edu
NR 20
TC 1
Z9 2
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1398-2273
J9 TRANSPL INFECT DIS
JI Transpl. Infect. Dis.
PD AUG
PY 2012
VL 14
IS 4
BP E13
EP E18
DI 10.1111/j.1399-3062.2012.00726.x
PG 6
WC Immunology; Infectious Diseases; Transplantation
SC Immunology; Infectious Diseases; Transplantation
GA 991VT
UT WOS:000307731800003
PM 22429703
ER
PT J
AU Berg, LJ
Delgado, MK
Ginde, AA
Montoy, JC
Bendavid, E
Camargo, CA
AF Berg, Laura J.
Delgado, M. Kit
Ginde, Adit A.
Montoy, Juan Carlos
Bendavid, Eran
Camargo, Carlos A., Jr.
TI Characteristics of US Emergency Departments That Offer Routine Human
Immunodeficiency Virus Screening
SO ACADEMIC EMERGENCY MEDICINE
LA English
DT Article
ID HEALTH-CARE SETTINGS; FOR-DISEASE-CONTROL; RECOMMENDATIONS; COHORT; RISK
AB ACADEMIC EMERGENCY MEDICINE 2012; 19:894900 (c) 2012 by the Society for Academic Emergency Medicine Abstract Objectives: The association between emergency department (ED) characteristics, ED directors perceptions of preventive services, and the availability of human immunodeficiency virus (HIV) screening are unknown. The authors hypothesized that, after adjusting for ED operational and demographic characteristics, teaching hospital status would be associated with increased availability, and ED crowding and ED director agreement with barriers to screening would be associated with decreased availability. Methods: This was a secondary, cross-sectional analysis on previously collected data from 2008 to 2009 regarding availability of ED preventive services. Data were obtained from a random sample of 277 EDs in which ED directors provided information on ED characteristics and availability of HIV screening and rated five barriers to providing preventive services. The association between the availability of HIV screening and teaching hospital and crowding status, ED volume, urbanrural location, ownership, geographic region, patient demographics, state HIV testing consent laws, and ED director opinions on barriers to providing preventive services were determined in univariate analyses and a multivariate logistic regression model. Results: Nineteen percent of the sampled EDs offer HIV screening. Teaching hospitals offer HIV screening more frequently than nonteaching hospitals (38% vs. 18%; p = 0.03), but after adjusting for other characteristics in a multivariate model, this association was not significant (relative risk ratio [RR] = 2.07, 95% confidence interval [CI] = 0.91 to 3.59). ED crowding also was not significantly associated with screening availability (RR = 0.66, 95% CI = 0.34 to 1.21). However, public ownership (RR = 2.13, 95% CI = 1.28 to 3.14), 24-hour social work (RR = 1.87, 95% CI = 1.02 to 2.99), uninsured population =35% (RR = 2.48, 95% CI = 1.39 to 3.69), increased local nonwhite minority population percentage (RR = 1.14 per 10%, 95% CI = 1.02 to 1.26), and state laws allowing opt-out consent for testing (RR = 1.76, 95% CI = 1.01 to 2.74) were associated with increased availability of screening in multivariable analysis. EDs whose directors were concerned about added costs were associated with decreased availability of screening (RR = 0.45, 95% CI = 0.23 to 0.85). Conclusions: After adjusting for other ED operational and demographic characteristics, ED crowding and teaching hospital affiliation were not independently associated with the availability of HIV screening. EDs whose directors were concerned about the cost of preventive services were less likely to provide routine HIV screening. Addressing ED directors concerns about the added costs of ED preventive services, increasing social work availability, and implementing testing laws consistent with Centers for Disease Control and Prevention (CDC) recommendations may facilitate increased adoption of ED HIV screening.
C1 [Delgado, M. Kit; Bendavid, Eran] Stanford Univ, Sch Med, Ctr Primary Care & Outcomes Res, Stanford, CA 94305 USA.
[Berg, Laura J.] Stanford Kaiser Emergency Med Residency, Stanford, CA USA.
[Delgado, M. Kit] Stanford Univ, Sch Med, Div Emergency Med, Stanford, CA 94305 USA.
[Bendavid, Eran] Stanford Univ, Sch Med, Div Gen Med Disciplines, Stanford, CA 94305 USA.
[Ginde, Adit A.] Univ Colorado, Sch Med, Dept Emergency Med, Aurora, CO USA.
[Montoy, Juan Carlos] Univ Calif San Francisco, San Francisco Gen Hosp, Boston, MA USA.
[Camargo, Carlos A., Jr.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Emergency Med, Boston, MA USA.
RP Delgado, MK (reprint author), Stanford Univ, Sch Med, Ctr Primary Care & Outcomes Res, Stanford, CA 94305 USA.
EM kdelgado@stanford.edu
RI bebarta, vikhyat/K-3476-2015; Siry, Bonnie/D-7189-2017
FU Agency for Health Care Research and Quality [T32HS00028]; NIH
FX Dr. Delgado was supported by the Agency for Health Care Research and
Quality training grant T32HS00028 to the Center for Primary Care and
Outcomes Research, Stanford University. Dr. Bendavid was supported in
part by an NIH Career Development award.
NR 17
TC 7
Z9 7
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1069-6563
J9 ACAD EMERG MED
JI Acad. Emerg. Med.
PD AUG
PY 2012
VL 19
IS 8
BP 894
EP 900
DI 10.1111/j.1553-2712.2012.01401.x
PG 7
WC Emergency Medicine
SC Emergency Medicine
GA 992JR
UT WOS:000307772300001
PM 22849642
ER
PT J
AU Ferencik, M
Schlett, CL
Bamberg, F
Truong, QA
Nichols, JH
Pena, AJ
Shapiro, MD
Rogers, IS
Seneviratne, S
Parry, BA
Cury, RC
Brady, TJ
Brown, DF
Nagurney, JT
Hoffmann, U
AF Ferencik, Maros
Schlett, Christopher L.
Bamberg, Fabian
Truong, Quynh A.
Nichols, John H.
Pena, Antonio J.
Shapiro, Michael D.
Rogers, Ian S.
Seneviratne, Sujith
Parry, Blair Alden
Cury, Ricardo C.
Brady, Thomas J.
Brown, David F.
Nagurney, John T.
Hoffmann, Udo
TI Comparison of Traditional Cardiovascular Risk Models and Coronary
Atherosclerotic Plaque as Detected by Computed Tomography for Prediction
of Acute Coronary Syndrome in Patients With Acute Chest Pain
SO ACADEMIC EMERGENCY MEDICINE
LA English
DT Article
ID EMERGENCY-DEPARTMENT PATIENTS; INTERNATIONAL MULTICENTER REGISTRY;
ELEVATION MYOCARDIAL-INFARCTION; ASSOCIATION TASK-FORCE; ACUTE CARDIAC
ISCHEMIA; PROGNOSTIC VALUE; UNSTABLE ANGINA; ARTERY-DISEASE; CT
ANGIOGRAPHY; INTRAVASCULAR ULTRASOUND
AB ACADEMIC EMERGENCY MEDICINE 2012; 19:934942 (c) 2012 by the Society for Academic Emergency Medicine Abstract Objectives: The objective was to determine the association of four clinical risk scores and coronary plaque burden as detected by computed tomography (CT) with the outcome of acute coronary syndrome (ACS) in patients with acute chest pain. The hypothesis was that the combination of risk scores and plaque burden improved the discriminatory capacity for the diagnosis of ACS. Methods: The study was a subanalysis of the Rule Out Myocardial Infarction Using Computer-Assisted Tomography (ROMICAT) triala prospective observational cohort study. The authors enrolled patients presenting to the emergency department (ED) with a chief complaint of acute chest pain, inconclusive initial evaluation (negative biomarkers, nondiagnostic electrocardiogram [ECG]), and no history of coronary artery disease (CAD). Patients underwent contrast-enhanced 64-multidetector-row cardiac CT and received standard clinical care (serial ECG, cardiac biomarkers, and subsequent diagnostic testing, such as exercise treadmill testing, nuclear stress perfusion imaging, and/or invasive coronary angiography), as deemed clinically appropriate. The clinical providers were blinded to CT results. The chest pain score was calculated and the results were dichotomized to =10 (high-risk) and <10 (low-risk). Three risk scores were calculated, Goldman, Sanchis, and Thrombolysis in Myocardial Infarction (TIMI), and each patient was assigned to a low-, intermediate-, or high-risk category. Because of the low number of subjects in the high-risk group, the intermediate- and high-risk groups were combined into one. CT images were evaluated for the presence of plaque in 17 coronary segments. Plaque burden was stratified into none, intermediate, and high (zero, one to four, and more than four segments with plaque). An outcome panel of two physicians (blinded to CT findings) established the primary outcome of ACS (defined as either an acute myocardial infarction or unstable angina) during the index hospitalization (from the presentation to the ED to the discharge from the hospital). Logistic regression modeling was performed to examine the association of risk scores and coronary plaque burden to the outcome of ACS. Unadjusted models were individually fitted for the coronary plaque burden and for Goldman, Sanchis, TIMI, and chest pain scores. In adjusted analyses, the authors tested whether the association between risk scores and ACS persisted after controlling for the coronary plaque burden. The prognostic discriminatory capacity of the risk scores and plaque burden for ACS was assessed using c-statistics. The differences in area under the receiver-operating characteristic curve (AUC) and c-statistics were tested by performing the -2 log likelihood ratio test of nested models. A p value <0.05 was considered statistically significant. Results: Among 368 subjects, 31 (8%) subjects were diagnosed with ACS. Goldman (AUC = 0.61), Sanchis (AUC = 0.71), and TIMI (AUC = 0.63) had modest discriminatory capacity for the diagnosis of ACS. Plaque burden was the strongest predictor of ACS (AUC = 0.86; p < 0.05 for all comparisons with individual risk scores). The combination of plaque burden and risk scores improved prediction of ACS (plaque + Goldman AUC = 0.88, plaque + Sanchis AUC = 0.90, plaque + TIMI AUC = 0.88; p < 0.01 for all comparisons with coronary plaque burden alone).
Conclusions: Risk scores (Goldman, Sanchis, TIMI) have modest discriminatory capacity and coronary plaque burden has good discriminatory capacity for the diagnosis of ACS in patients with acute chest pain. The combined information of risk scores and plaque burden significantly improves the discriminatory capacity for the diagnosis of ACS.
C1 [Ferencik, Maros; Truong, Quynh A.] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA.
[Schlett, Christopher L.; Bamberg, Fabian; Truong, Quynh A.; Nichols, John H.; Pena, Antonio J.; Shapiro, Michael D.; Rogers, Ian S.; Seneviratne, Sujith; Cury, Ricardo C.; Brady, Thomas J.; Hoffmann, Udo] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
[Parry, Blair Alden; Brown, David F.; Nagurney, John T.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA.
[Ferencik, Maros; Schlett, Christopher L.; Bamberg, Fabian; Truong, Quynh A.; Nichols, John H.; Pena, Antonio J.; Shapiro, Michael D.; Rogers, Ian S.; Seneviratne, Sujith; Cury, Ricardo C.; Brady, Thomas J.; Hoffmann, Udo] Massachusetts Gen Hosp, Cardiac MR PET CT Program, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA USA.
RP Ferencik, M (reprint author), Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA.
EM maros_ferencik@hms.harvard.edu
FU National Institutes of Health [RO1 HL080053, T32 HL076136]; Siemens
Medical Solutions; General Electrics Healthcare; Biosite
FX This work was supported by the National Institutes of Health (RO1
HL080053) and in part supported by Siemens Medical Solutions and General
Electrics Healthcare.; Drs. Ferencik, Rogers, Truong, and Shapiro were
supported by the National Institutes of Health grant (T32 HL076136). Dr.
Hoffmann has received research grants from Siemens Medical Solutions and
General Electric Healthcare. Dr. Nagurney is funded by Biosite for a
biomarker research study. The rest of the authors have no disclosures or
potential conflicts of interest to report.
NR 49
TC 11
Z9 11
U1 0
U2 8
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1069-6563
J9 ACAD EMERG MED
JI Acad. Emerg. Med.
PD AUG
PY 2012
VL 19
IS 8
BP 934
EP 942
DI 10.1111/j.1553-2712.2012.01417.x
PG 9
WC Emergency Medicine
SC Emergency Medicine
GA 992JR
UT WOS:000307772300006
PM 22849339
ER
PT J
AU Singh, JA
Lewallen, DG
AF Singh, Jasvinder A.
Lewallen, David G.
TI Peptic ulcer disease and heart disease are associated with
periprosthetic fractures after total hip replacement
SO ACTA ORTHOPAEDICA
LA English
DT Article
ID TOTAL KNEE ARTHROPLASTY; PROTON PUMP INHIBITORS; FEMORAL FRACTURES;
RISK; REVISION; REGISTER; COMORBIDITY; MORBIDITY; MORTALITY; PREDICT
AB Background and purpose There have been no published studies assessing the possible association of medical comorbidities with periprosthetic fracture risk. We therefore assessed whether medical comorbidity is associated with risk of periprosthetic fractures after total hip replacement (THR).
Material and methods We used prospectively collected data from 1989-2008 in the Mayo Clinic Total Joint Registry for 2 cohorts: primary THR and revision THR. The main variables of interest were Deyo-Charlson comorbidities at the time of surgery. Outcome of interest was p ostoperative periprosthetic fracture at postoperative day 1 onwards. Multivariable Cox regression models were additionally adjusted for age, sex, body mass index, American Society of Anesthesiology (ASA) class, and operative diagnosis.
Results We identified 14,065 primary THRs and 6,281 revision THRs with mean follow-up times of 6.3 and 5.6 years, respectively. There were 305 postoperative periprosthetic fractures in the primary THR cohort and 330 in the revision THR cohort. In patients who underwent primary THR, 2 comorbidities were associated with higher risk of periprosthetic fracture: peptic ulcer disease with adjusted hazard ratio of 1.5 (95% CI: 1.1-2.2) and heart disease with adjusted hazard ratio of 1.7 (CI: 1.2-2.4). In patients with revision THR, peptic ulcer disease was associated with a higher adjusted risk of periprosthetic fracture, 1.6 (CI: 1.1-2.3).
Interpretation Peptic ulcer disease and heart disease in primary THR patients and peptic ulcer disease in revision THR patients were associated with higher postoperative periprosthetic fracture risk. Further studies are needed to understand whether disease severity or specific medications used for treatment, or both, are responsible for this association. This may allow identification of modifiable factors.
C1 [Singh, Jasvinder A.] Birmingham VA Med Ctr, Med Serv, Birmingham, AL USA.
[Singh, Jasvinder A.] Birmingham VA Med Ctr, Ctr Surg Med Acute Care Res & Transit C SMART, Birmingham, AL USA.
[Singh, Jasvinder A.] Univ Alabama Birmingham, Sch Publ Hlth, Div Epidemiol, Birmingham, AL 35294 USA.
[Singh, Jasvinder A.] Univ Alabama Birmingham, Sch Med, Dept Med, Birmingham, AL USA.
[Singh, Jasvinder A.; Lewallen, David G.] Mayo Clin, Coll Med, Dept Orthoped Surg, Rochester, MN USA.
RP Singh, JA (reprint author), Birmingham VA Med Ctr, Med Serv, Birmingham, AL USA.
EM Jasvinder.md@gmail.com
OI singh, jasvinder/0000-0003-3485-0006
FU Mayo Clinic Orthopedic Surgery research funds; Birmingham VA Medical
Center, Alabama; NIH (Mayo Clinic Center for Clinical and Translational
Research) [1 KL2 RR024151-01]; URL Pharmaceuticals; Savient; Takeda;
Novartis; Zimmer; DePuy; Stryker
FX We thank Scott Harmsen and Matthew Jensen at the Mayo Clinic for
assistance in data programming and data analysis. This work was
supported through an NIH Clinical Translational Science Award (1 KL2
RR024151-01; Mayo Clinic Center for Clinical and Translational
Research), by Mayo Clinic Orthopedic Surgery research funds, and by the
Birmingham VA Medical Center, Alabama (resources and use of
facilities).; There are no financial conflicts relating directly to this
study. JA has received speaker honoraria from Abbott; research and
travel grants from Takeda, Savient, Wyeth and Amgen; and consultant fees
from URL Pharmaceuticals, Savient, Takeda, and Novartis. DGL has
received royalties/speaker fees from Zimmer, has been a paid consultant
to Zimmer, and has received institutional research funds from DePuy,
Stryker, and Zimmer. None of the sources of funding (NIH, Mayo Clinic,
Birmingham VA) had any role in the design or conduct of the study, data
analysis, interpretation of the results, or preparation of the
manuscript for publication.
NR 37
TC 3
Z9 4
U1 0
U2 3
PU INFORMA HEALTHCARE
PI NEW YORK
PA 52 VANDERBILT AVE, NEW YORK, NY 10017 USA
SN 1745-3674
J9 ACTA ORTHOP
JI Acta Orthop.
PD AUG
PY 2012
VL 83
IS 4
BP 353
EP 359
DI 10.3109/17453674.2012.717844
PG 7
WC Orthopedics
SC Orthopedics
GA 993HO
UT WOS:000307848600007
PM 22900908
ER
PT J
AU Armstrong, EJ
Kulkarni, AR
Hoffmayer, KS
Bhave, PD
MacGregor, JS
Hsue, P
Stein, JC
Kinlay, S
Ganz, P
McCabe, JM
AF Armstrong, Ehrin J.
Kulkarni, Ameya R.
Hoffmayer, Kurt S.
Bhave, Prashant D.
MacGregor, John S.
Hsue, Priscilla
Stein, John C.
Kinlay, Scott
Ganz, Peter
McCabe, James M.
TI Delaying Primary Percutaneous Coronary Intervention for Computed
Tomographic Scans in the Emergency Department
SO AMERICAN JOURNAL OF CARDIOLOGY
LA English
DT Article
ID ELEVATION MYOCARDIAL-INFARCTION; MASSIVE PULMONARY-EMBOLISM; ST-SEGMENT
ELEVATION; ISCHEMIC-STROKE; SYSTEM DELAY; CHEST-PAIN; DISEASE;
GUIDELINES; MANAGEMENT; REGISTRY
AB Patients presenting with suspected ST-segment elevation myocardial infarction (STEMI) may have important alternative diagnoses (e.g., aortic dissection, pulmonary emboli) or safety concerns for STEMI management (e.g., head trauma). Computed tomographic (CT) scanning may help in identifying these alternative diagnoses but may also needlessly delay primary percutaneous coronary intervention (PCI). We analyzed the ACTIVATE-SF Registry, which consists of consecutive patients with a clinical diagnosis of STEMI admitted to the emergency departments of 2 urban hospitals. Of 410 patients with a suspected diagnosis of STEMI, 45 (11%) underwent CT scanning before primary PCI. Presenting electrocardiograms, baseline risk factors, and presence of an angiographic culprit vessel were similar in those with and without CT scanning before PCI. Only 2 (4%) of these CT scans changed clinical management by identifying a stroke. Patients who underwent CT scanning had far longer door-to-balloon times (median 166 vs 75 minutes, p <0.001) and higher in-hospital mortality (20% vs 7.8%, p = 0.006). After multivariate adjustment, CT scanning in the emergency department before primary PCI remained independently associated with longer door-to-balloon times (100% longer, 95% confidence interval 60 to 160, p <0.001) but was no longer associated with mortality (odds ratio 1.4, p = 0.5). In conclusion, CT scanning before primary PCI rarely changed management and was associated with significant delays in door-to-balloon times. More judicious use of CT scanning should ne considered. (c) 2012 Elsevier Inc. All rights reserved. (Am J Cardiol 2012;110:345-349)
C1 [Kinlay, Scott; McCabe, James M.] Brigham & Womens Hosp, Div Cardiovasc Med, Boston, MA 02115 USA.
[Kinlay, Scott; McCabe, James M.] Harvard Univ, Sch Med, Boston, MA USA.
[Armstrong, Ehrin J.] Univ Calif Davis, Div Cardiovasc Med, Davis, CA 95616 USA.
[Kulkarni, Ameya R.; Hoffmayer, Kurt S.; MacGregor, John S.; Hsue, Priscilla; Ganz, Peter] Univ Calif San Francisco, Div Cardiol, San Francisco, CA USA.
[Bhave, Prashant D.] Northwestern Univ, Div Electrophysiol, Evanston, IL USA.
[MacGregor, John S.; Hsue, Priscilla; Ganz, Peter] San Francisco Gen Hosp, San Francisco, CA 94110 USA.
[Stein, John C.] Univ Calif San Francisco, Dept Emergency Med, San Francisco, CA 94143 USA.
[Kinlay, Scott] VA Boston Healthcare Syst, Div Cardiovasc, Boston, MA USA.
RP McCabe, JM (reprint author), Brigham & Womens Hosp, Div Cardiovasc Med, 75 Francis St, Boston, MA 02115 USA.
EM mccabe@aya.yale.edu
NR 16
TC 5
Z9 5
U1 1
U2 4
PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
PI BRIDGEWATER
PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA
SN 0002-9149
J9 AM J CARDIOL
JI Am. J. Cardiol.
PD AUG 1
PY 2012
VL 110
IS 3
BP 345
EP 349
DI 10.1016/j.amjcard.2012.03.032
PG 5
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 986DL
UT WOS:000307321000005
PM 22534052
ER
PT J
AU Thorpe, JM
Thorpe, CT
Kennelty, KA
Gellad, WF
Schulz, R
AF Thorpe, Joshua M.
Thorpe, Carolyn T.
Kennelty, Korey A.
Gellad, Walid F.
Schulz, Richard
TI The Impact of Family Caregivers on Potentially Inappropriate Medication
Use in Noninstitutionalized Older Adults With Dementia
SO AMERICAN JOURNAL OF GERIATRIC PHARMACOTHERAPY
LA English
DT Article
DE care quality; dementia; inappropriate medications; informal caregivers
ID RANDOMIZED CONTROLLED-TRIAL; BEERS CRITERIA; COMMUNITY; HOME;
PRESCRIPTION; CARE; HOSPITALIZATION; POLYPHARMACY; DISORDERS; FRAMEWORK
AB Background: The risk of potentially inappropriate medication (PIM), both prescription and over-the-counter, use in dementia patients is high. Informal caregivers often facilitate patients' use of medications, but the effect of caregiver factors on PIM use has not been a focus of previous research.
Objective: The aim of this study was to examine PIM use in dementia patients and caregivers and identify caregiver risk factors for PIM use in dementia patients.
Methods: We conducted a secondary data analysis of the baseline wave of the Resources for Enhancing Alzheimer's Caregiver's Health study. The sample comprised 566 persons with dementia aged 65 and older and their coresiding family caregiver. PIM was defined using the 2003 Beers criteria and was examined in both dementia patients and their caregivers. Caregiver and patient risk factors included a range of sociodemographic and health variables.
Results: In dementia patients, 33% were taking at least 1 PIM, and 39% of their caregivers were also taking a PIM. In fully adjusted models, the following caregiver factors were associated with an increased risk of dementia patient PIM use: caregiver's own PIM use, spouse caregivers, Hispanic caregivers, and greater number of years that the caregiver has lived in the United States. Increased caregiver age was associated with a decreased risk of PIM use in patients.
Conclusions: PIM use may be higher in dementia patients and their informal caregivers compared with the general older adult population. Further, patterns of medication use in 1 member of the dyad may influence PIM risk in the other dyad member. These results suggest that interventions to increase appropriate medication use in dementia patients and their caregivers should target both members of the dyad and target over-the-counter agents along with prescription medications. (Am J Geriatr Pharmacother. 2012;10:230-241) Published by Elsevier HS Journals, Inc.
C1 [Thorpe, Joshua M.; Thorpe, Carolyn T.] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Pittsburgh, PA 15261 USA.
[Thorpe, Joshua M.; Thorpe, Carolyn T.; Gellad, Walid F.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Kennelty, Korey A.] Univ Wisconsin, Madison Sch Pharm, Div Social & Adm Sci, Madison, WI USA.
[Gellad, Walid F.] Univ Pittsburgh, Sch Med, Dept Med Gen Med, Pittsburgh, PA USA.
[Gellad, Walid F.] RAND Corp, Pittsburgh, PA USA.
[Schulz, Richard] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA.
[Schulz, Richard] Univ Pittsburgh, Univ Ctr Social & Urban Res, Pittsburgh, PA 15260 USA.
RP Thorpe, JM (reprint author), Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, 916 Salk Hall,3501 Terrace St, Pittsburgh, PA 15261 USA.
EM jmthorpe@pitt.edu; ctthorpe@pitt.edu
RI Thorpe, Joshua/C-1188-2013
FU National Institute on Aging, National Institutes of Health; Veterans
Affairs Career Development Award [CDA 09-207]; Health Innovation
Program; Community-Academic Partnerships core of the University of
Wisconsin Institute for Clinical and Translational Research (UW ICTR);
Clinical and Translational Science Award (CTSA) program of the National
Center for Research Resources, National Institutes of Health [1UL1
RR025011]
FX This study was supported by grant R03AG029995 from the National
Institute on Aging, National Institutes of Health, and a Veterans
Affairs Career Development Award (CDA 09-207). Additional support was
provided by the Health Innovation Program and the Community-Academic
Partnerships core of the University of Wisconsin Institute for Clinical
and Translational Research (UW ICTR), grant 1UL1 RR025011 from the
Clinical and Translational Science Award (CTSA) program of the National
Center for Research Resources, National Institutes of Health. The views
expressed in this article are those of the authors and do not
necessarily reflect the position or policy of the Department of Veterans
Affairs or the United States government. No funding source had a role in
the design, methods, subject recruitment, data collection, analysis, or
preparation of the manuscript. The authors have indicated that they have
no other conflicts of interest regarding the content of this article.
NR 53
TC 14
Z9 14
U1 7
U2 14
PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
PI BRIDGEWATER
PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA
SN 1543-5946
J9 AM J GERIATR PHARMAC
JI Am. J. Geriatr. Pharmacother.
PD AUG
PY 2012
VL 10
IS 4
BP 230
EP 241
DI 10.1016/j.amjopharm.2012.05.001
PG 12
WC Geriatrics & Gerontology; Pharmacology & Pharmacy
SC Geriatrics & Gerontology; Pharmacology & Pharmacy
GA 992QV
UT WOS:000307795700002
PM 22683399
ER
PT J
AU Woltmann, E
Grogan-Kaylor, A
Perron, B
Georges, H
Kilbourne, AM
Bauer, MS
AF Woltmann, Emily
Grogan-Kaylor, Andrew
Perron, Brian
Georges, Hebert
Kilbourne, Amy M.
Bauer, Mark S.
TI Comparative Effectiveness of Collaborative Chronic Care Models for
Mental Health Conditions Across Primary, Specialty, and Behavioral
Health Care Settings: Systematic Review and Meta-Analysis
SO AMERICAN JOURNAL OF PSYCHIATRY
LA English
DT Article; Proceedings Paper
CT Annual Meeting of the VA-Health-Services-Research-and-Development
CY FEB 16, 2011
CL Baltimore, MD
SP VA Hlth Serv Res & Dev
ID RANDOMIZED-CONTROLLED-TRIAL; MEDICATION ALGORITHM PROJECT; IMPROVING
PRIMARY-CARE; LATE-LIFE DEPRESSION; DISSEMINATING QUALITY IMPROVEMENT;
STARTING ANTIDEPRESSANT TREATMENT; DISEASE MANAGEMENT PROGRAMS; REDUCING
SUICIDAL IDEATION; LONG-TERM EFFECTIVENESS; LOW-INCOME WOMEN
AB Objective: Collaborative chronic care models (CCMs) improve outcome in chronic medical illnesses and depression treated in primary care settings. The effect of such models across other treatment settings and mental health conditions has not been comprehensively assessed. The authors performed a systematic review and meta-analysis to assess the comparative effectiveness of CCMs for mental health conditions across disorders and treatment settings.
Method: Randomized controlled trials comparing CCMs with other care conditions, published or in press by August 15, 2011, were identified in a literature search and through contact with investigators. CCMs were defined a priori as interventions with at least three of the six components of the Improving Chronic Illness Care initiative (patient self-management support, clinical information systems, delivery system redesign, decision support, organizational support, and community,resource linkages). Articles were included if the CCM effect on mental health symptoms or mental quality of life was reported. Data extraction included analyses of these outcomes plus social role function, physical and overall quality of life, and costs. Meta-analyses included comparisons using unadjusted continuous measures.
Results: Seventy-eight articles yielded 161 analyses from 57 trials (depression, N=40; bipolar disorder, N=4; anxiety disorders, N=3; multiple/other disorders, N=10). The meta-analysis indicated significant effects across disorders and care settings for depression as well as for mental and physical quality of life and social role function (Cohen's d values, 0.20-0.33). Total health care costs did not differ between CCMs and comparison models. A systematic review largely confirmed and extended these findings across conditions and outcome domains.
Conclusions: CCMs can improve mental and physical outcomes for individuals with mental disorders across a wide variety of care settings, and they provide a robust clinical and policy framework for care integration.
C1 [Bauer, Mark S.] Washington Univ, Brown Sch, St Louis, MO 63130 USA.
Univ Michigan, Sch Social Work, Ann Arbor, MI 48109 USA.
Harvard Univ, Sch Med, Harvard S Shore Psychiat Residency Training Progr, Brockton, MA 02401 USA.
Ann Arbor VA Med Ctr, Ann Arbor, MI USA.
Univ Michigan Hlth Syst, Dept Psychiat, Ann Arbor, MI USA.
VA Boston Healthcare Syst, Ctr Org Leadership & Management Res, Boston, MA USA.
RP Bauer, MS (reprint author), Washington Univ, Brown Sch, St Louis, MO 63130 USA.
EM mark.bauer@va.gov
OI Grogan-Kaylor, Andrew/0000-0003-0065-9991
FU NIMH NIH HHS [R-01-MH-079994]
NR 139
TC 133
Z9 135
U1 7
U2 42
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 0002-953X
J9 AM J PSYCHIAT
JI Am. J. Psychiat.
PD AUG
PY 2012
VL 169
IS 8
BP 790
EP 804
DI 10.1176/appi.ajp.2012.11111616
PG 15
WC Psychiatry
SC Psychiatry
GA 980JH
UT WOS:000306888900007
PM 22772364
ER
PT J
AU Gray, KM
Carpenter, MJ
Baker, NL
DeSantis, SM
Kryway, E
Hartwell, KJ
McRae-Clark, AL
Brady, KT
AF Gray, Kevin M.
Carpenter, Matthew J.
Baker, Nathaniel L.
DeSantis, Stacia M.
Kryway, Elisabeth
Hartwell, Karen J.
McRae-Clark, Aimee L.
Brady, Kathleen T.
TI A Double-Blind Randomized Controlled Trial of N-Acetylcysteine in
Cannabis-Dependent Adolescents
SO AMERICAN JOURNAL OF PSYCHIATRY
LA English
DT Article
ID INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW; PLACEBO-CONTROLLED TRIAL;
YOUTH TREATMENT CYT; CONTINGENCY MANAGEMENT; MAIN FINDINGS; DRUG;
RELIABILITY; MEDICATIONS; ADDICTIONS; CESSATION
AB Objective: Preclinical findings suggest that the over-the-counter supplement N-acetylcysteine (NAC), via glutamate modulation in the nucleus accumbens, holds promise as a pharmacotherapy for substance dependence. The authors investigated NAC as a novel cannabis cessation treatment in adolescents, a vulnerable group for whom existing treatments have shown limited efficacy.
Method: In an 8-week double-blind randomized placebo-controlled trial, treatment-seeking cannabis-dependent adolescents (ages 15-21 years; N=116) received NAC (1200 mg) or placebo twice daily as well as a contingency management intervention and brief (< 10 minutes) weekly cessation counseling. The primary efficacy measure was the odds of negative weekly urine cannabinoid test results during treatment among participants receiving NAC compared with those receiving placebo, in an intent-to-treat analysis. The primary tolerability measure was frequency of adverse events, compared by treatment group.
Results: Participants receiving NAC had more than twice the odds, compared with those receiving placebo, of having negative urine cannabinoid test results during treatment (odds ratio=2.4, 95% CI=1.1-5.2). Exploratory secondary abstinence outcomes favored NAC but were not statistically significant. NAC was well tolerated, with minimal adverse events.
Conclusions: This is the first randomized controlled trial of pharmacotherapy for cannabis dependence in any age group to yield a positive primary cessation outcome in an intent-to-treat analysis. Findings support NAC as a pharmacotherapy to complement psychosocial treatment for cannabis dependence in adolescents.
C1 [Gray, Kevin M.] Med Univ S Carolina, Hollings Canc Ctr, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA.
Med Univ S Carolina, Dept Med, Div Biostat & Epidemiol, Charleston, SC USA.
Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA.
RP Gray, KM (reprint author), Med Univ S Carolina, Hollings Canc Ctr, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA.
EM graykm@musc.edu
RI McRae-Clark, Aimee/I-3341-2013
OI McRae-Clark, Aimee/0000-0002-9774-318X
FU Merck; Supernus Pharmaceuticals; Pfizer; Shire Pharmaceuticals;
GlaxoSmithKline; National Institute on Drug Abuse (NIDA) [R01DA026777];
National Center for Research Resources [UL1RR029882]; NIDA [K23DA020482]
FX Dr. Gray has received research funding from Merck and Supernus
Pharmaceuticals. Dr. Hartwell has received research funding from Pfizer.
Dr. McRae-Clark has received research funding from Shire
Pharmaceuticals. Dr. Brady has received research funding from
GlaxoSmithKline. The other authors report no financial relationships
with commercial interests.; Supported by National Institute on Drug
Abuse (NIDA) grant R01DA026777, via the American Recovery and
Reinvestment Act of 2009. Administrative and technical support was
provided by National Center for Research Resources grant UL1RR029882.
Dr. Carpenter's effort was supported by NIDA grant K23DA020482.
NR 40
TC 64
Z9 67
U1 7
U2 19
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 0002-953X
J9 AM J PSYCHIAT
JI Am. J. Psychiat.
PD AUG
PY 2012
VL 169
IS 8
BP 805
EP 812
DI 10.1176/appi.ajp.2012.12010055
PG 8
WC Psychiatry
SC Psychiatry
GA 980JH
UT WOS:000306888900008
PM 22706327
ER
PT J
AU Vizueta, N
Rudie, JD
Townsend, JD
Torrisi, S
Moody, TD
Bookheimer, SY
Altshuler, LL
AF Vizueta, Nathalie
Rudie, Jeffrey D.
Townsend, Jennifer D.
Torrisi, Salvatore
Moody, Teena D.
Bookheimer, Susan Y.
Altshuler, Lori L.
TI Regional fMRI Hypoactivation and Altered Functional Connectivity During
Emotion Processing in Nonmedicated Depressed Patients With Bipolar II
Disorder
SO AMERICAN JOURNAL OF PSYCHIATRY
LA English
DT Article
ID VOXEL-BASED METAANALYSIS; FACIAL EXPRESSIONS; AMYGDALA ACTIVATION;
RATING-SCALE; RESPONSES; MANIA; FACES; STATE; RECOGNITION; TRAIT
AB Objective: Although the amygdala and ventrolateral prefrontal cortex have been implicated in the pathophysiology of bipolar I disorder, the neural mechanisms underlying bipolar II disorder remain unknown. The authors examined neural activity in response to negative emotional faces during an emotion perception task that reliably activates emotion regulatory regions.
Method: Twenty-one nonmedicated depressed bipolar II patients and 21 healthy comparison subjects underwent functional MRI (fMRI) while performing an emotional face-matching task. Within- and between-group whole-brain fMRI activation and seed-based connectivity analyses were conducted.
Results: In depressed bipolar II patients, random-effects between-group fMRI analyses revealed a significant reduction in activation in several regions, including the left and right ventrolateral prefrontal cortices (Brodmann's area [BA] 47) and the right amygdala, a priori regions of interest. Additionally, bipolar patients exhibited significantly reduced negative functional connectivity between the right amygdala and the right orbitofrontal cortex (BA 10) as well as the right dorsolateral prefrontal cortex (BA 46) relative to healthy comparison subjects.
Conclusions: These findings suggest that bipolar II depression is characterized by reduced regional orbitofrontal and limbic activation and altered connectivity in a fronto-temporal circuit implicated in working memory and emotional learning. While the amygdala hypoactivation observed in bipolar II depression is opposite to the direction seen in bipolar I mania and may therefore be state dependent, the observed orbitofrontal cortex hypoactivation is consistent with findings in bipolar I depression, mania, and euthymia, suggesting a physiologic trait marker of the disorder.
C1 [Vizueta, Nathalie] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90095 USA.
Univ Calif Los Angeles, David Geffen Sch Med, Ahmanson Lovelace Brain Mapping Ctr, Los Angeles, CA 90095 USA.
Univ Calif Los Angeles, David Geffen Sch Med, Neurosci Interdept Program, Los Angeles, CA 90095 USA.
W Los Angeles Healthcare Ctr, VA Greater Los Angeles Healthcare Syst, Dept Psychiat, Los Angeles, CA USA.
RP Vizueta, N (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90095 USA.
EM vizuetan@gmail.com
FU NIMH [K24 MH-01848, T32 MH-17140]; University of California, Los
Angeles, Integrative Study Center in Mood Disorders; National Center for
Research Resources [RR12169, RR13642, RR00865]; Ahmanson Foundation;
Brain Mapping Medical Research Organization; Brain Mapping Support
Foundation; Capital Group Companies Charitable Foundation; Jennifer
Jones-Simon Foundation; Northstar Fund; Pierson-Lovelace Foundation;
Robson Family; Tamkin Foundation; Northern Piedmont Community Foundation
FX Supported by NIMH grants (K24 MH-01848, T32 MH-17140) and a fellowship
from the University of California, Los Angeles, Integrative Study Center
in Mood Disorders to Dr. Vizueta; by grants from the National Center for
Research Resources (RR12169, RR13642, and RR00865); and by the Ahmanson
Foundation, the Brain Mapping Medical Research Organization, the Brain
Mapping Support Foundation, the Capital Group Companies Charitable
Foundation, the Jennifer Jones-Simon Foundation, the Northstar Fund, the
Pierson-Lovelace Foundation, the Robson Family, the Tamkin Foundation,
and the William M. and Linda R. Dietel Philanthropic Fund at the
Northern Piedmont Community Foundation.
NR 46
TC 43
Z9 44
U1 1
U2 13
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 0002-953X
J9 AM J PSYCHIAT
JI Am. J. Psychiat.
PD AUG
PY 2012
VL 169
IS 8
BP 831
EP 840
DI 10.1176/appi.ajp.2012.11030349
PG 10
WC Psychiatry
SC Psychiatry
GA 980JH
UT WOS:000306888900011
PM 22773540
ER
PT J
AU Matsunaga, J
Coutinho, ML
AF Matsunaga, James
Coutinho, Mariana L.
TI Positive Regulation of Leptospira interrogans kdp Expression by KdpE as
Demonstrated with a Novel beta-Galactosidase Reporter in Leptospira
biflexa
SO APPLIED AND ENVIRONMENTAL MICROBIOLOGY
LA English
DT Article
ID ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; GENE-EXPRESSION; OUTER-MEMBRANE;
SPIROCHETE; INACTIVATION; MUTAGENESIS; CONSTRUCTION; PATHOGENESIS;
VIRULENCE
AB Leptospirosis is a potentially deadly zoonotic disease that afflicts humans and animals. Leptospira interrogans, the predominant agent of leptospirosis, encounters diverse conditions as it proceeds through its life cycle, which includes stages inside and outside the host. Unfortunately, the number of genetic tools available for examining the regulation of gene expression in L. interrogans is limited. Consequently, little is known about the genetic circuits that control gene expression in Leptospira. To better understand the regulation of leptospiral gene expression, the L. interrogans kdp locus, encoding homologs of the P-type ATPase KdpABC potassium transporter with their KdpD sensors and KdpE response regulators, was selected for analysis. We showed that a kdpE mutation in L. interrogans prevented the increase in kdpABC mRNA levels observed in the wild-type L interrogans strain when external potassium levels were low. To confirm that KdpE was a positive regulator of kdpABC transcription, we developed a novel approach for constructing chromosomal genetic fusions to the endogenous bgaL (beta-galactosidase) gene of the nonpathogen Leptospira biflexa. We demonstrated positive regulation of a kdpA'-bgaL fusion in L. biflexa by the L. interrogans KdpE response regulator. A control lipL32'-bgaL fusion was not regulated by KdpE. These results demonstrate the utility of genetic fusions to the bgaL gene of L. biflexa for examining leptospiral gene regulation.
C1 [Matsunaga, James; Coutinho, Mariana L.] Vet Affairs Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA USA.
[Matsunaga, James; Coutinho, Mariana L.] Univ Calif Los Angeles, Dept Med, David Geffen Sch Med, Los Angeles, CA 90024 USA.
[Coutinho, Mariana L.] Univ Fed Pelotas, Ctr Biotecnol, Pelotas, Brazil.
RP Matsunaga, J (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA USA.
EM jamesm@ucla.edu
RI Coutinho, Mariana/J-9024-2012
FU VA Medical Research Funds
FX This study was supported by VA Medical Research Funds (to J.M.).
NR 44
TC 8
Z9 8
U1 1
U2 5
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0099-2240
J9 APPL ENVIRON MICROB
JI Appl. Environ. Microbiol.
PD AUG
PY 2012
VL 78
IS 16
BP 5699
EP 5707
DI 10.1128/AEM.00713-12
PG 9
WC Biotechnology & Applied Microbiology; Microbiology
SC Biotechnology & Applied Microbiology; Microbiology
GA 983SR
UT WOS:000307139500028
PM 22685146
ER
PT J
AU Ginat, DT
Sedaghat, AR
Robson, CD
Whittemore, KR
AF Ginat, Daniel T.
Sedaghat, Ahmad R.
Robson, Caroline D.
Whittemore, Kenneth R., Jr.
TI Radiology Quiz Case 3 Malleus fixation
SO ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY
LA English
DT Editorial Material
C1 [Ginat, Daniel T.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Sedaghat, Ahmad R.] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA.
[Sedaghat, Ahmad R.; Whittemore, Kenneth R., Jr.] Harvard Univ, Sch Med, Boston, MA USA.
[Robson, Caroline D.; Whittemore, Kenneth R., Jr.] Childrens Hosp, Boston, MA 02115 USA.
RP Ginat, DT (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 6
TC 1
Z9 1
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 0886-4470
J9 ARCH OTOLARYNGOL
JI Arch. Otolaryngol. Head Neck Surg.
PD AUG
PY 2012
VL 138
IS 8
BP 775
EP 776
PG 2
WC Otorhinolaryngology; Surgery
SC Otorhinolaryngology; Surgery
GA 991YW
UT WOS:000307741400014
PM 22911306
ER
PT J
AU Naunheim, MR
Abbott, MM
Lin, HW
Faquin, WC
Deschler, DG
AF Naunheim, Matthew R.
Abbott, Megan M.
Lin, Harrison W.
Faquin, William C.
Deschler, Daniel G.
TI Pathology Quiz Case 3 Carcinoma ex pleomorphic adenoma (CXPA), salivary
duct carcinoma type, noninvasive
SO ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY
LA English
DT Editorial Material
ID POSTOPERATIVE RADIATION-THERAPY; PAROTID-GLAND
C1 [Naunheim, Matthew R.; Faquin, William C.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Abbott, Megan M.; Lin, Harrison W.; Deschler, Daniel G.] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA.
[Faquin, William C.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Naunheim, MR (reprint author), Harvard Univ, Sch Med, Boston, MA 02115 USA.
NR 10
TC 0
Z9 0
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 0886-4470
J9 ARCH OTOLARYNGOL
JI Arch. Otolaryngol. Head Neck Surg.
PD AUG
PY 2012
VL 138
IS 8
BP 781
EP 783
PG 3
WC Otorhinolaryngology; Surgery
SC Otorhinolaryngology; Surgery
GA 991YW
UT WOS:000307741400017
PM 22911312
ER
PT J
AU Malandraki, GA
Kaufman, A
Hind, J
Ennis, S
Gangnon, R
Waclawik, A
Robbins, J
AF Malandraki, Georgia A.
Kaufman, Andrew
Hind, Jacqueline
Ennis, Stephanie
Gangnon, Ronald
Waclawik, Andrew
Robbins, JoAnne
TI The Effects of Lingual Intervention in a Patient With Inclusion Body
Myositis and Sjogren's Syndrome: A Longitudinal Case Study
SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION
LA English
DT Article
DE Inclusion body myositis; Longitudinal studies; Neuromuscular diseases;
Rehabilitation; Swallowing
ID IDIOPATHIC INFLAMMATORY MYOPATHIES; PENETRATION-ASPIRATION SCALE; ORAL
MANIFESTATIONS; OLDER-ADULTS; DYSPHAGIA; EXERCISE; STRENGTH; MUSCLE
AB Objective: To report the 5-year course of a patient's swallowing disorder in the context of progressive neuromuscular disease and the effectiveness of a lingual strengthening treatment program.
Design: This is a case report that describes a lingual treatment protocol that was repeated 3 times over a 5-year period with and without maintenance periods.
Setting: The study was completed in 2 settings an outpatient swallowing clinic at an acute care hospital and the patient's home.
Participant: The subject was a 77-year-old woman who was diagnosed with inclusion body myositis and Sjogren's syndrome.
Intervention: The patient participated in an intensive 8-week lingual strengthening protocol 3 times (at years 1, 4, and 5) and a subsequent maintenance program twice (at years 4 and 5).
Main Outcome Measures: Three outcome measures were collected during the study: (I) lingual manometric pressures at the anterior and posterior tongue, measured by using a lingual manometric device, (2) airway invasion measured by using an 8-point Penetration-Aspiration Scale, and (3) clearance of the bolus measured by using a 3-point residue scale.
Result: Isometric lingual strengthening was effective in maintaining posterior tongue lingual pressure and Penetration-Aspiration Scale scores during the treatment periods. Residue scale scores did not significantly change during treatment.
Conclusions: We conclude that, in this patient, lingual strengthening slowed the progression of disease-related lingual strength loss and extended functional swallowing performance. Thus, this type of intervention may hold promise as an effective swallowing treatment option for patients with neurodegenerative inflammatory diseases such as inclusion body myositis and Sjogren's syndrome.
C1 [Malandraki, Georgia A.] Columbia Univ, Dept Biobehav Sci, Teachers Coll, Program Speech & Language Pathol, New York, NY 10027 USA.
[Malandraki, Georgia A.; Hind, Jacqueline; Robbins, JoAnne] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI USA.
[Malandraki, Georgia A.; Hind, Jacqueline; Robbins, JoAnne] Univ Wisconsin, Dept Med, Madison, WI USA.
[Gangnon, Ronald] Univ Wisconsin, Dept Biostat & Med Informat, Madison, WI USA.
[Gangnon, Ronald] Univ Wisconsin, Dept Populat Hlth Sci, Madison, WI USA.
[Waclawik, Andrew] Univ Wisconsin, Dept Neurol, Madison, WI 53706 USA.
[Kaufman, Andrew] Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Bethesda, MD USA.
[Ennis, Stephanie] Univ Washington, Seattle, WA 98195 USA.
RP Malandraki, GA (reprint author), Columbia Univ, Dept Biobehav Sci, Teachers Coll, Program Speech & Language Pathol, 1052A Thorndike Hall,525 W 120th St, New York, NY 10027 USA.
EM malandraki@tc.columbia.edu
FU Department of Veterans Affairs, Veterans Health Administration, Office
of Research and Development, Rehabilitation Research and Development
Service
FX Supported in part by the Department of Veterans Affairs, Veterans Health
Administration, Office of Research and Development, Rehabilitation
Research and Development Service.
NR 37
TC 6
Z9 6
U1 1
U2 10
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0003-9993
J9 ARCH PHYS MED REHAB
JI Arch. Phys. Med. Rehabil.
PD AUG
PY 2012
VL 93
IS 8
BP 1469
EP 1475
DI 10.1016/j.apmr.2012.02.010
PG 7
WC Rehabilitation; Sport Sciences
SC Rehabilitation; Sport Sciences
GA 983XJ
UT WOS:000307151700028
PM 22480545
ER
PT J
AU Flower, C
Hennis, AJM
Hambleton, IR
Nicholson, GD
Liang, MH
AF Flower, Cindy
Hennis, Anselm J. M.
Hambleton, Ian R.
Nicholson, George D.
Liang, Matthew H.
CA Barbados Natl Lupus Registry Grp
TI Systemic Lupus Erythematosus in an African Caribbean Population:
Incidence, Clinical Manifestations, and Survival in the Barbados
National Lupus Registry
SO ARTHRITIS CARE & RESEARCH
LA English
DT Article
ID REVISED CRITERIA; WEST-AFRICA; MORTALITY; COHORT; CLASSIFICATION; RACE;
EPIDEMIOLOGY; PREVALENCE; RATES; BALTIMORE
AB Objective. To assess the epidemiology, clinical features, and outcomes of systemic lupus erythematosus (SLE) in the predominantly African Caribbean population of Barbados.
Methods. A national registry of all patients diagnosed with SLE was established in 2007. Complete case ascertainment was facilitated by collaboration with the island's sole rheumatology service, medical practitioners, and the lupus advocacy group. Informed consent was required for inclusion.
Results. Between January 1, 2000 and December 31, 2009, there were 183 new cases of SLE (98% African Caribbean) affecting 172 women and 11 men for unadjusted annual incidence rates of 12.21 (95% confidence interval [95% CI] 10.46-14.18) and 0.84 (95% CI 0.42-1.51) per 100,000 person-years, respectively. Excluding pediatric cases (ages <18 years), the unadjusted incidence rate among women was 15.14 per 100,000 person-years. The principal presenting manifestations were arthritis (84%), nephritis (47%), pleuritis (41.5%), malar rash (36.4%), and discoid lesions (33.1%). Antinuclear antibody positivity was 95%. The overall 5-year survival rate was 79.9% (95% CI 69.6-87.1), decreasing to 68% in patients with nephritis. A total of 226 persons with SLE were alive at the end of the study for point prevalences of 152.6 (95% CI 132.8-174.5) and 10.1 (95% CI 5.4-17.2) per 100,000 among women and men, respectively.
Conclusion. Rates of SLE in Barbadian women are among the highest reported to date, with clinical manifestations similar to African American women and high mortality. Further study of this population and similar populations of West African descent might assist our understanding of environmental, genetic, and health care issues underpinning disparities in SLE.
C1 [Flower, Cindy] Univ W Indies, Fac Med Sci, Bridgetown, Barbados.
[Liang, Matthew H.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Liang, Matthew H.] VA Boston Healthcare Syst, Massachusetts Vet Epidemiol Res & Informat Ctr, Boston, MA USA.
RP Flower, C (reprint author), Univ W Indies, Fac Med Sci, Cave Hill Campus, Bridgetown, Barbados.
EM cindy.flower@cavehill.uwi.edu
FU Alliance for Lupus Research [55506]
FX Supported by the Alliance for Lupus Research (award 55506).
NR 51
TC 16
Z9 16
U1 2
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2151-464X
J9 ARTHRIT CARE RES
JI Arthritis Care Res.
PD AUG
PY 2012
VL 64
IS 8
BP 1151
EP 1158
DI 10.1002/acr.21656
PG 8
WC Rheumatology
SC Rheumatology
GA 995SM
UT WOS:000308032900007
PM 22392730
ER
PT J
AU Larkin, ME
Lorenzi, GM
Bayless, M
Cleary, PA
Barnie, A
Golden, E
Hitt, S
Genuth, S
AF Larkin, Mary E.
Lorenzi, Gayle M.
Bayless, Meg
Cleary, Patricia A.
Barnie, Annette
Golden, Ellen
Hitt, Susan
Genuth, Saul
TI Evolution of the study coordinator role: The 28-year experience in
Diabetes Control and Complications Trial/Epidemiology of Diabetes
Interventions and Complications (DCCT/EDIC)
SO CLINICAL TRIALS
LA English
DT Article
ID CLINICAL-TRIALS; NEUROPATHY; COHORT; NURSE
AB Background The role of the study coordinator (SC) in multicenter studies of long duration has received limited attention.
Purpose To describe the evolution of the SC's role during the 28-year Diabetes Control and Complications Trial (DCCT) and its follow-up study, the Epidemiology of Diabetes Interventions and Complications (EDIC) study.
Methods The evolution of the SC's position from the traditional role of protocol implementation to that of research collaborator and co-investigator, based on personal experience and observation, is described in detail. Findings from a survey regarding professional demographics and job satisfaction, completed by all 28 SCs in 2010, provided additional information. We used dimensions of the SC's role specific to DCCT/EDIC to construct a classification schema of functions and responsibilities that describe the SC's role.
Results Among the 28 SCs, 24 were nurses, 12 held bachelor's degrees, 11 had a master's degree, 19 were certified diabetes educators (CDEs), 12 had worked with DCCT/ EDIC for more than 20 years, and 5 had been with the study since its inception (>26 years). Responses confirmed a high degree of functional consistency across sites with data acquisition, performing study procedures, recruitment and consent for additional ancillary studies, regulatory management, scheduling, clinical consultation, and ongoing contact with study participants frequently reported. Study-wide leadership activities, a category not generally included in the usual SC role, were reported by approximately 30% of the SCs. The level of professional satisfaction was high with two-thirds being very satisfied, one-third moderately to quite satisfied, and none dissatisfied.
Limitations The limitations include a relatively small sample size, self-reported data, and a single long-term multicenter trial and observational follow-up study on which we based our findings and conclusions.
Conclusions By optimizing their organizational and scientific contributions to the overall research endeavor, SCs in DCCT/EDIC have made major contributions to the unprecedented success of the study and report high job satisfaction. The efforts of the SCs have been integral to the remarkably high participant retention and data completion rates. The DCCT/EDIC experience may serve as a model for the role of the SC in future diabetes and other multicenter clinical trials. Clinical Trials 2012; 9 : 418-425. http://ctj.sagepub.com
C1 [Larkin, Mary E.] Harvard Univ, Massachusetts Gen Hosp, Ctr Diabet, Sch Med, Boston, MA 02114 USA.
[Lorenzi, Gayle M.] Univ Calif San Diego, La Jolla, CA 92093 USA.
[Bayless, Meg] Univ Iowa, Iowa City, IA USA.
[Cleary, Patricia A.] George Washington Univ, Rockville, MD USA.
[Barnie, Annette] Univ Toronto, Toronto, ON M5S 1A1, Canada.
[Golden, Ellen] Joslin Diabet Ctr, Boston, MA 02215 USA.
[Hitt, Susan] Univ Missouri, Columbia, MO USA.
[Genuth, Saul] Case Western Reserve Univ, Cleveland, OH 44106 USA.
RP Larkin, ME (reprint author), Harvard Univ, Massachusetts Gen Hosp, Ctr Diabet, Sch Med, 50 Staniford St, Boston, MA 02114 USA.
EM mlarkin1@partners.org
FU Division of Diabetes, Endocrinology and Metabolic Diseases of the
National Institute of Diabetes and Digestive and Kidney Diseases;
National Eye Institute; National Institute of Neurological Disorders and
Stroke; General Clinical Research Centers Program; Clinical and
Translational Science Awards Program; National Center for Research
Resources; Genentech through a Cooperative Research and Development
Agreement; National Institute of Diabetes and Digestive and Kidney
Diseases, National Institutes of Health; US Department of Health and
Human Services
FX The DCCT/EDIC project is supported by contracts with the Division of
Diabetes, Endocrinology and Metabolic Diseases of the National Institute
of Diabetes and Digestive and Kidney Diseases; National Eye Institute;
National Institute of Neurological Disorders and Stroke; the General
Clinical Research Centers Program and the Clinical and Translational
Science Awards Program; National Center for Research Resources; and
Genentech through a Cooperative Research and Development Agreement with
the National Institute of Diabetes and Digestive and Kidney Diseases,
National Institutes of Health, and US Department of Health and Human
Services.
NR 23
TC 2
Z9 2
U1 1
U2 6
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1740-7745
J9 CLIN TRIALS
JI Clin. Trials
PD AUG
PY 2012
VL 9
IS 4
BP 418
EP 425
DI 10.1177/1740774512449532
PG 8
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 995BV
UT WOS:000307982600005
PM 22729476
ER
PT J
AU Blum, MA
Ibrahim, SA
AF Blum, Marissa A.
Ibrahim, Said A.
TI Race/Ethnicity and Use of Elective Joint Replacement in the Management
of End-Stage Knee/Hip Osteoarthritis A Review of the Literature
SO CLINICS IN GERIATRIC MEDICINE
LA English
DT Review
DE Disparity; Joint arthroplasty; Osteoarthritis; Race/ethnicity
ID TOTAL HIP-ARTHROPLASTY; STATES MEDICARE POPULATION; UNITED-STATES;
RACIAL DISPARITIES; AFRICAN-AMERICANS; DECISION-MAKING; HEALTH-SERVICES;
ETHNIC-DIFFERENCES; NATIONAL-HEALTH; OLDER PATIENTS
AB Osteoarthritis is the most prevalent form of arthritis for which elective knee and hip joint replacement are effective treatment options in the management of end-stage disease. There are marked racial disparities in the utilization of joint arthroplasty. This article reviews the rationale for understanding this disparity, the evidence base that supports the disparity, and some known potential explanations, as well as additional data on racial disparities emerging in research on postarthroplasty outcomes and quality of care. The article concludes with a call for more research examining patient, provider and system-level factors that underlie these disparities.
C1 [Blum, Marissa A.] Temple Univ, Sch Med, Div Rheumatol, Philadelphia, PA 19140 USA.
[Ibrahim, Said A.] Philadelphia VA Med Ctr, Dept Med, Philadelphia, PA 19104 USA.
[Ibrahim, Said A.] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA.
RP Blum, MA (reprint author), Temple Univ, Sch Med, Div Rheumatol, 3322 N Broad St,Suite 205, Philadelphia, PA 19140 USA.
EM Marissa.blum@tuhs.temple.edu
NR 71
TC 8
Z9 8
U1 3
U2 10
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0749-0690
J9 CLIN GERIATR MED
JI Clin. Geriatr. Med.
PD AUG
PY 2012
VL 28
IS 3
BP 521
EP +
DI 10.1016/j.cger.2012.05.002
PG 13
WC Geriatrics & Gerontology
SC Geriatrics & Gerontology
GA 998VG
UT WOS:000308267900011
PM 22840312
ER
PT J
AU Wilson, BZ
Anzueto, A
Restrepo, MI
Pugh, MJV
Mortensen, EM
AF Wilson, Bryan Z.
Anzueto, Antonio
Restrepo, Marcos I.
Pugh, Mary Jo V.
Mortensen, Eric M.
TI Comparison of two guideline-concordant antimicrobial combinations in
elderly patients hospitalized with severe community-acquired pneumonia
SO CRITICAL CARE MEDICINE
LA English
DT Article
DE antimicrobial therapy; length of stay; mortality; pneumonia
ID BACTEREMIC PNEUMOCOCCAL PNEUMONIA; INITIAL EMPIRIC THERAPY; MACROLIDE
ANTIBIOTICS; CLINICAL-OUTCOMES; COMORBIDITY INDEX; MEDICAL OUTCOMES;
BETA-LACTAM; MORTALITY; IMPACT; VALIDATION
AB Objective: Two of the guideline-concordant therapies for severe community-acquired pneumonia are either a beta-lactam and fluoroquinolone or beta-lactam and macrolide. However it is unclear if there is a benefit for one vs. the other for elderly patients with severe community-acquired pneumonia.
Design: A retrospective population-based cohort study of patients with community-acquired pneumonia.
Setting: Patients admitted to an intensive care unit of any Department of Veterans Affairs hospital during 5-yr period.
Patients: We included only those patients >65 yrs of age admitted to the intensive care unit with community-acquired pneumonia who received either beta-lactam +fluoroquinolone or beta-lactam + macrolide antibiotic therapy for pneumonia.
Intervention: Not applicable.
Measurements: We used multilevel regression models to examine the effect of beta-lactam + fluoroquinolone vs. beta-lactam + macrolide on each of the outcomes after adjusting for potential confounders using propensity scores.
Main Results: The cohort consisted of 1,989 patients: 98.5% male and a mean age of 74 yrs. For treatment, 44% of subjects received beta-lactam + fluoroquinolone and 56% received beta-lactam + macrolide. Unadjusted 30-day mortality was 27% for beta-lactam + fluoroquinolone and 24% for beta-lactam + macrolide (p = .11). In the multilevel models, the use of beta-lactam + fluoroquinolone was not significantly associated with 30-day mortality (odds ratio 1.05, 95% confidence interval 0.85-1.30). However, the use of beta-lactam + fluoroquinolone was significantly associated with increased mean length of stay (incidence rate ratio 1.30, 95% confidence interval 1.27-1.33).
Conclusions: We found no significant difference for 30-day mortality but did demonstrate an association with increase in length of stay associated with the use of beta-lactam + fluoroquinolone. Randomized controlled trials are needed to determine the most effective antibiotics regimes for patients with severe pneumonia. (Crit Care Med 2012; 40:2310-2314)
C1 [Anzueto, Antonio; Restrepo, Marcos I.; Pugh, Mary Jo V.; Mortensen, Eric M.] VERDICT S Texas Vet Hlth Care Syst, San Antonio, TX USA.
[Mortensen, Eric M.] Univ Texas Hlth Sci Ctr San Antonio, Div Hosp Med, San Antonio, TX 78229 USA.
[Anzueto, Antonio; Restrepo, Marcos I.] Univ Texas Hlth Sci Ctr San Antonio, Div Pulm & Crit Care Med, San Antonio, TX 78229 USA.
[Pugh, Mary Jo V.] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA.
[Wilson, Bryan Z.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
RP Mortensen, EM (reprint author), VERDICT S Texas Vet Hlth Care Syst, San Antonio, TX USA.
EM Eric.Mortensen@UTSouthwestern.edu
RI Restrepo, Marcos/H-4442-2014;
OI Pugh, Mary Jo/0000-0003-4196-7763; Mortensen, Eric/0000-0002-3880-5563
FU National Institute of Nursing Research [R01NR010828]; National Heart,
Lung, and Blood Institute [K23HL096054]; National Institute of Health
[K23HL096054]
FX The project described was supported by Grant Number R01NR010828 from the
National Institute of Nursing Research. Dr. Restrepo is supported by
grant K23HL096054 from the National Heart, Lung, and Blood Institute.
The content is solely the responsibility of the authors and does not
necessarily represent the official views of the National Institute of
Nursing Research or the National Institutes of Health. Dr. Marcos I.
Restrepo participated in advisory boards for Theravan, Forest
Laboratories, Johnson and Johnson, and Novartis and was a consultant for
Trius, Theravan and Pfizer (Wyeth). The content is solely the
responsibility of the authors and does not necessarily represent the
official views of the Department of Veterans Affairs and National
Institutes of Health. This material is the result of work supported with
resources and the use of facilities at the South Texas Veterans Health
Care System. The funding agencies had no role in conducting the study,
or role in the preparation, review, or approval of the manuscript.; Drs.
Restrepo and Mortensen received funding from the National Institute of
Health K23HL096054. The remaining authors have not disclosed any
potential conflicts of interest.
NR 37
TC 15
Z9 16
U1 1
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0090-3493
J9 CRIT CARE MED
JI Crit. Care Med.
PD AUG
PY 2012
VL 40
IS 8
BP 2310
EP 2314
DI 10.1097/CCM.0b013e31825151a8
PG 5
WC Critical Care Medicine
SC General & Internal Medicine
GA 976SM
UT WOS:000306604900006
PM 22622401
ER
PT J
AU Laghi, F
AF Laghi, Franco
TI Proteasome inhibition and ventilator-induced diaphragmatic dysfunction:
Is the glass half full or half empty?
SO CRITICAL CARE MEDICINE
LA English
DT Editorial Material
DE diaphragm weakness; diaphragmatic function; mechanical ventilation;
oxidative stress; proteasome; proteolysis; respiratory muscles; weaning
failure
ID MECHANICAL VENTILATION; ATROPHY; RATS; PROTEOLYSIS
C1 [Laghi, Franco] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Div Pulm & Crit Care Med, Hines, IL 60141 USA.
[Laghi, Franco] Loyola Univ, Maywood, IL 60153 USA.
RP Laghi, F (reprint author), US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Div Pulm & Crit Care Med, Roosevelt Rd & 5th Ave, Hines, IL 60141 USA.
NR 18
TC 1
Z9 1
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0090-3493
J9 CRIT CARE MED
JI Crit. Care Med.
PD AUG
PY 2012
VL 40
IS 8
BP 2525
EP 2526
DI 10.1097/CCM.0b013e318258ebc5
PG 2
WC Critical Care Medicine
SC General & Internal Medicine
GA 976SM
UT WOS:000306604900050
PM 22809936
ER
PT J
AU Seo, JH
Guo, SZ
Lok, J
Navaratna, D
Whalen, MJ
Kim, KW
Lo, EH
AF Seo, Ji Hae
Guo, Shuzhen
Lok, Josephine
Navaratna, Deepti
Whalen, Michael J.
Kim, Kyu-Won
Lo, Eng H.
TI Neurovascular Matrix Metalloproteinases and the Blood-Brain Barrier
SO CURRENT PHARMACEUTICAL DESIGN
LA English
DT Review
DE Brain edema; neuroprotection; neurodegeneration; neurovascular unit;
stroke recovery
ID FOCAL CEREBRAL-ISCHEMIA; OLIGODENDROCYTE PRECURSOR CELLS;
SPINAL-CORD-INJURY; GENE KNOCK-OUT; HEMORRHAGIC TRANSFORMATION;
SUBARACHNOID HEMORRHAGE; ENDOTHELIAL-CELLS; CARDIOEMBOLIC STROKE;
MATRIX-METALLOPROTEINASE-9; EXPRESSION
AB Blood-brain barrier (BBB) leakage and brain edema is a critical part of stroke pathophysiology. In this mini-review, we briefly survey the potential role of matrix metalloproteinases (MMPs) in BBB dysfunction. A large body of data in both experimental models as well as clinical patient populations suggests that MMPs may disrupt BBB permeability and interfere with cell-cell signaling in the neurovascular unit. Hence, ongoing efforts are underway to validate MMPs as potential biomarkers in stroke as well as pursue MMP blockers as therapeutic opportunities. Because BBB perturbations may also occur in neurodegeneration, MMPs and associated neurovascular unit mechanisms may also be potential targets in a broader range of CNS disorders.
C1 [Seo, Ji Hae; Guo, Shuzhen; Lok, Josephine; Navaratna, Deepti; Whalen, Michael J.; Lo, Eng H.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Neurol Radiol & Pediat, Boston, MA 02115 USA.
[Seo, Ji Hae; Kim, Kyu-Won] Seoul Natl Univ, Coll Pharm, NeuroVasc Coordinat Res Ctr, Seoul, South Korea.
[Kim, Kyu-Won] Seoul Natl Univ, Grad Sch Convergence Sci & Technol, Dept Mol Med & Biopharmaceut Sci, Seoul 151742, South Korea.
[Kim, Kyu-Won] Seoul Natl Univ Hosp, Dept Internal Med, Seoul 110744, South Korea.
[Kim, Kyu-Won] Seoul Natl Univ Hosp, Innovat Res Inst Cell Therapy, Seoul 110744, South Korea.
RP Lo, EH (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Neurol Radiol & Pediat, Boston, MA 02115 USA.
EM Lo@helix.mgh.harvard.edu
FU NIH [R01-NS56458, R37-NS37074, P01-NS55104, K08-NS57339]; National
Research Foundation of Korea (NRF); Ministry of Education, Science and
Technology (MEST) through the Creative Research Initiative Program
[R16-2004-001-01001-0]; World Class University Program
[R31-2008-000-10103-0]; Global Research Laboratory Program
[2011-0021874]
FX Supported in part by NIH grants R01-NS56458, R37-NS37074, P01-NS55104
and K08-NS57339. Kyu-Won Kim is supported by National Research
Foundation of Korea (NRF) grant funded by the Ministry of Education,
Science and Technology (MEST) through the Creative Research Initiative
Program (R16-2004-001-01001-0), the World Class University Program
(R31-2008-000-10103-0) and the Global Research Laboratory Program
(2011-0021874).
NR 71
TC 24
Z9 27
U1 0
U2 11
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
EMIRATES
SN 1381-6128
J9 CURR PHARM DESIGN
JI Curr. Pharm. Design
PD AUG
PY 2012
VL 18
IS 25
BP 3645
EP 3648
PG 4
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 993OR
UT WOS:000307869600004
PM 22574977
ER
PT J
AU Hu, XM
Zhang, MJ
Leak, RK
Gan, Y
Li, PY
Gao, YQ
Chen, J
AF Hu, Xiaoming
Zhang, Meijuan
Leak, Rehana K.
Gan, Yu
Li, Peiying
Gao, Yanqin
Chen, Jun
TI Delivery of Neurotherapeutics Across the Blood Brain Barrier in Stroke
SO CURRENT PHARMACEUTICAL DESIGN
LA English
DT Review
DE Cell penetrating peptide; TAT protein transduction domains; blood brain
barrier; stroke; neuroprotection
ID CELL-PENETRATING PEPTIDE; FOCAL CEREBRAL-ISCHEMIA; VECTOR-MEDIATED
STRATEGY; ARGININE-RICH PEPTIDES; TAT-FUSION PROTEINS; KINASE-C-DELTA;
POLY(BUTYL CYANOACRYLATE) NANOPARTICLES; HUMAN IMMUNODEFICIENCY VIRUS;
MEMBRANE-PERMEABLE PEPTIDES; NEURONAL PRECURSOR CELLS
AB Stroke is a devastating disease with few therapeutic options. Despite our growing understanding of the critical mechanistic events in post-stroke brain injury, the clinical translation of these findings has been less effective. A monumental hurdle to the field has been the inability of many systemically applied therapies to efficiently cross the blood brain barrier (BBB) and enter brain cells. Over the last two decades, however, significant technological achievements have overcome this obstacle to facilitate central nervous system (CNS) drug delivery. Noninvasive drug carriers, especially cell penetrating peptide (CPP) show great potential to deliver neurotherapeutics across the BBB for the treatment of ischemic brain injury. This review begins with a brief introduction to the BBB in relation to drug delivery and then provides an overview of the development of drug carriers for neurotherapeutics, with a focus on CPP-mediated transduction. We discuss recent advances and limitations in this field, as well as mechanisms underlying CPP-mediated brain targeting. We also summarize the application of CPPs in stroke research. Continuing modifications and improvements of CPPs are expected to enhance both their feasibility in clinical stroke management and their specificity towards particular cell types.
C1 [Hu, Xiaoming; Zhang, Meijuan; Gan, Yu; Li, Peiying; Chen, Jun] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15213 USA.
[Hu, Xiaoming; Zhang, Meijuan; Gan, Yu; Li, Peiying; Chen, Jun] Univ Pittsburgh, Sch Med, Ctr Cerebrovasc Dis Res, Pittsburgh, PA 15213 USA.
[Hu, Xiaoming; Gan, Yu; Li, Peiying; Gao, Yanqin; Chen, Jun] Fudan Univ, Inst Brain Sci, Shanghai 200433, Peoples R China.
[Hu, Xiaoming; Gan, Yu; Li, Peiying; Gao, Yanqin; Chen, Jun] Fudan Univ, State Key Lab Med Neurobiol, Shanghai 200433, Peoples R China.
[Leak, Rehana K.] Duquesne Univ, Mylan Sch Pharm, Div Pharmaceut Sci, Pittsburgh, PA 15282 USA.
[Chen, Jun] Vet Affairs Pittsburgh Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15261 USA.
RP Chen, J (reprint author), Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15213 USA.
EM yqgao@shmu.edu.cn; chenj2@upmc.edu
RI Gao, Yanqin/I-6790-2016;
OI Gao, Yanqin/0000-0002-4915-9819; Leak, Rehana/0000-0003-2817-7417
FU American Heart Association [10POST4150028]; National Institutes of
Health/NINDS Grants [NS36736, NS43802, NS56118, NS45048]; Chinese
Natural Science Foundation grants [30670642, 30870794, 81020108021]
FX XIAOMING HU is supported by a grant (10POST4150028) from the American
Heart Association. JUN CHEN is supported by National Institutes of
Health/NINDS Grants NS36736, NS43802, NS56118, and NS45048. YANQIN GAO
is supported by Chinese Natural Science Foundation grants 30670642,
30870794, and 81020108021. We thank Pat Strickler for excellent
secretarial support.
NR 188
TC 4
Z9 4
U1 1
U2 37
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
EMIRATES
SN 1381-6128
EI 1873-4286
J9 CURR PHARM DESIGN
JI Curr. Pharm. Design
PD AUG
PY 2012
VL 18
IS 25
BP 3704
EP 3720
PG 17
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 993OR
UT WOS:000307869600012
PM 22574984
ER
PT J
AU Wolf, EJ
Lunney, CA
Miller, MW
Resick, PA
Friedman, MJ
Schnurr, PP
AF Wolf, Erika J.
Lunney, Carole A.
Miller, Mark W.
Resick, Patricia A.
Friedman, Matthew J.
Schnurr, Paula P.
TI THE DISSOCIATIVE SUBTYPE OF PTSD: A REPLICATION AND EXTENSION
SO DEPRESSION AND ANXIETY
LA English
DT Article
DE dissociation; PTSD; multivariate analysis; taxonomy; Veterans
ID BORDERLINE PERSONALITY-DISORDER; POSTTRAUMATIC-STRESS-DISORDER;
CHILDHOOD ABUSE; TRAUMA; SCALE; VETERANS; VALIDITY; THERAPY; MIXTURE;
NUMBER
AB Background: The nature of the relationship between dissociation and posttraumatic stress disorder (PTSD) has clinical and nosological importance. The aim of this study was to evaluate the evidence for a dissociative subtype of PTSD in two independent samples and to examine the pattern of personality disorder (PD) comorbidity associated with the dissociative subtype of PTSD. Methods: Latent profile analyses were conducted on PTSD and dissociation items reflecting derealization and depersonalization in two samples of archived data: Study 1 included 360 male Vietnam War Veterans with combat-related PTSD; Study 2 included 284 female Veterans and active duty service personnel with PTSD and a high base rate of exposure to sexual trauma. Results: The latent profile analysis yielded evidence for a three-class solution in both samples: the model was defined by moderate and high PTSD classes and a class marked by high PTSD severity coupled with high levels of dissociation. Approximately 15% of the male sample and 30% of the female sample were classified into the dissociative class. Women (but not men) in the dissociative group exhibited higher levels of comorbid avoidant and borderline PD diagnoses. Conclusions: Results provide support for a dissociative subtype of PTSD and also suggest that dissociation may play a role in the frequent co-occurrence of PTSD and borderline PD among women. These results are pertinent to the on-going revisions to the DSM and suggest that consideration should be given to incorporating a dissociative subtype into the revised PTSD criteria. Depression and Anxiety 29: 679-688, 2012. (c) 2012 Wiley Periodicals, Inc.
C1 [Wolf, Erika J.; Miller, Mark W.; Resick, Patricia A.] VA Boston Healthcare Syst, Natl Ctr PTSD, Boston, MA USA.
[Wolf, Erika J.; Miller, Mark W.; Resick, Patricia A.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA.
[Lunney, Carole A.; Friedman, Matthew J.; Schnurr, Paula P.] Natl Ctr PTSD, White River Jct, VT USA.
[Friedman, Matthew J.; Schnurr, Paula P.] Geisel Sch Med Dartmouth, Dept Psychiat, Hanover, NH USA.
RP Schnurr, PP (reprint author), VA Med Ctr, Natl Ctr PTSD 116D, White River Jct, VT 05009 USA.
EM paula.schnurr@dartmouth.edu
RI Miller, Mark/G-7322-2011;
OI Miller, Mark/0000-0001-6393-8563; Wolf, Erika/0000-0003-2666-2435;
Lunney, Carole A./0000-0002-0077-1281
FU VA Cooperative Studies Program [420, 494]; Department of Defense [494];
VA Career Development Award
FX The data reported in this article were drawn from grants CSP #420 and
#494 from the VA Cooperative Studies Program and support from the
Department of Defense for CSP #494. However, the views expressed in this
article are those of the authors and do not necessarily represent the
views of the Department of Veterans Affairs, the Department of Defense,
or any US government agency. Trial registration information for CSP
#494: clinicaltrials.gov Identifier NCT00032617. This work was also
supported by a VA Career Development Award to Erika J. Wolf.
NR 42
TC 54
Z9 54
U1 3
U2 30
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1091-4269
J9 DEPRESS ANXIETY
JI Depress. Anxiety
PD AUG
PY 2012
VL 29
IS 8
BP 679
EP 688
DI 10.1002/da.21946
PG 10
WC Psychology, Clinical; Psychiatry; Psychology
SC Psychology; Psychiatry
GA 981ZR
UT WOS:000307012000003
PM 22639402
ER
PT J
AU Resick, PA
Suvak, MK
Johnides, BD
Mitchell, KS
Iverson, KM
AF Resick, Patricia A.
Suvak, Michael K.
Johnides, Benjamin D.
Mitchell, Karen S.
Iverson, Katherine M.
TI THE IMPACT OF DISSOCIATION ON PTSD TREATMENT WITH COGNITIVE PROCESSING
THERAPY
SO DEPRESSION AND ANXIETY
LA English
DT Article
DE posttraumatic stress disorder; dissociation; cognitive processing
therapy; randomized controlled trial
ID POSTTRAUMATIC-STRESS-DISORDER; CHILDHOOD SEXUAL-ABUSE; EXPOSURE;
RESPONSES; VICTIMS; IMAGERY; TRIAL
AB Background This secondary analysis of data from a randomized controlled trial of cognitive processing therapy (CPT) and its constituent components investigated whether dissociation decreased over the course of treatment primarily targeting symptoms of posttraumatic stress disorder (PTSD) and explored whether levels of dissociation predicted treatment outcome differentially by treatment condition. Methods An intention to treat sample of 150 women were randomized to CPT, cognitive therapy only (CPT-C) or written trauma accounts only (WA). Dissociation was measured by the dissociation subscale of the Traumatic Stress Inventory and the Multiscale Dissociation Inventory. Results Multilevel regression analyses revealed significant decreases in dissociation that did not vary as a function of treatment condition. Growth curve modeling revealed significant treatment condition by dissociation interactions such that the impact of pretreatment levels of dissociation impacted the treatment conditions differently. Conclusions Women who endorsed low pretreatment levels of dissociation responded most efficiently to CPT-C, whereas women with the highest levels of dissociation, in particular high levels of depersonalization, responded better to CPT.
C1 [Resick, Patricia A.] VA Boston Healthcare Syst, WHSD 116B 3, Natl Ctr Posttraumat Stress Disorder, Boston, MA 02130 USA.
[Resick, Patricia A.; Mitchell, Karen S.; Iverson, Katherine M.] Boston Univ, Boston, MA 02215 USA.
[Suvak, Michael K.] Suffolk Univ, Boston, MA 02114 USA.
RP Resick, PA (reprint author), VA Boston Healthcare Syst, WHSD 116B 3, Natl Ctr Posttraumat Stress Disorder, 150 S Huntington St, Boston, MA 02130 USA.
EM Patricia.Resick@va.gov
FU NIMH [2-R01-MH51509]
FX Contract grant sponsor: NIMH; Contract grant number: 2-R01-MH51509 to
PAS.
NR 38
TC 35
Z9 35
U1 7
U2 26
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1091-4269
J9 DEPRESS ANXIETY
JI Depress. Anxiety
PD AUG
PY 2012
VL 29
IS 8
BP 718
EP 730
DI 10.1002/da.21938
PG 13
WC Psychology, Clinical; Psychiatry; Psychology
SC Psychology; Psychiatry
GA 981ZR
UT WOS:000307012000007
PM 22473922
ER
PT J
AU Levine, M
Brown, DFM
AF Levine, Michael
Brown, David F. M.
TI SUCCINYLCHOLINE-INDUCED HYPERKALEMIA IN A PATENT WITH MULTIPLE SCLEROSIS
SO JOURNAL OF EMERGENCY MEDICINE
LA English
DT Article
DE succinylcholine; multiple sclerosis; hyperkalemia; intubation; RSI
ID ACETYLCHOLINE-RECEPTORS; CARDIAC-ARREST; BLOCKERS
AB Background: Succinylcholine administration is associated with hyperkalemia in patients with a variety of medical conditions, including many neuromuscular disorders. Nonetheless, there is a paucity of literature describing hyperkalemia after the administration of succinylcholine to patients with multiple sclerosis. Case Report: This case report describes a 38-year-old woman with multiple sclerosis who developed life-threatening hyperkalemia after the administration of succinylcholine during rapid sequence intubation. Conclusion: This case highlights the potential for iatrogenic hyperkalemia after succinylcholine in patients with neurologic diseases, including multiple sclerosis. (C) 2012 Elsevier Inc.
C1 [Levine, Michael] Univ So Calif, Sect Med Toxicol, Dept Emergency Med, Los Angeles, CA 90033 USA.
[Brown, David F. M.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA.
RP Levine, M (reprint author), Univ So Calif, Sect Med Toxicol, Dept Emergency Med, 1200 N State St,Room 1011, Los Angeles, CA 90033 USA.
NR 16
TC 6
Z9 6
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0736-4679
J9 J EMERG MED
JI J. Emerg. Med.
PD AUG
PY 2012
VL 43
IS 2
BP 279
EP 282
DI 10.1016/j.jemermed.2011.06.062
PG 4
WC Emergency Medicine
SC Emergency Medicine
GA 994HC
UT WOS:000307920500013
PM 22142672
ER
PT J
AU Martindale, JL
Hwang, JQ
Nadel, ES
Brown, DFM
AF Martindale, Jennifer L.
Hwang, James Q.
Nadel, Eric S.
Brown, David F. M.
TI ACUTE ATRAUMATIC QUADRIPLEGIA
SO JOURNAL OF EMERGENCY MEDICINE
LA English
DT Editorial Material
ID SPINAL EPIDURAL HEMATOMA; PROTHROMBIN COMPLEX CONCENTRATE; ORAL
ANTICOAGULANT REVERSAL; INTRACEREBRAL HEMORRHAGE; AORTIC DISSECTION;
WARFARIN REVERSAL; MANAGEMENT; EFFICACY; THERAPY
C1 [Nadel, Eric S.; Brown, David F. M.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA.
[Martindale, Jennifer L.; Nadel, Eric S.; Brown, David F. M.] Harvard Univ, Sch Med, Div Emergency Med, Boston, MA USA.
[Hwang, James Q.; Nadel, Eric S.] Brigham & Womens Hosp, Dept Emergency Med, Boston, MA 02115 USA.
RP Brown, DFM (reprint author), Massachusetts Gen Hosp, Dept Emergency Med, Founders 114,55 Fruit St, Boston, MA 02114 USA.
NR 27
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0736-4679
J9 J EMERG MED
JI J. Emerg. Med.
PD AUG
PY 2012
VL 43
IS 2
BP 335
EP 338
PG 4
WC Emergency Medicine
SC Emergency Medicine
GA 994HC
UT WOS:000307920500023
PM 22494603
ER
PT J
AU Wajnberg, A
Hwang, U
Torres, L
Yang, S
AF Wajnberg, Ania
Hwang, Ula
Torres, Lucille
Yang, Samuel
TI CHARACTERISTICS OF FREQUENT GERIATRIC USERS OF AN URBAN EMERGENCY
DEPARTMENT
SO JOURNAL OF EMERGENCY MEDICINE
LA English
DT Article; Proceedings Paper
CT Annual Meeting of the Society-for-Academic-Emergency-Medicine
CY MAY 13-17, 2009
CL New Orleans, LA
SP Soc Acad Emergency Med
DE geriatrics; ED overcrowding; access to care; primary care
ID PRIMARY-CARE; ELDERLY-PATIENTS; BARRIERS; VISITS; ACCESS
AB Background: As the population ages, it is projected that older adults will increase emergency department (ED) utilization and contribute to ED crowding. Older patients are at risk of decreased health-related quality of life after an ED visit. Characteristics of older adults that frequently use the ED have not been well studied, and prior studies have shown that lack of access to primary care may influence ED utilization. Objective: Determine factors associated with frequent Emergency Department (ED) utilization by older adults. Methods: Retrospective chart review of all patients >= 65 years of age seen in an urban ED between December 2007 and September 2008. A prospective telephone survey was done of "frequent" (>= 4 ED visits over a 6-month period) geriatric users. "Frequent" and "infrequent" geriatric ED users were compared using chi-squared and t-test. Survey results are univariate descriptive statistics. Results: There were 8520 ED visits of adults >= 65 years of age analyzed, of which 5718 were unique patients. Of these, 268 (5%) were frequent ED users. Frequent geriatric ED users were more likely to be Black or Hispanic and were considered less urgent at triage. Of the 59 surveyed frequent users of the ED, 95% reported having a usual source of care, though only 36% contacted their outpatient provider before a visit to the ED. Conclusion: Frequent geriatric users of the ED were considered less urgent at triage, and although most identified themselves as having a primary care provider in the community, many did not contact them before going to the ED. (C) 2012 Elsevier Inc.
C1 [Wajnberg, Ania; Torres, Lucille; Yang, Samuel] Mt Sinai Sch Med, Dept Gen Internal Med, Mt Sinai Visiting Doctors Program, New York, NY 10029 USA.
[Hwang, Ula; Torres, Lucille; Yang, Samuel] Mt Sinai Sch Med, Dept Emergency Med, New York, NY 10029 USA.
[Hwang, Ula] Mt Sinai Sch Med, Brookdale Dept Geriatr & Adult Dev, New York, NY 10029 USA.
[Hwang, Ula] James J Peters VA Med Ctr, Ctr Geriatr Res Educ & Clin, Bronx, NY USA.
RP Wajnberg, A (reprint author), Mt Sinai Sch Med, Dept Gen Internal Med, Mt Sinai Visiting Doctors Program, 1 Gustave L Levy Pl,Box 1216, New York, NY 10029 USA.
FU NIA NIH HHS [K24 AG022345]
NR 20
TC 9
Z9 9
U1 1
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0736-4679
J9 J EMERG MED
JI J. Emerg. Med.
PD AUG
PY 2012
VL 43
IS 2
BP 376
EP 381
DI 10.1016/j.jemermed.2011.06.056
PG 6
WC Emergency Medicine
SC Emergency Medicine
GA 994HC
UT WOS:000307920500034
PM 22040771
ER
PT J
AU Hu, YY
Kwok, AC
Jiang, W
Taback, N
Loggers, ET
Ting, GV
Lipsitz, SR
Weeks, JC
Greenberg, CC
AF Hu, Yue-Yung
Kwok, Alvin C.
Jiang, Wei
Taback, Nathan
Loggers, Elizabeth T.
Ting, Gladys V.
Lipsitz, Stuart R.
Weeks, Jane C.
Greenberg, Caprice C.
TI High-Cost Imaging in Elderly Patients with Stage IV Cancer
SO JOURNAL OF THE NATIONAL CANCER INSTITUTE
LA English
DT Article
ID CELL LUNG-CANCER; AMERICAN-SOCIETY; BREAST-CANCER; MEDICARE
BENEFICIARIES; COLORECTAL-CANCER; UNITED-STATES; TRENDS; LIFE; CARE; END
AB Background Medicare expenditures for high-cost diagnostic imaging have risen faster than those for total cancer care and have been targeted for potential cost reduction. We sought to determine recent and long-term patterns in high-cost diagnostic imaging use among elderly (aged >= 65 years) patients with stage IV cancer.
Methods We identified claims within the Surveillance, Epidemiology, and End Results (SEER)-Medicare database with computed tomography, magnetic resonance imaging, positron emission tomography, and nuclear medicine scans between January 1994 and December 2009 for patients diagnosed with stage IV breast, colorectal, lung, or prostate cancer between January 1995 and December 2006 (N = 100 594 patients). The proportion of these patients imaged and rate of imaging per-patient per-month of survival were calculated for each phase of care in patients diagnosed between January 2002 and December 2006 (N = 55 253 patients). Logistic regression was used to estimate trends in imaging use in stage IV patients diagnosed between January 1995 and December 2006, which were compared with trends in imaging use in early-stage (stages I and II) patients with the same tumor types during the same period (N = 192 429 patients).
Results Among the stage IV patients diagnosed between January 2002 and December 2006, 95.9% underwent a high-cost diagnostic imaging procedure, with a mean number of 9.79 (SD = 9.77) scans per patient and 1.38 (SD = 1.24) scans per-patient per-month of survival. After the diagnostic phase, 75.3% were scanned again; 34.3% of patients were scanned in the last month of life. Between January 1995 and December 2006, the proportion of stage IV cancer patients imaged increased (relative increase = 4.6%, 95% confidence interval [CI] = 3.7% to 5.6%), and the proportion of early-stage cancer patients imaged decreased (relative decrease = -2.5%, 95% CI = -3.2% to -1.9%).
Conclusions Diagnostic imaging is used frequently in patients with stage IV disease, and its use increased more rapidly over the decade of study than that in patients with early-stage disease.
C1 [Greenberg, Caprice C.] Univ Wisconsin, Dept Surg, Wisconsin Surg Outcomes Res Program, Madison, WI USA.
[Greenberg, Caprice C.] Univ Wisconsin, Dept Surg, Hlth Innovat Program, Madison, WI USA.
[Hu, Yue-Yung; Kwok, Alvin C.; Jiang, Wei; Lipsitz, Stuart R.; Greenberg, Caprice C.] Brigham & Womens Hosp, Dept Surg, Ctr Surg & Publ Hlth, Boston, MA 02115 USA.
[Hu, Yue-Yung] Beth Israel Deaconess Med Ctr, Dept Surg, Boston, MA 02215 USA.
[Taback, Nathan; Ting, Gladys V.; Weeks, Jane C.; Greenberg, Caprice C.] Dana Farber Canc Inst, Dept Med Oncol, Ctr Outcomes & Policy Res, Boston, MA 02115 USA.
[Loggers, Elizabeth T.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA.
[Loggers, Elizabeth T.] Grp Hlth Res Inst, Seattle, WA USA.
RP Greenberg, CC (reprint author), Univ Wisconsin Hosp & Clin, Dept Surg, 600 Highland Ave,H4-730, Madison, WI 53792 USA.
EM greenberg@surgery.wisc.edu
RI JIANG, WEI /F-3930-2015
FU National Institutes of Health [RC2CA148185-01, 2T32DK00754-12]
FX National Institutes of Health (RC2CA148185-01 to JCW and 2T32DK00754-12
to Richard Hodin, Department of Surgery, Massachusetts General Hospital,
Boston, MA.
NR 33
TC 11
Z9 11
U1 0
U2 2
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0027-8874
J9 J NATL CANCER I
JI J. Natl. Cancer Inst.
PD AUG
PY 2012
VL 104
IS 15
BP 1164
EP 1172
DI 10.1093/jnci/djs286
PG 9
WC Oncology
SC Oncology
GA 992VW
UT WOS:000307809300009
PM 22851271
ER
PT J
AU Gierach, GL
Ichikawa, L
Kerlikowske, K
Brinton, LA
Farhat, GN
Vacek, PM
Weaver, DL
Schairer, C
Taplin, SH
Sherman, ME
AF Gierach, Gretchen L.
Ichikawa, Laura
Kerlikowske, Karla
Brinton, Louise A.
Farhat, Ghada N.
Vacek, Pamela M.
Weaver, Donald L.
Schairer, Catherine
Taplin, Stephen H.
Sherman, Mark E.
TI Relationship Between Mammographic Density and Breast Cancer Death in the
Breast Cancer Surveillance Consortium
SO JOURNAL OF THE NATIONAL CANCER INSTITUTE
LA English
DT Article
ID PARENCHYMAL PATTERNS; TUMOR CHARACTERISTICS; POSTMENOPAUSAL WOMEN;
SUBSEQUENT RISK; ASSOCIATION; FEATURES; MENOPAUSE; ACCURACY; SURVIVAL;
MARKERS
AB Women with elevated mammographic density have an increased risk of developing breast cancer. However, among women diagnosed with breast cancer, it is unclear whether higher density portends reduced survival, independent of other factors.
We evaluated relationships between mammographic density and risk of death from breast cancer and all causes within the US Breast Cancer Surveillance Consortium. We studied 9232 women diagnosed with primary invasive breast carcinoma during 19962005, with a mean follow-up of 6.6 years. Mammographic density was assessed using the Breast Imaging Reporting and Data System (BI-RADS) density classification. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated by Cox proportional hazards regression; women with scattered fibroglandular densities (BI-RADS 2) were the referent group. All statistical tests were two-sided.
A total of 1795 women died, of whom 889 died of breast cancer. In multivariable analyses (adjusted for site, age at and year of diagnosis, American Joint Committee on Cancer stage, body mass index, mode of detection, treatment, and income), high density (BI-RADS 4) was not related to risk of death from breast cancer (HR = 0.92, 95% CI = 0.71 to 1.19) or death from all causes (HR = 0.83, 95% CI = 0.68 to 1.02). Analyses stratified by stage and other prognostic factors yielded similar results, except for an increased risk of breast cancer death among women with low density (BI-RADS 1) who were either obese (HR = 2.02, 95% CI = 1.37 to 2.97) or had tumors of at least 2.0cm (HR = 1.55, 95% CI = 1.14 to 2.09).
High mammographic breast density was not associated with risk of death from breast cancer or death from any cause after accounting for other patient and tumor characteristics. Thus, risk factors for the development of breast cancer may not necessarily be the same as factors influencing the risk of death after breast cancer has developed.
C1 [Gierach, Gretchen L.; Brinton, Louise A.; Sherman, Mark E.] NCI, Hormonal & Reprod Epidemiol Branch, NIH, Rockville, MD USA.
[Schairer, Catherine] NCI, Biostat Branch, Div Canc Epidemiol & Genet, NIH, Rockville, MD USA.
[Taplin, Stephen H.] NCI, Proc Care Res Branch, Behav Res Program, Div Canc Control & Populat Sci,NIH, Rockville, MD USA.
[Ichikawa, Laura] Grp Hlth Res Inst, Seattle, WA USA.
[Kerlikowske, Karla] Univ Calif San Francisco, Gen Internal Med Sect, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA.
[Farhat, Ghada N.] Univ Balamand, Beirut, Lebanon.
[Vacek, Pamela M.] Univ Vermont, Coll Med, Dept Med Biostat, Burlington, VT USA.
[Weaver, Donald L.] Vermont Canc Ctr, Burlington, VT USA.
[Weaver, Donald L.] Univ Vermont, Coll Med, Dept Pathol, Burlington, VT 05405 USA.
RP Gierach, GL (reprint author), 6120 Execut Blvd,Ste 550,Rm 5016, Rockville, MD 20852 USA.
EM gierachg@mail.nih.gov
RI Brinton, Louise/G-7486-2015; Gierach, Gretchen/E-1817-2016
OI Brinton, Louise/0000-0003-3853-8562; Gierach,
Gretchen/0000-0002-0165-5522
FU National Institutes of Health, National Cancer Institute (NCI); NCI
[U01CA63740, U01CA86076, U01CA86082, U01CA63736, U01CA70013, U01CA69976,
U01CA63731, U01CA70040, HHSN261201100031C]
FX This work was supported (in part) by the Intramural Research Program of
the National Institutes of Health, National Cancer Institute (NCI), and
the NCI-funded Breast Cancer Surveillance Consortium (U01CA63740 to KK,
U01CA86076 to DM, U01CA86082 to TO, U01CA63736 to GC, U01CA70013 to BG,
U01CA69976 to RR, U01CA63731 to DB, U01CA70040 to BY, and
HHSN261201100031C to DM).
NR 32
TC 54
Z9 54
U1 1
U2 6
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0027-8874
J9 J NATL CANCER I
JI J. Natl. Cancer Inst.
PD AUG
PY 2012
VL 104
IS 16
BP 1218
EP 1227
DI 10.1093/jnci/djs327
PG 10
WC Oncology
SC Oncology
GA 998JO
UT WOS:000308234100006
PM 22911616
ER
PT J
AU Regan, MM
Bouzyk, M
Rae, JM
Viale, G
Leyland-Jones, B
AF Regan, Meredith M.
Bouzyk, Mark
Rae, James M.
Viale, Giuseppe
Leyland-Jones, Brian
TI Re: CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women With
Endocrine-Responsive Breast Cancer: The Breast International Group 1-98
Trial Response
SO JOURNAL OF THE NATIONAL CANCER INSTITUTE
LA English
DT Letter
ID ASSOCIATION; VARIANTS; OUTCOMES; SULT1A1
C1 [Regan, Meredith M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, IBCSG Stat Ctr,Dept Biostat & Computat Biol, Boston, MA 02115 USA.
[Bouzyk, Mark] AKESOgen Inc, Norcross, GA USA.
[Rae, James M.] Univ Michigan, Med Ctr, Dept Internal Med, Breast Oncol Program, Ann Arbor, MI 48109 USA.
[Leyland-Jones, Brian] Edith Sanford Breast Canc Res, Sioux Falls, SD USA.
[Viale, Giuseppe] European Inst Oncol, Div Pathol & Lab Med, IBCSG Cent Pathol Off, Milan, Italy.
RP Regan, MM (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, IBCSG Stat Ctr,Dept Biostat & Computat Biol, 44 Binney St, Boston, MA 02115 USA.
EM mregan@jimmy.harvard.edu; mbouzyk@akesogen.com; jimmyrae@med.umich.edu;
brian.leyland-jones@sanfordhealth.org
NR 7
TC 1
Z9 1
U1 1
U2 4
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0027-8874
J9 J NATL CANCER I
JI J. Natl. Cancer Inst.
PD AUG
PY 2012
VL 104
IS 16
BP 1266
EP 1267
DI 10.1093/jnci/djs313
PG 2
WC Oncology
SC Oncology
GA 998JO
UT WOS:000308234100014
ER
PT J
AU Ryan, ML
Thorson, CM
King, DR
Van Haren, RM
Manning, RJ
Andrews, DM
Livingstone, AS
Proctor, KG
AF Ryan, Mark L.
Thorson, Chad M.
King, David R.
Van Haren, Robert M.
Manning, Ronald J.
Andrews, David M.
Livingstone, Alan S.
Proctor, Kenneth G.
TI Insertion of central venous catheters induces a hypercoagulable state
SO JOURNAL OF TRAUMA AND ACUTE CARE SURGERY
LA English
DT Article
DE Venous thromboembolism; deep venous thrombosis; thromboelastography
ID PULMONARY-ARTERY CATHETERS; RAPID THROMBELASTOGRAPHY; RISK-FACTORS;
HEPARIN; THROMBOEMBOLISM; THROMBOGENICITY; ANTICOAGULATION;
COAGULOPATHY; THROMBOSIS; BLOOD
AB BACKGROUND: Central venous catheters (CVCs) increase the risk of venous thromboembolism. We have previously demonstrated that pulmonary artery catheters are associated with a hypercoagulable state in an animal model and in patients. The purpose of this study is to determine whether the insertion of a CVC is associated with a similar response.
METHODS: Animal: 7F femoral artery catheters were placed in healthy anesthetized swine (N = 16). Serial arterial blood samples were drawn immediately before and after an 8.5F jugular vein CVC and then for 3 hours after CVC removal. Samples were analyzed using kaolin-activated thromboelastography (TEG) at precisely 2 minutes. Human: An institutional review board-approved prospective observational trial was conducted, with informed consent, in patients with critical illness (N = 8) at a Level I trauma center. Blood was drawn from indwelling arterial catheters immediately before and 60 minutes after CVC insertion. Samples were stored in sodium citrate for 15 minutes before TEG. Routine and special coagulation tests were performed on stored samples in the hospital pathology laboratory.
RESULTS: Insertion of a CVC decreased TEG clotting time (R) by 55% in swine and by 29% in humans (p < 0.001 and 0.019, respectively). Initial clot formation time (K) was reduced by 41% in swine and by 36% in humans (p = 0.003 and 0.019). Fibrin cross-linking (alpha) was accelerated by 28% in swine and by 17% in humans (p = 0.007 and 0.896), but overall clot strength (maximum amplitude) was not affected. There was no change in routine or special coagulation factors, including von Willebrand factor, antithrombin III, prothrombin time, international normalized ratio, or activated partial thromboplastin time. In animals, the hypercoagulable TEG response was persistent for 3 hours after CVC removal and was prevented by pretreatment with enoxaparin (n = 4) but not heparin (n = 2).
CONCLUSION: In healthy swine and patients with critical illness, a systemic hypercoagulable state occurred after CVC insertion, and this may partially account for an increased risk of venous thromboembolism. However, because the sample size was small and not powered to detect changes in coagulation proteins, no inferences can be made about the mechanism for the hypercoagulable response. (J Trauma Acute Care Surg. 2012; 73: 385-390. Copyright (C) 2012 by Lippincott Williams & Wilkins)
C1 [Ryan, Mark L.; Thorson, Chad M.; Van Haren, Robert M.; Manning, Ronald J.; Livingstone, Alan S.; Proctor, Kenneth G.] Univ Miami, Sch Med, Div Trauma & Surg Crit Care, Daughtry Family Dept Surg,Ryder Trauma Ctr, Miami, FL 33136 USA.
[Andrews, David M.] Univ Miami, Sch Med, Dept Pathol, Ryder Trauma Ctr, Miami, FL 33136 USA.
[King, David R.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Trauma Emergency Surg & Surg Crit Care, Boston, MA USA.
RP Proctor, KG (reprint author), Univ Miami, Sch Med, Div Trauma & Surg Crit Care, Daughtry Family Dept Surg,Ryder Trauma Ctr, 1800 NW 10th Ave, Miami, FL 33136 USA.
EM kproctor@miami.edu
OI King, David/0000-0003-1028-1478
FU Office of Naval Research [N140610670]; US Army Medical Research &
Materiel Command [W81XWH-11-2-0098]
FX This work was supported in part by Grant No. N140610670 from the Office
of Naval Research and by Grant No. W81XWH-11-2-0098 from the US Army
Medical Research & Materiel Command. The authors thank the nurses and
support staff of the trauma ICU for their cooperation. This study would
have been impossible otherwise. The authors also thank Christian Otero,
MD, and Thai Vu, MD, for helping in the consent of patients and Sarita
Paulino in the Department of Pathology for assaying the coagulation
factors.
NR 27
TC 10
Z9 10
U1 1
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 2163-0755
J9 J TRAUMA ACUTE CARE
JI J. Trauma Acute Care Surg.
PD AUG
PY 2012
VL 73
IS 2
BP 385
EP 390
DI 10.1097/TA.0b013e31825a0519
PG 6
WC Critical Care Medicine; Surgery
SC General & Internal Medicine; Surgery
GA 992VG
UT WOS:000307807400023
PM 22846944
ER
PT J
AU Brasky, TM
Baik, CS
Slatore, CG
Potter, JD
White, E
AF Brasky, Theodore M.
Baik, Christina S.
Slatore, Christopher G.
Potter, John D.
White, Emily
TI Non-steroidal anti-inflammatory drugs and small cell lung cancer risk in
the VITAL study
SO LUNG CANCER
LA English
DT Article
DE Aspirin; Ibuprofen; NSAID; Small cell lung cancer
ID SEX-DIFFERENCES; WOMENS HEALTH; ASPIRIN USE; EXPRESSION; COHORT;
METAANALYSIS; ASSOCIATION; SMOKING; USERS; MEN
AB Few studies have examined the association between non-steroidal anti-inflammatory drug (NSAID) use and risk of small cell lung cancer (SCLC); among them, findings are mixed. Recently, we found that use of NSAIDs was differentially associated with lung cancer risk by histology. Here, we examine, more comprehensively, the association between individual NSAIDs and SCLC risk. 75,546 residents of western Washington State, ages 50-76, completed a baseline questionnaire in 2000-2002 and reported on their use of individual NSAIDs over the past 10 years. NSAID use was categorized as non-users, low (<4 days/week or <4 years), and high (>= 4 days/week and >= 4 years). 111 SCLC were identified through linkage to a population-based cancer registry. Multivariable-adjusted Cox proportional hazards models including strong adjustment for smoking were used to estimate hazard ratios (HR) and 95% confidence intervals (95% CI). Compared to non-use, high use of regular-strength aspirin was associated with an elevated risk of SCLC (HR 1.78,95% CI: 1.05-3.02; P-trend = 0.03). Findings for low-dose aspirin were elevated but did not reach statistical significance. Use of non-aspirin NSAIDs was not associated with SCLC risk. Our findings provide further indication of heterogeneity in the association between aspirin and lung cancer morphologies. Large, prospective studies with comprehensive assessments of NSAID use and smoking history and data on both men and women, are needed in order to better understand the association between use of aspirin and SCLC. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
C1 [Brasky, Theodore M.; Baik, Christina S.; Potter, John D.; White, Emily] Fred Hutchinson Canc Res Ctr, Canc Prevent Program, Seattle, WA 98109 USA.
[Brasky, Theodore M.] Ohio State Univ, James Comprehens Canc Ctr, Dept Canc Prevent & Control, Columbus, OH 43210 USA.
[Slatore, Christopher G.] Portland VA Med Ctr, Portland, OR USA.
[Slatore, Christopher G.] Oregon Hlth & Sci Univ, Div Pulm & Crit Care Med, Portland, OR 97201 USA.
RP Brasky, TM (reprint author), Fred Hutchinson Canc Res Ctr, Canc Prevent Program, 1100 Fairview Ave N,M4-B402, Seattle, WA 98109 USA.
EM tbrasky@fhcrc.org
OI Potter, John/0000-0001-5439-1500; Slatore,
Christopher/0000-0003-0958-8122
FU National Institutes of Health [R25-CA094880, K05-CA154337]; VA HSRD
Career Development Awards
FX This work is supported by National Institutes of Health grants
R25-CA094880 (National Cancer Institute) and K05-CA154337 (National
Cancer Institute and Office of Dietary Supplements). Dr. Slatore is a
recipient of a VA HSRD Career Development Awards and is supported by
resources from the Portland VA Medical Center. The Department of
Veterans Affairs did not have a role in the conduct of the study, in the
collection, management, analysis, or interpretation of data, or in the
preparation of the manuscript. The views expressed in this article are
those of the authors and do not necessarily represent the views of the
Department of Veterans Affairs or the US Government.
NR 26
TC 3
Z9 3
U1 0
U2 3
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0169-5002
J9 LUNG CANCER
JI Lung Cancer
PD AUG
PY 2012
VL 77
IS 2
BP 260
EP 264
DI 10.1016/j.lungcan.2012.04.015
PG 5
WC Oncology; Respiratory System
SC Oncology; Respiratory System
GA 982IM
UT WOS:000307036500004
PM 22608142
ER
PT J
AU Milford, CE
Ferris, TG
AF Milford, Creagh E.
Ferris, Timothy G.
TI A Modified "Golden Rule" for Health Care Organizations
SO MAYO CLINIC PROCEEDINGS
LA English
DT Editorial Material
C1 [Milford, Creagh E.; Ferris, Timothy G.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
[Ferris, Timothy G.] Partners Healthcare, Boston, MA USA.
RP Milford, CE (reprint author), Massachusetts Gen Hosp, Dept Med, 55 Fruit St,BUL 205, Boston, MA 02114 USA.
EM Cmilford1@partners.org
NR 7
TC 7
Z9 7
U1 2
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0025-6196
EI 1942-5546
J9 MAYO CLIN PROC
JI Mayo Clin. Proc.
PD AUG
PY 2012
VL 87
IS 8
BP 717
EP 720
DI 10.1016/j.mayocp.2012.05.009
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA 994NL
UT WOS:000307937400008
PM 22862860
ER
PT J
AU Shampo, MA
Kyle, RA
Steensma, DP
AF Shampo, Marc A.
Kyle, Robert A.
Steensma, David P.
TI Catherine Verfaillie-Stem Cell Researcher
SO MAYO CLINIC PROCEEDINGS
LA English
DT Biographical-Item
C1 [Shampo, Marc A.; Kyle, Robert A.] Mayo Clin, Rochester, MN 55905 USA.
[Steensma, David P.] Dana Farber Canc Inst, Boston, MA 02115 USA.
RP Shampo, MA (reprint author), Mayo Clin, Rochester, MN 55905 USA.
OI Steensma, David/0000-0001-5130-9284
NR 1
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0025-6196
J9 MAYO CLIN PROC
JI Mayo Clin. Proc.
PD AUG
PY 2012
VL 87
IS 8
BP E59
EP E59
DI 10.1016/j.mayocp.2012.05.013
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 994NL
UT WOS:000307937400002
PM 22862876
ER
PT J
AU Karam, C
Quinn, CC
Paganoni, S
David, WS
AF Karam, Chafic
Quinn, Colin C.
Paganoni, Sabrina
David, William S.
TI Teaching NeuroImages: Ganglion cyst causing pure sensory ulnar
neuropathy at the wrist
SO NEUROLOGY
LA English
DT Editorial Material
C1 [Karam, Chafic; Quinn, Colin C.; Paganoni, Sabrina; David, William S.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Neuromuscular Diagnost Ctr, Boston, MA 02115 USA.
RP Karam, C (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Neuromuscular Diagnost Ctr, Boston, MA 02115 USA.
EM chafickaram@gmail.com
NR 1
TC 1
Z9 1
U1 2
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
J9 NEUROLOGY
JI Neurology
PD AUG
PY 2012
VL 79
IS 8
BP E76
EP E76
DI 10.1212/WNL.0b013e318266200c
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA 996JD
UT WOS:000308080100003
PM 22915183
ER
PT J
AU Lee, JJ
Drakaki, A
Iliopoulos, D
Struhl, K
AF Lee, J-J
Drakaki, A.
Iliopoulos, D.
Struhl, K.
TI MiR-27b targets PPAR gamma to inhibit growth, tumor progression and the
inflammatory response in neuroblastoma cells
SO ONCOGENE
LA English
DT Article
DE miR-27b; PPAR gamma; NHE1; NF-kappa beta; inflammation; neuroblastomas
ID ACTIVATED-RECEPTOR-GAMMA; FACTOR-KAPPA-B; BREAST-CANCER; TERMINAL
DIFFERENTIATION; INTRACELLULAR PH; EXPRESSION; ROSIGLITAZONE; MICRORNAS;
AGONISTS; TRANSFORMATION
AB The peroxisome proliferators-activated receptor (PPAR)gamma pathway is involved in cancer, but it appears to have both tumor suppressor and oncogenic functions. In neuroblastoma cells, miR-27b targets the 30 untranslated region of PPAR gamma and inhibits its mRNA and protein expression. miR-27b overexpression or PPAR gamma inhibition blocks cell growth in vitro and tumor growth in mouse xenografts. PPAR gamma activates expression of the pH regulator NHE1, which is associated with tumor progression. Lastly, miR-27b through PPAR gamma regulates nuclear factor-kappa B activity and transcription of inflammatory target genes. Thus, in neuroblastoma, miR-27b functions as a tumor suppressor by inhibiting the tumor-promoting function of PPAR gamma, which triggers an increased inflammatory response. In contrast, in breast cancer cells, PPAR gamma inhibits NHE1 expression and the inflammatory response, and it functions as a tumor suppressor. We suggest that the ability of PPAR gamma to promote or suppress tumor formation is linked to cell type-specific differences in regulation of NHE1 and other target genes. Oncogene (2012) 31, 3818-3825; doi: 10.1038/onc.2011.543; published online 28 November 2011
C1 [Lee, J-J; Iliopoulos, D.; Struhl, K.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.
[Drakaki, A.] Beth Israel Deaconess Med Ctr, Div Hematol Oncol, Boston, MA 02215 USA.
[Iliopoulos, D.] Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA.
RP Struhl, K (reprint author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.
EM kevin@hms.harvard.edu
FU Dana Farber Cancer Institute; National Institutes of Health [CA 107486]
FX This work was supported by start-up funds to DI from the Dana Farber
Cancer Institute and by a research grant to KS from the National
Institutes of Health (CA 107486).
NR 44
TC 49
Z9 52
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
J9 ONCOGENE
JI Oncogene
PD AUG
PY 2012
VL 31
IS 33
BP 3818
EP 3825
DI 10.1038/onc.2011.543
PG 8
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
Heredity
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
Heredity
GA 994IU
UT WOS:000307924900008
PM 22120719
ER
PT J
AU Chen, LM
Aktas, BH
Wang, YB
He, XY
Sahoo, R
Zhang, NC
Denoyelle, S
Kabha, E
Yang, HW
Freedman, RY
Supko, JG
Chorev, M
Wagner, G
Halperin, JA
AF Chen, Limo
Aktas, Bertal H.
Wang, Yibo
He, Xiaoying
Sahoo, Rupam
Zhang, Nancy
Denoyelle, Severine
Kabha, Eihab
Yang, Hongwei
Freedman, Revital Yefidoff
Supko, Jeffrey G.
Chorev, Michael
Wagner, Gerhard
Halperin, Jose A.
TI Tumor suppression by small molecule inhibitorss of translation
initiation
SO ONCOTARGET
LA English
DT Article
DE Translation; eIF4F; eIF4E; ternary complex; eIF2
ID MAMMARY EPITHELIAL-CELLS; 4E PROTEIN ELEVATION; MESSENGER-RNA; EIF4E
EXPRESSION; MAMMALIAN TARGET; CANCER; PROGRESSION; PHOSPHORYLATION;
TRANSFORMATION; MALIGNANCIES
AB Translation initiation factors are over-expressed and/or activated in many human cancers and may contribute to their genesis and/or progression. Removal of physiologic restraints on translation initiation causes malignant transformation. Conversely, restoration of physiological restrains on translation initiation reverts malignant phenotypes. Here, we extensively characterize the anti-cancer activity of two small molecule inhibitors of translation initiation: #1181, which targets the eIF2-GTP-Met-tRNA(i) ternary complex, and 4EGI-1, which targets the eIF4F complex. In vitro, both molecules inhibit translation initiation, abrogate preferentially translation of mRNAs coding for oncogenic proteins, and inhibit proliferation of human cancer cells. In vivo, both #1181 and 4EGI-1 strongly inhibit growth of human breast and melanoma cancer xenografts without any apparent macroscopic-or microscopictoxicity. Mechanistically, #1181 phosphorylates eIF2 alpha while 4EGI-1 disrupts eIF4G/eIF4E interaction in the tumors excised from mice treated with these agents. These data indicate that inhibition of translation initiation is a new paradigm in cancer therapy.
C1 [Chen, Limo; Aktas, Bertal H.; Wang, Yibo; He, Xiaoying; Sahoo, Rupam; Zhang, Nancy; Denoyelle, Severine; Kabha, Eihab; Yang, Hongwei; Freedman, Revital Yefidoff; Supko, Jeffrey G.; Chorev, Michael; Wagner, Gerhard; Halperin, Jose A.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
[Aktas, Bertal H.; Chorev, Michael; Halperin, Jose A.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[He, Xiaoying; Supko, Jeffrey G.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Halperin, JA (reprint author), Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
EM jose_halperin@hms.harvard.edu
RI wang, yibo/A-6484-2013; SAHOO, RUPAM/B-3935-2016
FU NCI NIH HHS [5R01CA121357, 1R01CA152312, R01 CA068262, R01 CA121357, R01
CA152312]
NR 50
TC 38
Z9 39
U1 0
U2 13
PU IMPACT JOURNALS LLC
PI ALBANY
PA 6211 TIPTON HOUSE, STE 6, ALBANY, NY 12203 USA
SN 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD AUG
PY 2012
VL 3
IS 8
BP 869
EP U3
PG 13
WC Oncology; Cell Biology
SC Oncology; Cell Biology
GA 997ZD
UT WOS:000308206100015
PM 22935625
ER
PT J
AU Zhang, C
Ruvkun, G
AF Zhang, Chi
Ruvkun, Gary
TI New insights into siRNA amplification and RNAi
SO RNA BIOLOGY
LA English
DT Editorial Material
DE rde-10; rde-11; RNAi; small interfering RNAs; C. elegans
ID GERM-LINE DEVELOPMENT; CAENORHABDITIS-ELEGANS; C-ELEGANS; INTERFERENCE;
GENES; SID-1; REVEALS
AB In the nematode Caenorhabditis elegans (C. elegans), gene inactivation by RNA interference can achieve remarkable potency due to the amplification of initial silencing triggers by RNA-dependent RNA polymerases (RdRPs). RdRPs catalyze the biogenesis of an abundant species of secondary small interfering RNAs (siRNAs) using the target mRNA as template. The interaction between primary siRNAs derived from the exogenous double-stranded RNA (dsRNA) trigger and the target mRNA is required for the recruitment of RdRPs. Other genetic requirements for RdRP activities have not been characterized. Recent studies have identified the RDE-10/RDE-11 complex which interacts with the primary siRNA bound target mRNA and acts upstream of the RdRPs. rde-10 and rde-11 mutants show an RNAi defective phenotype because the biogenesis of secondary siRNAs is completely abolished. In addition, the RDE-10/RDE-11 complex plays a similar role in the endogenous RNAi pathway for the biogenesis of a subset of siRNAs targeting recently acquired, duplicated genes.
C1 [Zhang, Chi; Ruvkun, Gary] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.
[Zhang, Chi; Ruvkun, Gary] Harvard Univ, Sch Med, Dept Genet, Boston, MA USA.
RP Ruvkun, G (reprint author), Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.
EM ruvkun@molbio.mgh.harvard.edu
FU NIGMS NIH HHS [R01 GM044619]
NR 33
TC 6
Z9 9
U1 0
U2 9
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA
SN 1547-6286
J9 RNA BIOL
JI RNA Biol.
PD AUG
PY 2012
VL 9
IS 8
BP 1045
EP 1049
DI 10.4161/rna.21246
PG 5
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 003EG
UT WOS:000308590400003
PM 22858672
ER
PT J
AU Voils, CI
Coffman, CJ
Edelman, D
Maciejewski, ML
Grubber, JM
Sadeghpour, A
Cho, A
McKenzie, J
Blanpain, F
Scheuner, M
Sandelowski, M
Gallagher, MP
Ginsburg, GS
Yancy, WS
AF Voils, Corrine I.
Coffman, Cynthia J.
Edelman, David
Maciejewski, Matthew L.
Grubber, Janet M.
Sadeghpour, Azita
Cho, Alex
McKenzie, Jamiyla
Blanpain, Francoise
Scheuner, Maren
Sandelowski, Margarete
Gallagher, M. Patrick
Ginsburg, Geoffrey S.
Yancy, William S., Jr.
TI Examining the impact of genetic testing for type 2 diabetes on health
behaviors: study protocol for a randomized controlled trial
SO TRIALS
LA English
DT Article
DE Genetic testing; Type II diabetes; Weight loss
ID LOW-CARBOHYDRATE DIET; WEIGHT-LOSS; SELF-EFFICACY; RISK; PREVENTION;
QUESTIONNAIRE; INTERVENTION; RELIABILITY; PROGRESSION; NUMERACY
AB Background: We describe the study design, procedures, and development of the risk counseling protocol used in a randomized controlled trial to evaluate the impact of genetic testing for diabetes mellitus (DM) on psychological, health behavior, and clinical outcomes.
Methods/Design: Eligible patients are aged 21 to 65 years with body mass index (BMI) >= 27 kg/m(2) and no prior diagnosis of DM. At baseline, conventional DM risk factors are assessed, and blood is drawn for possible genetic testing. Participants are randomized to receive conventional risk counseling for DM with eye disease counseling or with genetic test results. The counseling protocol was pilot tested to identify an acceptable graphical format for conveying risk estimates and match the length of the eye disease to genetic counseling. Risk estimates are presented with a vertical bar graph denoting risk level with colors and descriptors. After receiving either genetic counseling regarding risk for DM or control counseling on eye disease, brief lifestyle counseling for prevention of DM is provided to all participants.
Discussion: A standardized risk counseling protocol is being used in a randomized trial of 600 participants. Results of this trial will inform policy about whether risk counseling should include genetic counseling.
C1 [Voils, Corrine I.; Coffman, Cynthia J.; Edelman, David; Maciejewski, Matthew L.; Grubber, Janet M.; Sadeghpour, Azita; McKenzie, Jamiyla; Gallagher, M. Patrick; Yancy, William S., Jr.] Durham Vet Affairs Med Ctr, Ctr Hlth Serv Res Primary Care, Durham, NC USA.
[Voils, Corrine I.; Edelman, David; Maciejewski, Matthew L.; Yancy, William S., Jr.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA.
[Coffman, Cynthia J.] Duke Univ, Med Ctr, Dept Biostat & Bioinformat, Durham, NC USA.
[Cho, Alex; Ginsburg, Geoffrey S.] Duke Univ, Med Ctr, Inst Genom Sci & Policy, Durham, NC USA.
[Blanpain, Francoise] Duke Univ, Med Ctr, Clin Mol Diagnost Lab, Durham, NC USA.
[Scheuner, Maren] VA Greater Los Angeles Healthcare Syst, Div Med Genet, Los Angeles, CA USA.
[Scheuner, Maren] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
[Sandelowski, Margarete] Univ N Carolina, Sch Nursing, Chapel Hill, NC USA.
[Voils, Corrine I.] Vet Affairs Med Ctr 152, Durham, NC 27705 USA.
RP Voils, CI (reprint author), Durham Vet Affairs Med Ctr, Ctr Hlth Serv Res Primary Care, Durham, NC USA.
EM corrine.voils@dm.duke.edu
OI Voils, Corrine/0000-0003-1913-663X; Edelman, David/0000-0001-7112-6151
FU Department of Veterans Affairs (DVA) Health Services Research and
Development (HSRD) service [IIR 09-039]; Career Scientist Award from DVA
HSRD [RCS 10-391]
FX This research was supported by a grant from the Department of Veterans
Affairs (DVA) Health Services Research and Development (HSR&D) service
(IIR 09-039). Dr. Maciejewski was supported by a Career Scientist Award
from DVA HSR&D (RCS 10-391). The views expressed in this article are
those of the authors and do not necessarily represent the views of the
DVA. We express our deepest gratitude to Tamika Brown and Cherisa
Williams for their assistance with data collection, to Jennifer Hoff for
development of the study database, and to Karen Nicely, MS for delivery
of genetic counseling. Dr. Sadeghpour is now at Duke University Medical
Center. Ms. Blanpain is now at Pathgroup in Nashville, TN. Dr. Gallagher
is now at Altisource Solutions in Winston-Salem, NC.
NR 35
TC 6
Z9 6
U1 2
U2 10
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1745-6215
J9 TRIALS
JI Trials
PD AUG 1
PY 2012
VL 13
AR 121
DI 10.1186/1745-6215-13-121
PG 10
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 992YN
UT WOS:000307817600001
PM 22852560
ER
PT J
AU Choi, HG
Zhang, JW
Deng, XM
Hatcher, JM
Patricelli, MP
Zhao, Z
Alessi, DR
Gray, NS
AF Choi, Hwan Geun
Zhang, Jinwei
Deng, Xianming
Hatcher, John M.
Patricelli, Matthew P.
Zhao, Zheng
Alessi, Dario R.
Gray, Nathanael S.
TI Brain Penetrant LRRK2 Inhibitor
SO ACS MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE LRRK2; blood-brain barrier; brain penetrant inhibitor;
2,4-diaminopyrimidine
ID KINASE 2 LRRK2; PARKINSONS-DISEASE; POTENT; NEURODEGENERATION;
SELECTIVITY; TOXICITY; MODELS
AB Activating mutations in leucine-rich repeat kinase 2 (LARK2) are present in a subset of Parkinson's disease (PD) patients and may represent an attractive therapeutic target. Here, we report that a 2-anilino-4-methylamino-5-chloropyrimidine, HG-10-102-01 (4), is a potent and selective inhibitor of wild-type LRRK2 and the G2019S mutant. Compound 4 substantially inhibits Ser910 and Ser935 phosphorylation of both wild-type LRRK2 and G2019S mutant at a concentration of 0.1-0.3 mu M in cells and is the first compound reported to be capable of inhibiting Ser910 and Ser935 phosphorylation in mouse brain following intraperitoneal delivery of doses as low as 50 mg/kg.
C1 [Zhang, Jinwei; Alessi, Dario R.] Univ Dundee, Coll Life Sci, MRC Prot Phosphorylat Unit, Dundee DD1 5EH, Scotland.
[Choi, Hwan Geun; Deng, Xianming; Hatcher, John M.; Gray, Nathanael S.] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA.
[Choi, Hwan Geun; Deng, Xianming; Hatcher, John M.; Gray, Nathanael S.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, SGM 628, Boston, MA 02115 USA.
[Patricelli, Matthew P.] ActivX Biosci, La Jolla, CA 92037 USA.
[Zhao, Zheng] Chinese Acad Sci, High Field Magnet Lab, Hefei 230031, Anhui, Peoples R China.
RP Alessi, DR (reprint author), Univ Dundee, Coll Life Sci, MRC Prot Phosphorylat Unit, Dow St, Dundee DD1 5EH, Scotland.
EM d.r.alessi@dundee.ac.uk; Nathanael_Gray@dfci.harvard.edu
OI Alessi, Dario/0000-0002-2140-9185; Zhang, Jinwei/0000-0001-8683-509X
FU NIH [P41 GM079575-03]; Medical Research Council; Michael J. Fox
foundation for Parkinson's disease research; AstraZeneca;
Boehringer-Ingelheim; GlaxoSmithKline; Merck KgaA; Pfizer
FX This work was supported by NIH Grant P41 GM079575-03 (N.S.G.), the
Medical Research Council (D.R.A.), the Michael J. Fox foundation for
Parkinson's disease research (N.S.G. and D.R.A.), and the pharmaceutical
companies supporting the DSTT (AstraZeneca, Boehringer-Ingelheim,
GlaxoSmithKline, Merck KgaA, and Pfizer) (D.R.A.).
NR 23
TC 60
Z9 60
U1 1
U2 19
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1948-5875
J9 ACS MED CHEM LETT
JI ACS Med. Chem. Lett.
PD AUG
PY 2012
VL 3
IS 8
BP 658
EP 662
DI 10.1021/ml300123a
PG 5
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 988GX
UT WOS:000307478600015
PM 23066449
ER
PT J
AU Shaw, LJ
Weintraub, WS
Maron, DJ
Hartigan, PM
Hachamovitch, R
Min, JK
Dada, M
Mancini, GBJ
Hayes, SW
O'Rourke, RA
Spertus, JA
Kostuk, W
Gosselin, G
Chaitman, BR
Knudtson, M
Friedman, J
Slomka, P
Germano, G
Bates, ER
Teo, KK
Boden, WE
Berman, DS
AF Shaw, Leslee J.
Weintraub, William S.
Maron, David J.
Hartigan, Pamela M.
Hachamovitch, Rory
Min, James K.
Dada, Marcin
Mancini, G. B. John
Hayes, Sean W.
O'Rourke, Robert A.
Spertus, John A.
Kostuk, William
Gosselin, Gilbert
Chaitman, Bernard R.
Knudtson, Merill
Friedman, John
Slomka, Piotr
Germano, Guido
Bates, Eric R.
Teo, Koon K.
Boden, William E.
Berman, Daniel S.
TI Baseline stress myocardial perfusion imaging results and outcomes in
patients with stable ischemic heart disease randomized to optimal
medical therapy with or without percutaneous coronary intervention
SO AMERICAN HEART JOURNAL
LA English
DT Article
ID EMISSION COMPUTED-TOMOGRAPHY; EVALUATION COURAGE TRIAL; UTILIZING
REVASCULARIZATION; ARTERY-DISEASE; HIGH-RISK; STRATEGIES; PCI;
MANAGEMENT; INFARCTION; BENEFIT
AB Background The COURAGE trial reported similar clinical outcomes for patients with stable ischemic heart disease (SIHD) receiving optimal medical therapy (OMT) with or without percutaneous coronary intervention (PCI). The current post hoc substudy analysis examined the relationship between baseline stress myocardial ischemia and clinical outcomes based on randomized treatment assignment.
Methods A total of 1,381 randomized patients (OMT n = 699, PCI + OMT n = 682) underwent baseline stress myocardial perfusion single-photon emission computed tomographic imaging. Site investigators interpreted the extent of ischemia by the number of ischemic segments using a 6-segment myocardial model. Patients were divided into those with no to mild (<3 ischemic segments) and moderate to severe ischemia (>= 3 ischemic segments). Cox proportional hazards models were calculated to assess time to the primary end point of death or myocardial infarction.
Results At baseline, moderate to severe ischemia occurred in more than one-quarter of patients (n = 468), and the incidence was comparable in both treatment groups (P = .36). The primary end point, death or myocardial infarction, was similar in the OMT and PCI + OMT treatment groups for no to mild (18% and 19%, P = .92) and moderate to severe ischemia (19% and 22%, P = .53, interaction P value = .65). There was no gradient increase in events for the overall cohort with the extent of ischemia.
Conclusions From the COURAGE trial post hoc substudy, the extent of site-defined ischemia did not predict adverse events and did not alter treatment effectiveness. Currently, evidence supports equipoise as to whether the extent and severity of ischemia impact on therapeutic effectiveness. (Am Heart J 2012; 164: 243-50.)
C1 [Shaw, Leslee J.] Emory Univ, Emory Clin Cardiovasc Res Inst, Sch Med, Atlanta, GA 30306 USA.
[Weintraub, William S.] Christiana Care Hlth Syst, Newark, DE USA.
[Maron, David J.] Vanderbilt Univ, Med Ctr, Nashville, TN USA.
[Hartigan, Pamela M.] VA Connecticut Healthcare Syst, VA Cooperat Studies Program, Coordinating Ctr, West Haven, CT USA.
[Hachamovitch, Rory] Cleveland Clin Fdn, Cleveland, OH 44195 USA.
[Min, James K.; Hayes, Sean W.; Friedman, John; Slomka, Piotr; Germano, Guido] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA.
[Dada, Marcin] Hartford Hosp, Hartford, CT 06115 USA.
[Mancini, G. B. John] Vancouver Hosp & Hlth Sci Ctr, Vancouver, BC V5Z 1M9, Canada.
[O'Rourke, Robert A.] S Texas Vet HCS, San Antonio, TX USA.
[Spertus, John A.] Univ Missouri, St Lukes Mid Amer Heart Inst, Kansas City, MO 64110 USA.
[Kostuk, William] London Hlth Sci Ctr, London, ON, Canada.
[Gosselin, Gilbert] Montreal Heart Inst, Montreal, PQ H1T 1C8, Canada.
[Chaitman, Bernard R.] St Louis Univ, St Louis, MO 63103 USA.
[Knudtson, Merill] Foothills Prov Gen Hosp, Calgary, AB T2N 2T9, Canada.
[Bates, Eric R.] Univ Michigan, Ann Arbor, MI 48109 USA.
[Teo, Koon K.] McMaster Univ, Hamilton, ON, Canada.
[Boden, William E.] SUNY Buffalo, Buffalo Gen Hosp, Western New York VA Healthcare Network, Buffalo, NY 14260 USA.
RP Shaw, LJ (reprint author), Emory Univ, Emory Clin Cardiovasc Res Inst, Sch Med, Room 529,1462 Clifton Rd NE, Atlanta, GA 30306 USA.
EM leslee.shaw@emory.edu
FU Astellas Healthcare; Lantheus Medical Imaging; Cooperative Studies
Program of the Department of Veterans Affairs Office of Research and
Development; Canadian Institute of Health Research-Institute for
Circulatory and Respiratory Health
FX Partial funding for this substudy was provided by Astellas Healthcare
and Lantheus Medical Imaging. Drs Shaw and Berman have declared a
conflict for substudy 0 with grant support to the Department of
Veterans' Affairs, Astellas Healthcare, and Lantheus Medical Imaging. No
other authors have any conflicts to disclose.; Supported by the
Cooperative Studies Program of the Department of Veterans Affairs Office
of Research and Development and Canadian Institute of Health
Research-Institute for Circulatory and Respiratory Health. Additional
support for this nuclear substudy was provided by Astellas Healthcare
and Lantheus Imaging in the form of unrestricted research grants to the
Department of Veterans Affairs.
NR 29
TC 70
Z9 74
U1 1
U2 7
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-8703
J9 AM HEART J
JI Am. Heart J.
PD AUG
PY 2012
VL 164
IS 2
BP 243
EP 250
DI 10.1016/j.ahj.2012.05.018
PG 8
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 991AR
UT WOS:000307673700018
PM 22877811
ER
PT J
AU Kimmel, SE
Troxel, AB
Loewenstein, G
Brensinger, CM
Jaskowiak, J
Doshi, JA
Laskin, M
Volpp, K
AF Kimmel, Stephen E.
Troxel, Andrea B.
Loewenstein, George
Brensinger, Colleen M.
Jaskowiak, Jane
Doshi, Jalpa A.
Laskin, Mitchell
Volpp, Kevin
TI Randomized trial of lottery-based incentives to improve warfarin
adherence
SO AMERICAN HEART JOURNAL
LA English
DT Article
ID PAY-FOR-PERFORMANCE; IN-RANGE; PATIENT ADHERENCE; RISK-FACTORS; CARE;
ANTICOAGULATION; MEDICATION; QUALITY
AB Background Poor adherence to medications is a major cause of morbidity and inadequate drug effectiveness. Efforts to improve adherence have typically been either ineffective or too complex to implement in clinical practice. Lottery-based incentive interventions could be a scalable approach to improving adherence.
Methods This was a randomized, controlled clinical trial of a daily lottery-based incentive in patients on warfarin stratified by baseline international normalized ratio (INR). The trial randomized 100 patients to either a lottery-based incentive or no lottery intervention. Main outcome was out-of-range INRs.
Results Over 6 months, the overall percentage of out-of-range INRs did not differ between the 2 arms (mean 23.0% in lottery arm and 25.9% in control arm, adjusted odds ratio [OR] 0.93, 95% CI 0.62-1.41). However, among the a priori subgroup with a baseline INR below therapeutic range, there was a significant reduction in out-of-range INR in the lottery arm versus the control arm (adjusted OR 0.39, 95% CI 0.25-0.62), whereas there was no such effect among those with therapeutic INRs at baseline (adjusted OR 1.26, 95% CI, 0.76-2.09, P value for interaction = .0016). Among those with low INR at baseline, there was a nonsignificant 49% reduction in the odds of nonadherence with the intervention (OR 0.51, 95% CI 0.23-1.14
). Conclusions Although a lottery-based intervention was not associated with a significant improvement in anticoagulation control among all study participants, it improved control among an a priori group of patients at higher risk for poor adherence. (Am Heart J 2012; 164: 268-74.)
C1 [Kimmel, Stephen E.; Troxel, Andrea B.; Brensinger, Colleen M.; Jaskowiak, Jane] Univ Penn, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA.
[Kimmel, Stephen E.; Doshi, Jalpa A.; Volpp, Kevin] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA.
[Kimmel, Stephen E.; Troxel, Andrea B.; Loewenstein, George; Doshi, Jalpa A.; Volpp, Kevin] Univ Penn, Leonard Davis Inst Hlth Econ, Ctr Hlth Incent, Philadelphia, PA 19104 USA.
[Loewenstein, George] Carnegie Mellon Univ, Dept Social & Decis Sci, Pittsburgh, PA 15213 USA.
[Laskin, Mitchell] Hosp Univ Penn, Dept Pharm Serv, Philadelphia, PA 19104 USA.
[Volpp, Kevin] Philadelphia VA Med Ctr, Ctr Hlth Equity Res & Promot, Philadelphia, PA USA.
[Volpp, Kevin] Univ Penn, Wharton Sch, Dept Hlth Care Management, Philadelphia, PA 19104 USA.
RP Kimmel, SE (reprint author), Univ Penn, Sch Med, Dept Biostat & Epidemiol, 717 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.
EM stevek@mail.med.upenn.edu
OI Troxel, Andrea/0000-0002-1393-3075
FU Aetna Foundation
FX The study was funded by the Aetna Foundation who had no role in the
design of the study; execution of the study; analysis, interpretation,
and writing of the manuscript; or decision to submit the manuscript for
publication. Aetna also did not have access to the data. All authors had
access to the data.
NR 19
TC 28
Z9 28
U1 0
U2 8
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-8703
J9 AM HEART J
JI Am. Heart J.
PD AUG
PY 2012
VL 164
IS 2
BP 268
EP 274
DI 10.1016/j.ahj.2012.05.005
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 991AR
UT WOS:000307673700021
PM 22877814
ER
PT J
AU Hiramoto, JS
Katz, R
Peralta, CA
Ix, JH
Fried, L
Cushman, M
Siscovick, D
Palmas, W
Sarnak, M
Shlipak, MG
AF Hiramoto, Jade S.
Katz, Ronit
Peralta, Carmen A.
Ix, Joachim H.
Fried, Linda
Cushman, Mary
Siscovick, David
Palmas, Walter
Sarnak, Mark
Shlipak, Michael G.
TI Inflammation and Coagulation Markers and Kidney Function Decline: The
Multi-Ethnic Study of Atherosclerosis (MESA)
SO AMERICAN JOURNAL OF KIDNEY DISEASES
LA English
DT Article
DE Kidney function; inflammation; coagulation markers
ID C-REACTIVE PROTEIN; SERUM CYSTATIN-C; RENAL-FUNCTION; FACTOR-VIII;
VENOUS THROMBOEMBOLISM; PLASMA-CONCENTRATION; OLDER-ADULTS; RISK-FACTOR;
DISEASE; INTERLEUKIN-6
AB Background: The strength and direction of the associations between inflammation and coagulation biomarkers with kidney disease onset and progression remain unclear, especially in a population-based setting.
Study Design: Prospective observational study.
Setting & Participants: 4,966 participants from the Multi-Ethnic Study of Atherosclerosis (MESA) with a cystatin C-based estimate of glomerular filtration rate (eGFR(cys)) >60 mL/min/1.73 m(2) and at least one follow-up measurement of kidney function. All participants were free of cardiovascular disease at entry.
Predictor: We evaluated the associations of C-reactive protein (CRP), interleukin 6 (IL-6), fibrinogen, factor VIII, and D-dimer levels with kidney function decrease.
Outcomes & Measurements: Kidney function decrease was assessed primarily by repeated measurements of eGFR(cys) over 5 years. Rapid decrease in kidney function was defined as eGFR decrease >3 mL/min/1.73 m(2) per year. Incident low eGFR was defined as the onset of eGFR(cys) <60 mL/min/1.73 m(2) at any follow-up examination and eGFR(cys) decrease >= 1 mL/min/1.73 m(2) per year.
Results: Mean age was 60 years, 39% were white, 52% were women, and 11% had diabetes. Mean eGFR(cys) was 96 mL/min/1.73 m(2) and 7% had albuminuria. Median follow-up was 4.77 years. Higher factor VIII levels (per 1 standard deviation [SD] of biomarker) had the strongest association with kidney function decrease (beta = -0.25; 95% CI, -0.38 to -0.12; P < 0.001), followed by IL-6 (beta = -0.16; 95% CI, -0.29 to -0.03; P = 0.01), CRP (beta = -0.09; 95% CI, -0.22 to 0.03; P = 0.1), and fibrinogen levels (beta = -0.09; 95% CI, -0.22 to 0.04; P = 0.2). Each 1-SD higher concentration of IL-6 (OR, 1.15; 95% CI, 1.07-1.23), factor VIII (OR, 1.11; 95% CI, 1.03-1.18), and CRP (OR, 1.09; 95% CI, 1.02-1.16) at baseline was associated significantly with rapid kidney function decrease. Only IL-6 level was associated significantly with incident low eGFR (OR, 1.09; 95% CI, 1.00-1.19).
Limitations: Observational study design and absence of measured GFR.
Conclusions: Inflammation and coagulation biomarkers are associated with decreasing kidney function in ambulatory adults without established cardiovascular disease or chronic kidney disease. Am J Kidney Dis. 60(2):225-232. (C) 2012 by the National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.
C1 [Hiramoto, Jade S.] Univ Calif San Francisco, Dept Surg, San Francisco, CA USA.
[Katz, Ronit] Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
[Peralta, Carmen A.; Shlipak, Michael G.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
[Ix, Joachim H.] Univ Calif San Diego, Div Nephrol, San Diego, CA 92103 USA.
[Fried, Linda] VA Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA USA.
[Fried, Linda] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15260 USA.
[Fried, Linda] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA.
[Cushman, Mary] Univ Vermont, Dept Med, Thrombosis & Hemostasis Program, Burlington, VT USA.
[Siscovick, David] Univ Washington, Dept Epidemiol & Biostat, Seattle, WA 98195 USA.
[Palmas, Walter] Columbia Univ, Dept Med, New York, NY USA.
[Sarnak, Mark] Tufts Med Ctr, Dept Med, Div Nephrol, Boston, MA USA.
[Shlipak, Michael G.] San Francisco VA Med Ctr, Div Gen Internal Med, San Francisco, CA USA.
RP Hiramoto, JS (reprint author), UCSF Vasc Surg, 400 Parnassus Ave,A-581,Box 0222, San Francisco, CA 94143 USA.
EM jade.hiramoto@ucsfmedctr.org
FU National Institutes of Health (NIH)/National Center for Research
Resources/OD UCSF-CTSI [KL2 RR024130]; NIH/National Institute of
Diabetes and Digestive and Kidney Diseases [R01 DK066488-01]; American
Heart Association (AHA) [0640012N]
FX This publication was supported by National Institutes of Health
(NIH)/National Center for Research Resources/OD UCSF-CTSI grant KL2
RR024130 (Dr Hiramoto), NIH/National Institute of Diabetes and Digestive
and Kidney Diseases/R01 DK066488-01 (Dr Shlipak), and American Heart
Association (AHA) Established Investigator Award 0640012N (Dr Shlipak).
Its contents are the responsibility of the authors and do not
necessarily represent the official views of the NIH or AHA.
NR 45
TC 28
Z9 28
U1 0
U2 6
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0272-6386
J9 AM J KIDNEY DIS
JI Am. J. Kidney Dis.
PD AUG
PY 2012
VL 60
IS 2
BP 225
EP 232
DI 10.1053/j.ajkd.2012.02.335
PG 8
WC Urology & Nephrology
SC Urology & Nephrology
GA 974ZW
UT WOS:000306477200010
PM 22560844
ER
PT J
AU Vijayan, A
Palevsky, PM
AF Vijayan, Anitha
Palevsky, Paul M.
TI In Reply to 'Renal Replacement Therapy Dosing in Acute Kidney Injury'
SO AMERICAN JOURNAL OF KIDNEY DISEASES
LA English
DT Letter
ID CRITICALLY-ILL PATIENTS
C1 [Vijayan, Anitha] Washington Univ, St Louis, MO 63130 USA.
[Palevsky, Paul M.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Palevsky, Paul M.] Univ Pittsburgh, Pittsburgh, PA USA.
RP Vijayan, A (reprint author), Washington Univ, St Louis, MO 63130 USA.
OI Palevsky, Paul/0000-0002-7334-5400
NR 4
TC 0
Z9 0
U1 0
U2 1
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0272-6386
J9 AM J KIDNEY DIS
JI Am. J. Kidney Dis.
PD AUG
PY 2012
VL 60
IS 2
BP 328
EP 329
DI 10.1053/j.ajkd.2012.05.015
PG 3
WC Urology & Nephrology
SC Urology & Nephrology
GA 974ZW
UT WOS:000306477200026
ER
PT J
AU Souza, LCS
Yoo, AJ
Chaudhry, ZA
Payabvash, S
Kemmling, A
Schaefer, PW
Hirsch, JA
Furie, KL
Gonzalez, RG
Nogueira, RG
Lev, MH
AF Souza, L. C. S.
Yoo, A. J.
Chaudhry, Z. A.
Payabvash, S.
Kemmling, A.
Schaefer, P. W.
Hirsch, J. A.
Furie, K. L.
Gonzalez, R. G.
Nogueira, R. G.
Lev, M. H.
TI Malignant CTA Collateral Profile Is Highly Specific for Large Admission
DWI Infarct Core and Poor Outcome in Acute Stroke
SO AMERICAN JOURNAL OF NEURORADIOLOGY
LA English
DT Article
ID ACUTE ISCHEMIC-STROKE; CLINICAL-RESPONSE; LESION VOLUMES; SYMPTOM ONSET;
PERFUSION-CT; THROMBOLYSIS; DIFFUSION; ANGIOGRAPHY; RECANALIZATION;
PREDICTION
AB BACKGROUND AND PURPOSE: Large admission DWI lesion volumes are associated with poor outcomes despite acute stroke treatment. The primary aims of our study were to determine whether CTA collaterals correlate with admission DWI lesion volumes in patients with AIS with proximal occlusions, and whether a CTA collateral profile could identify large DWI volumes with high specificity.
MATERIALS AND METHODS: We studied 197 patients with AIS with M1 and/or intracranial ICA occlusions. We segmented admission and follow-up DWI lesion volumes, and categorized CTA collaterals by using a 5-point CS system. ROC analysis was used to determine CS accuracy in predicting DWI lesion volumes >100 mL. Patients were dichotomized into 2 categories: CS = 0 (malignant profile) or CS>0. Univariate and multivariate analyses were performed to compare imaging and clinical variables between these 2 groups.
RESULTS: There was a negative correlation between CS and admission DWI lesion volume (rho = -0.54, P < .0001). ROC analysis revealed that CTA CS was a good discriminator of DWI lesion volume >100 mL (AUC = 0.84, P < .001). CS = 0 had 97.6% specificity and 54.5% sensitivity for DWI volume >100 mL. CS = 0 patients had larger mean admission DWI volumes (165.8 mL versus 32.7 mL, P < .001), higher median NIHSS scores (21 versus 15, P < .001), and were more likely to become functionally dependent at 3 months (95.5% versus 64.0%, P = .003). Admission NIHSS score was the only independent predictor of a malignant CS (P = .007).
CONCLUSIONS: In patients with AIS with PAOs, CTA collaterals correlate with admission DWI infarct size. A malignant collateral profile is highly specific for large admission DWI lesion size and poor functional outcome.
C1 [Souza, L. C. S.; Yoo, A. J.; Chaudhry, Z. A.; Payabvash, S.; Kemmling, A.; Schaefer, P. W.; Hirsch, J. A.; Gonzalez, R. G.; Lev, M. H.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
[Furie, K. L.; Nogueira, R. G.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA USA.
RP Yoo, AJ (reprint author), Massachusetts Gen Hosp, Dept Radiol, 55 Fruit St,GRB241, Boston, MA 02114 USA.
EM ajyoo@partners.org
FU NIH SPOTRIAS Network [P50 NS051343]; Agency for Healthcare Research and
Quality [R01 HS11392]; MGH Clinical Research Center [1 UL1 RR025758-01];
Harvard Clinical and Translational Science Center (National Center for
Research Resources); Penumbra, Inc.; GE Healthcare; Care Fusion; PHS;
NINDS SPOTRIAS; DOD; NBIB
FX This work was supported by an NIH SPOTRIAS Network grant (P50 NS051343),
an Agency for Healthcare Research and Quality grant (R01 HS11392), and
the MGH Clinical Research Center (No. 1 UL1 RR025758-01) Harvard
Clinical and Translational Science Center (National Center for Research
Resources). A.J.Y. and R.G.G. receive research support from Penumbra,
Inc. M.H.L. receives research support from GE Healthcare and is
Consultant to Co-Axis, GE Healthcare, and Millennium Pharmaceuticals.;
Disclosures: Albert Yoo-UNRELATED. Grants/Grants Pending: Penumbra,
Inc.* Joshua Hirsch-UNRELATED: Consultancy: CareFusion, Phillips,
Comments: Vertebral Augmentatwo (Phillips Participated in focus group of
NI specialists for NI suites of the future; CareFusion-participated on
NextGen team for product development); Royalties: Care Fusion, Comments:
as above; Stock/Stock Options: Intratech, NFocus, Nevro, Comments:
Development stage companies that are working on NI products (IntraTech
and N-Focus) and nerve imaging (Nevro). Karen Furie-RELATED: Grants:
PHS.* Raul G. Nogueira-UNRELATED: Board Membership: Concentric Medical,
eV3 Neurovascular, Coaxia; Consultancy: Concentric Medical, eV3
Neurovascular, Coaxia. Michael Lev-RELATED: Grant: NINDS SPOTRIAS,* GE
Healthcare,* Comments: Research support; UNRELATED: Consultancy:
Millennium Pharmaceuticals, GE Healthcare, Comments: < $10K;
Grants/Grants Pending: DOD,* NBIB;* Royalties: Q&A color review of
neuroimaging, Comments: < $1K, Stock/Stock Options: GE, Comments: Own
common stock < $10K. (*Money paid to institution.)
NR 20
TC 67
Z9 69
U1 0
U2 3
PU AMER SOC NEURORADIOLOGY
PI OAK BROOK
PA 2210 MIDWEST RD, OAK BROOK, IL 60521 USA
SN 0195-6108
J9 AM J NEURORADIOL
JI Am. J. Neuroradiol.
PD AUG
PY 2012
VL 33
IS 7
BP 1331
EP 1336
DI 10.3174/ajnr.A2985
PG 6
WC Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical
Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA 990KA
UT WOS:000307628200024
PM 22383238
ER
PT J
AU Valente, AJ
Yoshida, T
Murthy, SN
Sakamuri, SSVP
Katsuyama, M
Clark, RA
Delafontaine, P
Chandrasekar, B
AF Valente, Anthony J.
Yoshida, Tadashi
Murthy, Subramanyam N.
Sakamuri, Siva S. V. P.
Katsuyama, Masato
Clark, Robert A.
Delafontaine, Patrice
Chandrasekar, Bysani
TI Angiotensin II enhances AT(1)-Nox1 binding and stimulates arterial
smooth muscle cell migration and proliferation through AT(1), Nox1, and
interleukin-18
SO AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY
LA English
DT Article
DE renin-angiotensin-aldosterone system; mitogenesis; migration;
atherosclerosis; restenosis; angiotensin II type 1 receptor
ID NF-KAPPA-B; NADPH OXIDASE; MATRIX METALLOPROTEINASES; NEOINTIMAL
FORMATION; INDUCED HYPERTENSION; SIGNALING PATHWAYS; OXIDATIVE STRESS;
TYPE-1 RECEPTOR; GENE-EXPRESSION; CROSS-TALK
AB Valente AJ, Yoshida T, Murthy SN, Sakamuri SS, Katsuyama M, Clark RA, Delafontaine P, Chandrasekar B. Angiotensin II enhances AT(1)-Nox1 binding and stimulates arterial smooth muscle cell migration and proliferation through AT(1), Nox1, and interleukin18. Am J Physiol Heart Circ Physiol 303: H282-H296, 2012. First published May 25, 2012; doi:10.1152/ajpheart.00231.2012.-The redox- sensitive transcription factors NF-kappa B and activator protein-1 (AP-1) are critical mediators of ANG II signaling. The promitogenic and promigratory factor interleukin (IL)-18 is an NF-kappa B- and AP-1-responsive gene. Therefore, we investigated whether ANG II-mediated smooth muscle cell (SMC) migration and proliferation involve IL-18. ANG II induced rat carotid artery SMC migration and proliferation and IL-18 and metalloproteinase (MMP)-9 expression via ANG II type 1 (AT1) receptor. ANG II-induced superoxide generation, NF-kappa B and AP-1 activation, and IL-18 and MMP-9 induction were all markedly attenuated by losartan, diphenyleneiodonium chloride (DPI), and Nox1 knockdown. Similar to ANG II, addition of IL-18 also induced superoxide generation, activated NF-kappa B and AP-1, and stimulated SMC migration and proliferation, in part via Nox1, and both ANG II and IL-18 induced NOX1 transcription in an AP-1-dependent manner. AT1 physically associates with Nox1 in SMC, and ANG II enhanced this binding. Interestingly, exogenous IL-18 neither induced AT1 binding to Nox1 nor enhanced the ANG II-induced increase in AT(1)/Nox1 binding. Importantly, IL-18 knockdown, or pretreatment with IL-18 neutralizing antibodies, or IL-18 binding protein, all attenuated the migratory and mitogenic effects of ANG II. Continuous infusion of ANG II for 7 days induced carotid artery hyperplasia in rats via AT1 and was associated with increased AT(1)/Nox1 binding (despite lower AT1 levels); increased DPI-inhibitable superoxide production; increased phospho-IKK beta, JNK, p65, and c-Jun; and induction of IL-18 and MMP-9 in endothelium-denuded carotid arteries. These results indicate that IL-18 amplifies the ANG II-induced, redox-dependent inflammatory cascades by activating similar promitogenic and promigratory signal transduction pathways. The ANG II/Nox1/IL-18 pathway may be critical in hyperplastic vascular diseases, including atherosclerosis and restenosis.
C1 [Yoshida, Tadashi; Sakamuri, Siva S. V. P.; Delafontaine, Patrice; Chandrasekar, Bysani] Tulane Univ, Inst Heart & Vasc, Sch Med, New Orleans, LA 70112 USA.
[Valente, Anthony J.; Clark, Robert A.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Valente, Anthony J.; Clark, Robert A.] S Texas Vet Hlth Care Syst, San Antonio, TX USA.
[Katsuyama, Masato] Kyoto Prefectural Univ Med, Radioisotope Ctr, Kamigyo Ku, Kyoto, Japan.
[Chandrasekar, Bysani] SE Louisiana Vet Hlth Care Syst, Res Serv, New Orleans, LA USA.
RP Chandrasekar, B (reprint author), Tulane Univ, Inst Heart & Vasc, Sch Med, 1430 Tulane Ave,SL 48, New Orleans, LA 70112 USA.
OI Delafontaine, Patrice/0000-0003-3744-3617; Yoshida,
Tadashi/0000-0002-4544-1497
FU Veterans Affairs Office of Research; Development-Biomedical Laboratory
Research; Development Service Award [1IO1BX000246]; National Heart,
Lung, and Blood Institute [HL-86787, HL-70241, HL-80682]
FX This work was supported by the Veterans Affairs Office of Research and
Development-Biomedical Laboratory Research and Development Service Award
1IO1BX000246 and National Heart, Lung, and Blood Institute Grant
HL-86787 to BC. P. Delafontaine is supported by National Heart, Lung,
and Blood Institute Grants HL-70241 and HL-80682.
NR 52
TC 35
Z9 37
U1 1
U2 7
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0363-6135
J9 AM J PHYSIOL-HEART C
JI Am. J. Physiol.-Heart Circul. Physiol.
PD AUG
PY 2012
VL 303
IS 3
BP H282
EP H296
DI 10.1152/ajpheart.00231.2012
PG 15
WC Cardiac & Cardiovascular Systems; Physiology; Peripheral Vascular
Disease
SC Cardiovascular System & Cardiology; Physiology
GA 984ZG
UT WOS:000307231900004
PM 22636674
ER
PT J
AU Vaporidi, K
Vergadi, E
Kaniaris, E
Hatziapostolou, M
Lagoudaki, E
Georgopoulos, D
Zapol, WM
Bloch, KD
Iliopoulos, D
AF Vaporidi, Katerina
Vergadi, Eleni
Kaniaris, Evangelos
Hatziapostolou, Maria
Lagoudaki, Eleni
Georgopoulos, Dimitrios
Zapol, Warren M.
Bloch, Kenneth D.
Iliopoulos, Dimitris
TI Pulmonary microRNA profiling in a mouse model of ventilator-induced lung
injury
SO AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
LA English
DT Article
DE inflammation; miR-21; TGF-beta; miRNA-gene network
ID RESPIRATORY-DISTRESS-SYNDROME; MECHANICAL VENTILATION; INFLAMMATORY
RESPONSE; EXPRESSION; ACTIVATION; FIBROSIS; MIR-21; PTEN;
LIPOPOLYSACCHARIDE; DIFFERENTIATION
AB Vaporidi K, Vergadi E, Kaniaris E, Hatziapostolou M, Lagoudaki E, Georgopoulos D, Zapol WM, Bloch KD, Iliopoulos D. Pulmonary microRNA profiling in a mouse model of ventilator-induced lung injury. Am J Physiol Lung Cell Mol Physiol 303: L199-L207, 2012. First published June 1, 2012; doi:10.1152/ajplung.00370.2011.-The aim of this study was to investigate the changes induced by high tidal volume ventilation (HVTV) in pulmonary expression of micro-RNAs (miRNAs) and identify potential target genes and corresponding miRNA-gene networks. Using a real-time RT-PCR-based array in RNA samples from lungs of mice subjected to HVTV for 1 or 4 h and control mice, we identified 65 miRNAs whose expression changed more than twofold upon HVTV. An inflammatory and a TGF-beta-signaling miRNA-gene network were identified by in silico pathway analysis being at highest statistical significance (P = 10(-43) and P = 10(-28), respectively). In the inflammatory network, IL-6 and SOCS-1, regulated by miRNAs let-7 and miR-155, respectively, appeared as central nodes. In TGF-beta-signaling network, SMAD-4, regulated by miR-146, appeared as a central node. The contribution of miRNAs to the development of lung injury was evaluated in mice subjected to HVTV treated with a precursor or antagonist of miR-21, a miRNA highly upregulated by HVTV. Lung compliance was preserved only in mice treated with anti-miR-21 but not in mice treated with pre-miR-21 or negative-control miRNA. Both alveolar-arterial oxygen difference and protein levels in bronchoalveolar lavage were lower in mice treated with anti-miR-21 than in mice treated with pre-miR-21 or negative-control miRNA (DA-a: 66 +/- 27 vs. 131 +/- 22, 144 +/- 10 mmHg, respectively, P < 0.001; protein concentration: 1.1 +/- 0.2 vs. 2.3 +/- 1, 2.1 +/- 0.4 mg/ml, respectively, P < 0.01). Our results show that HVTV induces changes in miRNA expression in mouse lungs. Modulation of miRNA expression can affect the development of HVTV-induced lung injury.
C1 [Vaporidi, Katerina; Vergadi, Eleni; Kaniaris, Evangelos; Georgopoulos, Dimitrios] Univ Crete, Fac Med, Dept Intens Care Med, Iraklion, Crete, Greece.
[Lagoudaki, Eleni] Univ Crete, Fac Med, Dept Med, Iraklion, Crete, Greece.
[Vaporidi, Katerina; Zapol, Warren M.; Bloch, Kenneth D.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Anesthesia Ctr Crit Care Res,Dept Anesthesia Crit, Boston, MA USA.
[Hatziapostolou, Maria; Iliopoulos, Dimitris] Harvard Univ, Sch Med, Dept Microbiol Immunol, Boston, MA USA.
[Iliopoulos, Dimitris] Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA.
RP Vaporidi, K (reprint author), Univ Crete, Fac Med, Dept Intens Care Med, Iraklion, Crete, Greece.
EM vaporidi@med.uoc.gr
RI Hatziapostolou, Maria/N-1820-2015
OI Hatziapostolou, Maria/0000-0003-2493-7028
FU US Public Health Service [HL-42397, HL74352]; LeDucq Foundation;
European Society of Intensive Care Medicine research grant; University
of Crete Research Committee [KA 2869, 3500]
FX This work has been supported by US Public Health Service grant HL-42397
to W. M. Zapol, by the LeDucq Foundation and US Public Health Service
grant HL74352 to K.D. Bloch, by European Society of Intensive Care
Medicine research grant to K. Vaporidi, and by University of Crete
Research Committee grants to D. Georgopoulos and K. Vaporidi (KA 2869,
3500).
NR 48
TC 30
Z9 33
U1 1
U2 19
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 1040-0605
J9 AM J PHYSIOL-LUNG C
JI Am. J. Physiol.-Lung Cell. Mol. Physiol.
PD AUG
PY 2012
VL 303
IS 3
BP L199
EP L207
DI 10.1152/ajplung.00370.2011
PG 9
WC Physiology; Respiratory System
SC Physiology; Respiratory System
GA 984VH
UT WOS:000307220000004
PM 22659882
ER
PT J
AU Goldstein, JE
Massof, RW
Deremeik, JT
Braudway, S
Jackson, ML
Kehler, KB
Primo, SA
Sunness, JS
AF Goldstein, Judith E.
Massof, Robert W.
Deremeik, James T.
Braudway, Sonya
Jackson, Mary Lou
Kehler, K. Bradley
Primo, Susan A.
Sunness, Janet S.
CA Low Vision Res Network Study Grp
TI Baseline Traits of Low Vision Patients Served by Private Outpatient
Clinical Centers in the United States
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID BLUE-MOUNTAINS-EYE; AGE-RELATED MACULOPATHY; QUALITY-OF-LIFE; BEAVER DAM
EYE; VISUAL IMPAIRMENT; OLDER-ADULTS; MACULAR DEGENERATION;
HEARING-LOSS; REHABILITATION SERVICES; COGNITIVE IMPAIRMENT
AB Objective: To characterize the traits of low vision patients who seek outpatient low vision rehabilitation (LVR) services in the United States.
Methods: In a prospective observational study, we enrolled 764 new low vision patients seeking outpatient LVR services from 28 clinical centers in the United States. Before their initial appointment, multiple questionnaires assessing daily living and vision, physical, psychological, and cognitive health states were administered by telephone. Baseline clinical visual impairment measures and disorder diagnoses were recorded.
Results: Patients had a median age of 77 years, were primarily female (66%), and had macular disease (55%), most of which was nonneovascular age-related macular degeneration. More than one-third of the patients (37%) had mild vision impairment with habitual visual acuity (VA) of 20/60 or greater. The VA correlated well with contrast sensitivity (r=-0.52) but poorly with self-reported vision quality. The intake survey revealed self-reported physical health limitations, including decreased endurance (68%) and mobility problems (52%). Many patients reported increased levels of frustration (42%) and depressed mood (22%); memory and cognitive impairment (11%) were less frequently endorsed. Patients relied on others for daily living support (87%), but many (31%) still drove.
Conclusions: Most patients seeking LVR are geriatric and have macular disease with relatively preserved VA. The disparity between VA and subjective quality of vision suggests that LVR referrals are based on symptoms rather than on VA alone. Patients seen for LVR services have significant physical, psychological, and cognitive disorders that can amplify vision disabilities and decrease rehabilitation potential.
C1 [Goldstein, Judith E.; Massof, Robert W.; Deremeik, James T.] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Lions Vis Res & Rehabil Ctr, Baltimore, MD 21205 USA.
[Braudway, Sonya] Ctr Retina & Macular Dis, Winter Haven, FL USA.
[Jackson, Mary Lou] Harvard Univ, Sch Med, Dept Ophthalmol, Massachusetts Eye & Ear Infirm, Boston, MA USA.
[Kehler, K. Bradley] Vanderbilt Eye Inst, Nashville, TN USA.
[Primo, Susan A.] Emory Eye Ctr, Atlanta, GA USA.
[Sunness, Janet S.] Greater Baltimore Med Ctr, Hoover Low Vis Rehabil Serv, Baltimore, MD USA.
RP Goldstein, JE (reprint author), Lions Vis Ctr, 6th Floor,550 N Broadway, Baltimore, MD 21205 USA.
EM jgolds28@jhmi.edu
FU National Eye Institute, National Institutes of Health [EY012045,
EY018696]; Reader's Digest Partners for Sight Foundation; Research to
Prevent Blindness; National Eye Institute [P30EY006360]
FX This study was supported by grants EY012045 and EY018696 from the
National Eye Institute, National Institutes of Health, and by a grant
from Reader's Digest Partners for Sight Foundation. Dr Kehler was
supported by an unrestricted grant from Research to Prevent Blindness.
Dr Primo was supported in part by an unrestricted departmental grant
from Research to Prevent Blindness and National Eye Institute Core Grant
for Vision Research P30EY006360.
NR 71
TC 21
Z9 21
U1 4
U2 11
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 0003-9950
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD AUG
PY 2012
VL 130
IS 8
BP 1028
EP 1037
PG 10
WC Ophthalmology
SC Ophthalmology
GA 987YU
UT WOS:000307455800011
PM 22893074
ER
PT J
AU Bandopadhayay, P
Dagi, L
Robison, N
Goumnerova, L
Ullrich, NJ
AF Bandopadhayay, Pratiti
Dagi, Linda
Robison, Nathan
Goumnerova, Liliana
Ullrich, Nicole J.
TI Morning Glory Disc Anomaly in Association With Ipsilateral Optic Nerve
Glioma
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Letter
ID DEFECTS
C1 [Ullrich, Nicole J.] Boston Childrens Hosp, Dept Neurol, Boston, MA 02115 USA.
[Bandopadhayay, Pratiti; Robison, Nathan] Boston Childrens Hosp, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA USA.
[Dagi, Linda] Boston Childrens Hosp, Dept Ophthalmol, Boston, MA 02115 USA.
[Goumnerova, Liliana] Boston Childrens Hosp, Dept Neurosurg, Boston, MA 02115 USA.
RP Ullrich, NJ (reprint author), Boston Childrens Hosp, Dept Neurol, 300 Longwood Ave, Boston, MA 02115 USA.
EM nicole.ullrich@childrens.harvard.edu
NR 6
TC 3
Z9 3
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 0003-9950
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD AUG
PY 2012
VL 130
IS 8
BP 1082
EP 1083
PG 3
WC Ophthalmology
SC Ophthalmology
GA 987YU
UT WOS:000307455800029
PM 22893090
ER
PT J
AU Morikawa, T
Tanaka, N
Kuchiba, A
Nosho, K
Yamauchi, M
Hornick, JL
Swanson, RS
Chan, AT
Meyerhardt, JA
Huttenhower, C
Schrag, D
Fuchs, CS
Ogino, S
AF Morikawa, Teppei
Tanaka, Noriko
Kuchiba, Aya
Nosho, Katsuhiko
Yamauchi, Mai
Hornick, Jason L.
Swanson, Richard S.
Chan, Andrew T.
Meyerhardt, Jeffrey A.
Huttenhower, Curtis
Schrag, Deborah
Fuchs, Charles S.
Ogino, Shuji
TI Predictors of Lymph Node Count in Colorectal Cancer Resections Data From
US Nationwide Prospective Cohort Studies
SO ARCHIVES OF SURGERY
LA English
DT Article
ID ISLAND METHYLATOR PHENOTYPE; MOLECULAR PATHOLOGICAL EPIDEMIOLOGY;
COLON-CANCER; MICROSATELLITE INSTABILITY; BRAF MUTATION; TUMOR FACTORS;
SURVIVAL; RETRIEVAL; SPECIMENS; NUMBER
AB Objective: To identify factors that influence the total and negative lymph node counts in colorectal cancer resection specimens independent of pathologists and surgeons.
Design: We used multivariate negative binomial regression. Covariates included age, sex, body mass index, family history of colorectal carcinoma, year of diagnosis, hospital setting, tumor location, resected colorectal length (specimen length), tumor size, circumferential growth, TNM stage, lymphocytic reactions and other pathological features, and tumor molecular features (microsatellite instability, CpG island methylator phenotype, long interspersed nucleotide element 1 [LINE-1] methylation, and BRAF, KRAS, and PIK3CA mutations).
Setting: Two US nationwide prospective cohort studies.
Patients: Patients with rectal and colon cancer (N = 918).
Main Outcome Measures: The negative and total node counts (continuous).
Results: Specimen length, tumor size, ascending colon location, T3N0M0 stage, and year of diagnosis were positively associated with the negative node count (all P <= .002). Mutation of KRAS might also be positively associated with the negative node count (P = . 03; borderline significance considering multiple hypothesis testing). Among node-negative (stages I and II) cases, specimen length, tumor size, and ascending colon location remained significantly associated with the node count (all P <= .002), and PIK3CA and KRAS mutations might also be positively associated (P = . 03 and P = . 049, respectively, with borderline significance).
Conclusions: This molecular pathological epidemiology study shows that specimen length, tumor size, tumor location, TNM stage, and year of diagnosis are operator-independent predictors of the lymph node count. These crucial variables should be examined in any future evaluation of the adequacy of lymph node harvest and nodal staging when devising individualized treatment plans for patients with colorectal cancer.
C1 [Ogino, Shuji] Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Med Oncol, Ctr Mol Oncol Pathol, Boston, MA 02215 USA.
[Morikawa, Teppei; Kuchiba, Aya; Yamauchi, Mai; Meyerhardt, Jeffrey A.; Schrag, Deborah; Fuchs, Charles S.; Ogino, Shuji] Harvard Univ, Sch Med, Boston, MA USA.
[Hornick, Jason L.; Ogino, Shuji] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02215 USA.
[Swanson, Richard S.] Brigham & Womens Hosp, Dept Surg, Boston, MA 02215 USA.
[Chan, Andrew T.; Fuchs, Charles S.] Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA 02215 USA.
[Chan, Andrew T.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Gastrointestinal Unit, Boston, MA USA.
[Huttenhower, Curtis] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
[Tanaka, Noriko] Natl Surg Adjuvant Breast & Bowel Project Operat, Pittsburgh, PA USA.
[Nosho, Katsuhiko] Sapporo Med Univ, Dept Internal Med 1, Sapporo, Hokkaido, Japan.
RP Ogino, S (reprint author), Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Med Oncol, Ctr Mol Oncol Pathol, 450 Brookline Ave,Room JF 215C, Boston, MA 02215 USA.
EM shuji_ogino@dfci.harvard.edu
FU National Institutes of Health [P01 CA87969, P01 CA55075, P50 CA127003,
R01 CA151993, R01 CA137178]; Bennett Family Fund for Targeted Therapies
Research; Entertainment Industry Foundation through the National
Colorectal Cancer Research Alliance
FX This work was supported by grants P01 CA87969, P01 CA55075, P50 CA127003
(Dr Fuchs), R01 CA151993 (Dr Ogino), and R01 CA137178 (Dr Chan) from the
National Institutes of Health; the Bennett Family Fund for Targeted
Therapies Research; and the Entertainment Industry Foundation through
the National Colorectal Cancer Research Alliance.
NR 55
TC 20
Z9 20
U1 0
U2 4
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 0004-0010
J9 ARCH SURG-CHICAGO
JI Arch. Surg.
PD AUG
PY 2012
VL 147
IS 8
BP 715
EP 723
DI 10.1001/archsurg.2012.353
PG 9
WC Surgery
SC Surgery
GA 991VV
UT WOS:000307732100006
PM 22508672
ER
PT J
AU Nasr, S
AF Nasr, S.
TI Sensitivity of event-related brain potentials to task rules
SO ATTENTION PERCEPTION & PSYCHOPHYSICS
LA English
DT Article
DE Decision-making; Object Recognition; Perceptual categorization and
identification; Sensory perception; Visual matching
ID PERCEPTUAL DECISION-MAKING; FACE REPRESENTATIONS; NAME RECOGNITION;
REPETITION; ERP; MECHANISMS; OBJECT; CORTEX; MEMORY; SCALP
AB Previous studies have suggested that brain potentials evoked around 300 ms after stimulus onset index the processes underlying perceptual decision-making. However, the sensitivity of these evoked potentials to the task rules, which link sensory perception to the proper action, has not been studied previously. In this study, event-related potentials (ERPs) of the human brain were examined when subjects randomly performed delayed-matching-to-identity (DMI) and delayed-matching-to-category (DMC) tasks. The results showed that the amplitudes of the brain potentials evoked 228-328 ms after test-stimulus onset varied according to the task rules and indexed the processes responsible for decision-making. In contrast to these potentials, the preceding evoked activity (< 228 ms) did not show any sensitivity to the changes in the subjects' responses and indexed the processes responsible for stimulus perception. These findings support the idea that the potentials evoked after 228 ms from stimulus onset are influenced by the task rules and do not index simple sensory perception.
C1 [Nasr, S.] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA.
[Nasr, S.] Inst Res Fundamental Sci IPM, Sch Cognit Sci, Tehran, Iran.
[Nasr, S.] Shahid Beheshti Univ, Res Ctr Brain & Cognit Sci, Sch Med, Tehran, Iran.
RP Nasr, S (reprint author), Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA.
EM shahin@nmr.mgh.harvard.edu
NR 47
TC 1
Z9 1
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1943-3921
J9 ATTEN PERCEPT PSYCHO
JI Atten. Percept. Psychophys.
PD AUG
PY 2012
VL 74
IS 6
BP 1343
EP 1354
DI 10.3758/s13414-012-0309-9
PG 12
WC Psychology; Psychology, Experimental
SC Psychology
GA 981EQ
UT WOS:000306950100022
PM 22585340
ER
PT J
AU Steensma, DP
AF Steensma, David P.
TI Tuning the Rigging before Sailing off into the Stormy Sea of Stem Cell
Transplants for Patients with Myelodysplastic Syndromes
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Editorial Material
ID ACUTE MYELOID-LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; MDS; AML;
FEASIBILITY; AZACITIDINE; REGIMENS; THERAPY; ADULTS; OLDER
C1 [Steensma, David P.] Dana Farber Canc Inst, Div Hematol Malignancies, Dept Med Oncol, Boston, MA 02215 USA.
[Steensma, David P.] Harvard Univ, Sch Med, Boston, MA 02215 USA.
RP Steensma, DP (reprint author), Dana Farber Canc Inst, Div Hematol Malignancies, Dept Med Oncol, 450 Brookline Ave,Suite D1B30,Mayer 1B21, Boston, MA 02215 USA.
EM david_steensma@dfci.harvard.edu
OI Steensma, David/0000-0001-5130-9284
NR 22
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD AUG
PY 2012
VL 18
IS 8
BP 1145
EP 1147
DI 10.1016/j.bbmt.2012.05.004
PG 3
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA 982KB
UT WOS:000307040800001
PM 22609039
ER
PT J
AU Martin, PJ
Rizzo, JD
Wingard, JR
Ballen, K
Curtin, PT
Cutler, C
Litzow, MR
Nieto, Y
Savani, BN
Schriber, JR
Shaughnessy, PJ
Wall, DA
Carpenter, PA
AF Martin, Paul J.
Rizzo, J. Douglas
Wingard, John R.
Ballen, Karen
Curtin, Peter T.
Cutler, Corey
Litzow, Mark R.
Nieto, Yago
Savani, Bipin N.
Schriber, Jeffrey R.
Shaughnessy, Paul J.
Wall, Donna A.
Carpenter, Paul A.
TI First- and Second-Line Systemic Treatment of Acute Graft-versus-Host
Disease: Recommendations of the American Society of Blood and Marrow
Transplantation
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Review
DE Acute graft-versus-host disease; Hematopoietic cell transplantation;
Treatment
ID STEROID-REFRACTORY ACUTE; STEM-CELL TRANSPLANTATION; RECEPTOR
MONOCLONAL-ANTIBODY; MYCOPHENOLATE-MOFETIL; ACUTE GVHD;
RANDOMIZED-TRIAL; ANTITHYMOCYTE GLOBULIN; DENILEUKIN DIFTITOX; THYMOCYTE
GLOBULIN; IMPROVED SURVIVAL
AB Despite prophylaxis with innmunosuppressive agents or a variety of other approaches, many patients suffer from acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic cell transplantation. Although consensus has emerged supporting the use of high-dose methylprednisolone or prednisone for initial treatment of aGVHD, practices differ among centers with respect to the initial glucocorticoid dose, the use of additional immunosuppressive agents, and the approach to withdrawal of treatment after initial improvement. Despite many studies, practices vary considerably with respect to the selection of agents for treatment of glucocorticoid-resistant or refractory GVHD. Investigators and clinicians have recognized the lack of progress and lamented the absence of an accepted standard of care for secondary treatment of aGVHD. The American Society of Blood and Marrow Transplantation has developed recommendations for treatment of aGVHD to be considered by care providers, based on a comprehensive and critical review of published reports. Because the literature provides little basis for a definitive guideline, this review also provides a framework for the interpretation of previous results and the design of future studies. Biol Blood Marrow Transplant 18: 1150-1163 (2012) (C) 2012 American Society for Blood and Marrow Transplantation
C1 [Martin, Paul J.; Carpenter, Paul A.] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA.
[Rizzo, J. Douglas] Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA.
[Wingard, John R.] Univ Florida, Coll Med, Gainesville, FL USA.
[Ballen, Karen] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Curtin, Peter T.] Moores Univ Calif San Diego Canc Ctr, San Diego, CA USA.
[Cutler, Corey] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Litzow, Mark R.] Mayo Clin, Rochester, MN USA.
[Nieto, Yago] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Savani, Bipin N.] Vanderbilt Univ, Med Ctr, Nashville, TN USA.
[Schriber, Jeffrey R.] Virginia G Piper Canc Ctr, Scottsdale, AZ USA.
[Shaughnessy, Paul J.] Texas Transplant Inst, San Antonio, TX USA.
[Wall, Donna A.] Univ Manitoba Canc Care Manitoba, Winnipeg, MB, Canada.
RP Martin, PJ (reprint author), Univ Washington, Fred Hutchinson Canc Res Ctr, POB 19024, Seattle, WA 98109 USA.
EM pmartin@fhcrc.org
FU Department of Health and Human Services [CA18029]; Soligenix, Inc.;
Roche Laboratories
FX Funding for this work was provided in part by CA18029 (P.J.M.) from the
Department of Health and Human Services.; P.J.M. has received research
support from Soligenix, Inc. and Roche Laboratories, administered
through the Fred Hutchinson Cancer Research Center. P.J.S. has received
honoraria from Millenium, Otsuka, and Sanofi/Genzyme. The other authors
declared no conflict of interest.
NR 50
TC 111
Z9 114
U1 2
U2 14
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD AUG
PY 2012
VL 18
IS 8
BP 1150
EP 1163
DI 10.1016/j.bbmt.2012.04.005
PG 14
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA 982KB
UT WOS:000307040800003
PM 22510384
ER
PT J
AU Freytes, CO
Zhang, MJ
Carreras, J
Burns, LJ
Gale, RP
Isola, L
Perales, MA
Seftel, M
Vose, JM
Miller, AM
Gibson, J
Gross, TG
Rowlings, PA
Inwards, DJ
Pavlovsky, S
Martino, R
Marks, DI
Hale, GA
Smith, SM
Schouten, HC
Slavin, S
Klumpp, TR
Lazarus, HM
van Besien, K
Hari, PN
AF Freytes, Cesar O.
Zhang, Mei-Jie
Carreras, Jeanette
Burns, Linda J.
Gale, Robert Peter
Isola, Luis
Perales, Miguel-Angel
Seftel, Matthew
Vose, Julie M.
Miller, Alan M.
Gibson, John
Gross, Thomas G.
Rowlings, Philip A.
Inwards, David J.
Pavlovsky, Santiago
Martino, Rodrigo
Marks, David I.
Hale, Gregory A.
Smith, Sonali M.
Schouten, Harry C.
Slavin, Simon
Klumpp, Thomas R.
Lazarus, Hillard M.
van Besien, Koen
Hari, Parameswaran N.
TI Outcome of Lower-Intensity Allogeneic Transplantation in Non-Hodgkin
Lymphoma after Autologous Transplantation Failure
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Article
DE Allogeneic; Relapse; Reduced-intensity
ID STEM-CELL TRANSPLANTATION; PROGRESSIVE DISEASE; REGISTRY; BLOOD;
MALIGNANCIES; RELAPSE; THERAPY; EXPERIENCE; REMISSION
AB We studied the outcome of allogeneic hematopoietic stem cell transplantation after lower-intensity conditioning regimens (reduced-intensity conditioning and nonmyeloablative) in patients with non-Hodgkin lymphoma who relapsed after autologous hematopoietic stem cell transplantation. Nonrelapse mortality, lymphoma progression/relapse, progression-free survival (PFS), and overall survival were analyzed in 263 patients with non-Hodgkin lymphoma. All 263 patients had relapsed after a previous autologous hematopoietic stem cell transplantation and then had undergone allogeneic hematopoietic stem cell transplantation from a related (n = 26) or unrelated (n = 237) donor after reduced-intensity conditioning (n = 128) or nonmyeloablative (n = 135) and were reported to the Center for International Blood and Marrow Transplant Research between 1996 and 2006. The median follow-up of survivors was 68 months (range, 3-111 months). Three-year nonrelapse mortality was 44% (95% confidence interval [CI], 37%-50%). Lymphoma progression/relapse at 3 years was 35% (95% CI, 29%-41%). Three-year probabilities of PFS and overall survival were 21% (95% CI, 16%-27%) and 32% (95% CI, 27%-38%), respectively. Superior Karnofsky Performance Score, longer interval between transplantations, total body irradiation-based conditioning regimen, and lymphoma remission at transplantation were correlated with improved PFS. Allogeneic hematopoietic stem cell transplantation after lower-intensity conditioning is associated with significant nonrelapse mortality but can result in long-term PFS. We describe a quantitative risk model based on pretransplantation risk factors to identify those patients likely to benefit from this approach. Biol Blood Marrow Transplant 18: 1255-1264 (2012) (C) 2012 American Society for Blood and Marrow Transplantation
C1 [Zhang, Mei-Jie; Carreras, Jeanette; Hari, Parameswaran N.] Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA.
[Freytes, Cesar O.] Univ Texas Hlth Sci Ctr San Antonio, S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA.
[Burns, Linda J.] Univ Minnesota, Med Ctr, Minneapolis, MN 55455 USA.
[Gale, Robert Peter] Celgene Corp, Summit, NJ USA.
[Isola, Luis] Mt Sinai Hosp, New York, NY 10029 USA.
[Perales, Miguel-Angel] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
[Seftel, Matthew] Univ Manitoba, Winnipeg, MB, Canada.
[Vose, Julie M.] Univ Nebraska Med Ctr, Omaha, NE USA.
[Miller, Alan M.] Baylor Univ, Med Ctr, Dallas, TX USA.
[Gibson, John] Royal Prince Alfred Hosp, Camperdown, NSW 2050, Australia.
[Gross, Thomas G.] Ohio State Univ, Nationwide Childrens Hosp, Columbus, OH 43210 USA.
[Rowlings, Philip A.] Calvary Mater Hosp, Waratah, Australia.
[Inwards, David J.] Mayo Clin, Rochester, MN USA.
[Pavlovsky, Santiago] Fundaleu, Buenos Aires, DF, Argentina.
[Martino, Rodrigo] Hosp Santa Creu & Sant Pau, Barcelona, Spain.
[Marks, David I.] Bristol Childrens Hosp, Bristol, Avon, England.
[Hale, Gregory A.] Univ S Florida, All Childrens Hosp, St Petersburg, FL 33701 USA.
[Smith, Sonali M.; van Besien, Koen] Univ Chicago Hosp, Chicago, IL 60637 USA.
[Schouten, Harry C.] Univ Hosp Maastricht, Maastricht, Netherlands.
[Slavin, Simon] Hadassah Med Ctr, Tel Aviv, Israel.
[Klumpp, Thomas R.] Temple Univ, BMT Program, Philadelphia, PA 19122 USA.
[Lazarus, Hillard M.] Univ Hosp Cleveland, Case Med Ctr, Cleveland, OH 44106 USA.
RP Hari, PN (reprint author), Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, POB 26509, Milwaukee, WI 53226 USA.
EM phari@mcw.edu
RI van Besien, Koen/G-4221-2012;
OI van Besien, Koen/0000-0002-8164-6211; PERALES,
MIGUEL-ANGEL/0000-0002-5910-4571; Hari, Parameswaran/0000-0002-8800-297X
FU National Cancer Institute, Public Health Service [U24-CA76518]; National
Heart, Lung and Blood Institute; National Institute of Allergy and
Infectious Diseases; National Cancer Institute [5U01HL069294]; Health
Resources and Services Administration [HHSH234200637015C]; Office of
Naval Research [N00014-06-1-0704, N00014-08-1-0058]; Allos; Amgen;
Angioblast; Ariad; Be the Match Foundation; Blue Cross and Blue Shield
Association; Buchanan Family Foundation; CaridianBCT; Celgene;
CellGenix; Children's Leukemia Research Association; Fresenius-Biotech
North America, Gamida Cell Teva Joint Venture; Genentech; Genzyme;
GlaxoSmithKline; Kiadis Pharma; Leukemia and Lymphoma Society; Medical
College of Wisconsin; Millennium Pharmaceuticals; Milliman USA; Miltenyi
Biotec, National Marrow Donor Program; Optum Healthcare Solutions;
Otsuka America Pharmaceutical; Seattle Genetics; Sigma-Tau
Pharmaceuticals; Soligenix; Swedish Orphan Biovitrum; THERAKOS;
Well-point
FX The CIBMTR is supported by Public Health Service Grant/Cooperative
Agreement U24-CA76518 from the National Cancer Institute, National
Heart, Lung and Blood Institute, and National Institute of Allergy and
Infectious Diseases; Grant/Cooperative Agreement 5U01HL069294 from the
National Cancer Institute and National Heart, Lung and Blood Institute;
Contract HHSH234200637015C with the Health Resources and Services
Administration; Grants N00014-06-1-0704 and N00014-08-1-0058 from the
Office of Naval Research; and grants from Allos, Amgen, Angioblast,
anonymous donation to the Medical College of Wisconsin, Ariad, Be the
Match Foundation, Blue Cross and Blue Shield Association, Buchanan
Family Foundation, CaridianBCT, Celgene, CellGenix, Children's Leukemia
Research Association, Fresenius-Biotech North America, Gamida Cell Teva
Joint Venture, Genentech, Genzyme, GlaxoSmithKline, Kiadis Pharma,
Leukemia and Lymphoma Society, Medical College of Wisconsin, Millennium
Pharmaceuticals, Milliman USA, Miltenyi Biotec, National Marrow Donor
Program, Optum Healthcare Solutions, Otsuka America Pharmaceutical,
Seattle Genetics, Sigma-Tau Pharmaceuticals, Soligenix, Swedish Orphan
Biovitrum, THERAKOS, and Well-point. The views expressed in this article
do not reflect the official policy or position of the National
Institutes of Health, Department of the Navy, Department of Defense, or
any other agency of the US Government. The authors have no conflicts of
interest to disclose.
NR 29
TC 15
Z9 15
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
EI 1523-6536
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD AUG
PY 2012
VL 18
IS 8
BP 1255
EP 1264
DI 10.1016/j.bbmt.2011.12.581
PG 10
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA 982KB
UT WOS:000307040800015
PM 22198543
ER
PT J
AU Battiwalla, M
Ellis, K
Li, PG
Pavletic, SZ
Akpek, G
Hematti, P
Klumpp, TR
Maziarz, RT
Savani, BN
Aljurf, MD
Cairo, MS
Drobyski, WR
George, B
Hahn, T
Khera, N
Litzow, MR
Loren, AW
Saber, W
Arora, M
Urbano-Ispizua, A
Cutler, C
Flowers, MED
Spellman, SR
AF Battiwalla, Minoo
Ellis, Kristin
Li, Peigang
Pavletic, Steven Z.
Akpek, Gorgun
Hematti, Peiman
Klumpp, Thomas R.
Maziarz, Richard T.
Savani, Bipin N.
Aljurf, Mahmoud D.
Cairo, Mitchell S.
Drobyski, William R.
George, Biju
Hahn, Theresa
Khera, Nandita
Litzow, Mark R.
Loren, Alison W.
Saber, Wael
Arora, Mukta
Urbano-Ispizua, Alvaro
Cutler, Corey
Flowers, Mary E. D.
Spellman, Stephen R.
TI HLA DR15 Antigen Status Does Not Impact Graft-versus-Host Disease or
Survival in HLA-Matched Sibling Transplantation for Hematologic
Malignancies
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Article
DE DR15; Hematopoietic stem cell transplantation (HSCT); GVHD; Survival;
graft-versus-lymphoma
ID APLASTIC-ANEMIA PATIENTS; PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA; STEM-CELL
TRANSPLANTATION; REDUCED RELAPSE RATE; IMMUNOSUPPRESSIVE THERAPY;
MYELODYSPLASTIC SYNDROME; INCREASED FREQUENCY; POPULATION; HLA-DR15; DR2
AB The HLA class II DRB1 antigen DR15 is an important prognostic marker in immune-mediated marrow failure states. DR15 has also been associated with favorable outcomes (reduced acute graft-versus-host disease [aGVHD] and relapse) after allogeneic hematopoietic cell transplant. To elucidate the impact of DR15 on transplantation outcomes, we conducted a retrospective study of 2891 recipients of first allogeneic stem cell transplant from MLA-matched sibling donors for the treatment of acute leukemia, chronic myeloid leukemia, or myelodysplastic syndrome (MDS) between 1990 and 2007. All patients received conventional myeloablative conditioning. T-replete grafts, and cyclosporine plus methotrexate-based GVHD prophylaxis. DNA-based HLA typing allowed categorization of 732 patients (25.3%) as positive and 2159 patients (74.7%) as negative for DRBI*15:01 or *15:02 (DR15). There were no significant differences in baseline characteristics between the HLA DR15 positive and negative groups. In univariate analysis, HLA-DR15 status had no impact on neutrophil engraftment, aGVHD, chronic GVHD (cGVHD), treatment-related mortality, relapse, disease-free survival, or overall survival (OS). In multivariate analysis, DR15 status showed no significant difference in aGVHD, cGVHD, OS, or relapse. In conclusion, DR15 status had no impact on major HLA-matched sibling donor hematopoietic cell transplant outcomes in this large and homogenous cohort of patients with leukemia and MDS. Biol Blood Marrow Transplant 18: 1302-1308 (2012) Published by Elsevier Inc on behalf of American Society for Blood and Mal-row Transplantation
C1 [Battiwalla, Minoo] NHLBI, NIH, Hematol Branch, Bethesda, MD 20892 USA.
[Ellis, Kristin; Li, Peigang; Saber, Wael] Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA.
[Pavletic, Steven Z.] NCI, NIH, Bethesda, MD 20892 USA.
[Akpek, Gorgun] Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD 21201 USA.
[Hematti, Peiman] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA.
[Klumpp, Thomas R.] Temple Bone Marrow Transplant Program, Philadelphia, PA USA.
[Maziarz, Richard T.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Savani, Bipin N.] Vanderbilt Univ, Med Ctr, Brentwood, TN USA.
[Aljurf, Mahmoud D.] King Faisal Specialist Hosp & Res Ctr, Riyadh 11211, Saudi Arabia.
[Cairo, Mitchell S.] New York Med Coll, Valhalla, NY 10595 USA.
[George, Biju] Christian Med Coll & Hosp, Vellore, Tamil Nadu, India.
[Hahn, Theresa] Roswell Pk Canc Inst, Buffalo, NY 14263 USA.
[Khera, Nandita; Flowers, Mary E. D.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
[Litzow, Mark R.] Mayo Clin, Rochester, MN USA.
[Loren, Alison W.] Univ Penn, Med Ctr, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
[Arora, Mukta] Univ Minnesota, Med Ctr, Minneapolis, MN 55455 USA.
[Urbano-Ispizua, Alvaro] Hosp Clin Barcelona, Dept Hematol, Barcelona, Spain.
[Cutler, Corey] Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA.
[Spellman, Stephen R.] Ctr Int Blood & Marrow Transplant Res, Minneapolis, MN USA.
RP Battiwalla, M (reprint author), NHLBI, NIH, Hematol Branch, 10-CRC,Rm 5-3581,9000 Rockville Pike, Bethesda, MD 20892 USA.
EM minoo.battiwalla@nih.gov
FU National Institute of Health (NIH) intramural research programs of the
NHLBI; NCI; Public Health Service from the National Cancer Institute
(NCI) [U24-CA76518]; National Heart, Lung and Blood Institute (NHLBI)
[5U01HL069294]; National Institute of Allergy and Infectious Diseases
(NIAID); Health Resources and Services Administration (HRSA/DHHS)
[HHSH234200637015C]; Office of Naval Research [N00014-10-1-0204,
N00014-1-1-0339]; Altos, Inc.; Amgen, Inc.; Angioblast; Ariad; Be the
Match Foundation; Blue Cross and Blue Shield Association; Buchanan
Family Foundation; CaridianBCT; Celgene Corporation; CellGenix, GmbH;
Children's Leukemia Research Association; Fresenius-Biotech North
America, Inc.; Gamida Cell Teva Joint Venture Ltd.; Genentech, Inc.;
Genzyme Corporation; GlaxoSmithKline; Kiadis Pharma; Leukemia & Lymphoma
Society; Medical College of Wisconsin; Millennium Pharmaceuticals, Inc.;
Milliman USA, Inc.; Miltenyi Biotec, Inc.; National Marrow Donor
Program; OptumHealth Care Solutions, Inc.; Otsuka America
Pharmaceutical, Inc.; Seattle Genetics; Sigma-Tau Pharmaceuticals;
Soligenix, Inc.; Swedish Orphan Biovitrum; THERAKOS, Inc.; Wellpoint,
Inc.
FX This work was supported by the National Institute of Health (NIH)
intramural research programs of the NHLBI and NCI. CIBMTR is supported
by Public Health Service Grant/Cooperative Agreement U24-CA76518 from
the National Cancer Institute (NCI), the National Heart, Lung and Blood
Institute (NHLBI) and the National Institute of Allergy and Infectious
Diseases (NIAID); a Grant/Cooperative Agreement 5U01HL069294 from NHLBI
and NCI; a contract HHSH234200637015C with Health Resources and Services
Administration (HRSA/DHHS); two grants N00014-10-1-0204 and
N00014-1-1-0339 from the Office of Naval Research; and grants from
Altos, Inc.; Amgen, Inc.; Angioblast; anonymous donation to the Medical
College of Wisconsin; Ariad; Be the Match Foundation; Blue Cross and
Blue Shield Association; Buchanan Family Foundation; CaridianBCT;
Celgene Corporation; CellGenix, GmbH; Children's Leukemia Research
Association; Fresenius-Biotech North America, Inc.; Gamida Cell Teva
Joint Venture Ltd.; Genentech, Inc.; Genzyme Corporation;
GlaxoSmithKline; Kiadis Pharma; The Leukemia & Lymphoma Society; The
Medical College of Wisconsin; Millennium Pharmaceuticals, Inc.; Milliman
USA, Inc.; Miltenyi Biotec, Inc.; National Marrow Donor Program;
OptumHealth Care Solutions, Inc.; Otsuka America Pharmaceutical, Inc.;
Seattle Genetics; Sigma-Tau Pharmaceuticals; Soligenix, Inc.; Swedish
Orphan Biovitrum; THERAKOS, Inc.; and Wellpoint, Inc.
NR 25
TC 3
Z9 3
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD AUG
PY 2012
VL 18
IS 8
BP 1302
EP 1308
DI 10.1016/j.bbmt.2012.02.011
PG 7
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA 982KB
UT WOS:000307040800021
PM 22414493
ER
PT J
AU Goh, EJ
Kim, KS
Kim, YR
Jung, HS
Beack, S
Kong, WH
Scarcelli, G
Yun, SH
Hahn, SK
AF Goh, Eun Ji
Kim, Ki Su
Kim, Yi Rang
Jung, Ho Sang
Beack, Songeun
Kong, Won Ho
Scarcelli, Giuliano
Yun, Seok Hyun
Hahn, Sei Kwang
TI Bioimaging of Hyaluronic Acid Derivatives Using Nanosized Carbon Dots
SO BIOMACROMOLECULES
LA English
DT Article
ID SEMICONDUCTOR QUANTUM DOTS; NEAR-INFRARED FLUORESCENCE; NANOTUBES; MICE;
NANOPARTICLES; DELIVERY; BRIGHT; CELLS; OXIDE
AB Fluorescent nanosized carbon dots (Cdots) are an emerging bioimaging agent with excellent chemical inertness and marginal cytotoxicity in comparison to widely used semiconductor quantum dots. In this work, we report the application of Cdots for real time bioimaging of target specific delivery of hyaluronic acid (HA) derivatives. Polyethylene glycol (PEG) diamine-capped Cdots were synthesized by the pyrolysis of citric acid in a hot solvent The synthesized Cdots showed strong fluorescence under UV excitation with emission properties dependending on the excitation wavelength. HA-Cdot conjugates were synthesized by amide bond formation between amine groups of Cdot and carboxylic groups of HA. After confirmation of the negligible cytotoxicity of Cdots and HA Cdot conjugates, in vitro bioimaging was carried out for target specific intracellular delivery of the HA-Cdot conjugates by HA receptor mediated endocytosis. Furthermore, in vivo real-time bioimaging of Cdots and HA-Cdot conjugates exhibited the target specific delivery of HA-Cdot conjugates to the liver with abundant HA receptors. Taken together, we could confirm the feasibility of HA derivatives as a target specific drug delivery carrier for the treatment of liver diseases and Cdots as a promising bioimaging agent.
C1 [Goh, Eun Ji; Kim, Ki Su; Jung, Ho Sang; Beack, Songeun; Kong, Won Ho; Hahn, Sei Kwang] Pohang Univ Sci & Technol POSTECH, Dept Mat Sci & Engn, Pohang 790784, Kyungbuk, South Korea.
[Kim, Yi Rang; Yun, Seok Hyun] Korea Adv Inst Sci & Technol, Grad Sch Nanosci & Technol WCU, Taejon 305701, South Korea.
[Scarcelli, Giuliano; Yun, Seok Hyun; Hahn, Sei Kwang] Harvard Univ, Sch Med, Wellman Ctr Photomed, Cambridge, MA 02139 USA.
[Scarcelli, Giuliano; Yun, Seok Hyun; Hahn, Sei Kwang] Massachusetts Gen Hosp, Cambridge, MA 02139 USA.
RP Hahn, SK (reprint author), Pohang Univ Sci & Technol POSTECH, Dept Mat Sci & Engn, San 31, Pohang 790784, Kyungbuk, South Korea.
EM skhanb@postech.ac.kr
OI scarcelli, giuliano/0000-0002-1736-077X
FU LG Yeonam Foundation Scholarship; Convergence Research Center Program
through the National Research Foundation (NRF) of Korea; Ministry of
Education, Science and Technology [2009-0081871]
FX This research was financially supported by the LG Yeonam Foundation
Scholarship. This work was also financially supported by the Convergence
Research Center Program through the National Research Foundation (NRF)
of Korea funded by the Ministry of Education, Science and Technology
(2009-0081871).
NR 36
TC 69
Z9 73
U1 20
U2 161
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1525-7797
J9 BIOMACROMOLECULES
JI Biomacromolecules
PD AUG
PY 2012
VL 13
IS 8
BP 2554
EP 2561
DI 10.1021/bm300796q
PG 8
WC Biochemistry & Molecular Biology; Chemistry, Organic; Polymer Science
SC Biochemistry & Molecular Biology; Chemistry; Polymer Science
GA 987MV
UT WOS:000307422300039
PM 22804331
ER
PT J
AU Holmes, LB
Hernandez-Diaz, S
AF Holmes, Lewis B.
Hernandez-Diaz, Sonia
TI Newer anticonvulsants: Lamotrigine, topiramate and gabapentin
SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY
LA English
DT Article
ID NEWER ANTIEPILEPTIC DRUGS; ISOLATED CLEFT-PALATE; EXPOSED IN-UTERO;
INCREASED FREQUENCY; PREGNANCY-REGISTER; SODIUM VALPROATE; UK-EPILEPSY;
CHILDREN; MALFORMATIONS; INFANTS
AB BACKGROUND The second generation antiepileptic drugs (AEDs), which include lamotrigine, topiramate, and gabapentin, have been introduced during the past 20 years. Because the newer AEDs differ in their pharmacokinetics from the first generation AEDs, it is hoped that the second generation AEDs will be less teratogenic. METHODS The findings in pregnancy cohorts and case-control studies concerning lamotrigine, topiramate and gabapentin-exposed pregnancies have been analyzed. RESULTS The rate of all malformations in lamotrigine monotherapy-exposed pregnancies has been between 2.0 and 5.6%, in comparison to baseline rates of 1.1 to 3.6% in two unexposed comparison groups. Compared to reference populations, a higher risk (0.4%) of isolated oral clefts has been observed in one cohort of 1562 lamotrigine-exposed pregnancies, but the risk was lower (0.1%) in other studies. In topiramate-exposed pregnancies, the rate of all malformations has been 4.2 to 4.9%, with an increase in oral clefts with and without other anomalies. The limited information available now for gabapentin has shown no evidence of teratogenicity. Concerning other developmental effects of these drugs, young children exposed to lamotrigine in utero have shown no deficits in cognitive function. Prenatal exposure to topiramate has been associated with an elevated frequency of small size for gestational age newborns. CONCLUSIONS The information available suggests an increased risk of oral clefts in infants exposed to topiramate, and perhaps lamotrigine, early in pregnancy, and of growth retardation for topiramate-exposed infants. Larger sample sizes are needed to clarify the questions that have been raised. Birth Defects Research (Part A) 94:599606, 2012. (c) 2012 Wiley Periodicals, Inc.
C1 [Holmes, Lewis B.] Harvard Univ, Dept Pediat, Genet Unit, MassGen Hosp Children,Med Sch, Boston, MA 02114 USA.
[Hernandez-Diaz, Sonia] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02114 USA.
[Holmes, Lewis B.; Hernandez-Diaz, Sonia] Massachusetts Gen Hosp, N Amer Antiepilept Drug Pregnancy Registry, Somerville, MA USA.
RP Holmes, LB (reprint author), Harvard Univ, Dept Pediat, Genet Unit, MassGen Hosp Children,Med Sch, 175 Cambridge St,504, Boston, MA 02114 USA.
EM holmes.lewis@mgh.harvard.edu
NR 51
TC 27
Z9 28
U1 0
U2 15
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1542-0752
EI 1542-0760
J9 BIRTH DEFECTS RES A
JI Birth Defects Res. Part A-Clin. Mol. Teratol.
PD AUG
PY 2012
VL 94
IS 8
SI SI
BP 599
EP 606
DI 10.1002/bdra.23028
PG 8
WC Developmental Biology; Toxicology
SC Developmental Biology; Toxicology
GA 986YF
UT WOS:000307382900004
PM 22730257
ER
PT J
AU De Zwart, AD
Beeres, FJP
Ring, D
Kingma, LM
Coerkamp, EG
Meylaerts, SAG
Rhemrev, SJ
AF De Zwart, A. D.
Beeres, F. J. P.
Ring, D.
Kingma, L. M.
Coerkamp, E. G.
Meylaerts, S. A. G.
Rhemrev, S. J.
TI MRI as a reference standard for suspected scaphoid fractures
SO BRITISH JOURNAL OF RADIOLOGY
LA English
DT Article
ID BONE-SCINTIGRAPHY
AB Objectives: Some have suggested that MRI might be the best reference standard for a true fracture among patients with suspected scaphoid fractures. The primary aim of this study was to determine the rate of false-positive diagnosis of an acute scaphoid fracture in a cohort of healthy volunteers.
Methods: In a prospective study, 33 healthy volunteers were recruited and both wrists of each were scanned, except for 2 volunteers for whom only one wrist was scanned. To simulate the usual clinical context the 64 scans of healthy volunteers were mixed with 60 MRI scans of clinically suspected scaphoid fractures but normal scaphoid radiographs. These 124 MRI scans were blinded and randomly ordered. Five radiologists evaluated the MRI scans independently for the presence or absence of a scaphoid fracture and other injuries according to a standard protocol.
Results: To answer the primary question, only the diagnoses from the 64 scans of healthy volunteers were used. The radiologists diagnosed a total of 13 scaphoid fractures; therefore, specificity for diagnosis of scaphoid fracture was 96% (95% confidence interval: range 94-98%). The 5 observers had a moderate interobserver agreement regarding diagnosis of scaphoid fracture in healthy volunteers (multirater kappa=0.44; p<0.001).
Conclusions: The specificity of MRI for scaphoid fractures is high (96%), but false-positives do occur. Radiologists have only moderate agreement when interpreting MRI scans from healthy volunteers. MRI is not an adequate reference standard for true fractures among patients with suspected scaphoid fractures.
C1 [De Zwart, A. D.; Beeres, F. J. P.; Meylaerts, S. A. G.; Rhemrev, S. J.] Med Ctr Haaglanden, Dept Surg, NL-2501 CK The Hague, Netherlands.
[Coerkamp, E. G.] Med Ctr Haaglanden, Dept Radiol, NL-2501 CK The Hague, Netherlands.
[Ring, D.] Massachusetts Gen Hosp, Dept Orthopaed Surg, Boston, MA 02114 USA.
[Beeres, F. J. P.] Leiden Univ, Med Ctr, Dept Surg, Leiden, Netherlands.
[Kingma, L. M.] Univ Groningen, Univ Med Ctr Groningen, Dept Radiol, NL-9713 AV Groningen, Netherlands.
RP De Zwart, AD (reprint author), Med Ctr Haaglanden, Dept Surg, Postbus 432, NL-2501 CK The Hague, Netherlands.
EM andeledezwart@gmail.com
OI Beeres, Frank/0000-0002-7277-3438
NR 12
TC 6
Z9 6
U1 1
U2 6
PU BRITISH INST RADIOLOGY
PI LONDON
PA 36 PORTLAND PLACE, LONDON W1N 4AT, ENGLAND
SN 0007-1285
J9 BRIT J RADIOL
JI Br. J. Radiol.
PD AUG
PY 2012
VL 85
IS 1016
BP 1098
EP 1101
DI 10.1259/bjr/73145885
PG 4
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 988OK
UT WOS:000307500200040
PM 22815412
ER
PT J
AU Cheng, G
AF Cheng, G.
TI The diagnostic value of FDG-PET cannot be judged by iliac bone marrow
biopsy
SO BRITISH JOURNAL OF RADIOLOGY
LA English
DT Letter
ID POSITRON-EMISSION-TOMOGRAPHY; NON-HODGKINS-LYMPHOMA; MALIGNANT-LYMPHOMA;
INVOLVEMENT; UTILITY
C1 Philadelphia VA Med Ctr, Dept Radiol, Philadelphia, PA 19104 USA.
RP Cheng, G (reprint author), Philadelphia VA Med Ctr, Dept Radiol, 3900 Woodland Ave, Philadelphia, PA 19104 USA.
EM gangcheng99@yahoo.com
NR 17
TC 2
Z9 2
U1 0
U2 2
PU BRITISH INST RADIOLOGY
PI LONDON
PA 36 PORTLAND PLACE, LONDON W1N 4AT, ENGLAND
SN 0007-1285
J9 BRIT J RADIOL
JI Br. J. Radiol.
PD AUG
PY 2012
VL 85
IS 1016
BP 1204
EP 1205
DI 10.1259/bjr/61638269
PG 2
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 988OK
UT WOS:000307500200057
PM 22815418
ER
PT J
AU Mullen, JT
Kobayashi, W
Wang, JJ
Harmon, DC
Choy, E
Hornicek, FJ
Rosenberg, AE
Chen, YL
Spiro, IJ
DeLaney, TF
AF Mullen, John T.
Kobayashi, Wendy
Wang, Jing Jing
Harmon, David C.
Choy, Edwin
Hornicek, Francis J.
Rosenberg, Andrew E.
Chen, Yen-Lin
Spiro, Ira J.
DeLaney, Thomas F.
TI Long-term follow-up of patients treated with neoadjuvant chemotherapy
and radiotherapy for large, extremity soft tissue sarcomas
SO CANCER
LA English
DT Article
DE soft tissue sarcoma; neoadjuvant chemotherapy; radiotherapy; follow-up;
extremity sarcoma; mesna; Adriamycin (doxorubicin); ifosfamide; and
dacarbazine (MAID)
ID ADJUVANT CHEMOTHERAPY; HIGH-GRADE; HIGH-RISK; RADIATION-THERAPY;
LOCAL-CONTROL; BODY-WALL; PHASE-II; SURGERY; TRIAL; METAANALYSIS
AB BACKGROUND: Patients with large, high-grade, extremity soft tissue sarcomas (STS) are at significant risk for distant recurrence and death. A regimen of preoperative chemotherapy consisting of mesna, Adriamycin (doxorubicin), ifosfamide, and dacarbazine (MAID), interdigitated with radiotherapy (RT) and followed by resection and postoperative chemotherapy with or without RT, has demonstrated high rates of local and distant control. We report the long-term follow-up data on 48 patients treated with this regimen compared to an historical matched-control patient population. METHODS: Adult patients with high-grade extremity STS = 8 cm were treated with 3 cycles of preoperative chemotherapy combined with 44 Gy of RT followed by surgery. Three cycles of postoperative MAID were planned. For patients with positive surgical margins, 16 Gy of RT was delivered postoperatively. RESULTS: Patients received the MAID/RT regimen from 1989 through 1999. After a median follow-up of 9.3 years in surviving patients in the MAID group and 13.2 years in surviving patients in the control group, the 7-year disease-specific and overall survival rates were 81% and 50% (P = .004) and 79% and 45% (P = .003) for the MAID and control patients, respectively. Five of 11 patients in the MAID group and 7 of 25 control patients died of sarcoma =5 years after treatment. One patient in the MAID group developed a fatal myelodysplasia at 53 months. CONCLUSIONS: For patients with high-risk, extremity STS, the significant survival benefits conferred by an intense regimen of neoadjuvant chemoradiotherapy and surgery are sustained even with long-term follow-up. Cancer 2012. (C) 2011 American Cancer Society.
C1 [Mullen, John T.] Massachusetts Gen Hosp, Div Surg Oncol, Dept Surg, Boston, MA 02114 USA.
[Kobayashi, Wendy; Wang, Jing Jing; Chen, Yen-Lin; Spiro, Ira J.; DeLaney, Thomas F.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
[Harmon, David C.; Choy, Edwin] Massachusetts Gen Hosp, Dept Med Oncol, Boston, MA 02114 USA.
[Hornicek, Francis J.] Massachusetts Gen Hosp, Dept Orthoped Surg, Boston, MA 02114 USA.
[Rosenberg, Andrew E.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
RP Mullen, JT (reprint author), Massachusetts Gen Hosp, Div Surg Oncol, Dept Surg, 55 Fruit St,Yawkey 7B, Boston, MA 02114 USA.
EM jmullen@partners.org
OI Choy, Edwin/0000-0001-9896-8084
NR 18
TC 22
Z9 24
U1 1
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-543X
J9 CANCER-AM CANCER SOC
JI Cancer
PD AUG 1
PY 2012
VL 118
IS 15
BP 3758
EP 3765
DI 10.1002/cncr.26696
PG 8
WC Oncology
SC Oncology
GA 977NU
UT WOS:000306671300014
PM 22180344
ER
PT J
AU Demark-Wahnefried, W
Platz, EA
Ligibel, JA
Blair, CK
Courneya, KS
Meyerhardt, JA
Ganz, PA
Rock, CL
Schmitz, KH
Wadden, T
Philip, EJ
Wolfe, B
Gapstur, SM
Ballard-Barbash, R
McTiernan, A
Minasian, L
Nebeling, L
Goodwin, PJ
AF Demark-Wahnefried, Wendy
Platz, Elizabeth A.
Ligibel, Jennifer A.
Blair, Cindy K.
Courneya, Kerry S.
Meyerhardt, Jeffrey A.
Ganz, Patricia A.
Rock, Cheryl L.
Schmitz, Kathryn H.
Wadden, Thomas
Philip, Errol J.
Wolfe, Bruce
Gapstur, Susan M.
Ballard-Barbash, Rachel
McTiernan, Anne
Minasian, Lori
Nebeling, Linda
Goodwin, Pamela J.
TI The Role of Obesity in Cancer Survival and Recurrence
SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
LA English
DT Review
ID BODY-MASS INDEX; STAGE BREAST-CANCER; III COLON-CANCER; GROWTH-FACTOR-I;
RANDOMIZED CONTROLLED-TRIAL; TREATMENT-RELATED TOXICITY; LIFE-STYLE
INTERVENTION; QUALITY-OF-LIFE; PHYSICAL-ACTIVITY; PROSTATE-CANCER
AB Obesity and components of energy imbalance, that is, excessive energy intake and suboptimal levels of physical activity, are established risk factors for cancer incidence. Accumulating evidence suggests that these factors also may be important after the diagnosis of cancer and influence the course of disease, as well as overall health, well-being, and survival. Lifestyle and medical interventions that effectively modify these factors could potentially be harnessed as a means of cancer control. However, for such interventions to be maximally effective and sustainable, broad sweeping scientific discoveries ranging from molecular and cellular advances, to developments in delivering interventions on both individual and societal levels are needed. This review summarizes key discussion topics that were addressed in a recent Institute of Medicine Workshop entitled, "The Role of Obesity in Cancer Survival and Recurrence"; discussions included (i) mechanisms associated with obesity and energy balance that influence cancer progression; (ii) complexities of studying and interpreting energy balance in relation to cancer recurrence and survival; (iii) associations between obesity and cancer risk, recurrence, and mortality; (iv) interventions that promote weight loss, increased physical activity, and negative energy balance as a means of cancer control; and (v) future directions. Cancer Epidermal Biomarkers Prev; 21(8); 1244-59. (c) 2012 AACR.
C1 [Demark-Wahnefried, Wendy; Blair, Cindy K.] Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35294 USA.
[Platz, Elizabeth A.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
[Ligibel, Jennifer A.; Meyerhardt, Jeffrey A.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Courneya, Kerry S.] Univ Alberta, Fac Phys Educ & Recreat, Edmonton, AB, Canada.
[Ganz, Patricia A.] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA.
[Ganz, Patricia A.] Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90024 USA.
[Rock, Cheryl L.] Univ Calif San Diego, Dept Family & Prevent Med, La Jolla, CA 92093 USA.
[Schmitz, Kathryn H.] Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA.
[Wadden, Thomas] Univ Penn, Ctr Weight & Eating Disorders, Philadelphia, PA 19104 USA.
[Philip, Errol J.] Mem Sloan Kettering Canc Ctr, Dept Psychiat & Behav Sci, New York, NY 10021 USA.
[Wolfe, Bruce] Oregon Hlth & Sci Univ, Dept Surg, Portland, OR 97201 USA.
[Gapstur, Susan M.] Amer Canc Soc, Epidemiol Res Program, Atlanta, GA 30329 USA.
[Ballard-Barbash, Rachel] NCI, Appl Res Program, Bethesda, MD 20892 USA.
[Minasian, Lori] NCI, Community Oncol & Prevent Trials Res Grp, Bethesda, MD 20892 USA.
[Nebeling, Linda] NCI, Behav Res Program, Bethesda, MD 20892 USA.
[McTiernan, Anne] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
[Goodwin, Pamela J.] Univ Toronto, Mt Sinai Hosp, Dept Med, Toronto, ON M5G 1X5, Canada.
RP Demark-Wahnefried, W (reprint author), Univ Alabama Birmingham, Dept Nutr Sci, 1675 Univ Blvd,Room 346, Birmingham, AL 35294 USA.
EM demark@uab.edu
RI Goodwin, Pamela/K-1477-2013
FU Nutrisystem; [CA13148]; [CA148791]; [CA047888]
FX T. Wadden is a recipient of commercial research grant from Nutrisystem
and is also a consultant and an advisory board member of Novo Nordisk
and Orexigen. E.J. Philip is a consultant and an advisory board member
of Kantar Health. A. McTiernan has ownership interest (including
patents) in Merck and is a consultant and an advisory board member of
Metagenics.; The work was supported by the following grants: CA13148 (W.
Demark-Wahnefried), CA148791 (C.L. Rock, W. Demark-Wahnefried), and
CA047888 (C.K. Blair)
NR 144
TC 79
Z9 81
U1 3
U2 25
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1055-9965
J9 CANCER EPIDEM BIOMAR
JI Cancer Epidemiol. Biomarkers Prev.
PD AUG
PY 2012
VL 21
IS 8
BP 1244
EP 1259
DI 10.1158/1055-9965.EPI-12-0485
PG 16
WC Oncology; Public, Environmental & Occupational Health
SC Oncology; Public, Environmental & Occupational Health
GA 987RC
UT WOS:000307433800003
PM 22695735
ER
PT J
AU Caan, BJ
Kwan, ML
Shu, XO
Pierce, JP
Patterson, RE
Nechuta, SJ
Poole, EM
Kroenke, CH
Weltzien, EK
Flatt, SW
Quesenberry, CP
Holmes, MD
Chen, WY
AF Caan, Bette J.
Kwan, Marilyn L.
Shu, Xiao Ou
Pierce, John P.
Patterson, Ruth E.
Nechuta, Sarah J.
Poole, Elizabeth M.
Kroenke, Candyce H.
Weltzien, Erin K.
Flatt, Shirley W.
Quesenberry, Charles P., Jr.
Holmes, Michelle D.
Chen, Wendy Y.
TI Weight Change and Survival after Breast Cancer in the After Breast
Cancer Pooling Project
SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
LA English
DT Article
ID BODY-MASS INDEX; CARDIOVASCULAR-DISEASE MORTALITY;
CORONARY-ARTERY-DISEASE; ALL-CAUSE MORTALITY; OBESITY PARADOX; ADJUVANT
CHEMOTHERAPY; POSTMENOPAUSAL WOMEN; RISK-FACTORS; OLDER WOMEN; LIVING
WHEL
AB Background: Weight change after a breast cancer diagnosis has been linked to lower survival. To further understand effects of postchagnostic weight variation on survival, we examined the relationship by comorbid status and initial body mass index (BMI).
Methods: The current analysis included 12,915 patients with breast cancer diagnosed between 1990 and 2006 with stage I-III tumors from four prospective cohorts in the United States and China. HRs and 95% confidence intervals (CI) representing the associations of five weight change categories [within <5% (reference); 5%-<10% and >= 10% loss and gain] with mortality were estimated using Cox proportional hazards models.
Results: Mean weight change was 1.6 kg. About 14.7% women lost and 34.7% gained weight. Weight stability in the early years postdiagnosis was associated with the lowest overall mortality risk. Weight loss >= 10% was related to a 40% increased risk of death (HR, 1.41; 95% CI, 1.14-1.75) in the United States and over three times the risk of death (HR, 3.25; 95% CI: 2.24, 4.73) in Shanghai. This association varied by prediagnosis BMI, and in the United States, lower survival was seen for women who lost weight and had comorbid conditions. Weight gain >= 10% was associated with a nonsignificant increased risk of death.
Conclusions: Prevention of excessive weight gain is a valid public health goal for breast cancer survivors. Although intentionality of weight loss could not be determined, women with comorbid conditions may be particularly at risk of weight loss and mortality.
Impact: Weight control strategies for breast cancer survivors should be personalized to the individual's medical history. Cancer Epidemiol Biomarkers Prey; 21(8); 1260-71. (c) 2012 AACR.
C1 [Caan, Bette J.; Kwan, Marilyn L.; Kroenke, Candyce H.; Weltzien, Erin K.; Quesenberry, Charles P., Jr.] Kasier Permanente, Div Res, Oakland, CA 94612 USA.
[Shu, Xiao Ou; Nechuta, Sarah J.] Vanderbilt Univ, Sch Med, Dept Med, Div Epidemiol, Nashville, TN 37212 USA.
[Pierce, John P.; Patterson, Ruth E.; Flatt, Shirley W.] Univ Calif San Diego, Moores UCSD Canc Ctr, Canc Prevent & Control Program, San Diego, CA 92103 USA.
[Poole, Elizabeth M.; Holmes, Michelle D.; Chen, Wendy Y.] Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA USA.
[Poole, Elizabeth M.; Holmes, Michelle D.; Chen, Wendy Y.] Harvard Univ, Sch Med, Boston, MA USA.
[Chen, Wendy Y.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
RP Caan, BJ (reprint author), Kasier Permanente, Div Res, 2000 Broadway, Oakland, CA 94612 USA.
EM bette.caan@kp.org
FU NIH grants [3R01CA118229-03S1, R01 CA118229, R01 CA 129059, P01
CA87969]; Susan G. Komen Foundation [KG100988]; Department of Defense
[DAMD 17-02-1-0607]
FX This work was supported by the NIH grants (3R01CA118229-03S1, R01
CA118229, R01 CA 129059, P01 CA87969); Susan G. Komen Foundation
(KG100988); and the Department of Defense (DAMD 17-02-1-0607).
NR 66
TC 33
Z9 33
U1 0
U2 12
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1055-9965
J9 CANCER EPIDEM BIOMAR
JI Cancer Epidemiol. Biomarkers Prev.
PD AUG
PY 2012
VL 21
IS 8
BP 1260
EP 1271
DI 10.1158/1055-9965.EPI-12-0306
PG 12
WC Oncology; Public, Environmental & Occupational Health
SC Oncology; Public, Environmental & Occupational Health
GA 987RC
UT WOS:000307433800004
PM 22695738
ER
PT J
AU Ding, YC
McGuffog, L
Healey, S
Friedman, E
Laitman, Y
Shani-Paluch-Shimon
Kaufman, B
Liljegren, A
Lindblom, A
Olsson, H
Kristoffersson, U
Stenmark-Askmalm, M
Melin, B
Domchek, SM
Nathanson, KL
Rebbeck, TR
Jakubowska, A
Lubinski, J
Jaworska, K
Durda, K
Gronwald, J
Huzarski, T
Cybulski, C
Byrski, T
Osorio, A
Cajal, TR
Stavropoulou, AV
Benitez, J
Hamann, U
Rookus, M
Aalfs, CM
de Lange, JL
Meijers-Heijboer, HEJ
Oosterwijk, JC
van Asperen, CJ
Garcia, EBG
Hoogerbrugge, N
Jager, A
van der Luijt, RB
Easton, DF
Peock, S
Frost, D
Ellis, SD
Platte, R
Fineberg, E
Evans, DG
Lalloo, F
Izatt, L
Eeles, R
Adlard, J
Davidson, R
Eccles, D
Cole, T
Cook, J
Brewer, C
Tischkowitz, M
Godwin, AK
Pathak, H
Stoppa-Lyonnet, D
Sinilnikova, OM
Mazoyer, S
Barjhoux, L
Leone, M
Gauthier-Villars, M
Caux-Moncoutier, V
de Pauw, A
Hardouin, A
Berthet, P
Dreyfus, H
Ferrer, SF
Collonge-Rame, MA
Sokolowska, J
Buys, S
Daly, M
Miron, A
Terry, MB
Chung, W
John, EM
Southey, M
Goldgar, D
Singer, CF
Tea, MKM
Gschwantler-Kaulich, D
Fink-Retter, A
Hansen, TVO
Ejlertsen, B
Johannsson, OT
Offit, K
Sarrel, K
Gaudet, MM
Vijai, J
Robson, M
Piedmonte, MR
Andrews, L
Cohn, D
DeMars, LR
DiSilvestro, P
Rodriguez, G
Toland, AE
Montagna, M
Agata, S
Imyanitov, E
Isaacs, C
Janavicius, R
Lazaro, C
Blanco, I
Ramus, SJ
Sucheston, L
Karlan, BY
Gross, J
Ganz, PA
Beattie, MS
Schmutzler, RK
Wappenschmidt, B
Meindl, A
Arnold, N
Niederacher, D
Preisler-Adams, S
Gadzicki, D
Varon-Mateeva, R
Deissler, H
Gehrig, A
Sutter, C
Kast, K
Nevanlinna, H
Aittomaki, K
Simard, J
Spurdle, AB
Beesley, J
Chen, XQ
Tomlinson, GE
Weitzel, J
Garber, JE
Olopade, OI
Rubinstein, WS
Tung, N
Blum, JL
Narod, SA
Brummel, S
Gillen, DL
Lindor, N
Fredericksen, Z
Pankratz, VS
Couch, FJ
Radice, P
Peterlongo, P
Greene, MH
Loud, JT
Mai, PL
Andrulis, IL
Glendon, G
Ozcelik, H
Gerdes, AM
Thomassen, M
Jensen, UB
Skytte, AB
Caligo, MA
Lee, A
Chenevix-Trench, G
Antoniou, AC
Neuhausen, SL
AF Ding, Yuan C.
McGuffog, Lesley
Healey, Sue
Friedman, Eitan
Laitman, Yael
Shani-Paluch-Shimon
Kaufman, Bella
Liljegren, Annelie
Lindblom, Annika
Olsson, Hakan
Kristoffersson, Ulf
Stenmark-Askmalm, Marie
Melin, Beatrice
Domchek, Susan M.
Nathanson, Katherine L.
Rebbeck, Timothy R.
Jakubowska, Anna
Lubinski, Jan
Jaworska, Katarzyna
Durda, Katarzyna
Gronwald, Jacek
Huzarski, Tomasz
Cybulski, Cezary
Byrski, Tomasz
Osorio, Ana
Ramony Cajal, Teresa
Stavropoulou, Alexandra V.
Benitez, Javier
Hamann, Ute
Rookus, Matti
Aalfs, Cora M.
de Lange, Judith L.
Meijers-Heijboer, Hanne E. J.
Oosterwijk, Jan C.
van Asperen, Christi J.
Garcia, Encarna B. Gomez
Hoogerbrugge, Nicoline
Jager, Agnes
van der Luijt, Rob B.
Easton, Douglas F.
Peock, Susan
Frost, Debra
Ellis, Steve D.
Platte, Radka
Fineberg, Elena
Evans, D. Gareth
Lalloo, Fiona
Izatt, Louise
Eeles, Ros
Adlard, Julian
Davidson, Rosemarie
Eccles, Diana
Cole, Trevor
Cook, Jackie
Brewer, Carole
Tischkowitz, Marc
Godwin, Andrew K.
Pathak, Harsh
Stoppa-Lyonnet, Dominique
Sinilnikova, Olga M.
Mazoyer, Sylvie
Barjhoux, Laure
Leone, Melanie
Gauthier-Villars, Marion
Caux-Moncoutier, Virginie
de Pauw, Antoine
Hardouin, Agnes
Berthet, Pascaline
Dreyfus, Helene
Ferrer, Sandra Fert
Collonge-Rame, Marie-Agnes
Sokolowska, Johanna
Buys, Saundra
Daly, Mary
Miron, Alex
Terry, Mary Beth
Chung, Wendy
John, Esther M.
Southey, Melissa
Goldgar, David
Singer, Christian F.
Tea, Muy-Kheng Maria
Gschwantler-Kaulich, Daphne
Fink-Retter, Anneliese
Hansen, Thomas V. O.
Ejlertsen, Bent
Johannsson, Oskar T.
Offit, Kenneth
Sarrel, Kara
Gaudet, Mia M.
Vijai, Joseph
Robson, Mark
Piedmonte, Marion R.
Andrews, Lesley
Cohn, David
DeMars, Leslie R.
DiSilvestro, Paul
Rodriguez, Gustavo
Toland, Amanda Ewart
Montagna, Marco
Agata, Simona
Imyanitov, Evgeny
Isaacs, Claudine
Janavicius, Ramunas
Lazaro, Conxi
Blanco, Ignacio
Ramus, Susan J.
Sucheston, Lara
Karlan, Beth Y.
Gross, Jenny
Ganz, Patricia A.
Beattie, Mary S.
Schmutzler, Rita K.
Wappenschmidt, Barbara
Meindl, Alfons
Arnold, Norbert
Niederacher, Dieter
Preisler-Adams, Sabine
Gadzicki, Dorotehea
Varon-Mateeva, Raymonda
Deissler, Helmut
Gehrig, Andrea
Sutter, Christian
Kast, Karin
Nevanlinna, Heli
Aittomaki, Kristiina
Simard, Jacques
Spurdle, Amanda B.
Beesley, Jonathan
Chen, Xiaoqing
Tomlinson, Gail E.
Weitzel, Jeffrey
Garber, Judy E.
Olopade, Olufunmilayo I.
Rubinstein, Wendy S.
Tung, Nadine
Blum, Joanne L.
Narod, Steven A.
Brummel, Sean
Gillen, Daniel L.
Lindor, Noralane
Fredericksen, Zachary
Pankratz, Vernon S.
Couch, Fergus J.
Radice, Paolo
Peterlongo, Paolo
Greene, Mark H.
Loud, Jennifer T.
Mai, Phuong L.
Andrulis, Irene L.
Glendon, Gord
Ozcelik, Hilmi
Gerdes, Anne-Marie
Thomassen, Mads
Jensen, Uffe Birk
Skytte, Anne-Bine
Caligo, Maria A.
Lee, Andrew
Chenevix-Trench, Georgia
Antoniou, Antonis C.
Neuhausen, Susan L.
CA SWE-BRCA
HEBON
EMBRACE
GEMO Study Collaborators
KConFab Investigators
OCGN
Consortium Investigators Modifiers
TI A Nonsynonymous Polymorphism in IRS1 Modifies Risk of Developing Breast
and Ovarian Cancers in BRCA1 and Ovarian Cancer in BRCA2 Mutation
Carriers
SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
LA English
DT Article
ID AMINO-ACID POLYMORPHISM; GROWTH-FACTOR-I; GENETIC-VARIATION; INSULIN;
RECEPTOR; EXPRESSION; IGF; NEOPLASIA; PROTEINS; FAMILY
AB Background: We previously reported significant associations between genetic variants in insulin receptor substrate 1 (IRS1) and breast cancer risk in women carrying BRCA1 mutations. The objectives of this study were to investigate whether the IRS1 variants modified ovarian cancer risk and were associated with breast cancer risk in a larger cohort of BRCA1 and BRCA2 mutation carriers.
Methods: IRS1 rs1801123, rs1330645, and rs1801278 were genotyped in samples from 36 centers in the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Data were analyzed by a retrospective cohort approach modeling the associations with breast and ovarian cancer risks simultaneously. Analyses were stratified by BRCA1 and BRCA2 status and mutation class in BRCA1 carriers.
Results: Rs1801278 (Gly972Arg) was associated with ovarian cancer risk for both BRCA1 (HR, 1.43; 95% confidence interval (CI), 1.06-1.92; P = 0.019) and BRCA2 mutation carriers (HR, 2.21; 95% CI, 1.39-3.52, P = 0.0008). For BRCA1 mutation carriers, the breast cancer risk was higher in carriers with class II mutations than class I mutations (class II HR, 1.86; 95% CI, 1.28-2.70; class I HR, 0.86; 95%CI, 0.69-1.09; P-difference, 0.0006). Rs13306465 was associated with ovarian cancer risk in BRCA1 class II mutation carriers (HR, 2.42; P = 0.03).
Conclusion: The IRS1 Gly972Arg single-nucleotide polymorphism, which affects insulin-like growth factor and insulin signaling, modifies ovarian cancer risk in BRCA1 and BRCA2 mutation carriers and breast cancer risk in BRCA1 class II mutation carriers.
Impact: These findings may prove useful for risk prediction for breast and ovarian cancers in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev; 21(8); 1362-70. (C)2012 AACR.
C1 [McGuffog, Lesley; Lee, Andrew; Antoniou, Antonis C.] Univ Cambridge Worts Causeway, Strangeways Res Lab, Dept Publ Hlth & Primary Care, Cambridge, England.
[Easton, Douglas F.; Peock, Susan; Frost, Debra; Ellis, Steve D.; Platte, Radka; Fineberg, Elena; EMBRACE] Univ Cambridge, Dept Publ Hlth & Primary Care, Ctr Canc Genet Epidemiol, Cambridge, England.
[Tischkowitz, Marc] Univ Cambridge, Dept Med Genet, Cambridge, England.
[Healey, Sue; Spurdle, Amanda B.; Beesley, Jonathan; Chen, Xiaoqing; Chenevix-Trench, Georgia] Royal Brisbane Hosp, Queensland Inst Med Res, Genet & Populat Hlth Div, Brisbane, Qld 4029, Australia.
[Friedman, Eitan; Laitman, Yael; Shani-Paluch-Shimon; Kaufman, Bella] Chaim Sheba Med Ctr, Oncogenet Unit, IL-52621 Tel Hashomer, Israel.
[Friedman, Eitan; Laitman, Yael; Shani-Paluch-Shimon; Kaufman, Bella] Chaim Sheba Med Ctr, Inst Oncol, IL-52621 Tel Hashomer, Israel.
[Friedman, Eitan; Laitman, Yael; Shani-Paluch-Shimon; Kaufman, Bella] Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel.
[Liljegren, Annelie] Karolinska Univ Hosp, Dept Oncol, Stockholm, Sweden.
[Lindblom, Annika] Karolinska Univ Hosp, Dept Clin Genet, Stockholm, Sweden.
[Olsson, Hakan] Univ Lund Hosp, Dept Oncol, S-22185 Lund, Sweden.
[Kristoffersson, Ulf] Univ Lund Hosp, Dept Clin Genet, S-22185 Lund, Sweden.
[Stenmark-Askmalm, Marie] Linkoping Univ, Dept Clin & Expt Med, Div Clin Genet, Linkoping, Sweden.
[Melin, Beatrice] Umea Univ, Dept Radiat Sci, Umea, Sweden.
[Domchek, Susan M.; Nathanson, Katherine L.; Rebbeck, Timothy R.] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
[Daly, Mary] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
[Jakubowska, Anna; Lubinski, Jan; Jaworska, Katarzyna; Durda, Katarzyna; Gronwald, Jacek; Huzarski, Tomasz; Cybulski, Cezary; Byrski, Tomasz] Pomeranian Med Univ, Dept Genet & Pathol, Szczecin, Poland.
[Osorio, Ana; Benitez, Javier] Spanish Natl Canc Res Ctr, Human Canc Genet Programme, Human Genet Grp, Madrid, Spain.
[Osorio, Ana; Benitez, Javier] Spanish Natl Canc Res Ctr, Human Canc Genet Programme, Genotyping Unit, Madrid, Spain.
[Osorio, Ana; Benitez, Javier] Spanish Network Rare Dis CIBERER, Barcelona, Spain.
[Ramony Cajal, Teresa] Hosp Santa Creu & Sant Pau, Oncol Serv, Barcelona, Spain.
[Lazaro, Conxi] Inst Catala Oncol, Lab Recerca Translac, Hereditary Canc Program, Mol Diagnost Unit, Barcelona, Spain.
[Blanco, Ignacio] IDIBELL Catalan Inst Oncol, Hereditary Canc Program, Genet Counseling Unit, Barcelona, Spain.
[Stavropoulou, Alexandra V.] Natl Ctr Sci Res Demokritos, IRRP, Mol Diagnost Lab, Athens, Greece.
[Hamann, Ute] Deutsch Krebsforschungszentrum DKFZ, Heidelberg, Germany.
[Rookus, Matti; de Lange, Judith L.] Netherlands Canc Inst, Dept Epidemiol, Amsterdam, Netherlands.
[Aalfs, Cora M.] Univ Amsterdam, Acad Med Ctr, Dept Clin Genet, NL-1105 AZ Amsterdam, Netherlands.
[Meijers-Heijboer, Hanne E. J.] Vrije Univ Amsterdam Med Ctr, Dept Clin Genet, Amsterdam, Netherlands.
[Evans, D. Gareth; Lalloo, Fiona] Cent Manchester Univ Hosp NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England.
[Izatt, Louise] Guys & St Thomas NHS Fdn Trust, London, England.
[Eeles, Ros] Inst Canc Res, Oncogenet Team, London SW3 6JB, England.
[Eeles, Ros] Royal Marsden NHS Fdn Trust, London, England.
[Adlard, Julian] Yorkshire Reg Genet Serv, Leeds, W Yorkshire, England.
[Davidson, Rosemarie] Yorkhill Hosp, Ferguson Smith Ctr Clin Genet, Glasgow, Lanark, Scotland.
[Eccles, Diana] Univ Hosp Southampton NHS Fdn Trust, Wessex Clin Genet Serv, Southampton, Hants, England.
[Cole, Trevor] Birmingham Womens Hosp Healthcare NHS Trust, W Midlands Reg Genet Serv, Birmingham, W Midlands, England.
[Cook, Jackie] Sheffield Childrens Hosp, Sheffield Clin Genet Serv, Sheffield, S Yorkshire, England.
[Brewer, Carole] Royal Devon & Exeter Hosp, Dept Clin Genet, Exeter EX2 5DW, Devon, England.
[Godwin, Andrew K.; Pathak, Harsh] Univ Kansas, Med Ctr, Dept Pathol & Lab Med, Kansas City, KS 66103 USA.
[Stoppa-Lyonnet, Dominique; Gauthier-Villars, Marion; Caux-Moncoutier, Virginie; de Pauw, Antoine] Inst Curie, Dept Tumour Biol, Paris, France.
[Stoppa-Lyonnet, Dominique] Inst Curie, Unite INSERM U830, Paris, France.
[Stoppa-Lyonnet, Dominique] Univ Paris 05, Fac Med, Paris, France.
[Dreyfus, Helene] CHU Grenoble, Dept Genet, F-38043 Grenoble, France.
[Dreyfus, Helene] Univ Grenoble, Inst Albert Bonniot, Grenoble, France.
[Sinilnikova, Olga M.; Mazoyer, Sylvie; Barjhoux, Laure] Univ Lyon 1, CNRS, UMR5286, Ctr Rech Cancerol Lyon,INSERM,U1052, F-69365 Lyon, France.
[Sinilnikova, Olga M.; Leone, Melanie] Ctr Hosp Univ Lyon, Ctr Leon Berard, Unite Mixte Genet Constitut Canc Frequents, Lyon, France.
[Collonge-Rame, Marie-Agnes] CHU Besancon, Serv Genet Biol Histol Biol Dev & Reprod, F-25030 Besancon, France.
[Sokolowska, Johanna] Nancy Univ, Ctr Hosp Reg & Univ, Med Genet Lab, Vandoeuvre Les Nancy, France.
[Hardouin, Agnes; Berthet, Pascaline] Ctr Francois Baclesse, F-14021 Caen, France.
[Buys, Saundra] Univ Utah, Huntsman Canc Inst, Dept Oncol Sci, Salt Lake City, UT USA.
[Goldgar, David] Univ Utah, Sch Med, Dept Dermatol, Salt Lake City, UT USA.
[Miron, Alex] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA.
[Garber, Judy E.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
[Tung, Nadine] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
[Brummel, Sean] Harvard Univ, Sch Publ Hlth, Ctr Biostat AIDS Res, Boston, MA 02115 USA.
[Terry, Mary Beth; Chung, Wendy] Columbia Univ, Dept Epidemiol, New York, NY USA.
[John, Esther M.] Canc Prevent Inst Calif, Fremont, CA USA.
[John, Esther M.] Stanford Univ, Sch Med, Palo Alto, CA 94304 USA.
[John, Esther M.] Stanford Canc Inst, Palo Alto, CA USA.
[Southey, Melissa] Univ Melbourne, Dept Pathol, Genet Epidemiol Lab, Melbourne, Vic 3010, Australia.
[Singer, Christian F.; Tea, Muy-Kheng Maria; Gschwantler-Kaulich, Daphne; Fink-Retter, Anneliese] Med Univ Vienna, Dept OB GYN, Vienna, Austria.
[Hansen, Thomas V. O.] Copenhagen Univ Hosp, Rigshosp, Ctr Genom Med, Copenhagen, Denmark.
[Ejlertsen, Bent] Copenhagen Univ Hosp, Rigshosp, Dept Oncol, Copenhagen, Denmark.
[Johannsson, Oskar T.] Landspitali Univ Hosp, Dept Oncol, Reykjavik, Iceland.
[Johannsson, Oskar T.] Univ Iceland, Fac Med, Reykjavik, Iceland.
[Offit, Kenneth; Sarrel, Kara; Vijai, Joseph] Clin Canc Genet Lab, Buffalo, NY USA.
[Robson, Mark] Mem Sloan Kettering Canc Ctr, Buffalo, NY USA.
[Piedmonte, Marion R.] Roswell Pk Canc Inst, Stat & Data Ctr, Gynecol Oncol Grp, Buffalo, NY 14263 USA.
[Sucheston, Lara] Roswell Pk Canc Inst, Dept Canc Prevent & Control, Buffalo, NY 14263 USA.
[Ding, Yuan C.; Weitzel, Jeffrey; Neuhausen, Susan L.] City Hope Natl Med Ctr, Beckman Res Inst, Dept Populat Sci, Duarte, CA 91010 USA.
[Gaudet, Mia M.] Amer Canc Soc, Epidemiol Res Program, Atlanta, GA 30329 USA.
[Ferrer, Sandra Fert] Hotel Dieu Ctr Hosp, Lab Genet Chromosom, Chambery, France.
[Andrews, Lesley] Australia New Zealand Gynaecol Oncol Grp, Camperdown, NSW, Australia.
[Cohn, David] Ohio State Univ, Columbus Canc Council, Columbus, OH 43210 USA.
[Toland, Amanda Ewart] Ohio State Univ, Dept Internal Med, OSU Comprehens Canc Ctr, Div Human Canc Genet, Columbus, OH 43210 USA.
[Toland, Amanda Ewart] Ohio State Univ, OSU Comprehens Canc Ctr, Dept Mol Virol Immunol & Med Genet, Div Human Canc Genet, Columbus, OH 43210 USA.
[DeMars, Leslie R.] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA.
[DiSilvestro, Paul] Brown Univ, Women & Infants Hosp, Providence, RI USA.
[Rodriguez, Gustavo] NorthShore Univ Hlth Syst, Evanston, IL USA.
[Montagna, Marco; Agata, Simona] Ist Oncol Veneto IOV IRCCS, Immunol & Mol Oncol Unit, Padua, Italy.
[Imyanitov, Evgeny] NN Petrov Oncol Res Inst, St Petersburg, Russia.
[Isaacs, Claudine] Georgetown Univ, Lombardi Comprehens Canc Ctr, Washington, DC USA.
[Janavicius, Ramunas] Vilnius Univ Hosp, Santariskiu Clin, Hematol Oncol & Transfus Med Ctr, Dept Mol & Regenerat Med, Vilnius, Lithuania.
[Ramus, Susan J.] Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA.
[Karlan, Beth Y.; Gross, Jenny] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Womens Canc Program, Los Angeles, CA 90048 USA.
[Ganz, Patricia A.] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Sch Med, Div Canc Prevent & Control Res, Los Angeles, CA 90024 USA.
[Ganz, Patricia A.] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Sch Publ Hlth, Div Canc Prevent & Control Res, Los Angeles, CA 90024 USA.
[Beattie, Mary S.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
[Beattie, Mary S.] Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94143 USA.
[Beattie, Mary S.] Univ Calif San Francisco, Dept Biostat, San Francisco, CA 94143 USA.
[Schmutzler, Rita K.; Wappenschmidt, Barbara] Univ Hosp Cologne, Dept Obstet & Gynaecol, Ctr Familial Breast & Ovarian Canc, Cologne, Germany.
[Schmutzler, Rita K.; Wappenschmidt, Barbara] Univ Hosp Cologne, CIO, Cologne, Germany.
[Meindl, Alfons] Tech Univ Munich, Klinikum Rechts Isar, Div Tumor Genet, Dept Obstet & Gynaecol, D-8000 Munich, Germany.
[Arnold, Norbert] Univ Kiel, Univ Hosp Schleswig Holstein, Dept Obstet & Gynaecol, Kiel, Germany.
[Niederacher, Dieter] Univ Dusseldorf, Univ Hosp Dusseldorf, Dept Obstet & Gynaecol, D-40225 Dusseldorf, Germany.
[Preisler-Adams, Sabine] Univ Munster, Inst Human Genet, D-4400 Munster, Germany.
[Gadzicki, Dorotehea] Hannover Med Sch, Inst Cell & Mol Pathol, D-3000 Hannover, Germany.
[Varon-Mateeva, Raymonda] Charite, Campus Virchov Klinikum, Inst Human Genet, Berlin, Germany.
[Deissler, Helmut] Univ Hosp Ulm, Dept Obstet & Gynaecol, Ulm, Germany.
[Gehrig, Andrea] Univ Wurzburg, Inst Human Genet, Dept Med Genet, Ctr Familial Breast & Ovarian Canc, D-8700 Wurzburg, Germany.
[Sutter, Christian] Univ Heidelberg Hosp, Dept Human Genet, Inst Human Genet, Heidelberg, Germany.
[Kast, Karin] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Dept Obstet & Gynaecol, D-01062 Dresden, Germany.
[Nevanlinna, Heli] Univ Helsinki, Dept Obstet & Gynecol, Helsinki, Finland.
[Nevanlinna, Heli] Univ Helsinki, Dept Clin Genet, Helsinki, Finland.
Univ Helsinki, Cent Hosp, Helsinki, Finland.
[Simard, Jacques] Ctr Hosp Univ Quebec, Canc Genom Lab, Canada Res Chair Oncogenet, Quebec City, PQ, Canada.
[Simard, Jacques] Univ Laval, Quebec City, PQ, Canada.
[KConFab Investigators] Peter MacCallum Canc Ctr, Kathleen Cuningham Consortium Res Familial Breast, Melbourne, Vic, Australia.
[Tomlinson, Gail E.] Univ Texas Hlth Sci Ctr San Antonio, Div Pediat Hematol Oncol, San Antonio, TX 78229 USA.
[Olopade, Olufunmilayo I.] Univ Chicago, Dept Med, Chicago, IL 60637 USA.
[Olopade, Olufunmilayo I.] Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA.
[Rubinstein, Wendy S.] NorthShore Univ HealthSyst, Evanston, IL USA.
[Blum, Joanne L.] Baylor Charles A Sammons Canc Ctr, Dallas, TX USA.
[Narod, Steven A.] Womens Coll Hosp, Toronto, ON M5S 1B2, Canada.
[OCGN] Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Ontario Canc Genet Network, Toronto, ON M5G 1X5, Canada.
[Andrulis, Irene L.] Univ Toronto, Dept Mol Genet, Toronto, ON, Canada.
[Andrulis, Irene L.; Ozcelik, Hilmi] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada.
[Gillen, Daniel L.] Univ Calif Irvine, Dept Stat, Irvine, CA USA.
[Gillen, Daniel L.] Univ Calif Irvine, Dept Epidemiol, Irvine, CA USA.
[Lindor, Noralane] Mayo Clin, Dept Med Genet, Rochester, MN USA.
[Fredericksen, Zachary; Pankratz, Vernon S.] Mayo Clin, Dept Hlth Sci Res, Rochester, MN USA.
[Couch, Fergus J.] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA.
[Radice, Paolo; Peterlongo, Paolo] Fdn IRCCS Ist Nazl Tumori INT, Dept Expt Oncol & Mol Med, Unit Genet Susceptibil Canc, Milan, Italy.
[Radice, Paolo; Peterlongo, Paolo] Fdn Ist FIRC Oncol Mol, IFOM, Milan, Italy.
[Greene, Mark H.; Loud, Jennifer T.; Mai, Phuong L.] NCI, Clin Genet Branch, Div Canc Epidemiol & Genet, Rockville, MD USA.
[Thomassen, Mads] Odense Univ Hosp, Dept Clin Genet, DK-5000 Odense, Denmark.
[Jensen, Uffe Birk] Skejby Hosp, Dept Clin Genet, Aarhus, Denmark.
[Skytte, Anne-Bine] Vejle Hosp, Dept Clin Genet, Vejle, Denmark.
[Caligo, Maria A.] Univ Pisa, Dept Lab Med, Sect Genet Oncol, Pisa, Italy.
[Caligo, Maria A.] Univ Hosp Pisa, Pisa, Italy.
[Oosterwijk, Jan C.] Univ Groningen, Univ Med Ctr, Dept Genet, Groningen, Netherlands.
[van Asperen, Christi J.] Leiden Univ, Med Ctr, Dept Clin Genet, Leiden, Netherlands.
[Garcia, Encarna B. Gomez] MUMC, Sch Oncol & Dev Biol, Dept Clin Genet, Maastricht, Netherlands.
[Garcia, Encarna B. Gomez] MUMC, Sch Oncol & Dev Biol, GROW, Maastricht, Netherlands.
[Hoogerbrugge, Nicoline] Radboud Univ Nijmegen, Med Ctr, Hereditary Canc Clin, NL-6525 ED Nijmegen, Netherlands.
[Jager, Agnes] Erasmus Univ, Med Ctr, Family Canc Clin, Dept Med Oncol, Rotterdam, Netherlands.
[van der Luijt, Rob B.; HEBON] Univ Med Ctr Utrecht, Dept Med Genet, Utrecht, Netherlands.
RP Neuhausen, SL (reprint author), City Hope Natl Med Ctr, Beckman Res Inst, Dept Populat Sci, 1500 E Duarte Rd, Duarte, CA 91010 USA.
EM sneuhausen@coh.org
RI Arnold, Norbert/E-3012-2010; Gronwald, Jacek/A-4576-2017; montagna,
marco/E-2225-2012; Andrulis, Irene/E-7267-2013; Toland,
Amanda/E-4202-2011; Joseph, Vijai/J-9158-2013; Hoogerbrugge,
Nicoline/O-1016-2013; Radice, Paolo/O-3119-2013; Blanco,
Ignacio/D-2565-2013; Oosterwijk, Jan C./G-5770-2011; Osorio,
Ana/I-4324-2014; Jakubowska, Anna/O-8050-2014; Spurdle,
Amanda/A-4978-2011;
OI Arnold, Norbert/0000-0003-4523-8808; Gronwald,
Jacek/0000-0002-3643-2871; Janavicius, Ramunas/0000-0002-3773-8485;
montagna, marco/0000-0002-4929-2150; Joseph, Vijai/0000-0002-7933-151X;
Blanco, Ignacio/0000-0002-7414-7481; Osorio, Ana/0000-0001-8124-3984;
Robson, Mark/0000-0002-3109-1692; Eeles, Rosalind/0000-0002-3698-6241;
Nathanson, Katherine/0000-0002-6740-0901; Ramus,
Susan/0000-0003-0005-7798; Spurdle, Amanda/0000-0003-1337-7897;
Nevanlinna, Heli/0000-0002-0916-2976; Evans, Gareth/0000-0002-8482-5784
FU NIH [R01CA74415, P30CA033752]; Israel cancer association; Mutua
Madrilena Foundation; Red de Investigacion en Cancer [RD06/0020/1160];
Spanish Ministry of Science and Innovation [FIS P1081120,
SAF2010-20493]; Cancer Research UK [C1287/A10118, C1287/A11990,
C5047/A8385]; NIHR; NEYE Foundation; Clinical Genetics Branch, DCEG
National Cancer Institute (NCI); Community Oncology and Prevention
Trials Program-COPTRG National Cancer Institute (NCI); Russian
Foundation for Basic Research [10-04-92110, 10-04-92601, 11-04-00227];
Federal Agency for Science and Innovations [02.740.11.0780]; Royal
Society [JP090615]; Research Council of Lithuania [LIG-19/2010];
Institut Catala d'Oncologia (ICO); Asociacion Espanola Contra el Cancer,
Spanish Health Research Fund; Carlos III Health Institute; Catalan
Health Institute; Autonomous Government of Catalonia [ISCIIIRETIC
RD06/0020/1051, PI10/01422, PI10/31488, 2009SGR290]; American Cancer
Society [120950-SIOP-06-258-06-COUN]; German Cancer Aid [DKH 109076];
Helsinki University Central Hospital; Academy of Finland [132473];
Finnish Cancer Society; Sigrid Juselius Foundation; Canadian Institutes
of Health Research; Canadian Breast Cancer Research Alliance [019511];
NCI, under RFA [CA-06-503]; Cancer Care Ontario [U01 CA69467]; Cancer
Prevention Institute of California [U01 CA69417]; Columbia University
[U01 CA69398]; Fox Chase Cancer Center [U01 CA69631]; Huntsman Cancer
Institute [U01 CA69446]; University of Melbourne [U01 CA69638]; National
Health and Medical Research Council of Australia; New South Wales Cancer
Council; Victorian Health Promotion Foundation (Australia); Victorian
Breast Cancer Research Consortium; NITA [P01 CA16094, R01 CA22435];
National Institutes of Health [P30 CA13696, P30 ES009089, UL1 RR025764,
R01278978]; National Center for Research Resources; National Center for
Advancing Translational Sciences; NCI [P30 CA042014]; NHMRC [145684,
288704, 454508]; US NCI at the NIH [NO2-CP-11019-50, N02-CP-65504];
Westat, Inc.; Breast cancer Research Foundation; Komen Foundation for
the Cure; Dutch Cancer Society [NKI1998-1854, NKI2004-3088,
NKI2007-3756]; ZonMW [91109024]; OSU Comprehensive Cancer Center;
[R01-CA083855]; [R01-CA102776]; [R01CA140323]; [U01CA69631];
[5U01CA113916]
FX Beckman Research Institute of the City of Hope (BRICOH) study was
supported by NIH R01CA74415 (S.L. Neuhausen) and P30CA033752. S.L.
Neuhausen is the Morris and Horowitz Families Endowed Professor. Sheba
Medical Center Study (SMC) was in part sponsored by a grant from the
Israel cancer association to E. Friedman on behalf of the Israeli
consortium of inherited breast cancer. University of Pennsylvania
(UPENN) study was supported by R01-CA083855 and R01-CA102776 (T. R.
Rebbeck). Spanish National Cancer Center (CNIO) study has been partially
funded by Mutua Madrilena Foundation, "Red de Investigacion en Cancer
RD06/0020/1160", and Spanish Ministry of Science and Innovation (FIS
P1081120 and SAF2010-20493). Epidemiologic study of BRCA1 and BRCA2
mutation carriers (EMBRACE) is supported by Cancer Research UK Grants
C1287/A10118 and C1287/A11990. D.G. Evans and F. Lalloo are supported by
an NIHR grant to the Biomedical Research Centre (Manchester, UK). The
Investigators at The Institute of Cancer Research and The Royal Marsden
NMS Foundation Trust are supported by an NIHR grant to the Biomedical
Research Centre at The Institute of Cancer Research and The Royal
Marsden NHS Foundation Trust. R. Eeles and E. B. Gomez Garcia are
supported by Cancer Research UK Grant C5047/A8385. Fox Chase Cancer
Center (FCCC) study was supported by R01CA140323, U01CA69631, and
5U01CA113916 (to A.K. Godwin). Copenhagen Breast Cancer Study (CBCS) was
supported by the NEYE Foundation. Gynecologic Oncology Group (COG) was
supported through funding provided by both intramural (Clinical Genetics
Branch, DCEG) and extramural (Community Oncology and Prevention Trials
Program-COPTRG) National Cancer Institute (NCI) programs, and was based
in GOG's Cancer Prevention and Control Committee. N.N. Petrov Institute
of Oncology (NNPIO) study is supported by the Russian Foundation for
Basic Research (grants 10-04-92110, 10-04-92601, and 11-04-00227), the
Federal Agency for Science and Innovations (contract 02.740.11.0780),
and through a Royal Society International Joint Grant (JP090615). The
Baltic Familial Breast and Ovarian Cancer Consortium (BFBOCC, Latvia and
Lithuania) study is supported by the Research Council of Lithuania grant
LIG-19/2010 to R.J. Institut Catala d'Oncologia (ICO); Asociacion
Espanola Contra el Cancer, Spanish Health Research Fund; Carlos III
Health Institute; Catalan Health Institute, and Autonomous Government of
Catalonia. Contract grant numbers: ISCIIIRETIC RD06/0020/1051,
PI10/01422, PI10/31488, and 2009SGR290. UK and Gilds Radner Familial
Ovarian Cancer Registries (UKGRFOCR) study was supported by a project
grant from CRUK (to P. Peterlongo). Women's Cancer Program at the Samuel
Oschin Comprehensive Cancer Institute (WCP) is supported by American
Cancer Society (120950-SIOP-06-258-06-COUN). The German Consortium of
Hereditary Breast and Ovarian Cancer (GC-HBOC) was supported by a grant
of the German Cancer Aid (DKH 109076). Helsinki Breast Cancer Study
(HEBCS) was supported by the Helsinki University Central Hospital
Research Fund, Academy of Finland (132473), the Finnish Cancer Society,
and the Sigrid Juselius Foundation. Interdisciplinary Health Research
International Team Breast Cancer Susceptibility (INHERIT BRCAs) was
supported by the Canadian Institutes of Health Research for the "CIHR
Team in Familial Risks of Breast Cancer" program and by the Canadian
Breast Cancer Research Alliance-grant #019511.; The Breast Cancer Family
Registry (BCFR) was supported by the NCI, under RFA # CA-06-503, and
through cooperative agreements with members of the BCFR and principal
investigators, including Cancer Care Ontario (U01 CA69467), Cancer
Prevention Institute of California (U01 CA69417), Columbia University
(U01 CA69398), Fox Chase Cancer Center (U01 CA69631), Huntsman Cancer
Institute (U01 CA69446), and University of Melbourne (U01 CA69638). The
Australian BCFR was also supported by the National Health and Medical
Research Council of Australia, the New South Wales Cancer Council, the
Victorian Health Promotion Foundation (Australia), and the Victorian
Breast Cancer Research Consortium. M.C. Southey is an NHMRC Senior
Research Fellow and a Victorian Breast Cancer Research Consortium Group
Leader. J.L. Hopper is an Australia Fellow of the NHMRC and a Victorian
Breast Cancer Research Consortium Group Leader. Carriers at FCCC were
also identified with support from the NITA grants P01 CA16094 and R01
CA22435. The New York BCFR was also supported by National Institutes of
Health grants P30 CA13696 and P30 ES009089. The Utah BCFR was also
supported by the National Center for Research Resources and the National
Center for Advancing Translational Sciences, NIH Grant UL1 RR025764, and
by Award Number P30 CA042014 from the NCI. Kathleen Cuningham Consortium
for Research into Familial Breast Cancer (KCONFAB) is funded by NHMRC
grants 145684, 288704, and 454508. A.B. Spurdle is supported by an NHMRC
Senior Research Fellowship, and G-CT by an NHMRC Senior Principal
Research Fellowship. National Cancer Institute (NCI): P.L. Mai, J.T.
Loud, and M.H. Greene were funded by the Intramural Research Program of
the US NCI at the NIH with infrastructure support from contracts
NO2-CP-11019-50 and N02-CP-65504 with Westat, Inc. Mayo Clinic Study
(MAYO) was supported by NIH R01278978 and grants from the Breast cancer
Research Foundation and the Komen Foundation for the Cure. The
Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON)
study is supported by the Dutch Cancer Society grants NKI1998-1854,
NKI2004-3088, NKI2007-3756, and the ZonMW grant 91109024. OSU CCG: This
work was funded by the OSU Comprehensive Cancer Center.
NR 31
TC 9
Z9 9
U1 2
U2 14
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1055-9965
J9 CANCER EPIDEM BIOMAR
JI Cancer Epidemiol. Biomarkers Prev.
PD AUG
PY 2012
VL 21
IS 8
BP 1362
EP 1370
DI 10.1158/1055-9965.EPI-12-0229
PG 9
WC Oncology; Public, Environmental & Occupational Health
SC Oncology; Public, Environmental & Occupational Health
GA 987RC
UT WOS:000307433800016
PM 22729394
ER
PT J
AU Hess, DR
Branson, RD
AF Hess, Dean R.
Branson, Richard D.
TI Know Your Ventilator to Beat the Leak
SO CHEST
LA English
DT Editorial Material
ID NONINVASIVE VENTILATION; ICU VENTILATORS; HOSPITALS; MODEL
C1 [Hess, Dean R.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Hess, Dean R.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
[Branson, Richard D.] Univ Cincinnati, Cincinnati, OH 45221 USA.
RP Hess, DR (reprint author), Massachusetts Gen Hosp, Ellison 401,55 Fruit St, Boston, MA 02114 USA.
EM dhess@partners.org
NR 14
TC 6
Z9 6
U1 0
U2 1
PU AMER COLL CHEST PHYSICIANS
PI NORTHBROOK
PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA
SN 0012-3692
J9 CHEST
JI Chest
PD AUG
PY 2012
VL 142
IS 2
BP 274
EP 275
DI 10.1378/chest.12-0489
PG 2
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 987LJ
UT WOS:000307418200002
PM 22871746
ER
PT J
AU Harbst, K
Staaf, J
Lauss, M
Karlsson, A
Masback, A
Johansson, I
Bendahl, PO
Vallon-Christersson, J
Torngren, T
Ekedahl, H
Geisler, J
Hoglund, M
Ringner, M
Lundgren, L
Jirstrom, K
Olsson, H
Ingvar, C
Borg, A
Tsao, H
Jonsson, G
AF Harbst, Katja
Staaf, Johan
Lauss, Martin
Karlsson, Anna
Masback, Anna
Johansson, Iva
Bendahl, Par-Ola
Vallon-Christersson, Johan
Torngren, Therese
Ekedahl, Henrik
Geisler, Jurgen
Hoglund, Markus
Ringner, Mattias
Lundgren, Lotta
Jirstrom, Karin
Olsson, Hakan
Ingvar, Christian
Borg, Ake
Tsao, Hensin
Jonsson, Goran
TI Molecular Profiling Reveals Low- and High-Grade Forms of Primary
Melanoma
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID TUMOR-INFILTRATING LYMPHOCYTES; PRIMARY CUTANEOUS MELANOMA;
GENE-EXPRESSION; PROGNOSTIC-SIGNIFICANCE; MALIGNANT-MELANOMA; SURVIVAL;
FEATURES; MITF
AB Purpose: For primary melanomas, tumor thickness, mitotic rate, and ulceration are well-laid cornerstones of prognostication. However, a molecular exposition of melanoma aggressiveness is critically missing. We recently uncovered a four-class structure in metastatic melanoma, which predicts outcome and informs biology. This raises the possibility that a molecular structure exists even in the early stages of melanoma and that molecular determinants could underlie histophenotype and eventual patient outcome.
Experimental Design: We subjected 223 archival primary melanomas to a horizontally integrated analysis of RNA expression, oncogenic mutations at 238 lesions, histomorphometry, and survival data.
Results: Our previously described four-class structure that was elucidated in metastatic lesions was evident within the expression space of primary melanomas. Because these subclasses converged into two larger prognostic and phenotypic groups, we used the metastatic lesions to develop a binary subtype-based signature capable of distinguishing between "high" and "low" grade forms of the disease. The two-grade signature was subsequently applied to the primary melanomas. Compared with low-grade tumors, high-grade primary melanomas were significantly associated with increased tumor thickness, mitotic rate, ulceration (all P < 0.01), and poorer relapse-free (HR = 4.94; 95% CI, 2.84-8.59), and overall (HR 3.66; 95% CI, 2.40-5.58) survival. High-grade melanomas exhibited elevated levels of proliferation and BRCA1/DNA damage signaling genes, whereas low-grade lesions harbored higher expression of immune genes. Importantly, the molecular-grade signature was validated in two external gene expression data sets.
Conclusions: We provide evidence for a molecular organization within melanomas, which is preserved across all stages of disease. Clin Cancer Res; 18(15); 4026-36. (C)2012 AACR.
C1 [Harbst, Katja; Staaf, Johan; Lauss, Martin; Karlsson, Anna; Bendahl, Par-Ola; Vallon-Christersson, Johan; Torngren, Therese; Ekedahl, Henrik; Hoglund, Markus; Ringner, Mattias; Lundgren, Lotta; Olsson, Hakan; Borg, Ake; Jonsson, Goran] Lund Univ, Dept Oncol, S-22185 Lund, Sweden.
[Harbst, Katja; Staaf, Johan; Lauss, Martin; Vallon-Christersson, Johan; Hoglund, Markus; Ringner, Mattias; Borg, Ake; Jonsson, Goran] Lund Univ, CRE ATE Hlth Strateg Ctr Clin Canc Res, S-22185 Lund, Sweden.
[Masback, Anna; Johansson, Iva; Jirstrom, Karin] Lund Univ, Dept Pathol, S-22185 Lund, Sweden.
[Ingvar, Christian] Lund Univ, Dept Surg, S-22185 Lund, Sweden.
[Geisler, Jurgen] Univ Oslo, Akershus Univ Hosp, Dept Oncol, N-0316 Oslo, Norway.
[Tsao, Hensin] Harvard Univ, Sch Med, Dept Dermatol, Cambridge, MA 02138 USA.
[Tsao, Hensin] Massachusetts Gen Hosp, MGH Canc Ctr, Wellman Ctr Photomed, Boston, MA 02114 USA.
RP Jonsson, G (reprint author), Lund Univ, Dept Oncol, S-22185 Lund, Sweden.
EM htsao@partners.org; goran_b.jonsson@med.lu.se
RI Ringner, Markus/G-3641-2011; Jonsson, Goran/D-1212-2014
OI Vallon-Christersson, Johan/0000-0002-2195-0385; Hoglund,
Mattias/0000-0001-9283-4421; Ringner, Markus/0000-0001-5469-8940;
FU Swedish Cancer Society; Crafoord Foundation; Mrs. Berta Kamprad
Foundation; Gunnar Nilsson Cancer Foundation; Lund University Hospital
Research Funds; Lund University Medical Faculty/ALF, BioCare; Gustav Vth
Jubilee Foundation; U.S. NIH [K24 CA149202, P50 CA93683]
FX This work was supported by the Swedish Cancer Society, the Crafoord
Foundation, the Mrs. Berta Kamprad Foundation, the Gunnar Nilsson Cancer
Foundation, the Lund University Hospital Research Funds, Lund University
Medical Faculty/ALF, BioCare, and the Gustav Vth Jubilee Foundation.
This activity was also supported in part by the U.S. NIH (K24 CA149202
and P50 CA93683) and by the generous donors to the MGH Millennium
Melanoma Fund.
NR 22
TC 37
Z9 37
U1 0
U2 2
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD AUG 1
PY 2012
VL 18
IS 15
BP 4026
EP 4036
DI 10.1158/1078-0432.CCR-12-0343
PG 11
WC Oncology
SC Oncology
GA 988PS
UT WOS:000307503600005
PM 22675174
ER
PT J
AU Smits, M
van Rijn, S
Hulleman, E
Biesmans, D
van Vuurden, DG
Kool, M
Haberler, C
Aronica, E
Vandertop, WP
Noske, DP
Wurdinger, T
AF Smits, Michiel
van Rijn, Sjoerd
Hulleman, Esther
Biesmans, Dennis
van Vuurden, Dannis G.
Kool, Marcel
Haberler, Christine
Aronica, Eleonora
Vandertop, W. Peter
Noske, David P.
Wuerdinger, Thomas
TI EZH2-Regulated DAB2IP Is a Medulloblastoma Tumor Suppressor and a
Positive Marker for Survival
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID ABERRANT PROMOTER METHYLATION; PROTEIN HDAB2IP GENE; GENOME-WIDE
ASSOCIATION; PROSTATE-CANCER; MOUSE MODEL; SPORADIC MEDULLOBLASTOMAS;
DOWN-REGULATION; CELL-LINES; DE-NOVO; EXPRESSION
AB Purpose: Medulloblastoma is the most common malignant brain tumor in children. Despite recent improvements, the molecular mechanisms driving medulloblastoma are not fully understood and further elucidation could provide cues to improve outcome prediction and therapeutic approaches.
Experimental Design: Here, we conducted a meta-analysis of mouse and human medulloblastoma gene expression data sets, to identify potential medulloblastoma tumor suppressor genes.
Results: We identified DAB2IP, a member of the RAS-GTPase-activating protein family (RAS GAP), and showed that DAB2IP expression is repressed in medulloblastoma by EZH2-induced trimethylation. Moreover, we observed that reduced DAB2IP expression correlates significantly with a poor overall survival of patients with medulloblastoma, independent of metastatic stage. Finally, we showed that ectopic DAB2IP expression enhances stress-induced apoptosis in medulloblastoma cells and that reduced expression of DAB2IP in medulloblastoma cells conveys resistance to irradiation-induced cell death.
Conclusion: These results suggest that repression of DAB2IP may at least partly protect medulloblastoma cells from apoptotic cell death. Moreover, DAB2IP may represent a molecular marker to distinguish patients with medulloblastoma at high risk from those with a longer survival prognosis. Clin Cancer Res; 18(15); 4048-58. (C)2012 AACR.
C1 [Smits, Michiel; van Rijn, Sjoerd; Hulleman, Esther; Biesmans, Dennis; van Vuurden, Dannis G.; Vandertop, W. Peter; Noske, David P.; Wuerdinger, Thomas] Vrije Univ Amsterdam, Med Ctr, Canc Ctr Amsterdam, Neurooncol Res Grp,Dept Neurosurg, NL-1081 HV Amsterdam, Netherlands.
[Smits, Michiel; van Rijn, Sjoerd; Hulleman, Esther; Biesmans, Dennis; van Vuurden, Dannis G.; Vandertop, W. Peter; Noske, David P.; Wuerdinger, Thomas] Vrije Univ Amsterdam, Med Ctr, Canc Ctr Amsterdam, Dept Pediat Oncol Hematol, NL-1081 HV Amsterdam, Netherlands.
[Aronica, Eleonora] Univ Amsterdam, Acad Med Ctr, Dept Neuropathol, NL-1105 AZ Amsterdam, Netherlands.
[Vandertop, W. Peter] Univ Amsterdam, Acad Med Ctr, Neurosurg Ctr Amsterdam, NL-1105 AZ Amsterdam, Netherlands.
[Kool, Marcel] German Canc Res Ctr, Dept Mol Genet, Heidelberg, Germany.
[Haberler, Christine] Inst Curie, Lab Genet & Biol Canc, Paris, France.
[Wuerdinger, Thomas] Harvard Univ, Sch Med, Dept Neurol, Massachusetts Gen Hosp,Mol Neurogenet Unit, Boston, MA 02115 USA.
[Wuerdinger, Thomas] Harvard Univ, Sch Med, Dept Radiol, Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Wuerdinger, Thomas] Harvard Univ, Sch Med, Neurosci Program, Boston, MA 02115 USA.
RP Wurdinger, T (reprint author), Vrije Univ Amsterdam, Med Ctr, Canc Ctr Amsterdam, Neurooncol Res Grp,Dept Neurosurg, CCA Room 3-60,De Boelelaan 1117, NL-1081 HV Amsterdam, Netherlands.
EM t.wurdinger@vumc.nl
RI Kool, Marcel/H-2541-2013;
OI Van Vuurden, Dannis/0000-0002-1364-9007
NR 57
TC 22
Z9 24
U1 0
U2 2
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD AUG 1
PY 2012
VL 18
IS 15
BP 4048
EP 4058
DI 10.1158/1078-0432.CCR-12-0399
PG 11
WC Oncology
SC Oncology
GA 988PS
UT WOS:000307503600007
PM 22696229
ER
PT J
AU Cantu-Brito, C
Chiquete, E
Ruiz-Sandoval, JL
Gaxiola, E
Albuquerque, DC
Corbalan, R
Ramos, A
Bhatt, DL
Steg, PG
AF Cantu-Brito, Carlos
Chiquete, Erwin
Ruiz-Sandoval, Jose L.
Gaxiola, Efrain
Albuquerque, Denilson C.
Corbalan, Ramon
Ramos, Alma
Bhatt, Deepak L.
Steg, P. Gabriel
CA REACH Latin Amer Collaborative Grp
TI Atherothrombotic Disease, Traditional Risk Factors, and 4-Year Mortality
in a Latin American Population: The REACH Registry
SO CLINICAL CARDIOLOGY
LA English
DT Article
ID CARDIOVASCULAR EVENT RATES; PERIPHERAL ARTERY-DISEASE; ACUTE
ISCHEMIC-STROKE; BODY-MASS INDEX; OBESITY PARADOX;
MYOCARDIAL-INFARCTION; VASCULAR-DISEASE; HEART-FAILURE; FOLLOW-UP;
OUTPATIENTS
AB Background: Atherothrombosis is becoming the leading cause of chronic morbidity in developing countries. This epidemiological transition will represent an unbearable socioeconomic burden in the near future. We investigated factors associated with 4-year all-cause mortality in a Latin American population at high risk. Hypothesis: Largely modifiable risk factors as well as polyvascular disease are the main predictors of 4-year all-cause and cardiovascular mortality in this Latin American cohort. Methods: We analyzed 1816 Latin American stable outpatients (62.3% men, mean age 67 years) with symptomatic atherothrombosis (87.1%) or with multiple risk factors only (12.9%), in the Reduction of Atherothrombosis for Continued Health registry. Results: Of patients with symptomatic atherothrombosis, 57.3% had coronary artery disease, 32% cerebrovascular disease, and 11.7% peripheral artery disease at baseline (9.1% polyvascular). The main risk factors were hypertension (76%), hypercholesterolemia (60%), and smoking (52.3%) in patients with established atherothrombosis; and hypertension (89.7%), diabetes (80.8%), and hypercholesterolemia (73.9%) in those with risk factors only. Four-year all-cause mortality steeply increased with none (6.8%), 1 (9.2%), 2 (15.5%), and 3 (29.2%) symptomatic arterial disease locations. In patients with only 1 location, cardiovascular mortality was significantly higher with peripheral artery disease (11.3%) than with cerebrovascular disease (6%) or coronary artery disease (5.1%). Significant baseline predictors of 4-year all-cause mortality were congestive heart failure (hazard ratio [HR]: 3.81), body mass index <20 (HR: 2.32), hypertension (HR: 1.84), polyvascular disease (HR: 1.69), and age =65 years (HR: 1.47), whereas statin use (HR: 0.49) and body mass index =30 (HR: 0.58) were associated with a reduced risk. Conclusions: Hypertension was the main modifiable risk factor for atherothrombosis and all-cause mortality in this Latin American cohort. Nearly one-third of the population with 3 symptomatic vascular-disease locations died at 4-year follow-up. The REACH registry is sponsored by sanofi, Bristol-Myers Squibb, and the Waksman Foundation (Tokyo, Japan). The REACH registry is endorsed by the World Heart Federation. The REACH registry enforces a no-ghostwriting policy. This manuscript was written and edited by the authors, who take full responsibility for its content. Dr. Cantu-Brito and Dr. Chiquete wrote the first draft of this manuscript. Dr. Cantu-Brito has received research grants from sanofi, Ferrer Grupo and Bayer, as well as speaker honoraria from sanofi. Dr. Chiquete has received research grants from sanofi and Ferrer Grupo, as well as speaker honoraria from Novartis. Dr. Ruiz-Sandoval has received research grants from sanofi, Boehringer Ingelheim, and Ferrer Grupo. Dr. Gaxiola has received research grants from sanofi and Eli Lilly, as well as consultancy and speaker honoraria from Sanofi, Eli Lilly, Pfizer, AstraZeneca, and Abbott. Dr. Albuquerque has received research grants from sanofi, AstraZeneca, Servier, Roche, and BMS/Pfizer, as well as consultancy and speaker honoraria from sanofi and AstraZeneca. Dr. Corbalan has no relevant disclosures. Mrs. Ramos is an employee at sanofi, in the Clinical Research Department. Dr. Deepak L.
Bhatt discloses the following relationships - Advisory Board: Medscape Cardiology; Board of Directors: Boston VA Research Institute, Society of Chest Pain Centers; Chair: American Heart Association Get With The Guidelines Science Subcommittee; Honoraria: American College of Cardiology (Editor, Clinical Trials, Cardiosource), Duke Clinical Research Institute (clinical trial steering committees), Slack Publications (Chief Medical Editor, Cardiology Today Intervention), WebMD (CME steering committees); Research Grants: Amarin, AstraZeneca, Bristol-Myers Squibb, Eisai, Ethicon, Medtronic, Sanofi Aventis, The Medicines Company; Unfunded Research: PLx Pharma, Takeda. Dr. Steg has received research grants from Servier; consultancy fees/honoraria from Amgen, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo/Eli Lilly alliance, Eisai, GlaxoSmithKline, Medtronic, Merck Sharpe and Dohme, Pfizer, Roche, sanofi, Servier, and The Medicines Company; and has equity ownership in Aterovax. The authors have no other funding, financial relationships, or conflicts of interest to disclose.
C1 [Cantu-Brito, Carlos] Salvador Zubiran Natl Inst Med Sci & Nutr, Dept Neurol & Psychiat, Mexico City, DF, Mexico.
[Ruiz-Sandoval, Jose L.] Fray Antonio Alcalde Publ Hosp, Dept Neurol, Guadalajara, Jalisco, Mexico.
[Gaxiola, Efrain] Jardines Specialty Hosp, Dept Cardiol, Zapopan, Jalisco, Mexico.
[Albuquerque, Denilson C.] Univ Estado Rio De Janeiro, Hosp Pedro Ernesto, Dept Cardiol, Rio De Janeiro, Brazil.
[Corbalan, Ramon] Pontificia Univ Catolica Chile, Dept Cardiovasc Dis, Santiago, Chile.
[Ramos, Alma] Dept Sci, Dept Clin Res, Sanofi, Mexico.
[Bhatt, Deepak L.] Brigham & Womens Hosp, VA Boston Healthcare Syst, Dept Cardiol, Boston, MA 02115 USA.
[Steg, P. Gabriel] Univ Hosp N Paris Val Seine, Hop Bichat Claude Bernard, Paris, France.
[Bhatt, Deepak L.] Harvard Univ, Sch Med, Boston, MA USA.
[Steg, P. Gabriel] Paris Diderot Univ, Paris, France.
RP Cantu-Brito, C (reprint author), Salvador Zubiran Natl Inst Med Sci & Nutr, Dept Neurol & Psychiat, Mexico City, DF, Mexico.
RI Pazin Filho, Antonio/E-9495-2010
OI Pazin Filho, Antonio/0000-0001-5242-329X
FU sanofi; Bristol-Myers Squibb; Waksman Foundation (Tokyo, Japan); Ferrer
Grupo; Bayer; Boehringer Ingelheim; Eli Lilly; AstraZeneca; Servier;
Roche; BMS/ Pfizer; Amarin; Eisai; Ethicon; Medtronic; Sanofi Aventis;
Amgen; Astellas; GlaxoSmithKline; Merck Sharpe and Dohme; Daiichi
Sankyo/ Eli Lilly alliance
FX The REACH registry is sponsored by sanofi, Bristol-Myers Squibb, and the
Waksman Foundation (Tokyo, Japan). The REACH registry is endorsed by the
World Heart Federation. The REACH registry enforces a no-ghostwriting
policy. This manuscript was written and edited by the authors, who take
full responsibility for its content. Dr. Cantu-Brito and Dr. Chiquete
wrote the first draft of this manuscript.; Dr. Cantu-Brito has received
research grants from sanofi, Ferrer Grupo and Bayer, as well as speaker
honoraria from sanofi. Dr. Chiquete has received research grants from
sanofi and Ferrer Grupo, as well as speaker honoraria from Novartis. Dr.
Ruiz-Sandoval has received research grants from sanofi, Boehringer
Ingelheim, and Ferrer Grupo. Dr. Gaxiola has received research grants
from sanofi and Eli Lilly, as well as consultancy and speaker honoraria
from Sanofi, Eli Lilly, Pfizer, AstraZeneca, and Abbott. Dr. Albuquerque
has received research grants from sanofi, AstraZeneca, Servier, Roche,
and BMS/Pfizer, as well as consultancy and speaker honoraria from sanofi
and AstraZeneca. Dr. Corbalan has no relevant disclosures. Mrs. Ramos is
an employee at sanofi, in the Clinical Research Department. Dr. Deepak
L. Bhatt discloses the following relationships-Advisory Board: Medscape
Cardiology; Board of Directors: Boston VA Research Institute, Society of
Chest Pain Centers; Chair: American Heart Association Get With The
Guidelines Science Subcommittee; Honoraria: American College of
Cardiology (Editor, Clinical Trials, Cardiosource), Duke Clinical
Research Institute (clinical trial steering committees), Slack
Publications (Chief Medical Editor, Cardiology Today Intervention),
WebMD (CME steering committees); Research Grants: Amarin, AstraZeneca,
Bristol-Myers Squibb, Eisai, Ethicon, Medtronic, Sanofi Aventis, The
Medicines Company; Unfunded Research: PLx Pharma, Takeda. Dr. Steg has
received research grants from Servier; consultancy fees/honoraria from
Amgen, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers
Squibb, Daiichi Sankyo/Eli Lilly alliance, Eisai, GlaxoSmithKline,
Medtronic, Merck Sharpe and Dohme, Pfizer, Roche, sanofi, Servier, and
The Medicines Company; and has equity ownership in Aterovax. The authors
have no other funding, financial relationships, or conflicts of interest
to disclose.
NR 38
TC 7
Z9 7
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0160-9289
J9 CLIN CARDIOL
JI Clin. Cardiol.
PD AUG
PY 2012
VL 35
IS 8
BP 451
EP 457
DI 10.1002/clc.22005
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 983JV
UT WOS:000307116500001
PM 22653654
ER
PT J
AU Hails, K
Brill, CD
Chang, T
Yeung, A
Fava, M
Trinh, NH
AF Hails, Katherine
Brill, Charlotte D.
Chang, Trina
Yeung, Albert
Fava, Maurizio
Trinh, Nhi-Ha
TI Cross-Cultural Aspects of Depression Management in Primary Care
SO CURRENT PSYCHIATRY REPORTS
LA English
DT Article
DE Major depressive disorder; Cross-cultural psychiatry; Primary care;
Collaborative care; Interventions; Minority patients
ID SENSITIVE COLLABORATIVE TREATMENT; RANDOMIZED CONTROLLED-TRIAL;
LATE-LIFE DEPRESSION; CHINESE-AMERICANS; UNITED-STATES; HEALTH;
DISORDER; OUTCOMES; DISPARITIES; ADAPTATION
AB Major depressive disorder (MDD) is a prevalent illness in minority populations. Minority patients with MDD are often unrecognized and untreated. This review examines promising interventions to address MDD in primary care settings, where minority groups are more likely to seek care. Since 2010, eleven interventions have been developed to address patient-specific and provider-specific barriers, many of which are adaptations of the collaborative care model. Other promising interventions include cultural tailoring of the collaborative care model, as well as the addition of telepsychiatry, motivational interviewing, cultural consultation, and innovations in interpreting. Overall, collaborative care was found feasible and improved satisfaction and treatment engagement of depressed minority patients in primary care. It remains inconclusive whether these newer intervention models improve MDD treatment outcomes. Future research will be needed to establish the effectiveness of these intervention models in improving the treatment outcomes of minority populations with MDD.
C1 [Hails, Katherine; Brill, Charlotte D.; Chang, Trina; Yeung, Albert; Fava, Maurizio; Trinh, Nhi-Ha] Massachusetts Gen Hosp, Depress Clin & Res Program, Boston, MA 02114 USA.
[Yeung, Albert] S Cove Community Hlth Ctr, Boston, MA 02111 USA.
RP Hails, K (reprint author), Massachusetts Gen Hosp, Depress Clin & Res Program, 1 Bowdoin Sq,6th Floor, Boston, MA 02114 USA.
EM khails@partners.org
FU AstraZeneca; CeNeRx BioPharma; Euthymics Bioscience; Forest
Pharmaceuticals; GlaxoSmithKline; Johnson Johnson; Pfizer; Lippincott
Williams Wilkins; Wolters Kluwer; World Scientific Publishing; MGH
Cognitive and Physical Functioning Questionnaire (CPFQ); Sexual
Functioning Inventory (SFI); Antidepressant Treatment Response
Questionnaire (ATRQ); Discontinuation-Emergent Signs & Symptoms (DESS);
SAFER; National Institute of Mental Health (NIMH); National Center for
Complementary and Alternative Medicine (NCCAM); National Institutes of
Health (NIH); NIDA; Bristol-Myers Squibb; Ganeden Biotech; Pamlab;
Clinical Trials Solutions; Pfizer Forest; i3Research; Covance; Novartis;
Roche; Sanofi-Aventis
FX Dr. Chang has served as a consultant for OptumInsight; has received
research support from AstraZeneca, CeNeRx BioPharma, Euthymics
Bioscience, Forest Pharmaceuticals, GlaxoSmithKline, Johnson & Johnson,
and Pfizer; and has received honoraria from and had
travel/accommodations expenses covered/reimbursed by Bristol-Myers
Squibb.; Dr. Fava has received equity holdings from Compellis; has
received royalties from Lippincott Williams & Wilkins, Wolters Kluwer,
and World Scientific Publishing; has received compensation for editing
from Belvoir Media Group, Massachusetts General Hospital Psychiatry
Academy, CME Institute/Physicians Postgraduate Press, and Association
for Health Research & Development (ACINDES); has received honoraria from
Eisai, Johnson & Johnson Pharmaceutical Research & Development,
Lundbeck, Pfizer, and Servier Laboratories; has served as a board member
of BrainCells, Bristol-Myers Squibb, Eisai, EnVivo Pharmaceuticals,
Ganeden Biotech, Genomind, Johnson & Johnson, Lundbeck/Takeda, National
Institute on Drug Abuse (NIDA), Neuronetics, PsychoGenics, Psylin
Neurosciences, Schering-Plough, Transcept Pharmaceuticals; has received
patents for Sequential Parallel Comparison Design (SPCD), a patent for
research and licensing of SPCD with RCT Logic, a patent application for
a combination of azapirones and bupropion in major depressive disorder
(MDD), and copyright royalties for the MGH Cognitive and Physical
Functioning Questionnaire (CPFQ), Sexual Functioning Inventory (SFI),
Antidepressant Treatment Response Questionnaire (ATRQ),
Discontinuation-Emergent Signs & Symptoms (DESS), and SAFER; has
received research support from National Institute of Mental Health
(NIMH), National Center for Complementary and Alternative Medicine
(NCCAM), National Institutes of Health (NIH), NIDA, Bristol-Myers
Squibb, Ganeden Biotech, Johnson & Johnson, Pamlab, Clinical Trials
Solutions, Pfizer Forest, CeNeRx BioPharma, i3Research, Euthymics
Bioscience, Covance, GlaxoSmithKline, AstraZeneca, Novartis, Roche, and
Sanofi-Aventis; and has served as a consultant for Abbott Laboratories,
Affectis Pharmaceuticals, Alkermes, Amarin Pharma, Aspect Medical
Systems, AstraZeneca, Auspex Pharmaceuticals, Bayer, Best Practice
Project Management, BioMarin Pharmaceutical, Biovail Corporation,
BrainCells, Bristol-Myers Squibb, CeNeRx BioPharma, Cephalon, Clinical
Trials Solutions, CNS Response, Compellis Pharmaceuticals, Cypress
Pharmaceutical, DiagnoSearch Life Sciences, Dainippon Sumitomo Pharma,
DOV Pharmaceutical, Edgemont Pharmaceuticals, Eisai, Eli Lilly and
Company, EnVivo Pharmaceuticals, ePharmaSolutions, EPIX Pharmaceuticals,
Euthymics Bioscience, Fabre-Kramer Pharmaceuticals, Forest
Pharmaceuticals, Genomind, GlaxoSmithKline, Grunenthal, i3
Innovus/Ingenis, Janssen Pharmaceuticals, Jazz Pharmaceuticals, Johnson
& Johnson Pharmaceutical Research & Development, Knoll Pharmaceuticals,
Labopharm, Lorex Pharmaceuticals, Lundbeck, MedAvante, Merck & Co., MSI
Methylation Sciences, Naurex; Neuronetics, NextWave Pharmaceuticals,
Novartis, Nutrition 21, Orexigen Therapeutics, Organon Pharmaceuticals,
Otsuka Pharmaceuticals, Pamlab, Pfizer, PharmaStar, Pharmavite, PharmoRx
Therapeutics, Precision Human Biolaboratory, Prexa Pharmaceuticals,
Puretech Ventures, PsychoGenics, Psylin Neurosciences, Rexahn
Pharmaceuticals, Ridge Diagnostics, Roche, RCT Logic, Sanofi-Aventis,
Sepracor, Servier Laboratories; Schering-Plough, Solvay Pharmaceuticals,
Somaxon Pharmaceuticals, Somerset Pharmaceuticals, Sunovion
Pharmaceuticals; Supernus Pharmaceuticals, Synthelabo, Takeda, Tal
Medical, Tetragenex Pharmaceuticals, TransForm Pharmaceuticals,
Transcept Pharmaceuticals, Vanda Pharmaceuticals.
NR 38
TC 5
Z9 5
U1 2
U2 9
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1523-3812
J9 CURR PSYCHIAT REP
JI Curr. Psychiatry Rep.
PD AUG
PY 2012
VL 14
IS 4
BP 336
EP 344
DI 10.1007/s11920-012-0276-9
PG 9
WC Psychiatry
SC Psychiatry
GA 985NR
UT WOS:000307273900009
PM 22580834
ER
PT J
AU Izikson, L
Helm, T
Sroa, N
Zeitouni, NC
AF Izikson, Leonid
Helm, Thomas
Sroa, Novie
Zeitouni, Nathalie C.
TI Clinical Stage of Merkel Cell Carcinoma and Survival Are Not Associated
with Breslow Thickness of Biopsied Tumor
SO DERMATOLOGIC SURGERY
LA English
DT Article
ID SINGLE INSTITUTION; SPECIMENS; SKIN
AB Background Merkel cell carcinoma (MCC) is an aggressive malignancy that often presents on the skin with concurrent metastatic disease. Objective To determine whether Breslow thickness of biopsied MCC correlates with clinical disease stage. Materials and Methods We performed a retrospective review of clinical data and histopathology specimens from 34 individuals with MCC treated at the Roswell Park Cancer Institute for whom complete clinical information and histopathology specimens were available. Results There was no correlation between Breslow thickness of biopsied MCC on the head and neck or body and clinical stage of disease, progression-free survival, or overall survival. Hence, thin MCCs should not be taken to represent lesions with less-aggressive clinical behavior. Conclusion Our findings validate the current practice of staging all newly diagnosed MCC, irrespective of size or Breslow thickness.
C1 [Sroa, Novie; Zeitouni, Nathalie C.] Roswell Pk Canc Inst, Dept Dermatol, Buffalo, NY 14263 USA.
[Izikson, Leonid] Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02114 USA.
[Helm, Thomas] SUNY Buffalo, Dept Dermatol, Buffalo, NY 14260 USA.
RP Zeitouni, NC (reprint author), Roswell Pk Canc Inst, Dept Dermatol, Elm & Carlton St, Buffalo, NY 14263 USA.
EM nathalie.zeitouni@roswellpark.org
NR 12
TC 5
Z9 5
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1076-0512
J9 DERMATOL SURG
JI Dermatol. Surg.
PD AUG
PY 2012
VL 38
IS 8
BP 1351
EP 1356
DI 10.1111/j.1524-4725.2012.02398.x
PG 6
WC Dermatology; Surgery
SC Dermatology; Surgery
GA 983KX
UT WOS:000307119300014
PM 22455371
ER
PT J
AU Dalamaga, M
Diakopoulos, KN
Mantzoros, CS
AF Dalamaga, Maria
Diakopoulos, Kalliope N.
Mantzoros, Christos S.
TI The Role of Adiponectin in Cancer: A Review of Current Evidence
SO ENDOCRINE REVIEWS
LA English
DT Review
ID ACTIVATED PROTEIN-KINASE; HIGH-MOLECULAR-WEIGHT; RENAL-CELL CARCINOMA;
CHRONIC HEPATITIS-C; NF-KAPPA-B; RANDOMIZED CONTROLLED-TRIAL;
COMPLEMENT-RELATED PROTEIN; INDUCED INSULIN-RESISTANCE; CHRONIC
MYELOID-LEUKEMIA; NECROSIS-FACTOR-ALPHA
AB Excess body weight is associated not only with an increased risk of type 2 diabetes and cardiovascular disease (CVD) but also with various types of malignancies. Adiponectin, the most abundant protein secreted by adipose tissue, exhibits insulin-sensitizing, antiinflammatory, antiatherogenic, proapoptotic, and antiproliferative properties. Circulating adiponectin levels, which are determined predominantly by genetic factors, diet, physical activity, and abdominal adiposity, are decreased in patients with diabetes, CVD, and several obesity-associated cancers. Also, adiponectin levels are inversely associated with the risk of developing diabetes, CVD, and several malignancies later in life. Many cancer cell lines express adiponectin receptors, and adiponectin in vitro limits cell proliferation and induces apoptosis. Recent in vitro studies demonstrate the antiangiogenic and tumor growth-limiting properties of adiponectin. Studies in both animals and humans have investigated adiponectin and adiponectin receptor regulation and expression in several cancers. Current evidence supports a role of adiponectin as a novel risk factor and potential diagnostic and prognostic biomarker in cancer. In addition, either adiponectin per se or medications that increase adiponectin levels or up-regulate signaling pathways downstream of adiponectin may prove to be useful anticancer agents.
This review presents the role of adiponectin in carcinogenesis and cancer progression and examines the pathophysiological mechanisms that underlie the association between adiponectin and malignancy in the context of a dysfunctional adipose tissue in obesity. Understanding of these mechanisms may be important for the development of preventive and therapeutic strategies against obesity-associated malignancies. (Endocrine Reviews 33: 547-594, 2012)
C1 [Diakopoulos, Kalliope N.; Mantzoros, Christos S.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Endocrinol Diabet & Metab,Dept Internal Med, Boston, MA 02215 USA.
[Mantzoros, Christos S.] VA Boston Healthcare Syst, Endocrinol Sect, Boston, MA 02130 USA.
[Dalamaga, Maria] Univ Athens, Sch Med, Lab Clin Biochem, Attikon Gen Univ Hosp, Athens 12462, Greece.
RP Mantzoros, CS (reprint author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Endocrinol Diabet & Metab,Dept Internal Med, 330 Brookline Ave,FD-876, Boston, MA 02215 USA.
EM cmantzor@bidmc.harvard.edu
OI Diakopoulos, Kalliope/0000-0002-9236-0489; Dalamaga,
Maria/0000-0002-7008-388X
FU Beth Israel Deaconess Medical Center; National Institute of Diabetes and
Digestive and Kidney Diseases [DK058785, DK079929, DK081913]; National
Institute on Aging [AG032030]; VA Merit Award; California Walnut
Commission
FX This work was supported by a discretionary grant from Beth Israel
Deaconess Medical Center (to C. S. M.). The Mantzoros laboratory is
supported by the National Institute of Diabetes and Digestive and Kidney
Diseases (Grants DK058785, DK079929, and DK081913), the National
Institute on Aging (Grant AG032030), a VA Merit Award, and the
California Walnut Commission.
NR 434
TC 151
Z9 159
U1 3
U2 40
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0163-769X
J9 ENDOCR REV
JI Endocr. Rev.
PD AUG
PY 2012
VL 33
IS 4
BP 547
EP 594
DI 10.1210/er.2011-1015
PG 48
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 987IA
UT WOS:000307409200004
PM 22547160
ER
PT J
AU Xu, YH
Cai, WL
Nappi, J
Yoshida, H
AF Xu, Yonghua
Cai, Wenli
Nappi, Janne
Yoshida, Hiro
TI Fecal-tagging CT colonography with structure-analysis electronic
cleansing for detection of colorectal flat lesions
SO EUROPEAN JOURNAL OF RADIOLOGY
LA English
DT Article
DE Colonography; Computed tomographic; Diagnosis; Electronic cleansing;
Flat polyps
ID COMPUTED TOMOGRAPHIC COLONOGRAPHY; VIRTUAL COLONOSCOPY; ASYMPTOMATIC
ADULTS; POLYPS; COLON
AB Purpose: To evaluate the feasibility and sensitivity of the 3D-reading of fecal-tagging CT colonography (CTC) with a novel structure-analysis electronic cleansing (SAEC) in detecting colorectal flat lesions in comparison with a cleansed 3D reading with Viatronix V3D Colon system (V3D) and primary uncleansed 2D reading (2D).
Materials and methods: Forty CTC cases with flat lesions were retrospectively observed. The Subjects from a multicenter clinical trial underwent cathartic bowel preparation with orally administrated barium-based fecal-tagging. Sixty-nine flat lesions were confirmed using colonoscopy and histopathology as a reference standard. The results from SAEC reading were compared with those of prospective V3D and 2D readings.
Results: Overall detection sensitivity with SAEC was 52% (36/69), which was statistically higher than that of 32% (22/69) and 29% (20/69) with V3D and 2D readings, respectively (p < 0.05). The sensitivities in detecting not-on-fold flat lesions were 63% (24/38), 45% (17/38), and 42% (16/38) with SAEC, V3D, and 2D readings, respectively; whereas those of on-fold flat lesions were 39% (12/31), 16% (5/31), and 13% (4/31), respectively. None of the eight flat lesions (2-9 mm) at cecum was detected by any of the three reading methods. Excluding the flat lesions at cecum, the sensitivity with SAEC for detecting flat lesion >= 4 mm increased to 84% (31/37).
Conclusions: The fecal-tagging CTC with structure-analysis electronic cleansing could yield a high sensitivity for detecting flat lesions >= 4 mm. The not-on-fold flat lesions were detected with higher sensitivity than on-fold flat lesions. (c) 2011 Elsevier Ireland Ltd. All rights reserved.
C1 [Xu, Yonghua] Xuhui Cent Hosp Shanghai, Dept Radiol, Shanghai 200031, Peoples R China.
[Xu, Yonghua] Chinese Acad Sci, Shanghai Med Ctr, Shanghai 200031, Peoples R China.
[Xu, Yonghua] Chongqing Med Univ, Dept Biomed Engn, Chongqing 400016, Peoples R China.
[Cai, Wenli; Nappi, Janne; Yoshida, Hiro] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
[Cai, Wenli; Nappi, Janne; Yoshida, Hiro] Harvard Univ, Sch Med, Boston, MA 02114 USA.
RP Xu, YH (reprint author), Xuhui Cent Hosp Shanghai, Dept Radiol, 966 Huai Hai Cent Rd, Shanghai 200031, Peoples R China.
EM howardyonghua@gmail.com
NR 15
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0720-048X
J9 EUR J RADIOL
JI Eur. J. Radiol.
PD AUG
PY 2012
VL 81
IS 8
BP 1712
EP 1716
DI 10.1016/j.ejrad.2011.04.051
PG 5
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 983NO
UT WOS:000307126200026
PM 21596500
ER
PT J
AU Li, G
De La Garza, B
Shih, YYI
Muir, ER
Duong, TQ
AF Li, Guang
De La Garza, Bryan
Shih, Yen-Yu I.
Muir, Eric R.
Duong, Timothy Q.
TI Layer-specific blood-flow MRI of retinitis pigmentosa in RCS rats
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE retinal degeneration; retinitis pigmentosa; arterial spin labeling;
blood flow; retina; choroid
ID OPTICAL COHERENCE TOMOGRAPHY; MANGANESE-ENHANCED MRI; HEREDITARY RETINAL
DEGENERATION; OXYGEN-METABOLISM; ABYSSINIAN CATS; OCULAR FUNDUS; MOUSE
RETINA; MUTATIONS; PERFUSION; GENE
AB The Royal College of Surgeons (RCS) rat is an established animal model of retinitis pigmentosa, a family of inherited retinal diseases which starts with loss of peripheral vision and progresses to eventual blindness. Blood flow (BF), an important physiological parameter, is intricately coupled to metabolic function under normal physiological conditions and is perturbed in many neurological and retinal diseases. This study reports non-invasive high-resolution MRI (44 x 44 x 600 pm) to image quantitative retinal and choroidal BF and layer-specific retinal thicknesses in RCS rat retinas at different stages of retinal degeneration compared with age-matched controls. The unique ability to separate retinal and choroidal BF was made possible by the depth-resolved MRI technique. RBF decreased with progressive retinal degeneration, but ChBF did not change in RCS rats up to post-natal day 90. We concluded that choroidal and retinal circulations have different susceptibility to progressive retinal degeneration in RCS rats. Layer-specific retinal thickness became progressively thinner and was corroborated by histological analysis in the same animals. MRI can detect progressive anatomical and BF changes during retinal degeneration with laminar resolution. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Li, Guang; De La Garza, Bryan; Shih, Yen-Yu I.; Muir, Eric R.; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Ctr, San Antonio, TX 78229 USA.
[Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Ophthalmol, San Antonio, TX 78229 USA.
[Li, Guang; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Radiol, San Antonio, TX 78229 USA.
[Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78229 USA.
[Duong, Timothy Q.] S Texas Vet Hlth Care Syst, San Antonio, TX USA.
RP Duong, TQ (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Ctr, 8403 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM duongt@uthscsa.edu
RI Duong, Timothy/B-8525-2008; Li, Guang/C-9539-2011; Muir,
Eric/H-8830-2013;
OI Li, Guang/0000-0002-7648-0464; Shih, Yen-Yu Ian/0000-0001-6529-911X
FU NIH/NEI [R01 EY014211, EY018855]; MERIT Award from the Department of
Veterans Affairs; Clinical Translational Science Award Supplement
(parent grant) [UL1RR025767]
FX Grant support: This work was supported in part by the NIH/NEI (R01
EY014211 and EY018855), and a MERIT Award from the Department of
Veterans Affairs, and a Clinical Translational Science Award Supplement
(parent grant UL1RR025767).
NR 58
TC 13
Z9 13
U1 0
U2 0
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
J9 EXP EYE RES
JI Exp. Eye Res.
PD AUG
PY 2012
VL 101
BP 90
EP 96
DI 10.1016/j.exer.2012.06.006
PG 7
WC Ophthalmology
SC Ophthalmology
GA 984QE
UT WOS:000307205300012
PM 22721720
ER
PT J
AU Prosser, LA
Grosse, SD
Kemper, AR
Tarini, BA
Perrin, JM
AF Prosser, Lisa A.
Grosse, Scott D.
Kemper, Alex R.
Tarini, Beth A.
Perrin, James M.
TI Decision analysis, economic evaluation, and newborn screening:
challenges and opportunities
SO GENETICS IN MEDICINE
LA English
DT Review
DE cost-effectiveness; decision analysis; economic evaluation; health
policy; newborn screening
ID COA DEHYDROGENASE-DEFICIENCY; CONGENITAL ADRENAL-HYPERPLASIA; SEVERE
COMBINED IMMUNODEFICIENCY; TANDEM MASS-SPECTROMETRY; COST-UTILITY;
PRIMER; DISORDERS; AUSTRALIA; MORTALITY; DIAGNOSIS
AB The number of conditions included in newborn screening panels has increased rapidly in the United States during the past decade, and many more conditions are under consideration for addition to state panels. The rare nature of candidate conditions for newborn screening makes their evaluation challenging. The scarcity of data on the costs of screening, follow-up, treatment, and long-term disability must be addressed to improve the evaluation process for nominated conditions. Decision analyses and economic evaluations can help inform policy decisions for newborn screening programs by providing a systematic approach to synthesizing available evidence and providing projected estimates of long-term clinical and economic outcomes when long-term data are not available. In this review, we outline the types of data required for the development of decision analysis and cost-effectiveness models for newborn screening programs and discuss the challenges faced when applying these methods in the arena of newborn screening to help inform policy decisions. Genet Med 2012:14(8):703-712
C1 [Prosser, Lisa A.; Tarini, Beth A.] Univ Michigan, Div Gen Pediat, Child Hlth Evaluat & Res Unit, Ann Arbor, MI 48109 USA.
[Grosse, Scott D.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA.
[Kemper, Alex R.] Duke Univ, Dept Pediat, Durham, NC 27706 USA.
[Perrin, James M.] Harvard Univ, Sch Med, MassGen Hosp Children, Ctr Child & Adolescent Hlth Policy, Boston, MA USA.
RP Prosser, LA (reprint author), Univ Michigan, Div Gen Pediat, Child Hlth Evaluat & Res Unit, Ann Arbor, MI 48109 USA.
EM lisapros@med.umich.edu
FU University of Michigan; Duke University; MassGeneral Hospital for
Children [HHSP23320045014XI]; Department of Health and Human Services;
Health Resources and Services Administration; Maternal and Child Health
Bureau
FX This work was supported by subcontracts to the University of Michigan,
Duke University, and MassGeneral Hospital for Children under prime
contract (HHSP23320045014XI) to the Altarum Institute from the
Department of Health and Human Services, the Health Resources and
Services Administration, and the Maternal and Child Health Bureau. We
also appreciate the expert research assistance of Kara Lamarand.
NR 54
TC 8
Z9 9
U1 1
U2 9
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1098-3600
J9 GENET MED
JI Genet. Med.
PD AUG
PY 2012
VL 14
IS 8
BP 703
EP 712
DI 10.1038/gim.2012.24
PG 10
WC Genetics & Heredity
SC Genetics & Heredity
GA 985SC
UT WOS:000307288900001
ER
PT J
AU Aronson, SJ
Clark, EH
Varugheese, M
Baxter, S
Babb, LJ
Rehm, HL
AF Aronson, Samuel J.
Clark, Eugene H.
Varugheese, Matthew
Baxter, Samantha
Babb, Lawrence J.
Rehm, Heidi L.
TI Communicating new knowledge on previously reported genetic variants
SO GENETICS IN MEDICINE
LA English
DT Article
DE clinical decision support; electronic health record; GeneInsight;
genetic reports; knowledge base; report updating; variant classification
AB Genetic tests often identify variants whose significance cannot be determined at the time they are reported. In many situations, it is critical that clinicians be informed when new information emerges on these variants. It is already extremely challenging for laboratories to provide these updates. These challenges will grow rapidly as an increasing number of clinical genetic tests are ordered and as the amount of patient DNA assayed per test expands; the challenges will need to be addressed before whole-genome sequencing is used on a widespread basis.
Information technology infrastructure can be useful in this context. We have deployed an infrastructure enabling clinicians to receive knowledge updates when a laboratory changes the classification of a variant. We have gathered statistics from this deployment regarding the frequency of both variant classification changes and the effects of these classification changes on patients. We report on the system's functionality as well as the statistics derived from its use. Genet Med 2012:14(8):713-719
C1 [Aronson, Samuel J.; Clark, Eugene H.; Varugheese, Matthew; Babb, Lawrence J.] Partners HealthCare Ctr Personalized Genet Med, Informat Syst Dept, Cambridge, MA USA.
[Aronson, Samuel J.; Clark, Eugene H.; Varugheese, Matthew; Babb, Lawrence J.] Partners HealthCare, Informat Syst Dept, Cambridge, MA USA.
[Baxter, Samantha; Rehm, Heidi L.] Partners HealthCare Ctr Personalized Genet Med, Lab Mol Med, Cambridge, MA USA.
[Rehm, Heidi L.] Massachusetts Gen Hosp, Dept Pathol, Brigham & Womens Hosp, Boston, MA 02114 USA.
[Rehm, Heidi L.] Harvard Univ, Sch Med, Boston, MA USA.
RP Aronson, SJ (reprint author), Partners HealthCare Ctr Personalized Genet Med, Informat Syst Dept, Cambridge, MA USA.
EM saronson@partners.org
FU Partners HealthCare and National Institutes of Health (NIH) Challenge
Grant through the National Library of Medicine [RC1LM010526];
GeneInsight Lab
FX We acknowledge all of our colleagues at the Partners HealthCare Center
for Personalized Genetic Medicine who contributed to developing,
testing, and rolling out the GeneInsight Suite, the GeneInsight Suite
user community, which provided constant feedback, and the Refining IT
Support for Genetics in Medicine team for its guidance. This work was
supported in part by Partners HealthCare and National Institutes of
Health (NIH) Challenge Grant RC1LM010526 administered through the
National Library of Medicine. GeneInsight Lab licensing fees also
supported this effort.
NR 7
TC 28
Z9 28
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1098-3600
J9 GENET MED
JI Genet. Med.
PD AUG
PY 2012
VL 14
IS 8
BP 713
EP 719
DI 10.1038/gim.2012.19
PG 7
WC Genetics & Heredity
SC Genetics & Heredity
GA 985SC
UT WOS:000307288900002
ER
PT J
AU Leshchiner, I
Alexa, K
Kelsey, P
Adzhubei, I
Austin-Tse, CA
Cooney, JD
Anderson, H
King, MJ
Stottmann, RW
Garnaas, MK
Ha, SS
Drummond, IA
Paw, BH
North, TE
Beier, DR
Goessling, W
Sunyaev, SR
AF Leshchiner, Ignaty
Alexa, Kristen
Kelsey, Peter
Adzhubei, Ivan
Austin-Tse, Christina A.
Cooney, Jeffrey D.
Anderson, Heidi
King, Matthew J.
Stottmann, Rolf W.
Garnaas, Maija K.
Ha, Seungshin
Drummond, Iain A.
Paw, Barry H.
North, Trista E.
Beier, David R.
Goessling, Wolfram
Sunyaev, Shamil R.
TI Mutation mapping and identification by whole-genome sequencing
SO GENOME RESEARCH
LA English
DT Article
ID ZEBRAFISH; GENERATION; LINEAGES; GENE; MICE
AB Genetic mapping of mutations in model systems has facilitated the identification of genes contributing to fundamental biological processes including human diseases. However, this approach has historically required the prior characterization of informative markers. Here we report a fast and cost-effective method for genetic mapping using next-generation sequencing that combines single nucleotide polymorphism discovery, mutation localization, and potential identification of causal sequence variants. In contrast to prior approaches, we have developed a hidden Markov model to narrowly define the mutation area by inferring recombination breakpoints of chromosomes in the mutant pool. In addition, we created an interactive online software resource to facilitate automated analysis of sequencing data and demonstrate its utility in the zebrafish and mouse models. Our novel methodology and online tools will make next-generation sequencing an easily applicable resource for mutation mapping in all model systems.
C1 [Leshchiner, Ignaty; Alexa, Kristen; Kelsey, Peter; Adzhubei, Ivan; Stottmann, Rolf W.; Garnaas, Maija K.; Ha, Seungshin; Beier, David R.; Goessling, Wolfram; Sunyaev, Shamil R.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Genet, Boston, MA 02115 USA.
[Austin-Tse, Christina A.; Drummond, Iain A.] Massachusetts Gen Hosp, Dept Genet, Boston, MA 02114 USA.
[Cooney, Jeffrey D.; Anderson, Heidi; King, Matthew J.; Paw, Barry H.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Hematol, Boston, MA 02114 USA.
[North, Trista E.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02115 USA.
[Goessling, Wolfram] Harvard Stem Cell Inst, Cambridge, MA 02138 USA.
[Goessling, Wolfram] Harvard MIT Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
[Goessling, Wolfram] Dana Farber Canc Inst, Gastrointestinal Canc Ctr, Boston, MA 02115 USA.
RP Goessling, W (reprint author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Genet, Boston, MA 02115 USA.
EM wgoessling@partners.org; ssunyaev@rics.bwh.harvard.edu
OI Austin-Tse, Christina/0000-0001-6492-6716; Goessling,
Wolfram/0000-0001-9972-1569
FU Harvard Stem Cell Institute; American Heart Association; Sigrid Juselius
Foundation; March of Dimes grant; NIH [1R01DK090311, 5R01MH084676,
R01HD036404, R01MH081187, R01DK070838, P01HL032262]
FX This work was supported by a Junior Faculty Grant from the Harvard Stem
Cell Institute and institutional start-up funds to W.G., American Heart
Association grants to J.D.C. and M.J.K., Sigrid Juselius Foundation
grant to H.A., March of Dimes grant to B.H.P., and NIH grants
1R01DK090311 to W.G., 5R01MH084676 to S.S., R01HD036404 and R01MH081187
to D.R.B, R01DK070838 and P01HL032262 to B.H.P.
NR 25
TC 52
Z9 53
U1 3
U2 24
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 1088-9051
J9 GENOME RES
JI Genome Res.
PD AUG
PY 2012
VL 22
IS 8
BP 1541
EP 1548
DI 10.1101/gr.135541.111
PG 8
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
Genetics & Heredity
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
Genetics & Heredity
GA 983BD
UT WOS:000307090300016
PM 22555591
ER
PT J
AU Brastianos, PK
Batchelor, TT
AF Brastianos, Priscilla K.
Batchelor, Tracy T.
TI Primary Central Nervous System Lymphoma Overview of Current Treatment
Strategies
SO HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
LA English
DT Article
DE Primary central nervous system lymphoma; Treatment; Chemotherapy;
Radiation
ID PRIMARY CNS LYMPHOMA; HIGH-DOSE METHOTREXATE; NON-HODGKINS-LYMPHOMA;
WHOLE-BRAIN RADIOTHERAPY; STEM-CELL TRANSPLANTATION; RECURRENT PRIMARY
CNS; MULTICENTER PHASE-II; IMMUNOCOMPETENT PATIENTS; RADIATION-THERAPY;
INTRAOCULAR LYMPHOMA
AB Primary central nervous system lymphoma (PCNSL) is an uncommon and aggressive variant of non-Hodgkin lymphoma that involves the brain, eyes, leptomeninges, or spinal cord. Therapeutic progress has been modest, and our understanding of the molecular mechanisms that drive this disease is limited. Clinicians treating PCNSL face a challenge to balance the need to administer aggressive regimens to achieve a cure with the risks of delayed neurotoxicity after treatment. The standard treatment is a methotrexate-containing chemotherapy regimen. The timing and dose of whole-brain radiation therapy is controversial, given the significant risks of late neurotoxic effects, particularly in elderly patients.
C1 [Brastianos, Priscilla K.; Batchelor, Tracy T.] Harvard Univ, Massachusetts Gen Hosp Canc Ctr, Stephen E & Catherine Pappas Ctr Neurooncol, Div Hematol & Oncol,Dept Neurol,Med Sch, Boston, MA 02114 USA.
[Brastianos, Priscilla K.] Harvard Univ, Dept Med Oncol, Dana Farber Brigham & Womens Canc Ctr, Sch Med, Boston, MA 02115 USA.
[Batchelor, Tracy T.] Harvard Univ, Dept Radiat Oncol, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA.
RP Brastianos, PK (reprint author), Harvard Univ, Massachusetts Gen Hosp Canc Ctr, Stephen E & Catherine Pappas Ctr Neurooncol, Div Hematol & Oncol,Dept Neurol,Med Sch, 55 Fruit St,Yawkey 9 E, Boston, MA 02114 USA.
EM pbrastianos@partners.org
OI Brastianos, Priscilla/0000-0003-4470-8425
NR 93
TC 10
Z9 13
U1 0
U2 6
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0889-8588
J9 HEMATOL ONCOL CLIN N
JI Hematol. Oncol. Clin. North Am.
PD AUG
PY 2012
VL 26
IS 4
BP 897
EP +
DI 10.1016/j.hoc.2012.05.003
PG 21
WC Oncology; Hematology
SC Oncology; Hematology
GA 989ZW
UT WOS:000307601800011
PM 22794289
ER
PT J
AU Delmonico, FL
AF Delmonico, Francis L.
TI Organ transplantation in China-the 21st century
SO HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL
LA English
DT Editorial Material
C1 Harvard Univ, Massachusetts Gen Hosp, Dept Surg, Boston, MA 02115 USA.
RP Delmonico, FL (reprint author), Harvard Univ, Massachusetts Gen Hosp, Dept Surg, Boston, MA 02115 USA.
EM francis_delmonico@neob.org
NR 2
TC 1
Z9 1
U1 1
U2 5
PU ZHEJIANG UNIV SCH MEDICINE
PI HANGZHOU
PA FIRST AFFILIATED HOSPITAL, 79 QINGCHUN ROAD, HANGZHOU, 310003, PEOPLES R
CHINA
SN 1499-3872
J9 HEPATOB PANCREAT DIS
JI Hepatob. Pancreatic. Dis. Int.
PD AUG
PY 2012
VL 11
IS 4
BP 346
EP 348
DI 10.1016/S1499-3872(12)60191-X
PG 3
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 984RX
UT WOS:000307210300001
PM 22893460
ER
PT J
AU Wen, HY
Schumacher, HR
Li, XF
Gu, JR
Ma, L
Wei, H
Yokogawa, N
Shiroto, K
Baker, JF
Dinnella, J
Ogdie, A
AF Wen, Hongyan
Schumacher, H. Ralph
Li, Xiaofeng
Gu, Jieruo
Ma, Li
Wei, Hua
Yokogawa, Naoto
Shiroto, Katsuaki
Baker, Joshua F.
Dinnella, Janet
Ogdie, Alexis
TI Comparison of expectations of physicians and patients with rheumatoid
arthritis for rheumatology clinic visits: a pilot, multicenter,
international study
SO INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES
LA English
DT Article
DE clinical aspects; drug treatment; education; rehabilitation; rheumatoid
arthritis
ID DISEASE-ACTIVITY; DEPRESSION; COMMUNICATION; OUTCOMES; PARTICIPATION;
PREVALENCE; DISORDERS; SYMPTOM
AB Aim To describe and compare expectations of patients with rheumatoid arthritis (RA) and their physicians with regard to what is most important to achieve during a rheumatology clinic visit. Methods Subjects were RA patients enrolled in four centers from China, one from Japan and one from the USA, and rheumatologists at those centers. The questionnaires were provided at clinics and patients were asked to list their three top priorities for the rheumatology clinic visit. Physicians were contacted separately and asked to give three general expectations, not for specific visits. We classified clinical expectations into a series of 24 terms for patients and 17 for physicians. We compared physicians' to patients' responses, compared expectations among centers in China, Japan and the USA, and evaluated relationships between patients' responses and age, gender, nationality, disease duration and DAS-28 (Disease Activity Score-28). Results Patients' clinical expectations for visits focused primarily on control of pain (63.7%), improvement of function (49.3%) and discussion of effects of medication (38.1%). Physicians also included control of pain (59.5%), but also emphasized inquiry about drug side-effects (47.8%) and objective assessment of disease activity (41.4%). We found no differences related to patients' gender, disease duration and DAS-28, but there were some differences related to age and nationality. Conclusion We found some agreement and some discordance of clinical expectations between RA patients and physicians. There appear to be some different expectations in different countries. Findings from this pilot survey may help physicians consider patients' expectations in planning rheumatology clinic visits and may lead to further hypothesis-driven studies.
C1 [Schumacher, H. Ralph] Philadelphia Vet Affairs Med Ctr, Dept Med, Div Rheumatol, Philadelphia, PA 19104 USA.
[Wen, Hongyan; Schumacher, H. Ralph; Baker, Joshua F.; Dinnella, Janet; Ogdie, Alexis] Univ Penn, Dept Med, Div Rheumatol, Philadelphia, PA 19104 USA.
[Wen, Hongyan; Li, Xiaofeng] Shanxi Med Univ, Hosp 2, Taiyuan, Shanxi Province, Peoples R China.
[Gu, Jieruo] Sun Yat Sen Univ, Affiliated Hosp 3, Guangzhou 510275, Guangdong, Peoples R China.
[Ma, Li] China Japan Friendship Hosp, Beijing, Peoples R China.
[Wei, Hua] No Jiangsu Peoples Hosp, Yangzhou, Jiangsu, Peoples R China.
[Yokogawa, Naoto; Shiroto, Katsuaki] Tokyo Metropolitan Tama Med Ctr, Sect Rheumatol 2 8 29, Tokyo, Japan.
RP Schumacher, HR (reprint author), Philadelphia Vet Affairs Med Ctr, Dept Med, Div Rheumatol, 151K Univ & Woodland Aves, Philadelphia, PA 19104 USA.
EM schumacr@mail.med.upenn.edu
OI Ogdie, Alexis/0000-0002-4639-0775
NR 29
TC 9
Z9 10
U1 0
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1756-1841
J9 INT J RHEUM DIS
JI Int. J. Rheum. Dis.
PD AUG
PY 2012
VL 15
IS 4
BP 380
EP 389
DI 10.1111/j.1756-185X.2012.01752.x
PG 10
WC Rheumatology
SC Rheumatology
GA 989OK
UT WOS:000307569600014
PM 22898218
ER
PT J
AU Gaggin, HK
Mohammed, AA
Bhardwaj, A
Rehman, SU
Gregory, SA
Weiner, RB
Baggish, AL
Moore, SA
Semigran, MJ
Januzzi, JL
AF Gaggin, Hanna K.
Mohammed, Asim A.
Bhardwaj, Anju
Rehman, Shafiq U.
Gregory, Shawn A.
Weiner, Rory B.
Baggish, Aaron L.
Moore, Stephanie A.
Semigran, Marc J.
Januzzi, James L., Jr.
TI Heart Failure Outcomes and Benefits of NT-proBNP-Guided Management in
the Elderly: Results From the Prospective, Randomized ProBNP Outpatient
Tailored Chronic Heart Failure Therapy (PROTECT) Study
SO JOURNAL OF CARDIAC FAILURE
LA English
DT Article
DE Natriuretic peptides; age; outcomes; biomarker
ID BRAIN NATRIURETIC PEPTIDE; CLINICAL EPIDEMIOLOGY; EMERGENCY-DEPARTMENT;
MEDICAL THERAPY; BETA-BLOCKER; VAL-HEFT; TRIAL; DYSFUNCTION; PREDICTION;
VALSARTAN
AB Background: Elderly patients with heart failure (HF) have a worse prognosis than younger patients. We wished to study whether elders benefit from natriuretic peptide-guided HF care in this single-center study.
Methods and Results: A total of 151 patients with HF resulting from left ventricular systolic dysfunction (LVSD) were treated with HF treatment by standard-of-care (SOC) management or guided by N-terminal pro-B type natriuretic peptide (NT-proBNP) values (with a goal to lower NT-proBNP <= 1000 pg/mL) over 10 months. The primary end point for this post-hoc analysis was total cardiovascular events in 2 age categories (<75 and >= 75 years). In those >= 75 years of age (n = 38), NT-proBNP values increased in the SOC arm (2570 to 3523 pg/mL, P = .01), but decreased in the NT-proBNP guided arm (2664 to 1418 pg/mL, P = .001). Elderly patients treated with SOC management had the highest rate of cardiovascular events, whereas the elderly with NT-proBNP management had the lowest rate of cardiovascular events (1.76 events per patient versus 0.71 events per patient, P = .03); the adjusted logistic odds for cardiovascular events related to NT-proBNP guided care for elders was 0.24 (P = .008), whereas in those <75 years (n = 113), the adjusted logistic odds for events following NT-proBNP guided care was 0.61 (P = .10).
Conclusions: Natriuretic peptide guided HF care was well tolerated and resulted in substantial improvement in cardiovascular event rates in elders (Clinical Trials.Gov #00351390). (J Cardiac Fail 2012;18:626-634)
C1 [Gaggin, Hanna K.; Mohammed, Asim A.; Bhardwaj, Anju; Rehman, Shafiq U.; Gregory, Shawn A.; Weiner, Rory B.; Baggish, Aaron L.; Moore, Stephanie A.; Semigran, Marc J.; Januzzi, James L., Jr.] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA.
RP Januzzi, JL (reprint author), 55 Fruit St,Yawkey 5984, Boston, MA 02114 USA.
EM jjanuzzi@partners.org
FU Roche Diagnostics, Inc.; Dennis and Marilyn Barry Cardiology Fellowship;
Balson Cardiac Scholar Fund; Siemens Diagnostics; Critical Diagnostics;
Thermo-Fisher Diagnostics
FX Dr Januzzi reports the following disclosures: Roche Diagnostics,
research grants, consultancy; Siemens Diagnostics, research grants;
Critical Diagnostics, research grants, consultancy; and Thermo-Fisher
Diagnostics, research grants. None of the other authors have
disclosures. This work was supported in part by Roche Diagnostics, Inc.
S.U.R., Drs Mohammed, Bhardwaj, and Gaggin are supported by the Dennis
and Marilyn Barry Cardiology Fellowship. Dr Januzzi is supported in part
by the Balson Cardiac Scholar Fund.
NR 30
TC 32
Z9 37
U1 1
U2 9
PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS
PI PHILADELPHIA
PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA
SN 1071-9164
J9 J CARD FAIL
JI J. Card. Fail.
PD AUG
PY 2012
VL 18
IS 8
BP 626
EP 634
DI 10.1016/j.cardfail.2012.05.005
PG 9
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 991CP
UT WOS:000307679400006
PM 22858078
ER
PT J
AU Groessl, EJ
Liu, L
Ho, SB
Kanwal, F
Gifford, AL
Asch, SM
AF Groessl, Erik J.
Liu, Lin
Ho, Samuel B.
Kanwal, Fasiha
Gifford, Allen L.
Asch, Steven M.
TI National patterns and predictors of liver biopsy use for management of
hepatitis C
SO JOURNAL OF HEPATOLOGY
LA English
DT Article
DE Hepatitis C; Liver biopsy; Guidelines
ID GENOTYPE 1 INFECTION; VIRUS-INFECTION; AMINOTRANSFERASE LEVELS; PLUS
RIBAVIRIN; UNITED-STATES; HEALTH-CARE; VETERANS; HCV; CARRIERS;
PEGINTERFERON
AB Background & Aims: Liver biopsy remains the standard, recommended method for assessing liver damage associated with chronic hepatitis C (HCV) infection. However, there is considerable debate about how liver biopsy should best be used, especially with the advent of more efficacious antiviral therapies. To identify the factors that influence the use of liver biopsy for HCV patients, we describe variations in liver biopsy use at the delivery system and patient level in a national VA sample.
Methods: We analyzed VA HCV registry data for 171,893 VA patients with confirmed chronic HCV. Delivery system characteristics included geographic region and specialist time. Patient characteristics included antiviral treatment indicators, contraindications, volume of healthcare visits, and demographic variables. Logistic regression was used to explore correlates of biopsy use.
Results: Liver biopsy use in the VA system increased from 1997 to 2003 but began declining in 2004. Rates of liver biopsy from 2004 to 2006 varied by VA region, ranging from 5% to 18%. Treatment contraindications and laboratory tests were significantly associated with more biopsies. Demographic variables (higher age, lower BMI, race/ethnicity, and less% service connected disability) were associated with fewer biopsies. Regional variability remained significant independent of volume of care and specialist time.
Conclusions: Liver biopsy rates in the VA system have variability that seems unrelated to clinical need. New antiviral therapies and non-invasive assessment techniques may create additional uncertainty for the role of liver biopsy, perhaps explaining its decline in recent years. The availability of more effective antiviral therapies may also affect biopsy rates in the future. Published by Elsevier B.V. on behalf of the European Association for the Study of the Liver.
C1 [Groessl, Erik J.; Ho, Samuel B.] VA San Diego Healthcare Syst, La Jolla, CA 92161 USA.
[Groessl, Erik J.; Liu, Lin; Ho, Samuel B.] Univ Calif San Diego, La Jolla, CA 92093 USA.
[Gifford, Allen L.] Edith Nourse Rogers Mem Vet Hosp, Bedford, MA USA.
[Gifford, Allen L.] Boston Univ, Boston, MA 02215 USA.
[Asch, Steven M.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Asch, Steven M.] Univ Calif Los Angeles, Los Angeles, CA 90024 USA.
[Kanwal, Fasiha] VA St Louis, St Louis, MO USA.
[Kanwal, Fasiha] Washington Univ, St Louis, MO 63130 USA.
RP Groessl, EJ (reprint author), VA San Diego Healthcare Syst, 3550 La Jolla Village Dr,Mail Code 111 N-1, La Jolla, CA 92161 USA.
EM egroessl@ucsd.edu
FU VA HSRD [SHP - 08-203]
FX VA HSR&D, Project SHP - 08-203.
NR 36
TC 4
Z9 4
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
J9 J HEPATOL
JI J. Hepatol.
PD AUG
PY 2012
VL 57
IS 2
BP 252
EP 259
PG 8
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 991EW
UT WOS:000307685300008
PM 22521358
ER
PT J
AU Lucas, K
Karamichos, D
Mathew, R
Zieske, JD
Stein-Streilein, J
AF Lucas, Kenyatta
Karamichos, Dimitris
Mathew, Rose
Zieske, James D.
Stein-Streilein, Joan
TI Retinal Laser Burn-Induced Neuropathy Leads to Substance P-Dependent
Loss of Ocular Immune Privilege
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID NEUROKININ-1 RECEPTOR EXPRESSION; T-CELL-ACTIVATION; INFLAMMATORY
CONDITIONS; PIGMENT-EPITHELIUM; ANTERIOR-CHAMBER; NERVOUS-SYSTEM;
AQUEOUS-HUMOR; NEUROPEPTIDES; EYE; INDUCTION
AB Inflammation in the eye is tightly regulated by multiple mechanisms that together contribute to ocular immune privilege. Many studies have shown that it is very difficult to abrogate the immune privileged mechanism called anterior chamber-associated immune deviation (ACAID). Previously, we showed that retinal laser burn (RLB) to one eye abrogated immune privilege (ACAID) bilaterally for an extended period of time. In an effort to explain the inflammation in the nonburned eye, we postulated that neuronal signals initiated inflammation in the contralateral eye. In this study, we test the role of substance P, a neuroinflamatory peptide, in RLB-induced loss of ACAID. Histological examination of the retina with and without RLB revealed an increase of the substance P-inducible neurokinin 1 receptor (NK1-R) in the retina of first, the burned eye, and then the contralateral eye. Specific antagonists for NK1-R, given locally with Ag within 24 h, but not 3, 5, or 7 d post-RLB treatment, prevented the bilateral loss of ACAID. Substance P knockout (KO) mice retained their ability to develop ACAID post-RLB. These data support the postulate that substance P transmits early inflammatory signals from the RLB eye to the contralateral eye to induce changes to ocular immune privilege and has a central role in the bilateral loss of ACAID. The possibility is raised that blocking of the substance P pathway with NK1-R antagonists postocular trauma may prevent unwanted and perhaps extended consequences of trauma-induced inflammation in the eye. The Journal of Immunology, 2012, 189: 1237-1242.
C1 [Lucas, Kenyatta; Karamichos, Dimitris; Mathew, Rose; Zieske, James D.; Stein-Streilein, Joan] Harvard Univ, Sch Med, Dept Ophthalmol, Massachusetts Eye & Ear Infirm,Schepens Eye Res I, Boston, MA 02114 USA.
RP Stein-Streilein, J (reprint author), Harvard Univ, Sch Med, Dept Ophthalmol, Massachusetts Eye & Ear Infirm,Schepens Eye Res I, 20 Staniford St, Boston, MA 02114 USA.
EM joan.stein@schepens.harvard.edu
RI karamichos, dimitrios/D-9651-2015
FU National Institutes of Health [EY11983, EY016476, EY020614, F32
EY018983]; Department of Defense [W81XWH]
FX This work was supported in part by National Institutes of Health Grants
EY11983 (to J.S.-S.), EY016476 (to J.S.-S.), EY020614 (to J.S.-S.), and
F32 EY018983 (to K. L.) and Department of Defense Grant W81XWH (to
J.S.-S.).
NR 42
TC 10
Z9 10
U1 0
U2 3
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD AUG 1
PY 2012
VL 189
IS 3
BP 1237
EP 1242
DI 10.4049/jimmunol.1103264
PG 6
WC Immunology
SC Immunology
GA 976QJ
UT WOS:000306599100020
PM 22745377
ER
PT J
AU Su, CW
Cao, Y
Zhang, M
Kaplan, J
Su, LB
Fu, Y
Walker, WA
Xavier, R
Cherayil, BJ
Shi, HN
AF Su, Chien-wen
Cao, Yue
Zhang, Mei
Kaplan, Jess
Su, Libo
Fu, Ying
Walker, W. Allan
Xavier, Ramnik
Cherayil, Bobby J.
Shi, Hai Ning
TI Helminth Infection Impairs Autophagy-Mediated Killing of Bacterial
Enteropathogens by Macrophages
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID ALTERNATIVELY ACTIVATED MACROPHAGES; MYCOBACTERIUM-TUBERCULOSIS;
MONITORING AUTOPHAGY; TOXOPLASMA-GONDII; TRICHURIS-SUIS; GENE ATG16L1;
DISEASE; CELLS; SUPPRESSES; PATHOLOGY
AB Autophagy is an important mechanism used by macrophages to kill intracellular pathogens. The results reported in this study demonstrate that autophagy is also involved in the macrophage killing of the extracellular enteropathogen Citrobacter rodentium after phagocytosis. The process was significantly impaired in macrophages isolated from mice chronically infected with the helminth parasite Heligmosomoides polygyrus. The H. polygyrus-mediated inhibition of autophagy was Th2 dependent because it was not observed in macrophages isolated from helminth-infected STAT6-deficient mice. Moreover, autophagy of Citrobacter was inhibited by treating macrophages with IL-4 and IL-13. The effect of H. polygyrus on autophagy was associated with decreased expression and processing of L chain protein 3 (LC3), a key component of the autophagic machinery. The helminth-induced inhibition of LC3 expression and processing was STAT6 dependent and could be recapitulated by treatment of macrophages with IL-4 and IL-13. Knockdown of LC3 significantly inhibited autophagic killing of Citrobacter, attesting to the functional importance of the H. polygyrus-mediated downregulation of this process. These observations reveal a new aspect of the immunosuppressive effects of helminth infection and provide mechanistic insights into our earlier finding that H. polygyrus significantly worsens the in vivo course of Citrobacter infection. The Journal of Immunology, 2012, 189: 1459-1466.
C1 [Su, Chien-wen; Cao, Yue; Zhang, Mei; Kaplan, Jess; Su, Libo; Fu, Ying; Walker, W. Allan; Cherayil, Bobby J.; Shi, Hai Ning] Massachusetts Gen Hosp, Mucosal Immunol Lab, Charlestown, MA 02129 USA.
[Su, Chien-wen; Cao, Yue; Zhang, Mei; Kaplan, Jess; Su, Libo; Fu, Ying; Walker, W. Allan; Cherayil, Bobby J.; Shi, Hai Ning] Harvard Univ, Sch Med, Charlestown, MA 02129 USA.
[Xavier, Ramnik] Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA.
[Xavier, Ramnik] Harvard Univ, Sch Med, Boston, MA 02114 USA.
RP Shi, HN (reprint author), Massachusetts Gen Hosp, Mucosal Immunol Lab, Bldg 114,16th St,Room 3504, Charlestown, MA 02129 USA.
EM shiha@helix.mgh.harvard.edu
RI Fu, Ying/G-2899-2015
FU National Institutes of Health [DK074727, DK082427, AI089700]; Clinical
Nutrition Research Center at Harvard [P30 DK040561]; Inflammatory Bowel
Disease [DK43351]; Boston Area Diabetes and Endocrinology Research
Center [DK57521]
FX This work was supported by the National Institutes of Health (Grants
DK074727 and DK082427 to H.N.S.; Grant AI089700 to B.J.C.) and the
Clinical Nutrition Research Center at Harvard (Grant P30 DK040561 to W.
A. W.). Electron microscopy was supported by Inflammatory Bowel Disease
Grant DK43351 and Boston Area Diabetes and Endocrinology Research Center
Award DK57521.
NR 37
TC 16
Z9 16
U1 0
U2 6
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD AUG 1
PY 2012
VL 189
IS 3
BP 1459
EP 1466
DI 10.4049/jimmunol.1200484
PG 8
WC Immunology
SC Immunology
GA 976QJ
UT WOS:000306599100043
PM 22732589
ER
PT J
AU Hancock, KE
Chung, Y
Delgutte, B
AF Hancock, Kenneth E.
Chung, Yoojin
Delgutte, Bertrand
TI Neural ITD coding with bilateral cochlear implants: effect of binaurally
coherent jitter
SO JOURNAL OF NEUROPHYSIOLOGY
LA English
DT Article
DE binaural hearing; temporal coding; congenital deafness; inferior
colliculus; interaural time difference
ID INTERAURAL TIME DIFFERENCES; INFERIOR COLLICULUS NEURONS; SPIRAL
GANGLION NEURONS; DEAF WHITE CATS; ELECTRICAL-STIMULATION;
AUDITORY-NERVE; POTASSIUM CURRENTS; TEMPORAL RESOLUTION; RESPONSE
PROPERTIES; PULSE TRAINS
AB Hancock KE, Chung Y, Delgutte B. Neural ITD coding with bilateral cochlear implants: effect of binaurally coherent jitter. J Neurophysiol 108: 714-728, 2012. First published May 16, 2012; doi:10.1152/jn.00269.2012.-Poor sensitivity to the interaural time difference (ITD) constrains the ability of human bilateral cochlear implant users to listen in everyday noisy acoustic environments. ITD sensitivity to periodic pulse trains degrades sharply with increasing pulse rate but can be restored at high pulse rates by jittering the interpulse intervals in a binaurally coherent manner (Laback and Majdak. Binaural jitter improves interaural time-difference sensitivity of cochlear implantees at high pulse rates. Proc Natl Acad Sci USA 105: 814-817, 2008). We investigated the neural basis of the jitter effect by recording from single inferior colliculus (IC) neurons in bilaterally implanted, anesthetized cats. Neural responses to trains of biphasic pulses were measured as a function of pulse rate, jitter, and ITD. An effect of jitter on neural responses was most prominent for pulse rates above 300 pulses/s. High-rate periodic trains evoked only an onset response in most IC neurons, but introducing jitter increased ongoing firing rates in about half of these neurons. Neurons that had sustained responses to jittered high-rate pulse trains showed ITD tuning comparable with that produced by low-rate periodic pulse trains. Thus, jitter appears to improve neural ITD sensitivity by restoring sustained firing in many IC neurons. The effect of jitter on IC responses is qualitatively consistent with human psychophysics. Action potentials tended to occur reproducibly at sparse, preferred times across repeated presentations of high-rate jittered pulse trains. Spike triggered averaging of responses to jittered pulse trains revealed that firing was triggered by very short interpulse intervals. This suggests it may be possible to restore ITD sensitivity to periodic carriers by simply inserting short interpulse intervals at select times.
C1 [Hancock, Kenneth E.; Chung, Yoojin; Delgutte, Bertrand] Massachusetts Eye & Ear Infirm, Eaton Peabody Labs, Boston, MA 02114 USA.
[Hancock, Kenneth E.; Chung, Yoojin; Delgutte, Bertrand] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA.
[Delgutte, Bertrand] MIT, Elect Res Lab, Cambridge, MA 02139 USA.
RP Hancock, KE (reprint author), Massachusetts Eye & Ear Infirm, Eaton Peabody Labs, Boston, MA 02114 USA.
EM Ken_Hancock@meei.harvard.edu
OI , /0000-0003-1349-9608
FU National Institute on Deafness and Other Communication Disorders
[R01-DC-005775, P30-DC-005209]
FX This work was supported by National Institute on Deafness and Other
Communication Disorders Grants R01-DC-005775 and P30-DC-005209.
NR 59
TC 19
Z9 19
U1 0
U2 7
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-3077
J9 J NEUROPHYSIOL
JI J. Neurophysiol.
PD AUG
PY 2012
VL 108
IS 3
BP 714
EP 728
DI 10.1152/jn.00269.2012
PG 15
WC Neurosciences; Physiology
SC Neurosciences & Neurology; Physiology
GA 985BK
UT WOS:000307238100003
PM 22592306
ER
PT J
AU Sepulcre, J
Sabuncu, MR
Yeo, TB
Liu, HS
Johnson, KA
AF Sepulcre, Jorge
Sabuncu, Mert R.
Yeo, Thomas B.
Liu, Hesheng
Johnson, Keith A.
TI Stepwise Connectivity of the Modal Cortex Reveals the Multimodal
Organization of the Human Brain
SO JOURNAL OF NEUROSCIENCE
LA English
DT Article
ID INTRINSIC FUNCTIONAL CONNECTIVITY; HUMAN PARIETAL OPERCULUM; PRIMATE
CEREBRAL-CORTEX; CORTICAL NETWORK; MULTISENSORY INTEGRATION; SPATIAL
ATTENTION; BINDING PROBLEM; SOMATOTOPIC ORGANIZATION; NEUROCOGNITIVE
NETWORKS; SUPERIOR COLLICULUS
AB How human beings integrate information from external sources and internal cognition to produce a coherent experience is still not well understood. During the past decades, anatomical, neurophysiological and neuroimaging research in multimodal integration have stood out in the effort to understand the perceptual binding properties of the brain. Areas in the human lateral occipitotemporal, prefrontal, and posterior parietal cortices have been associated with sensory multimodal processing. Even though this, rather patchy, organization of brain regions gives us a glimpse of the perceptual convergence, the articulation of the flow of information from modality-related to the more parallel cognitive processing systems remains elusive. Using a method called stepwise functional connectivity analysis, the present study analyzes the functional connectome and transitions from primary sensory cortices to higher-order brain systems. We identify the large-scale multimodal integration network and essential connectivity axes for perceptual integration in the human brain.
C1 [Sepulcre, Jorge; Johnson, Keith A.] Harvard Univ, Sch Med, Dept Radiol, Div Nucl Med & Mol Imaging, Boston, MA 02114 USA.
[Johnson, Keith A.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
[Sepulcre, Jorge; Sabuncu, Mert R.; Yeo, Thomas B.; Liu, Hesheng] Athinioula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA.
[Sabuncu, Mert R.] MIT, Comp Sci & Artificial Intelligence Lab, Cambridge, MA 02139 USA.
[Yeo, Thomas B.] Duke Natl Univ Singapore, Grad Sch Med, Dept Neurosci & Behav Disorders, Singapore 169857, Singapore.
[Johnson, Keith A.] Brigham & Womens Hosp, Ctr Alzheimer Res & Treatment, Dept Neurol, Cambridge, MA 02139 USA.
[Johnson, Keith A.] Harvard Univ, Sch Med, Cambridge, MA 02139 USA.
RP Sepulcre, J (reprint author), Harvard Univ, 52 Oxford St,NW Bldg 280-02, Cambridge, MA 02138 USA.
EM sepulcre@nmr.mgh.harvard.edu
OI Liu, Hesheng/0000-0002-7233-1509; Yeo, B.T. Thomas/0000-0002-0119-3276
FU Alzheimer's Association Grants [NIRG-11-205690, ZEN-10-174210]; NIH
Grants [K25NS069805, K25EB013649-01, R01AG037497, R01AG036694]
FX This work was supported by the Alzheimer's Association Grants
NIRG-11-205690 (J.S.) and ZEN-10-174210 (K.A.J.) and NIH Grants
K25NS069805 (H. L.), K25EB013649-01 (M.R.S.), and R01AG037497 and
R01AG036694 (K.A.J.). We thank Randy L. Buckner for generously providing
the data and also for his valuable comments on this study. We thank Tom
Brady for his valuable comments on this study. We also recognize the
influence of Prof. Jon Driver's legacy in the study.
NR 73
TC 53
Z9 54
U1 0
U2 14
PU SOC NEUROSCIENCE
PI WASHINGTON
PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA
SN 0270-6474
J9 J NEUROSCI
JI J. Neurosci.
PD AUG 1
PY 2012
VL 32
IS 31
BP 10649
EP 10661
DI 10.1523/JNEUROSCI.0759-12.2012
PG 13
WC Neurosciences
SC Neurosciences & Neurology
GA 983NL
UT WOS:000307125900022
PM 22855814
ER
PT J
AU Liu, B
Yu, ZT
Chen, C
Kling, DE
Newburg, DS
AF Liu, Bo
Yu, Zhuoteng
Chen, Ceng
Kling, David E.
Newburg, David S.
TI Human Milk Mucin 1 and Mucin 4 Inhibit Salmonella enterica Serovar
Typhimurium Invasion of Human Intestinal Epithelial Cells In Vitro
SO JOURNAL OF NUTRITION
LA English
DT Article
ID ESCHERICHIA-COLI; CACO-2 CELLS; HOST-CELLS; ADHERENCE; INFANTS; SURFACE;
OLIGOSACCHARIDES; COMPONENTS; INFECTION; BINDING
AB Many human milk glycans inhibit pathogen binding to host receptors and their consumption by infants is associated with reduced risk of disease. Salmonella infection is more frequent among infants than among the general population, but the incidence is lower in breast-fed babies, suggesting that human milk could contain components that inhibit Salmonella. This study aimed to test whether human milk per se inhibits Salmonella invasion of human intestinal epithelial cells in vitro and, if so, to identify the milk components responsible for inhibition. Salmonella enterica serovar Typhimurium SL1344 (SL1344) invasion of FHs 74 Int and Caco-2 cells were the models of human intestinal epithelium infection. Internalization of fluorescein-5-isothiocyanate labeled SL1344 into intestinal cells was measured by flow cytometry to quantify infection. Human milk and its fractions inhibited infection; the inhibitory activity localized to the high molecular weight glycans. Mucin 1 and mucin 4 were isolated to homogeneity. At 150 mu g/L, a typical concentration in milk, human milk mucin 1 and mucin 4 inhibited SL1344 invasion of both target cell types. These mucins inhibited SL1344 invasion of epithelial cells in a dose-dependent manner. Thus, mucins may prove useful as a basis for developing novel oral prophylactic and therapeutic agents that inhibit infant diseases caused by Salmonella and related pathogens. J. Nutr. 142: 1504-1509, 2012.
C1 [Liu, Bo; Yu, Zhuoteng; Chen, Ceng; Newburg, David S.] Harvard Univ, Sch Med, Dept Pediat Gastroenterol & Nutr, Boston, MA 02115 USA.
[Liu, Bo; Yu, Zhuoteng; Chen, Ceng; Newburg, David S.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Liu, Bo; Yu, Zhuoteng; Chen, Ceng; Kling, David E.; Newburg, David S.] Boston Coll, Program Glycobiol, Dept Biol, Chestnut Hill, MA 02167 USA.
RP Newburg, DS (reprint author), Harvard Univ, Sch Med, Dept Pediat Gastroenterol & Nutr, Boston, MA 02115 USA.
EM david.newburg@bc.edu
FU NIH [HD013021, AI075563]; Abbott Nutrition
FX Supported by NIH grants HD013021 and AI075563 and by Abbott Nutrition.
NR 35
TC 10
Z9 12
U1 1
U2 11
PU AMER SOC NUTRITION-ASN
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-3166
J9 J NUTR
JI J. Nutr.
PD AUG
PY 2012
VL 142
IS 8
BP 1504
EP 1509
DI 10.3945/jn.111.155614
PG 6
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 980AE
UT WOS:000306865200013
PM 22718031
ER
PT J
AU van Leeuwen, DH
Guitton, TG
Lambers, K
Ring, D
AF van Leeuwen, Diederik H.
Guitton, Thierry G.
Lambers, Kaj
Ring, David
TI Quantitative measurement of radial head fracture location
SO JOURNAL OF SHOULDER AND ELBOW SURGERY
LA English
DT Article
DE Computed tomography; fractures; location; quantitative; radial head
ID DISTAL BICEPS TENDON; BONE
AB Background: The most common location of a displaced fracture of part of the radial head is often described as the anterior lateral aspect of the radial head with the forearm in neutral position, based on observation rather than precise measurements. The purpose of our study was to measure the exact location of fractures involving part of the radial head using quantitative 3-dimensional computed tomography (CT).
Materials and methods: We measured the fracture lines with respect to the biceps tuberosity in 24 patients with a displaced articular fracture of part of the radial head (Mason type 2). Two observers preformed each measurement twice. Reliability was measured using the concordance correlation coefficient according to Lin.
Results: The average start of the fracture was 97 degrees (standard deviation [SD]) 48.3 degrees; range 31 degrees-254 degrees) clockwise from the biceps tuberosity, the average end of the fracture was 241.6 degrees (SD, 61.0; range 19 degrees-330 degrees), and the average fracture subtends was 170 degrees (SD, 32.8 degrees; range 99 degrees-252 degrees). The fracture was through the anterolateral quadrant of the radial head in 22 of the 24 patients and through the posteromedial quadrant in 2 patients.
Conclusion: This quantitative analysis of CT scans of displaced articular fractures of part of the radial head (Mason type 2) confirms that the most common location is the anterolateral quadrant with the forearm in neutral rotation. Given the important role of the radial head in elbow stability, more accurate characterization of incomplete radial head fractures may improve our understanding of treatment and outcome of these fractures.
Level of evidence: Basic Science Study, Anatomic Study, Imaging. (C) 2012 Journal of Shoulder and Elbow Surgery Board of Trustees.
C1 [van Leeuwen, Diederik H.; Guitton, Thierry G.; Lambers, Kaj; Ring, David] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Orthopaed Hand & Upper Extrem Serv,Yawkey Ctr, Boston, MA 02114 USA.
RP Ring, D (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Orthopaed Hand & Upper Extrem Serv,Yawkey Ctr, Ste 2100,55 Fruit St, Boston, MA 02114 USA.
EM dring@partners.org
OI Guitton, Thierry/0000-0002-2599-1985
NR 13
TC 17
Z9 17
U1 0
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1058-2746
J9 J SHOULDER ELB SURG
JI J. Shoulder Elbow Surg.
PD AUG
PY 2012
VL 21
IS 8
BP 1013
EP 1017
DI 10.1016/j.jse.2011.08.056
PG 5
WC Orthopedics; Sport Sciences; Surgery
SC Orthopedics; Sport Sciences; Surgery
GA 992UP
UT WOS:000307805600009
PM 22071412
ER
PT J
AU Hodin, R
Angelos, P
Carty, S
Chen, H
Clark, O
Doherty, G
Duh, QY
Evans, DB
Heller, K
Inabnet, W
Kebebew, E
Pasieka, J
Perrier, N
Sturgeon, C
AF Hodin, Richard
Angelos, Peter
Carty, Sally
Chen, Herb
Clark, Orlo
Doherty, Gerard
Duh, Quan-Yang
Evans, Douglas B.
Heller, Keith
Inabnet, William
Kebebew, Electron
Pasieka, Janice
Perrier, Nancy
Sturgeon, Cord
TI No Need to Abandon Unilateral Parathyroid Surgery
SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
LA English
DT Letter
C1 [Hodin, Richard] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Angelos, Peter] Univ Chicago, Chicago, IL 60637 USA.
[Carty, Sally] Univ Pittsburgh, Pittsburgh, PA 15260 USA.
[Chen, Herb] Univ Wisconsin, Madison, WI 53706 USA.
[Clark, Orlo; Duh, Quan-Yang] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Doherty, Gerard] Boston Univ, Boston, MA 02215 USA.
[Evans, Douglas B.] Med Coll Wisconsin, Milwaukee, WI USA.
[Heller, Keith] NYU, Langone Med Ctr, New York, NY 10003 USA.
[Inabnet, William] Mt Sinai Sch Med, New York, NY USA.
[Kebebew, Electron] NCI, NIH, Bethesda, MD 20892 USA.
[Pasieka, Janice] Univ Calgary, Calgary, AB T2N 1N4, Canada.
[Sturgeon, Cord] Northwestern Univ, Evanston, IL 60208 USA.
[Perrier, Nancy] Univ Texas MD Anderson Canc Ctr, Houston, TX USA.
RP Hodin, R (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA.
OI Doherty, Gerard/0000-0002-1685-9552; Heller, Keith/0000-0003-2836-3359
NR 2
TC 12
Z9 12
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1072-7515
J9 J AM COLL SURGEONS
JI J. Am. Coll. Surg.
PD AUG
PY 2012
VL 215
IS 2
BP 297
EP 297
DI 10.1016/j.jamcollsurg.2012.04.024
PG 1
WC Surgery
SC Surgery
GA 988PL
UT WOS:000307502900020
PM 22818100
ER
PT J
AU von Mehren, M
Benjamin, RS
Bui, MM
Casper, ES
Conrad, EU
DeLaney, TF
Ganjoo, KN
George, S
Gonzalez, R
Heslin, MJ
Kane, JM
Mayerson, J
McGarry, SV
Meyer, C
O'Donnell, RJ
Paz, IB
Pfeifer, JD
Pollock, RE
Randall, RL
Riedel, RF
Schuetze, S
Schupak, KD
Schwartz, HS
Shankar, S
Van Tine, BA
Wayne, J
Sundar, H
McMillian, NR
AF von Mehren, Margaret
Benjamin, Robert S.
Bui, Marilyn M.
Casper, Ephraim S.
Conrad, Ernest U., III
DeLaney, Thomas F.
Ganjoo, Kristen N.
George, Suzanne
Gonzalez, Ricardo
Heslin, Martin J.
Kane, John M., III
Mayerson, Joel
McGarry, Sean V.
Meyer, Christian
O'Donnell, Richard J.
Paz, I. Benjamin
Pfeifer, John D.
Pollock, Raphael E.
Randall, R. Lor
Riedel, Richard F.
Schuetze, Scott
Schupak, Karen D.
Schwartz, Herbert S.
Shankar, Sridhar
Van Tine, Brian A.
Wayne, Jeffrey
Sundar, Hema
McMillian, Nicole R.
TI Soft Tissue Sarcoma, Version 2.2012 Featured Updates to the NCCN
Guidelines
SO JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
LA English
DT Article
ID GASTROINTESTINAL STROMAL TUMORS; OF-FUNCTION MUTATIONS; PHASE-II TRIAL;
IMATINIB MESYLATE; PROGNOSTIC-FACTORS; ADJUVANT IMATINIB; DESMOID TUMOR;
GIST; KIT; FIBROMATOSIS
AB The major changes to the 2012 and 2011 NCCN Guidelines for Soft Tissue Sarcoma pertain to the management of patients with gastrointestinal stromal tumors (GISTs) and desmoid tumors (aggressive fibromatosis). Postoperative imatinib following complete resection for primary GIST with no preoperative imatinib is now included as a category 1 recommendation for patients with intermediate or high risk of recurrence. The panel also reaffirmed the recommendation for preoperative use of imatinib in patients with GISTs that are resectable with negative margins but associated with significant surgical morbidity. Observation was included as an option for patients with resectable desmoid tumors that are small and asymptomatic, not causing morbidity, pain, or functional limitation. Sorafenib is included as an option for systemic therapy for patients with desmoid tumors. (JNCCN 2012;10:951-960)
C1 [von Mehren, Margaret] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
[Benjamin, Robert S.; Pollock, Raphael E.] Univ Texas MD Anderson Canc Ctr, Houston, TX USA.
[Bui, Marilyn M.; Gonzalez, Ricardo] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA.
[Casper, Ephraim S.; Schupak, Karen D.] Mem Sloan Kettering Canc Ctr, New York, NY USA.
[Conrad, Ernest U., III] Seattle Canc Care Alliance, Fred Hutchinson Canc Res Ctr, Seattle, WA USA.
[DeLaney, Thomas F.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
[Ganjoo, Kristen N.] Stanford Canc Inst, Stanford, CA USA.
[Heslin, Martin J.] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL USA.
[Kane, John M., III] Roswell Pk Canc Inst, Buffalo, NY USA.
[Mayerson, Joel] Ohio State Univ, Ctr Comprehens Canc, James Canc Hosp, Columbus, OH 43210 USA.
[McGarry, Sean V.] Nebraska Med Ctr, UNMC Eppley Canc Ctr, Omaha, NE USA.
[Meyer, Christian] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
[O'Donnell, Richard J.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA.
[Paz, I. Benjamin] City Hope Comprehens Canc Ctr, Duarte, CA USA.
[Pfeifer, John D.; Van Tine, Brian A.] Barnes Jewish Hosp, Siteman Canc Ctr, St Louis, MO USA.
[Pfeifer, John D.; Van Tine, Brian A.] Washington Univ, Sch Med, St Louis, MO 63130 USA.
[Randall, R. Lor] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA.
[Schuetze, Scott] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA.
[Schwartz, Herbert S.] Vanderbilt Ingram Canc Ctr, Nashville, TN USA.
[Shankar, Sridhar] Univ Tennessee, Inst Canc, St Jude Childrens Res Hosp, Knoxville, TN 37996 USA.
[Wayne, Jeffrey] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Evanston, IL 60208 USA.
RP von Mehren, M (reprint author), Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
RI Mayerson, Joel/E-3616-2011
NR 30
TC 61
Z9 65
U1 0
U2 1
PU HARBORSIDE PRESS
PI COLD SPRING HARBOR
PA 37 MAIN ST, COLD SPRING HARBOR, NY 11724 USA
SN 1540-1405
J9 J NATL COMPR CANC NE
JI J. Natl. Compr. Cancer Netw.
PD AUG
PY 2012
VL 10
IS 8
BP 951
EP 960
PG 10
WC Oncology
SC Oncology
GA 988MB
UT WOS:000307494000006
PM 22878820
ER
PT J
AU O'Donnell, MR
Abboud, CN
Altman, J
Appelbaum, FR
Arber, DA
Attar, E
Borate, U
Coutre, SE
Damon, LE
Goorha, S
Lancet, J
Maness, LJ
Marcucci, G
Millenson, MM
Moore, JO
Ravandi, F
Shami, PJ
Smith, BD
Stone, RM
Strickland, SA
Tallman, MS
Wang, ES
Naganuma, M
Gregory, KM
AF O'Donnell, Margaret R.
Abboud, Camille N.
Altman, Jessica
Appelbaum, Frederick R.
Arber, Daniel A.
Attar, Eyal
Borate, Uma
Coutre, Steven E.
Damon, Lloyd E.
Goorha, Salil
Lancet, Jeffrey
Maness, Lori J.
Marcucci, Guido
Millenson, Michael M.
Moore, Joseph O.
Ravandi, Farhad
Shami, Paul J.
Smith, B. Douglas
Stone, Richard M.
Strickland, Stephen A.
Tallman, Martin S.
Wang, Eunice S.
Naganuma, Maoko
Gregory, Kristina M.
TI Acute Myeloid Leukemia Clinical Practice Guidelines in Oncology
SO JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
LA English
DT Review
ID ACUTE MYELOGENOUS LEUKEMIA; INTERNAL TANDEM DUPLICATION; STEM-CELL
TRANSPLANTATION; HIGH-DOSE CYTARABINE; CORE-BINDING-FACTOR; RISK
MYELODYSPLASTIC SYNDROME; 1ST COMPLETE REMISSION; FAVORABLE
PROGNOSTIC-SIGNIFICANCE; ACUTE PROMYELOCYTIC LEUKEMIA; CONVENTIONAL CARE
REGIMENS
AB Acute myeloid leukemia (AML) remains the most common form of acute leukemia among adults and accounts for the largest number of annual deaths due to leukemias in the United States. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for AML provide recommendations on the diagnostic evaluation and workup for AML, risk assessment based on cytogenetic and molecular features, treatment options for induction and consolidation therapies for younger and older (age 65 years) adult patients, and key supportive care considerations. (JNCCN 2012;10:984-1021)
C1 [O'Donnell, Margaret R.] City Hope Comprehens Canc Ctr, Duarte, CA USA.
[Abboud, Camille N.] Barnes Jewish Hosp, Siteman Canc Ctr, St Louis, MO USA.
[Abboud, Camille N.] Washington Univ, Sch Med, St Louis, MO 63130 USA.
[Altman, Jessica] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Evanston, IL 60208 USA.
[Appelbaum, Frederick R.] Seattle Canc Care Alliance, Fred Hutchinson Canc Res Ctr, Seattle, WA USA.
[Arber, Daniel A.; Coutre, Steven E.] Stanford Canc Inst, Stanford, CA USA.
[Attar, Eyal] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
[Borate, Uma] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL USA.
[Damon, Lloyd E.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA.
[Goorha, Salil] Univ Tennessee, Inst Canc, St Jude Childrens Res Hosp, Knoxville, TN 37996 USA.
[Lancet, Jeffrey] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA.
[Maness, Lori J.] Nebraska Med Ctr, UNMC Eppley Canc Ctr, Omaha, NE USA.
[Marcucci, Guido] Ohio State Univ, Ctr Comprehens Canc, James Canc Hosp, Columbus, OH 43210 USA.
[Millenson, Michael M.] Fox Chase Canc Ctr, Philadelphia, PA USA.
[Moore, Joseph O.] Duke Canc Inst, Durham, NC USA.
[Ravandi, Farhad] Univ Texas MD Anderson Canc Ctr, Houston, TX USA.
[Shami, Paul J.] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA.
[Smith, B. Douglas] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
[Stone, Richard M.] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA.
[Strickland, Stephen A.] Vanderbilt Ingram Canc Ctr, Nashville, TN USA.
[Tallman, Martin S.] Mem Sloan Kettering Canc Ctr, New York, NY USA.
[Wang, Eunice S.] Roswell Pk Canc Inst, Buffalo, NY USA.
RP O'Donnell, MR (reprint author), City Hope Comprehens Canc Ctr, Duarte, CA USA.
FU NCI NIH HHS [P30 CA016672]
NR 113
TC 98
Z9 111
U1 1
U2 16
PU HARBORSIDE PRESS
PI COLD SPRING HARBOR
PA 37 MAIN ST, COLD SPRING HARBOR, NY 11724 USA
SN 1540-1405
J9 J NATL COMPR CANC NE
JI J. Natl. Compr. Cancer Netw.
PD AUG
PY 2012
VL 10
IS 8
BP 984
EP 1021
PG 38
WC Oncology
SC Oncology
GA 988MB
UT WOS:000307494000010
PM 22878824
ER
PT J
AU Brill, A
AF Brill, A.
TI Stroke-associated inflammation: is von Willebrand factor a 'bad guy'?
SO JOURNAL OF THROMBOSIS AND HAEMOSTASIS
LA English
DT Article
ID MIDDLE CEREBRAL-ARTERY; NITRIC-OXIDE SYNTHASE; ISCHEMIC-STROKE; FOCAL
ISCHEMIA; REPERFUSION INJURY; BRAIN-DAMAGE; NEUTROPHILS; MICE;
ACCUMULATION; PATHOGENESIS
C1 [Brill, A.] Childrens Hosp Boston, Program Cellular & Mol Med, Immune Dis Inst, Boston, MA 02115 USA.
[Brill, A.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA.
RP Brill, A (reprint author), Childrens Hosp Boston, Program Cellular & Mol Med, Immune Dis Inst, 3 Blackfan Circle,3rd Floor, Boston, MA 02115 USA.
EM brill@idi.harvard.edu
NR 33
TC 1
Z9 2
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1538-7933
J9 J THROMB HAEMOST
JI J. Thromb. Haemost.
PD AUG
PY 2012
VL 10
IS 8
BP 1662
EP 1664
DI 10.1111/j.1538-7836.2012.04820.x
PG 3
WC Hematology; Peripheral Vascular Disease
SC Hematology; Cardiovascular System & Cardiology
GA 989HW
UT WOS:000307551900026
PM 22712638
ER
PT J
AU Ishaque, B
Zayed, MA
Miller, J
Nguyen, D
Kaji, AH
Lee, JT
O'Connell, J
de Virgilio, C
AF Ishaque, Brandon
Zayed, Mohamed A.
Miller, Jessica
Nguyen, David
Kaji, Amy H.
Lee, Jason T.
O'Connell, Jessica
de Virgilio, Christian
TI Ethnic differences in arm vein diameter and arteriovenous fistula
creation rates in men undergoing hemodialysis access
SO JOURNAL OF VASCULAR SURGERY
LA English
DT Article; Proceedings Paper
CT 26th Annual Meeting of the Western-Vascular-Surgical-Society
CY SEP 17-20, 2011
CL Lihue, HI
SP Western Vasc Surg Soc
ID PREOPERATIVE NONINVASIVE EVALUATION; 1ST-TIME DIALYSIS ACCESS; VASCULAR
ACCESS; AUTOLOGOUS FISTULAS; NATURAL-HISTORY; INCREASING USE; KDOQI ERA;
MATURATION; FAILURE; IMPACT
AB Objective: The National Kidney Foundation recommends that arteriovenous fistulas (AVFs) be placed in at least 65% of hemodialysis patients. Some studies suggest that African American patients are less likely to receive a first-time AVF than patients of other ethnicities, although the reason for this disparity is unclear. The purpose of our study is to determine (1) whether there are ethnic differences in AVF creation, (2) whether this may be related to differences in vein diameters, and (3) whether AVF patency rates are similar between African American and non-African American male patients.
Methods: Consecutive male patients undergoing first-time hemodialysis access from 2006 to 2010 at two institutions were retrospectively reviewed. Data collected included age, ethnicity, weight, height, body mass index, diabetes, hypertension, congestive heart failure, smoking history, intravenous drug abuse, need for temporary access placement, and preoperative venous ultrasound measurements. Categoric variables were compared using chi(2) analysis, and the Wilcoxon rank-sum test was used to compare continuous variables.
Results: Of 249 male patients identified, 95 were African American. Median age in African American and non-African American patients was 63 years. Hypertension and hyperlipidemia were statistically significantly greater in African American patients. The need for temporary access before hemoaccess was similar between the cohorts. African American patients demonstrated significantly smaller median basilic and cephalic vein diameters at most measured sites. Overall, 221 of 249 (88.8%) underwent AVF first. An AV graft was created in 17.9% of African American patients vs in only 7.1% of non-African Americans (odds ratio, 2.8; 95% confidence interval, 1.3-6.4; P = .009). The difference between median vein diameters used for autologous fistula creation in African American and non-African American patients was not significant. There was no significant difference in the primary patency (80.8% vs 76.2%; P = .4), primary functional patency (73.1% vs 69.2%; P = .5), or secondary functional patency rates (91.0% vs 96.5%; P = .1). Average primary fistula survival time was 257 days in African American and 256 in non-African American patients (P = .2).
Conclusions: African American patients are less likely than non-African American patients to undergo AVF during first-time hemodialysis access surgery. This ethnic discrepancy appears to be due to smaller arm vein diameters in African American patients. In African American patients with appropriate vein diameters who do undergo AVF, primary and functional patencies are equivalent to non-African American patients. (J Vasc Surg 2012;56:424-32.)
C1 [de Virgilio, Christian] Harbor UCLA Med Ctr, Dept Surg, Los Angeles Biomed Res Inst, Torrance, CA 90509 USA.
[Ishaque, Brandon; Miller, Jessica; Nguyen, David; O'Connell, Jessica; de Virgilio, Christian] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Zayed, Mohamed A.; Lee, Jason T.] Stanford Univ, Med Ctr, Dept Vasc Surg, Stanford, CA 94305 USA.
[Kaji, Amy H.] Harbor UCLA Med Ctr, Dept Emergency Med, Torrance, CA 90509 USA.
[O'Connell, Jessica; de Virgilio, Christian] W Los Angeles Vet Affairs Hosp, Div Vasc Surg, Los Angeles, CA USA.
RP de Virgilio, C (reprint author), Harbor UCLA Med Ctr, Dept Surg, Los Angeles Biomed Res Inst, 1000 W Carson St, Torrance, CA 90509 USA.
EM cdevirgilio@labiomed.org
NR 27
TC 8
Z9 8
U1 0
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0741-5214
J9 J VASC SURG
JI J. Vasc. Surg.
PD AUG
PY 2012
VL 56
IS 2
BP 424
EP 432
DI 10.1016/j.jvs.2012.01.029
PG 9
WC Surgery; Peripheral Vascular Disease
SC Surgery; Cardiovascular System & Cardiology
GA 984AS
UT WOS:000307160400020
PM 22551911
ER
PT J
AU Lepantalo, MJA
Houbballah, R
Raux, M
LaMuraglia, G
AF Lepantalo, Mauri J. A.
Houbballah, Rabih
Raux, Maxime
LaMuraglia, Glenn
TI Lower extremity bypass vs endovascular therapy for young patients with
symptomatic peripheral arterial disease
SO JOURNAL OF VASCULAR SURGERY
LA English
DT Article
ID CRITICAL LIMB ISCHEMIA; SUPERFICIAL FEMORAL-ARTERY; RANDOMIZED
CONTROLLED-TRIAL; LEG BASIL TRIAL; PERCUTANEOUS TRANSLUMINAL
ANGIOPLASTY; FEMOROPOPLITEAL OCCLUSIVE DISEASE; ISOLATED TIBIAL
INTERVENTION; INTER-SOCIETY CONSENSUS; INFRAINGUINAL BYPASS;
VASCULAR-SURGERY
AB The uncertainty continues over the best approach to patients with symptomatic peripheral arterial disease. Medical therapy and risk factor modification is part of any treatment regimen; with this there is little disagreement. However, with the introduction of lesser invasive percutaneous technologies, the discussion regarding surgical and endovascular therapies has become more and more complicated. Unfortunately, there is a relative shortage of robust outcomes data to support many of our specific treatment recommendations. Younger patients are an especially troublesome patient cohort. They have consistently shown poorer outcomes after any intervention compared with older patients and may represent a subset of more aggressive atherosclerotic disease. Our debaters will discuss their preferred approaches to these difficult patients in the context of the currently available supporting literature. (J Vasc Surg 2012;56:545-55.)
C1 [Lepantalo, Mauri J. A.] Univ Helsinki, Cent Hosp, Dept Vasc Surg, Helsinki, Finland.
[Houbballah, Rabih; Raux, Maxime; LaMuraglia, Glenn] Massachusetts Gen Hosp, Gen Surg Serv, Div Vasc & Endovasc Surg, Boston, MA 02114 USA.
[Houbballah, Rabih; Raux, Maxime; LaMuraglia, Glenn] Harvard Univ, Sch Med, Boston, MA USA.
RP Lepantalo, MJA (reprint author), Univ Helsinki, Cent Hosp, Dept Vasc Surg, POB 40, Helsinki 00029, Finland.
EM mauri.lepantalo@hus.fi; glamuraglia@partners.org
FU Monte and Rita Goldman Fund; John F. Murphy and the Bay State Federal
Savings Foundation
FX Dr LaMuraglia was supported, in part, by grants from the Monte and Rita
Goldman Fund and John F. Murphy and the Bay State Federal Savings
Foundation.
NR 82
TC 3
Z9 3
U1 1
U2 5
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0741-5214
J9 J VASC SURG
JI J. Vasc. Surg.
PD AUG
PY 2012
VL 56
IS 2
BP 545
EP 555
DI 10.1016/j.jvs.2012.06.053
PG 12
WC Surgery; Peripheral Vascular Disease
SC Surgery; Cardiovascular System & Cardiology
GA 984AS
UT WOS:000307160400043
PM 22840905
ER
PT J
AU Lin, HW
Bhattacharyya, N
AF Lin, Harrison W.
Bhattacharyya, Neil
TI Balance disorders in the elderly: Epidemiology and functional impact
SO LARYNGOSCOPE
LA English
DT Article
DE Elderly; geriatric; balance disorder; dizziness; vertigo
ID PRIMARY-CARE; DIZZINESS; POPULATION; PREVALENCE; COMMUNITY
AB Objectives/Hypothesis: To quantify the prevalence and determine the impact of dizziness and balance disorders in the elderly. Study Design: Cross-sectional analysis of a national database. Methods: The balance problems survey module of the 2008 National Health Interview Survey was examined, and cases of reported dizziness or balance problems in persons =65 years old were identified. The prevalence of balance disorders and associated symptoms and their impacts on self-reported functional limitations were determined. The related impact on daily activities for elderly persons with balance problems was quantified. Sex-based differences in balance problems were determined. Results: Among 37.3 +/- 0.9 million elderly persons (mean age, 74.4 +/- 0.1 years; 56.9% +/- 0.9% female), 7.0 +/- 0.2 million persons (19.6% +/- 0.7%) reported a problem with dizziness or balance in the preceding 12 months. Balance problems included difficulty with unsteadiness (68.0%), walking on uneven surfaces (54.8%), vertigo (30.1%), and faintness (29.6%). Prescription medication triggered the balance problem in 18.7%. Among the 50.0% of elderly persons with balance problems who sought care, 85.6%, 30.3%, 23.9%, and 16.8% saw a general practitioner, internist, neurologist, or otolaryngologist, respectively. Of this group, 27.4% reported that balance problems specifically prevented them from participating in activities including exercise (61.2%), social events (45.8%), and driving (47.1%). Females were more likely to experience balance problems than males (21.0% vs. 17.7%, P = .025). Conclusions: Approximately one in five elderly persons experiences annual problems with dizziness or balance. Given the significant prevalence and negative effect of balance problems on daily activities in the elderly, balance disorders merit special attention, particularly in the face of an aging population.
C1 [Bhattacharyya, Neil] Brigham & Womens Hosp, Div Otolaryngol Head & Neck Surg, Boston, MA 02115 USA.
[Lin, Harrison W.] Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Boston, MA 02114 USA.
[Lin, Harrison W.; Bhattacharyya, Neil] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA.
RP Bhattacharyya, N (reprint author), Brigham & Womens Hosp, Div Otolaryngol Head & Neck Surg, 45 Francis St, Boston, MA 02115 USA.
EM neiloy@massmed.org
NR 12
TC 30
Z9 35
U1 0
U2 13
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0023-852X
J9 LARYNGOSCOPE
JI Laryngoscope
PD AUG
PY 2012
VL 122
IS 8
BP 1858
EP 1861
DI 10.1002/lary.23376
PG 4
WC Medicine, Research & Experimental; Otorhinolaryngology
SC Research & Experimental Medicine; Otorhinolaryngology
GA 980LK
UT WOS:000306894500035
PM 22645067
ER
PT J
AU Mar, BG
Bullinger, L
Basu, E
Schlis, K
Silverman, LB
Dohner, K
Armstrong, SA
AF Mar, B. G.
Bullinger, L.
Basu, E.
Schlis, K.
Silverman, L. B.
Doehner, K.
Armstrong, S. A.
TI Sequencing histone-modifying enzymes identifies UTX mutations in acute
lymphoblastic leukemia
SO LEUKEMIA
LA English
DT Letter
ID ACUTE MYELOID-LEUKEMIA; SOMATIC MUTATIONS; CANCER; INACTIVATION;
INSIGHTS; EZH2
C1 [Mar, B. G.; Schlis, K.; Silverman, L. B.; Armstrong, S. A.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA.
[Mar, B. G.; Schlis, K.; Silverman, L. B.; Armstrong, S. A.] Childrens Hosp Boston, Dept Hematol Oncol, Boston, MA USA.
[Bullinger, L.; Doehner, K.] Univ Ulm, Dept Internal Med 3, D-7900 Ulm, Germany.
[Basu, E.] Mem Sloan Kettering, Dept Pediat, New York, NY USA.
RP Mar, BG (reprint author), Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA.
EM Scott.Armstrong@childrens.harvard.edu
OI Mar, Brenton/0000-0002-3857-9324
FU NCI NIH HHS [P01 CA068484, P01CA684841]
NR 15
TC 30
Z9 33
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0887-6924
J9 LEUKEMIA
JI Leukemia
PD AUG
PY 2012
VL 26
IS 8
BP 1881
EP 1883
DI 10.1038/leu.2012.56
PG 4
WC Oncology; Hematology
SC Oncology; Hematology
GA 990RW
UT WOS:000307650000017
PM 22377896
ER
PT J
AU Ali, M
Ananthakrishnan, AN
Ahmad, S
Kumar, N
Kumar, G
Saeian, K
AF Ali, Muhammad
Ananthakrishnan, Ashwin N.
Ahmad, Shahryar
Kumar, Nilay
Kumar, Gagan
Saeian, Kia
TI Clostridium difficile infection in hospitalized liver transplant
patients: A nationwide analysis
SO LIVER TRANSPLANTATION
LA English
DT Article
ID INFLAMMATORY-BOWEL-DISEASE; DIARRHEA; OUTCOMES; COLITIS; MULTICENTER;
INPATIENT; DIAGNOSIS; CIRRHOSIS; SURGERY; IMPACT
AB The incidence of Clostridium difficile infection (CDI) is increasing among hospitalized patients. Liver transplantation (LT) patients are at higher risk for acquiring CDI. Small, single-center studies (but no nationwide analyses) have assessed this association. We used the Nationwide Inpatient Sample of the Healthcare Cost and Utilization Project (2004-2008) for this retrospective, cross-sectional study. Patients with any discharge diagnosis of LT composed the study population, and they were identified with International Classification of Diseases, Ninth Revision, Clinical Modification codes. Those with a discharge diagnosis of CDI were considered cases. Our primary outcomes were the prevalence of CDI and the effects of CDI on inpatient mortality. Our secondary outcomes included the length of stay and hospitalization charges. A regression analysis was used to derive odds ratios (ORs) adjusted for potential confounders. There were 193,174 discharges with a diagnosis of LT from 2004 to 2008. The prevalence of CDI was 2.7% in the LT population and 0.9% in the non-LT population (P < 0.001). Most of the LT patients were 50 to 64 years old. LT patients had higher odds of developing CDI [OR = 2.88, 95% confidence interval (CI) = 2.68-3.10]. Increasing age and increasing comorbidity (including inflammatory bowel disease and nasogastric tube placement) were also independent CDI risk factors. CDI was associated with a higher mortality rate: 5.5% for LT patients with CDI versus 3.2% for LT-only patients (adjusted OR = 1.70, 95% CI = 1.29-2.25). In conclusion, the prevalence of CDI is higher for LT patients versus non-LT patients (2.7% versus 0.9%). CDI is an independent risk factor for mortality in the LT population. Liver Transpl, 2012. (c) 2012 AASLD.
C1 [Ali, Muhammad; Ahmad, Shahryar; Kumar, Gagan] Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA.
[Kumar, Nilay; Saeian, Kia] Med Coll Wisconsin, Dept Gastroenterol & Hepatol, Milwaukee, WI 53226 USA.
[Ananthakrishnan, Ashwin N.] Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA.
RP Ali, M (reprint author), Med Coll Wisconsin, Dept Med, 9200 W Wisconsin Ave, Milwaukee, WI 53226 USA.
EM muali@mcw.edu
FU Clinical and Translational Science Institute of Southeast Wisconsin
(National Institutes of Health) [UL1RR031973]
FX This study was supported in part by the Clinical and Translational
Science Institute of Southeast Wisconsin (National Institutes of Health
grant UL1RR031973).
NR 34
TC 27
Z9 27
U1 2
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1527-6465
J9 LIVER TRANSPLANT
JI Liver Transplant.
PD AUG
PY 2012
VL 18
IS 8
BP 972
EP 978
DI 10.1002/lt.23449
PG 7
WC Gastroenterology & Hepatology; Surgery; Transplantation
SC Gastroenterology & Hepatology; Surgery; Transplantation
GA 979XU
UT WOS:000306858200014
PM 22505356
ER
PT J
AU Ensrud, KE
Joffe, H
Guthrie, KA
Larson, JC
Reed, SD
Newton, KM
Sternfeld, B
LaCroix, AZ
Landis, CA
Woods, NF
Freeman, EW
AF Ensrud, Kristine E.
Joffe, Hadine
Guthrie, Katherine A.
Larson, Joseph C.
Reed, Susan D.
Newton, Katherine M.
Sternfeld, Barbara
LaCroix, Andrea Z.
Landis, Carol A.
Woods, Nancy F.
Freeman, Ellen W.
TI Effect of escitalopram on insomnia symptoms and subjective sleep quality
in healthy perimenopausal and postmenopausal women with hot flashes: a
randomized controlled trial
SO MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY
LA English
DT Article
DE Randomized trial; Escitalopram; Sleep; Hot flashes; Menopause
ID MENOPAUSAL TRANSITION; HORMONE-THERAPY; CLINICAL-TRIAL; ANTIDEPRESSANTS;
INDEX; DISTURBANCE; POPULATION; MEDICATION; DEPRESSION; CITALOPRAM
AB Objective: The aim of this study was to determine the effect of escitalopram on insomnia symptoms and subjective sleep quality in healthy perimenopausal and postmenopausal women with hot flashes.
Methods: A randomized, blinded, multicenter, placebo-controlled parallel-group 8-week trial with 205 women (95 African American, 102 white, 8 other) was conducted between July 2009 and June 2010. The participants received escitalopram (10-20 mg/d) or placebo. Insomnia symptoms (Insomnia Severity Index [ISI]) and subjective sleep quality (Pittsburgh Sleep Quality Index [PSQI]) at weeks 4 and 8 were the prespecified secondary outcomes. A total of 199 women (97%) provided ISI data, and 194 (95%) women provided PSQI data at follow-up.
Results: At baseline, mean hot flash frequency was 9.78 per day (SD, 5.60), mean ISI was 11.4 (SD, 6.3), and mean PSQI was 8.0 (SD, 3.7). Treatment with escitalopram reduced ISI at week 8 (mean difference, -2.00; 95% CI, -3.43 to -0.57; P < 0.001 overall treatment effect), with mean differences of -4.73 (95% CI, -5.72 to -3.75) in the escitalopram group and -2.73 (95% CI, -3.78 to -1.69) in the placebo group. The reduction in PSQI was greater in the escitalopram than in the placebo group at week 8 (mean difference, -1.31; 95% CI, -2.14 to -0.49; P < 0.001 overall treatment effect). Clinical improvement in insomnia symptoms and subjective sleep quality (>= 50% decreases in ISI and PSQI from baseline) was observed more frequently in the escitalopram group than in the placebo group (ISI, 50.0% vs 35.4%, P = 0.04; PSQI, 29.6% vs 19.2%, P = 0.09).
Conclusions: Among healthy perimenopausal and postmenopausal women with hot flashes, escitalopram at 10 to 20 mg/day compared with placebo reduced insomnia symptoms and improved subjective sleep quality at 8 weeks of follow-up.
C1 [Ensrud, Kristine E.] Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA.
[Ensrud, Kristine E.] Univ Minnesota, Div Epidemiol & Community Hlth, Minneapolis, MN USA.
[Ensrud, Kristine E.] Minneapolis VA Hlth Care Syst, Ctr Chron Dis Outcomes Res, Minneapolis, MN USA.
[Joffe, Hadine] Massachusetts Gen Hosp, Dept Psychiat, Ctr Womens Mental Hlth, Boston, MA 02114 USA.
[Guthrie, Katherine A.; Larson, Joseph C.; LaCroix, Andrea Z.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
[Reed, Susan D.] Univ Washington, Dept Med, Seattle, WA USA.
[Newton, Katherine M.] Grp Hlth Res Inst, Oakland, CA USA.
[Sternfeld, Barbara] Kaiser Permanente, Div Res, Oakland, CA USA.
[Landis, Carol A.; Woods, Nancy F.] Univ Washington, Dept Biobehav Nursing & Hlth Syst, Seattle, WA 98195 USA.
[Freeman, Ellen W.] Univ Penn, Dept Obstet & Gynecol & Psychiat, Philadelphia, PA 19104 USA.
RP Ensrud, KE (reprint author), 1 Vet Dr,Gen Internal Med 111-0, Minneapolis, MN 55417 USA.
EM ensru001@umn.edu
FU National Institute on Aging (NIA); Eunice Kennedy Shriver National
Institute of Child Health and Human Development; National Center for
Complementary and Alternative Medicine; Office of Research on Women's
Health [U01 AG032656, U01AG032659, U01AG032669, U01AG032699,
U01AG032700]; Indiana Clinical and Translational Sciences Institute;
National Institutes of Health, National Center for Research Resources,
Clinical and Translational Sciences Award [UL1 RR025761]
FX This study was supported by a cooperative agreement issued by the
National Institute on Aging (NIA), in collaboration with the Eunice
Kennedy Shriver National Institute of Child Health and Human
Development, the National Center for Complementary and Alternative
Medicine, and the Office of Research on Women's Health (U01 AG032656,
U01AG032659, U01AG032669, U01AG032699, U01AG032700). At the University
of Indiana site, the project was funded, in part, with support from the
Indiana Clinical and Translational Sciences Institute, by Grant UL1
RR025761 from the National Institutes of Health, National Center for
Research Resources, Clinical and Translational Sciences Award.
Escitalopram and matching placebo pills were provided by Forest Research
Institute.
NR 36
TC 27
Z9 28
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1072-3714
J9 MENOPAUSE
JI Menopause-J. N. Am. Menopause Soc.
PD AUG
PY 2012
VL 19
IS 8
BP 848
EP 855
DI 10.1097/gme.0b013e3182476099
PG 8
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 979TZ
UT WOS:000306844000005
PM 22433978
ER
PT J
AU Vajaranant, TS
Pasquale, LR
AF Vajaranant, Thasarat S.
Pasquale, Louis R.
TI Estrogen deficiency accelerates aging of the optic nerve
SO MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY
LA English
DT Review
DE Aging; Glaucoma; Sex difference; Estrogen; Blindness
ID OPEN-ANGLE GLAUCOMA; HORMONE REPLACEMENT THERAPY; FEMALE REPRODUCTIVE
FACTORS; OXIDE SYNTHASE GENE; BLUE MOUNTAINS EYE; RETINAL BLOOD-FLOW;
ANGELES LATINO EYE; INTRAOCULAR-PRESSURE; FIBER LAYER; OCULAR
HYPERTENSION
AB The aim of this study was to provide a comprehensive review on hormone-based pathophysiology of aging of the optic nerve and glaucoma, including a literature review and expert opinions. Glaucoma, a group of intraocular pressure-related optic neuropathies, is characterized by the slow progressive neurodegeneration of retinal ganglion cells and their axons, resulting in irreversible visual sensitivity loss and blindness. Increasing evidence suggests that glaucoma represents the accelerated aging of the optic nerve and is a neurodegenerative disease of the central nervous system. This review highlights the high burden of glaucoma in older women and the importance of understanding the hormone-related pathophysiology of optic nerve aging and glaucoma in women. Strong epidemiological, clinical, and experimental evidence supports the proposed hypothesis that early loss of estrogen leads to premature aging and increased susceptibility of the optic nerve to glaucomatous damage. Future investigations into the hormone-related mechanisms of aging and glaucoma will support the development of novel sex-specific preventive and therapeutic strategies in glaucoma.
C1 [Vajaranant, Thasarat S.] Univ Illinois, Dept Ophthalmol & Visual Sci, Chicago, IL USA.
[Pasquale, Louis R.] Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Boston, MA 02114 USA.
RP Vajaranant, TS (reprint author), 1855 W Taylor St, Chicago, IL USA.
EM thasarat@uic.edu
FU National Institute of Child Health and Human Development (NICHD)
[K12HD055892]; Office of Research on Women's Health; National Eye
Institute (NEI) [EY015473]; Research to Prevent Blindness Physician
Scientist award; Harvard Glaucoma Center of Excellence; Distinguished
Ophthalmology Scholar from the Department of Ophthalmology, Harvard
Medical School
FX This study was supported by grant K12HD055892 (T.S.V.) from the National
Institute of Child Health and Human Development (NICHD) and the Office
of Research on Women's Health and EY015473 (L.R.P.) from the National
Eye Institute (NEI). Dr. Pasquale is also supported by a Research to
Prevent Blindness Physician Scientist award, the Harvard Glaucoma Center
of Excellence, and a Distinguished Ophthalmology Scholar from the
Department of Ophthalmology, Harvard Medical School.
NR 78
TC 22
Z9 22
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1072-3714
J9 MENOPAUSE
JI Menopause-J. N. Am. Menopause Soc.
PD AUG
PY 2012
VL 19
IS 8
BP 942
EP 947
DI 10.1097/gme.0b013e3182443137
PG 6
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 979TZ
UT WOS:000306844000017
PM 22415565
ER
PT J
AU Louissaint, A
Ferry, JA
Soupir, CP
Hasserjian, RP
Harris, NL
Zukerberg, LR
AF Louissaint, Abner, Jr.
Ferry, Judith A.
Soupir, Chad P.
Hasserjian, Robert P.
Harris, Nancy L.
Zukerberg, Lawrence R.
TI Infectious mononucleosis mimicking lymphoma: distinguishing
morphological and immunophenotypic features
SO MODERN PATHOLOGY
LA English
DT Article
DE Epstein-Barr virus; infectious mononucleosis; lymphoma
ID EPSTEIN-BARR-VIRUS; B-CELL LYMPHOMA; REED-STERNBERG CELLS; ATYPICAL
LYMPHOPROLIFERATIVE DISORDERS; HODGKINS-DISEASE; WALDEYERS-RING;
MALIGNANT-LYMPHOMA; ANTIGEN EXPRESSION; T-CELLS; LYMPHADENOPATHY
AB The diagnosis of infectious mononucleosis (acute Epstein-Barr virus (EBV) infection) is usually made on the basis of clinical and laboratory findings. However, an atypical clinical presentation occasionally results in a lymph node or tonsillar biopsy. The morphological features of EBV-infected lymphoid tissue can easily mimic lymphoma. Furthermore, the immunophenotype of the immunoblasts has not been well characterized. To assess the morphological spectrum of acute EBV infection and the utility of immunohistochemistry in diagnosing difficult cases that resemble lymphoma, we reviewed 18 cases of acute EBV infection submitted in consultation to our institution with an initial diagnosis of/or suspicion for lymphoma. Patients included nine male and nine female individuals with a median age of 18 years (range 9-69). Biopsies were obtained from lymph nodes (3/18) or Waldeyer's ring (15/18). Infectious mononucleosis was confirmed by monospot or serological assays in 72% of cases (13/18). All cases featured architectural distortion by a polymorphous infiltrate with an immunoblastic proliferation, sometimes forming sheets. Reed-Sternberg-like cells were present in 8/18 (44%) of the cases. Infiltrates were often accompanied by necrosis (10/18) and mucosal ulceration (6/15). The majority of immunoblasts in all cases were CD20+ B cells with a post-germinal center immunophenotype (strongly positive for MUM1/IRF4 (18/18), CD10- (18/18 negative) and BCL-6- (16/18 negative; 2/18 faint BCL-6 expression in <10% of immunoblasts)). Immunoblasts showed variable weak expression of BCL-2 and polyclonal expression of kappa and lambda immunoglobulin light chains in 81% cases. Reed-Sternberg-like cells in 8/8 cases were CD30+, CD15-, BOB.1+ and OCT-2+. In conclusion, an atypical lymphoid infiltrate with numerous MUM1+, CD10-, BCL-6- immunoblasts should raise the suspicion of a reactive process, such as infectious mononucleosis, and warrants additional consideration before a diagnosis of lymphoma is made. Modern Pathology (2012) 25, 1149-1159; doi:10.1038/modpathol.2012.70; published online 25 May 2012
C1 [Louissaint, Abner, Jr.; Ferry, Judith A.; Soupir, Chad P.; Hasserjian, Robert P.; Harris, Nancy L.; Zukerberg, Lawrence R.] Massachusetts Gen Hosp, James Homer Wright Pathol Labs, Boston, MA 02114 USA.
RP Louissaint, A (reprint author), Massachusetts Gen Hosp, James Homer Wright Pathol Labs, 55 Fruit St,Warren 2, Boston, MA 02114 USA.
EM alouissaint@partners.org
NR 45
TC 16
Z9 17
U1 1
U2 3
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0893-3952
J9 MODERN PATHOL
JI Mod. Pathol.
PD AUG
PY 2012
VL 25
IS 8
BP 1149
EP 1159
DI 10.1038/modpathol.2012.70
PG 11
WC Pathology
SC Pathology
GA 984WD
UT WOS:000307222200010
PM 22627742
ER
PT J
AU Heinrich, MC
Marino-Enriquez, A
Presnell, A
Donsky, RS
Griffith, DJ
McKinley, A
Patterson, J
Taguchi, T
Liang, CW
Fletcher, JA
AF Heinrich, Michael C.
Marino-Enriquez, Adrian
Presnell, Ajia
Donsky, Rachel S.
Griffith, Diana J.
McKinley, Arin
Patterson, Janice
Taguchi, Takahiro
Liang, Cher-Wei
Fletcher, Jonathan A.
TI Sorafenib Inhibits Many Kinase Mutations Associated with Drug-Resistant
Gastrointestinal Stromal Tumors
SO MOLECULAR CANCER THERAPEUTICS
LA English
DT Article
ID CHRONIC MYELOID-LEUKEMIA; DIAGNOSED CHRONIC-PHASE; FACTOR-RECEPTOR-BETA;
IMATINIB MESYLATE; IN-VITRO; KIT; MUTANTS; MECHANISMS; SUNITINIB;
FREQUENCY
AB Sorafenib has substantial clinical activity as third-or fourth-line treatment of imatinib-and sunitinib-resistant gastrointestinal stromal tumors (GIST). Because sorafenib targets both angiogenesis-related kinases (VEGFR) and the pathogenetic kinases found in GIST (KIT or PDGFRA), the molecular basis for sorafenib efficacy in this setting remains unknown. We sought to determine the spectrum of activity of sorafenib against different mutant kinases associated with drug-sensitive and drug-resistant GIST. We compared the activity of imatinib and sorafenib against transiently expressed mutant forms of KIT and PDGFRA, including various secondary mutations that have been identified in imatinib-resistant or sunitinib-resistant GISTs. We also examined these drugs against four GIST cell lines, three of which are imatinib resistant. In our in vitro studies, we determined that sorafenib inhibited imatinib-resistant mutations in exons encoding the ATP/drug-binding pocket and in exons encoding the activation loop, with the exception of substitutions at KIT codon D816 and PDGFRA codon 842. Notably our data indicate that sorafenib is more effective than imatinib or sunitinib for inhibiting the kinase activity of drug-resistant KIT mutants (as assessed by biochemical IC50). We hypothesize that a major determinant of the efficacy of sorafenib for treatment of advanced GIST is the activity of this agent against KIT or PDGFRA-mutant kinases. These results have implications for the further development of treatments for drug-resistant GIST. Mol Cancer Ther; 11(8); 1770-80. (C) 2012 AACR.
C1 [Heinrich, Michael C.] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Dept Med, Div Hematol Oncol, Portland, OR 97239 USA.
[Heinrich, Michael C.; Presnell, Ajia; Griffith, Diana J.; McKinley, Arin; Patterson, Janice] Oregon Hlth & Sci Univ, OHSU Knight Canc Inst, Portland, OR 97239 USA.
[Marino-Enriquez, Adrian; Donsky, Rachel S.; Liang, Cher-Wei; Fletcher, Jonathan A.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Marino-Enriquez, Adrian; Donsky, Rachel S.; Liang, Cher-Wei; Fletcher, Jonathan A.] Harvard Univ, Sch Med, Boston, MA USA.
[Taguchi, Takahiro] Kochi Univ, Kochi 780, Japan.
RP Heinrich, MC (reprint author), Oregon Hlth & Sci Univ, Portland VA Med Ctr, Dept Med, Div Hematol Oncol, R&D-19 3710,US Vet Hosp Rd, Portland, OR 97239 USA.
EM Heinrich@ohsu.edu
OI Patterson, Janice/0000-0002-8969-2933; LIANG,
CHER-WEI/0000-0001-8903-6082
FU Veterans Affairs Merit Review Grant; Life Raft Group; GIST Cancer
Research Fund; GI SPORE [1P50CA127003]; BP Lester Foundation; Virginia
and Daniel K. Ludwig Trust for Cancer Research; Fundacion Alfonso Martin
Escudero; Cathay General Hospital Research Fund; Novartis; AROG;
Imclone; Ariad
FX M.C. Heinrich is a recipient of commercial research grant from Novartis,
AROG, Imclone, and Ariad; has received honoraria from Speakers Bureau of
Novartis and has ownership interest (including patents) from
MolecularMD. He is also a consultant and advisory board member of
Novartis.; This work was supported in part from funding from a Veterans
Affairs Merit Review Grant (M. C. Heinrich), the Life Raft Group (M. C.
Heinrich, J. A. Fletcher), the GIST Cancer Research Fund (M. C.
Heinrich, J. A. Fletcher), GI SPORE 1P50CA127003 (J. A. Fletcher), BP
Lester Foundation (M. C. Heinrich), the Virginia and Daniel K. Ludwig
Trust for Cancer Research (J. A. Fletcher), Fundacion Alfonso Martin
Escudero (A. Marino-Enriquez), and Cathay General Hospital Research Fund
(C.-W. Liang).
NR 34
TC 23
Z9 23
U1 0
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1535-7163
J9 MOL CANCER THER
JI Mol. Cancer Ther.
PD AUG
PY 2012
VL 11
IS 8
BP 1770
EP 1780
DI 10.1158/1535-7163.MCT-12-0223
PG 11
WC Oncology
SC Oncology
GA 995PG
UT WOS:000308022100016
PM 22665524
ER
PT J
AU Shapiro, KA
Bove, RM
Volpicelli, ER
Mallery, RM
Stone, JH
AF Shapiro, Kevin A.
Bove, Riley M.
Volpicelli, Elgida R.
Mallery, Robert M.
Stone, John H.
TI RELAPSING COURSE OF IMMUNOGLOBULIN G4-RELATED PACHYMENINGITIS
SO NEUROLOGY
LA English
DT Editorial Material
ID IGG4-RELATED SYSTEMIC-DISEASE
C1 [Stone, John H.] Massachusetts Gen Hosp, Dept Med, Rheumatol Unit, Boston, MA 02114 USA.
[Shapiro, Kevin A.; Bove, Riley M.; Mallery, Robert M.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
[Shapiro, Kevin A.; Bove, Riley M.; Mallery, Robert M.] Brigham & Womens Hosp, Dept Neurol, Boston, MA 02115 USA.
[Volpicelli, Elgida R.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
RP Stone, JH (reprint author), Massachusetts Gen Hosp, Dept Med, Rheumatol Unit, Boston, MA 02114 USA.
EM jhstone@partners.org
NR 7
TC 17
Z9 18
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
J9 NEUROLOGY
JI Neurology
PD AUG
PY 2012
VL 79
IS 6
BP 604
EP 605
DI 10.1212/WNL.0b013e31826356fc
PG 2
WC Clinical Neurology
SC Neurosciences & Neurology
GA 987ZW
UT WOS:000307458800024
PM 22843267
ER
PT J
AU Schwarzschild, MA
AF Schwarzschild, Michael A.
TI Caffeine in Parkinson disease Better for cruise control than snooze
patrol?
SO NEUROLOGY
LA English
DT Editorial Material
ID ADENOSINE A(2A) RECEPTORS; MOTOR; BRAIN
C1 Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
RP Schwarzschild, MA (reprint author), Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
EM MichaelS@helix.mgh.harvard.edu
NR 10
TC 4
Z9 5
U1 1
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
J9 NEUROLOGY
JI Neurology
PD AUG
PY 2012
VL 79
IS 7
BP 616
EP 618
DI 10.1212/WNL.0b013e318263580e
PG 3
WC Clinical Neurology
SC Neurosciences & Neurology
GA 988FT
UT WOS:000307475200005
PM 22855870
ER
PT J
AU Wang, CY
Tian, R
Zhao, Q
Xu, H
Meyer, CA
Li, C
Zhang, Y
Liu, XS
AF Wang, Chengyang
Tian, Rui
Zhao, Qian
Xu, Han
Meyer, Clifford A.
Li, Cheng
Zhang, Yong
Liu, X. Shirley
TI Computational inference of mRNA stability from histone modification and
transcriptome profiles
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article
ID EMBRYONIC STEM-CELLS; MICRORNA TARGET SITES; GENE-EXPRESSION; HUMAN
GENOME; POLYMERASE-II; INTERACTION MAPS; CHROMATIN STATE; CANCER-CELLS;
SEQ DATA; DECAY
AB Histone modifications play important roles in regulating eukaryotic gene expression and have been used to model expression levels. Here, we present a regression model to systematically infer mRNA stability by comparing transcriptome profiles with ChIP-seq of H3K4me3, H3K27me3 and H3K36me3. The results from multiple human and mouse cell lines show that the inferred unstable mRNAs have significantly longer 3'Untranslated Regions (UTRs) and more microRNA binding sites within 3'UTR than the inferred stable mRNAs. Regression residuals derived from RNA-seq, but not from GRO-seq, are highly correlated with the half-lives measured by pulse-labeling experiments, supporting the rationale of our inference. Whereas, the functions enriched in the inferred stable and unstable mRNAs are consistent with those from pulse-labeling experiments, we found the unstable mRNAs have higher cell-type specificity under functional constraint. We conclude that the systematical use of histone modifications can differentiate non-expressed mRNAs from unstable mRNAs, and distinguish stable mRNAs from highly expressed ones. In summary, we represent the first computational model of mRNA stability inference that compares transcriptome and epigenome profiles, and provides an alternative strategy for directing experimental measurements.
C1 [Xu, Han; Meyer, Clifford A.; Li, Cheng; Liu, X. Shirley] Harvard Univ, Dana Farber Canc Inst, Sch Publ Hlth, Dept Biostat & Computat Biol, Boston, MA 02215 USA.
[Wang, Chengyang; Tian, Rui; Zhao, Qian; Zhang, Yong] Tongji Univ, Dept Bioinformat, Sch Life Sci & Technol, Shanghai 20092, Peoples R China.
RP Liu, XS (reprint author), Harvard Univ, Dana Farber Canc Inst, Sch Publ Hlth, Dept Biostat & Computat Biol, 450 Brookline Ave, Boston, MA 02215 USA.
EM xsliu@jimmy.harvard.edu
RI Zhang, Yong/B-4838-2011
OI Zhang, Yong/0000-0001-6316-2734
FU National Basic Research [973] Program of China [2010CB944904]; National
Natural Science Foundation of China [31028011]; NIH [HG4069]
FX National Basic Research [973] Program of China No. [2010CB944904],
National Natural Science Foundation of China NO. [31028011] and NIH
grant [HG4069]. Funding for open access charge: National Basic Research
[973] Program of China No. [2010CB944904], National Natural Science
Foundation of China No. [31028011] and NIH grant [HG4069].
NR 66
TC 8
Z9 9
U1 1
U2 13
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
EI 1362-4962
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD AUG
PY 2012
VL 40
IS 14
BP 6414
EP 6423
DI 10.1093/nar/gks304
PG 10
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 988QD
UT WOS:000307504700012
PM 22495509
ER
PT J
AU Reynolds, JJ
Walker, AK
Gilmore, EC
Walsh, CA
Caldecott, KW
AF Reynolds, John J.
Walker, Alexandra K.
Gilmore, Edward C.
Walsh, Christopher A.
Caldecott, Keith W.
TI Impact of PNKP mutations associated with microcephaly, seizures and
developmental delay on enzyme activity and DNA strand break repair
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article
ID HUMAN POLYNUCLEOTIDE KINASE; LIGASE-IV; SPINOCEREBELLAR ATAXIA;
TOPOISOMERASE-I; IMMUNODEFICIENCY; SUPERFAMILY; PHOSPHATASE; MECHANISMS;
XRCC1; RATES
AB Microcephaly with early-onset, intractable seizures and developmental delay (MCSZ) is a hereditary disease caused by mutations in polynucleotide kinase/phosphatase (PNKP), a DNA strand break repair protein with DNA 5'-kinase and DNA 3'-phosphatase activity. To investigate the molecular basis of this disease, we examined the impact of MCSZ mutations on PNKP activity in vitro and in cells. Three of the four mutations currently associated with MCSZ greatly reduce or ablate DNA kinase activity of recombinant PNKP at 30 degrees C (L176F, T424Gfs48X and exon15 delta fs4X), but only one of these mutations reduces DNA phosphatase activity under the same conditions (L176F). The fourth mutation (E326K) has little impact on either DNA kinase or DNA phosphatase activity at 30 degrees C, but is less stable than the wild-type enzyme at physiological temperature. Critically, all of the MCSZ mutations identified to date result in similar to 10-fold reduced cellular levels of PNKP protein, and reduced rates of chromosomal DNA strand break repair. Together, these data suggest that all four known MCSZ mutations reduce the cellular stability and level of PNKP protein, with three mutations likely ablating cellular DNA 5'-kinase activity and all of the mutations greatly reducing cellular DNA 3'-phosphatase activity.
C1 [Reynolds, John J.; Walker, Alexandra K.; Caldecott, Keith W.] Univ Sussex, Genome Damage & Stabil Ctr, Brighton BN1 9RQ, E Sussex, England.
[Gilmore, Edward C.; Walsh, Christopher A.] Harvard Univ, Sch Med, Howard Hughes Med Inst, Div Genet,Manton Ctr Orphan Dis,Childrens Hosp, Boston, MA 02115 USA.
[Gilmore, Edward C.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Child Neurol,Dept Neurol, Boston, MA 02114 USA.
[Walsh, Christopher A.] Broad Inst Massachusetts Inst Technol & Harvard, Cambridge, MA 02142 USA.
RP Caldecott, KW (reprint author), Univ Sussex, Genome Damage & Stabil Ctr, Sci Pk Rd, Brighton BN1 9RQ, E Sussex, England.
EM k.w.caldecott@sussex.ac.uk
FU Medical Research Council [G0600776]; Cancer Research UK [C6563/A10192];
Medical Research Council
FX Medical Research Council [G0600776] and Cancer Research UK
[C6563/A10192] (to K. W. C.). Funding for open access charge: Medical
Research Council.
NR 37
TC 22
Z9 25
U1 0
U2 4
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD AUG
PY 2012
VL 40
IS 14
BP 6608
EP 6619
DI 10.1093/nar/gks318
PG 12
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 988QD
UT WOS:000307504700027
PM 22508754
ER
PT J
AU Schiffman, ED
McCarthy, JC
Kwon, JY
AF Schiffman, Eric D.
McCarthy, Joseph C.
Kwon, John Y.
TI Ankle Fracture Following Hip Arthroscopy
SO ORTHOPEDICS
LA English
DT Article
ID COMPLICATIONS
AB This article describes a case of an ankle fracture following hip arthroscopy. A 58-year-old woman underwent hip arthroscopy for a labral tear. She was placed in a lateral decubitus position with her foot in a padded boot. Traction was maintained for approximately 30 minutes. She was instructed to bear weight as tolerated with crutches postoperatively. At 2-week follow-up, she reported ipsilateral ankle pain. Radiographs revealed a minimally displaced medial malleolus fracture. She was treated with a cast followed by a cam walker boot and successfully went on to complete union and resolution of her symptoms.
The following risk factors exist for ankle fracture after hip arthroscopy: history of ankle sprains, ligamentous laxity (more common in women), and small feet with large calves (more likely to become plantarflexed during traction). Distraction performed with the ankle rotated is also likely to place added stress on the medial or lateral ligamentous structures.
It is important to counsel patients preoperatively about the risk of ankle pain after hip arthroscopy, to be aware of the possibility of ankle pathology postoperatively, and to have a low threshold for ordering radiographs. Radiographs are warranted if patients continue to have ankle pain after 72 hours postoperatively.
C1 [Schiffman, Eric D.; McCarthy, Joseph C.; Kwon, John Y.] Massachusetts Gen Hosp, Dept Orthopaed Surg, Boston, MA 02114 USA.
RP Schiffman, ED (reprint author), Massachusetts Gen Hosp, Dept Orthopaed Surg, 55 Fruit St, Boston, MA 02114 USA.
EM ees24@partners.org
NR 23
TC 0
Z9 0
U1 0
U2 0
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 0147-7447
J9 ORTHOPEDICS
JI Orthopedics
PD AUG
PY 2012
VL 35
IS 8
BP E1290
EP E1292
DI 10.3928/01477447-20120725-38
PG 3
WC Orthopedics
SC Orthopedics
GA 988UI
UT WOS:000307515800028
PM 22868624
ER
PT J
AU Maserejian, NN
Trachtenberg, FL
Hauser, R
McKinlay, S
Shrader, P
Tavares, M
Bellinger, DC
AF Maserejian, Nancy N.
Trachtenberg, Felicia L.
Hauser, Russ
McKinlay, Sonja
Shrader, Peter
Tavares, Mary
Bellinger, David C.
TI Dental Composite Restorations and Psychosocial Function in Children
SO PEDIATRICS
LA English
DT Article
DE composite dental resin; composite resins; bisphenol A-glycidyl
methacrylate; compomers; child behavior; behavioral symptoms; affective
symptoms
ID RANDOMIZED CLINICAL-TRIAL; BISPHENOL-A EXPOSURE; AMALGAM TRIAL;
BEHAVIOR; MERCURY; RELEASE; RESIN; MICE; COMPONENTS; REMOVAL
AB BACKGROUND AND OBJECTIVE: Resin-based dental materials may intraorally release their chemical components and bisphenol A. The New England Children's Amalgam Trial found that children randomized to amalgam had better psychosocial outcomes than those assigned to composites for posterior tooth restorations. The objective of this study was to examine whether greater exposure to dental composites is associated with psychosocial problems in children.
METHODS: Analysis of treatment-level data from the New England Children's Amalgam Trial, a 2-group randomized safety trial comparing amalgam with the treatment plan of bisphenol A-glycidyl methacrylate (bisGMA)-based composite and urethane dimethacrylate-based polyacid-modified composite (compomer), among 534 children aged 6 to 10 years at baseline. Psychosocial function at follow-up (n = 434) was measured by using the self-reported Behavior Assessment System for Children (BASC-SR) and parent-reported Child Behavior Checklist (CBCL).
RESULTS: Children with higher cumulative exposure to bisGMA-based composite had poorer follow-up scores on 3 of 4 BASC-SR global scales: Emotional Symptoms (beta = 0.8, SE = 0.3, P = .003), Clinical Maladjustment (beta = 0.7, SE = 0.3, P = .02), and Personal Adjustment (beta = -0.8, SE = 0.2, P = .002). Associations were stronger with posterior-occlusal (chewing) surfaces, where degradation of composite wasmore likely. For CBCL change, associations were not statistically significant. At-risk or clinically significant scores were more common among children with greater exposure for CBCL Total Problem Behaviors (16.3% vs 11.2%, P-trend = .01) and numerous BASC-SR syndromes (eg, >= 13 vs 0 surface-years, Interpersonal Relations 13.7% vs 4.8%, P-trend = .01). No associations were found with compomer, nor with amalgam exposure levels among children randomized to amalgam.
CONCLUSIONS: Greater exposure to bisGMA-based dental composite restorations was associated with impaired psychosocial function in children, whereas no adverse psychosocial outcomes were observed with greater urethane dimethacrylate-based compomer or amalgam treatment levels. Pediatrics 2012;130:e328-e338
C1 [Maserejian, Nancy N.; Trachtenberg, Felicia L.; McKinlay, Sonja; Shrader, Peter] New England Res Inst, Dept Epidemiol, Watertown, MA 02172 USA.
[Hauser, Russ; Bellinger, David C.] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA.
[Hauser, Russ] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Hauser, Russ; Bellinger, David C.] Harvard Univ, Sch Med, Boston, MA USA.
[Hauser, Russ] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Tavares, Mary] Forsyth Inst, Cambridge, MA USA.
[Bellinger, David C.] Childrens Hosp, Dept Neurol, Boston, MA 02115 USA.
RP Maserejian, NN (reprint author), New England Res Inst Inc, 9 Galen St, Watertown, MA 02472 USA.
EM nmaserejian@neriscience.com
FU National Institute of Environmental Health Sciences [R01ES019155]; New
England Research Institutes [U01 DE11886]; National Institute of Dental
and Craniofacial Research [U01 DE11886]; National Institutes of Health
(NIH)
FX The analyses presented in this article were funded by award number
R01ES019155 from the National Institute of Environmental Health
Sciences. The data collection was supported by a cooperative agreement
(U01 DE11886) between the New England Research Institutes and the
National Institute of Dental and Craniofacial Research, both of which
participated in the design and conduct of the New England Children's
Amalgam Trial, including collection and management of data. Funded by
the National Institutes of Health (NIH).
NR 42
TC 24
Z9 26
U1 1
U2 11
PU AMER ACAD PEDIATRICS
PI ELK GROVE VILLAGE
PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA
SN 0031-4005
J9 PEDIATRICS
JI Pediatrics
PD AUG
PY 2012
VL 130
IS 2
BP E328
EP E338
DI 10.1542/peds.2011-3374
PG 11
WC Pediatrics
SC Pediatrics
GA 983MI
UT WOS:000307123000011
PM 22802599
ER
PT J
AU Min, C
Ohta, K
Kajiya, M
Zhu, T
Sharma, K
Shin, J
Mawardi, H
Howait, M
Hirschfeld, J
Bahammam, L
Ichimonji, I
Ganta, S
Amiji, M
Kawai, T
AF Min, Christine
Ohta, Kouji
Kajiya, Mikihito
Zhu, Tongbo
Sharma, Kanika
Shin, Jane
Mawardi, Hani
Howait, Mohammed
Hirschfeld, Josefine
Bahammam, Laila
Ichimonji, Isao
Ganta, Srinivas
Amiji, Mansoor
Kawai, Toshihisa
TI The antimicrobial activity of the appetite peptide hormone ghrelin
SO PEPTIDES
LA English
DT Article
DE Ghrelin; Peptide; Escherichia coli; Pseudomonas aeruginosa; LL37;
Antimicrobial activity
ID PROINFLAMMATORY CYTOKINE EXPRESSION; BETA-DEFENSINS; CARIOGENIC
BACTERIA; SUSCEPTIBILITY; CELLS; IDENTIFICATION; EPITHELIA; LEPTIN;
PLASMA; LL-37
AB The present study examined the antimicrobial activity of the peptide ghrelin. Both major forms of ghrelin, acylated ghrelin (AG) and desacylated ghrelin (DAG), demonstrated the same degree of bactericidal activity against Gram-negative Escherichia coli (E. coli) and Pseudomonas aeruginosa (P. aeruginosa), while bactericidal effects against Gram-positive Staphylococcus aureus (S. aureus) and Enterococcus faecalis (E. faecalis) were minimal or absent, respectively. To elucidate the bactericidal mechanism of AG and DAG against bacteria, we monitored the effect of the cationic peptides on the zeta potential of E. coli. Our results show that AG and DAG similarly quenched the negative surface charge of E. coli, suggesting that ghrelin-mediated bactericidal effects are influenced by charge-dependent binding and not by acyl modification. Like most cationic antimicrobial peptides (CAMPs), we also found that the antibacterial activity of AG was attenuated in physiological NaCl concentration (150 mM). Nonetheless, these findings indicate that both AG and DAG can act as CAMPs against Gram-negative bacteria. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Min, Christine; Ohta, Kouji; Kajiya, Mikihito; Zhu, Tongbo; Mawardi, Hani; Howait, Mohammed; Hirschfeld, Josefine; Bahammam, Laila; Ichimonji, Isao; Kawai, Toshihisa] Forsyth Inst, Dept Immunol, Cambridge, MA 02142 USA.
[Ohta, Kouji; Kajiya, Mikihito; Zhu, Tongbo; Sharma, Kanika; Shin, Jane; Mawardi, Hani; Howait, Mohammed; Kawai, Toshihisa] Harvard Univ, Sch Dent Med, Dept Oral Med Infect & Immun, Boston, MA 02115 USA.
[Mawardi, Hani] King Abdulaziz Univ, Fac Dent, Oral Basic & Clin Sci Dept, Ora Med & Oral Diag Div, Jeddah 21589, Saudi Arabia.
[Howait, Mohammed; Bahammam, Laila] King Abdulaziz Univ, Fac Dent, Dept Conservat Dent Sci, Endodont Div, Jeddah 21589, Saudi Arabia.
[Ganta, Srinivas; Amiji, Mansoor] Northeastern Univ, Dept Pharmaceut Sci, Boston, MA 02115 USA.
RP Kawai, T (reprint author), Forsyth Inst, Dept Immunol, 245 1st St, Cambridge, MA 02142 USA.
EM tkawai@forsyth.org
RI Amiji, Mansoor/A-4365-2014; howait, mohammed/K-4478-2016
OI Amiji, Mansoor/0000-0001-6170-881X; howait, mohammed/0000-0002-6268-4941
FU NIH from National Institute of Dental and Craniofacial Research
[DE-018310]; Harvard Catalyst
FX This study was supported by NIH grant DE-018310 from the National
Institute of Dental and Craniofacial Research and Pilot Grant from
Harvard Catalyst. We acknowledge Max Goodson at the Forsyth Institute
for his critical comments on this manuscript.
NR 28
TC 5
Z9 5
U1 2
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0196-9781
EI 1873-5169
J9 PEPTIDES
JI Peptides
PD AUG
PY 2012
VL 36
IS 2
BP 151
EP 156
DI 10.1016/j.peptides.2012.05.006
PG 6
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism;
Pharmacology & Pharmacy
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism;
Pharmacology & Pharmacy
GA 983YR
UT WOS:000307155100001
PM 22634233
ER
PT J
AU Pekary, AE
Sattin, A
AF Pekary, A. Eugene
Sattin, Albert
TI Rapid modulation of TRH and TRH-like peptide release in rat brain and
peripheral tissues by ghrelin and 3-TRP-ghrelin
SO PEPTIDES
LA English
DT Article
DE Ghrelin; TRH-like peptides; Rat; Limbic system
ID HORMONE TRH; MESSENGER-RNA; FOOD-INTAKE; SECRETION; RECEPTOR;
STIMULATION; MECHANISM; BEHAVIOR; SYSTEM; LEPTIN
AB Ghrelin is not only a modulator of feeding and energy expenditure but also regulates reproductive functions, CNS development and mood. Obesity and major depression are growing public health concerns which may derive, in part, from dysregulation of ghrelin feedback at brain regions regulating feeding and mood. We and others have previously reported that thyrotropin-releasing hormone (TRH, pGlu-His-Pro-NH2) and TRH-like peptides (pGIu-X-Pro-NH2, where "X" can be any amino acid residue) have neuroprotective, antidepressant, anti-epileptic, analeptic, anti-ataxic, and anorectic properties. For this reason male Sprague-Dawley rats were injected ip with 0.1 mg/kg rat ghrelin or 0.9 mg/kg 3-Trp-rat ghrelin. Twelve brain regions: cerebellum, medulla oblongata, anterior cingulate, posterior cingulate, frontal cortex, nucleus accumbens, hypothalamus, entorhinal cortex, hippocampus, striatum, amygdala, piriform cortex and 5 peripheral tissues (adrenals, testes, epididymis, pancreas and prostate) were analyzed. Rapid and profound decreases in TRH and TRH-like peptide levels (increased release) occurred throughout brain and peripheral tissues following ip ghrelin. Because ghrelin is rapidly deacylated in vivo we also studied 3-Trp-ghrelin which cannot be deacylated. Significant increases in TRH and TRH-like peptide levels following 3-Trp-ghrelin, relative to those after ghrelin were observed in all brain regions except posterior cingulate and all peripheral tissues except prostate and testis. The rapid stimulation of TRH and TRH-like peptide release by ghrelin in contrast with the inhibition of such release by 3-Trp-TRH is consistent with TRH and TRH-like peptides modulating the downstream effects of both ghrelin and unacylated ghrelin. Published by Elsevier Inc.
C1 [Pekary, A. Eugene; Sattin, Albert] VA Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA 90073 USA.
[Sattin, Albert] VA Greater Los Angeles Healthcare Syst, Psychiat Serv, Los Angeles, CA 90073 USA.
[Pekary, A. Eugene] VA Greater Los Angeles Healthcare Syst, Ctr Ulcer Res & Educ, Los Angeles, CA 90073 USA.
[Sattin, Albert] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90073 USA.
[Sattin, Albert] Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90024 USA.
[Pekary, A. Eugene] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA.
RP Pekary, AE (reprint author), VA Greater Los Angeles Healthcare Syst, Res Serv, Bldg 114,Rm 229,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM Eugene.Pekary@va.gov
FU Department of Veterans Affairs Medical Research funds; Pekary Trust
FX This work was supported by the Department of Veterans Affairs Medical
Research funds (AEP and AS) and the Pekary Trust.
NR 74
TC 6
Z9 6
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0196-9781
J9 PEPTIDES
JI Peptides
PD AUG
PY 2012
VL 36
IS 2
BP 157
EP 167
DI 10.1016/j.peptides.2012.04.021
PG 11
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism;
Pharmacology & Pharmacy
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism;
Pharmacology & Pharmacy
GA 983YR
UT WOS:000307155100002
PM 22634385
ER
PT J
AU Cohen, JM
Fagin, AP
Hariton, E
Niska, JR
Pierce, MW
Kuriyama, A
Whelan, JS
Jackson, JL
Dimitrakoff, JD
AF Cohen, Jeffrey M.
Fagin, Adam P.
Hariton, Eduardo
Niska, Joshua R.
Pierce, Michael W.
Kuriyama, Akira
Whelan, Julia S.
Jackson, Jeffrey L.
Dimitrakoff, Jordan D.
TI Therapeutic Intervention for Chronic Prostatitis/Chronic Pelvic Pain
Syndrome (CP/CPPS): A Systematic Review and Meta-Analysis
SO PLOS ONE
LA English
DT Review
ID CHRONIC NONBACTERIAL PROSTATITIS; PLACEBO-CONTROLLED TRIAL; SYNDROME
CATEGORY IIIA; DOUBLE-BLIND TRIAL; CLINICAL-TRIALS; CONTROLLED
MULTICENTER; TERAZOSIN THERAPY; SYMPTOM INDEX; MEN; TAMSULOSIN
AB Background: Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) has been treated with several different interventions with limited success. This meta-analysis aims to review all trials reporting on therapeutic intervention for CP/CPPS using the National Institutes of Health-Chronic Prostatitis Symptom Index (NIH-CPSI).
Methods: We searched Medline, PubMed, the Cochrane Pain, Palliative & Supportive Care Trials, the Cochrane Register of Controlled Trials, CINAHL, ClinicalTrials.gov, and the NIDDK website between 1947 and December 31, 2011 without language or study type restrictions. All RCTs for CP/CPPS lasting at least 6 weeks, with a minimum of 10 participants per arm, and using the NIH-CPSI score, the criterion standard for CP/CPPS, as an outcome measure were included. Data was extracted from each study by two independent reviewers. Gillbraith and I-squared plots were used for heterogeneity testing and Eggers and Peters methods for publication bias. Quality was assessed using a component approach and meta-regression was used to analyze sources of heterogeneity.
Results: Mepartricin, percutaneous tibial nerve stimulation (PTNS), and triple therapy comprised of doxazosin + ibuprofen + thiocolchicoside (DIT) resulted in clinically and statistically significant reduction in NIH-CPSI total score. The same agents and aerobic exercise resulted in clinically and statistically significant NIH-CPSI pain domain score reduction. Acupuncture, DIT, and PTNS were found to produce statistically and clinically significant reductions in the NIH-CPSI voiding domain. A statistically significant placebo effect was found for all outcomes and time analysis showed that efficacy of all treatments increased over time. Alpha-blockers, antibiotics, and combinations of the two failed to show statistically or clinically significant NIH-CPSI reductions.
Conclusion: Results from this meta-analysis reflect our current inability to effectively manage CP/CPPS. Clinicians and researchers must consider placebo effect and treatment efficacy over time and design studies creatively so we can more fully elucidate the etiology and role of therapeutic intervention in CP/CPPS.
C1 [Cohen, Jeffrey M.; Hariton, Eduardo; Niska, Joshua R.; Pierce, Michael W.; Whelan, Julia S.; Dimitrakoff, Jordan D.] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Dimitrakoff, Jordan D.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Fagin, Adam P.] Harvard Univ, Sch Dent Med, Boston, MA 02115 USA.
[Jackson, Jeffrey L.] Med Coll Wisconsin, Milwaukee, WI 53226 USA.
[Kuriyama, Akira] Kurashiki Cent Hosp, Okayama, Japan.
RP Cohen, JM (reprint author), Harvard Univ, Sch Med, Boston, MA 02114 USA.
EM jordan.dimitrakoff@gmail.com
OI Dimitrakoff, Jordan/0000-0001-6827-1382
NR 62
TC 21
Z9 26
U1 0
U2 16
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 1
PY 2012
VL 7
IS 8
AR e41941
DI 10.1371/journal.pone.0041941
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 984SU
UT WOS:000307212800045
PM 22870266
ER
PT J
AU Greaney, ML
Puleo, E
Sprunck-Harrild, K
Bennett, GG
Cunningham, MA
Gillman, MW
Coeling, M
Emmons, KM
AF Greaney, Mary L.
Puleo, Elaine
Sprunck-Harrild, Kim
Bennett, Gary G.
Cunningham, Moira A.
Gillman, Matthew W.
Coeling, Molly
Emmons, Karen M.
TI Electronic reminders for cancer prevention: Factors associated with
preference for automated voice reminders or text messages
SO PREVENTIVE MEDICINE
LA English
DT Article
DE SMS text messages; Automated voice recordings; Prompting; Electronic
reminders
ID PHYSICAL-ACTIVITY; INTERVENTIONS; PROMOTION; FRAMEWORK; CARE
AB Objective. Prompting may promote engagement with behavior change interventions. Prompts can be delivered inexpensively via automated voice response (AVR) reminders or short message service (SMS) text messages. We examined the association between participants' characteristics and preferred reminder modality.
Methods. Healthy Directions 2 is a cluster randomized controlled trial implemented in Boston, Massachusetts to promote change in multiple behavioral cancer risk factors. At baseline (2009), participants completed a survey assessing socio-demographics, health status, height/weight, and factors associated with technology. One-third of participants randomized to receive the intervention (n =598) were randomized to receive automated reminders, with participants selecting modality.
Results. 28% (167/598) of participants selected SMS reminders. Controlling for clustering by primary care provider, younger participants (OR = 0.97,95% CI = (0.95, 0.99), p<0.01), those most comfortable with computers (very uncomfortable OR = 0.54, 95% CI = (0.29, 1.01), p <= 0.05: referent group = very comfortable), and those who frequently sent/received text messages (never OR = 0.09 CI = (0.04, 0.16) p<0.01; 1-3 times/month OR = 038, 95% CI = (0.15, 0.93) p = 0.04: referent group = 1-5 times/week) were more likely to choose SMS.
Conclusions. Interventions should make both modalities available to ensure that more participants can benefit from prompting. Studies examining the effect of automated reminders may have reduced effectiveness or generalizability if they employ only one modality. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Greaney, Mary L.; Sprunck-Harrild, Kim; Emmons, Karen M.] Dana Farber Canc Inst, Ctr Community Based Res, Boston, MA 02215 USA.
[Puleo, Elaine] Univ Massachusetts, Dept Publ Hlth, Amherst, MA 01003 USA.
[Bennett, Gary G.] Duke Univ, Dept Psychol & Neurosci, Durham, NC USA.
[Bennett, Gary G.] Duke Univ, Duke Obes Prevent Program, Durham, NC USA.
[Emmons, Karen M.] Harvard Univ, Sch Publ Hlth, Dept Soc Human Dev & Hlth, Boston, MA 02115 USA.
[Cunningham, Moira A.] Harvard Vanguard Med Associates, Boston, MA USA.
[Gillman, Matthew W.] Harvard Univ, Sch Med, Dept Populat Med,Harvard Pilgrim Hth Care Inst, Obes Prevent Program, Boston, MA 02115 USA.
[Coeling, Molly] Univ Chicago, Chicago, IL 60637 USA.
RP Greaney, ML (reprint author), Dana Farber Canc Inst, Ctr Community Based Res, 450 Brookline Ave St, Boston, MA 02215 USA.
EM Mary_Greaney@dfci.harvard.edu
FU NIH [R01 CA123228, 1K05 CA124415]
FX This work was supported by NIH grants R01 CA123228 and 1K05 CA124415. We
thank Harvard Vanguard Medical Associates for the opportunity to conduct
our research in their clinical sites, and all of the health care
providers who participated in this study. We would like acknowledge Jess
Haines, PhD, RD, an HD2 co-investigator, as well as the HD2 staff:
Louisa Bloomstein, Joanne Chin, Lindsay ElShazly, Emma Issenberg, Fatima
Shahzad, Kim Skeete, Kristie Usher, and Val Varner. We also would like
to thank Martha Zorn for her statistical support.
NR 13
TC 8
Z9 8
U1 2
U2 9
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0091-7435
J9 PREV MED
JI Prev. Med.
PD AUG
PY 2012
VL 55
IS 2
BP 151
EP 154
DI 10.1016/j.ypmed.2012.05.014
PG 4
WC Public, Environmental & Occupational Health; Medicine, General &
Internal
SC Public, Environmental & Occupational Health; General & Internal Medicine
GA 983AO
UT WOS:000307088800014
PM 22659227
ER
PT J
AU Zivin, K
Ilgen, MA
Pfeiffer, PN
Welsh, DE
McCarthy, J
Valenstein, M
Miller, EM
Islam, K
Kales, HC
AF Zivin, Kara
Ilgen, Mark A.
Pfeiffer, Paul Nelson
Welsh, Deborah E.
McCarthy, John
Valenstein, Marcia
Miller, Erin M.
Islam, Khairul
Kales, Helen C.
TI Early Mortality and Years of Potential Life Lost Among Veterans Affairs
Patients With Depression
SO PSYCHIATRIC SERVICES
LA English
DT Article
ID SUICIDE MORTALITY; RISK-FACTOR; ILLNESS; CARE
AB Objective: Substantial literature documents excess and early mortality among individuals with serious mental illness, but there are relatively few data about mortality and depression. Methods: During fiscal year 2007, data from the U.S. Department of Veterans Affairs and the National Death Index were used to calculate mean age of death and years of potential life lost (YPLL) associated with 13 causes of death among veterans with (N=701,659) or without (N=4,245,193) depression. Results: Compared with nondepressed patients, depressed patients died younger (71.1 versus 75.9) and had more YPLL (13.4 versus 10.2) as a result of both natural and unnatural causes. Depending on the cause of death, depressed patients died between 2.5 and 8.7 years earlier and had 1.5 to 6.1 YPLL compared with nondepressed patients. Conclusions: These findings have important implications for clinical practice, given that improved quality of care may be needed to reduce early mortality among depressed VA patients. (Psychiatric Services 63:823-826, 2012; doi: 10.1176/appi.ps.201100317)
C1 [Zivin, Kara; Ilgen, Mark A.; Pfeiffer, Paul Nelson; Welsh, Deborah E.; McCarthy, John; Valenstein, Marcia; Miller, Erin M.; Kales, Helen C.] US Dept Vet Affairs, Natl Serious Mental Illness Treatment Res & Evalu, Ann Arbor, MI 48109 USA.
[Zivin, Kara; Ilgen, Mark A.; Pfeiffer, Paul Nelson; Welsh, Deborah E.; McCarthy, John; Valenstein, Marcia; Miller, Erin M.; Kales, Helen C.] US Dept Vet Affairs, Hlth Serv Res & Dev Ctr Clin Management Res, Ann Arbor, MI 48109 USA.
[Zivin, Kara; Ilgen, Mark A.; Pfeiffer, Paul Nelson; McCarthy, John; Valenstein, Marcia; Miller, Erin M.; Islam, Khairul; Kales, Helen C.] Univ Michigan, Sch Med, Dept Psychiat, Ann Arbor, MI USA.
RP Zivin, K (reprint author), US Dept Vet Affairs, Natl Serious Mental Illness Treatment Res & Evalu, N Campus Res Complex,2800 Plymouth Rd,Bldg 14, Ann Arbor, MI 48109 USA.
EM kzivin@umich.edu
FU U.S. Department of Veterans Affairs Health Services Research and
Development Service [IIR 10-176-3, CD2 07-206-1, CDA 10-036-1]
FX This study was funded by grants IIR 10-176-3, CD2 07-206-1, and CDA
10-036-1 from the U.S. Department of Veterans Affairs Health Services
Research and Development Service.
NR 14
TC 10
Z9 10
U1 1
U2 4
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 1075-2730
J9 PSYCHIAT SERV
JI Psychiatr. Serv.
PD AUG
PY 2012
VL 63
IS 8
BP 823
EP 826
DI 10.1176/appi.ps.201100317
PG 4
WC Health Policy & Services; Public, Environmental & Occupational Health;
Psychiatry
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health; Psychiatry
GA 984PX
UT WOS:000307204600015
PM 22854727
ER
PT J
AU Martin-Ibanez, R
Crespo, E
Esgleas, M
Urban, N
Wang, B
Waclaw, R
Georgopoulos, K
Martinez, S
Campbell, K
Vicario-Abejon, C
Alberch, J
Chan, S
Kastner, P
Rubenstein, JL
Canals, JM
AF Martin-Ibanez, Raquel
Crespo, Empar
Esgleas, Miriam
Urban, Noelia
Wang, Bei
Waclaw, Ronald
Georgopoulos, Katia
Martinez, Salvador
Campbell, Kenneth
Vicario-Abejon, Carlos
Alberch, Jordi
Chan, Susan
Kastner, Philippe
Rubenstein, John L.
Canals, Josep M.
TI Helios Transcription Factor Expression Depends on Gsx2 and Dlx1&2
Function in Developing Striatal Matrix Neurons
SO STEM CELLS AND DEVELOPMENT
LA English
DT Article
ID CELL FATE SPECIFICATION; NEURAL STEM-CELLS; OLFACTORY-BULB; MAMMALIAN
TELENCEPHALON; CEREBRAL-CORTEX; MOUSE TELENCEPHALON; PROGENITOR DOMAINS;
BASAL FOREBRAIN; NERVOUS-SYSTEM; HOMEOBOX GENES
AB Development of the nervous system is finely regulated by consecutive expression of cell-specific transcription factors. Here we show that Helios, a member of the Ikaros transcription factor family, is expressed in ectodermal and neuroectodermal-derived tissues. During embryonic development, Helios is expressed by several brain structures including the lateral ganglionic eminence (LGE, the striatal anlage); the cingulated, insular and retrosplenial cortex; the hippocampus; and the accessory olfactory bulb. Moreover, Helios is also expressed by Purkinje neurons during postnatal cerebellar development. Within the LGE, Helios expression follows a dynamic spatio-temporal pattern starting at embryonic stages (E14.5), peaking at E18.5, and completely disappearing during postnatal development. Helios is expressed by a small population of nestin-positive neural progenitor cells located in the subventricular zone as well as by a larger population of immature neurons distributed throughout the mantle zone. In the later, Helios is preferentially expressed in the matrix compartment, where it colocalizes with Bcl11b and Foxp1, well-known markers of striatal projection neurons. In addition, we observed that Helios expression is not detected in Dlx1/2 and Gsx2 null mutants, while its expression is maintained in Ascl1 mutants. These findings allow us to introduce a new transcription factor in the cascade of events that take part of striatal development postulating the existence of at least 4 different neural progenitors in the LGE. An Ascl1-independent but Gsx2- & Dlx1/2-dependent precursor will express Helios defining a new lineage for a subset of matrix striatal neurons.
C1 [Martin-Ibanez, Raquel; Crespo, Empar; Esgleas, Miriam; Urban, Noelia; Alberch, Jordi; Canals, Josep M.] Univ Barcelona, Fac Med, Dept Cell Biol Immunol & Neurosci, Inst Invest Biomed August Pi & Sunyer IDIBAPS, Barcelona 08036, Spain.
[Martin-Ibanez, Raquel; Crespo, Empar; Esgleas, Miriam; Urban, Noelia; Alberch, Jordi; Canals, Josep M.] Univ Barcelona, Fac Med, Cell Therapy Program, Inst Invest Biomed August Pi & Sunyer IDIBAPS, Barcelona 08036, Spain.
[Wang, Bei; Rubenstein, John L.] Univ Calif San Francisco, Dept Psychiat, Nina Ireland Lab Dev Neurobiol, San Francisco, CA USA.
[Waclaw, Ronald; Campbell, Kenneth] Childrens Hosp Res Fdn, Div Dev Biol, Cincinnati, OH 45229 USA.
[Georgopoulos, Katia] Harvard Univ, Cutaneous Biol Res Ctr, Massachusetts Gen Hosp, Sch Med, Charlestown, MA USA.
[Martinez, Salvador] Miguel Hernandez Univ, Alicante Neurosci Inst, Consejo Super Invest Cient CSIC, Alacant, Spain.
[Vicario-Abejon, Carlos] CSIC, Dept Neurobiol Mol Celular & Desarrollo, Inst Cajal, Madrid, Spain.
[Chan, Susan; Kastner, Philippe] CNRS, Dept Canc Biol, Inst Genet & Biol Mol & Cellulaire, INSERM, Illkirch Graffenstaden, France.
RP Canals, JM (reprint author), Univ Barcelona, Fac Med, Dept Cell Biol Immunol & Neurosci, Inst Invest Biomed August Pi & Sunyer IDIBAPS, C Casanova 143, Barcelona 08036, Spain.
EM jmcanals@ub.edu
RI Canals, Josep/M-3846-2014;
OI Canals, Josep/0000-0001-6829-7670; Martinez,
Salvador/0000-0002-9320-4103; Martinez, Salvador/0000-0002-2910-8926;
Urban Avellaneda, Noelia/0000-0003-4813-9274; Alberch,
Jordi/0000-0002-8684-2721
FU Ministerio de Ciencia e Innovacion, Spain [BFU2007-61230/BFI,
SAF2008-04360, SAF2009-07774, PLE2009-0089]; Instituto de Salud Carlos
III, Ministerio de Ciencia e Innovacion [CI-BERNED]; RETICS (Red de
Terapia Celular), Spain [RD06/0010/0006, RD06/0010/0023]; Generalitat de
Catalunya, Spain [2009SGR-00326]; Centre of Regenerative Medicine in
Barcelona (CMRB) [Promt-0901]; Generalitat de Catalunya, Spain
FX We would like to thank Cristina Herranz and Ana Lopez for technical
assistance and Dr. Maria Calvo from the confocal microscopy unit of the
Serveis Cientifico-Tecnics (Universitat de Barcelona) for their support
and advice on confocal techniques. We are also grateful to Dr. Rudolf
Grosschedl for Ebf-1-/- mice. We also thank Dr. Stephen T.
Smale (Howard Hughes Medical Institute, Molecular Biology Institute, and
Department of Microbiology and Immunology, University of California, Los
Angeles School of Medicine) for anti-Helios antibody and Dr. Christopher
A. Klug (Department of Microbiology, Division of Developmental, and
Clinical Immunology, University of Alabama at Birmingham) for the MSCV
plasmid encoding Helios. This study was supported by grants from the
Ministerio de Ciencia e Innovacion (BFU2007-61230/BFI to C. V.-A;
SAF2008-04360, to J. A.; and SAF2009-07774 and PLE2009-0089, to J. M.
C.), Spain; Instituto de Salud Carlos III, Ministerio de Ciencia e
Innovacion [CI-BERNED, to C. V.-A. and to J. A.; and RETICS (Red de
Terapia Celular, RD06/0010/0006 to J. M. C. and RD06/0010/0023 to S.
M.], Spain; and Generalitat de Catalunya (2009SGR-00326 to J. A.),
Spain. The Cell Therapy Program is supported by the Centre of
Regenerative Medicine in Barcelona (CMRB; Promt-0901 to J. M. C.);
Generalitat de Catalunya, Spain. E. C. was a fellow of the Ministerio de
Investigacion y Ciencia, Spain.
NR 70
TC 9
Z9 9
U1 1
U2 10
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1547-3287
J9 STEM CELLS DEV
JI Stem Cells Dev.
PD AUG
PY 2012
VL 21
IS 12
BP 2239
EP 2251
DI 10.1089/scd.2011.0607
PG 13
WC Cell & Tissue Engineering; Hematology; Medicine, Research &
Experimental; Transplantation
SC Cell Biology; Hematology; Research & Experimental Medicine;
Transplantation
GA 985UH
UT WOS:000307295500015
PM 22142223
ER
PT J
AU Eaddy, AC
Cummings, BS
Mchowat, J
Schnellmann, RG
AF Eaddy, Andre C.
Cummings, Brian S.
Mchowat, Jane
Schnellmann, Rick G.
TI The Role of Endoplasmic Reticulum Ca2+-Independent Phospholipase
A(2)gamma in Oxidant-Induced Lipid Peroxidation, Ca2+ Release, and Renal
Cell Death
SO TOXICOLOGICAL SCIENCES
LA English
DT Article
DE lipid peroxidation; phospholipase A(2); Ca2+ release; necrotic cell
death
ID ELECTROSPRAY MASS-SPECTROMETRY; OXIDATIVE STRESS; A(2) ENZYMES;
FATTY-ACIDS; IDENTIFICATION; INJURY; PERMEABILITY; IPLA(2)GAMMA;
SUPERFAMILY; METABOLISM
AB Oxidant-induced lipid peroxidation and cell death are major components of ischemia/reperfusion and toxicant injury. Our previous studies showed that renal proximal tubular cells (RPTCs) express Ca2+-independent phospholipase A(2)gamma (iPLA(2)gamma) in endoplasmic reticulum (ER) and mitochondria and that iPLA(2)gamma is cyto-protective. Our present studies reveal the role of ER-iPLA(2)gamma in oxidant-induced ER lipid peroxidation, Ca2+ release, and cell death. Oxidant tert-butyl hydroperoxide (TBHP) caused ER lipid peroxidation and Ca2+ release in isolated rabbit kidney cortex microsomes. ER-iPLA(2)gamma inhibition, using bromoenol lactone (BEL), potentiated both oxidant-induced ER lipid peroxidation and Ca2+ release. Assessment of fatty acids using electrospray ionization-mass spectrometry revealed that ER-iPLA(2)gamma mediates the TBHP-induced release of arachidonic acid (20:4), linoleic acid (18:2), and their oxidized forms (18:2-OH, 18:2-OOH, 20:4-OH, 20:4-OOH, 20:4-(OH)(3). iPLA(2)gamma inhibition also accelerated oxidant-induced ER Ca2+ release in RPTC. Depletion of ER Ca2+ stores in RPTC with thapsigargin, an ER Ca2+ pump inhibitor, prior to TBHP exposure reduced necrotic cell death and blocked the potentiation of TBHP-induced necrotic cell death by BEL. Together, these data provide strong evidence that ER-iPLA(2)gamma protects renal cells from oxidant-induced necrotic cell death by releasing unsaturated and/or oxidized fatty acids from ER membranes, thereby preserving ER membrane integrity and preventing ER Ca2+ release.
C1 [Eaddy, Andre C.; Schnellmann, Rick G.] Med Univ S Carolina, Dept Pharmaceut & Biomed Sci, Ctr Cell Death Injury & Regenerat, Charleston, SC 29425 USA.
[Cummings, Brian S.] Univ Georgia, Dept Pharmaceut & Biomed Sci, Athens, GA 30602 USA.
[Mchowat, Jane] St Louis Univ, Sch Med, Dept Pathol, St Louis, MO 63104 USA.
[Schnellmann, Rick G.] Ralph H Johnson VA Med Ctr, Charleston, SC 29401 USA.
RP Schnellmann, RG (reprint author), Med Univ S Carolina, Dept Pharmaceut & Biomed Sci, Ctr Cell Death Injury & Regenerat, 280 Calhoun St,MSC140, Charleston, SC 29425 USA.
EM schnell@musc.edu
FU National Institutes of Health (NIH) [DK-62028]; Biomedical Laboratory
Research and Development Program of the Department of Veterans Affairs;
Southern Regional Educational Board Predoctoral Scholarship; National
Institute of Environmental Health Sciences (NIEHS), NIH [T32 ESO12878,
F30 ES015964]; NIH [C06 RR-015455]
FX This research was supported by National Institutes of Health (NIH) Grant
DK-62028 and by the Biomedical Laboratory Research and Development
Program of the Department of Veterans Affairs to R.G.S. A.C.E. was
supported by a Southern Regional Educational Board Predoctoral
Scholarship, a training grant from the National Institute of
Environmental Health Sciences (NIEHS), NIH (T32 ESO12878), and an
Individual National Research Service Award Fellowship (F30 ES015964)
from NIEHS, NIH. The Medical University of South Carolina animal
facilities were funded by NIH Grant C06 RR-015455.
NR 32
TC 4
Z9 5
U1 0
U2 4
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1096-6080
J9 TOXICOL SCI
JI Toxicol. Sci.
PD AUG
PY 2012
VL 128
IS 2
BP 544
EP 552
DI 10.1093/toxsci/kfs175
PG 9
WC Toxicology
SC Toxicology
GA 991JY
UT WOS:000307698500023
PM 22584685
ER
PT J
AU Braquehais, MD
Picouto, MD
Casas, M
Sher, L
AF Dolores Braquehais, Maria
Dolores Picouto, Maria
Casas, Miquel
Sher, Leo
TI Hypothalamic-pituitary-adrenal axis dysfunction as a neurobiological
correlate of emotion dysregulation in adolescent suicide
SO WORLD JOURNAL OF PEDIATRICS
LA English
DT Review
DE adolescence; hypothalamic-pituitary-adrenal axis; suicide
ID DEXAMETHASONE-SUPPRESSION TEST; POSTTRAUMATIC-STRESS-DISORDER; SALIVARY
CORTISOL; PSYCHIATRIC-SYMPTOMS; ANXIETY DISORDER; HEALTHY CONTROLS;
YOUNG-ADULTS; CHILDHOOD; CHILDREN; DEPRESSION
AB Biological markers of vulnerability for current or future risk of suicide in adolescents could be important adjuncts to the treatment and prevention of this phenomenon.
We conducted a PubMed search of all English-language articles published between January 1990 and June 2011 using the following search terms: ("hypothalamic-pituitary-adrenal" OR "HPA") AND ("adolescence" OR "adolescent" OR "teenager") AND ("depression" OR "major depressive disorder" OR "suicidal behavior" OR "suicidal ideation" OR "suicidal thoughts" OR "deliberate self-harm" OR "suicidal attempt" OR "suicide").
HPA axis activity can be examined using different methods that do not have the same biological interpretation. An abnormal HPA axis functioning together with an anomalous interaction between HPA mechanisms and other systems such as the serotonergic system may be one of the neurobiological correlates of emotion dysregulation (ED). ED may play an important role in adolescent suicidal behavior. Some psychopathological conditions such as depression or childhood psychological trauma that increase suicidal risk in adolescents are also associated with HPA axis dysregulation. ED, a personality trait, can also be viewed as a predisposing factor that augments the vulnerability to suffer from psychiatric conditions.
Correlating HPA axis dysfunction with psychological factors such as ED could lead to a better understanding of the role of HPA abnormalities in adolescent suicide and may enhance preventive and treatment strategies.
C1 [Dolores Braquehais, Maria; Casas, Miquel] Univ Autonoma Barcelona, Vall Hebron Univ Hosp, Dept Psychiat & Legal Med, Barcelona 08035, Spain.
[Dolores Picouto, Maria] Univ Barcelona, St Joan de Deu Hosp, Dept Child & Adolescent Psychiat & Psychol, Barcelona, Spain.
[Sher, Leo] Mt Sinai Sch Med, Dept Psychiat, James J Peters Vet Adm Med Ctr, New York, NY USA.
RP Braquehais, MD (reprint author), Univ Autonoma Barcelona, Vall Hebron Univ Hosp, Dept Psychiat & Legal Med, Pg Vall Hebron 119-129, Barcelona 08035, Spain.
EM mdbraquehais@vhebron.net
FU Department of Health of the Government of Catalonia (Generalitat de
Catalonia), Spain; Department of Health of the Generalitat of Catalonia
FX The work of Dr. Maria Dolores Braquehais and Prof. Miquel Casas was
partly supported by a grant from the Department of Health of the
Government of Catalonia (Generalitat de Catalonia), Spain.; The work of
Dr. Braquehais and Dr. Casas was partly supported by a grant of the
Department of Health of the Generalitat of Catalonia.
NR 90
TC 7
Z9 7
U1 2
U2 13
PU ZHEJIANG UNIV SCH MEDICINE
PI HANGZHOU
PA CHILDRENS HOSPITAL, 57 ZHUGAN XIANG, HANGZHOU, 310003, PEOPLES R CHINA
SN 1708-8569
J9 WORLD J PEDIATR
JI World Journal of Pediatrics
PD AUG
PY 2012
VL 8
IS 3
BP 197
EP 206
DI 10.1007/s12519-012-0358-0
PG 10
WC Pediatrics
SC Pediatrics
GA 988RE
UT WOS:000307507400001
PM 22886191
ER
PT J
AU Siedner, MJ
Tsai, AC
Dworkin, S
Mukiibi, NFB
Emenyonu, NI
Hunt, PW
Haberer, JE
Martin, JN
Bangsberg, DR
Weiser, SD
AF Siedner, Mark J.
Tsai, Alexander C.
Dworkin, Shari
Mukiibi, Nozmo F. B.
Emenyonu, Nneka I.
Hunt, Peter W.
Haberer, Jessica E.
Martin, Jeffrey N.
Bangsberg, David R.
Weiser, Sheri D.
TI Sexual Relationship Power and Malnutrition Among HIV-Positive Women in
Rural Uganda
SO AIDS AND BEHAVIOR
LA English
DT Article
DE Gender Equality; Malnutrition; HIV/AIDS; Sub-Saharan Africa
ID INTIMATE-PARTNER VIOLENCE; SOUTH-AFRICA; SOCIAL INEQUALITIES; DISEASE
PROGRESSION; NUTRITIONAL-STATUS; FOOD INSECURITY; WEIGHT-LOSS;
INFECTION; RISK; INTERVENTION
AB Inequality within partner relationships is associated with HIV acquisition and gender violence, but little is known about more pervasive effects on women's health. We performed a cross-sectional analysis of associations between sexual relationship power and nutritional status among women in Uganda. Participants completed questionnaires and anthropometric measurements. We assessed sexual relationship power using the Sexual Relationship Power Scale (SRPS). We performed logistic regression to test for associations between sexual relationship power and poor nutritional status including body mass index, body fat percentage, and mid-upper arm circumference. Women with higher sexual relationship power scores had decreased odds of low body mass index (OR 0.29, p = 0.01), low body fat percentage (OR 0.54, p = 0.04), and low mid-upper arm circumference (OR 0.22, p = 0.01). These relationships persisted in multivariable models adjusted for potential confounders. Targeted interventions to improve intimate partner relationship equality should be explored to improve health status among women living with HIV in rural Africa.
C1 [Siedner, Mark J.; Haberer, Jessica E.; Bangsberg, David R.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Infect Dis, Boston, MA 02114 USA.
[Tsai, Alexander C.] Harvard Univ, Robert Wood Johnson Hlth & Soc Scholars Program, Boston, MA 02114 USA.
[Dworkin, Shari; Hunt, Peter W.; Martin, Jeffrey N.; Weiser, Sheri D.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Mukiibi, Nozmo F. B.; Emenyonu, Nneka I.; Bangsberg, David R.] Mbarara Univ Sci & Technol, Mbarara, Uganda.
[Bangsberg, David R.] MIT, Ragon Inst Massachusetts Gen Hosp, Boston, MA USA.
[Bangsberg, David R.] Harvard Univ, Sch Med, Boston, MA 02114 USA.
RP Siedner, MJ (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Infect Dis, 55 Fruit St,GRJ 5, Boston, MA 02114 USA.
EM msiedner@partners.org
OI Tsai, Alexander/0000-0001-6397-7917
FU NIAID NIH HHS [P30 AI027763, P30 AI027793, P30 AI060354]; NIMH NIH HHS
[K23 MH079713, K23 MH079713-03S1, K24 MH087227, R01 MH054907]
NR 48
TC 3
Z9 3
U1 3
U2 148
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1090-7165
J9 AIDS BEHAV
JI AIDS Behav.
PD AUG
PY 2012
VL 16
IS 6
BP 1542
EP 1548
DI 10.1007/s10461-012-0162-9
PG 7
WC Public, Environmental & Occupational Health; Social Sciences, Biomedical
SC Public, Environmental & Occupational Health; Biomedical Social Sciences
GA 977WI
UT WOS:000306695100019
PM 22382629
ER
PT J
AU Kreitchmann, R
Harris, DR
Kakehasi, F
Haberer, JE
Cahn, P
Losso, M
Teles, E
Pilotto, JH
Hofer, CB
Read, JS
AF Kreitchmann, Regis
Harris, D. Robert
Kakehasi, Fabiana
Haberer, Jessica E.
Cahn, Pedro
Losso, Marcelo
Teles, Elizabete
Pilotto, Jose H.
Hofer, Cristina B.
Read, Jennifer S.
CA NISDI LILAC Study Team
TI Antiretroviral Adherence During Pregnancy and Postpartum in Latin
America
SO AIDS PATIENT CARE AND STDS
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; SELF-REPORTED ADHERENCE; WOMENS
INTERAGENCY HIV; MEDICATION ADHERENCE; THERAPY ADHERENCE; INFECTED
WOMEN; DRUG-USE; ASSOCIATION; HAART; NONADHERENCE
AB Adherence to antiretrovirals by pregnant women (and postpartum women if breastfeeding) is crucial to effectively decrease maternal viral load and decrease the risk of mother-to-child transmission of HIV. Our objectives were to describe self-reported adherence to antiretrovirals during the antepartum (after 22 weeks of pregnancy) and postpartum periods (6-12 weeks and 6 months), and identify predictors of adherence among HIV-infected women enrolled and followed in a prospective cohort study from June 2008 to June 2010 at multiple sites in Latin America. Adherence was evaluated using the number of missed and expected doses during the 3 days before the study visit. At the pre-delivery visit, 340 of 376 women (90%) reported perfect adherence. This rate significantly decreased by 6-12 weeks (171/214 [80%]) and 6 months postpartum (163/199 [82%], p < 0.01). The odds for less than perfect adherence at the pre-delivery visit was significantly higher for pregnant women with current tobacco use (odds ratio [OR] = 2.9, 95% confidence interval [CI]: 1.46-6.14; p = 0.0029). At 6-12 weeks postpartum, the probability of non-perfect adherence increased by 6% for each 1 year increase in age (OR = 1.06, 95% CI: 1.00-1.12, p = 0.0497). At 6 months postpartum, the odds of nonperfect adherence was higher for those who were currently using alcohol (OR = 3.04, 95% CI: 1.34-6.90; p = 0.0079). Although a self-report measure of adherence based on only 3 days may lead to overestimation of actual adherence over time, women with perfect adherence had lower viral loads and higher CD4 counts. Adherence to antiretrovirals decreased significantly postpartum. Interventions should target women at high risk for lower adherence during pregnancy and postpartum, including tobacco and alcohol users.
C1 [Kreitchmann, Regis] Santa Casa de Misericordia Porto Alegre, Porto Alegre, RS, Brazil.
[Harris, D. Robert] WESTAT Corp, Rockville, MD 20850 USA.
[Kakehasi, Fabiana] Univ Fed Minas Gerais, Belo Horizonte, MG, Brazil.
[Haberer, Jessica E.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Cahn, Pedro] Hosp Gen Agudos Juan A Fernandez, Buenos Aires, DF, Argentina.
[Losso, Marcelo] Hosp Gen Agudos Jose Maria Ramos Mejia, Buenos Aires, DF, Argentina.
[Teles, Elizabete] Hosp Femina Grp Hosp Conceicao, Porto Alegre, RS, Brazil.
[Pilotto, Jose H.] Hosp Geral Nova Iguacu HIV Family Care Clin, Rio De Janeiro, Brazil.
[Pilotto, Jose H.] Lab AIDS & Imunol Mol IOC Fiocruz, Rio De Janeiro, Brazil.
[Hofer, Cristina B.] Univ Fed Rio de Janeiro, Inst Puericultura & Pediat Martagao Gesteira, Rio De Janeiro, Brazil.
[Hofer, Cristina B.] Univ Fed Rio de Janeiro, Dept Prevent Med, Rio De Janeiro, Brazil.
[Read, Jennifer S.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Pediat Adolescent & Maternal AIDS Branch, Bethesda, MD USA.
RP Kreitchmann, R (reprint author), STD AIDS Municipal Ctr, Hlth Secretary, Manoel Lobato 151, Porto Alegre, RS, Brazil.
EM regis.kr@terra.com.br
RI Mussi-Pinhata, Marisa/G-6568-2012; Inca, Inct/K-2204-2013
FU NICHD NIH HHS [N01-HD-3-3345, N01-HD-8-0001]; PHS HHS
[HHSN267200800001C]
NR 34
TC 20
Z9 20
U1 1
U2 6
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1087-2914
J9 AIDS PATIENT CARE ST
JI Aids Patient Care STDS
PD AUG
PY 2012
VL 26
IS 8
BP 486
EP 495
DI 10.1089/apc.2012.0013
PG 10
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA 983KS
UT WOS:000307118800007
PM 22663185
ER
PT J
AU Lemaitre, RN
Sitlani, C
Song, XL
King, IB
McKnight, B
Spiegelman, D
Sacks, FM
Djousse, L
Rimm, EB
Siscovick, DS
Mozaffarian, D
AF Lemaitre, Rozenn N.
Sitlani, Colleen
Song, Xiaoling
King, Irena B.
McKnight, Barbara
Spiegelman, Donna
Sacks, Frank M.
Djousse, Luc
Rimm, Eric B.
Siscovick, David S.
Mozaffarian, Dariush
TI Circulating and dietary alpha-linolenic acid and incidence of congestive
heart failure in older adults: the Cardiovascular Health Study
SO AMERICAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Article
ID N-3 FATTY-ACIDS; NATIONAL-HEART; FISH-OIL; ERYTHROCYTE-MEMBRANES;
MYOCARDIAL-INFARCTION; RISK; DISEASE; OMEGA-3-FATTY-ACIDS; LUNG; MEN
AB Background: Few studies have evaluated the association between the n-3 fatty acid alpha-linolenic acid (ALA) and the incidence of congestive heart failure (CHF).
Objective: We investigated whether plasma phospholipid concentrations and estimated dietary consumption of ALA are associated with incident CHF.
Design: We used data from the Cardiovascular Health Study, a prospective cohort study of cardiovascular diseases among adults aged >= 65 y, from 4 US communities. A total of 2957 participants free of prevalent heart disease and with available fatty acid measurements were included in biomarker analyses (30,722 person-years and 686 incident CHF events). A total of 4432 participants free of prevalent heart disease were included in dietary analyses (52,609 person-years and 1072 events). We investigated the association of ALA with incident CHF by using Cox regression.
Results: After adjustment for age, sex, race, education, smoking status, BMI, waist circumference, and alcohol consumption, plasma phospholipid ALA was not associated with incident CHF (HR for the highest compared with the lowest quartile: 0.97; 95% CI: 0.79, 1.21; P-trend = 0.85). Likewise, dietary ALA was not associated with incident CHF (adjusted HR for the highest compared with the lowest quartile: 0.96; 95% CI: 0.82, 1.20; P-trend = 0.97). We observed no association of biomarker or dietary ALA with nonvalvular CHF subtype. We also found little evidence of an association between ALA and CHF in subgroups based on age, sex, diabetes, fish consumption, BMI, or FADS2 genotype (rs1535).
Conclusion: ALA intake is not associated with incident CHF in older adults. This trial was registered at clinicaltrials.gov as NCT00005133. Am J Clin Nutr 2012;96:269-74.
C1 [Lemaitre, Rozenn N.; Sitlani, Colleen; Siscovick, David S.] Univ Washington, Dept Med, Cardiovasc Hlth Res Unit, Seattle, WA 98101 USA.
[McKnight, Barbara] Univ Washington, Dept Biostat, Seattle, WA 98101 USA.
[Siscovick, David S.] Univ Washington, Dept Epidemiol, Seattle, WA 98101 USA.
[Song, Xiaoling] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98104 USA.
[King, Irena B.] Univ New Mexico, Dept Internal Med, Albuquerque, NM 87131 USA.
[Spiegelman, Donna; Rimm, Eric B.; Mozaffarian, Dariush] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Spiegelman, Donna] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
[Sacks, Frank M.; Rimm, Eric B.; Mozaffarian, Dariush] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
[Djousse, Luc] Brigham & Womens Hosp, Div Aging, Boston, MA 02115 USA.
[Sacks, Frank M.; Mozaffarian, Dariush] Brigham & Womens Hosp, Div Cardiovasc Med, Boston, MA 02115 USA.
[Sacks, Frank M.; Siscovick, David S.; Mozaffarian, Dariush] Brigham & Womens Hosp, Channing Lab, Boston, MA 02115 USA.
Harvard Univ, Sch Med, Boston, MA USA.
[Djousse, Luc] Boston VA Healthcare Syst, Boston, MA USA.
RP Lemaitre, RN (reprint author), Univ Washington, Dept Med, Cardiovasc Hlth Res Unit, 1730 Minor Ave,Suite 1360, Seattle, WA 98101 USA.
EM rozenl@u.washington.edu
RI Djousse, Luc/F-5033-2017
OI Djousse, Luc/0000-0002-9902-3047
FU National Heart, Lung, and Blood Institute (NHLBI) [N01-HC-85239,
N01-HC-85079, N01-HC-85080, N01-HC-85081, N01-HC-85082, N01-HC-85083,
N01-HC-85084, N01-HC-85085, N01-HC-85086, N01-HC-35129, N01 HC-15103,
N01 HC-55222, N01-HC-75150, N01-HC-45133, HHSN268201200036C]; NHLBI
grants [HL080295, HL087652, HL105756, HL085710]; National Institute of
Neurological Disorders and Stroke; National Institute on Aging grants
[AG-023629, AG-15928, AG-20098, AG-027058]
FX The research reported in this article was supported by the National
Heart, Lung, and Blood Institute (NHLBI) contracts N01-HC-85239,
N01-HC-85079 through N01-HC-85086, N01-HC-35129, N01 HC-15103, N01
HC-55222, N01-HC-75150, N01-HC-45133, and HHSN268201200036C; NHLBI
grants HL080295, HL087652, HL105756, and HL085710; the National
Institute of Neurological Disorders and Stroke; and National Institute
on Aging grants AG-023629, AG-15928, AG-20098, and AG-027058. A full
list of principal CHS investigators and institutions can be found at
http://www.chs-nhlbi.org/pi.htm.
NR 39
TC 11
Z9 11
U1 1
U2 11
PU AMER SOC NUTRITION-ASN
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0002-9165
EI 1938-3207
J9 AM J CLIN NUTR
JI Am. J. Clin. Nutr.
PD AUG
PY 2012
VL 96
IS 2
BP 269
EP 274
DI 10.3945/ajcn.112.037960
PG 6
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 978TW
UT WOS:000306769700008
PM 22743310
ER
PT J
AU Garrett-Mayer, E
Wagner, CL
Hollis, BW
Kindy, MS
Gattoni-Celli, S
AF Garrett-Mayer, Elizabeth
Wagner, Carol L.
Hollis, Bruce W.
Kindy, Mark S.
Gattoni-Celli, Sebastiano
TI Vitamin D-3 supplementation (4000 IU/d for 1 y) eliminates differences
in circulating 25-hydroxyvitamin D between African American and white
Men
SO AMERICAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Article
ID RANDOMIZED CLINICAL-TRIAL; CARDIOVASCULAR HEALTH; US POPULATION;
DISPARITIES; SAFETY
AB Background: African Americans suffer disproportionately from diabetes and cardiovascular disease and are significantly more likely to have suboptimal concentrations of circulating 25-hydroxyvitamin D [25(OH)D]. The results of epidemiologic and observational studies suggest that there is a link between vitamin D deficiency and the risk of cardiometabolic disorders, which underscores the importance of maintaining healthy concentrations of 25(OH)D.
Objective: The objective was to investigate whether daily supplementation with 4000 IU vitamin D-3 for 1 y would eliminate any disparities in circulating concentrations of 25(OH)D between African American and white men.
Design: Serum concentrations of 25(OH)D were measured every 2 mo in 47 subjects who received a daily oral dose of 4000 IU vitamin D3 for I y.
Results: More than 90% of African Americans had serum concentrations of 25(OH)D <32 ng/mL, and approximately two-thirds had serum concentrations <20 ng/mL. Furthermore, there were significant disparities in serum concentrations of 25(OH)D between African American and white men. Supplementation with 4000 IU/d for 1 y eliminated any significant differences in circulating concentrations of 25(OH)D between African American and white men.
Conclusion: The results of this clinical study show the feasibility and efficacy of this approach in the elimination of hypovitaminosis D, which is a widespread health disparity among African Americans. This trial was registered at clinicaltrials.gov as NCT01045109. Am J Clin Num 2012:96:332-6.
C1 [Garrett-Mayer, Elizabeth] Med Univ S Carolina, Dept Med, Div Biostat & Epidemiol, Charleston, SC 29425 USA.
[Wagner, Carol L.; Hollis, Bruce W.] Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA.
[Kindy, Mark S.] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA.
[Gattoni-Celli, Sebastiano] Med Univ S Carolina, Dept Radiat Oncol, Charleston, SC 29425 USA.
[Kindy, Mark S.; Gattoni-Celli, Sebastiano] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
RP Gattoni-Celli, S (reprint author), Strom Thurmond Biomed Res Bldg,Room 338C,114 Doug, Charleston, SC 29403 USA.
EM gattonis@musc.edu
FU Gateway for Cancer Research; Health Services Research and Development
Program of the Department of Veterans Affairs; South Carolina Clinical
and Translational Research Institute; Biostatistics Shared Resource of
the Hollings Cancer Center at the Medical University of South Carolina
FX Supported in part by grants from the Gateway for Cancer Research, the
Health Services Research and Development Program of the Department of
Veterans Affairs, the South Carolina Clinical and Translational Research
Institute, and the Biostatistics Shared Resource of the Hollings Cancer
Center at the Medical University of South Carolina.
NR 32
TC 18
Z9 18
U1 0
U2 1
PU AMER SOC NUTRITION-ASN
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0002-9165
J9 AM J CLIN NUTR
JI Am. J. Clin. Nutr.
PD AUG
PY 2012
VL 96
IS 2
BP 332
EP 336
DI 10.3945/ajcn.112.034256
PG 5
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 978TW
UT WOS:000306769700016
PM 22760568
ER
PT J
AU Williams, BA
Stern, MF
Mellow, J
Safer, M
Greifinger, RB
AF Williams, Brie A.
Stern, Marc F.
Mellow, Jeff
Safer, Meredith
Greifinger, Robert B.
TI Aging in Correctional Custody: Setting a Policy Agenda for Older
Prisoner Health Care
SO AMERICAN JOURNAL OF PUBLIC HEALTH
LA English
DT Article
ID PALLIATIVE CARE; ALZHEIMERS-DISEASE; ELDERLY PERSONS; INMATES;
COMMUNITY; DEMENTIA; RELEASE; STATE; RISK; COMORBIDITIES
AB An exponential rise in the number of older prisoners is creating new and costly challenges for the criminal justice system, state economies, and communities to which older former prisoners return. We convened a meeting of 29 national experts in correctional health care, academic medicine, nursing, and civil rights to identify knowledge gaps and to propose a policy agenda to improve the care of older prisoners. The group identified 9 priority areas to be addressed: definition of the older prisoner, correctional staff training, definition of functional impairment in prison, recognition and assessment of dementia, recognition of the special needs of older women prisoners, geriatric housing units, issues for older adults upon release, medical early release, and prison-based palliative medicine programs. (Am J Public Health. 2012;102:1475-1481. doi:10.2105/AJPH.2012.300704)
C1 [Williams, Brie A.] Univ Calif San Francisco, Div Geriatr, Dept Med, San Francisco, CA 94117 USA.
[Williams, Brie A.] San Francisco VA Med Ctr, Div Geriatr, San Francisco, CA USA.
[Stern, Marc F.] Univ Washington, Sch Publ Hlth, Seattle, WA 98195 USA.
[Mellow, Jeff] CUNY John Jay Coll Criminal Justice, Dept Criminal Justice, New York, NY USA.
[Greifinger, Robert B.] CUNY John Jay Coll Criminal Justice, Ctr Evaluat & Res, New York, NY USA.
[Safer, Meredith] Liberian Minist Hlth & Social Welf, US Agcy Int Dev, Monrovia, Liberia.
RP Williams, BA (reprint author), Univ Calif San Francisco, Div Geriatr, Dept Med, 3333 Calif St,Suite 380, San Francisco, CA 94117 USA.
EM brie.williams@ucsf.edu
FU National Institute of Aging [K23AG033102]; Jacob and Valeria Langeloth
Foundation; University of California, San Francisco Hartford Center of
Excellence; Langeloth Foundation Leadership Symposia in Correctional
Health Care
FX B. A. Williams is supported by the National Institute of Aging (grant
K23AG033102), the Jacob and Valeria Langeloth Foundation, and the
University of California, San Francisco Hartford Center of Excellence.
This study and J. Mellow and R. B. Greifinger were also supported by a
grant from the Langeloth Foundation Leadership Symposia in Correctional
Health Care.
NR 60
TC 30
Z9 30
U1 3
U2 28
PU AMER PUBLIC HEALTH ASSOC INC
PI WASHINGTON
PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA
SN 0090-0036
J9 AM J PUBLIC HEALTH
JI Am. J. Public Health
PD AUG
PY 2012
VL 102
IS 8
BP 1475
EP 1481
DI 10.2105/AJPH.2012.300704
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 981AO
UT WOS:000306937900009
PM 22698042
ER
PT J
AU Kapuku, GK
Davis, HC
Thomas, P
Januzzi, J
Harshfield, GA
AF Kapuku, Gaston K.
Davis, Harry C.
Thomas, Patrick
Januzzi, James
Harshfield, Gregory A.
TI Does the Relationship Between Natriuretic Hormones and Diastolic
Function Differ by Race?
SO AMERICAN JOURNAL OF THE MEDICAL SCIENCES
LA English
DT Article
DE Natriuretic hormones; Mental stress; Diastolic function; Race
ID LEFT-VENTRICULAR HYPERTROPHY; CARDIOVASCULAR-DISEASE; HEART-FAILURE;
HYPERTENSIVE PATIENTS; AFRICAN-AMERICANS; PEPTIDE INFUSION; BRAIN;
PREVALENCE; PRESSURE; IMPACT
AB Introduction: Heart failure develops earlier and is more prevalent in blacks than whites because of their higher incidence of hypertension and diabetes and likely subsequent diastolic dysfunction. Natriuretic peptides (NP) prevent cardiac malfunction through pressure, natriuresis action. However, whether race affects the relationships of NP action with cardiac function is unknown. Methods: To assess this, 55 (21 whites and 27 males) normotensive adults underwent a 2-hour protocol of 40 minutes rest, video game stressor and recovery. Mitral inflow and myocardial velocities (tissue Doppler) were recorded every 20 minutes. Blood pressure and heart rate were obtained at 10-minute intervals. Blood samples for proatrial NP and pro-brain NP (pro-BNP) were collected every 40 minutes. Results: There were differences in the association between (1) the changes from rest to stress for E/A ratio and double product (whites, r = -0.42; blacks, r = 0. 10; P = 0.034 for difference between correlations); (2) stress E-m and pro-atrial NP (whites, r = 0.59; blacks, r = -0.25; P = 0.025); (3) rest E-m and BNP (whites, r = 0.83; blacks r = -0.17; P = 000); (4) rest E-m/A(m) and pro-BNP (whites, r = 0.70; blacks, r = -0.42; P = 0.003); (5) rest E/E-m and pro-BNP (whites, r = -0.61; blacks, r = 0.31; P = 0.015) and (6) stress E and pro-BNP (whites, r = 0.56; blacks, r = -0.18; P = 0.043). Conclusion: The higher correlations between levels of NP and diastolic function indices both at rest and stress suggest that NP protective action is more pronounced in whites than in blacks.
C1 [Kapuku, Gaston K.; Davis, Harry C.; Harshfield, Gregory A.] Georgia Hlth Sci Univ, Med Coll Georgia, Georgia Prevent Inst, Dept Pediat, Augusta, GA 30912 USA.
[Kapuku, Gaston K.] Georgia Hlth Sci Univ, Dept Med, Med Coll Georgia, Augusta, GA USA.
[Thomas, Patrick; Januzzi, James] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Kapuku, GK (reprint author), Georgia Hlth Sci Univ, Med Coll Georgia, Georgia Prevent Inst, Dept Pediat, MCG Annex HS 1640, Augusta, GA 30912 USA.
EM gkapuku@georgiahealth.edu
FU NIH [HL076696]; AHA [0530046N]
FX This study was supported by grants from NIH (HL076696) and AHA
(0530046N).
NR 28
TC 2
Z9 2
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0002-9629
J9 AM J MED SCI
JI Am. J. Med. Sci.
PD AUG
PY 2012
VL 344
IS 2
BP 96
EP 99
DI 10.1097/MAJ.0b013e31823673fd
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA 981KJ
UT WOS:000306966300003
PM 22314104
ER
PT J
AU Rosow, CE
AF Rosow, Carl E.
TI Making Sedation Safer Is Simulation the Answer?
SO ANESTHESIOLOGY
LA English
DT Editorial Material
ID MIDAZOLAM
C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02115 USA.
RP Rosow, CE (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02115 USA.
EM crosow@partners.org
NR 4
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0003-3022
J9 ANESTHESIOLOGY
JI Anesthesiology
PD AUG
PY 2012
VL 117
IS 2
BP 232
EP 233
DI 10.1097/ALN.0b013e31825fb1e9
PG 2
WC Anesthesiology
SC Anesthesiology
GA 981RG
UT WOS:000306986600004
PM 22692383
ER
PT J
AU Buvanendran, A
Rathmell, JP
AF Buvanendran, Asokumar
Rathmell, James P.
TI Ultrasound versus Fluoroscopy in Image-guided Pain Treatment Use Caution
SO ANESTHESIOLOGY
LA English
DT Editorial Material
ID STELLATE GANGLION BLOCK; MEDIAL BRANCH-BLOCK; NERVE; ACCURACY
C1 [Buvanendran, Asokumar] Rush Univ, Coll Med, Dept Anesthesiol, Chicago, IL 60612 USA.
[Rathmell, James P.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA.
[Rathmell, James P.] Harvard Univ, Sch Med, Dept Anaesthesia, Boston, MA 02115 USA.
RP Buvanendran, A (reprint author), Rush Univ, Coll Med, Dept Anesthesiol, Chicago, IL 60612 USA.
EM asokumar@aol.com
NR 9
TC 1
Z9 1
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0003-3022
J9 ANESTHESIOLOGY
JI Anesthesiology
PD AUG
PY 2012
VL 117
IS 2
BP 236
EP 237
DI 10.1097/ALN.0b013e3182605e2a
PG 2
WC Anesthesiology
SC Anesthesiology
GA 981RG
UT WOS:000306986600006
PM 22705570
ER
PT J
AU Wilhelm, S
Peterson, AL
Piacentini, J
Woods, DW
Deckersbach, T
Sukhodolsky, DG
Chang, S
Liu, HB
Dziura, J
Walkup, JT
Scahill, L
AF Wilhelm, Sabine
Peterson, Alan L.
Piacentini, John
Woods, Douglas W.
Deckersbach, Thilo
Sukhodolsky, Denis G.
Chang, Susanna
Liu, Haibei
Dziura, James
Walkup, John T.
Scahill, Lawrence
TI Randomized Trial of Behavior Therapy for Adults With Tourette Syndrome
SO ARCHIVES OF GENERAL PSYCHIATRY
LA English
DT Article
ID PLACEBO-CONTROLLED TRIAL; HABIT REVERSAL; TIC DISORDERS; SUPPORTIVE
PSYCHOTHERAPY; CHILDREN; SUPPRESSION; RISPERIDONE; ADOLESCENTS; SEVERITY
AB Context: Tics in Tourette syndrome begin in childhood, peak in early adolescence, and often decrease by early adulthood. However, some adult patients continue to have impairing tics. Medications for tics are often effective but can cause adverse effects. Behavior therapy may offer an alternative but has not been examined in a large-scale controlled trial in adults.
Objective: To test the efficacy of a comprehensive behavioral intervention for tics in adults with Tourette syndrome of at least moderate severity.
Design: A randomized controlled trial with posttreatment evaluations at 3 and 6 months for positive responders.
Setting: Three outpatient research clinics.
Patients: Patients (N=122; 78 males; age range, 16-69 years) with Tourette syndrome or chronic tic disorder were recruited between December 27, 2005, and May 21, 2009.
Interventions: Patients received 8 sessions of comprehensive behavioral intervention for tics or 8 sessions of supportive treatment for 10 weeks. Patients with a positive response were given 3 monthly booster sessions.
Main Outcome Measures: Total tic score on the Yale Global Tic Severity Scale and the Clinical Global Impression-Improvement scale rated by a clinician masked to treatment assignment.
Results: Behavior therapy was associated with a significantly greater mean (SD) decrease on the Yale Global Tic Severity Scale (24.0[6.47] to 17.8[7.32]) from baseline to end point compared with the control treatment (21.8[6.59] to 19.3[7.40]) (P < .001; effect size=0.57). Twenty-four of 63 patients (38.1%) were rated as much improved or very much improved on the Clinical Global Impression-Improvement scale compared with 4 of 63 (6.4%) in the control group (P < .001). Attrition was 13.9%, with no difference across groups. Patients receiving behavior therapy who were available for assessment at 6 months after treatment showed continued benefit.
Conclusion: Comprehensive behavior therapy is a safe and effective intervention for adults with Tourette syndrome.
C1 [Wilhelm, Sabine; Deckersbach, Thilo] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Peterson, Alan L.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Sukhodolsky, Denis G.; Scahill, Lawrence] Yale Univ, Sch Nursing, Yale Child Study Ctr, New Haven, CT 06536 USA.
[Liu, Haibei; Dziura, James] Yale Univ, Sch Med, New Haven, CT USA.
[Piacentini, John; Chang, Susanna] Univ Calif Los Angeles, Los Angeles, CA USA.
[Woods, Douglas W.] Univ Wisconsin, Milwaukee, WI 53201 USA.
[Walkup, John T.] Johns Hopkins Med Inst, Baltimore, MD 21205 USA.
RP Wilhelm, S (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Simches Res Bldg,185 Cambridge St,Ste 2282, Boston, MA 02114 USA.
EM wilhelm@psych.mgh.harvard.edu
OI Sukhodolsky, Denis/0000-0002-5401-792X; Scahill,
Lawrence/0000-0001-5073-1707
FU Oxford University Press; National Institutes of Health; Guilford
Publications; New Harbinger Publications; American Psychological
Association; National Institute of Mental Health; New Harbinger and
Springer Publications; American Psychiatric Press; Eli Lilly; JAZZ
Pharmaceuticals; CMP Media; Medical Education Reviews; McMahon Group;
DiMedix; Tourette Disorder Association; National Institute of Mental
Health [5R01MH069877, R01MH069874, RO1MH069875]; Yale University
Clinical and Translational Sciences Award [UL1 RR024139]; National
Center for Research Resources, National Institutes of Health; Tourette
Syndrome Association
FX Drs Wilhelm, Peterson, Piacentini, Woods, Deckersbach, Chang, Walkup,
and Scahill report receiving royalties from Oxford University Press for
a treatment manual on tic disorders. Drs Wilhelm, Peterson, Piacentini,
Woods, Chang, Sukhodolsky, Walkup, and Scahill report receiving
honoraria for continuing education presentations from the Tourette
Syndrome Association. Drs Piacentini, Woods, and Walkup receive
royalties from Guilford Press for a book on Tourette disorder. Dr
Wilhelm reports receiving support in the form of free medication and
matching placebo from Forest Laboratories for clinical trials funded by
the National Institutes of Health and receiving book royalties from
Guilford Publications, New Harbinger Publications, and Oxford University
Press and speaking honoraria from PRIMEDIA Healthcare, a publicly traded
company working as a logistics collaborator for the Massachusetts
General Hospital Psychiatry Academy (the education programs conducted by
the Massachusetts General Hospital Psychiatry Academy were supported
through independent medical education grants from pharmaceutical
companies cosupporting the overall program, along with participant
tuition). Dr Piacentini reports receiving royalties from Oxford
University Press for treatment manuals on child obsessive-compulsive
disorder and American Psychological Association Books for other books on
child mental health, speaking honoraria from Janssen-Cilag, and support
in the form of free medication and matching placebo from Pfizer for
clinical trials funded by the National Institute of Mental Health. Dr
Woods reports receiving book royalties from New Harbinger and Springer
Publications. Dr Scahill has received royalties from Oxford University
Press and American Psychiatric Press; has served as a consultant for
Boehringer-Ingelheim, Biomarin, Hoffman NeuroSearch, and Pfizer; and has
had research support from Shire Pharmaceutical and Seaside Therapeutics.
He also reports receiving support in the form of free medication and
matching placebo from Shire Pharmaceuticals for a clinical trial funded
by the National Institute of Mental Health. Dr Deckersbach reports
receiving consulting fees from the Constella Group for serving as a
reviewer for the Department of Defense's Congressionally Directed
Medical Research Program. He also reports receiving honoraria,
consulting fees, and/or royalties from Medacorp, Massachusetts General
Hospital Psychiatry Academy, BrainCells Inc, Systems Research and
Applications Corp, Boston University, the Catalan Agency for Health
Technology Assessment and Research, and the National Association of
Social Workers-Massachusetts. He reports participating in research
funded by Janssen, Forest Research Institute, Shire Development Inc,
Medtronic, Cyberonics, and Northstar. Dr Walkup reports receiving
consulting fees from Eli Lilly and JAZZ Pharmaceuticals and lecture fees
from CMP Media, Medical Education Reviews, McMahon Group, DiMedix, and
the Tourette Disorder Association. He reports receiving free drug and
matching placebo from Pfizer and Lilly and free drugs from Abbott for
National Institute of Mental Health-funded clinical trials. He reports
receiving fees for consultation with defense counsel and submission of
written reports in litigation involving GlaxoSmithKline. This work was
supported by grants 5R01MH069877 (Dr Wilhelm), R01MH069874 (Dr Scahill),
and RO1MH069875 (Dr Petersen) from the National Institute of Mental
Health with subcontracts to Drs Piacentini and Woods. Dr Walkup
consulted on this grant.; Drs Scahill and Dziura receive support from
the Yale University Clinical and Translational Sciences Award grant UL1
RR024139 from the National Center for Research Resources, National
Institutes of Health. This study was also supported by Tourette Syndrome
Association funding to Dr Scahill.
NR 47
TC 72
Z9 72
U1 1
U2 14
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 0003-990X
J9 ARCH GEN PSYCHIAT
JI Arch. Gen. Psychiatry
PD AUG
PY 2012
VL 69
IS 8
BP 795
EP 803
DI 10.1001/archgenpsychiatry.2011.1528
PG 9
WC Psychiatry
SC Psychiatry
GA 984JD
UT WOS:000307185000005
PM 22868933
ER
PT J
AU Mansbach, JM
Piedra, PA
Teach, SJ
Sullivan, AF
Forgey, T
Clark, S
Espinola, JA
Camargo, CA
AF Mansbach, Jonathan M.
Piedra, Pedro A.
Teach, Stephen J.
Sullivan, Ashley F.
Forgey, Tate
Clark, Sunday
Espinola, Janice A.
Camargo, Carlos A., Jr.
CA MARC-30 Investigators
TI Prospective Multicenter Study of Viral Etiology and Hospital Length of
Stay in Children With Severe Bronchiolitis
SO ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE
LA English
DT Article
ID RESPIRATORY SYNCYTIAL VIRUS; REAL-TIME PCR; RHINOVIRUS INFECTION; HUMAN
METAPNEUMOVIRUS; ASTHMA DEVELOPMENT; CLINICAL SYMPTOMS; DISEASE
SEVERITY; RISK-FACTORS; INFANTS; EXPRESSION
AB Objective: To determine whether hospital length of stay (LOS) for acute bronchiolitis is influenced by the infecting pathogen.
Design: A prospective observational cohort study was performed during 3 consecutive years.
Setting: Sixteen US hospitals participated in the study.
Participants: Children younger than 2 years hospitalized with bronchiolitis were included.
Main Exposure: The results of nasopharyngeal aspirate polymerase chain reaction pathogen testing served as the main exposure.
Main Outcome Measure: Hospital LOS was determined.
Results: Of 2207 participants, 72.0% had respiratory syncytial virus (RSV) and 25.6% had human rhinovirus (HRV); the incidence of each of the other viruses and bacteria was 7.8% or less. Multiple pathogen infections were present in 29.8% of the children. There were 1866 children (84.5%) with RSV and/or HRV. Among these 1866 children, the median age was 4 months and 59.5% were male. The median LOS was 2 days (interquartile range, 1-4 days). Compared with children who had only RSV, an LOS of 3 or more days was less likely among children with HRV alone (adjusted odds ratio [AOR], 0.36; 95% CI, 0.20-0.63; P < .001) and those with HRV plus non-RSV pathogens (AOR, 0.39; 95% CI, 0.23-0.66; P < .001) but more likely among children with RSV plus HRV(AOR, 1.33; 95% CI, 1.02-1.73; P =. 04), controlling for 15 demographic and clinical factors.
Conclusions: In this multicenter study of children hospitalized with bronchiolitis, RSV was the most common virus detected, but HRV was detected in one-quarter of the children. Since 1 in 3 children had multiple virus infections and HRV was associated with LOS, these data challenge the effectiveness of current RSV-based cohorting practices, the sporadic testing for HRV in bronchiolitis research, and current thinking that the infectious etiology of severe bronchiolitis does not affect short-term outcomes.
C1 [Mansbach, Jonathan M.] Harvard Univ, Sch Med, Childrens Hosp Boston, Dept Med, Boston, MA 02115 USA.
[Sullivan, Ashley F.; Forgey, Tate; Espinola, Janice A.; Camargo, Carlos A., Jr.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02115 USA.
[Piedra, Pedro A.] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA.
[Piedra, Pedro A.] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA.
[Teach, Stephen J.] Childrens Natl Med Ctr, Dept Pediat, Washington, DC 20010 USA.
[Clark, Sunday] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA.
RP Mansbach, JM (reprint author), Harvard Univ, Sch Med, Childrens Hosp Boston, Dept Med, 300 Longwood Ave,Main Clin Bldg 9 S,Ste 9157, Boston, MA 02115 USA.
EM jonathan.mansbach@childrens.harvard.edu
FU National Institutes of Health [U01 AI-67693, K23 AI-77801, UL1
RR-031988]
FX This study was supported by grants U01 AI-67693, K23 AI-77801, and UL1
RR-031988 from the National Institutes of Health.
NR 45
TC 95
Z9 102
U1 1
U2 6
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 1072-4710
J9 ARCH PEDIAT ADOL MED
JI Arch. Pediatr. Adolesc. Med.
PD AUG
PY 2012
VL 166
IS 8
BP 700
EP 706
DI 10.1001/archpediatrics.2011.1669
PG 7
WC Pediatrics
SC Pediatrics
GA 984KU
UT WOS:000307189300003
PM 22473882
ER
PT J
AU Morell, E
Wolfe, J
Scheurer, M
Thiagarajan, R
Morin, C
Beke, DM
Smoot, L
Cheng, H
Gauvreau, K
Blume, ED
AF Morell, Emily
Wolfe, Joanne
Scheurer, Mark
Thiagarajan, Ravi
Morin, Caroline
Beke, Dorothy M.
Smoot, Leslie
Cheng, Henry
Gauvreau, Kimberlee
Blume, Elizabeth D.
TI Patterns of Care at End of Life in Children With Advanced Heart Disease
SO ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE
LA English
DT Article
ID UNITED-STATES; CANCER; TRANSPLANTATION
AB Objective: To describe patterns of care for pediatric patients with advanced heart disease who experience in-hospital death.
Design: Retrospective single-institution medical record review.
Setting: A tertiary care pediatric hospital.
Participants: All patients younger than 21 years who died in the inpatient setting between January 1, 2007, and December 31, 2009, with primary cardiac diagnoses or who had ever received a cardiology consult (N = 468). After excluding patients with significant noncardiac primary diagnoses, 111 children formed the analytic sample.
Main Outcome Measure: In-hospital deaths of children with heart disease during a 3-year period.
Results: Median age at death was 4.8 months (age range, 1 day to 20.5 years), with 84 deaths (75.7%) occurring before age 1 year. Median length of terminal hospital stay was 22 days (range, 1-199 days). Diagnoses included 84 patients (75.7%) with congenital heart disease, 10 (9.0%) with cardiomyopathy/ myocarditis, 9 (8.1%) with pulmonary hypertension, and 8 (7.2%) with heart transplants. Sixty-two patients (55.9%) had received cardiopulmonary resuscitation during their last hospital admission. At the end of life, 21 children (18.9%) had gastrostomy tubes and 26 (23.4%) had peritoneal drains. Most patients (91.9%) received ventilation, with half also receiving mechanical circulatory support. Eighty-three patients (74.8%) experienced additional end-organ failure. Classified by mode of death, 76 patients (68.5%) had disease-directed support withdrawn, 28 (25.2%) died during resuscitation, and 7 (6.3%) died while receiving comfort care after birth. Eighty-three percent of parents were present at the time of death.
Conclusion: Infants and children who die of advanced heart disease frequently succumb in the intensive care setting with multisystem organ failure and exposure to highly technical care.
C1 [Scheurer, Mark; Thiagarajan, Ravi; Morin, Caroline; Beke, Dorothy M.; Smoot, Leslie; Cheng, Henry; Gauvreau, Kimberlee; Blume, Elizabeth D.] Childrens Hosp, Dept Cardiol, Boston, MA 02115 USA.
[Morell, Emily] Harvard Univ, Sch Med, Boston, MA USA.
[Wolfe, Joanne] Dana Farber Canc Inst, Div Palliat Care Med, Boston, MA 02115 USA.
[Scheurer, Mark] Med Univ S Carolina, Dept Pediat, Div Cardiol, Charleston, SC USA.
RP Blume, ED (reprint author), Childrens Hosp, Dept Cardiol, 300 Longwood Ave, Boston, MA 02115 USA.
EM Betsy.Blume@CARDIO.CHBOSTON.ORG
FU Heart Failure and Transplant Educational Fund; Kara Duclos Fund; Ghiso
Fellowship for Compassionate Medical Care, Harvard Medical School
FX This study was supported by the Heart Failure and Transplant Educational
Fund (Dr Blume), the Kara Duclos Fund, and the Ghiso Fellowship for
Compassionate Medical Care, Harvard Medical School (Ms Morell).
NR 9
TC 13
Z9 13
U1 0
U2 8
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 1072-4710
J9 ARCH PEDIAT ADOL MED
JI Arch. Pediatr. Adolesc. Med.
PD AUG
PY 2012
VL 166
IS 8
BP 745
EP 748
DI 10.1001/archpediatrics.2011.1829
PG 4
WC Pediatrics
SC Pediatrics
GA 984KU
UT WOS:000307189300010
PM 22473887
ER
PT J
AU Wong, S
Smith, M
Oudard, S
Karsh, L
Egerdie, B
Van Veldhuizen, P
Gomez-Veiga, F
Dearnaley, D
Dogliotti, L
Fisher, H
Wirth, M
Charu, V
Kueppers, F
de Oca, LM
Rendon, R
Pavlik, I
Julka, PK
Ye, Z
Dansey, R
Goessl, C
AF Wong, S.
Smith, M.
Oudard, S.
Karsh, L.
Egerdie, B.
Van Veldhuizen, P.
Gomez-Veiga, F.
Dearnaley, D.
Dogliotti, L.
Fisher, H.
Wirth, M.
Charu, V.
Kueppers, F.
Montes de Oca, L.
Rendon, R.
Pavlik, I.
Julka, P. K.
Ye, Z.
Dansey, R.
Goessl, C.
TI BONE METASTASIS-FREE SURVIVAL IN MEN WITH CASTRATION-RESISTANT PROSTATE
CANCER TREATED WITH DENOSUMAB: SUB-GROUP ANALYSES FROM A PHASE III
RANDOMISED, DOUBLE-BLIND TRIAL
SO ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 [Wong, S.] Western Hosp, Melbourne, Vic, Australia.
[Smith, M.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
[Oudard, S.] Georges Pompidou Hosp, Paris, France.
[Karsh, L.] Urol Ctr Colorado, Denver, CO USA.
[Egerdie, B.] Urol Associates Urol Med Res, Kitchener, ON, Canada.
[Van Veldhuizen, P.] Kansas City VA Med Ctr, Kansas City, MO USA.
[Gomez-Veiga, F.] Hosp Univ Juan Canalejo, La Coruna, Spain.
[Dearnaley, D.] Royal Marsden Hosp, Inst Canc Res, Sutton, Surrey, England.
[Dogliotti, L.] Osped San Luigi Gonzaga, Orbassano, Italy.
[Fisher, H.] Urol Inst NE New York, Albany, NY USA.
[Wirth, M.] Univ Klinikum Carl Gustav Carus, Dresden, Germany.
[Charu, V.] Pacific Canc Med Ctr Inc, Anaheim, CA USA.
[Kueppers, F.] Canterbury Urol Res Trust, Christchurch, New Zealand.
[Montes de Oca, L.] Ctr Diagnost Urol, Buenos Aires, DF, Argentina.
[Rendon, R.] Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada.
[Pavlik, I.] Gen Teaching Hosp, Prague, Czech Republic.
[Pavlik, I.] Fac Med 1, Prague, Czech Republic.
[Julka, P. K.] All India Inst Med Sci, New Delhi, India.
[Ye, Z.; Dansey, R.; Goessl, C.] Amgen Inc, Thousand Oaks, CA 91320 USA.
NR 1
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1743-7555
J9 ASIA-PAC J CLIN ONCO
JI Asia-Pac. J. Clin. Oncol.
PD AUG
PY 2012
VL 8
SU 2
SI SI
BP 41
EP 42
PG 2
WC Oncology
SC Oncology
GA 981IK
UT WOS:000306960100013
ER
PT J
AU Marx, GM
Smith, MR
Saad, F
Shore, ND
Oudard, S
Miller, K
Tombal, B
Sieber, P
Fizazi, K
Van Veldhuizen, PJ
Damiao, R
Morote, J
Feng, A
Dansey, R
Goessl, C
AF Marx, G. M.
Smith, M. R.
Saad, F.
Shore, N. D.
Oudard, S.
Miller, K.
Tombal, B.
Sieber, P.
Fizazi, K.
Van Veldhuizen, P. J.
Damiao, R.
Morote, J.
Feng, A.
Dansey, R.
Goessl, C.
TI DENOSUMAB PROLONGS BONE-METASTASIS-FREE SURVIVAL IN MEN WITH
NON-METASTATIC CASTRATE-RESISTANT PROSTATE CANCER PRESENTING WITH
AGGRESSIVE PROSTATE-SPECIFIC ANTIGEN KINETICS: A POST HOC SUBSET
ANALYSIS
SO ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 [Marx, G. M.] Sydney Haematol Oncol Clin, Sydney, NSW, Australia.
[Marx, G. M.] Univ Sydney, Sydney, NSW 2006, Australia.
[Smith, M. R.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
[Saad, F.] Univ Montreal, Ctr Hosp, Montreal, PQ, Canada.
[Shore, N. D.] Carolina Urol Res Ctr, Myrtle Beach, SC USA.
[Oudard, S.] Georges Pompidou European Hosp, Paris, France.
[Miller, K.] Charite, D-13353 Berlin, Germany.
[Tombal, B.] Catholic Univ Louvain, Clin Univ St Luc, B-1200 Brussels, Belgium.
[Sieber, P.] Urol Associates Lancaster Ltd, Lancaster, PA USA.
[Fizazi, K.] Univ Paris Sud, Inst Gustave Roussy, Paris, France.
[Van Veldhuizen, P. J.] Kansas City VA Med Ctr, Kansas City, MO USA.
[Damiao, R.] Hosp Univ Pedro Ernesto, Rio De Janeiro, Brazil.
[Morote, J.] Vall dHebron Univ Hosp, Barcelona, Spain.
[Feng, A.; Dansey, R.; Goessl, C.] Amgen Inc, Thousand Oaks, CA 91320 USA.
EM khutton@amgen.com
NR 1
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1743-7555
J9 ASIA-PAC J CLIN ONCO
JI Asia-Pac. J. Clin. Oncol.
PD AUG
PY 2012
VL 8
SU 2
SI SI
BP 45
EP 45
PG 1
WC Oncology
SC Oncology
GA 981IK
UT WOS:000306960100016
ER
PT J
AU Park, EY
Kazlauskas, A
AF Park, Eun Young
Kazlauskas, Andrius
TI Primary human endothelial cells secrete agents that reduce
responsiveness to lysophosphatidic acid (LPA)
SO BIOSCIENCE REPORTS
LA English
DT Article
DE conditioned medium; endothelial cell; intracellular signalling;
lysophosphatidic acid; vascular endothelial growth factor A
ID PHOSPHOLIPASE C-GAMMA; CELLULAR-RESPONSES; GROWTH-FACTOR;
PHOSPHORYLATION; RECEPTORS; AUTOTAXIN; BLOOD; DESENSITIZATION; GELSOLIN;
DISEASE
AB The plasma level of LPA (lysophosphatidic acid) (200-600 nM) is well within the range that promotes proliferation and migration of vascular ECs (endothelial cells), yet vessels are quiescent and stable. In this report, we considered one explanation for this paradox: that ECs secrete agents that attenuate responsiveness to LPA. Indeed, we observed that CM (conditioned medium) from confluent, quiescent cultures of primary HUVECs (human umbilical vein ECs) contained an agent that inhibited LPA-mediated signalling events and cellular responses. The putative inhibitor, which we tentatively call ILMR (inhibitor of LPA-mediated responsiveness) seemed to act on cells (instead of at the level of LPA) by suppressing the ability of LPA receptor 1 to signal. The amount and/or activity of ILMR was regulated by growth factors; exposing HUVECs to VEGF-A (vascular endothelial growth factor A), but not bFGF (basic fibroblast growth factor), reduced the amount and/or activity of ILMR in CM. We conclude that in addition to promoting angiogenesis directly, VEGF-A can also act indirectly by modulating the bioactivity of angiomodulators such as LPA.
C1 [Park, Eun Young; Kazlauskas, Andrius] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Schepens Eye Res Inst,Dept Ophthalmol, Boston, MA 02114 USA.
RP Kazlauskas, A (reprint author), Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Schepens Eye Res Inst,Dept Ophthalmol, Boston, MA 02114 USA.
EM andrius_kazlauskas@meei.harvard.edu
FU National Institutes of Health [EY018344]
FX This work was supported by the National Institutes of Health [grant
number EY018344 (to A.K.)].
NR 29
TC 5
Z9 5
U1 0
U2 2
PU PORTLAND PRESS LTD
PI LONDON
PA THIRD FLOOR, EAGLE HOUSE, 16 PROCTER STREET, LONDON WC1V 6 NX, ENGLAND
SN 0144-8463
J9 BIOSCIENCE REP
JI Biosci. Rep.
PD AUG
PY 2012
VL 32
IS 4
BP 393
EP 400
DI 10.1042/BSR20120033
PG 8
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 983TG
UT WOS:000307141000005
PM 22639801
ER
PT J
AU Yuen, HF
Abramczyk, O
Montgomery, G
Chan, KK
Huang, YH
Sasazuki, T
Shirasawa, S
Gopesh, S
Chan, KW
Fennell, D
Janne, P
El-Tanani, M
Murray, JT
AF Yuen, Hiu-Fung
Abramczyk, Olga
Montgomery, Grant
Chan, Ka-Kui
Huang, Yu-Han
Sasazuki, Takehiko
Shirasawa, Senji
Gopesh, Srivastava
Chan, Kwok-Wah
Fennell, Dean
Janne, Pasi
El-Tanani, Mohamed
Murray, James T.
TI Impact of oncogenic driver mutations on feedback between the PI3K and
MEK pathways in cancer cells
SO BIOSCIENCE REPORTS
LA English
DT Article
DE Akt; cancer cell; c-Met; K-Ras; mitogen-activated protein
kinase/extracellular-signal-regulated kinase kinase (MEK);
phosphoinositide 3-kinase (PI3K)
ID KINASE INHIBITOR CI-1040; PYRIDINYLFURANOPYRIMIDINE INHIBITOR;
PANCREATIC-CANCER; BREAST-CANCER; TUMOR-GROWTH; IN-VIVO; SURVIVAL;
PI-103; ACTIVATION; COLON
AB Inhibition of the PI3K (phosphoinositide 3-kinase)/Akt/mTORC1 (mammalian target of rapamycin complex 1) and Ras/MEK [MAPK (mitogen-activated protein kinase)/ERK (extracellular-signal-regulated kinase) kinase]/ERK pathways for cancer therapy has been pursued for over a decade with limited success. Emerging data have indicated that only discrete subsets of cancer patients have favourable responses to these inhibitors. This is due to genetic mutations that confer drug insensitivity and compensatory mechanisms. Therefore understanding of the feedback mechanisms that occur with respect to specific genetic mutations may aid identification of novel biomarkers that predict patient response. In the present paper, we show that feedback between the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways is cell-line-specific and highly dependent on the activating mutation of K-Ras or overexpression c-Met. We found that cell lines exhibited differential signalling and apoptotic responses to PD184352, a specific MEK inhibitor, and PI103, a second-generation class I PI3K inhibitor. We reveal that feedback from the PI3K/Akt/mTORC1 to the Ras/MEK/ERK pathway is present in cancer cells harbouring either K-Ras activating mutations or amplification of c-Met but not the wild-type counterparts. Moreover, we demonstrate that inhibition of protein phosphatase activity by OA (okadaic acid) restored PI103-mediated feedback in wild-type cells. Together, our results demonstrate a novel mechanism for feedback between the PI3K/Akt/mTORC1 and the Ras/MEK/ERK pathways that only occurs in K-Ras mutant and c-Met amplified cells but not the isogenic wild-type cells through a mechanism that may involve inhibition of a specific endogenous phosphatase(s) activity. We conclude that monitoring K-Ras and c-Met status are important biomarkers for determining the efficacy of PI103 and other PI3K/Akt inhibitors in cancer therapy.
C1 [Yuen, Hiu-Fung; Montgomery, Grant; Chan, Ka-Kui; El-Tanani, Mohamed; Murray, James T.] Queens Univ Belfast, CCRCB, Belfast, Antrim, North Ireland.
[Yuen, Hiu-Fung; Huang, Yu-Han] ASTAR, Inst Mol & Cell Biol, Singapore, Singapore.
[Abramczyk, Olga] M Nencki Inst Expt Biol, PL-02093 Warsaw, Poland.
[Sasazuki, Takehiko; Shirasawa, Senji] Fukuoka Univ, Fac Med, Dept Cell Biol, Fukuoka, Japan.
[Gopesh, Srivastava; Chan, Kwok-Wah] Univ Hong Kong, Fac Med, Dept Pathol, Hong Kong, Hong Kong, Peoples R China.
[Fennell, Dean] Univ Leicester, MRC Toxicol Unit, Leicester, Leics, England.
[Janne, Pasi] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
RP El-Tanani, M (reprint author), Queens Univ Belfast, CCRCB, Belfast, Antrim, North Ireland.
EM m.el-tanani@qub.ac.uk; j.t.murray@qub.ac.uk
RI ASTAR, IMCB/E-2320-2012;
OI Murray, James/0000-0002-6928-2347
FU Cancer Research, U.K. (China Fellowship); Almac Discovery, U.K.
FX This study was supported by Cancer Research, U.K. (China Fellowship to
H.-F.Y.) and Almac Discovery, U.K. (an exploratory grant to O.A.)
NR 40
TC 11
Z9 11
U1 0
U2 6
PU PORTLAND PRESS LTD
PI LONDON
PA THIRD FLOOR, EAGLE HOUSE, 16 PROCTER STREET, LONDON WC1V 6 NX, ENGLAND
SN 0144-8463
J9 BIOSCIENCE REP
JI Biosci. Rep.
PD AUG
PY 2012
VL 32
IS 4
BP 413
EP 422
DI 10.1042/BSR20120050
PG 10
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 983TG
UT WOS:000307141000007
PM 22668349
ER
PT J
AU Ancukiewicz, M
Miller, CL
Skolny, MN
O'Toole, J
Warren, LE
Jammallo, LS
Specht, MC
Taghian, AG
AF Ancukiewicz, Marek
Miller, Cynthia L.
Skolny, Melissa N.
O'Toole, Jean
Warren, Laura E.
Jammallo, Lauren S.
Specht, Michelle C.
Taghian, Alphonse G.
TI Comparison of relative versus absolute arm size change as criteria for
quantifying breast cancer-related lymphedema: the flaws in current
studies and need for universal methodology
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE Breast cancer-related lymphedema; Quantification of lymphedema; Arm
swelling; Quality of life
ID RANDOMIZED CONTROLLED-TRIAL; SENTINEL NODE BIOPSY; LIMB VOLUME CHANGE;
QUALITY-OF-LIFE; POSTMASTECTOMY LYMPHEDEMA; AXILLARY DISSECTION; LASER
THERAPY; RISK-FACTORS; SURGERY; SURVIVORS
AB The purpose of this article is to evaluate arm measurements of breast cancer patients to critically assess absolute change in arm size compared to relative arm volume change as criteria for quantifying breast cancer-related lymphedema (BCRL). We used pre-operative measurements of 677 patients screened for BCRL before and following treatment of unilateral breast cancer at Massachusetts General Hospital between 2005 and 2008 to model the effect of an absolute change in arm size of 200 mL or 2 cm compared to relative arm volume change. We also used sequential measurements to analyze temporal variation in unaffected arm volume. Pre-operative arm volumes ranged from 1,270 to 6,873 mL and correlated strongly (Kendall's tau = 0.55) with body mass index (BMI). An absolute arm volume change of 200 mL corresponded to relative arm volume changes ranging from 2.9 to 15.7 %. In a subset of 45 patients, modeling of a 2-cm change in arm circumference predicted relative arm volume changes ranging from 6.0 to 9.8 %. Sequential measurements of 124 patients with > 6 measurements demonstrated remarkable temporal variation in unaffected arm volume (median within-patient change 10.5 %). The magnitude of such fluctuations correlated (tau = 0.36, P < 0.0001) with pre-operative arm volume, patient weight, and BMI when quantified as absolute volume change, but was independent of these variables when quantified as relative arm volume change (P > .05). Absolute changes in arm size used as criteria for BCRL are correlated with pre-operative and temporal changes in body size. Therefore, utilization of absolute volume or circumference change in clinical trials is flawed because specificity depends strongly on patient body size. Relative arm volume change is independent of body size and should thus be used as the standard criterion for diagnosis of BCRL.
C1 [Ancukiewicz, Marek; Miller, Cynthia L.; Skolny, Melissa N.; Warren, Laura E.; Jammallo, Lauren S.; Taghian, Alphonse G.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
[O'Toole, Jean] Massachusetts Gen Hosp, Dept Phys & Occupat Therapy, Boston, MA 02114 USA.
[Specht, Michelle C.] Massachusetts Gen Hosp, Div Surg Oncol, Boston, MA 02114 USA.
RP Taghian, AG (reprint author), Massachusetts Gen Hosp, Dept Radiat Oncol, 55 Fruit St, Boston, MA 02114 USA.
EM ataghian@partners.org
FU National Cancer Institute [R01CA139118, P50CA089393]
FX The project described was supported by Award no. R01CA139118 (AGT) and
Award no. P50CA089393 (AGT) from the National Cancer Institute. The
content is solely the responsibility of the authors and does not
necessarily represent the official views of the National Cancer
Institute or the National Institutes of Health.
NR 61
TC 29
Z9 29
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-6806
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD AUG
PY 2012
VL 135
IS 1
BP 145
EP 152
DI 10.1007/s10549-012-2111-8
PG 8
WC Oncology
SC Oncology
GA 986HW
UT WOS:000307333700014
PM 22710706
ER
PT J
AU Jakubowiak, AJ
Richardson, PG
Zimmerman, T
Alsina, M
Kaufman, JL
Kandarpa, M
Kraftson, S
Ross, CW
Harvey, C
Hideshima, T
Sportelli, P
Poradosu, E
Gardner, L
Giusti, K
Anderson, KC
AF Jakubowiak, Andrzej J.
Richardson, Paul G.
Zimmerman, Todd
Alsina, Melissa
Kaufman, Jonathan L.
Kandarpa, Malathi
Kraftson, Stephanie
Ross, Charles W.
Harvey, Colleen
Hideshima, Teru
Sportelli, Peter
Poradosu, Enrique
Gardner, Lesa
Giusti, Kathy
Anderson, Kenneth C.
TI Perifosine plus lenalidomide and dexamethasone in relapsed and
relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma
Research Consortium study
SO BRITISH JOURNAL OF HAEMATOLOGY
LA English
DT Article
DE perifosine; lenalidomide; dexamethasone; relapsed multiple myeloma; Akt
ID DOSE DEXAMETHASONE; BORTEZOMIB; COMBINATION; AKT; DOXORUBICIN;
RAPAMYCIN; CELLS
AB The combination of lenalidomidedexamethasone is active in multiple myeloma (MM). Preclinical data showed that the Akt inhibitor, perifosine, sensitized MM cells to lenalidomide and dexamethasone, providing the rationale for this Phase I, multicentre, single-arm study to assess the safety and determine the maximum-tolerated dose (MTD) of perifosinelenalidomidedexamethasone in relapsed and relapsed/refractory MM. Patients received escalating doses of perifosine 50100mg daily and lenalidomide 1525mg once daily on days 121 of each 28-d cycle, plus dexamethasone 2040mg weekly thereafter, as indicated. Thirty-two patients were enrolled across four dose cohorts. MTD was not reached, with 31 patients evaluable for safety/tolerability. The most common all-causality grade 1-2 adverse events were fatigue (48%) and diarrhoea (45%), and grade 34 neutropenia (26%), hypophosphataemia (23%), thrombocytopenia (16%), and leucopenia (13%). Among 30 evaluable patients, 73% (95% confidence interval, 57.589.2%) achieved a minimal response or better, including 50% with a partial response or better. Median progression-free survival was 10.8months and median overall survival 30.6months. Response was associated with phospho-Akt in pharmacodynamic studies. Perifosinelenalidomidedexamethasone was well tolerated and demonstrated encouraging clinical activity in relapsed and relapsed/refractory MM.
C1 [Jakubowiak, Andrzej J.; Kandarpa, Malathi; Kraftson, Stephanie; Harvey, Colleen] Univ Michigan, Ctr Canc, Ann Arbor, MI 48109 USA.
[Richardson, Paul G.; Hideshima, Teru; Anderson, Kenneth C.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Zimmerman, Todd] Univ Chicago, Ctr Canc, Chicago, IL 60637 USA.
[Alsina, Melissa] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA.
[Kaufman, Jonathan L.] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA.
[Ross, Charles W.] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA.
[Sportelli, Peter; Poradosu, Enrique; Gardner, Lesa] Keryx Biopharmaceut Inc, New York, NY USA.
[Giusti, Kathy] Multiple Myeloma Res Consortium, Norwalk, CT USA.
RP Jakubowiak, AJ (reprint author), Univ Chicago, Med Ctr, 5841 S Maryland Ave,MC 2115, Chicago, IL 60637 USA.
EM ajakubowiak@medicine.bsd.uchicago.edu
FU Keryx Biopharmaceuticals, Inc.; MMRC; Celgene; Millennium;
Ortho-Biotech; Merck
FX This trial was supported by Keryx Biopharmaceuticals, Inc. and the MMRC.
Writing support was funded by Keryx Biopharmaceuticals, Inc.; Research
funding: MA (Celgene, Millennium, Ortho-Biotech), JLK (Merck, Celgene),
KG No conflicts of interest declared
NR 30
TC 29
Z9 29
U1 1
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0007-1048
J9 BRIT J HAEMATOL
JI Br. J. Haematol.
PD AUG
PY 2012
VL 158
IS 4
BP 472
EP 480
DI 10.1111/j.1365-2141.2012.09173.x
PG 9
WC Hematology
SC Hematology
GA 978QO
UT WOS:000306760500006
PM 22640031
ER
PT J
AU Yotsumoto, Y
Seitz, AR
Shimojo, S
Sakagami, M
Watanabe, T
Sasaki, Y
AF Yotsumoto, Yuko
Seitz, Aaron R.
Shimojo, Shinsuke
Sakagami, Masamichi
Watanabe, Takeo
Sasaki, Yuka
TI Performance Dip in Motor Response Induced by Task-Irrelevant Weaker
Coherent Visual Motion Signals
SO CEREBRAL CORTEX
LA English
DT Article
DE fMRI; performance dip; pre-SMA/SMA; task-irrelevant stimulus; visual
motion stimulus
ID SURFACE-BASED ANALYSIS; MEDIAL FRONTAL-CORTEX; EVENT-RELATED FMRI;
PREFRONTAL CORTEX; FUNCTIONAL MRI; PRE-SMA; MOVING STIMULI; MACAQUE MT;
AREA; INHIBITION
AB The Performance Dip is a newly characterized behavioral phenomenon, where, paradoxically, a weaker task-irrelevant visual stimulus causes larger disturbances on the accuracy of a main letter identification task than a stronger stimulus does. Understanding mechanisms of the Performance Dip may provide insight into unconsciousness behavior. Here, we investigated the generalization of the Performance Dip. Specifically, we tested whether the Performance Dip occurs in a motion-related Simon task, and if so, whether the Performance Dip involves the same brain region, that is, the dorsolateral prefrontal cortex (DLPFC), previously implicated in the Performance Dip, or the supplementary motor area (SMA) and pre-SMA, implicated in a motion-related Simon Task. Subjects made manual directional responses according to the color of stochastic moving dots while ignoring the global direction of moving dots, which could be either congruent or incongruent to the response appropriate to the main task. We found that weak incongruent task-irrelevant stimuli caused a Performance Dip, in which the SMA and pre-SMA, rather than DLPFC, played critical roles. Our results suggest a possible common brain mechanism across different neural circuits, in which weak, but not strong, task-irrelevant information is free from inhibition and intrudes into neural circuits relevant to the main task.
C1 [Yotsumoto, Yuko; Sasaki, Yuka] Massachusetts Gen Hosp, Dept Radiol, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA.
[Yotsumoto, Yuko; Seitz, Aaron R.] Boston Univ, Dept Psychol, Boston, MA 02215 USA.
[Yotsumoto, Yuko; Watanabe, Takeo] Keio Univ, Global Ctr Excellence Program, Ctr Adv Res Log & Sensibil, Minato Ku, Tokyo 1080073, Japan.
[Seitz, Aaron R.] Univ Calif Riverside, Dept Psychol, Riverside, CA 92521 USA.
[Shimojo, Shinsuke] CALTECH, Div Biol Computat & Neural Syst, Pasadena, CA 91125 USA.
[Sakagami, Masamichi] Tamagawa Univ, Brain Sci Res Ctr, Machida, Tokyo 1948610, Japan.
[Sasaki, Yuka] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA.
RP Sasaki, Y (reprint author), Massachusetts Gen Hosp, Dept Radiol, Athinoula A Martinos Ctr Biomed Imaging, 149 13th St, Charlestown, MA 02129 USA.
EM yuka@nmr.mgh.harvard.edu
FU National Institutes of Health (NIH) [R01EY015980, EY019466, AG031941,
MH091801]; National Science Foundation [BCS-0345746, BCS-0549036,
BSC-0946776]; Human Frontier Foundation [RGP 18/2004]; NIH National
Center for Research Resources [P41RR14075, S10RR021110]; Mental Illness
and Neuroscience Discovery Institute; Athinoula A. Martinos Center for
Biomedical Imaging; Massachusetts General Hospital; ministry of
education, culture, sports, science and technology, Japan (MEXT); Japan
Science and Technology Agency (CREST); ERATO Shimojo Implicit Brain
Function Project; [KAKENHI-22830081]; [23680028]
FX National Institutes of Health (NIH, R01EY015980, EY019466, AG031941,
MH091801); the National Science Foundation (BCS-0345746, BCS-0549036,
BSC-0946776); the Human Frontier Foundation (RGP 18/2004); the NIH
National Center for Research Resources (P41RR14075, S10RR021110);
grants-in-aid for Scientific Research (KAKENHI-22830081, 23680028); the
Mental Illness and Neuroscience Discovery Institute; Athinoula A.
Martinos Center for Biomedical Imaging; Massachusetts General Hospital;
The ministry of education, culture, sports, science and technology,
Japan (MEXT) (Tamagawa global COE program, Grant-in-aid for Scientific
Research (A), Grant-in-aid for Scientific Research On Innovative Areas);
Japan Science and Technology Agency (CREST); and the ERATO Shimojo
Implicit Brain Function Project for their support on this project.
NR 42
TC 2
Z9 2
U1 0
U2 6
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1047-3211
J9 CEREB CORTEX
JI Cereb. Cortex
PD AUG
PY 2012
VL 22
IS 8
BP 1887
EP 1893
DI 10.1093/cercor/bhr270
PG 7
WC Neurosciences
SC Neurosciences & Neurology
GA 988JI
UT WOS:000307486100015
PM 21940704
ER
PT J
AU Stevens, WD
Kahn, I
Wig, GS
Schacter, DL
AF Stevens, W. Dale
Kahn, Itamar
Wig, Gagan S.
Schacter, Daniel L.
TI Hemispheric Asymmetry of Visual Scene Processing in the Human Brain:
Evidence from Repetition Priming and Intrinsic Activity
SO CEREBRAL CORTEX
LA English
DT Article
DE conceptual; laterality; parahippocampal place area; repetition
suppression; resting-state functional connectivity
ID STATE FUNCTIONAL CONNECTIVITY; EVENT-RELATED FMRI; HUMAN PARAHIPPOCAMPAL
CORTEX; LATERAL OCCIPITAL COMPLEX; RIGHT CEREBRAL HEMISPHERE; DEFAULT
MODE NETWORK; RESTING HUMAN BRAIN; EXPLICIT MEMORY; STRUCTURAL
CONNECTIVITY; ATTENTIONAL MODULATION
AB Asymmetrical specialization of cognitive processes across the cerebral hemispheres is a hallmark of healthy brain development and an important evolutionary trait underlying higher cognition in humans. While previous research, including studies of priming, divided visual field presentation, and split-brain patients, demonstrates a general pattern of right/left asymmetry of form-specific versus form-abstract visual processing, little is known about brain organization underlying this dissociation. Here, using repetition priming of complex visual scenes and high-resolution functional magnetic resonance imaging (MRI), we demonstrate asymmetrical form specificity of visual processing between the right and left hemispheres within a region known to be critical for processing of visual spatial scenes (parahippocampal place area [PPA]). Next, we use resting-state functional connectivity MRI analyses to demonstrate that this functional asymmetry is associated with differential intrinsic activity correlations of the right versus left PPA with regions critically involved in perceptual versus conceptual processing, respectively. Our results demonstrate that the PPA comprises lateralized subregions across the cerebral hemispheres that are engaged in functionally dissociable yet complementary components of visual scene analysis. Furthermore, this functional asymmetry is associated with differential intrinsic functional connectivity of the PPA with distinct brain areas known to mediate dissociable cognitive processes.
C1 [Stevens, W. Dale; Wig, Gagan S.; Schacter, Daniel L.] Harvard Univ, Dept Psychol, Cambridge, MA 02138 USA.
[Stevens, W. Dale; Kahn, Itamar; Wig, Gagan S.; Schacter, Daniel L.] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA.
[Kahn, Itamar] Harvard Univ, Howard Hughes Med Inst, Cambridge, MA 02138 USA.
[Wig, Gagan S.] Washington Univ, Dept Neurol, Sch Med, St Louis, MO 63104 USA.
RP Stevens, WD (reprint author), NIMH, Lab Brain & Cognit, NIH, Bldg 10,Rm 4C-101, Bethesda, MD 20892 USA.
EM william.stevens@nih.gov
OI Schacter, Daniel/0000-0002-2460-6061
FU National Institutes of Health [MH060941]
FX National Institutes of Health grant (MH060941 to D.L.S.).
NR 120
TC 19
Z9 19
U1 10
U2 30
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1047-3211
J9 CEREB CORTEX
JI Cereb. Cortex
PD AUG
PY 2012
VL 22
IS 8
BP 1935
EP 1949
DI 10.1093/cercor/bhr273
PG 15
WC Neurosciences
SC Neurosciences & Neurology
GA 988JI
UT WOS:000307486100020
PM 21968568
ER
PT J
AU Arifuzzaman, M
Rashu, R
Leung, DT
Hosen, MI
Bhuiyan, TR
Bhuiyan, MS
Rahman, MA
Khanam, F
Saha, A
Charles, RC
LaRocque, RC
Weil, AA
Clements, JD
Holmes, RK
Calderwood, SB
Harris, JB
Ryan, ET
Qadri, F
AF Arifuzzaman, Mohammad
Rashu, Rasheduzzaman
Leung, Daniel T.
Hosen, M. Ismail
Bhuiyan, Taufiqur Rahman
Bhuiyan, M. Saruar
Rahman, Mohammad Arif
Khanam, Farhana
Saha, Amit
Charles, Richelle C.
LaRocque, Regina C.
Weil, Ana A.
Clements, John D.
Holmes, Randall K.
Calderwood, Stephen B.
Harris, Jason B.
Ryan, Edward T.
Qadri, Firdausi
TI Antigen-Specific Memory T Cell Responses after Vaccination with an Oral
Killed Cholera Vaccine in Bangladeshi Children and Comparison to
Responses in Patients with Naturally Acquired Cholera
SO CLINICAL AND VACCINE IMMUNOLOGY
LA English
DT Article
ID HELICOBACTER-PYLORI; IMMUNE-RESPONSE; HELPER-CELLS; O1 INFECTION;
WHOLE-BLOOD; FOLLOW-UP; CD4(+); TOXIN; TRIAL; IMMUNOGENICITY
AB Young children, older children, and adults develop comparable levels and durations of immunity following cholera. In comparison, young children receiving oral killed cholera vaccines (OCV) develop a lower level and shorter duration of protection than those of older children and adults. The reasons for this are unclear. We investigated OCV-induced memory T cell responses in younger and older children and compared responses to those in children with cholera. We found that patients with cholera developed significant levels of toxin-specific effector memory T cells (T-EM) with follicular helper and gut-homing characteristics. Older children (6 to 14 years of age) receiving two doses of OCV containing recombinant cholera toxin B subunit (rCTB) had more modest T-EM responses with follicular helper and gut-homing characteristics, but younger vaccinees (24 to 71 months of age) did not develop T-EM responses. The T-EM response correlated positively with subsequent IgG memory B cell responses specific to rCTB in older vaccinees. Cytokine analyses indicated that cholera patients developed significant Th1, Th17, and Th2 responses, while older children receiving vaccine developed more modest increases in Th1 and Th17 cells. Younger vaccinees had no increase in Th1 cells, a decrease in Th17 cells, and an increase in regulatory T (Treg) cells. Our findings suggest that T cell memory responses are markedly diminished in children receiving OCV, especially young children, compared to responses following naturally acquired cholera, and that these differences affect subsequent development of memory B cell responses. These findings may explain the lower efficacy and shorter duration of protection afforded by OCV in young children.
C1 [Arifuzzaman, Mohammad; Leung, Daniel T.; Charles, Richelle C.; LaRocque, Regina C.; Weil, Ana A.; Calderwood, Stephen B.; Harris, Jason B.; Ryan, Edward T.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.
[Arifuzzaman, Mohammad; Rashu, Rasheduzzaman; Leung, Daniel T.; Hosen, M. Ismail; Bhuiyan, Taufiqur Rahman; Bhuiyan, M. Saruar; Rahman, Mohammad Arif; Khanam, Farhana; Saha, Amit; Qadri, Firdausi] Ctr Diarrhoeal Dis Res Bangladesh Icddr B, Ctr Vaccine Sci, Dhaka, Bangladesh.
[Leung, Daniel T.; Charles, Richelle C.; LaRocque, Regina C.; Calderwood, Stephen B.; Ryan, Edward T.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
[Clements, John D.] Tulane Univ, Med Ctr, Dept Microbiol & Immunol, New Orleans, LA USA.
[Holmes, Randall K.] Univ Colorado, Sch Med, Dept Microbiol, Aurora, CO USA.
[Calderwood, Stephen B.] Harvard Univ, Sch Med, Dept Microbiol & Immunobiol, Boston, MA USA.
[Harris, Jason B.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA.
[Ryan, Edward T.] Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA.
RP Qadri, F (reprint author), Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.
EM fqadri@icddrb.org
OI leung, daniel/0000-0001-8401-0801
FU icddr,b; National Institutes of Health; National Institute of Allergy
and Infectious Diseases [U01 AI058935, R03 AI063079, U01 AI077883, R01
AI31940]; Training Grant in Vaccine Development and Public Health
[TW005572]; American Recovery and Reinvestment Act (ARRA) Post-doctoral
Fellowship in Global Infectious Diseases [TW05572]; Career Development
Awards [K01 TW07409, TW07144, K08 AI089721]; Fogarty International
Center [R24 TW007988]; Howard Hughes Medical Institute; Burroughs
Welcome Fund/American Society of Tropical Medicine and Hygiene
Postdoctoral Fellowship in Tropical Infectious Diseases; Swedish Agency
for International Development and Cooperation
FX This work was supported by the icddr,b and grants from the National
Institutes of Health, including the National Institute of Allergy and
Infectious Diseases (U01 AI058935 [to S.B.C. and E.T.R.], R03 AI063079
[to F.Q.], U01 AI077883 [to E.T.R.], R01 AI31940 [to R.K.H.]), a
Training Grant in Vaccine Development and Public Health (TW005572 [to
M.A., F.K., T.R.B., M.S.B., and F.Q.]), an American Recovery and
Reinvestment Act (ARRA) Post-doctoral Fellowship in Global Infectious
Diseases (TW05572 [to D.T.L.]), Career Development Awards (K01 TW07409
[to J.B.H.], TW07144 [to R.C.L.], K08 AI089721 [to R.C.C.]), a Clinical
Research Scholars Award (R24 TW007988 [to S.B.C.]) from the Fogarty
International Center, a Physician Scientist Early Career Award from the
Howard Hughes Medical Institute (to R.C.L.), the Burroughs Welcome
Fund/American Society of Tropical Medicine and Hygiene Postdoctoral
Fellowship in Tropical Infectious Diseases (to D.T.L.), and the Swedish
Agency for International Development and Cooperation (to F.Q.).
NR 48
TC 19
Z9 20
U1 0
U2 2
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 1556-6811
J9 CLIN VACCINE IMMUNOL
JI Clin. Vaccine Immunol.
PD AUG
PY 2012
VL 19
IS 8
BP 1304
EP 1311
DI 10.1128/CVI.00196-12
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 983HR
UT WOS:000307110900026
PM 22739692
ER
PT J
AU Leung, DT
Rahman, MA
Mohasin, M
Patel, SM
Aktar, A
Khanam, F
Uddin, T
Riyadh, MA
Saha, A
Alam, MM
Chowdhury, F
Khan, AI
Charles, R
LaRocque, R
Harris, JB
Calderwood, SB
Qadri, F
Ryan, ET
AF Leung, Daniel T.
Rahman, Mohammad Arif
Mohasin, M.
Patel, Sweta M.
Aktar, Amena
Khanam, Farhana
Uddin, Taher
Riyadh, M. Asrafuzzaman
Saha, Amit
Alam, Mohammad Murshid
Chowdhury, Fahima
Khan, Ashraful Islam
Charles, Richelle
LaRocque, Regina
Harris, Jason B.
Calderwood, Stephen B.
Qadri, Firdausi
Ryan, Edward T.
TI Memory B Cell and Other Immune Responses in Children Receiving Two Doses
of an Oral Killed Cholera Vaccine Compared to Responses following
Natural Cholera Infection in Bangladesh (vol 19, pg 690, 2012)
SO CLINICAL AND VACCINE IMMUNOLOGY
LA English
DT Correction
C1 [Leung, Daniel T.] Int Ctr Diarrhoeal Dis Res, Ctr Vaccine Sci, Dhaka 1000, Bangladesh.
Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA.
Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA.
Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA.
RP Leung, DT (reprint author), Int Ctr Diarrhoeal Dis Res, Ctr Vaccine Sci, GPO Box 128, Dhaka 1000, Bangladesh.
NR 1
TC 0
Z9 0
U1 0
U2 3
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 1556-6811
J9 CLIN VACCINE IMMUNOL
JI Clin. Vaccine Immunol.
PD AUG
PY 2012
VL 19
IS 8
BP 1337
EP 1337
DI 10.1128/CVI.00299-12
PG 1
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 983HR
UT WOS:000307110900033
ER
PT J
AU Harrington, KM
Miller, MW
Wolf, EJ
Reardon, AF
Ryabchenko, KA
Ofrat, S
AF Harrington, Kelly M.
Miller, Mark W.
Wolf, Erika J.
Reardon, Annemarie F.
Ryabchenko, Karen A.
Ofrat, Shani
TI Attention-deficit/hyperactivity disorder comorbidity in a sample of
veterans with posttraumatic stress disorder
SO COMPREHENSIVE PSYCHIATRY
LA English
DT Article
ID DEFICIT HYPERACTIVITY DISORDER; ADMINISTERED PTSD SCALE; CONFIRMATORY
FACTOR-ANALYSIS; SEXUALLY ABUSED-CHILDREN; PSYCHIATRIC-DISORDERS; SURVEY
REPLICATION; COLLEGE-STUDENTS; TRAUMA EXPOSURE; PARENT DATA; CHILDHOOD
AB This study examined attention-deficit/hyperactivity disorder (ADHD) comorbidity in military veterans with a high prevalence of posttraumatic stress disorder (PTSD) and evaluated the relationships between the 2 disorders and exposure to traumatic events. The sample included 222 male and female military veterans who were administered structured clinical interviews based on the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Results show that 54.5% met the criteria for current PTSD, 11.5% of whom also met the criteria for current adult ADHD. Level of trauma exposure and ADHD severity were significant predictors of current PTSD severity. Evaluation of the underlying structure of symptoms of PTSD and ADHD using confirmatory factor analysis yielded a best-fitting measurement model that comprised 4 PTSD factors and 3 ADHD factors. Standardized estimates of the correlations among PTSD and ADHD factors suggested that the largest proportion of shared variance underlying PTSD-ADHD comorbidity is related to problems with modulating arousal levels that are common to both disorders (ie, hyperarousal and hypoarousal). Published by Elsevier Inc.
C1 [Harrington, Kelly M.] VA Boston Healthcare Syst, MAVERIC, Boston, MA 02130 USA.
[Harrington, Kelly M.; Miller, Mark W.; Wolf, Erika J.; Reardon, Annemarie F.; Ofrat, Shani] VA Boston Healthcare Syst, Natl Ctr PTSD, Boston, MA 02130 USA.
[Harrington, Kelly M.; Miller, Mark W.; Wolf, Erika J.; Ofrat, Shani] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA.
RP Harrington, KM (reprint author), VA Boston Healthcare Syst, MAVERIC, 150 S Huntington Ave,151-MAV, Boston, MA 02130 USA.
EM kelly.harrington@va.gov; mark.miller5@va.gov
RI Miller, Mark/G-7322-2011;
OI Miller, Mark/0000-0001-6393-8563; Wolf, Erika/0000-0003-2666-2435
FU VA Merit Review Award; National Institute of MentalHealth [T32MH019836]
FX Funding for this study was provided by a VA Merit Review Award to Mark
W. Miller. Kelly M. Harrington was supported by National Institute of
MentalHealth Training Grant T32MH019836.
NR 82
TC 16
Z9 16
U1 5
U2 13
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0010-440X
J9 COMPR PSYCHIAT
JI Compr. Psychiat.
PD AUG
PY 2012
VL 53
IS 6
BP 679
EP 690
DI 10.1016/j.comppsych.2011.12.001
PG 12
WC Psychiatry
SC Psychiatry
GA 982FJ
UT WOS:000307027900004
PM 22305866
ER
PT J
AU Ponnusamy, S
Selvam, SP
Mehrotra, S
Kawamori, T
Snider, AJ
Obeid, LM
Shao, Y
Sabbadini, R
Ogretmen, B
AF Ponnusamy, Suriyan
Selvam, Shanmugam Panneer
Mehrotra, Shikhar
Kawamori, Toshihiko
Snider, Ashley J.
Obeid, Lina M.
Shao, Yuan
Sabbadini, Roger
Ogretmen, Besim
TI Communication between host organism and cancer cells is transduced by
systemic sphingosine kinase 1/sphingosine 1-phosphate signalling to
regulate tumour metastasis
SO EMBO MOLECULAR MEDICINE
LA English
DT Article
DE lung metastasis; sphingolipids; sphingomab; sphingosine kinase 1;
sphingosine 1-phosphate
ID MYELOID-LEUKEMIA CELLS; IMATINIB-INDUCED APOPTOSIS; PROTEIN-COUPLED
RECEPTOR; BREAST-CANCER; OVARIAN-CANCER; LUNG-CANCER;
SPHINGOSINE-1-PHOSPHATE; BRMS1; MIGRATION; SURVIVAL
AB Mechanisms by which cancer cells communicate with the host organism to regulate lung colonization/metastasis are unclear. We show that this communication occurs via sphingosine 1-phosphate (S1P) generated systemically by sphingosine kinase 1 (SK1), rather than via tumour-derived S1P. Modulation of systemic, but not tumour SK1, prevented S1P elevation, and inhibited TRAMP-induced prostate cancer growth in TRAMP+/+SK1-/- mice, or lung metastasis of multiple cancer cells in SK1-/- animals. Genetic loss of SK1 activated a master metastasis suppressor, Brms1 (breast carcinoma metastasis suppressor 1), via modulation of S1P receptor 2 (S1PR2) in cancer cells. Alterations of S1PR2 using pharmacologic and genetic tools enhanced Brms1. Moreover, Brms1 in S1PR2-/- MEFs was modulated by serum S1P alterations. Accordingly, ectopic Brms1 in MB49 bladder cancer cells suppressed lung metastasis, and stable knockdown of Brms1 prevented this process. Importantly, inhibition of systemic S1P signalling using a novel anti-S1P monoclonal antibody (mAb), Sphingomab, attenuated lung metastasis, which was prevented by Brms1 knockdown in MB49 cells. Thus, these data suggest that systemic SK1/S1P regulates metastatic potential via regulation of tumour S1PR2/Brms1 axis.
C1 [Ponnusamy, Suriyan; Selvam, Shanmugam Panneer; Ogretmen, Besim] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA.
[Ponnusamy, Suriyan; Selvam, Shanmugam Panneer; Mehrotra, Shikhar; Kawamori, Toshihiko; Snider, Ashley J.; Obeid, Lina M.; Shao, Yuan; Ogretmen, Besim] Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA.
[Mehrotra, Shikhar] Med Univ S Carolina, Dept Surg, Charleston, SC 29425 USA.
[Kawamori, Toshihiko; Shao, Yuan] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA.
[Snider, Ashley J.; Obeid, Lina M.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA.
[Snider, Ashley J.; Obeid, Lina M.] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
[Sabbadini, Roger] Lpath Inc, San Diego, CA USA.
RP Ogretmen, B (reprint author), Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA.
EM ogretmen@musc.edu
OI obeid, lina/0000-0002-0734-0847
FU National Institutes of Health [CA088932, DE016572, CA097165];
Biogen/IDEC, Inc. (San Diego, CA); CTSA/SCTR (MUSC); NIH [C06 RR015455,
P30 CA138313]
FX We thank Dr. Jennifer G. Schnellmann (Medical University of South
Carolina, MUSC, Charleston, SC) for her editorial review. We also thank
Dr. Yusuf A. Hannun (MUSC) for helpful discussions. SK1-/-
and S1PR2-/- mice were kindly provided to us by Dr. Richard
L. Proia (National Institute of Diabetes and Digestive and Kidney
Disease, National Institutes of Health, Bethesda, MD). This work was
supported by research grants obtained from the National Institutes of
Health (CA088932, DE016572 and CA097165 to BO), Biogen/IDEC, Inc. (San
Diego, CA) and CTSA/SCTR (MUSC). The core facilities utilized for animal
studies, lipidomics and imaging were constructed using support from NIH
(C06 RR015455, or P30 CA138313).
NR 51
TC 50
Z9 52
U1 1
U2 9
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1757-4676
J9 EMBO MOL MED
JI EMBO Mol. Med.
PD AUG
PY 2012
VL 4
IS 8
BP 761
EP 775
DI 10.1002/emmm.201200244
PG 15
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 983LL
UT WOS:000307120700011
PM 22707406
ER
PT J
AU Lynn, SK
Zhang, X
Barrett, LF
AF Lynn, Spencer K.
Zhang, Xuan
Barrett, Lisa Feldman
TI Affective State Influences Perception by Affecting Decision Parameters
Underlying Bias and Sensitivity
SO EMOTION
LA English
DT Article
DE threat perception; valence; arousal; signal detection theory; utility
ID MOOD; EMOTION; ATTENTION; CONTEXT
AB Studies of the effect of affect on perception often show consistent directional effects of a person's affective state on perception. Unpleasant emotions have been associated with a "locally focused" style of stimulus evaluation, and positive emotions with a "globally focused" style. Typically, however, studies of affect and perception have not been conducted under the conditions of perceptual uncertainty and behavioral risk inherent to perceptual judgments outside the laboratory. We investigated the influence of perceivers' experienced affect (valence and arousal) on the utility of social threat perception by combining signal detection theory and behavioral economics. We compared 3 perceptual decision environments that systematically differed with respect to factors that underlie uncertainty and risk: the base rate of threat, the costs of incorrect identification threat, and the perceptual similarity of threats and nonthreats. We found that no single affective state yielded the best performance on the threat perception task across the 3 environments. Unpleasant valence promoted calibration of response bias to base rate and costs, high arousal promoted calibration of perceptual sensitivity to perceptual similarity, and low arousal was associated with an optimal adjustment of bias to sensitivity. However, the strength of these associations was conditional upon the difficulty of attaining optimal bias and high sensitivity, such that the effect of the perceiver's affective state on perception differed with the cause and/or level of uncertainty and risk.
C1 [Lynn, Spencer K.; Barrett, Lisa Feldman] Northeastern Univ, Dept Psychol, Boston, MA 02115 USA.
[Zhang, Xuan] Boston Coll, Dept Psychol, Chestnut Hill, MA 02167 USA.
[Barrett, Lisa Feldman] Harvard Univ, Sch Med, Dept Psychiat, Massachusetts Gen Hosp,Martinos Ctr Biomed Imagin, Boston, MA 02115 USA.
RP Lynn, SK (reprint author), Northeastern Univ, Dept Psychol, 360 Huntington Ave, Boston, MA 02115 USA.
EM s.lynn@neu.edu
FU NIH HHS [DP1OD003312, DP1 OD003312]
NR 38
TC 13
Z9 13
U1 1
U2 20
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 1528-3542
J9 EMOTION
JI Emotion
PD AUG
PY 2012
VL 12
IS 4
BP 726
EP 736
DI 10.1037/a0026765
PG 11
WC Psychology, Experimental
SC Psychology
GA 982ZN
UT WOS:000307085800009
PM 22251054
ER
PT J
AU Ditre, JW
Oliver, JA
Myrick, H
Henderson, S
Saladin, ME
Drobes, DJ
AF Ditre, Joseph W.
Oliver, Jason A.
Myrick, Hugh
Henderson, Scott
Saladin, Michael E.
Drobes, David J.
TI Effects of Divalproex on Smoking Cue Reactivity and Cessation Outcomes
Among Smokers Achieving Initial Abstinence
SO EXPERIMENTAL AND CLINICAL PSYCHOPHARMACOLOGY
LA English
DT Article
DE smoking; cessation; craving; cue reactivity; divalproex
ID BRAIN REWARD AREAS; TOBACCO DEPENDENCE; SELF-QUITTERS; NICOTINE;
RELAPSE; WITHDRAWAL; CIGARETTE; ALCOHOL; URGES; PHARMACOTHERAPY
AB Divalproex, a GABA agonist, may be a useful agent in the treatment of tobacco dependence. Cue reactivity assessment paradigms are ideally suited to explore basic mechanisms underlying the pharmacological effects of medications that purport to have efficacy for smoking cessation. Our primary goal in the current study was to examine the effects of divalproex on in-treatment reactivity to smoking-relevant and affective cues, and to determine if these reactions were predictive of posttreatment smoking behavior. There were 120 nicotine dependent smokers enrolled in an 8-week double-blind clinical trial and randomly assigned to either divalproex or placebo conditions. Of these, 72 smokers (60% female) who achieved a minimal level of abstinence underwent an in-treatment cue reactivity assessment. Contrary to expectations, divalproex was associated with greater craving and arousal during smoking cue presentation. Divalproex also inhibited cardiovascular response to pleasant cues. Although no significant differences in cessation-related outcomes between divalproex- and placebo-treated participants were observed, cue-elicited craving to smoke predicted end-of-treatment and posttreatment smoking rates. These findings suggest that in-treatment cue reactivity assessment may proactively and dynamically inform ongoing treatment as well as provide a tool for screening potential medications for smoking cessation.
C1 [Ditre, Joseph W.] Texas A&M Univ, Dept Psychol, College Stn, TX 77843 USA.
[Oliver, Jason A.; Drobes, David J.] Univ S Florida, Dept Psychol, Tampa, FL 33620 USA.
[Oliver, Jason A.; Drobes, David J.] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA.
[Drobes, David J.] Univ S Florida, Dept Oncol Sci, Tampa, FL USA.
[Myrick, Hugh; Henderson, Scott] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
[Myrick, Hugh; Henderson, Scott; Saladin, Michael E.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC USA.
RP Drobes, DJ (reprint author), H Lee Moffitt Canc Ctr & Res Inst, Tobacco Res & Intervent Program, 4115 E Fowler Ave, Tampa, FL 33617 USA.
EM david.drobes@moffitt.org
FU Abbott Pharmaceutical
FX This study was supported by a grant from Abbott Pharmaceutical, who had
no role in the study beyond financial support. All authors made
substantive contributions and approved the manuscript. There are no
conflicts of interest to report. We thank Cynthia Myers, Laura Juliano,
Suzanne Wise, and Beth Platz for their assistance in conducting the
study and preparing the manuscript.
NR 57
TC 8
Z9 8
U1 1
U2 4
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 1064-1297
J9 EXP CLIN PSYCHOPHARM
JI Exp. Clin. Psychopharmacol.
PD AUG
PY 2012
VL 20
IS 4
BP 293
EP 301
DI 10.1037/a0027789
PG 9
WC Psychology, Biological; Psychology, Clinical; Pharmacology & Pharmacy;
Psychiatry
SC Psychology; Pharmacology & Pharmacy; Psychiatry
GA 986CZ
UT WOS:000307319700006
PM 22468897
ER
PT J
AU Riemer, AB
Keskin, DB
Reinherz, EL
AF Riemer, Angelika B.
Keskin, Derin B.
Reinherz, Ellis L.
TI Identification and validation of reference genes for expression studies
in human keratinocyte cell lines treated with and without
interferon-gamma - a method for qRT-PCR reference gene determination
SO EXPERIMENTAL DERMATOLOGY
LA English
DT Review
DE endogenous control; interferon-gamma (IFN-?); immunology; inflammatory
milieu; keratinocyte; normalization; real-time polymerase chain reaction
(RT-PCR)
ID REAL-TIME PCR; HUMAN EPIDERMAL-KERATINOCYTES; CANDIDATE HOUSEKEEPING
GENES; HUMAN-PAPILLOMAVIRUS TYPE-16; RT-PCR; BETA-ACTIN; NORMALIZATION;
SELECTION; CARCINOMA; MODEL
AB Based on the exquisite sensitivity, reproducibility and wide dynamic range of quantitative reverse-transcription real-time polymerase chain reaction (qRT-PCR), it is currently the gold standard for gene expression studies. Target gene expression is calculated relative to a stably expressed reference gene. An ideal reference should be uniformly expressed during all experimental conditions within the given experimental system. However, no commonly applicable best reference gene has been identified. Thus, endogenous controls must be determined for every experimental system. As no appropriate reference genes have been reported for immunological studies in keratinocytes, we aimed at identifying and validating a set of endogenous controls for these settings. An extensive validation of sixteen possible endogenous controls in a panel of 8 normal and transformed keratinocyte cell lines in experimental conditions with and without interferon-? was performed. RNA and cDNA quality was stringently controlled. Candidate reference genes were assessed by TaqMan (R) qRT-PCR. Two different statistical algorithms were used to determine the most stably and reproducibly expressed housekeeping genes. mRNA abundance was compared and reference genes with widely different ranges of expression than possible target genes were excluded. Subsequent geNorm and NormFinder analyses identified GAPDH, PGK1, IPO8 and PPIA as the most stably expressed genes in the keratinocyte panel under the given experimental conditions. We conclude that the geometric means of expression values of these four genes represents a robust normalization factor for qRT-PCR analyses in interferon-?-dependent gene expression studies in keratinocytes. The methodology and results herein may help other researchers by facilitating their choice of reference genes.
C1 [Riemer, Angelika B.] German Canc Res Ctr, D-69120 Heidelberg, Germany.
[Riemer, Angelika B.; Reinherz, Ellis L.] Dana Farber Canc Inst, Canc Vaccine Ctr, Boston, MA 02115 USA.
[Riemer, Angelika B.; Keskin, Derin B.; Reinherz, Ellis L.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
[Riemer, Angelika B.; Keskin, Derin B.; Reinherz, Ellis L.] Dana Farber Canc Inst, Dept Med Oncol, Immunobiol Lab, Boston, MA 02115 USA.
RP Riemer, AB (reprint author), German Canc Res Ctr, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.
EM a.riemer@dkfz.de
FU Erwin Schrodinger fellowship of the Austrian Science Fund; DoD; NIH
FX A.B. Riemer (ABR) performed the research and analysed the data; ABR, D.
B. Keskin and E. L. Reinherz (ELR) designed the research study and wrote
the paper. ABR was supported by an Erwin Schrodinger fellowship of the
Austrian Science Fund. This work was supported by DoD & NIH grants to
ELR. The authors want to thank Mel Hernandez for excellent technical and
scientific advice, and Linda K. Clayton for expert scientific advice and
proofreading of the manuscript.
NR 32
TC 10
Z9 11
U1 1
U2 16
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0906-6705
J9 EXP DERMATOL
JI Exp. Dermatol.
PD AUG
PY 2012
VL 21
IS 8
BP 625
EP 629
DI 10.1111/j.1600-0625.2012.01537.x
PG 5
WC Dermatology
SC Dermatology
GA 971RY
UT WOS:000306222700011
PM 22775998
ER
PT J
AU Doyle, JO
Attaman, JA
Styer, AK
Sabatini, ME
Petrozza, JC
Toth, TL
AF Doyle, Joseph O'Brien
Attaman, Jill Amanda
Styer, Aaron Kyle
Sabatini, Mary Elizabeth
Petrozza, John Christopher
Toth, Thomas Louis
TI Rescue human chorionic gonadotropin for false empty follicle syndrome:
optimism for successful pregnancy outcome
SO FERTILITY AND STERILITY
LA English
DT Article
DE False empty follicle syndrome; rescue hCG; live birth
ID CONTROVERSIAL SYNDROME
AB Objective: To describe two cases of successful pregnancy after a rescue course of hCG in the setting of false empty follicle syndrome.
Design: Case report.
Setting: Academic medical center.
Patient(s): Two patients undergoing ultrasound-guided oocyte retrieval with failure to obtain oocytes during oocyte retrieval.
Intervention(s): Rescue course of hCG with second oocyte retrieval 35 hours later.
Main Outcome Measure(s): Live birth.
Result(s): Two live-birth pregnancies.
Conclusion(s): Live-birth pregnancies are a realistic possibility after administration of a rescue course of hCG and repeat oocyte retrieval in the setting of false empty follicle syndrome. (Fertil Steril (R) 2012;98:450-2. (C) 2012 by American Society for Reproductive Medicine.)
C1 [Doyle, Joseph O'Brien; Attaman, Jill Amanda; Styer, Aaron Kyle; Sabatini, Mary Elizabeth; Petrozza, John Christopher; Toth, Thomas Louis] Massachusetts Gen Hosp, Vincent Dept Obstet & Gynecol, Fertil Ctr, Boston, MA 02114 USA.
RP Doyle, JO (reprint author), Massachusetts Gen Hosp, Vincent Dept Obstet & Gynecol, Fertil Ctr, 55 Fruit St, Boston, MA 02114 USA.
EM jodoyle@partners.org
NR 10
TC 1
Z9 2
U1 2
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0015-0282
J9 FERTIL STERIL
JI Fertil. Steril.
PD AUG
PY 2012
VL 98
IS 2
BP 450
EP 452
DI 10.1016/j.fertnstert.2012.04.043
PG 3
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA 981NP
UT WOS:000306975400033
PM 22608311
ER
PT J
AU Fallon, EM
Nehra, D
Le, HD
Nedder, AP
Guo, L
Mitchell, PD
Rueda, BR
Puder, M
AF Fallon, Erica M.
Nehra, Deepika
Le, Hau D.
Nedder, Arthur P.
Guo, Lankai
Mitchell, Paul D.
Rueda, Bo R.
Puder, Mark
TI Effect of sunitinib on functional reproductive outcome in a rabbit model
SO FERTILITY AND STERILITY
LA English
DT Article
DE Adhesion; uterine abrasion; reproductive function; animal
ID POSTSURGICAL ADHESION FORMATION; INTESTINAL-OBSTRUCTION;
CLINICAL-SIGNIFICANCE; ABDOMINAL ADHESIONS; SURGERY; PREVENTION;
REDUCTION; PATHOGENESIS; ETIOLOGY
AB Objective: To determine the effect of sunitinib (Sutent; SU11248; Pfizer), a US Food and Drug Administration-approved receptor tyrosine kinase inhibitor previously shown to reduce de novo pelvic adhesion formation, on reproductive function after surgical uterine abrasion in a rabbit model.
Design: Randomized placebo-controlled study.
Setting: Large animal facility within an academic hospital.
Animal(s): Thirty New Zealand White adult female rabbits (2.2-3.0 kg).
Intervention(s): Administration of 11 doses (one preoperative and 10 postoperative) of oral sunitinib (10 mg/kg/d) or placebo.
Main Outcome Measure(s): Effect of short-term postoperative sunitinib administration on reproductive function after surgical uterine abrasion.
Result(s): All animals were impregnated and survived until designated euthanasia. Sunitinib-treated animals had a larger average litter size (7.7 +/- 1.9 vs. 5.6 +/- 2.7 kits) and offspring viability (7.1 +/- 2.7 vs. 3.5 +/- 3.2 kits) compared with placebo-treated animals. There was no difference in gestational length or aberration in the maintainence of fertility. There were no gross abnormalities, detectable birth defects, or growth disparity in offspring from sunitinib versus placebo-treated mothers. The adhesion burden identified at euthanasia after parturition was lower in sunitinib compared with placebo-treated animals (N = 10/group).
Conclusion(s): Sunitinib ameliorated adhesion-induced reproductive aberrations after surgical uterine abrasion and may be an efficacious strategy to reduce postoperative pelvic adhesions. (Fertil Steril (R) 2012;98:496-502. (C) 2012 by American Society for Reproductive Medicine.)
C1 [Fallon, Erica M.; Nehra, Deepika; Le, Hau D.; Puder, Mark] Childrens Hosp, Dept Surg, Boston, MA 02115 USA.
[Fallon, Erica M.; Nehra, Deepika; Le, Hau D.; Puder, Mark] Childrens Hosp, Vasc Biol Program, Boston, MA 02115 USA.
[Fallon, Erica M.; Nehra, Deepika; Le, Hau D.; Guo, Lankai; Rueda, Bo R.; Puder, Mark] Harvard Univ, Sch Med, Boston, MA USA.
[Nedder, Arthur P.] Anim Resources Childrens Hosp Boston, Boston, MA USA.
[Guo, Lankai; Rueda, Bo R.] Massachusetts Gen Hosp, Dept Obstet & Gynecol, Vincent Ctr Reprod Biol, Boston, MA 02114 USA.
[Mitchell, Paul D.] Childrens Hosp, Clin Res Ctr, Design & Anal Core, Boston, MA 02115 USA.
RP Puder, M (reprint author), 300 Longwood Ave,Fegan 3, Boston, MA 02115 USA.
EM mark.puder@childrens.harvard.edu
FU Congressionally Funded Project entitled "Angiogenesis and Tissue
Engineering Research" [W81XWH-05-1-0115, 76344-01]; Children's Hospital
Surgical Foundation; Vascular Biology Program, Boston, MA; Joshua Ryan
Rappaport Fellowship; National Institutes of Health [T32DK007754-12];
Vincent Center for Reproductive Biology, Department of Obstetrics and
Gynecology, Massachusetts General Hospital, Boston, MA
FX Supported by a Congressionally Funded Project entitled "Angiogenesis and
Tissue Engineering Research," grant W81XWH-05-1-0115, fund 76344-01; the
Children's Hospital Surgical Foundation and The Vascular Biology
Program, Boston, MA (E. M. F., D.N., H. D. L., M. P.); the Joshua Ryan
Rappaport Fellowship (E. M. F., H. D. L.); the National Institutes of
Health grant T32DK007754-12 (D.N.); and Vincent Center for Reproductive
Biology, Department of Obstetrics and Gynecology, Massachusetts General
Hospital, Boston, MA (L.G., B.R.R.).
NR 29
TC 2
Z9 2
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0015-0282
J9 FERTIL STERIL
JI Fertil. Steril.
PD AUG
PY 2012
VL 98
IS 2
BP 496
EP 502
DI 10.1016/j.fertnstert.2012.05.020
PG 7
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA 981NP
UT WOS:000306975400039
PM 22698641
ER
PT J
AU Merchant, FM
Ikeda, T
Pedretti, RFE
Salerno-Uriarte, JA
Chow, T
Chan, PS
Bartone, C
Hohnloser, SH
Cohen, RJ
Armoundas, AA
AF Merchant, Faisal M.
Ikeda, Takanori
Pedretti, Roberto F. E.
Salerno-Uriarte, Jorge A.
Chow, Theodore
Chan, Paul S.
Bartone, Cheryl
Hohnloser, Stefan H.
Cohen, Richard J.
Armoundas, Antonis A.
TI Clinical utility of microvolt T-wave alternans testing in identifying
patients at high or low risk of sudden cardiac death
SO HEART RHYTHM
LA English
DT Article
DE T-wave alternans; Arrhythmia; Sudden cardiac death; Risk stratification;
ICD; heart failure
ID IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR; LEFT-VENTRICULAR DYSFUNCTION;
ACUTE MYOCARDIAL-INFARCTION; CONGESTIVE-HEART-FAILURE; DILATED
CARDIOMYOPATHY; PREDICTIVE-VALUE; ARRHYTHMIA VULNERABILITY; ISCHEMIC
CARDIOMYOPATHY; SYSTOLIC DYSFUNCTION; EJECTION FRACTION
AB BACKGROUND Previous studies have demonstrated that microvolt T-wave alternans (MTWA) testing is a robust predictor of ventricular tachyarrhythmias and sudden cardiac death (SCD) in at-risk patients. However, recent studies have suggested that MTWA testing is not as good a predictor of "appropriate" implantable cardioverter-defibrillator (ICD) therapy as it is a predictor of SCD in patients without ICDs.
OBJECTIVE To evaluate the utility of MTWA testing for SCD risk stratification in patients without ICDs.
METHODS Patient-level data were obtained from 5 prospective studies of MTWA testing in patients with no history of ventricular arrhythmia or SCD. In these studies, ICDs were implanted in only a minority of patients and patients with ICDs were excluded from the analysis. We conducted a pooled analysis and examined the 2-year risk for SCD based on the MTWA test result.
RESULTS The pooled cohort included 2883 patients. MTWA testing was positive in 856 (30%), negative in 1627 (56%), and indeterminate in 400 (14%) patients. Among patients with a left ventricular ejection fraction (LVEF) of <= 35%, annual SCD event rates were 4.0%, 0.9%, and 4.6% among groups with MTWA positive, negative, and indeterminate test results. The SCD rate was significantly lower among patients with a negative MTWA test result than in patients with either positive or indeterminate MTWA test results (P < .001 for both comparisons). In patients with an LVEF of >35%, annual SCD event rates were 3.0%, 0.3%, and 0.3% among the groups with MTWA positive, negative, and indeterminate test results. The SCD rate associated with a positive MTWA test result was significantly higher than that associated with either negative (P < .001) or indeterminate MTWA test results (P = .003).
CONCLUSIONS In patients without ICDs, MTWA testing is a powerful predictor of SCD. Among patients with an LVEF of <= 35%, a negative MTWA test result is associated with a low risk for SCD. Conversely, among patients with an LVEF of >35%, a positive MTWA test result identifies patients at significantly heightened SCD risk. These findings may have important implications for refining primary prevention ICD treatment algorithms.
C1 [Merchant, Faisal M.; Armoundas, Antonis A.] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Div Cardiol, Boston, MA 02129 USA.
[Merchant, Faisal M.] Emory Univ, Sch Med, Div Cardiol, Atlanta, GA 30322 USA.
[Ikeda, Takanori] Toho Univ, Med Ctr, Dept Cardiovasc Med, Tokyo, Japan.
[Pedretti, Roberto F. E.] IRCCS Fdn Salvatore Maugeri, Sci Inst Tradate, Div Cardiol, Tradate, Italy.
[Salerno-Uriarte, Jorge A.] Univ Insubria, Osped Circolo & Fdn Macchie, Dept Heart Sci, Varese, Italy.
[Chow, Theodore] Reg Med Ctr San Jose, San Jose, CA USA.
[Chan, Paul S.] Univ Missouri, Kansas City, MO 64110 USA.
[Chan, Paul S.] St Lukes Hosp, Mid Amer Heart Inst, Kansas City, MO 64111 USA.
[Bartone, Cheryl] Christ Hosp, Heart & Vasc Ctr, Cincinnati, OH 45219 USA.
[Hohnloser, Stefan H.] Goethe Univ Frankfurt, Dept Cardiol, Div Clin Electrophysiol, Frankfurt, Germany.
[Cohen, Richard J.; Armoundas, Antonis A.] MIT, Cambridge, MA 02139 USA.
[Cohen, Richard J.; Armoundas, Antonis A.] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
RP Armoundas, AA (reprint author), Massachusetts Gen Hosp, Cardiovasc Res Ctr, Div Cardiol, 149 13th St, Boston, MA 02129 USA.
EM aarmoundas@partners.org
FU National Institute of Aging (NIA) [1R21AG035128]; NIH [1RO1HL103961];
Center for Integration of Medicine and Innovative Technology (CIMIT);
Deane Institute for Integrative Research in Atrial Fibrillation and
Stroke; Cardiovascular Research Society; National Heart, Lung, And Blood
Institute [K23HL102224]
FX The work was supported by National Institute of Aging (NIA) grant
1R21AG035128 and NIH grant 1RO1HL103961. This work was also supported by
a Fellowship and a Science Award from the Center for Integration of
Medicine and Innovative Technology (CIMIT), the Deane Institute for
Integrative Research in Atrial Fibrillation and Stroke and the
Cardiovascular Research Society.; Dr Chow is associated with Medtronic,
Inc, and Dr Cohen is associated with Cambridge Heart, Inc. Dr Chan was
supported by Grant Number K23HL102224 from the National Heart, Lung, And
Blood Institute. Address for reprint requests and correspondence: Dr
Antonis A. Armoundas, PhD, Cardiology Division, Cardiovascular Research
Center, Massachusetts General Hospital, 149 13th St, Charlestown, MA
02129. E-mail address: aarmoundas@partners.org.
NR 36
TC 23
Z9 23
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1547-5271
J9 HEART RHYTHM
JI Heart Rhythm
PD AUG
PY 2012
VL 9
IS 8
BP 1256
EP +
DI 10.1016/j.hrthm.2012.03.014
PG 11
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 982UT
UT WOS:000307071600014
PM 22406384
ER
PT J
AU Lee, SE
Lee, EH
Park, H
Sung, JY
Lee, HW
Kang, SY
Seo, S
Kim, BH
Lee, H
Seo, AN
Ahn, G
Choi, YL
AF Lee, Seung Eun
Lee, Eun Hee
Park, Heejung
Sung, Ji-Youn
Lee, Hyoun Wook
Kang, So Young
Seo, Sungwook
Kim, Byung Heon
Lee, Hyojin
Seo, An Na
Ahn, Geunghwan
Choi, Yoon-La
TI The diagnostic utility of the GNAS mutation in patients with fibrous
dysplasia: meta-analysis of 168 sporadic cases
SO HUMAN PATHOLOGY
LA English
DT Article
DE Fibrous dysplasia; GNAS; Mutation
ID MCCUNE-ALBRIGHT-SYNDROME; ACTIVATING G(S)ALPHA MUTATION; STIMULATORY
G-PROTEIN; ALPHA-SUBUNIT; BONE; GENE; LESIONS; CELLS
AB GNAS mutations have been implicated in the development of fibrous dysplasia and multiple endocrinopathies of the Albright-McCune syndrome. To investigate the diagnostic utility of GNAS mutations in patients with fibrous dysplasia, we performed mutational analyses of histologically confirmed fibrous dysplasia and conducted a meta-analysis of the literature. We collected 48 cases of fibrous dysplasia from 3 institutions from 2002 to 2011 and performed polymerase chain reaction and direct bidirectional sequencing of exons 8 and 9 of GNAS using paraffin-embedded tissues. We searched MEDLINE, PubMed, and the KoreaMed databases from 1997 to 2011 and included an additional 155 cases of fibrous dysplasia from 8 representative studies to conduct a meta-analysis. In our sample, 28 (58.3%) of 48 cases showed point mutations of codon 201 at exon 8. Twenty-five cases had a substitution of arginine at codon 201 for histidine (p.R201H), and 3 cases had a substitution for cysteine (p.R201C). One case had a new mutation at codon 224 (p.V224A). The incidence of GNAS mutations was significantly greater in cases that involved long bones than in cases that involved flat bones (P = .017) and was higher in polyostotic cases than in monostotic cases (P = .067). In meta-analysis, 9 studies and 203 patients were included. The overall positive rate of GNAS mutation in fibrous dysplasia was 71.9% (146/203). The major types of mutations were missense mutations such as R201H (66.4%) and R201C (30.8%). As a result, the detection of GNAS mutation could be a valuable adjunct to conventional histopathologic diagnosis of fibrous dysplasia. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Lee, Seung Eun; Sung, Ji-Youn; Kang, So Young; Choi, Yoon-La] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Pathol, Seoul 135710, South Korea.
[Lee, Eun Hee; Lee, Hyoun Wook; Kim, Byung Heon] Sungkyunkwan Univ, Samsung Changwon Hosp, Sch Med, Dept Pathol, Chang Won 630732, South Korea.
[Park, Heejung] Yonsei Univ, Coll Med, Dept Pathol, Seoul 120752, South Korea.
[Seo, Sungwook] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Orthoped Surg, Seoul 135710, South Korea.
[Lee, Hyojin] Natl Police Hosp, Seoul 138708, South Korea.
[Seo, An Na] Kyungpook Natl Univ, Sch Med, Dept Pathol, Taegu 700721, South Korea.
[Ahn, Geunghwan] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Dept Pathol, San Francisco, CA 94121 USA.
[Choi, Yoon-La] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Inst Refractory Canc Res, Seoul 135710, South Korea.
RP Choi, YL (reprint author), Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Pathol, Irwon Ro 81, Seoul 135710, South Korea.
EM ylachoi@skku.edu
RI Sung, Ji-Youn/I-5016-2013
OI Sung, Ji-Youn/0000-0002-6607-2117
FU Ministry for Health and Welfare Affairs [A092255]; National Research
Foundation [NRF-M1AXA002-2010-0029795]; Ministry of Education, Science,
and Technology, South Korea
FX Grant support: This work was supported by a grant (A092255) from the
Korea Healthcare Technology R&D Project, Ministry for Health and Welfare
Affairs, and by the Global Frontier (NRF-M1AXA002-2010-0029795) grant of
National Research Foundation funded by the Ministry of Education,
Science, and Technology, South Korea.
NR 22
TC 22
Z9 24
U1 1
U2 8
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0046-8177
EI 1532-8392
J9 HUM PATHOL
JI Hum. Pathol.
PD AUG
PY 2012
VL 43
IS 8
BP 1234
EP 1242
DI 10.1016/j.humpath.2011.09.012
PG 9
WC Pathology
SC Pathology
GA 981OX
UT WOS:000306979800011
PM 22245114
ER
PT J
AU Mahalingam, M
Richards, JE
Selim, MA
Muzikansky, A
Hoang, MP
AF Mahalingam, Meera
Richards, Joanna E.
Selim, M. Angelica
Muzikansky, Alona
Hoang, Mai P.
TI An immunohistochemical comparison of cytokeratin 7, cytokeratin 15,
cytokeratin 19, CAM 5.2, carcinoembryonic antigen, and nestin in
differentiating porocarcinoma from squamous cell carcinoma
SO HUMAN PATHOLOGY
LA English
DT Article
DE Porocarcinoma; Cytokeratin 19; Cytokeratin 7; Cytokeratin 15; CAM5.2;
Nestin; Carcinoembryonic antigen
ID EPITHELIAL MEMBRANE ANTIGEN; MALIGNANT ECCRINE POROMA; FOLLICULAR
STEM-CELLS; MONOCLONAL-ANTIBODY; DIAGNOSTIC UTILITY; KERATIN EXPRESSION;
BASAL-CELL; SKIN; MARKERS; P63
AB The distinction of porocarcinoma from squamous cell carcinoma is clinically relevant but can often be a diagnostic dilemma. Current markers reported to be helpful in diagnosing porocarcinoma include carcinoembryonic antigen and cytokeratin 7; however, their expression has been demonstrated in 30% to 80% and 13% to 22% of squamous cell carcinoma cases, respectively. In this study, we assessed immunohistochemical expression of cytokeratin 7, cytokeratin 15, cytokeratin 19, CAM 5.2, carcinoembryonic antigen, and nestin in 67 cases (39 porocarcinomas and 28 moderately differentiated squamous cell carcinomas) to determine their use as histologic adjuncts. Expression of carcinoembryonic antigen, cytokeratin 19, cytokeratin 7, CAM 5.2, cytokeratin 15, and nestin was seen in 77%, 67%, 64%, 51%, 49%, and 13% of porocarcinomas, respectively; and in 57%, 18%, 26%, 32%, 30%, and 37% of squamous cell carcinomas, respectively. Of these, cytokeratin 19 was the most specific (specificity, 82%) in detecting porocarcinomas, and carcinoembryonic antigen was the most sensitive (sensitivity, 77%). By chi(2) test, statistically significant P values (<.05) were observed for cytokeratin 7, cytokeratin 19, and nestin in the distinction of porocarcinoma from squamous cell carcinoma. However, in a logistic regression and stepwise selection for predicting a porocarcinoma, statistical significance was observed only for cytokeratin 19 (P = .0003). In conclusion, we found cytokeratin 19 to be a helpful marker in the distinction of porocarcinoma from squamous cell carcinoma, although a focal staining pattern can be seen in a third of cases. The diagnostic sensitivity and specificity appear to be significantly improved using a selected panel of immunohistochemical stains that include cytokeratin 7, cytokeratin 19, and nestin. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Hoang, Mai P.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Muzikansky, Alona; Hoang, Mai P.] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Muzikansky, Alona] Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA.
[Selim, M. Angelica] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA.
[Mahalingam, Meera; Richards, Joanna E.] Boston Univ, Sch Med, Dept Dermatol, Dermatopathol Sect, Boston, MA 02118 USA.
RP Hoang, MP (reprint author), Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
EM mhoang@partners.org
OI Mahalingam, Meera/0000-0002-2800-9985
NR 38
TC 18
Z9 19
U1 0
U2 6
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0046-8177
J9 HUM PATHOL
JI Hum. Pathol.
PD AUG
PY 2012
VL 43
IS 8
BP 1265
EP 1272
DI 10.1016/j.humpath.2011.10.005
PG 8
WC Pathology
SC Pathology
GA 981OX
UT WOS:000306979800015
PM 22285043
ER
PT J
AU Foland-Ross, LC
Brooks, JO
Mintz, J
Bartzokis, G
Townsend, J
Thompson, PM
Altshuler, LL
AF Foland-Ross, Lara C.
Brooks, John O., III
Mintz, Jim
Bartzokis, George
Townsend, Jennifer
Thompson, Paul M.
Altshuler, Lori L.
TI Mood-state effects on amygdala volume in bipolar disorder
SO JOURNAL OF AFFECTIVE DISORDERS
LA English
DT Article
DE Bipolar disorder; Depression; Magnetic resonance imaging; MRI; Amygdala
ID TEMPORAL-LOBE STRUCTURES; RATING-SCALE; DEPRESSION; MANIA;
SCHIZOPHRENIA; MRI; MATTER; CORTEX
AB Background: Prior structural neuroimaging studies of the amygdala in patients with bipolar disorder have reported higher or lower volumes, or no difference relative to healthy controls. These inconsistent findings may have resulted from combining subjects in different mood states. The prefrontal cortex has recently been reported to have a lower volume in depressed versus euthymic bipolar patients. Here we examined whether similar mood state-dependent volumetric differences are detectable in the amygdala.
Methods: Forty subjects, including 28 with bipolar disorder type I (12 depressed and 16 euthymic), and 12 healthy comparison subjects were scanned on a 3 T magnetic resonance image (MRI) scanner. Amygdala volumes were manually traced and compared across subject groups, adjusting for sex and total brain volume.
Results: Statistical analyses found a significant effect of mood state and hemisphere on amygdala volume. Subsequent comparisons revealed that amygdala volumes were significantly lower in the depressed bipolar group compared to both the euthymic bipolar (p =0.005) and healthy control (p = 0.043) groups.
Limitations: Our study was cross-sectional and some patients were medicated.
Conclusions: Our results suggest that mood state influences amygdala volume in subjects with bipolar disorder. Future studies that replicate these findings in unmedicated patient samples scanned longitudinally are needed. Published by Elsevier B.V.
C1 [Altshuler, Lori L.] Univ Calif Los Angeles, Mood Disorders Res Program, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90095 USA.
[Foland-Ross, Lara C.; Thompson, Paul M.] Univ Calif Los Angeles, Lab Neuro Imaging, Dept Neurol, Sch Med, Los Angeles, CA 90095 USA.
[Mintz, Jim] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Altshuler, Lori L.] W Los Angeles Healthcare Ctr, VA Greater Los Angeles Healthcare Syst, Dept Psychiat, Los Angeles, CA USA.
RP Altshuler, LL (reprint author), Univ Calif Los Angeles, Mood Disorders Res Program, Semel Inst Neurosci & Human Behav, 300 Med Plaza,Suite 1544,Box 957057, Los Angeles, CA 90095 USA.
EM laltshuler@mednet.ucla.edu
RI Bartzokis, George/K-2409-2013
FU National Institutes of Health [MH078556, MH075944, MH001848, EB001561,
RR019771]; National Institute on Aging [AG016570]; National Association
for Research on Schizophrenia and Affective Disorders (NARSAD); Brain
Mapping Medical Research Organization; Brain Mapping Support Foundation;
Pierson-Lovelace Foundation; Ahmanson Foundation; William M. and Linda
R. Dietel Philanthropic Fund at the Northern Piedmont Community
Foundation; Tamkin Foundation; Jennifer Jones-Simon Foundation; Capital
Group Companies Charitable Foundation; Robson Family and Northstar Fund;
National Center for Research Resources [RR012169, RR013642, RR000865];
Abbott Laboratories; Pfizer Inc.
FX Funding for this study was provided by the National Institutes of Health
[MH078556 (LCFR), MH075944 (LLA), MH001848 (LEA) EB001561 (PMT),
RR019771 (PMT)]. The National Institute on Aging provided additional
support for algorithm development (AG016570). For their generous
support, the authors also thank the National Association for Research on
Schizophrenia and Affective Disorders (NARSAD), the Brain Mapping
Medical Research Organization, the Brain Mapping Support Foundation, the
Pierson-Lovelace Foundation, the Ahmanson Foundation, the William M. and
Linda R. Dietel Philanthropic Fund at the Northern Piedmont Community
Foundation, the Tamkin Foundation, the Jennifer Jones-Simon Foundation,
the Capital Group Companies Charitable Foundation, the Robson Family and
Northstar Fund and the National Center for Research Resources (RR012169,
RR013642 and RR000865). The study design was peer-reviewed by the
National Institutes of Health. Funding sources had no further role in
study design; in the collection, analysis and interpretation of data; in
the writing of the report; and in the decision to submit the paper for
publication.; Dr. Altshuler has received past (and potential future)
funding from Abbott Laboratories (research support and consulting
honoraria); Forest Laboratories (consulting and speakers bureau
honoraria); GlaxoSmithKline (speakers bureau honoraria); and no past,
but potential future honoraria from Astra-Zeneca (speakers bureau) and
Merck and Co. (consulting). Dr. Brooks has received funding from Pfizer
Inc. (research support), Merck (speakers bureau), and Sunovion (speakers
bureau).
NR 25
TC 14
Z9 14
U1 0
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0165-0327
J9 J AFFECT DISORDERS
JI J. Affect. Disord.
PD AUG
PY 2012
VL 139
IS 3
BP 298
EP 301
DI 10.1016/j.jad.2012.03.003
PG 4
WC Clinical Neurology; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 981QM
UT WOS:000306984500012
PM 22521854
ER
PT J
AU Marques, L
Porter, E
Keshaviah, A
Pollack, MH
Van Ameringen, M
Stein, MB
Simon, NM
AF Marques, Luana
Porter, Eliora
Keshaviah, Aparna
Pollack, Mark H.
Van Ameringen, Michael
Stein, Murray B.
Simon, Naomi M.
TI Avoidant personality disorder in individuals with generalized social
anxiety disorder: What does it add?
SO JOURNAL OF ANXIETY DISORDERS
LA English
DT Article
DE Generalized social anxiety disorder (GSAD); Avoidant personality
disorder (AvPD); Severity continuum hypothesis; Major depressive
disorder (MMD); Social phobia; Anxiety
ID OF-MENTAL-DISORDERS; DSM-IV; PSYCHOMETRIC PROPERTIES; INTERNAL
CONSISTENCY; PHOBIA; CRITERIA; VALIDITY; DISTINCTION; SCHIZOTYPAL;
OUTPATIENTS
AB Avoidant personality disorder (AvPD) has a high level of symptom overlap and comorbidity with generalized social anxiety disorder (GSAD). We examined whether the presence of comorbid AvPD adds significant clinically relevant information for individuals seeking treatment for GSAD. Results suggested that AvPD was significantly associated with poorer quality of life and greater disability in univariate, but not multivariate analyses. Endorsement of more AvPD symptoms was associated with increased disability, increased risk of intimacy, and lower social support, even after covariate adjustment. Specifically, AvPD item 3, hard to be "open" even with people you are close to, was most strongly correlated with quality of life and disability. A binary diagnosis of AvPD alone adds little beyond a marker of greater GSAD severity and depression among patients with GSAD, while a specific feature of AvPD not captured by the GSAD diagnosis, namely emotional guardedness, may be associated with greater impairment. Published by Elsevier Ltd.
C1 [Marques, Luana; Porter, Eliora; Keshaviah, Aparna; Simon, Naomi M.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
[Porter, Eliora] Univ Penn, Dept Psychol, Philadelphia, PA 19104 USA.
[Pollack, Mark H.] Rush Univ, Med Ctr, Dept Psychiat, Chicago, IL 60612 USA.
[Van Ameringen, Michael] St Josephs Healthcare Hamilton, Dept Psychiat & Behav Neurosci, Hamilton, ON L8P 3B5, Canada.
[Stein, Murray B.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92037 USA.
RP Marques, L (reprint author), Massachusetts Gen Hosp, Dept Psychiat, 1 Bowdoin Sq,6th Floor, Boston, MA 02114 USA.
EM lmarques@partners.org
FU NIMH NIH HHS [R01 MH070501, R01MH70919, R01MH70501, R01 MH070917,
R01MH70917, R01 MH070919, K23 MH096029]
NR 32
TC 14
Z9 14
U1 5
U2 29
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0887-6185
J9 J ANXIETY DISORD
JI J. Anxiety Disord.
PD AUG
PY 2012
VL 26
IS 6
BP 665
EP 672
DI 10.1016/j.janxdis.2012.05.004
PG 8
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA 981QU
UT WOS:000306985300005
PM 22705954
ER
PT J
AU Bui, AL
Grau-Sepulveda, MV
Hernandez, AF
Peterson, ED
Yancy, CW
Bhatt, DL
Fonarow, GC
AF Bui, Anh L.
Grau-Sepulveda, Maria V.
Hernandez, Adrian F.
Peterson, Eric D.
Yancy, Clyde W.
Bhatt, Deepak L.
Fonarow, Gregg C.
TI Admission Heart Rate and In-Hospital Outcomes in Patients Hospitalized
for Heart Failure in Sinus Rhythm and Atrial Fibrillation
SO JOURNAL OF CARDIAC FAILURE
LA English
DT Meeting Abstract
CT 16th Annual Scientific Meeting of the Heart-Failure-Society-of-America
CY SEP 09-12, 2012
CL Seattle, WA
SP Heart Failure Soc Amer
C1 [Bui, Anh L.] Kaiser Permanente Med Ctr, Los Angeles, CA 90034 USA.
[Grau-Sepulveda, Maria V.; Hernandez, Adrian F.; Peterson, Eric D.] Duke Univ, Durham, NC USA.
[Yancy, Clyde W.] Northwestern Univ, Chicago, IL 60611 USA.
[Bhatt, Deepak L.] Brigham & Womens Hosp, VA Boston Healthcare Syst, Boston, MA 02115 USA.
[Bhatt, Deepak L.] Harvard Univ, Sch Med, Boston, MA USA.
[Fonarow, Gregg C.] Univ Calif Los Angeles, Los Angeles, CA 90024 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS
PI PHILADELPHIA
PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA
SN 1071-9164
J9 J CARD FAIL
JI J. Card. Fail.
PD AUG
PY 2012
VL 18
IS 8
SU 1
MA 237
BP S73
EP S74
PG 2
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 991CS
UT WOS:000307679700238
ER
PT J
AU Kapuku, G
Davis, H
Choksy, P
Januzzi, J
Harshfield, G
AF Kapuku, Gaston
Davis, Harry
Choksy, Pratik
Januzzi, James
Harshfield, Gregory
TI Brain Natriuretic Hormone Predicts Stress Induced Alterations in
Diastolic Function
SO JOURNAL OF CARDIAC FAILURE
LA English
DT Meeting Abstract
CT 16th Annual Scientific Meeting of the Heart-Failure-Society-of-America
CY SEP 09-12, 2012
CL Seattle, WA
SP Heart Failure Soc Amer
C1 [Kapuku, Gaston; Davis, Harry; Choksy, Pratik; Harshfield, Gregory] Georgia Hlth Sci Univ, Georgia Prevent Ctr, Augusta, GA USA.
[Januzzi, James] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS
PI PHILADELPHIA
PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA
SN 1071-9164
J9 J CARD FAIL
JI J. Card. Fail.
PD AUG
PY 2012
VL 18
IS 8
SU 1
MA 032
BP S11
EP S12
PG 2
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 991CS
UT WOS:000307679700033
ER
PT J
AU Krim, SR
Vivo, RP
Krim, NR
Qian, F
Cox, M
Ventura, H
Hernandez, AF
Bhatt, DL
Fonarow, GC
AF Krim, Selim R.
Vivo, Rey P.
Krim, Nassim R.
Qian, Feng
Cox, Margueritte
Ventura, Hector
Hernandez, Adrian F.
Bhatt, Deepak L.
Fonarow, Gregg C.
TI Do BNP Levels and Prognostic Value Vary by Race/Ethnicity in Patients
Hospitalized With Heart Failure?
SO JOURNAL OF CARDIAC FAILURE
LA English
DT Meeting Abstract
CT 16th Annual Scientific Meeting of the Heart-Failure-Society-of-America
CY SEP 09-12, 2012
CL Seattle, WA
SP Heart Failure Soc Amer
C1 [Krim, Selim R.; Ventura, Hector] Ochsner Heart & Vasc Inst, New Orleans, LA USA.
[Vivo, Rey P.] Univ Texas Med Branch, Methodist DeBakey Heart & Vasc Ctr, Galveston, TX USA.
[Krim, Nassim R.] Bronx Lebanon Hosp Ctr, Montefiore Med Ctr, Bronx, NY 10467 USA.
[Qian, Feng] Univ Rochester, Med Ctr, Rochester, NY 14642 USA.
[Cox, Margueritte; Hernandez, Adrian F.] Duke Clin Res Inst, Durham, NC USA.
[Bhatt, Deepak L.] Brigham & Womens Hosp, VA Boston Healthcare System, Boston, MA 02115 USA.
[Fonarow, Gregg C.] Univ Calif Los Angeles, Med Ctr, Los Angeles, CA 90024 USA.
RI Ventura, Hector/A-7691-2011
NR 0
TC 0
Z9 0
U1 0
U2 0
PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS
PI PHILADELPHIA
PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA
SN 1071-9164
J9 J CARD FAIL
JI J. Card. Fail.
PD AUG
PY 2012
VL 18
IS 8
SU 1
MA 260
BP S80
EP S81
PG 2
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 991CS
UT WOS:000307679700261
ER
PT J
AU Parks, K
Castrillo, C
Canteli-Alvarez, A
Wood, M
Mahmud, A
Malhotra, R
Semigran, MJ
AF Parks, Kimberly
Castrillo, Cristina
Canteli-Alvarez, Angela
Wood, Malissa
Mahmud, Asma
Malhotra, Rajeev
Semigran, Marc J.
TI Allograft Left Ventricular Hypertrophy after Cardiac Transplantation
SO JOURNAL OF CARDIAC FAILURE
LA English
DT Meeting Abstract
CT 16th Annual Scientific Meeting of the Heart-Failure-Society-of-America
CY SEP 09-12, 2012
CL Seattle, WA
SP Heart Failure Soc Amer
C1 [Parks, Kimberly; Wood, Malissa; Mahmud, Asma; Malhotra, Rajeev; Semigran, Marc J.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Castrillo, Cristina; Canteli-Alvarez, Angela] Univ Hosp Marques de Valdecilla, Inst Formac & Invest, Santander, Spain.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS
PI PHILADELPHIA
PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA
SN 1071-9164
J9 J CARD FAIL
JI J. Card. Fail.
PD AUG
PY 2012
VL 18
IS 8
SU 1
MA 247
BP S76
EP S76
PG 1
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 991CS
UT WOS:000307679700248
ER
PT J
AU Shalaby, AA
Gorcsan, J
Fonarow, G
Singh, J
Bersohn, M
Halilovic, J
Gupta, M
Sonel, A
Saba, S
Abraham, W
Kadish, A
AF Shalaby, Alas A.
Gorcsan, John
Fonarow, Gregg
Singh, Jagmeet
Bersohn, Malcolm
Halilovic, Jasmina
Gupta, Manish
Sonel, Ali
Saba, Samir
Abraham, William
Kadish, Alan
TI Results of the RISK Trial: Renal Function and Female Gender Are Strongly
Associated with Early Response to Cardiac Resynchronization Therapy
SO JOURNAL OF CARDIAC FAILURE
LA English
DT Meeting Abstract
CT 16th Annual Scientific Meeting of the Heart-Failure-Society-of-America
CY SEP 09-12, 2012
CL Seattle, WA
SP Heart Failure Soc Amer
C1 [Shalaby, Alas A.; Gorcsan, John; Sonel, Ali; Saba, Samir] Univ Pittsburgh, Pittsburgh, PA 15260 USA.
[Fonarow, Gregg; Bersohn, Malcolm] Univ Calif Los Angeles, Los Angeles, CA USA.
[Singh, Jagmeet] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Halilovic, Jasmina; Gupta, Manish] St Jude Med, Sunnyvale, CA USA.
[Abraham, William] Ohio State Univ, Columbus, OH 43210 USA.
[Kadish, Alan] Touro Coll, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS
PI PHILADELPHIA
PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA
SN 1071-9164
J9 J CARD FAIL
JI J. Card. Fail.
PD AUG
PY 2012
VL 18
IS 8
SU 1
MA 184
BP S58
EP S58
PG 1
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 991CS
UT WOS:000307679700185
ER
PT J
AU Zavin, A
Daniels, K
Arena, R
Lecker, S
Allsup, K
Joseph, J
Lazzari, A
Davis, S
Schulze, PC
Forman, DE
AF Zavin, Alexandra
Daniels, Karla
Arena, Ross
Lecker, Stewart
Allsup, Kelly
Joseph, Jacob
Lazzari, Antonio
Davis, Samuel
Schulze, P. Christian
Forman, Daniel E.
TI Adiponectin is Associated With Reduced Muscular Strength in Elderly
Heart Failure Patients
SO JOURNAL OF CARDIAC FAILURE
LA English
DT Meeting Abstract
CT 16th Annual Scientific Meeting of the Heart-Failure-Society-of-America
CY SEP 09-12, 2012
CL Seattle, WA
SP Heart Failure Soc Amer
C1 [Zavin, Alexandra; Allsup, Kelly; Lazzari, Antonio; Davis, Samuel; Forman, Daniel E.] VA Boston Healthcare Syst, Boston, MA USA.
[Daniels, Karla; Joseph, Jacob; Forman, Daniel E.] Harvard Univ, Brigham & Womens Hosp, Div Cardiovasc Med, Sch Med, Boston, MA 02115 USA.
[Arena, Ross] Univ New Mexico, Sch Med, Dept Orthopaed, Albuquerque, NM 87131 USA.
[Arena, Ross] Univ New Mexico, Sch Med, Rehabil Phys Therapy Program, Albuquerque, NM 87131 USA.
[Arena, Ross] Univ New Mexico, Sch Med, Dept Internal Med, Div Cardiol, Albuquerque, NM 87131 USA.
[Lecker, Stewart] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Nephrol, Boston, MA 02215 USA.
[Joseph, Jacob; Forman, Daniel E.] VA Boston Healthcare Syst, Div Cardiovas Med, Boston, MA USA.
[Lazzari, Antonio] Boston Univ, Sch Med, Boston, MA 02118 USA.
[Schulze, P. Christian] Columbia Univ, Div Cardiol, Med Ctr, New York, NY USA.
RI Arena, Ross/A-3141-2008
OI Arena, Ross/0000-0002-6675-1996
NR 0
TC 0
Z9 0
U1 1
U2 1
PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS
PI PHILADELPHIA
PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA
SN 1071-9164
J9 J CARD FAIL
JI J. Card. Fail.
PD AUG
PY 2012
VL 18
IS 8
SU 1
MA 092
BP S29
EP S30
PG 2
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 991CS
UT WOS:000307679700093
ER
PT J
AU Eberling, J
Medhurst, A
Nash, K
Gill, A
Pollack, S
Cronk, D
Bacskai, B
Mathis, C
Mach, R
AF Eberling, Jamie
Medhurst, Andrew
Nash, Kevin
Gill, Andrew
Pollack, Scott
Cronk, David
Bacskai, Brian
Mathis, Chester
Mach, Robert
TI Consortium to develop an alpha-synuclein imaging agent
SO JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM
LA English
DT Meeting Abstract
CT 9th International Symposium on Functional Neuroreceptor Mapping of the
Living Brain (NRM)
CY AUG 09-11, 2012
CL Baltimore, MD
C1 [Eberling, Jamie] Michael J Fox Fdn, New York, NY USA.
[Medhurst, Andrew; Nash, Kevin; Gill, Andrew; Pollack, Scott; Cronk, David] BioFocus, Cambridge, England.
[Bacskai, Brian] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Mathis, Chester] Univ Pittsburgh, Pittsburgh, PA 15260 USA.
[Mach, Robert] Washington Univ, St Louis, MO USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0271-678X
J9 J CEREBR BLOOD F MET
JI J. Cereb. Blood Flow Metab.
PD AUG
PY 2012
VL 32
SU 1
BP S125
EP S126
PG 2
WC Endocrinology & Metabolism; Hematology; Neurosciences
SC Endocrinology & Metabolism; Hematology; Neurosciences & Neurology
GA 983SC
UT WOS:000307138000128
ER
PT J
AU Hansen, HD
Sander, C
Mandeville, JB
Vanduffel, W
Catana, C
Hooker, J
Rosen, B
Knudsen, GM
AF Hansen, Hanne D.
Sander, Christin
Mandeville, Joseph B.
Vanduffel, Wim
Catana, Ciprian
Hooker, Jacob
Rosen, Bruce
Knudsen, Gitte M.
TI Optimized bolus/infusion scheme and determination of in vivo K-d for
[C-11]AZ10419369 in non-human primates
SO JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM
LA English
DT Meeting Abstract
CT 9th International Symposium on Functional Neuroreceptor Mapping of the
Living Brain (NRM)
CY AUG 09-11, 2012
CL Baltimore, MD
C1 [Hansen, Hanne D.; Knudsen, Gitte M.] Rigshosp, Copenhagen Univ Hosp, Neurobiol Res Unit, DK-2100 Copenhagen, Denmark.
[Sander, Christin; Mandeville, Joseph B.; Vanduffel, Wim; Catana, Ciprian; Hooker, Jacob; Rosen, Bruce] Massachusetts Gen Hosp, AA Martinos Ctr Biomed Imaging, Charlestown, MA USA.
RI Hansen, Hanne Demant/C-9029-2013
OI Hansen, Hanne Demant/0000-0001-5564-7627
NR 2
TC 0
Z9 0
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0271-678X
J9 J CEREBR BLOOD F MET
JI J. Cereb. Blood Flow Metab.
PD AUG
PY 2012
VL 32
SU 1
BP S127
EP S127
PG 1
WC Endocrinology & Metabolism; Hematology; Neurosciences
SC Endocrinology & Metabolism; Hematology; Neurosciences & Neurology
GA 983SC
UT WOS:000307138000130
ER
PT J
AU Hicks, J
Sadovski, O
Parkes, J
Fowler, C
Houle, S
Tong, JC
Vasdev, N
Wilson, A
AF Hicks, Justin
Sadovski, Oleg
Parkes, Jun
Fowler, Chris
Houle, Sylvain
Tong, Junchao
Vasdev, Neil
Wilson, Alan
TI Evaluation of a small library of carbamates and ureas, including
PF-04457845, as potential imaging agents for fatty acid amide hydrolase
(FAAH)
SO JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM
LA English
DT Meeting Abstract
CT 9th International Symposium on Functional Neuroreceptor Mapping of the
Living Brain (NRM)
CY AUG 09-11, 2012
CL Baltimore, MD
C1 [Hicks, Justin; Sadovski, Oleg; Parkes, Jun; Houle, Sylvain; Tong, Junchao; Wilson, Alan] Ctr Addict & Mental Hlth, Toronto, ON, Canada.
[Vasdev, Neil] Mass Gen Hosp, Boston, MA USA.
[Fowler, Chris] Umea Univ, S-90187 Umea, Sweden.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0271-678X
J9 J CEREBR BLOOD F MET
JI J. Cereb. Blood Flow Metab.
PD AUG
PY 2012
VL 32
SU 1
BP S17
EP S17
PG 1
WC Endocrinology & Metabolism; Hematology; Neurosciences
SC Endocrinology & Metabolism; Hematology; Neurosciences & Neurology
GA 983SC
UT WOS:000307138000006
ER
PT J
AU Ishibashi, K
Robertson, C
London, E
Mandelkern, M
AF Ishibashi, Kenji
Robertson, Chelsea
London, Edythe
Mandelkern, Mark
TI Is the cerebellum the best reference region for a PET study with
[F-18]-fallypride?
SO JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM
LA English
DT Meeting Abstract
CT 9th International Symposium on Functional Neuroreceptor Mapping of the
Living Brain (NRM)
CY AUG 09-11, 2012
CL Baltimore, MD
C1 [Ishibashi, Kenji] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA.
[Ishibashi, Kenji] Univ Calif Los Angeles, Semel Inst, Los Angeles, CA USA.
[Ishibashi, Kenji; Mandelkern, Mark] Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Robertson, Chelsea; London, Edythe] Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA USA.
[Mandelkern, Mark] Univ Calif Irvine, Dept Phys, Irvine, CA 92717 USA.
NR 3
TC 0
Z9 0
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0271-678X
J9 J CEREBR BLOOD F MET
JI J. Cereb. Blood Flow Metab.
PD AUG
PY 2012
VL 32
SU 1
BP S178
EP S179
PG 2
WC Endocrinology & Metabolism; Hematology; Neurosciences
SC Endocrinology & Metabolism; Hematology; Neurosciences & Neurology
GA 983SC
UT WOS:000307138000187
ER
PT J
AU Ishibashi, K
Robertson, C
Brown, A
Morgan, A
Farahi, J
Mandelkern, M
Sabb, F
Cannon, T
London, E
AF Ishibashi, Kenji
Robertson, Chelsea
Brown, Amira
Morgan, Andrew
Farahi, Judah
Mandelkern, Mark
Sabb, Fred
Cannon, Tyrone
London, Edythe
TI Differential roles of dopamine D1-and D2-like receptors in impulsivity:
a preliminary PET study
SO JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM
LA English
DT Meeting Abstract
CT 9th International Symposium on Functional Neuroreceptor Mapping of the
Living Brain (NRM)
CY AUG 09-11, 2012
CL Baltimore, MD
C1 [Ishibashi, Kenji; Brown, Amira; Morgan, Andrew; Sabb, Fred; Cannon, Tyrone; London, Edythe] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA.
[Ishibashi, Kenji; Brown, Amira; Morgan, Andrew; Sabb, Fred; Cannon, Tyrone; London, Edythe] Univ Calif Los Angeles, Semel Inst, Los Angeles, CA USA.
[Ishibashi, Kenji; Morgan, Andrew; Farahi, Judah; Mandelkern, Mark] Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Robertson, Chelsea] Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA USA.
[Mandelkern, Mark] Univ Calif Irvine, Dept Phys, Irvine, CA 92717 USA.
[Cannon, Tyrone] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA.
NR 3
TC 1
Z9 1
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0271-678X
J9 J CEREBR BLOOD F MET
JI J. Cereb. Blood Flow Metab.
PD AUG
PY 2012
VL 32
SU 1
BP S82
EP S83
PG 2
WC Endocrinology & Metabolism; Hematology; Neurosciences
SC Endocrinology & Metabolism; Hematology; Neurosciences & Neurology
GA 983SC
UT WOS:000307138000080
ER
PT J
AU Normandin, M
Sander, C
Catana, C
Hooker, J
Jenkins, B
Vanduffel, W
El Fakhri, G
Rosen, B
Alpert, N
Mandeville, J
AF Normandin, Marc
Sander, Christin
Catana, Ciprian
Hooker, Jacob
Jenkins, Bruce
Vanduffel, Wim
El Fakhri, Georges
Rosen, Bruce
Alpert, Nathaniel
Mandeville, Joseph
TI A kinetic model for mapping dopamine function with simultaneous PET/MR
SO JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM
LA English
DT Meeting Abstract
CT 9th International Symposium on Functional Neuroreceptor Mapping of the
Living Brain (NRM)
CY AUG 09-11, 2012
CL Baltimore, MD
C1 [Normandin, Marc; Catana, Ciprian; Hooker, Jacob; Jenkins, Bruce; Vanduffel, Wim; El Fakhri, Georges; Rosen, Bruce; Alpert, Nathaniel; Mandeville, Joseph] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
[Sander, Christin] MIT, Cambridge, MA 02139 USA.
NR 2
TC 0
Z9 0
U1 1
U2 5
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0271-678X
J9 J CEREBR BLOOD F MET
JI J. Cereb. Blood Flow Metab.
PD AUG
PY 2012
VL 32
SU 1
BP S176
EP S177
PG 2
WC Endocrinology & Metabolism; Hematology; Neurosciences
SC Endocrinology & Metabolism; Hematology; Neurosciences & Neurology
GA 983SC
UT WOS:000307138000185
ER
PT J
AU Ouyang, J
Keeler, ML
Bonab, AA
Domigan, P
Zhu, XP
Normandin, M
Brady, T
El Fakhri, G
AF Ouyang, Jinsong
Keeler, Matthew L.
Bonab, Ali A.
Domigan, Paul
Zhu, Xuping
Normandin, Marc
Brady, Thomas
El Fakhri, Georges
TI Evaluation of the performance of a novel mobile brain PET-CT
SO JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM
LA English
DT Meeting Abstract
CT 9th International Symposium on Functional Neuroreceptor Mapping of the
Living Brain (NRM)
CY AUG 09-11, 2012
CL Baltimore, MD
C1 [Ouyang, Jinsong; Bonab, Ali A.; Zhu, Xuping; Normandin, Marc; Brady, Thomas; El Fakhri, Georges] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Keeler, Matthew L.; Domigan, Paul] PhotoDiagnost Syst Inc, Boxboro, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0271-678X
J9 J CEREBR BLOOD F MET
JI J. Cereb. Blood Flow Metab.
PD AUG
PY 2012
VL 32
SU 1
BP S175
EP S176
PG 2
WC Endocrinology & Metabolism; Hematology; Neurosciences
SC Endocrinology & Metabolism; Hematology; Neurosciences & Neurology
GA 983SC
UT WOS:000307138000184
ER
PT J
AU Robertson, C
Ishibashi, K
Brown, A
Morgan, A
Ghahremani, D
Congdon, E
Farahi, J
Mandelkern, M
Cannon, T
Sabb, F
London, E
AF Robertson, Chelsea
Ishibashi, Kenji
Brown, Amira
Morgan, Andrew
Ghahremani, Dara
Congdon, Eliza
Farahi, Judah
Mandelkern, Mark
Cannon, Tyrone
Sabb, Fred
London, Edythe
TI Relationships of D1-and D2-like receptor availability and response
inhibition in the stop-signal task: a preliminary PET study
SO JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM
LA English
DT Meeting Abstract
CT 9th International Symposium on Functional Neuroreceptor Mapping of the
Living Brain (NRM)
CY AUG 09-11, 2012
CL Baltimore, MD
C1 [Robertson, Chelsea; London, Edythe] Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA USA.
[Ishibashi, Kenji; Brown, Amira; Morgan, Andrew; Ghahremani, Dara; Congdon, Eliza; Cannon, Tyrone; Sabb, Fred; London, Edythe] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA.
[Ishibashi, Kenji; Brown, Amira; Morgan, Andrew; Ghahremani, Dara; Congdon, Eliza; Cannon, Tyrone; Sabb, Fred; London, Edythe] Univ Calif Los Angeles, Semel Inst, Los Angeles, CA USA.
[Morgan, Andrew; Farahi, Judah; Mandelkern, Mark] Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Mandelkern, Mark] Univ Calif Irvine, Dept Phys, Irvine, CA 92717 USA.
[London, Edythe] Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90024 USA.
[Cannon, Tyrone] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA.
NR 4
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0271-678X
J9 J CEREBR BLOOD F MET
JI J. Cereb. Blood Flow Metab.
PD AUG
PY 2012
VL 32
SU 1
BP S14
EP S15
PG 2
WC Endocrinology & Metabolism; Hematology; Neurosciences
SC Endocrinology & Metabolism; Hematology; Neurosciences & Neurology
GA 983SC
UT WOS:000307138000003
ER
PT J
AU Sander, CY
Hooker, JM
Catana, C
Normandin, M
Vanduffel, W
Rosen, BR
Mandeville, JB
AF Sander, Christin Y.
Hooker, Jacob M.
Catana, Ciprian
Normandin, Marc
Vanduffel, Wim
Rosen, Bruce R.
Mandeville, Joseph B.
TI Coupling of neurovascular response and receptor occupancy with
simultaneous PET/fMRI
SO JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM
LA English
DT Meeting Abstract
CT 9th International Symposium on Functional Neuroreceptor Mapping of the
Living Brain (NRM)
CY AUG 09-11, 2012
CL Baltimore, MD
C1 [Sander, Christin Y.; Hooker, Jacob M.; Catana, Ciprian; Vanduffel, Wim; Rosen, Bruce R.; Mandeville, Joseph B.] Massachusetts Gen Hosp, AA Martinos Ctr Biomed Imaging, Charlestown, MA USA.
[Sander, Christin Y.] MIT, Cambridge, MA 02139 USA.
[Normandin, Marc] Massachusetts Gen Hosp, Div Nucl Med, Boston, MA 02114 USA.
[Rosen, Bruce R.] Harvard MIT, Hlth Sci & Technol, Cambridge, MA USA.
NR 2
TC 0
Z9 0
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0271-678X
J9 J CEREBR BLOOD F MET
JI J. Cereb. Blood Flow Metab.
PD AUG
PY 2012
VL 32
SU 1
BP S177
EP S178
PG 2
WC Endocrinology & Metabolism; Hematology; Neurosciences
SC Endocrinology & Metabolism; Hematology; Neurosciences & Neurology
GA 983SC
UT WOS:000307138000186
ER
PT J
AU Chinman, M
Hannah, G
McCarthy, S
AF Chinman, Matthew
Hannah, Gordon
McCarthy, Sharon
TI Lessons Learned from a Quality Improvement Intervention with Homeless
Veteran Services
SO JOURNAL OF HEALTH CARE FOR THE POOR AND UNDERSERVED
LA English
DT Article
DE Quality improvement; homeless people; veterans; evidence-based practice;
capacity building
ID CRITICAL TIME INTERVENTION; SUPPORTED EMPLOYMENT; IMPLEMENTATION;
OUTCOMES; PROGRAM; DIFFUSION; DISSEMINATION; PREDICTORS; DISCHARGE;
MATTERS
AB Homeless veterans are a vulnerable population, with high mortality and morbidity rates. Evidence-based practices for homelessness have been challenging to implement. This study engaged staff members from three VA homeless programs to improve their quality using Getting-To-Outcomes (GTO), a model and intervention of trainings and technical assistance that builds practitioner capacity to plan, implement, and self-evaluate evidence-based practices. Primarily used in community-based, non-VA settings, this study piloted GTO in VA by creating a GTO project within each homeless program and one across all three. The feasibility and acceptability of GTO in VA is examined using the results of the projects, time spent on GTO, and data from focus groups and interviews. With staff members averaging 33 minutes per week on GTO, each team made significant programmatic changes. Homeless staff stated GTO was helpful, and that high levels of communication, staff member commitment to the program, and technical assistance were critical.
C1 [Chinman, Matthew; Hannah, Gordon; McCarthy, Sharon] VA Pittsburgh Healthcare Syst, MIRECC, VISN 4, Pittsburgh, PA 15206 USA.
RP Chinman, M (reprint author), VA Pittsburgh Healthcare Syst, MIRECC, VISN 4, 7180 Highland Dr 151-R, Pittsburgh, PA 15206 USA.
EM chinman@rand.org
NR 39
TC 3
Z9 3
U1 2
U2 12
PU JOHNS HOPKINS UNIV PRESS
PI BALTIMORE
PA JOURNALS PUBLISHING DIVISION, 2715 NORTH CHARLES ST, BALTIMORE, MD
21218-4363 USA
SN 1049-2089
J9 J HEALTH CARE POOR U
JI J. Health Care Poor Underserved
PD AUG
PY 2012
VL 23
IS 3
SU S
BP 210
EP 224
PG 15
WC Health Policy & Services; Public, Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA 987JR
UT WOS:000307413700019
PM 22864498
ER
PT J
AU Yeung, A
Feldman, G
Pedrelli, P
Hails, K
Fava, M
Reyes, T
Mundt, JC
AF Yeung, Albert
Feldman, Gregory
Pedrelli, Paola
Hails, Kate
Fava, Maurizio
Reyes, Tracy
Mundt, James C.
TI The Quick Inventory of Depressive Symptomatology, Clinician Rated and
Self-report A Psychometric Assessment in Chinese Americans With Major
Depressive Disorder
SO JOURNAL OF NERVOUS AND MENTAL DISEASE
LA English
DT Article
DE Depression; Chinese; psychometrics; severity of illness index;
psychiatric status rating scales
ID SEQUENCED TREATMENT ALTERNATIVES; REPORT QIDS-SR; PRIMARY-CARE; TRIAL
AB This study aimed to investigate the psychometric properties of the Chinese translations of the Quick Inventory of Depressive Symptomatology (QIDS(16)), including the Clinician-Rated (QIDS-C-16), Self-report (QIDS-SR16), and Interactive Voice Response (QIDS-SR-IVR16) formats. Thirty depressed Chinese Americans were assessed with Chinese translations of the QIDS-SR16, QIDS-SR-IVR16, and QIDS-C-16. Cronbach alpha estimates of internal scale consistency on the QIDS-SR16, QIDS-SR-IVR16, and QIDS-C-16 were 0.70, 0.74, and 0.79, respectively. Intercorrelations among the measures were QIDS-SR16 and QIDS-SR-IVR16, r = 0.79; QIDS-SR16 and QIDS-C-16, r = 0.61; and QIDS-SR-IVR16 and QIDS-C-16, r = 0.69 (all p values < 0.01). The areas under the curve for the receiver operating characteristics of the QIDS-SR16 and QIDS-SR-IVR16 were 0.78 (95% confidence interval, 0.61-0.95) and 0.81 (95% confidence interval, 0.65-0.96), respectively. The respective screening sensitivities/specificities were 0.73/0.74 and 0.86/0.58. The Chinese translations of the QIDS(16) have adequate psychometric properties and may be useful tools for depression screening.
C1 [Yeung, Albert; Feldman, Gregory; Pedrelli, Paola; Hails, Kate; Fava, Maurizio] Massachusetts Gen Hosp, Depress Clin & Res Program, Boston, MA 02114 USA.
[Feldman, Gregory] Simmons Coll, Boston, MA 02115 USA.
[Reyes, Tracy; Mundt, James C.] Ctr Psychol Consulting, Madison, WI USA.
RP Yeung, A (reprint author), Massachusetts Gen Hosp, Depress Clin & Res Program, 1 Bowdoin Sq 6-F, Boston, MA 02114 USA.
EM ayeung@partners.org
FU National Institutes of Mental Health [R44MH068950, R01MH079831]
FX This project was supported by grants R44MH068950 and R01MH079831 from
the National Institutes of Mental Health. The authors declare no
conflict of interest.
NR 21
TC 3
Z9 3
U1 1
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0022-3018
J9 J NERV MENT DIS
JI J. Nerv. Ment. Dis.
PD AUG
PY 2012
VL 200
IS 8
BP 712
EP 715
DI 10.1097/NMD.0b013e318261413d
PG 4
WC Clinical Neurology; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 983NJ
UT WOS:000307125700010
PM 22850307
ER
PT J
AU Sher, L
AF Sher, Leo
TI Mind and Brain: A Critical Appraisal of Cognitive Neuroscience
SO JOURNAL OF NERVOUS AND MENTAL DISEASE
LA English
DT Book Review
C1 [Sher, Leo] Mt Sinai Sch Med, New York, NY 10029 USA.
[Sher, Leo] James J Peters Vet Adm Med Ctr, New York, NY USA.
RP Sher, L (reprint author), Mt Sinai Sch Med, New York, NY 10029 USA.
NR 1
TC 0
Z9 0
U1 1
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0022-3018
J9 J NERV MENT DIS
JI J. Nerv. Ment. Dis.
PD AUG
PY 2012
VL 200
IS 8
BP 735
EP 736
DI 10.1097/NMD.0b013e31826143cf
PG 2
WC Clinical Neurology; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 983NJ
UT WOS:000307125700017
ER
PT J
AU Chun, SY
Reese, TG
Ouyang, JS
Guerin, B
Catana, C
Zhu, XP
Alpert, NM
El Fakhri, G
AF Chun, Se Young
Reese, Timothy G.
Ouyang, Jinsong
Guerin, Bastien
Catana, Ciprian
Zhu, Xuping
Alpert, Nathaniel M.
El Fakhri, Georges
TI MRI-Based Nonrigid Motion Correction in Simultaneous PET/MRI
SO JOURNAL OF NUCLEAR MEDICINE
LA English
DT Article
DE lesion detection; motion correction; PET/MRI
ID IMAGE-RECONSTRUCTION; ATTENUATION-CORRECTION; EMISSION-TOMOGRAPHY; PET
IMAGES; GATED PET; REGISTRATION; MODEL; COMPENSATION; FEASIBILITY;
SEQUENCES
AB Respiratory and cardiac motion is the most serious limitation to whole-body PET, resulting in spatial resolution close to 1 cm. Furthermore, motion-induced inconsistencies in the attenuation measurements often lead to significant artifacts in the reconstructed images. Gating can remove motion artifacts at the cost of increased noise. This paper presents an approach to respiratory motion correction using simultaneous PET/MRI to demonstrate initial results in phantoms, rabbits, and nonhuman primates and discusses the prospects for clinical application. Methods: Studies with a deformable phantom, a free-breathing primate, and rabbits implanted with radioactive beads were performed with simultaneous PET/MRI. Motion fields were estimated from concurrently acquired tagged MR images using 2 B-spline nonrigid image registration methods and incorporated into a PET list-mode ordered-subsets expectation maximization algorithm. Using the measured motion fields to transform both the emission data and the attenuation data, we could use all the coincidence data to reconstruct any phase of the respiratory cycle. We compared the resulting SNR and the channelized Hotelling observer (CHO) detection signal-to-noise ratio (SNR) in the motion-corrected reconstruction with the results obtained from standard gating and uncorrected studies. Results: Motion correction virtually eliminated motion blur without reducing SNR, yielding images with SNR comparable to those obtained by gating with 5-8 times longer acquisitions in all studies. The CHO study in dynamic phantoms demonstrated a significant improvement (166%-276%) in lesion detection SNR with MRI-based motion correction as compared with gating (P < 0.001). This improvement was 43%-92% for large motion compared with lesion detection without motion correction (P < 0.001). CHO SNR in the rabbit studies confirmed these results. Conclusion: Tagged MRI motion correction in simultaneous PET/MRI significantly improves lesion detection compared with respiratory gating and no motion correction while reducing radiation dose. In vivo primate and rabbit studies confirmed the improvement in PET image quality and provide the rationale for evaluation in simultaneous whole-body PET/MRI clinical studies.
C1 [Chun, Se Young; Ouyang, Jinsong; Guerin, Bastien; Zhu, Xuping; Alpert, Nathaniel M.; El Fakhri, Georges] Massachusetts Gen Hosp, Dept Radiol, Ctr Adv Radiol Sci Nucl Med & Mol Imaging, Boston, MA 02114 USA.
[Reese, Timothy G.; Catana, Ciprian] Massachusetts Gen Hosp, Dept Radiol, AA Martinos Ctr, Boston, MA 02114 USA.
[Chun, Se Young; Reese, Timothy G.; Ouyang, Jinsong; Guerin, Bastien; Catana, Ciprian; Zhu, Xuping; Alpert, Nathaniel M.; El Fakhri, Georges] Harvard Univ, Sch Med, Boston, MA USA.
RP El Fakhri, G (reprint author), Massachusetts Gen Hosp, Ctr Adv Radiol Sci, Radiol Div Nucl Med & Mol Imaging, 55 Fruit St, Boston, MA 02114 USA.
EM elfakhri@pet.mgh.harvard.edu
RI Chun, Se Young/B-6653-2013; Guerin, Bastien/P-1412-2014;
OI Chun, Se Young/0000-0001-8739-8960
FU [NIH-R21-EB012326]; [R01-CA165221]
FX We thank Dr. Koen Nelissen, Daniel Chonde, and Dr. Elie Moussallem for
their help with the animal studies. This work was supported in part by
NIH-R21-EB012326 and R01-CA165221. No other potential conflict of
interest relevant to this article was reported.
NR 34
TC 76
Z9 76
U1 1
U2 19
PU SOC NUCLEAR MEDICINE INC
PI RESTON
PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA
SN 0161-5505
J9 J NUCL MED
JI J. Nucl. Med.
PD AUG
PY 2012
VL 53
IS 8
BP 1284
EP 1291
DI 10.2967/jnumed.111.092353
PG 8
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 984OT
UT WOS:000307201300031
PM 22743250
ER
PT J
AU Harris, RS
Winkler, T
Venegas, JG
Medoff, B
AF Harris, R. Scott
Winkler, Tilo
Venegas, Jose G.
Medoff, Benjamin
TI F-18-FDG Uptake to Assess Eosinophilic Inflammation in Asthma: Would SUV
at Late Imaging Be Relevant? REPLY
SO JOURNAL OF NUCLEAR MEDICINE
LA English
DT Letter
C1 [Harris, R. Scott] Massachusetts Gen Hosp, Pulm & Crit Care Unit, Boston, MA 02114 USA.
RP Harris, RS (reprint author), Massachusetts Gen Hosp, Pulm & Crit Care Unit, Bulfinch 148,55 Fruit St, Boston, MA 02114 USA.
EM rsharris@mgh.harvard.edu
RI Winkler, Tilo/B-5337-2009
OI Winkler, Tilo/0000-0002-7276-5550
NR 2
TC 1
Z9 1
U1 0
U2 1
PU SOC NUCLEAR MEDICINE INC
PI RESTON
PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA
SN 0161-5505
J9 J NUCL MED
JI J. Nucl. Med.
PD AUG
PY 2012
VL 53
IS 8
BP 1328
EP 1329
DI 10.2967/jnumed.112.104018
PG 2
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 984OT
UT WOS:000307201300036
ER
PT J
AU Osei-Bonsu, PE
Spiro, A
Schultz, MR
Ryabchenko, KA
Smith, E
Herz, L
Eisen, SV
AF Osei-Bonsu, Princess E.
Spiro, Avron, III
Schultz, Mark R.
Ryabchenko, Karen A.
Smith, Eric
Herz, Lawrence
Eisen, Susan V.
TI Is DSM-IV criterion A2 associated with PTSD diagnosis and symptom
severity?
SO JOURNAL OF TRAUMATIC STRESS
LA English
DT Article
ID POSTTRAUMATIC-STRESS-DISORDER; NATIONAL COMORBIDITY SURVEY; EMOTIONAL
RESPONSE; SINGLE QUESTION; VETERANS; VIETNAM; TRAUMA; PREVALENCE;
LIFETIME; SAMPLE
AB The diagnostic criteria for posttraumatic stress disorder (PTSD) have received significant scrutiny. Several studies have investigated the utility of Criterion A2, the subjective emotional response to a traumatic event. The American Psychiatric Association (APA) has proposed elimination of A2 from the PTSD diagnostic criteria for DSM-5; however, there is mixed support for this recommendation and few studies have examined A2 in samples at high risk for PTSD such as veterans. In the current study of 908 veterans who screened positive for a traumatic event, A2 was not significantly associated with having been told by a doctor that the veteran had PTSD. Those who endorsed A2, however, reported greater PTSD symptom severity in the 3 DSM-IV symptom clusters of reexperiencing (d = 0.45), avoidance (d = 0.61), and hyperarousal (d = 0.44), and A2 was significantly associated with PTSD symptom severity for all 3 clusters (R2 = .25, .25, and .27, respectively) even with trauma exposure in the model. Thus, although A2 may not be a necessary criterion for PTSD diagnosis, its association with PTSD symptom severity warrants further exploration of its utility.
C1 [Osei-Bonsu, Princess E.; Schultz, Mark R.; Smith, Eric; Eisen, Susan V.] Edith Nourse Rogers Mem Vet Hosp, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA 01730 USA.
[Spiro, Avron, III; Ryabchenko, Karen A.] VA Boston Healthcare Syst, Boston, MA USA.
[Eisen, Susan V.] Boston Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA USA.
[Spiro, Avron, III; Ryabchenko, Karen A.] Boston Univ, Sch Med, Boston, MA 02118 USA.
[Smith, Eric] Univ Massachusetts, Sch Med, Dept Psychiat, Worcester, MA 01655 USA.
[Herz, Lawrence] Edith Nourse Rogers Mem Vet Hosp, MH Serv Line Gen Psychiat, Bedford, MA 01730 USA.
RP Eisen, SV (reprint author), Edith Nourse Rogers Mem Vet Hosp, Ctr Hlth Qual Outcomes & Econ Res, 200 Springs Rd 152, Bedford, MA 01730 USA.
EM susan.eisen@va.gov
OI Spiro III, Avron/0000-0003-4080-8621
NR 42
TC 6
Z9 6
U1 3
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0894-9867
J9 J TRAUMA STRESS
JI J. Trauma Stress
PD AUG
PY 2012
VL 25
IS 4
BP 368
EP 375
DI 10.1002/jts.21720
PG 8
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA 983HI
UT WOS:000307110000002
PM 22806767
ER
PT J
AU Marx, BP
Bovin, MJ
Suvak, MK
Monson, CM
Sloan, DM
Fredman, SJ
Humphreys, KL
Kaloupek, DG
Keane, TM
AF Marx, Brian P.
Bovin, Michelle J.
Suvak, Michael K.
Monson, Candice M.
Sloan, Denise M.
Fredman, Steffany J.
Humphreys, Kathryn L.
Kaloupek, Danny G.
Keane, Terence M.
TI Concordance between physiological arousal and subjective distress among
vietnam combat veterans undergoing challenge testing for PTSD
SO JOURNAL OF TRAUMATIC STRESS
LA English
DT Article
ID POSTTRAUMATIC-STRESS-DISORDER; SUBSTANCE USE DISORDERS;
INDIVIDUAL-DIFFERENCES; REACTIVITY; VALIDITY; THERAPY; EMOTION
AB This study examined concordance between physiological arousal and subjective distress during a laboratory challenge task. Data were collected during the multisite VA Cooperative Study 334 in the early 1990s examining psychophysiological arousal among combat-exposed Vietnam veterans with (n = 775) and without (n = 369) posttraumatic stress disorder (PTSD). Study participants were presented with 6 standardized neutral scenes and 6 standardized combat scenes. Participants provided a subjective rating of distress after each slide. During the presentation, levels of heart rate (HR) and skin conductance (SC) were recorded. Using linear mixed effects modeling, both HR level and SC level exhibited significant positive associations with subjective distress ratings (pr = .33, p < .001 and pr = .19, p < .001, respectively). Individuals with PTSD demonstrated greater concordance between their distress ratings and SC level during exposure to combat slides than participants without PTSD (pr = .28, p < .001 vs. pr = .18, p < .001). Although a significant association was found between subjective distress and HR reactivity and SC reactivity, these findings were not moderated by PTSD status. The results of these analyses suggest that patients' reports of distress during exposure-based treatments might serve as approximate measures of actual physiological arousal.
C1 [Marx, Brian P.; Bovin, Michelle J.; Suvak, Michael K.; Monson, Candice M.; Sloan, Denise M.; Fredman, Steffany J.; Kaloupek, Danny G.; Keane, Terence M.] VA Boston Healthcare Syst, Natl Ctr PTSD, Boston, MA USA.
[Marx, Brian P.; Sloan, Denise M.; Fredman, Steffany J.; Kaloupek, Danny G.; Keane, Terence M.] Boston Univ, Sch Med, Boston, MA 02118 USA.
[Suvak, Michael K.] Suffolk Univ, Dept Psychol, Boston, MA 02114 USA.
[Humphreys, Kathryn L.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA.
RP Marx, BP (reprint author), VA Boston Healthcare Syst 116B 4, Natl Ctr PTSD, 150 S Huntington Ave, Boston, MA 02130 USA.
EM brian.marx@va.gov
OI Sloan, Denise/0000-0002-0962-478X; Kaloupek, Danny/0000-0002-0795-593X
NR 41
TC 6
Z9 6
U1 3
U2 8
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0894-9867
J9 J TRAUMA STRESS
JI J. Trauma Stress
PD AUG
PY 2012
VL 25
IS 4
BP 416
EP 425
DI 10.1002/jts.21729
PG 10
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA 983HI
UT WOS:000307110000008
PM 22848013
ER
PT J
AU Marx, BP
Jackson, JC
Schnurr, PP
Murdoch, M
Sayer, NA
Keane, TM
Friedman, MJ
Greevy, RA
Owen, RR
Sinnott, PL
Speroff, T
AF Marx, Brian P.
Jackson, James C.
Schnurr, Paula P.
Murdoch, Maureen
Sayer, Nina A.
Keane, Terence M.
Friedman, Matthew J.
Greevy, Robert A.
Owen, Richard R.
Sinnott, Patricia L.
Speroff, Theodore
TI The reality of malingered PTSD among veterans: Reply to McNally and
Frueh (2012)
SO JOURNAL OF TRAUMATIC STRESS
LA English
DT Article
ID POSTTRAUMATIC-STRESS-DISORDER; US VETERANS; DISABILITY; PARTICIPATION;
THERAPY; VIETNAM; SERVICE; SEEKING; HEALTH
AB In this reply to McNally and Frueh (2012), we offer some additional insight into the studies they use to support their argument that we should be worried about malingering among veterans. We also describe other research on the disability system of the Department of Veterans Affairs and compensation-seeking behavior that challenges their conclusions.
C1 [Marx, Brian P.; Keane, Terence M.] VA Boston Healthcare Syst, VA Natl Ctr PTSD, Boston, MA USA.
[Marx, Brian P.; Keane, Terence M.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA.
[Jackson, James C.; Speroff, Theodore] VA Tennessee Valley Healthcare Syst, GRECC, Ctr Hlth Serv Res, Nashville, TN USA.
[Jackson, James C.] Vanderbilt Univ, Sch Med, Div Allergy Pulm Crit Care Med, Nashville, TN 37212 USA.
[Schnurr, Paula P.; Friedman, Matthew J.] White River Junct VA Med Ctr, VA Natl Ctr PTSD, White River Jct, VT USA.
[Schnurr, Paula P.; Friedman, Matthew J.] Geisel Sch Med Dartmouth, Dept Psychiat, Hanover, NH USA.
[Murdoch, Maureen; Sayer, Nina A.] Minneapolis VA Med Ctr, Gen Internal Med Sect, Minneapolis, MN USA.
[Murdoch, Maureen; Sayer, Nina A.] Minneapolis VA Med Ctr, Ctr Chron Dis Outcomes Res, Minneapolis, MN USA.
[Murdoch, Maureen; Sayer, Nina A.] Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA.
[Murdoch, Maureen; Sayer, Nina A.] Univ Minnesota, Dept Psychiat, Minneapolis, MN 55455 USA.
[Friedman, Matthew J.] Geisel Sch Med Dartmouth, Dept Pharmacol & Toxicol, Hanover, NH USA.
[Greevy, Robert A.; Speroff, Theodore] Vanderbilt Univ, Sch Med, Dept Biostat, Nashville, TN 37212 USA.
[Owen, Richard R.] Cent Arkansas VA Healthcare Syst, VA Mental Hlth Qual Enhancement Res Initiat MH QU, N Little Rock, AR USA.
[Owen, Richard R.] Univ Arkansas Med Sci, Coll Med, Dept Psychiat, Div Hlth Serv Res, Little Rock, AR 72205 USA.
[Sinnott, Patricia L.] VA Palo Alto Hlth Care Syst, Hlth Econ Resource Ctr, Palo Alto, CA USA.
[Sinnott, Patricia L.] Univ Calif San Francisco, Dept Phys Therapy & Rehabil Sci, San Francisco, CA 94143 USA.
[Speroff, Theodore] Vanderbilt Univ, Sch Med, Dept Med, Div Gen Internal Med, Nashville, TN 37212 USA.
RP Marx, BP (reprint author), 150 S Huntington Ave,116B-4, Boston, MA 02130 USA.
EM brian.marx@va.gov
RI Sayer, Nina/E-3249-2016
NR 22
TC 8
Z9 8
U1 1
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0894-9867
J9 J TRAUMA STRESS
JI J. Trauma Stress
PD AUG
PY 2012
VL 25
IS 4
BP 457
EP 460
DI 10.1002/jts.21714
PG 4
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA 983HI
UT WOS:000307110000014
ER
PT J
AU Lenhardt, JM
Howard, JM
Taft, CT
Kaloupek, DG
Keane, TM
AF Lenhardt, Jenna M.
Howard, Jamie M.
Taft, Casey T.
Kaloupek, Danny G.
Keane, Terence M.
TI Examining aggression in male vietnam veterans who receive VA services:
The role of traumatic events and combat exposure
SO JOURNAL OF TRAUMATIC STRESS
LA English
DT Article
ID POSTTRAUMATIC-STRESS-DISORDER; VIOLENCE; ABUSE
AB We examined the relationship between trauma exposure and the perpetration of aggression by male Vietnam veterans (N = 1,328) using archival data from a multisite study conducted by the Cooperative Studies Program of the Department of Veteran Affairs (CSP-334) in the early 1990s. Both traumatic events in civilian life and combat exposure were examined as correlates of aggression. Results indicated that pre- and postmilitary traumatic events and combat exposure were all related to perpetration of aggression at the bivariate level; r = .07, r = .20, and r = .13, respectively. When these variables were examined simultaneously, only combat exposure (beta = .14, p < .001) and postmilitary traumatic events (beta = .20, p < .001) were associated with aggression. No interaction effects were found for civilian traumatic events and combat in relation to aggression. Results highlight the importance of attending to the psychological aftermath of exposure to traumatic events experienced during and following deployment before aggressive patterns develop.
C1 [Taft, Casey T.] VA Boston Healthcare Syst, Behav Sci Div, Natl Ctr PTSD, Boston, MA 02130 USA.
[Howard, Jamie M.; Taft, Casey T.; Kaloupek, Danny G.; Keane, Terence M.] Boston Univ, Sch Med, Dept Psychol, Boston, MA 02118 USA.
RP Taft, CT (reprint author), VA Boston Healthcare Syst, Behav Sci Div, Natl Ctr PTSD, 150 S Huntington Ave 116B-4, Boston, MA 02130 USA.
EM Casey.Taft@va.gov
OI Kaloupek, Danny/0000-0002-0795-593X
NR 13
TC 1
Z9 1
U1 1
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0894-9867
J9 J TRAUMA STRESS
JI J. Trauma Stress
PD AUG
PY 2012
VL 25
IS 4
BP 461
EP 464
DI 10.1002/jts.21717
PG 4
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA 983HI
UT WOS:000307110000015
PM 22786658
ER
PT J
AU Steenkamp, MM
Dickstein, BD
Salters-Pedneault, K
Hofmann, SG
Litz, BT
AF Steenkamp, Maria M.
Dickstein, Benjamin D.
Salters-Pedneault, Kristalyn
Hofmann, Stefan G.
Litz, Brett T.
TI Trajectories of PTSD symptoms following sexual assault: Is resilience
the modal outcome?
SO JOURNAL OF TRAUMATIC STRESS
LA English
DT Article
ID POSTTRAUMATIC-STRESS-DISORDER; PSYCHOMETRIC PROPERTIES; TRAUMA;
PSYCHOPATHOLOGY; DEPRESSION; COMMUNITY; SURVIVORS; SCALES
AB Theoretical frameworks positing qualitatively distinct trajectories of posttrauma outcome have received initial empirical support, but have not been investigated in cases of severe interpersonal trauma. To address this limitation, we conducted latent class growth analysis with longitudinal data collected from 119 female sexual assault survivors at 1-, 2-, 3-, and 4-months postassault. Participants' mean age was 33 years; 63% were White. We hypothesized that given the severity of exposure associated with sexual assault, resilience would not be the modal course of adaptation. Four distinct PTSD growth trajectories, representing unique latent classes of participants, best fit the data: a high chronic trajectory, a moderate chronic trajectory, a moderate recovery trajectory, and a marked recovery trajectory. Contrary to previous studies and recent theoretical models, resilience and resistance trajectories were not observed, as high levels of distress were evident in nearly all participants at 1-month postassault. These results suggest that theoretical models of posttrauma response positing resilience as the modal outcome may not generalize to cases of sexual assault.
C1 [Steenkamp, Maria M.; Dickstein, Benjamin D.; Hofmann, Stefan G.; Litz, Brett T.] Boston Univ, Dept Psychol, Boston, MA 02215 USA.
[Steenkamp, Maria M.; Litz, Brett T.] VA Boston Healthcare Syst, Boston, MA USA.
[Salters-Pedneault, Kristalyn] Eastern Connecticut State Univ, Dept Psychol, Willimantic, CT 06226 USA.
RP Steenkamp, MM (reprint author), Boston Dept Vet Affairs Med Ctr, 150 S Huntington Ave, Boston, MA 02130 USA.
EM maria.steenkamp2@va.gov
RI Hofmann, Stefan/B-8769-2014
OI Hofmann, Stefan/0000-0002-3548-9681
NR 22
TC 20
Z9 20
U1 1
U2 21
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0894-9867
J9 J TRAUMA STRESS
JI J. Trauma Stress
PD AUG
PY 2012
VL 25
IS 4
BP 469
EP 474
DI 10.1002/jts.21718
PG 6
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA 983HI
UT WOS:000307110000017
PM 22807251
ER
PT J
AU Funnell, APW
Norton, LJ
Mak, KS
Burdach, J
Artuz, CM
Twine, NA
Wilkins, MR
Power, CA
Hung, TT
Perdomo, J
Koh, P
Bell-Anderson, KS
Orkin, SH
Fraser, ST
Perkins, AC
Pearson, RCM
Crossley, M
AF Funnell, Alister P. W.
Norton, Laura J.
Mak, Ka Sin
Burdach, Jon
Artuz, Crisbel M.
Twine, Natalie A.
Wilkins, Marc R.
Power, Carl A.
Hung, Tzong-Tyng
Perdomo, Jose
Koh, Philip
Bell-Anderson, Kim S.
Orkin, Stuart H.
Fraser, Stuart T.
Perkins, Andrew C.
Pearson, Richard C. M.
Crossley, Merlin
TI The CACCC-Binding Protein KLF3/BKLF Represses a Subset of KLF1/EKLF
Target Genes and Is Required for Proper Erythroid Maturation In Vivo
SO MOLECULAR AND CELLULAR BIOLOGY
LA English
DT Article
ID KRUPPEL-LIKE FACTOR; EKLF-NULL MICE; TRANSCRIPTION FACTOR;
BETA-THALASSEMIA; DEFICIENT MICE; CO-REPRESSOR; GLOBAL ROLE; CHIP-SEQ;
CELLS; DIFFERENTIATION
AB The CACCC-box binding protein erythroid Kruppel-like factor (EKLF/KLF1) is a master regulator that directs the expression of many important erythroid genes. We have previously shown that EKLF drives transcription of the gene for a second KLF, basic Kruppel-like factor, or KLF3. We have now tested the in vivo role of KLF3 in erythroid cells by examining Klf3 knockout mice. KLF3-deficient adults exhibit a mild compensated anemia, including enlarged spleens, increased red pulp, and a higher percentage of erythroid progenitors, together with elevated reticulocytes and abnormal erythrocytes in the peripheral blood. Impaired erythroid maturation is also observed in the fetal liver. We have found that KLF3 levels rise as erythroid cells mature to become TER119(+). Consistent with this, microarray analysis of both TER119(-) and TER119(+) erythroid populations revealed that KLF3 is most critical at the later stages of erythroid maturation and is indeed primarily a transcriptional repressor. Notably, many of the genes repressed by KLF3 are also known to be activated by EKLF. However, the majority of these are not currently recognized as erythroid-cell-specific genes. These results reveal the molecular and physiological function of KLF3, defining it as a feedback repressor that counters the activity of EKLF at selected target genes to achieve normal erythropoiesis.
C1 [Funnell, Alister P. W.; Norton, Laura J.; Mak, Ka Sin; Burdach, Jon; Artuz, Crisbel M.; Twine, Natalie A.; Wilkins, Marc R.; Pearson, Richard C. M.; Crossley, Merlin] Univ New S Wales, Sch Biotechnol & Biomol Sci, Sydney, NSW, Australia.
[Power, Carl A.; Hung, Tzong-Tyng] Univ New S Wales, Mark Wainwright Analyt Ctr, Sydney, NSW, Australia.
[Perdomo, Jose] Univ New S Wales, Dept Med, St George Clin Sch, Sydney, NSW, Australia.
[Koh, Philip; Perkins, Andrew C.] Univ Queensland, Div Mol Genet & Dev, Inst Mol Biosci, Brisbane, Qld, Australia.
[Bell-Anderson, Kim S.] Univ Sydney, Sch Mol Biosci, Sydney, NSW 2006, Australia.
[Orkin, Stuart H.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Hematol Oncol,Childrens Hosp Boston,Harvard S, Boston, MA 02115 USA.
[Orkin, Stuart H.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pediat Oncol,Harvard Stem Cell Inst, Boston, MA 02115 USA.
[Fraser, Stuart T.] Univ Sydney, Discipline Physiol, Sch Med Sci, Sydney, NSW 2006, Australia.
[Perkins, Andrew C.] Mater Med Res Inst, Brisbane, Qld, Australia.
RP Crossley, M (reprint author), Univ New S Wales, Sch Biotechnol & Biomol Sci, Sydney, NSW, Australia.
EM m.crossley@unsw.edu.au
RI Pearson, Richard/J-4411-2012; Burdach, Jon/B-4378-2012; Crossley,
Merlin/D-7888-2011; Perkins, Andrew/M-3216-2014;
OI Pearson, Richard/0000-0002-7918-9111; Crossley,
Merlin/0000-0003-2057-3642; Perkins, Andrew/0000-0003-3644-7093; Fraser,
Stuart/0000-0003-3795-9461; Funnell, Alister/0000-0002-1062-5296; Hung,
Tzong/0000-0002-2904-2664
FU Australian Research Council; National Health and Medical Research
Council
FX This work is supported by funding from the National Health and Medical
Research Council and the Australian Research Council.
NR 34
TC 18
Z9 18
U1 0
U2 12
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0270-7306
J9 MOL CELL BIOL
JI Mol. Cell. Biol.
PD AUG
PY 2012
VL 32
IS 16
BP 3281
EP 3292
DI 10.1128/MCB.00173-12
PG 12
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 984PM
UT WOS:000307203500008
PM 22711990
ER
PT J
AU Blattler, SM
Verdeguer, F
Liesa, M
Cunningham, JT
Vogel, RO
Chim, H
Liu, HF
Romanino, K
Shirihai, OS
Vazquez, F
Ruegg, MA
Shi, Y
Puigserver, P
AF Blaettler, Sharon M.
Verdeguer, Francisco
Liesa, Marc
Cunningham, John T.
Vogel, Rutger O.
Chim, Helen
Liu, Huifei
Romanino, Klaas
Shirihai, Orian S.
Vazquez, Francisca
Rueegg, Markus A.
Shi, Yang
Puigserver, Pere
TI Defective Mitochondrial Morphology and Bioenergetic Function in Mice
Lacking the Transcription Factor Yin Yang 1 in Skeletal Muscle
SO MOLECULAR AND CELLULAR BIOLOGY
LA English
DT Article
ID FACTOR YY1; OXIDATIVE-PHOSPHORYLATION; PGC-1 COACTIVATORS; FACTOR
YIN-YANG-1; GENE-EXPRESSION; ERR-ALPHA; IN-VIVO; BIOGENESIS; DISEASE;
PGC-1-ALPHA
AB The formation, distribution, and maintenance of functional mitochondria are achieved through dynamic processes that depend strictly on the transcription of nuclear genes encoding mitochondrial proteins. A large number of these mitochondrial genes contain binding sites for the transcription factor Yin Yang 1 (YY1) in their proximal promoters, but the physiological relevance is unknown. We report here that skeletal-muscle-specific YY1 knockout (YY1mKO) mice have severely defective mitochondrial morphology and oxidative function associated with exercise intolerance, signs of mitochondrial myopathy, and short stature. Gene set enrichment analysis (GSEA) revealed that the top pathways downregulated in YY1mKO mice were assigned to key metabolic and regulatory mitochondrial genes. This analysis was consistent with a profound decrease in the level of mitochondrial proteins and oxidative phosphorylation (OXPHOS) bioenergetic function in these mice. In contrast to the finding for wild-type mice, inactivation of the mammalian target of rapamycin (mTOR) did not suppress mitochondrial genes in YY1mKO mice. Mechanistically, mTOR-dependent phosphorylation of YY1 resulted in a strong interaction between YY1 and the transcriptional coactivator peroxisome proliferator-activated receptor gamma coactivator la (PGC1 alpha), a major regulator of mitochondrial function. These results underscore the important role of YY1 in the maintenance of mitochondrial function and explain how its inactivation might contribute to exercise intolerance and mitochondrial myopathies.
C1 [Blaettler, Sharon M.; Verdeguer, Francisco; Cunningham, John T.; Vogel, Rutger O.; Chim, Helen; Vazquez, Francisca; Puigserver, Pere] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA.
[Blaettler, Sharon M.; Verdeguer, Francisco; Cunningham, John T.; Vogel, Rutger O.; Chim, Helen; Liu, Huifei; Vazquez, Francisca; Shi, Yang; Puigserver, Pere] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA USA.
[Liesa, Marc; Shirihai, Orian S.] Boston Univ, Sch Med, Dept Med, Mitochondria ARC,Evans Biomed Res Ctr, Boston, MA 02118 USA.
[Romanino, Klaas; Rueegg, Markus A.] Univ Basel, Biozentrum, Dept Neurobiol, Basel, Switzerland.
RP Puigserver, P (reprint author), Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA.
EM Pere_Puigserver@dfci.harvard.edu
OI Liesa Roig, Marc/0000-0002-5909-8570; Cunningham,
John/0000-0001-6490-4533
FU postdoctoral fellowship from the Swiss National Science Foundation;
NIH/NIDDK grant [RO1 DK081418]; Muscular Dystrophy Association grant
[MDA202237]
FX These studies were supported by a postdoctoral fellowship from the Swiss
National Science Foundation (to S.M.B.) and by NIH/NIDDK grant RO1
DK081418 and Muscular Dystrophy Association grant MDA202237 (to P.P.).
NR 52
TC 30
Z9 31
U1 0
U2 10
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0270-7306
J9 MOL CELL BIOL
JI Mol. Cell. Biol.
PD AUG
PY 2012
VL 32
IS 16
BP 3333
EP 3346
DI 10.1128/MCB.00337-12
PG 14
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 984PM
UT WOS:000307203500012
PM 22711985
ER
PT J
AU Dunn, GP
Fecci, PE
Curry, WT
AF Dunn, Gavin P.
Fecci, Peter E.
Curry, William T.
TI Cancer Immunoediting in Malignant Glioma
SO NEUROSURGERY
LA English
DT Review
DE Cancer immunoediting; Elimination; Equilibrium; Glioma; Immunotherapy;
Tumor escape
ID REGULATORY T-CELLS; PRIMARY INTRACRANIAL TUMORS; GROWTH-FACTOR-RECEPTOR;
CENTRAL-NERVOUS-SYSTEM; BLOOD-BRAIN-BARRIER; MAJOR HISTOCOMPATIBILITY
COMPLEX; GLIOBLASTOMA-MULTIFORME PATIENTS; KIDNEY-TRANSPLANT RECIPIENTS;
IMMUNOLOGICAL SELF-TOLERANCE; NEWLY-DIAGNOSED GLIOBLASTOMA
AB Significant work from many laboratories over the last decade in the study of cancer immunology has resulted in the development of the cancer immunoediting hypothesis. This contemporary framework of the naturally arising immune system-tumor interaction is thought to comprise 3 phases: elimination, wherein immunity subserves an extrinsic tumor suppressor function and destroys nascent tumor cells; equilibrium, wherein tumor cells are constrained in a period of latency under immune control; and escape, wherein tumor cells outpace immunity and progress clinically. In this review, we address in detail the relevance of the cancer immunoediting concept to neurosurgeons and neuro-oncologists treating and studying malignant glioma by exploring the de novo immune response to these tumors, how these tumors may persist in vivo, the mechanisms by which these cells may escape/attenuate immunity, and ultimately how this concept may influence our immunotherapeutic approaches.
C1 [Curry, William T.] Harvard Univ, Massachusetts Gen Hosp, Dept Neurosurg, Pappas Ctr Neurooncol,Sch Med, Boston, MA 02114 USA.
RP Curry, WT (reprint author), Harvard Univ, Massachusetts Gen Hosp, Dept Neurosurg, Pappas Ctr Neurooncol,Sch Med, 55 Fruit St,Y9E, Boston, MA 02114 USA.
EM wcurry@partners.org
NR 317
TC 22
Z9 22
U1 5
U2 16
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0148-396X
J9 NEUROSURGERY
JI Neurosurgery
PD AUG
PY 2012
VL 71
IS 2
BP 201
EP 222
DI 10.1227/NEU.0b013e31824f840d
PG 22
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA 983HB
UT WOS:000307109300136
PM 22353795
ER
PT J
AU Markun, LC
Starr, PA
Air, EL
Marks, WJ
Volz, MM
Ostrem, JL
AF Markun, Leslie C.
Starr, Philip A.
Air, Ellen L.
Marks, William J., Jr.
Volz, Monica M.
Ostrem, Jill L.
TI Shorter Disease Duration Correlates With Improved Long-term Deep Brain
Stimulation Outcomes in Young-Onset DYT1 Dystonia
SO NEUROSURGERY
LA English
DT Article
DE Deep brain stimulation; DYT1 dystonia; Globus pallidus; Pediatrics
ID GLOBUS-PALLIDUS INTERNUS; PRIMARY GENERALIZED DYSTONIA; TORSION
DYSTONIA; FOLLOW-UP; EFFICACY
AB BACKGROUND: Treatment with deep brain stimulation (DBS) of the globus pallidus internus in children with DYT1 primary torsion dystonia is highly effective; however, individual response to stimulation is variable, and a greater understanding of predictors of long-term outcome is needed.
OBJECTIVE: To report the long-term outcomes of subjects with young-onset DYT1 primary torsion dystonia treated with bilateral globus pallidus DBS.
METHODS: Fourteen subjects (7 male, 7 female) treated consecutively from 2000 to 2010 at our center were included in this retrospective study. The Burke-Fahn-Marsden Dystonia Rating Scale was performed at baseline and at 1, 2, and up to 6 years postoperatively.
RESULTS: Pallidal DBS was well tolerated and highly effective, with mean Burke-Fahn-Marsden Dystonia Rating Scale movement scores improving from baseline by 61.5% (P < .001) at 1 year, 64.4% (P < .001) at 2 years, and 70.3% (P < .001) at the final follow-up visit (mean, 32 months; range, 7-77 months). Disability scores also improved significantly. Multiple linear regression analysis revealed a significant influence of duration of disease as a predictor of percent improvement in Burke-Fahn-Marsden Dystonia Rating Scale movement score at long-term follow-up (duration of disease, P < .05). Subjects with fixed orthopedic deformities (4) had less improvement in these regions. Location of the active DBS electrode used at final follow-up visit was not predictive of clinical outcome.
CONCLUSION: Our findings highlight the sustained benefit from DBS and the importance of early referral for DBS in children with medically refractory DYT1 primary torsion dystonia, which can lead to improved long-term benefits.
C1 [Markun, Leslie C.; Marks, William J., Jr.; Volz, Monica M.; Ostrem, Jill L.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA.
[Starr, Philip A.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA.
[Markun, Leslie C.; Starr, Philip A.; Marks, William J., Jr.; Volz, Monica M.; Ostrem, Jill L.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Air, Ellen L.] Univ Cincinnati, Dept Neurol Surg, Cincinnati, OH USA.
RP Ostrem, JL (reprint author), UCSF Mt Zion, Dept Neurol, Box 1838,1635 Divisadero St,5th Floor,Ste 520-530, San Francisco, CA 94115 USA.
EM Jill.Ostrem@ucsf.edu
NR 21
TC 26
Z9 27
U1 2
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0148-396X
J9 NEUROSURGERY
JI Neurosurgery
PD AUG
PY 2012
VL 71
IS 2
BP 325
EP 330
DI 10.1227/NEU.0b013e318258e21b
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA 983HB
UT WOS:000307109301022
PM 22811083
ER
PT J
AU Carmody, TP
McFall, M
Saxon, AJ
Malte, CA
Chow, B
Joseph, AM
Beckham, JC
Cook, JW
AF Carmody, Timothy P.
McFall, Miles
Saxon, Andrew J.
Malte, Carol A.
Chow, Bruce
Joseph, Anne M.
Beckham, Jean C.
Cook, Jessica W.
TI Smoking Outcome Expectancies in Military Veteran Smokers With
Posttraumatic Stress Disorder
SO NICOTINE & TOBACCO RESEARCH
LA English
DT Article
ID CONSEQUENCES QUESTIONNAIRE-ADULT; ADMINISTERED PTSD SCALE;
MENTAL-HEALTH-CARE; NEGATIVE AFFECT; NICOTINE DEPENDENCE;
CIGARETTE-SMOKING; SELF-EFFICACY; MOTIVATION; CESSATION; RELAPSE
AB Introduction: Smoking outcome expectancies were investigated in treatment-seeking military Veteran smokers with post-traumatic stress disorder (PTSD). The investigation of smoking outcome expectancies may enhance our understanding of the relationship between PTSD and cigarette smoking.
Methods: Participants were 943 military Veterans with a diagnosis of PTSD who were current smokers enrolled in a randomized multisite effectiveness trial to test whether the integration of smoking cessation treatment into mental health care (integrated care) improves prolonged abstinence rates compared with referral to specialized smoking cessation clinics (usual care). Using confirmatory factor analysis (CFA), we evaluated the conceptual model of smoking outcome expectancies measured on the Smoking Consequences Questionnaire Adult (SCQ-A) version. The Kraemer method of mediation analysis was used to investigate the role of smoking outcome expectancies in mediating relationships between PTSD symptoms and smoking behavior, tobacco dependence, and abstinence self-efficacy.
Results: The CFA supported the 10-factor structure of the SCQ-A in smokers with PTSD. Relationships between measures of PTSD symptoms and tobacco dependence were mediated by the smoking outcome expectancy regarding negative affect reduction. This same smoking outcome expectancy mediated relationships between PTSD symptoms and smoking abstinence self-efficacy.
Conclusions: The findings support the use of the SCQ-A as a valid measure of smoking outcome expectancies in military Veteran smokers with PTSD. Moreover, they suggest that smoking outcome expectancies may play an important role in explaining the relationship between PTSD and cigarette smoking.
C1 [Carmody, Timothy P.] Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA 94121 USA.
[Carmody, Timothy P.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA.
[McFall, Miles; Saxon, Andrew J.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Malte, Carol A.] Vet Affairs Puget Sound Hlth Care Syst, Ctr Excellence Substance Abuse Treatment & Educ, Seattle, WA USA.
[Chow, Bruce] VA Palo Alto Hlth Care Syst, Vet Affairs Cooperat Studies Program, Palo Alto, CA USA.
[Joseph, Anne M.] Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA.
[Beckham, Jean C.] Durham Vet Affairs Med Ctr, Vet Affairs Mid Atlantic Reg Mental Illness Res E, Durham, NC USA.
[Beckham, Jean C.] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC USA.
[Cook, Jessica W.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA.
RP Carmody, TP (reprint author), Univ Calif San Francisco, San Francisco VA Med Ctr, 4150 Clement St, San Francisco, CA 94121 USA.
EM timothy.carmody@va.gov
FU Department of Veterans Affairs, Veterans Health Administration, Office
of Research and Development Cooperative Studies Program [519]
FX This work was supported by the Department of Veterans Affairs, Veterans
Health Administration, Office of Research and Development Cooperative
Studies Program, Study #519.
NR 51
TC 11
Z9 11
U1 6
U2 17
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1462-2203
J9 NICOTINE TOB RES
JI Nicotine Tob. Res.
PD AUG
PY 2012
VL 14
IS 8
BP 919
EP 926
DI 10.1093/ntr/ntr304
PG 8
WC Substance Abuse; Public, Environmental & Occupational Health
SC Substance Abuse; Public, Environmental & Occupational Health
GA 987PX
UT WOS:000307430700005
PM 22271610
ER
PT J
AU Udoetuk, JD
Dai, Y
Ying, GS
Daniel, E
Gangaputra, S
Rosenbaum, JT
Suhler, EB
Thorne, JE
Foster, CS
Jabs, DA
Levy-Clarke, GA
Nussenblatt, RB
Kempen, JH
AF Udoetuk, Joshua D.
Dai, Yang
Ying, Gui-Shuang
Daniel, Ebenezer
Gangaputra, Sapna
Rosenbaum, James T.
Suhler, Eric B.
Thorne, Jennifer E.
Foster, C. Stephen
Jabs, Douglas A.
Levy-Clarke, Grace A.
Nussenblatt, Robert B.
Kempen, John H.
CA Systemic Immunosuppressive Therapy
TI Risk of Corticosteroid-Induced Hyperglycemia Requiring Medical Therapy
among Patients with Inflammatory Eye Diseases
SO OPHTHALMOLOGY
LA English
DT Article
ID INDUCED DIABETES-MELLITUS; PREVALENCE; GLUCOCORTICOIDS; MANAGEMENT;
UVEITIS
AB Objective: To identify the incidence and risk factors for corticosteroid-induced hyperglycemia requiring medical therapy among patients with inflammatory eye diseases.
Design: Retrospective cohort study.
Participants: Patients with ocular inflammation followed at 5 United States tertiary centers that initially were neither diabetic nor taking hypoglycemic medications.
Methods: Eligible patients who used oral corticosteroids during follow-up were identified and followed longitudinally for initiation of hypoglycemic medication over 1 year after beginning corticosteroids. The remaining eligible patients were followed for 1 year after their initial visit. Survival analysis was used to calculate the risk of hyperglycemia requiring medical therapy and to identify potential risk factors.
Main Outcome Measures: Initiation of hypoglycemic medications.
Results: Among 2073 non-diabetic patients treated with oral corticosteroids, 25 (1.21%) initiated hypoglycemic therapy compared with 5 of 2666 patients (0.19%) not treated with oral corticosteroids (relative risk [RR], 4.39; 95% confidence interval [CI], 1.68-11.5). The RR tended to be higher in association with higher initial doses (for initial doses <40 mg of prednisone per day: RR, 3.23; 95% CI, 1.08-9.64; for initial prednisone dose >= 40 mg/d: RR, 5.51; 95% CI, 2.01-15.1). Other risk factors for the initiation of hypoglycemic therapy included older age (RR [per each additional 10 years], 1.46; 95% CI, 1.15-1.85; P = 0.002) and African-American race (RR, 2.94; 95% CI, 1.34-6.43; P = 0.007).
Conclusions: These results suggest that the absolute risk of corticosteroid-induced hyperglycemia that is detected and treated with hypoglycemic therapy in the tertiary ocular inflammation setting is low (an excess cumulative risk on the order of 1% within 1 year), although on a relative scale it is approximately 4.4-fold higher than in patients not treated with oral corticosteroids. Older age and African-American race also were risk factors. Physicians who use systemic corticosteroids for ocular inflammatory diseases should be aware of this risk, and should consider surveillance for hyperglycemia among high-risk patients. However, given the low absolute risk, routine laboratory monitoring or referral for monitoring may not be necessary for low-risk patients.
Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references. Ophthalmology 2012;119:1569-1574 (C) 2012 by the American Academy of Ophthalmology.
C1 [Kempen, John H.] Univ Penn, Sch Med, Dept Ophthalmol, Ctr Prevent Ophthalmol & Biostat, Philadelphia, PA 19104 USA.
[Udoetuk, Joshua D.; Dai, Yang; Ying, Gui-Shuang; Daniel, Ebenezer; Kempen, John H.] Univ Penn, Ocular Inflammat Serv, Philadelphia, PA 19104 USA.
[Ying, Gui-Shuang; Kempen, John H.] Univ Penn, Dept Biostat & Epidemiol, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA.
[Udoetuk, Joshua D.] Baylor Coll Med, Dept Ophthalmol, Houston, TX 77030 USA.
[Daniel, Ebenezer; Gangaputra, Sapna] Univ Wisconsin, Dept Ophthalmol, Fundus Photograph Reading Ctr, Madison, WI USA.
[Gangaputra, Sapna; Thorne, Jennifer E.] Johns Hopkins Univ, Dept Ophthalmol, Baltimore, MD USA.
[Thorne, Jennifer E.; Jabs, Douglas A.] Johns Hopkins Univ, Dept Epidemiol, Baltimore, MD USA.
[Rosenbaum, James T.; Suhler, Eric B.] Oregon Hlth & Sci Univ, Dept Ophthalmol, Portland, OR 97201 USA.
[Rosenbaum, James T.] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA.
[Suhler, Eric B.] Portland VA Med Ctr, Portland, OR USA.
[Foster, C. Stephen] Massachusetts Eye Res & Surg Inst, Cambridge, MA USA.
[Foster, C. Stephen] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA.
[Jabs, Douglas A.] Mt Sinai Sch Med, Dept Ophthalmol, New York, NY USA.
[Jabs, Douglas A.] Mt Sinai Sch Med, Dept Med, New York, NY USA.
[Levy-Clarke, Grace A.; Nussenblatt, Robert B.] NEI, Immunol Lab, Bethesda, MD 20892 USA.
RP Kempen, JH (reprint author), Univ Penn, Sch Med, Dept Ophthalmol, Ctr Prevent Ophthalmol & Biostat, 3535 Market St,Suite 700, Philadelphia, PA 19104 USA.
EM john.kempen@uphs.upenn.edu
OI Daniel, Ebenezer/0000-0002-2027-2316
FU National Eye Institute [EY014943]; Research to Prevent Blindness; Paul
and Evanina Mackall Foundation; R.P.B. James S. Adams Special Scholar
Award; R.P.B. Harrington Special Scholar Award; Department of Veterans'
Affairs
FX Supported primarily by National Eye Institute Grant EY014943 (J.H.K.).
Additional support was provided by Research to Prevent Blindness and the
Paul and Evanina Mackall Foundation. J.H.K. was an R.P.B. James S. Adams
Special Scholar Award recipient, J.E.T. was an R.P.B. Harrington Special
Scholar Award recipient, and D.A.J. and J.T.R. were Research to Prevent
Blindness Senior Scientific Investigator Award recipients during the
course of the study. G. A. L.-C. was previously supported by and R.B.N.
continues to be supported by intramural funds of the National Eye
Institute. E. B. S. receives support from the Department of Veterans'
Affairs. None of the sponsors had any role in the design and conduct of
the report; collection, management, analysis, and interpretation of the
data; or in the preparation, review, and approval of this manuscript.
NR 13
TC 5
Z9 5
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD AUG
PY 2012
VL 119
IS 8
BP 1569
EP 1574
DI 10.1016/j.ophtha.2012.01.043
PG 6
WC Ophthalmology
SC Ophthalmology
GA 982YA
UT WOS:000307080100012
PM 22484116
ER
PT J
AU Christen, WG
Glynn, RJ
Sesso, HD
Kurth, T
MacFadyen, J
Bubes, V
Buring, JE
Manson, JE
Gaziano, JM
AF Christen, William G.
Glynn, Robert J.
Sesso, Howard D.
Kurth, Tobias
MacFadyen, Jean
Bubes, Vadim
Buring, Julie E.
Manson, JoAnn E.
Gaziano, J. Michael
TI Vitamins E and C and Medical Record-Confirmed Age-related Macular
Degeneration in a Randomized Trial of Male Physicians
SO OPHTHALMOLOGY
LA English
DT Article
ID BETA-CAROTENE; CARDIOVASCULAR-DISEASE; US PHYSICIANS; EYE DISEASE;
SUPPLEMENTATION; MACULOPATHY; PREVENTION; HEALTH; MEN; CATARACT
AB Purpose: To test whether supplementation with alternate-day vitamin E or daily vitamin C affects the incidence of the diagnosis of age-related macular degeneration (AMD) in a large-scale randomized trial of male physicians.
Design: Randomized, double-masked, placebo-controlled trial.
Participants: We included 14 236 apparently healthy United States male physicians aged >= 50 years who did not report a diagnosis of AMD at baseline.
Methods: Participants were randomly assigned to receive 400 international units (IU) of vitamin E or placebo on alternate days, and 500 mg of vitamin C or placebo daily. Participants reported new diagnoses of AMD on annual questionnaires and medical record data were collected to confirm the reports.
Main Outcome Measures: Incident diagnosis of AMD responsible for a reduction in best-corrected visual acuity to <= 20/30.
Results: After 8 years of treatment and follow-up, a total of 193 incident cases of visually significant AMD were documented. There were 96 cases in the vitamin E group and 97 in the placebo group (hazard ratio [HR], 1.03; 95% confidence interval [CI], 0.78-1.37). For vitamin C, there were 97 cases in the active group and 96 in the placebo group (HR, 0.99; 95% CI, 0.75-1.31).
Conclusions: In a large-scale, randomized trial of United States male physicians, alternate-day use of 400 IU of vitamin E and/or daily use of 500 mg of vitamin C for 8 years had no appreciable beneficial or harmful effect on risk of incident diagnosis of AMD.
Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references. Ophthalmology 2012;119:1642-1649 (C) 2012 by the American Academy of Ophthalmology.
C1 [Christen, William G.; Glynn, Robert J.; Sesso, Howard D.; Kurth, Tobias; MacFadyen, Jean; Bubes, Vadim; Buring, Julie E.; Manson, JoAnn E.; Gaziano, J. Michael] Brigham & Womens Hosp, Dept Med, Div Prevent Med, Boston, MA 02115 USA.
[Buring, Julie E.] Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Boston, MA USA.
[Sesso, Howard D.; Kurth, Tobias; Buring, Julie E.; Gaziano, J. Michael] Brigham & Womens Hosp, Dept Med, Div Aging, Boston, MA 02115 USA.
[Gaziano, J. Michael] Brigham & Womens Hosp, Dept Med, Div Cardiovasc Dis, Boston, MA 02115 USA.
[Gaziano, J. Michael] VA Boston Healthcare Syst, Boston, MA USA.
[Sesso, Howard D.; Kurth, Tobias; Buring, Julie E.; Manson, JoAnn E.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Kurth, Tobias] INSERM, Unit Neuroepidemiol 708, Paris, France.
RP Christen, WG (reprint author), 900 Commonwealth Ave E, Boston, MA 02215 USA.
EM wchristen@rics.bwh.harvard.edu
OI Kurth, Tobias/0000-0001-7169-2620
FU National Institutes of Health (Bethesda, MD) [CA 97193, CA 34944, CA
40360, HL 26490, HL 34595]; BASF Corporation (Florham Park, NJ);
National Eye Institute; National Institute on Aging
FX This work was supported by grants CA 97193 (which included funding from
the National Eye Institute and the National Institute on Aging), CA
34944, CA 40360, HL 26490, and HL 34595 from the National Institutes of
Health (Bethesda, MD), and an investigator-initiated grant from BASF
Corporation (Florham Park, NJ). Study agents and packaging were provided
by Wyeth Pharmaceuticals (Madison, NJ), BASF Corporation, and DSM
Nutritional Products Inc (formerly Roche Vitamins; Parsippany, NJ).
Wyeth Pharmaceuticals, BASF Corporation, and DSM Nutritional Products,
Inc, had no role in the design and conduct of the study; in the
collection, analysis, and interpretation of the data; or in the
preparation, review, or approval of the manuscript. Trial registration:
clinicaltrials.gov Identifier: NCT00270647 Dr. Christen had full access
to all the data in the study and takes responsibility for the integrity
of the data and the accuracy of the data analysis.
NR 20
TC 11
Z9 11
U1 1
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD AUG
PY 2012
VL 119
IS 8
BP 1642
EP 1649
DI 10.1016/j.ophtha.2012.01.053
PG 8
WC Ophthalmology
SC Ophthalmology
GA 982YA
UT WOS:000307080100023
PM 22503302
ER
PT J
AU Gerweck, LE
AF Gerweck, Leo E.
TI Modification of Cell Lethality at Elevated Temperatures The pH Effect
SO RADIATION RESEARCH
LA English
DT Article
ID CHINESE-HAMSTER CELLS; INTRACELLULAR PH; HYPERTHERMIA; SENSITIVITY;
HEAT; MULTIPLICATION; RADIATION; VIABILITY; INVITRO; TUMORS
AB Gerweck, L. E. Modification of Cell Lethality at Elevated Temperatures. The pH Effect. Radiat. Res. 70, 224-235 (1977).
The lethal response of Chinese hamster ovary cells to hyperthermia was determined at selected extracellular pH. Decreasing pH from 7.6 to 6.7 increased the lethal response of cells over the temperature range of 41 to 44 degrees C. Cell viability was not effected over this pH range at 37 degrees C. The pH sensitizing affect was most prominent at temperatures which were marginally lethal at normal pH (7.4). Four hours of exposure to 42 degrees C decreased survival to 10% at pH 7.4 and 0.01% at pH 6.7. Enhanced cell killing was observed when the cells were exposed to reduced pH and elevated temperatures simultaneously. Prolonging the time of pH exposure before and after hyperthermia did not influence survival. High-density culturing increased the sensitivity of cells to hyperthermia. This affect was due to metabolic acidification of the medium and could be reversed by adjusting the pH.
C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Edwin L Steele Lab Radiat Biol,Dept Radiat Med, Boston, MA 02114 USA.
RP Gerweck, LE (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Edwin L Steele Lab Radiat Biol,Dept Radiat Med, Boston, MA 02114 USA.
FU National Cancer Institute, DHEW [CA05163-01, CA13311]
FX This investigation was supported by Grants number CA05163-01 and CA13311
awarded by the National Cancer Institute, DHEW.
NR 22
TC 0
Z9 0
U1 1
U2 5
PU RADIATION RESEARCH SOC
PI LAWRENCE
PA 810 E TENTH STREET, LAWRENCE, KS 66044 USA
SN 0033-7587
J9 RADIAT RES
JI Radiat. Res.
PD AUG
PY 2012
VL 178
IS 2
BP AV198
EP AV203
DI 10.1667/RRAV16.1
PG 6
WC Biology; Biophysics; Radiology, Nuclear Medicine & Medical Imaging
SC Life Sciences & Biomedicine - Other Topics; Biophysics; Radiology,
Nuclear Medicine & Medical Imaging
GA 981PZ
UT WOS:000306983000017
PM 22870970
ER
PT J
AU Zhu, AX
AF Zhu, Andrew X.
TI Molecularly Targeted Therapy for Advanced Hepatocellular Carcinoma in
2012: Current Status and Future Perspectives
SO SEMINARS IN ONCOLOGY
LA English
DT Review
ID ENDOTHELIAL GROWTH-FACTOR; RECEPTOR TYROSINE KINASES; PHASE-II TRIAL;
PROGNOSTIC-SIGNIFICANCE; FACTOR-ALPHA; ANTITUMOR-ACTIVITY; TUMOR
PROGRESSION; OPEN-LABEL; EXPRESSION; BEVACIZUMAB
C1 Harvard Univ, Ctr Canc, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA.
RP Zhu, AX (reprint author), Harvard Univ, Ctr Canc, Massachusetts Gen Hosp, Sch Med, 55 Fruit St,LH POB 232, Boston, MA 02114 USA.
EM azhu@partners.org
FU Bayer; Onyx; ImClone-Lilly; Novartis
FX Advisory/consulting roles: Sanofi-Aventis, Abbott, Bristol-Myers Squibb,
Eisai. Research support: Bayer, Onyx, ImClone-Lilly, Novartis.
NR 65
TC 37
Z9 39
U1 0
U2 11
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0093-7754
EI 1532-8708
J9 SEMIN ONCOL
JI Semin. Oncol.
PD AUG
PY 2012
VL 39
IS 4
BP 493
EP 502
DI 10.1053/j.seminoncol.2012.05.014
PG 10
WC Oncology
SC Oncology
GA 987PO
UT WOS:000307429800013
PM 22846866
ER
PT J
AU Kokel, D
Rennekamp, AJ
Shah, AH
Liebel, U
Peterson, RT
AF Kokel, David
Rennekamp, Andrew J.
Shah, Asmi H.
Liebel, Urban
Peterson, Randall T.
TI Behavioral barcoding in the cloud: embracing data-intensive digital
phenotyping in neuropharmacology
SO TRENDS IN BIOTECHNOLOGY
LA English
DT Review
DE chemobehavioral data; data-intensive digital phenotyping; dataset
mining; neuroscience; pharmacology; high-thoughput screen
ID MINIMUM INFORMATION; LARVAL ZEBRAFISH; SMALL MOLECULES; DROSOPHILA;
IDENTIFICATION; MODULATION; DISCOVERY; PHENOMICS; SEARCH; SCREEN
AB For decades, studying the behavioral effects of individual drugs and genetic mutations has been at the heart of efforts to understand and treat nervous system disorders. High-throughput technologies adapted from other disciplines (e.g., high-throughput chemical screening, genomics) are changing the scale of data acquisition in behavioral neuroscience. Massive behavioral datasets are beginning to emerge, particularly from zebrafish labs, where behavioral assays can be performed rapidly and reproducibly in 96-well, high-throughput format. Mining these datasets and making comparisons across different assays are major challenges for the field. Here, we review behavioral barcoding, a process by which complex behavioral assays are reduced to a string of numeric features, Facilitating analysis and comparison within and across datasets.
C1 [Kokel, David; Rennekamp, Andrew J.; Peterson, Randall T.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cardiovasc Res Ctr, Charlestown, MA 02129 USA.
[Kokel, David; Rennekamp, Andrew J.; Peterson, Randall T.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol,Dept Med, Charlestown, MA 02129 USA.
[Kokel, David; Rennekamp, Andrew J.; Peterson, Randall T.] Broad Inst, Cambridge, MA 02142 USA.
[Shah, Asmi H.] KIT Karlsruhe Inst Technol, ITG, Karlsruhe, Germany.
[Liebel, Urban] KIT Karlsruhe Inst Technol, IAI, Karlsruhe, Germany.
RP Peterson, RT (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cardiovasc Res Ctr, 149 13th St, Charlestown, MA 02129 USA.
EM peterson@cvrc.mgh.harvard.edu
OI Rennekamp , Andrew /0000-0001-6174-7253; kokel,
david/0000-0002-1981-1511
FU National Institutes of Health [K01MH091449, T32HL07208, MH086867,
MH085205]; BOLD Marie Curie Initial Training Network [238821]; KIT
Biointerfaces program; Charles and Ann MGH Research Scholars Award
FX This work was supported by National Institutes of Health grants
K01MH091449 (D.K.), T32HL07208 (A.J.R.), MH086867 and MH085205 (R.T.P.),
the BOLD Marie Curie Initial Training Network grant 238821 (A.H.S.), the
KIT Biointerfaces program (U.L.), and by the Charles and Ann MGH
Research Scholars Award (R.T.P.).
NR 39
TC 23
Z9 23
U1 1
U2 14
PU ELSEVIER SCIENCE LONDON
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0167-7799
J9 TRENDS BIOTECHNOL
JI Trends Biotechnol.
PD AUG
PY 2012
VL 30
IS 8
BP 421
EP 425
DI 10.1016/j.tibtech.2012.05.001
PG 5
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA 980JD
UT WOS:000306888500005
PM 22652049
ER
PT J
AU Jones, RC
Capen, DE
AF Jones, Rosemary C.
Capen, Diane E.
TI A quantitative ultrastructural study of circulating (monocytic) cells
interacting with endothelial cells in high oxygen-injured and
spontaneously re-forming (FVB) mouse lung capillaries
SO ULTRASTRUCTURAL PATHOLOGY
LA English
DT Article
DE Endothelial-monocytic cell fusion; circulating monocytic cell
morphology; capillary remodeling in high oxygen; angiogenic-immunogenic
remodeling of lung capillaries
ID HEMATOPOIETIC PROGENITOR CELLS; BONE-MARROW; STEM-CELLS;
PULMONARY-HYPERTENSION; PERIPHERAL-BLOOD; NEOVASCULARIZATION MODEL;
HYPEROXIC INJURY; PRECURSOR CELLS; GROWTH-FACTOR; ADULT LUNG
AB The present study demonstrates the fine structure of blood-borne (monocytic) circulating cells (CCs), and their interaction with endothelial cells, in a mouse model of lung capillary injury and repair. Quantitative analysis highlights the diversity of CC profiles entering the lung, where they form contact and adhesion/fusion sites to endothelial plasmalemmal membranes, and to complexes of endothelial/basement membrane remnants, as capillary networks reorganize over time. Temporal patterns of CC influx and efflux in the lung, changing CC phenotypes, and the range of CC interactions with endothelium, underscore the potential for a complex angiogenic/immunogenic response, as capillary networks stabilize and undergo expansion and growth.
C1 [Jones, Rosemary C.; Capen, Diane E.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anesthesia Crit Care & Pain Management, Boston, MA 02115 USA.
RP Jones, RC (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anesthesia Crit Care & Pain Management, Boston, MA 02115 USA.
EM rcjones@partners.org
FU NIH [HL R01 089252]
FX Supported by NIH HL R01 089252. We thank Drs Rakesh Jain, Dai Fukumura
and Dan Duda (Department of Radiation Oncology, Harvard Medical School,
and Steele Laboratory for Tumor Biology, Massachusetts General Hospital,
Boston, MA) for providing FVB-Tie2 and FVB-WT mice and for helpful
advice in the course of the study.
NR 44
TC 5
Z9 5
U1 0
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0191-3123
EI 1521-0758
J9 ULTRASTRUCT PATHOL
JI Ultrastruct. Pathol.
PD AUG
PY 2012
VL 36
IS 4
BP 260
EP 279
DI 10.3109/01913123.2012.662820
PG 20
WC Microscopy; Pathology
SC Microscopy; Pathology
GA 981LA
UT WOS:000306968500009
PM 22849528
ER
PT J
AU Widera, EW
Block, SD
AF Widera, Eric W.
Block, Susan D.
TI Managing Grief and Depression at the End of Life
SO AMERICAN FAMILY PHYSICIAN
LA English
DT Article
ID ADVANCED CANCER-PATIENTS; TERMINALLY-ILL; PALLIATIVE CARE; OF-LIFE;
MENTAL-HEALTH; DEATH; SYMPTOMS; METHYLPHENIDATE; METAANALYSIS;
BEREAVEMENT
AB Psychological distress is common in terminally ill persons and can be a source of great suffering. Grief is an adaptive, universal, and highly personalized response to the multiple losses that occur at the end of life. This response may be intense early on after a loss manifesting itself physically, emotionally, cognitively, behaviorally, and spiritually; however, the impact of grief on daily life generally decreases with time. Although pharmacologic interventions are not warranted for uncomplicated grief, physicians are encouraged to support patients by acknowledging their grief and encouraging the open expression of emotions. It is important for the physician to distinguish uncomplicated grief reactions from more disabling psychiatric disorders such as major depression. The symptoms of grief may overlap with those of major depression or a terminal illness or its treatment; however, grief is a distinct entity. Feelings of pervasive hopelessness, helplessness, worthlessness, guilt, lack of pleasure, and suicidal ideation are present in patients with depression, but not in those experiencing grief. Psychotherapy and antidepressant medications reduce symptoms of distress and improve quality of life for patients with depression. Physicians may consider psychostimulants, such as methylphenidate, for patients who have depression with a life expectancy of only days to weeks. (Am Fam Physician. 2012;86(3):259-264. Copyright (c) 2012 American Academy of Family Physicians.)
C1 [Widera, Eric W.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Widera, Eric W.] San Francisco VA Med Ctr, Hosp & Palliat Care Serv, San Francisco, CA USA.
[Block, Susan D.] Dana Farber Canc Inst, Dept Psychosocial Oncol & Palliat Care, Boston, MA USA.
[Block, Susan D.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Block, Susan D.] Harvard Univ, Sch Med, Ctr Palliat Care, Boston, MA USA.
RP Widera, EW (reprint author), 4150 Clement St,Box 181G, San Francisco, CA 94121 USA.
EM eric.widera@ucsf.edu
NR 39
TC 4
Z9 4
U1 1
U2 17
PU AMER ACAD FAMILY PHYSICIANS
PI KANSAS CITY
PA 8880 WARD PARKWAY, KANSAS CITY, MO 64114-2797 USA
SN 0002-838X
J9 AM FAM PHYSICIAN
JI Am. Fam. Physician
PD AUG 1
PY 2012
VL 86
IS 3
BP 259
EP 264
PG 6
WC Primary Health Care; Medicine, General & Internal
SC General & Internal Medicine
GA 983XR
UT WOS:000307152500008
PM 22962989
ER
PT J
AU Lai, PS
Fresco, JM
Pinilla, MA
Macias, AA
Brown, RD
Englert, JA
Hofmann, O
Lederer, JA
Hide, W
Christiani, DC
Cernadas, M
Baron, RM
AF Lai, Peggy S.
Fresco, Jennifer M.
Pinilla, Miguel A.
Macias, Alvaro A.
Brown, Ronald D.
Englert, Joshua A.
Hofmann, Oliver
Lederer, James A.
Hide, Winston
Christiani, David C.
Cernadas, Manuela
Baron, Rebecca M.
TI Chronic Endotoxin Exposure Produces Airflow Obstruction and Lung
Dendritic Cell Expansion
SO AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
LA English
DT Article
DE airway resistance; inhalation; neutrophils; macrophages; dendritic
cells; endotoxin
ID COTTON TEXTILE WORKERS; ALVEOLAR MACROPHAGE ELIMINATION; REGULATORY
T-CELLS; IN-VIVO; FUNGAL-INFECTION; CIGARETTE-SMOKE; IMMUNE-RESPONSE;
LPS INHALATION; RETINOIC-ACID; MICE
AB Little is known about the mechanisms of persistent airflow obstruction that result from chronic occupational endotoxin exposure. We sought to analyze the inflammatory response underlying persistent airflow obstruction as a result of chronic occupational endotoxin exposure. We developed a murine model of daily inhaled endotoxin for periods of 5 days to 8 weeks. We analyzed physiologic lung dysfunction, lung histology, bronchoalveolar lavage fluid and total lung homogenate inflammatory cell and cytokine profiles, and pulmonary gene expression profiles. We observed an increase in airway hyperresponsiveness as a result of chronic endotoxin exposure. After 8 weeks, the mice exhibited an increase in bronchoalveolar lavage and lung neutrophils that correlated with an increase in proinflammatory cytokines. Detailed analyses of inflammatory cell subsets revealed an expansion of dendritic cells (DCs), and in particular, proinflammatory DCs, with a reduced percentage of macrophages. Gene expression profiling revealed the up-regulation of a panel of genes that was consistent with DC recruitment, and lung histology revealed an accumulation of DCs in inflammatory aggregates around the airways in 8-week-exposed animals. Repeated, low-dose LPS inhalation, which mirrors occupational exposure, resulted in airway hyperresponsiveness, associated with a failure to resolve the proinflammatory response, an inverted macrophage to DC ratio, and a significant rise in the inflammatory DC population. These findings point to a novel underlying mechanism of airflow obstruction as a result of occupational LPS exposure, and suggest molecular and cellular targets for therapeutic development.
C1 [Fresco, Jennifer M.; Pinilla, Miguel A.; Brown, Ronald D.; Englert, Joshua A.; Hofmann, Oliver; Hide, Winston; Cernadas, Manuela; Baron, Rebecca M.] Brigham & Womens Hosp, Dept Med, Div Pulm & Crit Care Med, Boston, MA 02115 USA.
[Macias, Alvaro A.] Brigham & Womens Hosp, Dept Anesthesiol Perioperat & Pain Med, Boston, MA 02115 USA.
[Lederer, James A.] Brigham & Womens Hosp, Div Immunol, Dept Surg, Boston, MA 02115 USA.
[Lai, Peggy S.; Christiani, David C.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
[Lai, Peggy S.; Christiani, David C.] Massachusetts Gen Hosp, Dept Med, Pulm & Crit Care Unit, Boston, MA 02114 USA.
RP Baron, RM (reprint author), Brigham & Womens Hosp, Dept Med, Div Pulm & Crit Care Med, 75 Francis St, Boston, MA 02115 USA.
EM rbaron@partners.org
RI Hofmann, Oliver/F-1800-2013;
OI Hofmann, Oliver/0000-0002-7738-1513; Lai, Peggy/0000-0001-9501-8606;
Hide, Winston/0000-0002-8621-3271
FU National Institutes of Health (National Institute of Allergy and
Infectious Diseases) grant [K08 AI054465]; National Institutes of Health
(National Heart, Lung, and Blood Institute) grant [R01 HL091957];
Centers for Disease Control (National Institute for Occupational Safety
and Health) grants [R01 OH 002421, T42OH008416]; National Institutes of
Health (National Institute of Environmental Health Sciences) grant [P42
00002]
FX This work was supported by National Institutes of Health (National
Institute of Allergy and Infectious Diseases) grant K08 AI054465
(R.M.B.), National Institutes of Health (National Heart, Lung, and Blood
Institute) grant R01 HL091957 (R.M.B.), Centers for Disease Control
(National Institute for Occupational Safety and Health) grants R01 OH
002421 (D.C.C.) and T42OH008416 (D.C.C.), and National Institutes of
Health (National Institute of Environmental Health Sciences) grant P42
00002 (D.C.C.).
NR 50
TC 10
Z9 10
U1 0
U2 9
PU AMER THORACIC SOC
PI NEW YORK
PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA
SN 1044-1549
J9 AM J RESP CELL MOL
JI Am. J. Respir. Cell Mol. Biol.
PD AUG
PY 2012
VL 47
IS 2
BP 209
EP 217
DI 10.1165/rcmb.2011-0447OC
PG 9
WC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
SC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
GA 986SQ
UT WOS:000307365300010
PM 22517795
ER
PT J
AU Liu, Q
Rehman, H
Krishnasamy, Y
Haque, K
Schnellmann, RG
Lemasters, JJ
Zhong, Z
AF Liu, Q.
Rehman, H.
Krishnasamy, Y.
Haque, K.
Schnellmann, R. G.
Lemasters, J. J.
Zhong, Z.
TI Amphiregulin Stimulates Liver Regeneration After Small-for-Size Mouse
Liver Transplantation
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Article
DE Growth factor; liver graft survival; liver regeneration; liver
transplantation; living donor transplantation; small-for-size syndrome
ID MITOCHONDRIAL PERMEABILITY TRANSITION; GROWTH-FACTOR-ALPHA;
N-TERMINAL-KINASE; RAT-LIVER; CYCLIN D1; GENE-EXPRESSION; FACTOR
RECEPTOR; GRAFT INJURY; IN-VIVO; MICE
AB This study investigated whether amphiregulin (AR), a ligand of the epidermal growth factor receptor (EGFR), improves liver regeneration after small-for-size liver transplantation. Livers of male C57BL/6 mice were reduced to similar to 50% and similar to 30% of original sizes and transplanted. After transplantation, AR and AR mRNA increased in 50% but not in 30% grafts. 5-Bromodeoxyuridine (BrdU) labeling, proliferating cell nuclear antigen (PCNA) expression and mitotic index increased substantially in 50% but not 30% grafts. Hyperbilirubinemia and hypoalbuminemia occurred and survival decreased after transplantation of 30% but not 50% grafts. AR neutralizing antibody blunted regeneration in 50% grafts whereas AR injection (5 mu g/mouse, iv) stimulated liver regeneration, improved liver function and increased survival after transplantation of 30% grafts. Phosphorylation of EGFR and its downstream signaling molecules Akt, mTOR, p70S6K, ERK and JNK increased markedly in 50% but not 30% grafts. AR stimulated EGFR phosphorylation and its downstream signaling pathways. EGFR inhibitor PD153035 suppressed regeneration of 50% grafts and largely abrogated stimulation of regeneration of 30% grafts by AR. AR also increased cyclin D1 and cyclin E expression in 30% grafts. Together, liver regeneration is suppressed in small-for-size grafts, as least in part, due to decreased AR formation. AR supplementation could be a promising therapy to stimulate regeneration of partial liver grafts.
C1 [Liu, Q.; Rehman, H.; Krishnasamy, Y.; Haque, K.; Schnellmann, R. G.; Lemasters, J. J.; Zhong, Z.] Med Univ S Carolina, Dept Pharmaceut, Charleston, SC 29425 USA.
[Liu, Q.; Rehman, H.; Krishnasamy, Y.; Haque, K.; Schnellmann, R. G.; Lemasters, J. J.; Zhong, Z.] Med Univ S Carolina, Dept Biomed Sci, Charleston, SC 29425 USA.
[Liu, Q.] Dalian Med Univ, Affiliated Hosp 2, Dept Gen Surg, Dalian, Peoples R China.
[Schnellmann, R. G.] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
[Lemasters, J. J.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA.
[Lemasters, J. J.; Zhong, Z.] Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA.
RP Zhong, Z (reprint author), Med Univ S Carolina, Dept Pharmaceut, Charleston, SC 29425 USA.
EM zhong@musc.edu
FU National Institutes of Health [DK70844, DK70844S1, DK084632, DK037034]
FX This study was supported, in part, by Grants DK70844, DK70844S1,
DK084632 and DK037034 from the National Institutes of Health.
NR 64
TC 10
Z9 11
U1 3
U2 8
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD AUG
PY 2012
VL 12
IS 8
BP 2052
EP 2061
DI 10.1111/j.1600-6143.2012.04069.x
PG 10
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 980OT
UT WOS:000306903400014
PM 22694592
ER
PT J
AU Lee, KM
Kim, JI
Stott, R
Soohoo, J
O'Connor, MR
Yeh, H
Zhao, G
Eliades, P
Fox, C
Cheng, N
Deng, S
Markmann, JF
AF Lee, K. M.
Kim, J. I.
Stott, R.
Soohoo, J.
O'Connor, M. R.
Yeh, H.
Zhao, G.
Eliades, P.
Fox, C.
Cheng, N.
Deng, S.
Markmann, J. F.
TI Anti-CD45RB/Anti-TIM-1-Induced Tolerance Requires Regulatory B Cells
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Article
DE Allograft; anti-CD45RB; regulatory B; TIM-1; tolerance
ID ANTIGEN-PRESENTING CELLS; ALLOGRAFT-REJECTION; T-CELLS; IN-VIVO; PROTEIN
ANTIGENS; ISLET ALLOGRAFTS; RESPONSES; LYMPHOCYTES; IL-10;
INTERLEUKIN-10
AB The role of B cells in transplant tolerance remains unclear. Although B-cell depletion often prolongs graft survival, sometimes it results in more rapid rejection, suggesting that B cells may have regulatory activity. We previously demonstrated that tolerance induction by anti-CD45RB antibody requires recipient B cells. Here, we show that anti-CD45RB in combination with anti-TIM-1 antibody has a synergistic effect, inducing tolerance in all recipients in a mouse islet allograft model. This effect depends on the presence of recipient B cells, requires B-cell IL-10 activity, and is antigen-specific. These data suggest the existence of a regulatory B-cell population that promotes tolerance via an IL-10-dependent pathway.
C1 [Lee, K. M.; Kim, J. I.; Stott, R.; Soohoo, J.; O'Connor, M. R.; Yeh, H.; Zhao, G.; Eliades, P.; Fox, C.; Cheng, N.; Deng, S.; Markmann, J. F.] Harvard Univ, Sch Med, Dept Surg, Div Transplantat,Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Zhao, G.; Deng, S.] Sichuan Prov Peoples Hosp, Dept Surg, Chengdu, Sichuan Provinc, Peoples R China.
[Zhao, G.; Deng, S.] Sichuan Acad Med Sci, Chengdu, Sichuan Provinc, Peoples R China.
RP Markmann, JF (reprint author), Harvard Univ, Sch Med, Dept Surg, Div Transplantat,Massachusetts Gen Hosp, Boston, MA 02115 USA.
EM jkim35@partners.org; jmarkmann@partners.org
OI Eliades, Philip/0000-0002-7985-6471
FU NIH [RO1AI057851-05, K01DK079207]
FX This work was supported in part by NIH grant RO1AI057851-05 (JFM) and
K01DK079207 (JIK).
NR 30
TC 34
Z9 38
U1 1
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD AUG
PY 2012
VL 12
IS 8
BP 2072
EP 2078
DI 10.1111/j.1600-6143.2012.04055.x
PG 7
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 980OT
UT WOS:000306903400016
PM 22494812
ER
PT J
AU Porcheray, F
DeVito, J
Helou, Y
Dargon, I
Fraser, JW
Nobecourt, P
Ferdman, J
Germana, S
Girouard, TC
Kawai, T
Saidman, SL
Wong, W
Colvin, RB
Leguern, C
Zorn, E
AF Porcheray, F.
DeVito, J.
Helou, Y.
Dargon, I.
Fraser, J. W.
Nobecourt, P.
Ferdman, J.
Germana, S.
Girouard, T. C.
Kawai, T.
Saidman, S. L.
Wong, W.
Colvin, R. B.
Leguern, C.
Zorn, E.
TI Expansion of Polyreactive B Cells Cross-Reactive to HLA and Self in the
Blood of a Patient With Kidney Graft Rejection
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Article
DE Human; humoral rejection; polyreactive antibodies
ID CORONARY-ARTERY-DISEASE; TRANSPLANT GLOMERULOPATHY;
MONOCLONAL-ANTIBODIES; CLINICAL-IMPLICATIONS; ALLOGRAFT-REJECTION;
ENDOTHELIAL-CELLS; DONOR; IMMUNOGLOBULIN; RECOMBINATION; REPERTOIRE
AB Antibody rejection is often accompanied by nondonor HLA specific antibodies (NDSA) and self-reactive antibodies that develop alongside donor-specific antibodies (DSA). To determine the source of these antibodies, we immortalized 107 B-cell clones from a kidney transplant recipient with humoral rejection. Two of these clones reacted to HLA class I or MICA. Both clones were also reactive to self-antigens and a lysate of a kidney cell line, hence revealing a pattern of polyreactivity. Monoclonality was verified by the identification of a single rearranged immunoglobulin heavy chain variable region (VH) sequence for each clone. By tracking their unique CDR3 sequence, we found that one such polyreactive clone was highly expanded in the patient blood, representing similar to 0.2% of circulating B cells. The VH sequence of this clone showed evidence of somatic mutations that were consistent with its memory phenotype and its expansion. Lastly, the reactivity of the expanded polyreactive B-cell clone was found in the patient serum at time of rejection. In conclusion, we provide here proof of principle at the clonal level that human antibodies can cross-react to HLA and self. Our findings strongly suggest that polyreactive antibodies contribute to DSA, NDSA as well as autoantibodies, in transplant recipients.
C1 [Porcheray, F.; DeVito, J.; Helou, Y.; Dargon, I.; Fraser, J. W.; Nobecourt, P.; Ferdman, J.; Germana, S.; Kawai, T.; Leguern, C.; Zorn, E.] Harvard Univ, Sch Med, Dept Surg, Transplant Ctr,Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Girouard, T. C.; Saidman, S. L.; Colvin, R. B.] Harvard Univ, Sch Med, Dept Pathol, Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Wong, W.] Harvard Univ, Sch Med, Dept Med, Renal Unit,Massachusetts Gen Hosp, Boston, MA 02115 USA.
RP Zorn, E (reprint author), Harvard Univ, Sch Med, Dept Surg, Transplant Ctr,Massachusetts Gen Hosp, Boston, MA 02115 USA.
EM ezorn@partners.org
FU Fahd and Nadia Alireza's Research Fund; Roche Organ Transplantation
Research Foundation (ROTRF); National Institute of Health, National
Institute of Diabetes, Digestive and Kidney Diseases [DK083352]
FX This work was supported by the Fahd and Nadia Alireza's Research Fund,
the Roche Organ Transplantation Research Foundation (ROTRF) and the
National Institute of Health, National Institute of Diabetes, Digestive
and Kidney Diseases Grant DK083352.
NR 34
TC 15
Z9 15
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD AUG
PY 2012
VL 12
IS 8
BP 2088
EP 2097
DI 10.1111/j.1600-6143.2012.04053.x
PG 10
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 980OT
UT WOS:000306903400018
PM 22510337
ER
PT J
AU Venkataramani, AS
Martin, EG
Vijayan, A
Wellen, JR
AF Venkataramani, A. S.
Martin, E. G.
Vijayan, A.
Wellen, J. R.
TI The Impact of Tax Policies on Living Organ Donations in the United
States
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Article
DE Living organ donation; state policy; tax; United States
ID KIDNEY DONORS; TRANSPLANTATION; INCENTIVES; ATTITUDES; INCREASE;
REGISTRY; LIVE
AB In an effort to increase living organ donation, fifteen states passed tax deductions and one a tax credit to help defray potential medical, lodging and wage loss costs between 2004 and 2008. To assess the impact of these policies on living donation rates, we used a differences-in-differences strategy that compares the pre- and postlegislation change in living donations in states that passed legislation against the same change in those states that did not. We found no statistically significant effect of these tax policies on donation rates. Furthermore, we found no evidence of any lagged effects, differential impacts by gender, race or donor relationship, or impacts on deceased donation. Possible hypotheses to explain our findings are: the cash value of the tax deduction may be too low to defray costs faced by donors, lack of public awareness about the existence of these policies, and that states that were proactive enough to pass tax policy laws may have already depleted donor pools with previous interventions.
C1 [Venkataramani, A. S.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
[Martin, E. G.] SUNY Albany, Rockefeller Coll Publ Affairs & Policy, New York, NY USA.
[Martin, E. G.] SUNY Albany, Nelson A Rockefeller Inst Govt, New York, NY USA.
[Vijayan, A.] Washington Univ, Sch Med, Dept Med, Div Renal Dis, St Louis, MO 63110 USA.
[Wellen, J. R.] Washington Univ, Sch Med, Dept Surg, Sect Transplantat, St Louis, MO 63110 USA.
RP Venkataramani, AS (reprint author), Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
EM avenkataramani@partners.org
NR 32
TC 9
Z9 9
U1 1
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD AUG
PY 2012
VL 12
IS 8
BP 2133
EP 2140
DI 10.1111/j.1600-6143.2012.04044.x
PG 8
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 980OT
UT WOS:000306903400023
PM 22487077
ER
PT J
AU Petri, M
Orbai, AM
Alarcon, GS
Gordon, C
Merrill, JT
Fortin, PR
Bruce, IN
Isenberg, D
Wallace, DJ
Nived, O
Sturfelt, G
Ramsey-Goldman, R
Bae, SC
Hanly, JG
Sanchez-Guerrero, J
Clarke, A
Aranow, C
Manzi, S
Urowitz, M
Gladman, D
Kalunian, K
Costner, M
Werth, VP
Zoma, A
Bernatsky, S
Ruiz-Irastorza, G
Khamashta, MA
Jacobsen, S
Buyon, JP
Maddison, P
Dooley, MA
van Vollenhoven, RF
Ginzler, E
Stoll, T
Peschken, C
Jorizzo, JL
Callen, JP
Lim, SS
Fessler, BJ
Inanc, M
Kamen, DL
Rahman, A
Steinsson, K
Franks, AG
Sigler, L
Hameed, S
Fang, H
Pham, N
Brey, R
Weisman, MH
McGwin, G
Magder, LS
AF Petri, Michelle
Orbai, Ana-Maria
Alarcon, Graciela S.
Gordon, Caroline
Merrill, Joan T.
Fortin, Paul R.
Bruce, Ian N.
Isenberg, David
Wallace, Daniel J.
Nived, Ola
Sturfelt, Gunnar
Ramsey-Goldman, Rosalind
Bae, Sang-Cheol
Hanly, John G.
Sanchez-Guerrero, Jorge
Clarke, Ann
Aranow, Cynthia
Manzi, Susan
Urowitz, Murray
Gladman, Dafna
Kalunian, Kenneth
Costner, Melissa
Werth, Victoria P.
Zoma, Asad
Bernatsky, Sasha
Ruiz-Irastorza, Guillermo
Khamashta, Munther A.
Jacobsen, Soren
Buyon, Jill P.
Maddison, Peter
Dooley, Mary Anne
van vollenhoven, Ronald F.
Ginzler, Ellen
Stoll, Thomas
Peschken, Christine
Jorizzo, Joseph L.
Callen, Jeffrey P.
Lim, S. Sam
Fessler, Barri J.
Inanc, Murat
Kamen, Diane L.
Rahman, Anisur
Steinsson, Kristjan
Franks, Andrew G., Jr.
Sigler, Lisa
Hameed, Suhail
Fang, Hong
Ngoc Pham
Brey, Robin
Weisman, Michael H.
McGwin, Gerald, Jr.
Magder, Laurence S.
TI Derivation and validation of the systemic lupus international
collaborating clinics classification criteria for systemic lupus
erythematosus
SO ARTHRITIS AND RHEUMATISM
LA English
DT Article
ID RHEUMATISM-ASSOCIATION CRITERIA; OF-RHEUMATOLOGY CRITERIA; WEIGHTED
CRITERIA; REVISED CRITERIA; ANTIBODIES; NEPHRITIS; ARTHRITIS
AB Objective The Systemic Lupus International Collaborating Clinics (SLICC) group revised and validated the American College of Rheumatology (ACR) systemic lupus erythematosus (SLE) classification criteria in order to improve clinical relevance, meet stringent methodology requirements, and incorporate new knowledge regarding the immunology of SLE. Methods The classification criteria were derived from a set of 702 expert-rated patient scenarios. Recursive partitioning was used to derive an initial rule that was simplified and refined based on SLICC physician consensus. The SLICC group validated the classification criteria in a new validation sample of 690 new expert-rated patient scenarios. Results Seventeen criteria were identified. In the derivation set, the SLICC classification criteria resulted in fewer misclassifications compared with the current ACR classification criteria (49 versus 70; P = 0.0082) and had greater sensitivity (94% versus 86%; P < 0.0001) and equal specificity (92% versus 93%; P = 0.39). In the validation set, the SLICC classification criteria resulted in fewer misclassifications compared with the current ACR classification criteria (62 versus 74; P = 0.24) and had greater sensitivity (97% versus 83%; P < 0.0001) but lower specificity (84% versus 96%; P < 0.0001). Conclusion The new SLICC classification criteria performed well in a large set of patient scenarios rated by experts. According to the SLICC rule for the classification of SLE, the patient must satisfy at least 4 criteria, including at least one clinical criterion and one immunologic criterion OR the patient must have biopsy-proven lupus nephritis in the presence of antinuclear antibodies or antidouble-stranded DNA antibodies.
C1 [Petri, Michelle] Johns Hopkins Univ, Sch Med, Baltimore, MD 21205 USA.
[Alarcon, Graciela S.; Fessler, Barri J.; McGwin, Gerald, Jr.] Univ Alabama Birmingham, Birmingham, AL USA.
[Gordon, Caroline] Univ Birmingham, Birmingham, W Midlands, England.
[Merrill, Joan T.] Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA.
[Fortin, Paul R.] Univ Laval, Ctr Hosp Univ Quebec, Quebec City, PQ, Canada.
[Bruce, Ian N.] Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England.
[Bruce, Ian N.] Univ Manchester, Manchester, Lancs, England.
[Isenberg, David; Rahman, Anisur] UCL, London, England.
[Wallace, Daniel J.; Weisman, Michael H.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA.
[Wallace, Daniel J.] Univ Calif Los Angeles, Los Angeles, CA USA.
[Nived, Ola; Sturfelt, Gunnar] Univ Lund Hosp, S-22185 Lund, Sweden.
[Ramsey-Goldman, Rosalind] Northwestern Univ, Chicago, IL 60611 USA.
[Bae, Sang-Cheol] Hanyang Univ Hosp Rheumat Dis, Seoul, South Korea.
[Hanly, John G.] Dalhousie Univ, Halifax, NS, Canada.
[Hanly, John G.] Capital Hlth, Halifax, NS, Canada.
[Sanchez-Guerrero, Jorge] Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada.
[Sanchez-Guerrero, Jorge] Univ Hlth Network, Toronto, ON, Canada.
[Clarke, Ann; Bernatsky, Sasha] McGill Univ, Ctr Hlth, Montreal, PQ, Canada.
[Aranow, Cynthia] Feinstein Inst Med Res, Manhasset, NY USA.
[Manzi, Susan] Allegheny Singer Res Inst, Pittsburgh, PA 15212 USA.
[Manzi, Susan] Allegheny Gen Hosp, Pittsburgh, PA 15212 USA.
[Urowitz, Murray; Gladman, Dafna] Toronto Western Hosp, Toronto, ON M5T 2S8, Canada.
[Urowitz, Murray; Gladman, Dafna] Univ Toronto, Toronto, ON, Canada.
[Kalunian, Kenneth] Univ Calif San Diego, La Jolla, CA 92093 USA.
[Costner, Melissa] N Dallas Dermatol Associates, Dallas, TX USA.
[Werth, Victoria P.] Philadelphia VA Med Ctr, Philadelphia, PA USA.
[Werth, Victoria P.] Univ Penn, Philadelphia, PA 19104 USA.
[Zoma, Asad] Lanarkshire Ctr Rheumatol, E Kilbride, Lanark, Scotland.
[Zoma, Asad] Hairmyres Hosp, E Kilbride, Lanark, Scotland.
[Ruiz-Irastorza, Guillermo] Hosp Univ Cruces, Baracaldo, Spain.
[Ruiz-Irastorza, Guillermo] Univ Basque Country, Baracaldo, Spain.
[Khamashta, Munther A.] Rayne Inst, London, England.
[Khamashta, Munther A.] St Thomas Hosp, London, England.
[Jacobsen, Soren] Copenhagen Univ Hosp, Rigshosp, Copenhagen, Denmark.
[Buyon, Jill P.; Franks, Andrew G., Jr.] NYU, New York, NY USA.
[Maddison, Peter] Ysbyty Gwynedd, Bangor, Gwynedd, Wales.
[Dooley, Mary Anne] Univ N Carolina, Chapel Hill, NC USA.
[van vollenhoven, Ronald F.] Karolinska Univ Hosp, Stockholm, Sweden.
[Ginzler, Ellen] Suny Downstate Med Ctr, Brooklyn, NY 11203 USA.
[Stoll, Thomas] Kantonsspital Schaffhausen, Schaffhausen, Switzerland.
[Peschken, Christine] Univ Manitoba, Winnipeg, MB, Canada.
[Jorizzo, Joseph L.] Wake Forest Univ, Winston Salem, NC 27109 USA.
[Callen, Jeffrey P.] Univ Louisville, Louisville, KY 40292 USA.
[Lim, S. Sam] Emory Univ, Atlanta, GA 30322 USA.
[Inanc, Murat] Istanbul Univ, Istanbul, Turkey.
[Kamen, Diane L.] Med Univ S Carolina, Charleston, SC USA.
[Steinsson, Kristjan] Landspitali Univ Hosp, Reykjavik, Iceland.
[Brey, Robin] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Magder, Laurence S.] Univ Maryland, Baltimore, MD 21201 USA.
RP Petri, M (reprint author), Johns Hopkins Univ, Sch Med, 1830 E Monument St,Suite 7500, Baltimore, MD 21205 USA.
EM mpetri@jhmi.edu
RI inanc, murat/I-3444-2012; Ruiz-Irastorza, Guillermo/P-7058-2014; ,
Ivan/D-6804-2012;
OI Ruiz-Irastorza, Guillermo/0000-0001-7788-1043; Peschken,
Christine/0000-0002-4269-5213; Isenberg, David/0000-0001-9514-2455; ,
Ivan/0000-0002-3108-058X; Franks, Andrew/0000-0001-5427-6369; Bruce,
Ian/0000-0003-3047-500X
FU NIH (National Institute of Arthritis and Musculoskeletal and Skin
Diseases) [R01-AR-043727]; Lupus Foundation of America; Human Genome
Sciences; NIH [T32-AR-048522]; GlaxoSmithKline; Roche; Abbott; MSD;
Pfizer; UCB Pharma; Amgen; LEO Pharma; Warner Chilcott
FX Supported by the NIH (National Institute of Arthritis and
Musculoskeletal and Skin Diseases grant R01-AR-043727), the Lupus
Foundation of America, and Human Genome Sciences (unrestricted research
grant). Dr. Orbai's work was supported by the NIH (grant
T32-AR-048522).; Dr. Fortin has received consulting fees, speaking fees,
and/or honoraria from GlaxoSmithKline (less than $10,000). Dr. Bruce has
received consulting fees, speaking fees, and/or honoraria from Human
Genome Sciences, GlaxoSmithKline, and Roche (less than $10,000 each).
Dr. Nived has received speaking fees from GlaxoSmithKline (less than
$10,000). Dr. van Vollenhoven has received honoraria from Abbott,
GlaxoSmithKline, MSD, Pfizer, Roche, and UCB Pharma (less than $10,000
each) and research support from Abbott, GlaxoSmithKline, MSD, Pfizer,
Roche, and UCB Pharma. Dr. Jorizzo has received consulting fees,
speaking fees, and/or honoraria from Amgen, LEO Pharma, and Warner
Chilcott (less than $10,000 each).
NR 33
TC 460
Z9 514
U1 10
U2 37
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD AUG
PY 2012
VL 64
IS 8
BP 2677
EP 2686
DI 10.1002/art.34473
PG 10
WC Rheumatology
SC Rheumatology
GA 980PX
UT WOS:000306906500028
PM 22553077
ER
PT J
AU Maleki, N
Linnman, C
Brawn, J
Burstein, R
Becerra, L
Borsook, D
AF Maleki, Nasim
Linnman, Clas
Brawn, Jennifer
Burstein, Rami
Becerra, Lino
Borsook, David
TI Her versus his migraine: multiple sex differences in brain function and
structure
SO BRAIN
LA English
DT Article
DE migraine; headache; pain; sex differences; fMRI; morphometry; precuneus;
insula
ID HUMAN CEREBRAL-CORTEX; MAGNETIC-RESONANCE IMAGES; VOXEL-BASED
MORPHOMETRY; GREY-MATTER CHANGES; GENDER-DIFFERENCES; GRAY-MATTER;
GEOMETRICALLY ACCURATE; CORTICAL THICKNESS; NEUROPATHIC PAIN; VISCERAL
STIMULI
AB Migraine is twice as common in females as in males, but the mechanisms behind this difference are still poorly understood. We used high-field magnetic resonance imaging in male and female age-matched interictal (migraine free) migraineurs and matched healthy controls to determine alterations in brain structure. Female migraineurs had thicker posterior insula and precuneus cortices compared with male migraineurs and healthy controls of both sexes. Furthermore, evaluation of functional responses to heat within the migraine groups indicated concurrent functional differences in male and female migraineurs and a sex-specific pattern of functional connectivity of these two regions with the rest of the brain. The results support the notion of a 'sex phenotype' in migraine and indicate that brains are differentially affected by migraine in females compared with males. Furthermore, the results also support the notion that sex differences involve both brain structure as well as functional circuits, in that emotional circuitry compared with sensory processing appears involved to a greater degree in female than male migraineurs.
C1 [Maleki, Nasim] Harvard Univ, Sch Med, Dept Anaesthesia, Childrens Hosp Boston,CHB, Boston, MA 02115 USA.
[Maleki, Nasim; Linnman, Clas; Brawn, Jennifer; Becerra, Lino; Borsook, David] Childrens Hosp, Dept Radiol, Ctr Pain & Brain, MCL,MGH, Boston, MA 02115 USA.
[Burstein, Rami; Borsook, David] Harvard Univ, Sch Med, Dept Anaesthesia, Beth Israel Deaconess Hosp, Boston, MA 02115 USA.
[Becerra, Lino] McLean Hosp, Dept Psychiat, PAIN Grp, Boston, MA 02478 USA.
[Becerra, Lino] Harvard Univ, Sch Med, Boston, MA 02478 USA.
[Becerra, Lino; Borsook, David] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Psychiat, Charlestown, MA 02114 USA.
[Becerra, Lino; Borsook, David] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol, Charlestown, MA 02114 USA.
RP Maleki, N (reprint author), Harvard Univ, Sch Med, Dept Anaesthesia, Childrens Hosp Boston,CHB, Boston, MA 02115 USA.
EM nasim.maleki@childrens.harvard.edu
FU NIH [K24 NS064050, R01-NS056195, R01-NS073997]; IASP Early Career Grant;
Swedish Society for Medical Research (SSMF)
FX The work was supported in by grants from NIH (K24 NS064050 (NINDS),
R01-NS056195 (NINDS) and R01-NS073997 (NINDS) to D. B. C. L. received
support from the IASP Early Career Grant and the Swedish Society for
Medical Research (SSMF).
NR 92
TC 53
Z9 58
U1 2
U2 15
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0006-8950
EI 1460-2156
J9 BRAIN
JI Brain
PD AUG
PY 2012
VL 135
BP 2546
EP 2559
DI 10.1093/brain/aws175
PN 8
PG 14
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 984DQ
UT WOS:000307170300033
PM 22843414
ER
PT J
AU Bosco, JLF
Palmer, JR
Boggs, DA
Hatch, EE
Rosenberg, L
AF Bosco, Jaclyn L. F.
Palmer, Julie R.
Boggs, Deborah A.
Hatch, Elizabeth E.
Rosenberg, Lynn
TI Cardiometabolic factors and breast cancer risk in U.S. black women
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE Metabolic syndrome; Obesity; Insulin resistance; Breast cancer
ID BODY-FAT DISTRIBUTION; DENSITY-LIPOPROTEIN CHOLESTEROL; NUTRITION
EXAMINATION SURVEY; POPULATION-BASED COHORT; 3RD NATIONAL-HEALTH;
WAIST-HIP RATIO; METABOLIC SYNDROME; DIABETES-MELLITUS;
PHYSICAL-ACTIVITY; UNITED-STATES
AB Previous studies have suggested that metabolic syndrome may be associated with an increased risk of breast cancer, particularly in postmenopausal women, but U.S. black women have not been assessed. We examined the associations of abdominal obesity, type 2 diabetes, hypertension, and high cholesterol individually and in combination with breast cancer incidence in the Black Women's Health Study. By means of Cox regression models, we estimated incidence rate ratios (IRR) and 95 % confidence intervals (CI) for the associations of baseline and time-dependent values of self-reported abdominal obesity, type 2 diabetes, hypertension, and high cholesterol with breast cancer incidence. During 516,452 person years of follow-up (mean years = 10.5; standard deviation = 2.9) from 1995 to 2007, 1,228 breast cancer cases were identified. After adjustment for age, education, body mass index at age 18, physical activity, and individual cardiometabolic factors, neither individual nor combinations of cardiometabolic factors were associated with breast cancer incidence overall; the multivariable IRR was 1.04 (95 % CI 0.86-1.25) for the combination of a parts per thousand yen3 factors relative to the absence of all factors, and 1.17 (0.85-1.60) for having all four factors. Among postmenopausal women, however, the comparable IRRs were 1.23 (0.93-1.62) and 1.63 (1.12-2.37), respectively. Our findings provide some support for an association between cardiometabolic factors and breast cancer incidence among postmenopausal U.S. black women.
C1 [Bosco, Jaclyn L. F.] Dana Farber Canc Inst, Boston, MA 02215 USA.
[Bosco, Jaclyn L. F.] Boston Univ, Sch Med, Dept Med, Sect Geriatr, Boston, MA 02118 USA.
[Palmer, Julie R.; Boggs, Deborah A.; Rosenberg, Lynn] Boston Univ, Slone Epidemiol Ctr, Boston, MA 02215 USA.
[Hatch, Elizabeth E.] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02118 USA.
RP Bosco, JLF (reprint author), Dana Farber Canc Inst, 450 Brookline Ave LW519, Boston, MA 02215 USA.
EM jaclyn_bosco@dfci.harvard.edu
OI Hatch, Elizabeth/0000-0001-7901-3928; Palmer, Julie/0000-0002-6534-335X
FU National Institutes of Health; National Cancer Institute [R01 CA058420]
FX The authors gratefully acknowledge the contributions of the participants
and the staff of the BWHS. This study was supported by the National
Institutes of Health, and the National Cancer Institute grant R01
CA058420. The content is solely the responsibility of the authors and
does not necessarily represent the official view of the National Cancer
Institute or the National Institutes of Health. Although data on breast
cancer pathology were obtained from several state cancer registries (AZ,
CA, CO, CT, DE, DC, FL, GA, IL, IN, KY, LA, MD, MA, MI, NJ, NY, NC, OK,
PA, SC, TN, TX, and VA), the results reported do not necessarily
represent their views.
NR 74
TC 6
Z9 6
U1 1
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-6806
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD AUG
PY 2012
VL 134
IS 3
BP 1247
EP 1256
DI 10.1007/s10549-012-2131-4
PG 10
WC Oncology
SC Oncology
GA 985NL
UT WOS:000307273300033
PM 22710709
ER
PT J
AU Ligibel, JA
O'Malley, AJ
Fisher, M
Daniel, GW
Winer, EP
Keating, NL
AF Ligibel, Jennifer A.
O'Malley, A. James
Fisher, Maxine
Daniel, Gregory W.
Winer, Eric P.
Keating, Nancy L.
TI Patterns of bone density evaluation in a community population treated
with aromatase inhibitors
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE Aromatase inhibitor; Breast cancer; Bone density
ID EARLY BREAST-CANCER; RECEIVING ADJUVANT LETROZOLE; POSTMENOPAUSAL WOMEN;
ZOLEDRONIC ACID; PRACTICAL GUIDANCE; RANDOMIZED-TRIAL; ZO-FAST;
TAMOXIFEN; HEALTH; ANASTROZOLE
AB Aromatase inhibitors (AIs) increase the risk of bone loss and fracture. Guidelines recommend routine bone density screening for women on AIs, but there are few data regarding the incorporation of these guidelines into clinical practice. We assessed bone density testing in a community-based cohort of breast cancer patients treated with AIs. By means of encounter and pharmacy data from WellPoint plans in the HealthCore Integrated Research Database, we assessed bone density testing among 9,138 women aged a parts per thousand yen50 years with breast cancer who were treated with AIs between 2002 and 2008. We used multivariable logistic regression to identify factors associated with baseline bone density testing in women initiating an AI, and among a subset of 2,086 women treated with AIs for at least 2 years, with testing during the first 2 years of therapy. Only 41.6 % of women underwent bone density testing when initiating AI therapy. Rates of bone density testing increased over time, but were lower for women who were older, lived in the Northeast (vs. other regions), had been treated with prior proton pump inhibitor or tamoxifen therapy, lived in areas with lower educational attainment, or were enrolled in a health maintenance organization (vs. other insurance types) (all P < 0.05). Among women treated with AIs for at least 2 years, 59.9 % of women underwent bone density testing during the first 2 years of AI therapy. Rates of testing were lower for women living in the Midwest or West (vs. Northeast), living in areas with lower education levels, enrolled in health maintenance organizations (vs. other insurance types), and with prior tamoxifen use. In conclusion, most women initiating AI therapy, and 40 % of those on long-term therapy, did not undergo recommended bone density evaluation in this community-based population. Attention is needed to insure that unnecessary fractures are avoided in breast cancer patients taking AIs.
C1 [Ligibel, Jennifer A.; Winer, Eric P.] Dana Farber Canc Inst, Boston, MA 02215 USA.
[O'Malley, A. James; Keating, Nancy L.] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA.
[Fisher, Maxine] HealthCore Inc, Newark, DE USA.
[Daniel, Gregory W.] Brookings Inst, Washington, DC 20036 USA.
[Keating, Nancy L.] Brigham & Womens Hosp, Boston, MA 02115 USA.
RP Ligibel, JA (reprint author), Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA.
EM jligibel@partners.org
FU National Institutes of Health [R01 CA127652]
FX This work was funded by the National Institutes of Health (R01 CA127652
to Dr. Keating).
NR 28
TC 5
Z9 6
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-6806
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD AUG
PY 2012
VL 134
IS 3
BP 1305
EP 1313
DI 10.1007/s10549-012-2151-0
PG 9
WC Oncology
SC Oncology
GA 985NL
UT WOS:000307273300039
PM 22791365
ER
PT J
AU Lynch, M
Dahlin, C
Bakitas, M
AF Lynch, Maureen
Dahlin, Constance
Bakitas, Marie
TI Bowel Obstruction and Delirium: Managing Difficult Symptoms at the End
of Life
SO CLINICAL JOURNAL OF ONCOLOGY NURSING
LA English
DT Article
ID PALLIATIVE CARE; ADVANCED CANCER; MANAGEMENT; PATIENT
AB Palliative care has become an essential component of oncology care, with a focus on maximizing quality of life and optimizing function, as well as promoting pain and symptom management. This article focuses on the care of a patient experiencing bowel obstruction and delirium, two common issues in patients with advanced cancer, and demonstrates the integration of palliative care and oncology care to achieve an individualized care plan. Management focuses on identifying and treating reversible causes and improving quality of life while respecting the patient's values and goals. Sometimes the causes are not easily identified or treatment of the cause may impair quality of life, at least temporarily. At other times, the causes may be irreversible and the focus is exclusively on quality of life. Determination of best care for individual patients requires synthesis of data from holistic assessment, including the patient's goals of care and values, as well as knowledge of the patient's disease state with evidence-based approaches to management.
C1 [Lynch, Maureen] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Bakitas, Marie] Dartmouth Hitchcock Med Ctr, Sect Palliat Med, Lebanon, NH 03766 USA.
[Bakitas, Marie] Dartmouth Hitchcock Med Ctr, Dept Anesthesiol, Lebanon, NH 03766 USA.
RP Lynch, M (reprint author), Dana Farber Canc Inst, Boston, MA 02115 USA.
EM mtlynch@partners.org
OI Bakitas, Marie/0000-0002-2913-2053
NR 32
TC 2
Z9 2
U1 0
U2 2
PU ONCOLOGY NURSING SOC
PI PITTSBURGH
PA 125 ENTERPRISE DR, PITTSBURGH, PA 15275 USA
SN 1092-1095
J9 CLIN J ONCOL NURS
JI Clin. J. Oncol. Nurs.
PD AUG
PY 2012
VL 16
IS 4
BP 391
EP 398
DI 10.1188/12.CJON.391-398
PG 8
WC Oncology; Nursing
SC Oncology; Nursing
GA 981AL
UT WOS:000306937500012
PM 22842690
ER
PT J
AU Sheldon, LK
Leonard, K
Gross, A
Hartnett, E
Poage, E
Squires, J
Ullemeyer, V
Schueller, M
Stary, S
Miller, MA
AF Sheldon, Lisa Kennedy
Leonard, Kathleen
Gross, Anne
Hartnett, Erin
Poage, Ellen
Squires, Jennifer
Ullemeyer, Vicki
Schueller, Mary
Stary, Susan
Miller, Mary Alice
TI Oncology Nursing in Cuba: Report of the Delegation
SO CLINICAL JOURNAL OF ONCOLOGY NURSING
LA English
DT Editorial Material
AB In December 2011, the first delegation of oncology nurses from the United States visited Havana, Cuba. The delegation included oncology nurses, educators, and leaders from across America and provided opportunities to learn about the healthcare system, cancer, and oncology nursing in Cuba. Delegation members attended lectures, toured facilities, and enjoyed Cuban culture. This exchange highlighted the similarities in cancer care and oncology nursing between countries and opened doors for future collaborations.
C1 [Sheldon, Lisa Kennedy] Univ Massachusetts, Boston, MA 02125 USA.
[Leonard, Kathleen; Hartnett, Erin] NYU, Langone Med Ctr, New York, NY USA.
[Gross, Anne] Dana Farber Canc Inst, Boston, MA USA.
[Poage, Ellen] Rehabil Associates Naples, Ft Myers, FL USA.
[Squires, Jennifer] NCI, Med Oncol Branch, NIH, Bethesda, MD 20892 USA.
[Ullemeyer, Vicki] Novartis Pharmaceut, Ft Myers, FL USA.
[Schueller, Mary] St Nicholas Hosp, Sheboygan, WI USA.
[Stary, Susan] Univ Texas MD Anderson Phys Network, Houston, TX USA.
[Miller, Mary Alice] Permanente Med Grp Inc, San Rafael, CA USA.
RP Sheldon, LK (reprint author), Univ Massachusetts, Harbor Campus, Boston, MA 02125 USA.
EM lisa.kennedysheldon@umb.edu
OI Sheldon, Lisa Kennedy/0000-0002-5958-8529
NR 15
TC 1
Z9 1
U1 0
U2 1
PU ONCOLOGY NURSING SOC
PI PITTSBURGH
PA 125 ENTERPRISE DR, PITTSBURGH, PA 15275 USA
SN 1092-1095
J9 CLIN J ONCOL NURS
JI Clin. J. Oncol. Nurs.
PD AUG
PY 2012
VL 16
IS 4
BP 421
EP 424
DI 10.1188/12.CJON.421-424
PG 4
WC Oncology; Nursing
SC Oncology; Nursing
GA 981AL
UT WOS:000306937500017
PM 22842695
ER
PT J
AU Zhao, KQ
Cowan, AT
Lee, RJ
Goldstein, N
Droguett, K
Chen, B
Zheng, CQ
Villalon, M
Palmer, JN
Kreindler, JL
Cohen, NA
AF Zhao, Ke-Qing
Cowan, Andrew T.
Lee, Robert J.
Goldstein, Natalia
Droguett, Karla
Chen, Bei
Zheng, Chunquan
Villalon, Manuel
Palmer, James N.
Kreindler, James L.
Cohen, Noam A.
TI Molecular modulation of airway epithelial ciliary response to sneezing
SO FASEB JOURNAL
LA English
DT Article
DE chronic rhinosinusitis; mucociliary clearance; ATP; calcium
ID BEAT FREQUENCY; EXTRACELLULAR ATP; CHRONIC RHINOSINUSITIS; MUCOCILIARY
TRANSPORT; INTRACELLULAR CALCIUM; PROTEIN-KINASE; CA2+ RELEASE; CELLS;
STIMULATION; RECEPTOR
AB Our purpose was to evaluate the effect of the mechanical force of a sneeze on sinonasal cilia function and determine the molecular mechanism responsible for eliciting the ciliary response to a sneeze. A novel model was developed to deliver a stimulation simulating a sneeze (55 mmHg for 50 ms) at 26 degrees C to the apical surface of mouse and human nasal epithelial cells. Ciliary beating was visualized, and changes in ciliary beat frequency (CBF) were determined. To interrogate the molecular cascades driving sneeze-induced changes of CBF, pharmacologic manipulation of intra- and extracellular calcium, purinergic, PKA, and nitric oxide (NO) signaling were performed. CBF rapidly increases by >= 150% in response to a sneeze, which is dependent on the release of adenosine triphosphate (ATP), calcium influx, and PKA activation. Furthermore, apical release of ATP is independent of calcium influx, but calcium influx and subsequent increase in CBF are dependent on the ATP release. Lastly, we observed a blunted ciliary response in surgical specimens derived from patients with chronic rhinosinusitis compared to control patients. Apical ATP release with subsequent calcium mobilization and PKA activation are involved in sinonasal ciliary response to sneezing, which is blunted in patients with upper-airway disease.-Zhao, K.-Q., Cowan, A. T., Lee, R. J., Goldstein, N., Droguett, K., Chen, B., Zheng, C., Villalon, M., Palmer, J. N., Kreindler, J. L., Cohen, N. A. Molecular modulation of airway epithelial ciliary response to sneezing. FASEB J. 26, 3178-3187 (2012). www.fasebj.org
C1 [Zhao, Ke-Qing; Lee, Robert J.; Goldstein, Natalia; Chen, Bei; Palmer, James N.; Cohen, Noam A.] Univ Penn, Dept Otorhinolaryngol Head & Neck Surg, Philadelphia, PA 19104 USA.
[Zhao, Ke-Qing; Zheng, Chunquan] Fudan Univ, Dept Otorhinolaryngol Head & Neck Surg, Sch Shanghai Med, Eye & Ear Nose & Throat Hosp, Shanghai 200433, Peoples R China.
[Cowan, Andrew T.] Temple Univ, Dept Otolaryngol Head & Neck Surg, Philadelphia, PA 19122 USA.
[Droguett, Karla; Villalon, Manuel] Pontificia Univ Catolica Chile, Dept Physiol, Santiago, Chile.
[Goldstein, Natalia] Pontificia Univ Catolica Chile, Dept Med Sci, Santiago, Chile.
[Kreindler, James L.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA.
[Kreindler, James L.] Univ Penn, Dept Pediat, Sch Med, Philadelphia, PA 19104 USA.
[Cohen, Noam A.] Philadelphia Vet Affairs Med Ctr, Surg Serv, Philadelphia, PA USA.
RP Cohen, NA (reprint author), Univ Penn, Dept Otorhinolaryngol Head & Neck Surg, Ravdin Bldg,5th Floor,3400 Spruce St, Philadelphia, PA 19104 USA.
EM cohenn@uphs.upenn.edu
OI Cohen, Noam/0000-0002-9462-3932; Lee, Robert/0000-0001-5826-6686
FU Flight Attendant Medical Research Institute (FAMRI) Clinical Innovator
Award (CIA) grant [082478]; Fondo Nacional de Desarrollo Cientifico y
Tecnologico (FONDECYT) grant [1080679]; Proyecto Anillo ACT-79; Comision
Nacional de Investigacion Cientifica y Tecnologica (CONICYT) grant
[24090041]
FX Financial support for these experiments was provided by Flight Attendant
Medical Research Institute (FAMRI) Clinical Innovator Award (CIA) grant
082478 to N.A.C., Fondo Nacional de Desarrollo Cientifico y Tecnologico
(FONDECYT) grant 1080679 to M.V., Proyecto Anillo ACT-79 to K.D., and
Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT)
grant 24090041 to M.V.
NR 58
TC 10
Z9 10
U1 0
U2 8
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD AUG
PY 2012
VL 26
IS 8
BP 3178
EP 3187
DI 10.1096/fj.11-202184
PG 10
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 984BI
UT WOS:000307162800009
PM 22516297
ER
PT J
AU Schurpf, T
Chen, Q
Liu, JH
Wang, R
Springer, TA
Wang, JH
AF Schuerpf, Thomas
Chen, Qiang
Liu, Jin-huan
Wang, Rui
Springer, Timothy A.
Wang, Jia-huai
TI The RGD finger of Del-1 is a unique structural feature critical for
integrin binding
SO FASEB JOURNAL
LA English
DT Article
DE crystal structure; cell adhesion; innate immunity; extracellular matrix
protein
ID EPIDERMAL-GROWTH-FACTOR; DEVELOPMENTAL ENDOTHELIAL LOCUS-1; FACTOR-LIKE
DOMAIN; CRYSTAL-STRUCTURE; APOPTOTIC CELLS; PROTEIN; RECEPTOR;
ALPHA-V-BETA-3; ANGIOGENESIS; RECOGNITION
AB Developmental endothelial cell locus-1 (Del-1) glycoprotein is secreted by endothelial cells and a subset of macrophages. Del-1 plays a regulatory role in vascular remodeling and functions in innate immunity through interaction with integrin alpha(v)beta 3. Del-1 contains 3 epidermal growth factor (EGF)-like repeats and 2 discoidin-like domains. An Arg-Gly-Asp (RGD) motif in the second EGF domain (EGF2) mediates adhesion by endothelial cells and phagocytes. We report the crystal structure of its 3 EGF domains. The RGD motif of EGF2 forms a type II' beta turn at the tip of a long protruding loop, dubbed the RGD finger. Whereas EGF2 and EGF3 constitute a rigid rod via an interdomain calcium ion binding site, the long linker between EGF1 and EGF2 lends considerable flexibility to EGF1. Two unique O-linked glycans and 1 N-linked glycan locate to the opposite side of EGF2 from the RGD motif. These structural features favor integrin binding of the RGD finger. Mutagenesis data confirm the importance of having the RGD motif at the tip of the RGD finger. A database search for EGF domain sequences shows that this RGD finger is likely an evolutionary insertion and unique to the EGF domain of Del-1 and its homologue milk fat globule-EGF 8.-Schurpf, T., Chen, Q., Liu, J., Wang, R., Springer, T. A., Wang, J. The RGD finger of Del-1 is a unique structural feature critical for integrin binding. FASEB J. 26, 3412-420 (2012). www.fasebj.org
C1 [Chen, Qiang; Liu, Jin-huan; Wang, Jia-huai] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Wang, Jia-huai] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA.
[Schuerpf, Thomas; Wang, Rui; Springer, Timothy A.] Harvard Univ, Sch Med, Immune Dis Inst, Boston, MA 02115 USA.
RP Wang, JH (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02115 USA.
EM jwang@red.dfci.harvard.edu
OI Chen, Qiang/0000-0002-2398-4482
FU U.S. National Institutes of Health [HL103526]
FX The authors acknowledge U.S. National Institutes of Health grant
HL103526 to T.A.S. and J.-H.W. The authors also thank the staff members
at Advanced Photon Source beamlines 24-ID and 19-ID (Argonne National
Laboratory, Argonne, IL, USA) for the help in X-ray data collection.
Structural data have been deposited in the Protein Data Bank (PDB code
4D90).
NR 48
TC 12
Z9 14
U1 0
U2 5
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD AUG
PY 2012
VL 26
IS 8
BP 3412
EP 3420
DI 10.1096/fj.11-202036
PG 9
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 984BI
UT WOS:000307162800028
PM 22601780
ER
PT J
AU Roosli, C
Chhan, D
Halpin, C
Rosowski, JJ
AF Roeoesli, Christof
Chhan, David
Halpin, Christopher
Rosowski, John J.
TI Comparison of umbo velocity in air- and bone-conduction
SO HEARING RESEARCH
LA English
DT Article
ID DOPPLER VIBROMETER LDV; MIDDLE-EAR; FLUID PATHWAY; HEARING; STIMULATION;
THRESHOLDS; MOTION; SOUND; PRESSURE; HUMANS
AB This study investigates the ossicular motion produced by bone-conducted (BC) sound in live human ears. Laser Doppler Vibrometry was used to measure air conduction (AC)- and BC-induced umbo velocity (V-U) in both ears of 10 subjects, 20 ears total. Sound pressure in the ear canal (P-EC) was measured simultaneously. For air conduction, V-U at standard hearing threshold level was calculated. For BC, Delta V was defined as the difference between V-U and the tympanic ring velocity (an estimate of the skull velocity measured in the ear canal). Delta V and P-EC at BC standard hearing threshold were calculated. Delta V at standard BC threshold was significantly smaller than Vu at standard AC threshold between 500 Hz and 2000 Hz. Ear canal pressure at BC threshold tended to be smaller than for AC below 3000 Hz (with significant differences at 1000 Hz and 2000 Hz). Our results are most consistent with inertia of the ossicles and cochlear fluid driving BC hearing below 500 Hz, but with other mechanisms playing a significant role at higher frequencies. Sound radiated into the external ear canal might contribute to BC hearing at 3000 Hz and above. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Roeoesli, Christof; Chhan, David; Rosowski, John J.] Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, Boston, MA 02114 USA.
[Roeoesli, Christof; Halpin, Christopher; Rosowski, John J.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA.
[Roeoesli, Christof] Univ Zurich Hosp, Clin Otorhinolaryngol Head & Neck Surg, CH-8091 Zurich, Switzerland.
[Chhan, David; Rosowski, John J.] MIT, Harvard Mit Div Hlth Sci & Technol, Speech & Hearing Biosci & Technol Program, Cambridge, MA 02139 USA.
[Halpin, Christopher] Massachusetts Eye & Ear Infirm, Dept Audiol, Boston, MA 02114 USA.
RP Roosli, C (reprint author), Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, 243 Charles St, Boston, MA 02114 USA.
EM christof_roosli@meei.harvard.edu
FU NIDCD NIH HHS [R01 DC004798, R01 DC000194]
NR 25
TC 8
Z9 8
U1 0
U2 5
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-5955
J9 HEARING RES
JI Hear. Res.
PD AUG
PY 2012
VL 290
IS 1-2
BP 83
EP 90
DI 10.1016/j.heares.2012.04.011
PG 8
WC Audiology & Speech-Language Pathology; Neurosciences;
Otorhinolaryngology
SC Audiology & Speech-Language Pathology; Neurosciences & Neurology;
Otorhinolaryngology
GA 983PS
UT WOS:000307131800009
PM 22609771
ER
PT J
AU Westover, MB
Eiseman, NA
Bianchi, MT
AF Westover, M. Brandon
Eiseman, Nathaniel A.
Bianchi, Matt T.
TI Should risky treatments be reserved for secondary prevention?
Theoretical considerations regarding risk-benefit tradeoffs
SO JOURNAL OF CLINICAL EPIDEMIOLOGY
LA English
DT Article
DE Clinical trials; Human; Trial design; Public health; Prevention; Risk
ID MEDICAL DECISION-ANALYSIS; CORONARY-HEART-DISEASE; COST-EFFECTIVENESS;
PRIMER; GUIDELINES; ASPIRIN; STATINS; WORKING; STROKE
AB Objective: Clinical intuition suggests that risk-reducing treatments are more beneficial for patients with greater risk of disease. This intuition contributes to our rationale for tolerating greater adverse event risk in the setting of secondary prevention of certain diseases such as myocardial infarction or stroke. However, under certain conditions treatment benefits may be greater in primary prevention, even when the treatment carries harmful adverse effect potential.
Study Design and Setting: We present simple decision-theoretic models that illustrate conditions of risk and benefit under which a treatment is predicted to be more beneficial in primary than in secondary prevention.
Results: The models cover a spectrum of possible clinical circumstances, and demonstrate that net benefit in primary prevention can occur despite no benefit (or even net harm) in secondary prevention.
Conclusion: This framework provides a rationale for extending the familiar concept of balancing risks and benefits to account for disease-specific considerations of primary vs. secondary prevention. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Westover, M. Brandon; Eiseman, Nathaniel A.; Bianchi, Matt T.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
RP Bianchi, MT (reprint author), Massachusetts Gen Hosp, Dept Neurol, 55 Fruit St, Boston, MA 02114 USA.
EM mtbianchi@partners.org
FU Department of Neurology, Massachusetts General Hospital; Clinical
Investigator Training Program: Harvard/MIT Health Sciences and
Technology-Beth Israel Deaconess Medical Center; Pfizer, Inc.; Merck Co.
FX The authors are supported by the Department of Neurology, Massachusetts
General Hospital (M.T.B. and M.B.W.), and the Clinical Investigator
Training Program: Harvard/MIT Health Sciences and Technology-Beth Israel
Deaconess Medical Center, in collaboration with Pfizer, Inc. and Merck &
Co. (M.T.B.). The funding sources had no role in the design,
interpretation, or publication of this work.
NR 22
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0895-4356
J9 J CLIN EPIDEMIOL
JI J. Clin. Epidemiol.
PD AUG
PY 2012
VL 65
IS 8
BP 877
EP 886
DI 10.1016/j.jclinepi.2012.02.011
PG 10
WC Health Care Sciences & Services; Public, Environmental & Occupational
Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA 987KC
UT WOS:000307414800010
PM 22640567
ER
PT J
AU Taulli, R
Pandolfi, PP
AF Taulli, Riccardo
Pandolfi, Pier Paolo
TI "Snorkeling" for missing players in cancer
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Editorial Material
ID SMALL NUCLEOLAR RNAS; SNORNA HOST GENES; NONCODING RNA;
MULTIPLE-MYELOMA; MICRORNA; GROWTH; MMSET; GAS5; PTEN
AB Small nucleolar RNAs (snoRNAs) are emerging as an important new class of genes deregulated in cancer. Orphans snoRNAs are encoded outside of ribosomal protein genes and are involved in either gene splicing or are microRNA precursors. In this issue of JCI, Chu et al. find that ACA11, an orphan snoRNA encoded in an intron of the WHSC1 gene, is aberrantly overexpressed in t(4;14)-positive patients with multiple myeloma (MM), in which it influences growth of MM cells, resistance to chemotherapy, and oxidative stress. These findings represent the first identification of a snoRNA overexpressed as a consequence of a chromosomal translocation, a potent driving force of the neoplastic process in general and hematopoietic malignancies in particular.
C1 [Taulli, Riccardo; Pandolfi, Pier Paolo] Harvard Univ, Beth Israel Deaconess Med Ctr, Canc Genet Program, Sch Med,Dept Med, Boston, MA 02215 USA.
[Taulli, Riccardo; Pandolfi, Pier Paolo] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Pathol, Boston, MA 02215 USA.
[Taulli, Riccardo] Univ Turin, Dept Anat Pharmacol & Forens Med, Turin, Italy.
[Taulli, Riccardo] Univ Turin, Ctr Expt Res & Med Studies, Turin, Italy.
RP Pandolfi, PP (reprint author), BIDMC, 3 Blackfan Circle,CLS 401, Boston, MA 02115 USA.
EM ppandolf@bidmc.harvard.edu
NR 23
TC 8
Z9 8
U1 0
U2 6
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA
SN 0021-9738
J9 J CLIN INVEST
JI J. Clin. Invest.
PD AUG
PY 2012
VL 122
IS 8
BP 2765
EP 2768
DI 10.1172/JCI63549
PG 4
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 983OM
UT WOS:000307128600011
PM 22751102
ER
PT J
AU Strong, A
Ding, QR
Edmondson, AC
Millar, JS
Sachs, KV
Li, XY
Kumaravel, A
Wang, MY
Ai, D
Guo, L
Alexander, ET
Nguyen, D
Lund-Katz, S
Phillips, MC
Morales, CR
Tall, AR
Kathiresan, S
Fisher, EA
Musunuru, K
Rader, DJ
AF Strong, Alanna
Ding, Qiurong
Edmondson, Andrew C.
Millar, John S.
Sachs, Katherine V.
Li, Xiaoyu
Kumaravel, Arthi
Wang, Margaret Ye
Ai, Ding
Guo, Liang
Alexander, Eric T.
Nguyen, David
Lund-Katz, Sissel
Phillips, Michael C.
Morales, Carlos R.
Tall, Alan R.
Kathiresan, Sekar
Fisher, Edward A.
Musunuru, Kiran
Rader, Daniel J.
TI Hepatic sortilin regulates both apolipoprotein B secretion and LDL
catabolism
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID LOW-DENSITY-LIPOPROTEIN; FAMILIAL COMBINED HYPERLIPIDEMIA; PLURIPOTENT
STEM-CELLS; LYSOSOMAL TRAFFICKING; INSULIN-RESISTANCE; PROTEIN;
DEGRADATION; CHOLESTEROL; RECEPTOR; TRIGLYCERIDE
AB Genome-wide association studies (GWAS) have identified a genetic variant at a locus on chromosome 1p13 that is associated with reduced risk of myocardial infarction, reduced plasma levels of LDL cholesterol (LDL-C), and markedly increased expression of the gene sortilin-1 (SORT1) in liver. Sortilin is a lysosomal sorting protein that binds ligands both in the Golgi apparatus and at the plasma membrane and traffics them to the lysosome. We previously reported that increased hepatic sortilin expression in mice reduced plasma LDL-C levels. Here we show that increased hepatic sortilin not only reduced hepatic apolipoprotein B (APOB) secretion, but also increased LDL catabolism, and that both effects were dependent on intact lysosomal targeting. Loss-of-function studies demonstrated that sortilin serves as a bona fide receptor for LDL in vivo in mice. Our data are consistent with a model in which increased hepatic sortilin binds intracellular APOB-containing particles in the Golgi apparatus as well as extracellular LDL at the plasma membrane and traffics them to the lysosome for degradation. We thus provide functional evidence that genetically increased hepatic sortilin expression both reduces hepatic APOB secretion and increases LDL catabolism, providing dual mechanisms for the very strong association between increased hepatic sortilin expression and reduced plasma LDL-C levels in humans.
C1 [Rader, Daniel J.] Univ Penn, Perelman Sch Med, Div Translat Med & Human Genet, Translat Res Ctr 11 125,Inst Translat Med,Cardiov, Philadelphia, PA 19104 USA.
[Ding, Qiurong; Musunuru, Kiran] Harvard Univ, Dept Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA.
[Ai, Ding; Tall, Alan R.] Columbia Univ, Dept Med, Div Mol Med, Med Ctr, New York, NY USA.
[Guo, Liang; Fisher, Edward A.] NYU, Sch Med, Dept Med, Leon H Charney Div Cardiol, New York, NY USA.
[Alexander, Eric T.; Nguyen, David; Lund-Katz, Sissel; Phillips, Michael C.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA.
[Morales, Carlos R.] McGill Univ, Dept Anat & Cell Biol, Montreal, PQ, Canada.
[Kathiresan, Sekar] Massachusetts Gen Hosp, Dept Med, Cambridge, MA USA.
RP Rader, DJ (reprint author), Univ Penn, Perelman Sch Med, Div Translat Med & Human Genet, Translat Res Ctr 11 125,Inst Translat Med,Cardiov, Bldg 421,3400 Civ Ctr Blvd, Philadelphia, PA 19104 USA.
EM rader@mail.med.upenn.edu
OI Guo, Liang/0000-0003-1633-1544; Fisher, Edward/0000-0001-9802-143X
FU American Heart Association (AHA) [10PRE3010061]; National Heart, Lung
and Blood Institute (NHLBI) [RC2HL101864, R01HL109489, K99 HL098364]
FX We acknowledge Hui Li, Aisha Wilson, Edwige Eduoard, and Mao-Sen Sun for
their help with the animal studies; Deborah Cromley for her help with
lipid measurements; and Jeffrey Billheimer, William Lagor, Ilia Fuki,
Robert Brown, and Jane Glick for scientific discussions and mentorship.
This work was supported by 10PRE3010061 from the American Heart
Association (AHA) (to A. Strong), RC2HL101864 and R01HL109489 from the
National Heart, Lung and Blood Institute (NHLBI) (to D.J. Rader), and
K99 HL098364 from the NHLBI (to K. Musunuru). We would also like to
acknowledge the NHLBI Gene Therapy Resource Program for providing
support for the vector production as well as the Vector Core Laboratory
of the University of Pennsylvania for producing the vectors.
NR 41
TC 70
Z9 70
U1 0
U2 8
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA
SN 0021-9738
J9 J CLIN INVEST
JI J. Clin. Invest.
PD AUG
PY 2012
VL 122
IS 8
BP 2807
EP 2816
DI 10.1172/JCI63563
PG 10
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 983OM
UT WOS:000307128600018
PM 22751103
ER
PT J
AU Kim, H
Chen, L
Lim, G
Sung, B
Wang, SX
McCabe, MF
Rusanescu, G
Yang, LL
Tian, YH
Mao, JR
AF Kim, Hyangin
Chen, Lucy
Lim, Grewo
Sung, Backil
Wang, Shuxing
McCabe, Michael F.
Rusanescu, Gabriel
Yang, Liling
Tian, Yinghong
Mao, Jianren
TI Brain indoleamine 2,3-dioxygenase contributes to the comorbidity of pain
and depression
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID HIPPOCAMPAL SLICE CULTURES; PERIPHERAL-NERVE INJURY; LOW-BACK-PAIN;
QUINOLINIC ACID; DENDRITIC CELLS; SICKNESS BEHAVIOR; NEUROPATHIC PAIN;
KYNURENIC ACID; OPEN-FIELD; RATS
AB Pain and depression are frequently comorbicl disorders, but the mechanism underlying this association is unknown. Here, we report that brain indoleamine 2,3-dioxygenase 1 (ID01), a rate-limiting enzyme in tryptophan metabolism, plays a key role in this comorbidity. We found that chronic pain in rats induced depressive behavior and IDO1 upregulation in the bilateral hippocampus. Upregulation of IDO1 resulted in the increased kynurenine/tryptophan ratio and decreased serotonin/tryptophan ratio in the bilateral hippocampus. We observed elevated plasma IDO activity in patients with both pain and depression, as well as in rats with anhedonia induced by chronic social stress. Intra-hippocampal administration of IL-6 in rats, in addition to in vitro experiments, demonstrated that IL-6 induces IDO1 expression through the JAK/STAT pathway. Further, either Ido1 gene knockout or pharmacological inhibition of hippocampal IDO1 activity attenuated both nociceptive and depressive behavior. These results reveal an ID01-mediated regulatory mechanism underlying the comorbidity of pain and depression and suggest a new strategy for the concurrent treatment of both conditions via modulation of brain IDO1 activity.
C1 [Kim, Hyangin; Chen, Lucy; Lim, Grewo; Sung, Backil; Wang, Shuxing; McCabe, Michael F.; Rusanescu, Gabriel; Yang, Liling; Tian, Yinghong; Mao, Jianren] Harvard Univ, Massachusetts Gen Hosp, Sch Med, MGH Ctr Translat Pain Res,Dept Anesthesia Crit Ca, Boston, MA 02114 USA.
RP Mao, JR (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, MGH Ctr Translat Pain Res,Dept Anesthesia Crit Ca, Boston, MA 02114 USA.
EM jmao@partners.org
FU NIH [R01DE18214, R01DE18538, P20DA26002]
FX This study was supported by NIH grants R01DE18214, R01DE18538, and
P20DA26002 (to J. Mao).
NR 79
TC 101
Z9 107
U1 2
U2 28
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA
SN 0021-9738
J9 J CLIN INVEST
JI J. Clin. Invest.
PD AUG
PY 2012
VL 122
IS 8
BP 2940
EP 2954
DI 10.1172/JCI61884
PG 15
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 983OM
UT WOS:000307128600030
PM 22751107
ER
PT J
AU Lee, RS
Stewart, C
Carter, SL
Ambrogio, L
Cibulskis, K
Sougnez, C
Lawrence, MS
Auclair, D
Mora, J
Golub, TR
Biegel, JA
Getz, G
Roberts, CWM
AF Lee, Ryan S.
Stewart, Chip
Carter, Scott L.
Ambrogio, Lauren
Cibulskis, Kristian
Sougnez, Carrie
Lawrence, Michael S.
Auclair, Daniel
Mora, Jaume
Golub, Todd R.
Biegel, Jaclyn A.
Getz, Gad
Roberts, Charles W. M.
TI A remarkably simple genome underlies highly malignant pediatric rhabdoid
cancers
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID CELL CARCINOMA; MUTATIONS; TUMOR; SNF5; TUMORIGENESIS; SMARCB1/INI1;
ARID1A; MICE
AB Cancer is principally considered a genetic disease, and numerous mutations are thought essential to drive its growth. However, the existence of genomically stable cancers and the emergence of mutations in genes that encode chromatin remodelers raise the possibility that perturbation of chromatin structure and epigenetic regulation are capable of driving cancer formation. Here we sequenced the exomes of 35 rhabdoid tumors, highly aggressive cancers of early childhood characterized by biallelic loss of SMARCB1, a subunit of the SWI/SNF chromatin remodeling complex. We identified an extremely low rate of mutation, with loss of SMARCB1 being essentially the sole recurrent event. Indeed, in 2 of the cancers there were no other identified mutations. Our results demonstrate that high mutation rates are dispensable for the genesis of cancers driven by mutation of a chromatin remodeling complex. Consequently, cancer can be a remarkably genetically simple disease.
C1 [Biegel, Jaclyn A.] Childrens Hosp Philadelphia, Div Human Genet, Philadelphia, PA 19104 USA.
[Lee, Ryan S.; Golub, Todd R.; Roberts, Charles W. M.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA.
[Lee, Ryan S.; Golub, Todd R.; Roberts, Charles W. M.] Harvard Univ, Sch Med, Boston, MA USA.
[Stewart, Chip; Carter, Scott L.; Ambrogio, Lauren; Cibulskis, Kristian; Sougnez, Carrie; Lawrence, Michael S.; Auclair, Daniel; Golub, Todd R.; Getz, Gad] Broad Inst, Cambridge, MA 02142 USA.
[Mora, Jaume] Hosp St Joan de Deu, Dept Pediat Oncol, Barcelona, Spain.
[Golub, Todd R.] Howard Hughes Med Inst, Chevy Chase, MD USA.
[Biegel, Jaclyn A.] Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA.
[Roberts, Charles W. M.] Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA.
RP Biegel, JA (reprint author), Childrens Hosp Philadelphia, Div Human Genet, ARC Room 1002,3615 Civ Ctr Blvd, Philadelphia, PA 19104 USA.
EM biegel@mail.med.upenn.edu; gadgetz@broadinstitute.org;
Charles_Roberts@dfci.harvard.edu
FU Carlos Slim Health Institute; NSF; Garrett B. Smith Foundation; PHS
awards [R01CA113794, U01-1156106]; American Association of Cancer
Research; NIH [R01CA46274]
FX We are graceful to K. Eaton and L. Tooke for technical assistance, A.
Sivachenko for indel detection, A. McKenna for germ line mutation
calling, C. Zhang for SegSeq, G. Saksema for SNP array processing, P.
Stojanov for MutSig advice, and M. Meyerson and T. Pugh for fruitful
discussions. We also thank all the members of the Broad Institute's
Biological Samples, Genetic Analysis, and Genomic Sequencing Platforms.
This project is part of the Slim Initiative for Genomic Medicine, a
joint US-Mexico project funded by the Carlos Slim Health Institute. R.S.
Lee is partly supported by a NSF Graduate Research Fellowship. C.W.M.
Roberts is partly supported by the Garrett B. Smith Foundation, PHS
awards R01CA113794 and U01-1156106, and a Stand Up to Cancer Innovative
Research Grant from the American Association of Cancer Research. J.A.
Biegel is partly supported by NIH grant R01CA46274.
NR 25
TC 139
Z9 142
U1 0
U2 11
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA
SN 0021-9738
J9 J CLIN INVEST
JI J. Clin. Invest.
PD AUG
PY 2012
VL 122
IS 8
BP 2983
EP 2988
DI 10.1172/JCI64400
PG 6
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 983OM
UT WOS:000307128600033
PM 22797305
ER
PT J
AU Deshpande, V
Huck, A
Ooi, E
Stone, JH
Faquin, WC
Nielsen, GP
AF Deshpande, Vikram
Huck, Amelia
Ooi, Esther
Stone, John H.
Faquin, William C.
Nielsen, G. Petur
TI Fibrosing variant of Hashimoto thyroiditis is an IgG4 related disease
SO JOURNAL OF CLINICAL PATHOLOGY
LA English
DT Article
ID IGG4-RELATED SYSTEMIC-DISEASE; AUTOIMMUNE PANCREATITIS; SCLEROSING
CHOLANGITIS; RIEDELS STRUMA; HYPOTHYROIDISM; PREVALENCE
AB Hashimoto thyroiditis (HT) and the fibrosing variant of Hashimoto thyroiditis (FVHT) are immune-mediated tumefactive lesions of the thyroid. Immunoglobulin G4-related disease (IgG4-RD) is now a widely recognised multi-organ system disease characterised by elevated serum and tissue concentrations of IgG4. In this study, the authors address several unresolved questions pertaining to the relationship between HT and FVHT, and the association of each of these diseases with IgG4-RD. The authors evaluated 28 consecutive cases of HT and nine cases of FVHT. The clinical, demographic and serological data were recorded. The slides were stained immunohistochemically using antibodies to IgG4 and IgG and the quantitative analysis was recorded. Data on thyroid function tests were available on seven cases of FVHT and 14 cases of HT. Based on the availability of data, hypothyroidism was noted in 62% (9/14) of HT and 86% of FVHT (6/7). FVHT demonstrated an exaggerated lobular pattern with lobules separated by cellular storiform-type fibrosis, resembling fibrosis seen in other forms of IgG-RD. The median IgG4 counts per high power field (x40) in HT and FVHT were 2.3 and 22, respectively. The median IgG4: IgG ratios in HT and FVHT were 0.11 and 0.58, respectively. The authors propose that FVHT belongs to the spectrum of IgG4-RD. Although a proportion of cases of HT show elevated numbers of IgG4 positive plasma cells, these cases lack the histological features typically associated with IgG4-RD, and thus the relationship between HT and IgG4-RD remains unproven.
C1 [Deshpande, Vikram; Huck, Amelia; Faquin, William C.; Nielsen, G. Petur] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Ooi, Esther] Univ Western Australia, Sch Med & Pharmacol, Perth, WA 6009, Australia.
[Stone, John H.] Massachusetts Gen Hosp, Dept Med, Div Rheumatol, Boston, MA 02114 USA.
RP Deshpande, V (reprint author), Massachusetts Gen Hosp, Dept Pathol, 55 Fruit St,Warren 2, Boston, MA 02114 USA.
EM vdeshpande@partners.org
RI Ooi, Esther/B-3257-2011
OI Ooi, Esther/0000-0002-2097-633X
FU National Health and Medical Research Council of Australia
FX Esther Ooi is supported by a National Health and Medical Research
Council of Australia Postdoctoral Research Fellowship.
NR 23
TC 26
Z9 27
U1 0
U2 4
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0021-9746
J9 J CLIN PATHOL
JI J. Clin. Pathol.
PD AUG
PY 2012
VL 65
IS 8
BP 725
EP 728
DI 10.1136/jclinpath-2011-200485
PG 4
WC Pathology
SC Pathology
GA 983LJ
UT WOS:000307120500010
PM 22659333
ER
PT J
AU Lou, E
Sumrall, AL
Turner, S
Peters, KB
Desjardins, A
Vredenburgh, JJ
McLendon, RE
Herndon, JE
McSherry, F
Norfleet, J
Friedman, HS
Reardon, DA
AF Lou, Emil
Sumrall, Ashley L.
Turner, Scott
Peters, Katherine B.
Desjardins, Annick
Vredenburgh, James J.
McLendon, Roger E.
Herndon, James E., II
McSherry, Frances
Norfleet, Julie
Friedman, Henry S.
Reardon, David A.
TI Bevacizumab therapy for adults with recurrent/progressive meningioma: a
retrospective series
SO JOURNAL OF NEURO-ONCOLOGY
LA English
DT Article
DE Meningioma; Angiogenesis; Vascular endothelial growth factor;
Bevacizumab
ID ENDOTHELIAL GROWTH-FACTOR; RECURRENT MENINGIOMA; PHASE-II; INTRACRANIAL
MENINGIOMAS; BRAIN EDEMA; HYDROXYUREA; ANGIOGENESIS; EXPRESSION;
CHEMOTHERAPY; PROGRESSION
AB Intracranial meningiomas are often indolent tumors which typically grow over years to decades. Nonetheless, meningiomas that progress after maximum safe resection and radiation therapy pose a significant therapeutic challenge and effective therapies have yet to be identified. Preclinical studies implicate angiogenesis in the pathophysiology of more aggressive meningiomas, suggesting that anti-angiogenic therapies may be of utility in this setting. We performed a retrospective review of fourteen patients with recurrent meningioma treated at Duke University Medical Center with bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor, administered either alone or in combination with chemotherapy. Most patients were heavily pre-treated. Progression-free survival at 6 months was 86 % and was comparable regardless of meningioma grade and whether bevacizumab was administered as monotherapy or in combination with chemotherapy. Most toxicities were mild however single patients developed CNS hemorrhage (grade 1) and intestinal perforation (grade 4), respectively. Bevacizumab can be administered safely to patients with meningioma and appears to be associated with encouraging anti-tumor effect when administered as either a single agent or in combination with chemotherapy. Phase II trials investigating bevacizumab in patients with progressive/recurrent meningioma are warranted.
C1 [Reardon, David A.] Dana Farber Canc Inst, Ctr Neurooncol, Boston, MA 02215 USA.
[Friedman, Henry S.; Reardon, David A.] Duke Univ, Med Ctr, Dept Pediat, Preston Robert Tisch Brain Tumor Ctr Duke, Durham, NC 27710 USA.
[Herndon, James E., II; McSherry, Frances] Duke Univ, Med Ctr, Canc Ctr Biostat, Preston Robert Tisch Brain Tumor Ctr, Durham, NC 27710 USA.
[Lou, Emil; Sumrall, Ashley L.; Turner, Scott; Norfleet, Julie; Friedman, Henry S.; Reardon, David A.] Duke Univ, Med Ctr, Dept Surg, Preston Robert Tisch Brain Tumor Ctr Duke, Durham, NC 27710 USA.
[Peters, Katherine B.; Desjardins, Annick; Vredenburgh, James J.] Duke Univ, Med Ctr, Dept Med, Preston Robert Tisch Brain Tumor Ctr Duke, Durham, NC 27710 USA.
[McLendon, Roger E.] Duke Univ, Med Ctr, Dept Pathol, Preston Robert Tisch Brain Tumor Ctr Duke, Durham, NC 27710 USA.
RP Reardon, DA (reprint author), Dana Farber Canc Inst, Ctr Neurooncol, 450 Brookline Ave SW,460G, Boston, MA 02215 USA.
EM david_reardon@dfci.harvard.edu
FU NIH [5P50-NS-20023, 5 R37 CA11898, MO1 RR 30]; GCRC Program; NCRR; NCI
SPORE [1 P20 CA096890]; Genentech Pharmaceuticals
FX This work was supported by NIH Grants 5P50-NS-20023 and 5 R37 CA11898;
NIH Grant MO1 RR 30, GCRC Program, NCRR; and NCI SPORE 1 P20 CA096890;
and a grant from Genentech Pharmaceuticals.
NR 42
TC 51
Z9 51
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-594X
EI 1573-7373
J9 J NEURO-ONCOL
JI J. Neuro-Oncol.
PD AUG
PY 2012
VL 109
IS 1
BP 63
EP 70
DI 10.1007/s11060-012-0861-0
PG 8
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA 981FU
UT WOS:000306953100008
PM 22535433
ER
PT J
AU Nayak, L
Iwamoto, FM
Rudnick, JD
Norden, AD
Lee, EQ
Drappatz, J
Omuro, A
Kaley, TJ
AF Nayak, Lakshmi
Iwamoto, Fabio M.
Rudnick, Jeremy D.
Norden, Andrew D.
Lee, Eudocia Quant
Drappatz, Jan
Omuro, Antonio
Kaley, Thomas J.
TI Atypical and anaplastic meningiomas treated with bevacizumab
SO JOURNAL OF NEURO-ONCOLOGY
LA English
DT Article
DE Meningioma; Atypical; Anaplastic; Bevacizumab; Vascular endothelial
growth factor (VEGF)
ID RECURRENT MENINGIOMA; PHASE-II
AB Atypical and anaplastic (WHO Grades II and III) meningiomas are aggressive tumors, and patients often progress despite surgery and radiation. There is no known effective chemotherapeutic option for these patients. Meningiomas have a high expression of vascular endothelial growth factor receptor (VEGFR). We sought to retrospectively study the activity of bevacizumab, which is an anti-angiogenic agent targeting the VEGF pathway in these tumors. This is a retrospective review of WHO Grade II and III meningiomas treated at four institutions, selecting only those patients who received bevacizumab. We analyzed radiographic response according to standard RANO criteria, progression-free survival (PFS) and overall survival from the initiation of bevacizumab therapy using Kaplan-Meier statistics. We identified 15 patients across four institutions who carried a diagnosis of atypical or anaplastic meningioma and were treated with bevacizumab. Best radiographic response was stable disease. MR perfusion studies showed decreased tumor blood volume in one patient. Three patients developed non-fatal intratumoral hemorrhage. Median PFS was 26 weeks (95 % CI, 10-29 weeks). Six month PFS rate was 43.8 % (95 % CI, 15.7-69.1 %). Bevacizumab was well-tolerated in our patients, and may be considered in patients who have exhausted radiation and surgical options. Prospective studies are required to define the safety and efficacy of bevacizumab in atypical and anaplastic meningiomas.
C1 [Nayak, Lakshmi; Omuro, Antonio; Kaley, Thomas J.] Mem Sloan Kettering Canc Ctr, Dept Neurol, New York, NY 10065 USA.
[Iwamoto, Fabio M.] NCI, Neurooncol Branch, NIH, Bethesda, MD 20892 USA.
[Rudnick, Jeremy D.] Cedars Sinai Med Ctr, Dept Neurol & Neurosurg, Los Angeles, CA 90048 USA.
[Norden, Andrew D.; Lee, Eudocia Quant; Drappatz, Jan] Univ Pittsburgh, Ctr Neurooncol, Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA.
RP Kaley, TJ (reprint author), Mem Sloan Kettering Canc Ctr, Dept Neurol, 1275 York Ave, New York, NY 10065 USA.
EM Kaleyt@mskcc.org
OI Kaley, Thomas/0000-0002-2540-8518; Omuro, Antonio/0000-0003-4299-3664
FU NCI NIH HHS [P30 CA008748]
NR 10
TC 51
Z9 51
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-594X
EI 1573-7373
J9 J NEURO-ONCOL
JI J. Neuro-Oncol.
PD AUG
PY 2012
VL 109
IS 1
BP 187
EP 193
DI 10.1007/s11060-012-0886-4
PG 7
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA 981FU
UT WOS:000306953100023
PM 22544653
ER
PT J
AU Han, SS
Nam, EC
Won, JY
Lee, KU
Chun, W
Choi, HK
Levine, RA
AF Han, Seon-Sook
Nam, Eui-Cheol
Won, Jun Yeon
Lee, Kang Uk
Chun, Wanjoo
Choi, Hyun Kyung
Levine, Robert Aaron
TI Clonazepam Quiets tinnitus: a randomised crossover study with Ginkgo
Biloba
SO JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
LA English
DT Article
ID ANIMAL-MODEL; ALPRAZOLAM
AB Objective To assess the effect of Ginkgo biloba and clonazepam, a gamma-aminobutyric acid (GABA)-receptor agonist, upon tinnitus.
Methods This was an open-label, randomised, crossover study. 27 men and 11 women (aged 16-80 (mean 58)) with tinnitus for more than 2 months were enrolled. Participants were randomised to either clonazepam or G biloba for the first 3 weeks. For the next 2 weeks of washout no medication was taken. For the final 3 weeks, subjects were given the other drug. The initial dose of clonazepam and G biloba was one tablet daily (clonazepam 0.5 mg; G biloba 40 mg). Subjects were instructed to increase the dose by one tablet every 3 days to a maximum of four tablets daily until they perceived a satisfactory decrease in tinnitus loudness or intolerable side effects. Tinnitus was assessed with pitch and loudness matching, tinnitus handicap inventory, and visual analogue scales of loudness, duration and annoyance.
Results Comparing before and after each drug, clonazepam significantly improved tinnitus loudness (74% of subjects), duration (63%), annoyance (79%), and tinnitus handicap inventory score (61%), whereas the G biloba showed no significant differences on any of these measures.
Conclusion Clonazepam is effective in treating tinnitus; G biloba is ineffective.
C1 [Nam, Eui-Cheol; Won, Jun Yeon] Kangwon Natl Univ, Dept Otolaryngol, Sch Med, Chunchon 200701, Kangwon Do, South Korea.
[Han, Seon-Sook] Kangwon Natl Univ, Dept Internal Med, Sch Med, Chunchon 200701, Kangwon Do, South Korea.
[Nam, Eui-Cheol; Chun, Wanjoo] Kangwon Natl Univ, Inst Med Sci, Sch Med, Chunchon 200701, Kangwon Do, South Korea.
[Lee, Kang Uk] Kangwon Natl Univ, Dept Psychiat, Sch Med, Chunchon 200701, Kangwon Do, South Korea.
[Chun, Wanjoo] Kangwon Natl Univ, Dept Pharmacol, Sch Med, Chunchon 200701, Kangwon Do, South Korea.
[Choi, Hyun Kyung] Kangwon Natl Univ Hosp, Dept Otolaryngol, Chunchon, South Korea.
[Levine, Robert Aaron] Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Eaton Peabody Lab, Boston, MA 02114 USA.
[Levine, Robert Aaron] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA.
[Levine, Robert Aaron] Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA.
RP Nam, EC (reprint author), Kangwon Natl Univ, Dept Otolaryngol, Sch Med, 1 Kangwondaehak Gil, Chunchon 200701, Kangwon Do, South Korea.
EM birdynec@kangwon.ac.kr
FU Basic Science Research Program through the National Research Foundation
(NRF) of Korea; Ministry of Education, Science and Technology
[2011-0006602]
FX This research was supported by the Basic Science Research Program
through the National Research Foundation (NRF) of Korea funded by the
Ministry of Education, Science and Technology (2011-0006602).
NR 23
TC 17
Z9 19
U1 0
U2 4
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0022-3050
J9 J NEUROL NEUROSUR PS
JI J. Neurol. Neurosurg. Psychiatry
PD AUG
PY 2012
VL 83
IS 8
BP 821
EP 827
DI 10.1136/jnnp-2012-302273
PG 7
WC Clinical Neurology; Psychiatry; Surgery
SC Neurosciences & Neurology; Psychiatry; Surgery
GA 985QJ
UT WOS:000307282600013
PM 22626945
ER
PT J
AU Kassam-Adams, N
Palmieri, PA
Rork, K
Delahanty, DL
Kenardy, J
Kohser, KL
Landolt, MA
Le Brocque, R
Marsac, ML
Meiser-Stedman, R
Nixon, RDV
Bui, E
McGrath, C
AF Kassam-Adams, Nancy
Palmieri, Patrick A.
Rork, Kristine
Delahanty, Douglas L.
Kenardy, Justin
Kohser, Kristen L.
Landolt, Markus A.
Le Brocque, Robyne
Marsac, Meghan L.
Meiser-Stedman, Richard
Nixon, Reginald D. V.
Bui, Eric
McGrath, Caitlin
TI Acute Stress Symptoms in Children: Results From an International Data
Archive
SO JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY
LA English
DT Article
DE acute stress disorder; DSM-5; diagnostic criteria
ID MOTOR-VEHICLE ACCIDENTS; POSTTRAUMATIC-STRESS; INJURED CHILDREN; EVENT
SCALE; DISORDER; PTSD; INTERVENTION; YOUTH; ADOLESCENTS; IMPACT
AB Objective: To describe the prevalence of acute stress disorder (ASD) symptoms and to examine proposed DSM-5 symptom criteria in relation to concurrent functional impairment in children and adolescents. Method: From an international archive, datasets were identified that included assessment of acute traumatic stress reactions and concurrent impairment in children and adolescents 5 to 17 years of age. Data came from 15 studies conducted in the United States, United Kingdom, Australia, and Switzerland and included 1,645 children and adolescents. Dichotomized items were created to indicate the presence or absence of each of the 14 proposed ASD symptoms and functional impairment. The performance of a proposed diagnostic criterion (number of ASD symptoms required) was examined as a predictor of concurrent impairment. Results: Each ASD symptom was endorsed by 14% to 51% of children and adolescents; 41% reported clinically relevant impairment. Children and adolescents reported from 0 to 13 symptoms (mean = 3.6). Individual ASD symptoms were associated with greater likelihood of functional impairment. The DSM-5 proposed eight-symptom requirement was met by 202 individuals (12.3%) and had low sensitivity (0.25) in predicting concurrent clinically relevant impairment. Requiring fewer symptoms (three to four) greatly improved sensitivity while maintaining moderate specificity. Conclusions: This group of symptoms appears to capture aspects of traumatic stress reactions that can create distress and interfere with children's and adolescents' ability to function in the acute post-trauma phase. Results provide a benchmark for comparison with adult samples; a smaller proportion of children and adolescents met the eight-symptom criterion than reported for adults. Symptom requirements for the ASD diagnosis may need to be lowered to optimally identify children and adolescents whose acute distress warrants clinical attention. J. Am. Acad. Child Adolesc. Psychiatry, 2012;51(8):812-820.
C1 [Kassam-Adams, Nancy] Childrens Hosp Philadelphia, Ctr Injury Res & Prevent, Philadelphia, PA 19104 USA.
[Kassam-Adams, Nancy] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Rork, Kristine] Case Western Reserve Univ, Univ Hosp, Rainbow Babies & Childrens Hosp, Cleveland, OH 44106 USA.
[Delahanty, Douglas L.] Kent State Univ, Kent, OH USA.
[Kenardy, Justin; Le Brocque, Robyne; McGrath, Caitlin] Univ Queensland, Brisbane, Qld 4072, Australia.
[Landolt, Markus A.] Univ Childrens Hosp Zurich, Zurich, Switzerland.
[Meiser-Stedman, Richard] Med Res Council Cognit & Brain Sci Unit, Cambridge, England.
[Nixon, Reginald D. V.] Flinders Univ S Australia, Adelaide, SA, Australia.
[Bui, Eric] Univ Toulouse, Toulouse, France.
[Bui, Eric] Ctr Hosp Univ CHU Toulouse, Toulouse, France.
[Bui, Eric] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Bui, Eric] Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
RP Kassam-Adams, N (reprint author), Childrens Hosp Philadelphia, Ctr Injury Res & Prevent, 3535 Market St,Suite 1150, Philadelphia, PA 19104 USA.
EM nlkaphd@mail.med.upenn.edu
RI Le Brocque, Robyne/F-4848-2010; Meiser-Stedman, Richard/F-7478-2013;
Nixon, Reginald/A-6095-2015; Bui, Eric/J-8347-2015; Meiser-Stedman,
Richard/B-6128-2016;
OI Le Brocque, Robyne/0000-0002-4574-1254; Meiser-Stedman,
Richard/0000-0002-0262-623X; Nixon, Reginald/0000-0003-1507-8428; Bui,
Eric/0000-0002-1413-6473; Meiser-Stedman, Richard/0000-0002-0262-623X;
Landolt, Markus/0000-0003-0760-5558
FU National Institute of Mental Health [R21MH086304]
FX This work was supported by grant R21MH086304 from the National Institute
of Mental Health.
NR 33
TC 9
Z9 9
U1 0
U2 18
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0890-8567
J9 J AM ACAD CHILD PSY
JI J. Am. Acad. Child Adolesc. Psychiatr.
PD AUG
PY 2012
VL 51
IS 8
BP 812
EP 820
DI 10.1016/j.jaac.2012.05.013
PG 9
WC Psychology, Developmental; Pediatrics; Psychiatry
SC Psychology; Pediatrics; Psychiatry
GA 983OJ
UT WOS:000307128300009
PM 22840552
ER
PT J
AU Kortagere, S
Madani, N
Mankowski, MK
Schon, A
Zentner, I
Swaminathan, G
Princiotto, A
Anthony, K
Oza, A
Sierra, LJ
Passic, SR
Wang, XZ
Jones, DM
Stavale, E
Krebs, FC
Martin-Garcia, J
Freire, E
Ptak, RG
Sodroski, J
Cocklin, S
Smith, AB
AF Kortagere, Sandhya
Madani, Navid
Mankowski, Marie K.
Schoen, Arne
Zentner, Isaac
Swaminathan, Gokul
Princiotto, Amy
Anthony, Kevin
Oza, Apara
Sierra, Luz-Jeannette
Passic, Shendra R.
Wang, Xiaozhao
Jones, David M.
Stavale, Eric
Krebs, Fred C.
Martin-Garcia, Julio
Freire, Ernesto
Ptak, Roger G.
Sodroski, Joseph
Cocklin, Simon
Smith, Amos B., III
TI Inhibiting Early-Stage Events in HIV-1 Replication by Small-Molecule
Targeting of the HIV-1 Capsid
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; REVERSE-TRANSCRIPTASE; CA PROTEIN;
BINDING; ENTRY; INTEGRATION; INFECTION; LIGANDS; REVEAL; DOMAIN
AB The HIV-1 capsid (CA) protein plays essential roles in both early and late stages of virl replication and has emerged as a novel drug target. We report hybrid structure-based virtual screening to identify small molecules with the potential to interact with the N-terminal domain (NTD) of HIV-1 CA and disrupt early, preintegration steps of the HIV-1 replication cycle. The small molecule 4,4'-[dibenzo[b,d]furan-2,8-diylbis(5-phenyl-1H-imidazole-4,2-diyl)]dibenzoic acid (CK026), which had anti-HIV-1 activity in single- and multiple-round infections but failed to inhibit viral replication in peripheral blood mononuclear cells (PBMCs), was identified. Three analogues of CK026 with reduced size and better drug-like properties were synthesized and assessed. Compound I-XW-053 (4-(4,5-diphenyl-1H-imidazol-2-yl)benzoic acid) retained all of the antiviral activity of the parental compound and inhibited the replication of a diverse panel of primary HIV-1 isolates in PBMCs, while displaying no appreciable cytotoxicity. This antiviral activity was specific to HIV-1, as I-XW-053 displayed no effect on the replication of SIV or against a panel of nonretroviruses. Direct interaction of I-XW-053 was quantified with wild-type and mutant CA protein using surface plasmon resonance and isothermal titration calorimetry. Mutation of Ile37 and Arg173, which are required for interaction with compound I-XW-053, crippled the virus at an early, preintegration step. Using quantitative PCR, we demonstrated that treatment with I-XW-053 inhibited HIV-1 reverse transcription in multiple cell types, indirectly pointing to dysfunction in the uncoating process. In summary, we have identified a CAs-pecific compound that targets and inhibits a novel region in the NTD-NTD interface, affects uncoating, and possesses broad-spectrum anti-HIV-1 activity.
C1 [Zentner, Isaac; Cocklin, Simon] Drexel Univ, Coll Med, Dept Biochem & Mol Biol, Philadelphia, PA 19104 USA.
[Kortagere, Sandhya; Swaminathan, Gokul; Oza, Apara; Sierra, Luz-Jeannette; Passic, Shendra R.; Krebs, Fred C.; Martin-Garcia, Julio] Drexel Univ, Coll Med, Dept Microbiol & Immunol, Philadelphia, PA 19104 USA.
[Madani, Navid; Princiotto, Amy] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS,Div AIDS, Boston, MA 02115 USA.
[Mankowski, Marie K.; Ptak, Roger G.; Sodroski, Joseph] So Res Inst, Dept Infect Dis Res, Frederick, MD USA.
[Schoen, Arne; Freire, Ernesto] Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA.
[Wang, Xiaozhao; Jones, David M.; Smith, Amos B., III] Univ Penn, Dept Chem, Philadelphia, PA 19104 USA.
[Anthony, Kevin; Stavale, Eric] USA IBT Bioservices, Baltimore, MD USA.
RP Cocklin, S (reprint author), Drexel Univ, Coll Med, Dept Biochem & Mol Biol, Philadelphia, PA 19104 USA.
EM simon.cocklin@drexelmed.edu; smithab@sas.upenn.edu
RI Martin-Garcia, Julio/A-5666-2009
OI Martin-Garcia, Julio/0000-0001-5450-5029
FU Pennsylvania Department of Health
FX This project was funded by a grant obtained from the Pennsylvania
Department of Health (Tobacco Settlement Formula Funds, SK and SC).
NR 44
TC 19
Z9 20
U1 1
U2 21
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD AUG
PY 2012
VL 86
IS 16
BP 8472
EP 8481
DI 10.1128/JVI.05006-11
PG 10
WC Virology
SC Virology
GA 984NS
UT WOS:000307198300013
PM 22647699
ER
PT J
AU Kumthip, K
Chusri, P
Jilg, N
Zhao, L
Fusco, DN
Zhao, H
Goto, K
Cheng, D
Schaefer, EA
Zhang, LL
Pantip, C
Thongsawat, S
O'Brien, A
Peng, LF
Maneekarn, N
Chung, RT
Lin, WY
AF Kumthip, Kattareeya
Chusri, Pattranuch
Jilg, Nikolaus
Zhao, Lei
Fusco, Dahlene N.
Zhao, Hong
Goto, Kaku
Cheng, Du
Schaefer, Esperance A.
Zhang, Leiliang
Pantip, Chansom
Thongsawat, Satawat
O'Brien, Amornrat
Peng, Lee F.
Maneekarn, Niwat
Chung, Raymond T.
Lin, Wenyu
TI Hepatitis C Virus NS5A Disrupts STAT1 Phosphorylation and Suppresses
Type I Interferon Signaling
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID NONSTRUCTURAL 5A PROTEIN; SENSITIVITY-DETERMINING REGION; RIBAVIRIN
COMBINATION THERAPY; PEGINTERFERON ALPHA-2B; INHIBITOR BMS-790052; RNA
REPLICATION; HCV GENOTYPE-2; PLUS RIBAVIRIN; IFN-ALPHA; INFECTION
AB Responses to alpha interferon (IFN-alpha)-based treatment are dependent on both host and viral factors and vary markedly among patients infected with different hepatitis C virus (HCV) genotypes (GTs). Patients infected with GT3 viruses consistently respond better to IFN treatment than do patients infected with GT1 viruses. The mechanisms underlying this difference are not well understood. In this study, we sought to determine the effects of HCV NS5A proteins from different genotypes on IFN signaling. We found that the overexpression of either GT1 or GT3 NS5A proteins significantly inhibited IFN-induced IFN-stimulated response element (ISRE) signaling, phosphorylated STAT1 (P-STAT1) levels, and IFN-stimulated gene (ISG) expression compared to controls. GT1 NS5A protein expression exhibited stronger inhibitory effects on IFN signaling than did GT3 NS5A protein expression. Furthermore, GT1 NS5A bound to STAT1 with a higher affinity than did GT3 NS5A. Domain mapping revealed that the C-terminal region of NS5A conferred these inhibitory effects on IFN signaling. The overexpression of HCV NS5A increased HCV replication levels in JFH1-infected cells through the further reduction of levels of P-STAT1, ISRE signaling, and downstream ISG responses. We demonstrated that the overexpression of GT1 NS5A proteins resulted in less IFN responsiveness than did the expression of GT3 NS5A proteins through stronger binding to STAT1. We confirmed that GT1 NS5A proteins exerted stronger IFN signaling inhibition than did GT3 NS5A proteins in an infectious recombinant JFH1 virus. The potent antiviral NS5A inhibitor BMS-790052 did not block NS5A-mediated IFN signaling suppression in an overexpression model, suggesting that NS5A's contributions to replication are independent of its subversive action on IFN. We propose a model in which the binding of the C-terminal region of NS5A to STAT1 leads to decreased levels of P-STAT1, ISRE signaling, and ISG transcription and, ultimately, to preferential GT1 resistance to IFN treatment.
C1 [Kumthip, Kattareeya; Chusri, Pattranuch; Jilg, Nikolaus; Zhao, Lei; Fusco, Dahlene N.; Zhao, Hong; Goto, Kaku; Cheng, Du; Schaefer, Esperance A.; Zhang, Leiliang; Peng, Lee F.; Chung, Raymond T.; Lin, Wenyu] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Gastrointestinal Unit,Dept Med, Boston, MA 02115 USA.
[Kumthip, Kattareeya; Chusri, Pattranuch; Pantip, Chansom; O'Brien, Amornrat; Maneekarn, Niwat] Chiang Mai Univ, Fac Med, Dept Microbiol, Chiang Mai 50000, Thailand.
[Thongsawat, Satawat] Chiang Mai Univ, Fac Med, Dept Internal Med, Chiang Mai 50000, Thailand.
[Zhao, Hong] Peking Univ, Hosp 1, Dept Infect Dis, Beijing 100871, Peoples R China.
RP Chung, RT (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Gastrointestinal Unit,Dept Med, Boston, MA 02115 USA.
EM rtchung@partners.org
FU NIH [AI069939, AI082630]; NIH-MGH Center for Human Immunology
pilot/feasibility study grant; Royal Golden Jubilee Ph.D. Program of
Thailand Research Fund; German Research Foundation (Deutsche
Forschungsgemeinschaft) [Ji 145/1-1]
FX This work was supported in part by NIH grants AI069939 (R.T.C.) and
AI082630 (R.T.C.), an NIH-MGH Center for Human Immunology
pilot/feasibility study grant (W.L.), the Royal Golden Jubilee Ph.D.
Program of Thailand Research Fund (K.K.), and German Research Foundation
(Deutsche Forschungsgemeinschaft) grant Ji 145/1-1 (N.J.).
NR 50
TC 36
Z9 38
U1 0
U2 8
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD AUG
PY 2012
VL 86
IS 16
BP 8581
EP 8591
DI 10.1128/JVI.00533-12
PG 11
WC Virology
SC Virology
GA 984NS
UT WOS:000307198300024
PM 22674974
ER
PT J
AU Chavarri-Guerra, Y
Villarreal-Garza, C
Liedke, PER
Knaul, F
Mohar, A
Finkelstein, DM
Goss, PE
AF Chavarri-Guerra, Yanin
Villarreal-Garza, Cynthia
Liedke, Pedro E. R.
Knaul, Felicia
Mohar, Alejandro
Finkelstein, Dianne M.
Goss, Paul E.
TI Breast cancer in Mexico: a growing challenge to health and the health
system
SO LANCET ONCOLOGY
LA English
DT Review
ID NEEDLE-ASPIRATION-CYTOLOGY; LATIN-AMERICA; UNITED-STATES; CONSERVING
THERAPY; CERVICAL-CANCER; WOMEN; DIAGNOSIS; COUNTRIES; RISK; MORTALITY
AB Breast cancer is a major public health issue in low-income and middle-income countries. In Mexico, incidence and mortality of breast cancer have risen in the past few decades. Changes in health-care policies in Mexico have incorporated programmes for access to early diagnosis and treatment of this disease. This Review outlines the status of breast cancer in Mexico, regarding demographics, access to care, and strategies to improve clinical outcomes. We identify factors that contribute to the existing disease burden, such as low mammography coverage, poor quality control, limited access to diagnosis and treatment, and insufficient physical and human resources for clinical care.
C1 [Goss, Paul E.] Massachusetts Gen Hosp, Ctr Canc, Avon Int Breast Canc Res Program, Boston, MA 02114 USA.
[Chavarri-Guerra, Yanin] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Hematol Oncol Dept, Mexico City, DF, Mexico.
[Villarreal-Garza, Cynthia] Inst Nacl Cancerol, Breast Canc Dept, Mexico City, DF, Mexico.
[Chavarri-Guerra, Yanin; Liedke, Pedro E. R.; Knaul, Felicia; Goss, Paul E.] Harvard Univ, Sch Med, Boston, MA USA.
[Knaul, Felicia] Harvard Global Equ Initiat, Boston, MA USA.
[Knaul, Felicia] Mexican Hlth Fdn, Mexico City, DF, Mexico.
[Knaul, Felicia] Tomatelo Pecho, Mexico City, DF, Mexico.
[Mohar, Alejandro] Univ Nacl Autonoma Mexico, Unidad Invest Biomed Canc, Mexico City 04510, DF, Mexico.
RP Goss, PE (reprint author), Massachusetts Gen Hosp, Ctr Canc, Avon Int Breast Canc Res Program, Boston, MA 02114 USA.
EM pgoss@partners.org
FU GlaxoSmithKline; National Council of Science and Technology (CONACYT)
[85055]
FX FK is the wife of Julio Frenk, former Secretary of Health of Mexico;
participated in the design and research of Seguro Popular; and is a
co-investigator in a study funded by GlaxoSmithKline. All other authors
declare that they have no conflicts of interest.; PEG, DMF, PERL, and
YC-G thank the Avon Foundation New York. We thank the National Council
of Science and Technology (CONACYT) for their finacial support to
breast-cancer research (grant number 85055, Sector Research Fund for
Education), and Gustavo Nigenda and Hector Arreola for reviewing the
manuscript.
NR 74
TC 41
Z9 43
U1 2
U2 36
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1470-2045
J9 LANCET ONCOL
JI Lancet Oncol.
PD AUG
PY 2012
VL 13
IS 8
BP E335
EP E343
PG 9
WC Oncology
SC Oncology
GA 981MU
UT WOS:000306973200020
PM 22846838
ER
PT J
AU Sugarbaker, PH
Ryan, DP
AF Sugarbaker, Paul H.
Ryan, David P.
TI Cytoreductive surgery plus hyperthermic perioperative chemotherapy to
treat peritoneal metastases from colorectal cancer: standard of care or
an experimental approach?
SO LANCET ONCOLOGY
LA English
DT Article
ID INTRAPERITONEAL CHEMOTHERAPY; SYSTEMIC CHEMOTHERAPY; OVARIAN-CANCER;
HEPATIC RESECTION; RANDOMIZED-TRIAL; CARCINOMATOSIS; SURVIVAL;
FLUOROURACIL; OXALIPLATIN; LEUCOVORIN
AB Peritoneal carcinomatosis is a common presentation in patients with metastatic colorectal cancer and the overall survival is poor. In most patients, the disease remains limited to the peritoneal cavity. Therefore, investigators have applied cytoreductive surgery and hyperthermic perioperative chemotherapy as the standard approach for selected patients with peritoneal metastases from colorectal cancer. Overall, very promising long-term survival has been shown in a subset of patients with a limited extent of peritoneal disease before treatment. Whether randomised, controlled trials are needed to definitively show the magnitude of benefit, if any, of this approach is an important question. This Debate outlines the arguments on each side of this issue.
C1 [Sugarbaker, Paul H.] Washington Canc Inst, Washington, DC USA.
[Ryan, David P.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
[Ryan, David P.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
RP Sugarbaker, PH (reprint author), Washington Canc Inst, Washington, DC USA.
EM paul.sugarbaker@Medstar.net; dpryan@partners.org
NR 44
TC 35
Z9 35
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1470-2045
J9 LANCET ONCOL
JI Lancet Oncol.
PD AUG
PY 2012
VL 13
IS 8
BP E362
EP E369
PG 8
WC Oncology
SC Oncology
GA 981MU
UT WOS:000306973200023
PM 22846841
ER
PT J
AU Zhou, XH
Ma, YB
AF Zhou XiaoHua
Ma YunBei
TI BATE curve in assessment of clinical utility of predictive biomarkers
SO SCIENCE CHINA-MATHEMATICS
LA English
DT Article
DE predictive biomarker; cutoff points; interaction; BATE curve;
time-to-event outcome
ID CONFIDENCE BANDS; TRIAL DESIGNS; SURVIVAL-DATA; COX MODEL; REGRESSION;
VALIDATION; SUBSETS
AB In this paper, for time-to-event data, we propose a new statistical framework for casual inference in evaluating clinical utility of predictive biomarkers and in selecting an optimal treatment for a particular patient. This new casual framework is based on a new concept, called Biomarker Adjusted Treatment Effect (BATE) curve. The BATE curve can be used for assessing clinical utility of a predictive biomarker, for designing a subsequent confirmation trial, and for guiding clinical practice. We then propose semi-parametric methods for estimating the BATE curves of biomarkers and establish asymptotic results of the proposed estimators for the BATE curves. We also conduct extensive simulation studies to evaluate finite-sample properties of the proposed estimation methods. Finally, we illustrate the application of the proposed method in a real-world data set.
C1 [Zhou XiaoHua] VA Puget Sound Hlth Care Syst, NW HSR&D Ctr Excellence, Seattle, WA 98198 USA.
[Zhou XiaoHua] Univ Washington, Dept Biostat, Seattle, WA 98198 USA.
[Zhou XiaoHua] Peking Univ, Beijing Int Ctr Math Res, Beijing 100871, Peoples R China.
[Ma YunBei] Princeton Univ, Dept Operat Res & Financial Engn, Princeton, NJ 08540 USA.
[Ma YunBei] SW Univ Finance & Econ, Sch Stat, Chengdu 611130, Peoples R China.
RP Zhou, XH (reprint author), VA Puget Sound Hlth Care Syst, NW HSR&D Ctr Excellence, Seattle, WA 98198 USA.
EM azhou@u.washington.edu; jamie82.ma@gmail.com
FU Department of Veterans Affairs Medical Center, Seattle, WA; Department
of Veterans Affairs, Veterans Health Administration, Health Services
Research and Development Service [XVA 61-036]; [RCS OS-196]
FX This work was supported by a Core Investigator, Research Career
Scientist (Grant No. RCS OS-196), Biostatistics Unit Director at the
Northwest HSR&D Center of Excellence, Department of Veterans Affairs
Medical Center, Seattle, WA and Department of Veterans Affairs, Veterans
Health Administration, Health Services Research and Development Service,
project (Grant No. XVA 61-036). The views expressed in this article are
those of the authors, and do not necessarily represent the views of the
Department of Veterans Affairs. The authors are grateful to Dr. Yi Li
for the data analyzed in the paper. We would also like to thank an
associated editor and two reviewers for their valuable comments and
suggestions, which have helped us to improve the paper.
NR 19
TC 1
Z9 1
U1 2
U2 9
PU SCIENCE PRESS
PI BEIJING
PA 16 DONGHUANGCHENGGEN NORTH ST, BEIJING 100717, PEOPLES R CHINA
SN 1674-7283
J9 SCI CHINA MATH
JI Sci. China-Math.
PD AUG
PY 2012
VL 55
IS 8
BP 1529
EP 1552
DI 10.1007/s11425-012-4473-0
PG 24
WC Mathematics, Applied; Mathematics
SC Mathematics
GA 985OX
UT WOS:000307277600002
ER
PT J
AU Souza, D
Ledbetter, S
AF Souza, Daniel
Ledbetter, Stephen
TI Diagnostic Errors in the Evaluation of Nontraumatic Aortic Emergencies
SO SEMINARS IN ULTRASOUND CT AND MRI
LA English
DT Article
ID MULTIDETECTOR-ROW CT; INTRAMURAL HEMATOMA; IMPENDING RUPTURE;
DISTINGUISH TRUE; THORACIC AORTA; FALSE LUMEN; SPIRAL CT; DISSECTION;
ANGIOGRAPHY; ANEURYSMS
AB Nontraumatic aortic emergencies (NTAE) are a complex and dynamic group of serious, potentially fatal conditions affecting the aorta. These entities most often present in the emergency department setting, and include aortic dissection, intramural hematoma, penetrating atherosclerotic ulcer, as well as aortic rupture and impending rupture. The radiologist plays a critical role in prompt diagnosis and evaluation since presenting signs and symptoms are often nonspecific. This article focuses on the potential sources of error in the imaging evaluation of patients presenting with NTAE. Semin Ultrasound CT MRI 33:318-336 (c) 2012 Elsevier Inc. All rights reserved.
C1 [Ledbetter, Stephen] Harvard Univ, Sch Med, Faulkner Hosp Brigham & Womens Hlth Care, Boston, MA 02115 USA.
[Ledbetter, Stephen] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA.
[Souza, Daniel] Harvard Univ, Sch Med, Brigham & Womens Hosp, Boston, MA USA.
RP Souza, D (reprint author), Harvard Univ, Sch Med, Brigham & Womens Hosp & Canc Imaging, Dana Farber Canc Inst, 75 Francis St, Boston, MA 02115 USA.
EM dasouza@partners.org
NR 40
TC 3
Z9 3
U1 0
U2 1
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0887-2171
J9 SEMIN ULTRASOUND CT
JI Semin. Ultrasound CT MRI
PD AUG
PY 2012
VL 33
IS 4
BP 318
EP 336
DI 10.1053/j.sult.2012.02.001
PG 19
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 983ZS
UT WOS:000307157800007
PM 22824122
ER
PT J
AU Khan, MAS
Farkhondeh, M
Crombie, J
Jacobson, L
Kaneki, M
Martyn, JAJ
AF Khan, Mohammed Abdul Sattar
Farkhondeh, Mina
Crombie, Jennifer
Jacobson, Leslie
Kaneki, Masao
Martyn, J. A. Jeevendra
TI LIPOPOLYSACCHARIDE UPREGULATES alpha 7 ACETYLCHOLINE RECEPTORS:
STIMULATION WITH GTS-21 MITIGATES GROWTH ARREST OF MACROPHAGES AND
IMPROVES SURVIVAL IN BURNED MICE
SO SHOCK
LA English
DT Article
DE alpha 7 acetylcholine receptor agonist; alpha 7 acetylcholine receptor
antagonists; alpha-bungarotoxin; tumor necrosis factor alpha;
upregulation; vecuronium
ID TUMOR-NECROSIS-FACTOR; CHOLINERGIC ANTIINFLAMMATORY PATHWAY;
SKELETAL-MUSCLE; AGONIST; INJURY; INFLAMMATION; EXPRESSION; SEPSIS;
TARGET; TISSUE
AB Nicotinic stimulation of the alpha 7 acetylcholine receptors (alpha 7AChRs) mitigates the lipopolysaccharide (LPS)-induced tumor necrosis factor alpha (TNF-alpha) and other cytokines release in macrophages. This effect is blocked by alpha 7AChR antagonist, alpha-bungarotoxin (BTX). We tested and confirmed the hypotheses that LPS upregulates alpha 7AChRs, and the prototypical alpha 7AChR antagonists, vecuronium and BTX, do not block the effects of GTS-21, a specific alpha 7AChR agonist, on TNF-alpha release. With the knockdown of alpha 7AChR expression by short interference RNA, GTS-21 effects on inhibition of TNF-alpha release were not demonstrable. In addition, GTS-21 mitigated the LPS-induced growth arrest of macrophages in vitro in J774A.1 cells and ex vivo in peritoneal macrophages obtained from mice at 3 days after burn. Moreover, GTS-21 reduced mortality after burn injury in mice. These results indicate that (i) LPS upregulates alpha 7AChRs; (ii) the therapeutic beneficial effects of GTS-21 on cytokine release are specifically mediated via alpha 7AChRs and are preserved even when cotreated with prototypical antagonist, BTX, or clinically used muscle nicotinic antagonist, vecuronium; (iii) activation of alpha 7AChRs by GTS-21 partially reverses the LPS-induced proliferation arrest; and (iv) GTS-21 reduces mortality in mice with burn injury. The in vivo beneficial effects of GTS-21 in burn injury warrant further studies.
C1 [Martyn, J. A. Jeevendra] Massachusetts Gen Hosp, Shriners Hosp Children, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA USA.
RP Martyn, JAJ (reprint author), Massachusetts Gen Hosp, Shriners Hosp Children, Dept Anesthesia Crit Care & Pain Med, 51 Blossom St,Room 206, Boston, MA 02114 USA.
EM jmartyn@partners.org
FU National Institutes of Health [RO1-055082, P50-2500]; Shriners Hospitals
for Children
FX This work was supported by grants from the National Institutes of Health
RO1-055082 and P50-2500 project IV and from Shriners Hospitals for
Children.
NR 29
TC 14
Z9 17
U1 1
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1073-2322
J9 SHOCK
JI Shock
PD AUG
PY 2012
VL 38
IS 2
BP 213
EP 219
DI 10.1097/SHK.0b013e31825d628c
PG 7
WC Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease
SC General & Internal Medicine; Hematology; Surgery; Cardiovascular System
& Cardiology
GA 977PO
UT WOS:000306677100014
PM 22683726
ER
PT J
AU Mejia, P
Davis, AE
AF Mejia, Pedro
Davis, Alvin E., III
TI C1 INHIBITOR SUPPRESSES THE ENDOTOXIC ACTIVITY OF A WIDE RANGE OF
LIPOPOLYSACCHARIDES AND INTERACTS WITH LIVE GRAM-NEGATIVE BACTERIA
SO SHOCK
LA English
DT Article
DE LPS neutralization; endotoxin shock protection; suppression of
inflammation; protein-bacteria interactions
ID N-LINKED GLYCOSYLATION; SALMONELLA-TYPHIMURIUM; MEDIATED PROTECTION;
SEPTIC SHOCK; SEPSIS; CORE; DEFECTS; MUTANT; LPS
AB Human C1 inhibitor (C1INH) prevents endotoxin shock via a direct interaction with Gram-negative bacterial lipopolysaccharide (LPS) and improves survival in animal models of sepsis. In this report, we further characterize the interaction of C1INH with LPS and whole live bacteria. We investigate C1INH interactions with LPS from five different strains of Gram-negative enteric bacteria known to participate in the pathogenesis of human sepsis. Treatment with C1INH improved survival in mice with endotoxin shock induced by LPS from Salmonella enterica serovar typhimurium as previously shown, as well as LPS from Escherichia coli O55:B5 and Pseudomonas aeruginosa, and a trend to improved survival was observed when Klebsiella pneumoniae and Serratia marcescens LPS were used. Enzyme-linked immunosorbent assay and native polyacrylamide gel electrophoresis shift experiments demonstrated a direct interaction of C1INH with LPS from all the strains studied. The binding of both native and reactive center-cleaved, inactive C1INH results in inhibition of LPS-induced proinflammatory cytokine production. Furthermore, we demonstrate the ability of C1INH to bind at the surface of only a restricted number of whole live Gram-negative bacteria as well as mutant bacteria expressing a truncated LPS lacking the O-antigen. These data reveal the interaction of C1INH with a wide range of enteric bacterial LPS and strongly suggest that the interaction between C1INH and the surface of Gram-negative microorganisms is determined by the length of the polysaccharide chain of the endotoxin molecule.
C1 [Mejia, Pedro; Davis, Alvin E., III] Harvard Univ, Sch Med, Immune Dis Inst, Program Cellular & Mol Med,Childrens Hosp Boston, Boston, MA 02115 USA.
RP Mejia, P (reprint author), Harvard Univ, Sch Publ Hlth, Dept Genet & Complex Dis, 665 Huntington Ave,Bldg 2,1st Floor,Room 127, Boston, MA 02115 USA.
EM pmejia@hsph.harvard.edu
NR 22
TC 6
Z9 6
U1 1
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1073-2322
J9 SHOCK
JI Shock
PD AUG
PY 2012
VL 38
IS 2
BP 220
EP 225
DI 10.1097/SHK.0b013e31825bf40e
PG 6
WC Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease
SC General & Internal Medicine; Hematology; Surgery; Cardiovascular System
& Cardiology
GA 977PO
UT WOS:000306677100015
PM 22576004
ER
PT J
AU Padmanabhan, S
Newton-Cheh, C
Dominiczak, AF
AF Padmanabhan, Sandosh
Newton-Cheh, Christopher
Dominiczak, Anna F.
TI Genetic basis of blood pressure and hypertension
SO TRENDS IN GENETICS
LA English
DT Review
DE hypertension; blood pressure; genetics; sodium; artery; kidney
ID GENOME-WIDE ASSOCIATION; COMMON VARIANTS; WILL UNLOCK; RISK LOCI;
EXPRESSION; DISEASE; POPULATION; HERITABILITY; METAANALYSIS; MUTATIONS
AB Blood pressure (BP) is a complex trait regulated by an intricate network of physiological pathways involving extracellular fluid volume homeostasis, cardiac contractility and vascular tone through renal, neural or endocrine systems. Untreated high BP, or hypertension (HTN), is associated with increased mortality, and thus a better understanding of the pathophysiological and genetic underpinnings of BP regulation will have a major impact on public health. However, identifying genes that contribute to BP and HTN has proved challenging. In this review we describe our current understanding of the genetic architecture of BP and HTN, which has accelerated over the past five years primarily owing to genome-wide association studies (GWAS) and the continuing progress in uncovering rare gene mutations, epigenetic markers and regulatory pathways involved in the physiology of BP. We also look ahead to future studies characterizing novel pathways that affect BP and HTN and discuss strategies for translating current findings to the clinic.
C1 [Padmanabhan, Sandosh; Dominiczak, Anna F.] Univ Glasgow, Coll Med Vet & Life Sci, Inst Cardiovasc & Med Sci, Glasgow G12 8TA, Lanark, Scotland.
[Newton-Cheh, Christopher] Harvard Univ, Broad Inst, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA.
[Newton-Cheh, Christopher] MIT, Boston, MA 02114 USA.
RP Dominiczak, AF (reprint author), Univ Glasgow, Coll Med Vet & Life Sci, Inst Cardiovasc & Med Sci, Glasgow G12 8TA, Lanark, Scotland.
EM Anna.Dominiczak@glasgow.ac.uk
RI Padmanabhan, Sandosh/S-3963-2016;
OI Padmanabhan, Sandosh/0000-0003-3869-5808
NR 69
TC 53
Z9 57
U1 3
U2 32
PU ELSEVIER SCIENCE LONDON
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0168-9525
J9 TRENDS GENET
JI Trends Genet.
PD AUG
PY 2012
VL 28
IS 8
BP 397
EP 408
DI 10.1016/j.tig.2012.04.001
PG 12
WC Genetics & Heredity
SC Genetics & Heredity
GA 983ZR
UT WOS:000307157700006
PM 22622230
ER
PT J
AU Ebrahimi-Fakhari, D
Wahlster, L
McLean, PJ
AF Ebrahimi-Fakhari, Darius
Wahlster, Lara
McLean, Pamela J.
TI Protein degradation pathways in Parkinson's disease: curse or blessing
SO ACTA NEUROPATHOLOGICA
LA English
DT Review
DE Parkinson's disease; Neurodegeneration; alpha-Synuclein; Autophagy;
Lysosome; Ubiquitin-proteasome system; Molecular chaperones
ID CHAPERONE-MEDIATED AUTOPHAGY; LEWY BODY DISEASE; UBIQUITIN-PROTEASOME
SYSTEM; ALPHA-SYNUCLEIN AGGREGATION; APOPTOTIC CELL-DEATH;
NIGRA-PARS-COMPACTA; REPEAT KINASE 2; IN-VIVO MODELS;
HUNTINGTONS-DISEASE; SUBSTANTIA-NIGRA
AB Protein misfolding, aggregation and deposition are common disease mechanisms in many neurodegenerative diseases including Parkinson's disease (PD). Accumulation of damaged or abnormally modified proteins may lead to perturbed cellular function and eventually to cell death. Thus, neurons rely on elaborated pathways of protein quality control and removal to maintain intracellular protein homeostasis. Molecular chaperones, the ubiquitin-proteasome system (UPS) and the autophagy-lysosomal pathway (ALP) are critical pathways that mediate the refolding or removal of abnormal proteins. The successive failure of these protein degradation pathways, as a cause or consequence of early pathological alterations in vulnerable neurons at risk, may present a key step in the pathological cascade that leads to spreading neurodegeneration. A growing number of studies in disease models and patients have implicated dysfunction of the UPS and ALP in the pathogenesis of Parkinson's disease and related disorders. Deciphering the exact mechanism by which the different proteolytic systems contribute to the elimination of pathogenic proteins, like alpha-synuclein, is therefore of paramount importance. We herein review the role of protein degradation pathways in Parkinson's disease and elaborate on the different contributions of the UPS and the ALP to the clearance of altered proteins. We examine the interplay between different degradation pathways and provide a model for the role of the UPS and ALP in the evolution and progression of alpha-synuclein pathology. With regards to exciting recent studies we also discuss the putative potential of using protein degradation pathways as novel therapeutic targets in Parkinson's disease.
C1 [Ebrahimi-Fakhari, Darius; Wahlster, Lara; McLean, Pamela J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, MassGen Inst Neurodegenerat Dis,Dept Neurol, Charlestown, MA 02129 USA.
[Ebrahimi-Fakhari, Darius] Univ Heidelberg, Inst Anat & Cell Biol, D-69120 Heidelberg, Germany.
[Wahlster, Lara] Univ Heidelberg, Inst Physiol & Pathophysiol, D-69120 Heidelberg, Germany.
[McLean, Pamela J.] Mayo Clin Florida, Dept Neurosci, Jacksonville, FL 32224 USA.
RP McLean, PJ (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, MassGen Inst Neurodegenerat Dis,Dept Neurol, 114 16th St, Charlestown, MA 02129 USA.
EM ebrahimi@stud.uni-heidelberg.de; wahlster@stud.uni-heidelberg.de;
mclean.pamela@mayo.edu
OI Ebrahimi-Fakhari, Darius/0000-0002-0026-4714
FU NIH [NS063963, NS073740]; German National Academic Foundation
(Studienstiftung des deutschen Volkes); Hamburg Foundation for
International Research and Studies; Parkinson's Disease Foundation
FX We thank the peer reviewers for their valuable and thoughtful comments,
which have led to a substantial improvement of the manuscript. This work
was supported by NIH NS063963 and NS073740 (P.J.M.), the German National
Academic Foundation (Studienstiftung des deutschen Volkes to D.E.-F. and
L. W.), the Hamburg Foundation for International Research and Studies
(D.E.-F.) and the Parkinson's Disease Foundation (D.E-F.).
NR 180
TC 81
Z9 84
U1 2
U2 36
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0001-6322
J9 ACTA NEUROPATHOL
JI Acta Neuropathol.
PD AUG
PY 2012
VL 124
IS 2
BP 153
EP 172
DI 10.1007/s00401-012-1004-6
PG 20
WC Clinical Neurology; Neurosciences; Pathology
SC Neurosciences & Neurology; Pathology
GA 976LQ
UT WOS:000306586600001
PM 22744791
ER
PT J
AU Kim, LA
D'Amore, PA
AF Kim, Leo A.
D'Amore, Patricia A.
TI A Brief History of Anti-VEGF for the Treatment of Ocular Angiogenesis
SO AMERICAN JOURNAL OF PATHOLOGY
LA English
DT Editorial Material
ID ENDOTHELIAL GROWTH-FACTOR; METASTATIC COLORECTAL-CANCER;
VASCULAR-PERMEABILITY FACTOR; RETINAL-PIGMENT EPITHELIUM; DIABETIC
MACULAR EDEMA; IRIS NEOVASCULARIZATION; ISCHEMIC RETINOPATHY; TUMOR
ANGIOGENESIS; RANDOMIZED-TRIAL; NONHUMAN PRIMATE
AB In 1994, The American Journal of Pathology published a key article reporting that hypoxic retina produces vascular endothelial growth factor (VEGF), suggesting a role for VEGF in ocular neovascularization. Subsequent developments in anti-VEGF treatment for neovascular eye disease have improved visual outcomes and changed the standard of care in retinal medicine and ophthalmology. (Am J Pathol 2012, 181: 376-379; http://dx.doi.org/10.1016/j.ajpath.2012.06.006)
C1 [Kim, Leo A.; D'Amore, Patricia A.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Schepens Eye Res Inst,Dept Ophthalmol, Boston, MA 02114 USA.
RP D'Amore, PA (reprint author), Schepens Eye Inst, 20 Staniford St, Boston, MA 02114 USA.
EM patricia.damore@schepens.harvard.edu
FU NEI NIH HHS [R01 EY015435, EY05318, K12-EY16335, R01 EY005318, K12
EY016335, EY015435]
NR 40
TC 30
Z9 30
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9440
J9 AM J PATHOL
JI Am. J. Pathol.
PD AUG
PY 2012
VL 181
IS 2
BP 376
EP 379
DI 10.1016/j.ajpath.2012.06.006
PG 4
WC Pathology
SC Pathology
GA 983TO
UT WOS:000307141800001
PM 22749677
ER
PT J
AU Vinjamoori, AH
Jagannathan, JP
Shinagare, AB
Taplin, ME
Oh, WK
Van den Abbeele, AD
Ramaiya, NH
AF Vinjamoori, Anant H.
Jagannathan, Jyothi P.
Shinagare, Atul B.
Taplin, Mary-Ellen
Oh, William K.
Van den Abbeele, Annick D.
Ramaiya, Nikhil H.
TI Atypical Metastases From Prostate Cancer: 10-Year Experience at a Single
Institution
SO AMERICAN JOURNAL OF ROENTGENOLOGY
LA English
DT Article
DE atypical metastatic sites; oncologic imaging; osseous metastases;
prostate cancer
ID RADICAL PROSTATECTOMY; UNITED-STATES; MORTALITY; PATTERNS; TRENDS;
RECURRENCE; CARCINOMA
AB OBJECTIVE. The purpose of the study was to retrospectively review the frequency, sites, and patterns of atypical metastases from prostate cancer and to determine whether any correlation exists between the atypical sites and biochemical or histologic variables.
MATERIALS AND METHODS. All available imaging studies of 620 consecutive patients with biopsy-proven prostate carcinoma seen at our institute between 1999 and 2009 were reviewed. Eighty-two patients (mean age, 72 years; age range, 58-87 years) with atypical sites of metastases were identified. Patients were separated into groups on the basis of the presence or absence of concurrent osseous metastasis and high or low Gleason grade, and metastatic patterns were compared using the Fisher exact test. The maximum prostate-specific antigen (PSA) level for each patient was recorded and correlated with metastatic pattern using the Mann-Whitney test.
RESULTS. The most frequent sites of atypical metastases were the lungs and pleura (40%, 33/82), liver (37%, 30/82), supradiaphragmatic lymph nodes (34%, 28/82), and adrenal glands (15%, 12/82). Supradiaphragmatic lymphadenopathy was more common in patients with osseous metastases (45%, 25/56) than in patients without concurrent osseous involvement (12%, 3/26; p < 0.05). There was no significant correlation between the other atypical metastatic sites and osseous metastases. Abdominal visceral metastasis occurred more frequently in patients with a high Gleason grade (25/43, 58%) than in patients with a low Gleason grade (9/29, 31%; p < 0.05). There was no significant correlation between metastatic pattern and PSA level.
CONCLUSION. The lungs and pleura, liver, supradiaphragmatic lymph nodes, and adrenal glands are the most common extranodal metastatic sites of prostate cancer. Supradiaphragmatic lymphadenopathy was strongly associated with concurrent osseous metastases.
C1 [Vinjamoori, Anant H.; Jagannathan, Jyothi P.; Shinagare, Atul B.; Taplin, Mary-Ellen; Oh, William K.; Van den Abbeele, Annick D.; Ramaiya, Nikhil H.] Harvard Univ, Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Imaging,Med Sch, Boston, MA 02115 USA.
RP Shinagare, AB (reprint author), Harvard Univ, Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Imaging,Med Sch, 450 Brookline Ave, Boston, MA 02115 USA.
EM ashinagare@partners.org
RI Oh, William/B-9163-2012
OI Oh, William/0000-0001-5113-8147
NR 26
TC 17
Z9 18
U1 0
U2 1
PU AMER ROENTGEN RAY SOC
PI RESTON
PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA
SN 0361-803X
J9 AM J ROENTGENOL
JI Am. J. Roentgenol.
PD AUG
PY 2012
VL 199
IS 2
BP 367
EP 372
DI 10.2214/AJR.11.7533
PG 6
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 977SY
UT WOS:000306686200033
PM 22826398
ER
PT J
AU Bakri, A
Shinagare, AB
Krajewski, KM
Howard, SA
Jagannathan, JP
Hornick, JL
Ramaiya, NH
AF Bakri, Amit
Shinagare, Atul B.
Krajewski, Katherine M.
Howard, Stephanie A.
Jagannathan, Jyothi P.
Hornick, Jason L.
Ramaiya, Nikhil H.
TI Synovial Sarcoma: Imaging Features of Common and Uncommon Primary Sites,
Metastatic Patterns, and Treatment Response
SO AMERICAN JOURNAL OF ROENTGENOLOGY
LA English
DT Article
DE CT; MRI; PET/CT; synovial sarcoma
AB OBJECTIVE. The purpose of this review is to describe the imaging features, common and uncommon sites, metastatic pattern, and treatment response of synovial sarcoma.
CONCLUSION. Synovial sarcoma primarily occurs in young adults, most commonly in the lower extremities; presents as a large, noninfiltrative, well-circumscribed mass adjacent to joints, often with punctuate calcifications; and may exhibit a triple signal pattern on T2-weighted images. Small synovial sarcomas can mimic benign lesions. This tumor has a propensity for late local recurrence and metastasis, most commonly to lung.
C1 [Bakri, Amit; Shinagare, Atul B.; Krajewski, Katherine M.; Howard, Stephanie A.; Jagannathan, Jyothi P.; Ramaiya, Nikhil H.] Dana Farber Canc Inst, Dept Imaging, Boston, MA 02115 USA.
[Bakri, Amit] Brigham & Womens Hosp, Dept Radiol, Boston, MA 02115 USA.
[Hornick, Jason L.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA.
RP Shinagare, AB (reprint author), Dana Farber Canc Inst, Dept Imaging, 450 Brookline Ave, Boston, MA 02115 USA.
EM ashinagare@partners.org
NR 21
TC 14
Z9 18
U1 0
U2 3
PU AMER ROENTGEN RAY SOC
PI RESTON
PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA
SN 0361-803X
J9 AM J ROENTGENOL
JI Am. J. Roentgenol.
PD AUG
PY 2012
VL 199
IS 2
BP W208
EP W215
DI 10.2214/AJR.11.8039
PG 8
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 977SY
UT WOS:000306686200009
PM 22826423
ER
PT J
AU Kaewlai, R
Abujudeh, H
AF Kaewlai, Rathachai
Abujudeh, Hani
TI Peer Review in Clinical Radiology Practice
SO AMERICAN JOURNAL OF ROENTGENOLOGY
LA English
DT Review
DE peer review; performance evaluation; quality assurance
ID PERFORMANCE IMPROVEMENT; AMERICAN-COLLEGE; ASSOCIATION; STANDARDS
C1 [Abujudeh, Hani] Ramathibodi Hosp, Dept Radiol, Div Emergency Radiol, Bangkok, Thailand.
[Abujudeh, Hani] Mahidol Univ, Bangkok 10700, Thailand.
[Kaewlai, Rathachai] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
RP Abujudeh, H (reprint author), Ramathibodi Hosp, Dept Radiol, Div Emergency Radiol, Bangkok, Thailand.
EM habujudeh@partners.org
OI Kaewlai, Rathachai/0000-0002-0650-9380
NR 20
TC 10
Z9 10
U1 0
U2 0
PU AMER ROENTGEN RAY SOC
PI RESTON
PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA
SN 0361-803X
J9 AM J ROENTGENOL
JI Am. J. Roentgenol.
PD AUG
PY 2012
VL 199
IS 2
BP W158
EP W162
DI 10.2214/AJR.11.8143
PG 5
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 977SY
UT WOS:000306686200002
PM 22826416
ER
PT J
AU Zukotynski, K
Lewis, A
O'Regan, K
Jacene, H
Sakellis, C
Krajewski, K
Israel, D
AF Zukotynski, Katherine
Lewis, Aaron
O'Regan, Kevin
Jacene, Heather
Sakellis, Christopher
Krajewski, Katherine
Israel, David
TI PET/CT and Renal Pathology: A Blind Spot for Radiologists? Part 1,
Primary Pathology
SO AMERICAN JOURNAL OF ROENTGENOLOGY
LA English
DT Review
DE FDG PET/CT; oncology; renal pathology
ID CELL CARCINOMA; FDG PET/CT
AB OBJECTIVE. PET/CT with F-18-FDG shows metabolically active disease and is widely used for the diagnosis and follow-up of patients with cancer. Nonmetabolically active renal pathology may be missed without close attention to the CT portion of the study, whereas metabolically active pathology may be missed on PET because of physiologic tracer excretion in the kidneys. This article illustrates primary lesions of the kidney on FDG PET/CT with emphasis on key anatomic features and the appearance of tracer uptake.
CONCLUSION. Close attention to both the FDG PET and CT portions of the study is essential to interpret renal pathology correctly on FDG PET/CT examinations.
C1 [Zukotynski, Katherine; Lewis, Aaron; O'Regan, Kevin; Jacene, Heather; Sakellis, Christopher; Krajewski, Katherine; Israel, David] Harvard Univ, Sch Med, Dept Imaging, Dana Farber Canc Inst, Boston, MA 02115 USA.
RP Zukotynski, K (reprint author), Harvard Univ, Sch Med, Dept Imaging, Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02115 USA.
EM kzukotynski@partners.org
NR 15
TC 11
Z9 11
U1 0
U2 1
PU AMER ROENTGEN RAY SOC
PI RESTON
PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA
SN 0361-803X
J9 AM J ROENTGENOL
JI Am. J. Roentgenol.
PD AUG
PY 2012
VL 199
IS 2
BP W163
EP W167
DI 10.2214/AJR.11.7790
PG 5
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 977SY
UT WOS:000306686200003
PM 22826417
ER
PT J
AU Zukotynski, K
Lewis, A
O'Regan, K
Jacene, H
Sakellis, C
Almodovar, S
Israel, D
AF Zukotynski, Katherine
Lewis, Aaron
O'Regan, Kevin
Jacene, Heather
Sakellis, Christopher
Almodovar, Samuel
Israel, David
TI PET/CT and Renal Pathology: A Blind Spot for Radiologists? Part
2-Lymphoma, Leukemia, and Metastatic Disease
SO AMERICAN JOURNAL OF ROENTGENOLOGY
LA English
DT Review
DE FDG PET/CT; oncology; renal pathology
ID NON-HODGKINS-LYMPHOMA; FDG-PET; GRANULOCYTIC SARCOMA;
MALIGNANT-LYMPHOMA; CELL-CARCINOMA; CT; INVOLVEMENT; SPECTRUM; LESIONS;
KIDNEY
AB OBJECTIVE. PET/CT with F-18-FDG is a powerful tool to evaluate patients with hematologic malignancy or to assess the burden of metastatic disease from solid tumors. Metabolically active renal pathology associated with lymphoma, leukemia, or metastatic disease can be missed without close attention to both the PET and CT portions of the study because of physiologic FDG excretion in the kidneys. This article illustrates the appearance of tracer uptake and the key anatomic features of lymphoma, leukemia, and metastatic disease involving the kidney on FDG PET/CT.
CONCLUSION. Close attention to both the FDG PET and CT portions of an FDG PET/CT study is essential to evaluate the kidneys in oncology patients.
C1 [Zukotynski, Katherine; Lewis, Aaron; O'Regan, Kevin; Jacene, Heather; Sakellis, Christopher; Israel, David] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Imaging, Boston, MA 02115 USA.
[Almodovar, Samuel] Univ Alabama Birmingham, Dept Radiol, Birmingham, AL USA.
RP Zukotynski, K (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Imaging, 450 Brookline Ave, Boston, MA 02115 USA.
EM kzukotynski@partners.org
NR 28
TC 7
Z9 7
U1 0
U2 1
PU AMER ROENTGEN RAY SOC
PI RESTON
PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA
SN 0361-803X
J9 AM J ROENTGENOL
JI Am. J. Roentgenol.
PD AUG
PY 2012
VL 199
IS 2
BP W168
EP W174
DI 10.2214/AJR.11.7923
PG 7
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 977SY
UT WOS:000306686200004
PM 22826418
ER
PT J
AU Tan, KM
Shishkov, M
Chee, A
Applegate, MB
Bouma, BE
Suter, MJ
AF Tan, K. M.
Shishkov, M.
Chee, A.
Applegate, M. B.
Bouma, B. E.
Suter, M. J.
TI Flexible transbronchial optical frequency domain imaging smart needle
for biopsy guidance
SO BIOMEDICAL OPTICS EXPRESS
LA English
DT Article
ID COHERENCE TOMOGRAPHY; BRONCHIAL LESIONS; PROBE; BRONCHOSCOPY; DIAGNOSIS
AB Transbronchial needle aspiration (TBNA) is a procedure routinely performed to diagnose peripheral pulmonary lesions. However, TBNA is associated with a low diagnostic yield due to inappropriate needle placement. We have developed a flexible transbronchial optical frequency domain imaging (TB-OFDI) catheter that functions as a "smart needle" to confirm the needle placement within the target lesion prior to biopsy. The TB-OFDI smart needle consists of a flexible and removable OFDI catheter (430 mu m dia.) that operates within a standard 21-gauge TBNA needle. The OFDI imaging core is based on an angle polished ball lens design with a working distance of 160 mu m from the catheter sheath and a spot size of 25 mu m. To demonstrate the potential of the TB-OFDI smart needle for transbronchial imaging, an inflated excised swine lung was imaged through a standard bronchoscope. Cross-sectional and longitudinal OFDI results reveal the detailed network of alveoli in the lung parenchyma suggesting that the TB-OFDI smart needle may be a useful tool for guiding biopsy acquisition to increase the diagnostic yield. (C) 2012 Optical Society of America
C1 [Tan, K. M.; Chee, A.; Applegate, M. B.; Suter, M. J.] Massachusetts Gen Hosp, Dept Med, Pulm & Crit Care Unit, Boston, MA 02114 USA.
[Tan, K. M.; Shishkov, M.; Chee, A.; Applegate, M. B.; Bouma, B. E.; Suter, M. J.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
[Tan, K. M.; Shishkov, M.; Chee, A.; Bouma, B. E.; Suter, M. J.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
RP Tan, KM (reprint author), Massachusetts Gen Hosp, Dept Med, Pulm & Crit Care Unit, 40 Blossom St, Boston, MA 02114 USA.
EM bbouma@partners.org; msuter@partners.org
FU American Lung Association Biomedical Research Grant [RG-194681-N];
National Institutes of Health [R00CA134920, P41EB015903]
FX This work was funded in part by the American Lung Association Biomedical
Research Grant (RG-194681-N) and the National Institutes of Health
(R00CA134920 and P41EB015903).
NR 23
TC 17
Z9 17
U1 0
U2 6
PU OPTICAL SOC AMER
PI WASHINGTON
PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA
SN 2156-7085
J9 BIOMED OPT EXPRESS
JI Biomed. Opt. Express
PD AUG 1
PY 2012
VL 3
IS 8
BP 1947
EP 1954
PG 8
WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine &
Medical Imaging
SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine &
Medical Imaging
GA 983JY
UT WOS:000307116800016
PM 22876357
ER
PT J
AU Martelon, M
Wilens, TE
Anderson, JP
Morrison, NR
Wozniak, J
AF Martelon, MaryKate
Wilens, Timothy E.
Anderson, Jesse P.
Morrison, Nicholas R.
Wozniak, Janet
TI Are obstetrical, perinatal, and infantile difficulties associated with
pediatric bipolar disorder?
SO BIPOLAR DISORDERS
LA English
DT Article
DE bipolar disorder; obstetrical complications; perinatal
ID SUBSTANCE USE DISORDERS; MAJOR AFFECTIVE-DISORDERS; SPECTRUM DISORDERS;
COMPLICATIONS; CHILDREN; SCHIZOPHRENIA; ADOLESCENTS; RISK; INTERVIEW;
FAMILY
AB Martelon MK, Wilens TE, Anderson JP, Morrison NR, Wozniak J. Are obstetrical, perinatal, and infantile difficulties associated with pediatric bipolar disorder? Bipolar Disord 2012: 14: 507514. (c) 2012 The Authors. Journal compilation (c) 2012 John Wiley & Sons A/S. Objectives: Despite increasing acknowledgement of bipolar disorder (BD) in childhood, there is a paucity of literature that has investigated obstetrical, perinatal, and infantile difficulties and their potential link with BD. To this end, we examined difficulties during delivery, immediate post-birth, and infancy and the association with BD in childhood. Methods: From two similarly designed, ongoing, longitudinal, case-control family studies of pediatric BD (N = 327 families), we analyzed 338 children and adolescents [mean (+/- standard deviation) age: 12.00 +/- 3.37 years]. We stratified them into three groups: healthy controls (N = 98), BD probands (N = 120), and their non-affected siblings (N = 120). All families were comprehensively assessed with a structured psychiatric diagnostic interview for psychopathology and substance use. Mothers were directly questioned regarding the pregnancy, delivery, and infancy difficulties that occurred with each child using a module from the Diagnostic Interview for Children and Adolescents-Parent Version (DICA-P). Results: Mothers of BD subjects were more likely to report difficulties during infancy than mothers of controls [odds ratio (95% confidence interval) = 6.6 (3.0, 14.6)]. Specifically, children with BD were more likely to have been reported as a stiffened infant [7.2 (1.1, 47.1)] and more likely to have experienced other infantile difficulties [including acting colicky; 4.9 (1.3, 18.8)] compared to controls. We found no significant differences between groups in regards to obstetrical or perinatal difficulties (all p values > 0.05). Conclusions: While our results add to previous literature on obstetrical and perinatal difficulties and BD, they also highlight characteristics in infancy that may be prognostic indicators for pediatric BD.
C1 [Martelon, MaryKate; Wilens, Timothy E.; Anderson, Jesse P.; Morrison, Nicholas R.; Wozniak, Janet] Massachusetts Gen Hosp, Pediat Psychopharmacol Unit, Boston, MA 02114 USA.
RP Wilens, TE (reprint author), Massachusetts Gen Hosp, Pediat Psychopharmacol Unit, 55 Parkman St,YAW 6A, Boston, MA 02114 USA.
EM twilens@partners.org
FU NIH [RO1 DA12945, K24 DA016264, NIH R01 MH066237]; Abbott; AstraZeneca;
Eli Lilly Co.; McNeil; NextWave; NIH/NIDA; Novartis; Merck; Shire;
Boehringer-Ingelheim; Axon Labs; GlaxoSmithKline; UCB (Schwarz) Pharma;
Sanofi-aventis; Sepracor; Jazz Pharmaceuticals; Neurogen; Pfizer; Takeda
FX This study was supported by NIH RO1 DA12945 (TW), K24 DA016264 (TW), and
NIH R01 MH066237 (JW).; TEW receives or has received research support
from, has been a speaker for, or is or has been on the advisory boards
of Abbott, AstraZeneca, Eli Lilly & Co., McNeil, NextWave, NIH/NIDA,
Novartis, Merck, and Shire; and has published the book Straight Talk
about Psychiatric Medications for Kids with Guilford Press. JW is the
author of Is Your Child Bipolar?, published in May 2008 by Bantam Books;
and her spouse, John Winkelman, M.D., Ph.D., receives research support,
is a speaker for, or is on the advisory board of Boehringer-Ingelheim,
Axon Labs, GlaxoSmithKline, UCB (Schwarz) Pharma, Sanofi-aventis,
Sepracor, Jazz Pharmaceuticals, Novartis, Neurogen, Pfizer, and Takeda.
MKM, JPA, and NRM declare that they have no conflicts of interest to
report.
NR 41
TC 3
Z9 3
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1398-5647
J9 BIPOLAR DISORD
JI Bipolar Disord.
PD AUG
PY 2012
VL 14
IS 5
BP 507
EP 514
DI 10.1111/j.1399-5618.2012.01027.x
PG 8
WC Clinical Neurology; Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 979GI
UT WOS:000306805000006
PM 22642419
ER
PT J
AU McAdam, AJ
Hooper, DC
DeMaria, A
Limbago, BM
O'Brien, TF
McCaughey, B
AF McAdam, Alexander J.
Hooper, David C.
DeMaria, Alfred
Limbago, Brandi M.
O'Brien, Thomas F.
McCaughey, Betsy
TI Antibiotic Resistance: How Serious Is the Problem, and What Can Be Done?
SO CLINICAL CHEMISTRY
LA English
DT Editorial Material
C1 [McAdam, Alexander J.] Childrens Hosp, Dept Lab Med, Boston, MA 02115 USA.
[Hooper, David C.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.
[Hooper, David C.] Massachusetts Gen Hosp, Infect Control Unit, Boston, MA 02114 USA.
[DeMaria, Alfred] Massachusetts Dept Publ Hlth, Bur Infect Dis, Boston, MA USA.
[Limbago, Brandi M.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA USA.
[O'Brien, Thomas F.] Brigham & Womens Hosp, Div Infect Dis, Boston, MA 02115 USA.
[O'Brien, Thomas F.] Alliance Prudent Use Antibiot, Boston, MA USA.
[McCaughey, Betsy] Comm Reduce Infect Deaths RID, New York, NY USA.
RP McAdam, AJ (reprint author), Childrens Hosp, Dept Lab Med, 300 Longwood Ave, Boston, MA 02115 USA.
EM alexander.mcadam@childrens.harvard.edu
NR 0
TC 11
Z9 12
U1 0
U2 2
PU AMER ASSOC CLINICAL CHEMISTRY
PI WASHINGTON
PA 2101 L STREET NW, SUITE 202, WASHINGTON, DC 20037-1526 USA
SN 0009-9147
J9 CLIN CHEM
JI Clin. Chem.
PD AUG
PY 2012
VL 58
IS 8
BP 1182
EP 1186
DI 10.1373/clinchem.2011.181636
PG 5
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA 982JW
UT WOS:000307040300004
ER
PT J
AU Crepeau, R
Matar, A
Spitzer, TR
Robson, S
Pathiraja, V
Sachs, DH
Huang, CA
Duran-Struuck, R
AF Crepeau, Rebecca
Matar, Abraham
Spitzer, Thomas R.
Robson, Simon
Pathiraja, Vimukthi
Sachs, David H.
Huang, Christene A.
Duran-Struuck, Raimon
TI Edema and Tetraparesis in a Miniature Pig after Allogeneic Hematopoietic
Cell Transplantation
SO COMPARATIVE MEDICINE
LA English
DT Article
ID BONE-MARROW-TRANSPLANTATION; VERSUS-HOST-DISEASE; ESCHERICHIA-COLI;
LYMPHOPROLIFERATIVE DISEASE; SHIGA TOXIN; SWINE; INFECTION; DIARRHEA;
GENES; MODEL
AB A 3-mo-old, 12-kg, intact, miniature pig presented with severe neurologic signs on day 8 after hematopoietic cell transplantation. This pig had received an immunosuppressive regimen before transplantation that included an antiCD3 immunotoxin for T-cell depletion, 100 cGy of total-body irradiation, and cyclosporine for 45 d. The pig began exhibiting erythematous lesions on post-transplantation day 7. He also demonstrated increased conscious proprioceptive deficits and recumbency but normal mentation. Neurologic signs worsened over several days; the pig became lethargic but remained afebrile. Conjunctival swelling developed on posttransplantation day 9, which subsequently spread to the animal's head, ears and hocks by day 10. Analgesics were given for pain, and cyclosporine levels were decreased. Despite the measures taken, neurologic signs progressed. Given the worsening subcutaneous edema and neurologic status, Escherichia coli infection was suspected, and treatment with a third-generation cephalosporin was instituted. The clinical signs resolved within 12 h after the start of antibiotics. 'Shiga-like' toxin from E. coli can cause peracute toxemia and induce ataxia, paralysis, and recumbency. Other common and pathognomonic findings include periocular edema and variable edema in other subcutaneous regions. A fecal sample demonstrated an overgrowth of gram-negative, lactose-fermenting colonies. On the basis of the clinical presentation, exclusion of other potential conditions compatible with edema and neurologic diseases, physical exam findings, microbiology and the resolution of signs after therapy, the pig was diagnosed with edema disease.
C1 [Crepeau, Rebecca; Matar, Abraham; Spitzer, Thomas R.; Pathiraja, Vimukthi; Sachs, David H.; Huang, Christene A.; Duran-Struuck, Raimon] Massachusetts Gen Hosp, Transplantat Biol Res Ctr, Boston, MA 02114 USA.
[Robson, Simon] Beth Israel Deaconess Med Ctr Boston, Boston, MA USA.
RP Duran-Struuck, R (reprint author), Massachusetts Gen Hosp, Transplantat Biol Res Ctr, Boston, MA 02114 USA.
EM Raimon.Duran-Struuck@tbrc.mgh.harvard.edu
FU NIAID NIH HHS [R01 AI084657]
NR 36
TC 0
Z9 0
U1 1
U2 4
PU AMER ASSOC LABORATORY ANIMAL SCIENCE
PI MEMPHIS
PA 9190 CRESTWYN HILLS DR, MEMPHIS, TN 38125 USA
SN 1532-0820
J9 COMPARATIVE MED
JI Comparative Med.
PD AUG
PY 2012
VL 62
IS 4
BP 298
EP 302
PG 5
WC Veterinary Sciences; Zoology
SC Veterinary Sciences; Zoology
GA 983YP
UT WOS:000307154900009
PM 23043783
ER
PT J
AU Singh, JP
Mela, T
AF Singh, Jagmeet P.
Mela, Theofanie
TI Anatomical left ventricular lead location and clinical outcome: not a
one size fit all strategy
SO EUROPACE
LA English
DT Editorial Material
ID CARDIAC-RESYNCHRONIZATION THERAPY; HEART-FAILURE PATIENTS; ELECTRICAL
DELAY; PLACEMENT; SITE
C1 [Singh, Jagmeet P.; Mela, Theofanie] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cardiac Arrhythmia Serv,Heart Ctr, Boston, MA 02114 USA.
RP Singh, JP (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cardiac Arrhythmia Serv,Heart Ctr, Boston, MA 02114 USA.
EM jsingh@partners.org
NR 16
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1099-5129
J9 EUROPACE
JI Europace
PD AUG
PY 2012
VL 14
IS 8
BP 1076
EP 1078
DI 10.1093/europace/eus239
PG 3
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 980WU
UT WOS:000306925700003
PM 22832575
ER
PT J
AU Biteker, M
Ilhan, E
Biteker, G
Duman, D
Bozkurt, B
AF Biteker, Murat
Ilhan, Erkan
Biteker, Gul
Duman, Dursun
Bozkurt, Biykem
TI Delayed recovery in peripartum cardiomyopathy: an indication for
long-term follow-up and sustained therapy
SO EUROPEAN JOURNAL OF HEART FAILURE
LA English
DT Article
DE Peripartum cardiomyopathy; Late recovery; Treatment
ID ECHOCARDIOGRAPHY; RECOMMENDATIONS; PREDICTORS; PROGNOSIS; SOCIETY; HEART
AB Persistence of left ventricular (LV) systolic dysfunction after 6 months of diagnosis is believed to be a marker of an irreversible cardiomyopathy in peripartum cardiomyopathy (PPCM). We sought to determine the length of time required for recovery of LV systolic function (LVSF) in patients with PPCM.
Forty-two consecutive women with PPCM were enrolled in this prospective study. The minimum required time of follow-up for inclusion was 30 months. Each patient underwent transthoracic echocardiography, and plasma brain natriuretic peptide (BNP) and C-reactive protein measurement at admission, and every 3 months. Early recovery was defined as normalization of LVSF at 6 months post-diagnosis. Delayed recovery was defined if the length of time required for recovery of LVSF was longer than 6 months. Persistent left ventricular dysfunction (PLVD) was defined as an ejection fraction of 50 at the end of follow-up. Twenty patients (47.6) recovered completely, 10 died (23.8), and 12 (28.6) had PLVD. Average time to complete recovery was 19.3 months after initial diagnosis (342 months). Early recovery was observed only in six patients (30), whereas delayed recovery was observed in 14 out of 20 patients (70). Patients with complete recovery were more likely to have a higher LV ejection fraction and smaller LV end-systolic dimensions at baseline.
Full recovery of LVSF in PPCM patients often requires longer than 6 months.
C1 [Biteker, Murat; Duman, Dursun] Haydarpasa Numune Educ & Res Hosp, Dept Cardiol, Istanbul, Turkey.
[Ilhan, Erkan] Siyami Ersek Cardiovasc Surg Ctr, Dept Cardiol, Istanbul, Turkey.
[Biteker, Gul] Ortaca Yucelen Hosp, Dept Obstet & Gynecol, Istanbul, Turkey.
[Bozkurt, Biykem] Baylor Coll Med, Dept Med, Cardiol Sect, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
[Bozkurt, Biykem] Baylor Coll Med, Winters Ctr Heart Failure Res, Houston, TX 77030 USA.
RP Biteker, M (reprint author), 4-7 Cevizli Kartal, Istanbul, Turkey.
EM murbit2@yahoo.com
NR 19
TC 25
Z9 27
U1 0
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1388-9842
J9 EUR J HEART FAIL
JI Eur. J. Heart Fail.
PD AUG
PY 2012
VL 14
IS 8
BP 895
EP 901
DI 10.1093/eurjhf/hfs070
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 980WM
UT WOS:000306924900006
PM 22588321
ER
PT J
AU Costanzo, MR
Heywood, JT
Massie, BM
Iwashita, J
Henderson, L
Mamatsashvili, M
Sisakian, H
Hayrapetyan, H
Sager, P
van Veldhuisen, DJ
Albrecht, D
AF Costanzo, Maria Rosa
Heywood, J. Thomas
Massie, Barry M.
Iwashita, Julie
Henderson, Lee
Mamatsashvili, Merab
Sisakian, Hamayak
Hayrapetyan, Hamlet
Sager, Philip
van Veldhuisen, Dirk J.
Albrecht, Detlef
TI A double-blind, randomized, parallel, placebo-controlled study examining
the effect of cross-linked polyelectrolyte in heart failure patients
with chronic kidney disease
SO EUROPEAN JOURNAL OF HEART FAILURE
LA English
DT Article
DE Heart failure; Chronic kidney disease; Cross-linked polyelectrolyte;
Potassium
ID LEFT-VENTRICULAR DYSFUNCTION; EUROPEAN-SOCIETY; 6-MINUTE WALK;
MORTALITY; OUTCOMES; ADHERE; ASSOCIATION; CARDIOLOGY; MORBIDITY;
STATEMENT
AB This double-blind, randomized, parallel, placebo-controlled investigation evaluated the effects of cross-linked polyelectrolyte (CLP) on serum potassium and measures of congestion in patients with heart failure (HF) and chronic kidney disease (CKD).
The primary endpoint was change in serum potassium over time. Exploratory endpoints included: weight, physician and patient assessment of exertional dyspnoea, effect on N-terminal pro brain natriuretic peptide (NT-proBNP) levels, New York Heart Association (NYHA) classification, 6 min walk test (6MWT), and quality of life by Kansas City Cardiomyopathy Questionnaire (KCCQ). Serum potassium was similar in CLP (n 59) and placebo (n 52) groups throughout the 8-week study. Weight loss was greater in the CLP than in the placebo group at Weeks 1 (P 0.014) and 2 (P 0.004), and this trend continued until the end of the study. After 8 weeks, by physician assessment, the percentage of patients experiencing marked or disabling dyspnoea tended to be lower in the CLP than in the placebo group (7.3 vs. 23.9, P 0.128). Fewer patients in the CLP than in the placebo group had NT-proBNP levels 1000 pg/mL at Week 4 (P 0.039) and Week 8 (P 0.065). The proportion of patients improving by at least one NYHA functional class over the study was higher in the CLP than in the placebo group (48.8 vs. 17.4; P 0.002). Effects on 6MWT at Week 8 (p 0.072) and quality of life (overall KCCQ score) at Week 4 (p 0.005) and 8 (P 0.062) all favoured the CLP cohort. Four treatment-unrelated deaths occurred in the CLP group and none in the placebo group (P 0.056).
In advanced, symptomatic HF with CKD, CLP is associated with beneficial clinical effects without significant serum potassium changes.
Trial registration: NCT01265524.
C1 [Costanzo, Maria Rosa] Edward Heart Hosp, Midwest Heart Fdn, Naperville, IL 60566 USA.
[Heywood, J. Thomas] Scripps Clin, La Jolla, CA 92037 USA.
[Massie, Barry M.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Massie, Barry M.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Iwashita, Julie; Henderson, Lee; Albrecht, Detlef] Sorbent Therapeut Inc, Sunnyvale, CA USA.
[Mamatsashvili, Merab] Adapti Angiocardiol Clin, Tbilisi, Rep of Georgia.
[Sisakian, Hamayak] Yerevan State Med Univ, Yerevan, Armenia.
[Hayrapetyan, Hamlet] Erebouni Med Ctr, Yerevan, Armenia.
[Sager, Philip] Sager Consulting Experts Inc, San Francisco, CA USA.
[van Veldhuisen, Dirk J.] Univ Groningen, Univ Med Ctr Groningen, NL-9713 AV Groningen, Netherlands.
RP Costanzo, MR (reprint author), Edward Heart Hosp, Midwest Heart Fdn, POB 3226, Naperville, IL 60566 USA.
EM mariarosa.costanzo@advocatehealth.com
RI van Veldhuisen, Dirk Jan/E-8967-2014
FU Sorbent Therapeutics, Inc.
FX Sorbent Therapeutics, Inc.
NR 30
TC 11
Z9 11
U1 0
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1388-9842
J9 EUR J HEART FAIL
JI Eur. J. Heart Fail.
PD AUG
PY 2012
VL 14
IS 8
BP 922
EP 930
DI 10.1093/eurjhf/hfs074
PG 9
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 980WM
UT WOS:000306924900010
PM 22613585
ER
PT J
AU Ghio, S
Bonderman, D
Felix, SB
Ghofrani, HA
Michelakis, ED
Mitrovic, V
Oudiz, RJ
Frey, R
Roessig, L
Semigran, MJ
AF Ghio, Stefano
Bonderman, Diana
Felix, Stephan B.
Ghofrani, Hossein A.
Michelakis, Evangelos D.
Mitrovic, Veselin
Oudiz, Ronald J.
Frey, Reiner
Roessig, Lothar
Semigran, Marc J.
TI Left ventricular systolic dysfunction associated with pulmonary
hypertension riociguat trial (LEPHT): rationale and design
SO EUROPEAN JOURNAL OF HEART FAILURE
LA English
DT Article
DE Pulmonary hypertension; Systolic heart failure; Clinical trial; Soluble
guanylate cyclase stimulator; Riociguat
ID CHRONIC HEART-FAILURE; SOLUBLE GUANYLATE-CYCLASE; ARTERIAL-HYPERTENSION;
MEDIATED VASODILATION; DIAGNOSIS; CARDIOMYOPATHY; ENDOTHELIUM;
GUIDELINES; PRESSURE; SURVIVAL
AB Pulmonary hypertension (PH) due to systolic left ventricular dysfunction (PH-sLVD) frequently complicates heart failure (HF), and greatly worsens the prognosis of patients with sLVD, but as yet has no approved treatment. The LEPHT study aims to characterize the haemodynamic profile, safety, tolerability, and pharmacokinetic profile of riociguat (BAY 63-2521), an oral stimulator of soluble guanylate cyclase, in patients with PH-sLVD.
This 16-week, phase IIb, randomized, placebo-controlled, double-blind study enrols patients with PH-sLVD, defined as left ventricular ejection fraction (LVEF) 40 and mean pulmonary arterial pressure (PAP(mean)) epsilon 25 mmHg at rest. Patients using optimized HF medication will receive placebo or riociguat 0.5 mg, 1 mg, or up to 2 mg three times daily. The dose will be titrated for 8 weeks, based on systolic blood pressure and well-being, followed by 8 weeks of treatment at a stable dose. The primary efficacy variable is PAP(mean), while secondary efficacy endpoints include LVEF, exercise capacity, quality of life, and other haemodynamic and echocardiographic measurements. Safety and pharmacokinetics will also be assessed. After the 16-week study, patients will have the opportunity to be treated with riociguat in a long-term extension phase.
The LEPHT study will provide valuable information on the haemodynamic, echocardiographic, and preliminary clinical effects of riociguat in patients with PH-sLVD.
NCT01065454.
C1 [Semigran, Marc J.] Massachusetts Gen Hosp, Dept Med, Div Cardiol, Boston, MA 02114 USA.
[Ghio, Stefano] Univ Hosp, Fdn IRCCS Policlin San Matteo, Dept Cardiol, Pavia, Italy.
[Bonderman, Diana] Med Univ Vienna, Dept Internal Med 2, Vienna, Austria.
[Felix, Stephan B.] Ernst Moritz Arndt Univ Greifswald, Univ Med, Dept Cardiol & Internal Med B, D-17487 Greifswald, Germany.
[Ghofrani, Hossein A.] Univ Giessen, Univ Hosp Giessen & Marburg GmbH, D-35390 Giessen, Germany.
[Michelakis, Evangelos D.] Univ Alberta, Dept Med, Edmonton, AB, Canada.
[Mitrovic, Veselin] Kerckhoff Klin Forsch Gesell mbH, Bad Nauheim, Germany.
[Oudiz, Ronald J.] Harbor UCLA Med Ctr, Torrance, CA 90509 USA.
[Frey, Reiner] Bayer Pharma AG Berlin, Clin Pharmacol, Berlin, Germany.
[Roessig, Lothar] Bayer Pharma AG Berlin, Global Clin Dev, Berlin, Germany.
[Semigran, Marc J.] Harvard Univ, Sch Med, Boston, MA USA.
RP Semigran, MJ (reprint author), Massachusetts Gen Hosp, Dept Med, Div Cardiol, Boston, MA 02114 USA.
EM msemigran@partners.org
FU Bayer; Actelion; Gilead; Medtronic; Novartis; Pfizer; United
Therapeutics
FX The LEPHT study is funded by Bayer.; G. and S. B. F. have received
lecture honoraria from Bayer, Actelion, and Pfizer. H. A. G. has
received honoraria for consultations and lecturing from Bayer, Actelion,
Encysive, Pfizer, Ergonex, Lilly, and Novartis, and is also a member of
advisory boards for GSK, Lilly, and Merck. V. M. has received research
grants from Bayer and consults for CardioPep and Daiichi-Sankyo. R.J.O.
has received speaker, consulting, and/or research support from Actelion,
Bayer, Gilead, Medtronic, Novartis, Pfizer, and United Therapeutics. E.
D. M. has received consultant honoraria from Merck, Bayer, and United
Therapeutics. R. F. and L. R. are full-time employees of Bayer. D. B.
and M.J.S. have received research support from Bayer.
NR 35
TC 15
Z9 16
U1 0
U2 6
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1388-9842
J9 EUR J HEART FAIL
JI Eur. J. Heart Fail.
PD AUG
PY 2012
VL 14
IS 8
BP 946
EP 953
DI 10.1093/eurjhf/hfs071
PG 8
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 980WM
UT WOS:000306924900013
PM 22719060
ER
PT J
AU Carroll, K
Dovey, M
Cutting, C
Gorelick, D
Harris, J
Sheward, L
Halpern, M
Goessling, W
North, T
AF Carroll, Kelli
Dovey, Michael
Cutting, Claire
Gorelick, Daniel
Harris, James
Sheward, Lea
Halpern, Marnie
Goessling, Wolfram
North, Trista
TI EXPOSURE TO EXOGENOUS ESTROGENS IMPAIRS FORMATION OF THE HEMATOPOIETIC
NICHE IN EMBRYONIC ZEBRAFISH VIA INHIBITION OF NOTCH SIGNALING
SO EXPERIMENTAL HEMATOLOGY
LA English
DT Meeting Abstract
CT ISEH 41st Annual Scientific Meeting of the
Society-for-Hematology-and-Stem-Cells
CY AUG 23-26, 2012
CL Amsterdam, NETHERLANDS
SP Soc Hematol Stem Cells, Novartis Oncol, Johnson & Johnshon, Jansen Pharmaceut Co, Celgene, Beckman Coulter, Sanquin Blood Supply, MPN Stichting, CellGenix, Life Technol, Miltenyi Biotec, Primorigen Biosci, Inc, STEMCELL Technol
C1 [Carroll, Kelli; Dovey, Michael; Harris, James; Sheward, Lea; North, Trista] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
[Cutting, Claire; Goessling, Wolfram] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Goessling, Wolfram] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Goessling, Wolfram] Harvard Univ, Sch Med, Boston, MA USA.
[Gorelick, Daniel; Halpern, Marnie] Carnegie Inst Sci, Baltimore, MD USA.
[North, Trista] Harvard Stem Cell Inst, Cambridge, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0301-472X
J9 EXP HEMATOL
JI Exp. Hematol.
PD AUG
PY 2012
VL 40
IS 8
SU 1
BP S20
EP S21
PG 2
WC Hematology; Medicine, Research & Experimental
SC Hematology; Research & Experimental Medicine
GA 986CY
UT WOS:000307319600034
ER
PT J
AU Ernst, P
Mishra, B
Zaffuto, K
Li, B
Chen, YF
Myerson, M
Artinger, E
AF Ernst, Patricia
Mishra, Bibhu
Zaffuto, Kristin
Li, Bin
Chen, Yufei
Myerson, Matthew
Artinger, Erika
TI MLL1 IS A MASTER COORDINATOR OF HSC FATE, PROLIFERATION, AND
SELF-RENEWAL
SO EXPERIMENTAL HEMATOLOGY
LA English
DT Meeting Abstract
CT ISEH 41st Annual Scientific Meeting of the
Society-for-Hematology-and-Stem-Cells
CY AUG 23-26, 2012
CL Amsterdam, NETHERLANDS
SP Soc Hematol Stem Cells, Novartis Oncol, Johnson & Johnshon, Jansen Pharmaceut Co, Celgene, Beckman Coulter, Sanquin Blood Supply, MPN Stichting, CellGenix, Life Technol, Miltenyi Biotec, Primorigen Biosci, Inc, STEMCELL Technol
C1 [Ernst, Patricia; Mishra, Bibhu; Zaffuto, Kristin; Li, Bin; Chen, Yufei; Artinger, Erika] Geisel Sch Med Dartmouth, Hanover, NH USA.
[Myerson, Matthew] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0301-472X
J9 EXP HEMATOL
JI Exp. Hematol.
PD AUG
PY 2012
VL 40
IS 8
SU 1
BP S12
EP S12
PG 1
WC Hematology; Medicine, Research & Experimental
SC Hematology; Research & Experimental Medicine
GA 986CY
UT WOS:000307319600019
ER
PT J
AU Esain, V
Sheward, L
Goessling, W
North, T
AF Esain, Virginie
Sheward, Lea
Goessling, Wolfram
North, Trista
TI REGULATION OF HEMATOPOIETIC STEM CELL FORMATION BY MEDIATORS OF
INFLAMMATION
SO EXPERIMENTAL HEMATOLOGY
LA English
DT Meeting Abstract
CT ISEH 41st Annual Scientific Meeting of the
Society-for-Hematology-and-Stem-Cells
CY AUG 23-26, 2012
CL Amsterdam, NETHERLANDS
SP Soc Hematol Stem Cells, Novartis Oncol, Johnson & Johnshon, Jansen Pharmaceut Co, Celgene, Beckman Coulter, Sanquin Blood Supply, MPN Stichting, CellGenix, Life Technol, Miltenyi Biotec, Primorigen Biosci, Inc, STEMCELL Technol
C1 [Esain, Virginie; Sheward, Lea; North, Trista] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
[Goessling, Wolfram] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Goessling, Wolfram] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Goessling, Wolfram; North, Trista] Harvard Univ, Sch Med, Boston, MA USA.
[North, Trista] Harvard Stem Cell Inst, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0301-472X
J9 EXP HEMATOL
JI Exp. Hematol.
PD AUG
PY 2012
VL 40
IS 8
SU 1
BP S11
EP S12
PG 2
WC Hematology; Medicine, Research & Experimental
SC Hematology; Research & Experimental Medicine
GA 986CY
UT WOS:000307319600018
ER
PT J
AU Etzrodt, M
Cortez-Retamozo, V
Pittet, M
AF Etzrodt, Martin
Cortez-Retamozo, Virna
Pittet, Mikael
TI EXTRA MEDULLARY ORIGIN OF TUMOR-ASSOCIATED MACROPHAGES
SO EXPERIMENTAL HEMATOLOGY
LA English
DT Meeting Abstract
CT ISEH 41st Annual Scientific Meeting of the
Society-for-Hematology-and-Stem-Cells
CY AUG 23-26, 2012
CL Amsterdam, NETHERLANDS
SP Soc Hematol Stem Cells, Novartis Oncol, Johnson & Johnshon, Jansen Pharmaceut Co, Celgene, Beckman Coulter, Sanquin Blood Supply, MPN Stichting, CellGenix, Life Technol, Miltenyi Biotec, Primorigen Biosci, Inc, STEMCELL Technol
C1 [Etzrodt, Martin; Cortez-Retamozo, Virna; Pittet, Mikael] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Syst Biol, Boston, MA USA.
RI Etzrodt, Martin/P-3325-2015
OI Etzrodt, Martin/0000-0003-1928-3904
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0301-472X
J9 EXP HEMATOL
JI Exp. Hematol.
PD AUG
PY 2012
VL 40
IS 8
SU 1
BP S126
EP S126
PG 1
WC Hematology; Medicine, Research & Experimental
SC Hematology; Research & Experimental Medicine
GA 986CY
UT WOS:000307319600196
ER
PT J
AU Etzrodt, M
Cortez-Retamozo, V
Baltimore, D
Weissleder, R
Pittet, M
AF Etzrodt, Martin
Cortez-Retamozo, Virna
Baltimore, David
Weissleder, Ralph
Pittet, Mikael
TI REGULATION OF THE LY-6CHI MONOCYTE RESPONSE BY MIR-146A
SO EXPERIMENTAL HEMATOLOGY
LA English
DT Meeting Abstract
CT ISEH 41st Annual Scientific Meeting of the
Society-for-Hematology-and-Stem-Cells
CY AUG 23-26, 2012
CL Amsterdam, NETHERLANDS
SP Soc Hematol Stem Cells, Novartis Oncol, Johnson & Johnshon, Jansen Pharmaceut Co, Celgene, Beckman Coulter, Sanquin Blood Supply, MPN Stichting, CellGenix, Life Technol, Miltenyi Biotec, Primorigen Biosci, Inc, STEMCELL Technol
C1 [Etzrodt, Martin; Cortez-Retamozo, Virna; Weissleder, Ralph; Pittet, Mikael] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Syst Biol, Boston, MA USA.
[Baltimore, David] CALTECH, Div Biol, Pasadena, CA 91125 USA.
RI Etzrodt, Martin/P-3325-2015
OI Etzrodt, Martin/0000-0003-1928-3904
NR 0
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0301-472X
J9 EXP HEMATOL
JI Exp. Hematol.
PD AUG
PY 2012
VL 40
IS 8
SU 1
BP S75
EP S75
PG 1
WC Hematology; Medicine, Research & Experimental
SC Hematology; Research & Experimental Medicine
GA 986CY
UT WOS:000307319600119
ER
PT J
AU Liddicoat, B
Hartner, J
Lu, J
Walkley, C
Orkin, S
AF Liddicoat, Brian
Hartner, Jochen
Lu, Jun
Walkley, Carl
Orkin, Stuart
TI ADAR1 IS ESSENTIAL FOR ERYTHROID DEVELOPMENT
SO EXPERIMENTAL HEMATOLOGY
LA English
DT Meeting Abstract
CT ISEH 41st Annual Scientific Meeting of the
Society-for-Hematology-and-Stem-Cells
CY AUG 23-26, 2012
CL Amsterdam, NETHERLANDS
SP Soc Hematol Stem Cells, Novartis Oncol, Johnson & Johnshon, Jansen Pharmaceut Co, Celgene, Beckman Coulter, Sanquin Blood Supply, MPN Stichting, CellGenix, Life Technol, Miltenyi Biotec, Primorigen Biosci, Inc, STEMCELL Technol
C1 [Liddicoat, Brian; Walkley, Carl] St Vincents Inst Med Res, Fitzroy, Vic 3065, Australia.
[Hartner, Jochen; Walkley, Carl; Orkin, Stuart] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA.
[Hartner, Jochen; Walkley, Carl] Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA.
[Orkin, Stuart] Howard Hughes Med Inst, Boston, MA 02115 USA.
[Orkin, Stuart] Harvard Stem Cell Inst, Boston, MA USA.
[Lu, Jun] Yale Univ, Yale Stem Cell Ctr, New Haven, CT USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0301-472X
J9 EXP HEMATOL
JI Exp. Hematol.
PD AUG
PY 2012
VL 40
IS 8
SU 1
BP S54
EP S54
PG 1
WC Hematology; Medicine, Research & Experimental
SC Hematology; Research & Experimental Medicine
GA 986CY
UT WOS:000307319600086
ER
PT J
AU Liddicoat, B
Hartner, J
Lu, J
Walkley, C
Orkin, S
AF Liddicoat, Brian
Hartner, Jochen
Lu, Jun
Walkley, Carl
Orkin, Stuart
TI ADAR1 IS ESSENTIAL FOR ERYTHROID DEVELOPMENT
SO EXPERIMENTAL HEMATOLOGY
LA English
DT Meeting Abstract
CT ISEH 41st Annual Scientific Meeting of the
Society-for-Hematology-and-Stem-Cells
CY AUG 23-26, 2012
CL Amsterdam, NETHERLANDS
SP Soc Hematol Stem Cells, Novartis Oncol, Johnson & Johnshon, Jansen Pharmaceut Co, Celgene, Beckman Coulter, Sanquin Blood Supply, MPN Stichting, CellGenix, Life Technol, Miltenyi Biotec, Primorigen Biosci, Inc, STEMCELL Technol
C1 [Liddicoat, Brian; Walkley, Carl] St Vincents Inst Med Res, Fitzroy, Vic 3065, Australia.
[Hartner, Jochen; Walkley, Carl; Orkin, Stuart] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA.
[Hartner, Jochen; Walkley, Carl] Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA.
[Orkin, Stuart] Howard Hughes Med Inst, Boston, MA 02115 USA.
[Orkin, Stuart] Harvard Stem Cell Inst, Boston, MA USA.
[Lu, Jun] Yale Univ, Yale Stem Cell Ctr, New Haven, CT USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0301-472X
J9 EXP HEMATOL
JI Exp. Hematol.
PD AUG
PY 2012
VL 40
IS 8
SU 1
BP S33
EP S34
PG 2
WC Hematology; Medicine, Research & Experimental
SC Hematology; Research & Experimental Medicine
GA 986CY
UT WOS:000307319600057
ER
PT J
AU Millerl, C
Serwold, T
Wagers, A
AF Millerl, Christine
Serwold, Thomas
Wagers, Amy
TI ERYTHROPOIETIC POTENTIAL OF IPS CELLS DERIVED FROM SWACHMAN-DIAMOND
SYNDROME
SO EXPERIMENTAL HEMATOLOGY
LA English
DT Meeting Abstract
CT ISEH 41st Annual Scientific Meeting of the
Society-for-Hematology-and-Stem-Cells
CY AUG 23-26, 2012
CL Amsterdam, NETHERLANDS
SP Soc Hematol Stem Cells, Novartis Oncol, Johnson & Johnshon, Jansen Pharmaceut Co, Celgene, Beckman Coulter, Sanquin Blood Supply, MPN Stichting, CellGenix, Life Technol, Miltenyi Biotec, Primorigen Biosci, Inc, STEMCELL Technol
C1 [Millerl, Christine; Serwold, Thomas; Wagers, Amy] Joslin Diabet Ctr, Boston, MA 02215 USA.
[Millerl, Christine; Wagers, Amy] Howard Hughes Med Inst, Cambridge, MA USA.
[Millerl, Christine; Wagers, Amy] Harvard Univ, Cambridge, MA 02138 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0301-472X
J9 EXP HEMATOL
JI Exp. Hematol.
PD AUG
PY 2012
VL 40
IS 8
SU 1
BP S54
EP S54
PG 1
WC Hematology; Medicine, Research & Experimental
SC Hematology; Research & Experimental Medicine
GA 986CY
UT WOS:000307319600087
ER
PT J
AU Nombela-Arrieta, C
Pivarnik, G
Winkel, B
Harley, B
Mahoney, J
Lu, JY
Protopopov, A
Silberstein, L
AF Nombela-Arrieta, Cesar
Pivarnik, Gegory
Winkel, Beatrice
Harley, Brendan
Mahoney, John
Lu, Jiayun
Protopopov, Alexei
Silberstein, Les
TI HYPOXIC HEMATOPOIETIC STEM AND PROGENITOR CELLS RESIDE IN STRUCTURALLY
DIVERSE PERIVASCULAR NICHES
SO EXPERIMENTAL HEMATOLOGY
LA English
DT Meeting Abstract
CT ISEH 41st Annual Scientific Meeting of the
Society-for-Hematology-and-Stem-Cells
CY AUG 23-26, 2012
CL Amsterdam, NETHERLANDS
SP Soc Hematol Stem Cells, Novartis Oncol, Johnson & Johnshon, Jansen Pharmaceut Co, Celgene, Beckman Coulter, Sanquin Blood Supply, MPN Stichting, CellGenix, Life Technol, Miltenyi Biotec, Primorigen Biosci, Inc, STEMCELL Technol
C1 [Nombela-Arrieta, Cesar; Pivarnik, Gegory; Winkel, Beatrice; Lu, Jiayun; Silberstein, Les] Childrens Hosp, Boston, MA 02115 USA.
[Harley, Brendan] Univ Illinois, Dept Chem & Biomol Engn, Champaign, IL 61820 USA.
[Mahoney, John; Protopopov, Alexei] Dana Farber Canc Ctr, Div Hematol Malignancies, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0301-472X
J9 EXP HEMATOL
JI Exp. Hematol.
PD AUG
PY 2012
VL 40
IS 8
SU 1
BP S48
EP S49
PG 2
WC Hematology; Medicine, Research & Experimental
SC Hematology; Research & Experimental Medicine
GA 986CY
UT WOS:000307319600080
ER
PT J
AU North, T
Harris, J
Harris, L
Frechette, G
Garnaas, M
Cox, A
Cortes, M
Carroll, K
Esain, V
Cutting, C
Paw, B
Vander Heiden, M
Goessling, W
AF North, Trista
Harris, James
Harris, Lauren
Frechette, Gregory
Garnaas, Maija
Cox, Andrew
Cortes, Mauricio
Carroll, Kelli
Esain, Virginie
Cutting, Claire
Paw, Barry
Vander Heiden, Mathew
Goessling, Wolfram
TI ENHANCED METABOLIC ACTIVITY IN RESPONSE TO GLYCEMIC STATE DETERMINES THE
TIMING AND MAGNITUDE OF HSC INDUCTION
SO EXPERIMENTAL HEMATOLOGY
LA English
DT Meeting Abstract
CT ISEH 41st Annual Scientific Meeting of the
Society-for-Hematology-and-Stem-Cells
CY AUG 23-26, 2012
CL Amsterdam, NETHERLANDS
SP Soc Hematol Stem Cells, Novartis Oncol, Johnson & Johnshon, Jansen Pharmaceut Co, Celgene, Beckman Coulter, Sanquin Blood Supply, MPN Stichting, CellGenix, Life Technol, Miltenyi Biotec, Primorigen Biosci, Inc, STEMCELL Technol
C1 [North, Trista; Harris, James; Harris, Lauren; Frechette, Gregory; Cortes, Mauricio; Carroll, Kelli; Esain, Virginie] Harvard Univ, Sch Med, Dept Pathol, BIDMC, Boston, MA 02115 USA.
[Garnaas, Maija; Cox, Andrew; Cutting, Claire; Paw, Barry; Goessling, Wolfram] Harvard Univ, Sch Med, Div Genet & Gastroenterol, Boston, MA USA.
[Vander Heiden, Mathew] MIT, Koch Inst, Cambridge, MA 02139 USA.
[North, Trista; Goessling, Wolfram] Harvard Stem Cell Inst, Cambridge, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0301-472X
J9 EXP HEMATOL
JI Exp. Hematol.
PD AUG
PY 2012
VL 40
IS 8
SU 1
BP S18
EP S18
PG 1
WC Hematology; Medicine, Research & Experimental
SC Hematology; Research & Experimental Medicine
GA 986CY
UT WOS:000307319600030
ER
PT J
AU Mack, JW
Smith, TJ
AF Mack, Jennifer W.
Smith, Thomas J.
TI Reasons Why Physicians Do Not Have Discussions About Poor Prognosis, Why
It Matters, and What Can Be Improved
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Editorial Material
ID STEM-CELL TRANSPLANTATION; ADVANCED CANCER; LUNG-CANCER; PALLIATIVE
CARE; PATIENT; HOPE; HOSPICE; COMMUNICATION; INFORMATION; SURVIVAL
C1 [Mack, Jennifer W.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Mack, Jennifer W.] Childrens Hosp, Boston, MA 02115 USA.
[Smith, Thomas J.] Johns Hopkins Med Inst, Baltimore, MD 21205 USA.
RP Mack, JW (reprint author), Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 32
TC 73
Z9 73
U1 1
U2 3
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD AUG 1
PY 2012
VL 30
IS 22
BP 2715
EP 2717
DI 10.1200/JCO.2012.42.4564
PG 3
WC Oncology
SC Oncology
GA 981FK
UT WOS:000306952100007
PM 22753911
ER
PT J
AU Mauguen, A
Le Pechoux, C
Saunders, MI
Schild, SE
Turrisi, AT
Baumann, M
Sause, WT
Ball, D
Belani, CP
Bonner, JA
Zajusz, A
Dahlberg, SE
Nankivell, M
Mandrekar, SJ
Paulus, R
Behrendt, K
Koch, R
Bishop, JF
Dische, S
Arriagada, R
De Ruysscher, D
Pignon, JP
AF Mauguen, Audrey
Le Pechoux, Cecile
Saunders, Michele I.
Schild, Steven E.
Turrisi, Andrew T.
Baumann, Michael
Sause, William T.
Ball, David
Belani, Chandra P.
Bonner, James A.
Zajusz, Aleksander
Dahlberg, Suzanne E.
Nankivell, Matthew
Mandrekar, Sumithra J.
Paulus, Rebecca
Behrendt, Katarzyna
Koch, Rainer
Bishop, James F.
Dische, Stanley
Arriagada, Rodrigo
De Ruysscher, Dirk
Pignon, Jean-Pierre
TI Hyperfractionated or Accelerated Radiotherapy in Lung Cancer: An
Individual Patient Data Meta-Analysis
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
ID PHASE-III TRIAL; COOPERATIVE-ONCOLOGY-GROUP; TWICE-DAILY RADIOTHERAPY;
THORACIC RADIOTHERAPY; RADIATION-THERAPY; FRACTIONATED RADIOTHERAPY;
RANDOMIZED-TRIALS; MULTICENTER TRIAL; DOSE-ESCALATION; CELL
AB Purpose
In lung cancer, randomized trials assessing hyperfractionated or accelerated radiotherapy seem to yield conflicting results regarding the effects on overall (OS) or progression-free survival (PFS). The Meta-Analysis of Radiotherapy in Lung Cancer Collaborative Group decided to address the role of modified radiotherapy fractionation.
Material and Methods
We performed an individual patient data meta-analysis in patients with nonmetastatic lung cancer, which included trials comparing modified radiotherapy with conventional radiotherapy.
Results
In non-small-cell lung cancer (NSCLC; 10 trials, 2,000 patients), modified fractionation improved OS as compared with conventional schedules (hazard ratio [HR] = 0.88, 95% CI, 0.80 to 0.97; P = .009), resulting in an absolute benefit of 2.5% (8.3% to 10.8%) at 5 years. No evidence of heterogeneity between trials was found. There was no evidence of a benefit on PFS (HR = 0.94; 95% CI, 0.86 to 1.03; P = .19). Modified radiotherapy reduced deaths resulting from lung cancer (HR = 0.89; 95% CI, 0.81 to 0.98; P = .02), and there was a nonsignificant reduction of non-lung cancer deaths (HR = 0.87; 95% CI, 0.66 to 1.15; P = .33). In small-cell lung cancer (SCLC; two trials, 685 patients), similar results were found: OS, HR = 0.87, 95% CI, 0.74 to 1.02, P = .08; PFS, HR = 0.88, 95% CI, 0.75 to 1.03, P = .11. In both NSCLC and SCLC, the use of modified radiotherapy increased the risk of acute esophageal toxicity (odds ratio [OR] = 2.44 in NSCLC and OR = 2.41 in SCLC; P < .001) but did not have an impact on the risk of other acute toxicities.
Conclusion
Patients with nonmetastatic NSCLC derived a significant OS benefit from accelerated or hyperfractionated radiotherapy; a similar but nonsignificant trend was observed for SCLC. As expected, there was increased acute esophageal toxicity.
C1 [Pignon, Jean-Pierre] Inst Cancerol Gustave Roussy, Dept Biostat & Epidemiol, Meta Anal Unit, F-94805 Villejuif, France.
[Saunders, Michele I.; Dische, Stanley] Univ Coll London, Northwood Middlesex, England.
[Saunders, Michele I.; Dische, Stanley] Mt Vernon Hosp, Marie Curie Res Wing, Northwood Middlesex, England.
[Nankivell, Matthew] MRC, Clin Trials Unit, London, England.
[Schild, Steven E.] Mayo Clin, Phoenix, AZ USA.
[Turrisi, Andrew T.] Sinai Grace Hosp, Detroit, MI USA.
[Baumann, Michael; Koch, Rainer] Univ Hosp, Dresden, Germany.
[Baumann, Michael; Koch, Rainer] Med Fac Carl Gustav Carus, Dresden, Germany.
[Sause, William T.] Intermt Med Ctr, Murray, UT USA.
[Ball, David] Univ Melbourne, Melbourne, Vic, Australia.
[Bishop, James F.] Victorian Comprehens Canc Ctr, Melbourne, Vic, Australia.
[Belani, Chandra P.] Penn State Milton S Hershey Med Ctr, Hershey, PA USA.
[Paulus, Rebecca] Radiat Therapy Oncol Grp, Philadelphia, PA USA.
[Bonner, James A.] Univ Alabama Birmingham, Birmingham, AL USA.
[Zajusz, Aleksander; Behrendt, Katarzyna] Maria Sklodowska Curie Mem Canc Ctr, Gliwice Branch, Gliwice, Poland.
[Dahlberg, Suzanne E.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Mandrekar, Sumithra J.] Mayo Clin, Rochester, MN USA.
[Mandrekar, Sumithra J.] N Cent Canc Treatment Grp, Rochester, MN USA.
[Arriagada, Rodrigo] Karolinska Inst, Stockholm, Sweden.
[De Ruysscher, Dirk] Maastricht Univ, Med Ctr, Maastricht, Netherlands.
RP Pignon, JP (reprint author), Inst Cancerol Gustave Roussy, Dept Biostat & Epidemiol, Meta Anal Unit, 114 Rue Edouard Vaillant, F-94805 Villejuif, France.
EM jppignon@igr.fr
OI Belani, Chandra/0000-0001-5049-5329; schild, steven/0000-0002-2850-4126;
Arriagada, Rodrigo/0000-0002-3134-1735; Mauguen,
Audrey/0000-0003-3236-6093
FU French Programme Hospitalier de Recherche Clinique; Ligue Nationale
Contre le Cancer; sanofi-aventis
FX Supported by unrestricted grants from French Programme Hospitalier de
Recherche Clinique, Ligue Nationale Contre le Cancer, and sanofi-aventis
(J.-P.P.). The funding sources had no role in study design, data
collection, data analysis, data interpretation, or manuscript writing.;
Employment or Leadership Position: None Consultant or Advisory Role:
None Stock Ownership: None Honoraria: None Research Funding: Jean-Pierre
Pignon, sanofi-aventis Expert Testimony: None Other Remuneration: None
NR 40
TC 90
Z9 92
U1 0
U2 12
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD AUG 1
PY 2012
VL 30
IS 22
BP 2788
EP 2797
DI 10.1200/JCO.2012.41.6677
PG 10
WC Oncology
SC Oncology
GA 981FK
UT WOS:000306952100018
PM 22753901
ER
PT J
AU Mullins, CD
Abernethy, AP
Hussain, A
Montgomery, RW
Pearson, SD
Tunis, S
AF Mullins, C. Daniel
Abernethy, Amy P.
Hussain, Arif
Montgomery, Russ W.
Pearson, Steven D.
Tunis, Sean
TI Tackling Off-Label Use of Anticancer Drugs Reply
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Letter
ID CANCER
C1 [Mullins, C. Daniel; Montgomery, Russ W.; Tunis, Sean] Ctr Med Technol Policy, Baltimore, MD USA.
[Mullins, C. Daniel; Hussain, Arif] Univ Maryland, Baltimore, MD 21201 USA.
[Abernethy, Amy P.] Duke Univ, Med Ctr, Duke Comprehens Canc Ctr, Durham, NC 27710 USA.
[Abernethy, Amy P.] Duke Univ, Sch Med, Durham, NC USA.
[Hussain, Arif] Baltimore Vet Affairs Med Ctr, Baltimore, MD USA.
[Montgomery, Russ W.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA.
[Pearson, Steven D.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Pearson, Steven D.] Harvard Univ, Sch Med, Boston, MA USA.
RP Mullins, CD (reprint author), Ctr Med Technol Policy, Baltimore, MD USA.
NR 4
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD AUG 1
PY 2012
VL 30
IS 22
BP 2801
EP 2801
DI 10.1200/JCO.2012.43.3854
PG 1
WC Oncology
SC Oncology
GA 981FK
UT WOS:000306952100021
ER
PT J
AU Serrano-Pozo, A
Mielke, ML
Muzitansky, A
Gomez-Isla, T
Growdon, JH
Bacskai, BJ
Betensky, RA
Frosch, MP
Hyman, BT
AF Serrano-Pozo, Alberto
Mielke, Matthew L.
Muzitansky, Alona
Gomez-Isla, Teresa
Growdon, John H.
Bacskai, Brian J.
Betensky, Rebecca A.
Frosch, Matthew P.
Hyman, Bradley T.
TI Stable Size Distribution of Amyloid Plaques Over the Course of Alzheimer
Disease
SO JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY
LA English
DT Article
DE Alzheimer disease; Amyloid plaques; APOE genotype; Dense-core plaques;
Plaque growth; Plaque size
ID APOLIPOPROTEIN-E GENOTYPE; BETA-PROTEIN FIBRILLOGENESIS; MILD COGNITIVE
IMPAIRMENT; SENILE PLAQUES; A-BETA; PATHOLOGICAL-CHANGES;
CEREBRAL-CORTEX; MOUSE MODEL; DEPOSITION; GROWTH
AB Amyloid A plaques are a key pathologic feature of Alzheimer disease (AD), but whether plaque sizes increase or stabilize over the course of AD is unknown. We measured the size distribution of total immunoreactive (10D5-positive) and dense-core (Thioflavin S-positive) plaques in the temporal neocortex of a large group of subjects with AD and age-matched plaque-bearing subjects without dementia to test the hypothesis that amyloid plaques continue to grow along with the progression of the disease. The size of amyloid beta (10D5)-positive plaques did not differ between groups, whereas dense-core plaques from the group with AD were slightly larger than those from the group without dementia (similar to 25%-30%, p - 0.01). Within the group with AD, dense-core plaque size did not independently correlate with duration of clinical disease (from 4 to 21 years, p = 0.68), whereas 10D5-positive plaque size correlated negatively with disease duration (p = 0.01). By contrast, an earlier age of symptom onset strongly predicted a larger postmortem plaque size; this effect was independent of disease duration and the presence of the APOE epsilon 4 allele (p = 0.0001). We conclude that plaques vary in size among patients, with larger size distributions correlating with an earlier age of onset, but plaques do not substantially increase in size over the clinical course of the disease.
C1 [Serrano-Pozo, Alberto; Mielke, Matthew L.; Gomez-Isla, Teresa; Growdon, John H.; Bacskai, Brian J.; Betensky, Rebecca A.; Frosch, Matthew P.; Hyman, Bradley T.] Massachusetts Gen Hosp, Massachusetts Alzheimer Dis Res Ctr, MassGen Inst Neurodegenerat Dis, Charlestown, MA USA.
Harvard Univ, Sch Med, Charlestown, MA USA.
[Muzitansky, Alona] Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA.
[Betensky, Rebecca A.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
[Frosch, Matthew P.] Massachusetts Gen Hosp, CS Kubik Lab Neuropathol, Boston, MA 02114 USA.
RP Hyman, BT (reprint author), Bldg 114,16th St 2009, Charlestown, MA 02129 USA.
EM bhyman@partners.org
RI SERRANO-POZO, ALBERTO/F-5119-2013;
OI SERRANO-POZO, ALBERTO/0000-0003-0899-7530
FU National Institutes of Health [P50AG05134, AG08487]; Fundacion Alfonso
Martin Escudero (Madrid, Spain)
FX This work was funded by the National Institutes of Health (Grants
P50AG05134 and AG08487). Dr Alberto Serrano-Pozo was funded by a
Research Fellowship from Fundacion Alfonso Martin Escudero (Madrid,
Spain).
NR 62
TC 12
Z9 12
U1 0
U2 10
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0022-3069
J9 J NEUROPATH EXP NEUR
JI J. Neuropathol. Exp. Neurol.
PD AUG
PY 2012
VL 71
IS 8
BP 694
EP 701
DI 10.1097/NEN.0b013e31825e77de
PG 8
WC Clinical Neurology; Neurosciences; Pathology
SC Neurosciences & Neurology; Pathology
GA 981NI
UT WOS:000306974700002
PM 22805771
ER
PT J
AU Sheehan, JP
Tanaka, S
Link, MJ
Pollock, BE
Kondziolka, D
Mathieu, D
Duma, C
Young, AB
Kaufmann, AM
McBride, H
Weisskopf, PA
Xu, ZY
Kano, H
Yang, HC
Lunsford, LD
AF Sheehan, Jason P.
Tanaka, Shota
Link, Michael J.
Pollock, Bruce E.
Kondziolka, Douglas
Mathieu, David
Duma, Christopher
Young, A. Byron
Kaufmann, Anthony M.
McBride, Heyoung
Weisskopf, Peter A.
Xu, Zhiyuan
Kano, Hideyuki
Yang, Huai-che
Lunsford, L. Dade
TI Gamma Knife surgery for the management of glomus tumors: a multicenter
study Clinical article
SO JOURNAL OF NEUROSURGERY
LA English
DT Article
DE stereotactic radiosurgery; Gamma Knife; glomus tumor
ID SKULL-BASE SURGERY; LONG-TERM CONTROL; JUGULARE TUMORS; STEREOTACTIC
RADIOSURGERY; SURGICAL-MANAGEMENT; RADIATION-THERAPY; RADIOTHERAPY;
NECK; HEAD; PARAGANGLIOMAS
AB Object. Glomus tumors are rare skull base neoplasms that frequently involve critical cerebrovascular structures and lower cranial nerves. Complete resection is often difficult and may increase cranial nerve deficits. Stereotactic radiosurgery has gained an increasing role in the management of glomus tumors. The authors of this study examine the outcomes after radiosurgery in a large, multicenter patient population.
Methods. Under the auspices of the North American Gamma Knife Consortium, 8 Gamma Knife surgery centers that treat glomus tumors combined their outcome data retrospectively. One hundred thirty-four patient procedures were included in the study (134 procedures in 132 patients, with each procedure being analyzed separately). Prior resection was performed in 51 patients, and prior fractionated external beam radiotherapy was performed in 6 patients. The patients' median age at the time of radiosurgery was 59 years. Forty percent had pulsatile tinnitus at the time of radiosurgery. The median dose to the tumor margin was 15 Gy. The median duration of follow-up was 50.5 months (range 5-220 months).
Results. Overall tumor control was achieved in 93% of patients at last follow-up; actuarial tumor control was 88% at 5 years postradiosurgery. Absence of trigeminal nerve dysfunction at the time of radiosurgery (p = 0.001) and higher number of isocenters (p = 0.005) were statistically associated with tumor progression free tumor survival. Patients demonstrating new or progressive cranial nerve deficits were also likely to demonstrate tumor progression (p = 0.002). Pulsatile tinnitus improved in 49% of patients who reported it at presentation. New or progressive cranial nerve deficits were noted in 15% of patients; improvement in preexisting cranial nerve deficits was observed in 11% of patients. No patient died as a result of tumor progression.
Conclusions. Gamma Knife surgery was a well-tolerated management strategy that provided a high rate of long-term glomus tumor control. Symptomatic tinnitus improved in almost one-half of the patients. Overall neurological status and cranial nerve function were preserved or improved in the vast majority of patients after radiosurgery. (http://thejns.org/doi/abs/10.3171/2012.4.JNS11214)
C1 [Sheehan, Jason P.; Xu, Zhiyuan] Univ Virginia Hlth Syst, Dept Neurol Surg, Charlottesville, VA 22908 USA.
[Tanaka, Shota] Massachusetts Gen Hosp, Neurooncol Program, Boston, MA 02114 USA.
[Link, Michael J.; Pollock, Bruce E.] Mayo Clin, Dept Neurol Surg, Rochester, MN USA.
[Kondziolka, Douglas; Kano, Hideyuki; Yang, Huai-che; Lunsford, L. Dade] Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15260 USA.
[Mathieu, David] Univ Sherbrooke, Div Neurosurg, Quebec City, PQ, Canada.
[Duma, Christopher] Hoag Mem Hosp, Hoag Neurosci Inst, Newport Beach, CA USA.
[Young, A. Byron] Univ Kentucky, Med Ctr, Dept Neurosurg, Lexington, KY USA.
[Kaufmann, Anthony M.] Univ Manitoba, Neurosurg Sect, Winnipeg, MB, Canada.
[McBride, Heyoung] Arizona Oncol Serv Fdn, Phoenix, AZ USA.
[McBride, Heyoung] Barrow Neurol Inst, Sect Radiat Oncol, Phoenix, AZ 85013 USA.
[Weisskopf, Peter A.] Barrow Neurol Inst, Sect Neurotol, Phoenix, AZ 85013 USA.
RP Sheehan, JP (reprint author), Univ Virginia Hlth Syst, Dept Neurol Surg, Box 800212, Charlottesville, VA 22908 USA.
EM jsheehan@virginia.edu
RI Xu, Zhiyuan/J-8698-2013;
OI Kaufmann, Anthony/0000-0001-6144-0382
NR 41
TC 16
Z9 17
U1 0
U2 0
PU AMER ASSOC NEUROLOGICAL SURGEONS
PI ROLLING MEADOWS
PA 5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA
SN 0022-3085
J9 J NEUROSURG
JI J. Neurosurg.
PD AUG
PY 2012
VL 117
IS 2
BP 246
EP 254
DI 10.3171/2012.4.JNS11214
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA 978ST
UT WOS:000306766800013
PM 22680240
ER
PT J
AU Flynn, TR
Paster, BJ
Stokes, LN
Susarla, SM
Shanti, RM
AF Flynn, Thomas R.
Paster, Bruce J.
Stokes, Lauren N.
Susarla, Srinivas M.
Shanti, Rabie M.
TI Molecular Methods for Diagnosis of Odontogenic Infections
SO JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY
LA English
DT Article
ID RIBOSOMAL-RNA ANALYSIS; REFRACTORY PERIODONTITIS; OROFACIAL INFECTIONS;
APICAL PERIODONTITIS; SUBGINGIVAL BIOFILM; BACTERIAL-FLORA;
IDENTIFICATION; MICROBIOTA; DIVERSITY; IMPLANTS
AB Purpose: Historically, the identification of microorganisms has been limited to species that could be cultured in the microbiology laboratory. The purpose of the present study was to apply molecular techniques to identify microorganisms in orofacial odontogenic infections (OIs).
Materials and Methods: Specimens were obtained from subjects with clinical evidence of OI. To identify the microorganisms involved, 16S rRNA sequencing methods were used on clinical specimens. The name and number of the clones of each species identified and the combinations of species present were recorded for each subject. Descriptive statistics were computed for the study variables.
Results: Specimens of pus or wound fluid were obtained from 9 subjects. A mean of 7.4 +/- 3.7 (standard deviation) species per case were identified. The predominant species detected in the present study that have previously been associated with OIs were Fusobacterium spp, Parvimonas micra, Porphyromonas endodontalis, and Prevotella oris. The predominant species detected in our study that have not been previously associated with OIs were Dialister pneumosintes and Eubacterium brachy. Unculturable phylotypes accounted for 24% of the species identified in our study. All species detected were obligate or facultative anaerobes. Streptococci were not detected.
Conclusions: Molecular methods have enabled us to detect previously cultivated and not-yet-cultivated species in OIs; these methods could change our understanding of the pathogenic flora of orofacial OIs. (C) 2012 American Association of Oral and Maxillofacial Surgeons J Oral Maxillofac Surg 70:1854-1859, 2012
C1 [Flynn, Thomas R.] Harvard Univ, Sch Dent Med, Dept Oral & Maxillofacial Surg, Boston, MA 02115 USA.
[Paster, Bruce J.; Stokes, Lauren N.] Forsyth Inst, Dept Mol Genet, Cambridge, MA USA.
[Paster, Bruce J.] Harvard Univ, Sch Dent Med, Dept Oral Med Infect & Immun, Boston, MA 02115 USA.
[Susarla, Srinivas M.] Massachusetts Gen Hosp, Dept Oral & Maxillofacial Surg, Boston, MA 02114 USA.
[Shanti, Rabie M.] Univ Med & Dent New Jersey, New Jersey Dent Sch, Dept Oral & Maxillofacial Surg, Newark, NJ 07103 USA.
RP Flynn, TR (reprint author), 1055 Waverly Dr, Reno, NV 89519 USA.
EM thomasrflynndmd@gmail.com
OI Susarla, Srinivas/0000-0003-0155-8260
FU Oral and Maxillofacial Research Foundation; Massachusetts General
Hospital; Oral and Maxillofacial Surgery Education and Research Fund;
Center for Applied Clinical Investigation; Oral and Maxillofacial
Surgery Foundation
FX This study was generously funded by the Oral and Maxillofacial Research
Foundation, Massachusetts General Hospital, Oral and Maxillofacial
Surgery Education and Research Fund and Center for Applied Clinical
Investigation, and the Oral and Maxillofacial Surgery Foundation
Fellowship in Clinical Investigation.
NR 41
TC 11
Z9 11
U1 0
U2 3
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0278-2391
J9 J ORAL MAXIL SURG
JI J. Oral Maxillofac. Surg.
PD AUG
PY 2012
VL 70
IS 8
BP 1854
EP 1859
DI 10.1016/j.joms.2011.09.009
PG 6
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA 981UJ
UT WOS:000306996100023
PM 22326175
ER
PT J
AU Peacock, ZS
Jordan, RCK
Schmidt, BL
AF Peacock, Zachary S.
Jordan, Richard C. K.
Schmidt, Brian L.
TI Giant Cell Lesions of the Jaws: Does the Level of Vascularity and
Angiogenesis correlate With Behavior?
SO JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; ANTIANGIOGENIC THERAPY; IN-VITRO; GRANULOMA;
INTERFERON; EXPRESSION; CALCITONIN; MARKERS; TUMOR; CD34
AB Purpose: To compare vascularity and angiogenic activity in aggressive and nonaggressive giant cell lesions (GCLs) of the jaws.
Materials and Methods: This is a retrospective study of 14 GCLs treated at the University of California, San Francisco. Immunohistochemistry was used to determine of the expression of vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), CD34, and CD31. VEGF and bFGF expression in giant cells (GCs) and surrounding mononuclear stroma was classified into 1) high immunoreactivity (>50% staining) and 2) low immunoreactivity (<50% staining). CD31- and CD34-stained vessels were counted at 200x magnification. Clinical and radiographic records were reviewed to classify lesions as aggressive or nonaggressive.
Results: Of the lesions, 8 were aggressive and 6 were nonaggressive. High VEGF expression was found within the GCs in 4 of 8 aggressive lesions compared with 1 of 6 nonaggressive lesions. The stroma in both groups had low staining. High staining of the GCs for bFGF was found in 6 of 8 aggressive lesions compared with 3 of 6 nonaggressive lesions. The stroma of all aggressive cases showed high expression of bFGF compared with 3 of 6 nonaggressive cases. The aggressive group had a mean of 20.1 +/- 5.4 vessels/high-powered field (hpf) stained for CD31 compared with 11.5 +/- 5.6 vessels/hpf in the nonaggressive group. The aggressive group had 24.6 +/- 7.0 vessels/hpf stained with CD34 compared with 18.5 +/- 4.0 vessels/hpf in the nonaggressive group.
Conclusions: The vascularity and level of angiogenesis within aggressive GCLs are higher than those in nonaggressive lesions. (C) 2012 American Association of Oral and Maxillofacial Surgeons J Oral Maxillofac Surg 70:1860-1866, 2012
C1 [Peacock, Zachary S.] Univ Calif San Francisco, Dept Oral & Maxillofacial Surg, San Francisco, CA USA.
[Schmidt, Brian L.] NYU, Coll Dent, Dept Oral & Maxillofacial Surg, New York, NY USA.
[Schmidt, Brian L.] NYU, Coll Dent, Bluestone Ctr Clin Res, New York, NY USA.
RP Peacock, ZS (reprint author), Massachusetts Gen Hosp, Warren 1201,55 Fruit St, Boston, MA 02114 USA.
EM zpeacock@partners.org
OI Schmidt, Brian/0000-0002-2409-8984
NR 34
TC 3
Z9 3
U1 0
U2 2
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0278-2391
J9 J ORAL MAXIL SURG
JI J. Oral Maxillofac. Surg.
PD AUG
PY 2012
VL 70
IS 8
BP 1860
EP 1866
DI 10.1016/j.joms.2011.08.020
PG 7
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA 981UJ
UT WOS:000306996100024
PM 22104131
ER
PT J
AU Chen, AB
Feng, Y
Neuberg, D
Recklitis, C
Diller, LR
Mauch, PN
Ng, AK
AF Chen, Aileen B.
Feng, Yang
Neuberg, Donna
Recklitis, Christopher
Diller, Lisa R.
Mauch, Peter N.
Ng, Andrea K.
TI Employment and insurance in survivors of Hodgkin lymphoma and their
siblings: a questionnaire study
SO LEUKEMIA & LYMPHOMA
LA English
DT Article
DE Employment; Hodgkin lymphoma; insurance; radiation therapy; survivorship
ID CHILDHOOD-CANCER SURVIVOR; LONG-TERM SURVIVORS; QUALITY-OF-LIFE; ADULT
SURVIVORS; DATA-BASE; DISEASE; RADIOTHERAPY; HEALTH; RETURN; WORK
AB Using a questionnaire study, we compared the employment and insurance of Hodgkin lymphoma (HL) survivors versus their siblings. A total of 511 survivors and 224 siblings completed questionnaires. HL survivors were more likely to report job denial, difficulty obtaining insurance due to medical history, and difficulty changing jobs due to fear of losing insurance. On multivariable analysis, male gender, income and scarring of the head and neck were associated with job denial. Male gender and impairment interfering with a job were associated with difficulty obtaining health insurance. Survivors with >4 physician visits in 2 years, <10years from diagnosis, or with permanent hair loss from treatment were more likely to report inability to change jobs due to fear of losing insurance. Compared to their siblings, HL survivors may face greater challenges in obtaining employment and insurance. Late effects from treatment, including permanent cosmetic changes, may contribute to these differences.
C1 [Chen, Aileen B.] Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02215 USA.
[Chen, Aileen B.; Mauch, Peter N.; Ng, Andrea K.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Diller, Lisa R.] Childrens Hosp, Boston, MA 02115 USA.
RP Chen, AB (reprint author), Dana Farber Canc Inst, Dept Radiat Oncol, 450 Brookline Ave,D1111, Boston, MA 02215 USA.
EM achen@lroc.harvard.edu
OI Chen, Aileen/0000-0002-5385-3360
NR 31
TC 4
Z9 4
U1 0
U2 4
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1042-8194
EI 1029-2403
J9 LEUKEMIA LYMPHOMA
JI Leuk. Lymphoma
PD AUG
PY 2012
VL 53
IS 8
BP 1474
EP 1480
DI 10.3109/10428194.2012.660629
PG 7
WC Oncology; Hematology
SC Oncology; Hematology
GA 976FJ
UT WOS:000306566000010
PM 22280535
ER
PT J
AU Zhang, HJ
Peng, C
Hu, YG
Li, HW
Sheng, Z
Chen, YY
Sullivan, C
Cerny, J
Hutchinson, L
Higgins, A
Miron, P
Zhang, XQ
Brehm, MA
Li, DG
Green, MR
Li, SG
AF Zhang, Haojian
Peng, Cong
Hu, Yiguo
Li, Huawei
Sheng, Zhi
Chen, Yaoyu
Sullivan, Con
Cerny, Jan
Hutchinson, Lloyd
Higgins, Anne
Miron, Patricia
Zhang, Xueqing
Brehm, Michael A.
Li, Dongguang
Green, Michael R.
Li, Shaoguang
TI The Blk pathway functions as a tumor suppressor in chronic myeloid
leukemia stem cells
SO NATURE GENETICS
LA English
DT Article
ID CHRONIC MYELOGENOUS LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; BCR-ABL;
TYROSINE KINASE; IMATINIB MESYLATE; BETA-CATENIN; HEMATOPOIETIC
PROGENITORS; IN-VITRO; CANCER; DIFFERENTIATION
AB A therapeutic strategy for treating cancer is to target and eradicate cancer stem cells (CSCs) without harming their normal stem cell counterparts. The success of this approach relies on the identification of molecular pathways that selectively regulate CSC function. Using BCR-ABL-induced chronic myeloid leukemia (CML) as a disease model for CSCs, we show that BCR-ABL downregulates the Blk gene (encoding B-lymphoid kinase) through c-Myc in leukemic stem cells (LSCs) in CML mice and that Blk functions as a tumor suppressor in LSCs but does not affect normal hematopoietic stem cells (HSCs) or hematopoiesis. Blk suppresses LSC function through a pathway involving an upstream regulator, Pax5, and a downstream effector, p27. Inhibition of this Blk pathway accelerates CML development, whereas increased activity of the Blk pathway delays CML development. Blk also suppresses the proliferation of human CML stem cells. Our results show the feasibility of selectively targeting LSCs, an approach that should be applicable to other cancers.
C1 [Zhang, Haojian; Peng, Cong; Li, Huawei; Chen, Yaoyu; Cerny, Jan; Li, Shaoguang] Univ Massachusetts, Sch Med, Dept Med, Div Hematol Oncol, Worcester, MA 01605 USA.
[Hu, Yiguo] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Sheng, Zhi; Green, Michael R.] Univ Massachusetts, Sch Med, Program Gene Funct & Express, Worcester, MA USA.
[Sheng, Zhi; Brehm, Michael A.; Green, Michael R.] Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA USA.
[Sullivan, Con] Univ Maine, Dept Mol & Biomed Sci, Orono, ME USA.
[Hutchinson, Lloyd; Higgins, Anne; Miron, Patricia] Univ Massachusetts, Dept Pathol, Div Anat Pathol, Mem Med Ctr, Worcester, MA 01605 USA.
[Zhang, Xueqing] Univ Massachusetts, Sch Med, Dept Pediat, Worcester, MA USA.
[Li, Dongguang] Edith Cowan Univ, Sch Comp & Informat Sci, Mt Lawley, WA, Australia.
[Green, Michael R.] Univ Massachusetts, Sch Med, Howard Hughes Med Inst, Worcester, MA 01605 USA.
RP Li, SG (reprint author), Univ Massachusetts, Sch Med, Dept Med, Div Hematol Oncol, Worcester, MA 01605 USA.
EM shaoguang.li@umassmed.edu
RI Zhang, Haojian/H-7897-2013
FU Leukemia & Lymphoma Society; US National Institutes of Health (NIH)
[R01-CA122142, R01-CA114199]; NIH [AI46629]
FX We thank A. Tarakhovsky (Rockefeller University) for providing
Blk-/- mice and K. Calame (Columbia University) for pGL3-Pax5
plasmid. We thank S. Deibler for editorial assistance. This work was
supported by grants from the Leukemia & Lymphoma Society and the US
National Institutes of Health (NIH) (R01-CA122142 and R01-CA114199) to
S.L. M.A.B. was supported by the NIH (AI46629). S.L. is a Scholar of the
Leukemia & Lymphoma Society.
NR 59
TC 26
Z9 26
U1 1
U2 12
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1061-4036
J9 NAT GENET
JI Nature Genet.
PD AUG
PY 2012
VL 44
IS 8
BP 861
EP +
DI 10.1038/ng.2350
PG 13
WC Genetics & Heredity
SC Genetics & Heredity
GA 979WV
UT WOS:000306854700009
PM 22797726
ER
PT J
AU Lu, XF
Wang, LY
Chen, SF
He, L
Yang, XL
Shi, YY
Cheng, J
Zhang, L
Gu, CC
Huang, JF
Wu, TC
Ma, YT
Li, JX
Cao, J
Chen, JC
Ge, DL
Fan, ZJ
Li, Y
Zhao, LC
Li, HF
Zhou, XY
Chen, LY
Liu, DH
Chen, JP
Duan, XF
Hao, YC
Wang, LG
Lu, FH
Liu, ZD
Yao, CL
Shen, C
Pu, XD
Yu, L
Fang, XH
Xu, LH
Mu, JJ
Wu, XP
Zheng, RP
Wu, NQ
Zhao, Q
Li, Y
Liu, XL
Wang, MP
Yu, DH
Hu, DS
Ji, X
Guo, DS
Sun, DL
Wang, QQ
Yang, Y
Liu, FC
Mao, QX
Liang, XH
Ji, JF
Chen, PP
Mo, XB
Li, DJ
Chai, GP
Tang, YD
Li, XD
Du, ZH
Liu, XH
Dou, CL
Yang, ZL
Meng, QJ
Wang, D
Wang, RP
Yang, J
Schunkert, H
Samani, NJ
Kathiresan, S
Reilly, MP
Erdmann, J
Peng, XZ
Wu, XG
Liu, DP
Yang, YJ
Chen, RS
Qiang, BQ
Gu, DF
AF Lu, Xiangfeng
Wang, Laiyuan
Chen, Shufeng
He, Lin
Yang, Xueli
Shi, Yongyong
Cheng, Jing
Zhang, Liang
Gu, C. Charles
Huang, Jianfeng
Wu, Tangchun
Ma, Yitong
Li, Jianxin
Cao, Jie
Chen, Jichun
Ge, Dongliang
Fan, Zhongjie
Li, Ying
Zhao, Liancheng
Li, Hongfan
Zhou, Xiaoyang
Chen, Lanying
Liu, Donghua
Chen, Jingping
Duan, Xiufang
Hao, Yongchen
Wang, Ligui
Lu, Fanghong
Liu, Zhendong
Yao, Cailiang
Shen, Chong
Pu, Xiaodong
Yu, Lin
Fang, Xianghua
Xu, Lihua
Mu, Jianjun
Wu, Xianping
Zheng, Runping
Wu, Naqiong
Zhao, Qi
Li, Yun
Liu, Xiaoli
Wang, Mengqin
Yu, Dahai
Hu, Dongsheng
Ji, Xu
Guo, Dongshuang
Sun, Dongling
Wang, Qianqian
Yang, Ying
Liu, Fangchao
Mao, Qunxia
Liang, Xiaohua
Ji, Jingfeng
Chen, Panpan
Mo, Xingbo
Li, Dianjiang
Chai, Guoping
Tang, Yida
Li, Xiangdong
Du, Zhenhan
Liu, Xuehui
Dou, Chenlong
Yang, Zili
Meng, Qingjie
Wang, Dong
Wang, Renping
Yang, Jun
Schunkert, Heribert
Samani, Nilesh J.
Kathiresan, Sekar
Reilly, Muredach P.
Erdmann, Jeanette
Peng, Xiaozhong
Wu, Xigui
Liu, Depei
Yang, Yuejin
Chen, Runsheng
Qiang, Boqin
Gu, Dongfeng
CA Coronary ARtery DIs Genome-Wide Re
TI Genome-wide association study in Han Chinese identifies four new
susceptibility loci for coronary artery disease
SO NATURE GENETICS
LA English
DT Article
ID BLOOD-PRESSURE; MYOCARDIAL-INFARCTION; COMMON VARIANTS; EAST ASIANS;
METAANALYSIS; POPULATION; SEQUENCE; ONSET
AB We performed a meta-analysis of 2 genome-wide association studies of coronary artery disease comprising 1,515 cases and 5,019 controls followed by replication studies in 15,460 cases and 11,472 controls, all of Chinese Han ancestry. We identify four new loci for coronary artery disease that reached the threshold of genome-wide significance (P < 5 x 10(-8)). These loci mapped in or near TTC32-WDR35, GUCY1A3, C6orf10-BTNL2 and ATP2B1. We also replicated four loci previously identified in European populations (in or near PHACTR1, TCF21, CDKN2A-CDKN2B and C12orf51). These findings provide new insights into pathways contributing to the susceptibility for coronary artery disease in the Chinese Han population.
C1 [Lu, Xiangfeng; Wang, Laiyuan; Chen, Shufeng; Yang, Xueli; Huang, Jianfeng; Li, Jianxin; Cao, Jie; Chen, Jichun; Ge, Dongliang; Li, Ying; Zhao, Liancheng; Chen, Lanying; Liu, Donghua; Chen, Jingping; Duan, Xiufang; Hao, Yongchen; Zhao, Qi; Yu, Dahai; Wang, Qianqian; Yang, Ying; Liu, Fangchao; Mao, Qunxia; Liang, Xiaohua; Ji, Jingfeng; Mo, Xingbo; Li, Dianjiang; Chai, Guoping; Li, Xiangdong; Du, Zhenhan; Wu, Xigui; Gu, Dongfeng] Chinese Acad Med Sci, State Key Lab Cardiovasc Dis, Fuwai Hosp, Natl Ctr Cardiovasc Dis, Beijing 100730, Peoples R China.
[Lu, Xiangfeng; Wang, Laiyuan; Chen, Shufeng; Yang, Xueli; Huang, Jianfeng; Li, Jianxin; Cao, Jie; Chen, Jichun; Ge, Dongliang; Li, Ying; Zhao, Liancheng; Chen, Lanying; Liu, Donghua; Chen, Jingping; Duan, Xiufang; Hao, Yongchen; Wu, Naqiong; Zhao, Qi; Yu, Dahai; Wang, Qianqian; Yang, Ying; Liu, Fangchao; Mao, Qunxia; Liang, Xiaohua; Ji, Jingfeng; Mo, Xingbo; Li, Dianjiang; Chai, Guoping; Tang, Yida; Li, Xiangdong; Du, Zhenhan; Peng, Xiaozhong; Wu, Xigui; Liu, Depei; Yang, Yuejin; Qiang, Boqin; Gu, Dongfeng] Peking Union Med Coll, Beijing 100021, Peoples R China.
[Wang, Laiyuan; Li, Hongfan; Liu, Xuehui; Dou, Chenlong] Natl Human Genome Ctr, Beijing, Peoples R China.
[He, Lin; Shi, Yongyong] Shanghai Jiao Tong Univ, Bio X Inst, Key Lab Genet Dev & Neuropsychiat Disorders, Minist Educ, Shanghai 200030, Peoples R China.
[Cheng, Jing; Zhang, Liang] NERCBBT, Beijing, Peoples R China.
[Cheng, Jing] Tsinghua Univ, Med Syst Biol Res Ctr, Sch Med, Beijing 100084, Peoples R China.
[Gu, C. Charles] Washington Univ, Sch Med, Div Biostat, St Louis, MO 63110 USA.
[Wu, Tangchun; Wang, Ligui] Huazhong Univ Sci & Technol, Key Lab Environm & Hlth, Sch Publ Hlth, Tongji Med Coll, Wuhan 430074, Peoples R China.
[Ma, Yitong] Xinjiang Med Univ, Dept Cardiol, Affiliated Hosp 1, Urumqi, Peoples R China.
[Fan, Zhongjie] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Cardiol, Beijing 100730, Peoples R China.
[Zhou, Xiaoyang] Wuhan Univ, Renmin Hosp, Dept Cardiol, Wuhan 430072, Peoples R China.
[Lu, Fanghong; Liu, Zhendong] Shandong Acad Med Sci, Inst Basic Med, Cardiocerebrovasc Control & Res Ctr, Jinan, Peoples R China.
[Yao, Cailiang; Shen, Chong] Nanjing Med Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Nanjing, Jiangsu, Peoples R China.
[Pu, Xiaodong; Yu, Lin] Fujian Prov Peoples Hosp, Dept Cardiol, Fuzhou, Peoples R China.
[Fang, Xianghua] Capital Med Univ, Xuanwu Hosp, Dept Epidemiol & Social Med, Beijing, Peoples R China.
[Xu, Lihua] Beihua Univ, Affiliated Hosp, Dept Cardiol, Jilin, Peoples R China.
[Mu, Jianjun] Xi An Jiao Tong Univ, Affiliated Hosp 1, Coll Med, Dept Cardiol, Xian 710049, Peoples R China.
[Wu, Xianping] Sichuan Ctr Dis Control & Prevent, Ctr Chron & Noncommunicable Dis Control & Prevent, Chengdu, Peoples R China.
[Zheng, Runping] Peking Univ, Shougang Hosp, Cardiovasc Dis Prevent Ctr, Beijing 100871, Peoples R China.
[Wu, Naqiong; Tang, Yida; Yang, Yuejin] Chinese Acad Med Sci, Fuwai Hosp, Natl Ctr Cardiovasc Dis, Dept Cardiol, Beijing 100730, Peoples R China.
[Li, Yun] Hebei United Univ, Sch Publ Hlth, Tangshan, Peoples R China.
[Liu, Xiaoli] Capital Med Univ, Anzhen Hosp, Dept Cardiol, Beijing, Peoples R China.
[Wang, Mengqin] Beijing Jishuitan Hosp, Dept Emergency Med, Beijing, Peoples R China.
[Hu, Dongsheng] Zhengzhou Univ, Sch Publ Hlth, Zhengzhou, Peoples R China.
[Hu, Dongsheng] Shenzhen Univ, Sch Med, Shenzhen, Peoples R China.
[Ji, Xu] Xinle Red Cross Hosp, Dept Internal Med, Xinle, Peoples R China.
[Guo, Dongshuang] Yuxian Renmin Hosp, Dept Internal Med, Yuxian, Peoples R China.
[Sun, Dongling] Chinese Peoples Liberat Army PLA Gen Hosp, Inst Geriatr, Beijing, Peoples R China.
[Chen, Panpan] Renqiu Heath Bur, Renqiu, Peoples R China.
[Yang, Zili] Nantong Ctr Dis Control & Prevent, Nantong, Peoples R China.
[Meng, Qingjie] Zhangqiu Heath Bur, Zhangqiu, Peoples R China.
[Wang, Dong] Xinan Heath Bur, Xinan, Peoples R China.
[Wang, Renping] Shijiazhuang Greatwall Hosp, Dept Internal Med, Shijiazhuang, Peoples R China.
[Yang, Jun] Hanzhong Renmin Hosp, Dept Cardiol, Hanzhong, Peoples R China.
[Schunkert, Heribert; Erdmann, Jeanette] Univ Lubeck, Med Klin 2, Lubeck, Germany.
[Schunkert, Heribert; Erdmann, Jeanette] Univ Lubeck, Deutsch Zentrum Herz Kreislauf Forsch DZHK, Lubeck, Germany.
[Samani, Nilesh J.] Univ Leicester, Dept Cardiovasc Sci, Glenfield Hosp, Leicester, Leics, England.
[Samani, Nilesh J.] Glenfield Hosp, Biomed Res Unit Cardiovasc Dis, Leicester Natl Inst Hlth Res, Leicester, Leics, England.
[Kathiresan, Sekar] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA.
[Kathiresan, Sekar] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
[Kathiresan, Sekar] Broad Inst MIT & Harvard, Program Med & Populat Genet, Cambridge, MA USA.
[Reilly, Muredach P.] Univ Penn, Cardiovasc Inst, Philadelphia, PA 19104 USA.
[Peng, Xiaozhong; Liu, Depei; Qiang, Boqin] Chinese Acad Med Sci, Inst Basic Med Sci, Beijing 100730, Peoples R China.
[Chen, Runsheng] Chinese Acad Sci, Inst Biophys, Beijing 100080, Peoples R China.
RP Gu, DF (reprint author), Chinese Acad Med Sci, State Key Lab Cardiovasc Dis, Fuwai Hosp, Natl Ctr Cardiovasc Dis, Beijing 100730, Peoples R China.
EM gudongfeng@vip.sina.com
RI Altshuler, David/A-4476-2009; Willenborg, Christina/D-2668-2012;
Gudnason, Vilmundur/K-6885-2015; Meitinger, Thomas/O-1318-2015; Gu,
Charles/A-7934-2010; Erdmann, Jeanette/P-7513-2014;
OI Altshuler, David/0000-0002-7250-4107; Willenborg,
Christina/0000-0001-5217-6882; Gudnason, Vilmundur/0000-0001-5696-0084;
Gu, Charles/0000-0002-8527-8145; Erdmann, Jeanette/0000-0002-4486-6231;
Kleber, Marcus/0000-0003-0663-7275
FU National Basic Research Program of China (973 Plan) from the Ministry of
Science and Technology of China [2011CB503901, 2006CB503805]; National
Science Foundation of China [30930047]; High-Tech Research and
Development Program of China (863 Plan) [2009AA022703, 2012AA02A516,
2006AA02A406]; Ministry of Science and Technology of China
[2006BAI01A01]; Biomedical Project from the Council of Science and
Technology, Beijing [H020220030130]
FX This study was funded by the National Basic Research Program of China
(973 Plan) (2011CB503901 and 2006CB503805) from the Ministry of Science
and Technology of China, by the National Science Foundation of China
(30930047), by the High-Tech Research and Development Program of China
(863 Plan) (2009AA022703, 2012AA02A516 and 2006AA02A406) and by a grant
from the Ministry of Science and Technology of China (2006BAI01A01).
This study was also supported by Biomedical Project from the Council of
Science and Technology, Beijing (H020220030130).
NR 40
TC 120
Z9 125
U1 4
U2 78
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1061-4036
EI 1546-1718
J9 NAT GENET
JI Nature Genet.
PD AUG
PY 2012
VL 44
IS 8
BP 890
EP +
DI 10.1038/ng.2337
PG 7
WC Genetics & Heredity
SC Genetics & Heredity
GA 979WV
UT WOS:000306854700013
PM 22751097
ER
PT J
AU Riviere, JB
Mirzaa, GM
O'Roak, BJ
Beddaoui, M
Alcantara, D
Conway, RL
St-Onge, J
Schwartzentruber, JA
Gripp, KW
Nikkel, SM
Worthylake, T
Sullivan, CT
Ward, TR
Butler, HE
Kramer, NA
Albrecht, B
Armour, CM
Armstrong, L
Caluseriu, O
Cytrynbaum, C
Drolet, BA
Innes, AM
Lauzon, JL
Lin, AE
Mancini, GMS
Meschino, WS
Reggin, JD
Saggar, AK
Lerman-Sagie, T
Uyanik, G
Weksberg, R
Zirn, B
Beaulieu, CL
Majewski, J
Bulman, DE
O'Driscoll, M
Shendure, J
Graham, JM
Boycott, KM
Dobyns, WB
AF Riviere, Jean-Baptiste
Mirzaa, Ghayda M.
O'Roak, Brian J.
Beddaoui, Margaret
Alcantara, Diana
Conway, Robert L.
St-Onge, Judith
Schwartzentruber, Jeremy A.
Gripp, Karen W.
Nikkel, Sarah M.
Worthylake, Thea
Sullivan, Christopher T.
Ward, Thomas R.
Butler, Hailly E.
Kramer, Nancy A.
Albrecht, Beate
Armour, Christine M.
Armstrong, Linlea
Caluseriu, Oana
Cytrynbaum, Cheryl
Drolet, Beth A.
Innes, A. Micheil
Lauzon, Julie L.
Lin, Angela E.
Mancini, Grazia M. S.
Meschino, Wendy S.
Reggin, James D.
Saggar, Anand K.
Lerman-Sagie, Tally
Uyanik, Goekhan
Weksberg, Rosanna
Zirn, Birgit
Beaulieu, Chandree L.
Majewski, Jacek
Bulman, Dennis E.
O'Driscoll, Mark
Shendure, Jay
Graham, John M., Jr.
Boycott, Kym M.
Dobyns, William B.
CA Finding Rare Dis Genes FORGE Canad
TI De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA
cause a spectrum of related megalencephaly syndromes
SO NATURE GENETICS
LA English
DT Article
ID MACROCEPHALY-CAPILLARY MALFORMATION; KINASE-B-GAMMA;
GLUCOSE-HOMEOSTASIS; ACTIVATING MUTATION; INSULIN-RESISTANCE;
CORPUS-CALLOSUM; CUTIS MARMORATA; COWDEN-DISEASE; GENE-MUTATIONS;
HIGH-FREQUENCY
AB Megalencephaly-capillary malformation (MCAP) and megalencephaly-polymicrogyria-polydactyly-hydrocephalus (MPPH) syndromes are sporadic overgrowth disorders associated with markedly enlarged brain size and other recognizable features(1-5). We performed exome sequencing in 3 families with MCAP or MPPH, and our initial observations were confirmed in exomes from 7 individuals with MCAP and 174 control individuals, as well as in 40 additional subjects with megalencephaly, using a combination of Sanger sequencing, restriction enzyme assays and targeted deep sequencing. We identified de novo germline or postzygotic mutations in three core components of the phosphatidylinositol 3-kinase (PI3K)-AKT pathway. These include 2 mutations in AKT3, 1 recurrent mutation in PIK3R2 in 11 unrelated families with MPPH and 15 mostly postzygotic mutations in PIK3CA in 23 individuals with MCAP and 1 with MPPH. Our data highlight the central role of PI3K-AKT signaling in vascular, limb and brain development and emphasize the power of massively parallel sequencing in a challenging context of phenotypic and genetic heterogeneity combined with postzygotic mosaicism.
C1 [Riviere, Jean-Baptiste; St-Onge, Judith; Sullivan, Christopher T.; Ward, Thomas R.; Butler, Hailly E.; Dobyns, William B.] Seattle Childrens Hosp, Ctr Integrat Brain Res, Seattle, WA USA.
[Mirzaa, Ghayda M.] Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA.
[O'Roak, Brian J.; Shendure, Jay] Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA.
[Beddaoui, Margaret; Worthylake, Thea; Beaulieu, Chandree L.; Boycott, Kym M.] Univ Ottawa, Childrens Hosp, Eastern Ontario Res Inst, Ottawa, ON, Canada.
[Alcantara, Diana; O'Driscoll, Mark] Univ Sussex, Genome Damage & Stabil Ctr, Brighton, E Sussex, England.
[Conway, Robert L.] Michigan State Univ, Dept Pediat & Human Dev, E Lansing, MI 48824 USA.
[Schwartzentruber, Jeremy A.] McGill Univ, Genome Quebec Innovat Ctr, Montreal, PQ, Canada.
[Gripp, Karen W.] Alfred I DuPont Hosp Children, Div Med Genet, Wilmington, DE USA.
[Nikkel, Sarah M.; Boycott, Kym M.] Childrens Hosp Eastern Ontario, Div Genet, Ottawa, ON K1H 8L1, Canada.
[Kramer, Nancy A.; Graham, John M., Jr.] Cedars Sinai Med Ctr, Inst Med Genet, Los Angeles, CA 90048 USA.
[Albrecht, Beate] Univ Hosp Essen, Dept Human Genet, Essen, Germany.
[Armour, Christine M.] Queens Univ, Dept Paediat, Kingston, ON, Canada.
[Armstrong, Linlea] Univ British Columbia, Dept Med Genet, Vancouver, BC, Canada.
[Caluseriu, Oana; Innes, A. Micheil; Lauzon, Julie L.] Univ Calgary, Dept Med Genet, Calgary, AB, Canada.
[Cytrynbaum, Cheryl; Weksberg, Rosanna] Hosp Sick Children, Div Clin & Metab Genet, Toronto, ON M5G 1X8, Canada.
[Drolet, Beth A.] Med Coll Wisconsin, Dept Dermatol, Milwaukee, WI 53226 USA.
[Drolet, Beth A.] Med Coll Wisconsin, Dept Pediat, Milwaukee, WI 53226 USA.
[Lin, Angela E.] MassGen Hosp Children, Dept Med Genet, Boston, MA USA.
[Mancini, Grazia M. S.] Erasmus MC, Dept Clin Genet, Rotterdam, Netherlands.
[Meschino, Wendy S.] N York Gen Hosp, Dept Genet, Toronto, ON, Canada.
[Reggin, James D.] Providence Sacred Heart Med Ctr, Spokane, WA USA.
[Reggin, James D.] Childrens Hosp, Spokane, WA USA.
[Saggar, Anand K.] Univ London, St Georges Hosp, Dept Clin Genet, London, England.
[Lerman-Sagie, Tally] Wolfson Med Ctr, Pediat Neurol Unit, Holon, Israel.
[Uyanik, Goekhan] Univ Med Ctr Hamburg Eppendorf, Inst Human Genet, Hamburg, Germany.
[Zirn, Birgit] Univ Goettingen, Dept Neuropediat, Gottingen, Germany.
[Majewski, Jacek] McGill Univ, Dept Human Genet, Montreal, PQ, Canada.
[Bulman, Dennis E.] Univ Ottawa, Ottawa Hosp, Res Inst, Ottawa, ON, Canada.
[Dobyns, William B.] Univ Washington, Dept Pediat, Seattle, WA 98195 USA.
[Dobyns, William B.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA.
RP Dobyns, WB (reprint author), Seattle Childrens Hosp, Ctr Integrat Brain Res, Seattle, WA USA.
EM wbd@uw.edu
RI Scherer, Stephen /B-3785-2013; innes, allan micheil/A-9955-2017;
OI Scherer, Stephen /0000-0002-8326-1999; Innes,
Micheil/0000-0001-9881-5467; O'Roak, Brian/0000-0002-4141-0095;
Schwartzentruber, Jeremy/0000-0002-6183-2092; Shendure,
Jay/0000-0002-1516-1865; Dobyns, William/0000-0002-7681-2844
FU US National Institutes of Health under National Institute of
Neurological Disorders and Stroke (NINDS) grant [NS058721]; National
Institute of Child Health & Human Development (NICHD) grant [HD36657];
National Institute of General Medical Sciences (NIGMS) grant
[5-T32-GM08243]; Government of Canada (to FORGE) through Genome Canada;
Canadian Institutes of Health Research (CIHR); Ontario Genomics
Institute [OGI-049]; Genome Quebec and Genome British Columbia; Banting
Postdoctoral Fellowship from the CIHR; Clinical Investigatorship Award
from the CIHR Institute of Genetics; Cancer Research UK (CR-UK); Medical
Research Council (UK); Leukaemia Lymphoma Research (UK); Simons
Foundation Autism Research Initiative (SFARI) [191889]; NIEHS
Environmental Genome Project [HHSN273200800010C]; NHLBI GO Exome
Sequencing Project and its ongoing studies [HL-102923, HL-102925,
HL-102926, HL-103010]; Women's Health Institute (WHI) [HL-102924]
FX This work was funded by the US National Institutes of Health under
National Institute of Neurological Disorders and Stroke (NINDS) grant
NS058721 (to W.B.D.), National Institute of Child Health & Human
Development (NICHD) grant HD36657 and National Institute of General
Medical Sciences (NIGMS) grant 5-T32-GM08243 (to J.M.G.), the Government
of Canada (to FORGE) through Genome Canada, the Canadian Institutes of
Health Research (CIHR) and the Ontario Genomics Institute (OGI-049).
Additional funding was provided to FORGE by Genome Quebec and Genome
British Columbia. J.-B.R. is supported by a Banting Postdoctoral
Fellowship from the CIHR. K.M.B. is supported by a Clinical
Investigatorship Award from the CIHR Institute of Genetics. The
laboratory of M.O. is funded by Cancer Research UK (CR-UK), the Medical
Research Council (UK) and Leukaemia Lymphoma Research (UK). M.O. is a
Senior CR-UK Research Fellow. We would like to thank the Simons
Foundation Autism Research Initiative (SFARI) for providing control
exome data (grant 191889 to J.S.). We also thank the NIEHS Environmental
Genome Project (contract HHSN273200800010C) and the NHLBI GO Exome
Sequencing Project and its ongoing studies-Lung GO (HL-102923), Broad GO
(HL-102925), Seattle GO (HL-102926), Heart GO (HL-103010) and the
Women's Health Institute (WHI; HL-102924) Sequencing Projects-for
providing exome variant calls for comparison.
NR 55
TC 212
Z9 216
U1 2
U2 17
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1061-4036
EI 1546-1718
J9 NAT GENET
JI Nature Genet.
PD AUG
PY 2012
VL 44
IS 8
BP 934
EP +
DI 10.1038/ng.2331
PG 9
WC Genetics & Heredity
SC Genetics & Heredity
GA 979WV
UT WOS:000306854700021
PM 22729224
ER
PT J
AU Kim, JK
Lee, WM
Kim, P
Choi, M
Jung, K
Kim, S
Yun, SH
AF Kim, Jun Ki
Lee, Woei Ming
Kim, Pilhan
Choi, Myunghwan
Jung, Keehoon
Kim, Seonghoon
Yun, Seok Hyun
TI Fabrication and operation of GRIN probes for in vivo fluorescence
cellular imaging of internal organs in small animals
SO NATURE PROTOCOLS
LA English
DT Article
ID ENDOSCOPY; MICE; ENDOMICROSCOPY; MICROENDOSCOPY; RESOLUTION; CANCER;
CELLS
AB Intravital fluorescence microscopy has emerged as a powerful technique to visualize cellular processes in vivo. However, owing to their size, the objective lenses required have limited physical accessibility to various tissue sites in the internal organs of small animals. The use of small-diameter probes using graded-index (GRIN) lenses expands the capabilities of conventional intravital microscopes to minimally invasive imaging of internal organs. In this protocol, we describe the detailed steps for the fabrication of front-and side-view GRIN probes and the integration and operation of the probes in a confocal microscope to enable visualization of fluorescent cells and microvasculature in various mouse organs. Some experience in building an optical setup is required to complete the protocol. We also present longitudinal imaging of immune cells in renal allografts and tumor development in the colon. Fabrication and integration can be completed in 5-7 h, and a typical in vivo imaging session takes 1-2 h.
C1 [Kim, Jun Ki; Lee, Woei Ming; Kim, Pilhan; Choi, Myunghwan; Jung, Keehoon; Kim, Seonghoon; Yun, Seok Hyun] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Kim, Jun Ki; Lee, Woei Ming; Kim, Pilhan; Choi, Myunghwan; Jung, Keehoon; Kim, Seonghoon; Yun, Seok Hyun] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
[Kim, Pilhan; Choi, Myunghwan; Kim, Seonghoon; Yun, Seok Hyun] Korea Adv Inst Sci & Technol, Grad Sch Nanosci & Technol WCU, Taejon 305701, South Korea.
[Yun, Seok Hyun] Harvard MIT Hlth Sci & Technol, Cambridge, MA USA.
RP Yun, SH (reprint author), Harvard Univ, Sch Med, Boston, MA 02115 USA.
EM syun@hms.harvard.edu
RI Kim, Pilhan/C-1836-2011;
OI Kim, Pilhan/0000-0001-8388-1840; Lee, W M Steve/0000-0002-3912-6095;
Choi, Myunghwan/0000-0002-4235-7003
FU US National Institutes of Health [R21AI081010, RC1DK086242, RC2DK088661,
U54CA143837, R01AI081734, P41EB015903]; US Department of Defense
[FA9550-10-1-0537]; National Research Foundation of Korea [WCU
R31-2008-000-10071-0, 2009-352-C00042, 2011-0009503, WCI 2011-001]
FX We thank R. Colvin and C. Chase for providing the mice with renal
transplantation; R. Kucherlapati and K. Hung for the mouse model of
spontaneous colorectal tumor; H. Ploegh for the MHCII-GFP mice; C. Lin,
D. Cote, L. Kaplan, M. Ferrari and G. Y. Koh for discussions; and D.
Stevenson for proofreading of the manuscript. This work was supported by
grants from the US National Institutes of Health (R21AI081010,
RC1DK086242, RC2DK088661, U54CA143837, R01AI081734, P41EB015903), the US
Department of Defense (FA9550-10-1-0537) and the National Research
Foundation of Korea (WCU R31-2008-000-10071-0, 2009-352-C00042,
2011-0009503, WCI 2011-001).
NR 13
TC 29
Z9 29
U1 2
U2 14
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1754-2189
J9 NAT PROTOC
JI Nat. Protoc.
PD AUG
PY 2012
VL 7
IS 8
BP 1456
EP 1469
DI 10.1038/nprot.2012.078
PG 14
WC Biochemical Research Methods
SC Biochemistry & Molecular Biology
GA 979UK
UT WOS:000306845200002
PM 22767088
ER
PT J
AU Rice, TR
Sher, L
AF Rice, Timothy R.
Sher, Leo
TI Educating non-mental healthcare providers about suicide-risk assessment
in adolescents
SO NEUROPSYCHIATRY
LA English
DT Editorial Material
ID PSYCHOLOGICAL DISTRESS; EMERGENCY-DEPARTMENT; GENERAL-PRACTITIONERS;
PEDIATRIC RESIDENTS; YOUTH SUICIDE; IDEATION; COMPLAINTS; BEHAVIOR
C1 [Rice, Timothy R.; Sher, Leo] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA.
[Rice, Timothy R.; Sher, Leo] James J Peters Vet Adm Med Ctr, Bronx, NY 10468 USA.
RP Rice, TR (reprint author), Mt Sinai Sch Med, Dept Psychiat, 1425 Madison Ave,Box 1230, New York, NY 10029 USA.
EM timothy.rice@mssm.edu
NR 31
TC 0
Z9 0
U1 1
U2 4
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
1QB, ENGLAND
SN 1758-2008
EI 1758-2016
J9 NEUROPSYCHIATRY-LOND
JI Neuropsychiatry
PD AUG
PY 2012
VL 2
IS 4
BP 267
EP 270
DI 10.2217/NPY.12.33
PG 4
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 980JF
UT WOS:000306888700002
ER
PT J
AU Montastruc, F
Schwarz, N
Schmitt, L
Bui, E
AF Montastruc, Francois
Schwarz, Noah
Schmitt, Laurent
Bui, Eric
TI An overview of the symptoms and typical disorders associated with Alice
in Wonderland syndrome
SO NEUROPSYCHIATRY
LA English
DT Article
ID BARR-VIRUS INFECTION; DEPRESSIVE DISORDER; PRESENTING SYMPTOM; H1N1
INFLUENZA; MIGRAINE; CHILDREN; HALLUCINATIONS; MONONUCLEOSIS; PATIENT;
AURA
AB The Alice in Wonderland syndrome refers to a set of symptoms characterized by perceptual distortions, such as visual distortions (i.e., metamorphopsia), body image and time distortions. The Alice in Wonderland syndrome has been described consistently over the past five decades in various cultural settings. Migraine headaches and epilepsy were the etiologies first described and most frequently reported in the literature; however, infectious, neurological, toxic and psychiatric causes have also been reported. Although little is known regarding the specific pathophysiological pathways, dysfunctions of the NMDA neurotransmission and inflammations, as well as edemas of cerebral regions close to the visual pathways may be implicated.
C1 [Montastruc, Francois; Schmitt, Laurent; Bui, Eric] CHU Toulouse, Toulouse, France.
[Montastruc, Francois; Schmitt, Laurent; Bui, Eric] Univ Toulouse, Toulouse, France.
[Schwarz, Noah; Bui, Eric] Massachusetts Gen Hosp, Ctr Anxiety & Traumat Stress Disorders, Boston, MA 02114 USA.
[Schwarz, Noah; Bui, Eric] Harvard Univ, Sch Med, Boston, MA 02114 USA.
RP Bui, E (reprint author), CHU Toulouse, Toulouse, France.
EM tebui@partners.org
RI Schwarz, Noah/B-8525-2015; Bui, Eric/J-8347-2015
OI Schwarz, Noah/0000-0002-4604-1209; Bui, Eric/0000-0002-1413-6473
NR 45
TC 0
Z9 0
U1 0
U2 19
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
1QB, ENGLAND
SN 1758-2008
J9 NEUROPSYCHIATRY-LOND
JI Neuropsychiatry
PD AUG
PY 2012
VL 2
IS 4
BP 281
EP 289
DI 10.2217/NPY.12.37
PG 9
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 980JF
UT WOS:000306888700008
ER
PT J
AU McGuire, JF
Lewin, AB
Geller, DA
Brown, A
Ramsey, K
Mutch, J
Mittelman, A
Micco, J
Jordan, C
Wilhelm, S
Murphy, TK
Small, BJ
Storch, EA
AF McGuire, Joseph F.
Lewin, Adam B.
Geller, Daniel A.
Brown, Ashley
Ramsey, Kesley
Mutch, Jane
Mittelman, Andrew
Micco, Jamie
Jordan, Cary
Wilhelm, Sabine
Murphy, Tanya K.
Small, Brent J.
Storch, Eric A.
TI Advances in the treatment of pediatric obsessive-compulsive disorder:
rationale and design for the evaluation of D-cycloserine with exposure
and response prevention
SO NEUROPSYCHIATRY
LA English
DT Article
ID COGNITIVE-BEHAVIORAL THERAPY; RANDOMIZED CONTROLLED-TRIAL; SOCIAL
ANXIETY DISORDER; FACILITATES EXTINCTION; FUNCTIONAL IMPAIRMENT;
CONDITIONED FEAR; ADVERSE EVENTS; OCD TREATMENT; CHILDREN; ADOLESCENTS
AB Exposure-based cognitive-behavioral therapy and serotonin reuptake inhibitor medications are efficacious treatment options for the management of pediatric obsessive compulsive disorder. Despite established efficacy, many youths receiving either therapy remain symptomatic after acute treatment. Regardless of the rationale for persistent symptoms, a clear need emerges for treatment options that restore functioning efficiently to symptomatic youths. One innovative approach builds upon the identified role of NMDA receptors in the fear extinction process. Instead of breaking existing connections during fear extinction, new associations develop that eventually predominate over prior associations. Recent investigations have explored augmenting exposure-based cognitive-behavioral therapy with the NMDA partial agonist D-cycloserine, with preliminary results demonstrating expedited treatment gains and moderately larger effects above exposure and response prevention therapy alone. A large randomized clinical trial is underway to evaluate the efficacy and efficiency of this therapeutic combination in pediatric obsessive-compulsive disorder. Results from this trial may translate into improved management practices.
C1 [McGuire, Joseph F.; Storch, Eric A.] Univ S Florida, Dept Psychol, Tampa, FL 33620 USA.
[McGuire, Joseph F.; Lewin, Adam B.; Mutch, Jane; Jordan, Cary; Murphy, Tanya K.; Storch, Eric A.] Univ S Florida, Dept Pediactr, St Petersburg, FL 33701 USA.
[Lewin, Adam B.; Murphy, Tanya K.; Storch, Eric A.] Univ S Florida, Dept Psychiat, St Petersburg, FL 33701 USA.
[Geller, Daniel A.; Brown, Ashley; Ramsey, Kesley; Mittelman, Andrew; Micco, Jamie; Wilhelm, Sabine] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Geller, Daniel A.; Brown, Ashley; Ramsey, Kesley; Mittelman, Andrew; Micco, Jamie; Wilhelm, Sabine] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Small, Brent J.] Univ S Florida, Sch Aging Studies, Tampa, FL 33620 USA.
RP Storch, EA (reprint author), Univ S Florida, Dept Psychol, 4202 E Fowler Ave, Tampa, FL 33620 USA.
EM estorch@health.usf.edu
RI Storch, Eric/I-4935-2012; Lewin, Adam/A-9832-2013; Murphy,
Tanya/J-7079-2013;
OI Small, Brent/0000-0002-7444-4689
FU NIH; Agency for Healthcare Research and Quality; National Alliance for
Research on Schizophrenia, Affective Disorders; Boehringer Ingelheim;
Janssen Pharmaceuticals; International OCD Foundation; Tourette Syndrome
Association; All Children's Hospital Research Foundation; CDC; National
Alliance for Research on Schizophrenia and Affective Disorders;
Foundation for Research on Prader-Willi Syndrome; All Children's
Hospital Guild Endowed Chair; Forest Laboratories
FX AB Lewin receives grant funding from the NIH, Agency for Healthcare
Research and Quality, National Alliance for Research on Schizophrenia,
Affective Disorders and International OCD Foundation. He is also a
consultant for Prophase, Inc. DA Geller has received grant funding in
the last 3 years from the NIH. In the last 3 years DA Geller has
received research support from Boehringer Ingelheim. In addition, he has
received honoraria for speaking engagements from Eli Lily and has sat on
the Eli Lily Bureau and Medical Advisory Board. S Wilhelm receives
research funding from the NIH. She also receives royalties from Oxford
University Press, New Harbinger Publications and Guilford Publications.
S Wilhelm receives support in the form of free medication and matching
placebo from Forest Laboratories for a clinical trial funded by the NIH.
She also receives speaking honoraria from PRIMEDIA Healthcare, a
publicly traded company working as a logistics collaborator for the
Massachusetts General Hospital Psychiatry Academy (the education
programs conducted by the Massachusetts General Hospital Psychiatry
Academy were supported through Independent Medical Education grants from
pharmaceutical companies co-supporting the overall program, along with
participant tuition). She has also received speaking honoraria from
various academic institutions. TK Murphy has received research support
in the past 3 years from the NIH, Forest Laboratories, Janssen
Pharmaceuticals, International OCD Foundation, Tourette Syndrome
Association, All Children's Hospital Research Foundation, CDC and
National Alliance for Research on Schizophrenia and Affective Disorders.
TK Murphy is on the Medical Advisory Board for Tourette Syndrome
Association. She receives textbook honorarium from Lawrence Erlbaum. BJ
Small receives grant funding from the NIH. EA Storch has received grant
funding in the last 3 years from the NIH, All Children's Hospital
Research Foundation, CDC, Agency for Healthcare Research and Quality,
National Alliance for Research on Schizophrenia and Affective Disorders,
International OCD Foundation, Tourette Syndrome Association, Janssen
Pharmaceuticals and Foundation for Research on Prader-Willi Syndrome. He
receives textbook honorarium from Springer publishers, American
Psychological Association and Lawrence Erlbaum. EA Scorch has been an
educational consultant for Rogers Memorial Hospital. He is a consultant
for Prophase, Inc. and CroNos, Inc., and is on the Speaker's Bureau and
Scientific Advisory Board for the International OCD Foundation. He
receives research support from the All Children's Hospital Guild Endowed
Chair. The authors have no other relevant affiliations or financial
involvement with any organization or entity with a financial interest in
or financial conflict with the subject matter or materials discussed in
the manuscript apart from those disclosed.
NR 74
TC 5
Z9 5
U1 4
U2 8
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
1QB, ENGLAND
SN 1758-2008
J9 NEUROPSYCHIATRY-LOND
JI Neuropsychiatry
PD AUG
PY 2012
VL 2
IS 4
BP 291
EP 300
DI 10.2217/NPY.12.38
PG 10
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 980JF
UT WOS:000306888700009
ER
PT J
AU Wilens, TE
Morrison, NR
AF Wilens, Timothy E.
Morrison, Nicholas R.
TI Substance-use disorders in adolescents and adults with ADHD: focus on
treatment
SO NEUROPSYCHIATRY
LA English
DT Review
ID ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; DEFICIT HYPERACTIVITY
DISORDER; RANDOMIZED CONTROLLED-TRIAL; OSMOTIC-RELEASE METHYLPHENIDATE;
COMORBIDITY SURVEY REPLICATION; COGNITIVE-BEHAVIORAL THERAPY;
PLACEBO-CONTROLLED TRIAL; PRESCRIPTION STIMULANTS; DOUBLE-BLIND;
COLLEGE-STUDENTS
AB A high prevalence of comorbidity of ADHD and substance-use disorders (SUDs) has been shown in the literature. In this article, the literature for the treatment of adolescents and adults with co-occurring ADHD and SUD is examined. Findings from pharmacotherapy suggest mild improvement in ADHD without demonstrable changes in SUD unless the addiction was stabilized prior to treating the ADHD. No unique adverse effects, worsening of SUD, misuse or diversion of stimulants are reported in the included studies. Treating ADHD pharmacologically in individuals with ADHD plus SUD only has a modest impact on ADHD and SUD that is not observed in controlled trials. Limited data in adults with ADHD and brief abstinence of their SUD showed improvements in both ADHD and SUD with treatment. Further studies of cognitive behavioral therapy, sequencing of therapies and longer term treatment outcomes for groups with ADHD and active SUD are necessary.
C1 [Wilens, Timothy E.; Morrison, Nicholas R.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Child Psychiat Serv,Ctr Addict Med, Boston, MA 02114 USA.
RP Wilens, TE (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Child Psychiat Serv,Ctr Addict Med, YAW 6A,55 Fruit St, Boston, MA 02114 USA.
EM twilens@partners.org
FU NIH [K24 DA016264]; Abbott; Euthymics; McNeil; Lilly; NIH (NIDA); Merck;
Novartis; Shire
FX This research was supported by the NIH grant K24 DA016264 to TE Wilens.
TE Wilens has received or receives grant support, has been a speaker
for, or receives research support from Abbott, Euthymics, McNeil, Lilly,
NIH (NIDA), Merck, Novartis and Shire. The authors have no other
relevant affiliations or financial involvement with any organization or
entity with a financial interest in or financial conflict with the
subject matter or materials discussed in the manuscript apart from those
disclosed.
NR 71
TC 5
Z9 5
U1 3
U2 19
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
1QB, ENGLAND
SN 1758-2008
EI 1758-2016
J9 NEUROPSYCHIATRY-LOND
JI Neuropsychiatry
PD AUG
PY 2012
VL 2
IS 4
BP 301
EP 312
DI 10.2217/NPY.12.39
PG 12
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 980JF
UT WOS:000306888700010
PM 23105949
ER
PT J
AU Abramovitch, A
Mittelman, A
Henin, A
Geller, D
AF Abramovitch, Amitai
Mittelman, Andrew
Henin, Aude
Geller, Daniel
TI Neuroimaging and neuropsychological findings in pediatric
obsessive-compulsive disorder: a review and developmental considerations
SO NEUROPSYCHIATRY
LA English
DT Review
ID CEREBRAL-BLOOD-FLOW; COGNITIVE-BEHAVIORAL THERAPY; TRAUMATIC
BRAIN-INJURY; DEFICIT HYPERACTIVITY DISORDER; NONVERBAL MEMORY
IMPAIRMENT; OSTERRIETH COMPLEX FIGURE; EXECUTIVE FUNCTION;
NEUROCOGNITIVE ENDOPHENOTYPES; STRUCTURAL ABNORMALITIES; STREPTOCOCCAL
INFECTION
AB Obsessive-compulsive disorder (OCD) is one of the most prevalent psychiatric disorders affecting children and adolescents. In the last decade, our knowledge base of pediatric OCD has increased greatly. In examining pediatric OCD, neuropsychological performance may serve as a bridge between brain functioning and the phenomenology of the disorder. Recent advances in neuropsychological and neuroimaging techniques have led to significant interest in the neurobiological underpinnings of OCD. Although considerable research has been conducted on adults with this disorder, relatively little research has been directed towards similarly afflicted youth. Neurobiological research including lesion, structural and functional imaging studies are reviewed, along with the literature on neuropsychological testing and deficits associated with the disorder. Emphasizing both the neural and cognitive developmental processes within the pediatric population, these findings are examined and critiqued within a developmental framework.
C1 [Abramovitch, Amitai; Henin, Aude; Geller, Daniel] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02114 USA.
[Abramovitch, Amitai; Mittelman, Andrew; Henin, Aude; Geller, Daniel] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
RP Abramovitch, A (reprint author), Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02114 USA.
EM aabramovitch@partners.org
RI Abramovitch, Amitai/I-3333-2012
OI Abramovitch, Amitai/0000-0001-9640-0970
FU AstraZeneca; Bristol-Myers Squibb; Forest Laboratories Inc.; Janssen;
Lilly; McNeil Pediatrics; Pfizer; Prechter Foundation; Sanofi Aventis;
Shire; Stanley Foundation; UCB Pharma, Inc.; Wyetb; NIH; Boehringer
Ingelheim; Pharmacia
FX A Henin has received honoraria from Reed Medical Education (a logistics
collaborator for the MGH Psychiatry Academy). The education programs
conducted by the MGH Psychiatry Academy were supported, in part, through
independent medical education grants from pharmaceutical companies,
including AstraZeneca, Bristol-Myers Squibb, Forest Laboratories Inc.,
Janssen, Lilly, McNeil Pediatrics, Pfizer, Pharmacia, the Prechter
Foundation, Sanofi Aventis, Shire, the Stanley Foundation, UCB Pharma,
Inc. and Wyetb. In addition, A Henin has received honoraria from Shire,
Abbott Laboratories and American Academy of Child and Adolescent
Psychiatry and she receives royalties from Oxford University Press. She
has been a consultant for Pfizer, Prophase and Concordant Rater Systems.
D Geller has received grant funding in the last 3 years from the NIH. In
the last 3 years D Geller has received research support from Boehringer
Ingelheim. In addition, he has received honoraria for speaking
engagements from Eli Lily and has sat on the Eli Lily Bureau and Medical
Advisory Board. The authors have no other relevant affiliations or
financial involvement with any organization or entity with a financial
interest in or financial conflict with the subject matter or materials
discussed in the manuscript apart from those disclosed.
NR 162
TC 10
Z9 11
U1 10
U2 34
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
1QB, ENGLAND
SN 1758-2008
EI 1758-2016
J9 NEUROPSYCHIATRY-LOND
JI Neuropsychiatry
PD AUG
PY 2012
VL 2
IS 4
BP 313
EP 329
DI 10.2217/NPY.12.40
PG 17
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 980JF
UT WOS:000306888700011
ER
PT J
AU Bacha, F
Pyle, L
Nadeau, K
Cuttler, L
Goland, R
Haymond, M
Levitsky, L
Lynch, J
Weinstock, RS
White, NH
Caprio, S
Arslanian, S
AF Bacha, Fida
Pyle, Laura
Nadeau, Kristen
Cuttler, Leona
Goland, Robin
Haymond, Morey
Levitsky, Lynne
Lynch, Jane
Weinstock, Ruth S.
White, Neil H.
Caprio, Sonia
Arslanian, Silva
CA TODAY Study Grp
TI Determinants of glycemic control in youth with type 2 diabetes at
randomization in the TODAY study
SO PEDIATRIC DIABETES
LA English
DT Article
DE disposition index; glycemic control; insulin secretion; insulin
sensitivity; youth type 2 diabetes
ID GLUCOSE-TOLERANCE TEST; BETA-CELL FUNCTION; INSULIN-RESISTANCE; OBESE
YOUTH; FOLLOW-UP; SENSITIVITY; ADOLESCENTS; SECRETION; FAILURE; MELLITUS
AB Objective To investigate insulin sensitivity and secretion indices and determinants of glycemic control in youth with recent-onset type 2 diabetes (T2DM) at randomization in the TODAY study, the largest study of youth with T2DM to date. Methods We examined estimates of insulin sensitivity [1/fasting insulin (1/IF), fasting glucose/insulin (GF/IF), 1/fasting C-peptide (1/CF), GF/CF], beta-cell function [insulinogenic index (?I30/?G30), and ?C30/?G30], and disposition index (DI) in the TODAY cohort of 704 youth (14.0 +/- 2.0 yr; diabetes duration 7.8 +/- 5.8 months; 64.9% female; 41.1% Hispanic, 31.5% Black, 19.6% White, 6.1% American Indian, and 1.7% Asian) according to hemoglobin A1c (HbA1c) quartiles at study randomization. The randomization visit followed a run-in period (median 71 d) during which glycemic control (HbA1c = 8% for at least 2 months) was achieved with metformin alone. These measures were also examined in relation to screening HbA1c levels before run-in. Results Insulin secretion indices declined with increasing HbA1c quartiles, at randomization (?C30/?G30: 0.11 +/- 0.09, 0.10 +/- 0.19, 0.07 +/- 0.06, and 0.03 +/- 0.03 ng/mL per mg/dL, p < 0.0001; DI: 0.03 +/- 0.03, 0.03 +/- 0.05, 0.02 +/- 0.02, and 0.01 +/- 0.01 mg/dL-1, p < 0.0001) and at screening, with no significant difference in insulin sensitivity. There were no significant differences in estimates of insulin sensitivity or secretion between genders or across the different racial groups. At randomization and screening, HbA1c correlated with DI (r = -0.3, p < 0.001), with ?C30/?G30, but not with insulin sensitivity estimates. Conclusions In youth with recent-onset T2DM treated with metformin, glycemic control, as measured by HbA1c, appears to be associated with residual beta-cell function and not insulin sensitivity.
C1 [Pyle, Laura] George Washington Univ, Ctr Biostat, TODAY Study Grp, Rockville, MD 20853 USA.
[Bacha, Fida; Arslanian, Silva] UPMC, Childrens Hosp Pittsburgh, Pittsburgh, PA USA.
[Nadeau, Kristen] Univ Colorado, Childrens Hosp Colorado, Div Pediat Endocrinol, Denver, CO 80202 USA.
[Cuttler, Leona] Case Western Reserve Univ, Rainbow Babies & Childrens Hosp, Cleveland, OH 44106 USA.
[Goland, Robin] Columbia Univ, Naomi Berrie Diabet Ctr, New York, NY USA.
[Bacha, Fida; Haymond, Morey] Baylor Coll Med, Childrens Nutr Res Ctr, Houston, TX 77030 USA.
[Levitsky, Lynne] Massachusetts Gen Hosp, Ctr Diabet, Pediat Endocrine Unit, Boston, MA 02114 USA.
[Lynch, Jane] Univ Texas Hlth Sci Ctr San Antonio, Div Pediat Endocrinol, San Antonio, TX 78229 USA.
[Weinstock, Ruth S.] SUNY Upstate Med Univ, Dept Med, Syracuse, NY USA.
[White, Neil H.] Washington Univ, Dept Pediat, St Louis, MO 63130 USA.
[Caprio, Sonia] Yale Univ, Dept Pediat, New Haven, CT 06520 USA.
RP Pyle, L (reprint author), George Washington Univ, Ctr Biostat, TODAY Study Grp, 6110 Execut Blvd,Suite 750, Rockville, MD 20853 USA.
EM lpyle@bsc.gwu.edu
OI Zeitler, Philip/0000-0001-5756-7858
FU Becton, Dickinson and Company; Bristol-Myers Squibb; Eli Lilly and
Company; GlaxoSmithKline; LifeScan, Inc.; Pfizer; Sanofi-aventis;
NIDDK/NIH [U01-DK61212, U01-DK61230, U01-DK61239, U01-DK61242,
U01DK61254]; National Center for Research Resources General Clinical
Research Centers [M01-RR00036, M01-RR00043-45, M01RR00069, M01-RR00084,
M01-RR01066, M01-RR00125, M01-RR14467]; NCRR [UL1-RR024134,
UL1-RR024139, UL1-RR024153, UL1RR024989, UL1-RR024992, UL1-RR025758,
UL1-RR025780]
FX The TODAY Study Group thanks the following companies for donations in
support of the study's efforts: Becton, Dickinson and Company;
Bristol-Myers Squibb; Eli Lilly and Company; GlaxoSmithKline; LifeScan,
Inc.; Pfizer; Sanofi-aventis. This work was completed with funding from
NIDDK/NIH grant numbers U01-DK61212, U01-DK61230, U01-DK61239,
U01-DK61242, and U01DK61254; from the National Center for Research
Resources General Clinical Research Centers Program grant numbers
M01-RR00036 (Washington University School of Medicine), M01-RR00043-45
(Children's Hospital Los Angeles), M01RR00069 (University of Colorado
Denver), M01-RR00084 (Children's Hospital of Pittsburgh), M01-RR01066
(Massachusetts General Hospital), M01-RR00125 (Yale University), and
M01-RR14467 (University of Oklahoma Health Sciences Center); and from
the NCRR Clinical and Translational Science Awards grant numbers
UL1-RR024134 (Children's Hospital of Philadelphia), UL1-RR024139 (Yale
University), UL1-RR024153 (Children's Hospital of Pittsburgh),
UL1RR024989 (Case Western Reserve University), UL1-RR024992 (Washington
University), UL1-RR025758 (Massachusetts General Hospital), and
UL1-RR025780 (University of Colorado Denver).
NR 19
TC 12
Z9 12
U1 0
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1399-543X
J9 PEDIATR DIABETES
JI Pediatr. Diabetes
PD AUG
PY 2012
VL 13
IS 5
BP 377
EP 384
DI 10.1111/j.1399-5448.2011.00841.x
PG 8
WC Endocrinology & Metabolism; Pediatrics
SC Endocrinology & Metabolism; Pediatrics
GA 981HJ
UT WOS:000306957300002
PM 22332798
ER
PT J
AU Laffel, L
Chang, N
Grey, M
Hale, D
Higgins, L
Hirst, K
Izquierdo, R
Larking, M
Macha, C
Pham, T
Wauters, A
Weinstock, RS
AF Laffel, Lori
Chang, Nancy
Grey, Margaret
Hale, Dan
Higgins, Laurie
Hirst, Kathryn
Izquierdo, Roberto
Larking, Mary
Macha, Christina
Trang Pham
Wauters, Aimee
Weinstock, Ruth S.
CA TODAY Study Grp
TI Metformin monotherapy in youth with recent onset type 2 diabetes:
experience from the prerandomization run-in phase of the TODAY study
SO PEDIATRIC DIABETES
LA English
DT Article
DE clinical trial; hemoglobin A1c; metformin; pediatric onset; type 2
diabetes
ID GLYCEMIC CONTROL; ADOLESCENTS; CHILDREN; INTERVENTION; PREVALENCE;
MELLITUS; SEARCH; LIFE
AB Background TODAY (Treatment Options for type 2 Diabetes in Adolescents and Youth) is a federally funded multicenter randomized clinical trial comparing three treatments of youth onset type 2 diabetes. Objective To describe the experience of youth participating in a 26 month run-in period in preparation for randomization into TODAY. Subjects An ethnically diverse sample of 927 youth, 65.4% females, aged 13.7 +/- 2.0 yr old, with type 2 diabetes for a median of 2 months (0.77.8 months, 25th75th percentiles). Methods A run-in period was conducted to achieve HbA1c <8% with metformin monotherapy and diabetes education, and to evaluate adherence to pill taking, visit attendance, and other procedures. Results At entry, mean body mass index (BMI) and z-BMI were 35.6 +/- 7.7 and 2.3 +/- 0.4, respectively, mean HbA1c was 7.7 +/- 2.2%, only 42.5% were on a hypoglycemic treatment, and 35.6% had HbA1c =8%. Comorbid conditions were common; 18.8% had hypertension, 24.2% had elevated cholesterol, and 6.5% had abnormal liver enzymes. After a median 71 d of run-in, 90.9% had HbA1c <8%, 77.9% had HbA1c <7%, and 46.4% had HbA1c <6%. Of the 772 youth achieving the target HbA1c <8%, 704 (91.2%) were randomized; non-adherence to metformin treatment was the main cause for non-randomization. Youth proceeding to randomization decreased weight by 0.68?kg and HbA1c by 1.45% compared to a weight gain of 0.71?kg and HbA1c decrease of 0.74% in the non-randomized youth (p = 0.01 in both cases). However, change in z-BMI was not significantly different between the two groups. Conclusions Most youth with recent onset type 2 diabetes can achieve target HbA1c <8.0% with short-term metformin monotherapy and standard diabetes education ( identifier: NCT00081328).
C1 [Hirst, Kathryn; Trang Pham] George Washington Univ, Ctr Biostat, Rockville, MD 20852 USA.
[Laffel, Lori; Higgins, Laurie] Joslin Diabet Ctr, Boston, MA 02215 USA.
[Chang, Nancy] Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA.
[Grey, Margaret] Yale Univ, New Haven, CT 06519 USA.
[Hale, Dan; Wauters, Aimee] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Izquierdo, Roberto; Weinstock, Ruth S.] SUNY Upstate Med Univ, Syracuse, NY 13214 USA.
[Larking, Mary] Massachusetts Gen Hosp, Ctr Diabet, Boston, MA 02114 USA.
[Macha, Christina] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK 73104 USA.
RP Hirst, K (reprint author), George Washington Univ, Ctr Biostat, 6110 Execut Blvd,Suite 750, Rockville, MD 20852 USA.
EM khirst@bsc.gwu.edu
OI Zeitler, Philip/0000-0001-5756-7858
FU NIDDK/NIH [01-DK61212, U01-DK61230, U01-DK61239, U01-DK61242,
U01-DK61254]; National Center for Research Resources General Clinical
Research Centers [M01-RR00036, M01-RR00043-45, M01-RR00069, M01-RR00084,
M01-RR01066, M01-RR00125, M01-RR14467]; NCRR [UL1-RR024134,
UL1-RR024139, UL1-RR024153, UL1-RR024989, UL1-RR024992, UL1-RR025758,
UL1-RR025780]; Becton, Dickinson and Company; Bristol-Myers Squibb; Eli
Lilly and Company; Eli Lilly and Company, GlaxoSmithKline; LifeScan,
Inc.; Pfizer; Sanofi-Aventis
FX This work was completed with funding from NIDDK/NIH grant numbers
U01-DK61212, U01-DK61230, U01-DK61239, U01-DK61242, and U01-DK61254;
from the National Center for Research Resources General Clinical
Research Centers Program grant numbers M01-RR00036 (Washington
University School of Medicine), M01-RR00043-45 (Childrens Hospital Los
Angeles), M01-RR00069 (University of Colorado Denver), M01-RR00084
(Children's Hospital of Pittsburgh), M01-RR01066 (Massachusetts General
Hospital), M01-RR00125 (Yale University), and M01-RR14467 (University of
Oklahoma Health Sciences Center); and from the NCRR Clinical and
Translational Science Awards grant numbers UL1-RR024134 (Children's
Hospital of Philadelphia), UL1-RR024139 (Yale University), UL1-RR024153
(Children's Hospital of Pittsburgh), UL1-RR024989 (Case Western Reserve
University), UL1-RR024992 (Washington University), UL1-RR025758
(Massachusetts General Hospital), and UL1-RR025780 (University of
Colorado Denver).; The TODAY Study Group thanks the following companies
for donations in support of the study's efforts: Becton, Dickinson and
Company, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline,
LifeScan, Inc., Pfizer, and Sanofi-Aventis.
NR 17
TC 10
Z9 13
U1 1
U2 13
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1399-543X
J9 PEDIATR DIABETES
JI Pediatr. Diabetes
PD AUG
PY 2012
VL 13
IS 5
BP 385
EP 391
DI 10.1111/j.1399-5448.2011.00846.x
PG 7
WC Endocrinology & Metabolism; Pediatrics
SC Endocrinology & Metabolism; Pediatrics
GA 981HJ
UT WOS:000306957300003
PM 22369102
ER
PT J
AU Cooper, RA
Grindle, GG
Vazquez, JJ
Xu, J
Wang, H
Candiotti, J
Chung, C
Salatin, B
Houston, E
Kelleher, A
Cooper, R
Teodorski, E
Beach, S
AF Cooper, Rory A.
Grindle, G. G.
Vazquez, J. J.
Xu, J.
Wang, H.
Candiotti, J.
Chung, C.
Salatin, B.
Houston, E.
Kelleher, A.
Cooper, R.
Teodorski, E.
Beach, S.
TI Personal Mobility and Manipulation Appliance-Design, Development, and
Initial Testing
SO PROCEEDINGS OF THE IEEE
LA English
DT Article
DE Electric powered wheelchair (EPW); manipulation; people with
disabilities; rehabilitation; robotics
ID ASSISTIVE TECHNOLOGY; WHEELCHAIR; REHABILITATION; ROBOT; USERS
AB The ability to perform activities of daily living and mobility-related activities of daily living are substantial indicators of one's ability to live at home and to participate in one's community. Technologies to assist with mobility and manipulation are among the most important tools that clinicians can provide to people with disabilities to promote independence and community participation. For people with severe disabilities involving both the upper and lower extremities, there are few systems that provide practical and coordinated assistance with mobility and manipulation tasks. The personal mobility and manipulation appliance (PerMMA) was created in response to goals set forth by a team of clinicians and people with disabilities.
C1 [Cooper, Rory A.; Grindle, G. G.; Vazquez, J. J.; Wang, H.; Candiotti, J.; Salatin, B.; Kelleher, A.; Cooper, R.; Teodorski, E.] Dept Vet Affairs, Human Engn Res Labs, Rehabil Res & Dev Serv, Pittsburgh, PA 15206 USA.
[Cooper, Rory A.; Grindle, G. G.; Vazquez, J. J.; Xu, J.; Wang, H.; Candiotti, J.; Chung, C.; Salatin, B.; Houston, E.; Kelleher, A.; Cooper, R.; Teodorski, E.] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA 15260 USA.
[Xu, J.; Chung, C.; Houston, E.] VA Pittsburgh Healthcare Syst, Rehabil Res & Dev Serv, Dept Vet Affairs VA, Human Engn Res Labs, Pittsburgh, PA 15206 USA.
[Beach, S.] Univ Pittsburgh, Univ Ctr Social & Urban Res, Pittsburgh, PA 15260 USA.
RP Cooper, RA (reprint author), Dept Vet Affairs, Human Engn Res Labs, Rehabil Res & Dev Serv, Pittsburgh, PA 15206 USA.
EM RCOOPER@pitt.edu
RI Wang, Hongwu/J-6133-2013
OI Wang, Hongwu/0000-0002-6567-9144
FU NSF-ERC Quality of Life Technology [EEC-0540865]; VA Rehabilitation
Research & Development Center [B6789C]
FX This work was supported in part by the NSF-ERC Quality of Life
Technology (EEC-0540865) and the VA Rehabilitation Research &
Development Center (B6789C). The contents of this paper do not represent
the views of the Department of Veterans Affairs or the United States
Government.
NR 12
TC 10
Z9 10
U1 0
U2 7
PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC
PI PISCATAWAY
PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA
SN 0018-9219
J9 P IEEE
JI Proc. IEEE
PD AUG
PY 2012
VL 100
IS 8
SI SI
BP 2505
EP 2511
DI 10.1109/JPROC.2012.2200537
PG 7
WC Engineering, Electrical & Electronic
SC Engineering
GA 976NV
UT WOS:000306592500010
ER
PT J
AU Bartels, CM
Kind, AJH
Thorpe, CT
Everett, CM
Cook, RJ
McBride, PE
Smith, MA
AF Bartels, Christie M.
Kind, Amy J. H.
Thorpe, Carolyn T.
Everett, Christine M.
Cook, Rachel J.
McBride, Patrick E.
Smith, Maureen A.
TI Lipid Testing in Patients with Rheumatoid Arthritis and Key
Cardiovascular-Related Comorbidities: A Medicare Analysis
SO SEMINARS IN ARTHRITIS AND RHEUMATISM
LA English
DT Review
DE rheumatoid arthritis; cardiovascular disease; prevention and control;
preventive medicine; cholesterol
ID QUALITY-OF-CARE; POSITIVE PREDICTIVE-VALUE; ADMINISTRATIVE DATA;
ORTHOPEDIC-SURGERY; CLAIMS; RISK; MANAGEMENT; RECOMMENDATIONS;
ASSOCIATION; SENSITIVITY
AB Objective: For patients with rheumatoid arthritis (RA) and comorbid cardiovascular disease (CVD), diabetes, or hyperlipidemia, annual lipid testing is recommended to reduce morbidity and mortality from comorbidities. Given trends encouraging complex patients to receive care in "medical homes," we examined associations between regularly seeing a primary care provider (PCP) and lipid testing in RA patients with cardiovascular-related comorbidities.
Methods: We performed a retrospective cohort study examining a 5% random USA Medicare sample (2004-06) of beneficiaries over 65 years old with RA and concomitant CVD, diabetes, or hyperlipidemia (n = 16,893). We examined the relationship between receiving lipid testing in 2006 and having at least 1 PCP visit per year in 2004, 2005, and 2006 using multivariate regression.
Results: Ninety percent of patients had prevalent CVD; 46% had diabetes, and 64% had hyperlipidemia. However, annual lipid testing was only performed in 63% of these RA patients. Thirty percent of patients saw a PCP less than once per year, despite frequent visits (mean >9) with other providers. Patients without at least 1 annual PCP visit were 16% less likely to have lipid testing. Increased age, complexity scores, hospitalization, and large town residence predicted decreased lipid testing.
Conclusions: Despite comorbid CVD, diabetes, or hyperlipidemia, 30% of Medicare RA patients saw a PCP less than once per year, and 1 in 3 lacked annual lipid testing. Findings support advocating primary care visits at least once per year. Remaining gaps in lipid testing suggest the need for additional strategies to improve lipid testing in at-risk RA patients. (C) 2012 Elsevier Inc. All rights reserved. Semin Arthritis Rheum 42:9-16
C1 [Bartels, Christie M.] Univ Wisconsin, Rheumatol Sect, Dept Med, Sch Med & Publ Hlth, Madison, WI USA.
[Kind, Amy J. H.; Everett, Christine M.] Univ Wisconsin, Dept Med, Div Geriatr, Sch Med & Publ Hlth, Madison, WI USA.
[Kind, Amy J. H.] William S Middleton Hosp, GRECC, US Dept Vet Affairs, Madison, WI USA.
[Thorpe, Carolyn T.] Vet Affairs Pittsburgh Healthcare Syst, Hlth Serv Res & Dev, Pittsburgh, PA USA.
[Thorpe, Carolyn T.] Univ Pittsburgh, Dept Pharm & Therapeut, Pittsburgh, PA USA.
[Cook, Rachel J.] Univ Wisconsin, Dept Med, Hematol Oncol Sect, Sch Med & Publ Hlth, Madison, WI USA.
[McBride, Patrick E.] Univ Wisconsin, Dept Med, Cardiovasc Div, Sch Med & Publ Hlth, Madison, WI USA.
[Smith, Maureen A.] Univ Wisconsin, Dept Populat Hlth Sci, Sch Med & Publ Hlth, Madison, WI USA.
[Smith, Maureen A.] Univ Wisconsin, Dept Family Med, Sch Med & Publ Hlth, Madison, WI USA.
[Smith, Maureen A.] Univ Wisconsin, Dept Surg, Sch Med & Publ Hlth, Madison, WI USA.
RP Bartels, CM (reprint author), 1685 Highland Ave,Room 4132, Madison, WI 53705 USA.
EM cb4@medicine.wisc.edu
FU University of Wisconsin Institute for Clinical and Translational
Research; National Center for Research Resources, National Institutes of
Health [1UL1RR025011]
FX This project was supported by a training grant and partnership with the
Health Innovation Program and the Community-Academic Partnerships core
of the University of Wisconsin Institute for Clinical and Translational
Research (UW-ICTR). Grant 1UL1RR025011 from the Clinical and
Translational Science Award (CTSA) program of the National Center for
Research Resources, National Institutes of Health. Additional support
was provided by the UW School of Medicine and Public Health from the
Wisconsin Partnership Program. The authors have no potential conflicts
of interest. The Health Innovation Program assisted with data management
and manuscript preparation.
NR 38
TC 12
Z9 12
U1 1
U2 4
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0049-0172
EI 1532-866X
J9 SEMIN ARTHRITIS RHEU
JI Semin. Arthritis Rheum.
PD AUG
PY 2012
VL 42
IS 1
BP 9
EP 16
DI 10.1016/j.semarthrit.2012.01.005
PG 8
WC Rheumatology
SC Rheumatology
GA 982GF
UT WOS:000307030300002
PM 22424813
ER
PT J
AU Fukudome, EY
Li, YQ
Kochanek, AR
Lu, J
Smith, EJ
Liu, BL
Kim, K
Velmahos, GC
Demoya, MA
Alam, HB
AF Fukudome, Eugene Y.
Li, Yongqing
Kochanek, Ashley R.
Lu, Jennifer
Smith, Eleanor J.
Liu, Baoling
Kim, Kyuseok
Velmahos, George C.
deMoya, Marc A.
Alam, Hasan B.
TI Pharmacologic resuscitation decreases circulating cytokine-induced
neutrophil chemoattractant-1 levels and attenuates hemorrhage-induced
acute lung injury
SO SURGERY
LA English
DT Article; Proceedings Paper
CT 6th Annual Academic Surgical Congress
CY FEB 01-03, 2011
CL Huntington Beach, CA
SP Assoc Acad Surg (AAS), Soc Univ Surg (SUS)
ID KERATINOCYTE-DERIVED CHEMOKINE; HISTONE DEACETYLASE ACTIVITY; VALPROIC
ACID; FLUID RESUSCITATION; CARDIAC HISTONES; MESSENGER-RNA; SHOCK; RAT;
ACETYLATION; IDENTIFICATION
AB Background. Acute lung injury (ALI) is a complication of hemorrhagic shock (HS). Histone deacetylase inhibitors, such as valproic acid (VPA), can improve survival after HS; however, their effects on late organ injury are unknown. Herein, we have investigated the effects of HS and VPA treatment on ALI and circulating cytokines that may serve as biomarkers for the development of organ injury.
Methods. Anesthetized Wistar-Kyoto rats (250-300 g) underwent 40% blood volume hemorrhage over 10 minutes followed by 30 minutes of unresuscitated shock and were treated with either VPA (300 mg/kg) or vehicle control. Blood samples were obtained at baseline, after shock, and before death (at 1, 4, and 20 hours; n = 3-4/timepoint/group). Serum samples were screened for possible biomarkers using a multiplex electrochemiluminescence detection assay, and results were confirmed using enzyme-linked immunosorbent assay (ELISA). In addition, lung tissue lysate was examined for chemokine and myeloperoxidase (MPO) levels as a marker for neutrophil infiltration and ALL Lung cytokine-induced neutrophil chemoattractant-1 (CINC-1; a chemokine belonging to the interleukin-8 family that promotes neutrophil chemotaxis) mRNA levels were measured by real-time polymerase chain reaction studies.
Results. Serum screening revealed that hemorrhage rapidly altered levels of circulating CINC-1. ELISA confirmed that CINC-1 protein was significantly elevated in the serum as early as 4 hours and in the lung at 20 hours after hemorrhage, without any significant changes in CINC-1 mRNA expression. Lung MPO levels were also elevated at both 4 and 20 hours after hemorrhage. VPA treatment attenuated these changes.
Conclusion. Hemorrhage resulted in the development of ALI, which was prevented with VPA treatment. Circulating CINC-1 levels rose rapidly after hemorrhage, and serum CINC-1 levels correlated with lung CINC-1 and MPO levels. This suggests that circulating CINC-1 levels could be used as an early marker for the subsequent development of organ inflammation and injury. (Surgery 2012;152:254-61.)
C1 [Fukudome, Eugene Y.; Li, Yongqing; Kochanek, Ashley R.; Lu, Jennifer; Smith, Eleanor J.; Liu, Baoling; Kim, Kyuseok; Velmahos, George C.; deMoya, Marc A.; Alam, Hasan B.] Harvard Univ, Massachusetts Gen Hosp, Div Trauma Emergency Surg & Surg Crit Care, Sch Med,Dept Surg, Boston, MA 02114 USA.
RP Alam, HB (reprint author), Harvard Univ, Massachusetts Gen Hosp, Div Trauma Emergency Surg & Surg Crit Care, Sch Med,Dept Surg, 165 Cambridge St,Suite 810, Boston, MA 02114 USA.
EM hbalam@partners.org
OI Kim, Kyuseok/0000-0002-7991-9428
FU NIGMS NIH HHS [R01 GM084127]
NR 37
TC 10
Z9 11
U1 3
U2 10
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0039-6060
J9 SURGERY
JI Surgery
PD AUG
PY 2012
VL 152
IS 2
BP 254
EP 261
DI 10.1016/j.surg.2012.03.013
PG 8
WC Surgery
SC Surgery
GA 983ZP
UT WOS:000307157500016
PM 22657731
ER
PT J
AU Ginat, DT
Mangla, R
Yeaney, G
Schaefer, PW
Wang, H
AF Ginat, Daniel T.
Mangla, Rajiv
Yeaney, Gabrielle
Schaefer, Pamela W.
Wang, Henry
TI Correlation between Dynamic Contrast-enhanced Perfusion MRI Relative
Cerebral Blood Volume and Vascular Endothelial Growth Factor Expression
in Meningiomas
SO ACADEMIC RADIOLOGY
LA English
DT Article
DE Meningioma; dynamic-susceptibility contrast-enhanced MR perfusion; VEGF;
CBV
ID MALIGNANT MENINGIOMAS; ANGIOGENESIS; GLIOMAS; DIFFERENTIATION;
PERMEABILITY; THERAPIES; EDEMA; GRADE
AB Purpose: To determine whether there is a correlation between vascular endothelial growth factor (VEGF) expression and cerebral blood flow (CBV) measurements in dynamic contrast-enhanced susceptibility perfusion magnetic resonance imaging (MRI) and to correlate the perfusion characteristics in high- versus low-grade meningiomas.
Methods and Materials: A total of 48 (24 high-grade and 24 low-grade) meningiomas with available dynamic susceptibility-weighted MRI were retrospectively reviewed for maximum CBV and semiquantitative VEGF immunoreactivity. Correlation between normalized CBV and VEGF was made using the Spearman rank test and comparison between CBV in high- versus low-grade meningiomas was made using the Wilcoxon test.
Results: There was a significant (P =.01) correlation between normalized maximum CBV and VEGF scores with a Spearman correlation coefficient of 0.37. In addition, there was a significant (P <.01) difference in normalized maximum CBV ratios between high-grade meningiomas (mean 12.6; standard deviation 5.2) and low-grade meningiomas (mean 8.2; standard deviation 5.2).
Conclusion: The data suggest that CBV accurately reflects VEGF expression and tumor grade in meningiomas. Perfusion-weighted MRI can potentially serve as a useful biomarker for meningiomas, pending prospective studies.
C1 [Ginat, Daniel T.; Mangla, Rajiv; Wang, Henry] Univ Rochester, Med Ctr, Dept Imaging Sci, Rochester, NY 14642 USA.
[Yeaney, Gabrielle] Univ Rochester, Med Ctr, Dept Pathol, Rochester, NY 14642 USA.
[Schaefer, Pamela W.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
RP Ginat, DT (reprint author), Univ Rochester, Med Ctr, Dept Imaging Sci, 601 Elmwood Ave, Rochester, NY 14642 USA.
EM ginatd01@gmail.com
FU SIR Grant [5-28644]
FX From the Departments of Imaging Sciences (D.T.G., R.M., H.W.) and
Pathology (G.Y.), University of Rochester Medical Center, 601 Elmwood
Avenue, Rochester, NY 14642; Department of Radiology, Massachusetts
General Hospital, Boston, MA (P.W.S.). Received January 30, 2012;
accepted April 4, 2012. Funded by SIR Grant 5-28644. We also thank Rui
Hu, PhD, for his assistance with the statistical analysis. Address
correspondence to: D.T.G. e-mail: ginatd01@gmail.com
NR 26
TC 6
Z9 7
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1076-6332
EI 1878-4046
J9 ACAD RADIOL
JI Acad. Radiol.
PD AUG
PY 2012
VL 19
IS 8
BP 986
EP 990
DI 10.1016/j.acra.2012.04.006
PG 5
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 978DE
UT WOS:000306720000011
PM 22591719
ER
PT J
AU Demidova-Rice, TN
Hamblin, MR
Herman, IM
AF Demidova-Rice, Tatiana N.
Hamblin, Michael R.
Herman, Ira M.
TI Acute and Impaired Wound Healing: Pathophysiology and Current Methods
for Drug Delivery, Part 2: Role of Growth Factors in Normal and
Pathological Wound Healing: Therapeutic Potential and Methods of
Delivery
SO ADVANCES IN SKIN & WOUND CARE
LA English
DT Article
DE acute wound healing; drug delivery; growth factors; wound healing
ID SMOOTH-MUSCLE-CELLS; GENETICALLY DIABETIC MOUSE; GENE-TRANSFER;
IN-VITRO; TGF-BETA; EXTRACELLULAR-MATRIX; COLLAGEN MATRICES;
BIOLOGICAL-ACTIVITY; PDGF-BB; PHOTOCROSSLINKABLE CHITOSAN
AB This is the second of 2 articles that discuss the biology and pathophysiology of wound healing, reviewing the role that growth factors play in this process and describing the current methods for growth factor delivery into the wound bed.
C1 [Herman, Ira M.] Tufts Univ, Sackler Sch Grad Biomed Sci, Program Cellular & Mol Physiol, Boston, MA 02111 USA.
[Herman, Ira M.] Ctr Innovat Wound Healing Res, Boston, MA USA.
[Demidova-Rice, Tatiana N.; Herman, Ira M.] Tufts Univ, Sch Med, Boston, MA 02111 USA.
[Demidova-Rice, Tatiana N.] Massachusetts Gen Hosp, EL Steele Lab Tumor Biol, Boston, MA 02114 USA.
[Hamblin, Michael R.] Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02114 USA.
[Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
RP Herman, IM (reprint author), Tufts Univ, Sackler Sch Grad Biomed Sci, Program Cellular & Mol Physiol, Boston, MA 02111 USA.
EM ira.herman@tufts.edu
OI Hamblin, Michael/0000-0001-6431-4605
FU National Institutes of Health; Wound Care Partners, LLC
FX Tatiana N. Demidova-Rice, PhD, was a postdoctoral Fellow at Tufts
University School of Medicine, Boston, Massachusetts, when this article
was submitted. She is a postdoctoral fellow at E. L. Steele Laboratory
of Tumor Biology, Massachusetts General Hospital, Boston. Michael R.
Hamblin, PhD, is Associate Professor, Department of Dermatology and
Principal Investigator, Wellman Center for Photomedicine, Massachusetts
General Hospital, Boston. Ira M. Herman, PhD, is Professor and Director,
Program in Cellular and Molecular Physiology, Sackler School of Graduate
Biomedical Sciences and The Center for Innovations in Wound Healing
Research, and Tufts University School of Medicine, Boston,
Massachusetts. Drs Demidova-Rice and Hamblin have disclosed they have no
financial relationships related to this article. Dr Herman has disclosed
that he is/was a recipient of grant/research funding from the National
Institutes of Health, and Wound Care Partners, LLC; is/was a
consultant/advisor to Healthpoint Biotherapeutics, Inc, and Nell One,
Inc; was a consultant/advisor to Healthpro Bioventures and Amach
Partners; and is a stock shareholder in Wound Care Partners, LLC.
Correspondence may be sent to Dr Herman at ira.herman@tufts.edu.
Submitted January 27, 2011; accepted in revised version June 8, 2011.
NR 188
TC 25
Z9 25
U1 3
U2 19
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1527-7941
J9 ADV SKIN WOUND CARE
JI Adv. Skin Wound Care
PD AUG
PY 2012
VL 25
IS 8
BP 349
EP 370
DI 10.1097/01.ASW.0000418541.31366.a3
PG 22
WC Dermatology; Nursing; Surgery
SC Dermatology; Nursing; Surgery
GA 978MZ
UT WOS:000306747500003
PM 22820962
ER
PT J
AU Byers, AL
Covinsky, KE
Barnes, DE
Yaffe, K
AF Byers, Amy L.
Covinsky, Kenneth E.
Barnes, Deborah E.
Yaffe, Kristine
TI Dysthymia and Depression Increase Risk of Dementia and Mortality Among
Older Veterans
SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Article
DE Dementia; depression; dysthymia; mortality
ID MILD COGNITIVE IMPAIRMENT; CARDIOVASCULAR HEALTH; LATE-LIFE;
ALZHEIMERS-DISEASE; VASCULAR-DISEASE; ELDERLY PERSONS; SYMPTOMS;
ASSOCIATION; WOMEN; DECLINE
AB Objective: To determine whether less severe depression spectrum diagnoses such as dysthymia, as well as depression, are associated with risk of developing dementia and mortality in a "real-world" setting. Design: Retrospective cohort study conducted using the Department of Veterans Affairs (VA) National Patient Care Database (1997-2007). Setting: VA medical centers in the United States. Participants: A total of 281,540 veterans aged 55 years and older without dementia at study baseline (1997-2000). Measurements: Depression status and incident dementia were ascertained from International Classification of Diseases, Ninth Revision codes during study baseline (1997-2000) and follow-up (2001-2007), respectively. Mortality was ascertained by time of death dates in the VA Vital Status File. Results: Ten percent of veterans had baseline diagnosis of depression and nearly 1% had dysthymia. The unadjusted incidence of dementia was 11.2% in veterans with depression, 10.2% with dysthymia and 6.4% with neither. After adjusting for demographics and comorbidities, patients diagnosed with dysthymia or depression were twice as likely to develop incident dementia compared with those with no dysthymia/depression (adjusted dysthymia hazard ratio [HR]: 1.96, 95% confidence interval [CI]: 1.71-2.25; and depression HR: 2.18, 95% CI: 2.08-2.28). Dysthymia and depression also were associated with increased risk of death (31.6% dysthymia and 32.9% depression versus 28.5% neither; adjusted dysthymia HR: 1.41, 95% CI: 1.31-1.53; and depression HR: 1.47, 95% CI: 1.43-1.51). Conclusions: Findings suggest that older adults with dysthymia or depression need to be monitored closely for adverse outcomes. Future studies should determine whether treatment of depression spectrum disorders may reduce risk of these outcomes. (Am J Geriatr Psychiatry 2012; 20:664-672)
C1 [Byers, Amy L.; Covinsky, Kenneth E.; Barnes, Deborah E.; Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA 94121 USA.
[Byers, Amy L.; Barnes, Deborah E.; Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA.
[Covinsky, Kenneth E.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
[Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA.
[Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
RP Byers, AL (reprint author), San Francisco VA Med Ctr, 4150 Clement St 116H, San Francisco, CA 94121 USA.
EM Amy.Byers@ucsf.edu
FU Department of Defense [W81XWH-05-2-0094]; National Institute of Mental
Health [K01 MH079093]; National Institute on Aging [AG031155, AG029812];
NARSAD
FX This work was supported by the Department of Defense (W81XWH-05-2-0094
[KY]) and the National Institute of Mental Health (K01 MH079093 [ALB]).
Drs. Yaffe and Covinsky are supported in part by K24 Midcareer
Investigator Awards from the National Institute on Aging (AG031155 [KY]
and AG029812 [KEC]). Dr. Barnes was supported in part by NARSAD.
NR 40
TC 31
Z9 34
U1 4
U2 11
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1064-7481
J9 AM J GERIAT PSYCHIAT
JI Am. J. Geriatr. Psychiatr.
PD AUG
PY 2012
VL 20
IS 8
BP 664
EP 672
DI 10.1097/JGP.0b013e31822001c1
PG 9
WC Geriatrics & Gerontology; Gerontology; Psychiatry
SC Geriatrics & Gerontology; Psychiatry
GA 977UX
UT WOS:000306691400004
PM 21597358
ER
PT J
AU Schneider, B
Ercoli, L
Siddarth, P
Lavretsky, H
AF Schneider, Brooke
Ercoli, Linda
Siddarth, Prabha
Lavretsky, Helen
TI Vascular Burden and Cognitive Functioning in Depressed Older Adults
SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Article
DE Cerebrovascular risk factors; cognitive impairment; geriatric
depression; vascular disease
ID LATE-LIFE DEPRESSION; PRIMARY-CARE PATIENTS; SUBCORTICAL ISCHEMIC
DEPRESSION; CEREBROVASCULAR RISK-FACTORS; EXECUTIVE DYSFUNCTION;
GERIATRIC DEPRESSION; NEUROPSYCHIATRIC SYMPTOMS; CARDIOVASCULAR HEALTH;
RATING-SCALE; IMPAIRMENT
AB Background: Vascular burden is known to contribute to geriatric depression and cognitive impairment. The objective of our study was to evaluate the relationship between vascular burden and pattern of cognitive impairment in older adults with depression. Methods: Ninety-four community-dwelling older adults (mean age = 70.8 years; SD = 7.63) diagnosed with major depression were recruited to participate in the tai chi complementary use study aimed to improve antidepressant response to an antidepressant medication. All participants received comprehensive evaluations of depression, apathy, and vascular risk factors, and completed a battery of cognitive measures of memory, cognitive control, verbal fluency, and attention. Results: The severity of vascular burden was significantly correlated with depression severity and impaired performance on measures of cognitive control (i.e., inhibition/mental flexibility), and attention, but not memory or verbal fluency. Neither the severity of comorbid apathy nor medical illness burden was related to cognitive impairment. Conclusions: Vascular burden in older depressed adults contributes to cognitive impairment, particularly in domains of attention and cognitive control. Our findings suggest that aggressive treatment of vascular risk factors may reduce risk for further cognitive decline in depressed older adults. (Am J Geriatr Psychiatry 2012; 20:673-681)
C1 [Lavretsky, Helen] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90095 USA.
[Schneider, Brooke] Greater Los Angeles VA Healthcare Ctr, Psychol Serv, Los Angeles, CA USA.
RP Lavretsky, H (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Semel Inst Neurosci & Human Behav, 760 Westwood Plaza,C9-948A, Los Angeles, CA 90095 USA.
EM hlavrets@ucla.edu
RI Lavretsky, Helen/M-5711-2015
OI Lavretsky, Helen/0000-0001-9990-5085
FU NIH [MH077650, MH086481, AT003480]; Forest Research Institute;
Alzheimer's Prevention Research Foundation
FX This work was supported by the NIH grants MH077650, MH086481, and
AT003480 to Dr. Lavretsky. Research grants from the Forest Research
Institute; Alzheimer's Prevention Research Foundation.
NR 65
TC 4
Z9 4
U1 1
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1064-7481
J9 AM J GERIAT PSYCHIAT
JI Am. J. Geriatr. Psychiatr.
PD AUG
PY 2012
VL 20
IS 8
BP 673
EP 681
DI 10.1097/JGP.0b013e31822ccd64
PG 9
WC Geriatrics & Gerontology; Gerontology; Psychiatry
SC Geriatrics & Gerontology; Psychiatry
GA 977UX
UT WOS:000306691400005
PM 21857219
ER
PT J
AU Brenes, GA
Miller, ME
Williamson, JD
McCall, WV
Knudson, M
Stanley, MA
AF Brenes, Gretchen A.
Miller, Michael E.
Williamson, Jeff D.
McCall, W. Vaughn
Knudson, Mark
Stanley, Melinda A.
TI A Randomized Controlled Trial of Telephone-Delivered
Cognitive-Behavioral Therapy for Late-Life Anxiety Disorders
SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Article
DE Anxiety; cognitive-behavioral therapy; elderly; generalized anxiety
disorder; panic disorder; telephone-delivered psychotherapy
ID WORKING ALLIANCE INVENTORY; OLDER-ADULTS; PRIMARY-CARE; PSYCHOMETRIC
PROPERTIES; MENTAL-DISORDERS; HEALTH SURVEY; SHORT-FORM; VALIDATION;
DEPRESSION; STATE
AB Objectives: Older adults face a number of barriers to receiving psychotherapy, such as a lack of transportation and access to providers. One way to overcome such barriers is to provide treatment by telephone. The purpose of this study was to examine the effects of cognitive behavioral therapy delivered by telephone (CBT-T) to older adults diagnosed with an anxiety disorder. Design: Randomized controlled trial. Setting: Participants' homes. Participants: Sixty participants age 60 and older with a diagnosis of generalized anxiety disorder, panic disorder, or anxiety disorder not otherwise specified. Intervention: CBT-T versus information-only comparison. Measurements: Coprimary outcomes included worry (Penn State Worry Questionnaire) and general anxiety (State Trait Anxiety Inventory). Secondary outcomes included clinician-rated anxiety (Hamilton Anxiety Rating Scale), anxiety sensitivity (Anxiety Sensitivity Index), depressive symptoms (Beck Depression Inventory), quality of life (SF-36), and sleep (Insomnia Severity Index). Assessments were completed prior to randomization, immediately upon completion of treatment, and 6 months after completing treatment. Results: CBT-T was superior to information-only in reducing general anxiety (ES = 0.71), worry (ES = 0.61), anxiety sensitivity (ES = 0.85), and insomnia (ES = 0.82) at the posttreatment assessment; however, only the reductions in worry were maintained by the 6-month follow-up assessment (ES = 0.80). Conclusions: These results suggest that CBT-T may be efficacious in reducing anxiety and worry in older adults, but additional sessions may be needed to maintain these effects. (Am J Geriatr Psychiatry 2012; 20:707-716)
C1 [Brenes, Gretchen A.; McCall, W. Vaughn] Wake Forest Univ, Bowman Gray Sch Med, Dept Psychiat & Behav Med, Winston Salem, NC 27157 USA.
[Miller, Michael E.] Wake Forest Univ, Bowman Gray Sch Med, Dept Biostat Sci, Winston Salem, NC 27157 USA.
[Williamson, Jeff D.] Wake Forest Univ, Bowman Gray Sch Med, Dept Internal Med, Sect Gerontol & Geriatr Med, Winston Salem, NC 27157 USA.
[Knudson, Mark] Wake Forest Univ, Bowman Gray Sch Med, Dept Family & Community Med, Winston Salem, NC 27157 USA.
[Stanley, Melinda A.] Houston Ctr Qual Care & Utilizat Studies, Menninger Dept Psychiat & Behav Sci, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA.
RP Brenes, GA (reprint author), Wake Forest Univ, Bowman Gray Sch Med, Dept Psychiat & Behav Med, Med Ctr Blvd, Winston Salem, NC 27157 USA.
EM gbrenes@wfubmc.edu
FU National Institute of Mental Health [MH65281, MH53932]; Wake Forest
University Claude D. Pepper Older Americans Independence Center
[P30-AG21332]; VA HSR&D Houston Center of Excellence [HFP90-020]
FX This research was supported by National Institute of Mental Health Grant
MH65281 to Gretchen A. Brenes, Wake Forest University Claude D. Pepper
Older Americans Independence Center (P30-AG21332), and National
Institute of Mental Health Grant MH53932 to Melinda A. Stanley. It was
also partly supported by the VA HSR&D Houston Center of Excellence
(HFP90-020). The content is solely the responsibility of the authors and
does not necessarily represent the official views of the NIMH, the NIH,
the Department of Veterans Affairs or Baylor College of Medicine. The
NIMH had no role in the design and conduct of the study; the collection,
management, analysis and interpretation of the data; or the preparation,
review or approval of the manuscript.
NR 39
TC 17
Z9 17
U1 3
U2 23
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1064-7481
J9 AM J GERIAT PSYCHIAT
JI Am. J. Geriatr. Psychiatr.
PD AUG
PY 2012
VL 20
IS 8
BP 707
EP 716
DI 10.1097/JGP.0b013e31822ccd3e
PG 10
WC Geriatrics & Gerontology; Gerontology; Psychiatry
SC Geriatrics & Gerontology; Psychiatry
GA 977UX
UT WOS:000306691400009
PM 22828172
ER
PT J
AU Smith, SE
Mullen, TE
Graham, D
Sims, KB
Rehm, HL
AF Smith, Sharon E.
Mullen, Thomas E.
Graham, Dionne
Sims, Katherine B.
Rehm, Heidi L.
TI Norrie disease: Extraocular clinical manifestations in 56 patients
SO AMERICAN JOURNAL OF MEDICAL GENETICS PART A
LA English
DT Article
DE Norrie disease; hearing loss; congenital blindness; peripheral vascular
disease; developmental delay; autism; pervasive developmental disorder;
intellectual disability; erectile dysfunction
ID VENOUS INSUFFICIENCY; VASCULAR DEVELOPMENT; RETINAL VASCULATURE; NDP
GENE; PHENOTYPE; FRIZZLED-4; MUTATIONS; DELETION; MICE; ANGIOGENESIS
AB Norrie disease (ND) is an X-linked recessive disorder characterized by congenital blindness, progressive sensorineural hearing loss and cognitive impairment. The ocular phenotype has been well described, while the extraocular manifestations of the disorder are not well understood. We present the data from the Norrie Disease Registry, which consists of 56 patients with detailed clinical histories and genotype data. This study represents the largest, detailed investigation into the phenotypic spectrum of ND to date and more importantly expands knowledge of the extraocular clinical manifestations. We identify several novel aspects of the syndrome that will improve the management of these patients. In particular, we expand our understanding of the neurologic manifestations in ND and identify a chronic seizure disorder in approximately 10% of all patients. In addition, details of the hearing phenotype are described including the median age of onset (12 years of age) and how genotype affects onset. Moreover, we find vascular disease to be a significant component of ND; and vascular health should be, in the future, a component of patient clinical care. In summary, the results expand our understanding of the phenotypic variability and genotypic heterogeneity in ND patients. (C) 2012 Wiley Periodicals, Inc.
C1 [Smith, Sharon E.] Harvard Univ, Sch Med, Genet Training Program, Boston, MA USA.
[Mullen, Thomas E.; Rehm, Heidi L.] Brigham & Womens Hosp, Dept Pathol, Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Graham, Dionne] Childrens Hosp, Clin Res Program, Boston, MA 02115 USA.
[Sims, Katherine B.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
[Sims, Katherine B.] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
RP Rehm, HL (reprint author), Mol Med Lab, 65 Landsdowne St, Cambridge, MA 02139 USA.
EM hrehm@partners.org
NR 35
TC 8
Z9 8
U1 0
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1552-4825
EI 1552-4833
J9 AM J MED GENET A
JI Am. J. Med. Genet. A
PD AUG
PY 2012
VL 158A
IS 8
BP 1909
EP 1917
DI 10.1002/ajmg.a.35469
PG 9
WC Genetics & Heredity
SC Genetics & Heredity
GA 977IT
UT WOS:000306651400016
PM 22786811
ER
PT J
AU Burris, HH
Rifas-Shiman, SL
Camargo, CA
Litonjua, AA
Huh, SY
Rich-Edwards, JW
Gillman, MW
AF Burris, Heather H.
Rifas-Shiman, Sheryl L.
Camargo, Carlos A., Jr.
Litonjua, Augusto A.
Huh, Susanna Y.
Rich-Edwards, Janet W.
Gillman, Matthew W.
TI Plasma 25-hydroxyvitamin D during pregnancy and small-for-gestational
age in black and white infants
SO ANNALS OF EPIDEMIOLOGY
LA English
DT Article
DE Vitamin D; Infant; Small-for-gestational age; African continental
ancestry group; Health status disparities; Pregnancy
ID VITAMIN-D STATUS; INTRAUTERINE GROWTH-RETARDATION; OFFSPRING BIRTH SIZE;
FETAL-GROWTH; D SUPPLEMENTATION; D DEFICIENCY; SERUM CONCENTRATIONS; D
INSUFFICIENCY; WOMEN; OUTCOMES
AB Purpose: In a prospective prenatal cohort study, we examined associations of second trimester and cord plasma 25-hydroxyvitamin D (25[OH]D) with small-for-gestational age (SGA) and the extent to which vitamin D might explain black/white differences in SGA.
Methods: We studied 1067 white and 236 black mother-infant pairs recruited from eight obstetrical offices early in pregnancy in Massachusetts. We analyzed 25(OH)D levels using an immunoassay and performed multivariable logistic models to estimate the odds of SGA by category of 25(OH)D level.
Results: Mean (SD) second trimester 25(OH)D level was 60 nmol/L (SD, 21) and was lower for black (46 nmol/L [SD, 221) than white (62 nmol/L [SD, 201) women. Fifty-nine infants were SGA (4.5%), and more black than white infants were SGA (8.5% vs. 3.7%). The odds of SGA were higher with maternal 25(OH)D levels less than 25 versus 25 nmol/L or greater (adjusted odds ratio, 3.17; 95% confidence interval, 1.16-8.63). The increased odds of SGA among black versus white participants decreased from an odds ratio of 2.04(1.04, 4.04) to 1.68(0.82, 3.46) after adjusting for 25(OH)D.
Conclusions: Second trimester 25(OH)D levels less than 25 nmol/L were associated with higher odds of SGA. Our data raise the possibility that vitamin D status may contribute to racial disparities in SGA. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Burris, Heather H.] Harvard Univ, Dept Neonatol, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA.
[Burris, Heather H.] Harvard Univ, Childrens Hosp Boston, Div Newborn Med, Sch Med, Boston, MA 02215 USA.
[Rifas-Shiman, Sheryl L.; Gillman, Matthew W.] Harvard Univ, Dept Populat Med, Obes Prevent Program, Sch Med, Boston, MA 02215 USA.
[Rifas-Shiman, Sheryl L.; Gillman, Matthew W.] Harvard Pilgrim Hlth Care Inst, Boston, MA USA.
[Camargo, Carlos A., Jr.] Harvard Univ, Massachusetts Gen Hosp, Dept Emergency Med, Sch Med, Boston, MA 02215 USA.
[Camargo, Carlos A., Jr.; Litonjua, Augusto A.] Harvard Univ, Brigham & Womens Hosp, Dept Med, Charming Lab,Med Sch, Boston, MA 02215 USA.
[Litonjua, Augusto A.] Brigham & Womens Hosp, Div Pulm & Crit Care, Boston, MA 02115 USA.
[Huh, Susanna Y.] Harvard Univ, Childrens Hosp Boston, Div Gastroenterol & Nutr, Sch Med, Boston, MA 02215 USA.
[Rich-Edwards, Janet W.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Womens Hlth,Dept Med, Boston, MA 02215 USA.
[Rich-Edwards, Janet W.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02215 USA.
[Gillman, Matthew W.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02215 USA.
RP Burris, HH (reprint author), Harvard Univ, Dept Neonatol, Beth Israel Deaconess Med Ctr, Sch Med, 330 Brookline Ave,RO 318, Boston, MA 02215 USA.
EM heburris@bidmc.harvard.edu
OI Burris, Heather/0000-0003-4510-9547; Litonjua,
Augusto/0000-0003-0422-5875
FU U.S.National Institutes of Health [HD 034568, HL 068041, HL 064925];
Harvard Medical School; Harvard Pilgrim Health Care Foundation; Klarman
Scholars Program at Beth Israel Deaconess Medical Center
FX This work was supported by the U.S.National Institutes of Health (HD
034568, HL 068041, and HL 064925), Harvard Medical School, the Harvard
Pilgrim Health Care Foundation, and the Klarman Scholars Program at Beth
Israel Deaconess Medical Center.
NR 50
TC 36
Z9 37
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1047-2797
J9 ANN EPIDEMIOL
JI Ann. Epidemiol.
PD AUG
PY 2012
VL 22
IS 8
BP 581
EP 586
DI 10.1016/j.annepidem.2012.04.015
PG 6
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 978UH
UT WOS:000306770800007
PM 22658824
ER
PT J
AU Yoon, SS
AF Yoon, Sam S.
TI Staging Gastric Cancer Patients after Complete Surgical Resection: Which
System Should We Use?
SO ANNALS OF SURGICAL ONCOLOGY
LA English
DT Editorial Material
ID SURGERY; ADENOCARCINOMA; SURVIVAL; CARCINOMA; MORTALITY; EDITION; VOLUME
C1 Harvard Univ, Sch Med, Dept Surg, Div Surg Oncol,Massachusetts Gen Hosp, Boston, MA 02115 USA.
RP Yoon, SS (reprint author), Harvard Univ, Sch Med, Dept Surg, Div Surg Oncol,Massachusetts Gen Hosp, Boston, MA 02115 USA.
EM syoon@partners.org
NR 28
TC 2
Z9 2
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1068-9265
J9 ANN SURG ONCOL
JI Ann. Surg. Oncol.
PD AUG
PY 2012
VL 19
IS 8
BP 2423
EP 2425
DI 10.1245/s10434-012-2405-4
PG 3
WC Oncology; Surgery
SC Oncology; Surgery
GA 979BD
UT WOS:000306789000001
PM 22618720
ER
PT J
AU Hong, NJL
Pandalai, PK
Hornick, JL
Shekar, PS
Harmon, DC
Chen, YL
Butrynski, JE
Baldini, EH
Raut, CP
AF Hong, Nicole J. Look
Pandalai, Prakash K.
Hornick, Jason L.
Shekar, Prem S.
Harmon, David C.
Chen, Yen-Lin
Butrynski, James E.
Baldini, Elizabeth H.
Raut, Chandrajit P.
TI Cardiac Angiosarcoma Management and Outcomes: 20-Year Single-institution
Experience
SO ANNALS OF SURGICAL ONCOLOGY
LA English
DT Article; Proceedings Paper
CT 92nd Annual Meeting of the New-England-Surgical-Society
CY SEP 23-25, 2011
CL Bretton Woods, NH
SP New England Surg Soc
ID HEART-TRANSPLANTATION; SURGICAL-TREATMENT; TERM SURVIVAL; TUMORS;
SARCOMAS; PACLITAXEL; DOCETAXEL; DISEASE
AB To identify the clinicopathologic characteristics, treatments, and outcomes of a series of patients with primary cardiac angiosarcoma (AS).
This retrospective case series was set in a tertiary referral center with a multidisciplinary clinic. Consecutive patients with institutionally confirmed pathologic diagnosis of cardiac AS from January 1990 to May 2011 were reviewed. Main outcome measures included patient demographics, tumor characteristics, management strategies, disease response, and survival.
Data from 18 patients (78 % male) were reviewed. Sixteen patients (89 %) had AS originating in the right atrium. At diagnosis, eight patients (44 %) had localized/locally advanced disease and ten patients (56 %) had metastatic disease. Initial treatment strategies included resection (44 %), chemotherapy (39 %), and radiotherapy (11 %). Of the eight patients with localized/locally advanced AS, two underwent macroscopically complete resection with negative microscopic margins, one underwent macroscopically complete resection with positive microscopic margins, one underwent macroscopically incomplete resection, two received chemotherapy followed by surgery and intraoperative radiotherapy, one received chemotherapy alone, and one died before planned radiotherapy. Median follow-up was 12 months. Median overall survival (OS) was 13 months for the entire cohort; median OS was 19.5 months for those presenting with localized/locally advanced AS and 6 months for those with metastatic disease at presentation (p = 0.08). Patients who underwent primary tumor resection had improved median OS compared with patients whose tumors remained in situ (17 vs. 5 months, p = 0.01).
Cardiac AS is associated with poor prognosis. Resection of primary tumor should be attempted when feasible, as OS may be improved. Nevertheless, most patients die of disease progression.
C1 [Hong, Nicole J. Look; Raut, Chandrajit P.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Surg Oncol,Brigham & Womens Hosp,Ctr Sarcoma, Boston, MA 02115 USA.
[Pandalai, Prakash K.] NCI, NIH, Surg Branch, Bethesda, MD 20892 USA.
[Hornick, Jason L.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pathol,Brigham & Womens Hosp,Ctr Sarcoma & B, Boston, MA 02115 USA.
[Shekar, Prem S.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Cardiac Surg, Boston, MA 02115 USA.
[Harmon, David C.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Med Oncol, Boston, MA 02115 USA.
[Chen, Yen-Lin] Harvard Univ, Sch Med, Div Radiat Oncol, Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Butrynski, James E.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Med Oncol,Brigham & Womens Hosp,Ctr Sarcoma &, Boston, MA 02115 USA.
[Baldini, Elizabeth H.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Radiat Oncol,Brigham & Womens Hosp,Ctr Sarcom, Boston, MA 02115 USA.
RP Hong, NJL (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Surg Oncol,Brigham & Womens Hosp,Ctr Sarcoma, 44 Binney St, Boston, MA 02115 USA.
EM n.lookhong@utoronto.ca
NR 38
TC 11
Z9 12
U1 1
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1068-9265
EI 1534-4681
J9 ANN SURG ONCOL
JI Ann. Surg. Oncol.
PD AUG
PY 2012
VL 19
IS 8
BP 2707
EP 2715
DI 10.1245/s10434-012-2334-2
PG 9
WC Oncology; Surgery
SC Oncology; Surgery
GA 979BD
UT WOS:000306789000040
ER
PT J
AU Bakaeen, FG
Sethi, G
Wagner, TH
Kelly, R
Lee, K
Upadhyay, A
Thai, H
Juneman, E
Goldman, S
Holman, WL
AF Bakaeen, Faisal G.
Sethi, Gulshan
Wagner, Todd H.
Kelly, Rosemary
Lee, Kelvin
Upadhyay, Anjali
Hoang Thai
Juneman, Elizabeth
Goldman, Steven
Holman, William L.
TI Coronary Artery Bypass Graft Patency: Residents Versus Attending
Surgeons
SO ANNALS OF THORACIC SURGERY
LA English
DT Article; Proceedings Paper
CT Late-Breaking Clinical Trial Abstract Session on Congenital Heart
Surgery at the 48th Annual Meeting of the Society-of-Thoracic-Surgeons /
Surgical Motion Picture Session
CY JAN 28-FEB 01, 2012
CL Fort Lauderdale, FL
SP Soc Thorac Surg
ID VOLUME-OUTCOME RELATIONSHIP; TRAIN RESIDENTS; IMPACT; EXPERIENCE; LEVEL;
SAFE
AB Background. Data are limited regarding the patency of coronary artery bypass grafts performed by residents versus attending surgeons.
Methods. We analyzed data from a multicenter, randomized Veterans Affairs Cooperative Study in which the left internal mammary artery was used preferentially to graft the left anterior descending coronary artery, and the best remaining coronary vessel received (per random assignment) either a radial artery or a saphenous vein graft. The study vessel's 1-year graft patency was the primary outcome measure. Secondary outcomes included operative times, operative morbidity, mortality, repeat revascularization, cost, angina symptoms, and quality of life. Multivariate analyses were used to compare patient outcomes for residents versus attendings.
Results. Residents were designated as primary surgeons in 23% of cases (167 of 725). Among the 531 patients who had a 1-year angiogram, study graft patency rates for resident cases (n = 122) and attending cases (n = 409) were not significantly different (86% versus 90%, p = 0.22). Residents' cases had longer perfusion time (119 versus 105 minutes, p < 0.0001) and cross-clamp time (84 versus 68 minutes, p < 0.0001). After risk adjustment, all outcome measures did not differ between the two groups, and there was no apparent interaction effect between resident/attending designation and radial artery versus saphenous vein use or on-pump versus off-pump approach.
Conclusions. Surgeons in training perform coronary artery bypass surgery without compromising graft patency or patient outcomes. Ongoing evaluation of residents' performance and surgical outcomes is needed, given the major changes that are occurring in residency training. (Ann Thorac Surg 2012;94:482-8) (c) 2012 by The Society of Thoracic Surgeons
C1 Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
Baylor Coll Med, Div Cardiothorac Surg, Michael E DeBakey Dept Surg, Houston, TX 77030 USA.
St Lukes Episcopal Hosp, Texas Heart Inst, Div Cardiovasc Surg, Houston, TX USA.
Univ Arizona, Hlth Sci Ctr, Dept Cardiothorac Surg, Tucson, AZ USA.
Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA.
Univ Minnesota Hosp, Dept Cardiovasc Surg, Minneapolis, MN USA.
So Arizona Vet Affairs Hlth Care Syst, Tucson, AZ USA.
Univ Arizona, Tucson, AZ USA.
Univ Alabama Birmingham, Div Cardiothorac Surg, Birmingham, AL USA.
RP Bakaeen, FG (reprint author), Michael E DeBakey VAMC, Dept Cardiothorac Surg, OCL 112,2002 Holcombe Blvd, Houston, TX 77030 USA.
EM fbakaeen@bcm.edu
NR 25
TC 4
Z9 4
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0003-4975
J9 ANN THORAC SURG
JI Ann. Thorac. Surg.
PD AUG
PY 2012
VL 94
IS 2
BP 482
EP 488
DI 10.1016/j.athoracsur.2012.04.039
PG 7
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA 977YA
UT WOS:000306700100031
PM 22698772
ER
PT J
AU Jacobs, JP
Shahian, DM
Edwards, FH
O'Brien, SM
Blackstone, EH
Puskas, JD
Schaffer, J
Grover, FL
Mayer, JE
AF Jacobs, Jeffrey P.
Shahian, David M.
Edwards, Fred H.
O'Brien, Sean M.
Blackstone, Eugene H.
Puskas, John D.
Schaffer, Justin
Grover, Frederick L.
Mayer, John E., Jr.
TI Fundamental Flaw in a Fundamental Measure: Inaccuracies in Death Data
Reporting Reply
SO ANNALS OF THORACIC SURGERY
LA English
DT Letter
C1 [Jacobs, Jeffrey P.] Univ S Florida, Congenital Heart Inst Florida, All Childrens Hosp, Coll Med, St Petersburg, FL 33701 USA.
[Shahian, David M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
[Edwards, Fred H.] Univ Florida, Coll Med Jacksonville, Jacksonville, FL USA.
[O'Brien, Sean M.] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA.
[Blackstone, Eugene H.] Cleveland Clin, Cleveland, OH 44106 USA.
[Puskas, John D.] Emory Univ, Emory Univ Hosp Midtown, Atlanta, GA 30322 USA.
[Schaffer, Justin] Stanford Univ, Med Ctr, Stanford, CA 94305 USA.
[Grover, Frederick L.] Univ Colorado Denver, Sch Med, Aurora, CO USA.
[Mayer, John E., Jr.] Harvard Univ, Sch Med, Childrens Hosp Boston, Boston, MA USA.
RP Jacobs, JP (reprint author), Univ S Florida, Congenital Heart Inst Florida, All Childrens Hosp, Coll Med, 625 6th Ave S,Ste 475, St Petersburg, FL 33701 USA.
EM jeffjacobs@msn.com
RI O'Brien, Sean/H-6268-2013
NR 5
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0003-4975
J9 ANN THORAC SURG
JI Ann. Thorac. Surg.
PD AUG
PY 2012
VL 94
IS 2
BP 693
EP 694
PG 2
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA 977YA
UT WOS:000306700100086
ER
PT J
AU Fu, K
Tang, QZ
Feng, JX
Liu, XS
Zhang, Y
AF Fu, Kai
Tang, Qianzi
Feng, Jianxing
Liu, X. Shirley
Zhang, Yong
TI DiNuP: a systematic approach to identify regions of differential
nucleosome positioning
SO BIOINFORMATICS
LA English
DT Article
ID DYNAMIC NUCLEOSOMES; HIGH-RESOLUTION; HUMAN GENOME; GENE; CHROMATIN;
TRANSCRIPTION; ORGANIZATION; PARTICLE; YEAST; MAP
AB Motivation: With the rapid development of high-throughput sequencing technologies, the genome-wide profiling of nucleosome positioning has become increasingly affordable. Many future studies will investigate the dynamic behaviour of nucleosome positioning in cells that have different states or that are exposed to different conditions. However, a robust method to effectively identify the regions of differential nucleosome positioning (RDNPs) has not been previously available.
Results: We describe a novel computational approach, DiNuP, that compares nucleosome profiles generated by high-throughput sequencing under various conditions. DiNuP provides a statistical P-value for each identified RDNP based on the difference of read distributions. DiNuP also empirically estimates the false discovery rate as a cutoff when two samples have different sequencing depths and differentiate reliable RDNPs from the background noise. Evaluation of DiNuP showed it to be both sensitive and specific for the detection of changes in nucleosome location, occupancy and fuzziness. RDNPs that were identified using publicly available datasets revealed that nucleosome positioning dynamics are closely related to the epigenetic regulation of transcription.
C1 [Fu, Kai; Tang, Qianzi; Feng, Jianxing; Zhang, Yong] Tongji Univ, Sch Life Sci & Technol, Dept Bioinformat, Shanghai 200092, Peoples R China.
[Liu, X. Shirley] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
[Liu, X. Shirley] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
RP Zhang, Y (reprint author), Tongji Univ, Sch Life Sci & Technol, Dept Bioinformat, 1239 Siping Rd, Shanghai 200092, Peoples R China.
EM yzhang@tongji.edu.cn
RI Zhang, Yong/B-4838-2011
OI Zhang, Yong/0000-0001-6316-2734
FU National Basic Research Program of China (973 Program) [2010CB944904,
2011CB965104]; National Natural Science Foundation of China [31071114];
Shanghai Rising-Star Program [10QA1407300]; New Century Excellent
Talents in the University of China [NCET-11-0389]; Innovative Research
Team Program Ministry of Education of China [IRT1168]
FX The National Basic Research Program of China (973 Program; No.
2010CB944904 and 2011CB965104), the National Natural Science Foundation
of China (31071114), the Shanghai Rising-Star Program (10QA1407300), the
New Century Excellent Talents in the University of China (NCET-11-0389)
and the Innovative Research Team Program Ministry of Education of China
(IRT1168).
NR 23
TC 8
Z9 8
U1 2
U2 3
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1367-4803
J9 BIOINFORMATICS
JI Bioinformatics
PD AUG 1
PY 2012
VL 28
IS 15
BP 1965
EP 1971
DI 10.1093/bioinformatics/bts329
PG 7
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
Computer Science, Interdisciplinary Applications; Mathematical &
Computational Biology; Statistics & Probability
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
Computer Science; Mathematical & Computational Biology; Mathematics
GA 977TA
UT WOS:000306686400003
PM 22668788
ER
PT J
AU Sarkar, U
Bonacum, D
Strull, W
Spitzmueller, C
Jin, N
Lopez, A
Giardina, TD
Meyer, AND
Singh, H
AF Sarkar, Urmimala
Bonacum, Doug
Strull, William
Spitzmueller, Christiane
Jin, Nancy
Lopez, Andrea
Giardina, Traber Davis
Meyer, Ashley N. D.
Singh, Hardeep
TI Challenges of making a diagnosis in the outpatient setting: a multi-site
survey of primary care physicians
SO BMJ QUALITY & SAFETY
LA English
DT Article
ID ADVERSE EVENTS; MALPRACTICE CLAIMS; FOLLOW-UP; MEDICAL-RECORDS; ERRORS;
NEGLIGENT; REFORM; SAFETY
AB Background: Although misdiagnosis in the outpatient setting leads to significant patient harm and wasted resources, it is not well studied. The authors surveyed primary care physicians (PCPs) about barriers to timely diagnosis in the outpatient setting and assessed their perceptions of diagnostic difficulty.
Methods: Surveys of PCPs practicing in an integrated health system across 10 geographically dispersed states in 2005. The survey elicited information on key cognitive failures (including in clinical knowledge or judgement) for a specific case, and solicited strategies for reducing diagnostic delays. Content analysis was used to categorise cognitive failures and strategies for improvement. The authors examined the extent and predictors of diagnostic difficulty, defined as reporting >5% patients difficult to diagnose.
Results: Of 1817 physicians surveyed, 1054 (58%) responded; 848 (80%) respondents primarily practiced in outpatient settings and had an assigned patient panel (inclusion sample). Inadequate knowledge (19.9%) was the most commonly reported cognitive factor. Half reported >5% of their patients were difficult to diagnose; more experienced physicians reported less diagnostic difficulty. In adjusted analyses, problems with information processing (information availability and time to review it) and the referral process were associated with greater diagnostic difficulty. Strategies for improvement most commonly involved workload issues (panel size, non-visit tasks).
Conclusions: PCPs report a variety of reasons for diagnostic difficulties in primary care practice. In this study, knowledge gaps appear to be a prominent concern. Interventions that address these gaps as well as practice level issues such as time to process diagnostic information and better subspecialty input may reduce diagnostic difficulties in primary care.
C1 [Sarkar, Urmimala; Jin, Nancy; Lopez, Andrea] Univ Calif San Francisco, Div Gen Internal Med, San Francisco, CA 94143 USA.
[Sarkar, Urmimala; Jin, Nancy; Lopez, Andrea] Univ Calif San Francisco, San Francisco Gen Hosp, Ctr Vulnerable Populat, San Francisco, CA 94143 USA.
[Strull, William] Kaiser Permanente, Permanente Federat, Oakland, CA USA.
[Spitzmueller, Christiane] Univ Houston, Houston, TX USA.
[Giardina, Traber Davis; Meyer, Ashley N. D.; Singh, Hardeep] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston VA HSR&D Ctr Excellence, Houston, TX 77030 USA.
[Giardina, Traber Davis; Meyer, Ashley N. D.; Singh, Hardeep] Baylor Coll Med, Dept Med, Sect Hlth Serv Res, Houston, TX 77030 USA.
RP Sarkar, U (reprint author), Univ Calif San Francisco, Dept Med, SFGH Div Gen Internal Med, Ward 13, Box 1364,1001 Potrero,Bldg 10,Floor 3, San Francisco, CA 94143 USA.
EM usarkar@medsfgh.ucsf.edu
OI Davis Giardina, Traber/0000-0002-9184-6524; Meyer,
Ashley/0000-0001-7993-8584
FU Agency for Healthcare Research and Quality [K08 HS017594]; NIH
[K23CA125585]; Houston VA HSR&D Center of Excellence [HFP90-020]
FX Dr Sarkar is supported by the Agency for Healthcare Research and Quality
K08 HS017594. Dr. Singh is supported by an NIH K23 career development
award (K23CA125585), and in part by the Houston VA HSR&D Center of
Excellence (HFP90-020). Manuscript contents are solely the
responsibility of the authors and do not necessarily represent the
official views of the NIH or any of the other funders. None of the
funders had any role in design and conduct of the study; collection,
management, analysis or interpretation of the data; or preparation,
review or approval of the manuscript.
NR 30
TC 17
Z9 17
U1 2
U2 6
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-5415
J9 BMJ QUAL SAF
JI BMJ Qual. Saf.
PD AUG
PY 2012
VL 21
IS 8
BP 641
EP 648
DI 10.1136/bmjqs-2011-000541
PG 8
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA 977IH
UT WOS:000306649700005
PM 22626738
ER
PT J
AU Fleming, LM
Novack, V
Novack, L
Cohen, SA
Negoita, M
Cutlip, DE
AF Fleming, Lisa M.
Novack, Victor
Novack, Lena
Cohen, Sidney A.
Negoita, Manuela
Cutlip, Donald E.
TI Frequency and impact of bleeding in elective coronary stent clinical
trials-Utility of three commonly used definitions
SO CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS
LA English
DT Article
DE bleeding; stent
ID SIROLIMUS-ELUTING STENTS; RANDOMIZED CONTROLLED-TRIAL;
MYOCARDIAL-INFARCTION; ARTERY-DISEASE; ACUITY TRIAL; INTERVENTION;
PREDICTORS; MORTALITY; REGISTRY; LESIONS
AB Background: Bleeding events are common after percutaneous coronary intervention (PCI) and have been shown to increase mortality in studies of acute coronary syndrome (ACS) and anti-thrombotic therapy. Despite this evidence, bleeding has not been included as a traditional major endpoint in clinical trials of low-risk populations enrolled in PCI clinical trials. Thus, the impact of specific bleeding definitions has not been evaluated fully among these patients. Methods and Results: Using patient-level pooled data from sirolimus and zotarolimus drug-eluting stent clinical trials, we identified bleeding events using three common definitions of bleeding, ACUITY, TIMI, and GUSTO, and assessed the impact on mortality and MI at 12 months after PCI. The GUSTO, ACUITY, and TIMI classifications identified bleeding rates of 2.3%, 1.9%, and 2.1%, respectively. The GUSTO criteria classified all 118 suspected bleeding events. There were 22 (18.6%) and 8 (6.8%) suspected bleeding events that did not meet ACUITY and TIMI criteria, respectively. The combined endpoint of all-cause death or myocardial infarction (MI) at 12 months was significantly higher for patients with a bleeding event compared with those who did not bleed [hazard ratio 1.95 (95% CI 1.063.60)]. Conclusion: There is a substantial variability in the utility and inclusiveness of three widely used bleeding definitions in identifying clinically significant bleeding events in clinical trials of low risk patients undergoing PCI with DES. Patients with bleeding after elective PCI have an increased one-year risk of death or MI compared to those patients who do not bleed. (C) 2012 Wiley Periodicals, Inc.
C1 [Fleming, Lisa M.; Cutlip, Donald E.] Beth Israel Deaconess Med Ctr, Dept Cardiol, Boston, MA 02215 USA.
[Novack, Victor; Novack, Lena; Cutlip, Donald E.] Harvard Clin Res Inst, Boston, MA USA.
[Cohen, Sidney A.] Cordis Corp, Bridgewater, NJ USA.
[Cohen, Sidney A.] Hosp Univ Penn, Div Cardiovasc, Philadelphia, PA 19104 USA.
[Negoita, Manuela] Medtron Cardiovasc, Santa Rosa, CA USA.
RP Fleming, LM (reprint author), BIDMC Med, 330 Brookline Ave,HCA Atrium Suite, Boston, MA USA.
EM lisa.fleming04@gmail.com
NR 35
TC 2
Z9 2
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1522-1946
J9 CATHETER CARDIO INTE
JI Catheter. Cardiovasc. Interv.
PD AUG 1
PY 2012
VL 80
IS 2
BP E23
EP E29
DI 10.1002/ccd.23332
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 977GY
UT WOS:000306645900005
PM 22109802
ER
PT J
AU Kulkarni, RN
AF Kulkarni, Rohit N.
TI Identifying Biomarkers of Subclinical Diabetes
SO DIABETES
LA English
DT Editorial Material
ID GIP; PROLIFERATION; POLYPEPTIDE; PROFILES; RECEPTOR; ISLET; MICE
C1 [Kulkarni, Rohit N.] Joslin Diabet Ctr, Boston, MA 02215 USA.
[Kulkarni, Rohit N.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA.
RP Kulkarni, RN (reprint author), Joslin Diabet Ctr, Boston, MA 02215 USA.
EM rohit.kulkarni@joslin.harvard.edu
FU NIDDK NIH HHS [R01-DK67536, R01 DK067536]
NR 14
TC 4
Z9 6
U1 2
U2 6
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0012-1797
J9 DIABETES
JI Diabetes
PD AUG
PY 2012
VL 61
IS 8
BP 1925
EP 1926
DI 10.2337/db12-0599
PG 2
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 980KC
UT WOS:000306891100006
PM 22826312
ER
PT J
AU Greenbaum, CJ
Beam, CA
Boulware, D
Gitelman, SE
Gottlieb, PA
Herold, KC
Lachin, JM
McGee, P
Palmer, JP
Pescovitz, MD
Krause-Steinrauf, H
Skyler, JS
Sosenko, JM
AF Greenbaum, Carla J.
Beam, Craig A.
Boulware, David
Gitelman, Stephen E.
Gottlieb, Peter A.
Herold, Kevan C.
Lachin, John M.
McGee, Paula
Palmer, Jerry P.
Pescovitz, Mark D.
Krause-Steinrauf, Heidi
Skyler, Jay S.
Sosenko, Jay M.
CA Type 1 Diabet TrialNet Study Grp
TI Fall in C-Peptide During First 2 Years From Diagnosis Evidence of at
Least Two Distinct Phases From Composite Type 1 Diabetes Trial Net Data
SO DIABETES
LA English
DT Article
ID BETA-CELL FUNCTION; ANTI-CD3 MONOCLONAL-ANTIBODY; NATURAL-HISTORY;
TOLERANCE-TEST; DOUBLE-BLIND; ONSET; INSULIN; MELLITUS; THERAPY; RISK
AB Interpretation of clinical trials to alter the decline in beta-cell function after diagnosis of type 1 diabetes depends on a robust understanding of the natural history of disease. Combining data from the Type 1 Diabetes TrialNet studies, we describe the natural history of beta-cell function from shortly after diagnosis through 2 years post study randomization, assess the degree of variability between patients, and investigate factors that may be related to C-peptide preservation or loss. We found that 93% of individuals have detectable C-peptide 2 years from diagnosis. In 11% of subjects, there was no significant fall from baseline by 2 years. There was a biphasic decline in C-peptide; the C-peptide slope was -0.0245 pmol/mL/month (95% CI -0.0271 to -0.0215) through the first 12 months and -0.0079 (-0.0113 to -0.0050) from 12 to 24 months (P < 0.001). This pattern of fall in C-peptide over time has implications for understanding trial results in which effects of therapy are most pronounced early and raises the possibility that there are time-dependent differences in pathophysiology. The robust data on the C-peptide obtained under clinical trial conditions should be used in planning and interpretation of clinical trials. Diabetes 61:2066-2073, 2012
C1 [Greenbaum, Carla J.] Benaroya Res Inst, Seattle, WA USA.
[Beam, Craig A.; Boulware, David] Univ S Florida, Dept Pediat, Tampa, FL 33620 USA.
[Gitelman, Stephen E.] Univ Calif San Francisco, Dept Pediat, San Francisco, CA USA.
[Gottlieb, Peter A.] Univ Colorado Denver, Barbara Davis Ctr Childhood Diabet, Aurora, CO USA.
[Herold, Kevan C.] Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT USA.
[Lachin, John M.; McGee, Paula; Krause-Steinrauf, Heidi] George Washington Univ, Ctr Biostat, Washington, DC USA.
[Palmer, Jerry P.] Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98195 USA.
[Palmer, Jerry P.] Univ Washington, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA.
[Pescovitz, Mark D.] Indiana Univ, Dept Surg, Indianapolis, IN 46204 USA.
[Pescovitz, Mark D.] Indiana Univ, Dept Microbiol & Immunol, Indianapolis, IN 46204 USA.
[Skyler, Jay S.; Sosenko, Jay M.] Univ Miami, Diabet Res Inst, Miami, FL USA.
RP Greenbaum, CJ (reprint author), Benaroya Res Inst, Seattle, WA USA.
EM cjgreen@benaroyaresearch.org
RI Skyler, Jay/F-4211-2016;
OI Lachin, John/0000-0001-9838-2841; Gallagher, Mary/0000-0002-5844-2309
FU National Institutes of Health (NIH) through the National Institute of
Diabetes and Digestive and Kidney Diseases; National Institute of
Allergy and Infectious Diseases; Eunice Kennedy Shriver National
Institute of Child Health and Human Development [U01-DK-061010,
U01-DK-061016, U01-DK-061034, U01-DK-061036, U01-DK-061040,
U01-DK-061041, U01-DK-061042, U01-DK-061055, U01-DK-061058,
U01-DK-084565, U01-DK-085453, U01-DK-085461, U01-DK-085463,
U01-DK-085466, U01-DK-085499, U01-DK-085505, U01-DK-085509,
HHSN267200800019C]; National Center for Research Resources
[UL1-RR-024131, UL1-RR-024139, UL1-RR-024153, UL1-RR-024975,
UL1-RR-024982, UL1-RR-025744, UL1-RR-025761, UL1-RR-025780,
UL1-RR-029890, UL1-RR-031986]; General Clinical Research Center Award
[M01-RR-00400]; Juvenile Diabetes Research Foundation International
(JDRF); American Diabetes Association (ADA)
FX The sponsor of the trial was the Type 1 Diabetes Trial Net Study Group.
Type I Diabetes Trial Net Study Group is a clinical trials network
funded by the National Institutes of Health (NIH) through the National
Institute of Diabetes and Digestive and Kidney Diseases, the National
Institute of Allergy and Infectious Diseases, and the Eunice Kennedy
Shriver National Institute of Child Health and Human Development,
through Cooperative Agreements U01-DK-061010, U01-DK-061016,
U01-DK-061034, U01-DK-061036, U01-DK-061040, U01-DK-061041,
U01-DK-061042, U01-DK-061055, U01-DK-061058, U01-DK-084565,
U01-DK-085453, U01-DK-085461, U01-DK-085463, U01-DK-085466,
U01-DK-085499, U01-DK-085505, U01-DK-085509, and Contract
HHSN267200800019C, the National Center for Research Resources, through
Clinical Translational Science Awards UL1-RR-024131, UL1-RR-024139,
UL1-RR-024153, UL1-RR-024975, UL1-RR-024982, UL1-RR-025744,
UL1-RR-025761, UL1-RR-025780, UL1-RR-029890, UL1-RR-031986, and General
Clinical Research Center Award M01-RR-00400, the Juvenile Diabetes
Research Foundation International (JDRF), and the American Diabetes
Association (ADA).
NR 33
TC 85
Z9 86
U1 2
U2 5
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0012-1797
J9 DIABETES
JI Diabetes
PD AUG
PY 2012
VL 61
IS 8
BP 2066
EP 2073
DI 10.2337/db11-1538
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 980KC
UT WOS:000306891100022
PM 22688329
ER
PT J
AU Wang, ZW
Cheng, ZY
Cristofaro, V
Li, JJ
Xiao, XY
Gomez, P
Ge, RB
Gong, E
Strle, K
Sullivan, MP
Adam, RM
White, MF
Olumi, AF
AF Wang, Zongwei
Cheng, Zhiyong
Cristofaro, Vivian
Li, Jijun
Xiao, Xingyuan
Gomez, Pablo
Ge, Rongbin
Gong, Edward
Strle, Klemen
Sullivan, Maryrose P.
Adam, Rosalyn M.
White, Morris F.
Olumi, Aria F.
TI Inhibition of TNF-alpha Improves the Bladder Dysfunction That Is
Associated With Type 2 Diabetes
SO DIABETES
LA English
DT Article
ID TRAIL-INDUCED APOPTOSIS; SMOOTH-MUSCLE; URINARY-BLADDER;
ENDOTHELIAL-CELLS; IN-VITRO; MICE; RATS; KINASE; RHO; INFLAMMATION
AB Diabetic bladder dysfunction (DBD) is common and affects 80% of diabetic patients. However, the molecular mechanisms underlying DBD remain elusive because of a lack of appropriate animal models. We demonstrate DBD in a mouse model that harbors hepatic-specific insulin receptor substrate 1 and 2 deletions (double knockout [DKO]), which develops type 2 diabetes. Bladders of DKO animals exhibited detrusor overactivity at an early stage: increased frequency of nonvoiding contractions during bladder filling, decreased voided volume, and dispersed urine spot patterns. In contrast, older animals with diabetes exhibited detrusor hypoactivity, findings consistent with clinical features of diabetes in humans. The tumor necrosis factor (TNF) superfamily genes were upregulated in DKO bladders. In particular, TNF-alpha was upregulated in serum and in bladder smooth muscle tissue. TNF-alpha augmented the contraction of primary cultured bladder smooth muscle cells through upregulating Rho kinase activity and phosphotylating myosin light chain. Systemic treatment of DKO animals with soluble TNF receptor 1 (TNFRI) prevented upregulation of Rho A signaling and reversed the bladder dysfunction, without affecting hyperglycemia. TNFRI combined with the antidiabetic agent, metfonnin, improved DBD beyond that achieved with metformin alone, suggesting that therapies targeting TNF-alpha may have utility in reversing the secondary urologic complications of type 2 diabetes. Diabetes 61:2134-2145,2012
C1 [Wang, Zongwei; Li, Jijun; Xiao, Xingyuan; Ge, Rongbin; Olumi, Aria F.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Urol, Boston, MA 02115 USA.
[Cheng, Zhiyong; White, Morris F.] Harvard Univ, Sch Med, Howard Hughes Med Inst, Div Endocrinol,Childrens Hosp Boston, Boston, MA 02115 USA.
[Cristofaro, Vivian; Sullivan, Maryrose P.] Harvard Univ, Sch Med, Vet Adm Boston Healthcare Syst, Boston, MA USA.
[Li, Jijun] Shanghai Jiao Tong Univ, Sch Med, Dept Integrat Med, Shanghai Childrens Med Ctr, Shanghai 200030, Peoples R China.
[Xiao, Xingyuan] Huazhong Univ Sci & Technol, Wuhan Union Hosp, Dept Urol, Wuhan 430074, Peoples R China.
[Gomez, Pablo; Gong, Edward; Adam, Rosalyn M.] Harvard Univ, Sch Med, Childrens Hosp Boston, Urol Res Ctr, Boston, MA USA.
[Strle, Klemen] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med,Div Allergy Immunol, Boston, MA USA.
RP Olumi, AF (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Urol, Boston, MA 02115 USA.
EM olumi.aria@mgh.harvard.edu
FU National Institutes of Health/National Institute of Diabetes and
Digestive and Kidney Diseases grant [09MCG72]; American Urological
Association/Pfizer Pharmaceutical Company
FX This work was funded by National Institutes of Health/National Institute
of Diabetes and Digestive and Kidney Diseases grant (Animal Models of
Diabetic Complications Pilot & Feasibility Project, 09MCG72) and the
American Urological Association/Pfizer Pharmaceutical Company
competitive grants to A.F.O. No other potential conflicts of interest
relevant to this article were reported.
NR 40
TC 17
Z9 19
U1 0
U2 4
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0012-1797
J9 DIABETES
JI Diabetes
PD AUG
PY 2012
VL 61
IS 8
BP 2134
EP 2145
DI 10.2337/db11-1763
PG 12
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 980KC
UT WOS:000306891100029
PM 22688336
ER
PT J
AU Billings, LK
Hsu, YH
Ackerman, RJ
Dupuis, J
Voight, BF
Rasmussen-Torvik, LJ
Hercberg, S
Lathrop, M
Barnes, D
Langenberg, C
Hui, JN
Fu, M
Bouatia-Naji, N
Lecoeur, C
An, P
Magnusson, PK
Surakka, I
Ripatti, S
Christiansen, L
Dalgard, C
Folkersen, L
Grundberg, E
Eriksson, P
Kaprio, J
Kyvik, KO
Pedersen, NL
Borecki, IB
Province, MA
Balkau, B
Froguel, P
Shuldiner, AR
Palmer, LJ
Wareham, N
Meneton, P
Johnson, T
Pankow, JS
Karasik, D
Meigs, JB
Kiel, DP
Florez, JC
AF Billings, Liana K.
Hsu, Yi-Hsiang
Ackerman, Rachel J.
Dupuis, Josee
Voight, Benjamin F.
Rasmussen-Torvik, Laura J.
Hercberg, Serge
Lathrop, Mark
Barnes, Daniel
Langenberg, Claudia
Hui, Jennie
Fu, Mao
Bouatia-Naji, Nabila
Lecoeur, Cecile
An, Ping
Magnusson, Patrik K.
Surakkaza, Ida
Ripatti, Samuli
Christiansen, Lene
Dalgard, Christine
Folkersen, Lasse
Grundberg, Elin
Eriksson, Per
Kaprio, Jaakko
Kyvik, Kirsten Ohm
Pedersen, Nancy L.
Borecki, Ingrid B.
Province, Michael A.
Balkau, Beverley
Froguel, Philippe
Shuldiner, Alan R.
Palmer, Lyle J.
Wareham, Nick
Meneton, Pierre
Johnson, Toby
Pankow, James S.
Karasik, David
Meigs, James B.
Kiel, Douglas P.
Florez, Jose C.
CA MAGIC Investigators
DIAGRAM Consortium
MuTHER Consortium
ASCOT Investigators
GEFOS Consortium
TI Impact of Common Variation in Bone-Related Genes on Type 2 Diabetes and
Related Traits
SO DIABETES
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; BODY-MASS INDEX; MINERAL DENSITY; FRACTURE
RISK; OSTEOPOROTIC FRACTURES; INSULIN-RESISTANCE; ENERGY-METABOLISM;
FASTING GLUCOSE; LOCI; METAANALYSIS
AB Exploring genetic pleiotropy can provide clues to a mechanism underlying the observed epidemiological association between type 2 diabetes and heightened fracture risk. We examined genetic variants associated with bone mineral density (BMD) for association with type 2 diabetes and glycemic traits in large well-phenotyped and -genotyped consortia. We undertook follow-up analysis in similar to 19,000 individuals and assessed gene expression. We queried single nucleotide polymorphisms (SNPs) associated with BMD at levels of genome-wide significance, variants in linkage disequilibrium (r(2) > 0.5), and BMD candidate genes. SNP rs6867040, at the ITGA1 locus, was associated with a 0.0166 mmol/L (0.004) increase in fasting glucose per C allele in the combined analysis. Genetic variants in the ITGA1 locus were associated with its expression in the liver but not in adipose tissue. ITGA1 variants appeared among the top loci associated with type 2 diabetes, fasting insulin, beta-cell function by homeostasis model assessment, and 2-h post-oral glucose tolerance test glucose and insulin levels. ITGA1 has demonstrated genetic pleiotropy in prior studies, and its suggested role in liver fibrosis, insulin secretion, and bone healing lends credence to its contribution to both osteoporosis and type 2 diabetes. These findings further underscore the link between skeletal and glucose metabolism and highlight a locus to direct future investigations. Diabetes 61:2176-2186, 2012
C1 [Billings, Liana K.; Ackerman, Rachel J.; Voight, Benjamin F.; Florez, Jose C.] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
[Billings, Liana K.; Voight, Benjamin F.; Meigs, James B.; Kiel, Douglas P.; Florez, Jose C.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
[Billings, Liana K.; Florez, Jose C.] Massachusetts Gen Hosp, Diabet Unit, Diabet Res Ctr, Boston, MA 02114 USA.
[Hsu, Yi-Hsiang; Karasik, David; Kiel, Douglas P.] Hebrew Senior Life Inst Aging Res, Boston, MA USA.
[Hsu, Yi-Hsiang] Harvard Univ, Sch Publ Hlth, Mol & Integrat Physiol Sci Program, Boston, MA 02115 USA.
[Hsu, Yi-Hsiang; Dupuis, Josee; Karasik, David; Meigs, James B.; Kiel, Douglas P.] Framingham Heart Dis Epidemiol Study, Framingham, MA USA.
[Voight, Benjamin F.; Florez, Jose C.] Broad Inst Harvard & Massachusetts Inst Technol, Cambridge, MA USA.
[Rasmussen-Torvik, Laura J.; Florez, Jose C.] Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, Chicago, IL 60611 USA.
[Hercberg, Serge] Univ Paris, INSERM, Natl Inst Agron Res, Bobigny, France.
[Lathrop, Mark] Atom Energy Commiss, Natl Genotyping Ctr, Inst Genom, Evry, France.
[Barnes, Daniel; Langenberg, Claudia; Wareham, Nick] Addenbrookes Hosp, Inst Metab Sci, Med Res Council Epidemiol Unit, Cambridge, England.
[Hui, Jennie] PathWest Lab Med Western Australia, Nedlands, WA, Australia.
[Hui, Jennie] Univ Western Australia, Sch Populat Hlth, Nedlands, WA 6009, Australia.
[Hui, Jennie] Univ Western Australia, Sch Pathol & Lab Med, Nedlands, WA 6009, Australia.
[Hui, Jennie] Sir Charles Gairdner Hosp, Busselton Populat Med Res Fdn, Nedlands, WA 6009, Australia.
[Fu, Mao; Shuldiner, Alan R.] Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA.
[Bouatia-Naji, Nabila; Lecoeur, Cecile; Froguel, Philippe] Lille Nord France Univ, Natl Ctr Sci Res, UMR 8199, Lille Pasteur Inst, Lille, France.
[An, Ping; Borecki, Ingrid B.] Washington Univ, Sch Med, Div Stat Genom, St Louis, MO USA.
[An, Ping; Borecki, Ingrid B.] Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA.
[Magnusson, Patrik K.; Pedersen, Nancy L.; Province, Michael A.] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden.
[Surakkaza, Ida; Ripatti, Samuli; Kaprio, Jaakko] Univ Helsinki, Inst Mol Med Finland, Helsinki, Finland.
[Surakkaza, Ida; Ripatti, Samuli] Natl Inst Hlth & Welf, Publ Hlth Genom Unit, Helsinki, Finland.
[Christiansen, Lene] Univ So Denmark, Inst Publ Hlth, Danish Twin Registry, Odense, Denmark.
[Dalgard, Christine] Univ So Denmark, Dept Environm Med, Inst Publ Hlth, Odense, Denmark.
[Folkersen, Lasse; Eriksson, Per] Karolinska Inst, Dept Med, Atherosclerosis Res Unit, Stockholm, Sweden.
[Grundberg, Elin] Wellcome Trust Sanger Inst, Hinxton, England.
[Grundberg, Elin] Kings Coll London, Dept Twin Res & Genet Epidemiol, London, England.
Erasmus Med Coll, Coordinating Ctr, Rotterdam, Netherlands.
[Kaprio, Jaakko] Natl Inst Hlth & Welf, Unit Child & Adolescent Mental Hlth, Helsinki, Finland.
[Kaprio, Jaakko] Univ Helsinki, Dept Publ Hlth, Helsinki, Finland.
[Kyvik, Kirsten Ohm] Univ So Denmark, Inst Reg Hlth Serv Res, Odense, Denmark.
[Kyvik, Kirsten Ohm] Odense Univ Hosp, Odense Patient Data Explorat Network, DK-5000 Odense, Denmark.
[Balkau, Beverley] INSERM, CESP Ctr Res Epidemiol & Hlth Populat, U1018, Epidemiol Diabet Obes & Chron Kidney Dis Life Cou, Villejuif, France.
[Balkau, Beverley] Univ Paris 11, UMRS 1018, Villejuif, France.
[Froguel, Philippe] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, London, England.
[Shuldiner, Alan R.] Baltimore VA Med Ctr, Geriatr Res Educ & Clin Ctr, Baltimore, MD USA.
[Palmer, Lyle J.] Ontario Inst Canc Res, Toronto, ON, Canada.
[Meneton, Pierre] INSERM, Cordeliers Ctr Res, Paris, France.
[Johnson, Toby] Queen Mary Univ London, Clin Pharmacol & Genome Ctr, William Harvey Res Inst, Barts & London Sch Med & Dent, London, England.
[Pankow, James S.] Univ Minnesota, Div Epidemiol & Community Hlth, Minneapolis, MN USA.
[Dupuis, Josee] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA.
RP Florez, JC (reprint author), Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
EM jcflorez@partners.org
RI Palmer, Lyle/K-3196-2014; Ripatti, Samuli/H-9446-2014; Kyvik, Kirsten
/K-5680-2016; BOUATIA-NAJI, NABILA/D-5863-2013; Magnusson,
Patrik/C-4458-2017;
OI Kaprio, Jaakko/0000-0002-3716-2455; Pankow, James/0000-0001-7076-483X;
Karasik, David/0000-0002-8826-0530; Folkersen,
Lasse/0000-0003-0708-9530; Palmer, Lyle/0000-0002-1628-3055; Ripatti,
Samuli/0000-0002-0504-1202; Kyvik, Kirsten /0000-0003-2981-0245;
Bouatia-Naji, Nabila/0000-0001-5424-2134; Barnes,
Daniel/0000-0002-3781-7570; Johnson, Toby/0000-0002-5998-3270; Dupuis,
Josee/0000-0003-2871-3603; Kiel, Douglas/0000-0001-8474-0310
FU National Research Service Award Institutional Training Grant
[T32-DK-007028-35]; National Institutes of Health (NIH) Loan Repayment
Award National Institute of Diabetes and Digestive and Kidney Diseases
(NIDDK) [1-L30-DK-089944-01]; Endocrine Society Lilly Endocrine Scholars
Award; Doris Duke Charitable Foundation Distinguished Scientist Clinical
Award; NIH/National Institute of Arthritis and Musculoskeletal and Skin
Diseases (NIAMS) [R21-AR-056405]; NIDDK [R0I-DK-078616, R01-DK-078616,
NIDDK K24-DK-080140, 5-R01-DK-07568102, 5-R01-DK-06833603]; NIAMS;
National Institute on Aging Grant [R01-AR/AG-41398]; Doris Duke
Charitable Foundation Clinical Scientist Development Award; European
Commission [HEALTH-F2-2008-201865-GEFOS, Health-F2-2008-200647];
National Heart, Lung, and Blood Institute (NHLBI) [HHSN268201100005C,
HHSN2682011000 06C, HHSN268201100007C, HEISN268201100008C, HHSN26
8201100009C, HHSN268201100010C, HHSN268201100011C, HHSN268201100012C,
R01-HL-087641, R01-HL-59367, R01-HL-086694]; National Human Genome
Research Institute contract [U01-HG-004402]; NIH [HHSN26 8200625226C,
U01-HL-72515, R0I-DK-04261, R01-AG-18728]; Wellcome Trust; Medical
Research Council; Healthway, Western Australia [199411995]; University
of Maryland General Clinical Research Center Grant [M01-RR-16500];
Mid-Atlantic Nutrition and Obesity Research Center [P30-DK-072488];
Baltimore Diabetes Research and Training Center [P60-DK-079637];
Baltimore Veterans Administration Medical Center Geriatric Research and
Education Clinical Center; Conseil Regional Nord-Pas-de-Calais: Fonds
europeen de developpement economique et regional; Genome Quebec Genome
Canada; British Medical Research Council; NIH from the NIMBI
[5-R01-HL-08770003, 5-R01-BL-08821502]; European Commission under the
program Quality of Life and Management of the Living Resources of Fifth
Framework Programme [QLG2-CT-2002-01254]; European Community's Seventh
Framework Programme [FP7/2007-2013]; ENGAGE Consortium; Danish Medical
Research Council; Danish Heart Association; Danish Diabetes Association;
GenomEUtwin; NHLBI's FHS [N01-HC-25195]; Affymetrix, Inc.
[N02-HL-6-4278]; NIH National Center for Research Resources Shared
Instrumentation Grant [1-S10-RR-163736-01A1]; Robert Dawson Evans
Endowment of the Department of Medicine at Boston University School of
Medicine and Boston Medical Center; Swedish Research Council [12660];
Swedish Heart-Lung Foundation; [HEALTH-F4-2007-201413]
FX L.K.B. has received support from National Research Service Award
Institutional Training Grant T32-DK-007028-35 to the Massachusetts
General Hospital, National Institutes of Health (NIH) Loan Repayment
Award National Institute of Diabetes and Digestive and Kidney Diseases
(NIDDK) 1-L30-DK-089944-01, the Endocrine Society Lilly Endocrine
Scholars Award, and a Doris Duke Charitable Foundation Distinguished
Scientist Clinical Award to David Altshuler. Y.-H.H. was supported by
NIH/National Institute of Arthritis and Musculoskeletal and Skin
Diseases (NIAMS) Grant R21-AR-056405. J.D. has received support from
NIDDK R0I-DK-078616. J.B.M. was supported by NIDDK R01-DK-078616 and
NIDDK K24-DK-080140. D.P.K. has received support from NIAMS and National
Institute on Aging Grant R01-AR/AG-41398. J.C.F. was supported by NIDDK
R01-DK-078616 and a Doris Duke Charitable Foundation Clinical Scientist
Development Award.; The authors would like to thank Denis Rybin at
Boston University School of Public Health for creating Fig. 2. The
authors acknowledge the contribution of the GIANT Consortium, which
provided summary statistics for the association between selected SNPs
and BMI. Individual cohort acknowledgments are as follows: GEFOS
Consortium (www.gefos.org) is funded by the European Commission
(HEALTH-F2-2008-201865-GEFOS). ARIC is carried out as a collaborative
study supported by National Heart, Lung, and Blood Institute (NHLBI)
contracts (HHSN268201100005C, HHSN2682011000 06C, HHSN268201100007C,
HEISN268201100008C, HHSN26 8201100009C, HHSN268201100010C,
HHSN268201100011C, and HHSN268201100012C), R01-HL-087641, R01-HL-59367,
and R01-HL-086694, National Human Genome Research Institute contract
U01-HG-004402, and NIH contract HHSN26 8200625226C. The authors thank
the staff and participants of the ARIC study for their important
contributions. Infrastructure of the ARIC study was partly supported by
Grant UL1-RR-025005, a component of the NIH and NIH Roadmap for Medical
Research. The Fenland Study is funded by the Wellcome Trust and the
Medical Research Council. The authors are grateful to all the volunteers
for their time and help and to the general practitioners and practice
staff for help with recruitment The authors thank the Fen land Study
Investigators, Fen land Study Co-ordination Team and the Epidemiology
Field, Data, and Technical Teams. Biochemical assays were performed by
the National Institute for Health Research, Cambridge Biomedical
Research Centre, Core Biochemistry Assay Laboratory, and the Cambridge
University Hospitals National Health Service Foundation Trust,
Department of Clinical Biochemistry. The BHS acknowledges the generous
support for the 199411995 follow-up study from Healthway, Western
Australia, and the numerous Busselton community volunteers who assisted
with data collection and the study participants from the Shire of
Busselton. The BHS is supported by the Great Wine Estates of the
Margaret River region of Western Australia The AMISH Cohort was
supported by NIH research grants U01-HL-72515, R0I-DK-04261, and
R01-AG-18728; University of Maryland General Clinical Research Center
Grant M01-RR-16500; the Mid-Atlantic Nutrition and Obesity Research
Center (P30-DK-072488); the Baltimore Diabetes Research and Training
Center (P60-DK-079637); and the Baltimore Veterans Administration
Medical Center Geriatric Research and Education Clinical Center. French
genetic studies (DESIR and French Obese) were supported in part by the
Conseil Regional Nord-Pas-de-Calais: Fonds europeen de developpement
economique et regional, Genome Quebec Genome Canada and the British
Medical Research Council. The authors acknowledge INSERM (employer of
N.B.-N.). FamHS work was supported in part by NIH grants
5-R01-HL-08770003 and 5-R01-BL-08821502 from the NIMBI (to M.A.P.) and
5-R01-DK-07568102 and 5-R01-DK-06833603 from NIDDK (to I.B.B.). The
GenomEUtwin project is supported by the European Commission under the
program Quality of Life and Management of the Living Resources of Fifth
Framework Programme (no. QLG2-CT-2002-01254) and the European
Community's Seventh Framework Programme (FP7/2007-2013), ENGAGE
Consortium, Grant Agreement HEALTH-F4-2007-201413. The Swedish Twin
Cohort would like to acknowledge the Swedish Research Council and the
Swedish Foundation for Strategic Research. The Finnish Twin Cohort would
like to acknowledge the Center of Excellence in Complex Disease Genetics
of the Academy of Finland.; The GEMINAKAR study was supported by the
Danish Medical Research Council, the Danish Heart Association, the
Danish Diabetes Association, and GenomEUtwin. The FHS component of this
work was supported by the NHLBI's FHS (Contract N01-HC-25195), its
contract with Affymetrix, Inc. for genotyping services (Contract
N02-HL-6-4278), and the resources of the FHS SNP Health Association
Resource (SHARe) project, the Boston University Linux Cluster for
Genetic Analysis (LinGA) funded by the NIH National Center for Research
Resources Shared Instrumentation Grant 1-S10-RR-163736-01A1, and the
Robert Dawson Evans Endowment of the Department of Medicine at Boston
University School of Medicine and Boston Medical Center. The ASAP study
liver eQTL data were supported by the Swedish Research Council (12660),
the Swedish Heart-Lung Foundation, the European Commission (FAD,
Health-F2-2008-200647), and a donation by Fredrik Lundberg.
NR 51
TC 7
Z9 9
U1 1
U2 6
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0012-1797
EI 1939-327X
J9 DIABETES
JI Diabetes
PD AUG
PY 2012
VL 61
IS 8
BP 2176
EP 2186
DI 10.2337/db11-1515
PG 11
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 980KC
UT WOS:000306891100033
PM 22698912
ER
PT J
AU Williams, WW
Salem, RM
McKnight, AJ
Sandholm, N
Forsblom, C
Taylor, A
Guiducci, C
McAteer, JB
McKay, GJ
Isakova, T
Brennan, EP
Sadlier, DM
Palmer, C
Soderlund, J
Fagerholm, E
Harjutsalo, V
Lithovius, R
Gordin, D
Hietala, K
Kyto, J
Parkkonen, M
Rosengard-Barlund, M
Thorn, L
Syreeni, A
Tolonen, N
Saraheimo, M
Waden, J
Pitkaniemi, J
Sarti, C
Tuomilehto, J
Tryggvason, K
Osterholm, AM
He, B
Bain, S
Martin, F
Godson, C
Hirschhorn, JN
Maxwel, AP
Groop, PH
Florez, JC
AF Williams, Winfred W.
Salem, Rany M.
McKnight, Amy Jayne
Sandholm, Niina
Forsblom, Carol
Taylor, Andrew
Guiducci, Candace
McAteer, Jarred B.
McKay, Gareth J.
Isakova, Tamara
Brennan, Eoin P.
Sadlier, Denise M.
Palmer, Cameron
Soederlund, Jenny
Fagerholm, Emma
Harjutsalo, Valma
Lithovius, Raija
Gordin, Daniel
Hietala, Kustaa
Kyto, Janne
Parkkonen, Maija
Rosengard-Barlund, Milla
Thorn, Lena
Syreeni, Anna
Tolonen, Nina
Saraheimo, Markku
Waden, Johan
Pitkaniemi, Jamie
Sarti, Cinzia
Tuomilehto, Jaakko
Tryggvason, Karl
Osterholm, Anne-May
He, Bing
Bain, Steve
Martin, Finian
Godson, Catherine
Hirschhorn, Joel N.
Maxwel, Alexander P.
Groop, Per-Henrik
Florez, Jose C.
CA GENIE Consortium
TI Association Testing of Previously Reported Variants in a Large
Case-Control Meta-analysis of Diabetic Nephropathy
SO DIABETES
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; GENETIC SUSCEPTIBILITY; PIMA-INDIANS;
POPULATION; DISEASE; LINKAGE; SCAN
AB We formed the GEnetics of Nephropathy-an International Effort (GENIE) consortium to examine previously reported genetic associations with diabetic nephropathy (DN) in type 1 diabetes. GENIE consists of 6,366 similarly ascertained participants of European ancestry with type 1 diabetes, with and without DN, from the All Ireland-Warren 3-Genetics of Kidneys in Diabetes U.K. and Republic of Ireland (U.K.-R.O.I.) collection and the Finnish Diabetic Nephropathy Study (FinnDiane), combined with reanalyzed data from the Genetics of Kidneys in Diabetes U.S. Study (U.S. GoKinD). We found little evidence for the association of the EPO promoter polymorphism, rs161740, with the combined phenotype of proliferative retinopathy and end-stage renal disease in U.K.-R.O.I. (odds ratio [OR] 1.14, P = 0.19) or FinnDiane (OR 1.06, P = 0.60). However, a fixed-effects meta-analysis that included the previously reported cohorts retained a genome-wide significant association with that phenotype (OR 1.31, P = 2 x 10(-9)). An expanded investigation of the ELMO1 locus and genetic regions reported to be associated with DN in the U.S. GoKinD yielded only nominal statistical significance for these loci. Finally, top candidates identified in a recent meta-analysis failed to reach genome-wide significance. In conclusion, we were unable to replicate most of the previously reported genetic associations for DN, and significance for the EPO promoter association was attenuated. Diabetes 61:2187-2194, 2012
C1 [Williams, Winfred W.; Taylor, Andrew; McAteer, Jarred B.; Godson, Catherine; Florez, Jose C.] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
[Williams, Winfred W.; Salem, Rany M.; Taylor, Andrew; Guiducci, Candace; McAteer, Jarred B.; Palmer, Cameron; Godson, Catherine; Hirschhorn, Joel N.; Florez, Jose C.] Broad Inst, Program Med & Populat Genet, Cambridge, MA USA.
[Williams, Winfred W.] Massachusetts Gen Hosp, Dept Med, Div Nephrol, Boston, MA 02114 USA.
[Williams, Winfred W.; Florez, Jose C.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
[Salem, Rany M.; Palmer, Cameron; Hirschhorn, Joel N.] Childrens Hosp, Dept Endocrinol, Endocrine Res Unit, Boston, MA 02115 USA.
[McKnight, Amy Jayne; McKay, Gareth J.; Maxwel, Alexander P.] Queens Univ Belfast, Ctr Publ Hlth, Belfast, Antrim, North Ireland.
[Sandholm, Niina; Forsblom, Carol; Soederlund, Jenny; Fagerholm, Emma; Harjutsalo, Valma; Lithovius, Raija; Gordin, Daniel; Hietala, Kustaa; Kyto, Janne; Parkkonen, Maija; Rosengard-Barlund, Milla; Thorn, Lena; Syreeni, Anna; Tolonen, Nina; Saraheimo, Markku; Waden, Johan; Sarti, Cinzia; Groop, Per-Henrik] Biomedicum, Folkhalsan Res Ctr, Folkhalsan Inst Genet, Helsinki, Finland.
[Sandholm, Niina; Forsblom, Carol; Soederlund, Jenny; Fagerholm, Emma; Harjutsalo, Valma; Lithovius, Raija; Gordin, Daniel; Parkkonen, Maija; Rosengard-Barlund, Milla; Thorn, Lena; Syreeni, Anna; Tolonen, Nina; Saraheimo, Markku; Waden, Johan; Groop, Per-Henrik] Univ Helsinki, Cent Hosp, Dept Med, Div Nephrol, Helsinki, Finland.
[Sandholm, Niina] Aalto Univ, Dept Biomed Engn & Computat Sci, Helsinki, Finland.
[Taylor, Andrew; McAteer, Jarred B.; Florez, Jose C.] Massachusetts Gen Hosp, Diabet Unit, Diabet Res Ctr, Boston, MA 02114 USA.
[Isakova, Tamara] Univ Miami, Miller Sch Med, Div Nephrol, Miami, FL 33136 USA.
[Brennan, Eoin P.; Sadlier, Denise M.; Martin, Finian] Univ Coll Dublin, Conway Inst, UCD Diabet Res Ctr, Dublin 2, Ireland.
[Brennan, Eoin P.; Sadlier, Denise M.; Godson, Catherine] Univ Coll Dublin, Sch Med, Dublin 2, Ireland.
[Sadlier, Denise M.] Mater Univ Hosp, Dublin, Ireland.
[Harjutsalo, Valma; Tuomilehto, Jaakko] Natl Inst Hlth & Welf, Welf & Hlth Promot Div, Dept Chron Dis Prevent, Helsinki, Finland.
[Hietala, Kustaa; Kyto, Janne] Univ Helsinki, Cent Hosp, Dept Ophthalmol, Helsinki, Finland.
[Kyto, Janne; Tuomilehto, Jaakko] Univ Helsinki, Dept Publ Hlth, Helsinki, Finland.
[Tuomilehto, Jaakko] S Ostrobothnia Cent Hosp, Seinajoki, Finland.
[Tryggvason, Karl; Osterholm, Anne-May; He, Bing] Karolinska Inst, Dept Med Biochem & Biophys, Div Matrix Biol, Stockholm, Sweden.
[Bain, Steve] Swansea Univ, Inst Life Sci, Swansea, W Glam, Wales.
[Martin, Finian] Univ Coll Dublin, Sch Biomol & Biomed Sci, Dublin 2, Ireland.
RP Florez, JC (reprint author), Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
EM jcflorez@partners.org
RI Tolonen, Nina/F-2819-2012;
OI McKnight, Amy Jayne/0000-0002-7482-709X; Sandholm,
Niina/0000-0003-4322-6942; Maxwell, Alexander P./0000-0002-6110-7253
FU National Institutes of Health National Institute of Diabetes and
Digestive and Kidney Diseases Grant [R01-DK-081923]; Science Foundation
Ireland U.S.-Ireland RD partnership; Health Research Board Ireland;
Juvenile Diabetes Research Foundation postdoctoral fellowship
[3-2011-70]; Folkhalsan Research Foundation; Wilhelm and Else Stockmann
Foundation; Livoch Halsa Foundation; Helsinki University Central
Hospital Research Funds; Sigrid Juselius Foundation; Signe and Arne
Gyllenberg Foundation; Finska Lakaresallskapet; European Commission;
European Union's Seventh Framework Program [IMI/115006]
FX Funding for this study was provided by National Institutes of Health
National Institute of Diabetes and Digestive and Kidney Diseases Grant
R01-DK-081923 to J.N.H., P.-H.G., and J.C.F., a Science Foundation
Ireland U.S.-Ireland R&D partnership, and The Health Research Board
Ireland. R.M.S. was supported by a Juvenile Diabetes Research Foundation
postdoctoral fellowship (#3-2011-70). The Finn Diane Study was supported
by grants from the Folkhalsan Research Foundation, the Wilhelm and Else
Stockmann Foundation, Livoch Halsa Foundation, Helsinki University
Central Hospital Research Funds (EVO), the Sigrid Juselius Foundation,
the Signe and Arne Gyllenberg Foundation, Finska Lakaresallskapet, the
European Commission, and the European Union's Seventh Framework Program
(FP7/2007-2013) for the Innovative Medicine Initiative under Grant
Agreement No. IMI/115006 (the Surrogate Markers for Micro- and
Macro-vascular Hard Endpoints for Innovative Diabetes Tools [SUMMIT]
consortium).
NR 32
TC 40
Z9 41
U1 0
U2 7
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0012-1797
J9 DIABETES
JI Diabetes
PD AUG
PY 2012
VL 61
IS 8
BP 2187
EP 2194
DI 10.2337/db11-0751
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 980KC
UT WOS:000306891100034
PM 22721967
ER
PT J
AU Rovner, AJ
Nansel, TR
Mehta, SN
Higgins, LA
Haynie, DL
Laffel, LM
AF Rovner, Alisha J.
Nansel, Tonja R.
Mehta, Sanjeev N.
Higgins, Laurie A.
Haynie, Denise L.
Laffel, Lori M.
TI Development and Validation of the Type 1 Diabetes Nutrition Knowledge
Survey
SO DIABETES CARE
LA English
DT Article
ID GLYCEMIC CONTROL; COMPLICATIONS TRIAL; CHILDREN; YOUTH; CARBOHYDRATE;
ADOLESCENTS; BEHAVIORS; MELLITUS; THERAPY; OBESITY
AB OBJECTIVE-The purpose of this study was to develop a survey of general and diabetes-specific nutrition knowledge for youth with type 1 diabetes and their parents and to assess the survey's psychometric properties.
RESEARCH DESIGN AND METHODS-A multidisciplinary pediatric team developed the Nutrition Knowledge Survey (NKS) and administered it to youth with type I diabetes (n = 282,49% females, 13.3 +/- 2.9 years) and their parents (82% mothers). The NKS content domains included healthful eating, carbohydrate counting, blood glucose response to foods, and nutrition label reading. Higher NKS scores reflect greater nutrition knowledge (score range is 0-100%). In youths, glycemic control was assessed by A1C, and dietary quality was determined by the Healthy Eating Index-2005 (HEI-2005) derived from 3-day diet records. Validity was based on associations of NKS scores with A1C and dietary quality. Reliability was assessed using the Kuder-Richardson Formula 20 (KR-20) and correlations of domain scores to total score.
RESULTS-Mean NKS scores (23 items) were 56.9 +/- 16.4% for youth and 73.4 +/- 12.5% for parents. The KR-20 was 0.70 for youth and 0.59 for parents, representing acceptable internal consistency of the measure. In multivariate analysis, controlling for youth age, family income, parent education, diabetes duration, and insulin regimen, parent NKS scores were associated with corresponding youth A1C (beta = -0.13, P = 0.03). Both parent (beta = 0.20, P = 0.002) and youth (beta = 0.25, P < 0.001) NKS scores were positively associated with youth HEI-2005 scores.
CONCLUSIONS-The NKS appears to be a useful measure of general and diabetes-specific nutrition knowledge for youth with type 1 diabetes and their parents.
C1 [Rovner, Alisha J.; Nansel, Tonja R.; Haynie, Denise L.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Div Epidemiol Stat & Prevent, NIH, US Dept Hlth & Human Serv, Bethesda, MD USA.
[Mehta, Sanjeev N.; Higgins, Laurie A.; Laffel, Lori M.] Harvard Univ, Sch Med, Joslin Diabet Ctr, Pediat Adolescent & Young Adult Sect, Boston, MA 02115 USA.
RP Nansel, TR (reprint author), Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Div Epidemiol Stat & Prevent, NIH, US Dept Hlth & Human Serv, Bethesda, MD USA.
EM nanselt@mail.nih.gov
OI Nansel, Tonja/0000-0002-8298-7595; Haynie, Denise/0000-0002-8270-6079
FU National Institutes of Health, Eunice Kennedy Shriver National Institute
of Child Health and Human Development [HH-SN-267200703434C]
FX This research was supported by the intramural research program of the
National Institutes of Health, Eunice Kennedy Shriver National Institute
of Child Health and Human Development (Contract HH-SN-267200703434C).
NR 20
TC 4
Z9 4
U1 0
U2 17
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0149-5992
J9 DIABETES CARE
JI Diabetes Care
PD AUG
PY 2012
VL 35
IS 8
BP 1643
EP 1647
DI 10.2337/dc11-2371
PG 5
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 980KD
UT WOS:000306891200004
PM 22665217
ER
PT J
AU Garvey, KC
Wolpert, HA
Rhodes, ET
Laffel, LM
Kleinman, K
Beste, MG
Wolfsdorf, JI
Finkelstein, JA
AF Garvey, Katharine C.
Wolpert, Howard A.
Rhodes, Erinn T.
Laffel, Lori M.
Kleinman, Ken
Beste, Margaret G.
Wolfsdorf, Joseph I.
Finkelstein, Jonathan A.
TI Health Care Transition in Patients With Type 1 Diabetes Young adult
experiences and relationship to glycemic control
SO DIABETES CARE
LA English
DT Article
ID FOLLOW-UP; ADOLESCENTS; MELLITUS; SYSTEMS; CHILDREN; PEOPLE; FAMILY;
COHORT; YOUTH
AB OBJECTIVE-To examine characteristics of the transition from pediatric to adult care in emerging adults with type 1 diabetes and evaluate associations between transition characteristics and glycemic control.
RESEARCH DESIGN AND METHODS-We developed and mailed a survey to evaluate the transition process in emerging adults with type 1 diabetes, aged 22 to 30 years, receiving adult diabetes care at a single center. Current A1C data were obtained from the medical record.
RESULTS-The response rate was 53% (258 of 484 eligible). The mean transition age was 19.5 +/- 2.9 years, and 34% reported a gap >6 months in establishing adult care. Common reasons for transition included feeling too old (44%), pediatric provider suggestion (41%), and college (33%). Less than half received an adult provider recommendation and <15% reported having a transition preparation visit or receiving written transition materials. The most recent A1C was 8.1 +/- 1.3%. Respondents who felt mostly/completely prepared for transition had lower likelihood of a gap >6 months between pediatric and adult care (adjusted odds ratio 0.47 [95% CI 0.25-0.88]). In multivariate analysis, pretransition A1C (beta = 0.49, P < 0.0001), current age (beta = -0.07, P = 0.03), and education (beta = -0.55, P = 0.01) significantly influenced current posttransition A1C. There was no independent association of transition preparation with posttransition A1C (beta = -0.17, P = 0.28).
CONCLUSIONS-Contemporary transition practices may help prevent gaps between pediatric and adult care but do not appear to promote improvements in A1C. More robust preparation strategies and handoffs between pediatric and adult care should be evaluated.
C1 [Garvey, Katharine C.; Rhodes, Erinn T.; Wolfsdorf, Joseph I.] Childrens Hosp, Div Endocrinol, Boston, MA 02115 USA.
[Wolpert, Howard A.; Beste, Margaret G.] Joslin Diabet Ctr, Adult Sect, Boston, MA 02215 USA.
[Laffel, Lori M.] Joslin Diabet Ctr, Pediat Adolescent & Young Adult Sect, Boston, MA 02215 USA.
[Kleinman, Ken; Finkelstein, Jonathan A.] Harvard Univ, Sch Med, Dept Populat Med, Boston, MA USA.
[Finkelstein, Jonathan A.] Childrens Hosp, Div Gen Pediat, Boston, MA 02115 USA.
RP Garvey, KC (reprint author), Childrens Hosp, Div Endocrinol, Boston, MA 02115 USA.
EM katharine.garvey@childrens.harvard.edu
FU Agency for Healthcare Research and Quality as part of the Harvard
Pediatric Health Services [T32-HS000063]; National Institute of Diabetes
and Digestive and Kidney Diseases [T32DK007699-30]; William Randolph
Hearst Foundation; National Institute of Child Health and Human
Development [K24-HD-060786]
FX K.C.G. was supported by the Agency for Healthcare Research and Quality
(T32-HS000063) as part of the Harvard Pediatric Health Services Research
Fellowship, as well as the National Institute of Diabetes and Digestive
and Kidney Diseases (T32DK007699-30) and the William Randolph Hearst
Foundation. J.A.F. was funded by a grant from the National Institute of
Child Health and Human Development (K24-HD-060786).
NR 29
TC 38
Z9 41
U1 3
U2 14
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0149-5992
J9 DIABETES CARE
JI Diabetes Care
PD AUG
PY 2012
VL 35
IS 8
BP 1716
EP 1722
DI 10.2337/dc11-2434
PG 7
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 980KD
UT WOS:000306891200016
PM 22699289
ER
PT J
AU Laste, G
Caumo, W
Adachi, LNS
Rozisky, JR
de Macedo, IC
Marques, PR
Partata, WA
Fregni, F
Torres, ILS
AF Laste, Gabriela
Caumo, Wolnei
Spezia Adachi, Lauren Naomi
Rozisky, Joanna Ripoll
de Macedo, Isabel Cristina
Marques Filho, Paulo Ricardo
Partata, Wania Aparecida
Fregni, Felipe
Torres, Iraci L. S.
TI After-effects of consecutive sessions of transcranial direct current
stimulation (tDCS) in a rat model of chronic inflammation
SO EXPERIMENTAL BRAIN RESEARCH
LA English
DT Article
DE Transcranial direct current stimulation (tDCS); Motor cortex;
Neuromodulation; Inflammatory pain
ID MOTOR CORTEX STIMULATION; CHRONIC NEUROPATHIC PAIN; DC-STIMULATION;
BRAIN-STIMULATION; NERVE-TERMINALS; SPINAL-CORD; EXCITABILITY;
MECHANISMS; MEMORY; HYPERSENSITIVITY
AB Transcranial direct current stimulation (tDCS) induces cortical excitability changes in animals and humans that can last beyond the duration of stimulation. Preliminary evidence suggests that tDCS may have an analgesic effect; however, the timing of these effects, especially when associated with consecutive sessions of stimulation in a controlled animal experiment setting, has yet to be fully explored. To evaluate the effects of tDCS in inflammatory chronic pain origin immediately and 24 h after the last treatment session, complete Freund's adjuvant (CFA) was injected (100 mu l) in the right footpad to induce inflammation. On the 15th day after CFA injection, rats were divided into two groups: tDCS (n = 9) and sham (n = 9). The tDCS was applied for 8 days. The hot plate and Von Frey tests were applied immediately and 24 h after the last tDCS session. Eight 20-min sessions of 500 mu A anodal tDCS resulted in antinociceptive effects as assessed by the hot plate test immediately (P = 0.04) and 24 h after the last tDCS session (P = 0.006), for the active tDCS group only. There was increased withdrawal latency in the Von Frey test at 24 h after the last session (P = 0.01). Our findings confirm the hypothesis that tDCS induces significant, long-lasting, neuroplastic effects and expands these findings to a chronic pain model of peripheral inflammation, thus supporting the exploration of this technique in conditions associated with chronic pain and peripheral inflammation, such as osteoarthritis.
C1 [Laste, Gabriela; Caumo, Wolnei; Spezia Adachi, Lauren Naomi; Rozisky, Joanna Ripoll; de Macedo, Isabel Cristina; Marques Filho, Paulo Ricardo; Torres, Iraci L. S.] Univ Fed Rio Grande do Sul, Dept Pharmacol, Inst Basic Hlth Sci, BR-90050170 Porto Alegre, RS, Brazil.
[Laste, Gabriela; Caumo, Wolnei; Spezia Adachi, Lauren Naomi; Rozisky, Joanna Ripoll; de Macedo, Isabel Cristina; Marques Filho, Paulo Ricardo; Torres, Iraci L. S.] Anim Models Lab, Porto Alegre, RS, Brazil.
[Laste, Gabriela; Caumo, Wolnei; Spezia Adachi, Lauren Naomi; Rozisky, Joanna Ripoll; Torres, Iraci L. S.] Univ Fed Rio Grande do Sul, Grad Program Med Sci, BR-90050170 Porto Alegre, RS, Brazil.
[Laste, Gabriela; Spezia Adachi, Lauren Naomi; Rozisky, Joanna Ripoll; de Macedo, Isabel Cristina; Torres, Iraci L. S.] Hosp Clin Porto Alegre, Anim Experimentat Unit, Grad Res Grp, Porto Alegre, RS, Brazil.
[Partata, Wania Aparecida] Univ Fed Rio Grande do Sul, Dept Physiol, Inst Biol Sci, BR-90050170 Porto Alegre, RS, Brazil.
[Fregni, Felipe] Spaulding Rehabil Hosp, Lab Neuromodulat, Dept Phys Med & Rehabil, Boston, MA USA.
[Fregni, Felipe] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Fregni, Felipe] Harvard Univ, Beth Israel Deaconess Med Ctr, Ctr Noninvas Brain Stimulat, Sch Med, Boston, MA 02215 USA.
RP Torres, ILS (reprint author), Univ Fed Rio Grande do Sul, Dept Pharmacol, Inst Basic Hlth Sci, Rua Sarmento Leite,500 Sala 202, BR-90050170 Porto Alegre, RS, Brazil.
EM gabrielalaste@gmail.com; caumo@cpovo.net; lauren_adachi@hotmail.com;
joannarozisky@gmail.com; icc.macedo@gmail.com; paulo.prmf1@gmail.com;
partataw@gmail.com; fregni.felipe@mgh.harvard.edu; iracitorres@gmail.com
RI Torres, iraci/G-6693-2012; Laste, Gabriela/A-3033-2014; Rozisky,
Joanna/F-6584-2015;
OI Torres, iraci/0000-0002-3081-115X; Macedo, Isabel
Cristina/0000-0001-6215-1371
FU National Council for Scientific and Technological Development-CNPq
[307772/2008-0/2008]; PROPESQ/UFRGS/PIBIC/CNPq : Committee for the
Development of Higher Education Personnel-CAPES; Graduate Research Group
(GPPG) of Hospital de Clinicas de Porto Alegre-HCPA [100013]
FX This study was supported by the following Brazilian funding agencies:
National Council for Scientific and Technological Development-CNPq (Dr.
I. L. S. Torres, Grant no. 307772/2008-0/2008, Dr. W. Caumo);
PROPESQ/UFRGS/PIBIC/CNPq : Committee for the Development of Higher
Education Personnel-CAPES (J.R. Rozisky, G. Laste, L.S.N. Adachi); and
Graduate Research Group (GPPG) of Hospital de Clinicas de Porto
Alegre-HCPA (Dr I. L. S. Torres-Grant 100013). We would like to thank
the engineering staff of HCPA for developing the tDCS stimulator.
NR 74
TC 14
Z9 15
U1 0
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0014-4819
J9 EXP BRAIN RES
JI Exp. Brain Res.
PD AUG
PY 2012
VL 221
IS 1
BP 75
EP 83
DI 10.1007/s00221-012-3149-x
PG 9
WC Neurosciences
SC Neurosciences & Neurology
GA 977WT
UT WOS:000306696200009
PM 22752510
ER
PT J
AU Lionetto, L
Casolla, B
Mastropietri, F
D'Alonzo, L
Negro, A
Simmaco, M
Martelletti, P
AF Lionetto, Luana
Casolla, Barbara
Mastropietri, Fabiola
D'Alonzo, Lidia
Negro, Andrea
Simmaco, Maurizio
Martelletti, Paolo
TI Pharmacokinetic evaluation of zolmitriptan for the treatment of
migraines
SO EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY
LA English
DT Review
DE zolmitriptan; pharmacokinetics; pharmacodynamics; triptans; migraine;
menstrual-related-migraine; cluster hedache
ID ANTIMIGRAINE COMPOUND ZOLMITRIPTAN; DOUBLE-BLIND;
PHARMACOLOGICAL-TREATMENT; ABSOLUTE BIOAVAILABILITY;
MYOCARDIAL-INFARCTION; TRIPTAN FORMULATIONS; HEALTHY-VOLUNTEERS;
5-HT1B/1D AGONISTS; RECEPTOR AGONIST; CLUSTER HEADACHE
AB Introduction: Migraine is a multifactorial neurovascular disorder characterized by recurrent episodes of disabling pain attacks, accompanied with gastrointestinal, neurological systems dysfunction. The pharmacologic treatment of migraine is classically divided in the management of the acute attack and preventive strategies. Acute treatments consist of triptan, ergot, opioid, antiemetic and NSAIDs.
Areas covered: This article discusses pharmacodynamics and pharmacokinetics of zolmitriptan. The data were obtained by searching the following keywords in MEDLINE: zolmitriptan, pharmacokinetics, pharmacodynamics, triptans, migraine, menstrual-related migraine, cluster headache, relatively to the period 1989 - 2012.
Expert opinion: Zolmitriptan has been considered effective treatment in the acute phase of migraine, menstrual-related migraine and cluster headache attacks. Pharmacokinetic parameters may vary as a consequence of gender differences, inter- and intra-subjects variability and delivery system. Zolmitriptan was developed with the aim of obtaining a lipophilic compound in order to be more rapidly absorbed and centrally active. Pharmacologically, pharmacokinetic parameters are responsible for its wide efficacy and the limited adverse effect profile.
C1 [D'Alonzo, Lidia; Negro, Andrea; Martelletti, Paolo] Univ Roma La Sapienza, Reg Referral Headache Ctr, Dept Clin & Mol Med, I-00189 Rome, Italy.
[Lionetto, Luana; Casolla, Barbara; Mastropietri, Fabiola; Simmaco, Maurizio] Univ Roma La Sapienza, St Andrea Hosp, Adv Mol Diagnost Unit, NESMOS Dept, I-00189 Rome, Italy.
[Negro, Andrea] Harvard Univ, Sch Med, Dept Radiol, Massachusetts Gen Hosp,Stroke & Neurovasc Regulat, Boston, MA 02115 USA.
RP Martelletti, P (reprint author), Univ Roma La Sapienza, Reg Referral Headache Ctr, Dept Clin & Mol Med, Via Grottarossa 1035, I-00189 Rome, Italy.
EM paolo.martelletti@uniroma1.it
RI Lionetto, Luana/J-3632-2016
OI Lionetto, Luana/0000-0002-5272-6642
NR 52
TC 9
Z9 11
U1 0
U2 3
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1742-5255
J9 EXPERT OPIN DRUG MET
JI Expert Opin. Drug Metab. Toxicol.
PD AUG
PY 2012
VL 8
IS 8
BP 1043
EP 1050
DI 10.1517/17425255.2012.701618
PG 8
WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA 975PT
UT WOS:000306524000010
PM 22762358
ER
PT J
AU Ramanadhan, S
Crisostomo, J
Alexander-Molloy, J
Gandelman, E
Grullon, M
Lora, V
Reeves, C
Savage, C
Viswanath, K
AF Ramanadhan, Shoba
Crisostomo, Josephine
Alexander-Molloy, Jaclyn
Gandelman, Ediss
Grullon, Milagro
Lora, Vilma
Reeves, Chrasandra
Savage, Clara
Viswanath, Kasisomayajula
CA PLANET MassCONECT C-PAC
TI Perceptions of evidence-based programs among community-based
organizations tackling health disparities: a qualitative study
SO HEALTH EDUCATION RESEARCH
LA English
DT Article
ID PUBLIC-HEALTH; DISSEMINATION; INTERVENTIONS; PREVENTION; IMPLEMENTATION;
TRANSLATION; POLICY; GAINS; GAP
AB Dissemination of prevention-focused evidence-based programs (EBPs) from research to community settings may improve population health and reduce health disparities, but such flow has been limited. Academic-community partnerships using community-based participatory research (CBPR) principles may support increased dissemination of EBPs to community-based organizations (CBOs). This qualitative study examined the EBP-related perceptions and needs of CBOs targeting underserved populations. As part of PLANET MassCONECT, a CBPR study, we conducted six key informant interviews with community leaders and four focus groups with CBO staff members in Boston, Worcester and Lawrence, Massachusetts, in 2008. Working definitions of EBPs among CBO staff members varied greatly from typical definitions used by researchers or funders. Key barriers to using EBPs included: resource constraints, program adaptation challenges and conflicts with organizational culture. Important facilitators of EBP usage included: program supports for implementation and adaptation, collaborative technical assistance and perceived benefits of using established programs. This exploratory study highlights differences among key stakeholders regarding the role of evidence in program planning and delivery. An updated perspective should better incorporate CBO perspectives on evidence and place greater, and much needed, emphasis on the impact of context for EBP dissemination in community settings.
C1 [Ramanadhan, Shoba; Crisostomo, Josephine; Alexander-Molloy, Jaclyn; Viswanath, Kasisomayajula; PLANET MassCONECT C-PAC] Dana Farber Canc Inst, Ctr Community Based Res, Boston, MA 02115 USA.
[Gandelman, Ediss] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
[Grullon, Milagro] Lawrence Community Connect, Lawrence, MA 01840 USA.
[Lora, Vilma] YWCA Greater Lawrence City Lawrence Mayors Hlth T, Lawrence, KS 01840 USA.
[Reeves, Chrasandra] Boston Alliance Community Hlth, Boston, MA 02118 USA.
[Savage, Clara] Common Pathways, Worcester, MA 01609 USA.
[Viswanath, Kasisomayajula] Harvard Univ, Sch Publ Hlth, Dept Soc Human Dev & Hlth, Boston, MA 02115 USA.
RP Ramanadhan, S (reprint author), Dana Farber Canc Inst, Ctr Community Based Res, Boston, MA 02115 USA.
EM shoba_ramanadhan@dfci.harvard.edu
FU NCI NIH HHS [R01 CA132651]
NR 60
TC 4
Z9 4
U1 0
U2 12
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0268-1153
J9 HEALTH EDUC RES
JI Health Educ. Res.
PD AUG
PY 2012
VL 27
IS 4
BP 717
EP 728
DI 10.1093/her/cyr088
PG 12
WC Education & Educational Research; Public, Environmental & Occupational
Health
SC Education & Educational Research; Public, Environmental & Occupational
Health
GA 977HS
UT WOS:000306647900014
PM 22012968
ER
PT J
AU Exner, DV
Auricchio, A
Singh, JP
AF Exner, Derek V.
Auricchio, Angelo
Singh, Jagmeet P.
TI Contemporary and future trends in cardiac resynchronization therapy to
enhance response
SO HEART RHYTHM
LA English
DT Article
DE Biventricular pacing; Cardiac resynchronization therapy; Endocardial
pacing; Epicardial pacing; Left ventricular lead; Transvenous pacing
ID HEART-FAILURE PATIENTS; VENTRICULAR LEAD POSITION; POSTEROLATERAL SCAR
TISSUE; ACUTE HEMODYNAMIC-RESPONSE; BUNDLE-BRANCH BLOCK; PACING SITES;
IMPLANTABLE DEFIBRILLATOR; PREDICTS RESPONSE; ELECTRICAL DELAY;
CORONARY-SINUS
AB The rationale for cardiac resynchronization therapy (CRT), expectations in terms of patient benefit, patient selection for CRT, selection of a CRT pacemaker (CRT-P) vs CRT plus implantable cardioverter-defibrillator (CRT-D) platform, and studies evaluating device programming to enhance benefit from CRT are reviewed. The notion of an "optimal" left ventricular (LV) pacing site, the rationale for identifying and avoiding LV pacing in regions of scar, the use of anatomic, hemodynamic, and electrical parameters to identify an optimal LV pacing site, and the potential utility of multisite LV pacing to enhance benefit from CRT are discussed. Finally, the advantages and disadvantages of the various methods for LV lead delivery are reviewed.
C1 [Exner, Derek V.] Univ Calgary, Libin Cardiovasc Inst Alberta, Calgary, AB, Canada.
[Auricchio, Angelo] Fdn Cardioctr Ticino, Lugano, Switzerland.
[Singh, Jagmeet P.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
RP Exner, DV (reprint author), 3280 Hosp Dr NW,Room GE63, Calgary, AB T2N 4Z6, Canada.
EM exner@ucalgary.ca
FU Boehringer Ingelheim; GE Healthcare; Heart Force Medical; Medtronic; St.
Jude; AudiCor; Cambridge Heart; St. Jude Medical; Sorin Group;
Biotronik; EBR Systems; Merck Sharpe Dohme; Daiichi Sankyo; Impulse
Dynamics; Abbott; Cordis; Boston Scientific Corp; CardioInsight;
Thoratec; Biosense Webster; Guidant Corp
FX Dr. Exner is a Clinical Scholar of Alberta Innovates Health Solutions
and Canada Research Chair in Cardiovascular Clinical Trials. Dr. Exner
has received consulting fees/honoraria (modest) from Boehringer
Ingelheim, GE Healthcare, Heart Force Medical, Medtronic, and St. Jude;
research support (modest) from AudiCor and Cambridge Heart; and research
support (significant) from GE Healthcare, Heart Force Medical,
Medtronic, and St. Jude Medical. Dr. Auricchio has received financial
support (modest) from Sorin Group, Medtronic, Biotronik, EBR Systems,
Merck Sharpe & Dohme, Daiichi Sankyo, Impulse Dynamics, St. Jude
Medical, Abbott, and Cordis. Dr. Singh has received research grants
(significant) from St. Jude Medical, Medtronic, Boston Scientific Corp,
and Biotronik; advisory board/steering committee/consultant fees
(modest) from Boston Scientific Corp, Biotronik, St. Jude Medical,
Medtronic, CardioInsight, Thoratec, and Biosense Webster; and
honoraria/speaker fees (modest) from Medtronic, Biotronik, Guidant Corp,
St. Jude Medical, and Sorin Group. Address reprint requests and
correspondence: Dr. Derek V. Exner, 3280 Hospital Dr NW, Room GE63,
Calgary, AB Canada T2N 4Z6. E-mail address: exner@ucalgary.ca.
NR 77
TC 10
Z9 10
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1547-5271
J9 HEART RHYTHM
JI Heart Rhythm
PD AUG
PY 2012
VL 9
IS 8
SU S
BP S27
EP S35
DI 10.1016/j.hrthm.2012.04.022
PG 9
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 976TB
UT WOS:000306606800005
PM 22521939
ER
PT J
AU Parks, KA
Costanzo, MR
AF Parks, Kimberly A.
Costanzo, Maria Rosa
TI Thinking beyond resynchronization therapy in the failing heart
SO HEART RHYTHM
LA English
DT Article
DE Artificial heart; Cardiac resynchronization therapy; Cardiac
transplantation; End-stage heart failure; Ventricular assist device
ID VENTRICULAR ASSIST DEVICE; IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR; TOTAL
ARTIFICIAL-HEART; SUDDEN CARDIAC DEATH; INTERNATIONAL EXPERIENCE;
CIRCULATORY SUPPORT; CATHETER ABLATION; SCREENING SCALE; FAILURE;
TRANSPLANTATION
C1 [Parks, Kimberly A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Adv Heart Failure Sect, Boston, MA 02114 USA.
[Costanzo, Maria Rosa] Edwards Heart Hosp, Midwest Heart Fdn, Ctr Adv Heart Failure, Lombard, IL USA.
RP Parks, KA (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Adv Heart Failure Sect, 55 Fruit St,GB 800, Boston, MA 02114 USA.
EM kaparks@partners.org
FU Thoratec; St. Jude Medical; Paracor Medical; CardioMems; CHF Solutions;
Medtronic
FX Dr. Parks has received consultancy fees from Thoratec. Dr. Costanzo has
received research support from St. Jude Medical, Paracor Medical, and
CardioMems; honoraria from CHF Solutions, St. Jude Medical, and Gilead;
and consultancy fees form CHF Solutions, Medtronic, and St. Jude
Medical. Address reprint requests and correspondence: Dr. Kimberly
Parks, Harvard Medical School, Massachusetts General Hospital, 55 Fruit
St/GB 800, Boston, MA 02114-2621. E-mail address: kaparks@partners.org.
NR 68
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1547-5271
J9 HEART RHYTHM
JI Heart Rhythm
PD AUG
PY 2012
VL 9
IS 8
SU S
BP S36
EP S44
DI 10.1016/j.hrthm.2012.04.025
PG 9
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 976TB
UT WOS:000306606800006
PM 22521932
ER
PT J
AU Singh, JP
AF Singh, Jagmeet P.
TI Advances in electrical therapy for heart failure: Papers from the
International ADVANCE CRT Summit
SO HEART RHYTHM
LA English
DT Editorial Material
DE sp.
C1 [Singh, Jagmeet P.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cardiac Arrhythmia Serv,Heart Ctr, Boston, MA 02114 USA.
RP Singh, JP (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cardiac Arrhythmia Serv,Heart Ctr, Boston, MA 02114 USA.
EM jsingh@partners.org
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1547-5271
J9 HEART RHYTHM
JI Heart Rhythm
PD AUG
PY 2012
VL 9
IS 8
SU S
BP S1
EP S2
DI 10.1016/j.hrthm.2012.04.023
PG 2
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 976TB
UT WOS:000306606800001
PM 22521940
ER
PT J
AU Upadhyay, GA
Steinberg, JS
AF Upadhyay, Gaurav A.
Steinberg, Jonathan S.
TI Managing atrial fibrillation in the CRT patient: Controversy or
consensus?
SO HEART RHYTHM
LA English
DT Article
DE Atrial fibrillation; Cardiac resynchronization therapy; Heart failure;
Treatment strategies
ID CARDIAC RESYNCHRONIZATION THERAPY; IMPLANTABLE
CARDIOVERTER-DEFIBRILLATOR; ATRIOVENTRICULAR JUNCTION ABLATION;
CONGESTIVE-HEART-FAILURE; PULMONARY-VEIN ISOLATION; LEFT-VENTRICULAR
DYSFUNCTION; SINUS RHYTHM; LIFETIME RISK; MORTALITY; SURVIVAL
AB The cumulative incidence of new onset atrial fibrillation (AF) in patients undergoing cardiac resynchronization therapy (CRT) is substantial, exceeding 25% in multiple recent studies. Although AF patients undergoing CRT show improved echocardiographic parameters, functional status, and quality of life in, they benefit to a lesser degree than do patients in normal sinus rhythm. They also exhibit a trend toward increased mortality. Understanding the barriers to response from CRT among AF patients is critical to addressing the needs of growing populations of patients with AF and HF. Foremost among these are suboptimal biventricular pacing, often characterized by fusion or pseudo-fusion complexes, leading to inefficient CRT delivery. Furthermore, AF increases the risk of inappropriate shocks, which lead to substantial psychiatric morbidity, increased risk of heart failure hospitalization, and may also increase mortality. Assiduous rate control is reasonable for all AF patients receiving CRT, but there is a paucity of data regarding specific antiarrhythmic drug therapy recommendations. For patients with permanent AF and severe symptoms, atrioventricular junction ablation appears effective in improving response by ensuring biventricular capture and reducing implantable cardioverter-defibrillator shock burden in selected patients. Catheter-based techniques such as pulmonary vein isolation appear more attractive and in the future may offer further advantages and lower risks, particularly for patients with paroxysmal AF.
C1 [Upadhyay, Gaurav A.] Massachusetts Gen Hosp, Div Cardiol, Dept Med, Boston, MA 02114 USA.
[Upadhyay, Gaurav A.] Massachusetts Gen Hosp, Cardiac Arrhythmia Serv, Boston, MA 02114 USA.
[Steinberg, Jonathan S.] Columbia Univ Coll Phys & Surg, Arrhythmia Inst Valley Hlth Syst, New York, NY 10032 USA.
RP Upadhyay, GA (reprint author), Massachusetts Gen Hosp, Div Cardiol, Dept Med, Gray Bigelow 109, Boston, MA 02114 USA.
EM gaupadhyay@partners.org
FU Biosense Webster; Cameron Health; Ambucor; Medtronic; St. Jude Medical;
Sanofi-Aventis
FX Dr. Upadhyay has no financial disclosures that are relevant to this
publication. Dr. Steinberg is on the speakers' bureau for
Sanofi-Aventis; receives consultant fees/honoraria from Biosense
Webster, Cameron Health, Ambucor, Medtronic, St. Jude Medical, and
Sanofi-Aventis; and receives research/research grants from Biosense
Webster and Medtronic. Address reprint requests and correspondence: Dr.
Gaurav A. Upadhyay, Division of Cardiology and the Cardiac Arrhythmia
Service, Massachusetts General Hospital, Gray Bigelow 109, Boston, MA
02114. E-mail address: gaupadhyay@partners.org.
NR 56
TC 4
Z9 4
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1547-5271
J9 HEART RHYTHM
JI Heart Rhythm
PD AUG
PY 2012
VL 9
IS 8
SU S
BP S51
EP S59
DI 10.1016/j.hrthm.2012.04.030
PG 9
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 976TB
UT WOS:000306606800008
PM 22521931
ER
PT J
AU Mihara, M
Kisu, I
Hara, H
Iida, T
Araki, J
Shim, T
Narushima, M
Yamamoto, T
Moriguchi, H
Kato, Y
Tonsho, M
Banno, K
Aoki, D
Suganuma, N
Kagawa, N
Takehara, Y
Kato, O
Koshima, I
AF Mihara, Makoto
Kisu, Iori
Hara, Hisako
Iida, Takuya
Araki, Jun
Shim, Timothy
Narushima, Mitsunaga
Yamamoto, Takumi
Moriguchi, Hisashi
Kato, Yojiro
Tonsho, Makoto
Banno, Kouji
Aoki, Daisuke
Suganuma, Nobuhiko
Kagawa, Noriko
Takehara, Yuji
Kato, Osamu
Koshima, Isao
TI Uterine autotransplantation in cynomolgus macaques: the first case of
pregnancy and delivery
SO HUMAN REPRODUCTION
LA English
DT Article
DE uterine transplantation; cynomolgus macaque; indocyanine green
angiography; ICG; autotransplantation
ID UTERUS TRANSPLANTATION; SURGICAL TECHNIQUE; SURROGACY; FERTILITY; MODEL
AB For women with congenital uterine infertility, or for those who have undergone hysterectomy, uterine transplantation is one of the potential treatments to regain fertility. In this study, we utilized a primate model of uterine transplantation, and evaluated the patency of our microsurgical anastomoses, and the perfusion of the transplanted uterus.
Two female cynomolgus monkeys underwent surgery. We anastomosed two arteries and one vein in Case 1 and two arteries and two veins in Case 2. The arteries used were the uterine arteries and the anastomosis was done to the external iliac artery. We used one of the ovarian veins in both animals, but resected the ovary from the Fallopian tube. Uterine arterial blood flow and uterine size were determined by intraoperative indocyanine green (ICG) angiography and ultrasonography. The biopsy of the uterine cervix was performed after surgery.
ICG angiography showed that the unilateral uterine artery perfused the bilateral uterine bodies and cervix. In Case 1, ICG angiography showed the occlusion of one of the anastomosed arteries during the operation and the uterus appeared atrophied 2 months after operation. In Case 2, the transplanted uterus survived and normal menstruation occurred. The animal achieved a natural pregnancy and was delivered by the Caeserean section due to early separation of the placenta. The newborn suffered fetal distress.
These results show the anastomosis of at least the bilateral uterine arteries and the unilateral ovarian vein is required for uterus transplantation. This is the first report of a natural pregnancy in a primate following uterine autotransplantation.
C1 [Mihara, Makoto; Hara, Hisako; Iida, Takuya; Araki, Jun; Shim, Timothy; Narushima, Mitsunaga; Yamamoto, Takumi; Moriguchi, Hisashi; Koshima, Isao] Univ Tokyo, Dept Plast & Reconstruct Surg, Tokyo, Japan.
[Kisu, Iori; Banno, Kouji; Aoki, Daisuke] Keio Univ, Sch Med, Dept Obstet & Gynecol, Tokyo 160, Japan.
[Kato, Yojiro] Columbia Univ, Dept Surg, Med Ctr, Ctr Liver Dis & Transplantat,CCTI, New York, NY USA.
[Tonsho, Makoto] Massachusetts Gen Hosp, Dept Transplantat, Boston, MA 02114 USA.
[Tonsho, Makoto] Harvard Univ, Sch Med, Boston, MA USA.
[Suganuma, Nobuhiko] Kyoto Univ, Grad Sch Med, Dept Human Hlth Sci, Tokyo, Japan.
[Kagawa, Noriko; Takehara, Yuji; Kato, Osamu] Kato Ladies Clin, Adv Res Inst Fertil, Tokyo, Japan.
RP Mihara, M (reprint author), Univ Tokyo, Dept Plast & Reconstruct Surg, Tokyo, Japan.
EM mihara@keiseigeka.name
RI Banno, Kouji/C-9638-2014
FU Program for the Next Generation of World-leading Research of the
Japanese Cabinet Office [LS039]
FX The funding for this study was provided by the Program for the Next
Generation of World-leading Research of the Japanese Cabinet Office
(LS039).
NR 26
TC 28
Z9 29
U1 1
U2 12
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0268-1161
J9 HUM REPROD
JI Hum. Reprod.
PD AUG
PY 2012
VL 27
IS 8
BP 2332
EP 2340
DI 10.1093/humrep/des169
PG 9
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA 977HZ
UT WOS:000306648600010
PM 22647448
ER
PT J
AU Hirsch, MS
Kuritzkes, DR
AF Hirsch, Martin S.
Kuritzkes, Daniel R.
TI The Future of HIV Treatment
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE antiretroviral therapy; HIV treatment; eradication; development of
therapeutics
ID INFECTION
AB Antiretroviral therapy has transformed the management of HIV-infected individuals over the past quarter century. However, important challenges remain. These include attempts to eradicate HIV from reservoirs within the body, thereby eliminating the need for lifetime therapy. In addition, improvements in drug development, clinical trial, and regulatory pathways are necessary to expeditiously evaluate novel therapeutic regimens and strategies. Antiretroviral drug scarcity remains a major problem in underserved populations worldwide, and partnerships among pharmaceutical companies, academic investigators, and both governmental and nongovernmental agencies are necessary to improve access to these life-saving regimens.
C1 [Hirsch, Martin S.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
[Hirsch, Martin S.; Kuritzkes, Daniel R.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
[Hirsch, Martin S.] Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA.
[Kuritzkes, Daniel R.] Harvard Univ, Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA.
RP Hirsch, MS (reprint author), 65 Landsdowne St,Room 419, Cambridge, MA 02139 USA.
EM hirsch.martin@mgh.harvard.edu
FU Gilead; Merck
FX D.R.K. is a consultant to Abbott, Aileron, Avexa, Boehringer-Ingelheim,
Bristol-Myers Squibb, Gilead, InnoVirVax, Merck, Pathogenica, Roche,
Tobira, Vertex, Viiv, ViroStatics and VIRxSYS and has received grants
from Gilead and Merck and speaking honorarium from Roche. M.S.H. has no
funding or conflicts of interest to disclose.
NR 12
TC 1
Z9 1
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1525-4135
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD AUG 1
PY 2012
VL 60
SU 2
BP S39
EP S40
DI 10.1097/QAI.0b013e318258bc9f
PG 2
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 977GJ
UT WOS:000306644400006
PM 22772389
ER
PT J
AU Mayer, KH
Pape, JW
Wilson, P
Diallo, DD
Saavedra, J
Mimiaga, MJ
Koenig, S
Farmer, P
AF Mayer, Kenneth H.
Pape, Jean W.
Wilson, Phill
Diallo, Dazon D.
Saavedra, Jorge
Mimiaga, Matthew J.
Koenig, Serena
Farmer, Paul
TI Multiple Determinants, Common Vulnerabilities, and Creative Responses:
Addressing the AIDS Pandemic in Diverse Populations Globally
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE disparities; inequity; health care access; homophobia; sex inequality
ID ACQUIRED IMMUNODEFICIENCY SYNDROME; HIV-INFECTION; RISK; HAITI; MEN;
SETTINGS; EPIDEMIC; AFRICA; SEX
AB The AIDS epidemic has been fueled by global inequities. Ranging from sexual inequality and underdevelopment to homophobia impeding health care access for men who have sex with men, imbalanced resource allocations, and social biases have potentiated the spread of the epidemic. However, recognition of culturally specific aspects of each microepidemic has yielded development of community-based organizations, which have resulted in locally effective responses to AIDS. This effective approach to HIV prevention, care, and treatment is illustrated through examples of community-based responses in Haiti, the United States, Africa, and other impoverished settings.
C1 [Mayer, Kenneth H.] Fenway Hlth, Fenway Inst, Boston, MA 02215 USA.
[Mayer, Kenneth H.] Harvard Univ, Beth Israel Deaconess Med Ctr, Div Infect Dis, Sch Med, Boston, MA 02215 USA.
[Pape, Jean W.] Weill Cornell Med Coll, Dept Med, New York, NY USA.
[Pape, Jean W.] GHESKIO, Port Au Prince, Haiti.
[Wilson, Phill] Black AIDS Inst, Los Angeles, CA USA.
[Diallo, Dazon D.] SisterLove Inc, Atlanta, GA USA.
[Saavedra, Jorge] AIDS Hlth Care Fdn, Los Angeles, CA USA.
Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Psychiat, Boston, MA USA.
[Mimiaga, Matthew J.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Koenig, Serena] Harvard Univ, Brigham & Womens Hosp, Div Global Hlth Equ, Sch Med, Boston, MA 02115 USA.
[Koenig, Serena] Harvard Univ, Brigham & Womens Hosp, Div Infect Dis, Sch Med, Boston, MA 02115 USA.
[Farmer, Paul] Harvard Univ, Sch Med, Dept Global Hlth & Social Med, Boston, MA USA.
[Farmer, Paul] Partners Hlth, Boston, MA USA.
RP Mayer, KH (reprint author), Fenway Hlth, Fenway Inst, 1340 Boylston St, Boston, MA 02215 USA.
EM mayer@fenwayhealth.org
FU NIAID NIH HHS [UM1 AI069421, U01 AI069421]
NR 25
TC 6
Z9 6
U1 1
U2 12
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1525-4135
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD AUG 1
PY 2012
VL 60
SU 2
BP S31
EP S34
DI 10.1097/QAI.0b013e31825c16d9
PG 4
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 977GJ
UT WOS:000306644400004
PM 22772387
ER
PT J
AU Bergevin, C
Walsh, EJ
McGee, J
Shera, CA
AF Bergevin, Christopher
Walsh, Edward J.
McGee, Joann
Shera, Christopher A.
TI Probing cochlear tuning and tonotopy in the tiger using otoacoustic
emissions
SO JOURNAL OF COMPARATIVE PHYSIOLOGY A-NEUROETHOLOGY SENSORY NEURAL AND
BEHAVIORAL PHYSIOLOGY
LA English
DT Article
ID AUDITORY-NERVE FIBERS; CHARACTERISTIC FREQUENCY; COHERENT REFLECTION;
TRAVELING-WAVES; EAR; MECHANISMS; MAP; CHINCHILLA; HUMANS; CAT
AB Otoacoustic emissions (sound emitted from the ear) allow cochlear function to be probed noninvasively. The emissions evoked by pure tones, known as stimulus-frequency emissions (SFOAEs), have been shown to provide reliable estimates of peripheral frequency tuning in a variety of mammalian and non-mammalian species. Here, we apply the same methodology to explore peripheral auditory function in the largest member of the cat family, the tiger (Panthera tigris). We measured SFOAEs in 9 unique ears of 5 anesthetized tigers. The tigers, housed at the Henry Doorly Zoo (Omaha, NE), were of both sexes and ranged in age from 3 to 10 years. SFOAE phase-gradient delays are significantly longer in tigers-by approximately a factor of two above 2 kHz and even more at lower frequencies-than in domestic cats (Felis catus), a species commonly used in auditory studies. Based on correlations between tuning and delay established in other species, our results imply that cochlear tuning in the tiger is significantly sharper than in domestic cat and appears comparable to that of humans. Furthermore, the SFOAE data indicate that tigers have a larger tonotopic mapping constant (mm/octave) than domestic cats. A larger mapping constant in tiger is consistent both with auditory brainstem response thresholds (that suggest a lower upper frequency limit of hearing for the tiger than domestic cat) and with measurements of basilar-membrane length (about 1.5 times longer in the tiger than domestic cat).
C1 [Bergevin, Christopher] Columbia Univ, Dept Otolaryngol Head & Neck Surg, New York, NY 10032 USA.
[Walsh, Edward J.; McGee, Joann] Boys Town Natl Res Hosp, Omaha, NE 68131 USA.
[Shera, Christopher A.] Massachusetts Eye & Ear Infirm, Eaton Peabody Labs, Boston, MA 02114 USA.
[Shera, Christopher A.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA.
RP Bergevin, C (reprint author), Columbia Univ, Dept Otolaryngol Head & Neck Surg, 630 W 168th St,P&S 11-452, New York, NY 10032 USA.
EM dolemitecb@gmail.com
FU National Science Foundation [0823417, 0602173]; Howard Hughes Medical
Institute [52003749]; National Institutes of Health [R01 DC003687, P30
DC05209]
FX The support, advice, and assistance of the veterinarians and staff of
the Henry Doorly Zoo were invaluable to the completion of this study.
All procedures were approved by the Institutional Animal Care and Use
Committee. We thank Sebastiaan Meenderink and John Rosowski for helpful
comments on the manuscript. The work was supported by the National
Science Foundation (grants 0823417 and 0602173), the Howard Hughes
Medical Institute (grant 52003749), and the National Institutes of
Health (grants R01 DC003687 and P30 DC05209).
NR 41
TC 1
Z9 1
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0340-7594
J9 J COMP PHYSIOL A
JI J. Comp. Physiol. A -Neuroethol. Sens. Neural Behav. Physiol.
PD AUG
PY 2012
VL 198
IS 8
BP 617
EP 624
DI 10.1007/s00359-012-0734-1
PG 8
WC Behavioral Sciences; Neurosciences; Physiology; Zoology
SC Behavioral Sciences; Neurosciences & Neurology; Physiology; Zoology
GA 977XM
UT WOS:000306698200005
PM 22645048
ER
PT J
AU Hornsby, PJ
AF Hornsby, Peter J.
TI Adrenarche: a cell biological perspective
SO JOURNAL OF ENDOCRINOLOGY
LA English
DT Review
ID EMBRYONIC STEM-CELLS; ADRENOCORTICAL-CELLS; STEROIDOGENIC CELLS;
ZONA-RETICULARIS; DEHYDROEPIANDROSTERONE-SULFATE; ANDROGEN PRODUCTION;
MESENCHYMAL CELLS; SONIC HEDGEHOG; IN-VIVO; DIFFERENTIATION
AB Adrenarche is a cell biological and endocrinological puzzle. The differentiation of the zona reticularis in childhood in humans requires special techniques for study because it is confined to humans and possibly a small number of other primates. Despite the rapid progress in the definition of adrenocortical stem/progenitor cells in the mouse, the factors that cause the differentiation of adrenocortical cells into zonal cell types have not been identified. There are, however, many candidates in the Wnt, Hedgehog, and other families of signaling molecules. A suitable system for identifying authentic stem cells, capable of differentiation into all zones, has yet to be developed. It is proposed here that the in vitro differentiation of pluripotent cells, combined with appropriate in vitro and in vivo methods for validating authentic adrenocortical stem cells, is a promising approach to solving these questions. Journal of Endocrinology (2012) 214, 113-119
C1 [Hornsby, Peter J.] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78245 USA.
[Hornsby, Peter J.] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78245 USA.
[Hornsby, Peter J.] S Texas Vet Hlth Care Syst, San Antonio, TX USA.
RP Hornsby, PJ (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, 15355 Lambda Dr, San Antonio, TX 78245 USA.
EM hornsby@uthscsa.edu
NR 53
TC 4
Z9 4
U1 0
U2 3
PU BIOSCIENTIFICA LTD
PI BRISTOL
PA EURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT,
ENGLAND
SN 0022-0795
J9 J ENDOCRINOL
JI J. Endocrinol.
PD AUG
PY 2012
VL 214
IS 2
BP 113
EP 119
DI 10.1530/JOE-12-0022
PG 7
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 976CR
UT WOS:000306558600002
PM 22573830
ER
PT J
AU Rodriguez, L
Irani, K
Jiang, HY
Goldstein, AM
AF Rodriguez, Leonel
Irani, Katayun
Jiang, Hongyu
Goldstein, Allan M.
TI Clinical Presentation, Response to Therapy, and Outcome of Gastroparesis
in Children
SO JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION
LA English
DT Article
DE delayed gastric emptying; gastroparesis; nausea; prokinetic therapy;
vomiting
ID GASTRIC ELECTRICAL-STIMULATION; DIABETIC GASTROPARESIS; DOMPERIDONE;
METOCLOPRAMIDE; ERYTHROMYCIN; SYMPTOMS; TERM; SCINTIGRAPHY; PROKINETICS;
DYSPEPSIA
AB Objectives: The aims of the present study was to define the clinical features, response to therapy, and outcome of pediatric gastroparesis.
Methods: Retrospective review of 230 children with gastroparesis. Demographics, gastric emptying times, symptoms, response to medications, and outcome were determined for each of 3 groups (infants, children, and adolescents).
Results: Mean age was 9 years, with boys predominating among infants and girls among adolescents. Postviral gastroparesis occurred in 18% and mitochondrial dysfunction (MD) in 8%. Symptoms varied with age, with children experiencing more vomiting and adolescents reporting more nausea and abdominal pain. The addition of promotility drugs was an effective therapy. Overall rates of symptom resolution were 22% at 6 months, 53% at 18 months, and 61% at 36 months, with median time to resolution of 14 months. Factors associated with symptom resolution included younger age, male sex, postviral gastroparesis, shorter duration of symptoms, response to addition of promotility therapy, and absence of MD. In multivariate analysis, longer duration of symptoms and MD both predicted lower rates of resolution, whereas younger age and response to addition of promotility therapy predicted a higher rate.
Conclusions: Pediatric gastroparesis is a complex condition with variable symptomatology and outcome depending on multiple parameters. Understanding the clinical features and response to therapy will improve our diagnosis and treatment of this disorder.
C1 [Rodriguez, Leonel] Childrens Hosp, Dept Med, Div Gastroenterol, Ctr Motil & Funct Gastrointestinal Disorders, Boston, MA 02115 USA.
[Irani, Katayun; Goldstein, Allan M.] Massachusetts Gen Hosp, Dept Pediat Surg, Boston, MA 02114 USA.
[Jiang, Hongyu] Harvard Univ, Childrens Hosp, Sch Med, Dept Biostat Core, Boston, MA 02115 USA.
RP Rodriguez, L (reprint author), Childrens Hosp, Dept Med, Div Gastroenterol, Ctr Motil & Funct Gastrointestinal Disorders, 300 Longwood Ave, Boston, MA 02115 USA.
EM leonel.ro-driguez@childrens.harvard.edu
NR 26
TC 11
Z9 11
U1 1
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0277-2116
J9 J PEDIATR GASTR NUTR
JI J. Pediatr. Gastroenterol. Nutr.
PD AUG
PY 2012
VL 55
IS 2
BP 185
EP 190
DI 10.1097/MPG.0b013e318248ed3f
PG 6
WC Gastroenterology & Hepatology; Nutrition & Dietetics; Pediatrics
SC Gastroenterology & Hepatology; Nutrition & Dietetics; Pediatrics
GA 977ZM
UT WOS:000306705400019
PM 22228004
ER
PT J
AU Germain, A
Richardson, R
Moul, D
Mammen, O
Haas, G
Forman, S
Rode, N
Begley, A
Nofzinger, E
AF Germain, Anne
Richardson, Robin
Moul, Douglas
Mammen, Oommen
Haas, Gretchen
Forman, Steven
Rode, Noelle
Begley, Amy
Nofzinger, Eric
TI Response to Dr. Mommersteeg and colleagues on Germain et al.,
"Placebo-controlled comparison of prazosin and cognitive-behavioral
treatments for sleep disturbances in US Military Veterans"
SO JOURNAL OF PSYCHOSOMATIC RESEARCH
LA English
DT Letter
ID QUALITY INDEX ADDENDUM; INSOMNIA; PTSD
C1 [Germain, Anne] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15260 USA.
Cleveland Clin Fdn, Sleep Disorders Ctr, Neurol Inst, Cleveland, OH 44195 USA.
VA Pittsburgh Healthcare Syst, MIRECC VSN4, Pittsburgh, PA USA.
RP Germain, A (reprint author), Univ Pittsburgh, Sch Med, Pittsburgh, PA 15260 USA.
EM germax@upmc.edu
NR 10
TC 0
Z9 0
U1 0
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0022-3999
J9 J PSYCHOSOM RES
JI J. Psychosomat. Res.
PD AUG
PY 2012
VL 73
IS 2
BP 154
EP 155
DI 10.1016/j.jpsychores.2012.05.004
PG 2
WC Psychiatry
SC Psychiatry
GA 977BZ
UT WOS:000306632700014
ER
PT J
AU Little, EC
Wang, CD
Watson, PM
Watson, DK
Cole, DJ
Camp, ER
AF Little, Elizabeth C.
Wang, Cindy
Watson, Patricia M.
Watson, Dennis K.
Cole, David J.
Camp, E. Ramsay
TI Novel Immunocompetent Murine Models Representing Advanced Local and
Metastatic Pancreatic Cancer
SO JOURNAL OF SURGICAL RESEARCH
LA English
DT Article
DE pancreatic cancer; murine model; gemcitabine
ID IN-VIVO; TUMOR BURDEN; ANTITUMOR IMMUNITY; MOUSE MODELS; CELLS; MICE;
GEMCITABINE; INDUCTION; SURVIVAL; GROWTH
AB Background. The development of novel therapeutics for pancreatic cancer has been hindered by a lack of relevant preclinical models. The purpose of this study was to evaluate the clinical relevancy of two pancreatic cancer models using standard-of-care therapeutic agent gemcitabine.
Materials and Methods. Murine Panc02 cells were injected directly into the spleen or pancreas of C57BL/6 mice to respectively create models of metastatic and locally advanced pancreatic cancer. Beginning 7 d post-Panc02 injection, treated mice received 20 mg/kg gemcitabine i.p. every 3 d. Animals were sacrificed when the untreated mice became moribund and tumor/liver weight used to assess tumor burden.
Results. Untreated mice became moribund 22 d after pancreatic Panc02 injection. Gross analysis revealed localized pancreatic tumors weighing 1.063 g. Intrasplenic Panc02 injection produced extensive liver metastasis by d 15 when the untreated mice first became moribund. Liver weights at this time averaged 3.6 g compared with the average non-tumor-bearing weight of 1.23 g. Gemcitabine therapy resulted in a 54% decrease in localized pancreatic tumor weight and 62.5% decrease in metastatic liver weight. Additionally, gemcitabine therapy extended animal survival to 20.5 d compared with 18.0 d average for the untreated mice.
Conclusions. We describe two models depicting both locally advanced and metastatic pancreatic cancer in immunocompetent mice. In efforts to establish baseline therapeutic efficacy, we determined that gemcitabine reduces tumor burden in both models and enhances survival in the metastatic model. These clinically relevant models provide valuable tools to evaluate novel therapeutics in pancreatic cancer. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Wang, Cindy; Cole, David J.; Camp, E. Ramsay] Med Univ S Carolina, Dept Surg, Charleston, SC 29425 USA.
[Watson, Patricia M.; Watson, Dennis K.] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA.
[Little, Elizabeth C.; Cole, David J.] Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA.
[Watson, Dennis K.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA.
[Little, Elizabeth C.; Wang, Cindy; Watson, Patricia M.; Watson, Dennis K.; Cole, David J.; Camp, E. Ramsay] Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA.
[Camp, E. Ramsay] Ralph H Johnson VA Med Ctr, Charleston, SC 29425 USA.
RP Camp, ER (reprint author), Med Univ S Carolina, Dept Surg, 25 Courtenay Dr,Room 7018,MSC795, Charleston, SC 29425 USA.
EM campe@musc.edu
FU National Institutes of Health [5R01CA123159-05, 1K08CA142904]
FX The authors thank Dr. Michael Rosol at the Small Animal Imaging Core
Facility at MUSC for his assistance with bioluminescence imaging. This
research was supported by the National Institutes of Health,
5R01CA123159-05 (DJC, DKW) and 1K08CA142904 (ERC).
NR 28
TC 8
Z9 9
U1 0
U2 6
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0022-4804
J9 J SURG RES
JI J. Surg. Res.
PD AUG
PY 2012
VL 176
IS 2
BP 359
EP 366
DI 10.1016/j.jss.2011.10.025
PG 8
WC Surgery
SC Surgery
GA 975EC
UT WOS:000306488700007
PM 22221605
ER
PT J
AU Davidson, BP
Giraud, GD
AF Davidson, Brian P.
Giraud, George D.
TI Left Ventricular Function and the Systemic Arterial Vasculature:
Remembering What We Have Learned
SO JOURNAL OF THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY
LA English
DT Editorial Material
ID PRESERVED EJECTION FRACTION; HEART-FAILURE; FILLING PRESSURE; INTACT
HEART; FORCE; LOAD
C1 [Giraud, George D.] Portland VA Med Ctr, Cardiol Sect, Portland, OR 97207 USA.
Oregon Hlth & Sci Univ, Dept Med, Div Cardiovasc Med, Portland, OR USA.
RP Giraud, GD (reprint author), Portland VA Med Ctr, Cardiol Sect, P3Card,POB 1034, Portland, OR 97207 USA.
EM giraudg@ohsu.edu
FU NHLBI NIH HHS [T32 HL094294, T32HL094294, R01 HL102763, R21 HL093617];
NICHD NIH HHS [P01 HD 34430, P01 HD034430]
NR 22
TC 0
Z9 0
U1 0
U2 2
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0894-7317
J9 J AM SOC ECHOCARDIOG
JI J. Am. Soc. Echocardiogr.
PD AUG
PY 2012
VL 25
IS 8
BP 891
EP 894
DI 10.1016/j.echo.2012.06.020
PG 4
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 977KJ
UT WOS:000306657900014
PM 22824174
ER
PT J
AU Schittone, SA
Dionne, KR
Tyler, KL
Clarke, P
AF Schittone, Stephanie A.
Dionne, Kalen R.
Tyler, Kenneth L.
Clarke, Penny
TI Activation of Innate Immune Responses in the Central Nervous System
during Reovirus Myelitis
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID TOLL-LIKE RECEPTOR; ACUTE FLACCID PARALYSIS; ASTROCYTIC METABOLIC
PHENOTYPE; INTERFERON-STIMULATED GENES; THEILERS VIRUS-INFECTION;
NECROSIS-FACTOR-ALPHA; SPINAL-CORD; NEURODEGENERATIVE DISEASES;
MAMMALIAN REOVIRUS; ANIMAL-MODELS
AB Reovirus infection of the murine spinal cord (SC) was used as a model system to investigate innate immune responses during viral myelitis, including the activation of glia (microglia and astrocytes) and interferon (IFN) signaling and increased expression of inflammatory mediators. Reovirus myelitis was associated with the pronounced activation of SC glia, as evidenced by characteristic changes in cellular morphology and increased expression of astrocyte and microglia-specific proteins. Expression of inflammatory mediators known to be released by activated glia, including interleukin-1 beta (IL-1 beta), tumor necrosis factor alpha (TNF-alpha), chemokine (C-C motif) ligand 5 (CCL 5), chemokine (C-X-C motif) ligand 10 (CXCL10), and gamma interferon (IFN-gamma), was also significantly upregulated in the SC of reovirus-infected animals compared to mock-infected controls. Reovirus infection of the mouse SC was also associated with increased expression of genes involved in IFN signaling, including IFN-stimulated genes (ISG). Further, reovirus infection of mice deficient in the expression of the IFN-alpha/beta receptor (IFNAR(-/-)) resulted in accelerated mortality, demonstrating that IFN signaling is protective during reovirus myelitis. Experiments performed in ex vivo SC slice cultures (SCSC) confirmed that resident SC cells contribute to the production of at least some of these inflammatory mediators and ISG during reovirus infection. Microglia, but not astrocytes, were still activated, and glia-associated inflammatory mediators were still produced in reovirus-infected INFAR(-/-) mice, demonstrating that IFN signaling is not absolutely required for these neuroinflammatory responses. Our results suggest that activated glia and inflammatory mediators contribute to a local microenvironment that is deleterious to neuronal survival.
C1 [Schittone, Stephanie A.; Dionne, Kalen R.; Tyler, Kenneth L.; Clarke, Penny] Univ Colorado, Dept Neurol, Aurora, CO 80045 USA.
[Schittone, Stephanie A.; Tyler, Kenneth L.] Univ Colorado, Dept Microbiol, Aurora, CO USA.
[Dionne, Kalen R.; Tyler, Kenneth L.] Univ Colorado, Dept Neurosci, Aurora, CO USA.
[Tyler, Kenneth L.] Univ Colorado, Dept Med, Aurora, CO USA.
[Dionne, Kalen R.; Tyler, Kenneth L.] Univ Colorado, Med Scientist Training Program, Aurora, CO USA.
[Tyler, Kenneth L.] Denver Vet Affairs Med Ctr, Denver, CO USA.
RP Clarke, P (reprint author), Univ Colorado, Dept Neurol, Anshutz Med Campus, Aurora, CO 80045 USA.
EM Penny.Clarke@ucdenver.edu
OI Tyler, Kenneth/0000-0003-3294-5888
FU NIH [R01 NS076512, F31 NS06258303, F30 NS071630, T32 GM008497]; VA merit
grant; NIH/NCRR Colorado CTSI [UL1 RR025780]
FX This publication was supported by NIH grants R01 NS076512 (K.L.T.), F31
NS06258303 (S.A.S.), F30 NS071630 (K.R.D.), and T32 GM008497 (K.R.D.)
and by a VA merit grant (K.L.T.). K.L.T. is supported by the
Reuler-Lewin Family Professorship. The Advanced Microscopy Core at the
Division of Renal Disease and Hypertension, University of Colorado
School of Medicine is funded by NIH/NCRR Colorado CTSI grant number UL1
RR025780.
NR 80
TC 6
Z9 7
U1 0
U2 5
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD AUG
PY 2012
VL 86
IS 15
BP 8107
EP 8118
DI 10.1128/JVI.00171-12
PG 12
WC Virology
SC Virology
GA 976VE
UT WOS:000306614400035
PM 22623770
ER
PT J
AU Bhattacharya, D
Ansari, IH
Mehle, A
Striker, R
AF Bhattacharya, Dipankar
Ansari, Israrul H.
Mehle, Andrew
Striker, Rob
TI Fluorescence Resonance Energy Transfer-Based Intracellular Assay for the
Conformation of Hepatitis C Virus Drug Target NS5A
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID NONSTRUCTURAL PROTEIN 5A; MEMBRANE ANCHOR; RNA REPLICATION; LIVING
CELLS; DOMAIN 3; IDENTIFICATION; CYCLOPHILINS; INHIBITOR; SUBSTRATE;
DYNAMICS
AB Nonstructural protein 5A (NS5A) is essential for hepatitis C virus (HCV) replication and assembly and is a critical drug target. Biochemical data suggest large parts of NS5A are unfolded as an isolated protein, but little is known about its folded state in the cell. We used fluorescence resonance energy transfer (FRET) to probe whether or not different regions of NS5A are in close proximity within the cell. Twenty-three separate reporter constructs were created by inserting one or more fluorophores into different positions throughout the three domains of NS5A. FRET efficiency was maximal when donor and acceptor fluorophores were positioned next to each other but also could be observed when the two fluorophores flanked NS5A domain I or domain 3. Informatic and biochemical analysis suggests that large portions of the carboxy terminus of NS5A are in an unfolded and disordered state. Quercetin, a natural product known to disrupt NS5A function in cells, specifically disrupted a conformationally specific domain 3 FRET signal. Intermolecular FRET indicated that the NS5A amino termini, but not other regions, are in close proximity in multimeric complexes. Overall, this assay provides a new window on the intracellular conformation(s) of NS5A and how the conformation changes in response to cellular and viral components of the replication and assembly complex as well as antiviral drugs.
C1 [Striker, Rob] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA.
[Bhattacharya, Dipankar; Ansari, Israrul H.; Striker, Rob] Univ Wisconsin, Dept Med, Madison, WI USA.
[Mehle, Andrew] Univ Wisconsin, Dept Med Microbiol & Immunol, Madison, WI 53706 USA.
RP Striker, R (reprint author), William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA.
EM rtstriker@wisc.edu
FU American Cancer Society [07-077-01]; Office of Research and Development,
Biomedical Laboratory R&D Service, Department of Veterans Affairs;
[R00GM088484]
FX This work was supported by the American Cancer Society Research Scholar
Grant (07-077-01) to R.S., by the Office of Research and Development,
Biomedical Laboratory R&D Service, Department of Veterans Affairs, and
by R00GM088484 to A.M.
NR 38
TC 6
Z9 6
U1 2
U2 8
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD AUG
PY 2012
VL 86
IS 15
BP 8277
EP 8286
DI 10.1128/JVI.00645-12
PG 10
WC Virology
SC Virology
GA 976VE
UT WOS:000306614400050
PM 22623794
ER
PT J
AU Shamsi, KS
Pierce, A
Ashton, AS
Halade, DG
Richardson, A
Espinoza, SE
AF Shamsi, Kinza S.
Pierce, Anson
Ashton, Aaron S.
Halade, Dipti G.
Richardson, Arlan
Espinoza, Sara E.
TI Proteomic Screening of Glycoproteins in Human Plasma for Frailty
Biomarkers
SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL
SCIENCES
LA English
DT Article
DE Proteomics; Frailty
ID HUMAN SERUM; AFFINITY-CHROMATOGRAPHY; ALZHEIMERS-DISEASE;
MASS-SPECTROMETRY; OLDER-ADULTS; INFLAMMATION; COAGULATION;
GLYCOSYLATION; ACTIVATION; AMERICAN
AB The application of proteomics methodology for analyzing human blood samples is of increasing importance as a noninvasive method for understanding, detecting, and monitoring disease. In particular, glycoproteomic analysis may be useful in the study of age-related diseases and syndromes, such as frailty. This study demonstrates the use of methodology for isolating plasma glycoproteins using lectins, comparing the glycoproteome by frailty status using two-dimensional polyacrylamide gel electrophoresis and identifying glycoproteins using mass spectrometry. In a pilot study, we found seven glycoproteins to differ by at least twofold in prefrail compared with nonfrail older adults, including haptoglobin, transferrin, and fibrinogen, consistent with known inflammatory and hematologic changes associated with frailty. Enzyme-linked immunosorbent assay analysis found that plasma transferrin concentration was increased in frail and prefrail older adults compared with nonfrail, confirming our proteomic findings. This work provides evidence for using a reproducible methodology for conducting clinical proteomic comparative studies of age-related diseases.
C1 [Espinoza, Sara E.] Univ Texas Hlth Sci Ctr San Antonio, Sch Med, Div Geriatr Gerontol & Palliat Med, Dept Med, San Antonio, TX 78229 USA.
[Shamsi, Kinza S.; Ashton, Aaron S.; Richardson, Arlan; Espinoza, Sara E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA.
[Pierce, Anson] Univ Texas Galveston, Med Branch, Dept Biochem & Mol Biol, Galveston, TX 77550 USA.
[Halade, Dipti G.; Richardson, Arlan; Espinoza, Sara E.] Univ Texas Hlth Sci Ctr San Antonio, Sam & Ann Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA.
[Halade, Dipti G.; Richardson, Arlan; Espinoza, Sara E.] S Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX USA.
RP Espinoza, SE (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Sch Med, Div Geriatr Gerontol & Palliat Med, Dept Med, 7703 Floyd Curl Dr,Mail Code 7875, San Antonio, TX 78229 USA.
EM espinozas2@uthscsa.edu
RI Pierce, Anson/D-1079-2012
OI Pierce, Anson/0000-0002-1383-0180
FU Veterans Affairs Research & Development (VISN 17 New Investigator Award)
[10N17]; San Antonio Area Foundation; Biomedical Research Foundation of
South Texas; University Research Council of the University of Texas
Health Science Center at San Antonio; National Center for Research
Resources [KL2 RR025766]
FX This work was supported by Veterans Affairs Research & Development (VISN
17 New Investigator Award, #10N17), the San Antonio Area Foundation, the
Biomedical Research Foundation of South Texas, The University Research
Council of the University of Texas Health Science Center at San Antonio,
and The Clinical and Translational Science Award (KL2 RR025766) from the
National Center for Research Resources.
NR 36
TC 9
Z9 10
U1 1
U2 7
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1079-5006
J9 J GERONTOL A-BIOL
JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci.
PD AUG
PY 2012
VL 67
IS 8
BP 853
EP 864
DI 10.1093/gerona/glr224
PG 12
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 977CE
UT WOS:000306633200005
PM 22219522
ER
PT J
AU Marcum, ZA
Pugh, MJV
Amuan, ME
Aspinall, SL
Handler, SM
Ruby, CM
Hanlon, JT
AF Marcum, Zachary A.
Pugh, Mary Jo V.
Amuan, Megan E.
Aspinall, Sherrie L.
Handler, Steven M.
Ruby, Christine M.
Hanlon, Joseph T.
TI Prevalence of Potentially Preventable Unplanned Hospitalizations Caused
by Therapeutic Failures and Adverse Drug Withdrawal Events Among Older
Veterans
SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL
SCIENCES
LA English
DT Article
DE Drug-related problems; Hospitalizations; Veterans
ID DISCONTINUING MEDICATIONS; CARE; QUALITY; POPULATION; ADMISSIONS;
MORTALITY; INDICATOR; PEOPLE; RISK
AB Background. Studies of drug-related hospitalizations have focused on adverse drug reactions, but few data are available on therapeutic failures (TFs) and adverse drug withdrawal events (ADWEs) leading to hospitalization among community-dwelling older adults. Thus, we sought to describe the prevalence of unplanned hospitalizations caused by TFs and ADWEs. In addition, we evaluated factors associated with these events in a nationally representative sample of older Veterans.
Methods. This study included 678 randomly selected unplanned hospitalizations of older (age >= 65 years) Veterans between December 1, 2003, and November 9, 2006. The main outcomes were hospitalizations caused by a TF and/or an ADWE as determined by a pair of health professionals from review of medication charts and application of the Therapeutic Failure Questionnaire and/or Naranjo ADWE algorithm, respectively. Preventability (ie, medication error) of the admission was also assessed.
Results. Thirty-four TFs and eight ADWEs involving 54 drugs were associated with 40 (5.9%) Veterans' hospitalizations; of these admissions, 90.0% (36/40) were rated as potentially preventable mostly due to medication nonadherence and suboptimal prescribing. The most common TFs that occurred were heart failure exacerbations (n = 8), coronary heart disease symptoms (n = 6), tachyarrhythmias (n = 3), and chronic obstructive pulmonary disease exacerbations (n = 3). Half (4/8) of the ADWEs that occurred were cardiovascular in nature. Multivariable logistic regression modeling indicated that black Veterans (adjusted odds ratio 2.92, 95% CI 1.25-6.80) were significantly more likely to experience a TF-related admission compared with white Veterans.
Conclusions. TF-related unplanned hospitalizations occur more frequently than ADWE-related admissions among older Veterans. Almost all TFs and/or ADWEs are potentially preventable.
C1 [Marcum, Zachary A.; Handler, Steven M.; Ruby, Christine M.; Hanlon, Joseph T.] Univ Pittsburgh, Sch Med Geriatr, Dept Med, Pittsburgh, PA 15213 USA.
[Marcum, Zachary A.; Aspinall, Sherrie L.; Hanlon, Joseph T.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA.
[Pugh, Mary Jo V.] S Texas Vet Hlth Care Syst, Vet Evidence Based Res Disseminat & Implementat C, San Antonio, TX USA.
[Pugh, Mary Jo V.] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA.
[Pugh, Mary Jo V.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Geriatr & Gerontol, San Antonio, TX 78229 USA.
[Amuan, Megan E.] Edith Nourse Rogers Mem Vet Hosp, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA USA.
[Aspinall, Sherrie L.; Ruby, Christine M.; Hanlon, Joseph T.] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Pittsburgh, PA 15213 USA.
[Aspinall, Sherrie L.] Vet Affairs Ctr Medicat Safety, Hines, IL USA.
[Handler, Steven M.] Univ Pittsburgh, Sch Med Biomed Informat, Dept Med, Pittsburgh, PA 15213 USA.
RP Marcum, ZA (reprint author), Univ Pittsburgh, Sch Med, Dept Med Geriatr, Kaufmann Med Bldg,Suite 500,3471 5th Ave, Pittsburgh, PA 15213 USA.
EM zam12@pitt.edu
OI Handler, Steven/0000-0002-3940-3224
FU VA Health Services Research and Development Service [IIR-06-062];
National Institute on Aging [R01AG027017, P30AG024827, T32 AG021885,
K07AG033174, R01AG034056]; National Institute of Mental Health [R34
MH082682]; National Institute of Nursing Research [R01 NR010135]; Agency
for Healthcare Research and Quality [R01 HS017695, R01HS018721];
National Institutes of Health, National Institute on Aging
[N01-AG-6-2101, N01-AG-6-2103, N01-AG-6-2106]
FX This work was supported by a VA Health Services Research and Development
Service grant (IIR-06-062). Study investigators were also supported by
National Institute on Aging grants and contracts (R01AG027017 and
P30AG024827, T32 AG021885, K07AG033174, and R01AG034056), a National
Institute of Mental Health) grant (R34 MH082682), a National Institute
of Nursing Research grant (R01 NR010135), and an Agency for Healthcare
Research and Quality grant (R01 HS017695 and R01HS018721). This research
was also supported in part by the Intramural Research program of the
National Institutes of Health, National Institute on Aging
(N01-AG-6-2101, N01-AG-6-2103, and N01-AG-6-2106).
NR 35
TC 18
Z9 18
U1 0
U2 3
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1079-5006
J9 J GERONTOL A-BIOL
JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci.
PD AUG
PY 2012
VL 67
IS 8
BP 867
EP 874
DI 10.1093/gerona/gls001
PG 8
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 977CE
UT WOS:000306633200006
PM 22389461
ER
PT J
AU Li, H
Hosseini, A
Li, JS
Gill, TJ
Li, GA
AF Li, Hong
Hosseini, Ali
Li, Jing-Sheng
Gill, Thomas J.
Li, Guoan
TI Quantitative magnetic resonance imaging (MRI) morphological analysis of
knee cartilage in healthy and anterior cruciate ligament-injured knees
SO KNEE SURGERY SPORTS TRAUMATOLOGY ARTHROSCOPY
LA English
DT Article
DE MRI; Cartilage; Knee; Anterior cruciate ligament
ID BONE-MARROW LESIONS; ARTICULAR-CARTILAGE; DEFORMATIONAL BEHAVIOR;
CONTACT DEFORMATION; JOINT CARTILAGE; SEX-DIFFERENCES; OSTEOARTHRITIS;
THICKNESS; AGE; ASSOCIATION
AB To analyze the morphological change in the cartilage of the knee after anterior cruciate ligament (ACL) injury by comparing with that of the intact contralateral knee.
A total of 22 participants (12 male and 10 female patients) who had unilateral ACL injury underwent MRI scan of both the injured and intact contralateral knees. Sagittal plane images were segmented using a modeling software to determine cartilage volume and cartilage thickness in each part of the knee cartilage that were compared between the ACL-injured and the intact contralateral knees. Furthermore, the male and female patients' data were analyzed in subgroups.
The ACL-injured knees had statistically significant lower total knee cartilage volume than the intact contralateral knees (P = 0.0020), but had similar mean thickness of total knee cartilage (not significant: n.s.). In the male subgroup, there was no significant difference in cartilage volume and thickness between normal and ACL-injured knees. In the female subgroup, the ACL-injured knees demonstrated statistically significant difference in total knee cartilage volume (P = 0.0004) and thickness (P = 0.0024) compared with the normal knees. The percentage change in the cartilage thickness in women was significantly greater than that in men.
Cartilage volume was significantly smaller in the ACL-injured knees than in the contralateral intact knees in this cohort. Women tended to display greater cartilage volume and thickness change after ACL injury than men. These findings indicated that women might be more susceptible to cartilage alteration after ACL injuries.
III.
C1 [Li, Hong; Hosseini, Ali; Li, Jing-Sheng; Gill, Thomas J.; Li, Guoan] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Orthopaed Surg,Bioengn Lab, Boston, MA 02114 USA.
[Li, Hong] Huashan Hosp, Dept Sports Med, Shanghai, Peoples R China.
RP Li, GA (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Orthopaed Surg,Bioengn Lab, 55 Fruit St,GRJ 1215, Boston, MA 02114 USA.
EM ahosseini@partners.org; jli30@partners.org; tgill@partners.org;
gli1@partners.org
FU National Institutes of Health (NIH) [R01 AR055612]
FX We would like to acknowledge the support of National Institutes of
Health (NIH, Grant # R01 AR055612).
NR 28
TC 9
Z9 9
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0942-2056
J9 KNEE SURG SPORT TR A
JI Knee Surg. Sports Traumatol. Arthrosc.
PD AUG
PY 2012
VL 20
IS 8
BP 1496
EP 1502
DI 10.1007/s00167-011-1723-6
PG 7
WC Orthopedics; Sport Sciences; Surgery
SC Orthopedics; Sport Sciences; Surgery
GA 978II
UT WOS:000306733600011
PM 22037812
ER
PT J
AU Desai, NR
Morrow, DA
AF Desai, Nihar R.
Morrow, David A.
TI Reducing door-to-balloon time for STEMI-success at a price
SO NATURE REVIEWS CARDIOLOGY
LA English
DT Editorial Material
ID PERCUTANEOUS CORONARY INTERVENTION; ST-SEGMENT ELEVATION; ACUTE
MYOCARDIAL-INFARCTION; ASSOCIATION; GUIDELINES
C1 [Desai, Nihar R.; Morrow, David A.] Harvard Univ, Brigham & Womens Hosp, Sch Med, TIMI Study Grp,Div Cardiovasc Med,Dept Med, Boston, MA 02115 USA.
RP Morrow, DA (reprint author), Harvard Univ, Brigham & Womens Hosp, Sch Med, TIMI Study Grp,Div Cardiovasc Med,Dept Med, 350 Longwood Ave,1st Floor, Boston, MA 02115 USA.
EM dmorrow@partners.org
NR 10
TC 1
Z9 1
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1759-5002
EI 1759-5010
J9 NAT REV CARDIOL
JI Nat. Rev. Cardiol.
PD AUG
PY 2012
VL 9
IS 8
BP 437
EP 438
DI 10.1038/nrcardio.2012.95
PG 2
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 977TU
UT WOS:000306688500002
PM 22751263
ER
PT J
AU Kramer, MA
Cash, SS
AF Kramer, Mark A.
Cash, Sydney S.
TI Epilepsy as a Disorder of Cortical Network Organization
SO NEUROSCIENTIST
LA English
DT Review
DE seizure; coupling; functional network; structural network; rhythms
ID TEMPORAL-LOBE EPILEPSY; GRAPH-THEORETICAL ANALYSIS; SMALL-WORLD
NETWORKS; HIGH-FREQUENCY OSCILLATIONS; COMPLEX BRAIN NETWORKS;
FUNCTIONAL CONNECTIVITY; SEIZURE ONSET; INTRACRANIAL EEG; FOCAL
SEIZURES; IN-VIVO
AB The brain is naturally considered as a network of interacting elements which, when functioning properly, produces an enormous range of dynamic, adaptable behavior. However, when elements of this network fail, pathological changes ensue, including epilepsy, one of the most common brain disorders. This review examines some aspects of cortical network organization that distinguish epileptic cortex from normal brain as well as the dynamics of network activity before and during seizures, focusing primarily on focal seizures. The review is organized around four phases of the seizure: the interictal period, onset, propagation, and termination. For each phase, the authors discuss the most common rhythmic characteristics of macroscopic brain voltage activity and outline the observed functional network features. Although the characteristics of functional networks that support the epileptic seizure remain an area of active research, the prevailing trends point to a complex set of network dynamics between, before, and during seizures.
C1 [Kramer, Mark A.] Boston Univ, Dept Math & Stat, Boston, MA 02215 USA.
[Cash, Sydney S.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
[Cash, Sydney S.] Harvard Univ, Sch Med, Boston, MA USA.
RP Kramer, MA (reprint author), Boston Univ, Dept Math & Stat 111, Cummington St, Boston, MA 02215 USA.
EM mak@math.bu.edu
RI Kramer, Mark/A-1291-2014
FU Scientific Interface from the Burroughs Wellcome Fund; National
Institute of Neurological Disorders and Stroke [R01 NS062092]
FX The author(s) disclosed receipt of the following financial support for
the research, authorship, and/or publication of this article: M. A. K.
holds a Career Award at the Scientific Interface from the Burroughs
Wellcome Fund. S. S. C. was supported by funds from the National
Institute of Neurological Disorders and Stroke Grant R01 NS062092.
NR 81
TC 88
Z9 89
U1 2
U2 30
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1073-8584
J9 NEUROSCIENTIST
JI Neuroscientist
PD AUG
PY 2012
VL 18
IS 4
BP 360
EP 372
DI 10.1177/1073858411422754
PG 13
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 978HW
UT WOS:000306732400010
PM 22235060
ER
PT J
AU Jimenez, M
Hu, FB
Marino, M
Li, Y
Joshipura, KJ
AF Jimenez, Monik
Hu, Frank B.
Marino, Miguel
Li, Yi
Joshipura, Kaumudi J.
TI Prospective Associations Between Measures of Adiposity and Periodontal
Disease
SO OBESITY
LA English
DT Article
ID MALE HEALTH-PROFESSIONALS; CORONARY-HEART-DISEASE; PHYSICAL-ACTIVITY;
SYSTEMIC-DISEASE; SMOKING HISTORY; ORAL-HEALTH; OBESITY; VALIDITY;
QUESTIONNAIRE; INFLAMMATION
AB Obesity induced inflammation may promote periodontal tissue destruction and bone resorption inducing tooth loss. We examined the association between measures of adiposity and self-reported periodontal disease, using data from 36,910 healthy male participants of the Health Professionals Follow-Up Study (HPFS) who were free of periodontal disease at baseline and followed for <= 20 years (1986-2006). Self-reported height, weight, and periodontal disease data were collected at baseline, weight and periodontal disease were additionally collected on biennial follow-up questionnaires and waist and hip circumference were self-reported in 1987. These self-reported measures have been previously validated. The multivariable adjusted associations between BMI (kg/m(2)), waist circumference (WC), waist-to-hip ratio (WHR), and first report of periodontal disease diagnosis were evaluated using time-varying Cox models. We observed 2,979 new periodontal disease diagnoses during 596,561 person-years of follow-up. Significant associations and trends were observed between all measures of adiposity and periodontal disease after adjusting for age, smoking, race, dental profession, physical activity, fruit and vegetable intake, alcohol consumption, and diabetes status at baseline. BMI >= 30 kg/m(2) compared to BMI 18.5-24.9 kg/m(2) was significantly associated with greater risk of periodontal disease (hazard ratios (HR) = 1.30; 95% confidence interval (CI): 1.17-1.45). Elevated WC and WHR were significantly associated with a greater risk of periodontal disease (HR for extreme quintiles: WC = 1.27, 95% CI: 1.11-1.46; WHR = 1.34, 95% CI: 1.17-1.54). The associations of BMI and WC were significant even among nondiabetics and never smokers. Given the high prevalence of overweight, obesity, and periodontal disease this association may be of substantial public health importance.
C1 [Hu, Frank B.; Joshipura, Kaumudi J.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Jimenez, Monik] Brigham & Womens Hosp, Div Prevent Med, Boston, MA 02115 USA.
[Hu, Frank B.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
[Hu, Frank B.] Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA 02115 USA.
[Hu, Frank B.] Harvard Univ, Sch Med, Boston, MA USA.
[Marino, Miguel; Li, Yi] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
[Li, Yi] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Joshipura, Kaumudi J.] Univ Puerto Rico, Sch Dent, Ctr Clin Res & Hlth Promot, San Juan, PR 00936 USA.
[Joshipura, Kaumudi J.] Harvard Univ, Sch Dent Med, Dept Oral Hlth Policy & Epidemiol, Boston, MA 02115 USA.
RP Joshipura, KJ (reprint author), Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
EM kaumudi.joshipura@upr.edu
OI Joshipura, Kaumudi/0000-0003-1964-7579
FU NCI NIH HHS [CA55075, P01 CA055075]; NHLBI NIH HHS [R01 HL088521,
R01HL088521]; NIDCR NIH HHS [K24 DE016884, K24DE016884, T32 DE007151,
T32DE07151]; NIDDK NIH HHS [DK58845, R01 DK058845]; NIGMS NIH HHS [R25
GM055353, R25GM55353]; NIMHD NIH HHS [L32 MD006283]
NR 39
TC 17
Z9 17
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1930-7381
J9 OBESITY
JI Obesity
PD AUG
PY 2012
VL 20
IS 8
BP 1718
EP 1725
DI 10.1038/oby.2011.291
PG 8
WC Endocrinology & Metabolism; Nutrition & Dietetics
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA 980UY
UT WOS:000306920900024
PM 21979390
ER
PT J
AU Halpin, C
Shi, H
Reda, D
Antonelli, PJ
Babu, S
Carey, JP
Gantz, BJ
Goebel, JA
Hammerschlag, PE
Harris, JP
Isaacson, B
Lee, D
Linstrom, CJ
Parnes, LS
Slattery, WH
Telian, SA
Vrabec, JT
Rauch, S
AF Halpin, Chris
Shi, Helen
Reda, Domenic
Antonelli, Patrick J.
Babu, Seilesh
Carey, John P.
Gantz, Bruce J.
Goebel, Joel A.
Hammerschlag, Paul E.
Harris, Jeffrey P.
Isaacson, Brandon
Lee, Daniel
Linstrom, Chris J.
Parnes, Lorne S.
Slattery, William H.
Telian, Steven A.
Vrabec, Jeffrey T.
Rauch, Steven
TI Audiology in the Sudden Hearing Loss Clinical Trial
SO OTOLOGY & NEUROTOLOGY
LA English
DT Article
DE Audiometry; Sudden hearing loss; Word recognition
AB Objective: To report the pretreatment and posttreatment population characteristics and the overall stability of the audiologic outcomes found during the Sudden Hearing Loss Clinical Trial (ClinicalTrials.gov: Identifier NCT00097448).
Study Design: Multicenter, prospective randomized noninferiority trial of oral versus intratympanic (IT) steroid treatment of sudden sensorineural hearing loss (SSNHL).
Setting: Fifteen academically based otology practices.
Patients: Two hundred fifty patients with unilateral SSNHL presenting within 14 days of onset with 50 dBHL or greater pure tone average hearing threshold in the affected ear.
Intervention: Either 60 mg/d oral prednisone for 14 days with a 5-day taper (121 patients) or 4 IT doses for 14 days of 40 mg/ml methylprednisolone (129 patients).
Main Outcome Measure: Primary end point was change in hearing [dB PTA] at 2 months after treatment. Noninferiority was defined as less than 10 dB difference in hearing outcome between treatments. In this article, pretreatment and posttreatment hearing findings will be reported in detail.
Results: A general (and stable) effect of treatment and a specific effect of greater improvement at low frequencies were found in both treatment groups.
Conclusion: Hearing improvements are stable, and a significantly greater improvement occurs with lower frequency after either oral or IT steroid treatment of SSNHL.
C1 [Halpin, Chris] Massachusetts Eye & Ear Infirm, Dept Audiol, Boston, MA 02114 USA.
[Halpin, Chris; Lee, Daniel; Rauch, Steven] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA.
[Shi, Helen; Reda, Domenic] Hines Cooperat Studies Coordinating Ctr, Hines, IL USA.
[Antonelli, Patrick J.] Univ Florida, Dept Otolaryngol, Gainesville, FL USA.
[Babu, Seilesh] Michigan Ear Inst, Dept Otol Skull Base Surg, Farmington Hills, MI USA.
[Carey, John P.] Johns Hopkins Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Baltimore, MD 21205 USA.
[Gantz, Bruce J.] Univ Iowa Hosp & Clin, Dept Otolaryngol Head & Neck Surg, Iowa City, IA 52242 USA.
[Goebel, Joel A.] Washington Univ, Sch Med, Dept Otolaryngol, St Louis, MO 63110 USA.
[Hammerschlag, Paul E.] NYU, Sch Med, Dept Otolaryngol, New York, NY USA.
[Harris, Jeffrey P.] Univ Calif San Diego, Med Ctr, Div Otolaryngol Head & Neck Surg, San Diego, CA 92103 USA.
[Isaacson, Brandon] Univ Texas SW Med Ctr Dallas, Dept Otolaryngol Head & Neck Surg, Dallas, TX 75390 USA.
[Linstrom, Chris J.] New York Eye & Ear Infirm, Dept Otolaryngol Head & Neck Surg, New York, NY 10003 USA.
[Parnes, Lorne S.] London Hlth Sci Ctr Res Inc, Dept Otolaryngol, London, ON, Canada.
[Slattery, William H.] Univ So Calif, House Ear Inst, Los Angeles, CA USA.
[Telian, Steven A.] Univ Michigan, Dept Otolaryngol, Ann Arbor, MI 48109 USA.
[Vrabec, Jeffrey T.] Baylor Coll Med, Dept Otolaryngol Head & Neck Surg, Houston, TX 77030 USA.
RP Halpin, C (reprint author), Massachusetts Eye & Ear Infirm, Dept Audiol, 243 Charles St, Boston, MA 02114 USA.
EM chris_halpin@meei.harvard.edu
RI Isaacson, Brandon/A-6358-2013
FU NCATS NIH HHS [UL1 TR000064]; NIDCD NIH HHS [U01 DC006296, P50 DC000242]
NR 10
TC 6
Z9 6
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1531-7129
J9 OTOL NEUROTOL
JI Otol. Neurotol.
PD AUG
PY 2012
VL 33
IS 6
BP 907
EP 911
DI 10.1097/MAO.0b013e31825d9a44
PG 5
WC Clinical Neurology; Otorhinolaryngology
SC Neurosciences & Neurology; Otorhinolaryngology
GA 977ZD
UT WOS:000306703900008
PM 22805100
ER
PT J
AU Plotkin, SR
Merker, VL
Halpin, C
Jennings, D
McKenna, MJ
Harris, GJ
Barker, FG
AF Plotkin, Scott R.
Merker, Vanessa L.
Halpin, Chris
Jennings, Dominique
McKenna, Michael J.
Harris, Gordon J.
Barker, Fred G., II
TI Bevacizumab for Progressive Vestibular Schwannoma in Neurofibromatosis
Type 2: A Retrospective Review of 31 Patients
SO OTOLOGY & NEUROTOLOGY
LA English
DT Article
DE Angiogenesis; Bevacizumab; Neurofibromatosis; Schwannoma; VEGF;
Vestibular
ID NATURAL-HISTORY CONSORTIUM; QUALITY-OF-LIFE; HEARING IMPAIRMENT; GROWTH;
TRIAL; GLIOBLASTOMA; INHIBITION; REGRESSION; CRITERIA; DRUG
AB Objective: Early studies suggest that bevacizumab treatment can result in tumor shrinkage and hearing improvement for some patients with neurofibromatosis type 2 (NF2). The aim of this study was to report extended follow-up in a larger cohort of similarly treated patients. \
Study Design: Retrospective study.
Setting: Tertiary referral center
Patients: Thirty-one consecutive NF2 patients who received bevacizumab for progressive vestibular schwannomas.
Main Outcome Measure: Hearing improvement, defined as an improvement in word recognition score above the 95% critical difference compared with baseline, and radiographic response, defined as a 20% or greater decrease in tumor volume compared with baseline.
Results: The median age was 26 years (range, 12-73 yr). The median volumetric tumor growth rate before treatment was 64% per year. At the time of analysis, the median duration of treatment was 14 months (range, 6-41 mo) with a total of 47 patient-years of follow-up. A hearing response occurred in 57% (13/23) of evaluable patients and a radiographic response in 55% (17/31) of target vestibular schwannomas. The median time to response was 3 months for both end points. The only clinical or radiographic feature at baseline that correlated with change in tumor volume at 3 months was the mean apparent diffusion coefficient value, a radiologic marker of edema (p = 0.036). Ninety percent of patients had stable or improved hearing after 1 year of treatment and 61% at 3 years; 88% of patients had stable or decreased tumor size after 1 year of treatment and 54% at 3 years. Overall, treatment was well tolerated.
Conclusion: Bevacizumab treatment was followed by hearing improvement and tumor shrinkage in more than 50% of progressive vestibular schwannomas in NF2 patients. Stable or improved hearing was retained in the majority of patients.
C1 [Plotkin, Scott R.; Merker, Vanessa L.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
[Halpin, Chris] Massachusetts Eye & Ear Infirm, Dept Audiol, Boston, MA 02114 USA.
[Jennings, Dominique] AA Martinos Ctr Biomed Imaging, Charlestown, MA USA.
[McKenna, Michael J.] Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Boston, MA 02114 USA.
[McKenna, Michael J.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA.
[Harris, Gordon J.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
[Barker, Fred G., II] Massachusetts Gen Hosp, Neurosurg Serv, Boston, MA 02114 USA.
RP Plotkin, SR (reprint author), Massachusetts Gen Hosp, Dept Neurol, Yawkey 9E,55 Fruit St, Boston, MA 02114 USA.
EM splotkin@partners.org
OI Merker, Vanessa/0000-0002-4542-5227
FU Department of Defense [NF050202]; Children's Tumor Foundation; National
Institutes of Health
FX Dr. Harris is a consultant for Fovia, Inc., and Tele3D Advantage. Dr.
Plotkin has received grants from the Department of Defense (NF050202),
Children's Tumor Foundation, and National Institutes of Health.
NR 32
TC 57
Z9 58
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1531-7129
J9 OTOL NEUROTOL
JI Otol. Neurotol.
PD AUG
PY 2012
VL 33
IS 6
BP 1046
EP 1052
DI 10.1097/MAO.0b013e31825e73f5
PG 7
WC Clinical Neurology; Otorhinolaryngology
SC Neurosciences & Neurology; Otorhinolaryngology
GA 977ZD
UT WOS:000306703900031
PM 22805104
ER
PT J
AU Kilmer, G
Bell, P
Festa, F
Rollins, S
Jensen, P
McBride, A
Hommema, E
Webb, B
LaBaer, J
Vattem, K
AF Kilmer, Greg
Bell, Peter
Festa, Fernanda
Rollins, Sean
Jensen, Penny
McBride, Aaron
Hommema, Eric
Webb, Brian
LaBaer, Josh
Vattem, Krishna
TI Human In Vitro Translation Systems for Rapid and High Yield Expression
of Functional Proteins
SO PROTEIN SCIENCE
LA English
DT Meeting Abstract
CT 26th Annual Symposium of the Protein-Society
CY AUG 05-08, 2012
CL San Diego, CA
SP Prot Soc, Genentech, BioSilta, Aviv Biomed, Inc, Jasco, Purtein, Wyatt Technol Corp, Emerald Biosyst
C1 [Kilmer, Greg; Bell, Peter; Jensen, Penny; McBride, Aaron; Hommema, Eric; Webb, Brian; Vattem, Krishna] Thermofisher, R&D, Rockford, IL USA.
[Festa, Fernanda; LaBaer, Josh] Arizona State Univ, Biodesign Inst, Tempe, AZ USA.
[Rollins, Sean] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0961-8368
J9 PROTEIN SCI
JI Protein Sci.
PD AUG
PY 2012
VL 21
SU 1
SI SI
BP 212
EP 212
PG 1
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 982CR
UT WOS:000307019800396
ER
PT J
AU Liu, J
Kurella, V
Lecour, L
Worthylake, D
AF Liu, Jing
Kurella, Vinodh
Lecour, Louis
Worthylake, David
TI Crystal structure and in vitro analysis of human IQGAP1 Calponin
homology domain: implication for its interactions with Ca2+bound
Calmodulin and F-actin
SO PROTEIN SCIENCE
LA English
DT Meeting Abstract
CT 26th Annual Symposium of the Protein-Society
CY AUG 05-08, 2012
CL San Diego, CA
SP Prot Soc, Genentech, BioSilta, Aviv Biomed, Inc, Jasco, Purtein, Wyatt Technol Corp, Emerald Biosyst
C1 [Liu, Jing; Lecour, Louis; Worthylake, David] LSU Sch Med New Orleans, New Orleans, LA 70112 USA.
[Kurella, Vinodh] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0961-8368
J9 PROTEIN SCI
JI Protein Sci.
PD AUG
PY 2012
VL 21
SU 1
SI SI
BP 227
EP 228
PG 2
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 982CR
UT WOS:000307019800433
ER
PT J
AU Horan, WP
Foti, D
Hajcak, G
Wynn, JK
Green, MF
AF Horan, W. P.
Foti, D.
Hajcak, G.
Wynn, J. K.
Green, M. F.
TI Impaired neural response to internal but not external feedback in
schizophrenia
SO PSYCHOLOGICAL MEDICINE
LA English
DT Article
DE Error-related negativity; event-related potential (ERP); feedback
negativity; reward sensitivity; schizophrenia
ID PSYCHIATRIC RATING-SCALE; STRIATAL REWARD PREDICTION; CINGULATE CORTEX
ACTIVITY; ERROR-RELATED NEGATIVITY; QUALITY-ASSURANCE; BRAIN ACTIVITY;
DYSFUNCTION; ACTIVATION; SENSITIVITY; PERFORMANCE
AB Background. Accurate monitoring and integration of both internal and external feedback is crucial for guiding current and future behavior. These aspects of performance monitoring are commonly indexed by two event-related potential (ERP) components: error-related negativity (ERN) and feedback negativity (FN). The ERN indexes internal response monitoring and is sensitive to the commission of erroneous versus correct responses, and the FN indexes external feedback monitoring of positive versus negative outcomes. Although individuals with schizophrenia consistently demonstrate a diminished ERN, the integrity of the FN has received minimal consideration.
Method. The current research sought to clarify the scope of feedback processing impairments in schizophrenia in two studies: study 1 examined the ERN elicited in a flanker task in 16 out-patients and 14 healthy controls; study 2 examined the EN on a simple monetary gambling task in expanded samples of 35 out-patients and 33 healthy controls.
Results. Study 1 replicated prior reports of an impaired ERN in schizophrenia. By contrast, patients and controls demonstrated comparable FN differentiation between reward and non-reward feedback in study 2.
Conclusions. The differential pattern across tasks suggests that basic sensitivity to external feedback indicating reward versus non-reward is intact in schizophrenia, at least under the relatively simple task conditions used in this study. Further efforts to specify intact and impaired reward-processing subcomponents in schizophrenia may help to shed light on the diminished motivation and goal-seeking behavior that are commonly seen in this disorder.
C1 [Horan, W. P.; Wynn, J. K.; Green, M. F.] Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA.
[Foti, D.; Hajcak, G.] SUNY Stony Brook, Stony Brook, NY 11794 USA.
RP Horan, WP (reprint author), Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, MIRECC 210A,Bldg 210,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM horan@ucla.edu
RI Wynn, Jonathan/H-3749-2014
OI Wynn, Jonathan/0000-0002-1763-8540
FU NARSAD Young Investigator Award; NIMH [MH043292, MH065707]
FX Funding for this project came from a NARSAD Young Investigator Award (to
W.P.H.) and NIMH grants MH043292 and MH065707 (to M.F.G.)
NR 51
TC 18
Z9 18
U1 2
U2 8
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0033-2917
EI 1469-8978
J9 PSYCHOL MED
JI Psychol. Med.
PD AUG
PY 2012
VL 42
IS 8
BP 1637
EP 1647
DI 10.1017/S0033291711002819
PG 11
WC Psychology, Clinical; Psychiatry; Psychology
SC Psychology; Psychiatry
GA 980JS
UT WOS:000306890100007
PM 22152069
ER
PT J
AU Sosnovik, DE
Nahrendorf, M
Caravan, P
AF Sosnovik, David E.
Nahrendorf, Matthias
Caravan, Peter
TI Science to Practice: How Will Myocardial Inflammation Be Imaged with MR
Imaging?
SO RADIOLOGY
LA English
DT Article
ID INFARCTED MYOCARDIUM; IN-VIVO; RESONANCE; ATORVASTATIN; NANOPARTICLE;
CLEARANCE; ISCHEMIA
AB The elegant study by Naresh and colleagues (1) synthesizes many of the best aspects of molecular magnetic resonance (MR) imaging: Quantitative serial imaging of a well-defined molecular process is performed in vivo, and its results are correlated with sensitive measures of left ventricular function. The technique described adds a valuable tool to the molecular imaging armamentarium. How, then, will myocardial inflammation be imaged with MR imaging? The only clinical experience to date has been with iron oxide nanoparticles (2,3). Their excellent sensitivity, dynamic range, and safety record make them a highly appealing choice. It will be critical, however, for any iron oxide nanoparticle that is used clinically to be well studied and validated in animal models of the disease before it is used in humans. A "group effect" cannot be assumed, even in the case of fairly similar iron oxide nanoparticles. The use of MR imaging-detectable liposomes appears promising, and initial clinical studies with fluorine-containing liposomes are likely to begin shortly. The clinical use of gadolinium-labeled liposomes appears further away, and the approach described by Naresh and colleagues is thus likely to remain confined to preclinical investigation for the foreseeable future. The development of novel anti-inflammatory therapies, however, will require robust imaging tools to shepherd these agents through preclinical studies and into the clinical arena. The approach described by Naresh et al adds a valuable tool to the preclinical molecular imaging armamentarium.
C1 [Sosnovik, David E.; Caravan, Peter] Massachusetts Gen Hosp, Martinos Ctr Biomed Imaging, Dept Radiol, Charlestown, MA 02129 USA.
[Sosnovik, David E.] Massachusetts Gen Hosp, Div Cardiol, Charlestown, MA 02129 USA.
[Nahrendorf, Matthias] Massachusetts Gen Hosp, Ctr Syst Biol, Charlestown, MA 02129 USA.
RP Sosnovik, DE (reprint author), Massachusetts Gen Hosp, Martinos Ctr Biomed Imaging, Dept Radiol, 149 13th St, Charlestown, MA 02129 USA.
FU Siemens Medical
FX D.E.S. Financial activities related to the present article: none to
disclose. Financial activities not related to the present article: is a
consultant for Siemens Medical; institution has patent pending with
Vital Imaging Agents and receives research support from Siemens Medical.
Other relationships: none to disclose. M.N. No potential conflicts of
interest to disclose. P.C. Financial activities related to the present
article: none to disclose. Financial activities not related to the
present article: institution has grants or grants pending with Sanofi;
holds stock or stock options in Collagen Medical, Factor 1A, and
Catalyst Medical. Other relationships: none to disclose.
NR 13
TC 1
Z9 1
U1 0
U2 8
PU RADIOLOGICAL SOC NORTH AMERICA
PI OAK BROOK
PA 820 JORIE BLVD, OAK BROOK, IL 60523 USA
SN 0033-8419
J9 RADIOLOGY
JI Radiology
PD AUG
PY 2012
VL 264
IS 2
BP 309
EP 311
DI 10.1148/radiol.12121094
PG 3
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 977KX
UT WOS:000306660000001
PM 22821689
ER
PT J
AU Thrall, JH
AF Thrall, James H.
TI Radiation Exposure in CT Scanning and Risk: Where Are We?
SO RADIOLOGY
LA English
DT Article
ID IONIZING-RADIATION; DOSE REDUCTION
C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol, Boston, MA 02114 USA.
RP Thrall, JH (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol, 55 Fruit St,FND 216, Boston, MA 02114 USA.
EM jthrall@partners.org
NR 20
TC 27
Z9 29
U1 0
U2 1
PU RADIOLOGICAL SOC NORTH AMERICA
PI OAK BROOK
PA 820 JORIE BLVD, OAK BROOK, IL 60523 USA
SN 0033-8419
J9 RADIOLOGY
JI Radiology
PD AUG
PY 2012
VL 264
IS 2
BP 325
EP 328
DI 10.1148/radiol.12121137
PG 4
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 977KX
UT WOS:000306660000004
PM 22821692
ER
PT J
AU Marconescu, P
Graviss, EA
Musher, DM
AF Marconescu, Praveena
Graviss, Edward A.
Musher, Daniel M.
TI Rates of killing of methicillin-resistant Staphylococcus aureus by
ceftaroline, daptomycin, and telavancin compared to that of vancomycin
SO SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
ID IN-VITRO ACTIVITY; BACTEREMIA; INTERMEDIATE; STRAINS; IMPACT
AB Treatment failure of methicillin-resistant Staphylococcus aureus (MRSA) remains an important concern. In order to investigate new MRSA treatment modalities, we used standard time-kill assays to determine the in vitro killing rate of 22 strains of MRSA by vancomycin, telavancin, daptomycin, and ceftaroline. Studies were carried out with 7-10-times the minimum bactericidal concentrations of each antibiotic in broth culture for 24 h, with subculture at 4, 8, and 24 h. We found that killing by ceftaroline closely paralleled that of vancomycin. Telavancin killed bacteria significantly more slowly, whereas daptomycin killed significantly more rapidly.
C1 [Marconescu, Praveena; Musher, Daniel M.] ME DeBakey Vet Affairs Med Ctr, Houston, TX 77040 USA.
[Marconescu, Praveena] Univ Calif San Diego, Sch Med, San Diego, CA 92103 USA.
[Graviss, Edward A.; Musher, Daniel M.] Baylor Coll Med, Dept Med, Infect Dis Sect, Houston, TX 77030 USA.
[Graviss, Edward A.] Baylor Coll Med, Dept Pathol & Immunol, Houston, TX 77030 USA.
[Graviss, Edward A.] Methodist Hosp, Res Inst, Dept Pathol & Genom Med, Houston, TX 77030 USA.
[Musher, Daniel M.] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA.
RP Musher, DM (reprint author), ME DeBakey Vet Affairs Med Ctr, 2002 Holcombe, Houston, TX 77040 USA.
EM daniel.musher@va.gov
NR 10
TC 11
Z9 11
U1 0
U2 8
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 0036-5548
J9 SCAND J INFECT DIS
JI Scand. J. Infect. Dis.
PD AUG
PY 2012
VL 44
IS 8
BP 620
EP 622
DI 10.3109/00365548.2012.669843
PG 3
WC Infectious Diseases
SC Infectious Diseases
GA 976EL
UT WOS:000306563500011
PM 22668202
ER
PT J
AU Ma, Y
Shurin, GV
Gutkin, DW
Shurin, MR
AF Ma, Yang
Shurin, Galina V.
Gutkin, Dmitriy W.
Shurin, Michael R.
TI Tumor associated regulatory dendritic cells
SO SEMINARS IN CANCER BIOLOGY
LA English
DT Review
DE Dendritic cells; Cancer; Immunosuppression; Immune escape; Tolerance;
Immune regulatory cells
ID EXPRESSING INDOLEAMINE 2,3-DIOXYGENASE; ANTITUMOR IMMUNE-RESPONSES;
DRAINING LYMPH-NODES; CD4(+) T-CELLS; IN-VIVO; BREAST-CANCER; CUTTING
EDGE; MULTIPLE-MYELOMA; OVARIAN-CANCER; LUNG-CANCER
AB Immune effector and regulatory cells in the tumor microenvironment are key factors in tumor development and progression as the pathogenesis of cancer vitally depends on the multifaceted interactions between various microenvironmental stimuli provided by tumor-associated immune cells. Immune regulatory cells participate in all stages of cancer development from the induction of genomic instability to the maintenance of intratumoral angiogenesis, proliferation and spreading of malignant cells, and formation of premetastatic niches in distal tissues. Dendritic cells in the tumor microenvironment serve as a double-edged sword and, in addition to initiating potent anti-tumor immune responses, may mediate genomic damage, support neovascularization, block anti-tumor immunity and stimulate cancerous cell growth and spreading. Regulatory dendritic cells in cancer may directly and indirectly maintain antigen-specific and non-specific T cell unresponsiveness by controlling T cell polarization, MDSC and Treg differentiation and activity, and affecting specific microenvironmental conditions in premalignant niches. Understanding the mechanisms involved in regulatory dendritic cell polarization and operation and revealing pharmacological means for harnessing these pathways will provide additional opportunities for modifying the tumor microenvironment and improving the efficacy of different therapeutic approaches to cancer. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Ma, Yang; Shurin, Galina V.; Shurin, Michael R.] Univ Pittsburgh, Med Ctr, Dept Pathol, Pittsburgh, PA 15261 USA.
[Gutkin, Dmitriy W.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Shurin, Michael R.] Univ Pittsburgh, Med Ctr, Dept Immunol, Pittsburgh, PA USA.
RP Shurin, MR (reprint author), Univ Pittsburgh, Med Ctr, Dept Pathol, 5735 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA.
EM shurinmr@upmc.edu
FU NCI NIH HHS [R01 CA154369-01A1, R01 CA154369]
NR 150
TC 34
Z9 40
U1 1
U2 30
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1044-579X
J9 SEMIN CANCER BIOL
JI Semin. Cancer Biol.
PD AUG
PY 2012
VL 22
IS 4
BP 298
EP 306
DI 10.1016/j.semcancer.2012.02.010
PG 9
WC Oncology
SC Oncology
GA 978FF
UT WOS:000306725300005
PM 22414911
ER
PT J
AU Tao, WD
Liu, M
Fisher, M
Wang, DR
Li, J
Furie, KL
Hao, ZL
Lin, S
Zhang, CF
Zeng, QT
Wu, B
AF Tao, Wen-Dan
Liu, Ming
Fisher, Marc
Wang, De-Ren
Li, Jie
Furie, Karen L.
Hao, Zi-Long
Lin, Sen
Zhang, Cai-Fei
Zeng, Quan-Tao
Wu, Bo
TI Posterior Versus Anterior Circulation Infarction How Different Are the
Neurological Deficits?
SO STROKE
LA English
DT Article
DE posterior circulation infarction; anterior circulation infarction;
neurological deficits
ID OXFORDSHIRE COMMUNITY STROKE; CEREBRAL-ARTERY OCCLUSION; PURE MOTOR
HEMIPARESIS; RADIOLOGICAL CORRELATION; CLINICAL CLASSIFICATION;
ISCHEMIC-STROKE; REGISTRY; TERRITORIES; DISABILITY; HEMIPLEGIA
AB Background and Purpose-Distinguishing between symptoms of posterior circulation infarction (PCI) and anterior circulation infarction (ACI) can be challenging. This study evaluated the frequency of symptoms/signs in the 2 vascular territories to determine the diagnostic value of particular symptoms/signs for PCI.
Methods-Neurological deficits were reviewed and compared from 1174 consecutive patients with a diagnosis of PCI or ACI confirmed by magnetic resonance imaging in the Chengdu Stroke Registry. The diagnostic value of specific symptoms/signs for PCI was determined by measuring their sensitivity, specificity, positive predictive value (PPV), and the OR.
Results-Homolateral hemiplegia (PCI, 53.6% versus ACI, 74.9%; P<0.001), central facial/lingual palsy (PCI, 40.7% versus ACI, 62.2%; P<0.001), and hemisensory deficits (PCI, 36.4% versus ACI, 34.2%; P=0.479) were the 3 most common symptoms/signs in PCI and ACI. The signs with the highest predictive values favoring a diagnosis of PCI were Horner's syndrome (4.0% versus 0%; P<0.001; PPV=100.0%; OR=4.00), crossed sensory deficits (3.0% versus 0%; P<0.001; PPV=100.0%; OR=3.98), quadrantanopia (1.3% versus 0%; P<0.001; PPV=100.0%; OR=3.93), oculomotor nerve palsy (4.0% versus 0%; P<0.001; PPV=100.0%; OR=4.00), and crossed motor deficits (4.0% versus 0.1%; P<0.001; PPV=92.3%; OR=36.04); however, all had a very low sensitivity, ranging from 1.3% to 4.0%.
Conclusions-This study indicates that the symptoms/signs considered typical of PCI occur far less often than was expected. Inaccurate localization would occur commonly if clinicians relied on the clinical neurological deficits alone to differentiate PCI from ACI. Neuroimaging is vital to ensure accurate localization of cerebral infarction. (Stroke. 2012;43:2060-2065.)
C1 [Tao, Wen-Dan; Liu, Ming; Wang, De-Ren; Li, Jie; Hao, Zi-Long; Lin, Sen; Zhang, Cai-Fei; Zeng, Quan-Tao; Wu, Bo] Sichuan Univ, W China Hosp, Dept Neurol, Stroke Clin Res Unit, Chengdu 610041, Sichuan Provinc, Peoples R China.
[Liu, Ming] Sichuan Univ, W China Hosp, State Key Lab Biotherapy, Chengdu 610041, Sichuan Provinc, Peoples R China.
[Liu, Ming] Sichuan Univ, W China Hosp, Ctr Canc, Chengdu 610041, Sichuan Provinc, Peoples R China.
[Tao, Wen-Dan; Furie, Karen L.] Massachusetts Gen Hosp, Dept Neurol, J Philip Kistler Stroke Res Ctr, Boston, MA 02114 USA.
[Fisher, Marc] Univ Massachusetts, Sch Med, Dept Neurol, Worcester, MA USA.
RP Liu, M (reprint author), Sichuan Univ, W China Hosp, Dept Neurol, Stroke Clin Res Unit, 37 Guo Xue Xiang, Chengdu 610041, Sichuan Provinc, Peoples R China.
EM wyplmh@hotmail.com
OI Wang, Deren/0000-0002-2388-3585
FU Science and Technology Department of Sichuan Province of China
[2011SZ0202]
FX This work was funded by Science and Technology Department of Sichuan
Province of China (Project No. 2011SZ0202).
NR 29
TC 15
Z9 17
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0039-2499
J9 STROKE
JI Stroke
PD AUG
PY 2012
VL 43
IS 8
BP 2060
EP 2065
DI 10.1161/STROKEAHA.112.652420
PG 6
WC Clinical Neurology; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA 977UC
UT WOS:000306689300018
PM 22678088
ER
PT J
AU Silva, GS
Farrell, S
Shandra, E
Viswanathan, A
Schwamm, LH
AF Silva, Gisele S.
Farrell, Shawn
Shandra, Emma
Viswanathan, Anand
Schwamm, Lee H.
TI The Status of Telestroke in the United States A Survey of Currently
Active Stroke Telemedicine Programs
SO STROKE
LA English
DT Article
DE telemedicine; telestroke; inventory; barriers
ID ACUTE ISCHEMIC-STROKE; TISSUE-PLASMINOGEN ACTIVATOR;
AMERICAN-HEART-ASSOCIATION; THROMBOLYSIS; BARRIERS; CARE; CENTERS;
SYSTEMS; RATES
AB Background and Purpose-Little is known about adoption or success of telestroke networks outside of published or federally funded programs. Under contract to the Health Resource Services Administration, we conducted an environmental scan of telestroke programs in the United States.
Methods-An analyst contacted all potential programs identified in comprehensive online searches, interviewed respondents, and collected response data about structural and functional components of currently operating telestroke programs.
Results-Among 97 potential programs contacted, 56 programs had confirmed telestroke activity, and 38 programs (68%) from 27 states participated. Hospital and community characteristics of nonparticipating programs were similar to those of participating ones. The top 3 clinical needs met by the telestroke were emergency department consultation (100%), patient triage (83.8%), and inpatient teleconsultation (46.0%). Telestroke programs were in operation a median of 2.44 years (interquartile range, 1.36-3.44 years); 94.6% used 2-way, real-time interactive video plus imaging, but only 44% used dedicated telemedicine consultation software. The mean number of spokes per hub increased significantly from 2007 to 2008 to 2009 (3.78 versus 7.60; P < 0.05), and >80% of spoke sites were rural or small hospitals. Reimbursement was absent for >40% of sites. Sites rated inability to obtain physician licensure (27.77%), lack of program funds (27.77%), and lack of reimbursement (19.44%) as the most important barriers to program growth.
Conclusions-Telestroke is a widespread and growing practice model. Important barriers to expansion amenable to change relate to organizational, technical, and educational domains and external economic and regulatory forces. (Stroke. 2012;43:2078-2085.)
C1 [Silva, Gisele S.] Univ Fed Sao Paulo, Dept Neurol & Neurosurg, Sao Paulo, Brazil.
[Silva, Gisele S.] Albert Einstein Hosp, Neurol Program, Sao Paulo, Brazil.
[Farrell, Shawn] Childrens Hosp, Ctr Innovat, Boston, MA 02115 USA.
[Shandra, Emma] Massachusetts Gen Hosp, Dept Obstet & Gynecol, Boston, MA 02114 USA.
[Viswanathan, Anand; Schwamm, Lee H.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
RP Silva, GS (reprint author), Altino Arantes Ave,Apt 81, BR-04042033 Sao Paulo, Brazil.
EM giselesampaio@hotmail.com
OI Schwamm, Lee/0000-0003-0592-9145
FU Health Resource Services Administration Requisition [09-HRS9923-AB]
FX This study was supported (Dr Silva, S. Farrell, MBA, Dr Schwamm) in part
by a contract from Health Resource Services Administration Requisition
09-HRS9923-AB (Stroke and Traumatic Brain Injury Telehealth Services).
NR 28
TC 55
Z9 55
U1 1
U2 12
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0039-2499
J9 STROKE
JI Stroke
PD AUG
PY 2012
VL 43
IS 8
BP 2078
EP U138
DI 10.1161/STROKEAHA.111.645861
PG 31
WC Clinical Neurology; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA 977UC
UT WOS:000306689300021
PM 22700532
ER
PT J
AU Brouwers, HB
Biffi, A
McNamara, KA
Ayres, AM
Valant, V
Schwab, K
Romero, JM
Viswanathan, A
Greenberg, SM
Rosand, J
Goldstein, JN
AF Brouwers, H. Bart
Biffi, Alessandro
McNamara, Kristen A.
Ayres, Alison M.
Valant, Valerie
Schwab, Kristin
Romero, Javier M.
Viswanathan, Anand
Greenberg, Steven M.
Rosand, Jonathan
Goldstein, Joshua N.
TI Apolipoprotein E Genotype Is Associated With CT Angiography Spot Sign in
Lobar Intracerebral Hemorrhage
SO STROKE
LA English
DT Article
DE APOE; CTA spot sign; genetics; hematoma expansion; intracerebral
hemorrhage
ID CEREBRAL AMYLOID ANGIOPATHY; PREDICTS HEMATOMA EXPANSION; CONTRAST
EXTRAVASATION; IDENTIFIES PATIENTS; HIGHEST RISK; MORTALITY; GROWTH;
SCORE
AB Background and Purpose-The CT angiography (CTA) spot sign predicts hematoma expansion and poor outcome in patients with primary intracerebral hemorrhage (ICH). The biological underpinnings of the spot sign remain poorly understood; it may be that the underlying vasculopathy influences its presence. Therefore, we conducted a study to identify genetic predictors of the spot sign.
Methods-In an ongoing prospective cohort study, we analyzed 371 patients with CTA and genetic data available. CTAs were reviewed for the spot sign by 2 experienced readers, blinded to clinical data, according to validated criteria. Analyses were stratified by ICH location.
Results-In multivariate analysis, patients on warfarin were more likely to have a spot sign regardless of ICH location (OR, 3.85; 95% CI, 1.33-11.13 in deep ICH and OR, 2.86; 95% CI, 1.33-6.13 in lobar ICH). Apolipoprotein E epsilon 2, but not epsilon 4, was associated with the presence of a spot sign in lobar ICH (OR, 2.09; 95% CI, 1.05-4.19). There was no effect for epsilon 2 or epsilon 4 in deep ICH.
Conclusions-Patients with ICH on warfarin are more likely to present with a spot sign regardless of ICH location. Among patients with lobar ICH, those who possess the apolipoprotein E epsilon 2 allele are more likely to have a spot sign. Given the established relationship between apolipoprotein E epsilon 2 and vasculopathic changes in cerebral amyloid angiopathy, our findings suggest that both hemostatic factors and vessel pathology influence spot sign presence. (Stroke. 2012;43:2120-2125.)
C1 [Brouwers, H. Bart] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Human Genet Res,Rosand Lab, Boston, MA 02114 USA.
[Brouwers, H. Bart; Biffi, Alessandro; McNamara, Kristen A.; Ayres, Alison M.; Valant, Valerie; Schwab, Kristin; Viswanathan, Anand; Greenberg, Steven M.; Rosand, Jonathan; Goldstein, Joshua N.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Hemorrhag Stroke Res Grp, Boston, MA 02114 USA.
[Brouwers, H. Bart; Biffi, Alessandro; McNamara, Kristen A.; Ayres, Alison M.; Schwab, Kristin; Viswanathan, Anand; Greenberg, Steven M.; Rosand, Jonathan; Goldstein, Joshua N.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, J Philip Kistler Stroke Res Ctr, Boston, MA 02114 USA.
[Romero, Javier M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Serv Neuroradiol, Boston, MA 02114 USA.
[Goldstein, Joshua N.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol,Dept Emergency Med, Boston, MA 02114 USA.
[Brouwers, H. Bart; Biffi, Alessandro; Viswanathan, Anand; Rosand, Jonathan; Goldstein, Joshua N.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Neurocrit Care & Emergency Neurol,Dept Neurol, Boston, MA 02114 USA.
RP Brouwers, HB (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Human Genet Res,Rosand Lab, 185 Cambridge St,CPZN 6818, Boston, MA 02114 USA.
EM brouwers@chgr.mgh.harvard.edu
RI Goldstein, Joshua/H-8953-2016;
OI Ayres, Alison/0000-0002-5492-1695
FU National Institutes of Health-National Institute of Neurological
Disorders and Stroke (NIH-NINDS) [R01NS073344, R01NS059727,
5K23NS059774]; Edward and Maybeth Sonn Research Fund; NIH-NINDS
Specialized Program of Translational Research in Acute Stroke (SPOTRIAS)
fellowship [P50NS051343]; American Heart Association/Bugher Foundation
Centers for Stroke Prevention Research [0775010N]; National Institutes
of Health; American Heart Association; National Institute of
Neurological Disorders and Stroke
FX All funding entities had no involvement in study design, data
collection, analysis, and interpretation, or writing of the article or
in the decision to submit for publication. The project described was
supported by National Institutes of Health-National Institute of
Neurological Disorders and Stroke (NIH-NINDS) grants R01NS073344,
R01NS059727, and 5K23NS059774 and the Edward and Maybeth Sonn Research
Fund. Dr Brouwers was supported by the NIH-NINDS Specialized Program of
Translational Research in Acute Stroke (SPOTRIAS) fellowship grant
P50NS051343. Dr Biffi was supported in part by the American Heart
Association/Bugher Foundation Centers for Stroke Prevention Research
(0775010N). The content is solely the responsibility of the authors and
does not necessarily represent the official views of the NIH or the
NINDS.; J.M.R. is on the Imaging Committee of the Desmoteplase in Acute
Ischemic Stroke Trial (DIAS) trial and on the advisory board of Lundbeck
Pharmaceuticals. S.M.G. received a research grant the National
Institutes of Health; received honoraria from Medtronic and Pfizer; and
is a consultant/on the advisory board of Hoffman-La Roche, Janssen
Alzheimer Immunotherapy, and Bristol-Myers Squibb Company. J.R. received
research grants from the National Institutes of Health and the American
Heart Association. J.N.G. received a research grant from the National
Institute of Neurological Disorders and Stroke and is a consultant/on
the advisory board of CSL Behring.
NR 24
TC 18
Z9 18
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0039-2499
J9 STROKE
JI Stroke
PD AUG
PY 2012
VL 43
IS 8
BP 2120
EP 2125
DI 10.1161/STROKEAHA.112.659094
PG 6
WC Clinical Neurology; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA 977UC
UT WOS:000306689300028
PM 22621984
ER
PT J
AU McKinney, JS
Kostis, WJ
AF McKinney, James S.
Kostis, William J.
TI Statin Therapy and the Risk of Intracerebral Hemorrhage A Meta-Analysis
of 31 Randomized Controlled Trials
SO STROKE
LA English
DT Article
DE hemorrhagic stroke; intracerebral hemorrhage; meta-analysis; statin
ID PLACEBO-CONTROLLED TRIAL; CORONARY-HEART-DISEASE; AVERAGE CHOLESTEROL
LEVELS; HIGH-DOSE ATORVASTATIN; MYOCARDIAL-INFARCTION; CARDIOVASCULAR
EVENTS; PRIMARY PREVENTION; LDL CHOLESTEROL; BLOOD-PRESSURE;
DOUBLE-BLIND
AB Background and Purpose-Statin therapy decreases the risk of ischemic stroke. An increased risk of intracerebral hemorrhage (ICH) has been observed in some studies. To investigate this issue, we performed a meta-analysis of randomized controlled trials using statins that reported ICH.
Methods-We performed a literature search of Medline, Web of Science, and The Cochrane Library through January 25, 2012, and identified additional randomized controlled trials by reviewing reference lists of retrieved studies and prior meta-analyses. All randomized controlled trials of statin therapy that reported ICH or hemorrhagic stroke were included. The primary outcome variable was ICH. Thirty-one randomized controlled trials were included. All analyses used random effects models and heterogeneity was not observed in any of the analyses.
Results-A total of 91 588 subjects were included in the active group and 91 215 in the control group. There was no significant difference in incidence of ICH observed in the active treatment group versus control (OR, 1.08; 95% CI, 0.88-1.32; P = 0.47). ICH risk was not related to the degree of low-density lipoprotein reduction or achieved low-density lipoprotein cholesterol. Total stroke (OR, 0.84; 95% CI, 0.78-0.91; P < 0.0001) and all-cause mortality (OR, 0.92; CI, 0.87-0.96; P = 0.0007) were significantly reduced in the active therapy group. There was no evidence of publication bias.
Conclusions-Active statin therapy was not associated with significant increase in ICH in this meta-analysis of 31 randomized controlled trials of statin therapy. A significant reduction in all stroke and all-cause mortality was observed with statin therapy. (Stroke. 2012; 43: 2149-2156.)
C1 [McKinney, James S.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Neurol, New Brunswick, NJ 08901 USA.
[McKinney, James S.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Cardiovasc Inst New Jersey, New Brunswick, NJ 08901 USA.
[Kostis, William J.] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA.
RP McKinney, JS (reprint author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Neurol, 125 Paterson St, New Brunswick, NJ 08901 USA.
EM mckinnjs@umdnj.edu
FU Robert Wood Johnson Foundation; Schering-Plough Foundation
FX This study was funded in part by the Robert Wood Johnson Foundation and
the Schering-Plough Foundation.
NR 56
TC 90
Z9 92
U1 0
U2 12
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0039-2499
EI 1524-4628
J9 STROKE
JI Stroke
PD AUG
PY 2012
VL 43
IS 8
BP 2149
EP U238
DI 10.1161/STROKEAHA.112.655894
PG 21
WC Clinical Neurology; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA 977UC
UT WOS:000306689300033
PM 22588266
ER
PT J
AU Cheung, JS
Wang, EF
Lo, EH
Sun, PZ
AF Cheung, Jerry S.
Wang, Enfeng
Lo, Eng H.
Sun, Phillip Zhe
TI Stratification of Heterogeneous Diffusion MRI Ischemic Lesion With
Kurtosis Imaging Evaluation of Mean Diffusion and Kurtosis MRI Mismatch
in an Animal Model of Transient Focal Ischemia
SO STROKE
LA English
DT Article
DE acute ischemia; diffusion; kurtosis
ID CEREBRAL-ISCHEMIA; BRAIN; INJURY; DAMAGE; WATER
AB Background and Purpose-Ischemic tissue damage is heterogeneous, resulting in complex patterns in the widely used diffusion-weighted MRI. Our study examined the spatiotemporal characteristics of diffusion kurtosis imaging in an animal model of transient middle cerebral artery occlusion.
Methods-Adult male Wistar rats (N = 18) were subjected to 90 minutes middle cerebral artery occlusion. Multiparametric MR images were obtained during middle cerebral artery occlusion and 20 minutes after reperfusion with diffusion-weighted MRI obtained using 8 b-values from 250 to 3000 s/mm(2) in 6 diffusion gradient directions. Diffusion and kurtosis lesions were outlined in shuffled images by 2 investigators independently. T-2 MRI was obtained 24 hours after middle cerebral artery occlusion to evaluate stroke outcome.
Results-Mean diffusion lesion (23.5% +/- 8.1%, percentage of the brain slice) was significantly larger than mean kurtosis lesion (13.2% +/- 2.0%) during middle cerebral artery occlusion. Mean diffusion lesion decreased significantly after reperfusion (13.8% +/- 4.3%), whereas mean kurtosis lesion showed little change (13.0% +/- 2.5%) with their lesion size difference being insignificant.
Conclusions-We demonstrated that mean diffusion/mean kurtosis mismatch recovered reasonably well on reperfusion, whereas regions with concurrent mean diffusion and mean kurtosis deficits showed poor recovery. Diffusion kurtosis imaging may help stratify heterogeneous diffusion-weighted MRI lesions for enhanced characterization of ischemic tissue injury. (Stroke. 2012; 43: 2252-2254.)
C1 [Cheung, Jerry S.; Wang, Enfeng; Sun, Phillip Zhe] Massachusetts Gen Hosp, Athinoula A Martinos Ctr, Boston, MA 02114 USA.
[Lo, Eng H.; Sun, Phillip Zhe] Massachusetts Gen Hosp, Neuroprotect Res Lab, Boston, MA 02114 USA.
Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA USA.
RP Sun, PZ (reprint author), MGH, Martinos Ctr, Room 2301,149-13th St, Charlestown, MA 02129 USA.
EM pzhesun@nmr.mgh.harvard.edu
FU National Science Foundation of China [30900365]; American Heart
Association [0835384N]; National Institutes of Health/National Institute
of Biomedical Imaging and Bioengineering [1K01EB009771]; National
Institutes of Health/National Canter for Research Resources [P41RR14075]
FX This study was partially supported by National Science Foundation of
China-30900365, American Heart Association/Scientist Development
Grant-0835384N, National Institutes of Health/National Institute of
Biomedical Imaging and Bioengineering-1K01EB009771, and National
Institutes of Health/National Canter for Research Resources-P41RR14075.
NR 15
TC 39
Z9 44
U1 0
U2 9
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0039-2499
J9 STROKE
JI Stroke
PD AUG
PY 2012
VL 43
IS 8
BP 2252
EP U461
DI 10.1161/STROKEAHA.112.661926
PG 4
WC Clinical Neurology; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA 977UC
UT WOS:000306689300051
PM 22773558
ER
PT J
AU Small, W
Strauss, JB
Jhingran, A
Yashar, CM
Cardenes, HR
Erickson-Wittmann, BA
Gullett, N
Kidd, E
Lee, LJ
Mayr, NA
Moore, D
Puthawala, AA
Rao, GG
Varia, MA
Wahl, AO
Wolfson, AH
Yuh, W
Gaffney, DK
AF Small, William, Jr.
Strauss, Jonathan B.
Jhingran, Anuja
Yashar, Catheryn M.
Cardenes, Higinia R.
Erickson-Wittmann, Beth A.
Gullett, Norleena
Kidd, Elizabeth
Lee, Larissa J.
Mayr, Nina A.
Moore, David
Puthawala, Ajmel A.
Rao, Gautam G.
Varia, Mahesh A.
Wahl, Andrew O.
Wolfson, Aaron H.
Yuh, William
Gaffney, David K.
TI ACR Appropriateness Criteria (R) Definitive Therapy for Early-Stage
Cervical Cancer
SO AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
LA English
DT Review
DE Appropriateness criteria; ACR; cervix; cancer; radiotherapy
ID GYNECOLOGIC-ONCOLOGY-GROUP; INTENSITY-MODULATED RADIOTHERAPY;
POSITRON-EMISSION-TOMOGRAPHY; EXTENDED-FIELD IRRADIATION; SQUAMOUS-CELL
CARCINOMA; PARAAORTIC LYMPH-NODES; PHASE-III TRIAL; RADIATION-THERAPY;
NEOADJUVANT CHEMOTHERAPY; RANDOMIZED-TRIAL
AB Objectives: The definitive treatment of early-stage cervical cancer involves multidisciplinary decision making. This expert panel was convened to reach consensus on the selection of appropriate therapies based on patient and disease characteristics at presentation. Methods: The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed every 2 years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances where evidence is lacking or not definitive, expert opinion may be used to recommend imaging or the treatment. Results: Three clinical variants were developed to represent common scenarios in the treatment of early-stage cervical cancer. Group members reached consensus on the appropriateness of therapeutic options. This process yielded numerical ratings and descriptive commentary. Conclusions: This manuscript represents the consensus opinion of an expert panel based on a survey of all available medical literature. This manuscript may be used to inform the clinical decision making of physicians involved in the treatment of early-stage cervical cancer.
C1 [Small, William, Jr.] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA.
[Strauss, Jonathan B.] Northwestern Univ, Dept Radiat Oncol, Chicago, IL 60611 USA.
[Jhingran, Anuja] Univ Texas Houston, MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Yashar, Catheryn M.] Univ Calif San Diego, Dept Radiat Oncol, San Diego, CA 92103 USA.
[Kidd, Elizabeth] Stanford Canc Ctr, Stanford, CA USA.
[Puthawala, Ajmel A.] Long Beach Mem Med Ctr, Long Beach, CA USA.
[Cardenes, Higinia R.; Gullett, Norleena] Indiana Univ, Med Ctr, Indianapolis, IN USA.
[Moore, David] Indiana Univ, Sch Med, Indianapolis, IN USA.
[Erickson-Wittmann, Beth A.] Med Coll Wisconsin, Milwaukee, WI 53226 USA.
[Lee, Larissa J.] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Mayr, Nina A.] James Canc Hosp, Ohio State Comprehens Canc Ctr, Columbus, OH USA.
[Yuh, William] Ohio State Univ, Dept Radiol, Columbus, OH 43210 USA.
[Rao, Gautam G.] Univ Maryland, Sch Med, Baltimore, MD 21201 USA.
[Varia, Mahesh A.] Univ N Carolina, Sch Med, Chapel Hill, NC USA.
[Wahl, Andrew O.] Univ Nebraska, Med Ctr, Omaha, NE USA.
[Wolfson, Aaron H.] Univ Miami, Dept Radiat Oncol, Miami, FL USA.
[Gaffney, David K.] Univ Utah, Med Ctr, Salt Lake City, UT USA.
[Moore, David] Amer Congress Obstetricians & Gynecologists, Washington, DC USA.
[Rao, Gautam G.] Amer Soc Clin Oncol, Alexandria, VA USA.
RP Small, W (reprint author), Amer Coll Radiol, 1891 Preston White Dr, Reston, VA 20191 USA.
EM wsmall@nmff.org
OI Strauss, Jonathan/0000-0003-0175-7251
NR 63
TC 4
Z9 4
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0277-3732
EI 1537-453X
J9 AM J CLIN ONCOL-CANC
JI Am. J. Clin. Oncol.-Cancer Clin. Trials
PD AUG
PY 2012
VL 35
IS 4
BP 399
EP 405
DI 10.1097/COC.0b013e3182610537
PG 7
WC Oncology
SC Oncology
GA 976QK
UT WOS:000306599200017
PM 22810416
ER
PT J
AU Nishino, HT
Wilbur, DC
Tambouret, RH
AF Nishino, Ha T.
Wilbur, David C.
Tambouret, Rosemary H.
TI Low-Grade Squamous Intraepithelial Lesion, Cannot Exclude High-Grade
Squamous Intraepithelial Lesion A Category With an Increased Outcome of
High-Grade Lesions: Use as a Quality Assurance Measure
SO AMERICAN JOURNAL OF CLINICAL PATHOLOGY
LA English
DT Article
DE AP cytopathology; Cytology; AP gynecological; Quality control; Squamous
intraepithelial lesion
ID 2001 BETHESDA SYSTEM; UNDETERMINED SIGNIFICANCE; ASC/SIL RATIO; SIL
RATIO; CYTOLOGY; TERMINOLOGY; DIAGNOSIS; CELLS; HPV
AB "Low-grade squamous intraepithelial lesion (LSIL), cannot exclude high-grade squamous intraepithelial lesion" (LSIL-H) is an increasingly used, equivocal interpretive category in gynecologic cytology. In an effort to evaluate its potential usefulness as a measure of quality assurance, we studied patterns of use of the LSIL-H diagnosis compared with "LSIL" and "high-grade squamous intraepithelial lesion" (HSIL) with corresponding histologic outcomes for 10 cytopathologists in our practice. In our laboratory, while the overall rate of associated cervical intraepithelial neoplasia 2 or greater on histologic follow-up for LSIL-H was intermediate between that of LSIL and HSIL, the outcomes for individual cytopathologists varied widely. Monitoring this particular utilization-outcome data with periodic confidential feedback to individual cytopathologists offers an opportunity for practice improvement within a laboratory and serves as an additional measure of quality assurance. These data may be useful for establishing and/or realigning the diagnostic criteria for this equivocal cytologic interpretation endorsed by a pathology practice.
C1 [Tambouret, Rosemary H.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
RP Tambouret, RH (reprint author), Massachusetts Gen Hosp, Dept Pathol, 55 Fruit St,Warren 125, Boston, MA 02114 USA.
EM rtambouret@partners.org
NR 16
TC 4
Z9 4
U1 0
U2 0
PU AMER SOC CLINICAL PATHOLOGY
PI CHICAGO
PA 2100 W HARRISON ST, CHICAGO, IL 60612 USA
SN 0002-9173
J9 AM J CLIN PATHOL
JI Am. J. Clin. Pathol.
PD AUG
PY 2012
VL 138
IS 2
BP 198
EP 202
DI 10.1309/AJCP8J4ROAVWOSHQ
PG 5
WC Pathology
SC Pathology
GA 975UC
UT WOS:000306536000005
PM 22904130
ER
PT J
AU Renella, R
Stickney, C
Keswani, M
Mancuso, T
Casavant, D
Ferguson, M
Narla, A
AF Renella, Raffaele
Stickney, Carolyn
Keswani, Mahima
Mancuso, Thomas
Casavant, David
Ferguson, Michael
Narla, Anupama
TI Fulminant thrombotic microangiopathy in Pediatrics: Where diagnostic and
therapeutic dilemmas meet
SO AMERICAN JOURNAL OF HEMATOLOGY
LA English
DT Article
ID HEMOLYTIC-UREMIC SYNDROME; THROMBOCYTOPENIC PURPURA; ECULIZUMAB;
CHILDHOOD
C1 [Renella, Raffaele; Narla, Anupama] Harvard Univ, Sch Med, Childrens Hosp Boston, Div Hematol Oncol, Boston, MA USA.
[Stickney, Carolyn; Mancuso, Thomas; Casavant, David] Harvard Univ, Sch Med, Childrens Hosp Boston, Div Crit Care Med, Boston, MA USA.
[Keswani, Mahima; Ferguson, Michael] Harvard Univ, Sch Med, Childrens Hosp Boston, Div Nephrol, Boston, MA USA.
[Keswani, Mahima] Childrens Natl Med Ctr, Div Nephrol, Washington, DC 20010 USA.
RP Renella, R (reprint author), Dana Farber Canc Inst, Jimmy Fund Clin, Dept Pediat Oncol, Dana 3,450 Brookline Ave, Boston, MA 02115 USA.
EM raffaele.renella@childrens.harvard.edu
OI Renella, Raffaele/0000-0002-5041-2308
NR 17
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0361-8609
J9 AM J HEMATOL
JI Am. J. Hematol.
PD AUG
PY 2012
VL 87
IS 8
BP 816
EP 818
DI 10.1002/ajh.23166
PG 3
WC Hematology
SC Hematology
GA 975BW
UT WOS:000306482700011
PM 22407784
ER
PT J
AU Terry, J
Calicchio, ML
Rodriguez-Galindo, C
Perez-Atayde, AR
AF Terry, Jefferson
Calicchio, Monica L.
Rodriguez-Galindo, Carlos
Perez-Atayde, Antonio R.
TI Immunohistochemical Expression of CRX in Extracranial Malignant Small
Round Cell Tumors
SO AMERICAN JOURNAL OF SURGICAL PATHOLOGY
LA English
DT Article
DE neuroblastoma; retinoblastoma; children; malignant small round cell
tumor; PNET; Ewing; Wilms tumor; rhabdomyosarcoma; desmoplastic small
round cell tumor; melanocytic neoplasm
ID METASTATIC RETINOBLASTOMA; SURVIVORS; RISK
AB Tumor-specific immunohistochemical markers are valuable in the differential diagnosis of malignant small round cell tumors (MSRCTs). The cone-rod homeobox-containing gene (CRX) is a transcription factor that is preferentially expressed in retinal photoreceptor cells. It has been shown that the CRX antibody is a good immunohistochemical marker to differentiate retinoblastoma from other intracranial MSRCTs. Outside of the central nervous system, however, the usefulness of CRX immunohistochemistry in establishing a diagnosis of metastatic retinoblastoma is uncertain, as the expression of CRX in primitive neuroectodermal tumor/Ewing sarcoma (PNET/ES), neuroblastoma, and other MSRCTs is unknown. Archival specimens from resections, core biopsies, and bone marrow biopsies of 41 neuroblastomas, 24 PNET/ES, 19 embryonal rhabdomyosarcomas, 17 alveolar rhabdomyosarcomas, 17 Wilms tumors, 14 desmoplastic small round cell tumors, 20 medulloblastomas, 9 pineal tumors, 17 melanocytic tumors (compound and Spitz nevi), and 8 retinoblastomas were immunostained for CRX. All retinoblastomas had strong diffuse nuclear immunoreactivity for CRX; 8 of the 20 medulloblastomas showed strong nuclear immunoreactivity either in occasional clusters of tumor cells or in rare single scattered tumor cells; 3 of the 9 pineal tumors showed strong nuclear immunoreactivity in approximately 40% to 50% of the tumor cells. Neuroblastomas, PNET/ES, embryonal rhabdomyosarcomas, alveolar rhabdomyosarcomas, Wilms tumors, desmoplastic small round cell tumors, and melanocytic tumors were all negative. Scant nonspecific cytoplasmic staining was observed in some tumors, mostly PNET/ES. These findings suggest that CRX is a useful marker to discriminate metastatic retinoblastoma from other, more common, MSRCTs of childhood.
C1 [Terry, Jefferson; Calicchio, Monica L.; Rodriguez-Galindo, Carlos; Perez-Atayde, Antonio R.] Childrens Hosp, Dept Pathol, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Rodriguez-Galindo, Carlos] Childrens Hosp, Dept Hematol Oncol, Dana Farber Canc Inst, Boston, MA 02115 USA.
Harvard Univ, Sch Med, Boston, MA USA.
RP Perez-Atayde, AR (reprint author), Childrens Hosp, Dept Pathol, Dana Farber Canc Inst, 300 Longwood Ave, Boston, MA 02115 USA.
EM antonio.perezatayde@childrens.harvard.edu
OI Terry, Jefferson/0000-0001-5464-8679
NR 11
TC 11
Z9 11
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0147-5185
J9 AM J SURG PATHOL
JI Am. J. Surg. Pathol.
PD AUG
PY 2012
VL 36
IS 8
BP 1165
EP 1169
DI 10.1097/PAS.0b013e3182601d84
PG 5
WC Pathology; Surgery
SC Pathology; Surgery
GA 977JY
UT WOS:000306656500007
PM 22790857
ER
PT J
AU Evans, AG
French, CA
Cameron, MJ
Fletcher, CDM
Jackman, DM
Lathan, CS
Sholl, LM
AF Evans, Andrew G.
French, Christopher A.
Cameron, Michael J.
Fletcher, Christopher D. M.
Jackman, David M.
Lathan, Christopher S.
Sholl, Lynette M.
TI Pathologic Characteristics of NUT Midline Carcinoma Arising in the
Mediastinum
SO AMERICAN JOURNAL OF SURGICAL PATHOLOGY
LA English
DT Article
DE NUT midline carcinoma; mediastinum; squamous cell carcinoma
ID UPPER AERODIGESTIVE TRACT; DIFFERENTIATION; REARRANGEMENT; INHIBITION;
PROTEIN; KINASE
AB NUT midline carcinomas (NMCs) comprise a group of highly aggressive tumors that have been reported primarily in the head, neck, and mediastinum of younger individuals. These tumors overexpress the nuclear protein in the testis (NUT), most commonly due to a chromosomal translocation that fuses the NUT gene on chromosome 15 with the BRD4 gene on chromosome 19. Although the earliest recognized cases were described in the thymus or mediastinum, an extensive survey for NMCs among malignant thymic or other mediastinal neoplasms has not been reported. We examined NUT expression in 114 cases of poorly differentiated carcinomas or unclassified mediastinal malignancies using a clinically validated NUT-specific monoclonal antibody. Four of 114 (3.5%) cases showed nuclear NUT expression. A NUT translocation was confirmed by fluorescence in situ hybridization in 3 of these cases. These tumors arose in 2 men and 2 women with a median age of 50 years (range, 28 to 68 y). Three of the tumors were originally diagnosed as undifferentiated epithelioid or round cell malignant neoplasms; 1 tumor contained focal squamous differentiation and was originally diagnosed as a poorly differentiated squamous carcinoma of probable thymic origin. We find that the incidence of NMC within the mediastinum, particularly among undifferentiated tumors, is similar to that reported at other anatomic sites. NMC should be considered in the differential diagnosis of any poorly differentiated epithelioid mediastinal tumor, regardless of age.
C1 [Evans, Andrew G.; French, Christopher A.; Cameron, Michael J.; Fletcher, Christopher D. M.; Sholl, Lynette M.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
[Jackman, David M.; Lathan, Christopher S.] Dana Farber Canc Inst, Dept Thorac Oncol, Boston, MA 02115 USA.
RP Sholl, LM (reprint author), Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA.
EM lmsholl@partners.org
FU Dana Farber/Harvard Cancer Center [5P30CA06516-44]; US National
Institutes of Health [1R01CA124633]; Samuel Waxman Cancer Research
Foundation Reprogramming the Cancer Cell; American Association for
Cancer Research [10-20-03-FREN]
FX Supported by a Dana Farber/Harvard Cancer Center Nodal Award
5P30CA06516-44 (C.A.F.), US National Institutes of Health grant
1R01CA124633 (C.A.F.), the Samuel Waxman Cancer Research Foundation
Reprogramming the Cancer Cell, and the American Association for Cancer
Research grant 10-20-03-FREN (C.A.F.). The authors have disclosed that
they have no significant relationships with, or financial interest in,
any commercial companies pertaining to this article.
NR 20
TC 21
Z9 21
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0147-5185
J9 AM J SURG PATHOL
JI Am. J. Surg. Pathol.
PD AUG
PY 2012
VL 36
IS 8
BP 1222
EP 1227
DI 10.1097/PAS.0b013e318258f03b
PG 6
WC Pathology; Surgery
SC Pathology; Surgery
GA 977JY
UT WOS:000306656500014
PM 22790861
ER
PT J
AU McGrath, LM
Mustanski, B
Metzger, A
Pine, DS
Kistner-Griffin, E
Cook, E
Wakschlag, LS
AF McGrath, L. M.
Mustanski, B.
Metzger, A.
Pine, D. S.
Kistner-Griffin, E.
Cook, E.
Wakschlag, L. S.
TI A latent modeling approach to genotype-phenotype relationships: maternal
problem behavior clusters, prenatal smoking, and MAOA genotype
SO ARCHIVES OF WOMENS MENTAL HEALTH
LA English
DT Article
DE Female problem behavior; Antisocial behavior; Prenatal smoking;
Monoamine oxidase A (MAOA); Gene x environment interaction
ID X-CHROMOSOME INACTIVATION; OXIDASE-A GENE; MONOAMINE-OXIDASE;
ANTISOCIAL-BEHAVIOR; CONDUCT DISORDER; FUNCTIONAL POLYMORPHISM;
EXTERNALIZING SPECTRUM; SCREENING-TEST; LUNG-FUNCTION; SEXUAL-ABUSE
AB This study illustrates the application of a latent modeling approach to genotype-phenotype relationships and gene x environment interactions, using a novel, multidimensional model of adult female problem behavior, including maternal prenatal smoking. The gene of interest is the monoamine oxidase A (MAOA) gene which has been well studied in relation to antisocial behavior. Participants were adult women (N = 192) who were sampled from a prospective pregnancy cohort of non-Hispanic, white individuals recruited from a neighborhood health clinic. Structural equation modeling was used to model a female problem behavior phenotype, which included conduct problems, substance use, impulsive-sensation seeking, interpersonal aggression, and prenatal smoking. All of the female problem behavior dimensions clustered together strongly, with the exception of prenatal smoking. A main effect of MAOA genotype and a MAOA x physical maltreatment interaction were detected with the Conduct Problems factor. Our phenotypic model showed that prenatal smoking is not simply a marker of other maternal problem behaviors. The risk variant in the MAOA main effect and interaction analyses was the high activity MAOA genotype, which is discrepant from consensus findings in male samples. This result contributes to an emerging literature on sex-specific interaction effects for MAOA.
C1 [McGrath, L. M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Psychiat & Neurodev Genet Unit,Dept Psychiat, Boston, MA 02114 USA.
[McGrath, L. M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Human Genet Res, Boston, MA 02114 USA.
[Mustanski, B.; Wakschlag, L. S.] Northwestern Univ, Dept Med Social Sci, Feinberg Sch Med, Chicago, IL 60611 USA.
[Metzger, A.] W Virginia Univ, Dept Psychol, Morgantown, WV 26506 USA.
[Pine, D. S.] NIMH, Mood & Anxiety Disorders Program, Bethesda, MD 20892 USA.
[Kistner-Griffin, E.] Med Univ S Carolina, Div Biostat & Epidemiol, Charleston, SC 29425 USA.
[Cook, E.] Univ Illinois, Dept Psychiat, Inst Juvenile Res, Chicago, IL 60612 USA.
RP McGrath, LM (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Psychiat & Neurodev Genet Unit,Dept Psychiat, Simches Res Bldg,6th Floor,185 Cambridge St, Boston, MA 02114 USA.
EM mcgrath@pngu.mgh.harvard.edu
FU NIDA NIH HHS [R01 DA015223, R01 DA023653]
NR 80
TC 13
Z9 13
U1 1
U2 8
PU SPRINGER WIEN
PI WIEN
PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA
SN 1434-1816
J9 ARCH WOMEN MENT HLTH
JI Arch. Womens Ment. Health
PD AUG
PY 2012
VL 15
IS 4
BP 269
EP 282
DI 10.1007/s00737-012-0286-y
PG 14
WC Psychiatry
SC Psychiatry
GA 975CI
UT WOS:000306484000004
PM 22610759
ER
PT J
AU Romeo, GR
Lee, J
Shoelson, SE
AF Romeo, Giulio R.
Lee, Jongsoon
Shoelson, Steven E.
TI Metabolic Syndrome, Insulin Resistance, and Roles of Inflammation -
Mechanisms and Therapeutic Targets
SO ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
LA English
DT Article
DE atherosclerosis; immune system; anti-inflammatory agents; insulin
resistance; leukocytes
ID ADIPOSE-TISSUE MACROPHAGES; TYPE-2 DIABETES-MELLITUS; DIET-INDUCED
OBESITY; T-CELLS; GLYCEMIC CONTROL; IMMUNE-RESPONSE; GENE-EXPRESSION;
WEIGHT-LOSS; PPAR-GAMMA; IKK-BETA
AB Obesity and its comorbidities, including type 2 diabetes mellitus and cardiovascular disease, are associated with a state of chronic low-grade inflammation that can be detected both systemically and within specific tissues. Areas of active investigation focus on the molecular bases of metabolic inflammation and potential pathogenic roles in insulin resistance, diabetes, and cardiovascular disease. An increased accumulation of macrophages occurring in obese adipose tissue has emerged as a key process in metabolic inflammation. Recent studies have also begun to unravel the heterogeneity of adipose tissue macrophages, and their physical and functional interactions with adipocytes, endothelial cells, and other immune cells within the adipose tissue microenvironment. Translating the information gathered from experimental models of insulin resistance and diabetes into meaningful therapeutic interventions is a tantalizing goal with long-term global health implications. In this context, ongoing clinical studies are testing the effects of targeting inflammation systemically on metabolic and cardiovascular outcomes. (Arterioscler Thromb Vasc Biol. 2012;32:1771-1776.)
C1 [Shoelson, Steven E.] Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02115 USA.
Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA.
RP Shoelson, SE (reprint author), Harvard Univ, Sch Med, Joslin Diabet Ctr, 1 Joslin Pl, Boston, MA 02115 USA.
EM steven.shoelson@joslin.harvard.edu
FU JDRF-CDA [2-2004-609]; Pilot and Feasibility awards from the Joslin
Diabetes Research Center [DK036836]; Boston Obesity Nutrition Research
Center [DK046200]; NIH [DK51729, DK74556, DK90792]
FX The authors were supported by grants JDRF-CDA 2-2004-609 and Pilot and
Feasibility awards from the Joslin Diabetes Research Center DK036836 and
the Boston Obesity Nutrition Research Center DK046200 to GRR and NIH
grants DK51729, DK74556 and DK90792 to SES.
NR 57
TC 139
Z9 143
U1 2
U2 40
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1079-5642
J9 ARTERIOSCL THROM VAS
JI Arterioscler. Thromb. Vasc. Biol.
PD AUG
PY 2012
VL 32
IS 8
BP 1771
EP 1776
DI 10.1161/ATVBAHA.111.241869
PG 6
WC Hematology; Peripheral Vascular Disease
SC Hematology; Cardiovascular System & Cardiology
GA 976CM
UT WOS:000306558100013
PM 22815343
ER
PT J
AU Fuchs, TA
Brill, A
Wagner, DD
AF Fuchs, Tobias A.
Brill, Alexander
Wagner, Denisa D.
TI Neutrophil Extracellular Trap (NET) Impact on Deep Vein ThrombosisTobias
SO ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
LA English
DT Article
DE deep vein thrombosis; deoxyribonuclease; inflammation; mouse model;
neutrophil extracellular traps; thrombolytic therapy
ID VON-WILLEBRAND-FACTOR; PULMONARY-EMBOLISM; VENOUS THROMBOSIS; LEUKOCYTE
ELASTASE; MITOCHONDRIAL-DNA; ENDOTHELIAL-CELLS; INNATE IMMUNITY;
HUMAN-PLATELETS; CANCER-PATIENTS; RISK-FACTORS
AB Deep vein thrombosis (DVT) is a major health problem that requires improved prophylaxis and treatment. Inflammatory conditions such as infection, cancer, and autoimmune diseases are risk factors for DVT. We and others have recently shown that extracellular DNA fibers produced in inflammation and known as neutrophil extracellular traps (NETs) contribute to experimental DVT. NETs stimulate thrombus formation and coagulation and are abundant in thrombi in animal models of DVT. It appears that, in addition to fibrin and von Willebrand factor, NETs represent a third thrombus scaffold. Here, we review how NETs stimulate thrombosis and discuss known and potential interactions of NETs with endothelium, platelets, red blood cells, and coagulation factors and how NETs could influence thrombolysis. We propose that drugs that inhibit NET formation or facilitate NET degradation may prevent or treat DVT. (Arterioscler Thromb Vasc Biol. 2012;32:1777-1783.)
C1 [Wagner, Denisa D.] Immune Dis Inst, Boston, MA 02115 USA.
Childrens Hosp, Program Cellular & Mol Med, Boston, MA 02115 USA.
Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA.
RP Wagner, DD (reprint author), Immune Dis Inst, 3 Blackfan Cir,3rd Floor, Boston, MA 02115 USA.
EM wagner@idi.harvard.edu
RI Fuchs, Tobias/F-1189-2013
FU National Heart, Lung, and Blood Institute of National Institutes of
Health [R01 HL102101, R01 HL041002, R01 HL095091]
FX The present study was supported by National Heart, Lung, and Blood
Institute of National Institutes of Health grants R01 HL102101, R01
HL041002, and R01 HL095091 (to Dr Wagner).
NR 81
TC 119
Z9 123
U1 2
U2 15
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1079-5642
J9 ARTERIOSCL THROM VAS
JI Arterioscler. Thromb. Vasc. Biol.
PD AUG
PY 2012
VL 32
IS 8
BP 1777
EP 1783
DI 10.1161/ATVBAHA.111.242859
PG 7
WC Hematology; Peripheral Vascular Disease
SC Hematology; Cardiovascular System & Cardiology
GA 976CM
UT WOS:000306558100014
PM 22652600
ER
PT J
AU Brill, A
Yesilaltay, A
De Meyer, SF
Kisucka, J
Fuchs, TA
Kocher, O
Krieger, M
Wagner, DD
AF Brill, Alexander
Yesilaltay, Ayce
De Meyer, Simon F.
Kisucka, Janka
Fuchs, Tobias A.
Kocher, Olivier
Krieger, Monty
Wagner, Denisa D.
TI Extrahepatic High-Density Lipoprotein Receptor SR-BI and ApoA-I Protect
Against Deep Vein Thrombosis in Mice
SO ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
LA English
DT Article
DE deep vein thrombosis; scavenger receptor class B type I; apolipoprotein
A-I; high-density lipoprotein; endothelial nitric oxide synthase
ID APOLIPOPROTEIN-A-I; CORONARY-HEART-DISEASE; VENOUS THROMBOEMBOLISM;
DEFICIENT MICE; RISK-FACTORS; CHOLESTEROL; HDL; METABOLISM; PDZK1;
EXPRESSION
AB Objective-Deep vein thrombosis (DVT) and pulmonary embolism are frequent causes of morbidity and mortality. The goal of our study was to determine whether plasma high-density lipoprotein (HDL), which inversely correlates with the risk of cardiovascular events, affects DVT.
Methods and Results-Using a murine DVT model of inferior vena cava stenosis, we demonstrated that deficiency of the HDL receptor, scavenger receptor class B type I (SR-BI), promotes venous thrombosis. As SR-BI-/- mice have increased plasma cholesterol levels and abnormal HDL particles, we tested SR-BI-/- mice with an SR-BI liver transgene that normalizes both parameters. These mice also exhibited increased susceptibility to DVT, indicating a protective role of extrahepatic SR-BI. Mice lacking the major HDL apolipoprotein apoA-I or endothelial nitric oxide synthase (eNOS) (a downstream target of endothelial SR-BI signaling) also had a prothrombotic phenotype. Intravenous infusion of human apoA-I, an HDL component and SR-BI ligend, prevented DVT in wild-type but not SR-BI-/- or eNOS(-/-) mice, suggesting that its effect is mediated by SR-BI and eNOS. Intravenous apoA-I infusion abolished histamine-induced platelet-endothelial interactions, which are important for DVT initiation.
Conclusion-An apoA-I (HDL)-SR-BI-eNOS axis is highly protective in DVT and may provide new targets for prophylaxis and treatment of venous thrombosis. (Arterioscler Thromb Vasc Biol. 2012;32:1841-1848.)
C1 [Brill, Alexander; De Meyer, Simon F.; Fuchs, Tobias A.; Wagner, Denisa D.] Harvard Univ, Sch Med, Immune Dis Inst, Boston, MA USA.
[Brill, Alexander; De Meyer, Simon F.; Fuchs, Tobias A.; Wagner, Denisa D.] Harvard Univ, Sch Med, Childrens Hosp Boston, Program Cellular & Mol Med, Boston, MA USA.
[Brill, Alexander; De Meyer, Simon F.; Fuchs, Tobias A.; Wagner, Denisa D.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA.
[Yesilaltay, Ayce; Kisucka, Janka; Krieger, Monty] MIT, Dept Biol, Cambridge, MA USA.
[Kocher, Olivier] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Pathol, Boston, MA 02215 USA.
[Kocher, Olivier] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Vasc Biol Res Ctr, Boston, MA 02215 USA.
[De Meyer, Simon F.] KULeuven, Lab Thrombosis Res, Kortrijk, Belgium.
RP Wagner, DD (reprint author), 3 Blackfan Circle,3rd Floor, Boston, MA 02115 USA.
EM wagner@idi.harvard.edu
RI Fuchs, Tobias/F-1189-2013
FU National Heart, Lung, and Blood Institute of the National Institutes of
Health [P01 HL066105, HL52212, R01 HL041002]; Fond voor Wetenschappelijk
Onderzoek Vlaanderen (FWO)
FX This work was supported by the National Heart, Lung, and Blood Institute
of the National Institutes of Health grants P01 HL066105 (to M.K. and
D.D.W.), HL52212 (to M.K.), and R01 HL041002 to (D.D.W.). S.F.D.M. is a
postdoctoral fellow of the Fond voor Wetenschappelijk Onderzoek
Vlaanderen (FWO).
NR 52
TC 15
Z9 15
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1079-5642
J9 ARTERIOSCL THROM VAS
JI Arterioscler. Thromb. Vasc. Biol.
PD AUG
PY 2012
VL 32
IS 8
BP 1841
EP U308
DI 10.1161/ATVBAHA.112.252130
PG 12
WC Hematology; Peripheral Vascular Disease
SC Hematology; Cardiovascular System & Cardiology
GA 976CM
UT WOS:000306558100022
PM 22652597
ER
PT J
AU De Meyer, SF
Suidan, GL
Fuchs, TA
Monestier, M
Wagner, DD
AF De Meyer, Simon F.
Suidan, Georgette L.
Fuchs, Tobias A.
Monestier, Marc
Wagner, Denisa D.
TI Extracellular Chromatin Is an Important Mediator of Ischemic Stroke in
Mice
SO ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
LA English
DT Article
DE stroke; chromatin; histones; DNase 1
ID VON-WILLEBRAND-FACTOR; EARLY CEREBRAL STROKE; DEEP-VEIN THROMBOSIS;
ACTIVATED PROTEIN-C; PLATELET POLYPHOSPHATES; MYOCARDIAL-INFARCTION;
GLYCOPROTEIN-IIB/IIIA; PROGNOSTIC MARKER; LIVER-INJURY; IN-VIVO
AB Objective-Recently, a growing number of studies have revealed a prothrombotic and cytotoxic role for extracellular chromatin. Cerebral ischemia/reperfusion injury is characterized by a significant amount of cell death and neutrophil activation, both of which may result in the release of chromatin. The goal of this study was to assess the effect of extracellular chromatin in ischemic stroke using a mouse model of transient middle cerebral artery occlusion.
Methods and Results-Similar to reports in stroke patients, we observed increased levels of circulating nucleosomes and DNA after ischemic stroke in mice. In addition, we observed that general hypoxia also augmented extracellular chromatin. We hypothesized that targeting extracellular chromatin components would be protective in ischemic stroke. Indeed, treatment with recombinant human DNase 1 significantly improved stroke outcome. Neutralization of histones using an antihistone antibody was also protective as evidenced by smaller infarct volumes, whereas increasing levels of extracellular histones via histone infusion exacerbated stroke outcome by increasing infarct size and worsening functional outcome.
Conclusion-Our results indicate that extracellular chromatin is generated and is detrimental during cerebral ischemia/reperfusion in mice. Targeting DNA and histones may be a new therapeutic strategy to limit injury resulting from ischemic stroke. (Arterioscler Thromb Vasc Biol. 2012;32:1884-1891.)
C1 [Wagner, Denisa D.] Harvard Univ, Sch Med, Immune Dis Inst, Boston, MA 02115 USA.
[De Meyer, Simon F.; Suidan, Georgette L.; Fuchs, Tobias A.; Wagner, Denisa D.] Childrens Hosp Boston, Program Cellular & Mol Med, Boston, MA USA.
[De Meyer, Simon F.; Suidan, Georgette L.; Fuchs, Tobias A.; Wagner, Denisa D.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA.
[De Meyer, Simon F.] KULeuven Kulak, Lab Thrombosis Res, Kortrijk, Belgium.
[Monestier, Marc] Temple Univ, Sch Med, Temple Autoimmun Ctr, Dept Microbiol & Immunol, Philadelphia, PA 19122 USA.
RP Wagner, DD (reprint author), Harvard Univ, Sch Med, Immune Dis Inst, 3 Blackfan Circle,3rd Floor, Boston, MA 02115 USA.
EM wagner@idi.harvard.edu
RI Ji, Haofeng/G-6206-2012; Fuchs, Tobias/F-1189-2013
FU National Heart, Lung, and Blood Institute of the National Institutes of
Health [R01 HL041002, R01 HL102101]; Deutsche Forschungsgemeinschaft,
Germany [FU 742/1-1]
FX This research was supported by National Heart, Lung, and Blood Institute
of the National Institutes of Health grants R01 HL041002 and R01
HL102101 (to D.D.W.) and a fellowship from the Deutsche
Forschungsgemeinschaft, Germany (FU 742/1-1) (to T.A.F.). S.F.D.M. is a
postdoctoral fellow of the Research Foundation Flanders (Fonds voor
Wetenschappelijk Onderzoek Vlaanderen).
NR 55
TC 41
Z9 42
U1 2
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1079-5642
J9 ARTERIOSCL THROM VAS
JI Arterioscler. Thromb. Vasc. Biol.
PD AUG
PY 2012
VL 32
IS 8
BP 1884
EP U394
DI 10.1161/ATVBAHA.112.250993
PG 11
WC Hematology; Peripheral Vascular Disease
SC Hematology; Cardiovascular System & Cardiology
GA 976CM
UT WOS:000306558100027
PM 22628431
ER
PT J
AU An, XJ
Jin, Y
Philbrick, MJ
Wu, JP
Messmer-Blust, A
Song, XX
Cully, BL
He, P
Xu, M
Duffy, HS
Li, J
AF An, Xiaojin
Jin, Yi
Philbrick, Melissa J.
Wu, Jiaping
Messmer-Blust, Angela
Song, Xiaoxiao
Cully, Brittany L.
He, Ping
Xu, Ming
Duffy, Heather S.
Li, Jian
TI Endothelial Cells Require Related Transcription Enhancer Factor-1 for
Cell-Cell Connections Through the Induction of Gap Junction Proteins
SO ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
LA English
DT Article
DE related transcription enhancer factor-1; endothelial cells; gap
junctions; connexin 43; cell-cell connections
ID OXYGEN-INDUCED RETINOPATHY; M-CAT ELEMENTS; VASCULAR DEVELOPMENT;
VE-CADHERIN; ANGIOGENESIS; MOUSE; EXPRESSION; MICE; GENE; ETS
AB Objective-Capillary network formation represents a specialized endothelial cell function and is a prerequisite to establish a continuous vessel lumen. Formation of endothelial cell connections that form the vascular structure is regulated, at least in part, at the transcriptional level. We report here that related transcription enhancer factor-1 (RTEF-1) plays an important role in vascular structure formation.
Methods and Results-Knockdown of RTEF-1 by small interfering RNA or blockage of RTEF-1 function by the transcription enhancer activators domain decreased endothelial connections in a Matrigel assay, whereas overexpression of RTEF-1 in endothelial cells resulted in a significant increase in cell connections and aggregation. In a model of oxygen-induced retinopathy, endothelial-specific RTEF-1 overexpressing mice had enhanced angiogenic sprouting and vascular structure remodeling, resulting in the formation of a denser and more highly interconnected superficial capillary plexus. Mechanistic studies revealed that RTEF-1 induced the expression of functional gap junction proteins including connexin 43, connexin 40, and connexin 37. Blocking connexin 43 function inhibited RTEF-1-induced endothelial cell connections and aggregation.
Conclusion-These findings provide novel insights into the transcriptional control of endothelial function in the coordination of cell-cell connections. (Arterioscler Thromb Vasc Biol. 2012;32:1951-1959.)
C1 [Li, Jian] Harvard Univ, Sch Med, Div Cardiovasc Med, Beth Israel Deaconess Med Ctr,Cardiovasc Inst, Boston, MA 02115 USA.
[An, Xiaojin; Jin, Yi; Li, Jian] Peking Univ, Inst Mol Med, Beijing 100871, Peoples R China.
RP Li, J (reprint author), Harvard Univ, Sch Med, Div Cardiovasc Med, Beth Israel Deaconess Med Ctr,Cardiovasc Inst, 3 Blackfan Circle, Boston, MA 02115 USA.
EM JLi@BIDMC.Harvard.edu
FU National Institutes of Health grant [HLR01082837]; China Scholarship
Council
FX This work was supported, in part, by National Institutes of Health grant
HLR01082837 (to J.L.) and China Scholarship Council (to X.A. and Y.J.).
NR 28
TC 3
Z9 3
U1 1
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1079-5642
J9 ARTERIOSCL THROM VAS
JI Arterioscler. Thromb. Vasc. Biol.
PD AUG
PY 2012
VL 32
IS 8
BP 1951
EP U523
DI 10.1161/ATVBAHA.112.250159
PG 14
WC Hematology; Peripheral Vascular Disease
SC Hematology; Cardiovascular System & Cardiology
GA 976CM
UT WOS:000306558100035
PM 22652601
ER
PT J
AU Salovich, JM
Vinson, PN
Sheffler, DJ
Lamsal, A
Utley, TJ
Blobaum, AL
Bridges, TM
Le, U
Jones, CK
Wood, MR
Daniels, JS
Conn, PJ
Niswender, CM
Lindsley, CW
Hopkins, CR
AF Salovich, James M.
Vinson, Paige N.
Sheffler, Douglas J.
Lamsal, Atin
Utley, Thomas J.
Blobaum, Anna L.
Bridges, Thomas M.
Le, Uyen
Jones, Carrie K.
Wood, Michael R.
Daniels, J. Scott
Conn, P. Jeffrey
Niswender, Colleen M.
Lindsley, Craig W.
Hopkins, Corey R.
TI Discovery of N-(4-methoxy-7-methylbenzo[d]thiazol-2-yl)isonicatinamide,
ML293, as a novel, selective and brain penetrant positive allosteric
modulator of the muscarinic 4 (M-4) receptor
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE Positive allosteric modulator; M-4; ML293; CNS penetration; Muscarinic
receptor 4
ID CENTRAL-NERVOUS-SYSTEM; ACETYLCHOLINE-RECEPTORS; KNOCKOUT MICE
AB Herein we describe the discovery and development of a novel class of M-4 positive allosteric modulators, culminating in the discovery of ML293. ML293 exhibited modest potency at the human M4 receptor (EC50 = 1.3 mu M) and excellent efficacy as noted by the 14.6-fold leftward shift of the agonist concentration-response curve. ML293 was also selective versus the other muscarinic subtypes and displayed excellent in vivo PK properties in rat with low IV clearance (11.6 mL/min/kg) and excellent brain exposure (PO PBL, 10 mg/kg at 1 h, [Brain] = 10.3 mu M, B: P = 0.85). (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Salovich, James M.; Vinson, Paige N.; Sheffler, Douglas J.; Lamsal, Atin; Utley, Thomas J.; Blobaum, Anna L.; Bridges, Thomas M.; Le, Uyen; Jones, Carrie K.; Wood, Michael R.; Daniels, J. Scott; Conn, P. Jeffrey; Niswender, Colleen M.; Lindsley, Craig W.; Hopkins, Corey R.] Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA.
[Wood, Michael R.; Lindsley, Craig W.; Hopkins, Corey R.] Vanderbilt Univ, Dept Chem, Nashville, TN 37232 USA.
[Salovich, James M.; Vinson, Paige N.; Sheffler, Douglas J.; Lamsal, Atin; Utley, Thomas J.; Blobaum, Anna L.; Bridges, Thomas M.; Le, Uyen; Jones, Carrie K.; Wood, Michael R.; Daniels, J. Scott; Conn, P. Jeffrey; Niswender, Colleen M.; Lindsley, Craig W.; Hopkins, Corey R.] Vanderbilt Univ, Med Ctr, Vanderbilt Ctr Neurosci Drug Discovery, Nashville, TN 37232 USA.
[Salovich, James M.; Vinson, Paige N.; Sheffler, Douglas J.; Lamsal, Atin; Utley, Thomas J.; Blobaum, Anna L.; Bridges, Thomas M.; Le, Uyen; Jones, Carrie K.; Wood, Michael R.; Daniels, J. Scott; Conn, P. Jeffrey; Niswender, Colleen M.; Lindsley, Craig W.; Hopkins, Corey R.] Vanderbilt Specialized Chem Ctr Probe Dev MLPCN, Nashville, TN 37232 USA.
[Jones, Carrie K.] Tennessee Valley Healthcare Syst, US Dept Vet Affairs, Nashville, TN 37232 USA.
RP Hopkins, CR (reprint author), Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA.
EM corey.r.hopkins@vanderbilt.edu
FU NIMH NIH HHS [R01 MH073676, U01 MH087965, U19 MH097056, U54 MH084659,
U54MH084659]
NR 15
TC 12
Z9 12
U1 1
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-894X
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD AUG 1
PY 2012
VL 22
IS 15
BP 5084
EP 5088
DI 10.1016/j.bmcl.2012.05.109
PG 5
WC Chemistry, Medicinal; Chemistry, Organic
SC Pharmacology & Pharmacy; Chemistry
GA 975BG
UT WOS:000306481100034
PM 22738637
ER
PT J
AU Dording, CM
Mischoulon, D
Shyu, I
Alpert, JE
Papakostas, GI
AF Dording, C. M.
Mischoulon, D.
Shyu, I.
Alpert, J. E.
Papakostas, G. I.
TI SAMe and sexual functioning
SO EUROPEAN PSYCHIATRY
LA English
DT Article
DE Antidepressants; Side effects; Major Depressive Disorder; S-adenosyl
methionine; Antidepressant-induced sexual dysfunction
ID MAJOR DEPRESSIVE DISORDER; SEROTONIN REUPTAKE INHIBITORS;
ADENOSYL-L-METHIONINE; S-ADENOSYLMETHIONINE; DYSFUNCTION; TRIAL;
RELAPSE; SAM
AB Background: Sexual dysfunction is a known side effect of antidepressant treatment (ADT), affecting up to 58-73% of those who receive ADT, potentially affecting antidepressant adherence. Consequently, it is vital to develop novel treatments that target antidepressant-induced sexual dysfunction.
Methods: We examined whether adjunctive S-adenosyl-L-methionine (SAMe) is associated with greater improvement in sexual functioning than adjunctive placebo by measuring changes in sexual functioning using the Massachusetts General Hospital-Sexual Functioning Questionnaire (MGH-SFQ) during a 6-week, single-center, randomized, double-blind trial of SAMe augmentation for SSRI/SNRI-nonresponders.
Results: Controlling for the degree of arousal dysfunction at baseline as well as the degree of change in HDRS-17 scale scores during the course of the study, men treated with adjunctive SAMe demonstrated significantly lower arousal dysfunction at endpoint than those treated with adjunctive placebo. In addition, controlling for the degree of erectile dysfunction at baseline as well as the degree of change in HDRS-17 scale scores, men treated with adjunctive SAMe demonstrated significantly lower erectile dysfunction at endpoint than those treated with adjunctive placebo.
Conclusions: In the present study, we have observed that adjunctive SAMe can have positive benefit on male arousal and erectile dysfunction, independent of improvement in depressive symptoms. These findings are preliminary, and warrant replication.
C1 [Dording, C. M.; Mischoulon, D.; Shyu, I.; Alpert, J. E.; Papakostas, G. I.] Massachusetts Gen Hosp, Depress Clin & Res Program, Dept Psychiat, Boston, MA 02114 USA.
RP Dording, CM (reprint author), Massachusetts Gen Hosp, Depress Clin & Res Program, Dept Psychiat, 1 Bowdoin Sq,6th Floor, Boston, MA 02114 USA.
EM cdording@partners.org
RI Papakostas, George/I-6905-2013;
OI Papakostas, George/0000-0002-2465-5103; Alpert,
Jonathan/0000-0002-4332-908X
FU NIMH [5K23 MH069629]; Abbott Laboratories; Alkermes; Aspect Medical
Systems; Astra-Zeneca; Bristol-Myers Squibb Company; Cephalon; Eli Lilly
Company; Forest Pharmaceuticals Inc.; GlaxoSmithkline; J & J
Pharmaceuticals; Lichtwer Pharma GmbH; Lorex Pharmaceuticals; Novartis;
Organon Inc.; PamLab, LLC; Pfizer Inc; Pharmavite; Roche;
Sanofi-Aventis; Solvay Pharmaceuticals, Inc.; Synthelabo; Wyeth-Ayerst
Laboratories
FX This study was funded by NIMH grant 5K23 MH069629.; C. M. D. has
received research support from Abbott Laboratories, Alkermes, Aspect
Medical Systems, Astra-Zeneca, Bristol-Myers Squibb Company, Cephalon,
Eli Lilly & Company, Forest Pharmaceuticals Inc., GlaxoSmithkline, J & J
Pharmaceuticals, Lichtwer Pharma GmbH, Lorex Pharmaceuticals, Novartis,
Organon Inc., PamLab, LLC, Pfizer Inc, Pharmavite, Roche,
Sanofi-Aventis, Solvay Pharmaceuticals, Inc., Synthelabo, Wyeth-Ayerst
Laboratories; has served as an advisor/consultant for Takeda; and has
been a speaker for Wyeth-Ayerst Laboratories.
NR 19
TC 10
Z9 10
U1 0
U2 2
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI PARIS
PA 23 RUE LINOIS, 75724 PARIS, FRANCE
SN 0924-9338
J9 EUR PSYCHIAT
JI Eur. Psychiat.
PD AUG
PY 2012
VL 27
IS 6
BP 451
EP 454
DI 10.1016/j.eurpsy.2011.01.003
PG 4
WC Psychiatry
SC Psychiatry
GA 974ZP
UT WOS:000306476500013
PM 21398094
ER
PT J
AU Foye, OT
Huang, IF
Chiou, CC
Walker, WA
Shi, HN
AF Foye, Ondulla T.
Huang, I-Fei
Chiou, Christine C.
Walker, W. Allan
Shi, Hai Ning
TI Early administration of probiotic Lactobacillus acidophilus and/or
prebiotic inulin attenuates pathogen-mediated intestinal inflammation
and Smad 7 cell signaling
SO FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY
LA English
DT Article
DE probiotics; prebiotics; synbiotic; enteric pathogens; cell signaling
ID NF-KAPPA-B; TGF-BETA; CITROBACTER-RODENTIUM; EPITHELIAL-CELLS;
ESCHERICHIA-COLI; IMMUNE-RESPONSES; BOWEL-DISEASE; HUMAN-MILK; NEGATIVE
REGULATION; GUT INFLAMMATION
AB Immaturity of gut-associated immunity may contribute to pediatric mortality associated with enteric infections. A murine model to parallel infantile enteric disease was used to determine the effects of probiotic, Lactobacillus acidophilus (La), prebiotic, inulin, or both (synbiotic, syn) on pathogen-induced inflammatory responses, NF-?B, and Smad 7 signaling. Newborn mice were inoculated bi-weekly for 4 similar to weeks with La, inulin, or syn and challenged with Citrobacter rodentium (Cr) at 5 similar to weeks. Mouse intestinal epithelial cells (CMT93) were exposed to Cr to determine temporal alterations in NF-Kappa B and Smad 7 levels. Mice with pretreatment of La, inulin, and syn show reduced intestinal inflammation following Cr infection compared with controls, which is associated with significantly reduced bacterial colonization in La, inulin, and syn animals. Our results further show that host defense against Cr infection correlated with enhanced colonic IL-10 and transforming growth factor-beta expression and inhibition of NF-?B in syn-treated mice, whereas mice pretreated with syn, La, or inulin had attenuation of Cr-induced Smad 7 expression. There was a temporal Smad 7 and NF-?B intracellular accumulation post-Cr infection and post-tumor necrosis factor stimulation in CMT93 cells. These results, therefore, suggest that probiotic, La, prebiotic inulin, or synbiotic may promote host-protective immunity and attenuate Cr-induced intestinal inflammation through mechanisms affecting NF-?B and Smad 7 signaling.
C1 [Foye, Ondulla T.; Huang, I-Fei; Walker, W. Allan; Shi, Hai Ning] Massachusetts Gen Hosp, Mucosal Immunol Lab, Charlestown, MA 02129 USA.
[Foye, Ondulla T.; Huang, I-Fei; Walker, W. Allan; Shi, Hai Ning] Harvard Univ, Sch Med, Charlestown, MA USA.
[Huang, I-Fei; Chiou, Christine C.] Kaohsiung Vet Gen Hosp, Dept Pediat, Kaohsiung, Taiwan.
[Huang, I-Fei; Chiou, Christine C.] Natl Yang Ming Univ, Taipei 112, Taiwan.
RP Shi, HN (reprint author), Massachusetts Gen Hosp, Mucosal Immunol Lab, Bldg 114,16th St,Room 3504, Charlestown, MA 02129 USA.
EM shiha@helix.mgh.harvard.edu
FU Clinical Nutrition Research Center at Harvard [P30 DK040561]; Kaohsiung
Veterans General Hospital, National Yang-Ming University, Taiwan;
[R21DK074727]; [R01DK082427]
FX This work was supported by R21DK074727 and R01DK082427 (to H.N.S.) and
the Clinical Nutrition Research Center at Harvard (P30 DK040561) (to W.
A. W.). I-F.H. is sponsored by Kaohsiung Veterans General Hospital,
National Yang-Ming University, Taiwan. The authors also acknowledge Drs
Bobby J. Cherayil and Michelle Conroy for their critical review of the
manuscript.
NR 63
TC 16
Z9 17
U1 0
U2 12
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0928-8244
EI 1574-695X
J9 FEMS IMMUNOL MED MIC
JI FEMS Immunol. Med. Microbiol.
PD AUG
PY 2012
VL 65
IS 3
BP 467
EP 480
DI 10.1111/j.1574-695X.2012.00978.x
PG 14
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 975NA
UT WOS:000306516800008
PM 22524476
ER
PT J
AU Abu Dayyeh, BK
Jirapinyo, P
Weitzner, Z
Barker, C
Flicker, MS
Lautz, DB
Thompson, CC
AF Abu Dayyeh, Barham K.
Jirapinyo, Pichamol
Weitzner, Zachary
Barker, Charlotte
Flicker, Michael S.
Lautz, David B.
Thompson, Christopher C.
TI Endoscopic sclerotherapy for the treatment of weight regain after
Roux-en-Y gastric bypass: outcomes, complications, and predictors of
response in 575 procedures
SO GASTROINTESTINAL ENDOSCOPY
LA English
DT Article
ID BARIATRIC SURGERY; DILATED GASTROJEJUNOSTOMY; ENERGY-EXPENDITURE; SODIUM
MORRHUATE; GHRELIN; OBESITY; HYPERTENSION; TRENDS; STOMA; GAIN
AB Background: Weight regain after Roux-en-Y gastric bypass (RYGB) is common. Endoscopic sclerotherapy is increasingly used to treat this weight regain.
Objectives: To report safety, outcomes, durability, and predictors of response to sclerotherapy in a large prospective cohort.
Design: Retrospective analysis of a prospective cohort study of patients with weight regain after RYGB.
Patients: A total of 231 consecutive patients undergoing 575 sclerotherapy procedures between September 2008 and March 2011.
Interventions: Single or multiple sclerotherapy procedures to inject sodium morrhuate into the rim of the gastrojejunal anastomosis.
Main Outcome Measurements: We report weight loss, complications, and predictors of response. We also used Kaplan-Meier survival analysis and log-rank test to compare time to continuation of weight regain after sclerotherapy in patients undergoing a single versus multiple sclerotherapy procedures.
Results: At 6 and 12 months from the last sclerotherapy procedure, weight regain stabilized in 92% and 78% of the cohort, respectively. Those who underwent 2 or 3 sclerotherapy sessions had significantly higher rates of weight regain stabilization than those who underwent a single session (90% vs 60% at 12 months; P = .003). The average weight loss at 6 months from the last sclerotherapy session for the entire cohort was 10 lb (standard deviation 16), representing 18% of the weight regained after RYGB. A subset of 73 patients (32% of the cohort) had greater weight loss at 6 months (26 lb, standard deviation 12), representing 61% of the weight regained. Predictors of a favorable outcome included greater weight regain and the number of sclerotherapy procedures. Bleeding was reported in 2.4% of procedures and transient diastolic blood pressure increases in 15%, without adverse health outcomes. No GI perforations were reported.
Conclusions: Endoscopic sclerotherapy appears to be a safe and effective tool for the management of weight regain after RYGB. (Gastrointest Endosc 2012;76:275-82.)
C1 [Abu Dayyeh, Barham K.; Jirapinyo, Pichamol; Weitzner, Zachary; Barker, Charlotte; Flicker, Michael S.; Thompson, Christopher C.] Brigham & Womens Hosp, Div Gastroenterol, Boston, MA 02115 USA.
[Lautz, David B.] Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA.
[Abu Dayyeh, Barham K.; Jirapinyo, Pichamol; Flicker, Michael S.; Lautz, David B.; Thompson, Christopher C.] Harvard Univ, Sch Med, Boston, MA USA.
[Abu Dayyeh, Barham K.] Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA.
[Abu Dayyeh, Barham K.] Mayo Clin, Div Gastroenterol & Hepatol, Rochester, MN USA.
RP Thompson, CC (reprint author), Brigham & Womens Hosp, Div Gastroenterol, 75 Francis St,Thorn 14, Boston, MA 02115 USA.
FU T32 National Institutes of Health [T32DK007191]
FX The following author disclosed financial relationships relevant to this
publication: Dr Thompson: consultant to and research grant from Olympus.
The other authors disclosed no financial relationships relevant to this
publication. This project was supported in part by a T32 National
Institutes of Health training grant to the Massachusetts General
Hospital and Dr. Abu Dayyeh (T32DK007191).
NR 31
TC 16
Z9 16
U1 0
U2 2
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0016-5107
J9 GASTROINTEST ENDOSC
JI Gastrointest. Endosc.
PD AUG
PY 2012
VL 76
IS 2
BP 275
EP 282
DI 10.1016/j.gie.2012.03.1407
PG 8
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 975OK
UT WOS:000306520400007
PM 22817783
ER
PT J
AU Babacan, SD
Luessi, M
Molina, R
Katsaggelos, AK
AF Babacan, S. Derin
Luessi, Martin
Molina, Rafael
Katsaggelos, Aggelos K.
TI Sparse Bayesian Methods for Low-Rank Matrix Estimation
SO IEEE TRANSACTIONS ON SIGNAL PROCESSING
LA English
DT Article
DE Bayesian methods; low-rankness; matrix completion; outlier detection;
robust principal component analysis; sparse Bayesian learning; sparsity;
variational Bayesian inference
ID PRINCIPAL COMPONENT ANALYSIS; APPROXIMATION
AB Recovery of low-rank matrices has recently seen significant activity in many areas of science and engineering, motivated by recent theoretical results for exact reconstruction guarantees and interesting practical applications. In this paper, we present novel recovery algorithms for estimating low-rank matrices in matrix completion and robust principal component analysis based on sparse Bayesian learning (SBL) principles. Starting from a matrix factorization formulation and enforcing the low-rank constraint in the estimates as a sparsity constraint, we develop an approach that is very effective in determining the correct rank while providing high recovery performance. We provide connections with existing methods in other similar problems and empirical results and comparisons with current state-of-the-art methods that illustrate the effectiveness of this approach.
C1 [Babacan, S. Derin] Univ Illinois, Beckman Inst Adv Sci & Technol, Urbana, IL 61801 USA.
[Luessi, Martin] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Martinos Ctr Biomed Imaging,Dept Radiol, Cambridge, MA 02139 USA.
[Molina, Rafael] Univ Granada, Dept Ciencias Comp & IA, E-18071 Granada, Spain.
[Katsaggelos, Aggelos K.] Northwestern Univ, Dept Elect Engn & Comp Sci, Evanston, IL 60208 USA.
RP Babacan, SD (reprint author), Univ Illinois, Beckman Inst Adv Sci & Technol, Urbana, IL 61801 USA.
EM dbabacan@illinois.edu; mluessi@nmr.mgh.harvard.edu; rms@decsai.ugr.es;
aggk@eecs.northwestern.edu
RI Katsaggelos, Aggelos/B-7233-2009; Katsaggelos, Aggelos/I-8002-2012;
Molina Soriano, Rafael/B-1849-2012
OI Molina Soriano, Rafael/0000-0003-4694-8588
FU Beckman Institute; Ministerio de Ciencia e Innovacion [TIN2010-15137];
Spanish research program Consolider Ingenio: MIPRCV [CSD2007-00018];
Department of Energy [DE-NA0000457]
FX This work was supported in part by the Beckman Institute postdoctoral
fellowship, "Ministerio de Ciencia e Innovacion" under contract
TIN2010-15137, the Spanish research program Consolider Ingenio 2010:
MIPRCV (CSD2007-00018), and a grant from the Department of Energy
(DE-NA0000457).
NR 50
TC 62
Z9 66
U1 7
U2 35
PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC
PI PISCATAWAY
PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA
SN 1053-587X
J9 IEEE T SIGNAL PROCES
JI IEEE Trans. Signal Process.
PD AUG
PY 2012
VL 60
IS 8
BP 3964
EP 3977
DI 10.1109/TSP.2012.2197748
PG 14
WC Engineering, Electrical & Electronic
SC Engineering
GA 975NF
UT WOS:000306517300004
ER
PT J
AU Smith, EG
Zhao, SB
Rosen, AK
AF Smith, Eric G.
Zhao, Shibei
Rosen, Amy K.
TI Using the patient safety indicators to detect potential safety events
among US veterans with psychotic disorders: clinical and research
implications
SO INTERNATIONAL JOURNAL FOR QUALITY IN HEALTH CARE
LA English
DT Article
DE hospital care; quality indicators; patient outcomes (health status;
quality of life; mortality); safety indicators; pressure ulcers;
appropriateness; under-use and over-use; mental health disorders;
psychosis; respiratory failure
ID SERIOUS MENTAL-ILLNESS; HEALTH-CARE RESEARCH; QUALITY IMPROVEMENT;
ADMINISTRATIVE DATA; ADVERSE EVENTS; MEDICAL COMORBIDITY; BIPOLAR
DISORDER; INCREASED RISK; SCHIZOPHRENIA; MORTALITY
AB Patients with psychotic disorders often experience poorer health outcomes, but whether they experience increased risks of medical errors/patient safety events is less clear. A single state-level US study found acute care inpatients with schizophrenia were at higher risk of incurring some of the Agency for Healthcare Research and Quality (AHRQ) patient safety indicators (PSIs). We examined a nationwide sample of US Veterans Health Administration (VHA) acute care inpatients to determine the rates observed among patients with psychotic disorders for a larger set of PSIs.
Retrospective cohort analysis using administrative data.
Veterans with (n 50 328) and without (n 1 812 897) psychotic disorders (schizophrenia/schizoaffective disorder and other psychoses) admitted for acute care to US VHA hospitals during fiscal years 200306.
PSI rates were calculated using AHRQs PSI software.
Patients with psychotic disorders had significantly higher rates of postoperative respiratory failure, postoperative wound dehiscence and decubitus ulcer than those without psychotic disorders, although postoperative respiratory failures rates were not significantly higher among patients specifically diagnosed with schizophrenia. Patients with psychotic disorders had significantly lower rates of accidental puncture/laceration, foreign body left in during procedure and failure to rescue. However, the odds of failure to rescue were not significantly lower among surgical patients (the current focus of this PSI).
Acute care inpatient veterans with psychotic disorders experienced higher rates of several PSIs, but lower rates of others. Whether lower rates of certain PSIs reflect better or worse care for this population is uncertain.
C1 [Smith, Eric G.; Zhao, Shibei] ENRM VA Med Ctr, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA 01730 USA.
[Smith, Eric G.] Univ Massachusetts, Sch Med, Dept Psychiat, Worcester, MA 01655 USA.
[Rosen, Amy K.] VA Boston HealthCare Syst, Ctr Org Leadership & Management Res, Boston, MA 02130 USA.
[Rosen, Amy K.] Boston Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02215 USA.
RP Smith, EG (reprint author), Bedford VAMC 152, Ctr Hlth Qual Outcomes & Econ Res, 200 Springs Rd, Bedford, MA 01730 USA.
EM eric.smith5@va.gov
FU Department of Veterans Affairs, Veterans Health Administration, Health
Services Research and Development Service [IIR-02-44-1]; Veterans Health
Administration Health Services Research and Development Service Career
Development Award
FX This work was supported by a grant (IIR-02-44-1, from the Department of
Veterans Affairs, Veterans Health Administration, Health Services
Research and Development Service), to A. M. R. E. G. S. is supported by
a Veterans Health Administration Health Services Research and
Development Service Career Development Award.
NR 42
TC 2
Z9 2
U1 4
U2 5
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1353-4505
J9 INT J QUAL HEALTH C
JI Int. J. Qual. Health Care
PD AUG
PY 2012
VL 24
IS 4
BP 321
EP 329
DI 10.1093/intqhc/mzs026
PG 9
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA 974DX
UT WOS:000306411100002
PM 22718516
ER
PT J
AU Grover, S
Kastrinos, F
Steyerberg, EW
Cook, EF
Dewanwala, A
Burbidge, LA
Wenstrup, RJ
Syngal, S
AF Grover, Shilpa
Kastrinos, Fay
Steyerberg, Ewout W.
Cook, E. Francis
Dewanwala, Akriti
Burbidge, Lynn Anne
Wenstrup, Richard J.
Syngal, Sapna
TI Prevalence and Phenotypes of APC and MUTYH Mutations in Patients With
Multiple Colorectal Adenomas
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Article
ID GERM-LINE MUTATIONS; MYH GENE-MUTATIONS; POLYPOSIS PATIENTS; CANCER
PATIENTS; FAMILIES; FAP; CHROMOSOME-5Q21; IDENTIFICATION; EXPRESSION;
GUIDELINES
AB Context Patients with multiple colorectal adenomas may carry germline mutations in the APC or MUTYH genes.
Objectives To determine the prevalence of pathogenic APC and MUTYH mutations in patients with multiple colorectal adenomas who had undergone genetic testing and to compare the prevalence and clinical characteristics of APC and MUTYH mutation carriers.
Design, Setting, and Participants Cross-sectional study conducted among 8676 individuals who had undergone full gene sequencing and large rearrangement analysis of the APC gene and targeted sequence analysis for the 2 most common MUTYH mutations (Y179C and G396D) between 2004 and 2011. Individuals with either mutation underwent full MUTYH gene sequencing. APC and MUTYH mutation prevalence was evaluated by polyp burden; the clinical characteristics associated with a pathogenic mutation were evaluated using logistic regression analyses.
Main Outcome Measure Prevalence of pathogenic mutations in APC and MUTYH genes.
Results Colorectal adenomas were reported in 7225 individuals; 1457 with classic polyposis (>= 100 adenomas) and 3253 with attenuated polyposis (20-99 adenomas). The prevalence of pathogenic APC and biallelic MUTYH mutations was 95 of 119 (80% [95% CI, 71%-87%]) and 2 of 119 (2% [95% CI, 0.2%-6%]), respectively, among individuals with 1000 or more adenomas, 756 of 1338 (56% [95% CI, 54%-59%]) and 94 of 1338 (7% [95% CI, 6%-8%]) among those with 100 to 999 adenomas, 326 of 3253 (10% [95% CI, 9%-11%]) and 233 of 3253 (7% [95% CI, 6%-8%]) among those with 20 to 99 adenomas, and 50 of 970 (5% [95% CI, 4%-7%]) and 37 of 970 (4% [95% CI, 3%-5%]) among those with 10 to 19 adenomas. Adenoma count was strongly associated with a pathogenic mutation in multivariable analyses.
Conclusions Among patients with multiple colorectal adenomas, pathogenic APC and MUTYH mutation prevalence varied considerably by adenoma count, including within those with a classic polyposis phenotype. APC mutations predominated in patients with classic polyposis, whereas prevalence of APC and MUTYH mutations was similar in attenuated polyposis. These findings require external validation. JAMA. 2012;308(5):485-492 www.jama.com
C1 [Grover, Shilpa; Dewanwala, Akriti; Syngal, Sapna] Dana Farber Canc Inst, Div Populat Sci, Boston, MA 02215 USA.
[Grover, Shilpa; Syngal, Sapna] Brigham & Womens Hosp, Div Gastroenterol, Boston, MA 02115 USA.
[Grover, Shilpa; Syngal, Sapna] Harvard Univ, Sch Med, Boston, MA USA.
[Cook, E. Francis] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
[Grover, Shilpa] Massachusetts Gen Hosp, Program Canc Outcomes Res Training, Boston, MA 02114 USA.
[Kastrinos, Fay] Columbia Univ, Med Ctr, New York, NY USA.
[Kastrinos, Fay] Herbert Irving Comprehens Canc Ctr, New York, NY USA.
[Steyerberg, Ewout W.] Erasmus MC, Ctr Med Decis Making, Rotterdam, Netherlands.
[Burbidge, Lynn Anne; Wenstrup, Richard J.] Myriad Genet Labs Inc, Salt Lake City, UT USA.
RP Syngal, S (reprint author), Dana Farber Canc Inst, Div Populat Sci, 450 Brookline Ave, Boston, MA 02215 USA.
EM ssyngal@partners.org
OI Steyerberg, Ewout/0000-0002-7787-0122
FU National Cancer Institute [R25 CA 092203, K07 CA151769]; National
Institutes of Health [K24113433]; Myriad Genetics Laboratories Inc.
FX This study was supported by National Cancer Institute grants R25 CA
092203 (Dr Grover) and K07 CA151769 (Dr Kastrinos) and by National
Institutes of Health grant K24113433 (Dr Syngal).; Independent
Statistical Analysis: Data sets were forwarded by investigators at
Myriad Genetics Laboratories Inc to independent investigators at the
Dana-Farber Cancer Institute, Boston, Massachusetts (Drs Grover and
Syngal) and the Herbert Irving Comprehensive Cancer Center, New York,
New York (Dr Kastrinos). Drs Grover, Kastrinos, and Steyerberg (Center
for Medical Decision Making, Erasmus Medical Center, Rotterdam, the
Netherlands) performed independent statistical analyses. All results
reported in the article are from the independent statistical analyses.
None of the coauthors not employed by Myriad Genetics Laboratories Inc
received any funding for the study from Myriad Genetics Laboratories
Inc.
NR 36
TC 47
Z9 47
U1 2
U2 8
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD AUG 1
PY 2012
VL 308
IS 5
BP 485
EP 492
DI 10.1001/jama.2012.8780
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA 981DQ
UT WOS:000306947400026
PM 22851115
ER
PT J
AU Teodorescu, M
Polomis, DA
Teodorescu, MC
Gangnon, RE
Peterson, AG
Consens, FB
Chervin, RD
Jarjour, NN
AF Teodorescu, Mihaela
Polomis, David A.
Teodorescu, Mihai C.
Gangnon, Ronald E.
Peterson, Andrea G.
Consens, Flavia B.
Chervin, Ronald D.
Jarjour, Nizar N.
TI Association of Obstructive Sleep Apnea Risk or Diagnosis with Daytime
Asthma in Adults
SO JOURNAL OF ASTHMA
LA English
DT Article
DE asthma; asthma control; obstructive sleep apnea; obstructive sleep apnea
risk; sleep
ID POSITIVE AIRWAY PRESSURE; HYPOXIA SUPPRESSES; NOCTURNAL ASTHMA; INDUCED
SPUTUM; DISEASE; QUESTIONNAIRE; INFLAMMATION; POPULATION; REFLUX; MODEL
AB Objective. Obstructive sleep apnea (OSA) worsens nocturnal asthma, but its potential impact on daytime asthma remains largely unassessed. We investigated whether the sleep disorder is associated with daytime, in addition to nighttime, asthma symptoms. Methods. Asthma patients at tertiary-care centers completed the Sleep Apnea scale of the Sleep Disorders Questionnaire (SA-SDQ), and an asthma control questionnaire. SA-SDQ scores >= 36 for males and >= 32 for females defined high OSA risk. Medical records were reviewed for established diagnosis of OSA and continuous positive airway pressure (CPAP) use. Results. Among 752 asthma patients, high OSA risk was associated similarly with persistent daytime and nighttime asthma symptoms (p < .0001 for each). A diagnosis of OSA was robustly associated with persistent daytime (p < .0001) in addition to nighttime (p = .0008) asthma symptoms. In regression models that included obesity and other known asthma aggravators, high OSA risk retained associations with persistent daytime (odds ratio [OR] = 1.96 [95% confidence interval [CI] = 1.31-2.94]) and nighttime (1.97 [1.32-2.94]) asthma symptoms. Diagnosed OSA retained an association with persistent daytime (2.08 [1.13-3.82]) but not with nighttime (1.48 [0.82-2.69]) asthma symptoms. CPAP use was associated with lower likelihood of persistent daytime symptoms (0.46 [0.23-0.94]). Conclusions. Questionnaire-defined OSA risk and historical diagnosis were each associated with persistent daytime asthma symptoms, to an extent that matched or exceeded associations with nighttime asthma symptoms. Unrecognized OSA may be a reason for persistent asthma symptoms during the day as well as the night.
C1 [Teodorescu, Mihaela; Polomis, David A.; Peterson, Andrea G.; Jarjour, Nizar N.] Univ Wisconsin, Sch Med & Publ Hlth, Sect Allergy Pulm & Crit Care Med, Madison, WI 53792 USA.
[Teodorescu, Mihaela; Teodorescu, Mihai C.] William S Middleton Mem Vet Adm Med Ctr, Med Serv, Madison, WI USA.
[Teodorescu, Mihai C.] Univ Wisconsin, Sch Med & Publ Hlth, Sect Geriatr & Gerontol, Madison, WI 53792 USA.
[Gangnon, Ronald E.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Biostat & Med Informat & Populat Hlth Sci, Madison, WI 53792 USA.
[Consens, Flavia B.; Chervin, Ronald D.] Univ Michigan Hlth Syst, Dept Neurol, Ann Arbor, MI USA.
[Consens, Flavia B.; Chervin, Ronald D.] Univ Michigan Hlth Syst, Sleep Disorders Ctr, Ann Arbor, MI USA.
RP Teodorescu, M (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Sect Allergy Pulm & Crit Care Med, K4-910 CSC 9988,600 Highland Ave, Madison, WI 53792 USA.
EM mt3@medicine.wisc.edu
FU National Institutes of Health [T32 NS007222, MO1 RR00042, 1UL1RR025011];
University of Wisconsin School of Medicine and Public Health, Medical
Education and Research Committee-New Investigator Award; University of
Wisconsin School of Medicine and Public Health Department of Medicine;
University of Michigan Department of Neurology Training Grant [T32
NS007222]; General Clinical Research Center [MO1 RR00042]; University of
Wisconsin School of Medicine and Public Health; Medical Education and
Research Committee-New Investigator Award; Department of Medicine;
Clinical and Translational Science Award (CTSA) program of the National
Center for Research Resources, National Institutes of Health
[1UL1RR025011]; William S. Middleton Memorial Veteran's Hospital,
Madison, Wisconsin; National Institutes of Health; Fox Foundation;
GlaxoSmithKline (GSK); Bristol Meyer Squib
FX Received funding support from the National Institutes of Health (nos.
T32 NS007222, MO1 RR00042, and 1UL1RR025011); the University of
Wisconsin School of Medicine and Public Health, Medical Education and
Research Committee-New Investigator Award; and the University of
Wisconsin School of Medicine and Public Health Department of Medicine.
Additional resources from the William S. Middleton Memorial Veteran's
Hospital, Madison, Wisconsin.; Funding support for this study was from
the University of Michigan Department of Neurology Training Grant (T32
NS007222) and General Clinical Research Center (MO1 RR00042); the
University of Wisconsin School of Medicine and Public Health, Medical
Education and Research Committee-New Investigator Award, Department of
Medicine, and 1UL1RR025011 from the Clinical and Translational Science
Award (CTSA) program of the National Center for Research Resources,
National Institutes of Health; and the William S. Middleton Memorial
Veteran's Hospital, Madison, Wisconsin.; Dr R.D. Chervin has received
research support from the National Institutes of Health and Fox
Foundation and has served on the advisory boards for Pavad Medical,
not-for-profit Sweet Dreamzzz, and the NHLBI (Sleep Disorders Research
Advisory Board). Chervin is a section editor for UpToDate, Inc.;
received support for educational purposes from Philips Respironics, Inc.
and Fisher Paykel, Inc.; and has consulted for Arena Pharmaceuticals,
Proctor & Gamble, and Zansors. Chervin serves on the Board of Directors
of the American Academy of Sleep Medicine and the International
Pediatric Sleep Association and is named in University of Michigan
patents for algorithms and devices to facilitate diagnosis and treatment
of sleep disorders.; Dr N.N. Jarjour received funding support from the
National Institutes of Health, GlaxoSmithKline (GSK), and Bristol Meyer
Squib, and received honorarium <$5000 from the Saudi Thoracic Society
for a GSK-supported continuing medical education program.
NR 49
TC 15
Z9 18
U1 1
U2 6
PU INFORMA HEALTHCARE
PI NEW YORK
PA 52 VANDERBILT AVE, NEW YORK, NY 10017 USA
SN 0277-0903
EI 1532-4303
J9 J ASTHMA
JI J. Asthma
PD AUG
PY 2012
VL 49
IS 6
BP 620
EP 628
DI 10.3109/02770903.2012.689408
PG 9
WC Allergy; Respiratory System
SC Allergy; Respiratory System
GA 974IH
UT WOS:000306426300011
PM 22742082
ER
PT J
AU Ferrer, RA
Klein, WMP
Zajac, LE
Land, SR
Ling, BS
AF Ferrer, Rebecca A.
Klein, William M. P.
Zajac, Laura E.
Land, Stephanie R.
Ling, Bruce S.
TI An affective booster moderates the effect of gain- and loss-framed
messages on behavioral intentions for colorectal cancer screening
SO JOURNAL OF BEHAVIORAL MEDICINE
LA English
DT Article
DE Message framing; Anticipated emotion; Anticipatory emotion; Colorectal
cancer screening
ID RISK PERCEPTIONS; HEALTH BEHAVIOR; ANTICIPATED REGRET; DECISION-MAKING;
INFLUENZA VACCINATION; FEAR APPEALS; BREAST; WORRY; MAMMOGRAPHY;
PREVENTION
AB Previous research has demonstrated that loss-framed messages are more effective than gain-framed messages in motivating detection behaviors such as screening. The present study examined whether affective context moderates the degree to which message frame is associated with behavioral intentions to engage in colorectal cancer screening. In particular, we buttressed a framing manipulation with an "affective booster" to increase anticipated and anticipatory emotions associated with the framed messages. Consistent with previous research, we found that loss-framed messages are more effective in increasing intentions to screen. However, we found that among individuals who received gain-framed messages (but not loss-framed messages), the affective booster increased message persuasiveness. This effect on intentions was partially mediated by self-efficacy for engaging in screening. This study indicates that in the presence of emotional boosters, loss-framed messages may lose their advantage over gain-framed messages in motivating detection behaviors, and that self-efficacy may partially explain these effects.
C1 [Ferrer, Rebecca A.; Klein, William M. P.] NCI, Behav Res Program, Div Canc Control & Populat Sci, Rockville, MD 20852 USA.
[Klein, William M. P.; Zajac, Laura E.] Univ Pittsburgh, Dept Psychol, Pittsburgh, PA 15260 USA.
[Land, Stephanie R.] Univ Pittsburgh, Dept Biostat, Pittsburgh, PA 15261 USA.
[Ling, Bruce S.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA.
RP Ferrer, RA (reprint author), NCI, Behav Res Program, Div Canc Control & Populat Sci, 6130 Execut Blvd,Room 4083, Rockville, MD 20852 USA.
EM ferrerra@mail.nih.gov
NR 63
TC 8
Z9 8
U1 4
U2 27
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0160-7715
J9 J BEHAV MED
JI J. Behav. Med.
PD AUG
PY 2012
VL 35
IS 4
BP 452
EP 461
DI 10.1007/s10865-011-9371-3
PG 10
WC Psychology, Clinical
SC Psychology
GA 974KS
UT WOS:000306434500009
PM 21850516
ER
PT J
AU Rowe, GC
Vialou, V
Sato, K
Saito, H
Yin, M
Green, TA
Lotinun, S
Kveiborg, M
Horne, WC
Nestler, EJ
Baron, R
AF Rowe, Glenn C.
Vialou, Vincent
Sato, Kazusa
Saito, Hiroaki
Yin, Min
Green, Thomas A.
Lotinun, Sutada
Kveiborg, Marie
Horne, William C.
Nestler, Eric J.
Baron, Roland
TI Energy expenditure and bone formation share a common sensitivity to AP-1
transcription in the hypothalamus
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE AP-1; HYPOTHALAMUS; ENERGY EXPENDITURE; BONE FORMATION
ID SYMPATHETIC-NERVOUS-SYSTEM; FOSB TRANSGENIC MICE; DELTA-FOSB; INSULIN
SENSITIVITY; NUCLEUS-ACCUMBENS; EXPRESSION; MASS; BRAIN; LEPTIN; COCAINE
AB The regulation of bone and fat homeostasis and its relationship to energy expenditure has recently been the focus of increased attention because of its potential relevance to osteoporosis, obesity, and diabetes. Although central effectors within the hypothalamus have been shown to contribute to the regulation of both energy balance and bone homeostasis, little is known of the underlying mechanisms, including the possible involvement of transcriptional factors within the hypothalamus. Transgenic mice overexpressing ?FosB, a splice variant of the AP-1 transcription factor FosB with mixed agonist-antagonistic properties, have increased energy expenditure and bone mass. Because these mice express ?FosB in bone, fat, and hypothalamus, we sought to determine 1) whether overexpression of ?FosB within the hypothalamus was sufficient to regulate energy expenditure and whether it would also regulate bone mass, and 2) whether these effects were the result of antagonism to AP-1. Our results show that stereotactic injection of an adeno-associated virus vector to restrict overexpression of ?FosB to the ventral hypothalamus of wild-type mice induced a profound increase in both energy expenditure and bone formation and bone mass. This effect was phenocopied, at an even stronger level, by overexpression of a dominant-negative DNJunD, a pure AP-1 antagonist. Taken together, these results suggest that downregulation of AP-1 activity in the hypothalamus profoundly increases energy expenditure and bone formation, leading to both a decrease in adipose mass and an increase in bone mass. These findings may have physiological implications because ?FosB is expressed and regulated in the hypothalamus. (C) 2012 American Society for Bone and Mineral Research.
C1 [Rowe, Glenn C.; Sato, Kazusa; Saito, Hiroaki; Yin, Min; Lotinun, Sutada; Kveiborg, Marie; Horne, William C.; Baron, Roland] Harvard Univ, Sch Dent Med, Dept Oral Med Infect & Immun, Boston, MA 02115 USA.
[Rowe, Glenn C.; Sato, Kazusa; Saito, Hiroaki; Yin, Min; Lotinun, Sutada; Kveiborg, Marie; Horne, William C.; Baron, Roland] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med,Endocrine Unit, Boston, MA 02115 USA.
[Vialou, Vincent; Green, Thomas A.; Nestler, Eric J.] Mt Sinai Sch Med, Fishberg Dept Neurosci, New York, NY USA.
[Vialou, Vincent; Green, Thomas A.; Nestler, Eric J.] Mt Sinai Sch Med, Friedman Brain Inst, New York, NY USA.
RP Baron, R (reprint author), Harvard Univ, Sch Dent Med, Dept Oral Med, 188 Longwood Ave, Boston, MA 02115 USA.
EM roland_baron@hsdm.harvard.edu
RI vialou, vincent/F-2968-2013;
OI vialou, vincent/0000-0002-8212-751X; Kveiborg,
Marie/0000-0002-1293-1019; Lotinun, Sutada/0000-0002-5127-3039
FU NIA [AG 040222]; NIMH [MH51399]; UNCF-Merck Dissertation Fellowship;
NIH, NIAMS [AR 048218]
FX This work was supported by grants from the NIH, NIAMS (AR 048218), and
NIA (AG 040222) to RB, NIMH (MH51399) to EJN, and a UNCF-Merck
Dissertation Fellowship to GCR.
NR 49
TC 5
Z9 5
U1 0
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0884-0431
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD AUG
PY 2012
VL 27
IS 8
BP 1649
EP 1658
DI 10.1002/jbmr.1618
PG 10
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 974XQ
UT WOS:000306471300005
PM 22461201
ER
PT J
AU Yang, DQ
Feng, SM
Chen, W
Zhao, HB
Paulson, C
Li, YP
AF Yang, De-Qin
Feng, Shengmei
Chen, Wei
Zhao, Haibo
Paulson, Christie
Li, Yi-Ping
TI V-ATPase subunit ATP6AP1 (Ac45) regulates osteoclast differentiation,
extracellular acidification, lysosomal trafficking, and protease
exocytosis in osteoclast-mediated bone resorption
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE V-ATPase SUBUNIT ATP6AP1 (Ac45); OSTEOCLAST; LYSOSOMAL TRAFFICKING;
PROTEASE EXOCYTOSIS; BONE RESORPTION
ID VACUOLAR H+-ATPASE; INTRACELLULAR MEMBRANE TRAFFICKING; PROTON PUMP;
RUFFLED BORDER; RESORBING OSTEOCLASTS; VESICULAR TRAFFICKING; ESSENTIAL
COMPONENT; PLASMA-MEMBRANE; DC-STAMP; F-ACTIN
AB Lysosomal trafficking and protease exocytosis in osteoclasts are essential for ruffled border formation and bone resorption. Yet the mechanism underlying lysosomal trafficking and the related process of exocytosis remains largely unknown. We found ATP6ap1 (Ac45), an accessory subunit of vacuolar-type H+-ATPases (V-ATPases), to be highly induced by receptor activator for nuclear factor kappa B ligand (RANKL) in osteoclast differentiation. Ac45 knockdown osteoclasts formed normal actin rings, but had severely impaired extracellular acidification and bone resorption. Ac45 knockdown significantly reduced osteoclast formation. The decrease in the number of osteoclasts does not result from abnormal apoptosis; rather, it results from decreased osteoclast precursor cell proliferation and fusion, which may be partially due to the downregulation of extracellular signal-regulated kinase (ERK) phosphorylation and FBJ osteosarcoma oncogene (c-fos), nuclear factor of activated T-cells, cytoplasmic 1 (NFATc1), and transmembrane 7 superfamily member 4 (Tm7sf4) expression. Notably, Ac45 knockdown osteoclasts exhibited impaired lysosomal trafficking and exocytosis, as indicated by the absence of lysosomal trafficking to the ruffled border and a lack of cathepsin K exocytosis into the resorption lacuna. Our data revealed that the impaired exocytosis is specifically due to Ac45 deficiency, and not the general consequence of a defective V-ATPase. Together, our results demonstrate the essential role of Ac45 in osteoclast-mediated extracellular acidification and protease exocytosis, as well as the ability of Ac45 to guide lysosomal intracellular trafficking to the ruffled border, potentially through its interaction with the small guanosine-5'-triphosphatase (GTPase) Rab7. Our work indicates that Ac45 may be a novel therapeutic target for osteolytic disease. (C) 2012 American Society for Bone and Mineral Research.
C1 [Yang, De-Qin; Feng, Shengmei; Chen, Wei; Paulson, Christie; Li, Yi-Ping] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA.
[Yang, De-Qin; Feng, Shengmei; Chen, Wei; Paulson, Christie; Li, Yi-Ping] Forsyth Inst, Dept Cytokine Biol, Boston, MA USA.
[Yang, De-Qin] Stomatol Hosp, Zunyi Med Coll, Zunyi, Guizhou Provinc, Peoples R China.
[Yang, De-Qin] Chongqing Med Univ, Affiliated Hosp Stomatol, Chongqing, Peoples R China.
[Feng, Shengmei] Shanghai Jiao Tong Univ, Sch Med, Shanghai Key Lab Prevent & Treatment Bone & Joint, Shanghai Inst Trauma & Orthopaed,Ruijin Hosp, Shanghai 200030, Peoples R China.
[Zhao, Haibo] Univ Arkansas Med Sci, Coll Med, Dept Internal Med, Little Rock, AR 72205 USA.
RP Li, YP (reprint author), Univ Alabama Birmingham, Dept Pathol, SHEL 810,1825 Univ Blvd, Birmingham, AL 35294 USA.
EM ypli@uab.edu
FU NIH [AR-44741, AR-055307]; Talents Training Program for Western China of
China Scholarship Council
FX We express our deep gratitude to Dr. Weiguo Zou for his excellent help
in the selection of siRNA. We also thank Dr. Lai Ding, Dr. Daniel Tom,
and Dr. Shawn R Williams for their excellent technical assistance in
confocal microscopy and three-dimensional reconstruction. We thank Dr.
Peter V. Hauschka (Children's Hospital Boston) for providing us with
dentin slices. This work was supported by NIH grants: AR-44741 (Y-PL)
and AR-055307 (Y-PL), and by the Talents Training Program for Western
China of China Scholarship Council.
NR 40
TC 15
Z9 15
U1 4
U2 15
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0884-0431
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD AUG
PY 2012
VL 27
IS 8
BP 1695
EP 1707
DI 10.1002/jbmr.1623
PG 13
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 974XQ
UT WOS:000306471300009
PM 22467241
ER
PT J
AU Gill, JS
Wang, HB
Alston, TA
AF Gill, Jatinder S.
Wang, Haibin
Alston, Theodore A.
TI An Unusual Cause for an Irregularly Irregular Pulse
SO JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA
LA English
DT Article
DE arrhythmia; electromechanical dissociation; pulseless electrical
activity
ID ELECTROMECHANICAL DISSOCIATION; AUTO-PEEP
C1 [Gill, Jatinder S.; Wang, Haibin; Alston, Theodore A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anesthesia Crit Care & Pain Med, Boston, MA USA.
RP Gill, JS (reprint author), Beth Israel Deaconess Med Ctr, Dept Anesthesia Crit Care & Pain Med, 330 Brookline Ave, Boston, MA 02215 USA.
EM jsgill@bidmc.harvard.edu
NR 6
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 1053-0770
J9 J CARDIOTHOR VASC AN
JI J. Cardiothorac. Vasc. Anesth.
PD AUG
PY 2012
VL 26
IS 4
BP 751
EP 752
DI 10.1053/j.jvca.2011.04.004
PG 2
WC Anesthesiology; Cardiac & Cardiovascular Systems; Respiratory System;
Peripheral Vascular Disease
SC Anesthesiology; Cardiovascular System & Cardiology; Respiratory System
GA 974PK
UT WOS:000306448500036
PM 21684765
ER
PT J
AU Sulemanji, DS
Bloom, JD
Dzik, WH
Jiang, YD
AF Sulemanji, Demet S.
Bloom, Jonathan D.
Dzik, Walter H.
Jiang, Yandong
TI New insights into the effect of rapid transfusion of fresh frozen plasma
on ionized calcium
SO JOURNAL OF CLINICAL ANESTHESIA
LA English
DT Article
DE Cardiac output; Citrate; Fresh frozen plasma; Hypocalcemia; Ionized
calcium; Transfusion
ID CARDIAC PURKINJE-CELL; VENTRICULAR PUMP PERFORMANCE; MASSIVE
BLOOD-TRANSFUSIONS; SARCOPLASMIC-RETICULUM; ANESTHETIZED MAN; CAPILLARY
BLOOD; SODIUM-CITRATE; SERUM; ION; HYPOCALCEMIA
AB Study Objectives: 1) To develop an in vitro system to simulate the kinetics of ionized calcium in mixed venous blood during rapid transfusion of fresh frozen plasma (FFP) and 2) to use the in vitro data to estimate the effect of the transfusion rate relative to cardiac output (CO) on ionized calcium.
Design: Experimental study.
Setting: Research laboratory of an academic hospital.
Measurements: Citrated FFP was mixed with compatible heparinized whole blood at various volume ratios in vitro to simulate the mixed venous blood obtained at various flow ratios of FFP transfusion to the recipient's venous system in vivo. Ionized calcium was measured after each mixture.
Main Results: Mixing FFP and whole blood at volume ratios of 0:100, 5:95, 10:90, and 15:85 yielded ionized calcium levels (mean +/- SD, mmol/L) of 1.23, 0.81 +/- 0.02, 0.54 +/- 0.08, and 0.34 +/- 0.02, respectively. The 50% reduction in ionized calcium occurred at a volume ratio of 7:93.
Conclusions: An instantaneous 50% reduction in ionized calcium occurs in vitro at a proportion equivalent to a transfusion rate of FFP representing 7% of CO. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Sulemanji, Demet S.; Jiang, Yandong] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA.
[Sulemanji, Demet S.; Jiang, Yandong] Harvard Univ, Sch Med, Dept Anaesthesia, Boston, MA 02115 USA.
[Bloom, Jonathan D.] Univ Pittsburgh, Dept Anesthesiol, Pittsburgh, PA 15213 USA.
[Dzik, Walter H.] Massachusetts Gen Hosp, Blood Transfus Serv, Boston, MA 02114 USA.
RP Jiang, YD (reprint author), Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, 55 Fruit St,Jackson 422, Boston, MA 02114 USA.
EM yjiang@partners.org
FU Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts
General Hospital
FX Supported by the Department of Anesthesia, Critical Care and Pain
Medicine, Massachusetts General Hospital, only.
NR 31
TC 1
Z9 2
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0952-8180
J9 J CLIN ANESTH
JI J. Clin. Anesth.
PD AUG
PY 2012
VL 24
IS 5
BP 364
EP 369
DI 10.1016/j.jclinane.2011.10.008
PG 6
WC Anesthesiology
SC Anesthesiology
GA 974QK
UT WOS:000306451200003
PM 22575605
ER
PT J
AU Lombardo, I
Sachs, G
Kolluri, S
Kremer, C
Yang, RY
AF Lombardo, Ilise
Sachs, Gary
Kolluri, Sheela
Kremer, Charlotte
Yang, Ruoyong
TI Two 6-Week, Randomized, Double-Blind, Placebo-Controlled Studies of
Ziprasidone in Outpatients With Bipolar I Depression Did Baseline
Characteristics Impact Trial Outcome?
SO JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
LA English
DT Article
DE bipolar depression; atypical antipsychotic; placebo response
ID RATING-SCALE; MONOTHERAPY; QUETIAPINE; LAMOTRIGINE; REMISSION; EFFICACY;
MANIA
AB Two randomized, double-blind, placebo-controlled, 6-week studies comparing ziprasidone versus placebo for treatment of bipolar depression (BPD) failed to meet their primary study objectives, indicating that either ziprasidone is ineffective in the treatment of BPD or the study failed.
Adult outpatients with bipolar I depression with 17-item Hamilton Rating Scale for Depression total score more than 20 at screening and baseline received either ziprasidone 40 to 80 mg/d, 120 to 160 mg/d, or placebo (study 1), or ziprasidone 40 to 160 mg/d or placebo (study 2). Primary efficacy measure in both studies was change from baseline in Montgomery-Asberg Depression Rating Scale total scores at week 6 (end of the study). Mixed-model repeated-measures methodology was used to analyze the primary efficacy measure in both studies. Secondary efficacy measures in both studies included Hamilton Rating Scale for Depression total score and Clinical Global Impression-Improvement score. Post hoc analyses were conducted for both studies to examine potential reasons for study failure. In both, ziprasidone treatment groups failed to separate statistically from placebo for change from baseline Montgomery-Asberg Depression Rating Scale score at week 6. Response rates were 49%, 53%, and 46% for placebo, ziprasidone 40 to 80 mg/d, and ziprasidone 120 to 160 mg/d, respectively (study 1), and 51% and 53% for placebo and ziprasidone 40 to 160 mg/d, respectively (study 2).
Ziprasidone 40 to 160 mg/d did not show superiority over placebo at week 6 in the treatment of BPD. Post hoc analyses revealed serious inconsistencies in subject rating that may have limited the ability to detect a difference between drug and placebo response. Rating reliability warrants further investigation to improve clinical trial methodology in psychiatry.
C1 [Lombardo, Ilise; Kolluri, Sheela; Kremer, Charlotte; Yang, Ruoyong] Pfizer Inc, New York, NY 10017 USA.
[Sachs, Gary] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Sachs, Gary] Harvard Univ, Cambridge, MA 02138 USA.
RP Lombardo, I (reprint author), Pfizer Inc, 235 E 42nd St, New York, NY 10017 USA.
EM ilise.lombardo@pfizer.com
FU Pfizer Inc.; Abbott; GlaxoSmithKline; Janssen; Pfizer
FX This study was funded by Pfizer Inc. Editorial support was provided by
Annie Neild, PhD, of PAREXEL and was funded by Pfizer Inc.; Drs
Lombardo, Kolluri, Kremer, and Yang are employees of Pfizer Inc. Dr
Sachs, owned stock in Concordant Rater Systems, Inc, and is now an
employee of United BioSource Corporation. He has received grants for
clinical research from Abbott, GlaxoSmithKline, Janssen, and Pfizer. Dr
Sachs is on advisory boards for Abbott, Bristol-Myers Squibb, Dainippon
Sumitomo Pharma, GlaxoSmithKline, Janssen, Eli Lilly, Merck, Otsuka,
Pfizer, and Repligen.
NR 25
TC 35
Z9 35
U1 1
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0271-0749
J9 J CLIN PSYCHOPHARM
JI J. Clin. Psychopharmacol.
PD AUG
PY 2012
VL 32
IS 4
BP 470
EP 478
DI 10.1097/JCP.0b013e31825ccde5
PG 9
WC Pharmacology & Pharmacy; Psychiatry
SC Pharmacology & Pharmacy; Psychiatry
GA 970GE
UT WOS:000306115300006
PM 22722504
ER
PT J
AU Hunt, KJ
Gebregziabher, M
Egede, LE
AF Hunt, Kelly J.
Gebregziabher, Mulugeta
Egede, Leonard E.
TI Racial and Ethnic Differences in Cardio-Metabolic Risk in Individuals
with Undiagnosed Diabetes: National Health and Nutrition Examination
Survey 1999-2008
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Article
DE undiagnosed diabetes; disparities; cardio-metabolic risk; HbA1c
ID IMPAIRED GLUCOSE-TOLERANCE; CARDIOVASCULAR-DISEASE; FASTING GLUCOSE;
CORONARY-DISEASE; US POPULATION; ADULTS; PREVALENCE; MELLITUS; BLACK;
MEN
AB Although early recognition and treatment of diabetes may be essential to prevent complications, roughly one-fifth of diabetes remains undiagnosed.
Examine cardio-metabolic risk factors and their control in non-Hispanic white (NHW), non-Hispanic black (NHB) and Mexican American (MA) individuals with undiagnosed diabetes.
Nationally representative cross-sectional study of participants in the National Health and Nutrition Examination Survey (NHANES) continuous cycles conducted 1999 through 2008.
Of 22,621 non-pregnant individuals aged a parts per thousand yen20 years, 2521 had diagnosed diabetes. Of the remaining 20,100 individuals, 17,963 had HbA1c measured, 551 of whom were classified as having undiagnosed diabetes and comprise the study population.
Undiagnosed diabetes was defined as HbA1c a parts per thousand yenaEuro parts per thousand 6.5% without a self-report of physician diagnosed diabetes. Cardio-metabolic risk factor control was examined using regression methods for complex survey data.
Among individuals with undiagnosed diabetes, mean HbA1c level was 7.7% (95% CI: 7.5, 7.9), 19.3% (95% CI: 14.2, 24.3) smoked, 59.7% (95% CI: 54.5, 64.8%) had hypertension and 96.5% (95% CI: 94.6, 98.4%) had dyslipidemia. Lipid profiles were remarkably different across racial-ethnic groups: NHB had the highest LDL- and HDL-cholesterol, but the lowest triglycerides, while MA had the highest triglycerides and the lowest LDL-cholesterol. After adjusting for age, sex, NHANES examination cycle and use of either blood pressure or lipid medication, the odds of having blood pressure a parts per thousand yen130/80 mmHg was higher in NHB [1.92 (95% CI: 1.09, 3.55)] than NHW, while the odds of having LDL-cholesterol > 100 mg/dl was higher in NHW[2.93 (95% CI: 1.37, 6.24)] and NHB[3.34 (95% CI: 1.08, 10.3)] than MA.
In a nationally representative sample of individuals with undiagnosed diabetes, cardio-metabolic risk factor levels were high across all racial/ethnic groups, but NHB and MA had poorer control compared to NHW. Interventions that target identification of diabetes and treatment of cardio-metabolic risk factors are needed.
C1 [Hunt, Kelly J.; Gebregziabher, Mulugeta] Med Univ S Carolina, Div Biostat & Epidemiol, Charleston, SC 29425 USA.
[Egede, Leonard E.] Med Univ S Carolina, Div Gen Internal Med, Ctr Hlth Dispar Res, Charleston, SC 29425 USA.
[Hunt, Kelly J.; Gebregziabher, Mulugeta; Egede, Leonard E.] Ralph H Johnson Dept Vet Affairs Med Ctr, Ctr Dis Prevent & Hlth Intervent Diverse Populat, Charleston, SC USA.
RP Hunt, KJ (reprint author), Med Univ S Carolina, Div Biostat & Epidemiol, 135 Cannon St,Suite 302,POB 250835, Charleston, SC 29425 USA.
EM huntke@musc.edu
OI Gebregziabher, Mulugeta/0000-0002-4826-481X
FU Office of Research and Development; Department of Veterans Affairs;
Ralph H. Johnson VAMC; VA HSRD REAP [IIR-06-219]; National Center on
Minority Health and Health Disparities [R01-MD004251]
FX This material is based upon work supported in part by the Office of
Research and Development, Department of Veterans Affairs, and the Ralph
H. Johnson VAMC. Further support is provided through VA HSR&D REAP Award
(grant #IIR-06-219) as well as the National Center on Minority Health
and Health Disparities (R01-MD004251). The funding agency did not
participate in the design and conduct of the study; collection,
management, analysis, and interpretation of the data; and preparation,
review, or approval of the manuscript.
NR 40
TC 10
Z9 10
U1 1
U2 9
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD AUG
PY 2012
VL 27
IS 8
BP 893
EP 900
DI 10.1007/s11606-012-2023-7
PG 8
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 974LB
UT WOS:000306435500004
PM 22415867
ER
PT J
AU Zhang, Z
Xie, DW
Kurichi, JE
Streim, J
Zhang, GY
Stineman, MG
AF Zhang, Zi
Xie, Dawei
Kurichi, Jibby E.
Streim, Joel
Zhang, Guangyu
Stineman, Margaret G.
TI Mortality Predictive Indexes for the Community-Dwelling Elderly US
Population
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Article
DE mortality; prediction; score system; community; instrumental activities
of daily living.
ID NURSING-HOME RESIDENTS; QUALITY-OF-LIFE; OLDER-ADULTS; INSTRUMENTAL
ACTIVITIES; COGNITIVE IMPAIRMENT; FUNCTIONAL STATUS; METHODOLOGICAL
STANDARDS; HOSPITAL DISCHARGE; ADVANCED DEMENTIA; PHYSICAL FUNCTION
AB Few predictive indexes for long-term mortality have been developed for community-dwelling elderly populations. Parsimonious predictive indexes are important decision-making tools for clinicians, policy makers, and epidemiologists.
To develop 1-, 5-, and 10-year mortality predictive indexes for nationally representative community-dwelling elderly people.
Cohort study.
The Second Longitudinal Study of Aging (LSOA II).
Nationally representative civilian community-dwelling persons at least 70 years old. We randomly selected 60% of the sample for prediction development and used the remaining 40% for validation.
Sociodemographics, impairments, and medical diagnoses were collected from the LSOA II baseline interviews. Instrumental activities of daily living (IADLs) stages were derived to measure functional status. All-cause mortality was obtained from the LSOA II Linked Mortality Public-use File.
The analyses included 7,373 sample persons with complete data, among which mortality rates were 3.7%, 23.3%, and 49.8% for 1, 5, and 10 years, respectively. Four, eight, and ten predictors were identified for 1-, 5-, and 10-year mortality, respectively, in multiple logistic regression models to create three predictive indexes. Age, sex, coronary artery disease, and IADL stages were the most essential predictors for all three indexes. C-statistics of the three indexes were 0.72, 0.74, and 0.75 in the development cohort and 0.72, 0.72, and 0.74 in the validation cohort for 1-, 5-, and 10-year mortality, respectively. Five risk groups were defined based on the scores.
The 1-, 5-, and 10-year mortality indexes include parsimonious predictor sets maximizing ease of mortality prediction in community settings. Thus, they may provide valuable information for prognosis of elderly patients and guide the comparison of alternative interventions. Including IADL stage as a predictor yields simplified mortality prediction when detailed disease information is not available.
C1 [Zhang, Zi; Xie, Dawei; Kurichi, Jibby E.; Stineman, Margaret G.] Univ Penn, Dept Biostat & Epidemiol, Ctr Clin Epidemiol & Biostat, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Streim, Joel] Univ Penn, Dept Psychiat, Perelman Sch Med, Geriatr Psychiat Sect, Philadelphia, PA 19104 USA.
[Streim, Joel] Philadelphia Vet Affairs Med Ctr, VISN Mental Illness Res Educ & Clin Ctr 4, Philadelphia, PA USA.
[Zhang, Guangyu] Univ Maryland, Dept Epidemiol & Biostat, College Pk, MD 20742 USA.
[Stineman, Margaret G.] Univ Penn, Dept Phys Med & Rehabil, Perelman Sch Med, Philadelphia, PA 19104 USA.
RP Stineman, MG (reprint author), Univ Penn, Dept Biostat & Epidemiol, Ctr Clin Epidemiol & Biostat, Perelman Sch Med, 904 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.
EM mstinema@exchange.upenn.edu
FU National Institutes of Health [AG032420-01A1]
FX The research for this manuscript was supported by the National
Institutes of Health (AG032420-01A1). There are no personal conflicts of
interest of any of the authors, and no authors reported disclosures
beyond the funding source. The opinions and conclusions of the authors
are not necessarily those of the sponsoring agency or of the NCHS who is
responsible only for provision of the data.
NR 57
TC 9
Z9 9
U1 4
U2 8
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD AUG
PY 2012
VL 27
IS 8
BP 901
EP 910
DI 10.1007/s11606-012-2027-3
PG 10
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 974LB
UT WOS:000306435500005
PM 22422075
ER
PT J
AU Fowler, FJ
Gallagher, PM
Bynum, JPW
Barry, MJ
Lucas, FL
Skinner, JS
AF Fowler, Floyd J., Jr.
Gallagher, Patricia M.
Bynum, Julie P. W.
Barry, Michael J.
Lucas, F. Leslie
Skinner, Jonathan S.
TI Decision-Making Process Reported by Medicare Patients Who Had Coronary
Artery Stenting or Surgery for Prostate Cancer
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Article
DE shared decision making; decision quality; patient-centered care
ID QUALITY-OF-LIFE; RADICAL PROSTATECTOMY; PRIMARY-CARE; DISEASE; THERAPY;
INTERVENTION; BENEFITS; OUTCOMES; PCI
AB Patients facing decisions should be told about their options, have the opportunity to discuss the pros and cons, and have their preferences reflected in the final decision.
To learn how decisions were made for two major preference-sensitive interventions.
Mail survey of probability samples of patients who underwent the procedures.
Fee-for-service Medicare beneficiaries who had surgery for prostate cancer or elective coronary artery stenting in the last half of 2008.
Patients' reports of which options were presented for serious consideration, the amount of discussion of the pros and cons of the chosen option, and if they were asked about their preferences.
The majority (64%) of prostate cancer surgery patients reported that at least one alternative to surgery was presented as a serious option. Almost all (94%) said they and their doctors discussed the pros, and 63% said they discussed the cons of surgery "a lot" or "some". Most (76%) said they were asked about their treatment preferences. Few who received stents said they were presented with options to seriously consider (10%). While most (77%) reported talking with doctors about the reasons for stents "a lot" or "some", few (19%) reported talking about the cons. Only 16% said they were asked about their treatment preferences.
While prostate cancer surgery patients reported more involvement in decision making than elective stent patients, the reports of both groups document the need for increased efforts to inform and involve patients facing preference-sensitive intervention decisions.
C1 [Fowler, Floyd J., Jr.; Gallagher, Patricia M.] Univ Massachusetts Boston, Survey Res Ctr, Boston, MA USA.
[Fowler, Floyd J., Jr.; Barry, Michael J.] Fdn Informed Med Decis Making, Boston, MA USA.
[Bynum, Julie P. W.] Dartmouth Hitchcock Med Ctr, Dept Gen Internal Med, Hanover, NH USA.
[Barry, Michael J.] Massachusetts Gen Hosp, Div Gen Med, Boston, MA 02114 USA.
[Lucas, F. Leslie] Maine Med Ctr, Ctr Outcomes Res, Portland, ME 04102 USA.
[Skinner, Jonathan S.] Dartmouth Coll, Dept Econ, Hanover, NH 03755 USA.
[Bynum, Julie P. W.; Skinner, Jonathan S.] Dartmouth Coll, Dartmouth Inst, Hanover, NH 03755 USA.
RP Fowler, FJ (reprint author), Univ Massachusetts Boston, Survey Res Ctr, Boston, MA USA.
EM Floyd.fowler@umb.edu
FU National Institutes on Aging (NIA) [PO1-AG19783, AG028947]
FX The work reported in this paper was supported by Grant NoPO1-AG19783 to
Dartmouth Medical School from the National Institutes on Aging (NIA).
Dr. Bynum's time was supported by NIA K23 Grant No. AG028947.
NR 28
TC 19
Z9 19
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD AUG
PY 2012
VL 27
IS 8
BP 911
EP 916
DI 10.1007/s11606-012-2009-5
PG 6
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 974LB
UT WOS:000306435500006
PM 22370767
ER
PT J
AU Momplaisir, F
Long, JA
Badolato, G
Brady, KA
AF Momplaisir, Florence
Long, Judith A.
Badolato, Gia
Brady, Kathleen A.
TI The Role of Primary Care Physicians in Improving Colorectal Cancer
Screening in Patients with HIV
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Article
DE colorectal cancer screening; HIV; primary care; infectious diseases
specialists; model of care
ID HUMAN-IMMUNODEFICIENCY-VIRUS; UNITED-STATES; ADULTS; SPECIALIZATION;
DEATH; OLDER; AIDS
AB As HIV positive patients live longer, they become susceptible to the development of non-AIDS defining malignancies. Little is known about routine cancer screening practices in that population and the factors associated with cancer screening.
Evaluate 1) the proportion of patients with HIV who had any type of colorectal cancer (CRC) screening and 2) whether having a primary care physician (PCP) or seeking care in an integrated care practice is associated with higher CRC screening.
A cross-sectional chart abstraction study of patients with HIV enrolled in the Philadelphia Medical Monitoring Project (MMP).
MMP participants age 50 and older.
CRC screening defined as having a documented colonoscopy, sigmoidoscopy, barium enema, or fecal occult blood test after the age of 50.
Out of 123 chart abstractions performed, 115 had a complete clinical record from MMP. The majority of the population was male (71.3%), Black/Hispanic (73.8%) and between the age of 50 and 59 (71.3%). 45.2% of patients did not have a PCP. The overall proportion of patients who received CRC screening was 46.9%. Having a documented PCP was the only factor strongly associated with CRC screening. Rates of screening were 66.7% among those with a PCP versus 28.5% among those without a PCP (chi(2) p < 0.001). After adjusting for race, socioeconomic status, substance and alcohol abuse, the odds of getting CRC screening in those with a PCP was 4.59 (95% CI 2.01-10.48, p < 0.001). The type of practice where patients were enrolled into care was not associated with CRC screening.
Having a PCP significantly increases the likelihood of receiving CRC screening in patients with HIV. Competency in addressing primary care needs in HIV clinics will only become more important as patients with HIV age.
C1 [Momplaisir, Florence; Long, Judith A.] Univ Penn, Div Gen Internal Med, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Long, Judith A.] Philadelphia VA Ctr Hlth Equ Res & Promot, Philadelphia, PA USA.
[Badolato, Gia; Brady, Kathleen A.] Philadelphia Dept Publ Hlth, Philadelphia, PA USA.
RP Momplaisir, F (reprint author), Univ Penn, Div Gen Internal Med, Perelman Sch Med, 423 Guardian Dr,13th Floor,Blockley Hall, Philadelphia, PA 19104 USA.
EM fmo@mail.med.upenn.edu
FU Philadelphia Department of Public Health [U62 PS001608-01]; Centers for
Disease Control and Prevention [U62 PS001608-01]
FX Supported by funding by a cooperative agreement between the Philadelphia
Department of Public Health and the Centers for Disease Control and
Prevention (grant # U62 PS001608-01).
NR 14
TC 5
Z9 5
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD AUG
PY 2012
VL 27
IS 8
BP 940
EP 944
DI 10.1007/s11606-012-2010-z
PG 5
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 974LB
UT WOS:000306435500010
PM 22370768
ER
PT J
AU Offutt-Powell, TN
Ojha, RP
Tota, JE
Gurney, JG
AF Offutt-Powell, Tabatha N.
Ojha, Rohit P.
Tota, Joseph E.
Gurney, James G.
TI Human Papillomavirus Infection and Bladder Cancer: An Alternate
Perspective From a Modified Meta-Analysis
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Letter
C1 [Offutt-Powell, Tabatha N.] Univ N Carolina, Dept Epidemiol, Gillings Sch Global Publ Hlth, Chapel Hill, NC 27599 USA.
[Ojha, Rohit P.] Dana Farber Canc Inst, Div Populat Sci, Boston, MA 02115 USA.
[Tota, Joseph E.] McGill Univ, Dept Epidemiol Biostat & Occupat Hlth, Montreal, PQ, Canada.
[Ojha, Rohit P.; Gurney, James G.] St Jude Childrens Hosp, Dept Epidemiol & Canc Control, Memphis, TN 38105 USA.
RP Offutt-Powell, TN (reprint author), Univ N Carolina, Dept Epidemiol, Gillings Sch Global Publ Hlth, 2103B McGavran Greenberg Hall, Chapel Hill, NC 27599 USA.
EM topowell@email.unc.edu
OI Ojha, Rohit/0000-0003-0595-8990
NR 10
TC 0
Z9 1
U1 1
U2 3
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD AUG 1
PY 2012
VL 206
IS 3
BP 453
EP U184
DI 10.1093/infdis/jis364
PG 2
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 973OI
UT WOS:000306369100019
PM 22615320
ER
PT J
AU Gonzalez, RG
AF Gonzalez, R. Gilberto
TI Clinical MRI of acute ischemic stroke
SO JOURNAL OF MAGNETIC RESONANCE IMAGING
LA English
DT Review
DE ischemic stroke; MR angiography; diffusion MRI; perfusion MRI
ID TISSUE-PLASMINOGEN ACTIVATOR; DIFFUSION-WEIGHTED MRI; THROMBOLYTIC
THERAPY; CEREBRAL-ISCHEMIA; HYPERACUTE STROKE; ARTERY-OCCLUSION;
PERFUSION MRI; DIFFUSION/PERFUSION MISMATCH; INTRAARTERIAL THROMBOLYSIS;
INTERVENTIONAL MANAGEMENT
AB The most important service that imaging provides to patients with ischemic stroke is to rapidly identify those patients who are most likely to benefit from immediate treatment. This group includes patients who have severe neurological symptoms due to an occlusion of a major artery, and who are candidates for recanalization using intravenous thrombolysis or intra-arterial intervention to remove the occlusion. Outcomes for these patients are determined by symptom severity, the artery that is occluded, the size of the infarct at the time of presentation, and the effect of treatment. MRI provides key physiological information through MR angiography and diffusion MRI that has been proven to be of high clinical value in identify patients who are in need of immediate treatment. Perfusion MRI provides information about the ischemic penumbra, but its clinical value is unproven. In current clinical practice, the time since stroke onset is dominant over physiologic information provided by MRI in treatment decisions. This will change only when clinical trials prove that stroke physiology as revealed by MRI is superior to time from stroke onset in promoting good clinical outcomes. J. Magn. Reson. Imaging 2012;36:259271. (c) 2012 Wiley Periodicals, Inc.
C1 [Gonzalez, R. Gilberto] Massachusetts Gen Hosp, Neuroradiol Div, Boston, MA 02114 USA.
[Gonzalez, R. Gilberto] Martinos Ctr Biomed Imaging, Charlestown, MA USA.
[Gonzalez, R. Gilberto] Harvard Univ, Sch Med, Boston, MA USA.
RP Gonzalez, RG (reprint author), Massachusetts Gen Hosp, Neuroradiol Div, Fruit St, Boston, MA 02114 USA.
EM rggonzalez@partners.org
FU NIH [NS050041, NS051343]
FX Contract grant sponsor: NIH; Contract grant number: NS050041, NS051343.
NR 61
TC 12
Z9 12
U1 0
U2 9
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1053-1807
J9 J MAGN RESON IMAGING
JI J. Magn. Reson. Imaging
PD AUG
PY 2012
VL 36
IS 2
BP 259
EP +
DI 10.1002/jmri.23595
PG 13
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 974ZA
UT WOS:000306475000001
PM 22807220
ER
PT J
AU Tancredi, FB
Gauthier, CJ
Madjar, C
Bolar, DS
Fisher, JA
Wang, DJJ
Hoge, RD
AF Tancredi, Felipe B.
Gauthier, Claudine J.
Madjar, Cecile
Bolar, Divya S.
Fisher, Joseph A.
Wang, Danny J. J.
Hoge, Richard D.
TI Comparison of pulsed and pseudocontinuous arterial spin-labeling for
measuring CO2-induced cerebrovascular reactivity
SO JOURNAL OF MAGNETIC RESONANCE IMAGING
LA English
DT Article
DE ASL; hypercapnia; cerebrovascular reactivity
ID CEREBRAL-BLOOD-FLOW; TIDAL CARBON-DIOXIDE; TRANSIT-TIME;
VISUAL-STIMULATION; BOLD; FMRI; METABOLISM; EFFICIENCY; FREQUENCY;
RESPONSES
AB Purpose: To compare the performance of pulsed and pseudocontinuous arterial spin-labeling (PASL and pCASL) methods in measuring CO2-induced cerebrovascular reactivity (CVR). Materials and Methods: Subjects were scanned using both ASL sequences during a controlled hypercapnia procedure and visual stimulation. CVR was computed as the percent CO2-induced increase in cerebral blood flow (?%CBF) per mmHg increase in end-tidal PCO2. Visually evoked responses were expressed as ?%CBF. Resting CBF and temporal signal-to-noise ratio were also computed. Regionally averaged values for the different quantities were compared in gray matter (GM) and visual cortex (VC) using t-tests. Results: Both PASL and pCASL yielded comparable respective values for resting CBF (56 +/- 3 and 56 +/- 4 mL/min/100g) and visually evoked responses (75 +/- 5% and 81 +/- 4%). Values of CVR determined using pCASL (GM 4.4 +/- 0.2, VC 8 +/- 1 ?%CBF/mmHg), however, were significantly higher than those measured using PASL (GM 3.0 +/- 0.6, VC 5 +/- 1 ?%CBF/mmHg) in both GM and VC. The percentage of GM voxels in which statistically significant hypercapnia responses were detected was also higher for pCASL (27 +/- 5% vs. 16 +/- 3% for PASL). Conclusion: pCASL may be less prone to underestimation of CO2-induced flow changes due to improved label timing control. J. Magn. Reson. Imaging 2012;36:312321. (c) 2012 Wiley Periodicals, Inc.
C1 [Tancredi, Felipe B.; Hoge, Richard D.] Univ Montreal, Dept Physiol, Inst Genie Biomed, Montreal, PQ H3C 3J7, Canada.
[Tancredi, Felipe B.; Gauthier, Claudine J.; Madjar, Cecile; Hoge, Richard D.] Inst Univ Geriatrie Montreal, Ctr Rech, Unite Neuroimagerie Fonct, Montreal, PQ, Canada.
[Gauthier, Claudine J.; Hoge, Richard D.] Univ Montreal, Fac Med, Dept Physiol, Montreal, PQ H3C 3J7, Canada.
[Bolar, Divya S.] Massachussets Gen Hosp, Athinoula A Matinos Ctr Biomed Imaging, Charlestown, MA USA.
[Bolar, Divya S.] Harvard Univ, MIT, Sch Med, Harvard MIT Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
[Bolar, Divya S.] MIT, Dept Elect Engn & Comp Sci, Cambridge, MA 02139 USA.
[Fisher, Joseph A.] Univ Toronto, Dept Anesthesiol, Univ Hlth Network, Toronto, ON, Canada.
[Wang, Danny J. J.] Univ Calif Los Angeles, Los Angeles, CA USA.
RP Tancredi, FB (reprint author), 4545 Queen Mary,M6808, Montreal, PQ H3W 1W5, Canada.
EM felipe.tancredi@umontreal.ca
RI Tancredi, Felipe/L-2187-2014
OI Tancredi, Felipe/0000-0002-4419-8245
FU Canadian Institutes for Health Research [MOP 84378]; Canadian Foundation
for Innovation [17380]; Ministere du developpement economique, de
l'innovation et de l'exportation [PSR-SIIRI-239]
FX Contract grant sponsor: Canadian Institutes for Health Research;
Contract grant number: MOP 84378 (Banting and Best Scholarship held by
C.J.G.); Contract grant sponsor: Canadian Foundation for Innovation;
Contract grant number: Leaders Opportunity Fund 17380; Contract grant
sponsor: Ministere du developpement economique, de l'innovation et de
l'exportation; Contract grant number: PSR-SIIRI-239.
NR 31
TC 20
Z9 20
U1 0
U2 10
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1053-1807
J9 J MAGN RESON IMAGING
JI J. Magn. Reson. Imaging
PD AUG
PY 2012
VL 36
IS 2
BP 312
EP 321
DI 10.1002/jmri.23658
PG 10
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 974ZA
UT WOS:000306475000005
PM 22544711
ER
PT J
AU Li, X
Wan, LY
Geng, J
Wu, CL
Bai, XY
AF Li, Xiao
Wan, Liyan
Geng, Jian
Wu, Chin-Lee
Bai, Xiaoyan
TI Aldehyde Dehydrogenase 1A1 Possesses Stem-Like Properties and Predicts
Lung Cancer Patient Outcome
SO JOURNAL OF THORACIC ONCOLOGY
LA English
DT Article
DE ALDH1A1; ALDEFLUOR assay; Small interfering RNA transfection; Tissue
microarray; Prognosis
ID GENE-EXPRESSION; CELL-LINES; ADENOCARCINOMA; PROGNOSIS; MARKER
AB Introduction: Lung cancer contains a small population of cancer stem cells that contribute to its initiation and progression. We investigated the biological function and clinical significance of aldehyde dehydrogenase 1A1 (ALDH1A1) in non-small-cell lung carcinoma (NSCLC).
Methods: ALDH1A1 assay or small interfering RNA transfection was employed to isolate ALDH1A1+ cells or knock down ALDH1A1 expression in H2087 cells, respectively. Biological functions of ALDH1A1+ and ALDH1A1 silenced cells were investigated using in vitro and in vivo methods. ALDH1A1 expression was analyzed using immunohistochemistry on tissue microarrays with 179 lung cancer tissues and 26 normal lung tissues.
Results: The abilities of clone formation, proliferation, cell growth, and migration were increased in ALDH1A1+ and ALDH1A1 silenced cells. ALDH1A1+ lung cancer cells initiated tumors that resembled the histopathologic characteristics and heterogeneity of the parental lung cancer cells in mice. The silencing of ALDH1A1 expression in H2087 lung cancer cells inhibited cell proliferation and migration significantly. ALDH1A1 was expressed in 42% of normal lung tissues (11 of 26), with strong expression in the basal cells and globular cells of the normal bronchus and weak expression in the alveolar epithelial cells. Compared with normal lung tissues, 45% of NSCLC samples (81 of 179) were read as positive for ALDH1A1. Positive ALDH1A1 expression was correlated with patients' smoking status (p = 0.022), lymph-node metastasis (p = 0.006), clinical stage (p = 0.004), and a decreased overall survival time (p < 0.001). Positive ALDH1A1 expression in lung cancer tissues was an independent prognostic factor for NSCLC (odds ratio = 5.232, p < 0.001).
Conclusion: Elucidating the biological functions of ALDH1A1 could be helpful in studying lung tumorigenesis and for developing new therapeutic approaches.
C1 [Bai, Xiaoyan] So Med Univ, Nanfang Hosp, Guangdong Prov Inst Nephrol, Div Nephrol, Guangzhou 510515, Guangdong, Peoples R China.
[Li, Xiao] So Med Univ, Nanfang Hosp, Dept Emergency, Guangzhou 510515, Guangdong, Peoples R China.
[Wan, Liyan; Geng, Jian] So Med Univ, Nanfang Hosp, Dept Pathol, Guangzhou 510515, Guangdong, Peoples R China.
[Wu, Chin-Lee] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pathol, Boston, MA USA.
[Wu, Chin-Lee] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Urol, Boston, MA USA.
RP Bai, XY (reprint author), So Med Univ, Nanfang Hosp, Guangdong Prov Inst Nephrol, Div Nephrol, 1838 Guangzhou N Rd, Guangzhou 510515, Guangdong, Peoples R China.
EM xiaoyanbai@fimmu.com
FU National Natural Science Foundation of China [81100496]
FX We thank Shan Wang from University of Texas Southwestern Medical Center,
and John Basgen, from Charles R. Drew University of Medicine and Science
for their critical reading of the manuscript. This study was supported
by a grant (Grant No. 81100496) from the National Natural Science
Foundation of China.
NR 28
TC 28
Z9 29
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1556-0864
J9 J THORAC ONCOL
JI J. Thorac. Oncol.
PD AUG
PY 2012
VL 7
IS 8
BP 1235
EP 1245
DI 10.1097/JTO.0b013e318257cc6d
PG 11
WC Oncology; Respiratory System
SC Oncology; Respiratory System
GA 974TD
UT WOS:000306459000010
PM 22617249
ER
PT J
AU Bui, AH
Bonaca, MP
Sabatine, MS
Ray, KK
Rifai, N
Cannon, CP
Morrow, DA
AF Bui, An H.
Bonaca, Marc P.
Sabatine, Marc S.
Ray, Kausik K.
Rifai, Nader
Cannon, Christopher P.
Morrow, David A.
TI Elevated concentration of placental growth factor (PlGF) and long term
risk in patients with acute coronary syndrome in the PROVE IT-TIMI 22
trial
SO JOURNAL OF THROMBOSIS AND THROMBOLYSIS
LA English
DT Article
DE PlGF; Inflammation; Acute coronary syndrome; Prognosis
ID C-REACTIVE PROTEIN; MYOCARDIAL-INFARCTION; HEART-DISEASE; INFLAMMATION;
RECEPTOR; REVASCULARIZATION; ATHEROSCLEROSIS; INHIBITION; EXPRESSION;
DISORDERS
AB Placental growth factor (PlGF), a member of the vascular endothelial growth factor (VEGF) family, acts via the flt-1 receptor and promotes endothelial activation and macrophage recruitment into atherosclerotic lesions. We investigated the relationship of PlGF with cardiovascular outcomes in a large cohort of patients presenting across the spectrum of ACS. PlGF was measured at baseline (n = 3,761) and at four-months (n = 3,369) in patients randomized to atorvastatin 80 mg or pravastatin 40 mg after ACS in the PROVE IT-TIMI 22 trial. The primary endpoint was death, myocardial infarction (MI), unstable angina, revascularization or stroke (mean follow-up 24 months). Elevated baseline PlGF was associated with a higher incidence of the primary endpoint through 2 years (Q1 vs. Q5: 18.7 vs. 29.3%, p < 0.0001). The risk of death or MI was also higher in patients with elevated baseline PlGF (Q1 vs. Q5: 7.0 vs. 11.6%, p = 0.029). Adjusting for baseline characteristics and risk factors, elevated baseline PlGF was independently associated with the risk of the primary endpoint (adjusted-HR for Q5 vs. Q1 1.45; 95% CI 1.16-1.83; p = 0.001). Elevated PlGF at four months was associated with higher risk of death or MI (Adjusted HR Q5 vs. Q1 2.79, 95% CI: 1.37-5.68; p = 0.005), and higher risk of the primary endpoint (Adjusted HR Q5 vs. Q1 1.78, 95% CI: 1.26-2.51; p = 0.001). Higher concentration of PlGF after ACS is associated with long-term risk of recurrent cardiovascular events independent of traditional risk factors. This association is present early after ACS and appears to be stronger at four months.
C1 [Bui, An H.; Bonaca, Marc P.; Sabatine, Marc S.; Cannon, Christopher P.; Morrow, David A.] Brigham & Womens Hosp, Dept Med, Thrombolysis Myocardial Infarct TIMI Study Grp, Boston, MA 02115 USA.
[Bui, An H.; Bonaca, Marc P.; Sabatine, Marc S.; Cannon, Christopher P.; Morrow, David A.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Bonaca, Marc P.; Sabatine, Marc S.; Cannon, Christopher P.; Morrow, David A.] Brigham & Womens Hosp, Dept Med, Div Cardiovasc, Boston, MA 02115 USA.
[Ray, Kausik K.] Univ Cambridge, Dept Publ Hlth & Primary Care, Cambridge, England.
[Rifai, Nader] Childrens Hosp, Dept Lab Med NR, Boston, MA 02115 USA.
RP Bonaca, MP (reprint author), Brigham & Womens Hosp, Dept Med, Thrombolysis Myocardial Infarct TIMI Study Grp, 350 Longwood Ave,1st Floor, Boston, MA 02115 USA.
EM mbonaca@partners.org
FU Bristol Myers Squibb; Accumetrics; Astra-Zeneca; Bayer Healthcare;
Beckman Coulter; Biosite; Bristol-Myers Squibb; CV Therapeutics; Daiichi
Sankyo; Eli Lilly and Co; GlaxoSmithKline; Merck and Company;
Nanosphere; Novartis Pharmaceuticals; Ortho-Clinical Diagnostics;
Pfizer; Roche Diagnostics; Sanofi-Aventis; Schering-Plough; Siemens;
Singulex; NHLBI [HHSN268201000033C]; Abbott; BRAHMS; Critical
Diagnostics
FX PROVE IT-TIMI 22 was funded by Bristol Myers Squibb. The TIMI Study
Group has received significant research grant support from Accumetrics,
Astra-Zeneca, Bayer Healthcare, Beckman Coulter, Biosite, Bristol-Myers
Squibb, CV Therapeutics, Daiichi Sankyo, Eli Lilly and Co,
GlaxoSmithKline, Merck and Company, Nanosphere, Novartis
Pharmaceuticals, Ortho-Clinical Diagnostics, Pfizer, Roche Diagnostics,
Sanofi-Aventis, Schering-Plough, Siemens, and Singulex. Dr Sabatine was
supported in part by contract HHSN268201000033C from the NHLBI. Dr.
Sabatine also receives research grant support from Abbott, BRAHMS,
Critical Diagnostics, Nanosphere, and Roche Diagnostics. Dr. Ray
received an unrestricted research grant support from Pfizer. Dr. Morrow
has received honoraria for educational presentations from CV
Therapeutics, and Sanofi-Aventis. He has served as a consultant for
Beckman Coulter, Sanofi-Aventis, Schering Plough, and Siemens. Drs.
Bonaca, Bui, Cannon, and Rifai have no additional relationships to
report.
NR 18
TC 4
Z9 5
U1 0
U2 4
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0929-5305
EI 1573-742X
J9 J THROMB THROMBOLYS
JI J. Thromb. Thrombolysis
PD AUG
PY 2012
VL 34
IS 2
BP 222
EP 228
DI 10.1007/s11239-012-0704-z
PG 7
WC Hematology; Peripheral Vascular Disease
SC Hematology; Cardiovascular System & Cardiology
GA 974IR
UT WOS:000306427900008
PM 22446996
ER
PT J
AU Vora, AN
Bonaca, MP
Ruff, CT
Jarolim, P
Murphy, S
Croce, K
Sabatine, MS
Simon, DI
Morrow, DA
AF Vora, Amit N.
Bonaca, Marc P.
Ruff, Christian T.
Jarolim, Petr
Murphy, Sabina
Croce, Kevin
Sabatine, Marc S.
Simon, Daniel I.
Morrow, David A.
TI Diagnostic evaluation of the MRP-8/14 for the emergency assessment of
chest pain
SO JOURNAL OF THROMBOSIS AND THROMBOLYSIS
LA English
DT Article
DE Biomarkers; Unstable angina; Myocardial infarction; Platelets
ID ELEVATION MYOCARDIAL-INFARCTION; ACUTE CORONARY SYNDROMES;
PLASMA-PROTEIN-A; CARDIOVASCULAR EVENTS; PRACTICE GUIDELINES; SENSITIVE
MARKER; FOCUSED UPDATE; MYELOID-RELATED-PROTEIN-8/14; MANAGEMENT;
OCCLUSION
AB Elevated levels of myeloid-related protein (MRP)-8/14 (S100A8/A9) are associated with first cardiovascular events in healthy individuals and worse prognosis in patients with acute coronary syndrome (ACS). The diagnostic utility of MRP-8/14 in patients presenting to the emergency room with symptoms concerning for ACS is uncertain. MRP-8/14 was measured in serial serum and plasma samples in a single center prospective cohort-study of patients presenting to the emergency room with non-traumatic chest pain concerning for ACS. Final diagnosis was adjudicated by an endpoint committee. Of patients with baseline MRP-8/14 results (n = 411), the median concentration in serum was 1.57 mu g/ml (25th, 75th: 0.87, 2.68) and in plasma was 0.41 mu g/ml (< 0.4, 1.15) with only moderate correlation between serum and plasma (rho = 0.40). A final diagnosis of MI was made in 106 (26%). Peak serum MRP-8/14 was higher in patients presenting with MI (p < 0.001). However, the overall diagnostic performance of MRP-8/14 was poor: sensitivity 28% (95% CI 20-38), specificity 82% (78-86), positive predictive value 36% (26-47), and negative predictive value 77% (72-81). The area under the ROC curve for diagnosis of MI with MRP-8/14 was 0.55 (95% CI 0.51-0.60) compared with 0.95 for cTnI. The diagnostic performance was not improved in early-presenters, patients with negative initial cTnI, or using later MRP-8/14 samples. Patients presenting with MI had elevated levels of serum MRP-8/14 compared to patients with non-cardiac chest pain. However, overall diagnostic performance of MRP-8/14 was poor and neither plasma nor serum MRP-8/14 offered diagnostic utility comparable to cardiac troponin.
C1 [Vora, Amit N.; Bonaca, Marc P.; Ruff, Christian T.; Murphy, Sabina; Sabatine, Marc S.; Morrow, David A.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,TIMI Study Grp, Boston, MA 02115 USA.
[Jarolim, Petr] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA.
[Croce, Kevin] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Cardiovasc,Dept Med, Boston, MA 02115 USA.
[Simon, Daniel I.] Case Western Reserve Univ, Univ Hosp Case Med Ctr, Harrington McLaughlin Heart & Vasc Inst, Sch Med, Cleveland, OH 44106 USA.
RP Bonaca, MP (reprint author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,TIMI Study Grp, 350 Longwood Ave,1st Floor Off, Boston, MA 02115 USA.
EM mbonaca@partners.org
FU Accumetrics; Astra-Zeneca; Bayer Healthcare; Beckman Coulter; Biosite;
Bristol-Myers Squibb; CV Therapeutics; Daiichi Sankyo; Eli Lilly and Co;
GlaxoSmithKline; Merck and Company; Nanosphere; Novartis
Pharmaceuticals; Ortho-Clinical Diagnostics; Pfizer; Roche Diagnostics;
Sanofi-Aventis; Schering-Plough; Siemens; Singulex; Amgen; BRAMS;
Abbott; Merck and Co.; NHLBI [K08HL086672, R01 HL096738, R01 HL098280,
HHSN268201000033C]; BRAHMS; National Institutes of Health [HL57506]
FX The TIMI Study Group has received significant research grant support
from Accumetrics, Astra-Zeneca, Bayer Healthcare, Beckman Coulter,
Biosite, Bristol-Myers Squibb, CV Therapeutics, Daiichi Sankyo, Eli
Lilly and Co, GlaxoSmithKline, Merck and Company, Nanosphere, Novartis
Pharmaceuticals, Ortho-Clinical Diagnostics, Pfizer, Roche Diagnostics,
Sanofi-Aventis, Schering-Plough, Siemens, and Singulex. Dr. Jarolim has
consulted for T2 Biosystems and Quanterix and has received grant support
from Daiichi Sankyo, Roche Diagnostics, Amgen, BRAMS, Abbott, and Merck
and Co. Dr. Croce was supported in part by NHLBI grant K08HL086672. Dr.
Sabatine was supported in part by grant R01 HL096738, grant R01
HL098280, and contract HHSN268201000033C from the NHLBI. Dr. Sabatine
also receives research grant support from Abbott, BRAHMS, Critical
Diagnostics, Nanosphere, and Roche Diagnostics. Dr. Simon was supported
in part by National Institutes of Health grant to DIS (HL57506 MERIT
Award). Dr. Morrow has received honoraria for educational presentations
from CV Therapeutics, and Sanofi-Aventis. He has served as a consultant
for Beckman Coulter, Sanofi-Aventis, Schering Plough, and Siemens. Ms.
Murphy and Drs. Bonaca, and Ruff have no additional relationships to
report.
NR 23
TC 9
Z9 11
U1 1
U2 2
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0929-5305
J9 J THROMB THROMBOLYS
JI J. Thromb. Thrombolysis
PD AUG
PY 2012
VL 34
IS 2
BP 229
EP 234
DI 10.1007/s11239-012-0705-y
PG 6
WC Hematology; Peripheral Vascular Disease
SC Hematology; Cardiovascular System & Cardiology
GA 974IR
UT WOS:000306427900009
PM 22446997
ER
PT J
AU Navathe, AS
Volpp, KG
Konetzka, RT
Press, MJ
Zhu, JS
Chen, W
Lindrooth, RC
AF Navathe, Amol S.
Volpp, Kevin G.
Konetzka, R. Tamara
Press, Matthew J.
Zhu, Jingsan
Chen, Wei
Lindrooth, Richard C.
TI A Longitudinal Analysis of the Impact of Hospital Service Line
Profitability on the Likelihood of Readmission
SO MEDICAL CARE RESEARCH AND REVIEW
LA English
DT Article
DE quality of care; Medicare; payment reform; intensity of services;
service line profitability; readmission rates
ID DUTY HOUR REFORM; BALANCED BUDGET ACT; LENGTH-OF-STAY; ADMINISTRATIVE
DATA; MEDICARE BENEFICIARIES; COMORBIDITY MEASURES; PROSPECTIVE PAYMENT;
STAFFING DECISIONS; COMPETING RISKS; COX REGRESSION
AB Quality of care may be linked to the profitability of admissions in addition to level of reimbursement. Prior policy reforms reduced payments that differentially affected the average profitability of various admission types. The authors estimated a Cox competing risks model, controlling for the simultaneous risk of mortality post discharge, to determine whether the average profitability of hospital service lines to which a patient was admitted was associated with the likelihood of readmission within 30 days. The sample included 12,705,933 Medicare Fee for Service discharges from 2,438 general acute care hospitals during 1997, 2001, and 2005. There was no evidence of an association between changes in average service line profitability and changes in readmission risk, even when controlling for risk of mortality. These findings are reassuring in that the profitability of patients' admissions did not affect readmission rates, and together with other evidence may suggest that readmissions are not an unambiguous quality indicator for in-hospital care.
C1 [Navathe, Amol S.] Univ Penn, Wharton Sch, Dept Hlth Care Management, Philadelphia, PA 19146 USA.
[Navathe, Amol S.] Dept Hlth & Human Serv, Washington, DC USA.
[Navathe, Amol S.] Harvard Univ, Sch Med, Boston, MA USA.
[Volpp, Kevin G.; Chen, Wei] Vet Adm Hosp, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA.
[Konetzka, R. Tamara] Univ Chicago, Chicago, IL 60637 USA.
[Press, Matthew J.] Weill Cornell Med Coll, New York, NY USA.
[Lindrooth, Richard C.] Univ Colorado Denver, Aurora, CO USA.
RP Navathe, AS (reprint author), Univ Penn, Wharton Sch, Dept Hlth Care Management, 3641 Locust Walk,Room 202, Philadelphia, PA 19146 USA.
EM amol@wharton.upenn.edu
RI Lindrooth, Richard/J-8607-2012;
OI Lindrooth, Richard/0000-0001-9538-9749
FU Robert Wood Johnson Foundation's Health Care Financing and Organization
program
FX This research was funded, in part, by a grant from the Robert Wood
Johnson Foundation's Health Care Financing and Organization program.
NR 45
TC 3
Z9 3
U1 0
U2 5
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1077-5587
J9 MED CARE RES REV
JI Med. Care Res. Rev.
PD AUG
PY 2012
VL 69
IS 4
BP 414
EP 431
DI 10.1177/1077558712441085
PG 18
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA 976TW
UT WOS:000306609400003
PM 22466577
ER
PT J
AU Singer, SJ
Moore, SC
Meterko, M
Williams, S
AF Singer, Sara J.
Moore, Scott C.
Meterko, Mark
Williams, Sandra
TI Development of a Short-Form Learning Organization Survey: The LOS-27
SO MEDICAL CARE RESEARCH AND REVIEW
LA English
DT Article
DE organizational learning; psychometric analysis; survey
ID INTENSIVE-CARE UNITS; PATIENT SAFETY; HEALTH-CARE; HOSPITALS; IMPROVE;
IMPLEMENTATION; QUALITY; FAILURE; CLIMATE; WORK
AB Despite urgent need for innovation, adaptation, and change in health care, few tools enable researchers or practitioners to assess the extent to which health care facilities perform as learning organizations or the effects of initiatives that require learning. This study's objective was to develop and test a short-form Learning Organization Survey to fill this gap. The authors applied exploratory factor analysis and confirmatory factor analysis to data from Veterans Health Administration personnel to derive a short-form survey and then conducted further confirmatory factor analysis and factor invariance testing on additional Veterans Health Administration data to evaluate the short form. Results suggest that a 27-item, 7-factor survey (2 environmental factors, 1 on leadership, and 4 on concrete learning processes and practices) reliably measures key features of organizational learning, allowing researchers to evaluate theoretical propositions about organizational learning, its antecedents, and outcomes and enabling managers to assess and enhance organizations' learning capabilities and performance.
C1 [Singer, Sara J.] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA.
[Singer, Sara J.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Singer, Sara J.] Massachusetts Gen Hosp, Mongan Inst Hlth Policy, Boston, MA 02114 USA.
[Moore, Scott C.] Vet Hlth Adm Natl Ctr Org Dev, Cincinnati, OH USA.
[Meterko, Mark; Williams, Sandra] VA Boston Healthcare Syst, Ctr Org Leadership & Management Res, Boston, MA USA.
[Meterko, Mark] Boston Univ, Sch Publ Hlth, Boston, MA USA.
RP Singer, SJ (reprint author), Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, 677 Huntington Ave, Boston, MA 02115 USA.
EM ssinger@hsph.harvard.edu
FU Veterans Health Administration, Office of Academic Affiliations
FX The author(s) disclosed receipt of the following financial support for
the research, authorship, and/or publication of this article:
Development and validation of the revised instrument was financially
supported by a grant from the Veterans Health Administration, Office of
Academic Affiliations, as well as in-kind support from the Veterans
Health Administration, National Center for Organization Development.
NR 34
TC 13
Z9 13
U1 22
U2 45
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1077-5587
J9 MED CARE RES REV
JI Med. Care Res. Rev.
PD AUG
PY 2012
VL 69
IS 4
BP 432
EP 459
DI 10.1177/1077558712448135
PG 28
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA 976TW
UT WOS:000306609400004
PM 22635274
ER
PT J
AU Frazier-Wood, AC
Garvey, WT
Dall, T
Honigberg, R
Pourfarzib, R
AF Frazier-Wood, Alexis C.
Garvey, W. Timothy
Dall, Tara
Honigberg, Robert
Pourfarzib, Ray
TI Opportunities for Using Lipoprotein Subclass Profile by Nuclear Magnetic
Resonance Spectroscopy in Assessing Insulin Resistance and Diabetes
Prediction
SO METABOLIC SYNDROME AND RELATED DISORDERS
LA English
DT Review
ID HOMEOSTASIS MODEL ASSESSMENT; LOW-DENSITY LIPOPROTEINS; PARTICLE-SIZE;
METABOLIC SYNDROME; FASTING GLUCOSE; GLOBAL BURDEN; UNITED-STATES;
FOLLOW-UP; RISK; ATHEROSCLEROSIS
AB The incidence of type 2 diabetes mellitus (T2DM) has reached epidemic levels, and current trends indicate that its prevalence will continue to rise. The development of T2DM can be delayed by several years, and may even be prevented, by identifying individuals at risk for T2DM and treating them with lifestyle modification and/or pharmacological therapies. There are a number of methods available for assessing the insulin resistance (IR) that characterizes, and is the precursor to, T2DM. However, current clinical methods for assessing IR, based on measures of plasma glucose and/or insulin are either laborious and time-consuming or show a low specificity. IR manifests its earliest measurable abnormalities through changes in lipoproteins, and thus we propose that by examining lipoprotein subclass profile, it may be possible to alert physicians and patients to a heightened risk of developing diabetes. This will allow us to institute appropriate lifestyle changes and treatment potentially to delay the onset or possibly prevent the progression to diabetes.
C1 [Frazier-Wood, Alexis C.] Univ Alabama Birmingham, Dept Epidemiol, Birmingham, AL 35294 USA.
[Frazier-Wood, Alexis C.] Univ Alabama Birmingham, Sect Stat Genet, Birmingham, AL 35294 USA.
[Frazier-Wood, Alexis C.] Univ Alabama Birmingham, Off Energet, Birmingham, AL 35294 USA.
[Garvey, W. Timothy] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
[Honigberg, Robert; Pourfarzib, Ray] LipoScience Inc, Raleigh, NC USA.
RP Frazier-Wood, AC (reprint author), Univ Alabama Birmingham, Dept Epidemiol, RPHB 230P, Birmingham, AL 35294 USA.
EM lekkiwood@gmail.com
RI Frazier-Wood, Alexis (Lekki)/B-8053-2010
OI Frazier-Wood, Alexis (Lekki)/0000-0001-7616-2119
FU National Institutes of Health (NIH) [DK-038764, DK-083562]; Merit Review
program of the Department of Veterans Affairs; UAB Diabetes Research and
Training Center [P60DK079626]; NIH National Heart, Lung, and Blood
Institute grant [U01HL072524-04]
FX The authors acknowledge research support from the National Institutes of
Health (NIH; DK-038764, DK-083562) and the Merit Review program of the
Department of Veterans Affairs. We also gratefully acknowledge the
support of the UAB Diabetes Research and Training Center (P60DK079626).
Dr. Frazier-Wood is supported by NIH National Heart, Lung, and Blood
Institute grant U01HL072524-04.
NR 37
TC 6
Z9 6
U1 0
U2 1
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1540-4196
J9 METAB SYNDR RELAT D
JI Metab. Syndr. Relat. Disord.
PD AUG
PY 2012
VL 10
IS 4
BP 244
EP 251
DI 10.1089/met.2011.0148
PG 8
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 976OR
UT WOS:000306594700002
PM 22533466
ER
PT J
AU Samkoe, KS
Sexton, K
Tichauer, KM
Hextrum, SK
Pardesi, O
Davis, SC
O'Hara, JA
Hoopes, PJ
Hasan, T
Pogue, BW
AF Samkoe, Kimberley S.
Sexton, Kristian
Tichauer, Kenneth M.
Hextrum, Shannon K.
Pardesi, Omar
Davis, Scott C.
O'Hara, Julia A.
Hoopes, P. Jack
Hasan, Tayyaba
Pogue, Brian W.
TI High Vascular Delivery of EGF, but Low Receptor Binding Rate Is Observed
in AsPC-1 Tumors as Compared to Normal Pancreas
SO MOLECULAR IMAGING AND BIOLOGY
LA English
DT Article
DE Three-compartment model; Epidermal growth factor receptor; Pancreatic
tumor; Fluorescence imaging; Cellular associated rate constant
ID EPIDERMAL-GROWTH-FACTOR; FACTOR-ALPHA; CANCER; THERAPY; GEMCITABINE;
EXPRESSION; BLOCKADE; MODELS; AGENTS; MOUSE
AB Cellular receptor targeted imaging agents present the potential to target extracellular molecular expression in cancerous lesions; however, the image contrast in vivo does not reflect the magnitude of overexpression expected from in vitro data. Here, the in vivo delivery and binding kinetics of epidermal growth factor receptor (EGFR) was determined for normal pancreas and AsPC-1 orthotopic pancreatic tumors known to overexpress EGFR.
EGFR in orthotopic xenograft AsPC-1 tumors was targeted with epidermal growth factor (EGF) conjugated with IRDye800CW. The transfer rate constants (k (e,) K (12), k (21), k (23), and k (32)) associated with a three-compartment model describing the vascular delivery, leakage rate and binding of targeted agents were determined experimentally. The plasma excretion rate, k (e), was determined from extracted blood plasma samples. K (12), k (21), and k (32) were determined from ex vivo tissue washing studies at time points a parts per thousand yen24 h. The measured in vivo uptake of IRDye800CW-EGF and a non-targeted tracer dye, IRDye700DX-carboxylate, injected simultaneously was used to determined k (23).
The vascular exchange of IRDye800CW-EGF in the orthotopic tumor (K (12) and k (21)) was higher than in the AsPC-1 tumor as compared to normal pancreas, suggesting that more targeted agent can be taken up in tumor tissue. However, the cellular associated (binding) rate constant (k (23)) was slightly lower for AsPC-1 pancreatic tumor (4.1 x 10(-4) s(-1)) than the normal pancreas (5.5 x 10(-4) s(-1)), implying that less binding is occurring.
Higher vascular delivery but low cellular association in the AsPC-1 tumor compared to the normal pancreas may be indicative of low receptor density due to low cellular content. This attribute of the AsPC-1 tumor may indicate one contributing cause of the difficulty in treating pancreatic tumors with cellular targeted agents.
C1 [Samkoe, Kimberley S.; Sexton, Kristian; Tichauer, Kenneth M.; Hextrum, Shannon K.; Pardesi, Omar; Davis, Scott C.; O'Hara, Julia A.; Hoopes, P. Jack; Pogue, Brian W.] Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA.
[Hoopes, P. Jack; Pogue, Brian W.] Dartmouth Med Sch, Dept Surg, Hanover, NH 03755 USA.
[Hasan, Tayyaba; Pogue, Brian W.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
RP Samkoe, KS (reprint author), Dartmouth Coll, Thayer Sch Engn, 8000 Cummings Hall, Hanover, NH 03755 USA.
EM kimberley.s.samkoe@dartmouth.edu; brian.w.pogue@dartmouth.edu
OI Tichauer, Kenneth/0000-0003-1667-3026
FU NIH [P01CA84201, R01CA109558, R01CA156177]
FX This work was funded by NIH grants P01CA84201, R01CA109558, and
R01CA156177.
NR 30
TC 13
Z9 13
U1 0
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1536-1632
EI 1860-2002
J9 MOL IMAGING BIOL
JI Mol. Imaging. Biol.
PD AUG
PY 2012
VL 14
IS 4
BP 472
EP 479
DI 10.1007/s11307-011-0503-5
PG 8
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 975YU
UT WOS:000306548500012
PM 21847690
ER
PT J
AU Gavasso, S
Gjertsen, BT
Anderssen, E
Myhr, KM
Vedeler, C
AF Gavasso, S.
Gjertsen, B. T.
Anderssen, E.
Myhr, K. M.
Vedeler, C.
TI Immunogenic effects of recombinant interferon-beta therapy disrupt the
JAK/STAT pathway in primary immune cells from patients with multiple
sclerosis
SO MULTIPLE SCLEROSIS JOURNAL
LA English
DT Article
DE interferon-beta; JAK/STAT signalling; immunogenicity; neutralizing
antibodies; PBMC; phospho-flow cytometry
ID RELAPSING-REMITTING MS; NEUTRALIZING ANTIBODIES; FLOW-CYTOMETRY;
IFN-BETA; EXPRESSION; BIOACTIVITY; PROGRESSION; RESPONSES; IMPACT; TITER
AB Background: Immunogenicity of recombinant interferon-beta (IFN-beta) is a known complication in the therapy of relapsing-remitting multiple sclerosis (RRMS). Neutralizing antibodies (NAbs) that can interfere with efficacy are quantified using in vitro bioassays; however, these assays do not reveal the immunogenic state of the patient and are not predictive of treatment outcome.
Objective: Assessment of the impact of NAbs on IFN-beta responsive cells and signalling pathways in peripheral blood mononuclear cells (PBMCs) with phospho-specific flow cytometry.
Method: PBMCs from 10 IFN-beta-treated patients with RRMS, two untreated patients, and two healthy controls were re-stimulated in autologous sera and media with a serial dilution of IFN-beta (0-8000 U/ml) and levels of phosphorylation of STAT1/3/4/5/6 transcription factors were quantified in PBMC subtypes (NAb titres 0 to > 6000 neutralizing units). Data was subjected to principal component analysis, Hotelling's T-2, and partial least squares analysis.
Results: Three significantly distinct clusters of individuals were revealed in autologous sera: therapy-naive and healthy, treated NAb-negative, and treated NAb-positive. Compared with controls STATs signalling patterns were modulated in treated NAb-negative patients and inhibited in all treated NAb-positive patients independently of NAb titres. In media no clustering of patients could be found. The predictability of NAb titres based on the phospho-flow data was 74%.
Conclusion: Phospho-specific flow cytometry can delineate subset-specific cell responses that can act as surrogates for NAb exposure in blood. Immunogenic effects alter the response in primary cells even at low NAb levels. Cell line-based immunogenicity testing is not readily transferable to the immunogenic response in patients.
C1 [Gavasso, S.] Haukeland Hosp, Neurol Res Lab, Dept Neurol, N-5021 Bergen, Norway.
[Gavasso, S.; Myhr, K. M.; Vedeler, C.] Univ Bergen, Inst Clin Med, N-5020 Bergen, Norway.
[Gavasso, S.; Myhr, K. M.] Haukeland Hosp, Dept Neurol, Norwegian Multiple Sclerosis Competence Ctr, N-5021 Bergen, Norway.
[Gjertsen, B. T.] Univ Bergen, Haematol Sect, Inst Med, N-5020 Bergen, Norway.
[Gjertsen, B. T.] Haukeland Hosp, Dept Internal Med, N-5021 Bergen, Norway.
[Anderssen, E.] Massachusetts Gen Hosp, Ctr Canc Res, Boston, MA 02114 USA.
[Myhr, K. M.; Vedeler, C.] Univ Bergen, KG Jebsen Ctr MS Res, Dept Clin Med, N-5020 Bergen, Norway.
RP Gavasso, S (reprint author), Haukeland Hosp, Neurol Res Lab, Dept Neurol, N-5021 Bergen, Norway.
EM sonia.gavasso@helse-bergen.no
RI Gjertsen, Bjorn T/O-1542-2015
OI Gjertsen, Bjorn T/0000-0001-9358-9704
FU Norwegian Multiple Sclerosis Competence Center, Bergen, Norway; Research
Council of Norway's National Program for Research in Functional
Genomics; Bayer Health Care; Bayer Schering Pharma, Norway; Biogen Idec,
Norway; Sanofi-Aventis, Norway
FX This research was funded by the Norwegian Multiple Sclerosis Competence
Center, Bergen, Norway; the Research Council of Norway's National
Program for Research in Functional Genomics; and unrestricted grants
from Bayer Health Care and Bayer Schering Pharma, Norway; Biogen Idec,
Norway; and Sanofi-Aventis, Norway.
NR 39
TC 4
Z9 4
U1 0
U2 2
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1352-4585
J9 MULT SCLER J
JI Mult. Scler. J.
PD AUG
PY 2012
VL 18
IS 8
BP 1116
EP 1124
DI 10.1177/1352458511434066
PG 9
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 975KQ
UT WOS:000306510600010
PM 22287540
ER
PT J
AU Quintana, FJ
Jin, HL
Burns, EJ
Nadeau, M
Yeste, A
Kumar, D
Rangachari, M
Zhu, C
Xiao, S
Seavitt, J
Georgopoulos, K
Kuchroo, VK
AF Quintana, Francisco J.
Jin, Hulin
Burns, Evan J.
Nadeau, Meghan
Yeste, Ada
Kumar, Deepak
Rangachari, Manu
Zhu, Chen
Xiao, Sheng
Seavitt, John
Georgopoulos, Katia
Kuchroo, Vijay K.
TI Aiolos promotes T(H)17 differentiation by directly silencing Il2
expression
SO NATURE IMMUNOLOGY
LA English
DT Article
ID REGULATORY T-CELLS; ARYL-HYDROCARBON RECEPTOR; TH17 CELLS; HELPER-CELLS;
ROR-GAMMA; IN-VIVO; INTERLEUKIN-2; TRANSCRIPTION; GENE; IL-2
AB CD4(+) interleukin 17 (IL-17)-producing helper T cells (T(H)17 cells) are instrumental in the immune response to pathogens. However, an overactive T(H)17 response results in tissue inflammation and autoimmunity, and therefore it is important to identify the molecular mechanisms that control the development of T(H)17 cells. IL-2 suppresses such development, but how IL-2 production is actively suppressed during T(H)7 differentiation is not understood. Here we report that under T(H)17-polarizing conditions, the transcription factors STAT3 and AhR upregulated the expression of Aiolos, a member of the Ikaros family of transcription factors. Using Aiolos-deficient mice, we demonstrated that Aiolos silenced the Il2 locus, promoting T(H)17 differentiation in vitro and in vivo. Thus, we have identified a module in the transcriptional program of T(H)17 cells that actively limits IL-2 production and promotes their differentiation.
C1 [Quintana, Francisco J.; Jin, Hulin; Burns, Evan J.; Nadeau, Meghan; Yeste, Ada; Rangachari, Manu; Zhu, Chen; Xiao, Sheng; Kuchroo, Vijay K.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Neurol Dis, Boston, MA 02115 USA.
[Kumar, Deepak] Harvard Univ, Sch Med, Boston, MA USA.
[Seavitt, John; Georgopoulos, Katia] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Charlestown, MA USA.
RP Quintana, FJ (reprint author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Neurol Dis, Boston, MA 02115 USA.
EM fquintana@rics.bwh.harvard.edu; vkuchroo@rics.bwh.harvard.edu
FU US National Institutes of Health [P01AI073748, P01NS038037, P01AI056299,
R01NS030843, AI075285, AI093903]; National Multiple Sclerosis Society
[RG4111A1, FG1850-A-1]; Harvard Medical School Office for Diversity and
Community Partnership
FX We thank D. Kozoriz for cell sorting, and B. Waksman and I.R. Cohen for
discussions. Supported by the US National Institutes of Health
(P01AI073748, P01NS038037, P01AI056299 and R01NS030843 to V.K.K.; and
AI075285 and AI093903 to F.J.Q.), the National Multiple Sclerosis
Society (RG4111A1 to F.J.Q.), the Harvard Medical School Office for
Diversity and Community Partnership (F.J.Q.) and the National Multiple
Sclerosis Society (FG1850-A-1 to H.J.).
NR 45
TC 83
Z9 89
U1 1
U2 16
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1529-2908
J9 NAT IMMUNOL
JI Nat. Immunol.
PD AUG
PY 2012
VL 13
IS 8
BP 770
EP +
DI 10.1038/ni.2363
PG 9
WC Immunology
SC Immunology
GA 976GT
UT WOS:000306569600013
PM 22751139
ER
PT J
AU O'Connor, S
Ayres, A
Cortellini, L
Rosand, J
Rosenthal, E
Kimberly, WT
AF O'Connor, Sydney
Ayres, Alison
Cortellini, Lynelle
Rosand, Jonathan
Rosenthal, Eric
Kimberly, W. Taylor
TI Process Improvement Methods Increase the Efficiency, Accuracy, and
Utility of a Neurocritical Care Research Repository
SO NEUROCRITICAL CARE
LA English
DT Article
DE Neurocritical care; Research repository; Process improvement; Root-cause
analysis; Plan-do-study-act
AB Reliable and efficient data repositories are essential for the advancement of research in Neurocritical care. Various factors, such as the large volume of patients treated within the Neuro ICU, their differing length and complexity of hospital stay, and the substantial amount of desired information can complicate the process of data collection.
We adapted the tools of process improvement to the data collection and database design of a research repository for a Neuroscience intensive care unit. By the Shewhart-Deming method, we implemented an iterative approach to improve the process of data collection for each element. After an initial design phase, we re-evaluated all data fields that were challenging or time-consuming to collect. We then applied root-cause analysis to optimize the accuracy and ease of collection, and to determine the most efficient manner of collecting the maximal amount of data.
During a 6-month period, we iteratively analyzed the process of data collection for various data elements. For example, the pre-admission medications were found to contain numerous inaccuracies after comparison with a gold standard (sensitivity 71 % and specificity 94 %). Also, our first method of tracking patient admissions and discharges contained higher than expected errors (sensitivity 94 % and specificity 93 %). In addition to increasing accuracy, we focused on improving efficiency. Through repeated incremental improvements, we reduced the number of subject records that required daily monitoring from 40 to 6 per day, and decreased daily effort from 4.5 to 1.5 h/day.
By applying process improvement methods to the design of a Neuroscience ICU data repository, we achieved a threefold improvement in efficiency and increased accuracy. Although individual barriers to data collection will vary from institution to institution, a focus on process improvement is critical to overcoming these barriers.
C1 [O'Connor, Sydney; Ayres, Alison; Cortellini, Lynelle; Rosand, Jonathan; Rosenthal, Eric; Kimberly, W. Taylor] Massachusetts Gen Hosp, Dept Neurol, Div Neurocrit Care & Emergency Neurol, Boston, MA 02114 USA.
RP Kimberly, WT (reprint author), Massachusetts Gen Hosp, Dept Neurol, Div Neurocrit Care & Emergency Neurol, Lunder 644,45 Fruit St, Boston, MA 02114 USA.
EM wtkimberly@partners.org
OI Ayres, Alison/0000-0002-5492-1695; Rosenthal, Eric/0000-0003-3900-356X
FU NIH [R01NS059727, R01NS073344, 1K23NS076597]; Beth Israel Deaconess
Medical Center - Harvard Medical School; Pfizer Inc.; Merck Co
FX Funded by NIH R01NS059727 (J. R.), NIH R01NS073344 (J. R.), NIH
1K23NS076597 (W. T. K.) and the Clinical Investigator Training Program:
Beth Israel Deaconess Medical Center - Harvard Medical School, in
collaboration with Pfizer Inc. and Merck & Co (W.T.K.).
NR 9
TC 0
Z9 0
U1 0
U2 4
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 1541-6933
J9 NEUROCRIT CARE
JI Neurocrit. Care
PD AUG
PY 2012
VL 17
IS 1
BP 90
EP 96
DI 10.1007/s12028-012-9689-x
PG 7
WC Critical Care Medicine; Clinical Neurology
SC General & Internal Medicine; Neurosciences & Neurology
GA 976NG
UT WOS:000306591000012
PM 22434546
ER
PT J
AU Wu, XB
Tucker, JD
Hong, FC
Messina, J
Lan, LN
Hu, YF
Feng, TJ
Emch, ME
Liu, XL
Zhang, CL
Wen, LZ
AF Wu, Xiaobing
Tucker, Joseph D.
Hong, Fuchang
Messina, Jane
Lan, Lina
Hu, Yufeng
Feng, Tiejian
Emch, Michael E.
Liu, Xiaoli
Zhang, Chunlai
Wen, Lizhang
TI Multilevel and spatial analysis of syphilis in Shenzhen, China, to
inform spatially targeted control measures
SO SEXUALLY TRANSMITTED INFECTIONS
LA English
DT Article
ID SEX WORK; HIV; RISK; MEN; SURVEILLANCE; PERCEPTIONS; INFECTIONS;
BEHAVIORS; CONTEXT; HEALTH
AB Objectives The present study investigates the varied spatial distribution of syphilis cases in Shenzhen, China, and explores the individual-, neighbourhood- and district-level factors affecting the distribution.
Methods This study uses spatial analysis and multi-level generalised estimating equations to explore the spatial distribution of reported syphilis cases among individuals in Shenzhen, Guangdong Province, China. The spatial distribution of primary/secondary and latent cases was investigated using the Moran's I-statistic. Primary/secondary syphilis cases were compared with all syphilis cases using a three-level model with individual (n=6496), neighbourhood (n=55) and district (n=6) levels.
Results A total of 6496 syphilis cases were reported in 2009 with 35.8% primary and secondary syphilis cases. Both primary/secondary syphilis cases (Moran's I value=0.33, p<0.01) and latent syphilis cases (Moran's I value=0.19, p<0.01) showed significant spatial clustering at the neighbourhood level. Adjusting for the number of reporting hospitals, the best model found that the following characteristics were associated with primary/secondary syphilis infection: individuals who are younger in age (p=0.003), male (p<0.001), migrant labourers (p=0.047) and those who live in districts with a higher gross domestic product (p<0.001).
Conclusions There is substantial clustering of primary and secondary syphilis cases at the neighbourhood level in Shenzhen, suggesting the need for greater STD health service provision in these clustered neighbourhoods. Spatially targeted syphilis control measures may be useful to optimise testing, treatment and partner services.
C1 [Wu, Xiaobing; Hong, Fuchang; Lan, Lina; Hu, Yufeng; Feng, Tiejian; Liu, Xiaoli; Zhang, Chunlai; Wen, Lizhang] Shenzhen Ctr Chron Dis Control, Shenzhen, Peoples R China.
[Tucker, Joseph D.] Massachusetts Gen Hosp, Infect Dis Unit, Boston, MA 02114 USA.
[Tucker, Joseph D.] Univ N Carolina, Sch Med, Div Infect Dis, Chapel Hill, NC USA.
[Messina, Jane; Emch, Michael E.] Univ N Carolina, Dept Geog, Chapel Hill, NC USA.
RP Feng, TJ (reprint author), Shenzhen Ctr Chron Dis Control & Prevent, 2021 Buxin Rd, Shenzhen, Peoples R China.
EM tiejian.feng@gmail.com
FU Shenzhen Municipal Health Bureau for STI Prevention and Control Program;
Mega Project of China National Science Research for the 11th 5-year Plan
[2008ZX10001-005]; NIH Fogarty Career Development Award [US NIH
1K01TW008200-01A1]
FX This work was supported by grants from the Shenzhen Municipal Health
Bureau for STI Prevention and Control Program, the Mega Project of China
National Science Research for the 11th 5-year Plan (2008ZX10001-005) and
an NIH Fogarty Career Development Award (US NIH 1K01TW008200-01A1).
NR 28
TC 7
Z9 7
U1 1
U2 10
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1368-4973
J9 SEX TRANSM INFECT
JI Sex. Transm. Infect.
PD AUG
PY 2012
VL 88
IS 5
BP 325
EP 329
DI 10.1136/sextrans-2011-050397
PG 5
WC Infectious Diseases
SC Infectious Diseases
GA 974CC
UT WOS:000306406400005
PM 22378936
ER
PT J
AU Wang, AL
Peng, RR
Tucker, JD
Cohen, MS
Chen, XS
AF Wang, Alberta L.
Peng, Rui-Rui
Tucker, Joseph D.
Cohen, Myron S.
Chen, Xiang-Sheng
TI Partner notification uptake for sexually transmitted infections in
China: a systematic literature review
SO SEXUALLY TRANSMITTED INFECTIONS
LA English
DT Review
ID CHLAMYDIAL INFECTION; HIDDEN EPIDEMIC; SEX PARTNERS; DISEASES; HIV;
MANAGEMENT; HIV/AIDS; TANZANIA; STIGMA; CARE
AB Objective China's sexually transmitted infection (STI) epidemic requires comprehensive control programmes. Partner services are traditional pillars of STI control but have not been widely implemented in China. This study was a systematic literature review to examine STI partner notification (PN) uptake in China.
Methods Four English and four Chinese language databases were searched up to March 2011 to identify articles on PN of STIs including HIV in China. PN uptake was defined as the number of partners named, notified, evaluated or diagnosed per index patient.
Results A total of 11 studies met inclusion criteria. For STI (excluding HIV) PN, a median 31.6% (IQR 27.4%-65.8%) of named partners were notified, 88.8% (IQR 88.4%-90.8%) of notified partners were evaluated and 37.9% (IQR 33.1%-43.6%) of evaluated partners were diagnosed. For HIV PN, a median 15.7% (IQR 13.2%-36.5%) of named partners were notified, 86.7% (IQR 72.9%-90.4%) of notified partners were evaluated and 27.6% (IQR 24.1%-27.7%) of evaluated partners were diagnosed. A mean of 80.6% (SD=12.6%) of patients attempted PN, and 72.4% (IQR 63.8%=81.1%) chose self-referral when offered more than one method of PN. Perceived patient barriers included social stigma, fear of relationship breakdown, uncertainty of how to notify and lack of partner contact information. Perceived infrastructure barriers included limited time and trained staff, mistrust of health workers and lack of PN guidelines.
Conclusion PN programmes are feasible in China. Further research on STI PN, particularly among men who have sex with men and other high-risk groups, is an important public health priority. PN policies and guidelines are urgently needed in China.
C1 [Wang, Alberta L.; Peng, Rui-Rui; Chen, Xiang-Sheng] Chinese Acad Med Sci, Nanjing 210042, Jiangsu, Peoples R China.
[Wang, Alberta L.; Peng, Rui-Rui; Chen, Xiang-Sheng] Peking Union Med Coll, Inst Dermatol, Nanjing 210042, Jiangsu, Peoples R China.
[Wang, Alberta L.; Peng, Rui-Rui; Chen, Xiang-Sheng] Natl Ctr STD Control, Nanjing 210042, Jiangsu, Peoples R China.
[Wang, Alberta L.] Univ Texas Hlth Sci Ctr Houston, Houston, TX USA.
[Tucker, Joseph D.; Cohen, Myron S.] Univ N Carolina, Sch Med, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA.
[Tucker, Joseph D.] Massachusetts Gen Hosp, Div Infect Dis, Cambridge, MA USA.
RP Chen, XS (reprint author), Chinese Acad Med Sci, 12 Jiangwangmiao St, Nanjing 210042, Jiangsu, Peoples R China.
EM chenxs@ncstdlc.org
FU National Institutes of Health; Office of the Director; Fogarty
International Center; Office of AIDS Research; National Cancer
Institute; National Eye Institute; National Heart, Blood and Lung
Institute; National Institute of Dental & Craniofacial Research;
National Institute On Drug Abuse; National Institute of Mental Health;
National Institute of Allergy and Infectious Diseases Health, through
the International Clinical Research Fellows Program at Vanderbilt
University [R24 TW007988]; Mega Project of China National Science
Research for the 11th Five-Year Plan [2008ZX10001-005]
FX The authors thank Frank Wong at Emory University for his review and
comments of the paper, Meridith Blevins at Vanderbilt University for
statistical advice, and Yan Hong-Jing at the Jiangsu CDC and Jiang Ning
at the Chinese National STD Control Center for PN policy information.
NIMH International Clinical Research Fellows Program at Vanderbilt
University and China Mega Project. Grant Number: R24 TW007988 and
2008ZX10001-005.; This study was funded by the National Institutes of
Health; Office of the Director; Fogarty International Center; Office of
AIDS Research; National Cancer Institute; National Eye Institute;
National Heart, Blood and Lung Institute; National Institute of Dental &
Craniofacial Research; National Institute On Drug Abuse; National
Institute of Mental Health; and the National Institute of Allergy and
Infectious Diseases Health, through the International Clinical Research
Fellows Program at Vanderbilt University (R24 TW007988) and the Mega
Project of China National Science Research for the 11th Five-Year Plan
(2008ZX10001-005).
NR 30
TC 8
Z9 11
U1 2
U2 9
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1368-4973
J9 SEX TRANSM INFECT
JI Sex. Transm. Infect.
PD AUG
PY 2012
VL 88
IS 5
BP 386
EP 393
DI 10.1136/sextrans-2011-050275
PG 8
WC Infectious Diseases
SC Infectious Diseases
GA 974CC
UT WOS:000306406400020
PM 22427489
ER
PT J
AU Wilkinson, JE
Burmeister, L
Brooks, SV
Chan, CC
Friedline, S
Harrison, DE
Hejtmancik, JF
Nadon, N
Strong, R
Wood, LK
Woodward, MA
Miller, RA
AF Wilkinson, John E.
Burmeister, Lisa
Brooks, Susan V.
Chan, Chi-Chao
Friedline, Sabrina
Harrison, David E.
Hejtmancik, James F.
Nadon, Nancy
Strong, Randy
Wood, Lauren K.
Woodward, Maria A.
Miller, Richard A.
TI Rapamycin slows aging in mice
SO AGING CELL
LA English
DT Article
DE interventions; longevity pathology; TOR
ID AMES DWARF MICE; GENETICALLY HETEROGENEOUS MICE; LIFE-SPAN EXTENSION;
SIGNALING PATHWAY; CELL-CYCLE; TOR; TARGET; CANCER; AGE; RESTRICTION
AB Rapamycin increases lifespan in mice, but whether this represents merely inhibition of lethal neoplastic diseases, or an overall slowing in multiple aspects of aging is currently unclear. We report here that many forms of age-dependent change, including alterations in heart, liver, adrenal glands, endometrium, and tendon, as well as age-dependent decline in spontaneous activity, occur more slowly in rapamycin-treated mice, suggesting strongly that rapamycin retards multiple aspects of aging in mice, in addition to any beneficial effects it may have on neoplastic disease. We also note, however, that mice treated with rapamycin starting at 9 months of age have significantly higher incidence of testicular degeneration and cataracts; harmful effects of this kind will guide further studies on timing, dosage, and tissue-specific actions of rapamycin relevant to the development of clinically useful inhibitors of TOR action.
C1 [Wilkinson, John E.; Burmeister, Lisa; Friedline, Sabrina; Miller, Richard A.] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA.
[Burmeister, Lisa; Friedline, Sabrina; Miller, Richard A.] Univ Michigan, Geriatr Ctr, Ann Arbor, MI 48109 USA.
[Wilkinson, John E.] Univ Michigan, Unit Lab Anim Med, Ann Arbor, MI 48109 USA.
[Brooks, Susan V.; Wood, Lauren K.] Univ Michigan, Dept Mol & Integrat Physiol & Biomed Engn, Ann Arbor, MI 48109 USA.
[Chan, Chi-Chao] NEI, Histol Core, NIH, Bethesda, MD 20892 USA.
[Harrison, David E.] Jackson Lab, Bar Harbor, ME 04609 USA.
[Hejtmancik, James F.] NEI, Ophthalm Genet & Visual Funct Branch, NIH, Bethesda, MD 20892 USA.
[Nadon, Nancy] NIA, Div Aging Biol, Bethesda, MD 20892 USA.
[Woodward, Maria A.] Univ Michigan, WK Kellogg Eye Ctr, Dept Ophthalmol, Ann Arbor, MI 48105 USA.
[Strong, Randy] Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, San Antonio, TX 78229 USA.
[Strong, Randy] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA.
[Strong, Randy] S Texas Vet Hlth Care Syst, Res Serv, San Antonio, TX 78229 USA.
[Strong, Randy] S Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX 78229 USA.
RP Miller, RA (reprint author), Univ Michigan, Dept Pathol, BSRB Room 3001,Box 2200,109 Zina Pitcher Pl, Ann Arbor, MI 48109 USA.
EM millerr@umich.edu
OI Zaseck, Lauren/0000-0002-8604-0032
FU [AG022303]; [AG007996]; [AG013283]
FX This work was supported by grants AG022303, AG007996, and AG013283. We
thank Vivian Diaz, Lynn Winkleman, and Mike Astle for expert technical
assistance.
NR 35
TC 208
Z9 213
U1 2
U2 39
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1474-9718
J9 AGING CELL
JI Aging Cell
PD AUG
PY 2012
VL 11
IS 4
BP 675
EP 682
DI 10.1111/j.1474-9726.2012.00832.x
PG 8
WC Cell Biology; Geriatrics & Gerontology
SC Cell Biology; Geriatrics & Gerontology
GA 973ZY
UT WOS:000306400600014
PM 22587563
ER
PT J
AU Riegel, B
Ratcliffe, SJ
Sayers, SL
Potashnik, S
Buck, HG
Jurkovitz, C
Fontana, S
Weaver, TE
Weintraub, WS
Goldberg, LR
AF Riegel, Barbara
Ratcliffe, Sarah J.
Sayers, Steven L.
Potashnik, Sheryl
Buck, Harleah G.
Jurkovitz, Claudine
Fontana, Sarah
Weaver, Terri E.
Weintraub, William S.
Goldberg, Lee R.
TI Determinants of Excessive Daytime Sleepiness and Fatigue in Adults With
Heart Failure
SO CLINICAL NURSING RESEARCH
LA English
DT Article
DE fatigue; physical activity; exercise; diuretics; functional class;
excessive daytime sleepiness; heart failure
ID RANDOMIZED CONTROLLED-TRIAL; MODERATE-INTENSITY EXERCISE;
QUALITY-OF-LIFE; OLDER-ADULTS; WAKEFULNESS TEST; APNEA SYNDROME;
RISK-FACTORS; CONSEQUENCES; DISORDERS; HEALTH
AB Little is known about excessive daytime sleepiness (EDS) in heart failure (HF). The aim of this cross-sectional descriptive study was to describe the prevalence of EDS and factors associated with it in HF. A secondary purpose was to explore the correlates of fatigue. We enrolled a consecutive sample of 280 adults with a confirmed diagnosis of chronic HF from three outpatient settings in the northeastern United States. Patients with major depressive illness were excluded. Clinical, sociodemographic, behavioral, and perceptual factors were explored as possible correlates of EDS. Using an Epworth Sleepiness Scale score > 10, the prevalence of EDS was 23.6%. Significant determinants of EDS were worse sleep quality (p = .048), worse functional class (p = .004), not taking a diuretic (p = .005), and lack of physical activity (p = .04). Only sleep quality was associated with fatigue (p < .001). Sleep-disordered breathing was not significantly associated with EDS or with fatigue. These factors may be amenable to intervention.
C1 [Riegel, Barbara] Univ Penn, Sch Nursing, Biobehav Res Ctr, Philadelphia, PA 19104 USA.
[Sayers, Steven L.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
[Ratcliffe, Sarah J.; Sayers, Steven L.; Goldberg, Lee R.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA.
[Buck, Harleah G.] Penn State Univ, Sch Nursing, University Pk, PA 16802 USA.
[Jurkovitz, Claudine; Weintraub, William S.] Christiana Care Hlth Syst, Christiana Care Ctr Outcomes Res, Newark, DE USA.
[Weaver, Terri E.] Univ Illinois, Coll Nursing, Chicago, IL USA.
[Fontana, Sarah] Univ Penn, Heart Failure & Transplant Ctr, Philadelphia, PA 19104 USA.
[Goldberg, Lee R.] Univ Penn, Med Ctr, Heart Lung Transplant Program, Philadelphia, PA 19104 USA.
RP Riegel, B (reprint author), Univ Penn, Sch Nursing, Biobehav Res Ctr, 418 Curie Blvd, Philadelphia, PA 19104 USA.
EM briegel@nursing.upenn.edu
OI Goldberg, Lee/0000-0002-7906-9638
FU National Heart, Lung & Blood Institute [RO1 HL084394-01A1]; Philadelphia
Veterans Affairs Medical Center; VISN 4 Mental Illness Research,
Education, and Clinical Center (MIREC)
FX The authors disclosed receipt of the following financial support for the
research, authorship, and/or publication of this article: This work was
funded by a grant from the National Heart, Lung & Blood Institute (RO1
HL084394-01A1) and by the Philadelphia Veterans Affairs Medical Center,
VISN 4 Mental Illness Research, Education, and Clinical Center (MIREC).
NR 65
TC 11
Z9 12
U1 0
U2 9
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1054-7738
J9 CLIN NURS RES
JI Clin. Nurs. Res.
PD AUG
PY 2012
VL 21
IS 3
BP 271
EP 293
DI 10.1177/1054773811419842
PG 23
WC Nursing
SC Nursing
GA 973QL
UT WOS:000306374800004
PM 21878581
ER
PT J
AU Forman, SA
AF Forman, Stuart A.
TI Monod-Wyman-Changeux allosteric mechanisms of action and the
pharmacology of etomidate
SO CURRENT OPINION IN ANESTHESIOLOGY
LA English
DT Review
DE allosteric model; co-agonism; equilibrium; general anesthetic; Gibbs
free energy; mutation
ID GENERAL ANESTHETIC ETOMIDATE; GABA(A) RECEPTOR; A RECEPTOR; ACID;
ACTIVATION; MUTATIONS; MODULATION; BINDING; SITES; MODEL
AB Purpose of review
Formal Monod-Wyman-Changeux allosteric mechanisms have proven valuable in framing research on the mechanism of etomidate action on its major molecular targets, gamma-aminobutyric acid type A (GABA(A)) receptors. However, the mathematical formalism of these mechanisms makes them difficult to comprehend.
Recent findings
We illustrate how allosteric models represent shifting equilibria between various functional receptor states (closed versus open) and how co-agonism can be readily understood as simply addition of gating energy associated with occupation of distinct agonist sites. We use these models to illustrate how the functional effects of a point mutation, alpha 1M236W, in GABA(A) receptors can be translated into an allosteric model phenotype.
Summary
Allosteric co-agonism provides a robust framework for design and interpretation of structure-function experiments aimed at understanding where and how etomidate affects its GABA(A) receptor target molecules.
C1 Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA.
RP Forman, SA (reprint author), Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Jackson 444, Boston, MA 02114 USA.
EM saforman@partners.org
FU NIH [P01GM58448, R01GM089745]
FX This work was supported by the NIH grants (P01GM58448 and R01GM089745).
NR 27
TC 9
Z9 9
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0952-7907
J9 CURR OPIN ANESTHESIO
JI Curr. Opin. Anesthesiol.
PD AUG
PY 2012
VL 25
IS 4
BP 411
EP 418
DI 10.1097/ACO.0b013e328354feea
PG 8
WC Anesthesiology
SC Anesthesiology
GA 972JR
UT WOS:000306273900003
PM 22614249
ER
PT J
AU Coppola, G
Chinnathambi, S
Lee, JJ
Dombroski, BA
Baker, MC
Soto-Ortolaza, AI
Lee, SE
Klein, E
Huang, AY
Sears, R
Lane, JR
Karydas, AM
Kenet, RO
Biernat, J
Wang, LS
Cotman, CW
DeCarli, CS
Levey, AI
Ringman, JM
Mendez, MF
Chui, HC
Le Ber, I
Brice, A
Lupton, MK
Preza, E
Lovestone, S
Powell, J
Graff-Radford, N
Petersen, RC
Boeve, BF
Lippa, CF
Bigio, EH
Mackenzie, I
Finger, E
Kertesz, A
Caselli, RJ
Gearing, M
Juncos, JL
Ghetti, B
Spina, S
Bordelon, YM
Tourtellotte, WW
Frosch, MP
Vonsattel, JPG
Zarow, C
Beach, TG
Albin, RL
Lieberman, AP
Lee, VM
Trojanowski, JQ
Van Deerlin, VM
Bird, TD
Galasko, DR
Masliah, E
White, CL
Troncoso, JC
Hannequin, D
Boxer, AL
Geschwind, MD
Kumar, S
Mandelkow, EM
Wszolek, ZK
Uitti, RJ
Dickson, DW
Haines, JL
Mayeux, R
Pericak-Vance, MA
Farrer, LA
Ross, OA
Rademakers, R
Schellenberg, GD
Miller, BL
Mandelkow, E
Geschwind, DH
AF Coppola, Giovanni
Chinnathambi, Subashchandrabose
Lee, Jason JiYong
Dombroski, Beth A.
Baker, Matt C.
Soto-Ortolaza, Alexandra I.
Lee, Suzee E.
Klein, Eric
Huang, Alden Y.
Sears, Renee
Lane, Jessica R.
Karydas, Anna M.
Kenet, Robert O.
Biernat, Jacek
Wang, Li-San
Cotman, Carl W.
DeCarli, Charles S.
Levey, Allan I.
Ringman, John M.
Mendez, Mario F.
Chui, Helena C.
Le Ber, Isabelle
Brice, Alexis
Lupton, Michelle K.
Preza, Elisavet
Lovestone, Simon
Powell, John
Graff-Radford, Neill
Petersen, Ronald C.
Boeve, Bradley F.
Lippa, Carol F.
Bigio, Eileen H.
Mackenzie, Ian
Finger, Elizabeth
Kertesz, Andrew
Caselli, Richard J.
Gearing, Marla
Juncos, Jorge L.
Ghetti, Bernardino
Spina, Salvatore
Bordelon, Yvette M.
Tourtellotte, Wallace W.
Frosch, Matthew P.
Vonsattel, Jean Paul G.
Zarow, Chris
Beach, Thomas G.
Albin, Roger L.
Lieberman, Andrew P.
Lee, Virginia M.
Trojanowski, John Q.
Van Deerlin, Vivianna M.
Bird, Thomas D.
Galasko, Douglas R.
Masliah, Eliezer
White, Charles L.
Troncoso, Juan C.
Hannequin, Didier
Boxer, Adam L.
Geschwind, Michael D.
Kumar, Satish
Mandelkow, Eva-Maria
Wszolek, Zbigniew K.
Uitti, Ryan J.
Dickson, Dennis W.
Haines, Jonathan L.
Mayeux, Richard
Pericak-Vance, Margaret A.
Farrer, Lindsay A.
Ross, Owen A.
Rademakers, Rosa
Schellenberg, Gerard D.
Miller, Bruce L.
Mandelkow, Eckhard
Geschwind, Daniel H.
CA Alzheimer's Dis Genetics Consortiu
TI Evidence for a role of the rare p.A152T variant in MAPT in increasing
the risk for FTD-spectrum and Alzheimers diseases
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID FRONTOTEMPORAL DEMENTIA; COMMON VARIANTS; TAU-PROTEIN; AGGREGATION;
ASSOCIATION; HAPLOTYPE; MUTATION; PHOSPHORYLATION; PARKINSONISM;
INCLUSIONS
AB Tau p.A152T significantly increases the risk for both FTD-s (n 2139, OR 3.0, CI: 1.65.6, P 0.0005) and Alzheimers disease (AD) (n 3345, OR 2.3, CI: 1.34.2, P 0.004) compared with 9047 controls. Functionally, p.A152T (i) decreases the binding of tau to microtubules and therefore promotes microtubule assembly less efficiently; and (ii) reduces the tendency to form abnormal fibers. However, there is a pronounced increase in the formation of tau oligomers. Importantly, these findings suggest that other regions of the tau protein may be crucial in regulating normal function, as the p.A152 residue is distal to the domains considered responsible for microtubule interactions or aggregation. These data provide both the first genetic evidence and functional studies supporting the role of MAPT p.A152T as a rare risk factor for both FTD-s and AD and the concept that rare variants can increase the risk for relatively common, complex neurodegenerative diseases, but since no clear significance threshold for rare genetic variation has been established, some caution is warranted until the findings are further replicated.
C1 [Geschwind, Daniel H.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Program Neurogenet, Los Angeles, CA 90095 USA.
[Coppola, Giovanni; Geschwind, Daniel H.] Univ Calif Los Angeles, Dept Psychiat, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90095 USA.
[Lee, Suzee E.; Karydas, Anna M.; Boxer, Adam L.; Geschwind, Michael D.; Miller, Bruce L.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA.
[Cotman, Carl W.] Univ Calif Irvine, Dept Neurol, Irvine, CA 92717 USA.
[DeCarli, Charles S.] Univ Calif Davis, Dept Neurol, Davis, CA 95616 USA.
[Chinnathambi, Subashchandrabose; Biernat, Jacek; Kumar, Satish; Mandelkow, Eva-Maria; Mandelkow, Eckhard] German Ctr Neurodegenerat Dis, DZNE, D-53175 Bonn, Germany.
[Chinnathambi, Subashchandrabose; Biernat, Jacek; Kumar, Satish; Mandelkow, Eva-Maria; Mandelkow, Eckhard] CAESAR Res Ctr, D-53175 Bonn, Germany.
[Dombroski, Beth A.; Wang, Li-San; Lee, Virginia M.; Trojanowski, John Q.; Van Deerlin, Vivianna M.; Schellenberg, Gerard D.] Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA.
[Baker, Matt C.; Soto-Ortolaza, Alexandra I.; Graff-Radford, Neill; Wszolek, Zbigniew K.; Uitti, Ryan J.; Dickson, Dennis W.; Ross, Owen A.; Rademakers, Rosa] Mayo Clin Florida, Dept Neurosci, Jacksonville, FL USA.
[Baker, Matt C.; Soto-Ortolaza, Alexandra I.; Graff-Radford, Neill; Wszolek, Zbigniew K.; Uitti, Ryan J.; Dickson, Dennis W.; Ross, Owen A.; Rademakers, Rosa] Mayo Clin Florida, Dept Neurol, Jacksonville, FL USA.
[Baker, Matt C.; Soto-Ortolaza, Alexandra I.; Graff-Radford, Neill; Wszolek, Zbigniew K.; Uitti, Ryan J.; Dickson, Dennis W.; Ross, Owen A.; Rademakers, Rosa] Mayo Clin Florida, Dept Pathol, Jacksonville, FL USA.
[Kenet, Robert O.] Weill Cornell Med Coll, New York Presbyterian Hosp, Dept Med, New York, NY USA.
[Levey, Allan I.; Gearing, Marla; Juncos, Jorge L.] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA.
[Levey, Allan I.; Gearing, Marla; Juncos, Jorge L.] Emory Univ, Sch Med, Dept Pathol, Atlanta, GA 30322 USA.
[Levey, Allan I.; Gearing, Marla; Juncos, Jorge L.] Emory Univ, Sch Med, Dept Lab Med, Atlanta, GA 30322 USA.
[Chui, Helena C.] Univ So Calif, Dept Neurol, Downey, CA USA.
[Zarow, Chris] Univ So Calif, Rancho Amigos Natl Rehabil Ctr, Downey, CA USA.
[Brice, Alexis] Hop La Pitie Salpetriere, AP HP, Dept Genet & Cytogenet, F-75013 Paris, France.
[Lupton, Michelle K.; Preza, Elisavet; Lovestone, Simon; Powell, John] Kings Coll London, Inst Psychiat, London WC2R 2LS, England.
[Petersen, Ronald C.; Boeve, Bradley F.] Mayo Clin Rochester, Dept Neurol, Rochester, MN USA.
[Lippa, Carol F.] Drexel Univ, Dept Neurol, Coll Med, Philadelphia, PA 19104 USA.
[Bigio, Eileen H.] Northwestern Univ, Cognit Neurol & Alzheimer Dis Ctr, Feinberg Sch Med, Chicago, IL 60611 USA.
[Mackenzie, Ian] Univ British Columbia, Dept Pathol, Vancouver, BC, Canada.
[Finger, Elizabeth; Kertesz, Andrew] Univ Western Ontario, Dept Clin Neurol Sci, London, ON, Canada.
[Caselli, Richard J.] Mayo Clin Scottsdale, Dept Neurol, Scottsdale, AZ USA.
[Ghetti, Bernardino; Spina, Salvatore] Indiana Univ Sch Med, Dept Pathol & Lab Med, Indianapolis, IN USA.
[Tourtellotte, Wallace W.] Vet Affairs W Los Angeles Healthcare Ctr, Human Brain & Spinal Fluid Resource Ctr, Los Angeles, CA USA.
[Frosch, Matthew P.] Massachusetts Gen Hosp, CS Kubik Lab Neuropathol, Boston, MA 02114 USA.
[Frosch, Matthew P.] Massachusetts Gen Hosp, Mass Gen Inst Neurodegenerat Dis, Boston, MA 02114 USA.
[Frosch, Matthew P.] Harvard Univ, Sch Med, Boston, MA USA.
[Vonsattel, Jean Paul G.; Mayeux, Richard] Columbia Univ, Dept Neurol, New York, NY USA.
[Vonsattel, Jean Paul G.; Mayeux, Richard] Columbia Univ, Dept Pathol, New York, NY USA.
[Vonsattel, Jean Paul G.; Mayeux, Richard] Columbia Univ, Taub Inst Res Alzheimers Dis & Aging Brain, New York, NY USA.
[Beach, Thomas G.] Banner Sun Hlth Res Inst, Civin Lab Neuropathol, Sun City, AZ USA.
[Albin, Roger L.; Lieberman, Andrew P.] Univ Michigan, Dept Neurol, Ann Arbor, MI USA.
[Albin, Roger L.; Lieberman, Andrew P.] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA.
[Albin, Roger L.; Lieberman, Andrew P.] VA Ann Arbor Hlth Syst, Geriatr Res Educ & Clin Ctr, Ann Arbor, MI USA.
[Bird, Thomas D.] Univ Washington, Dept Med, Seattle, WA USA.
[Bird, Thomas D.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA.
[Bird, Thomas D.] Univ Washington, Dept Med Genet, Seattle, WA 98195 USA.
[Galasko, Douglas R.; Masliah, Eliezer] Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA.
[Galasko, Douglas R.; Masliah, Eliezer] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA.
[White, Charles L.] Univ Texas SW Med Ctr Dallas, Dept Pathol, Dallas, TX 75390 USA.
[Troncoso, Juan C.] Johns Hopkins Univ Sch Med, Dept Neurol, Baltimore, MD USA.
[Hannequin, Didier] CHU Charles Nicolle, CNR MAJ, INSERM, U614, Rouen, France.
[Hannequin, Didier] CHU Charles Nicolle, Dept Neurol, Rouen, France.
[Haines, Jonathan L.] Vanderbilt Univ, Dept Mol Physiol & Biophys, Vanderbilt Ctr Human Genet Res, Nashville, TN 37232 USA.
[Pericak-Vance, Margaret A.] Univ Miami, John P Hussman Inst Human Genom, Miami, FL USA.
[Pericak-Vance, Margaret A.] Univ Miami, Dr John T Macdonald Fdn, Dept Human Genet, Miami, FL USA.
[Farrer, Lindsay A.] Boston Univ, Dept Biostat, Boston, MA 02215 USA.
[Farrer, Lindsay A.] Boston Univ, Dept Med, Genet Program, Boston, MA 02215 USA.
[Farrer, Lindsay A.] Boston Univ, Dept Ophthalmol, Boston, MA 02215 USA.
[Farrer, Lindsay A.] Boston Univ, Dept Neurol, Boston, MA 02215 USA.
[Farrer, Lindsay A.] Boston Univ, Dept Epidemiol, Boston, MA 02215 USA.
[Le Ber, Isabelle; Brice, Alexis] CNRS, Ctr Rech, Inst Cerveau & Moelle Epiniere, UMRS975,INSERM,U975,UMR 7225, Paris, France.
[Le Ber, Isabelle] Hop La Pitie Salpetriere, AP HP, Ctr Reference Demences Rares, F-75013 Paris, France.
RP Geschwind, DH (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Program Neurogenet, Los Angeles, CA 90095 USA.
EM dhg@ucla.edu
RI Powell, John/G-4412-2011; Preza, Elisavet/C-1829-2013; Haines,
Jonathan/C-3374-2012; Ross, Owen/D-7573-2013; Finger,
Elizabeth/B-6453-2015; Sonnen, 37382016/H-3738-2016;
OI Powell, John/0000-0001-6124-439X; Dickson, Dennis W/0000-0001-7189-7917;
Sonnen, 37382016/0000-0001-9267-8705; Sears, Renee/0000-0003-0523-9291;
Roberson, Erik/0000-0002-1810-9763; Farrer, Lindsay/0000-0001-5533-4225;
Carroll, Steven/0000-0001-6714-4373; Demirci, F.
Yesim/0000-0001-6907-9843; Kaye, Jeffrey/0000-0002-9971-3478; Kukull,
Walter/0000-0001-8761-9014; Buros, Jacqueline/0000-0001-9588-4889;
Kamboh, M. Ilyas/0000-0002-3453-1438; Barmada, M
Michael/0000-0002-3604-6460; Stern, Robert/0000-0002-5008-077X; Crane,
Paul/0000-0003-4278-7465; Cruchaga, Carlos/0000-0002-0276-2899; Buxbaum,
Joseph/0000-0001-8898-8313
FU National Institutes of Health [R01 AG026938, RC1AG035610, P50 AG-16570,
AG13854, R37 AG11762, P50-AG05142, P50 AG025688, R01 AG038791, R01
NS078086, R01 NS065782, P50 AG023501, P50NS072187]; Tau Consortium;
Irene and Abe Pollin Fund for CBD Research; CurePSP Foundation; Peebler
PSP Research Foundation; NIHR Biomedical Research Centre for Mental
Health at SLAM and KCL; Medical Research Council; Alzheimer's Research
UK; European Union [HEALTH-F4-2009-242257]; Agence Nationale de la
Recherche [R R08104DS]; National Institute on Aging (NIA) [U24 AG21886,
P30 AG19610]; Arizona Department of Health Services [211002]; Arizona
Biomedical Research Commission [4001, 0011, 05-901, 1001]; Michael J.
Fox Foundation for Parkinson's Research
FX This work was supported by grants from the National Institutes of Health
(grant numbers R01 AG026938 to D. H. G., RC1AG035610 to G. C., P50
AG-16570 to J.R., AG13854 to E. B., R37 AG11762 to G. D. S., P50-AG05142
to H. C. C., P50 AG025688 to A. I. L., R01 AG038791 to A. L. B., R01
NS078086 to O.A.R., R01 NS065782 to R. R., P50 AG023501 to B. L. M.,
Mayo Udall Center P50NS072187 to O.A.R., Z.K.W., R.J.U., D. W. D.); the
Tau Consortium (G. C., R.O.K., S. E. L., E-M. M., B. L. M., E. M., D. H.
G.); a gift from Carl Edward Bolch, Jr, and Susan Bass Bolch (O.A.R., Z.
K. W., R.J.U., D. W. D.); the Irene and Abe Pollin Fund for CBD Research
(A. L. B. and R. R.); the CurePSP Foundation (G. D. S.); the Peebler PSP
Research Foundation (G. D. S.); the NIHR Biomedical Research Centre for
Mental Health at SLAM and KCL
(http://www.slam.nhs.uk/about-us/biomedical-research-centre/brc-home.asp
x); the Medical Research Council (http://www.mrc.ac.uk/index.htm)
through PhD studentship funding; the Alzheimer's Research UK
(http://www.alzheimersresearchuk.org), the 7th framework program of the
European Union (ADAMS project, http://www.adams-consortium.eu/,
HEALTH-F4-2009-242257, to S. L. and J.P]; and the Agence Nationale de la
Recherche (FTDGenes, R R08104DS, to I. L. B. and A. B.). In the NCRAD
series, samples from the National Cell Repository for Alzheimer's
Disease (NCRAD), which receives government support under a cooperative
agreement grant (U24 AG21886) awarded by the National Institute on Aging
(NIA), were used in this study. The National Cell Repository for
Alzheimer's Disease (NCRAD) receives government support under a
cooperative agreement grant (U24 AG21886) awarded by the National
Institute on Aging (NIA). Costs for tissue samples submitted by T. G. B.
were supported by the National Institute on Aging (P30 AG19610 Arizona
Alzheimer's Disease Core Center), the Arizona Department of Health
Services (contract 211002, Arizona Alzheimer's Research Center), the
Arizona Biomedical Research Commission (contracts 4001, 0011, 05-901 and
1001 to the Arizona Parkinson's Disease Consortium) and the Michael J.
Fox Foundation for Parkinson's Research. The funders had no role in the
study design, data collection and analysis, decision to publish or
preparation of the manuscript.
NR 46
TC 59
Z9 60
U1 0
U2 11
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD AUG 1
PY 2012
VL 21
IS 15
BP 3500
EP 3512
DI 10.1093/hmg/dds161
PG 13
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 974FE
UT WOS:000306414900017
PM 22556362
ER
PT J
AU Ibrahimi, OA
On, SCJ
Fung, MA
Eisen, DB
AF Ibrahimi, Omar A.
On, Shelbi C. Jim
Fung, Maxwell A.
Eisen, Daniel B.
TI A longstanding deep-seated nuchal tumor
SO INTERNATIONAL JOURNAL OF DERMATOLOGY
LA English
DT Editorial Material
ID DESMOID TUMORS
C1 [Ibrahimi, Omar A.] Univ Connecticut, Dept Dermatol, Farmington, CT 06032 USA.
[Ibrahimi, Omar A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA USA.
[On, Shelbi C. Jim] Univ Hawaii, Sch Med, Honolulu, HI 96822 USA.
[Fung, Maxwell A.; Eisen, Daniel B.] Univ Calif Davis, Dept Dermatol, Sacramento, CA 95817 USA.
[Fung, Maxwell A.] Univ Calif Davis, Dept Pathol, Sacramento, CA 95817 USA.
RP Ibrahimi, OA (reprint author), Univ Connecticut, Dept Dermatol, 21 South Rd, Farmington, CT 06032 USA.
EM omar.ibrahimi@gmail.com
OI Eisen, Daniel/0000-0001-6741-3182
NR 8
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0011-9059
J9 INT J DERMATOL
JI Int. J. Dermatol.
PD AUG
PY 2012
VL 51
IS 8
BP 910
EP 912
DI 10.1111/j.1365-4632.2011.05364.x
PG 3
WC Dermatology
SC Dermatology
GA 973RP
UT WOS:000306377800003
PM 22788805
ER
PT J
AU Alexander, KA
Coleman, CL
Deatrick, JA
Jemmott, LS
AF Alexander, Kamila A.
Coleman, Christopher L.
Deatrick, Janet A.
Jemmott, Loretta S.
TI Moving beyond safe sex to women-controlled safe sex: a concept analysis
SO JOURNAL OF ADVANCED NURSING
LA English
DT Article
DE concept analysis; gender equity; HIV; AIDS; sexuality; sexually
transmitted infections; unintended pregnancy; women-controlled safe sex
ID FEMALE-CONDOM USE; RANDOMIZED CONTROLLED-TRIAL; RISK-REDUCTION
HIERARCHY; FAMILY-PLANNING CLINICS; HIV PREVENTION METHODS; URBAN US
WOMEN; VAGINAL MICROBICIDE; BARRIER METHODS; DIAPHRAGM USERS;
UNITED-STATES
AB alexander k.a., coleman c.l., deatrick j.a. & jemmott l.s. (2011) Moving beyond safe sex to women-controlled safe sex: a concept analysis. Journal of Advanced Nursing68(6), 18581869. Abstract Aim. This paper is a report of a conceptual analysis of women-controlled safe sex. Background. Women bear disproportionate burdens from sexually related health compromising outcomes. Imbalanced societal gender and power positions contribute to high morbidities. The expression, women-controlled safe sex, aims to empower women to gain control of their sexual lives. Few researchers focus on contextualized socio-cultural definitions of sexual safety among women. Data sources. The sample included scientific literature from Scopus, CINAHL, PubMed, PsychINFO and Sociological Abstracts. Papers were published 20002010. Review methods. Critical analyses of literature about women-controlled safe sex were performed in May 2011 using Rodgers evolutionary concept analysis methods. The search focused on social and cultural influences on sexual practices aimed at increasing womens control over their sexual safety. Results. The analysis uncovered five attributes of women-controlled safe sex: technology; access to choices; women at-risk; condom migration panic; and communication. Three antecedents included: male partner influence; body awareness; and self-efficacy. Consequences were categorized as positive or negative. Nine surrogate terms included: empowerment; gender power; female-controlled sexual barrier method; microbicides; diaphragm; sexual negotiation and communication; female condom; women-initiated disease transmission prevention; and spermicides. Finally, a consensus definition was identified: a socio-culturally influenced multi-level process for initiating sexual safety by women deemed at-risk for sexually related dangers, usually sexually transmitted infections and/or HIV/AIDS. Conclusion. This concept analysis described current significance, uses, and applications of women-controlled safe sex in the scientific literature. The authors clarified its limited nature and conclude that additional conceptual refinement in nursing is necessary to influence womens health.
C1 [Alexander, Kamila A.; Deatrick, Janet A.; Jemmott, Loretta S.] Univ Penn, Sch Nursing, Ctr Hlth Equ Res, Philadelphia, PA 19104 USA.
RP Alexander, KA (reprint author), Univ Penn, Sch Nursing, Ctr Hlth Equ Res, Philadelphia, PA 19104 USA.
EM kamilaa@nursing.upenn.edu
FU NINR/NIH [T32NR007100, F31NR013121]
FX This work was supported by NINR/NIH Ruth L. Kirschstein NRSA Predoctoral
Fellowship and Research Training to Promote Health in Vulnerable
Populations (T32NR007100) and Award Number F31NR013121 (PI: Alexander).
The content is solely the responsibility of the authors and does not
necessarily represent the official views of the National Institute of
Nursing Research or the National Institutes of Health.
NR 77
TC 3
Z9 3
U1 3
U2 10
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0309-2402
J9 J ADV NURS
JI J. Adv. Nurs.
PD AUG
PY 2012
VL 68
IS 8
BP 1858
EP 1869
DI 10.1111/j.1365-2648.2011.05881.x
PG 12
WC Nursing
SC Nursing
GA 972IX
UT WOS:000306271900018
PM 22111843
ER
PT J
AU Lin, SI
Lo, CC
Lin, PY
Chen, JJJ
AF Lin, Sang-I
Lo, Chao-Chen
Lin, Pei-Yi
Chen, Jia-Jin J.
TI Biomechanical assessments of the effect of visual feedback on cycling
for patients with stroke
SO JOURNAL OF ELECTROMYOGRAPHY AND KINESIOLOGY
LA English
DT Article
DE Cycling; Electromyography; Visual feedback; Stroke
ID LOWER-LIMB; POSTSTROKE HEMIPARESIS; KINEMATIC ANALYSIS; PEDALING
EXERCISE; FORCE OUTPUT; REHABILITATION; MOVEMENT; GAIT; COORDINATION;
ACTIVATION
AB Stroke patients exhibit abnormal pattern in leg cycling exercise. The aim of this study was to investigate the effects of visual feedback on the control of cycling motion in stroke patients from kinesiological, kinematic and kinetic aspects. The cycling performance derived from cycling electromyography (EMG), cycling cadence, and torque of forty stroke subjects was evaluated under conditions with and without visual feedback of cycling cadence. Kinesiological indices, shape symmetry index (SSI) and area symmetry index (ASI) were extracted from EMG linear envelopes to evaluate the symmetry of muscle firing patterns during cycling. Roughness index (RI) was calculated from cycling cadence to represent cycling smoothness from kinematic aspects. Averaged cycling power (Pav), the product of cadence and torque, was used to represent force output. The rectus femoris EMG showed significantly greater ASI with visual feedback, however, the difference in SSI between the two conditions was not significant. For the biceps femoris, there was a significant decrease in SSI with visual feedback, while the ASI was not affected significantly by the task conditions. The cycling smoothness was better and the average power generated was larger when visual feedback was provided. This study found that the addition of visual feedback improved both neuromuscular control and overall performance. Such improvement is likely to be the result of better control of the rectus femoris muscle activation and coordination of both legs. (c) 2012 Elsevier Ltd. All rights reserved.
C1 [Lo, Chao-Chen; Lin, Pei-Yi; Chen, Jia-Jin J.] Natl Cheng Kung Univ, Dept Biomed Engn, Tainan 70101, Taiwan.
[Lin, Sang-I] Natl Cheng Kung Univ, Dept Phys Therapy, Tainan 70101, Taiwan.
[Lin, Pei-Yi] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Cambridge, MA 02138 USA.
[Chen, Jia-Jin J.] Natl Cheng Kung Univ, Med Device Innovat Ctr, Tainan 70101, Taiwan.
RP Chen, JJJ (reprint author), Natl Cheng Kung Univ, Dept Biomed Engn, 1 Ta Hsueh Rd, Tainan 70101, Taiwan.
EM jason@jason.bme.ncku.edu.tw
FU National Health Research Institutes (NHRI) of R.O.C. [NHRI-EX99-9734EI,
NSC 100-2321-B-006-018]; National Science Council (NSC) of R.O.C.
[NHRI-EX99-9734EI, NSC 100-2321-B-006-018]; Medical Device Innovation
Center (MDIC)
FX The authors would like to appreciate the National Health Research
Institutes (NHRI) and National Science Council (NSC) of R.O.C. for
financially supporting this research under Contract Nos.
NHRI-EX99-9734EI and NSC 100-2321-B-006-018, as well as Medical Device
Innovation Center (MDIC).
NR 35
TC 7
Z9 7
U1 2
U2 12
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1050-6411
EI 1873-5711
J9 J ELECTROMYOGR KINES
JI J. Electromyogr. Kinesiol.
PD AUG
PY 2012
VL 22
IS 4
BP 582
EP 588
DI 10.1016/j.jelekin.2012.03.009
PG 7
WC Neurosciences; Physiology; Rehabilitation; Sport Sciences
SC Neurosciences & Neurology; Physiology; Rehabilitation; Sport Sciences
GA 973RQ
UT WOS:000306377900012
PM 22538084
ER
PT J
AU Li, WH
Ahn, AC
AF Li, Weihui
Ahn, Andrew C.
TI Pulsatile hemodynamics of hypertension: systematic review of aortic
input impedance
SO JOURNAL OF HYPERTENSION
LA English
DT Review
DE characteristic impedance; hypertension; input impedance; wave reflection
ID ISOLATED SYSTOLIC HYPERTENSION; PULSE-WAVE VELOCITY; ARTERIAL
HEMODYNAMICS; PRESSURE; DETERMINANTS; NIFEDIPINE; STIFFNESS; LOAD; AGE
AB Objective: Input impedance is the frequency-dependent afterload to pulsatile blood flow. Studies of input impedance have been performed as early as the 1960s and have been applied to hypertension (HTN). However, to date, these studies have not been systematically evaluated. This systematic review aims to summarize the literature, interpret existing data from the perspective of impedance theory, and to discuss their potential for generating physiological insights into HTN.
Methods: We identified 11 studies wherein computed impedance moduli from both HTN and control (CNT) groups were reported. In addition, we performed bivariate analyses of raw data from three of these studies.
Results: Major findings include HTN groups had consistently elevated impedance moduli at 0 Hz (Z(0)) and at heart rate frequency (Z(1)), an increased frequency wherein impedance phase first crosses 0 (f(0)), but no consistent pattern in characteristic impedance (Z(c)), when compared to CNT groups; SBP and DBP are highly correlated with Z(0) and Z(1), moderately correlated with f(0), less correlated with Z(c); the measurement and calculation methods for Z(c) are varied and inconsistent; and a not insignificant proportion of hypertensive individuals have 'normal' Z(0), Z(1) and Z(c) values. These findings are limited by the heterogeneous study populations and small sample sizes.
Conclusion: These findings suggest that Z(0), Z(1) and f(0) are significantly associated with HTN, whereas the role of Z(c) is less clear. Additional studies are needed to evaluate these input impedance variables in order to generate substantial implications in clinic settings.
C1 [Li, Weihui; Ahn, Andrew C.] Massachusetts Gen Hosp, Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA.
[Ahn, Andrew C.] Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, Boston, MA 02215 USA.
RP Li, WH (reprint author), Massachusetts Gen Hosp, Martinos Ctr Biomed Imaging, 149 13th St,Room 2328, Charlestown, MA 02129 USA.
EM weihuil@gmail.com
FU National Center for Complementary Alternative Medicine (NCCAM)
[P30AT005895]; Clinical Translational Science Award from the National
Center for Research Resources [UL1RR025758]
FX This research was supported by grant number P30AT005895 of the National
Center for Complementary Alternative Medicine (NCCAM). The project
described was supported by Clinical Translational Science Award
UL1RR025758 to Harvard University and Massachusetts General Hospital
from the National Center for Research Resources. The content is solely
the responsibility of the authors and does not necessarily represent the
official views of the National Center for Complementary Alternative
Medicine or the National Center for Research Resources or the National
Institutes of Health. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the
manuscript.
NR 23
TC 2
Z9 2
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0263-6352
EI 1473-5598
J9 J HYPERTENS
JI J. Hypertens.
PD AUG
PY 2012
VL 30
IS 8
BP 1493
EP 1499
DI 10.1097/HJH.0b013e328354e81d
PG 7
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 973PE
UT WOS:000306371400001
PM 22635138
ER
PT J
AU He, SN
Lamers, GEM
Beenakker, JWM
Cui, C
Ghotra, VPS
Danen, EHJ
Meijer, AH
Spaink, HP
Snaar-Jagalska, BE
AF He, Shuning
Lamers, Gerda E. M.
Beenakker, Jan-Willem M.
Cui, Chao
Ghotra, Veerander P. S.
Danen, Erik H. J.
Meijer, Annemarie H.
Spaink, Herman P.
Snaar-Jagalska, B. Ewa
TI Neutrophil-mediated experimental metastasis is enhanced by VEGFR
inhibition in a zebrafish xenograft model
SO JOURNAL OF PATHOLOGY
LA English
DT Article
DE zebrafish; neutrophils; macrophages; tumour vascularization;
micrometastasis; VEGFR inhibition
ID ENDOTHELIAL GROWTH-FACTOR; BLOOD STEM-CELLS; TRANSGENIC ZEBRAFISH;
IN-VIVO; MESENCHYMAL TRANSITION; DISEASE PROGRESSION; AORTIC
ENDOTHELIUM; FACTOR RECEPTOR; MYELOID CELLS; TUMOR-GROWTH
AB Inhibition of VEGF signalling effectively suppresses localized tumour growth but accelerates tumour invasiveness and micrometastasis by unknown mechanisms. To study the dynamic and reciprocal interactions between tumour cells and their microenvironment during these processes, we established a xenograft model by injecting tumour cells into the blood circulation of transparent zebrafish embryos. This reproducibly results in rapid simultaneous formation of a localized tumour and experimental micrometastasis, allowing time-resolved imaging of both processes at single-cell resolution within 1 week. The tumour vasculature was initiated de novo by remodelling of primitive endothelial cells into a functional network. Roles of myeloid cells in critical tumourigenesis steps such as vascularization and invasion were revealed by genetic and pharmaceutical approaches. We discovered that the physiological migration of neutrophils controlled tumour invasion by conditioning the collagen matrix and forming the metastatic niche, as detected by two-photon confocal microscopy and second harmonic generation. Administration of VEGFR inhibitors blocked tumour vascularization and a localized tumour growth but enhanced migration of neutrophils, which in turn promoted tumour invasion and formation of micrometastasis. This demonstrates the in vivo cooperation between VEGF signalling and myeloid cells in metastasis and provides a new mechanism underlying the recent findings that VEGFR targeting can promote tumour invasiveness. Copyright (C) 2012 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
C1 [He, Shuning; Lamers, Gerda E. M.; Cui, Chao; Meijer, Annemarie H.; Spaink, Herman P.; Snaar-Jagalska, B. Ewa] Leiden Univ, Inst Biol, NL-2333 CC Leiden, Netherlands.
[Beenakker, Jan-Willem M.] Leiden Univ, Leiden Inst Phys, NL-2300 RA Leiden, Netherlands.
[Ghotra, Veerander P. S.; Danen, Erik H. J.] Leiden Univ, Div Toxicol, Leiden Amsterdam Ctr Drug Res, NL-2300 RA Leiden, Netherlands.
[He, Shuning] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA.
[He, Shuning] Harvard Univ, Sch Med, Childrens Hosp Boston, Boston, MA 02115 USA.
RP Snaar-Jagalska, BE (reprint author), Leiden Univ, Inst Biol, Einsteinweg 55, NL-2333 CC Leiden, Netherlands.
EM b.e.snaar-jagalska@biology.leidenuniv.nl
OI danen, erik/0000-0002-0491-6345
FU European Community [HEALTH-F2-2008-201439]
FX We thank M Presta and P ten Dijke for providing cell lines; RC Hoeben
for lentiviral viruses; B Weinstein and S Renshaw for providing
zebrafish lines; A Huttenlocher for providing antibody; W van der Ent,
MJ Rabelink and S Rueb for assistance in cell culture and generation of
stable fluorescent cell lines; A van der Laan for support in two-photon
second-harmonic generation microscopy; D de Witt and U Nehrdich for
zebrafish maintenance; M Mione, P ten Dijke and T Oosterkamp for
stimulating discussions; and EE Patton for critical reading of the
manuscript. This project was financially supported by the European
Community under the FP7 ZF-Cancer Project (Grant No.
HEALTH-F2-2008-201439).
NR 57
TC 52
Z9 52
U1 1
U2 19
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3417
J9 J PATHOL
JI J. Pathol.
PD AUG
PY 2012
VL 227
IS 4
BP 431
EP 445
DI 10.1002/path.4013
PG 15
WC Oncology; Pathology
SC Oncology; Pathology
GA 971UJ
UT WOS:000306229100008
PM 22374800
ER
PT J
AU Sylvia, LG
Dupuy, JM
Ostacher, MJ
Cowperthwait, CM
Hay, AC
Sachs, GS
Nierenberg, AA
Perlis, RH
AF Sylvia, Louisa G.
Dupuy, Jamie M.
Ostacher, Michael J.
Cowperthwait, Colleen M.
Hay, Aleena C.
Sachs, Gary S.
Nierenberg, Andrew A.
Perlis, Roy H.
TI Sleep disturbance in euthymic bipolar patients
SO JOURNAL OF PSYCHOPHARMACOLOGY
LA English
DT Article
DE Bipolar disorder; relapse prevention; sleep disturbance; treatment
ID TREATMENT ENHANCEMENT PROGRAM; DISORDER STEP-BD; CIRCADIAN-RHYTHMS;
DEPRESSED-PATIENTS; DEPRIVATION; MANIA; MOOD; RELIABILITY; IMPROVEMENT;
INSOMNIA
AB Sleep disturbance is a common feature during mood episodes in bipolar disorder. The aim of this study was to investigate the prevalence of such symptoms among euthymic bipolar patients, and their association with risk for mood episode recurrence. A cohort of bipolar I and II subjects participating in the Systematic Treatment Enhancement Program for Bipolar Disorder who were euthymic for at least 8 weeks were included in this analysis. Survival analysis was used to examine the association between sleep disturbance on the Montgomery-Asberg Depression Rating Scale (MADRS) and recurrence risk. A total of 73/483 bipolar I and II subjects reported at least mild sleep disturbance (MADRS sleep item >= 2) for the week prior to study entry. The presence of sleep problems was associated with a history of psychosis, number of previous suicide attempts, and anticonvulsant use. Sleep disturbance at study entry was significantly associated with risk for mood episode recurrence. Sleep disturbance is not uncommon between episodes for individuals with bipolar disorder and may be associated with a more severe course of illness. This suggests that sleep disturbance is an important prodromal symptom of bipolar disorder and should be considered a target for pharmacologic or psychosocial maintenance treatment.
C1 [Sylvia, Louisa G.; Dupuy, Jamie M.; Hay, Aleena C.; Sachs, Gary S.; Nierenberg, Andrew A.] Massachusetts Gen Hosp, Bipolar Clin & Res Program, Dept Psychiat, Boston, MA 02114 USA.
[Sylvia, Louisa G.; Dupuy, Jamie M.; Sachs, Gary S.; Nierenberg, Andrew A.; Perlis, Roy H.] Harvard Univ, Sch Med, Boston, MA USA.
[Ostacher, Michael J.] Stanford Univ, Sch Med, Stanford, CA 94305 USA.
[Ostacher, Michael J.] VA Palo Alto Heath Care Syst, Palo Alto, CA USA.
[Cowperthwait, Colleen M.] Emory Univ, Dept Psychol, Atlanta, GA 30322 USA.
[Perlis, Roy H.] Massachusetts Gen Hosp, Ctr Expt Drugs & Diagnost, Dept Psychiat, Boston, MA 02114 USA.
RP Sylvia, LG (reprint author), Massachusetts Gen Hosp, Bipolar Clin & Res Program, Dept Psychiat, 50 Staniford St,Suite 580, Boston, MA 02114 USA.
EM lsylvia2@partners.org
OI Cowperthwait, Colleen/0000-0001-6190-7579; Ostacher,
Michael/0000-0003-0353-7535
FU National Institute of Mental Health [N01MH80001]; Concordant Rater
Systems; United BioSource Corporation; Bracket; Repligen; AHRQ; NIMH;
PamLabs; Pfizer Pharmaceuticals; Shire; Wyss Institute for Biologically
Inspired Engineering; AstraZeneca; Genomind; Proteus Biomedical;
RIDVentures
FX This study was funded by the National Institute of Mental Health
(contract number N01MH80001).; In the past 12 months Dr Sylvia has
received consulting fees from Concordant Rater Systems, United BioSource
Corporation, and Bracket.; Dr Sachs is a full time Employee of Bracket.
Dr Sachs has served on advisory/consulting boards of Abbott
Laboratories, AstraZeneca Pharmaceuticals, Bristol Myers Squibb,
Cephalon, CNS Response, Dianippon Sumitomo Pharmaceuticals, Elan
Pharmaceuticals, Memory Pharmaceuticals, Merck, Novartis
Pharmaceuticals, Organon, Otsuka, Pfizer, Schering Plough, Sepracor,
Repligen, Sanofi-Aventis, Shire, Sigma-Tau, Solvay Pharmaceuticals,
Takeda, and Wyeth. Dr Sachs and his spouse own stock in Medco. In the
past 12 months, Dr Sachs has received research support from Repligen. In
the past 12 months, Dr Sachs has served on the advisory/consulting
boards of Concordant Rater Systems, Dianippon Sumitomo Pharmaceuticals,
Merck, Otsuka, Pfizer, Takeda, and Repligen.; Dr Nierenberg has served
as a consultant to: Appliance Computing Inc. (Mindsite), Medergy.
Through the MGH Clinical Trials Network and Institute (CTNI), he has
consulted for: Brain Cells, Inc, Johnson and Johnson, Labopharm, Merck,
PGx Health, Ridge Diagnostics, Targacept, Takeda/Lundbeck
Pharmaceuticals. He received grant/research support through MGH from:
AHRQ, NIMH, PamLabs, Pfizer Pharmaceuticals, Shire, Wyss Institute for
Biologically Inspired Engineering. He received honoraria from: American
Soc Clinical Psychopharmacology, American Society for Clinical
Psychopharmacology, APSARD, Belvior Publishing, Canadian Psychiatric
Association, CNS Spectrums, Dartmouth Medical School, Johns Hopkins
Medical School, MBL Publishing, Montreal McGill Douglas Hospital,
Northeast Counseling Center Directors, PamLab, Physicians Postgraduate
Press, SciMed, Slack Med, University of Florida, WebMD, Wolters Klower
Publishing Dr Nierenberg is a presenter for: Massachusetts General
Hospital Psychiatry Academy (MGHPA). The education programs conducted by
the MGHPA and presented by Dr Nierenberg were supported through
Independent Medical Education (IME) grants from the following
pharmaceutical companies: AstraZeneca. He is on the advisory boards of:
Appliance Computing, Inc., Brain Cells, Inc., InfoMedic, Johnson and
Johnson, Takeda/Lundbeck Pharmaceuticals, Targacept. Dr Nierenberg owns
stock options in: Appliance Computing, Inc. and Brain Cells, Inc.
Through MGH, he is named for copyrights to: The Clinical Positive Affect
Scale and the MGH Structured Clinical Interview for the Montgomery
Asberg Depression Scale exclusively licensed to the CTNI.; In the past
12 months Dr Perlis has received consulting fees from Concordant Rater
Systems, Genomind, Proteus Biomedical, and RIDVentures, grant support
from Proteus Biomedical, and royalties from Concordant Rater Systems.
NR 37
TC 31
Z9 32
U1 0
U2 11
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0269-8811
J9 J PSYCHOPHARMACOL
JI J. Psychopharmacol.
PD AUG
PY 2012
VL 26
IS 8
BP 1108
EP 1112
DI 10.1177/0269881111421973
PG 5
WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA 975JX
UT WOS:000306508700007
PM 21965189
ER
PT J
AU Hirschmann, JV
Raugi, GJ
AF Hirschmann, Jan V.
Raugi, Gregory J.
TI Lower limb cellulitis and its mimics Part II. Conditions that simulate
lower limb cellulitis
SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
LA English
DT Article
DE carcinoma erysipeloides; dependent rubor; eczema; erythromelalgia; gout;
hereditary periodic fevers; lymphedema; necrotizing soft tissue
infections; venous disease
ID SERUM URIC-ACID; NECROTIZING FASCIITIS; PERIODIC SYNDROME;
ERYTHROMELALGIA; CARCINOMA; LIPODERMATOSCLEROSIS; ERYTHERMALGIA;
MANAGEMENT; MORTALITY; RISK
AB Several common conditions can mimic cellulitis, creating a potential for misdiagnosis and incorrect management. The most common disorders mistaken for lower limb cellulitis include venous eczema, lipodermatosclerosis, irritant dermatitis, and lymphedema. The dermatologist is often consulted when a patient has failed to respond to therapy, and a thorough knowledge of the differential diagnosis is essential. This article focuses on entities that can mimic cellulitis, with an emphasis of elements of the history and physical examination that can help to distinguish between lower limb cellulitis and its simulators. (J Am Acad Dermatol 2012; 67: 177. e1-9.)
C1 [Raugi, Gregory J.] VA Puget Sound Hlth Care Syst, Dermatol 111D, Dept Dermatol, Seattle, WA 98108 USA.
Univ Washington, Sch Med, Seattle, WA USA.
RP Raugi, GJ (reprint author), VA Puget Sound Hlth Care Syst, Dermatol 111D, Dept Dermatol, 1660 Columbian Way S, Seattle, WA 98108 USA.
EM gregory.raugi@va.gov
NR 35
TC 2
Z9 2
U1 0
U2 2
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0190-9622
J9 J AM ACAD DERMATOL
JI J. Am. Acad. Dermatol.
PD AUG
PY 2012
VL 67
IS 2
AR 177.e1
DI 10.1016/j.jaad.2012.03.023
PG 9
WC Dermatology
SC Dermatology
GA 973OD
UT WOS:000306368600011
PM 22794816
ER
PT J
AU Waibel, J
Wulkan, AJ
Lupo, M
Beer, K
Anderson, RR
AF Waibel, Jill
Wulkan, Adam J.
Lupo, Mary
Beer, Kenneth
Anderson, R. Rox
TI Treatment of burn scars with the 1,550 nm nonablative fractional Erbium
Laser
SO LASERS IN SURGERY AND MEDICINE
LA English
DT Article
DE burn scars; nonablative fractional laser; keloid scars; hypertrophic
scars; atrophic scars
ID HYPERTROPHIC SCARS; KELOIDS; MANAGEMENT; TRIAL
AB Background Scarring is a major source of morbidity in patients with burns. Burn scars are difficult to treat and are among the worst scars seen in clinical medicine. Fractional laser resurfacing is a promising treatment option because of its unique wound healing response and depth of penetration. Objective To evaluate the efficacy of nonablative fractional resurfacing as a therapeutic option for extensive cutaneous scarring in burn patients. Methods Prospective, single-arm, pilot study. Ten subjects with second and third degree burn scars were treated with five nonablative fractional resurfacing treatments given at 4-week intervals. Three independent investigators evaluated subject outcomes at 3 months post-treatment (primary outcome); patients also provided subjective assessments of improvement (secondary outcome). Results Nonablative fractional resurfacing resulted in overall improvement in 90% of subjects, as determined by independent investigators; improvements were moderate to excellent in 60%. Ninety percent of subjects had improved skin texture, 80% had improved dyschromia, and 80% had improved hypertrophy/atrophy. Patients' self-reports also revealed moderate to excellent improvements (on average) in burn scar area, and significant improvements in self-esteem at 3 months post-treatment (P?=?0.03). Limitations Small sample size and lack of control group. Conclusions Fractional resurfacing is a promising new treatment modality for burn scars. We should continue to identify novel approaches and management strategies for the spectrum of diverse burn scars so that we can better treat this patient population. Lasers Surg. Med. 44: 441446, 2012. (C) Wiley Periodicals, Inc.
C1 [Waibel, Jill] Miami Dermatol & Laser Inst, Miami, FL 33173 USA.
[Wulkan, Adam J.] Univ Miami, Miller Sch Med, Miami, FL 33136 USA.
[Lupo, Mary] Lupo Ctr Aesthet & Gen Dermatol, New Orleans, LA 70124 USA.
[Beer, Kenneth] Palm Beach Esthet Dermatol & Laser Ctr, W Palm Beach, FL 33401 USA.
[Beer, Kenneth] Duke Univ, Dept Med, Durham, NC USA.
[Anderson, R. Rox] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Deparment Dermatol, Boston, MA 02114 USA.
[Anderson, R. Rox] Wellman Labs Photomed, Director Wellman Ctr, Dept Dermatol, Boston, MA 02114 USA.
RP Waibel, J (reprint author), Miami Dermatol & Laser Inst, 7800 SW 87th Ave, Miami, FL 33173 USA.
EM Jwaibelmd@MiamiDermLaser.com
FU Reliant Technologies, Inc.; Reliant Technologies
FX Contract grant sponsor: Reliant Technologies, Inc..; All authors have
completed and submitted the ICMJE Form for Disclosure of Potential
Conflicts of Interest and have disclosed the following: Dr. Waibel and
Dr. Beer received research grant from Reliant Technologies for this
work. In addition Dr. Lupo, Dr. Beer, and Dr. Waibel have been speakers,
and Dr. Anderson on Advisory Board for Solta Medical. No authors hold
stock, or receive royalties from Solta Medical.
NR 21
TC 27
Z9 27
U1 0
U2 9
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0196-8092
EI 1096-9101
J9 LASER SURG MED
JI Lasers Surg. Med.
PD AUG
PY 2012
VL 44
IS 6
BP 441
EP 446
DI 10.1002/lsm.22038
PG 6
WC Dermatology; Surgery
SC Dermatology; Surgery
GA 972YL
UT WOS:000306317500001
PM 22674649
ER
PT J
AU Huang, LY
Xuan, Y
Koide, Y
Zhiyentayev, T
Tanaka, M
Hamblin, MR
AF Huang, Liyi
Xuan, Yi
Koide, Yuichiro
Zhiyentayev, Timur
Tanaka, Masamitsu
Hamblin, Michael R.
TI Type I and Type II mechanisms of antimicrobial photodynamic therapy: An
in vitro study on gram-negative and gram-positive bacteria
SO LASERS IN SURGERY AND MEDICINE
LA English
DT Article
DE antimicrobial photodynamic inactivation; singlet oxygen; hydroxyl
radical; sodium azide; gram-positive and gram-negative bacteria;
antimicrobial photodynamic therapy; polyethylenimine chlorin(e6)
conjugate; tris-cationic fullerene
ID MESOSUBSTITUTED CATIONIC PORPHYRINS; SINGLET MOLECULAR-OXYGEN;
STAPHYLOCOCCUS-AUREUS; PHOTOPHYSICAL PROPERTIES; ANTIBIOTIC ERA;
INACTIVATION; AZIDE; RADICALS; INFECTIONS; FULLERENE
AB Background and Objectives Antimicrobial photodynamic therapy (APDT) employs a non-toxic photosensitizer (PS) and visible light, which in the presence of oxygen produce reactive oxygen species (ROS), such as singlet oxygen (1O2, produced via Type II mechanism) and hydroxyl radical (HO., produced via Type I mechanism). This study examined the relative contributions of 1O2 and HO. to APDT killing of Gram-positive and Gram-negative bacteria. Study Design/Materials and Methods Fluorescence probes, 3'-(p-hydroxyphenyl)-fluorescein (HPF) and singlet oxygen sensor green reagent (SOSG) were used to determine HO. and 1O2 produced by illumination of two PS: tris-cationic-buckminsterfullerene (BB6) and a conjugate between polyethylenimine and chlorin(e6) (PEIce6). Dimethylthiourea is a HO. scavenger, while sodium azide (NaN3) is a quencher of 1O2. Both APDT and killing by Fenton reaction (chemical generation of HO.) were carried out on Gram-positive bacteria (Staphylococcus aureus and Enterococcus faecalis) and Gram-negative bacteria (Escherichia coli, Proteus mirabilis, and Pseudomonas aeruginosa). Results Conjugate PEI-ce6 mainly produced 1O2 (quenched by NaN3), while BB6 produced HO. in addition to 1O2 when NaN3 potentiated probe activation. NaN3 also potentiated HPF activation by Fenton reagent. All bacteria were killed by Fenton reagent but Gram-positive bacteria needed a higher concentration than Gram-negatives. NaN3 potentiated Fenton-mediated killing of all bacteria. The ratio of APDT killing between Gram-positive and Gram-negative bacteria was 2 or 4:1 for BB6 and 25:1 for conjugate PEI-ce6. There was a NaN3 dose-dependent inhibition of APDT killing using both PEI-ce6 and BB6 against Gram-negative bacteria while NaN3 almost failed to inhibit killing of Gram-positive bacteria. Conclusion Azidyl radicals may be formed from NaN3 and HO.. It may be that Gram-negative bacteria are more susceptible to HO. while Gram-positive bacteria are more susceptible to 1O2. The differences in NaN3 inhibition may reflect differences in the extent of PS binding to bacteria (microenvironment) or differences in penetration of NaN3 into cell walls of bacteria. Lasers Surg. Med. 44: 490499, 2012. (C) Wiley Periodicals, Inc.
C1 [Huang, Liyi; Xuan, Yi; Koide, Yuichiro; Zhiyentayev, Timur; Tanaka, Masamitsu; Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
[Huang, Liyi] Guangxi Med Univ, Affiliated Coll & Hosp 1, Dept Infect Dis, Nanning 530021, Peoples R China.
[Huang, Liyi; Tanaka, Masamitsu; Hamblin, Michael R.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA.
[Xuan, Yi] Tufts Univ, Sch Engn, Medford, MA 02155 USA.
[Koide, Yuichiro] Univ Tokyo, Grad Sch Pharmaceut Sci, Tokyo, Japan.
[Zhiyentayev, Timur] CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA.
[Tanaka, Masamitsu] Natl Def Med Coll, Dept Orthopaed Surg, Tokorozawa, Saitama 3598513, Japan.
[Hamblin, Michael R.] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
RP Hamblin, MR (reprint author), Massachusetts Gen Hosp, Wellman Ctr Photomed, BAR414,40 Blossom St, Boston, MA 02114 USA.
EM hamblin@helix.mgh.harvard.edu
OI Hamblin, Michael/0000-0001-6431-4605
FU NIH [R01A1050875]; US Air Force MFEL [FA9550-04-1-0079]; ASLMS
FX Contract grant sponsor: NIH; Contract grant number: R01A1050875;
Contract grant sponsor: US Air Force MFEL Program; Contract grant
number: FA9550-04-1-0079.; This study was supported by NIH (R01A1050875
to M. R. H.) and US Air Force MFEL Program (FA9550-04-1-0079). These
data were presented at ASLMS meeting in 2010 by Dr Huang who received a
travel grant from ASLMS. This contribution satisfies the condition of
the travel grant that a manuscript should be submitted to LSM within 1
year after the annual conference.
NR 59
TC 51
Z9 54
U1 6
U2 81
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0196-8092
EI 1096-9101
J9 LASER SURG MED
JI Lasers Surg. Med.
PD AUG
PY 2012
VL 44
IS 6
BP 490
EP 499
DI 10.1002/lsm.22045
PG 10
WC Dermatology; Surgery
SC Dermatology; Surgery
GA 972YL
UT WOS:000306317500008
PM 22760848
ER
PT J
AU Kawakubo, M
Eguchi, K
Arai, T
Kobayashi, K
Hamblin, MR
AF Kawakubo, Masayoshi
Eguchi, Keisuke
Arai, Tsunenori
Kobayashi, Koichi
Hamblin, Michael R.
TI Surface layer-preserving photodynamic therapy (SPPDT) in a subcutaneous
mouse model of lung cancer
SO LASERS IN SURGERY AND MEDICINE
LA English
DT Article
DE photodynamic therapy; taloporfin sodium; pulsed laser; surface layer
preservation; trachbronchial cancer; lung cancer; Lewis lung carcinoma;
pig tracheal cartilage; mediastinal lymph node
ID ASPARTYL CHLORIN E6; PULSED-DYE-LASER; HYPERFRACTIONATED
RADIATION-THERAPY; SQUAMOUS-CELL CARCINOMA; VENA-CAVA-SYNDROME;
ARGON-DYE; TUMOR; CONCURRENT; PHOTOSENSITIZER; PHOTORADIATION
AB Background and Objectives Photodynamic therapy (PDT) may be a less invasive treatment for lung cancer. Our newly developed surface layer-preserving PDT (SPPDT) technique enables us to irradiate deep tumor while preserving the overlying tissue. The aim of this basic study was to verify that the SPPDT technique might be applied to lung cancer. Study Design/Materials and Methods PDT with talaporfin sodium was performed using a pulsed laser with different pulse dose rates (PDRs, 2.520.0?mJ/cm2/pulse) in a mouse model of subcutaneous tumor. To mimic the tracheal wall structure and a thoracic tumor in the tracheobronchus, we also made a mouse model in which a piece of swine cartilage was placed between the dermis and the tumor, and PDT was carried out 2 weeks after implantation. In both experiments, the tissue samples were collected 48?hours after PDT and evaluated microscopically. Results SPPDT using a high-PDR laser damaged the underlying tissue but left the superficial tissue intact in the mouse subcutaneous tumor model. In SPPDT, a higher PDR produced a thicker layer of intact superficial tissue than a lower PDR, while a lower PDR produced a deeper layer of damaged tissue than a higher PDR. SPPDT was also able to preserve the superficial tissue and to damage the tumor tissue beneath the cartilage implant. Conclusion SPPDT was able to damage tumor beneath the superficial normal tissue layer, which included tracheal cartilage in the mouse model. The thickness control of SPPDT was provided by controlling laser pulse intensity. SPPDT is a new technology, whose future potential is unknown. The initial clinical application of this technology could be endoscopic treatment (e.g., palliative therapy of thoracic malignancies via bronchoscopy). Lasers Surg. Med. 44: 500507, 2012. (C) Wiley Periodicals, Inc.
C1 [Kawakubo, Masayoshi; Eguchi, Keisuke; Kobayashi, Koichi] Keio Univ, Sch Med, Dept Thorac Surg, Tokyo, Japan.
[Eguchi, Keisuke] Saitama Med Univ, Saitama Med Ctr, Kawagoe, Saitama, Japan.
[Arai, Tsunenori] Keio Univ, Fac Sci & Technol, Dept Appl Phys & Physicoinformat, Yokohama, Kanagawa 223, Japan.
[Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
[Hamblin, Michael R.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA.
[Hamblin, Michael R.] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
RP Kawakubo, M (reprint author), 40 Blossom St, Boston, MA 02114 USA.
EM masayoshikaw@aol.com
OI Hamblin, Michael/0000-0001-6431-4605
FU US NIH [R01A1050875]
FX Contract grant sponsor: US NIH; Contract grant number: R01A1050875.
NR 44
TC 2
Z9 2
U1 0
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0196-8092
J9 LASER SURG MED
JI Lasers Surg. Med.
PD AUG
PY 2012
VL 44
IS 6
BP 500
EP 507
DI 10.1002/lsm.22046
PG 8
WC Dermatology; Surgery
SC Dermatology; Surgery
GA 972YL
UT WOS:000306317500009
PM 22752880
ER
PT J
AU Tisdall, MD
Hess, AT
Reuter, M
Meintjes, EM
Fischl, B
van der Kouwe, AJW
AF Tisdall, M. Dylan
Hess, Aaron T.
Reuter, Martin
Meintjes, Ernesta M.
Fischl, Bruce
van der Kouwe, Andre J. W.
TI Volumetric navigators for prospective motion correction and selective
reacquisition in neuroanatomical MRI
SO MAGNETIC RESONANCE IN MEDICINE
LA English
DT Article
DE prospective motion correction; navigator; brain morphometry; validation
ID MAGNETIC-RESONANCE IMAGES; HUMAN CEREBRAL-CORTEX; SURFACE-BASED
ANALYSIS; CORTICAL SURFACE; HEAD MOTION; COORDINATE SYSTEM; BRAIN;
ACCURATE; SEGMENTATION; REGISTRATION
AB We introduce a novel method of prospectively compensating for subject motion in neuroanatomical imaging. Short three-dimensional echo-planar imaging volumetric navigators are embedded in a long three-dimensional sequence, and the resulting image volumes are registered to provide an estimate of the subject's location in the scanner at a cost of less than 500 ms, similar to 1% change in contrast, and similar to 3% change in intensity. This time fits well into the existing gaps in sequences routinely used for neuroimaging, thus giving a motion-corrected sequence with no extra time required. We also demonstrate motion-driven selective reacquisition of k-space to further compensate for subject motion. We perform multiple validation experiments to evaluate accuracy, navigator impact on tissue intensity/contrast, and the improvement in final output. The complete system operates without adding additional hardware to the scanner and requires no external calibration, making it suitable for high-throughput environments. Magn Reson Med, 2012. (C) 2011 Wiley Periodicals, Inc.
C1 [Tisdall, M. Dylan; Fischl, Bruce; van der Kouwe, Andre J. W.] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA.
[Tisdall, M. Dylan; Fischl, Bruce; van der Kouwe, Andre J. W.] Harvard Univ, Sch Med, Dept Radiol, Brookline, MA USA.
[Hess, Aaron T.; Meintjes, Ernesta M.] Univ Cape Town, MRC UCT Med Imaging Res Unit, Dept Human Biol, ZA-7700 Rondebosch, South Africa.
[Reuter, Martin] Massachusetts Gen Hosp, Dept Neurol, Charlestown, MA USA.
[Reuter, Martin] Harvard Univ, Sch Med, Dept Neurol, Brookline, MA USA.
[Reuter, Martin; Fischl, Bruce] MIT, Comp Sci & AI Lab, Cambridge, MA 02139 USA.
RP Tisdall, MD (reprint author), Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Bldg 149,13th St, Charlestown, MA USA.
EM tisdall@nmr.mgh.harvard.edu
RI Reuter, Martin/B-3456-2010;
OI Reuter, Martin/0000-0002-2665-9693; Hess, Aaron/0000-0002-9289-5619
FU Center for Functional Neuroimaging Technologies [P41RR14075]; National
Center for Research Resources (NCRR), National Institutes of Health;
NCRR [S10RR021110, S10RR023401]; NIH [5R21EB008547, 5R21AA017410,
5R21DA026104, 5R01NS055754]; Ellison Medical Foundation
FX Grant sponsor: Center for Functional Neuroimaging Technologies; Grant
number: P41RR14075 [a P41 Regional Resource supported by Biomedical
Technology Program of the National Center for Research Resources (NCRR),
National Institutes of Health]; Grant sponsors: NCRR Shared
Instrumentation Grant Program and/or High-End Instrumentation Grant
Program; Grant numbers: S10RR021110, S10RR023401; Grant sponsor: NIH;
Grant numbers: 5R21EB008547, 5R21AA017410, 5R21DA026104, and
5R01NS055754; Grant sponsor: Ellison Medical Foundation.
NR 35
TC 57
Z9 57
U1 0
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0740-3194
J9 MAGN RESON MED
JI Magn. Reson. Med.
PD AUG
PY 2012
VL 68
IS 2
BP 389
EP 399
DI 10.1002/mrm.23228
PG 11
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 972YZ
UT WOS:000306318900010
PM 22213578
ER
PT J
AU Sundara-Rajan, K
Bestick, A
Rowe, GI
Klute, GK
Ledoux, WR
Wang, HC
Mamishev, AV
AF Sundara-Rajan, K.
Bestick, A.
Rowe, G. I.
Klute, G. K.
Ledoux, W. R.
Wang, H. C.
Mamishev, A. V.
TI An interfacial stress sensor for biomechanical applications
SO MEASUREMENT SCIENCE AND TECHNOLOGY
LA English
DT Article
DE biomechanical interfaces; prosthesis; capacitive sensor; interfacial
stress; pressure; sensor fabrication; shear stress
ID PROSTHETIC SOCKET INTERFACE; TIBIAL AMPUTEE SUBJECTS; SHEAR STRESSES;
PLANTAR SHEAR; RESIDUAL LIMB; PRESSURES; AMBULATION; SUCTION; FOOT; TIME
AB This paper presents a capacitive sensor that measures interfacial forces in prostheses and is promising for other biomedical applications. These sensors can be integrated into prosthetic devices to measure both normal and shear stress simultaneously, allowing for the study of prosthetic limb fit, and ultimately for the ability to better adapt prosthetics to individual users. A sensing cell with a 1.0 cm(2) spatial resolution and a measurement range of 0-220 kPa of shear and 0-2 MPa of pressure was constructed. The cell was load tested and found to be capable of isolating the applied shear and pressure forces. This paper discusses the construction of the prototype, the mechanical and electrode design, fabrication and characterization. The work presented is aimed at creating a class of adaptive prosthetic interfaces using a capacitive sensor.
C1 [Sundara-Rajan, K.; Bestick, A.; Rowe, G. I.; Mamishev, A. V.] Univ Washington, Dept Elect Engn, Sensors Energy & Automat Lab, Seattle, WA 98195 USA.
[Klute, G. K.; Ledoux, W. R.] VA Puget Sound Hlth Care Syst, Ctr Excellence Limb Loss Prevent & Prosthet Engn, Seattle, WA USA.
[Klute, G. K.; Ledoux, W. R.; Wang, H. C.] Univ Washington, Dept Mech Engn, Seattle, WA 98195 USA.
[Ledoux, W. R.] Univ Washington, Dept Orthopaed & Sports Med, Seattle, WA 98195 USA.
RP Sundara-Rajan, K (reprint author), Univ Washington, Dept Elect Engn, Sensors Energy & Automat Lab, Seattle, WA 98195 USA.
EM kishore@u.washington.edu
RI Ledoux, William/K-6815-2015
OI Ledoux, William/0000-0003-4982-7714
FU US National Institute of Health [R21HD052109-02]; Department of Veterans
Affairs [A4843C]; Washington NASA Space Grant scholarships
FX The authors would like to thank Dan Hemmons, Anthony Simon, John
Thomson, Michael Fassbind and Shruti Pai for their help with sensor
fabrication and the force measurement systems used in the experiments
reported in this paper, and also STREAM Tools [47] for the guide to
formatting documents in Word, and Meagan Schuver, Kenneth Yuen and Aaron
Zielinski for editing. This work was supported in part by the US
National Institute of Health under Grant R21HD052109-02, the Department
of Veterans Affairs Grant A4843C and the Washington NASA Space Grant
scholarships.
NR 47
TC 6
Z9 6
U1 0
U2 21
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 0957-0233
EI 1361-6501
J9 MEAS SCI TECHNOL
JI Meas. Sci. Technol.
PD AUG
PY 2012
VL 23
IS 8
AR 085701
DI 10.1088/0957-0233/23/8/085701
PG 10
WC Engineering, Multidisciplinary; Instruments & Instrumentation
SC Engineering; Instruments & Instrumentation
GA 973NJ
UT WOS:000306366600053
ER
PT J
AU Goroll, AH
AF Goroll, Allan H.
TI Risk Adjustment for Primary Care An Essential Tool for Health System
Reform
SO MEDICAL CARE
LA English
DT Editorial Material
ID PAYMENT
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Goroll, AH (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA.
EM ahgoroll@partners.org
NR 19
TC 1
Z9 1
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0025-7079
J9 MED CARE
JI Med. Care
PD AUG
PY 2012
VL 50
IS 8
BP 637
EP 639
DI 10.1097/MLR.0b013e31825cb499
PG 3
WC Health Care Sciences & Services; Health Policy & Services; Public,
Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA 973KX
UT WOS:000306360100003
PM 22683594
ER
PT J
AU Yoon, J
Yano, EM
Altman, L
Cordasco, KM
Stockdale, SE
Chow, A
Barnett, PG
Rubenstein, LV
AF Yoon, Jean
Yano, Elizabeth M.
Altman, Lisa
Cordasco, Kristina M.
Stockdale, Susan E.
Chow, Adam
Barnett, Paul G.
Rubenstein, Lisa V.
TI Reducing Costs of Acute Care for Ambulatory Care-sensitive Medical
Conditions The Central Roles of Comorbid Mental Illness
SO MEDICAL CARE
LA English
DT Article
DE mental health; primary care; avoidable admissions; ED visits
ID HEALTH-CARE; PREVENTABLE HOSPITALIZATIONS; VETERANS-AFFAIRS;
COLLABORATIVE CARE; DEPRESSION; DISORDERS; BENEFICIARIES; QUALITY;
ACCESS; IMPACT
AB Background: New patient-centered models of ambulatory care aim to substitute better primary care for preventable acute care within existing primary care practices. This study aims to identify whether mental illness and other characteristics of primary care patients are related to risk for an acute event for an ambulatory care-sensitive condition (ACSC).
Methods: We conducted a 2-year, longitudinal analysis comparing ambulatory care-sensitive admissions and emergency department (ED) visits for a cohort of 18,526 primary care patients followed in 5 veterans affairs (VA) primary care sites. We compared rates, risks, and costs of ACSC-related acute events during a follow-up year for patients with and without mental illness seen during the previous year in primary care.
Results: The 12-month rate of ACSC admissions was 31.7 admissions per 1000 patients with mental health diagnoses compared with 21.0 admissions per 1000 patients without (P=0.0009). The ACSC-associated ED visit rate was also significantly higher (P<0.0001). In adjusted analyses controlling for demographics, chronic disease, illness severity, and prior ambulatory care, those with depression or drug use disorders had higher odds of receiving ACSC-related acute care (odds ratio=1.10, 95% confidence interval: 1.03, 1.17 for depression; odds ratio=1.48, 95% confidence interval: 1.05, 1.99 for drug use disorders). Costs per admission and ED visit were similar across patient groups. Higher medication use and lower medication regimen complexity were significantly associated with decreased risk for ACSC events.
Conclusions: Prior mental health diagnoses and medication use were independent risk factors for ACSC-related acute care. These risk factors require focused attention if the full benefits of new primary care models are to be achieved.
C1 [Yoon, Jean; Chow, Adam; Barnett, Paul G.] VA Palo Alto Hlth Care Syst, Hlth Econ Resource Ctr, Menlo Pk, CA 94025 USA.
[Yano, Elizabeth M.; Cordasco, Kristina M.; Stockdale, Susan E.; Rubenstein, Lisa V.] VA Greater Los Angeles, Ctr Excellence Study Healthcare Provider Behav, North Hills, CA USA.
[Yano, Elizabeth M.] Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90024 USA.
[Altman, Lisa] VA Greater Los Angeles, Dept Ambulatory Care, North Hills, CA USA.
[Cordasco, Kristina M.; Rubenstein, Lisa V.] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA.
[Cordasco, Kristina M.; Rubenstein, Lisa V.] RAND Corp, Santa Monica, CA USA.
[Barnett, Paul G.] Stanford Univ, Hlth Res & Policy Dept, Stanford, CA 94305 USA.
RP Yoon, J (reprint author), VA Palo Alto Hlth Care Syst, Hlth Econ Resource Ctr, 795 Willow Rd,152 MPD, Menlo Pk, CA 94025 USA.
EM jean.yoon@va.gov
FU Department of Veteran Affairs, Veterans Health Administration, Patient
Care Services, the VA Improvement and Assessment Laboratory [XVA 65-018]
FX The authors declare no conflict of interest. Funding for this study was
provided by the Department of Veteran Affairs, Veterans Health
Administration, Patient Care Services, the VA Improvement and Assessment
Laboratory (Project XVA 65-018).
NR 47
TC 19
Z9 19
U1 0
U2 10
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0025-7079
J9 MED CARE
JI Med. Care
PD AUG
PY 2012
VL 50
IS 8
BP 705
EP 713
DI 10.1097/MLR.0b013e31824e3379
PG 9
WC Health Care Sciences & Services; Health Policy & Services; Public,
Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA 973KX
UT WOS:000306360100013
PM 22437618
ER
PT J
AU Rubin, KM
Vona, K
Madden, K
McGettigan, S
Braun, IM
AF Rubin, Krista M.
Vona, Karen
Madden, Kathleen
McGettigan, Suzanne
Braun, Ilana M.
TI Side effects in melanoma patients receiving adjuvant interferon alfa-2b
therapy: a nurse's perspective
SO SUPPORTIVE CARE IN CANCER
LA English
DT Review
DE Adjuvant; Adverse effects; Interferon alfa; Therapy management
ID HIGH-RISK MELANOMA; DOSE INTERFERON-ALPHA-2B; CANCER-PATIENTS; PEGYLATED
INTERFERON-ALPHA-2B; DEPRESSIVE SYMPTOMS; MALIGNANT-MELANOMA; FATIGUE
INVENTORY; III MELANOMA; ALPHA; MANAGEMENT
AB The aim of this review was to examine the toxicity profile of adjuvant interferon (IFN) alfa-2b in melanoma patients from a nursing perspective and to summarize practical information to guide the effective management of common IFN toxicities to improve patient comfort.
This is a narrative summary of both research and review articles identified by searching PubMed, National Cancer Institute, and American Cancer Society websites. It also assesses recognized guidelines on the management of adjuvant IFN toxicity relevant to nurses who are caring for patients receiving adjuvant IFN therapy.
Adjuvant high-dose IFN alfa-2b (HDI) as compared with observation significantly prolongs relapse-free survival in patients with melanoma at high risk for recurrence after surgical resection; however, treatment compliance and patient quality of life can be compromised by its toxicity profile. HDI toxicities affect a number of organ systems and the majority of patients will experience some side effects. Common toxicities such as flu-like symptoms, fatigue, anorexia, neuropsychiatric symptoms, and laboratory abnormalities are discussed, along with both pharmacological and nonpharmacological management strategies.
The considerable side effects of HDI can be managed using established strategies. Oncology nurses play a significant role in the management of patients with melanoma receiving adjuvant HDI, and their prompt recognition of side effects, together with an understanding of effective pharmacological and nonpharmacological interventions, will improve patient comfort; this has the potential to positively influence treatment adherence and completion of the recommended treatment course.
C1 [Rubin, Krista M.] Massachusetts Gen Hosp, Ctr Canc, Ctr Melanoma, Boston, MA 02114 USA.
[Vona, Karen] Roswell Pk Canc Inst, Dept Med, Buffalo, NY 14263 USA.
[Madden, Kathleen] NYU, Langone Med Ctr, Ctr Clin Canc, New York, NY USA.
[McGettigan, Suzanne] Univ Penn Hlth Syst, Abramson Canc Ctr, Philadelphia, PA USA.
[Braun, Ilana M.] Dana Farber Canc Inst, Dept Psychosocial Oncol & Palliat Care, Boston, MA 02115 USA.
RP Rubin, KM (reprint author), Massachusetts Gen Hosp, Ctr Canc, Ctr Melanoma, 55 Fruit St,Yawkey Bldg,Suite 9E, Boston, MA 02114 USA.
EM kmrubin@partners.org
NR 58
TC 3
Z9 3
U1 0
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0941-4355
J9 SUPPORT CARE CANCER
JI Support. Care Cancer
PD AUG
PY 2012
VL 20
IS 8
BP 1601
EP 1611
DI 10.1007/s00520-012-1473-0
PG 11
WC Oncology; Health Care Sciences & Services; Rehabilitation
SC Oncology; Health Care Sciences & Services; Rehabilitation
GA 970LG
UT WOS:000306129600002
PM 22562583
ER
PT J
AU Lalla, RV
Gordon, GB
Schubert, M
Silverman, S
Hutten, M
Sonis, ST
LeVeque, F
Peterson, DE
AF Lalla, Rajesh V.
Gordon, Gary B.
Schubert, Mark
Silverman, Sol, Jr.
Hutten, Mark
Sonis, Stephen T.
LeVeque, Francis
Peterson, Douglas E.
TI A randomized, double-blind, placebo-controlled trial of misoprostol for
oral mucositis secondary to high-dose chemotherapy
SO SUPPORTIVE CARE IN CANCER
LA English
DT Article
DE Misoprostol; Prostaglandin E1; Mucositis; Chemotherapy
ID BONE-MARROW-TRANSPLANTATION; STEM-CELL TRANSPLANTATION;
NECROSIS-FACTOR-ALPHA; MUCOSAL INJURY; PROSTAGLANDIN-E1 ANALOG;
CANCER-PATIENTS; INFECTION; RADIATION; SEVERITY; PATIENT
AB Misoprostol, a synthetic analog of prostaglandin E1, has anti-inflammatory and mucosa-protecting properties. The objective of this study was to evaluate the efficacy of misoprostol oral rinse in reducing the severity of oral mucosal injury caused by high-dose chemotherapy.
The study used a randomized, double-blind, placebo-controlled, parallel-group design. Oncology patients receiving myeloablative high-dose chemotherapy, in preparation for a hematopoietic stem cell transplant, were randomized to misoprostol or placebo rinse. The primary outcome measure was the severity of oral mucositis, measured using the modified Oral Mucositis Index. Additional outcome measures included the severity of mouth pain (measured using a Visual Analog Scale and the Pain Affect Faces Scale), duration of hospital stay, and days on total parenteral nutrition.
This study was originally planned to accrue 160 subjects but was terminated early due to revised sponsor research priorities. The intent-to-treat population consisted of 22 subjects randomized to misoprostol rinse and 26 subjects randomized to placebo rinse. There was no significant difference between the two groups in mucositis or pain severity. In both groups, duration of hospital stay was approximately 19 days, and number of days on total parenteral nutrition was 17-18 days. There were no serious adverse events attributable to misoprostol rinse.
Although this study did not find a beneficial effect of a misoprostol rinse in mucositis secondary to high-dose chemotherapy, the small sample size limits the strength of this conclusion. Given the proposed importance of the prostaglandin pathway in the pathogenesis of oral mucositis, additional studies are warranted.
C1 [Lalla, Rajesh V.; Peterson, Douglas E.] Univ Connecticut, Ctr Hlth, Sect Oral Med, Farmington, CT USA.
[Lalla, Rajesh V.; Peterson, Douglas E.] Univ Connecticut, Ctr Hlth, Neag Comprehens Canc Ctr, Farmington, CT USA.
[Gordon, Gary B.] GD Searle, Skokie, IL USA.
[Schubert, Mark] Univ Washington, Seattle, WA 98195 USA.
[Schubert, Mark] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
[Silverman, Sol, Jr.] Univ Calif San Francisco, Sch Dent, Dept Orofacial Sci, San Francisco, CA USA.
[Hutten, Mark] Northwestern Univ, Feinberg Sch Med, Dept Otolaryngol Head & Neck Surg, Chicago, IL 60611 USA.
[Sonis, Stephen T.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Sonis, Stephen T.] Brigham & Womens Hosp, Div Oral Med, Boston, MA 02115 USA.
[LeVeque, Francis] Wayne State Univ, Sch Med, Detroit, MI USA.
RP Lalla, RV (reprint author), Univ Connecticut, Ctr Hlth, Sect Oral Med, Farmington, CT USA.
EM Lalla@nso2.uchc.edu
FU G.D. Searle and Company, Pfizer, Inc.
FX This study was supported by G.D. Searle and Company, now a component of
Pfizer, Inc. The authors acknowledge the contributions of the subjects
who participated in this study.
NR 32
TC 6
Z9 8
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0941-4355
EI 1433-7339
J9 SUPPORT CARE CANCER
JI Support. Care Cancer
PD AUG
PY 2012
VL 20
IS 8
BP 1797
EP 1804
DI 10.1007/s00520-011-1277-7
PG 8
WC Oncology; Health Care Sciences & Services; Rehabilitation
SC Oncology; Health Care Sciences & Services; Rehabilitation
GA 970LG
UT WOS:000306129600024
PM 21964618
ER
PT J
AU Biederman, J
AF Biederman, Joseph
TI Is ADHD Overdiagnosed in Scandinavia?
SO ACTA PSYCHIATRICA SCANDINAVICA
LA English
DT Editorial Material
C1 [Biederman, Joseph] Massachusetts Gen Hosp, Clin & Res Program Pediat Psychopharmacol, Boston, MA 02114 USA.
[Biederman, Joseph] Massachusetts Gen Hosp, Clin & Res Program Adult ADHD, Boston, MA 02114 USA.
[Biederman, Joseph] Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
RP Biederman, J (reprint author), Massachusetts Gen Hosp, Clin & Res Program Pediat Psychopharmacol, Boston, MA 02114 USA.
EM biederman@helix.mgh.harvard.edu
NR 5
TC 2
Z9 2
U1 1
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0001-690X
J9 ACTA PSYCHIAT SCAND
JI Acta Psychiatr. Scand.
PD AUG
PY 2012
VL 126
IS 2
BP 85
EP 86
DI 10.1111/j.1600-0447.2012.01878.x
PG 2
WC Psychiatry
SC Psychiatry
GA 970IO
UT WOS:000306121800002
PM 22764752
ER
PT J
AU Angin, M
Streeck, H
Wen, F
King, M
Pereyra, F
Altfeld, M
Walker, BD
Addo, MM
AF Angin, Mathieu
Streeck, Hendrik
Wen, Fang
King, Melanie
Pereyra, Florencia
Altfeld, Marcus
Walker, Bruce D.
Addo, Marylyn M.
TI Regulatory T Cell Frequencies Do Not Correlate with Breadth or Magnitude
of HIV-1-Specific T Cell Responses
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Letter
ID HIV-INFECTED INDIVIDUALS; PERIPHERAL-BLOOD; IMMUNE-RESPONSES;
ACTIVATION; SUPPRESSION; DEPLETION; CD4(+)
C1 [Angin, Mathieu; Streeck, Hendrik; Wen, Fang; King, Melanie; Pereyra, Florencia; Altfeld, Marcus; Walker, Bruce D.; Addo, Marylyn M.] Ragon Inst MGH MIT & Harvard, Boston, MA USA.
[Walker, Bruce D.] Howard Hughes Med Inst, Chevy Chase, MD USA.
[Addo, Marylyn M.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.
RP Addo, MM (reprint author), Ragon Inst MGH MIT & Harvard, 149 13th St,6th Floor,Suite 6620, Charlestown, MA 02129 USA.
EM maddo@partners.org
OI Angin, Mathieu/0000-0002-6867-4680
FU NIAID NIH HHS [AI074405-03S1, KO8 AI074405, P01 AI074415, P30AI 060354,
R01 AI091450]
NR 14
TC 3
Z9 4
U1 2
U2 3
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD AUG
PY 2012
VL 28
IS 8
BP 749
EP 751
DI 10.1089/aid.2011.0353
PG 3
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 977SA
UT WOS:000306683600002
PM 22214208
ER
PT J
AU Wanderer, J
Forman, S
Baker, K
AF Wanderer, Jonathan
Forman, Stuart
Baker, Keith
TI RESIDENTS HELPING IN NAVIGATING OR SCHEDULING (RHINOS): FACILITATING
SELF-DIRECTED LEARNING
SO ANESTHESIA AND ANALGESIA
LA English
DT Meeting Abstract
C1 [Wanderer, Jonathan; Forman, Stuart; Baker, Keith] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0003-2999
J9 ANESTH ANALG
JI Anesth. Analg.
PD AUG
PY 2012
VL 115
SU 1
PG 1
WC Anesthesiology
SC Anesthesiology
GA V45WM
UT WOS:000209846700036
ER
PT J
AU Fagenholz, PJ
Bowler, GMR
Carnochan, FM
Walker, WS
AF Fagenholz, P. J.
Bowler, G. M. R.
Carnochan, F. M.
Walker, W. S.
TI Systemic local anaesthetic toxicity from continuous thoracic
paravertebral block
SO BRITISH JOURNAL OF ANAESTHESIA
LA English
DT Article
DE anaesthetic techniques; regional; thoracic; anaesthetics local;
bupivacaine; complications; death; surgery; thoracic
ID RANDOMIZED-TRIALS; BUPIVACAINE; THORACOTOMY; ROPIVACAINE; ANALGESIA;
PHARMACOKINETICS; ENANTIOMERS; EFFICACY; INFUSION; PAIN
AB Continuous paravertebral block is commonly used for post-thoracotomy analgesia and compares favourably with other systemic and regional methods with regard to safety and efficacy. No major complications of continuous paravertebral block for post-thoracotomy analgesia have been reported previously. We report here a case of systemic local anaesthetic toxicity from continuous paravertebral block administration after thoracotomy and lobectomy leading to seizure, aspiration, and ultimately, death. Potential contributing factors in this case included small patient size, concomitant antifungal therapy, extensive surgical disruption of the pleurae, and inappropriate paravertebral bolus administration. Postoperative delirium was a diagnostic confounder. We discuss the potential causes and means of avoiding similar complications in the future.
C1 [Fagenholz, P. J.; Bowler, G. M. R.; Carnochan, F. M.; Walker, W. S.] Royal Infirm Edinburgh NHS Trust, Dept Anaesthesia Theatres & Pain Med, Edinburgh EH16 4SU, Midlothian, Scotland.
[Fagenholz, P. J.; Bowler, G. M. R.; Carnochan, F. M.; Walker, W. S.] Royal Infirm Edinburgh NHS Trust, Dept Cardiothorac Surg, Edinburgh EH16 4SU, Midlothian, Scotland.
RP Fagenholz, PJ (reprint author), Massachusetts Gen Hosp, Dept Surg, Div Trauma Emergency Surg & Crit Care, CPZ 810,165 Cambridge St, Boston, MA 02114 USA.
EM pfagenholz@partners.org
NR 15
TC 13
Z9 13
U1 0
U2 7
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0007-0912
J9 BRIT J ANAESTH
JI Br. J. Anaesth.
PD AUG
PY 2012
VL 109
IS 2
BP 260
EP 262
DI 10.1093/bja/aes126
PG 3
WC Anesthesiology
SC Anesthesiology
GA 973MJ
UT WOS:000306363900020
PM 22581806
ER
PT J
AU Keliher, EJ
Reiner, T
Thurber, GM
Upadhyay, R
Weissleder, R
AF Keliher, Edmund J.
Reiner, Thomas
Thurber, Greg M.
Upadhyay, Rabi
Weissleder, Ralph
TI Efficient F-18-Labeling of Synthetic Exendin-4 Analogues for Imaging
Beta Cells
SO CHEMISTRYOPEN
LA English
DT Article
DE F-18-trans-cyclooctene; cancer; diabetes; exendin-4; insulinoma;
positron emission tomography
ID IN-VIVO; RECEPTOR; INSULINOMA; PEPTIDE; GLP-1; MASS
AB A number of exendin derivatives have been developed to target glucagon-like peptide 1 (GLP-1) receptors on beta cells in vivo. Modifications of exendin analogues have been shown to have significant effects on pharmacokinetics and, as such, have been used to develop a variety of therapeutic compounds. Here, we show that an exendin-4, modified at position 12 with a cysteine conjugated to a tetrazine, can be labeled with F-18-trans-cyclooctene and converted into a PET imaging agent at high yields and with good selectivity. The agent accumulates in beta cells in vivo and has sufficiently high accumulation in mouse models of insulinomas to enable in vivo imaging.
C1 [Keliher, Edmund J.; Reiner, Thomas; Thurber, Greg M.; Upadhyay, Rabi; Weissleder, Ralph] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA.
[Weissleder, Ralph] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA.
RP Keliher, EJ (reprint author), Massachusetts Gen Hosp, Ctr Syst Biol, 185 Cambridge St,CPZN 5206, Boston, MA 02114 USA.
EM rweissleder@mgh.harvard.edu
OI Reiner, Thomas/0000-0002-7819-5480; Thurber, Greg/0000-0001-7570-2080
FU National Institutes of Health (NIH) [P01 AI54904, U24 CA092782, K01
1KO1K093766-01]; German Academy of Sciences [2009-24]
FX The authors thank Jessica Truelove (Center for Systems Biology,
Massachusetts General Hospital (CSB, MGH)) for image processing and
generation, Rostic Gorbatov (CSB, MGH) for surgery, Dr. Yvonna
Fisher-Jeffes (CSB, MGH) for critical review of the article and Dr.
Ralph Mazitschek (CSB, MGH) for many helpful discussions. We especially
recognize the many helpful discussions with Drs. Diane Mathis,
Christophe Benoist (Department of Pathology, Harvard Medical School) and
Jason Gaglia (Joslin Diabetes Center, Harvard Medical School). This work
was supported, in part, by the following grants: National Institutes of
Health (NIH) Grants P01 AI54904 (to R. W.), U24 CA092782 (to R. W.), K01
1KO1K093766-01 (to G. M. T.). R. U. is a Howard Hughes Medical Institute
Medical Research Fellow. T. R. was supported by German Academy of
Sciences Leopoldina Grant LPDS 2009-24.
NR 28
TC 25
Z9 25
U1 0
U2 14
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY
SN 2191-1363
J9 CHEMSTRYOPEN
JI ChemistryOpen
PD AUG
PY 2012
VL 1
IS 4
BP 177
EP 183
DI 10.1002/open.201200014
PG 7
WC Chemistry, Multidisciplinary
SC Chemistry
GA 274LY
UT WOS:000328609200004
PM 23997998
ER
PT J
AU Moed, BR
Vrahas, MS
AF Moed, Berton R.
Vrahas, Mark S.
TI Disruptions of the Pelvic Ring: An Update: Editorial Comment
SO CLINICAL ORTHOPAEDICS AND RELATED RESEARCH
LA English
DT Editorial Material
C1 [Moed, Berton R.] St Louis Univ, Sch Med, Dept Orthopaed Surg, St Louis, MO 63110 USA.
[Vrahas, Mark S.] Harvard Univ, Dept Orthopaed Surg, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
RP Moed, BR (reprint author), St Louis Univ, Sch Med, Dept Orthopaed Surg, 3635 Vista Ave,7th Floor,Desloge Towers, St Louis, MO 63110 USA.
EM moedbr@slu.edu
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0009-921X
J9 CLIN ORTHOP RELAT R
JI Clin. Orthop. Rel. Res.
PD AUG
PY 2012
VL 470
IS 8
BP 2073
EP 2074
DI 10.1007/s11999-012-2365-9
PG 2
WC Orthopedics; Surgery
SC Orthopedics; Surgery
GA 971PD
UT WOS:000306215400001
PM 22528391
ER
PT J
AU Weaver, MJ
Bruinsma, W
Toney, E
Dafford, E
Vrahas, MS
AF Weaver, Michael J.
Bruinsma, Wendy
Toney, Eugene
Dafford, Erica
Vrahas, Mark S.
TI What Are the Patterns of Injury and Displacement Seen in Lateral
Compression Pelvic Fractures?
SO CLINICAL ORTHOPAEDICS AND RELATED RESEARCH
LA English
DT Article
ID SACRAL FRACTURES; RING; BURGESS; YOUNG
AB Lateral compression (LC)-type pelvic fractures encompass a wide spectrum of injuries. Current classification systems are poorly suited to help guide treatment and do not adequately describe the wide range of injuries seen in clinical practice.
We therefore (1) defined the spectrum of injuries that compose LC fractures with respect to both anterior and posterior ring injuries, with particular focus on the morphology of sacral fractures, and (2) identified fracture patterns associated with displacement at presentation.
We retrospectively reviewed 318 LC pelvic fractures. Displacement of the anterior pelvic ring was identified and measured on plain radiographs and posterior displacement was identified by CT.
All 318 patients had an anterior injury and all but 13 (4%) had a posterior injury; 263 of the 318 fractures (87%) included a sacral fracture, with 162 of 318 (51%) having an anterior incomplete sacral fracture, 53 (17%) a complete simple fracture, and 48 (15%) a complete comminuted fracture. Forty-two of 318 (13%) had a crescent fracture. One hundred six of 318 (33%) were displaced at presentation. There was a higher incidence of initial displacement observed in fractures including bilateral rami fractures, a comminuted sacral fracture, or a crescent fracture.
LC pelvic fractures represent a heterogeneous group of injuries with a wide range of associated fracture patterns. In particular, there is a wide range of fracture types represented by injuries classified as LC1 (involving any sacral fracture). Fractures with more complex sacral fractures, crescent fractures, or bilateral pubic rami fractures tend to have higher degrees of initial displacement.
Level IV, diagnostic study. See Instructions for Authors for a complete description of levels of evidence.
C1 [Bruinsma, Wendy; Dafford, Erica; Vrahas, Mark S.] Harvard Univ, Sch Med, Dept Orthopaed Surg, Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Weaver, Michael J.; Toney, Eugene] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Orthopaed Surg, Boston, MA 02115 USA.
RP Vrahas, MS (reprint author), Harvard Univ, Sch Med, Dept Orthopaed Surg, Massachusetts Gen Hosp, 55 Fruit St,YAW 3, Boston, MA 02114 USA.
EM mvrahas@partners.org
NR 14
TC 7
Z9 7
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0009-921X
J9 CLIN ORTHOP RELAT R
JI Clin. Orthop. Rel. Res.
PD AUG
PY 2012
VL 470
IS 8
BP 2104
EP 2110
DI 10.1007/s11999-012-2364-x
PG 7
WC Orthopedics; Surgery
SC Orthopedics; Surgery
GA 971PD
UT WOS:000306215400008
PM 22585347
ER
PT J
AU Shazly, TA
Latina, MA
Dagianis, JJ
Chitturi, S
AF Shazly, Tarek A.
Latina, Mark A.
Dagianis, John J.
Chitturi, Satyakant
TI Effect of Central Corneal Thickness on the Long-Term Outcome of
Selective Laser Trabeculoplasty as Primary Treatment for Ocular
Hypertension and Primary Open-Angle Glaucoma
SO CORNEA
LA English
DT Article
DE selective laser trabeculoplasty; central corneal thickness; ocular
hypertension; primary open-angle glaucoma; intraocular pressure
ID RANDOMIZED CLINICAL-TRIAL; INTRAOCULAR-PRESSURE; SUCCESS
AB Purpose: To determine if central corneal thickness (CCT) impacts the intraocular pressure (IOP)-lowering effect of selective laser trabeculoplasty (SLT) in patients with ocular hypertension (OHT) and primary open-angle glaucoma (POAG).
Methods: A retrospective chart review of consecutive patients, who underwent SLT as primary treatment for OHT and POAG, between 2002 and 2005, was performed. Partial correlation analysis was performed to correlate the CCT to the percentage of IOP reduction at 3 to 30 months after SLT. Independent samples t test was performed to compare mean percentage of IOP reduction in eyes with CCT less than 555 mu m versus CCT 555 mu m or greater.
Results: Eighty eyes of 47 patients were identified. The partial correlation coefficient value between the CCT and percentage of IOP reduction after SLT at 3 months was -0.253 (P = 0.025), at 12 months it was -0.22 (P = 0.049), and at 30 months it was 0.301 (P = 0.007). Independent samples t test showed that the mean percentage of IOP reduction in eyes with thinner corneas (CCT, 555 mu m) was greater than that in thicker corneas (CCT >= 555 mu m) at 3-, 6-, 9-, 12-, and 30-month post-SLT (P < 0.05).
Conclusions: In patients with POAG and OHT, percentage of IOP reduction after SLT was significantly greater in eyes with thinner corneas (CCT, 555 mu m). These findings indicate that patients treated with SLT as primary therapy who had thinner corneas demonstrated better IOP control for at least 30 months after SLT.
C1 [Shazly, Tarek A.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol, Boston, MA USA.
[Shazly, Tarek A.] Assiut Univ Hosp, Dept Ophthalmol, Assiut, Egypt.
[Latina, Mark A.] Reading Hlth Ctr, Reading, MA USA.
[Dagianis, John J.] Nashua Eye Associates, Nashua, NH USA.
[Chitturi, Satyakant] Andhra Med Coll, Visakhapatnam, Andhra Pradesh, India.
RP Shazly, TA (reprint author), 20 Pondmeadow Dr,Suite 203, Reading, MA 01867 USA.
EM shazlyt@gmail.com
NR 21
TC 5
Z9 5
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0277-3740
J9 CORNEA
JI Cornea
PD AUG
PY 2012
VL 31
IS 8
BP 883
EP 886
DI 10.1097/ICO.0b013e318243f684
PG 4
WC Ophthalmology
SC Ophthalmology
GA 973BG
UT WOS:000306325500008
PM 22525783
ER
PT J
AU Sepulcre, J
Sabuncu, MR
Johnson, KA
AF Sepulcre, Jorge
Sabuncu, Mert R.
Johnson, Keith A.
TI Network assemblies in the functional brain
SO CURRENT OPINION IN NEUROLOGY
LA English
DT Review
DE brain connectome; brain network; functional connectivity; graph theory;
neuroimaging
ID DEFAULT MODE; NEUROCOGNITIVE NETWORKS; CORTICAL CONNECTIONS;
CEREBRAL-CORTEX; ORGANIZATION; COGNITION; MRI; HUBS; PRINCIPLES; DISEASE
AB Purpose of review
This review focuses on recent advances in functional connectivity MRI and renewed interest in studying the large-scale functional network assemblies in the brain. We also consider some methodological aspects of graph theoretical analysis.
Recent findings
Recent years have witnessed a rapid increase in the number of studies that apply network science to neuroscience. A major motivation comes from the fields of neurology and psychiatry, where a central goal is the characterization of the functional connectome of the brain under normal and pathological conditions. Recent findings have provided new insights into the pivotal role of network epicenters and specific configurations of large-scale functional networks in the brain.
Summary
Functional connectivity MRI and corresponding analytical tools continue to reveal novel properties of the functional organization of the brain, which will in turn be key for understanding pathologies in neurology.
C1 [Sepulcre, Jorge; Johnson, Keith A.] Massachusetts Gen Hosp, Dept Radiol, Div Nucl Med & Mol Imaging, Cambridge, MA 02138 USA.
[Sepulcre, Jorge; Johnson, Keith A.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
[Sepulcre, Jorge; Sabuncu, Mert R.] Athinioula A Martinos Ctr Biomed Imaging, Charlestown, MA USA.
[Sabuncu, Mert R.] MIT, Comp Sci & Artificial Intelligence Lab, Cambridge, MA 02139 USA.
[Johnson, Keith A.] Brigham & Womens Hosp, Dept Neurol, Ctr Alzheimer Res & Treatment, Boston, MA 02115 USA.
[Johnson, Keith A.] Harvard Univ, Sch Med, Boston, MA USA.
[Johnson, Keith A.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
RP Sepulcre, J (reprint author), Massachusetts Gen Hosp, Dept Radiol, Div Nucl Med & Mol Imaging, 52 Oxford St,Northwest Bldg,280-02, Cambridge, MA 02138 USA.
EM sepulcre@nmr.mgh.harvard.edu
FU Alzheimer's Association [NIRG-11-205690, ZEN-10-174210]; NIH
[K25EB013649-01, R01AG037497, R01AG036694]
FX We thank Randy L. Buckner and Fenna Krienen for generously providing the
raw data used in Fig. 4, and Emily Shire for her helpful comments to the
article. This work was supported by the Alzheimer's Association
(NIRG-11-205690 to JS; ZEN-10-174210 to KAJ) and the NIH (K25EB013649-01
to MRS; R01AG037497 and R01AG036694 to KAJ).
NR 64
TC 20
Z9 22
U1 1
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1350-7540
J9 CURR OPIN NEUROL
JI Curr. Opin. Neurol.
PD AUG
PY 2012
VL 25
IS 4
BP 384
EP 391
DI 10.1097/WCO.0b013e328355a8e8
PG 8
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 970KB
UT WOS:000306125900003
PM 22766721
ER
PT J
AU Pike, MC
Kelley, L
AF Pike, Marilyn C.
Kelley, Lexy
TI Data Quality Challenges in Systemic Lupus Erythematosus Trials: How Can
This Be Optimized?
SO CURRENT RHEUMATOLOGY REPORTS
LA English
DT Article
DE Systemic lupus erythematosus; SLE; Data quality; Challenge; New agents;
Therapy; Central adjudication committees; Disease Activity Index;
Trials; Optimize
ID B-LYMPHOCYTE STIMULATOR; DISEASE-ACTIVITY INDEX; INTERNATIONAL
CLINICAL-TRIAL; INFARCTION END-POINTS; RHEUMATOID-ARTHRITIS; INITIAL
VALIDATION; THERAPY; BILAG; SLE; ADJUDICATION
AB Major scientific advances in basic science, pharmacology, and translational medicine have allowed the discovery of new molecular targets whose manipulation by new chemical entities has led to treatments for inflammatory diseases, including rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease. Development of new agents for systemic lupus erythematosus (SLE) has lagged, however, because the protean manifestations of SLE present challenges for measuring therapeutic effects in a consistent manner. Composite end points combining several Disease Activity Indices (DAIs) are being used in ongoing global studies, but the uniform application of these complex DAIs across large numbers of clinical sites has proven difficult. We describe herein approaches that are being utilized to facilitate collection, review, and analysis of the clinical measures utilizing independent central adjudication committees.
C1 [Pike, Marilyn C.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Rheumatol, Boston, MA USA.
[Pike, Marilyn C.] MedPharm Consulting, Cambridge, MA 02138 USA.
[Kelley, Lexy] ReS Pharmaceut Serv, Ft Washington, PA 19034 USA.
RP Pike, MC (reprint author), MedPharm Consulting, 8 Craigie St, Cambridge, MA 02138 USA.
EM mp@marilynpike.com; lkelley@rpsweb.com
FU UCB Pharma, Inc.; MedImmune, Inc.; RPS, Inc.
FX MCP receives consultancy fees from UCB Pharma, Inc., MedImmune, Inc. and
RPS, Inc. LK is a current employee of RPS, Inc. and a former employee of
UCB Pharma, Inc.
NR 55
TC 6
Z9 6
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1523-3774
J9 CURR RHEUMATOL REP
JI Curr. Rheumatol. Rep.
PD AUG
PY 2012
VL 14
IS 4
BP 324
EP 333
DI 10.1007/s11926-012-0261-7
PG 10
WC Rheumatology
SC Rheumatology
GA 225UX
UT WOS:000324990600005
PM 22580894
ER
PT J
AU Yoon, WJ
Brugge, WR
AF Yoon, Won Jae
Brugge, William R.
TI Endoscopic Ultrasound and Pancreatic Cystic Lesions-Diagnostic and
Therapeutic Applications
SO ENDOSCOPIC ULTRASOUND
LA English
DT Review
DE endosonography; pancreatic cyst
AB Pancreatic cystic lesions are being detected with an increasing frequency. Endoscopic ultrasound (EUS) provides both diagnostic and therapeutic means for pancreatic cystic lesions. Detailed imaging and EUS-guided fine-needle aspiration provide additional information on pancreatic cystic lesions. EUS-guided pseudocyst drainage has advantages over conventional drainage modalities. EUS-guided cyst ablation is a promising therapeutic modality
C1 [Yoon, Won Jae; Brugge, William R.] Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA.
[Brugge, William R.] Harvard Univ, Sch Med, Boston, MA 02114 USA.
RP Brugge, WR (reprint author), Harvard Univ, Sch Med, 55 Fruit St, Boston, MA 02114 USA.
EM wbrugge@partners.org
NR 48
TC 5
Z9 6
U1 0
U2 1
PU SPRING MEDIA
PI HONG KONG
PA BLDG 8, WANG KWUN RD, KIN BAY, HONG KONG, SAR 00000, PEOPLES R CHINA
SN 2303-9027
EI 2226-7190
J9 ENDOSC ULTRASOUND
JI Endosc. Ultrasound
PD AUG
PY 2012
VL 1
IS 2
BP 75
EP 79
DI 10.7178/eus.02.004
PG 5
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA V31PG
UT WOS:000208894900004
PM 24949341
ER
PT J
AU Doba, N
Tokuda, Y
Goldstein, NE
Kushiro, T
Hinohara, S
AF Doba, Nobutaka
Tokuda, Yasuharu
Goldstein, Nathan E.
Kushiro, Toshio
Hinohara, Shigeaki
TI A pilot trial to predict frailty syndrome: The Japanese Health Research
Volunteer Study
SO EXPERIMENTAL GERONTOLOGY
LA English
DT Article
DE Frailty; Prediction; Gait speed; Pulse pressure; Cognitive deficits;
Hearing deficits
ID COMPREHENSIVE GERIATRIC ASSESSMENT; ANDROGEN-DEPRIVATION THERAPY;
DWELLING OLDER-PEOPLE; IANA TASK-FORCE; BODY-COMPOSITION;
PROSTATE-CANCER; GAIT SPEED; DISEASE; MANAGEMENT; PROMOTION
AB Most definitions of frailty utilize US populations in their development. The concept of frailty has not been well studied in Japan, which has the largest percentage of older patients ( per capita) in the world. We created a 5-year prospective cohort study of community-dwelling older Japanese adults. Participants were not frail at baseline, based on our definition adapted from the Canadian Study for Health and Aging Clinical Frailty Scale. Participants underwent a comprehensive geriatric assessment (CGA) at baseline, and final assessments were either in person or via mailed survey. We enrolled 407 individuals (184 men, mean age 78 +/- 4 years; 223 women, mean age 77 +/- 4 years). Sixty-five participants met criteria for frailty by the end of the study. In univariate analyses, eighteen separate parameters were associated with frailty, some of which included: age, gender, handgrip, timed walk, systolic blood pressure, pulse pressure, cognitive status, living alone, and hearing deficits. In multivariate analyses, the following elements remained associated with frailty: timed walk, pulse pressure, cognition deficits and hearing deficits. We established cut-off points for timed walk (5 m/3 s) and pulse pressure (60 mm Hg). We then created a simple additive score for these four factors (present = 1; absent = 0). A score of 0 had a 93% negative predictive value for frailty while a score of 4 had a 70% positive predictive value. While further study is needed, this work creates an easy-to-administer tool that may be generalizable to other populations. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Doba, Nobutaka] Sasakawa Kinen Kaikan, Life Planning Ctr Fdn, Div Res & Educ, Minato Ku, Tokyo 1080073, Japan.
[Tokuda, Yasuharu] Univ Tsukuba, Mito Kyodo Gen Hosp, Dept Med, Mito, Ibaraki 3100015, Japan.
[Goldstein, Nathan E.] Mt Sinai Sch Med, Brookdale Dept Geriatr & Palliat Med, New York, NY 10029 USA.
[Goldstein, Nathan E.] James J Peters VA Med Ctr Bronx, Bronx, NY USA.
[Kushiro, Toshio] Nihon Univ, Sch Med, Ctr Hlth Evaluat & Promot, Chiyoda Ku, Tokyo 1010062, Japan.
[Hinohara, Shigeaki] Sasakawa Kinen Kaikan, Life Planning Ctr Fdn, Minato Ku, Tokyo 1080073, Japan.
RP Doba, N (reprint author), Sasakawa Kinen Kaikan, Life Planning Ctr Fdn, Div Res & Educ, Minato Ku, 11th Floor,12-12,Mita 3 Chome, Tokyo 1080073, Japan.
EM doba@krd.biglobe.ne.jp; yasuharu.tokuda@gmail.com;
Nathan.goldstein@mssm.edu; Kushiro@med.nihon-u.ac.jp;
shosler@mrj.biglobe.ne.jp
FU Life Planning Center
FX The research reported in this paper was supported by the institutional
research fund from the Life Planning Center, a not-for-profit
organization. The authors have no conflict of interest to disclose. We
thank all the participants who joined the study as well as the members
of the study committee. Also we express our gratitude to other research
members at the LPC for their professional and technical assistance.
NR 43
TC 15
Z9 16
U1 2
U2 7
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0531-5565
J9 EXP GERONTOL
JI Exp. Gerontol.
PD AUG
PY 2012
VL 47
IS 8
BP 638
EP 643
DI 10.1016/j.exger.2012.05.016
PG 6
WC Geriatrics & Gerontology
SC Geriatrics & Gerontology
GA 970CU
UT WOS:000306106500014
PM 22664579
ER
PT J
AU Rose, AJ
Petrakis, BA
Callahan, P
Mambourg, S
Patel, D
Hylek, EM
Bokhour, BG
AF Rose, Adam J.
Petrakis, Beth Ann
Callahan, Patricia
Mambourg, Scott
Patel, Dimple
Hylek, Elaine M.
Bokhour, Barbara G.
TI Organizational Characteristics of High- and Low-Performing
Anticoagulation Clinics in the Veterans Health Administration
SO HEALTH SERVICES RESEARCH
LA English
DT Article
DE Qualitative research; quality of health care; anticoagulants;
pharmacists; organization and administration
ID VITAMIN-K ANTAGONISTS; THERAPY; WARFARIN; QUALITY
AB Objective Anticoagulation clinics (ACCs) can improve anticoagulation control and prevent adverse events. However, ACCs vary widely in their performance on anticoagulation control. Our objective was to compare the organization and management of top-performing with that of bottom-performing ACCs. Data Sources/Study Setting Three high outlier and three low outlier ACCs in the Veterans Health Administration (VA). Study Design Site visits with qualitative data collection and analysis. Data Collection/Extraction Methods We conducted semi-structured interviews with ACC staff regarding work flow, staffing, organization, and quality assurance efforts. We also observed ACC operations and collected documents, such as the clinic protocol. We used grounded thematic analysis to examine site-level factors associated with high and low outlier status. Principal Findings High outlier sites were characterized by (1) adequate (pharmacist) staffing and effective use of (nonpharmacist) support personnel; (2) innovation to standardize clinical practice around evidence-based guidelines; (3) the presence of a quality champion for the ACC; (4) higher staff qualifications; (5) a climate of ongoing group learning; and (6) internal efforts to measure performance. Although high outliers had all of these features, no low outlier had more than two of them. Conclusions The top-performing ACCs in the VA system shared six relatively recognizable characteristics. Efforts to improve performance should focus on these domains.
C1 [Rose, Adam J.; Petrakis, Beth Ann; Hylek, Elaine M.; Bokhour, Barbara G.] Bedford VA Med Ctr, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA 01730 USA.
[Rose, Adam J.; Hylek, Elaine M.] Boston Univ, Sch Med, Dept Med, Gen Internal Med Sect, Boston, MA 02118 USA.
[Rose, Adam J.; Petrakis, Beth Ann; Callahan, Patricia; Mambourg, Scott; Patel, Dimple; Hylek, Elaine M.; Bokhour, Barbara G.] US Dept Vet Affairs, Washington, DC USA.
[Bokhour, Barbara G.] Boston Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA USA.
RP Rose, AJ (reprint author), Bedford VA Med Ctr, Ctr Hlth Qual Outcomes & Econ Res, 200 Springs Rd,Bldg 70, Bedford, MA 01730 USA.
EM adamrose@bu.edu
OI Bokhour, Barbara/0000-0001-8238-0745
FU VA Stroke Quality Enhancement Research Initiative (QUERI) [RRP-10-054];
VA HSR&D Career Development Award [CDA-2-08-017]
FX This study was funded by the VA Stroke Quality Enhancement Research
Initiative (QUERI), Project RRP-10-054. Dr. Rose is supported by a VA
HSR&D Career Development Award (CDA-2-08-017). The authors thank Russell
Buono, Mitchell Finkel, Elizabeth Goy, and Anthony Vo for their help
collecting the data. The authors thank Steve Spear, Rani Elwy, Dan
Berlowitz, Arlene Ash, and Vicky Parker for their helpful comments on
the manuscript. The authors thank all the interviewees for
participating.
NR 19
TC 15
Z9 15
U1 0
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0017-9124
J9 HEALTH SERV RES
JI Health Serv. Res.
PD AUG
PY 2012
VL 47
IS 4
BP 1541
EP 1560
DI 10.1111/j.1475-6773.2011.01377.x
PG 20
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA 970OL
UT WOS:000306141500009
PM 22299722
ER
PT J
AU Ryan, A
Burgess, J
Strawderman, R
Dimick, J
AF Ryan, Andrew
Burgess, James
Strawderman, Robert
Dimick, Justin
TI What Is the Best Way to Estimate Hospital Quality Outcomes? A Simulation
Approach
SO HEALTH SERVICES RESEARCH
LA English
DT Article
DE Biostatistical methods; incentives in health care; hospitals; Medicare;
patient outcomes; functional status; ADLs; IADLs; quality of care;
patient safety (measurement)
ID MORTALITY-RATES; HEALTH-CARE; PERFORMANCE-MEASURES; SURGICAL MORTALITY;
COMPOSITE MEASURES; ACCURACY; MODEL
AB Objective To test the accuracy of alternative estimators of hospital mortality quality using a Monte Carlo simulation experiment. Data Sources Data are simulated to create an admission-level analytic dataset. The simulated data are validated by comparing distributional parameters (e.g., mean and standard deviation of 30-day mortality rate, hospital sample size) with the same parameters observed in Medicare data for acute myocardial infarction (AMI) inpatient admissions. Study Design We perform a Monte Carlo simulation experiment in which true quality is known to test the accuracy of the Observed-over-Expected estimator, the Risk Standardized Mortality Rate (RSMR), the Dimick and Staiger (DS) estimator, the Hierarchical Poisson estimator, and the Moving Average estimator using hospital 30-day mortality for AMI as the outcome. Estimator accuracy is evaluated for all hospitals and for small, medium, and large hospitals. Data Extraction Methods Data are simulated. Principal Findings Significant and substantial variation is observed in the accuracy of the tested outcome estimators. The DS estimator is the most accurate for all hospitals and for small hospitals using both accuracy criteria (root mean squared error and proportion of hospitals correctly classified into quintiles). Conclusions The mortality estimator currently in use by Medicare for public quality reporting, the RSMR, has been shown to be less accurate than the DS estimator, although the magnitude of the difference is not large. Pending testing and validation of our findings using current hospital data, CMS should reconsider the decision to publicly report mortality rates using the RSMR.
C1 [Ryan, Andrew] Weill Cornell Med Coll, Dept Publ Hlth, Div Outcomes & Effectiveness, New York, NY 10065 USA.
[Burgess, James] Boston Univ, Ctr Org Leadership & Management Res, VA Boston Healthcare Syst, Boston, MA 02215 USA.
[Burgess, James] Boston Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA USA.
[Strawderman, Robert] Cornell Univ, Dept Biol Stat & Computat Biol, Ithaca, NY USA.
[Strawderman, Robert] Cornell Univ, Dept Stat Sci, Ithaca, NY USA.
[Dimick, Justin] Univ Michigan, Taubman Hlth Care Ctr, Ann Arbor, MI 48109 USA.
RP Ryan, A (reprint author), Weill Cornell Med Coll, Dept Publ Hlth, Div Outcomes & Effectiveness, 402 E 67th St, New York, NY 10065 USA.
EM amr2015@med.cornell.edu
OI Burgess, James/0000-0002-6646-7071
FU Agency for Healthcare Research and Quality [1 K01 HS018546-01A1, K08
HS017765]; Clinical and Translational Science Center at Weill Cornell
Medical College
FX Funding for Dr. Ryan was supported by a career development award from
the Agency for Healthcare Research and Quality (1 K01 HS018546-01A1).
Dr. Dimick was supported by a career development award from the Agency
for Healthcare Research and Quality (K08 HS017765). Dr. Dimick is a paid
consultant and equity owner in Arbor-Metrix, Inc., a company that
provides software and analytic services for assessing hospital quality
and efficiency. Dr. Strawderman was supported by a grant from the
Clinical and Translational Science Center at Weill Cornell Medical
College. The opinions are solely those of the authors and do not reflect
those of the US Department of Veterans Affairs, Centers for Medicare and
Medicaid Services, the United States government, Boston University,
Cornell University, or Weill Cornell Medical College.
NR 31
TC 8
Z9 8
U1 1
U2 15
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0017-9124
EI 1475-6773
J9 HEALTH SERV RES
JI Health Serv. Res.
PD AUG
PY 2012
VL 47
IS 4
BP 1699
EP 1718
DI 10.1111/j.1475-6773.2012.01382.x
PG 20
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA 970OL
UT WOS:000306141500017
PM 22352894
ER
PT J
AU Maliha, G
Morgan, J
Vrahas, M
AF Maliha, George
Morgan, Jordan
Vrahas, Mark
TI Transient osteoporosis of pregnancy
SO INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED
LA English
DT Review
DE Transient osteoporosis; Pregnancy
ID DISPLACED SUBCAPITAL FRACTURE; REGIONAL OSTEOPOROSIS; AVASCULAR
NECROSIS; FOLLOW-UP; HIP
AB Transient osteoporosis of pregnancy (TOP) is a rare yet perhaps under-reported condition that has affected otherwise healthy pregnancies throughout the world. The condition presents suddenly in the third trimester of a usually uneventful pregnancy and progressively immobilizes the mother. Radiographic studies detect drastic loss of bone mass, elevated rates of turnover in the bone, and oedema in the affected portion. Weakness of the bone can lead to fractures during delivery and other complications for the mother. Then, within weeks of labour, symptoms and radiological findings resolve. Aetiology is currently unknown, although neural, vascular, haematological, endocrine, nutrient-deficiency, and other etiologies have been proposed. Several treatments have also been explored, including simple bed rest, steroids, bisphosphonates, calcitonin, induced termination of pregnancy, and surgical intervention. The orthopedist plays an essential role in monitoring the condition (and potential complications) as well as ensuring satisfactory outcomes for both the mother and newborn. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Maliha, George; Morgan, Jordan; Vrahas, Mark] Massachusetts Gen Hosp, Harvard Orthopaed Trauma Serv, Boston, MA 02114 USA.
RP Morgan, J (reprint author), Massachusetts Gen Hosp, Orthopaed Trauma Serv, Yawkey Ctr, Suite 3C,55 Fruit St, Boston, MA 02114 USA.
EM gmaliha@princeton.edu; jhmorgan@partners.org; mvrahas@partners.org
NR 40
TC 8
Z9 9
U1 0
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0020-1383
J9 INJURY
JI Injury-Int. J. Care Inj.
PD AUG
PY 2012
VL 43
IS 8
BP 1237
EP 1241
DI 10.1016/j.injury.2012.03.009
PG 5
WC Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery
SC General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery
GA 970FG
UT WOS:000306112900002
PM 22464203
ER
PT J
AU Halasz, LM
Jacene, HA
Catalano, PJ
Van den Abbeele, AD
LaCasce, A
Mauch, PM
Ng, AK
AF Halasz, Lia M.
Jacene, Heather A.
Catalano, Paul J.
Van den Abbeele, Annick D.
LaCasce, Ann
Mauch, Peter M.
Ng, Andrea K.
TI Combined Modality Treatment for PET-Positive Non-Hodgkin Lymphoma:
Favorable Outcomes of Combined Modality Treatment for Patients With
Non-Hodgkin Lymphoma and Positive Interim or Postchemotherapy FDG-PET
SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
LA English
DT Article
DE Combined modality treatment; FDG-PET; non-Hodgkin lymphoma
ID POSITRON-EMISSION-TOMOGRAPHY; B-CELL LYMPHOMA;
COOPERATIVE-ONCOLOGY-GROUP; RESPONSE ASSESSMENT; INTERNATIONAL WORKSHOP;
AGGRESSIVE LYMPHOMA; CHEMOTHERAPY; RADIOTHERAPY; CHOP; RADIATION
AB Purpose: To evaluate outcomes of patients treated for aggressive non-Hodgkin lymphoma (NHL) with combined modality therapy based on [F-18]fluoro-2-deoxy-2-D-glucose positron emission tomography (FDG-PET) response.
Methods and Materials: We studied 59 patients with aggressive NHL, who received chemotherapy and radiation therapy (RT) from 2001 to 2008. Among them, 83% of patients had stage I/II disease. Patients with B-cell lymphoma received R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)-based chemotherapy, and 1 patient with anaplastic lymphoma kinase-negative anaplastic T-cell lymphoma received CHOP therapy. Interim and postchemotherapy FDG-PET or FDG-PET/computed tomography (CT) scans were performed for restaging. All patients received consolidated involved-field RT. Median RT dose was 36 Gy (range, 28.8-50 Gy). Progression-free survival (PFS) and local control (LC) rates were calculated with and without a negative interim or postchemotherapy FDG-PET scan.
Results: Median follow-up was 46.5 months. Thirty-nine patients had negative FDG-PET results by the end of chemotherapy, including 12 patients who had a negative interim FDG-PET scan and no postchemotherapy PET. Twenty patients were FDG-PET-positive, including 7 patients with positive interim FDG-PET and no postchemotherapy FDG-PET scans. The 3-year actuarial PFS rates for patients with negative versus positive FDG-PET scans were 97% and 90%, respectively. The 3-year actuarial LC rates for patients with negative versus positive FDG-PET scans were 100% and 90%, respectively.
Conclusions: Patients who had a positive interim or postchemotherapy FDG-PET had a PFS rate of 90% at 3 years after combined modality treatment, suggesting that a large proportion of these patients can be cured with consolidated RT. (C) 2012 Elsevier Inc.
C1 [Mauch, Peter M.; Ng, Andrea K.] Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA.
[Halasz, Lia M.] Harvard Radiat Oncol Program, Boston, MA USA.
[Jacene, Heather A.; Van den Abbeele, Annick D.] Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Imaging, Boston, MA 02115 USA.
[Jacene, Heather A.; Van den Abbeele, Annick D.] Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Radiol, Boston, MA 02115 USA.
[Catalano, Paul J.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
[LaCasce, Ann] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
RP Ng, AK (reprint author), Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Radiat Oncol, 75 Francis St,ASBI-L2, Boston, MA 02115 USA.
EM ang@lroc.harvard.edu
NR 27
TC 9
Z9 9
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0360-3016
J9 INT J RADIAT ONCOL
JI Int. J. Radiat. Oncol. Biol. Phys.
PD AUG 1
PY 2012
VL 83
IS 5
BP E647
EP E654
DI 10.1016/j.ijrobp.2012.01.060
PG 8
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA 970KT
UT WOS:000306128100013
PM 22607911
ER
PT J
AU Ackerman, RH
AF Ackerman, Robert H.
TI Celebrating the life of C. Miller Fisher
SO INTERNATIONAL JOURNAL OF STROKE
LA English
DT Editorial Material
C1 [Ackerman, Robert H.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Ackerman, Robert H.] Harvard Univ, Sch Med, Boston, MA USA.
RP Ackerman, RH (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1747-4930
J9 INT J STROKE
JI Int. J. Stroke
PD AUG
PY 2012
VL 7
IS 6
BP 444
EP 446
DI 10.1111/j.1747-4949.2012.00877.x
PG 3
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 974AM
UT WOS:000306402100005
PM 22805573
ER
PT J
AU Goveas, JS
Hogan, PE
Kotchen, JM
Smoller, JW
Denburg, NL
Manson, JE
Tummala, A
Mysiw, WJ
Ockene, JK
Woods, NF
Espeland, MA
Wassertheil-Smoller, S
AF Goveas, Joseph S.
Hogan, Patricia E.
Kotchen, Jane M.
Smoller, Jordan W.
Denburg, Natalie L.
Manson, JoAnn E.
Tummala, Aruna
Mysiw, W. Jerry
Ockene, Judith K.
Woods, Nancy F.
Espeland, Mark A.
Wassertheil-Smoller, Sylvia
TI Depressive symptoms, antidepressant use, and future cognitive health in
postmenopausal women: the Women's Health Initiative Memory Study
SO INTERNATIONAL PSYCHOGERIATRICS
LA English
DT Article
DE antidepressants; selective serotonin reuptake inhibitors; late-life
depression; cognitive decline; mild cognitive impairment; dementia
ID LATE-LIFE DEPRESSION; ALZHEIMERS-DISEASE; GERIATRIC DEPRESSION; PROBABLE
DEMENTIA; IMPAIRMENT; RISK; OUTCOMES; DECLINE; METAANALYSIS; THERAPY
AB Background: Antidepressants are commonly prescribed medications in the elderly, but their relationship with incident mild cognitive impairment (MCI) and probable dementia is unknown.
Methods: The study cohort included 6,998 cognitively healthy, postmenopausal women, aged 65-79 years, who were enrolled in a hormone therapy clinical trial and had baseline depressive symptoms and antidepressant use history assessments at enrollment, and at least one postbaseline cognitive measurement. Participants were followed annually and the follow-up averaged 7.5 years for MCI and probable dementia outcomes. A central adjudication committee classified the presence of MCI and probable dementia based on extensive neuropsychiatric examination.
Results: Three hundred and eighty-three (5%) women were on antidepressants at baseline. Antidepressant use was associated with a 70% increased risk of MCI, after controlling for potential covariates including the degree of depressive symptom severity. Selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs) were both associated with MCI (SSRIs: hazard ratios (HR), 1.78 [95% CI, 1.01-3.13]; TCAs: HR, 1.78 [95% CI, 0.99-3.21]). Depressed users (HR, 2.44 [95% CI, 1.24-4.80]), non-depressed users (HR, 1.79 [95% CI, 1.13-2.85]), and depressed non-users (HR, 1.62 [95% CI, 1.13-2.32]) had increased risk of incident MCI. Similarly, all three groups had increased risk of either MCI or dementia, relative to the control cohort.
Conclusions: Antidepressant use and different levels of depression severity were associated with subsequent cognitive impairment in a large cohort of postmenopausal women. Future research should examine the role of antidepressants in the depression-dementia relationship and determine if antidepressants can prevent incident MCI and dementia in individuals with late-life depression subtypes with different levels of severity.
C1 [Goveas, Joseph S.; Tummala, Aruna] Med Coll Wisconsin, Dept Psychiat & Behav Med, Milwaukee, WI 53226 USA.
[Hogan, Patricia E.; Espeland, Mark A.] Wake Forest Univ, Bowman Gray Sch Med, Dept Biostat Sci, Winston Salem, NC USA.
[Kotchen, Jane M.] Med Coll Wisconsin, Dept Populat Hlth, Milwaukee, WI 53226 USA.
[Smoller, Jordan W.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
[Denburg, Natalie L.] Univ Iowa, Coll Med, Dept Neurol, Iowa City, IA 52242 USA.
[Manson, JoAnn E.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Prevent Med, Boston, MA 02115 USA.
[Mysiw, W. Jerry] Ohio State Univ, Med Ctr, Dept Phys Med & Rehabil, Columbus, OH 43210 USA.
[Ockene, Judith K.] Univ Massachusetts, Sch Med, Div Prevent & Behav Med, Worcester, MA 01605 USA.
[Woods, Nancy F.] Univ Washington, Seattle, WA 98195 USA.
[Wassertheil-Smoller, Sylvia] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, New York, NY USA.
RP Goveas, JS (reprint author), Med Coll Wisconsin, Dept Psychiat & Behav Med, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.
EM jgoveas@mcw.edu
RI Mysiw, Walter/E-3724-2011
FU National Heart, Lung, and Blood Institute, National Institutes of
Health, US Department of Health and Human Services [N01WH22110, 24152,
32100-2, 32105-6, 32108-9, 32111-13, 32115, 32118-32119, 32122]; Wyeth
Pharmaceuticals
FX The Women's Health Initiative (WHI) program is funded by the National
Heart, Lung, and Blood Institute, National Institutes of Health, US
Department of Health and Human Services through contracts N01WH22110,
24152, 32100-2, 32105-6, 32108-9, 32111-13, 32115, 32118-32119, and
32122. The active study drug and placebo were supplied by Wyeth-Ayerst
Research Laboratories, Philadelphia, PA. The Women's Health Initiative
Memory Study was funded in part by Wyeth Pharmaceuticals as an ancillary
study to the WHI. Wyeth Pharmaceuticals did not participate in the
design and conduct of the studies, in the collection, analysis, and
interpretation of the data, nor in the preparation, review, or approval
of this paper.
NR 35
TC 9
Z9 9
U1 1
U2 4
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 1041-6102
J9 INT PSYCHOGERIATR
JI Int. Psychogeriatr.
PD AUG
PY 2012
VL 24
IS 8
SI SI
BP 1252
EP 1264
DI 10.1017/S1041610211002778
PG 13
WC Psychology, Clinical; Geriatrics & Gerontology; Gerontology; Psychiatry;
Psychology
SC Psychology; Geriatrics & Gerontology; Psychiatry
GA 971LZ
UT WOS:000306206700007
PM 22301077
ER
PT J
AU Chow, FC
Regan, S
Feske, S
Meigs, JB
Grinspoon, SK
Triant, VA
AF Chow, Felicia C.
Regan, Susan
Feske, Steven
Meigs, James B.
Grinspoon, Steven K.
Triant, Virginia A.
TI Comparison of Ischemic Stroke Incidence in HIV-Infected and
Non-HIV-Infected Patients in a US Health Care System
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE HIV; stroke; cerebrovascular; cardiovascular; vascular risk factors
ID ACQUIRED-IMMUNODEFICIENCY-SYNDROME; MYOCARDIAL-INFARCTION RATES;
DEFICIENCY-SYNDROME AIDS; CORONARY-HEART-DISEASE; T-CELL COUNT;
CARDIOVASCULAR-DISEASE; RISK-FACTORS; ENDOTHELIAL DYSFUNCTION;
CEREBROVASCULAR-DISEASE; METABOLIC SYNDROME
AB Background: Cardiovascular disease is increased among HIV-infected patients, but little is known regarding ischemic stroke rates. We sought to compare stroke rates and determine stroke risk factors in HIV-infected versus non-HIV-infected patients.
Methods: An HIV cohort and matched non-HIV comparator cohort seen between 1996 and 2009 were identified from a Boston health care system. The primary endpoint was ischemic stroke, defined using International Classification of Diseases (ICD) codes. Unadjusted stroke incidence rates were calculated. Cox proportional hazards modeling was used to determine adjusted hazard ratios (HRs).
Results: The incidence rate of ischemic stroke was 5.27 per 1000 person-years in HIV-infected compared with 3.75 in non-HIV-infected patients, with an unadjusted HR of 1.40 [95% confidence interval (CI): 1.17 to 1.69, P, 0.001]. HIV remained an independent predictor of stroke after controlling for demographics and stroke risk factors (HR: 1.21, 95% CI: 1.01 to 1.46, P = 0.043). The relative increase in stroke rates (HIV vs. non-HIV) was significantly higher in younger HIV patients (incidence rate ratio: 4.42, 95% CI: 1.56 to 11.09, age 18-29; 2.96, 1.69-4.96, age: 30-39; 1.53, 1.06-2.17, age: 40-49), and in women [HR: 2.16 (95% CI: 1.53 to 3.04) for women vs. HR: 1.18 (95% CI: 0.95 to 1.47) for men]. Among HIV patients, increased HIV RNA (HR: 1.10, 95% CI: 1.04 to 1.17, P = 0.001) was associated with an increased risk of stroke.
Conclusions: Stroke rates were increased among HIV-infected patients, independent of common stroke risk factors, particularly among young patients and women.
C1 [Triant, Virginia A.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.
[Chow, Felicia C.; Feske, Steven] Brigham & Womens Hosp, Dept Neurol, Boston, MA 02115 USA.
[Chow, Felicia C.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA.
[Regan, Susan; Meigs, James B.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
[Grinspoon, Steven K.] Massachusetts Gen Hosp, Program Nutr Metab, Boston, MA 02114 USA.
RP Triant, VA (reprint author), Massachusetts Gen Hosp, Div Infect Dis, 55 Fruit St,LON207, Boston, MA 02114 USA.
EM vtriant@partners.org
FU National Institutes of Health [5T32MH090847, K01 AI073109]
FX Supported in part by National Institutes of Health grant numbers
5T32MH090847 (F.C.C.) and K01 AI073109 (V.A.T.).
NR 48
TC 74
Z9 74
U1 1
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1525-4135
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD AUG 1
PY 2012
VL 60
IS 4
BP 351
EP 358
DI 10.1097/QAI.0b013e31825c7f24
PG 8
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 971YF
UT WOS:000306242300009
PM 22580566
ER
PT J
AU Kaplan, RC
Landay, AL
Hodis, HN
Gange, SJ
Norris, PJ
Young, M
Anastos, K
Tien, PC
Xue, XN
Lazar, J
Parrinello, CM
Benning, L
Tracy, RP
AF Kaplan, Robert C.
Landay, Alan L.
Hodis, Howard N.
Gange, Stephen J.
Norris, Philip J.
Young, Mary
Anastos, Kathryn
Tien, Phyllis C.
Xue, Xiaonan
Lazar, Jason
Parrinello, Christina M.
Benning, Lorie
Tracy, Russell P.
TI Potential Cardiovascular Disease Risk Markers Among HIV-Infected Women
Initiating Antiretroviral Treatment
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE antiretroviral therapy; cardiovascular diseases; cytokines; hemostasis;
HIV; inflammation
ID MONOCYTE CHEMOATTRACTANT PROTEIN-1; INTIMA-MEDIA THICKNESS;
T-CELL-ACTIVATION; INTERAGENCY HIV; CAROTID-ARTERY; COAGULATION
BIOMARKERS; THERAPY EXPOSURE; SOLUBLE CD14; COHORT; ATHEROSCLEROSIS
AB Background: Inflammation and hemostasis perturbation may be involved in vascular complications of HIV infection. We examined atherogenic biomarkers and subclinical atherosclerosis in HIV-infected adults before and after beginning highly active antiretroviral therapy (HAART).
Methods: In the Women's Interagency HIV Study, 127 HIV-infected women studied pre and post HAART were matched to HIV-uninfected controls. Six semiannual measurements of soluble CD14, tumor necrosis factor (TNF) alfa, soluble interleukin (IL) 2 receptor, IL-6, IL-10, monocyte chemoattractant protein 1, D-dimer, and fibrinogen were obtained. Carotid artery intima-media thickness was measured by B-mode ultrasound.
Results: Relative to HIV-uninfected controls, HAART-naive HIVinfected women had elevated levels of soluble CD14 (1945 vs 1662 ng/mL, Wilcoxon signed rank P < 0.0001), TNF-alpha (6.3 vs 3.4 pg/mL, P < 0.0001), soluble IL-2 receptor (1587 vs 949 pg/mL, P < 0.0001), IL-10 (3.3 vs 1.9 pg/mL, P < 0.0001), monocyte chemo-attractant protein 1 (190 vs 163 pg/mL, P, 0.0001), and D-dimer (0.43 vs 0.31 mu g/mL, P < 0.01). Elevated biomarker levels declined after HAART. Although most biomarkers normalized to HIV-uninfected levels, in women on effective HAART, TNF-alpha levels remained elevated compared with HIV-uninfected women (+ 0.8 pg/mL, P = 0.0002). Higher post-HAART levels of soluble IL-2 receptor (P = 0.02), IL-6 (P = 0.05), and D-dimer (P = 0.03) were associated with increased carotid artery intima-media thickness.
Conclusions: Untreated HIV infection is associated with abnormal hemostasis (eg, D-dimer), proatherogenic (eg, TNF-alpha), and antiatherogenic (eg, IL-10) inflammatory markers. HAART reduces most inflammatory mediators to HIV-uninfected levels. Increased inflammation and hemostasis are associated with subclinical atherosclerosis in recently treated women. These findings have potential implications for long-term risk of cardiovascular disease in HIV-infected patients, even with effective therapy.
C1 [Kaplan, Robert C.; Anastos, Kathryn; Xue, Xiaonan; Parrinello, Christina M.] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10461 USA.
[Landay, Alan L.] Rush Univ, Med Ctr, Dept Immunol Microbiol, Chicago, IL USA.
[Hodis, Howard N.] Univ So Calif, Atherosclerosis Res Unit, Los Angeles, CA 90089 USA.
[Gange, Stephen J.; Benning, Lorie] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
[Norris, Philip J.] Univ Calif San Francisco, Dept Lab Med, Blood Syst Res Inst, San Francisco, CA 94143 USA.
[Young, Mary] Georgetown Univ, Med Ctr, Dept Med, Washington, DC 20007 USA.
[Tien, Phyllis C.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
[Tien, Phyllis C.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Lazar, Jason] Suny Downstate Med Ctr, Dept Med, Brooklyn, NY 11203 USA.
[Tracy, Russell P.] Univ Vermont, Coll Med, Dept Pathol, Burlington, VT 05405 USA.
[Tracy, Russell P.] Univ Vermont, Coll Med, Dept Biochem, Burlington, VT 05405 USA.
RP Kaplan, RC (reprint author), Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, 1300 Morris Pk Ave,Belfer 1306C, Bronx, NY 10461 USA.
EM Robert.kaplan@einstein.yu.edu
OI Gange, Stephen/0000-0001-7842-512X
FU National Institutes of Health; National Institute of Allergy and
Infectious Diseases [UO1-AI-35004, UO1-AI-31834, UO1-AI-34994,
UO1-AI-34989, UO1-AI-34993, UO1-AI-42590]; Eunice Kennedy Shriver
National Institute of Child Health and Human Development [UO1-HD-32632];
National Cancer Institute; National Institute on Drug Abuse; National
Institute on Deafness and Other Communication Disorders; National Center
for Research Resources (UCSF-CTSI) [UL1 RR024131]; National Heart, Lung
and Blood Institute [1R01HL095140, 1R01HL083760]; University of
Washington's CVD and Metabolic Complications of HIV/AIDS Data
Coordinating Center [5R01HL095126]
FX Supported by the National Institutes of Health. The Women's Interagency
HIV Study is funded by the National Institute of Allergy and Infectious
Diseases (UO1-AI-35004, UO1-AI-31834, UO1-AI-34994, UO1-AI-34989,
UO1-AI-34993, and UO1-AI-42590) and by the Eunice Kennedy Shriver
National Institute of Child Health and Human Development (UO1-HD-32632).
The study was cofunded by the National Cancer Institute, the National
Institute on Drug Abuse, and the National Institute on Deafness and
Other Communication Disorders. Funding was also provided by the National
Center for Research Resources (UCSF-CTSI Grant Number UL1 RR024131).
Additional cofunding was provided by the National Heart, Lung and Blood
Institute (1R01HL095140, 1R01HL083760 to R.C.K.). Partial funding for
laboratory work and assistance with general study coordination was
provided by the University of Washington's CVD and Metabolic
Complications of HIV/AIDS Data Coordinating Center (5R01HL095126).
NR 36
TC 25
Z9 26
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1525-4135
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD AUG 1
PY 2012
VL 60
IS 4
BP 359
EP 368
DI 10.1097/QAI.0b013e31825b03be
PG 10
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 971YF
UT WOS:000306242300010
PM 22592585
ER
PT J
AU Medapalli, RK
Parikh, CR
Gordon, K
Brown, ST
Butt, AA
Gibert, CL
Rimland, D
Rodriguez-Barradas, MC
Chang, CCH
Justice, AC
He, JCJ
Wyatt, CM
AF Medapalli, Raj K.
Parikh, Chirag R.
Gordon, Kirsha
Brown, Sheldon T.
Butt, Adeel A.
Gibert, Cynthia L.
Rimland, David
Rodriguez-Barradas, Maria C.
Chang, Chung-Chou H.
Justice, Amy C.
He, John Cijiang
Wyatt, Christina M.
TI Comorbid Diabetes and the Risk of Progressive Chronic Kidney Disease in
HIV-Infected Adults: Data From the Veterans Aging Cohort Study
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE non-AIDS complications; HIV; chronic kidney disease; diabetes; risk
factors
ID GLOMERULAR-FILTRATION-RATE; CORONARY-HEART-DISEASE; ANTIRETROVIRAL
THERAPY; DATA-COLLECTION; ADVERSE EVENTS; HEPATITIS-C; MELLITUS; RATES
AB Introduction: Approximately, 15% of HIV-infected individuals have comorbid diabetes. Studies suggest that HIV and diabetes have an additive effect on chronic kidney disease (CKD) progression; however, this observation may be confounded by differences in traditional CKD risk factors.
Methods: We studied a national cohort of HIV-infected and matched HIV-uninfected individuals who received care through the Veterans Healthcare Administration. Subjects were divided into 4 groups based on baseline HIV and diabetes status, and the rate of progression to an estimated glomerular filtration rate (eGFR) <45 mL/min/ 1.73m(2) was compared using Cox-proportional hazards modeling to adjust for CKD risk factors.
Results: About 31,072 veterans with baseline eGFR >= 45 mL/min/1.73m(2) (10,626 with HIV only, 5088 with diabetes only, and 1796 with both) were followed for a median of 5 years. Mean baseline eGFR was 94 mL/min/1.73m(2), and 7% progressed to an eGFR < 45 mL/min/1.73m(2). Compared with those without HIV or diabetes, the relative rate of progression was increased in individuals with diabetes only [adjusted hazard ratio (HR) 2.48; 95% confidence interval (CI): 2.19 to 2.80], HIV only [HR: 2.80, 95% CI: 2.50 to 3.15], and both HIV and diabetes [HR: 4.47, 95% CI: 3.87 to 5.17].
Discussion: Compared with patients with only HIV or diabetes, patients with both diagnoses are at significantly increased risk of progressive CKD even after adjusting for traditional CKD risk factors. Future studies should evaluate the relative contribution of complex comorbidities and accompanying polypharmacy to the risk of CKD in HIV-infected individuals and prospectively investigate the use of cART, glycemic control, and adjunctive therapy to delay CKD progression.
C1 [Medapalli, Raj K.; He, John Cijiang; Wyatt, Christina M.] Mt Sinai Sch Med, Dept Med, Div Nephrol, New York, NY 10029 USA.
[Parikh, Chirag R.] Yale Univ, Dept Med, Nephrol Sect, New Haven, CT 06520 USA.
[Parikh, Chirag R.; Gordon, Kirsha] W Haven VA Med Ctr, Clin Epidemiol Res Ctr, West Haven, CT USA.
[Brown, Sheldon T.] James J Peters VA Med Ctr, Dept Med, Div Infect Dis, Bronx, NY USA.
[Brown, Sheldon T.] Mt Sinai Sch Med, Dept Med, Div Infect Dis, New York, NY 10029 USA.
[Butt, Adeel A.] VA Pittsburgh Healthcare Syst, Dept Med, Div Infect Dis, Pittsburgh, PA USA.
[Butt, Adeel A.] Univ Pittsburgh, Sch Med, Dept Med, Div Infect Dis, Pittsburgh, PA USA.
[Butt, Adeel A.] Dept Med, Sheikh Khalifa Med City, Abu Dhabi, U Arab Emirates.
[Gibert, Cynthia L.] VA Med Ctr, Dept Med, Div Infect Dis, Washington, DC USA.
[Gibert, Cynthia L.] George Washington Univ, Med Ctr, Dept Med, Div Infect Dis, Washington, DC 20037 USA.
[Rimland, David] VA Med Ctr, Dept Med, Div Infect Dis, Atlanta, GA USA.
[Rimland, David] Emory Univ, Sch Med, Dept Med, Div Infect Dis, Atlanta, GA USA.
[Rodriguez-Barradas, Maria C.] Michael E DeBakey VA Med Ctr, Dept Med, Infect Dis Sect, Houston, TX USA.
[Rodriguez-Barradas, Maria C.] Baylor Coll Med, Dept Med, Infect Dis Sect, Houston, TX 77030 USA.
[Justice, Amy C.] W Haven VA Med Ctr, Dept Med, New Haven, CT USA.
[He, John Cijiang] James J Peters VA Med Ctr, Dept Med, Div Nephrol, Bronx, NY USA.
RP Wyatt, CM (reprint author), Mt Sinai Sch Med, Dept Med, Div Nephrol, 1 Gustave L Levy Pl,Box 1243, New York, NY 10029 USA.
EM christina.wyatt@mssm.edu
FU National Institutes of Health, National Institute of Alcohol and Alcohol
Abuse [U01 AA13566]; Office of Research and Development, Department of
Veterans Affairs; National Institute of Diabetes and Digestive and
Kidney Disease [P01DK056492, R01DK088541, R01DK078897, K23DK077568]
FX The Veterans Aging Cohort Study is supported by the National Institutes
of Health, National Institute of Alcohol and Alcohol Abuse (U01 AA13566)
and by the Office of Research and Development, Department of Veterans
Affairs. This work was also supported in part by the National Institute
of Diabetes and Digestive and Kidney Disease (P01DK056492, R01DK088541,
R01DK078897, and K23DK077568).
NR 22
TC 24
Z9 24
U1 1
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1525-4135
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD AUG 1
PY 2012
VL 60
IS 4
BP 393
EP 399
DI 10.1097/QAI.0b013e31825b70d9
PG 7
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 971YF
UT WOS:000306242300014
PM 22592587
ER
PT J
AU Zhang, LT
Zhang, LJ
Zhou, KY
Ye, XX
Zhang, JJ
Xie, AM
Chen, LY
Kang, JX
Cai, C
AF Zhang, Liangtao
Zhang, Lijian
Zhou, Keyuan
Ye, Xiaoxia
Zhang, Junjie
Xie, Aimei
Chen, Liyu
Kang, Jing X.
Cai, Chun
TI Simultaneous Determination of Global DNA Methylation and
Hydroxymethylation Levels by Hydrophilic Interaction Liquid
Chromatography-Tandem Mass Spectrometry
SO JOURNAL OF BIOMOLECULAR SCREENING
LA English
DT Article
DE DNA methylation; DNA hydroxymethylation; hydrophilic interaction liquid
chromatography-MS/MS
ID 5-HYDROXYMETHYLCYTOSINE; CELLS; 5-METHYLCYTOSINE; CONVERSION; PATTERNS;
GENE
AB Methylation of DNA at the 5-position of cytosine (Cyt) is a well-studied epigenetic pathway implicated in gene silencing and embryogenesis. Recently, in addition to 5-methylcytosine (5mC), substantial amounts of 5-hydroxymethylcytosine (5hmC) have been detected in certain mammalian tissues. Here, we developed and validated a hydrophilic interaction liquid chromatography-tandem mass spectrometry (HILIC-MS/MS) method for the simultaneous determination of Cyt, 5mC, and 5hmC levels in biological samples. DNA was extracted with phenol-chloroform, hydrolyzed using 88% formic acid at 140 C, separated using a bridged ethylene hybrid HILIC column, and analyzed by tandem MS. The linearity was established over the concentration range of 1 to 500 ng/mL for Cyt, 0.2 to 100 ng/mL for 5mC, and 0.1 to 50 ng/mL for 5hmC, and the correlation coefficients were all >0.99. Limits of detection were 1 pg/mL for Cyt, 45 pg/mL for 5mC, and 57 pg/mL for 5hmC, and the limit of quantification values for Cyt, 5mC, and 5hmC were 2 pg/mL, 90 pg/mL, and 100 pg/mL, respectively. The relative standard deviation (RSD) of the intraday precision ranged from 1.87% to 4.84% and the interday precision from 2.69% to 4.98%. The recovery of the method varied from 88.25% to 104.39%. The method was then applied to the analysis of DNA from biological samples, establishing its potential for helping researchers understand the roles of modified nucleobases in DNA.
C1 [Zhang, Liangtao; Zhang, Lijian; Zhou, Keyuan; Ye, Xiaoxia; Zhang, Junjie; Xie, Aimei; Chen, Liyu; Cai, Chun] Guangdong Med Coll, Zhanjiang 524023, Guangdong, Peoples R China.
[Kang, Jing X.] Harvard Univ, Massachusetts Gen Hosp, Dept Med, Sch Med, Boston, MA USA.
RP Cai, C (reprint author), Guangdong Med Coll, Zhanjiang 524023, Guangdong, Peoples R China.
EM caichun2006@tom.com
FU Guangdong Medical College; National Natural Science Foundation of China
[30672741]
FX The authors disclosed receipt of the following financial support for the
research, authorship, and/or publication of this article: This work was
supported by grants from Guangdong Medical College; and the National
Natural Science Foundation of China (30672741).
NR 24
TC 10
Z9 12
U1 2
U2 22
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1087-0571
J9 J BIOMOL SCREEN
JI J. Biomol. Screen
PD AUG
PY 2012
VL 17
IS 7
BP 877
EP 884
DI 10.1177/1087057112447946
PG 8
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
Chemistry, Analytical
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
Chemistry
GA 973AX
UT WOS:000306324500003
PM 22644266
ER
PT J
AU Abraham, BP
Mehta, S
El-Serag, HB
AF Abraham, Bincy P.
Mehta, Seema
El-Serag, Hashem B.
TI Natural History of Pediatric-onset Inflammatory Bowel Disease A
Systematic Review
SO JOURNAL OF CLINICAL GASTROENTEROLOGY
LA English
DT Review
DE natural history; pediatric IBD; long-term risk; growth failure; disease
reclassification; disease extension; hospitalization; cancer; death
ID POPULATION-BASED COHORT; 10 YEARS OLD; CROHNS-DISEASE;
ULCERATIVE-COLITIS; GROWTH FAILURE; CLINICAL-FEATURES; ADULT LIFE;
FOLLOW-UP; CHILDREN; PROGNOSIS
AB Background/Aims: There has been no systematic review of natural history studies of pediatric-onset inflammatory bowel disease (IBD). We conducted a systematic review focused on understanding the long-term risks of growth failure, disease reclassification and extension, hospitalizations, cancer and death among patients with childhood IBD.
Methods: PubMed searches and subsequent data abstraction were performed by 2 independent investigators. Studies published full in english with a 5-year minimum average follow-up in at least 30 patients with IBD onset before age 18 years.
Results: We evaluated 41 total studies (only 2 population-based studies) with 3505 Crohn's disease (CD) patients, 2071 ulcerative colitis (UC) patients, and 461 indeterminate colitis (IC). Growth failure was reported in CD (10% and 56%) more often than UC (0% to 10%) or non-IBD controls. Improvements in growth occurred after surgical resection in patients with CD. There was an increase in disease reclassification over time from UC and indeterminate colitis diagnosis to CD diagnosis. Patients with CD had higher number of hospitalizations and hospital days per year in comparison with UC patients in most studies. The reported surgery rates in CD ranged between 10% and 72%; the colectomy rates in UC ranged between 0% and 50%. Cancers were reported in 6 CD patients during a total 18,270 patient-years (PY) follow-up, and 8 UC patients in 18,115 PY. Deaths directly related to IBD were 63 during 39,719 PY.
Conclusions: Childhood-onset IBD patients had growth failure reported in patients with CD more often than those with UC, had a reclassification of disease type to CD over time. Higher rates of surgery and hospitalizations were found with CD than with UC. The risk of cancer and death is low in this population.
C1 [Abraham, Bincy P.; Mehta, Seema; El-Serag, Hashem B.] Texas Childrens Hosp, Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
RP Abraham, BP (reprint author), 1709 Dryden St,Suite 800, Houston, TX 77030 USA.
EM bincya@bcm.edu
FU Houston VA HSR&D Center of Excellence [HFP90-020]; NIH/National
Institute of Diabetes and Digestive and Kidney Disease, Center [P30
DK56338]
FX Supported by Houston VA HSR&D Center of Excellence (HFP90-020) and
NIH/National Institute of Diabetes and Digestive and Kidney Disease,
Center Grant P30 DK56338.
NR 58
TC 40
Z9 43
U1 1
U2 9
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0192-0790
J9 J CLIN GASTROENTEROL
JI J. Clin. Gastroenterol.
PD AUG
PY 2012
VL 46
IS 7
BP 581
EP 589
DI 10.1097/MCG.0b013e318247c32f
PG 9
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 972OY
UT WOS:000306287600010
PM 22772738
ER
PT J
AU Hurrell, MJ
Monk, TG
Nicol, A
Norton, AN
Reich, DL
Walsh, JL
AF Hurrell, M. J.
Monk, T. G.
Nicol, A.
Norton, A. N.
Reich, D. L.
Walsh, J. L.
TI Implementation of a standards-based anaesthesia record compliant with
the health level 7 (HL7) clinical document architecture (CDA)
SO JOURNAL OF CLINICAL MONITORING AND COMPUTING
LA English
DT Article
DE Anesthetic record; HL7; CDA; XML; ISO 11073; IOTA; APSF DDTF
AB With the increasing use of anaesthesia information management systems (AIMS) there is the opportunity for different institutions to aggregate and share information both nationally and internationally. Potential uses of such aggregated data include outcomes research, benchmarking and improvement in clinical practice and patient safety. However, these goals can only be achieved if data contained in records from different sources are truly comparable and there is semantic inter-operability. This paper describes the development of a standard terminology for anaesthesia and also a Domain Analysis Model and implementation guide to facilitate a standard representation of AIMS records as extensible markup language documents that are compliant with the Health Level 7 Version 3 clinical document architecture. A representation of vital signs that is compliant with the International Standards Organization 11073 standard is also discussed.
C1 [Hurrell, M. J.; Nicol, A.] Informat CIS Ltd, Glasgow, Lanark, Scotland.
[Monk, T. G.] Duke Univ, Med Ctr, Durham, NC USA.
[Norton, A. N.] Pilgrim Hosp, Boston, MA USA.
[Reich, D. L.] Mt Sinai Sch Med, New York, NY USA.
[Walsh, J. L.] Massachussets Gen Hosp, Boston, MA USA.
RP Hurrell, MJ (reprint author), Informat CIS Ltd, Glasgow, Lanark, Scotland.
EM martinhurrell@gmail.com
NR 17
TC 3
Z9 3
U1 1
U2 5
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1387-1307
J9 J CLIN MONIT COMPUT
JI J. Clin. Monitor. Comp.
PD AUG
PY 2012
VL 26
IS 4
BP 295
EP 304
DI 10.1007/s10877-012-9360-2
PG 10
WC Anesthesiology
SC Anesthesiology
GA 970KZ
UT WOS:000306128800007
PM 22614336
ER
PT J
AU Blagev, DP
Hirshberg, EL
Sward, K
Thompson, BT
Brower, R
Truwit, J
Hite, D
Steingrub, J
Orme, JF
Clemmer, TP
Weaver, LK
Thomas, F
Grissom, CK
Sorenson, D
Sittig, DF
Wallace, CJ
East, TD
Warner, HR
Morris, AH
AF Blagev, Denitza P.
Hirshberg, Eliotte L.
Sward, Katherine
Thompson, B. Taylor
Brower, Roy
Truwit, Jonathon
Hite, Duncan
Steingrub, Jay
Orme, James F., Jr.
Clemmer, Terry P.
Weaver, Lindell K.
Thomas, Frank
Grissom, Colin K.
Sorenson, Dean
Sittig, Dean F.
Wallace, C. Jane
East, Thomas D.
Warner, Homer R.
Morris, Alan H.
TI The evolution of eProtocols that enable reproducible clinical research
and care methods
SO JOURNAL OF CLINICAL MONITORING AND COMPUTING
LA English
DT Article
DE Insulin; Decision support; Clinical decision support; Electronic
decision support tools; Quality improvement; Intensive care unit glucose
control; Integration of clinical decision support programs with
electronic medical record; Translation of clinical research into
clinical practice
ID ACUTE LUNG INJURY; COMPUTERIZED DECISION-SUPPORT;
RESPIRATORY-DISTRESS-SYNDROME; INVERSE RATIO VENTILATION; CRITICALLY-ILL
PATIENTS; BLOOD-GLUCOSE CONTROL; MECHANICAL VENTILATION; PROTOCOL;
OUTCOMES; TRIAL
AB Unnecessary variation in clinical care and clinical research reduces our ability to determine what healthcare interventions are effective. Reducing this unnecessary variation could lead to further healthcare quality improvement and more effective clinical research. We have developed and used electronic decision support tools (eProtocols) to reduce unnecessary variation. Our eProtocols have progressed from a locally developed mainframe computer application in one clinical site (LDS Hospital) to web-based applications available in multiple languages and used internationally. We use eProtocol-insulin as an example to illustrate this evolution. We initially developed eProtocol-insulin as a local quality improvement effort to manage stress hyperglycemia in the adult intensive care unit (ICU). We extended eProtocol-insulin use to translate our quality improvement results into usual clinical care at Intermountain Healthcare ICUs. We exported eProtocol-insulin to support research in other US and international institutions, and extended our work to the pediatric ICU. We iteratively refined eProtocol-insulin throughout these transitions, and incorporated new knowledge about managing stress hyperglycemia in the ICU. Based on our experience in the development and clinical use of eProtocols, we outline remaining challenges to eProtocol development, widespread distribution and use, and suggest a process for eProtocol development. Technical and regulatory issues, as well as standardization of protocol development, validation and maintenance, need to be addressed. Resolution of these issues should facilitate general use of eProtocols to improve patient care.
C1 [Blagev, Denitza P.] Sorenson Heart Lung Ctr, Pulm Crit Care Div, Murray, UT 84157 USA.
[Blagev, Denitza P.; Hirshberg, Eliotte L.; Orme, James F., Jr.; Clemmer, Terry P.; Weaver, Lindell K.; Thomas, Frank; Grissom, Colin K.; Sorenson, Dean; Morris, Alan H.] Intermt Healthcare Urban Cent Reg, Div Pulm, Dept Med, Salt Lake City, UT USA.
[Blagev, Denitza P.; Hirshberg, Eliotte L.; Orme, James F., Jr.; Clemmer, Terry P.; Weaver, Lindell K.; Thomas, Frank; Grissom, Colin K.; Sorenson, Dean; Morris, Alan H.] Intermt Healthcare Urban Cent Reg, Crit Care Div, Dept Med, Salt Lake City, UT USA.
[Sward, Katherine; Warner, Homer R.] Univ Utah, Sch Med, Dept Biomed Informat, Salt Lake City, UT USA.
[Hirshberg, Eliotte L.] Univ Utah, Dept Pediat, Salt Lake City, UT USA.
[Hirshberg, Eliotte L.] Primary Childrens Med Ctr, Pediat Crit Care Div, Salt Lake City, UT 84103 USA.
[Sward, Katherine] Univ Utah, Coll Nursing, Salt Lake City, UT 84112 USA.
[Brower, Roy] Johns Hopkins Univ, Baltimore, MD USA.
[Truwit, Jonathon] Univ Virginia, Charlottesville, VA USA.
[Hite, Duncan] Wake Forest Univ Hlth Sci, Sect Pulm & Crit Care, Winston Salem, NC USA.
[Steingrub, Jay] Baystate Med Ctr, Div Crit Care Med, Springfield, MA USA.
[Sittig, Dean F.] Univ Texas Mem Hermann, Ctr Healthcare Qual & Safety, Houston, TX USA.
[East, Thomas D.] Northshore Univ Hlth Syst, Chicago, IL USA.
[Thompson, B. Taylor] Massachusetts Gen Hosp, Pulm & Crit Care Unit, Boston, MA 02114 USA.
RP Blagev, DP (reprint author), Sorenson Heart Lung Ctr, Pulm Crit Care Div, 6th Floor Intermt Med Ctr,5121 S Cottonwood St, Murray, UT 84157 USA.
EM denitza.blagev@imail.org
FU NIH [HL36787, HHSN268200425210C/NO1-HC-45210,
HHSN268200425210C/N01-HR-56171, HHSN2682 00536179C/N01-HR-56179,
HHSN268200536170C/N01-HR-56170, HHSN268200536175C/N01-HR-56175,
HHSN268200536165C/N01-HR-56165]; Deseret Foundation; Intermountain
Healthcare, Inc.
FX We are indebted to our many RN, RRT, and MD clinician colleagues who
enabled the execution of our eProtocol work. Funded in part by the NIH
(HL36787, HHSN268200425210C/NO1-HC-45210,
HHSN268200425210C/N01-HR-56171, HHSN2682 00536179C/N01-HR-56179,
HHSN268200536170C/N01-HR-56170, HHSN268200536175C/N01-HR-56175,
HHSN268200536165C/N01-HR-56165), the Deseret Foundation, and
Intermountain Healthcare, Inc.
NR 57
TC 6
Z9 6
U1 0
U2 5
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1387-1307
J9 J CLIN MONIT COMPUT
JI J. Clin. Monitor. Comp.
PD AUG
PY 2012
VL 26
IS 4
BP 305
EP 317
DI 10.1007/s10877-012-9356-y
PG 13
WC Anesthesiology
SC Anesthesiology
GA 970KZ
UT WOS:000306128800008
PM 22491960
ER
PT J
AU Demetriou, SK
Ona-Vu, K
Teichert, AE
Cleaver, JE
Bikle, DD
Oh, DH
AF Demetriou, Stephanie K.
Ona-Vu, Katherine
Teichert, Arnaud E.
Cleaver, James E.
Bikle, Daniel D.
Oh, Dennis H.
TI Vitamin D Receptor Mediates DNA Repair and Is UV Inducible in Intact
Epidermis but Not in Cultured Keratinocytes
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Letter
ID MOUSE SKIN; DOSE UVB; GENE; SUSCEPTIBILITY; EXPRESSION; PROTEIN; MICE
C1 [Demetriou, Stephanie K.; Ona-Vu, Katherine; Oh, Dennis H.] San Francisco VA Med Ctr, Dermatol Res Unit, San Francisco, CA 94121 USA.
[Demetriou, Stephanie K.; Ona-Vu, Katherine; Cleaver, James E.; Bikle, Daniel D.; Oh, Dennis H.] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA.
[Teichert, Arnaud E.; Bikle, Daniel D.] San Francisco VA Med Ctr, Endocrine Unit, San Francisco, CA USA.
[Bikle, Daniel D.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
RP Demetriou, SK (reprint author), San Francisco VA Med Ctr, Dermatol Res Unit, San Francisco, CA 94121 USA.
EM ohd@derm.ucsf.edu
FU BLRD VA [I01 BX001066]; NIAMS NIH HHS [R01 AR050023, R01AR050023, R01
AR050023-05]
NR 15
TC 18
Z9 18
U1 1
U2 4
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0022-202X
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD AUG
PY 2012
VL 132
IS 8
BP 2097
EP 2100
DI 10.1038/jid.2012.107
PG 4
WC Dermatology
SC Dermatology
GA 974CT
UT WOS:000306408100024
PM 22495177
ER
PT J
AU Hirschmann, JV
Raugi, GJ
AF Hirschmann, Jan V.
Raugi, Gregory J.
TI Lower limb cellulitis and its mimics Part I. Lower limb cellulitis
SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
LA English
DT Article
DE beta-hemolytic streptococci; Cryptococcus neoformans; Gram-negative
bacilli; lower limb cellulitis; Staphylococcus aureus; Streptococcus
pneumoniae
ID SOFT-TISSUE INFECTIONS; LOWER-EXTREMITY CELLULITIS;
FINE-NEEDLE-ASPIRATION; BETA-HEMOLYTIC STREPTOCOCCI; RANDOMIZED
CONTROLLED-TRIAL; GRAM-NEGATIVE CELLULITIS; CORONARY-BYPASS SURGERY;
ACUTE LEG CELLULITIS; RECURRENT ERYSIPELAS; RISK-FACTORS
AB An aging population and obesity have both contributed to a rising incidence of lower limb cellulitis; the most important predisposing factors include older age, obesity, venous insufficiency, saphenous venectomy, and edema. Streptococci are the most commonly implicated pathogen, and often reside in the interdigital toes spaces. Any disruption of the skin surface can allow the organism to invade. Effective management requires an appropriate antibiotic and attention to the predisposing factors. This article summarizes the epidemiology and treatment of this common infection. (J Am Acad Dermatol 2012; 67: 163. e1-12.)
C1 [Raugi, Gregory J.] VA Puget Sound Hlth Care Syst, Dermatol 111D, Dept Dermatol, Seattle, WA 98108 USA.
Univ Washington, Sch Med, Seattle, WA USA.
RP Raugi, GJ (reprint author), VA Puget Sound Hlth Care Syst, Dermatol 111D, Dept Dermatol, 1660 Columbian Way S, Seattle, WA 98108 USA.
EM gregory.raugi@va.gov
NR 111
TC 0
Z9 1
U1 2
U2 11
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0190-9622
J9 J AM ACAD DERMATOL
JI J. Am. Acad. Dermatol.
PD AUG
PY 2012
VL 67
IS 2
AR 163.e1
DI 10.1016/j.jaad.2012.03.024
PG 12
WC Dermatology
SC Dermatology
GA 973OD
UT WOS:000306368600010
PM 22794815
ER
PT J
AU Boyer, NM
Laskey, WK
Cox, M
Hernandez, AF
Peterson, ED
Bhatt, DL
Cannon, CP
Fonarow, GC
AF Boyer, Nathan M.
Laskey, Warren K.
Cox, Margueritte
Hernandez, Adrian F.
Peterson, Eric D.
Bhatt, Deepak L.
Cannon, Christopher P.
Fonarow, Gregg C.
TI Trends in Clinical, Demographic, and Biochemical Characteristics of
Patients With Acute Myocardial Infarction From 2003 to 2008: A Report
From the American Heart Association Get With The Guidelines Coronary
Artery Disease Program
SO JOURNAL OF THE AMERICAN HEART ASSOCIATION
LA English
DT Article
DE coronary disease; epidemiology; myocardial infarction; population; risk
factors
ID BODY-MASS INDEX; RISK-FACTORS; US ADULTS; CARDIOVASCULAR HEALTH;
METABOLIC SYNDROME; NATIONAL-HEALTH; 52 COUNTRIES; PREVALENCE;
MORTALITY; REGISTRY
AB Background-An analysis of the changes in the clinical and demographic characteristics of patients with acute myocardial infarction could identify successes and failures of risk factor identification and treatment of patients at increased risk for cardiovascular events.
Methods and Results-We reviewed data collected from 138 122 patients with acute myocardial infarction admitted from 2003 to 2008 to hospitals participating in the American Heart Association Get With The Guidelines Coronary Artery Disease program. Clinical, demographic, and laboratory characteristics were analyzed for each year stratified on the electrocardiogram at presentation. Patients with non-ST-segment-elevation myocardial infarction were older, more likely to be women, and more likely to have hypertension, diabetes mellitus, and a history of past cardiovascular disease than were patients with ST-elevation myocardial infarction. In the overall patient sample, significant trends were observed of an increase over time in the proportions of non-ST-segment-elevation myocardial infarction, patient age of 45 to 65 years, obesity, and female sex. The prevalence of diabetes mellitus decreased over time, whereas the prevalences of hypertension and smoking were substantial and unchanging. The prevalence of "low" high-density lipoprotein increased over time, whereas that of "high" low-density lipoprotein decreased. Stratum-specific univariate analysis revealed quantitative and qualitative differences between strata in time trends for numerous demographic, clinical, and biochemical measures. On multivariable analysis, there was concordance between strata with regard to the increase in prevalence of patients 45 to 65 years of age, obesity, and "low" high-density lipoprotein and the decrease in prevalence of "high" low-density lipoprotein. However, changes in trends in age distribution, sex ratio, and prevalence of smokers and the magnitude of change in diabetes mellitus prevalence differed between strata.
Conclusions-There were notable differences in risk factors and patient characteristics among patients with ST-elevation myocardial infarction and those with non-ST-segment-elevation myocardial infarction. The increasing prevalence of dysmetabolic markers in a growing proportion of patients with acute myocardial infarction suggests further opportunities for risk factor modification.
C1 [Boyer, Nathan M.; Laskey, Warren K.] Univ New Mexico, Albuquerque, NM 87131 USA.
[Cox, Margueritte; Hernandez, Adrian F.; Peterson, Eric D.] Duke Clin Res Inst, Durham, NC USA.
[Bhatt, Deepak L.] Brigham & Womens Hosp, VA Boston Healthcare Syst, Boston, MA 02115 USA.
[Cannon, Christopher P.] Harvard Univ, Sch Med, Boston, MA USA.
[Fonarow, Gregg C.] Univ Calif Los Angeles, Los Angeles, CA USA.
RP Laskey, WK (reprint author), Univ New Mexico, MSC 10-5550, Albuquerque, NM 87131 USA.
EM wlaskey@salud.unm.edu
FU AHA Pharmaceutical Roundtable; Merck; Robert S. Flinn Endowment for
Cardiovascular Medicine (University of New Mexico School of Medicine)
FX The GWTG-CAD program was supported, in part, through the AHA
Pharmaceutical Roundtable and an unrestricted educational grant from
Merck. Drs Boyer and Laskey were supported, in part, by the Robert S.
Flinn Endowment for Cardiovascular Medicine (University of New Mexico
School of Medicine).
NR 37
TC 12
Z9 12
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2047-9980
J9 J AM HEART ASSOC
JI J. Am. Heart Assoc.
PD AUG
PY 2012
VL 1
IS 4
AR UNSP e001206
DI 10.1161/JAHA.112.001206
PG 18
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 243RO
UT WOS:000326334800003
PM 23130159
ER
PT J
AU Hilgendorf, I
Swirski, FK
AF Hilgendorf, Ingo
Swirski, Filip K.
TI Folate Receptor: A Macrophage "Achilles' Heel"?
SO JOURNAL OF THE AMERICAN HEART ASSOCIATION
LA English
DT Editorial Material
DE editorials; atherosclerosis; folate; folate receptor; immunotoxins;
macrophages
ID RHEUMATOID-ARTHRITIS; ACTIVATED MACROPHAGES; BETA; MICE;
ATHEROSCLEROSIS; THERAPEUTICS; THROMBOSIS; RATIONALE; PLAQUES; EVENTS
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA USA.
RP Swirski, FK (reprint author), Massachusetts Gen Hosp, Ctr Syst Biol, Simches Res Bldg,185 Cambridge St, Boston, MA 02114 USA.
EM fswirski@mgh.harvard.edu
FU NHLBI NIH HHS [R01 HL095612]
NR 20
TC 1
Z9 1
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2047-9980
J9 J AM HEART ASSOC
JI J. Am. Heart Assoc.
PD AUG
PY 2012
VL 1
IS 4
AR UNSP e004036
DI 10.1161/JAHA.112.004036
PG 3
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 243RO
UT WOS:000326334800013
PM 23130179
ER
PT J
AU Lin, CB
Peterson, ED
Smith, EE
Saver, JL
Liang, L
Xian, Y
Olson, DM
Shah, BR
Hernandez, AF
Schwamm, LH
Fonarow, GC
AF Lin, Cheryl B.
Peterson, Eric D.
Smith, Eric E.
Saver, Jeffrey L.
Liang, Li
Xian, Ying
Olson, DaiWai M.
Shah, Bimal R.
Hernandez, Adrian F.
Schwamm, Lee H.
Fonarow, Gregg C.
TI Patterns, Predictors, Variations, and Temporal Trends in Emergency
Medical Service Hospital Prenotification for Acute Ischemic Stroke
SO JOURNAL OF THE AMERICAN HEART ASSOCIATION
LA English
DT Article
DE stroke; emergency medicine; hospitals; registries
ID TISSUE-PLASMINOGEN ACTIVATOR; QUALITY-OF-CARE; PREHOSPITAL NOTIFICATION;
ASSOCIATION; GUIDELINES; STATEMENT; OUTCOMES; MANAGEMENT; COUNCIL;
PROGRAM
AB Background-Emergency medical services (EMS) hospital prenotification of an incoming stroke patient is guideline recommended as a means of increasing the timeliness with which stroke patients are evaluated and treated. Still, data are limited with regard to national use of, variations in, and temporal trends in EMS prenotification and associated predictors of its use.
Methods and Results-We examined 371 988 patients with acute ischemic stroke who were transported by EMS and enrolled in 1585 hospitals participating in Get With The Guidelines-Stroke from April 1, 2003, through March 31, 2011. Prenotification occurred in 249 197 EMS-transported patients (67.0%) and varied widely by hospital (range, 0% to 100%). Substantial variations by geographic regions and by state, ranging from 19.7% in Washington, DC, to 93.4% in Montana, also were noted. Patient factors associated with lower use of prenotification included older age, diabetes mellitus, and peripheral vascular disease. Prenotification was less likely for black patients than for white patients (adjusted odds ratio 0.94, 95% confidence interval 0.92-0.97, P<0.0001). Hospital factors associated with greater EMS prenotification use were absence of academic affiliation, higher annual volume of tissue plasminogen activator administration, and geographic location outside the Northeast. Temporal improvements in prenotification rates showed a modest general increase, from 58.0% in 2003 to 67.3% in 2011 (P temporal trend <0.0001).
Conclusions-EMS hospital prenotification is guideline recommended, yet among patients transported to Get With The Guidelines-Stroke hospitals it is not provided for 1 in 3 EMS-arriving patients with acute ischemic stroke and varies substantially by hospital, state, and region. These results support the need for enhanced implementation of stroke systems of care.
C1 [Lin, Cheryl B.] Duke Natl Univ Singapore, Singapore, Singapore.
[Peterson, Eric D.; Liang, Li; Xian, Ying; Olson, DaiWai M.; Shah, Bimal R.; Hernandez, Adrian F.] Duke Clin Res Inst, Durham, NC USA.
[Smith, Eric E.] Univ Calgary, Hotchkiss Brain Inst, Dept Clin Neurosci, Calgary, AB T2N 1N4, Canada.
[Saver, Jeffrey L.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA.
[Fonarow, Gregg C.] Univ Calif Los Angeles, Div Cardiol, Los Angeles, CA USA.
[Schwamm, Lee H.] Massachusetts Gen Hosp, Stroke Serv, Boston, MA 02114 USA.
RP Fonarow, GC (reprint author), Ronald Reagan UCLA Med Ctr, Ahmanson UCLA Cardiomyopathy Ctr, 10833 LeConte Ave,Room 47-123 CHS, Los Angeles, CA 90095 USA.
EM gfonarow@mednet.ucla.edu
FU Bristol-Myers Squibb / Sanofi Pharmaceuticals Partnership; AHA
Pharmaceutical Roundtable; Boehringer Ingelheim; Merck
FX The GWTG-Stroke program is provided by the AHA/ASA. The GWTG-Stroke
program currently is supported in part by a charitable contribution from
the Bristol-Myers Squibb / Sanofi Pharmaceuticals Partnership and the
AHA Pharmaceutical Roundtable. GWTG-Stroke has been funded in the past
through support from Boehringer Ingelheim and Merck.
NR 21
TC 5
Z9 5
U1 1
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2047-9980
J9 J AM HEART ASSOC
JI J. Am. Heart Assoc.
PD AUG
PY 2012
VL 1
IS 4
AR UNSP e002345
DI 10.1161/JAHA.112.002345
PG 15
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 243RO
UT WOS:000326334800017
PM 23130167
ER
PT J
AU Wisco, BE
Marx, BP
Keane, TM
AF Wisco, Blair E.
Marx, Brian P.
Keane, Terence M.
TI Screening, Diagnosis, and Treatment of Post-Traumatic Stress Disorder
SO MILITARY MEDICINE
LA English
DT Article
AB Post-traumatic stress disorder (PTSD) is a prevalent problem among military personnel and veterans. Identification of effective screening tools, diagnostic technologies, and treatments for PTSD is essential to ensure that all individuals in need of treatment are offered interventions with proven efficacy. Well-validated methods for screening and diagnosing PTSD are now available, and effective pharmacological and psychological treatments can be offered. Despite these advances, many military personnel and veterans do not receive evidence-based care. We review the literature on screening, diagnosis, and treatment of PTSD in military populations, and discuss the challenges to implementing the best evidence-based practices in clinical settings.
C1 [Wisco, Blair E.] VA Boston Healthcare Syst, VA Natl Ctr PTSD, Boston, MA 02130 USA.
Boston Univ, Sch Med, Boston, MA 02130 USA.
RP Wisco, BE (reprint author), VA Boston Healthcare Syst, VA Natl Ctr PTSD, 150 South Huntington Ave, Boston, MA 02130 USA.
NR 56
TC 9
Z9 9
U1 3
U2 9
PU ASSOC MILITARY SURG US
PI BETHESDA
PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA
SN 0026-4075
EI 1930-613X
J9 MIL MED
JI Milit. Med.
PD AUG
PY 2012
VL 177
IS 8
SU S
SI SI
BP 7
EP 13
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA V33OB
UT WOS:000209027000003
PM 22953436
ER
PT J
AU Hawkins, EJ
Grossbard, J
Benbow, J
Nacev, V
Kivlahan, DR
AF Hawkins, Eric J.
Grossbard, Joel
Benbow, Jim
Nacev, Vladimir
Kivlahan, Daniel R.
TI Evidence-Based Screening, Diagnosis, and Treatment of Substance Use
Disorders Among Veterans and Military Service Personnel
SO MILITARY MEDICINE
LA English
DT Article
AB Substance use disorders (SUDs) are among the most common and costly conditions in veterans and active duty military personnel, adversely affecting their health and occupational and personal functioning. The pervasive burden of SUD has been a continuing concern for the Department of Veterans Affairs (VA) and Department of Defense (DoD), particularly as large numbers of service members return from Operations Enduring and Iraqi Freedom. The VA and DoD have prioritized implementation of evidence-based practices and treatment services to enhance the recognition and management of SUD in general medical and SUD specialty-care settings. This article summarizes the clinical practice guidelines for identifying, diagnosing, and treating SUD in VA and DoD general medical and SUD specialty-care settings, highlights evidence-based pharmacotherapy and psychosocial interventions for managing SUD, and describes barriers to successful treatment of veterans and service members at risk for SUD in VA and DoD health care systems.
C1 [Hawkins, Eric J.; Grossbard, Joel; Benbow, Jim; Kivlahan, Daniel R.] VA Puget Sound Healthcare Syst, Ctr Excellence Substance Abuse Treatment & Educ, Hlth Serv Res & Dev, Seattle, WA 98108 USA.
[Hawkins, Eric J.; Kivlahan, Daniel R.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Nacev, Vladimir] Def Ctr Excellence Psychol Hlth & Traumat Brain I, Resilience & Prevent Directorate, Silver Spring, MD 20910 USA.
RP Hawkins, EJ (reprint author), VA Puget Sound Healthcare Syst, Ctr Excellence Substance Abuse Treatment & Educ, Hlth Serv Res & Dev, 1660 S Columbian Way, Seattle, WA 98108 USA.
NR 75
TC 9
Z9 9
U1 2
U2 5
PU ASSOC MILITARY SURG US
PI BETHESDA
PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA
SN 0026-4075
EI 1930-613X
J9 MIL MED
JI Milit. Med.
PD AUG
PY 2012
VL 177
IS 8
SU S
SI SI
BP 29
EP 38
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA V33OB
UT WOS:000209027000006
PM 22953439
ER
PT J
AU Tollison, SJ
Henderson, RC
Baer, JS
Saxon, AJ
AF Tollison, Sean J.
Henderson, Ryan C.
Baer, Johns S.
Saxon, Andrew J.
TI Next Steps in Addressing the Prevention, Screening, and Treatment of
Substance Use Disorder in Active Duty and Veteran Operation Enduring
Freedom and Operation Iraqi Freedom Populations
SO MILITARY MEDICINE
LA English
DT Article
AB The two articles presented previously in this volume provide state-of-the-art reviews of the etiology, epidemiology, screening and treatment of substance use disorder (SUD). This article identifies next steps in research and development for understanding and treating SUD in Operation Enduring Freedom/Operation Iraqi Freedom service members and veterans. Four promising areas are reviewed: advances in psychopharmacological treatment of SUD, innovations in behavioral treatments, the use of technological advances for the screening and treatment of SUD, and integration of treatment services. Future directions are explored and suggestions for research, development and implementation of each of these trends are discussed.
C1 [Tollison, Sean J.; Henderson, Ryan C.; Baer, Johns S.; Saxon, Andrew J.] VA Puget Sound Hlth Care Syst, CESATE, Seattle, WA 98108 USA.
RP Tollison, SJ (reprint author), VA Puget Sound Hlth Care Syst, CESATE, 1660 South Columbian Way, Seattle, WA 98108 USA.
FU Center of Excellence in Substance Abuse Treatment and Education at VA
Puget Sound Health Care System; Research and Development Service,
Department of Veterans Affairs
FX This work was supported by the Center of Excellence in Substance Abuse
Treatment and Education at VA Puget Sound Health Care System and by the
Research and Development Service, Department of Veterans Affairs.
NR 68
TC 1
Z9 1
U1 2
U2 3
PU ASSOC MILITARY SURG US
PI BETHESDA
PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA
SN 0026-4075
EI 1930-613X
J9 MIL MED
JI Milit. Med.
PD AUG
PY 2012
VL 177
IS 8
SU S
SI SI
BP 39
EP 46
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA V33OB
UT WOS:000209027000007
PM 22953440
ER
PT J
AU Yoder, JS
Verani, J
Heidman, N
Hoppe-Bauer, J
Alfonso, EC
Miller, D
Jones, DB
Bruckner, D
Langston, R
Jeng, BH
Joslin, CE
Tu, E
Colby, K
Vetter, E
Ritterband, D
Mathers, W
Kowalski, RP
Acharya, NR
Limaye, AP
Leiter, C
Roy, S
Lorick, S
Roberts, J
Beach, MJ
AF Yoder, Jonathan S.
Verani, Jennifer
Heidman, Nancy
Hoppe-Bauer, Joan
Alfonso, Eduardo C.
Miller, Darlene
Jones, Dan B.
Bruckner, David
Langston, Roger
Jeng, Bennie H.
Joslin, Charlotte E.
Tu, Elmer
Colby, Kathryn
Vetter, Emily
Ritterband, David
Mathers, William
Kowalski, Regis P.
Acharya, Nisha R.
Limaye, Ajit P.
Leiter, Charles
Roy, Sharon
Lorick, Suchita
Roberts, Jacquelin
Beach, Michael J.
TI Acanthamoeba keratitis: The Persistence of Cases Following a Multistate
Outbreak
SO OPHTHALMIC EPIDEMIOLOGY
LA English
DT Article
DE Acanthamoeba keratitis; Surveillance; Epidemiology; Contacts lens;
Outbreak
ID CONTACT-LENS SOLUTION; WATER; PREVALENCE; AMEBAS
AB Purpose: To describe the trend of Acanthamoeba keratitis case reports following an outbreak and the recall of a multipurpose contact lens disinfection solution. Acanthamoeba keratitis is a serious eye infection caused by the free-living amoeba Acanthamoeba that primarily affects contact lens users.
Methods: A convenience sample of 13 ophthalmology centers and laboratories in the USA, provided annual numbers of Acanthamoeba keratitis cases diagnosed between 1999-2009 and monthly numbers of cases diagnosed between 2007-2009. Data on ophthalmic preparations of anti-Acanthamoeba therapies were collected from a national compounding pharmacy.
Results: Data from sentinel site ophthalmology centers and laboratories revealed that the yearly number of cases gradually increased from 22 in 1999 to 43 in 2003, with a marked increase beginning in 2004 (93 cases) that continued through 2007 (170 cases; p < 0.0001). The outbreak identified from these sentinel sites resulted in the recall of a contact lens disinfecting solution. There was a statistically significant (p <= 0.0001) decrease in monthly cases reported from 28 cases in June 2007 (following the recall) to seven cases in June 2008, followed by an increase (p = 0.0004) in reported cases thereafter; cases have remained higher than pre-outbreak levels. A similar trend was seen in prescriptions for Acanthamoeba keratitis chemotherapy. Cases were significantly more likely to be reported during summer than during other seasons.
Conclusion: The persistently elevated number of reported cases supports the need to understand the risk factors and environmental exposures associated with Acanthamoeba keratitis. Further prevention efforts are needed to reduce the number of cases occurring among contact lens wearers.
C1 [Yoder, Jonathan S.; Verani, Jennifer; Roy, Sharon; Lorick, Suchita; Roberts, Jacquelin; Beach, Michael J.] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Hoppe-Bauer, Joan] Barnes Jewish Hosp, St Louis, MO USA.
[Alfonso, Eduardo C.; Miller, Darlene] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Coral Gables, FL 33124 USA.
[Jones, Dan B.] Baylor Coll Med, Dept Ophthalmol, Houston, TX 77030 USA.
[Jones, Dan B.] Baylor Coll Med, Cullen Eye Inst, Houston, TX 77030 USA.
[Bruckner, David] Univ Calif Los Angeles, Los Angeles, CA 90024 USA.
[Langston, Roger; Jeng, Bennie H.] Cleveland Clin, Cole Eye Inst, Cleveland, OH USA.
[Joslin, Charlotte E.; Tu, Elmer] Univ Illinois, Chicago, IL USA.
[Colby, Kathryn] Massachusetts Eye & Ear Infirm, Boston, MA USA.
[Vetter, Emily] Mayo Clin, Rochester, MN USA.
[Ritterband, David] New York Eye & Ear Infirm, New York, NY USA.
[Mathers, William] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Kowalski, Regis P.] Univ Pittsburgh, Med Ctr, Charles T Campbell Lab, Pittsburgh, PA 15260 USA.
[Acharya, Nisha R.] Univ Calif San Francisco, Proctor Fdn, San Francisco, CA 94143 USA.
[Jeng, Bennie H.; Limaye, Ajit P.] Univ Washington, Seattle, WA 98195 USA.
[Leiter, Charles] Leiters Pharm, San Jose, CA USA.
RP Yoder, JS (reprint author), 1600 Clifton Rd NE,MS C-09, Atlanta, GA 30333 USA.
EM jyoder@cdc.gov
RI Miller, Darlene /C-9053-2013;
OI Ritterband, David/0000-0001-7139-878X
FU FDA; NEI
FX No authors are employed by corporations financially impacted by the
results reported in this manuscript. Some authors are employed by the US
Government and some authors receive funding from FDA and NEI. Some
authors report consulting fees for Bausch and Lomb, BioTissue,
Foresight, VisionCare, Inspire, Kimberly Clark, Alcon, Santen,
Crofessionals; lecture fees for Alcon; and royalties from Roche
Diagnostics. Detailed information is available on request.
NR 20
TC 31
Z9 32
U1 1
U2 8
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 0928-6586
J9 OPHTHAL EPIDEMIOL
JI Ophthalmic Epidemiol.
PD AUG
PY 2012
VL 19
IS 4
BP 221
EP 225
DI 10.3109/09286586.2012.681336
PG 5
WC Ophthalmology
SC Ophthalmology
GA 971GH
UT WOS:000306191300008
PM 22775278
ER
PT J
AU Hyle, EP
Shu, B
Lindstrom, S
Klimov, A
Hancock, K
Ferraro, MJ
Traum, AZ
Michelow, IC
AF Hyle, Emily P.
Shu, Bo
Lindstrom, Stephen
Klimov, Alexander
Hancock, Kathy
Ferraro, Mary J.
Traum, Avram Z.
Michelow, Ian C.
TI A severely immunocompromised child with uncomplicated
oseltamivir-resistant 2009 H1N1 pandemic influenza infection
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE viral infection; kidney transplant; immunosuppression
ID VIRUS
AB Hyle EP, Shu B, Lindstrom S, Klimov A, Hancock K, Ferraro MJ, Traum AZ, Michelow IC. A severely immunocompromised child with uncomplicated oseltamivir-resistant 2009 H1N1 pandemic influenza infection. Abstract: 2009 H1N1 pandemic influenza was associated with increased risk for severe disease in children and the immunosuppressed. We report a case of uncomplicated pneumonia because of infection with oseltamivir-resistant 2009 H1N1 virus in an immunosuppressed pediatric renal transplant patient. Innate immunity and/or altered viral fitness may be responsible for the mild clinical phenotype of the case.
C1 [Hyle, Emily P.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
[Shu, Bo; Lindstrom, Stephen; Klimov, Alexander; Hancock, Kathy] Ctr Dis Control, Atlanta, GA 30333 USA.
[Ferraro, Mary J.; Traum, Avram Z.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Michelow, Ian C.] Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA.
RP Hyle, EP (reprint author), Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
EM ehyle@partners.org
NR 10
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD AUG
PY 2012
VL 16
IS 5
BP E158
EP E161
DI 10.1111/j.1399-3046.2011.01490.x
PG 4
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 970LW
UT WOS:000306131700006
PM 21429059
ER
PT J
AU Fu, SN
Fan, J
Blanco, J
Gimenez-Cassina, A
Danial, NN
Watkins, SM
Hotamisligil, GS
AF Fu, Suneng
Fan, Jason
Blanco, Joshua
Gimenez-Cassina, Alfredo
Danial, Nika N.
Watkins, Steve M.
Hotamisligil, Goekhan S.
TI Polysome Profiling in Liver Identifies Dynamic Regulation of Endoplasmic
Reticulum Translatome by Obesity and Fasting
SO PLOS GENETICS
LA English
DT Article
ID FARNESOID-X-RECEPTOR; RAT SKELETAL-MUSCLE; BILE-ACID SYNTHESIS;
PROTEIN-SYNTHESIS; MESSENGER-RNA; GLUCOSE-HOMEOSTASIS;
INSULIN-TREATMENT; MAMMALIAN TARGET; DIABETIC-RATS; AMINO-ACIDS
AB Obesity-associated metabolic complications are generally considered to emerge from abnormalities in carbohydrate and lipid metabolism, whereas the status of protein metabolism is not well studied. Here, we performed comparative polysome and associated transcriptional profiling analyses to study the dynamics and functional implications of endoplasmic reticulum (ER)-associated protein synthesis in the mouse liver under conditions of obesity and nutrient deprivation. We discovered that ER from livers of obese mice exhibits a general reduction in protein synthesis, and comprehensive analysis of polysome-bound transcripts revealed extensive down-regulation of protein synthesis machinery, mitochondrial components, and bile acid metabolism in the obese translatome. Nutrient availability also plays an important but distinct role in remodeling the hepatic ER translatome in lean and obese mice. Fasting in obese mice partially reversed the overall translatomic differences between lean and obese nonfasted controls, whereas fasting of the lean mice mimicked many of the translatomic changes induced by the development of obesity. The strongest examples of such regulations were the reduction in Cyp7b1 and Slco1a1, molecules involved in bile acid metabolism. Exogenous expression of either gene significantly lowered plasma glucose levels, improved hepatic steatosis, but also caused cholestasis, indicating the fine balance bile acids play in regulating metabolism and health. Together, our work defines dynamic regulation of the liver translatome by obesity and nutrient availability, and it identifies a novel role for bile acid metabolism in the pathogenesis of metabolic abnormalities associated with obesity.
C1 [Fu, Suneng; Fan, Jason; Blanco, Joshua; Watkins, Steve M.; Hotamisligil, Goekhan S.] Harvard Univ, Sch Publ Hlth, Dept Genet & Complex Dis, Boston, MA 02115 USA.
[Fu, Suneng; Fan, Jason; Blanco, Joshua; Watkins, Steve M.; Hotamisligil, Goekhan S.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
[Gimenez-Cassina, Alfredo; Danial, Nika N.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Hotamisligil, Goekhan S.] Broad Inst Harvard & MIT, Boston, MA USA.
RP Fu, SN (reprint author), Harvard Univ, Sch Publ Hlth, Dept Genet & Complex Dis, 665 Huntington Ave, Boston, MA 02115 USA.
EM ghotamis@hsph.harvard.edu
OI Gimenez-Cassina, Alfredo/0000-0002-2768-2350
FU National Institutes of Health [DK52539, 1RC4-DK090942, R01DK078081];
NIH/NIEHS [T32ES007155]; Naomi Berrie fellowship award
FX This work is supported in part by grants from the National Institutes of
Health to GSH (DK52539 and 1RC4-DK090942) and NND (R01DK078081). SF was
supported in part by the NIH/NIEHS postdoctoral training grant
(T32ES007155) and currently the recipient of the Naomi Berrie fellowship
award. The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
NR 60
TC 21
Z9 21
U1 3
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7404
J9 PLOS GENET
JI PLoS Genet.
PD AUG
PY 2012
VL 8
IS 8
AR e1002902
DI 10.1371/journal.pgen.1002902
PG 11
WC Genetics & Heredity
SC Genetics & Heredity
GA 002JX
UT WOS:000308529300056
PM 22927828
ER
PT J
AU Zhang, XY
Chen, DC
Xiu, MH
Tang, W
Zhang, FX
Liu, LJ
Chen, YL
Liu, JH
Yao, JK
Kosten, TA
Kosten, TR
AF Zhang, Xiang Yang
Chen, Da Chun
Xiu, Mei Hong
Tang, Wei
Zhang, Feixue
Liu, LianJing
Chen, Yuanling
Liu, JiaHong
Yao, Jeffrey K.
Kosten, Therese A.
Kosten, Thomas R.
TI Plasma total antioxidant status and cognitive impairments in
schizophrenia
SO SCHIZOPHRENIA RESEARCH
LA English
DT Article
DE Schizophrenia; Cognition; Oxidative stress; Psychopathology
ID SUPEROXIDE DISMUTASE/CATALASE MIMETICS; BRAIN OXIDATIVE STRESS;
FREE-RADICAL PATHOLOGY; AGE-RELATED-CHANGES; NEUROPSYCHOLOGICAL
PROFILES; THERAPEUTIC IMPLICATIONS; REPEATABLE BATTERY;
TARDIVE-DYSKINESIA; LIPID-PEROXIDATION; DIFFERENT FORMS
AB Oxidative stress-induced damage to neurons may contribute to cognitive deficits during aging and in neurodegenerative disorders. Schizophrenia has a range of cognitive deficits that may evolve from oxidative stress, and this study examines this association of oxidative stress with cognitive deficits in schizophrenia. We recruited 296 chronic schizophrenia patients and 181 healthy control subjects and examined the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) and plasma total antioxidant status (TAS) in both groups. Schizophrenia symptoms were assessed using the positive and negative syndrome scale (PANSS). Our results showed that TAS levels were significantly lower in patients than controls (179.6 +/- 81.0 U/ml vs. 194.8 +/- 46.0 U/ml, p<0.05). Cognitive scores on the RBANS and nearly all of its five subscales (all p<0.001) except for the Visuospatial/Constructional index (p>0.05) were significantly lower in schizophrenia patients than normal controls. For the patients, TAS was inversely associated with some domains of cognitive deficits in schizophrenia, such as Attention and Immediate Memory. Our findings suggest that oxidative stress may be involved in the pathophysiology of schizophrenia, and its associated cognitive impairment. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Zhang, Xiang Yang; Kosten, Therese A.; Kosten, Thomas R.] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA.
[Zhang, Xiang Yang; Chen, Da Chun; Xiu, Mei Hong; Kosten, Thomas R.] Beijing Hui Long Guan Hosp, Psychiat Res Ctr, Beijing, Peoples R China.
[Tang, Wei; Zhang, Feixue; Liu, LianJing; Chen, Yuanling; Liu, JiaHong] Kangning Hosp, Dept Psychiat, Wenzhou, Zhejiang, Peoples R China.
[Yao, Jeffrey K.] Univ Pittsburgh, Sch Med, Western Psychiat Inst & Clin, VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Yao, Jeffrey K.] Univ Pittsburgh, Western Psychiat Inst & Clin, Dept Psychiat, Sch Med, Pittsburgh, PA 15213 USA.
RP Zhang, XY (reprint author), VA Med Ctr, Res Bldg 109,Room 130,2002 Holcombe Blvd, Houston, TX 77030 USA.
EM xyzhang@bcm.edu; kosten@bcm.edu
FU Stanley Medical Research Institute [03T-459, 05T-726]; Department of
Veterans Affairs; VISN 16; Mental Illness Research, Education and
Clinical Center (MIRECC), United States National Institute of Health
[K05-DA0454, P50-DA18827, U01-MH79639]
FX Funding for this study was provided by grants from the Stanley Medical
Research Institute (03T-459 and 05T-726), and the Department of Veterans
Affairs, VA Senior Research Career Scientist Award (JKY), VISN 16,
Mental Illness Research, Education and Clinical Center (MIRECC), United
States National Institute of Health K05-DA0454, P50-DA18827 and
U01-MH79639. These sources had no further role in study design; in the
collection, analysis and interpretation of data; in the writing of the
report; and in the decision to submit the paper for publication. The
contents of this article do not represent the views of the VA or the
United States Government.
NR 71
TC 27
Z9 28
U1 1
U2 7
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0920-9964
J9 SCHIZOPHR RES
JI Schizophr. Res.
PD AUG
PY 2012
VL 139
IS 1-3
BP 66
EP 72
DI 10.1016/j.schres.2012.04.009
PG 7
WC Psychiatry
SC Psychiatry
GA 970JO
UT WOS:000306124400011
PM 22555016
ER
PT J
AU Lin, YC
Wynn, JK
Hellemann, G
Green, MF
AF Lin, Yu-chung
Wynn, Jonathan K.
Hellemann, Gerhard
Green, Michael F.
TI Factor structure of emotional intelligence in schizophrenia
SO SCHIZOPHRENIA RESEARCH
LA English
DT Article
DE Schizophrenia; MSCEIT; Emotional intelligence; Factor analysis
ID PSYCHIATRIC RATING-SCALE; QUALITY-ASSURANCE; SOCIAL COGNITION
AB Social cognition, which includes emotional intelligence, is impaired in schizophrenia. The Mayer-Salovey-Caruso Emotional Intelligence Test (MSCEIT) is a widely-used assessment of emotional intelligence, with a four-factor structure in healthy individual. However, a recent factor analysis in schizophrenia patients revealed a two-factor structure of the MSCEIT. The current study aimed to replicate this finding in a larger, more diverse, schizophrenia sample (n=194). Our findings revealed an identical two-factor structure as in the previously-reported study, indicating that emotional intelligence is organized in a different manner in schizophrenia than it is in healthy controls. Published by Elsevier B.V.
C1 [Wynn, Jonathan K.; Green, Michael F.] MIRECC, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA.
[Wynn, Jonathan K.; Hellemann, Gerhard; Green, Michael F.] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90024 USA.
[Lin, Yu-chung] China Med Univ, Grad Inst Clin Med Sci, Taichung, Taiwan.
RP Wynn, JK (reprint author), MIRECC, VA Greater Los Angeles Healthcare Syst, Bldg 210,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM jkwynn@ucla.edu
RI Wynn, Jonathan/H-3749-2014
OI Wynn, Jonathan/0000-0002-1763-8540
FU National Institute of Mental Health [MH043292]
FX Funding for this study was provided by the National Institute of Mental
Health grant MH043292 to Michael F. Green. The funding agency had no
further role in the analysis or interpretation of data, in writing the
report, or in the decision to submit the paper for publication.
NR 19
TC 9
Z9 10
U1 0
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0920-9964
EI 1573-2509
J9 SCHIZOPHR RES
JI Schizophr. Res.
PD AUG
PY 2012
VL 139
IS 1-3
BP 78
EP 81
DI 10.1016/j.schres.2012.04.013
PG 4
WC Psychiatry
SC Psychiatry
GA 970JO
UT WOS:000306124400013
PM 22584064
ER
PT J
AU Galvez-Buccollini, JA
Proal, AC
Tomaselli, V
Trachtenberg, M
Coconcea, C
Chun, J
Manschreck, T
Fleming, J
Delisi, LE
AF Galvez-Buccollini, Juan A.
Proal, Ashley C.
Tomaselli, Veronica
Trachtenberg, Melissa
Coconcea, Cristinel
Chun, Jinsoo
Manschreck, Theo
Fleming, Jerry
Delisi, Lynn E.
TI Association between age at onset of psychosis and age at onset of
cannabis use in non-affective psychosis
SO SCHIZOPHRENIA RESEARCH
LA English
DT Article
DE Cannabis; Psychosis; Age; Sex; Schizophrenia
ID SUBSTANCE USE; SCHIZOPHRENIA
AB Introduction: Several studies have associated cannabis use with the development of schizophrenia. However, it has been difficult to disentangle the effects of cannabis from that of other illicit drugs, as previous studies have not evaluated pure cannabis users. To test whether the onset of cannabis use had an effect on the initiation of psychosis, we examined the time relationship between onset of use and onset of psychosis, restricting our analysis to a cohort of individuals who only used cannabis and no other street drugs.
Methods: Fifty-seven subjects with non-affective psychoses who used cannabis prior to developing a psychosis were interviewed using the Diagnostic Interview for Genetic Studies (DIGS). The Family Interview for Genetic Studies (FIGS) was also used to interview a family informant about psychiatric illness in the patient and the entire family. Multiple linear regression techniques were used to estimate the association between variables.
Results: After adjusting for potential confounding factors such as sex, age, lifetime diagnosis of alcohol abuse or dependence, and family history of schizophrenia, the age at onset of cannabis was significantly associated with age at onset of psychosis (beta=0.4, 95% CI=0.1-0.7, p=0.004) and age at first hospitalization (beta=0.4, 95% CI=0.1-0.8, p=0.008). The mean time between beginning to use cannabis and onset of psychosis was 7.0 +/- 4.3. Age at onset of alcohol use was not associated with age at onset of psychosis or age at first hospitalization.
Conclusion: Age at onset of cannabis is directly associated with age at onset of psychosis and age at first hospitalization. These associations remain significant after adjusting for potential confounding factors and are consistent with the hypothesis that cannabis could cause or precipitate the onset of psychosis after a prolonged period of time. Published by Elsevier B.V.
C1 [Galvez-Buccollini, Juan A.; Proal, Ashley C.; Fleming, Jerry; Delisi, Lynn E.] VA Boston Healthcare Syst, Brockton, MA 02301 USA.
[Galvez-Buccollini, Juan A.; Delisi, Lynn E.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Tomaselli, Veronica] Columbia Univ, St Lukes Roosevelt Hosp, New York, NY 10027 USA.
[Tomaselli, Veronica; Trachtenberg, Melissa; Delisi, Lynn E.] NYU, Langone Sch Med, New York, NY 10016 USA.
[Coconcea, Cristinel; Chun, Jinsoo; Manschreck, Theo] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
RP Galvez-Buccollini, JA (reprint author), VA Boston Healthcare Syst, 940 Belmont St, Brockton, MA 02301 USA.
EM Juan_Galvez-Buccollini@hms.harvard.edu; Ashley_Proal@hms.harvard.edu;
veronica.tomaselli@gmail.com; ccoconce@bidmc.harvard.edu;
jchun1@bidmc.harvard.edu; manschreck@aol.com; Jerry.Fleming@va.gov;
Lynn.DeLisi@VA.gov
FU National Institute of Drug Abuse [R01 DA 021576]; NIH, NIDA [R01 DA
021576]
FX This project was funded through the National Institute of Drug Abuse
(R01 DA 021576; LE DeLisi, P.I.).; Funding for this study was provided
by NIH, NIDA (R01 DA 021576). The funding agency played no role in the
direction of this project.
NR 14
TC 29
Z9 29
U1 2
U2 12
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0920-9964
J9 SCHIZOPHR RES
JI Schizophr. Res.
PD AUG
PY 2012
VL 139
IS 1-3
BP 157
EP 160
DI 10.1016/j.schres.2012.06.007
PG 4
WC Psychiatry
SC Psychiatry
GA 970JO
UT WOS:000306124400025
PM 22727454
ER
PT J
AU Holman, KM
Wolff, M
Sena, AC
Martin, DH
Behets, F
Van Damme, K
Leone, P
McNeil, L
Gehrig, ML
Hook, EW
AF Holman, Katherine M.
Wolff, Mark
Sena, Arlene C.
Martin, David H.
Behets, Frieda
Van Damme, Kathleen
Leone, Peter
McNeil, Linda
Gehrig, Meredyth L.
Hook, Edward W., III
TI Rapid Plasma Reagin Titer Variation in the 2 Weeks After Syphilis
Therapy
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Article
AB Background: Serologic tests for syphilis results at the time of diagnosis are the basis for evaluating response to syphilis therapy. After treatment, however, serologic tests for syphilis titers may continue to increase for several weeks. We evaluated rapid plasma reagin (RPR) titer variation during the 14 days after therapy using data from a recent large, prospective randomized controlled trial.
Methods: Prospectively enrolled participants in North America and Madagascar with primary, secondary, or early latent syphilis were randomly assigned to penicillin, doxycycline (in the case of penicillin allergy), or azithromycin treatment. Blood for RPR analysis was drawn at days 0, 7, and 14 posttreatment. All RPR titers were determined simultaneously at a central laboratory.
Results: Four hundred and seventy patients had data available for at least 2 of 3 RPR measurements. Overall, 20% of patients showed a titer increase of at least 1 dilution in the 14 days after therapy. The greatest proportion of titer increases following therapy was observed in patients with primary syphilis. Comparing outcome of therapy using the initial (day 0) RPR titer versus the maximal RPR titer (during 14 days) resulted in outcome reclassification in 2.98% of participants.
Conclusions: Despite the fact that about 20% of early syphilis patients had increases in RPR titers immediately after treatment, these changes rarely influenced assessment of therapeutic outcome. Only 3% of patients treated would have been reclassified.
C1 [Holman, Katherine M.; Hook, Edward W., III] Univ Alabama Birmingham, Div Infect Dis, Dept Med, Birmingham, AL 35294 USA.
[Holman, Katherine M.] Birmingham VA Med Ctr, Dept Qual Management, Birmingham, AL USA.
[Wolff, Mark; Gehrig, Meredyth L.] Emmes Corp, Rockville, MD USA.
[Sena, Arlene C.; Behets, Frieda; Leone, Peter] Univ N Carolina, Dept Med, Div Infect Dis, Chapel Hill, NC USA.
[Martin, David H.] Louisiana State Univ, Div Infect Dis, Dept Med, Baton Rouge, LA 70803 USA.
[Behets, Frieda; Van Damme, Kathleen] Univ N Carolina Madagascar, Dept Med, Antananarivo, Madagascar.
[Behets, Frieda; Van Damme, Kathleen] Univ N Carolina Madagascar, Dept Epidemiol, Antananarivo, Madagascar.
[McNeil, Linda] Family Hlth Int, Res Triangle Pk, NC 27709 USA.
RP Holman, KM (reprint author), Univ Alabama Birmingham, Div Infect Dis, Dept Med, 1900 Univ Blvd,THT 229, Birmingham, AL 35294 USA.
EM holmkm@uab.edu; ehook@uab.edu
FU National Institute of Allergy and Infectious Diseases at the National
Institutes of Health [N01 A1 75329]; STI Clinical Trials Group [HHSN
26620040073C]; GSK; Abbott Diagnostics; Norvartis; Trinity Diagnostics;
GenProbe; Becton-Dickinson; Roche Molecular Diagnostics; Siemens
Diagnostics
FX Supported by the National Institute of Allergy and Infectious Diseases
at the National Institutes of Health (grant number N01 A1 75329, Myron
Cohen, MD, PI) and the STI Clinical Trials Group (grant number HHSN
26620040073C, Edward W. Hook, III, MD, PI).; K.H., M. W., A. S., F. B.,
K. V. D, L. M., and M. G. declare no conflict of interest. D. M. is a
share holder in Merck and has been a consultant to Cempra Pharma. P. L.
has received research funding from GSK, Abbott Diagnostics, Norvartis
and Trinity Diagnostics and has been on the speakers' bureaus for GSK,
Norvartis and Abbott Diagnostics. E. W. has received research funding
from GenProbe, Becton-Dickinson, Roche Molecular Diagnostics, Siemens
Diagnostics, and has been on the speakers' bureaus for GSK, Norvartis
and Abbott Diagnostics.
NR 7
TC 5
Z9 5
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0148-5717
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD AUG
PY 2012
VL 39
IS 8
BP 645
EP 647
DI 10.1097/OLQ.0b013e3182536574
PG 3
WC Infectious Diseases
SC Infectious Diseases
GA 974FA
UT WOS:000306414300013
PM 22801348
ER
PT J
AU Lohmann, AE
Saini, KS
Metzger, O
AF Lohmann, Ana Elisa
Saini, Kamal S.
Metzger-Filho, Otto
TI Pertuzumab in metastatic breast cancer: unanswered questions
SO TRANSLATIONAL CANCER RESEARCH
LA English
DT Article
C1 [Lohmann, Ana Elisa] British Columbia Canc Agcy, Dept Med Oncol, Vancouver, BC V5Z 4E6, Canada.
[Saini, Kamal S.] Inst Jules Bordet, Breast Int Grp, B-1000 Brussels, Belgium.
[Metzger-Filho, Otto] Dana Farber Canc Inst, Breast Oncol Ctr, Boston, MA 02115 USA.
RP Lohmann, AE (reprint author), BC Canc Agcy, 600 W,10th Ave, Vancouver, BC V5Z 4E6, Canada.
EM ana.lohmann@bccancer.bc.ca
NR 13
TC 2
Z9 2
U1 0
U2 0
PU AME PUBL CO
PI SHEUNG WAN
PA ROOM 604 6-F HOLLYWOOD CENTER, 77-91, QUEENS ROAD, SHEUNG WAN, HONG KONG
00000, PEOPLES R CHINA
SN 2218-676X
EI 2219-6803
J9 TRANSL CANCER RES
JI Transl. Cancer Res.
PD AUG
PY 2012
VL 1
IS 2
BP 122
EP 124
DI 10.3978/j.issn.2218-676X.2012.04.03
PG 3
WC Oncology
SC Oncology
GA V42VZ
UT WOS:000209642600010
ER
PT J
AU Juillerat, P
Schneeweiss, S
Cook, EF
Ananthakrishnan, AN
Mogun, H
Korzenik, JR
AF Juillerat, P.
Schneeweiss, S.
Cook, E. F.
Ananthakrishnan, A. N.
Mogun, H.
Korzenik, J. R.
TI Drugs that inhibit gastric acid secretion may alter the course of
inflammatory bowel disease
SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS
LA English
DT Article
ID PROTON PUMP INHIBITORS; CROHNS-DISEASE; RISK-FACTOR; OMEPRAZOLE;
GASTROENTERITIS; CIMETIDINE; RECEPTORS; HISTAMINE; DESIGN; SCORES
AB Background Recent data suggest that acid suppressive medications may alter factors central to the pathophysiology of inflammatory bowel diseases (IBD), whether through shifts in the intestinal microbiome due to acid suppression or effects on immune function. Aim To assess the relationship between the use of proton pump inhibitors (PPIs) or histamine2-receptor antagonists (H2Ra) and incidence of flares (hospitalisation/surgery and change in medication). Methods We conducted a new user cohort study including individuals diagnosed with IBD in British Columbia using linked healthcare utilisation databases (available from July 1996 through April 2006). Propensity-score matched incidence rates during a 6-month follow-up period and rate ratios (RR) and 95% CI were calculated. Results Among 16 151 IBD patients, 1307 Crohn's disease (CD) and 996 ulcerative colitis (UC) patients experienced a new use of PPIs, whereas 741 CD and 738 UC used H2Ra. All IBD subgroups were matched separately to an equal number of unexposed IBD patients. H2Ra use in CD doubled the risk of hospitalisation/surgery (RR = 1.94; 95%CI 1.243.10) and numerically less so in UC patients (RR = 1.11) with widely overlapping CIs (0.612.03). Proton pump inhibitors use was associated with medication change in UC (RR = 1.39; 95%CI 1.201.62), but without meaningfully, increased risk of hospitalisation/surgery for UC or CD patients. Extending follow-up showed persistence, but attenuation, of all effects. Conclusions Initiation of PPIs or H2Ra may be associated with short-term changes in the course of IBD. Although confounding by indication was adjusted using propensity score matching, residual confounding may persist and findings need to be interpreted cautiously.
C1 [Juillerat, P.; Ananthakrishnan, A. N.; Korzenik, J. R.] Massachusetts Gen Hosp, MGH Crohns & Colitis Ctr, Dept Gastroenterol & Hepatol, Boston, MA 02114 USA.
[Juillerat, P.; Schneeweiss, S.; Ananthakrishnan, A. N.; Mogun, H.; Korzenik, J. R.] Harvard Univ, Sch Med, Boston, MA USA.
[Juillerat, P.] Inselspital Bern, Univ Hosp, Div Gastroenterol, Clin Visceral Surg & Med, CH-3010 Bern, Switzerland.
[Schneeweiss, S.; Mogun, H.] Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol, Boston, MA 02115 USA.
[Cook, E. F.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
RP Juillerat, P (reprint author), Massachusetts Gen Hosp, MGH Crohns & Colitis Ctr, Dept Gastroenterol & Hepatol, 165 Cambridge St,9th Floor, Boston, MA 02114 USA.
EM pjuillerat@partners.org
RI Schneeweiss, Sebastian/C-2125-2013
FU Swiss National Science Foundation (SNF) [PBLAP3-124341]; Foundation for
Clinical Research in Inflammatory Bowel Diseases, New York City;
National Institutes of Health [RO1-LM010213, RC1-RR028231]
FX Declaration of personal interests: Dr Schneeweiss has received an
investigator-initiated research grant from Pfizer on the safety of
selective cox-2 inhibitors. Dr Korzenik has been a consultant for
Procter and Gamble, Shire Pharmaceuticals, CytokinePharma, and receives
research support from Procter and Gamble and Warner Chilcott. We
gratefully acknowledge the contribution of Susan Giddons for editorial
assistance. Declaration of funding interests: This study was supported
by the Swiss National Science Foundation (SNF) (grant number
PBLAP3-124341) and the Foundation for Clinical Research in Inflammatory
Bowel Diseases, New York City (http://www.myIBD.org) with additional
support from the National Institutes of Health to Dr Schneeweiss (grant
number RO1-LM010213, RC1-RR028231).
NR 35
TC 8
Z9 9
U1 1
U2 9
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0269-2813
J9 ALIMENT PHARM THER
JI Aliment. Pharmacol. Ther.
PD AUG
PY 2012
VL 36
IS 3
BP 239
EP 247
DI 10.1111/j.1365-2036.2012.05173.x
PG 9
WC Gastroenterology & Hepatology; Pharmacology & Pharmacy
SC Gastroenterology & Hepatology; Pharmacology & Pharmacy
GA 966FW
UT WOS:000305824200004
PM 22670722
ER
PT J
AU Richter, JM
Kushkuley, S
Barrett, JA
Oster, G
AF Richter, J. M.
Kushkuley, S.
Barrett, J. A.
Oster, G.
TI Treatment of new-onset ulcerative colitis and ulcerative proctitis: a
retrospective study
SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS
LA English
DT Article
ID INFLAMMATORY-BOWEL-DISEASE; PRACTICE GUIDELINES; MESALAZINE;
MAINTENANCE; MANAGEMENT; THERAPY; COHORT
AB Background Although guidelines recommend use of oral 5-aminosalicylates (5-ASAs) as first-line therapy in patients with mild to moderate ulcerative colitis (UC) and ulcerative proctitis (UP) and steroids with or without 5-ASAs in those more severely ill, little is known about how UC and UP are actually treated. Aim To document treatment of new-onset UC and UP in routine clinical practice. Methods Using a large US health insurance database, we identified all persons with new-onset UC or UP between 1 January 2005 and 31 December 2007, based on: (i) initial receipt of an oral 5ASA, mesalazine (mesalamine) suppository, 5-ASA enema, steroid, antimetabolite, budesonide or TNF inhibitor; (ii) sigmoidoscopy/colonoscopy in prior 30 days resulting in a new diagnosis of UC or UP and (iii) no prior encounters for Crohn's disease. We examined patterns of pharmacotherapy over 1 year. Results We identified 1516 UC patients and 636 UP patients who met study entry criteria. In UC, initial therapies most frequently used were oral 5-ASAs (53% of patients), oral 5-ASAs and systemic steroids (12%), systemic steroids (8%) and mesalazine suppositories (6%); in UP, mesalazine suppositories (42%) and oral 5-ASAs (19%) were most often used, followed by combination therapy (14%), mesalazine enema (11%) and rectal steroids (10%). Few patients received maintenance therapy, and there was limited use of antimetabolites and biological agents. Conclusions Oral 5-ASAs and systemic steroids are the mainstay of treatment in patients with new-onset ulcerative colitis; in those with new-onset ulcerative proctitis, it is mesalazine suppositories. Care of these patients appears consistent with treatment guidelines.
C1 [Kushkuley, S.; Oster, G.] Policy Anal Inc, Brookline, MA 02445 USA.
[Barrett, J. A.] Aptalis Pharma Inc, Mt St Hilaire, PQ, Canada.
[Richter, J. M.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Richter, J. M.] Harvard Univ, Sch Med, Boston, MA USA.
RP Oster, G (reprint author), Policy Anal Inc, 4 Davis Court, Brookline, MA 02445 USA.
EM goster@pai2.com
FU Donaldson Foundation; Aptalis
FX Declaration of personal interests: James M. Richter has served as a
consultant to the US Department of Justice and Policy Analysis Inc., and
has received research funding from the Donaldson Foundation. He is an
employee of the Massachusetts General Hospital and Harvard Medical
School, Boston, MA, USA. Sophie Kushkuley is a graduate student at
Brandeis University, and was an employee of Policy Analysis Inc. at the
time the study was conducted. Jeannette A. Barrett was an employee of
Aptalis (formerly, Axcan) at the time the study was conducted, and
currently is employed by Actavis Inc. Gerry Oster has served as a
speaker, consultant and advisory board member for many biomedical
companies. He is an employee of Policy Analysis Inc., which has received
research funding from Aptalis (formerly, Axcan) as well as other
healthcare companies and governmental organizations. Dr Oster owns stock
in other healthcare companies in his retirement accounts. Declaration of
funding interests: This study was funded in full by Aptalis (formerly,
Axcan) under a research contract. Study design, analysis and
interpretation of data, and manuscript preparation were undertaken by
the study authors and the authors only.
NR 21
TC 10
Z9 10
U1 0
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0269-2813
J9 ALIMENT PHARM THER
JI Aliment. Pharmacol. Ther.
PD AUG
PY 2012
VL 36
IS 3
BP 248
EP 256
DI 10.1111/j.1365-2036.2012.05175.x
PG 9
WC Gastroenterology & Hepatology; Pharmacology & Pharmacy
SC Gastroenterology & Hepatology; Pharmacology & Pharmacy
GA 966FW
UT WOS:000305824200005
PM 22690748
ER
PT J
AU Hayes-Skelton, SA
Usmani, A
Lee, JK
Roemer, L
Orsillo, SM
AF Hayes-Skelton, Sarah A.
Usmani, Aisha
Lee, Jonathan K.
Roemer, Lizabeth
Orsillo, Susan M.
TI A Fresh Look at Potential Mechanisms of Change in Applied Relaxation for
Generalized Anxiety Disorder: A Case Series
SO COGNITIVE AND BEHAVIORAL PRACTICE
LA English
DT Article
DE applied relaxation; mindfulness; decentering; acceptance; GAD
ID COGNITIVE-BEHAVIORAL THERAPY; STATE WORRY QUESTIONNAIRE; PSYCHOMETRIC
PROPERTIES; COMMITMENT THERAPY; STRESS SCALES; MINDFULNESS; DEPRESSION;
VALIDATION; ACCEPTANCE; AVOIDANCE
AB Applied relaxation (AR), which involves noticing early signs of anxiety and responding with a relaxation response, is an empirically supported treatment for generalized anxiety disorder (GAD). However, research on hypothesized mechanisms of AR (e.g., reduced muscle tension) has been mixed, making it likely that additional mechanisms are contributing to the efficacy of AR. Stemming from more recent conceptualizations of GAD, it is hypothesized that mindfulness, decentering, and acceptance may be potential mechanisms of change in AR. Outcome, mechanism data, and case descriptions from three individuals diagnosed with GAD who received 16 weeks of AR as part of a larger randomized controlled trial are presented to demonstrate the ways that AR may lead to clinical improvement through mindfulness, decentering, and acceptance.
C1 [Hayes-Skelton, Sarah A.] Univ Massachusetts, Dept Psychol, Boston, MA 02125 USA.
[Usmani, Aisha] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cambridge, MA 02138 USA.
[Lee, Jonathan K.; Orsillo, Susan M.] Suffolk Univ, Boston, MA USA.
RP Hayes-Skelton, SA (reprint author), Univ Massachusetts, Dept Psychol, 100 Morrissey Blvd, Boston, MA 02125 USA.
EM sarah.hayes@umb.edu
OI Roemer, Lizabeth/0000-0002-2453-5435
FU NIMH NIH HHS [K99 MH085060, R00 MH085060, R01 MH074589]
NR 51
TC 14
Z9 14
U1 3
U2 24
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1077-7229
J9 COGN BEHAV PRACT
JI Cogn. Behav. Pract.
PD AUG
PY 2012
VL 19
IS 3
BP 451
EP 462
PG 12
WC Psychology, Clinical
SC Psychology
GA 967OU
UT WOS:000305918500008
PM 23888107
ER
PT J
AU Auriel, E
Greenberg, SM
AF Auriel, Eitan
Greenberg, Steven Mark
TI The Pathophysiology and Clinical Presentation of Cerebral Amyloid
Angiopathy
SO CURRENT ATHEROSCLEROSIS REPORTS
LA English
DT Article
DE Cerebral amyloid angiopathy; Intracerebral hemorrhage; Vascular
dementia; Stroke
ID RECURRENT INTRACEREBRAL HEMORRHAGE; ALZHEIMERS-DISEASE; MOUSE MODEL;
COGNITIVE IMPAIRMENT; CEREBROVASCULAR PATHOLOGY; SUBARACHNOID
HEMORRHAGE; SUPERFICIAL SIDEROSIS; BETA-AMYLOIDOSIS; LOBAR HEMORRHAGE;
MICROBLEEDS
AB Cerebral amyloid angiopathy (CAA) is defined as the deposition of amyloid peptide within leptomeningial and cortical vessels, likely reflecting an imbalance between A beta production and clearance. Amyloid buildup triggers a series of destructive alterations in the cerebral vascular architecture, leading to a spectrum of neurological events including lobar intracerebral hemorrhage, brain ischemia and cognitive decline. Although traditionally diagnosed pathologically, neuroimaging has taken a central role in defining CAA. This review will discuss the pathological, clinical and radiological aspects of CAA.
C1 [Auriel, Eitan; Greenberg, Steven Mark] Massachusetts Gen Hosp, Dept Neurol, J Philip Kistler Stroke Res Ctr, Boston, MA 02114 USA.
[Auriel, Eitan; Greenberg, Steven Mark] Harvard Univ, Sch Med, Boston, MA 02114 USA.
RP Greenberg, SM (reprint author), Massachusetts Gen Hosp, Dept Neurol, J Philip Kistler Stroke Res Ctr, 175 Cambridge St,Suite 300, Boston, MA 02114 USA.
EM sgreenberg@partners.org
NR 85
TC 21
Z9 22
U1 0
U2 10
PU CURRENT MEDICINE GROUP
PI PHILADELPHIA
PA 400 MARKET STREET, STE 700, PHILADELPHIA, PA 19106 USA
SN 1523-3804
J9 CURR ATHEROSCLER REP
JI Curr. Atherosclerol. Rep.
PD AUG
PY 2012
VL 14
IS 4
BP 343
EP 350
DI 10.1007/s11883-012-0254-z
PG 8
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 968BT
UT WOS:000305952700008
PM 22565298
ER
PT J
AU Bayliss, G
Weinrauch, LA
D'Elia, JA
AF Bayliss, George
Weinrauch, Larry A.
D'Elia, John A.
TI Pathophysiology of Obesity-Related Renal Dysfunction Contributes to
Diabetic Nephropathy
SO CURRENT DIABETES REPORTS
LA English
DT Article
DE Obesity; Obstructive sleep apnea; Proteinuria; Insulin resistance;
Podocyte; Nephrin; Adipocyte; Diabetes; Renal dysfunction; Diabetic
nephropathy
ID OBSTRUCTIVE SLEEP-APNEA; CHRONIC KIDNEY-DISEASE; FETUIN-A; METABOLIC
SYNDROME; NEPHROTIC SYNDROME; MASSIVE OBESITY; WEIGHT-LOSS; ADIPONECTIN;
ASSOCIATION; PROTEINURIA
AB Recent studies have demonstrated the role of insulin resistance in renal injury related to obesity, with hyperfiltration leading to glomerulomegaly in a pattern similar to that found in diabetic nephropathy. Similarities in the histologic patterns of damage from obesity and diabetes point to overlapping mechanisms of injury. In this review, we will examine the hormonal mechanisms, signaling pathways and injury patterns in renal injury resulting from obesity and attempt to draw conclusions on the reasons for these similarities.
C1 [Bayliss, George] Brown Univ, Alpert Med Sch, Providence, RI 02912 USA.
[Bayliss, George] Rhode Isl & Miriam Hosp, Div Kidney Dis & Hypertens, Providence, RI USA.
[Weinrauch, Larry A.; D'Elia, John A.] Harvard Univ, Sch Med, Boston, MA USA.
[D'Elia, John A.] Beth Israel Deaconess Med Ctr, Joslin Diabet Ctr, Renal Unit, Boston, MA 02215 USA.
RP Bayliss, G (reprint author), Brown Univ, Alpert Med Sch, Providence, RI 02912 USA.
EM gbayliss@lifespan.org
OI D'Elia, John/0000-0001-9482-581X; Weinrauch, Larry/0000-0003-1357-9528
FU Pat Covelli Foundation; Amgen Corp.; Bayer Laboratories
FX G. Bayliss: none; L. A. Weinrauch: none; J.A. D'Elia: has received grant
support from the Pat Covelli Foundation, Amgen Corp., and Bayer
Laboratories as investigator-initiated research.
NR 42
TC 14
Z9 18
U1 0
U2 9
PU CURRENT MEDICINE GROUP
PI PHILADELPHIA
PA 400 MARKET STREET, STE 700, PHILADELPHIA, PA 19106 USA
SN 1534-4827
EI 1539-0829
J9 CURR DIABETES REP
JI Curr. Diabetes Rep.
PD AUG
PY 2012
VL 12
IS 4
BP 440
EP 446
DI 10.1007/s11892-012-0288-1
PG 7
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 968BW
UT WOS:000305953000014
PM 22638939
ER
PT J
AU Chen, XQ
Wu, GH
Schwarzschild, MA
AF Chen, Xiqun
Wu, Guanhui
Schwarzschild, Michael A.
TI Urate in Parkinson's Disease: More Than a Biomarker?
SO CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS
LA English
DT Review
DE Urate; Parkinson's disease; Oxidative stress; Clinical trial;
Antioxidant; Neuroprotectant; Neurodegeneration; Neuroprotection;
Biomarker; Disease modifier; Neurodegenerative diseases; Purine; Risk
factor
ID URIC-ACID LEVELS; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; MILD
COGNITIVE IMPAIRMENT; ISCHEMIC BRAIN-INJURY; SUBSTANTIA-NIGRA; OXIDATIVE
STRESS; PLASMA URATE; IN-VIVO; DOPAMINERGIC-NEURONS; ANTIOXIDANT
CAPACITY
AB Parkinson's disease (PD) is a progressive neurodegenerative disease with characteristic motor manifestations. Although appreciation of PD as a multisystem disorder has grown, loss of dopaminergic neurons in the substantia nigra remains a pathological and neurochemical hallmark, accounting for the substantial symptomatic benefits of dopamine replacement therapies. However, currently no treatment has been shown to prevent or forestall the progression of the disease in spite of tremendous efforts. Among multiple environmental and genetic factors that have been implicated in the pathogenesis of PD, oxidative stress is proposed to play a critical role. A recent confluence of clinical, epidemiological, and laboratory evidence identified urate, an antioxidant and end product of purine metabolism, as not only a molecular predictor for both reduced risk and favorable progression of PD but also a potential neuroprotectant for the treatment of PD. This review summarizes recent findings on urate in PD and their clinical implications.
C1 [Chen, Xiqun; Wu, Guanhui; Schwarzschild, Michael A.] Harvard Univ, Massachusetts Gen Hosp, Dept Neurol, Sch Med, Charlestown, MA 02129 USA.
[Wu, Guanhui] Suzhou Municipal Hosp, Suzhou, Peoples R China.
RP Chen, XQ (reprint author), Harvard Univ, Massachusetts Gen Hosp, Dept Neurol, Sch Med, 114 16th St, Charlestown, MA 02129 USA.
EM xchen17@partners.org; gwu4@partners.org; michaels@helix.mgh.harvard.edu
FU National Institutes of Health/National Institute of Neurological
Disorders and Stroke [K24NS060991]; US Department of Defense
[W81XWH-11-1-0150]
FX This paper is supported by the National Institutes of Health/National
Institute of Neurological Disorders and Stroke grant K24NS060991 and the
US Department of Defense grant W81XWH-11-1-0150.
NR 98
TC 20
Z9 20
U1 0
U2 9
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1528-4042
J9 CURR NEUROL NEUROSCI
JI Curr. Neurol. Neurosci. Rep.
PD AUG
PY 2012
VL 12
IS 4
BP 367
EP 375
DI 10.1007/s11910-012-0282-7
PG 9
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 966HW
UT WOS:000305829500005
PM 22580741
ER
PT J
AU Sonpavde, G
Bellmunt, J
Schutz, F
Choueiri, TK
AF Sonpavde, Guru
Bellmunt, Joaquim
Schutz, Fabio
Choueiri, Toni K.
TI The Double Edged Sword of Bleeding and Clotting from VEGF Inhibition in
Renal Cancer Patients
SO CURRENT ONCOLOGY REPORTS
LA English
DT Article
DE Renal cell carcinoma; VEGF inhibitors; Bleeding; Thrombosis
ID RANDOMIZED PHASE-II; ARTERIAL THROMBOEMBOLIC EVENTS; ANTIANGIOGENIC
AGENT SU5416; MOLECULAR-WEIGHT HEPARIN; CELL-CARCINOMA; VENOUS
THROMBOEMBOLISM; INTERFERON-ALPHA; BEVACIZUMAB; TRIAL; RISK
AB Vascular endothelial growth factor (VEGF) inhibitors have significantly improved outcomes in patients with advanced renal cell carcinoma (RCC). Multiple VEGF inhibiting orally administered tyrosine kinase inhibitors (TKIs) have been approved including sunitinib, sorafenib, pazopanib and most recently, axitinib. One VEGF inhibiting monoclonal antibody, bevacizumab, is approved in combination with interferon. However, these agents, besides the known progression-free survival benefits, are associated with a small but real risk of potentially life threatening and contrasting toxicities of thrombosis (both venous and arterial) and bleeding. Appropriate patient selection for VEGF inhibitors and prevention as well as prompt intervention to manage thrombosis and bleeding are necessary to forestall serious morbidities and mortality.
C1 [Bellmunt, Joaquim] UPF Univ, Univ Hosp Del Mar IMIM, Barcelona, Spain.
[Sonpavde, Guru] Vet Affairs Med Ctr, Houston, TX 77030 USA.
[Sonpavde, Guru] Baylor Coll Med, Houston, TX 77030 USA.
[Schutz, Fabio] Beneficencia Portuguesa Sao Paulo, Sao Jose Hosp, Sao Paulo, Brazil.
[Choueiri, Toni K.] Harvard Univ, Sch Med, Boston, MA USA.
[Choueiri, Toni K.] Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA.
[Sonpavde, Guru] Texas Oncol, Houston, TX USA.
RP Bellmunt, J (reprint author), UPF Univ, Univ Hosp Del Mar IMIM, Paseig Maritim 25-29, Barcelona, Spain.
EM jbellmunt@parcdesalutmar.cat
FU Novartis; Celgene; Teva; BMS; Pfizer
FX G. Sonpavde: research support from Novartis, Celgene, Teva, BMS, and
Pfizer, and speaking honoraria from Novartis and GSK; T. K. Choueiri:
research support from Pfizer, and advisory board for Pfizer, GSK,
Novartis, Aveo, and Bayer/Onyx; F. Schutz: none; J. Bellmunt: advisory
board for Pfizer, GSK, Novartis, Aveo, and Bayer/Onyx.
NR 60
TC 8
Z9 10
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1523-3790
J9 CURR ONCOL REP
JI Curr. Oncol. Rep.
PD AUG
PY 2012
VL 14
IS 4
BP 295
EP 306
DI 10.1007/s11912-012-0237-9
PG 12
WC Oncology
SC Oncology
GA 968CB
UT WOS:000305953500003
PM 22532265
ER
PT J
AU Kargi, AY
Merriam, GR
AF Kargi, Atil Y.
Merriam, George R.
TI Testing for growth hormone deficiency in adults: doing without growth
hormone-releasing hormone
SO CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY
LA English
DT Review
DE growth hormone; growth hormone deficiency; growth hormone stimulation
testing
ID INSULIN TOLERANCE-TEST; GLUCAGON STIMULATION TEST; BONE-MINERAL DENSITY;
IGF-I LEVELS; GH-DEFICIENCY; (GH)-RELEASING HORMONE; REPLACEMENT
THERAPY; PITUITARY DISEASE; CUTOFF LIMITS; PLUS ARGININE
AB Purpose of review
This article summarizes recent advances in testing for growth hormone deficiency (GHD) in adults, focusing on critical appraisal of existing growth hormone (GH) provocative tests as well as newer tests in development.
Recent findings
The diagnosis of GHD can be challenging and often requires the use of GH provocative testing. The most widely validated of these is insulin-induced hypoglycemia (ITT), which requires close supervision and has significant contraindications and side-effects. The arginine-growth hormone-releasing hormone (GHRH) test had become widely used as a safe and accurate alternative to the ITT, but GHRH is currently unavailable for clinical use in the USA. On the basis of review of recent literature we recommend that in the absence of GHRH, glucagon stimulation testing should be the preferred alternative to ITT. Several synthetic GH secretagogues that mimic the gastric peptide ghrelin are currently in development and may become available for use in the diagnosis of GHD in the near future. Other GH provocative tests suitable for use in children lack adequate specificity for the diagnosis of GHD in adults.
Summary
Due to the current unavailability of the arginine-GHRH test in the USA, when ITT is contraindicated or impractical we recommend the glucagon stimulation testing as the GH provocative test of choice. There remains a need for a simple, safe and accurate test for the diagnosis of GHD.
C1 [Kargi, Atil Y.] Univ Miami, Miller Sch Med, Div Endocrinol Diabet & Metab, Miami, FL 33136 USA.
[Merriam, George R.] Univ Washington, Sch Med, Div Metab Endocrinol & Nutr, VA Puget Sound Hlth Care Syst, Seattle, WA 98493 USA.
RP Merriam, GR (reprint author), VA Puget Sound Healthcare Syst A 151, Seattle, WA 98493 USA.
EM merriam@uw.edu
FU Ardana Biosciences; Aeterna Zentaris
FX A.Y.K. has nothing to disclose. G. R. M. received research grant support
from Ardana Biosciences and from Aeterna Zentaris.
NR 62
TC 7
Z9 7
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1752-296X
EI 1752-2978
J9 CURR OPIN ENDOCRINOL
JI Curr. Opin. Endocrinol. Diabetes Obes.
PD AUG
PY 2012
VL 19
IS 4
BP 300
EP 305
DI 10.1097/MED.0b013e32835430da
PG 6
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 970FX
UT WOS:000306114600008
PM 22596248
ER
PT J
AU Desai, GS
Uppot, RN
Yu, EW
Kambadakone, AR
Sahani, DV
AF Desai, Gaurav S.
Uppot, Raul N.
Yu, Elaine W.
Kambadakone, Avinash R.
Sahani, Dushyant V.
TI Impact of iterative reconstruction on image quality and radiation dose
in multidetector CT of large body size adults
SO EUROPEAN RADIOLOGY
LA English
DT Article
DE Iterative reconstruction; Computed tomography; Image quality; Radiation
dose; Obesity
ID TUBE CURRENT MODULATION; AUTOMATIC EXPOSURE CONTROL; ABDOMINAL CT;
COMPUTED-TOMOGRAPHY; PATIENT SIZE; OBESITY; REDUCTION; ALGORITHM;
PHANTOM; MDCT
AB To compare image quality and radiation dose using Adaptive Statistical Iterative Reconstruction (ASiR) and Filtered Back Projection (FBP) in patients weighing a parts per thousand yen91 kg.
In this Institution Review Board-approved retrospective study, single-phase contrast-enhanced abdominopelvic CT examinations of 100 adults weighing a parts per thousand yen91 kg (mean body weight: 107.6 +/- 17.4 kg range: 91-181.9 kg) with (1) ASiR and (2) FBP were reviewed by two readers in a blinded fashion for subjective measures of image quality (using a subjective standardized numerical scale and objective noise) and for radiation exposure. Imaging parameters and radiation dose results of the two techniques were compared within weight and BMI sub-categories.
All examinations were found to be of adequate quality. Both subjective (mean = 1.4 +/- 0.5 vs. 1.6 +/- 0.6, P < 0.05) and objective noise (13.0 +/- 3.2 vs.19.5 +/- 5.7, P < 0.0001) were lower with ASiR. Average radiation dose reduction of 31.5 % was achieved using ASiR (mean CTDIvol. ASiR: 13.5 +/- 7.3 mGy; FBP: 19.7 +/- 9.0 mGy, P < 0.0001). Other measures of image quality were comparable between the two techniques. Trends for all parameters were similar in patients across weight and BMI sub-categories.
In obese individuals, abdominal CT images reconstructed using ASiR provide diagnostic images with reduced image noise at lower radiation dose.
aEuro cent CT images in obese adults are noisy, even with high radiation dose.
aEuro cent Newer iterative reconstruction techniques have theoretical advantages in obese patients.
aEuro cent Adaptive statistical iterative reconstruction should reduce image noise and radiation dose.
aEuro cent This has been proven in abdominopelvic CT images of obese patients.
C1 [Sahani, Dushyant V.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Abdominal Imaging & Intervent,Dept Radiol, Boston, MA 02114 USA.
[Desai, Gaurav S.; Uppot, Raul N.; Kambadakone, Avinash R.; Sahani, Dushyant V.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Abdominal Imaging & Intervent, Boston, MA 02114 USA.
[Yu, Elaine W.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Endocrine Unit, Boston, MA 02114 USA.
RP Sahani, DV (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Abdominal Imaging & Intervent,Dept Radiol, 55 Fruit St,White 270, Boston, MA 02114 USA.
EM dsahani@partners.org
NR 57
TC 51
Z9 53
U1 0
U2 6
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0938-7994
J9 EUR RADIOL
JI Eur. Radiol.
PD AUG
PY 2012
VL 22
IS 8
BP 1631
EP 1640
DI 10.1007/s00330-012-2424-3
PG 10
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 967LQ
UT WOS:000305909800003
PM 22527370
ER
PT J
AU Denecke, T
Steffen, IG
Agarwal, S
Seehofer, D
Kroncke, T
Hanninen, EL
Kramme, IB
Neuhaus, P
Saini, S
Hamm, B
Grieser, C
AF Denecke, Timm
Steffen, Ingo G.
Agarwal, Sheela
Seehofer, Daniel
Kroencke, Thomas
Haenninen, Enrique Lopez
Kramme, Incken-Birthe
Neuhaus, Peter
Saini, Sanjay
Hamm, Bernd
Grieser, Christian
TI Appearance of hepatocellular adenomas on gadoxetic acid-enhanced MRI
SO EUROPEAN RADIOLOGY
LA English
DT Article
DE MRI; Hepatocellular adenoma; Adenoma; Liver; Gadoxetic acid
ID FOCAL NODULAR HYPERPLASIA; GD-EOB-DTPA; CONTRAST AGENT; LIVER
ADENOMATOSIS; HEPATIC ADENOMA; SUBTYPE CLASSIFICATION; PATHOLOGICAL
FINDINGS; INITIAL OBSERVATIONS; IMAGING FEATURES; MANAGEMENT
AB The purpose of this study was to evaluate enhancement characteristics of hepatocellular adenomas (HCAs) using gadoxetic acid as a hepatocyte-specific MR contrast agent.
Twenty-four patients with histopathologically proven HCAs were retrospectively identified. MRI consisted of T1- and T2-weighted (w) sequences with and without fat saturation (fs), multiphase dynamic T1-w images, and fs T1-w images during the hepatobiliary phase. Standard of reference was surgical resection (n = 19) or biopsy (n = 5). Images were analysed for morphology and contrast behaviour including signal intensity (SI) measurement on T1-w images normalised to the pre-contrast base line.
In total 34 HCAs were evaluated. All HCAs showed enhancement in the arterial phase; 38 % of HCAs showed reduced contrast enhancement ("wash-out") in the venous phase. All HCAs showed enhancement (SI increase, 56 +/- 53 %; P < 0.001) in the hepatobiliary phase, although liver uptake was stronger (96 +/- 58 %). Thus, 31 of all HCAs (91 %) appeared hypointense to the surrounding liver in the hepatobiliary phase, while 3 out of 34 lesions were iso-/hyperintense.
Gadoxetic acid accumulates in HCAs in the hepatobiliary phase, although significantly less than in surrounding liver. Thus, HCA appears in the vast majority of cases as a hypointense lesion on hepatobiliary phase images.
aEuro cent Magnetic resonance-specific contrast agents are now available for hepatic imaging.
aEuro cent Hepatocellular adenomas enhance with gadoxetic acid as in previous CT/MRI experience.
aEuro cent Enhancement during the hepatobiliary phase is less in HCAs than in liver.
aEuro cent Typical HCAs appear as hypointense lesions on T1-w hepatobiliary phase images.
aEuro cent True hyperintense HCA enhancement can occasionally occur during the hepatobiliary phase.
C1 [Denecke, Timm; Steffen, Ingo G.; Kroencke, Thomas; Haenninen, Enrique Lopez; Hamm, Bernd; Grieser, Christian] Charite, Campus Virchow Klinikum, Radiol Klin, D-13353 Berlin, Germany.
[Seehofer, Daniel; Neuhaus, Peter] Charite, Campus Virchow Klinikum, Klin Allgemein Viszeral & Transplantat Chirurg, D-13353 Berlin, Germany.
[Kramme, Incken-Birthe] Charite, Campus Virchow Klinikum, Inst Pathol, D-13353 Berlin, Germany.
[Agarwal, Sheela; Saini, Sanjay] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA.
[Agarwal, Sheela; Saini, Sanjay] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Grieser, C (reprint author), Charite, Campus Virchow Klinikum, Radiol Klin, Augustenburger Pl 1, D-13353 Berlin, Germany.
EM christian.grieser@charite.de
RI Kroencke, Thomas/H-6423-2011;
OI Denecke, Timm/0000-0003-3313-3208
NR 36
TC 16
Z9 20
U1 1
U2 7
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0938-7994
J9 EUR RADIOL
JI Eur. Radiol.
PD AUG
PY 2012
VL 22
IS 8
BP 1769
EP 1775
DI 10.1007/s00330-012-2422-5
PG 7
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 967LQ
UT WOS:000305909800019
PM 22437921
ER
PT J
AU Efstathiou, JA
Shipley, WU
Zietman, AL
AF Efstathiou, Jason A.
Shipley, William U.
Zietman, Anthony L.
TI Reply to Neeraj Kumar Goyal, Manish Garg, and Apul Goel's Letter to the
Editor re: Re: Jason A. Efstathiou, Daphna Y. Spiegel, William U.
Shipley, et al. Long-Term Outcomes of Selective Bladder Preservation by
Combined-Modality Therapy for Invasive Bladder Cancer: The MGH
Experience. Eur Urol 2012;61:705-11
SO EUROPEAN UROLOGY
LA English
DT Letter
C1 [Efstathiou, Jason A.; Shipley, William U.; Zietman, Anthony L.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
RP Efstathiou, JA (reprint author), Massachusetts Gen Hosp, Dept Radiat Oncol, 100 Blossom St,Cox 3, Boston, MA 02114 USA.
EM jefstathiou@partners.org
NR 1
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0302-2838
J9 EUR UROL
JI Eur. Urol.
PD AUG
PY 2012
VL 62
IS 2
BP E42
EP E42
DI 10.1016/j.eururo.2012.04.055
PG 1
WC Urology & Nephrology
SC Urology & Nephrology
GA 966MF
UT WOS:000305841100006
ER
PT J
AU Maciejewski, ML
Liu, CF
Kavee, AL
Olsen, MK
AF Maciejewski, Matthew L.
Liu, Chuan-Fen
Kavee, Andrew L.
Olsen, Maren K.
TI HOW PRICE RESPONSIVE IS THE DEMAND FOR SPECIALTY CARE?
SO HEALTH ECONOMICS
LA English
DT Article
DE costs; longitudinal; mixed model; random effects; health econometrics;
zero-inflated data; specialty care; co-payment; cost sharing
ID HEALTH MAINTENANCE ORGANIZATION; OFFICE VISIT COPAYMENTS; RISK
ADJUSTMENT; PREVENTIVE SERVICES; EMERGENCY; OUTCOMES; IMPACT; COSTS;
COINSURANCE; PERFORMANCE
AB Objectives Outpatient visit co-payments have increased in recent years. We estimate the patient response to a price change for specialty care, based on a co-payment increase from $15 to $50 per visit for veterans with hypertension. Design, Setting, and Patients A retrospective cohort of veterans required to pay co-payments was compared with veterans exempt from co-payments whose nonequivalence was reduced via propensity score matching. Specialty care expenditures in 20002003 were estimated via a two-part mixed model to account for the correlation of the use and level outcomes over time, and results from this correlated two-part model were compared with an uncorrelated two-part model and a correlated random intercept two-part mixed model. Results A $35 specialty visit co-payment increase had no impact on the likelihood of seeking specialty care but induced lower specialty expenditures over time among users who were required to pay co-payments. The log ratio of price responsiveness (semi-elasticity) for specialty care increased from -0.25 to -0.31 after the co-payment increase. Estimates were similar across the three models. Conclusion A significant increase in specialty visit co-payments reduced specialty expenditures among patients obtaining medications at the Veterans Affairs medical centers. Longitudinal expenditure analysis may be improved using recent advances in two-part model methods. Published 2011. This article is a US Government work and is in the public domain in the USA.
C1 [Maciejewski, Matthew L.; Kavee, Andrew L.; Olsen, Maren K.] Durham VA Med Ctr, Ctr Hlth Serv Res Primary Care, Durham, NC USA.
[Maciejewski, Matthew L.] Duke Univ, Div Gen Internal Med, Durham, NC USA.
[Liu, Chuan-Fen] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA.
[Liu, Chuan-Fen] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA.
[Olsen, Maren K.] Duke Univ, Dept Biostat & Bioinformat, Durham, NC USA.
RP Maciejewski, ML (reprint author), Durham VA Med Ctr, Ctr Hlth Serv Res Primary Care, 205 Fulton St, Durham, NC USA.
EM mlm34@duke.edu
FU Office of Research and Development, Health Services Research and
Development Service, Department of Veterans Affairs [IIR 03-200];
Department of Veterans Affairs [RCS 10-391]; Novartis; Takeda
Pharmaceuticals; Surgical Review Corporation
FX This work was supported by the Office of Research and Development,
Health Services Research and Development Service, Department of Veterans
Affairs, project number IIR 03-200. Dr Maciejewski was also supported by
a Research Career Scientist award from the Department of Veterans
Affairs (RCS 10-391). The authors are grateful for the helpful comments
from the editor, two reviewers, Jim Burgess, Steve Pizer, Anirban Basu,
Courtney Van Houtven, Santanu Datta, Valerie Smith, and the seminar
participants at the ASA Health Policy Statistics meeting in 2008. Dr
Maciejewski has received consultation funds from Novartis, Takeda
Pharmaceuticals, Surgical Review Corporation, and owns a stock in Amgen.
The views expressed are those of the authors and do not reflect the
views of the Department of Veterans Affairs, the Duke University, or the
University of Washington.
NR 44
TC 3
Z9 3
U1 1
U2 19
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1057-9230
J9 HEALTH ECON
JI Health Econ.
PD AUG
PY 2012
VL 21
IS 8
BP 902
EP 912
DI 10.1002/hec.1759
PG 11
WC Economics; Health Care Sciences & Services; Health Policy & Services
SC Business & Economics; Health Care Sciences & Services
GA 967KT
UT WOS:000305907400002
PM 21755570
ER
PT J
AU Yokoe, DS
Khan, Y
Olsen, MA
Hooper, DC
Greenbaum, M
Vostok, J
Lankiewicz, J
Fraser, VJ
Stevenson, KB
AF Yokoe, Deborah S.
Khan, Yosef
Olsen, Margaret A.
Hooper, David C.
Greenbaum, Maurice
Vostok, Johanna
Lankiewicz, Julie
Fraser, Victoria J.
Stevenson, Kurt B.
CA Ctr Dis Control Prevention
TI Enhanced Surgical Site Infection Surveillance Following Hysterectomy,
Vascular, and Colorectal Surgery
SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
LA English
DT Article
ID CARE-ASSOCIATED INFECTIONS; ADMINISTRATIVE CODING DATA; POSTOPERATIVE
INFECTIONS; IDENTIFICATION
AB OBJECTIVE. To evaluate the use of inpatient pharmacy and administrative data to detect surgical site infections (SSIs) following hysterectomy and colorectal and vascular surgery.
DESIGN. Retrospective cohort study.
SETTING. Five hospitals affiliated with academic medical centers.
PATIENTS. Adults who underwent abdominal or vaginal hysterectomy, colorectal surgery, or vascular surgery procedures between July 1, 2003, and June 30, 2005. methods. We reviewed the medical records of weighted, random samples drawn from 3,079 abdominal and vaginal hysterectomy, 4,748 colorectal surgery, and 3,332 vascular surgery procedures. We compared routine surveillance with screening of inpatient pharmacy data and diagnosis codes and then performed medical record review to confirm SSI status.
RESULTS. Medical records from 823 hysterectomy, 736 colorectal surgery, and 680 vascular surgery procedures were reviewed. SSI rates determined by antimicrobial-and/or diagnosis code-based screening followed by medical record review (enhanced surveillance) were substantially higher than rates determined by routine surveillance (4.3% [95% confidence interval, 3.6%-5.1%] vs 2.7% for hysterectomies, 7.1% [95% confidence interval, 6.7%-8.2%] vs 2.0% for colorectal procedures, and 2.3% [95% confidence interval, 1.9%-2.9%] vs 1.4% for vascular procedures). Enhanced surveillance had substantially higher sensitivity than did routine surveillance to detect SSI (92% vs 59% for hysterectomies, 88% vs 22% for colorectal procedures, and 72% vs 43% for vascular procedures). A review of medical records confirmed SSI for 31% of hysterectomies, 20% of colorectal procedures, and 31% of vascular procedures that met the enhanced screening criteria.
CONCLUSION. Antimicrobial-and diagnosis code-based screening may be a useful method for enhancing and streamlining SSI surveillance for a variety of surgical procedures, including those procedures targeted by the Centers for Medicare and Medicaid Services. Infect Control Hosp Epidemiol 2012;33(8):768-773
C1 [Yokoe, Deborah S.] Brigham & Womens Hosp, Channing Lab, Boston, MA 02115 USA.
[Yokoe, Deborah S.] Brigham & Womens Hosp, Div Infect Dis, Boston, MA 02115 USA.
[Yokoe, Deborah S.; Hooper, David C.] Harvard Univ, Sch Med, Boston, MA USA.
[Khan, Yosef; Stevenson, Kurt B.] Ohio State Univ, Coll Med, Div Infect Dis, Columbus, OH 43210 USA.
[Khan, Yosef; Stevenson, Kurt B.] Ohio State Univ, Div Epidemiol, Coll Publ Hlth, Columbus, OH 43210 USA.
[Olsen, Margaret A.; Fraser, Victoria J.] Washington Univ, Sch Med, Div Infect Dis, St Louis, MO 63110 USA.
[Hooper, David C.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.
[Greenbaum, Maurice] N Shore Med Ctr, Div Infect Dis, Salem, MA USA.
[Vostok, Johanna; Lankiewicz, Julie] Harvard Pilgrim Hlth Care Inst, Boston, MA USA.
[Fraser, Victoria J.] Barnes Jewish Hosp, St Louis, MO 63110 USA.
[Stevenson, Kurt B.] Ohio State Univ, Med Ctr, Dept Clin Epidemiol, Columbus, OH 43210 USA.
RP Yokoe, DS (reprint author), Brigham & Womens Hosp, Channing Lab, 181 Longwood Ave, Boston, MA 02115 USA.
EM dyokoe@partners.org
FU CDC [U01 CI000344, CI000333, CI000328]
FX This study was funded by the CDC Prevention Epicenters Program (U01
CI000344, CI000333, and CI000328).
NR 11
TC 25
Z9 25
U1 0
U2 1
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 0899-823X
J9 INFECT CONT HOSP EP
JI Infect. Control Hosp. Epidemiol.
PD AUG
PY 2012
VL 33
IS 8
BP 768
EP 773
DI 10.1086/666626
PG 6
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA 970CQ
UT WOS:000306106100002
PM 22759543
ER
PT J
AU Shenoy, ES
Walensky, RP
Lee, H
Orcutt, B
Hooper, DC
AF Shenoy, Erica S.
Walensky, Rochelle P.
Lee, Hang
Orcutt, Benjamin
Hooper, David C.
TI Resource Burden Associated with Contact Precautions for
Methicillin-Resistant Staphylococcus aureus and Vancomycin-Resistant
Enterococcus: The Patient Access Managers' Perspective
SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
LA English
DT Article
AB We surveyed patient access managers on the impact of contact precautions (CP) for methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococcus (VRE) on time to bed assignment, and we investigated the factors influencing infection control policies allowing for discontinuation of CP. The majority of respondents reported an increase in time to bed assignment for patients with a history of MRSA and/or VRE infection or colonization. Infect Control Hosp Epidemiol 2012;33(8):849-852
C1 [Shenoy, Erica S.; Walensky, Rochelle P.; Hooper, David C.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.
[Shenoy, Erica S.; Hooper, David C.] Massachusetts Gen Hosp, Infect Control Unit, Boston, MA 02114 USA.
[Walensky, Rochelle P.] Harvard Univ, Sch Med, Ctr AIDS Res, Boston, MA USA.
[Lee, Hang] Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA.
[Orcutt, Benjamin] Massachusetts Gen Hosp, Admitting Serv, Boston, MA 02114 USA.
RP Shenoy, ES (reprint author), Massachusetts Gen Hosp, Div Infect Dis, 55 Fruit St,Bulfinch 340, Boston, MA 02114 USA.
EM eseiguershenoy@partners.org
OI Walensky, Rochelle P./0000-0002-8795-379X
FU National Institutes of Health (NIH) [T32 A107061]; MGH Clinical
Innovation Award; Harvard Catalyst (NIH) [UL1 RR 025758]; Harvard
University and its affiliated academic healthcare centers
FX E.S.S. was supported by the National Institutes of Health (NIH; grant
T32 A107061) and a 2010 MGH Clinical Innovation Award. H. L. was
supported by Harvard Catalyst (NIH Award UL1 RR 025758 and financial
contributions from Harvard University and its affiliated academic
healthcare centers).
NR 8
TC 11
Z9 12
U1 2
U2 8
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 0899-823X
J9 INFECT CONT HOSP EP
JI Infect. Control Hosp. Epidemiol.
PD AUG
PY 2012
VL 33
IS 8
BP 849
EP 852
DI 10.1086/666629
PG 4
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA 970CQ
UT WOS:000306106100014
PM 22759555
ER
PT J
AU Faris, JE
Arnott, J
Zheng, H
Ryan, DP
Abrams, TA
Blaszkowsky, LS
Clark, JW
Enzinger, PC
Hezel, AF
Ng, K
Wolpin, BM
Kwak, EL
AF Faris, Jason E.
Arnott, Jamie
Zheng, Hui
Ryan, David P.
Abrams, Thomas A.
Blaszkowsky, Lawrence S.
Clark, Jeffrey W.
Enzinger, Peter C.
Hezel, Aram F.
Ng, Kimmie
Wolpin, Brian M.
Kwak, Eunice L.
TI A phase 2 study of oral MKC-1, an inhibitor of importin-beta, tubulin,
and the mTOR pathway in patients with unresectable or metastatic
pancreatic cancer
SO INVESTIGATIONAL NEW DRUGS
LA English
DT Article
DE Pancreatic cancer; Phase II; MKC-1; Importin; Tubulin
ID SOLID TUMORS; III TRIAL; GEMCITABINE; CARCINOMA; THERAPY; PLACEBO
AB Background MKC-1 is an orally available cell cycle inhibitor with downstream targets that include tubulin and the importin-beta family. We conducted an open-label Phase II study with MKC-1 in patients with advanced pancreatic cancer. Methods Eligibility criteria included unresectable or metastatic pancreatic cancer, performance status of 1 or better, and failure of at least one prior regimen of chemotherapy. MKC-1 was administered orally, twice daily, initially at 100 mg/m(2) dosing for 14 consecutive days of a 28-day cycle. This schedule was modified during the trial to fixed and continuous dosing of 150 mg per day. Results 20 of an original target of 33 patients were accrued, with a median age of 61 (range 44-81). No objective responses were observed, with one patient demonstrating stable disease. Overall survival was 101 days from the start of MKC-1 administration, and median time to progression was 42 days. The most common adverse events listed as related or possibly related to MKC-1 administration were hematologic toxicities and fatigue. One patient developed grade 5 (fatal) pancytopenia. Grade 3 and 4 events included cytopenias (lymphopenia, anemia), hyperbilirubinemia, pneumonia, mucositis, fatigue, infusion reaction, anorexia, and hypoalbuminemia. Conclusions MKC-1 administration was associated with substantial toxicity and did not demonstrate sufficient activity in patients with advanced pancreatic cancer to justify further exploration in this patient population.
C1 [Faris, Jason E.; Ryan, David P.; Blaszkowsky, Lawrence S.; Clark, Jeffrey W.; Kwak, Eunice L.] Massachusetts Gen Hosp, Dept Med Oncol, Ctr Canc, Boston, MA 02114 USA.
[Zheng, Hui] Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA.
[Arnott, Jamie] Entremed Inc, Durham, NC USA.
[Abrams, Thomas A.; Enzinger, Peter C.; Ng, Kimmie; Wolpin, Brian M.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Hezel, Aram F.] Univ Rochester, Sch Med, James P Wilmot Canc Ctr, Rochester, NY 14642 USA.
RP Kwak, EL (reprint author), Massachusetts Gen Hosp, Dept Med Oncol, Ctr Canc, Yawkey 7E, Boston, MA 02114 USA.
EM ekwak@partners.org
FU NCI NIH HHS [K07 CA140790, K07 CA148894]
NR 17
TC 5
Z9 5
U1 0
U2 4
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0167-6997
EI 1573-0646
J9 INVEST NEW DRUG
JI Invest. New Drugs
PD AUG
PY 2012
VL 30
IS 4
BP 1614
EP 1620
DI 10.1007/s10637-011-9708-3
PG 7
WC Oncology; Pharmacology & Pharmacy
SC Oncology; Pharmacology & Pharmacy
GA 968CT
UT WOS:000305955300037
PM 21800081
ER
PT J
AU Ozanne, EM
O'Connell, A
Bouzan, C
Bosinoff, P
Rourke, T
Dowd, D
Drohan, B
Millham, F
Griffin, P
Halpern, EF
Semine, A
Hughes, KS
AF Ozanne, Elissa M.
O'Connell, Adrienne
Bouzan, Colleen
Bosinoff, Phil
Rourke, Taryn
Dowd, Dana
Drohan, Brian
Millham, Fred
Griffin, Pat
Halpern, Elkan F.
Semine, Alan
Hughes, Kevin S.
TI Bias in the Reporting of Family History: Implications for Clinical Care
SO JOURNAL OF GENETIC COUNSELING
LA English
DT Article
DE Cancer; Family history; Self-reporting; Data collection
ID BREAST-CANCER; OVARIAN-CANCER; GENETIC RISK; POPULATION; MANAGEMENT;
COMMUNICATION; PREVALENCE; VALIDATION; HEALTH; WOMEN
AB Family history of cancer is critical for identifying and managing patients at risk for cancer. However, the quality of family history data is dependent on the accuracy of patient self reporting. Therefore, the validity of family history reporting is crucial to the quality of clinical care. A retrospective review of family history data collected at a community hospital between 2005 and 2009 was performed in 43,257 women presenting for screening mammography. Reported numbers of breast, colon, prostate, lung, and ovarian cancer were compared in maternal relatives vs. paternal relatives and in first vs. second degree relatives. Significant reporting differences were found between maternal and paternal family history of cancer, in addition to degree of relative. The number of paternal family histories of cancer was significantly lower than that of maternal family histories of cancer. Similarly, the percentage of grandparents' family histories of cancer was significantly lower than the percentage of parents' family histories of cancer. This trend was found in all cancers except prostate cancer. Self-reported family history in the community setting is often influenced by both bloodline of the cancer history and the degree of relative affected. This is evident by the underreporting of paternal family histories of cancer, and also, though to a lesser extent, by degree. These discrepancies in reporting family history of cancer imply we need to take more care in collecting accurate family histories and also in the clinical management of individuals in relation to hereditary risk.
C1 [Hughes, Kevin S.] Massachusetts Gen Hosp, Div Surg Oncol, Boston, MA 02114 USA.
[Halpern, Elkan F.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Inst Technol Assessment, Boston, MA USA.
[Hughes, Kevin S.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Avon Breast Evaluat Ctr,Newton Wellesley Hosp, Boston, MA USA.
[Hughes, Kevin S.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Surg,Newton Wellesley Hosp, Boston, MA USA.
[Ozanne, Elissa M.] Univ Calif San Francisco, Dept Surg, Inst Hlth Policy Studies, San Francisco, CA USA.
RP Hughes, KS (reprint author), Massachusetts Gen Hosp, Div Surg Oncol, 55 Fruit St,YAW 7, Boston, MA 02114 USA.
EM elissa.ozanne@ucsfmedctr.org; kshughes@partners.org
OI Hughes, Kevin/0000-0003-4084-6484
FU MGH; Sandra Perrin Fund for Women's Imaging Education at Newton
Wellesley Hospital; American Cancer Society [MRSG112037]
FX Supported by Philanthropic Funds from the MGH and the Sandra Perrin Fund
for Women's Imaging Education at Newton Wellesley Hospital. E. Ozanne's
work on this project was supported in part by grant number MRSG112037
from the American Cancer Society
NR 33
TC 16
Z9 16
U1 1
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1059-7700
J9 J GENET COUNS
JI J. Genet. Couns.
PD AUG
PY 2012
VL 21
IS 4
BP 547
EP 556
DI 10.1007/s10897-011-9470-x
PG 10
WC Genetics & Heredity
SC Genetics & Heredity
GA 967MV
UT WOS:000305913200008
PM 22237666
ER
PT J
AU Saadi, A
Bond, B
Percac-Lima, S
AF Saadi, Altaf
Bond, Barbara
Percac-Lima, Sanja
TI Perspectives on Preventive Health Care and Barriers to Breast Cancer
Screening Among Iraqi Women Refugees
SO JOURNAL OF IMMIGRANT AND MINORITY HEALTH
LA English
DT Article
DE Refugees; Immigrants; Arab; Breast cancer screening; Preventive health
ID UNITED-STATES; IMMIGRANT WOMEN; AMERICAN WOMEN; BELIEFS; BEHAVIORS;
KNOWLEDGE; ATTITUDES; ETHNICITY; SURVIVAL
AB Since the Iraq war began in 2003, over 4 million Iraqis have been displaced. Little is known about preventive cancer care in this population, but stark disparities have been documented. The purpose of this study was to assess the perspectives of Iraqi women refugees on preventive care and perceived barriers to breast cancer screening. Interviews were conducted in Arabic with twenty Iraqi refugee women by a bilingual (English/Arabic) medical student, transcribed, translated and coded according to established qualitative content and thematic analysis procedures. Psychosocial barriers, culturally mediated beliefs, and health consequences of war were identified as major themes, ultimately showing what factors, alone and collectively, have impeded Iraqi refugee women's ability and motivation to obtain breast cancer screening. To improve cancer prevention and decrease disparities in care in this most vulnerable population, culturally appropriate health education and outreach programs, as well as further community-level targeted studies, are needed.
C1 [Saadi, Altaf] Harvard Univ, Sch Med, Boston, MA 02150 USA.
[Bond, Barbara] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
[Bond, Barbara] Bridgewater State Univ, Dept Social Work, Bridgewater, MA 02325 USA.
[Percac-Lima, Sanja] MGH, Chelsea HealthCare Ctr, Chelsea, MA 02150 USA.
RP Saadi, A (reprint author), Harvard Univ, Sch Med, 260 Longwood Ave, Boston, MA 02150 USA.
EM altaf_saadi@hms.harvard.edu; bbond@partners.org;
spercaclima@partners.org
FU AHRQ HHS [1R18 HS019161-01]
NR 32
TC 7
Z9 7
U1 1
U2 7
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1557-1912
J9 J IMMIGR MINOR HEALT
JI J. Immigr. Minor. Health
PD AUG
PY 2012
VL 14
IS 4
BP 633
EP 639
DI 10.1007/s10903-011-9520-3
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 967MZ
UT WOS:000305913600015
PM 21901446
ER
PT J
AU Percac-Lima, S
Milosavljevic, B
Oo, SA
Marable, D
Bond, B
AF Percac-Lima, Sanja
Milosavljevic, Bosiljka
Oo, Sarah Abernethy
Marable, Danelle
Bond, Barbara
TI Patient Navigation to Improve Breast Cancer Screening in Bosnian
Refugees and Immigrants
SO JOURNAL OF IMMIGRANT AND MINORITY HEALTH
LA English
DT Article
DE Refugees; Breast cancer; Mammograms; Patient navigation
ID HEALTH
AB Refugee women have low breast cancer screening rates. This study highlights the culturally competent implementation and reports the outcomes of a breast cancer screening patient navigation program for refuge/immigrant women from Bosnia. Refugees/immigrant women from Bosnia age 40-79 were contacted by a Serbo-Croatian speaking patient navigator who addressed patient-reported barriers to breast cancer screening and, using individually tailored interventions, helped women obtain screening. The proportion of women up-to-date for mammography was compared at baseline and after 1-year using McNemar's Chi-Square test. 91 Serbo-Croatian speaking women were eligible for mammography screening. At baseline, 44.0% of women had a mammogram within the previous year, with the proportion increasing to 67.0% after 1-year (P = 0.001). A culturally-tailored, language-concordant navigator program designed to overcome specific barriers to breast cancer screening can significantly improve mammography rates in refugees/immigrants.
C1 [Percac-Lima, Sanja; Milosavljevic, Bosiljka; Oo, Sarah Abernethy] Massachusetts Gen Hosp, Chelsea HealthCare Ctr, Chelsea, MA 02150 USA.
[Percac-Lima, Sanja; Milosavljevic, Bosiljka; Oo, Sarah Abernethy; Marable, Danelle] Massachusetts Gen Hosp, Ctr Community Hlth Improvement, Boston, MA 02114 USA.
[Percac-Lima, Sanja] Massachusetts Gen Hosp, Dept Med, Div Gen Med, Boston, MA 02114 USA.
[Percac-Lima, Sanja] Harvard Univ, Sch Med, Boston, MA USA.
[Bond, Barbara] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
RP Percac-Lima, S (reprint author), Massachusetts Gen Hosp, Chelsea HealthCare Ctr, 151 Everett Ave, Chelsea, MA 02150 USA.
EM spercaclima@partners.org
FU AHRQ HHS [1R18 HS019161-01]
NR 10
TC 10
Z9 10
U1 0
U2 7
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1557-1912
J9 J IMMIGR MINOR HEALT
JI J. Immigr. Minor. Health
PD AUG
PY 2012
VL 14
IS 4
BP 727
EP 730
DI 10.1007/s10903-011-9539-5
PG 4
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 967MZ
UT WOS:000305913600027
PM 22009215
ER
PT J
AU Fields, EC
Kuperberg, GR
AF Fields, Eric C.
Kuperberg, Gina R.
TI It's All About You: An ERP Study of Emotion and Self-Relevance in
Discourse
SO NEUROIMAGE
LA English
DT Article
DE Emotion; Event-related Potentials; Language; Late positive potential;
Self-relevance; Perspective
ID NEGATIVITY BIAS; NEURAL MECHANISMS; VISUAL-ATTENTION; POSITIVITY BIAS;
STROOP TASK; STIMULI; NAME; FACE; VALENCE; BRAIN
AB Accurately communicating self-relevant and emotional information is a vital function of language, but we have little idea about how these factors impact normal discourse comprehension. In an event-related potential (ERP) study, we fully crossed self-relevance and emotion in a discourse context. Two-sentence social vignettes were presented either in the third or the second person (previous work has shown that this influences the perspective from which mental models are built). ERPs were time-locked to a critical word toward the end of the second sentence which was pleasant, neutral, or unpleasant (e.g., A man knocks on Sandra's/your hotel room door. She/You see(s) that he has a gift/tray/gun in his hand.). We saw modulation of early components (P1, N1, and P2) by self-relevance, suggesting that a self-relevant context can lead to top-down attentional effects during early stages of visual processing. Unpleasant words evoked a larger late positivity than pleasant words, which evoked a larger positivity than neutral words, indicating that, regardless of self-relevance, emotional words are assessed as motivationally significant, triggering additional or deeper processing at post-lexical stages. Finally, self-relevance and emotion interacted on the late positivity: a larger late positivity was evoked by neutral words in self-relevant, but not in non-self-relevant, contexts. This may reflect prolonged attempts to disambiguate the emotional valence of ambiguous stimuli that are relevant to the self. More broadly, our findings suggest that the assessment of emotion and self-relevance are not independent, but rather that they interactively influence one another during word-by-word language comprehension. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Fields, Eric C.] Tufts Univ, Dept Psychol, Medford, MA 02155 USA.
MGH HST Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA.
Massachusetts Gen Hosp, Dept Psychiat, Charlestown, MA USA.
RP Fields, EC (reprint author), Tufts Univ, Dept Psychol, 490 Boston Ave, Medford, MA 02155 USA.
EM Eric.Fields@tufts.edu
FU NIMH [R01 MH071635]; NARSAD; Sidney Baer Trust
FX This work was supported was supported by NIMH (R01 MH071635) and NARSAD
(with the Sidney Baer Trust) grants to Gina Kuperberg. We extend a big
thanks to Wonja Fairbrother for her help with stimuli creation, data
collection, and data analysis. We also thank Sorabh Kothari for his help
with stimuli norming and analysis and Nate Delaney-Busch for comments on
the manuscript and helpful conversations about these topics.
NR 82
TC 37
Z9 39
U1 10
U2 40
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1053-8119
J9 NEUROIMAGE
JI Neuroimage
PD AUG 1
PY 2012
VL 62
IS 1
BP 562
EP 574
DI 10.1016/j.neuroimage.2012.05.003
PG 13
WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical
Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA 966TC
UT WOS:000305859300054
PM 22584232
ER
PT J
AU Castro, NJ
Hacking, SA
Zhang, LG
AF Castro, Nathan J.
Hacking, S. Adam
Zhang, Lijie Grace
TI Recent Progress in Interfacial Tissue Engineering Approaches for
Osteochondral Defects
SO ANNALS OF BIOMEDICAL ENGINEERING
LA English
DT Article
DE Tissue engineering; Bone; Cartilage; Osteochondral; Interface;
Biomimetic; Nanotechnology
ID MESENCHYMAL STEM-CELLS; SCAFFOLD-FREE CARTILAGE; MARROW STROMAL CELLS;
BOVINE ARTICULAR-CARTILAGE; MUSCLE-DERIVED CELLS; GAS-FORMING AGENT;
SUBCHONDRAL BONE; PROGENITOR CELLS; GROWTH-FACTOR; IN-VITRO
AB This review provides a brief synopsis of the anatomy and physiology of the osteochondral interface, scaffold-based and non-scaffold based approaches for engineering both tissues independently as well as recent developments in the manufacture of gradient constructs. Novel manufacturing techniques and nanotechnology will be discussed with potential application in osteochondral interfacial tissue engineering.
C1 [Castro, Nathan J.; Zhang, Lijie Grace] George Washington Univ, Inst Biomed Engn, Dept Mech & Aerosp Engn, Washington, DC 20052 USA.
[Castro, Nathan J.; Zhang, Lijie Grace] George Washington Univ, Inst Nanotechnol, Washington, DC 20052 USA.
[Hacking, S. Adam] Massachusetts Gen Hosp, Dept Orthopaed, Boston, MA 02114 USA.
[Hacking, S. Adam] Harvard Univ, Sch Med, Boston, MA 02114 USA.
RP Zhang, LG (reprint author), George Washington Univ, Inst Biomed Engn, Dept Mech & Aerosp Engn, 726 Phillips Hall,801 22nd St NW, Washington, DC 20052 USA.
EM lgzhang@gwu.edu
FU George Washington University Facilitating Fund (UFF); Oak Ridge
Associated Universities (ORAU) organization
FX The authors would like to thank the financial support from the George
Washington University Facilitating Fund (UFF) and Ralph E. Powe Junior
Faculty Enhancement Award by the Oak Ridge Associated Universities
(ORAU) organization.
NR 124
TC 44
Z9 46
U1 3
U2 42
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0090-6964
J9 ANN BIOMED ENG
JI Ann. Biomed. Eng.
PD AUG
PY 2012
VL 40
IS 8
BP 1628
EP 1640
DI 10.1007/s10439-012-0605-5
PG 13
WC Engineering, Biomedical
SC Engineering
GA 965VK
UT WOS:000305795200002
PM 22677924
ER
PT J
AU Hegedus, C
Truta-Feles, K
Antalffy, G
Varady, G
Nemet, K
Ozvegy-Laczka, C
Keri, G
Orfi, L
Szakacs, G
Settleman, J
Varadi, A
Sarkadi, B
AF Hegedues, Csilla
Truta-Feles, Krisztina
Antalffy, Geza
Varady, Gyoergy
Nemet, Katalin
Oezvegy-Laczka, Csilla
Keri, Gyoergy
Orfi, Laszlo
Szakacs, Gergely
Settleman, Jeffrey
Varadi, Andras
Sarkadi, Balazs
TI Interaction of the EGFR inhibitors gefitinib, vandetanib, pelitinib and
neratinib with the ABCG2 multidrug transporter: Implications for the
emergence and reversal of cancer drug resistance
SO BIOCHEMICAL PHARMACOLOGY
LA English
DT Article
DE ABCG2; Multidrug resistance; Receptor tyrosine kinase; EGFR inhibitor;
Cancer stem cell
ID GROWTH-FACTOR RECEPTOR; TYROSINE KINASE INHIBITORS; SIDE-POPULATION
PHENOTYPE; STEM-CELLS; MONOCLONAL-ANTIBODY; LUNG-CANCER;
ACQUIRED-RESISTANCE; EXPRESSION; TUMORS; ZD6474
AB Human ABCG2 is a plasma membrane glycoprotein that provides physiological protection against xenobiotics. ABCG2 also significantly influences biodistribution of drugs through pharmacological tissue barriers and confers multidrug resistance to cancer cells. Moreover, ABCG2 is the molecular determinant of the side population that is characteristically enriched in normal and cancer stem cells. Numerous tumors depend on unregulated EGFR signaling, thus inhibition of this receptor by small molecular weight inhibitors such as gefitinib, and the novel second generation agents vandetanib, pelitinib and neratinib, is a promising therapeutic option. In the present study, we provide detailed biochemical characterization regarding the interaction of these EGFR inhibitors with ABCG2. We show that ABCG2 confers resistance to gefitinib and pelitinib, whereas the intracellular action of vandetanib and neratinib is unaltered by the presence of the transporter. At higher concentrations, however, all these EGFR inhibitors inhibit ABCG2 function, thereby promoting accumulation of ABCG2 substrate drugs. We also report enhanced expression of ABCG2 in gefitinib-resistant non-small cell lung cancer cells, suggesting potential clinical relevance of ABCG2 in acquired drug resistance. Since ABCG2 has important impact on both the pharmacological properties and anti-cancer efficiencies of drugs, our results regarding the novel EGFR inhibitors should provide useful information about their therapeutic applicability against ABCG2-expressing cancer cells depending on EGFR signaling. In addition, the finding that these EGFR inhibitors efficiently block ABCG2 function may help to design novel drug-combination therapeutic strategies. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Hegedues, Csilla; Truta-Feles, Krisztina; Antalffy, Geza; Varady, Gyoergy; Nemet, Katalin; Oezvegy-Laczka, Csilla; Sarkadi, Balazs] Semmelweis Univ, Dept Biophys, Hungarian Acad Sci, Membrane Res Grp, H-1113 Budapest, Hungary.
[Keri, Gyoergy] Semmelweis Univ, Dept Med Chem, Hungarian Acad Sci, Pathobiochem Res Grp, H-1113 Budapest, Hungary.
[Hegedues, Csilla; Truta-Feles, Krisztina; Antalffy, Geza; Varady, Gyoergy; Nemet, Katalin; Oezvegy-Laczka, Csilla; Sarkadi, Balazs] Natl Blood Ctr, Budapest, Hungary.
[Keri, Gyoergy; Orfi, Laszlo] VICHEM Chem Res Ltd, Budapest, Hungary.
[Orfi, Laszlo] Semmelweis Univ, Dept Pharmaceut Chem, H-1113 Budapest, Hungary.
[Szakacs, Gergely; Varadi, Andras] Hungarian Acad Sci, Inst Enzymol, Res Ctr Nat Sci, Budapest, Hungary.
[Settleman, Jeffrey] Massachusetts Gen Hosp, Ctr Canc, Ctr Mol Therapeut, Charlestown, MA USA.
[Sarkadi, Balazs] Hungarian Acad Sci, Inst Mol Pharmacol, Res Ctr Nat Sci, Budapest, Hungary.
RP Sarkadi, B (reprint author), Semmelweis Univ, Dept Biophys, Hungarian Acad Sci, Membrane Res Grp, Dioszegi U 64, H-1113 Budapest, Hungary.
EM csilla.hegedus@biomembrane.hu; kristina_feles@yahoo.se;
antalffy@biomembrane.hu; varady@biomembrane.hu; nemet@biomembrane.hu;
lozvegy@biomembrane.hu; gykeri@vichem.hu; lorfi@vichem.hu;
szakacs@biomembrane.hu; settleman.jeffrey@gene.com; varadi@enzim.hu;
sarkadi@biomembrane.hu
RI Szakacs, Gergely/A-2580-2009; Orfi, Laszlo/A-2116-2008; Sarkadi,
Balazs/I-5024-2013
OI Szakacs, Gergely/0000-0002-9311-7827; Orfi, Laszlo/0000-0001-6149-2385;
FU OTKA [NK83533, KMOP-1.1.2-07/1-2008-0003]; NKTH-ANR and Stemkill;
Hungarian Academy of Sciences
FX The technical help of Gyongyi Bezsenyi, Eva Krizsan and Zsuzsanna
Andrasi is greatly appreciated. This work has been supported by grants
from OTKA NK83533, KMOP-1.1.2-07/1-2008-0003, and NKTH-ANR and Stemkill.
Csilla ozvegy-Laczka is a recipient of the Jdnos Bolyai Scholarship of
the Hungarian Academy of Sciences. Gergely Szakacs is supported by the
Lendtilet grant from the Hungarian Academy of Sciences.
NR 48
TC 26
Z9 28
U1 1
U2 21
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0006-2952
EI 1873-2968
J9 BIOCHEM PHARMACOL
JI Biochem. Pharmacol.
PD AUG 1
PY 2012
VL 84
IS 3
BP 260
EP 267
DI 10.1016/j.bcp.2012.04.010
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 962LI
UT WOS:000305546200003
PM 22548830
ER
PT J
AU McDermott, PJ
Baicu, CF
Wahl, SR
Van Laer, AO
Zile, MR
AF McDermott, Paul J.
Baicu, Catalin F.
Wahl, Shaun R.
Van Laer, An O.
Zile, Michael R.
TI In vivo measurements of the contributions of protein synthesis and
protein degradation in regulating cardiac pressure overload hypertrophy
in the mouse
SO MOLECULAR AND CELLULAR BIOCHEMISTRY
LA English
DT Article
DE Myocardium; Amino acids; Infusion; Inbred C57BL mice
ID MYOSIN HEAVY-CHAIN; VENTRICULAR HYPERTROPHY; VOLUME OVERLOAD; MICE;
TURNOVER; CANINE; HEART; DYSFUNCTION; MECHANISMS; PROTEASOME
AB Cardiac hypertrophy is generated in response to hemodynamic overload by altering steady-state protein metabolism such that the rate of protein synthesis exceeds the rate of protein degradation. To determine the relative contributions of protein synthesis and degradation in regulating cardiac hypertrophy in mice, a continuous infusion strategy was developed to measure myocardial protein synthesis rates in vivo. Osmotic mini-pumps were implanted in the abdominal cavity to infuse radiolabeled leucine in mice that are conscious and ambulatory. Protein synthesis rates were calculated by measuring incorporation of leucine into myocardial protein over 24 h prior to each time point and dividing by the specific radioactivity of plasma leucine. Compared to sham-operated controls, fractional rates of protein synthesis (K (s)) increased significantly at days 1 and 3 of TAC, but was lower on day 7 and returned to control values by day 14. These changes coincided with the curvilinear increase in LV mass that characterizes the hypertrophic response. Fractional rates of protein degradation (K (d)) were calculated by subtracting the rate of myocardial growth from the corresponding K (s) value. K (d) fell at days 1 and 3 of TAC, increased at day 7 and returned to control on day 14. Thus, the increase in LV mass generated in response to pressure overload is caused by acceleration of K (s) and suppression of K (d). As the growth rate slows, a new steady-state is achieved once the hypertrophic response is completed.
C1 [McDermott, Paul J.; Baicu, Catalin F.; Wahl, Shaun R.; Van Laer, An O.; Zile, Michael R.] Med Univ S Carolina, Gazes Cardiac Res Inst, Dept Med, Charleston, SC 29403 USA.
[McDermott, Paul J.; Baicu, Catalin F.; Wahl, Shaun R.; Van Laer, An O.; Zile, Michael R.] Vet Affairs Med Ctr, Ralph H Johnson Dept, Charleston, SC 29403 USA.
RP McDermott, PJ (reprint author), Med Univ S Carolina, Gazes Cardiac Res Inst, Dept Med, Strom Thurmond Biomed Res Bldg,Room 303,114 Dough, Charleston, SC 29403 USA.
EM mcdermp@musc.edu
FU Department of Veterans Affairs
FX We thank Daisy Dominick and Dr. Harinath Kasiganesan for their excellent
technical assistance, and Dr. Francis G. Spinale for his help using
osmotic mini-pumps. This work was supported by Merit Review Awards (P.
J. McDermott and M. R. Zile) from the Health Services Research and
Development Program of the Department of Veterans Affairs.
NR 24
TC 0
Z9 0
U1 0
U2 3
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0300-8177
J9 MOL CELL BIOCHEM
JI Mol. Cell. Biochem.
PD AUG
PY 2012
VL 367
IS 1-2
BP 205
EP 213
DI 10.1007/s11010-012-1334-7
PG 9
WC Cell Biology
SC Cell Biology
GA 964GX
UT WOS:000305683100021
PM 22610791
ER
PT J
AU Grigoriev, Y
Lange, J
Peterson, SM
Takashima, JR
Ritchey, ML
Ko, D
Feusner, JH
Shamberger, RC
Green, DM
Breslow, NE
AF Grigoriev, Yevgeny
Lange, Jane
Peterson, Susan M.
Takashima, Janice R.
Ritchey, Michael L.
Ko, Dicken
Feusner, James H.
Shamberger, Robert C.
Green, Daniel M.
Breslow, Norman E.
TI Treatments and outcomes for end-stage renal disease following Wilms
tumor
SO PEDIATRIC NEPHROLOGY
LA English
DT Article
DE Chronic kidney failure; Transplantation; Graft failure
ID DENYS-DRASH-SYNDROME; KIDNEY-TRANSPLANTATION; CANCER-RISK; DISPARITIES;
RECIPIENTS; SURVIVAL; CHILDREN
AB Little is known about treatment outcomes for children who have end-stage renal disease (ESRD) after treatment for Wilms tumor (WT).
Time-to-transplant, graft failure, and survival outcomes were examined for 173 children enrolled on the National Wilms Tumor Study who developed ESRD.
Fifty-five patients whose ESRD resulted from progressive bilateral WT (PBWT) experienced high early mortality from WT that limited their opportunity for transplant (47% at 5 years) and survival (44% at 10 years) in comparison to population controls. The 118 patients whose ESRD was due to other causes (termed "chronic kidney disease"), many of whom had WT-associated congenital anomalies, had transplant (77% at 5 years) and survival (73% at 10 years) outcomes no worse than those for population controls. Graft failure following transplant was comparable for the two groups. Minority children had twice the median time to transplant as non-Hispanic whites and twice the mortality rates, also reflecting population trends.
In view of the continuing high mortality in patients with ESRD, and the dramatic improvement in outlook following kidney transplantation, re-evaluation of current guidelines for a 2-year delay in transplant following WT treatment may be warranted.
C1 [Lange, Jane; Breslow, Norman E.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
[Grigoriev, Yevgeny; Peterson, Susan M.; Takashima, Janice R.; Breslow, Norman E.] Fred Hutchinson Canc Res Ctr, Dept Biostat & Bioinformat, Seattle, WA 98104 USA.
[Ritchey, Michael L.] Phoenix Childrens Hosp, Dept Urol, Phoenix, AZ USA.
[Ko, Dicken] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA.
[Ko, Dicken] Massachusetts Gen Hosp, Dept Urol, Boston, MA 02114 USA.
[Ko, Dicken] Massachusetts Gen Hosp, Dept Pediat Surg, Boston, MA 02114 USA.
[Feusner, James H.] Childrens Hosp, Dept Hematol Oncol, Oakland, CA 94609 USA.
[Feusner, James H.] Res Ctr Oakland, Oakland, CA USA.
[Shamberger, Robert C.] Childrens Hosp, Dept Surg, Boston, MA 02115 USA.
[Green, Daniel M.] St Jude Childrens Res Hosp, Dept Epidemiol & Canc Control, Memphis, TN 38105 USA.
RP Breslow, NE (reprint author), Univ Washington, Dept Biostat, Mail Stop 357232, Seattle, WA 98195 USA.
EM norm@u.washington.edu
FU United States National Cancer Institute [CA054498]
FX This study was supported in part by grant CA054498 from the United
States National Cancer Institute. We thank investigators of the
Children's Oncology Group and the health professionals who managed the
care of children entered in the National Wilms Tumor Study.
NR 29
TC 9
Z9 9
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0931-041X
EI 1432-198X
J9 PEDIATR NEPHROL
JI Pediatr. Nephrol.
PD AUG
PY 2012
VL 27
IS 8
BP 1325
EP 1333
DI 10.1007/s00467-012-2140-x
PG 9
WC Pediatrics; Urology & Nephrology
SC Pediatrics; Urology & Nephrology
GA 964GS
UT WOS:000305682600014
PM 22430485
ER
PT J
AU Jaremko, JL
MacMahon, PJ
Torriani, M
Merker, VL
Mautner, VF
Plotkin, SR
Bredella, MA
AF Jaremko, Jacob L.
MacMahon, Peter J.
Torriani, Martin
Merker, Vanessa L.
Mautner, Victor F.
Plotkin, Scott R.
Bredella, Miriam A.
TI Whole-body MRI in neurofibromatosis: incidental findings and prevalence
of scoliosis
SO SKELETAL RADIOLOGY
LA English
DT Article
DE Whole-body MRI (WBMRI); Neurofibromatosis; Incidental findings
ID IDIOPATHIC SCOLIOSIS; SPINAL DEFORMITY; TUMOR BURDEN; SCHWANNOMATOSIS
AB To demonstrate incidental findings and scoliosis on whole-body MRI (WBMRI) in patients with neurofibromatosis type 1 and 2 (NF1 & NF2, respectively), and schwannomatosis.
Institutional review board approval and written informed consent were obtained for this prospective HIPAA-compliant study. A total of 247 subjects (141 with NF1, 55 with NF2, 51 with schwannomatosis; 132 women (53.5%); mean age, 41 years, range, 18-97 years) underwent WBMRI using coronal STIR (TR/TE: 4190/111 ms, TI: 150 ms) and T1-weighted images (TR/TE: 454/10 ms), 10-mm slice thickness, imaging time similar to 40 min. Images were reviewed for the presence of incidental findings, outside of nerve sheath tumors. The presence of scoliosis was recorded and curve morphology was assessed and quantified.
Incidental findings other than scoliosis were recorded in 104/247 (42%) patients, most often affecting the musculoskeletal system (65/247 patients, 26%). We found 16/247 (6.5%) significant incidental findings likely to affect clinical management, including avascular necrosis of bone in eight patients (five with NF2), eight insufficiency fractures, and four non-neurogenic neoplasms (Hodgkin's lymphoma, liposarcoma, dermoid cyst, large uterine myoma requiring excision). Scoliosis was seen in 50/247 patients (20%), including 8/55 with NF2 (15%) and 11/51 with schwannomatosis (22%).
Incidental findings in the neurofibromatoses frequently involve the skeleton. Given the relatively high incidence of unsuspected osteonecrosis and stress fractures, close attention to the skeleton on WBMRI is advised. In addition, knowledge of common incidental findings can help clinicians prepare patients who undergo WBMRI for potential unexpected findings.
C1 [Jaremko, Jacob L.; MacMahon, Peter J.; Torriani, Martin; Bredella, Miriam A.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
[Jaremko, Jacob L.; MacMahon, Peter J.; Torriani, Martin; Bredella, Miriam A.] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Merker, Vanessa L.; Plotkin, Scott R.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
[Merker, Vanessa L.; Plotkin, Scott R.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
[Mautner, Victor F.] Univ Med Ctr Hamburg Eppendorf, Dept Neurol, Hamburg, Germany.
RP Bredella, MA (reprint author), Massachusetts Gen Hosp, Dept Radiol, Yawkey 6E,55 Fruit St, Boston, MA 02114 USA.
EM mbredella@partners.org
OI Merker, Vanessa/0000-0002-4542-5227
FU Department of Defense Neurofibromatosis Research Program [NF0502020];
NIH/NINDS [P01NS024279]
FX Department of Defense Neurofibromatosis Research Program (NF0502020) and
the NIH/NINDS (P01NS024279).
NR 22
TC 9
Z9 10
U1 2
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0364-2348
J9 SKELETAL RADIOL
JI Skeletal Radiol.
PD AUG
PY 2012
VL 41
IS 8
BP 917
EP 923
DI 10.1007/s00256-011-1333-x
PG 7
WC Orthopedics; Radiology, Nuclear Medicine & Medical Imaging
SC Orthopedics; Radiology, Nuclear Medicine & Medical Imaging
GA 962HM
UT WOS:000305533800004
PM 22146869
ER
PT J
AU Ramdhian-Wihlm, R
Le Minor, JM
Schmittbuhl, M
Jeantroux, J
Mac Mahon, P
Veillon, F
Dosch, JC
Dietemann, JL
Bierry, G
AF Ramdhian-Wihlm, Reeta
Le Minor, Jean-Marie
Schmittbuhl, Matthieu
Jeantroux, Jeremy
Mac Mahon, Peter
Veillon, Francis
Dosch, Jean-Claude
Dietemann, Jean-Louis
Bierry, Guillaume
TI Cone-beam computed tomography arthrography: an innovative modality for
the evaluation of wrist ligament and cartilage injuries
SO SKELETAL RADIOLOGY
LA English
DT Article
DE Cone beam computed tomography; Wrist; Ligaments; Cartilage
ID TRIANGULAR FIBROCARTILAGE COMPLEX; MR ARTHROGRAPHY; CT ARTHROGRAPHY;
IMAGE QUALITY; MULTISLICE; EXPERIENCE; DIAGNOSIS; LANDMARKS; SYSTEM;
TEARS
AB Cone-beam computed tomography (CBCT) has become an important modality in dento-facial imaging but remains poorly used in the exploration of the musculoskeletal system. The purpose of this study was to prospectively evaluate the performance and radiation exposure of CBCT arthrography in the evaluation of ligament and cartilage injuries in cadaveric wrists, with gross pathology findings as the standard of reference.
Conventional arthrography was performed under fluoroscopic guidance on 10 cadaveric wrists, followed by MDCT acquisition and CBCT acquisition. CBCT arthrography and MDCT arthrography images were independently analyzed by two musculoskeletal radiologists working independently and then in consensus. The following items were observed: scapholunate and lunotriquetral ligaments, triangular fibrocartilage complex (TFCC) (tear, integrity), and proximal carpal row cartilage (chondral tears). Wrists were dissected and served as the standard of reference for comparisons. Interobserver agreement, sensitivity, specificity, and accuracy were determined. Radiation dose (CTDI) of both modalities was recorded.
CBCT arthrography provides equivalent results to MDCT arthrography in the evaluation of ligaments and cartilage with sensitivity and specificity between 82 and 100%, and interobserver agreement between 0.83 and 0.97. However, radiation dose was significantly lower (p < 0.05) for CBCT arthrography than for MDCT arthrography with a mean CTDI of 2.1 mGy (range 1.7-2.2) versus a mean of 15.1 mGy (range 14.7-16.1).
CBCT arthrography appears to be an innovative alternative to MDCT arthrography of the wrist as it allows an accurate and low radiation dose evaluation of ligaments and cartilage.
C1 [Jeantroux, Jeremy; Veillon, Francis; Dosch, Jean-Claude; Dietemann, Jean-Louis; Bierry, Guillaume] Univ Hosp Strasbourg, Dept Radiol, F-67098 Strasbourg, France.
[Ramdhian-Wihlm, Reeta] Univ Hosp Strasbourg, Dept Orthoped Surg, F-67098 Strasbourg, France.
[Le Minor, Jean-Marie] Univ Strasbourg, Inst Anat, Strasbourg, France.
[Le Minor, Jean-Marie; Schmittbuhl, Matthieu] Univ Strasbourg, Fac Dent, Strasbourg, France.
[Mac Mahon, Peter] Massachusetts Gen Hosp, Dept Musculoskeletal Radiol, Boston, MA 02114 USA.
RP Bierry, G (reprint author), Univ Hosp Strasbourg, Dept Radiol, 10 Ave Moliere, F-67098 Strasbourg, France.
EM Guillaume.bierry@chru-strasbourg.fr
NR 37
TC 9
Z9 9
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0364-2348
J9 SKELETAL RADIOL
JI Skeletal Radiol.
PD AUG
PY 2012
VL 41
IS 8
BP 963
EP 969
DI 10.1007/s00256-011-1305-1
PG 7
WC Orthopedics; Radiology, Nuclear Medicine & Medical Imaging
SC Orthopedics; Radiology, Nuclear Medicine & Medical Imaging
GA 962HM
UT WOS:000305533800010
PM 22064983
ER
PT J
AU Stephan, MT
Stephan, SB
Bak, P
Chen, JZ
Irvine, DJ
AF Stephan, Matthias T.
Stephan, Sirkka B.
Bak, Peter
Chen, Jianzhu
Irvine, Darrell J.
TI Synapse-directed delivery of immunomodulators using T-cell-conjugated
nanoparticles
SO BIOMATERIALS
LA English
DT Article
DE Cell therapy; Nanoparticle; Drug delivery; Immune synapse
ID IMMUNOLOGICAL SYNAPSE; CANCER-IMMUNOTHERAPY; TYROSINE PHOSPHATASES;
TRANSFERRIN RECEPTOR; TUMOR; LYMPHOCYTE; ACTIVATION; INHIBITOR; SHP-1;
TRANSPLANTATION
AB Regulating molecular interactions in the T-cell synapse to prevent autoimmunity or, conversely, to boost anti-tumor immunity has long been a goal in immunotherapy. However, delivering therapeutically meaningful doses of immune-modulating compounds into the synapse represents a major challenge. Here, we report that covalent coupling of maleimide-functionlized nanoparticles (NPs) to free thiol groups on T-cell membrane proteins enables efficient delivery of compounds into the T-cell synapse. We demonstrate that surface-linked NPs are rapidly polarized toward the nascent immunological synapse (IS) at the T-cell/APC contact zone during antigen recognition. To translate these findings into a therapeutic application we tested the NP delivery of NSC-87877, a dual inhibitor of Shp1 and Shp2, key phosphatases that downregulate T-cell receptor activation in the synapse, in the context of adoptive T cell therapy of cancer. Conjugating NSC-87877-loaded NPs to the surface of tumor-specific T cells just prior to adoptive transfer into mice with advanced prostate cancer promoted a much greater T-cell expansion at the tumor site, relative to co-infusing the same drug dose systemically, leading to enhanced survival of treated animals. In summary, our studies support the application of T-cell-linked synthetic NPs as efficient drug delivery vehicles into the IS, as well as the broad applicability of this new paradigm for therapeutically modulating signaling events at the T-cell/APC interface. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Stephan, Matthias T.; Irvine, Darrell J.] MIT, Dept Mat Sci & Engn, Cambridge, MA 02139 USA.
[Stephan, Matthias T.; Stephan, Sirkka B.; Bak, Peter; Chen, Jianzhu; Irvine, Darrell J.] MIT, Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA.
[Irvine, Darrell J.] MIT, Dept Biol Engn, Cambridge, MA 02139 USA.
[Irvine, Darrell J.] Massachusetts Gen Hosp, MIT, Ragon Inst, Boston, MA 02114 USA.
[Irvine, Darrell J.] Harvard Univ, Boston, MA 02115 USA.
[Irvine, Darrell J.] Howard Hughes Med Inst, Chevy Chase, MD USA.
RP Irvine, DJ (reprint author), MIT, Dept Mat Sci & Engn, Cambridge, MA 02139 USA.
EM djirvine@mit.edu
FU NIH [CA140476, EB123622]; Dept. of Defense Prostate Cancer Research
Program [W81XWH-10-1-0290]; Cancer Center from NCI [P30-CA14051]
FX This work was supported in part by the NIH (CA140476 to DJI and EB123622
to MTS), the Dept. of Defense Prostate Cancer Research Program
(W81XWH-10-1-0290), and a Cancer Center Support (core) grant P30-CA14051
from the NCI. SPB is an American Cancer Society Postdoctoral Fellow
(12109-PF-11-025-01-LIB). DJI is an investigator of the Howard Hughes
Medical Institute.
NR 69
TC 38
Z9 38
U1 2
U2 53
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142-9612
J9 BIOMATERIALS
JI Biomaterials
PD AUG
PY 2012
VL 33
IS 23
BP 5776
EP 5787
DI 10.1016/j.biomaterials.2012.04.029
PG 12
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 963CG
UT WOS:000305597100012
PM 22594972
ER
PT J
AU Khocht, A
Yaskell, T
Janal, M
Turner, BF
Rams, TE
Haffajee, AD
Socransky, SS
AF Khocht, A.
Yaskell, T.
Janal, M.
Turner, B. F.
Rams, T. E.
Haffajee, A. D.
Socransky, S. S.
TI Subgingival microbiota in adult Down syndrome periodontitis
SO JOURNAL OF PERIODONTAL RESEARCH
LA English
DT Article
DE Down syndrome; periodontal; periodontitis; subgingival microbiota
ID DNA-DNA HYBRIDIZATION; PORPHYROMONAS-GINGIVALIS; REFRACTORY
PERIODONTITIS; MICROBIOLOGICAL PARAMETERS; PERIODONTOPATHIC BACTERIA;
DISEASE; PLAQUE; FIBROBLASTS; MICROFLORA; HEALTH
AB Khocht A, Yaskell T, Janal M, Turner BF, Rams TE, Haffajee AD, Socransky SS. Subgingival microbiota in adult Down syndrome periodontitis. J Periodont Res 2012; 47: 500507. (c) 2012 John Wiley & Sons A/S Background and Objective: The subgingival microbiota in Down syndrome and non-Down syndrome adults receiving periodic dental care was examined for 40 bacterial species using checkerboard DNADNA hybridization and the results were related to clinical periodontal attachment loss. Material and Methods: A total of 44 Down syndrome, 66 non-Down syndrome mentally retarded and 83 mentally normal adults were clinically evaluated. This involved, for each subject, the removal of subgingival specimens from three interproximal sites on different teeth; all subgingival samples per subject were then pooled and assessed for the presence and levels of 40 bacterial species using species-specific whole-genomic DNA probes and checkerboard DNADNA hybridization. Significant group differences in species proportions averaged across subjects were evaluated using the KruskalWallis test, and associations between subgingival species and mean subject attachment loss within Down syndrome and non-Down syndrome subject groups were quantified using Pearson correlation and multiple linear regression analysis. Results: Down syndrome subjects exhibited greater attachment loss than non-Down syndrome subjects (p = 0.05). Most microbial species were present in Down syndrome subjects at levels similar to non-Down syndrome subjects, except for higher proportions of Selenomonas noxia, Propionibacterium acnes, Streptococcus gordonii, Streptococcus mitis and Streptococcus oralis in Down syndrome subjects compared with non-Down syndrome study subjects, higher proportions of Treponema socranskii in Down syndrome subjects compared with non-Down syndrome mentally retarded subjects, and higher proportions of Streptococcus constellatus in Down syndrome subjects compared with mentally normal subjects. Down syndrome adults classified with periodontitis revealed higher subgingival levels of T. socranskii than Down syndrome subjects with no periodontitis (p = 0.02). Higher subgingival proportions of S. constellatus, Fusobacterium nucleatum ssp. nucleatum, S. noxia and Prevotella nigrescens showed significant positive correlations (r = 0.350.42) and higher proportions of Actinomyces naeslundii II and Actinomyces odontolyticus showed negative correlations (r = -0.36 to -0.40), with increasing mean subject attachment loss in Down syndrome adults. Conclusion: Individuals with Down syndrome show higher levels of some subgingival bacterial species and specific associations between certain subgingival bacterial species and loss of periodontal attachment. These findings are consistent with the notion that certain subgingival bacteria may contribute to the increased level of periodontal disease seen in Down syndrome individuals and raise the question as to the reason for increased colonization in Down syndrome.
C1 [Khocht, A.] Temple Univ, Sch Dent, Dept Periodontol & Oral Implantol, Philadelphia, PA 19140 USA.
[Yaskell, T.; Haffajee, A. D.; Socransky, S. S.] Forsyth Inst, Cambridge, MA USA.
[Janal, M.] NYU, Coll Dent, New York, NY USA.
[Turner, B. F.] E Cent Reg Hosp, Gracewood, GA USA.
RP Khocht, A (reprint author), Temple Univ, Sch Dent, Dept Periodontol & Oral Implantol, 3223 N Broad St, Philadelphia, PA 19140 USA.
EM akhocht@temple.edu
FU National Institute of Dental and Craniofacial Research, Bethesda,
Maryland [R21 DE015012-02]
FX This study was supported by grant R21 DE015012-02 from the National
Institute of Dental and Craniofacial Research, Bethesda, Maryland.
NR 40
TC 8
Z9 10
U1 1
U2 9
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3484
J9 J PERIODONTAL RES
JI J. Periodont. Res.
PD AUG
PY 2012
VL 47
IS 4
BP 500
EP 507
DI 10.1111/j.1600-0765.2011.01459.x
PG 8
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA 962VN
UT WOS:000305575600012
PM 22221039
ER
PT J
AU Soria, JC
Mok, TS
Cappuzzo, F
Janne, PA
AF Soria, Jean-Charles
Mok, Tony S.
Cappuzzo, Federico
Jaenne, Pasi A.
TI EGFR-mutated oncogene-addicted non-small cell lung cancer: Current
trends and future prospects
SO CANCER TREATMENT REVIEWS
LA English
DT Review
DE Biological markers; Carcinoma; Non-small cell lung; Receptor; Epidermal
growth factor; Erlotinib; Gefitinib; Mutation; Oncogenes
ID GROWTH-FACTOR-RECEPTOR; PHASE-III TRIAL; TYROSINE KINASE INHIBITORS;
GENE COPY NUMBER; IN-SITU HYBRIDIZATION; CLINICAL-PRACTICE GUIDELINES;
HARBORING BRAF MUTATIONS; EML4-ALK FUSION GENE; GROUP-STUDY BR.21;
ACQUIRED-RESISTANCE
AB Non-small cell lung cancer (NSCLC) tumours with certain mutations in the epidermal growth factor receptor (EGFR) tyrosine kinase have been termed 'oncogene addicted' to reflect their dependence on EGFR-mediated pro-survival signalling and their high susceptibility to apoptosis induced by EGFR tyrosine kinase inhibitors (EGFR-TKIs, e.g. gefitinib and erlotinib). The most common mutations (L858R and exon 19 deletions) predict an improved clinical response to first-line oral EGFR-TKIs compared with standard platinum-based chemotherapy in patients with advanced NSCLC. Moreover, these mutations are also prognostic of a relatively indolent course of disease, regardless of treatment, as compared with classical NSCLC. Treatment strategies for oncogene-addicted NSCLC are therefore distinct from those for non-oncogene addicted NSCLC, and will depend on the specific genetic mutation present. (C) 2011 Published by Elsevier Ltd.
C1 [Soria, Jean-Charles] Inst Gustave Roussy, INSERM, Serv Innovat Therapeut Precoces, U981, F-94805 Villejuif, France.
[Soria, Jean-Charles] Univ Paris 11, F-94805 Villejuif, France.
[Mok, Tony S.] Chinese Univ Hong Kong, State Key Lab Oncol S China, Sir YK Pao Ctr Canc, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China.
[Cappuzzo, Federico] Osped Civile Livorno, Ist Toscano Tumori, I-57100 Livorno, Italy.
[Jaenne, Pasi A.] Dana Farber Canc Inst, Boston, MA 02215 USA.
RP Soria, JC (reprint author), Inst Gustave Roussy, INSERM, Serv Innovat Therapeut Precoces, U981, F-94805 Villejuif, France.
EM jean-charles.soria@igr.fr; tony@clo.cuhk.edu.hk;
f.cappuzzo@googlemail.com; Pasi_Janne@dfci.harvard.edu
RI Mendez, Pedro /J-8955-2016;
OI Mendez, Pedro /0000-0001-6713-7907; Cappuzzo,
Federico/0000-0002-6295-6767
FU Astrazeneca; Dana-Farber Cancer Institute; Boehringer-Ingelheim
FX J.C.S. has acted as a consultant for Abbott, Amgen, AstraZeneca,
Bristol-Myers Squibb, Boehringer-Ingelheim, glaxosmithkiline, Lilly,
Merck-Serono, Merck Sharp & Dohme, Pfizer, Roche-Genentech, Servier and
sanofi-aventis. T.S.M. has acted as a consultant for AstraZeneca, Roche,
Eli Lilly, Pfizer, Taiho, BMS, Merck Serono and Boellinger Ingelheim,
has received honoraria from AstraZeneca, Roche, Eli Lilly, Pfizer, Merck
Serono, Boehringer-Ingelheim, and has received research funding from
Astrazeneca. F.C. has acted as a consultant for Roche and holds a patent
for EGFR FISH testing. P.A.J. has acted as a consultant for
Boehringer-Ingelheim, Roche, Genentech, Abbott, AstraZeneca and Pfizer.
He owns stocks in Gatekeeper Pharmaceuticals and has received royalties
from intellectual property related to EGFR mutation tests owned by the
Dana-Farber Cancer Institute and licensed to Genzyme.; Editorial
assistance in the development of this paper, furnished by Prism Ideas
Ltd. (Nantwich, Cheshire, UK) was supported by an unrestricted grant
from Boehringer-Ingelheim.
NR 176
TC 67
Z9 72
U1 1
U2 27
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0305-7372
EI 1532-1967
J9 CANCER TREAT REV
JI Cancer Treat. Rev.
PD AUG
PY 2012
VL 38
IS 5
BP 416
EP 430
DI 10.1016/j.ctrv.2011.10.003
PG 15
WC Oncology
SC Oncology
GA 956SN
UT WOS:000305109500011
PM 22119437
ER
EF